{"createdAt":"2026-02-19T16:00:06.415Z","N":787,"df":{"10":201,"11":140,"12":85,"13":57,"14":59,"15":92,"16":85,"17":142,"18":52,"19":70,"20":109,"21":62,"22":78,"23":59,"24":68,"25":69,"26":45,"27":33,"28":43,"29":79,"30":87,"31":34,"32":49,"33":40,"34":35,"35":36,"36":38,"37":44,"38":50,"39":52,"40":68,"41":45,"42":30,"43":45,"44":55,"45":116,"46":41,"47":23,"48":41,"49":75,"50":44,"51":24,"52":19,"53":29,"54":31,"55":33,"56":26,"57":33,"58":33,"59":22,"60":33,"61":33,"62":28,"63":28,"64":33,"65":32,"66":20,"67":15,"68":22,"69":26,"70":50,"71":21,"72":25,"73":72,"74":26,"75":30,"76":21,"77":22,"78":26,"79":22,"80":32,"81":18,"82":22,"83":23,"84":16,"85":23,"86":23,"87":20,"88":21,"89":20,"90":35,"91":20,"92":18,"93":25,"94":16,"95":34,"96":14,"97":16,"98":19,"99":18,"100":56,"101":20,"102":17,"103":14,"104":19,"105":18,"106":21,"107":20,"108":22,"109":18,"110":29,"111":13,"112":13,"113":14,"114":17,"115":18,"116":20,"117":18,"118":20,"119":15,"120":15,"121":17,"122":14,"123":12,"124":14,"125":12,"126":12,"127":19,"128":17,"129":17,"130":14,"131":16,"132":16,"133":14,"134":8,"135":15,"136":11,"137":10,"138":13,"139":23,"140":28,"141":19,"142":19,"143":21,"144":9,"145":17,"146":12,"147":16,"148":12,"149":9,"150":21,"151":13,"152":10,"153":10,"154":20,"155":13,"156":9,"157":14,"158":14,"159":13,"160":19,"161":14,"162":9,"163":10,"164":15,"165":25,"166":11,"167":11,"168":10,"169":16,"170":17,"171":13,"172":8,"173":13,"174":15,"175":13,"176":10,"177":15,"178":16,"179":15,"180":26,"181":12,"182":14,"183":17,"184":17,"185":10,"186":8,"187":7,"188":10,"189":10,"190":9,"191":6,"192":10,"193":9,"194":9,"195":6,"196":6,"197":9,"198":6,"199":5,"200":28,"201":5,"202":5,"203":6,"204":5,"205":6,"206":6,"207":5,"208":6,"209":5,"210":5,"211":5,"212":3,"213":4,"214":4,"215":9,"216":12,"217":7,"218":4,"219":2,"220":6,"221":5,"222":6,"223":11,"224":8,"225":5,"226":4,"227":5,"228":9,"229":4,"230":4,"231":4,"232":4,"233":4,"234":4,"235":3,"236":4,"237":3,"238":6,"239":6,"240":4,"241":8,"242":4,"243":4,"244":10,"245":7,"246":4,"247":5,"248":7,"249":5,"250":16,"251":6,"252":7,"253":8,"254":10,"255":7,"256":8,"257":5,"258":8,"259":10,"260":8,"261":7,"262":5,"263":10,"264":6,"265":9,"266":11,"267":9,"268":7,"269":6,"270":5,"271":3,"272":6,"273":4,"274":7,"275":8,"276":7,"277":5,"278":12,"279":10,"280":9,"281":9,"282":4,"283":5,"284":8,"285":9,"286":7,"287":5,"288":10,"289":6,"290":7,"291":8,"292":8,"293":5,"294":5,"295":3,"296":6,"297":4,"298":8,"299":5,"300":37,"301":4,"302":3,"303":6,"304":8,"305":45,"306":7,"307":5,"308":4,"309":7,"310":9,"311":11,"312":6,"313":6,"314":7,"315":9,"316":6,"317":7,"318":9,"319":3,"320":3,"321":7,"322":4,"323":7,"324":3,"325":10,"326":3,"327":10,"328":6,"329":7,"330":6,"331":5,"332":3,"333":5,"334":3,"335":3,"336":5,"337":6,"338":6,"339":6,"340":41,"341":5,"342":3,"343":3,"344":9,"345":6,"346":8,"347":6,"348":4,"349":5,"351":1,"352":7,"353":2,"354":1,"355":7,"356":3,"357":4,"358":4,"359":8,"360":3,"361":1,"362":1,"364":1,"365":2,"366":4,"367":4,"368":1,"369":6,"370":1,"372":3,"373":8,"374":6,"375":8,"376":3,"377":8,"378":6,"379":2,"380":12,"381":9,"382":2,"383":14,"384":12,"385":19,"386":2,"387":11,"388":6,"389":3,"390":3,"391":7,"392":5,"393":9,"394":12,"396":3,"397":3,"398":5,"399":5,"400":2,"402":1,"403":3,"404":4,"405":4,"406":6,"407":1,"409":1,"410":3,"411":1,"412":3,"413":3,"415":12,"416":4,"417":2,"418":1,"419":4,"420":2,"421":1,"422":2,"423":3,"424":15,"426":2,"427":7,"428":2,"429":2,"430":4,"431":1,"432":2,"433":2,"436":2,"437":2,"438":1,"439":3,"440":3,"441":2,"442":2,"443":1,"444":1,"445":1,"447":1,"449":1,"450":3,"452":1,"453":1,"454":1,"456":3,"462":1,"465":4,"467":1,"468":1,"469":1,"472":2,"473":3,"474":2,"478":1,"481":1,"484":2,"486":1,"492":1,"493":2,"494":2,"495":2,"497":2,"498":2,"500":19,"501":1,"503":4,"504":1,"505":1,"507":2,"508":4,"509":2,"510":2,"512":1,"513":2,"515":5,"516":2,"517":4,"519":1,"521":1,"522":2,"523":2,"524":2,"526":4,"528":2,"529":1,"530":2,"531":5,"532":3,"534":4,"535":6,"537":3,"539":2,"540":3,"541":3,"542":2,"543":2,"544":2,"545":4,"546":1,"547":4,"548":2,"549":2,"550":2,"551":3,"552":1,"553":2,"555":1,"556":1,"559":2,"560":2,"561":2,"562":4,"563":1,"565":5,"566":1,"567":1,"568":2,"569":3,"570":1,"571":2,"573":1,"574":4,"575":5,"577":1,"578":3,"580":1,"583":1,"584":1,"585":3,"586":2,"588":4,"591":2,"592":1,"594":4,"596":2,"597":3,"598":4,"600":4,"601":1,"602":2,"603":1,"604":3,"605":3,"606":1,"608":1,"609":2,"611":1,"612":1,"613":5,"614":2,"616":1,"617":1,"619":1,"620":2,"621":1,"623":1,"625":1,"626":2,"627":3,"629":1,"630":1,"631":4,"633":1,"636":2,"637":3,"639":1,"640":1,"641":2,"643":4,"644":4,"647":1,"649":1,"650":2,"651":3,"653":4,"655":2,"657":2,"659":1,"660":1,"662":3,"664":1,"665":1,"667":1,"671":2,"673":1,"674":1,"675":1,"677":1,"678":2,"679":1,"681":2,"682":3,"686":1,"687":1,"688":1,"689":2,"690":1,"692":1,"696":2,"699":3,"701":2,"703":1,"704":2,"705":1,"706":1,"711":1,"712":2,"713":2,"714":1,"715":1,"716":1,"718":1,"719":2,"720":2,"723":2,"725":2,"728":2,"731":3,"732":1,"733":1,"735":1,"736":1,"739":2,"740":2,"741":2,"742":3,"743":1,"746":3,"747":1,"748":3,"749":2,"750":3,"751":1,"753":2,"754":2,"757":1,"761":1,"765":1,"770":1,"773":1,"774":2,"775":2,"776":2,"779":3,"782":1,"785":1,"788":1,"795":1,"796":1,"798":2,"799":1,"803":1,"805":1,"806":1,"807":4,"809":1,"810":2,"812":4,"813":2,"814":2,"815":2,"819":2,"821":3,"822":2,"823":1,"825":1,"832":2,"833":2,"835":1,"837":4,"839":1,"841":2,"842":2,"843":1,"845":3,"846":1,"848":1,"850":1,"851":1,"853":2,"854":1,"855":2,"856":1,"858":3,"859":2,"860":4,"861":2,"862":1,"863":1,"864":1,"866":4,"869":3,"873":1,"874":2,"875":1,"877":2,"878":2,"879":1,"880":1,"881":2,"884":2,"886":1,"887":2,"889":1,"893":2,"896":2,"897":3,"898":3,"899":1,"901":2,"902":2,"904":1,"905":2,"907":6,"909":3,"910":2,"911":1,"912":2,"913":1,"914":1,"918":3,"919":2,"920":2,"921":3,"922":1,"923":1,"925":1,"926":1,"929":5,"932":1,"933":1,"934":1,"936":1,"943":2,"944":1,"946":1,"948":1,"949":2,"950":1,"951":1,"953":2,"954":1,"957":3,"958":1,"959":1,"961":2,"962":1,"964":2,"965":1,"966":2,"967":1,"969":2,"971":2,"972":1,"974":1,"975":1,"978":1,"980":1,"982":1,"984":4,"985":1,"987":2,"989":2,"990":1,"991":2,"992":2,"993":2,"994":2,"996":1,"997":1,"998":1,"1000":7,"1001":20,"1002":7,"1005":1,"1007":8,"1009":1,"1010":1,"1011":1,"1013":1,"1016":41,"1017":2,"1020":1,"1022":1,"1024":3,"1025":2,"1027":2,"1030":1,"1031":1,"1034":1,"1038":1,"1039":2,"1040":2,"1041":2,"1042":1,"1043":1,"1044":2,"1046":5,"1049":1,"1051":2,"1053":2,"1056":21,"1059":1,"1061":2,"1063":2,"1065":1,"1066":1,"1067":1,"1070":1,"1071":1,"1072":1,"1074":3,"1075":1,"1077":1,"1080":1,"1083":1,"1088":1,"1089":2,"1093":2,"1097":5,"1104":1,"1105":1,"1107":2,"1110":2,"1111":6,"1113":2,"1115":1,"1116":1,"1117":1,"1121":1,"1124":3,"1128":1,"1133":2,"1136":9,"1141":2,"1143":2,"1145":1,"1147":1,"1151":1,"1152":1,"1153":3,"1154":3,"1155":5,"1156":1,"1157":3,"1158":1,"1159":3,"1160":2,"1161":18,"1162":1,"1163":2,"1164":3,"1165":3,"1166":2,"1167":4,"1172":1,"1173":1,"1175":2,"1177":5,"1178":1,"1179":2,"1180":2,"1183":1,"1185":1,"1186":5,"1188":1,"1190":2,"1196":3,"1200":1,"1201":1,"1210":1,"1211":1,"1212":1,"1213":1,"1220":1,"1223":1,"1224":2,"1228":2,"1234":1,"1237":1,"1239":1,"1242":2,"1243":1,"1245":1,"1246":1,"1248":1,"1249":1,"1251":1,"1253":1,"1254":1,"1255":1,"1257":2,"1258":1,"1261":1,"1263":1,"1268":1,"1275":2,"1277":1,"1279":1,"1283":2,"1285":1,"1287":1,"1289":1,"1290":1,"1295":1,"1296":1,"1297":1,"1299":1,"1301":1,"1302":1,"1304":1,"1305":1,"1307":1,"1309":2,"1310":1,"1313":2,"1315":2,"1317":3,"1318":1,"1320":1,"1321":2,"1324":2,"1325":1,"1326":2,"1331":2,"1337":2,"1339":1,"1346":2,"1349":2,"1350":2,"1352":1,"1353":2,"1355":1,"1357":1,"1359":4,"1362":1,"1364":1,"1367":1,"1368":2,"1369":1,"1375":2,"1376":2,"1378":3,"1381":4,"1383":1,"1387":2,"1390":1,"1394":2,"1396":1,"1398":1,"1399":1,"1402":1,"1403":3,"1407":1,"1409":1,"1413":5,"1414":3,"1421":1,"1424":2,"1425":5,"1426":2,"1431":1,"1435":1,"1436":3,"1437":1,"1439":2,"1445":1,"1446":1,"1450":2,"1451":4,"1454":2,"1460":1,"1461":2,"1462":1,"1463":1,"1464":1,"1465":1,"1467":1,"1475":1,"1476":1,"1479":3,"1481":2,"1485":1,"1486":2,"1491":3,"1492":1,"1497":1,"1498":1,"1499":2,"1509":2,"1512":1,"1514":1,"1516":2,"1518":2,"1519":5,"1520":1,"1524":2,"1525":1,"1528":1,"1529":2,"1530":7,"1531":1,"1540":1,"1541":3,"1542":1,"1543":2,"1545":1,"1547":1,"1548":1,"1551":1,"1552":3,"1555":1,"1556":1,"1559":2,"1560":3,"1568":2,"1569":1,"1577":4,"1579":1,"1581":2,"1588":2,"1589":2,"1596":2,"1606":1,"1609":1,"1615":1,"1622":2,"1628":1,"1629":2,"1631":3,"1634":2,"1635":1,"1636":1,"1638":3,"1641":3,"1642":2,"1643":1,"1645":1,"1646":3,"1647":1,"1649":1,"1655":1,"1657":1,"1669":1,"1672":2,"1676":2,"1681":1,"1693":2,"1701":1,"1702":2,"1707":1,"1710":2,"1717":2,"1718":1,"1725":2,"1742":1,"1749":1,"1751":1,"1754":5,"1757":1,"1761":3,"1789":3,"1790":1,"1796":4,"1797":1,"1799":2,"1801":1,"1803":2,"1804":1,"1807":1,"1809":1,"1811":2,"1812":2,"1813":1,"1815":2,"1822":2,"1824":2,"1828":1,"1831":2,"1834":2,"1838":1,"1841":1,"1845":1,"1853":1,"1857":2,"1859":1,"1866":1,"1867":2,"1868":4,"1870":2,"1877":2,"1882":2,"1886":2,"1891":2,"1892":1,"1893":2,"1903":1,"1908":1,"1916":1,"1919":1,"1922":1,"1923":1,"1929":1,"1934":1,"1938":1,"1940":1,"1961":1,"1962":1,"1964":2,"1972":5,"1973":2,"1976":3,"1979":2,"1980":4,"1988":1,"1989":1,"1992":1,"1995":8,"1996":1,"1997":2,"1998":10,"1999":6,"2000":3,"2001":10,"2002":6,"2003":10,"2004":6,"2005":13,"2006":11,"2007":7,"2008":32,"2009":15,"2010":16,"2011":27,"2012":22,"2013":29,"2014":43,"2015":69,"2016":67,"2017":80,"2018":98,"2019":103,"2020":98,"2021":144,"2022":159,"2023":102,"2024":51,"2025":44,"2026":89,"2033":1,"2034":1,"2045":1,"2047":2,"2049":1,"2052":1,"2054":1,"2056":2,"2062":3,"2067":1,"2069":1,"2072":1,"2075":2,"2076":1,"2077":1,"2081":1,"2082":1,"2083":1,"2089":3,"2098":1,"2099":3,"2101":2,"2108":1,"2109":2,"2113":2,"2116":4,"2117":7,"2122":1,"2124":3,"2125":1,"2126":1,"2128":5,"2133":1,"2135":1,"2137":2,"2139":1,"2140":3,"2144":2,"2147":2,"2154":2,"2155":2,"2161":2,"2183":1,"2190":1,"2196":2,"2199":2,"2200":2,"2211":1,"2215":2,"2216":2,"2217":1,"2219":1,"2224":1,"2225":2,"2228":2,"2229":1,"2230":1,"2231":1,"2234":2,"2237":1,"2239":1,"2241":1,"2242":1,"2243":4,"2247":2,"2249":1,"2250":1,"2251":2,"2252":2,"2253":1,"2259":1,"2260":2,"2262":4,"2263":2,"2266":1,"2269":1,"2272":4,"2273":2,"2274":1,"2275":2,"2277":1,"2280":2,"2283":1,"2284":1,"2287":1,"2291":1,"2294":1,"2295":5,"2297":1,"2306":3,"2307":1,"2309":2,"2310":1,"2313":3,"2315":1,"2320":1,"2332":2,"2337":21,"2343":1,"2354":1,"2356":1,"2361":1,"2367":2,"2369":1,"2370":1,"2375":1,"2376":1,"2377":2,"2388":2,"2396":2,"2415":1,"2424":1,"2427":2,"2438":1,"2443":1,"2444":1,"2447":1,"2461":2,"2463":1,"2464":1,"2465":2,"2468":1,"2476":1,"2496":1,"2498":2,"2501":1,"2502":2,"2505":1,"2545":2,"2556":2,"2559":2,"2560":1,"2564":2,"2565":2,"2566":1,"2572":1,"2589":2,"2592":1,"2594":1,"2599":1,"2602":1,"2619":1,"2625":2,"2628":1,"2635":1,"2669":1,"2671":1,"2676":1,"2686":1,"2692":1,"2696":1,"2701":1,"2709":1,"2716":3,"2724":2,"2730":1,"2735":1,"2736":1,"2743":1,"2749":1,"2753":44,"2754":2,"2755":1,"2756":2,"2757":2,"2758":1,"2759":2,"2760":1,"2761":2,"2762":2,"2763":1,"2764":1,"2765":1,"2766":2,"2767":2,"2768":2,"2769":1,"2770":1,"2771":1,"2772":1,"2773":1,"2774":1,"2775":2,"2776":2,"2777":1,"2778":1,"2779":2,"2780":1,"2781":2,"2782":1,"2783":1,"2784":1,"2785":2,"2786":6,"2812":1,"2813":1,"2840":1,"2842":2,"2851":2,"2873":1,"2877":1,"2880":2,"2889":1,"2890":1,"2891":2,"2899":1,"2908":1,"2918":1,"2919":1,"2924":1,"2926":1,"2928":1,"2933":1,"2934":2,"2939":1,"2960":1,"2984":1,"3007":1,"3015":1,"3075":1,"3080":1,"3086":1,"3090":1,"3106":1,"3109":1,"3132":1,"3137":1,"3143":3,"3224":1,"3235":1,"3243":1,"3389":1,"3402":1,"3421":1,"3579":1,"3780":1,"3912":1,"3917":1,"3945":3,"4073":1,"4126":1,"4158":7,"4250":1,"4296":2,"4304":2,"4401":1,"4466":1,"4511":1,"4528":1,"4541":1,"4550":1,"4744":1,"4819":1,"5000":1,"5312":1,"5321":1,"5471":1,"5477":1,"5868":1,"5988":1,"6135":1,"6147":1,"6530":2,"6736":10,"7160":1,"7258":1,"7326":4,"7444":1,"7643":1,"7993":1,"8587":7,"9111":1,"9131":1,"9149":1,"9323":1,"9324":2,"9716":1,"9739":1,"9961":1,"9982":3,"9990":1,"10057":1,"10077":1,"10208":2,"10354":1,"11063":1,"11324":1,"12528":2,"13088":1,"13871":1,"14455":1,"15364":3,"15585":1,"22063":1,"22347":1,"22539":1,"30069":1,"30309":3,"30388":1,"31009":1,"32131":1,"32256":1,"60576":1,"61965":1,"62225":1,"62459":2,"66504":1,"66515":1,"70006":1,"86888":1,"94945":1,"100044":1,"100249":1,"100776":1,"101102":2,"101163":2,"101586":1,"101594":1,"101624":1,"101833":1,"102382":1,"103190":1,"104596":1,"105052":1,"105342":1,"107882":1,"108101":1,"108532":1,"108632":2,"108723":1,"108734":1,"108737":1,"108921":1,"108984":1,"109003":1,"109119":1,"109230":1,"110263":1,"111026":1,"111091":1,"111668":1,"112111":1,"146803":1,"154941":1,"205637":1,"600497":1,"691567":39,"814251":2,"838277":1,"848851":19,"848878":33,"959247":1,"1446719":1,"1448728":1,"1473160":1,"4568903":1,"11881019":2,"14651858":1,"20800537":1,"21645515":1,"29262031":1,"37150579":1,"199909000":2,"200409210":1,"2018040443":1,"management":277,"of":747,"hyperglycemia":101,"in":724,"type":440,"diabetes":594,"consensus":101,"report":73,"by":298,"the":700,"american":77,"association":104,"ada":29,"and":748,"european":22,"for":623,"study":185,"easd":18,"melanie":2,"davies":52,"vanita":2,"aroda":21,"billy":2,"collins":7,"robert":3,"gabbay":3,"jennifer":2,"green":7,"nisa":2,"maruthur":7,"sylvia":2,"rosas":2,"stefano":2,"del":16,"prato":14,"chantal":2,"mathieu":9,"geltrude":2,"mingrone":3,"peter":3,"rossing":5,"tsvetalina":2,"tankova":2,"apostolos":2,"tsapas":13,"john":5,"buse":16,"care":359,"https":99,"doi":61,"org":179,"dci22":6,"0034":6,"downloaded":98,"from":333,"http":99,"diabetesjournals":104,"article":108,"pdf":107,"dci220034":37,"guest":89,"on":531,"february":89,"convened":1,"panel":20,"to":592,"update":40,"previous":18,"statements":8,"adults":169,"published":30,"since":7,"last":12,"updated":16,"target":63,"audience":1,"is":397,"full":17,"spectrum":6,"professional":23,"health":150,"team":35,"providing":12,"europe":5,"systematic":137,"examination":5,"publications":3,"informed":6,"new":64,"recommenda":5,"tions":46,"these":117,"include":69,"additional":73,"focus":14,"social":29,"determinants":21,"system":38,"physical":40,"activity":46,"behaviors":37,"including":116,"sleep":31,"there":84,"greater":43,"emphasis":6,"weight":165,"as":339,"part":17,"holistic":11,"approach":83,"results":70,"cardiovascular":191,"kidney":180,"outcomes":222,"trials":155,"involving":6,"sodium":68,"glucose":388,"cotransporter":42,"inhibitors":126,"glucagon":87,"like":70,"peptide":74,"leep":1,"receptor":91,"agonists":52,"assessment":44,"subgroups":15,"inform":14,"broader":3,"recommendations":76,"cardiorenal":70,"protection":21,"people":228,"with":694,"at":248,"high":132,"risk":341,"dis":30,"ease":11,"after":86,"summary":15,"listing":1,"practical":28,"tips":11,"implementation":26,"are":297,"provided":36,"chronic":69,"complex":7,"disease":180,"requires":23,"multifacto":1,"rial":2,"behavioral":18,"pharmacological":9,"treatments":27,"prevent":34,"or":475,"delay":13,"complications":95,"maintain":24,"quality":63,"life":52,"fig":83,"this":159,"includes":23,"blood":114,"lev":4,"els":5,"factors":97,"comorbidities":53,"necessi":1,"tates":1,"that":263,"be":356,"delivered":10,"an":281,"organized":1,"structured":24,"way":10,"such":90,"described":3,"model":17,"person":64,"centered":26,"enhance":6,"en":19,"gagement":2,"self":62,"activities":9,"careful":6,"consideration":22,"preferences":28,"living":33,"must":38,"individualiza":2,"tion":87,"treatment":308,"goals":98,"strategies":42,"addresses":4,"approaches":65,"levels":109,"nonpregnant":4,"principles":18,"appro":6,"ople":2,"achieving":28,"summarized":9,"not":214,"generally":24,"applicable":3,"individuals":176,"due":42,"other":119,"causes":16,"example":13,"monogenic":2,"secondary":26,"children":17,"leicester":2,"research":50,"centre":13,"university":16,"national":32,"institute":14,"biomedical":4,"hospitals":9,"nhs":2,"trust":2,"division":7,"endocrinology":33,"hypertension":26,"brigham":1,"women":12,"hospital":85,"harvard":2,"medical":66,"school":7,"boston":2,"ma":40,"heart":93,"lung":4,"bethesda":1,"md":16,"arlington":2,"va":9,"duke":2,"clinical":230,"medicine":40,"durham":3,"nc":6,"department":21,"johns":2,"hopkins":4,"baltimore":4,"unit":28,"joslin":1,"center":22,"experimental":2,"pisa":2,"italy":3,"ku":5,"leuven":3,"belgium":4,"universit":4,"cattolica":2,"sacro":2,"cuore":2,"rome":3,"es":22,"fondazione":1,"policlinico":1,"universitario":1,"gemelli":1,"irccs":1,"nutritional":18,"sciences":2,"metabolic":62,"king":3,"college":22,"london":7,"steno":1,"copenhagen":1,"herlev":1,"denmark":1,"so":23,"fi":338,"bulgaria":1,"volume":76,"november":29,"data":87,"sources":3,"searches":2,"selection":25,"writing":12,"group":119,"members":18,"were":68,"ap":26,"pointed":1,"associ":6,"ation":5,"largely":5,"worked":1,"virtually":2,"regular":45,"tele":2,"conferences":2,"september":5,"day":59,"workshop":1,"january":33,"face":8,"meeting":10,"april":2,"accepted":6,"editions":1,"starting":22,"point":18,"identify":19,"newer":12,"evidence":85,"search":7,"was":97,"conducted":10,"pubmed":2,"random":5,"ized":12,"control":148,"rcts":6,"re":105,"views":3,"meta":190,"analyses":41,"english":1,"between":58,"june":13,"eligible":3,"ex":15,"amined":1,"effectiveness":47,"safety":125,"nonpharmacological":1,"interventions":55,"dia":56,"betes":50,"reference":4,"lists":3,"reports":11,"scanned":7,"rel":2,"evant":1,"articles":3,"details":16,"keywords":1,"strategy":10,"available":126,"mendeley":3,"com":44,"datasets":3,"h5rcnxpk8w":3,"papers":1,"grouped":1,"according":9,"subject":4,"authors":16,"viewed":5,"up":59,"date":11,"evaluating":8,"effects":165,"therapeutic":33,"across":33,"clinically":21,"important":55,"subgroup":16,"populations":37,"assessed":22,"terms":6,"their":110,"credibility":6,"us":16,"ing":68,"relevant":16,"guidance":42,"praisal":2,"grading":8,"recom":21,"develop":12,"ment":67,"evaluation":39,"grade":29,"guidelines":41,"formulation":9,"practice":124,"draft":6,"con":56,"sensus":2,"evaluated":8,"invited":4,"reviewers":5,"presented":4,"public":7,"comment":3,"suggestions":1,"incor":2,"porated":2,"deemed":1,"appropriate":66,"see":75,"acknowledgments":4,"never":1,"theless":1,"although":44,"based":146,"stakeholder":1,"input":1,"herein":3,"fl":115,"ect":4,"values":15,"rationale":3,"importance":20,"context":20,"lowering":155,"fundamental":2,"aspects":8,"clude":6,"promoting":8,"healthy":31,"through":35,"nutrition":41,"therapy":273,"mnt":8,"psychological":7,"support":76,"well":63,"tobacco":3,"sub":16,"stance":1,"abuse":1,"counseling":8,"needed":63,"often":33,"education":69,"dsmes":29,"expanding":2,"number":20,"pharmacolog":2,"ical":8,"devices":22,"surgery":52,"growing":7,"information":51,"about":40,"ben":7,"ts":90,"risks":40,"provide":43,"more":122,"options":19,"wi":5,"providers":16,"but":114,"complicate":2,"decision":46,"making":36,"demon":9,"strated":9,"bene":126,"atherosclerotic":30,"cvd":56,"failure":89,"hf":105,"ckd":95,"afforded":1,"glp":213,"ra":155,"sglt2i":109,"prog":2,"ress":1,"aimed":3,"reducing":26,"progression":47,"burden":27,"its":48,"independent":14,"ef":111,"fects":4,"initially":4,"troduced":3,"agents":121,"now":9,"also":132,"prescribed":11,"organ":20,"protec":2,"we":32,"summa":2,"rize":1,"large":22,"body":33,"recent":33,"practitioners":5,"aim":6,"simplifying":2,"focusing":3,"our":18,"efforts":10,"pro":61,"viding":1,"attaining":3,"recommended":76,"glycemic":282,"tar":7,"gets":4,"yields":2,"substantial":8,"enduring":2,"ductions":8,"onset":34,"microvascular":28,"early":55,"intervention":39,"essential":25,"greatest":9,"absolute":15,"reduction":111,"comes":37,"fro":1,"improving":23,"very":30,"elevated":15,"modest":17,"near":7,"normalization":2,"plasma":18,"impact":60,"macrovascular":12,"less":47,"certain":14,"supported":13,"multiple":78,"epidemiological":1,"studies":77,"cause":66,"intensive":52,"emerge":1,"slowly":2,"while":69,"harms":8,"can":187,"immediate":12,"longer":21,"expectancy":7,"have":208,"gain":28,"reason":4,"able":17,"hba":36,"1c":36,"most":71,"suf":3,"cient":9,"years":45,"around":4,"mmol":63,"mol":24,"aiming":3,"lower":85,"level":50,"than":87,"may":198,"value":11,"if":131,"it":108,"achieved":31,"safely":13,"without":115,"signi":51,"cant":30,"hypogly":22,"cemia":30,"adverse":68,"reasonable":7,"particu":5,"larly":5,"when":144,"using":99,"associated":117,"hypoglycemic":21,"higher":53,"targets":51,"cases":14,"limited":26,"advanced":23,"poor":10,"tolerability":14,"frailty":12,"present":30,"thus":24,"gical":1,"should":259,"tailored":16,"individual":98,"preferen":2,"ces":5,"characteristics":18,"younger":10,"age":42,"compli":5,"cations":19,"comorbid":10,"conditions":15,"features":5,"hypoglycemia":186,"language":5,"matters":3,"communication":11,"core":4,"inte":4,"grated":3,"clinicians":38,"recognize":4,"aristotle":2,"thessaloniki":2,"greece":2,"harris":2,"manchester":1,"oxford":3,"north":4,"carolina":4,"chapel":2,"hill":6,"corresponding":3,"author":7,"jbuse":1,"med":150,"unc":1,"edu":4,"received":21,"august":25,"being":24,"simultaneously":5,"diabetologia":19,"s00125":4,"022":2,"05787":2,"ultaneously":1,"particular":16,"topic":3,"contains":1,"comprehensive":41,"authored":1,"expert":15,"represents":4,"collective":1,"analysis":197,"opinion":2,"co":36,"chairs":1,"reviewed":14,"committee":34,"affairs":4,"approved":38,"executive":12,"board":12,"supplementary":13,"material":2,"online":8,"gshare":1,"readers":4,"use":251,"long":74,"work":21,"properly":4,"cited":3,"educational":11,"altered":6,"www":48,"journals":5,"pages":5,"license":6,"figure":32,"cycle":3,"adapted":14,"et":308,"al":314,"permission":5,"bgm":6,"monitoring":92,"bp":22,"pressure":28,"cgm":57,"continuous":69,"associates":27,"how":31,"neutral":22,"free":4,"stigma":3,"facts":1,"strength":3,"what":15,"working":8,"respect":5,"ful":4,"inclusive":1,"encourage":4,"collaboration":3,"referred":8,"diabetics":3,"noncompliant":1,"blamed":1,"condition":3,"key":37,"plan":72,"pharmacotherapy":23,"cen":2,"tral":2,"establishing":1,"implementing":4,"grams":3,"usually":12,"involve":3,"contact":5,"sessions":6,"trained":8,"educators":2,"components":26,"shown":64,"table":78,"given":34,"ever":7,"changing":6,"nature":8,"fered":1,"ongoing":25,"basis":24,"critical":20,"junc":1,"tures":2,"diagnosis":44,"annually":6,"plications":6,"arise":1,"during":81,"transitions":9,"has":110,"consistently":8,"cantly":22,"improves":27,"knowledge":12,"reduces":21,"hos":10,"pital":3,"admissions":6,"all":130,"mortality":92,"cost":49,"effective":65,"programs":15,"train":1,"ntly":1,"specialists":14,"termed":2,"dces":1,"hereafter":1,"particularly":36,"following":37,"lifestyle":44,"eating":22,"man":22,"agement":19,"medication":92,"taking":35,"behavior":18,"cacy":92,"cop":1,"problem":3,"solving":1,"importantly":12,"which":83,"beliefs":4,"variety":4,"settings":29,"im":40,"portant":2,"know":5,"access":30,"local":11,"resources":23,"supports":8,"psychosocial":7,"replacement":18,"referral":11,"mental":9,"services":9,"they":52,"warranted":13,"di":19,"abetes":8,"distress":5,"remains":10,"psy":3,"chiatric":1,"disorders":16,"disordered":1,"common":16,"un":14,"recognized":6,"contribute":10,"out":53,"best":24,"theory":4,"curriculum":2,"time":110,"over":68,"line":25,"progr":1,"reinforce":1,"learning":8,"methods":6,"effec":10,"tive":15,"emerging":9,"demonstrates":1,"telehealth":3,"web":3,"used":96,"success":3,"coronavirus":3,"covid":14,"pandemic":7,"technologies":14,"mobile":5,"apps":7,"simula":1,"tools":23,"digital":6,"coaching":3,"deliver":5,"extend":1,"reach":21,"segment":2,"population":34,"comparable":9,"even":31,"better":33,"demonstrated":48,"increased":76,"engagement":3,"however":80,"digi":1,"tal":6,"change":29,"still":18,"preliminary":1,"quite":4,"heterogeneous":1,"individualized":43,"personalized":11,"variable":21,"related":69,"degree":8,"obesity":87,"insulin":335,"resistance":28,"tendency":2,"ad":44,"dresses":2,"multimorbidity":7,"respectful":2,"responsive":2,"indiv":2,"eterogeneous":1,"barriers":17,"differential":6,"costs":29,"therapies":66,"diabe":19,"tes":20,"shared":25,"facilitated":4,"aids":6,"show":8,"alter":8,"native":4,"useful":7,"strat":3,"egy":1,"determine":12,"course":13,"compelling":4,"indications":17,"indi":40,"viduals":19,"contextualize":1,"evaluate":13,"any":46,"suggested":13,"cognitive":11,"impairment":7,"literacy":6,"distinct":8,"cultural":5,"fears":1,"concerns":13,"factor":22,"implementa":2,"development":23,"furthermore":4,"rect":2,"poten":9,"tially":4,"representing":2,"lifelong":9,"addressed":8,"improve":81,"five":3,"urthermore":1,"areas":8,"been":110,"identi":13,"ed":33,"socioeconomic":3,"status":31,"income":2,"occupa":1,"multi":9,"sector":1,"domains":5,"housing":1,"criminal":1,"justice":2,"sociocultural":1,"practi":1,"experiences":3,"sociopolitical":1,"societal":1,"political":1,"norms":1,"root":4,"ideologies":1,"policies":10,"underlying":12,"disparities":5,"granularity":1,"pertain":3,"review":159,"lar":18,"issues":4,"faced":2,"afri":1,"subsequent":5,"environmental":1,"emotional":1,"known":12,"ence":2,"satisfactory":1,"chological":2,"faceted":2,"heterogeneity":6,"determi":5,"nants":6,"challenge":2,"families":7,"tempting":2,"integrate":4,"into":53,"daily":75,"current":23,"assessing":7,"char":1,"acteristics":1,"targeted":3,"mostly":6,"seen":26,"duce":5,"complica":7,"recently":16,"loss":79,"primary":50,"many":31,"magnitude":12,"confers":2,"improvement":20,"modifying":4,"effect":141,"lead":16,"remis":5,"sion":22,"de":104,"ned":10,"normal":17,"months":34,"absence":11,"exert":2,"tend":5,"beyond":32,"cardiometabolic":20,"primarily":6,"sessed":4,"test":15,"measure":6,"demonstrating":2,"laboratory":13,"mea":1,"surement":1,"limitations":7,"discrepancies":2,"sults":3,"true":1,"mean":9,"cial":16,"ethnic":6,"groups":21,"erythrocyte":1,"turnover":1,"anemia":3,"end":38,"stage":29,"espe":2,"cially":2,"erythropoietin":1,"pregnancy":15,"assay":1,"insensi":1,"hemoglobin":23,"variants":1,"someone":1,"hemoglobinopathy":1,"crepancies":1,"measured":7,"reported":16,"prompt":6,"one":56,"reliable":3,"help":22,"adjustment":24,"dividuals":5,"plans":35,"timely":12,"manner":6,"routine":8,"adding":27,"some":59,"individua":2,"ould":1,"insight":1,"medica":22,"symptoms":37,"combined":24,"technol":36,"ogies":1,"intermittently":5,"real":24,"those":115,"treated":54,"standardized":3,"single":23,"page":10,"ambula":1,"tory":5,"le":35,"uploaded":1,"considered":81,"standard":19,"metrics":7,"visual":8,"cues":1,"oppor":1,"tunities":1,"range":27,"per":50,"centage":1,"readings":2,"mg":108,"dl":68,"additionally":7,"above":32,"below":19,"varia":2,"bles":2,"regi":2,"mens":2,"attention":14,"minimizing":5,"hypo":21,"glycemia":61,"unawareness":7,"convey":4,"nt":3,"ambulatory":5,"assess":25,"goal":61,"parallel":11,"persistence":7,"adherence":21,"suboptimal":7,"low":64,"rates":54,"continued":35,"ther":54,"apy":17,"affects":2,"almost":3,"half":10,"leading":4,"subopti":1,"mal":1,"missions":1,"focuses":3,"pertinent":2,"contrib":3,"ute":1,"inconsistent":1,"discontinuation":15,"among":72,"perceived":3,"lack":18,"fear":3,"fa":8,"cilitators":2,"sistent":2,"family":6,"provider":9,"motivation":1,"cation":46,"medications":136,"foods":5,"observed":10,"vary":13,"classes":22,"tween":6,"differences":17,"ultimately":3,"prefer":6,"ences":5,"major":43,"driving":1,"choice":38,"charac":1,"teristics":1,"suggest":21,"evi":10,"dence":20,"garding":2,"route":6,"administration":65,"injection":30,"side":50,"inertia":24,"describes":1,"intensi":21,"met":20,"cludes":1,"intensify":8,"manage":40,"overtreated":1,"factorial":2,"occurring":4,"practitioner":2,"targeting":10,"facili":6,"tated":2,"improvements":15,"glycemi":2,"reated":1,"involvement":2,"multidisciplinary":4,"teams":6,"non":57,"physician":8,"authorization":3,"prescribe":6,"pharmacists":7,"specialist":14,"nurses":4,"reduce":89,"section":49,"summarizes":7,"speci":56,"pharmaco":7,"logical":4,"port":6,"standards":29,"integral":1,"supporting":18,"patterns":18,"addressing":7,"needs":27,"maintaining":9,"pleasure":2,"developing":13,"prov":1,"registered":6,"dieti":1,"tian":1,"dietitian":3,"nutritionist":3,"plements":1,"treat":53,"two":38,"dimensions":1,"dietary":27,"energy":10,"restriction":6,"no":86,"ratio":31,"carbohydrate":25,"proteins":2,"fat":20,"intake":33,"optimal":23,"every":39,"instead":3,"individually":4,"selected":9,"pat":3,"terns":1,"emphasize":3,"minimize":16,"harmful":1,"accommodate":1,"identifying":6,"habits":3,"feasible":10,"sustainable":2,"mended":15,"net":5,"cit":5,"cv":78,"cvot":12,"trial":229,"dka":40,"diabetic":55,"ketoacidosis":42,"dkd":7,"dpp":38,"dipeptidyl":24,"peptidase":23,"egfr":68,"estimated":30,"glomerular":25,"ltration":20,"rate":65,"gi":9,"gastroin":2,"testinal":2,"gip":56,"gastric":15,"inhibitory":1,"polypeptide":12,"agonist":40,"nash":11,"nonalcoholic":13,"steatohepatitis":17,"mace":46,"events":104,"sglt2":94,"sq":7,"subcutaneous":63,"t2dm":4,"mellitus":112,"agent":40,"dosing":45,"please":5,"refer":19,"manufacturers":6,"prescribing":20,"maintained":9,"network":43,"comparing":27,"nine":3,"weeks":12,"du":9,"ration":4,"reductions":26,"compared":95,"diet":27,"mediterranean":8,"carbohy":2,"drate":2,"diets":6,"evident":5,"follow":32,"duration":36,"delayed":15,"requirement":6,"cardio":22,"vascular":33,"similar":34,"ascribed":1,"vegan":3,"vege":1,"tarian":1,"interest":16,"restricted":4,"intermittent":4,"fasting":60,"variables":3,"though":10,"mixed":15,"differ":11,"having":8,"kg":34,"month":14,"rct":7,"092":2,"kj":10,"kcal":4,"nonco":1,"nergy":1,"nonconsecutive":1,"days":20,"week":26,"fol":3,"lowed":3,"usual":9,"021":4,"parable":1,"both":52,"baseline":35,"increase":52,"sulfonylureas":35,"highlighting":3,"need":49,"proactive":12,"changes":28,"nonsurgical":3,"overall":33,"conjunction":6,"consid":14,"ered":10,"remission":17,"direct":23,"etes":4,"program":27,"within":39,"led":10,"involved":5,"stepped":1,"food":38,"reintroduction":1,"term":53,"maintenance":16,"whole":3,"pop":1,"ulation":1,"directly":9,"varied":8,"gree":1,"year":41,"sustained":4,"correlated":1,"extent":8,"least":22,"only":30,"participants":29,"potential":62,"challenges":5,"durability":19,"look":6,"ahead":7,"action":26,"inter":12,"vention":9,"who":116,"overweight":44,"obese":16,"showed":30,"provements":5,"ss":11,"depression":8,"function":62,"apnea":12,"incontinence":2,"brain":2,"structure":2,"positive":27,"impacts":8,"composite":42,"indices":1,"geriatric":2,"syndromes":2,"disability":1,"balanced":4,"against":6,"po":7,"tential":4,"negative":10,"composi":1,"bone":9,"density":8,"fractures":5,"difference":10,"outcome":49,"post":34,"hoc":18,"explor":2,"atory":2,"rst":28,"progressive":10,"bolic":6,"grees":1,"suggestion":1,"required":47,"aero":1,"bic":1,"exercise":20,"muscle":10,"rhythmic":1,"resulting":8,"hyper":17,"induces":1,"clini":5,"cally":12,"cardiorespira":1,"tness":2,"maximized":1,"under":18,"postprandial":32,"period":19,"engaging":3,"min":64,"your":4,"own":6,"exibility":6,"balance":9,"creased":8,"impaired":28,"earlier":6,"wide":8,"cluding":11,"leisure":2,"small":12,"make":11,"crease":9,"steps":7,"decreased":22,"cardiovascu":9,"morbidity":13,"continuum":2,"human":42,"move":1,"breaking":2,"prolonged":15,"sitting":5,"light":2,"intensity":12,"interval":4,"training":21,"component":14,"guide":20,"lines":1,"hygiene":4,"mon":1,"distur":1,"bances":1,"quantity":3,"timing":17,"impairments":1,"daytime":4,"functioning":1,"metabo":1,"lism":1,"obstructive":10,"severity":14,"shaped":1,"short":40,"durations":2,"extending":2,"sleepers":2,"possible":21,"sensitivity":7,"catch":1,"weekend":3,"alone":30,"enough":1,"reverse":1,"insuf":5,"juncts":1,"found":42,"semaglutide":66,"peo":11,"ple":15,"step":27,"subcuta":2,"neous":2,"once":59,"adjunct":8,"performed":7,"either":31,"placebo":76,"thirds":2,"arm":10,"nounced":1,"vs":50,"tirzepatide":38,"novel":28,"dependent":33,"insulinotropic":15,"weekly":36,"doses":63,"duced":4,"respectiv":1,"respectively":8,"tir":12,"zepatide":4,"yet":3,"regulatory":9,"ities":5,"withdrawing":1,"leads":3,"creases":2,"obe":3,"sity":3,"option":14,"surgical":22,"didates":1,"appears":5,"bmi":16,"ci":20,"traditional":7,"strong":14,"te":6,"likelihood":6,"postoperative":11,"cently":5,"diagnosed":21,"likely":16,"experience":18,"decreases":6,"do":45,"achieve":50,"relapse":1,"initial":46,"medi":16,"potentially":8,"eradicate":1,"ciently":1,"stampede":4,"patient":59,"phys":6,"measures":9,"did":16,"prove":7,"note":9,"estimates":8,"cluded":3,"nonrandomized":3,"fective":6,"today":5,"protective":8,"oral":57,"enhanc":1,"urinary":9,"excretion":4,"intermediate":17,"timated":2,"scope":5,"expanded":4,"renal":63,"car":24,"diorenal":3,"death":46,"myocardial":21,"infarction":21,"hospitalization":47,"hhf":17,"mortal":4,"ity":13,"established":55,"cussed":2,"proach":4,"rec":7,"ommended":5,"process":16,"drug":62,"class":31,"mycotic":6,"genital":7,"infections":16,"typically":20,"mild":20,"treatable":1,"incidence":23,"incremental":2,"cvots":21,"mitigated":3,"signs":11,"temporary":5,"situations":8,"predispose":2,"acute":47,"illness":21,"perioperatively":1,"prior":39,"da":14,"pagli":2,"ozin":68,"respiratory":3,"patients":274,"dare":3,"dapagli":39,"acid":15,"base":7,"func":6,"inpatient":43,"admit":2,"ted":5,"wit":7,"brought":3,"several":22,"injury":6,"dehydration":4,"orthostatic":2,"hypotension":2,"amputation":7,"spectively":1,"monitored":10,"imbalance":2,"peripheral":6,"arterial":5,"derive":5,"limb":2,"reduced":86,"serious":4,"nonserious":1,"recovery":5,"kid":5,"ney":4,"augment":2,"secretion":9,"suppression":2,"decelerate":2,"emptying":11,"curb":2,"postmeal":2,"increments":3,"appetite":3,"ducing":1,"dulaglu":2,"tide":9,"liraglutide":51,"sema":4,"glutide":3,"dulaglutide":28,"subcutane":4,"ous":6,"titrated":25,"discussed":10,"sections":6,"individ":20,"ual":11,"injectable":22,"dose":129,"stud":6,"ies":5,"indicated":17,"proportions":1,"ability":15,"stepwise":21,"escalation":5,"gastrointestinal":23,"ly2189265":2,"award":8,"demonstrat":2,"superior":12,"esti":3,"mated":3,"etd":1,"inadequately":12,"controlled":129,"metformin":114,"likewise":2,"sustain":18,"forte":2,"studied":8,"previously":9,"reporting":10,"01":8,"nausea":9,"vomiting":8,"diarrhea":3,"occur":13,"initiation":49,"diminish":1,"gradual":6,"titration":39,"mitigate":14,"initiating":18,"promote":11,"sense":2,"satiety":2,"tating":2,"impor":5,"tant":8,"distinguish":1,"sensation":1,"mindful":2,"encouraged":9,"stopping":3,"hungry":2,"smaller":3,"meals":32,"snacks":1,"decreasing":6,"spicy":3,"moderating":1,"cohol":1,"increasing":19,"water":1,"slower":4,"exi":1,"ble":6,"escalations":1,"setting":53,"intoler":1,"ance":6,"pancreatitis":7,"pancreatic":3,"cancer":15,"medullary":3,"thyroid":7,"indicate":7,"contraindi":1,"cated":2,"rare":9,"medul":1,"lary":1,"history":32,"endocrine":63,"neoplasia":2,"cell":21,"tumors":3,"rodents":3,"preclinical":4,"retinopathy":10,"appear":8,"attributable":4,"rapidity":4,"pre":54,"exis":1,"existing":10,"gall":2,"bladder":3,"biliary":4,"diseases":6,"because":47,"minimal":10,"hypoglyce":13,"mia":20,"monotherapy":22,"neutrality":2,"good":10,"traditionally":1,"ongo":1,"acceptance":4,"notably":6,"indepen":4,"dent":4,"combination":83,"ceived":2,"ml":64,"result":20,"serum":13,"vitamin":13,"concentrations":2,"worsening":14,"neuropathy":5,"therefore":24,"periodic":2,"supple":2,"mentation":5,"dipep":2,"tidyl":2,"4i":15,"inhibit":2,"enzy":1,"matic":1,"inactivation":1,"endogenous":1,"incretin":12,"hormones":2,"release":19,"decrease":14,"glu":14,"cose":12,"fect":5,"tolerated":22,"reduc":5,"four":10,"saxagliptin":10,"alogliptin":8,"sitagliptin":19,"linagliptin":16,"albuminuria":21,"noted":11,"ou":3,"afety":2,"come":12,"carmelina":4,"ected":1,"label":34,"ar":10,"thralgia":1,"hypersensitivity":1,"reactions":6,"suitable":3,"siderations":1,"open":59,"lina":1,"gliptin":1,"basal":120,"glargine":58,"skilled":4,"nursing":7,"ties":1,"simi":3,"fewer":19,"plus":39,"safe":31,"older":34,"glyce":13,"mic":13,"variability":14,"episodes":11,"bolus":45,"regimen":21,"poly":3,"lyce":1,"fda":49,"administra":3,"addition":88,"phase":35,"iii":13,"dem":1,"onstrated":1,"gludec":2,"adjusted":14,"liver":33,"content":20,"visceral":1,"abdominal":8,"adipose":4,"tissue":8,"ndings":7,"tirzepa":1,"comparators":2,"acting":63,"odds":3,"partic":4,"ular":4,"warnings":7,"precautions":2,"included":23,"prescrib":2,"ally":4,"does":23,"versus":87,"robust":7,"diovascular":18,"will":32,"completion":1,"surpass":13,"union":1,"eu":3,"rable":1,"advantages":11,"inexpensive":2,"accessible":3,"stimulation":1,"relatively":10,"cohort":21,"uk":18,"prospective":37,"ukpds":16,"scoring":1,"observational":27,"raised":5,"nd":13,"ings":3,"reviews":10,"active":17,"sulfonylurea":19,"pioglitazone":33,"thiazolidinediones":8,"accidents":2,"tosca":3,"gli":8,"mepiride":3,"whose":8,"cardiovas":7,"cular":10,"tzds":5,"response":13,"potent":2,"preserving":1,"points":17,"cance":3,"pri":4,"mary":6,"resis":4,"tance":4,"stroke":41,"iris":7,"homa":1,"tran":1,"sient":1,"ischemic":11,"attack":11,"fatty":10,"nafld":23,"uid":2,"retention":4,"congestive":4,"fracture":4,"combining":10,"tzd":6,"detailed":12,"descriptions":1,"different":29,"insulins":36,"advantage":7,"lowers":9,"address":21,"facilitate":7,"pharmacokinetic":8,"pharmacodynamic":3,"les":22,"matching":3,"physiological":2,"require":44,"ments":6,"numerous":4,"formulations":13,"advances":3,"geared":1,"toward":1,"mimicking":1,"physio":1,"chal":2,"lenges":1,"approval":7,"biosimilar":2,"insu":23,"lins":2,"accessibility":1,"u100":9,"degludec":32,"dedicated":9,"educa":3,"technique":8,"sulin":22,"prevention":70,"adequate":22,"utmost":2,"intensifying":11,"lled":2,"syringes":5,"auto":2,"injectors":2,"intranasal":5,"ators":2,"administer":7,"severe":66,"nph":39,"analog":26,"units":27,"vidualized":13,"total":29,"nocturnal":16,"lin":30,"analogs":22,"generations":1,"concentrated":8,"allow":14,"erations":2,"rapid":47,"added":44,"prandial":51,"premixed":19,"combine":4,"mealtime":15,"same":15,"vial":9,"pen":18,"retaining":2,"properties":2,"offer":12,"convenience":2,"ixed":1,"formulated":1,"premixes":1,"mix":1,"protamine":5,"sus":12,"pension":1,"mixtures":2,"timed":3,"closer":1,"proximity":1,"nutrients":3,"routes":3,"haled":4,"delivery":46,"patch":5,"pump":26,"xed":7,"combinations":13,"ideglira":5,"lixisenatide":16,"iglarlixi":4,"ering":7,"monocomponents":1,"regimens":19,"switching":10,"achievement":14,"commonly":7,"glucosidase":8,"igni":1,"excursions":7,"cultures":1,"consumption":3,"reactive":4,"meglitinides":11,"colesevelam":5,"quick":2,"bromocrip":1,"tine":1,"pramlintide":4,"li":26,"censed":1,"comparative":27,"efficacy":67,"indicates":4,"followed":7,"utaneous":1,"pathophysiology":2,"tributing":1,"abnormalities":5,"natu":1,"rally":1,"tradi":1,"tional":14,"focused":9,"allowing":3,"clear":19,"delineation":1,"nega":1,"drugs":39,"proaches":3,"advan":2,"tages":3,"simultaneous":8,"pathophysiolog":1,"processes":3,"characterized":7,"comple":2,"mentary":2,"multicenter":14,"la":24,"bel":1,"designed":4,"compare":2,"partici":5,"pants":4,"had":20,"opti":1,"mized":2,"randomly":2,"assigned":4,"receive":7,"glimepiride":11,"liraglu":2,"rmed":4,"next":9,"visit":10,"remain":9,"threshold":13,"before":40,"addi":7,"reached":2,"signif":3,"icantly":1,"albeit":8,"modestly":6,"exhibited":2,"pooled":14,"three":15,"comprising":2,"revascularization":3,"unstable":5,"angina":4,"requiring":9,"hospi":9,"talization":2,"eration":2,"choosing":7,"prioritized":4,"vorable":1,"par":10,"ticularly":2,"ejection":37,"fraction":37,"completed":10,"pare":1,"presence":26,"background":14,"collectively":2,"systematically":4,"retrieved":2,"appraised":3,"incorporated":7,"aracteristics":1,"ertugli":9,"vertis":11,"cruited":1,"exclusively":4,"second":17,"ary":1,"except":2,"canagli":28,"nephropa":1,"thy":2,"credence":11,"000":10,"creatinine":18,"acei":16,"angiotensin":15,"converting":8,"enzyme":8,"inhibitor":61,"acr":3,"albumin":11,"arb":16,"blocker":8,"ascvd":51,"hfpef":17,"preserved":25,"hfref":12,"mi":31,"sdoh":3,"transporter":28,"t2d":87,"thiazolidinedione":4,"progres":4,"doubling":2,"dapa":16,"recruited":4,"uacr":16,"sgtl2i":1,"until":12,"dialysis":13,"transplantation":18,"sotagli":10,"moderate":29,"pairment":1,"scored":6,"dual":53,"sglt1i":1,"currently":19,"proved":4,"urgent":4,"visits":15,"empagli":41,"emperor":15,"irrespective":9,"regardless":19,"frac":2,"served":16,"wors":2,"ening":2,"soloist":8,"whf":8,"deaths":3,"hospitalizations":13,"gardless":2,"corroborate":1,"salutary":2,"finally":9,"efpeglenatide":8,"amplitude":7,"se":38,"vere":4,"exploratory":8,"osmotic":1,"minipump":1,"delivering":1,"exenatide":23,"subcutaneously":7,"itca":1,"neither":1,"nor":2,"marketing":1,"medicines":5,"agency":6,"mentioned":3,"laglutide":2,"comparator":5,"regardi":1,"regarding":30,"event":20,"exscel":6,"exe":1,"natide":1,"eqw":1,"attenuates":2,"decline":27,"prespeci":2,"receiv":1,"syntheses":1,"dated":1,"popula":3,"pairwise":4,"veri":2,"favorable":5,"ponents":1,"estimate":3,"seems":1,"driven":11,"albiglutide":5,"efpe":1,"glenatide":1,"similarly":15,"hard":2,"vidual":5,"ana":6,"lyzed":1,"separately":5,"pronounced":5,"conversely":3,"applicability":2,"ques":2,"tioned":2,"wed":1,"formin":7,"examined":6,"garded":1,"conclusive":1,"always":5,"formally":1,"ideally":8,"complemented":1,"explored":2,"role":31,"modi":28,"er":20,"further":34,"users":6,"nonusers":1,"larity":2,"direction":3,"uted":2,"parisons":3,"statistical":4,"imi":1,"implemented":6,"conclusions":6,"favoring":1,"consistency":1,"comparisons":5,"formal":5,"testing":18,"verifying":1,"similarity":1,"categories":6,"despite":23,"seemingly":1,"enrolment":1,"criteria":13,"estab":3,"lished":9,"certainty":2,"mendation":1,"former":2,"recorded":1,"ticipants":2,"ni":3,"identical":2,"general":42,"comprised":4,"smoking":11,"dy":4,"dyslipide":4,"relative":11,"posite":1,"sig":1,"moreover":12,"seemed":3,"consistent":15,"urine":12,"albumi":1,"ob":4,"nevertheless":2,"regarded":1,"caution":8,"contributing":4,"dividual":9,"analy":2,"ses":5,"inferences":2,"none":6,"them":8,"eff":2,"omparative":1,"cacious":6,"dif":8,"ferences":1,"servational":2,"pared":2,"hazard":11,"hr":16,"regard":7,"country":3,"considering":13,"heteroge":3,"neity":3,"infer":1,"made":21,"suggesting":7,"notable":5,"considerations":26,"accelerated":1,"biological":2,"ageing":3,"clines":2,"capacity":2,"underpinned":1,"dysfunction":13,"skeletal":1,"undertake":2,"simple":13,"functional":5,"exer":1,"cises":1,"middle":6,"decade":4,"tantly":1,"places":1,"turn":4,"increases":18,"increasingly":2,"recog":5,"nized":2,"complication":8,"pe":8,"decisions":14,"underrepre":1,"sentation":1,"ac":25,"preterax":1,"diamicron":1,"mr":14,"advance":11,"frail":8,"worse":3,"selecting":7,"improved":34,"requirements":11,"deter":4,"mine":1,"exam":1,"aged":9,"dci":1,"recommen":3,"dations":2,"obstacle":2,"choices":9,"quire":4,"tolera":1,"bility":2,"understand":6,"appropriately":8,"modify":5,"times":10,"sociated":1,"poorer":5,"prognosis":4,"attenuation":1,"avoid":30,"unneces":1,"sary":2,"harm":3,"tension":2,"tolerance":18,"adolescent":1,"young":20,"adult":21,"concert":3,"ve":13,"adoles":2,"cents":2,"gressi":1,"gression":3,"minority":3,"affected":8,"newly":15,"childhood":1,"cence":1,"hispanic":1,"black":3,"asian":5,"paci":1,"islander":1,"ameri":3,"indian":3,"deterio":1,"attenu":1,"ated":9,"adolescents":14,"verse":4,"adulthood":2,"hyperglycemic":46,"crises":18,"extremity":2,"ng":7,"correspondingly":1,"vildagliptin":7,"combi":6,"nation":8,"verify":10,"provides":14,"supe":1,"rior":1,"durable":8,"monother":1,"later":8,"poorly":6,"understood":3,"rollment":2,"statement":39,"unknown":12,"race":5,"ethnicity":3,"dispro":1,"portionately":1,"underrepresented":5,"six":7,"white":10,"enrolled":3,"portantly":1,"factored":3,"sonalized":1,"future":11,"recruit":1,"representative":1,"interven":6,"understudied":2,"ascertained":2,"sex":12,"reproductive":4,"highly":12,"contraception":9,"ensured":3,"eople":1,"versible":1,"intrauterine":1,"device":13,"progesterone":1,"implant":1,"scribing":1,"adversely":3,"affect":19,"fetus":1,"sexes":1,"men":11,"vas":1,"fact":4,"underrep":1,"resented":1,"prising":1,"scribed":3,"differing":1,"th":4,"roll":1,"iden":2,"tify":2,"intended":9,"sult":2,"frequently":12,"stages":5,"hepatic":13,"brosis":7,"cir":3,"rhosis":1,"consider":52,"pio":4,"glitazone":5,"fe":3,"licensed":1,"pur":1,"pose":2,"termediate":2,"piogli":1,"tazone":2,"enzymes":1,"he":12,"patic":1,"managed":10,"incident":9,"collected":2,"complete":6,"mediated":1,"offered":8,"systems":40,"prioritize":6,"optimizing":7,"adh":1,"hanges":1,"sup":8,"reaching":2,"trol":8,"compo":2,"nent":1,"engage":2,"regularly":5,"vig":1,"orous":1,"aerobic":9,"sedentary":5,"break":3,"frequent":17,"breaks":2,"mented":3,"sions":2,"mobility":1,"priate":5,"candidates":5,"ancestry":2,"sid":1,"provement":4,"hy":26,"perglycemia":12,"proven":26,"initiated":37,"thresholds":4,"region":1,"contra":4,"could":18,"combina":6,"exposure":6,"tus":3,"putting":2,"together":8,"integrated":11,"multifactorial":1,"account":16,"figs":6,"organization":7,"involves":2,"disciplines":1,"diabetologist":1,"die":1,"titian":2,"den":6,"tist":1,"eye":3,"podiatrist":1,"cardiologist":1,"nephrologist":1,"neurologist":1,"hepatologist":1,"pain":6,"technology":29,"tool":7,"tegrated":2,"nize":2,"acknowledge":4,"evolv":3,"coordinate":2,"ore":1,"individualization":4,"spect":1,"zyme":2,"blockers":11,"susceptibility":1,"bal":2,"each":30,"communicated":2,"estimator":1,"especially":17,"aware":13,"derived":4,"validated":5,"applied":5,"developed":15,"exclude":2,"underrepresent":1,"various":13,"corporating":1,"formulating":1,"equity":9,"sure":8,"expen":1,"sive":5,"protecting":6,"pharmacotherapies":4,"ras":48,"pertension":4,"dyslipidemia":23,"problems":5,"relationship":9,"obstruc":1,"pulmonary":5,"prevalent":6,"paid":3,"throughout":11,"span":6,"tai":5,"loring":1,"decrements":1,"substan":1,"fur":4,"screening":17,"formed":2,"culty":2,"unexplained":3,"falls":3,"substance":2,"ess":2,"cate":3,"bar":4,"rier":1,"text":6,"monitor":22,"inequity":1,"liv":1,"incorporate":8,"veloping":1,"complementary":7,"place":18,"embrace":2,"impress":1,"initiate":19,"diagno":2,"sis":4,"situation":11,"facilitating":8,"promotion":2,"central":7,"cessation":5,"ways":5,"personal":16,"advice":5,"reevaluated":2,"pattern":7,"pref":2,"erences":2,"explicit":2,"minimi":1,"zation":5,"cumstances":2,"minutes":6,"hour":4,"moder":2,"ate":3,"retino":1,"motivations":1,"circumstances":15,"expected":10,"chance":1,"dur":4,"nonsurgi":1,"cal":4,"accompanied":9,"behav":11,"ior":1,"procedure":7,"late":5,"situational":1,"interfere":1,"sur":7,"gery":4,"undergo":5,"centers":9,"experienced":5,"smart":6,"measurable":1,"attainable":1,"nonspeci":3,"ioral":5,"avoided":8,"oals":1,"achievements":1,"crucial":2,"psychologists":2,"ventions":4,"agreed":1,"deci":3,"discussion":12,"tracking":1,"sired":2,"educated":6,"undertaking":2,"tivity":5,"adopting":2,"ld":5,"dress":4,"ier":3,"directed":6,"comor":3,"bidities":3,"accompa":1,"nied":1,"onwards":1,"multifac":1,"torial":1,"lipid":17,"whereas":4,"pursuit":1,"mutually":1,"exclu":1,"confuse":1,"discus":2,"protect":2,"organs":2,"partl":1,"partly":3,"independently":6,"occurs":8,"predicted":2,"abso":1,"lute":1,"frames":2,"introduction":9,"ceive":3,"contraindicated":15,"preferred":30,"permitted":1,"stances":1,"inde":2,"pendent":1,"knowledged":2,"expensive":7,"resource":4,"constraints":2,"prioritization":3,"glt2i":1,"highest":9,"ative":3,"affordability":8,"ce":11,"main":4,"tain":4,"proposed":4,"determined":5,"special":8,"dangerous":3,"whom":7,"stringent":6,"prudent":1,"deprescribing":1,"asymptomatic":6,"ensues":1,"stated":1,"subpopulations":3,"racial":5,"continues":4,"withhold":3,"gen":7,"eral":6,"continually":3,"pharmacother":7,"iders":1,"lim":5,"ited":2,"impair":7,"depletion":2,"avoiding":5,"reassessment":4,"intervals":11,"dressing":1,"mechanisms":8,"pursued":2,"tradition":1,"advocated":1,"isting":2,"allows":3,"tighter":2,"dicated":2,"mediate":3,"presents":3,"opportu":1,"nity":1,"path":3,"ophysiology":1,"micro":5,"damage":3,"shares":1,"commonality":1,"thought":4,"guiding":2,"follows":5,"assumption":2,"ness":6,"third":9,"fourth":2,"solid":6,"exists":7,"promise":3,"bined":1,"sider":2,"interactions":3,"whether":8,"complexity":6,"become":3,"fixed":19,"preparations":8,"ca":15,"ineffective":1,"changed":6,"stopped":16,"redu":1,"outweighs":1,"ceasing":1,"started":15,"close":13,"substantially":4,"diag":6,"nosis":5,"would":18,"reeval":3,"uate":2,"clinic":12,"gl":11,"hat":1,"rather":6,"stitute":1,"prescription":12,"deintensi":1,"set":16,"ting":3,"causing":1,"measurements":7,"familiar":2,"availability":15,"acceptable":2,"postponed":1,"contraindications":10,"preferably":1,"pharmacologic":59,"fpg":5,"t1d":5,"bur":2,"add":32,"visiting":3,"rereferral":1,"themselves":1,"discontinued":8,"lowing":3,"nger":1,"sticking":1,"adaptation":1,"phone":1,"helpful":7,"ketonuria":2,"ketosis":11,"dysregulation":4,"derweight":1,"suspected":9,"affordable":7,"mulations":3,"titrat":1,"rweight":1,"administered":21,"bedtime":17,"possi":1,"progresses":3,"correct":8,"meet":13,"thera":9,"peutic":4,"ist":1,"straightforward":1,"introduce":1,"meal":36,"start":16,"largest":14,"excursion":5,"adds":4,"contrast":9,"ion":2,"another":14,"simpler":2,"popular":1,"sulting":1,"reemphasized":1,"kept":1,"whenever":3,"sidered":5,"fashion":4,"titrating":3,"get":6,"continue":23,"gan":3,"cati":1,"nsulin":1,"advancing":7,"broad":4,"remote":7,"planning":13,"havior":2,"mindfulness":1,"stress":9,"embedding":2,"overseeing":1,"pact":6,"needing":3,"pens":9,"pumps":9,"infusion":35,"cs":8,"csii":11,"scarce":2,"injections":35,"again":1,"embedded":1,"intermit":1,"tently":1,"gained":1,"traction":1,"wearables":4,"collecting":2,"walked":2,"ministered":3,"motivational":2,"convincing":1,"hybrid":10,"closed":11,"loop":12,"ported":1,"adapt":6,"optimize":11,"fortunate":1,"nu":2,"merous":1,"translating":1,"cannot":9,"rest":1,"front":4,"improv":3,"form":12,"drive":3,"design":8,"held":8,"epoc":3,"taxon":1,"omy":1,"outlines":1,"questions":8,"answered":1,"responsibility":2,"leaders":1,"ows":1,"easy":1,"continuing":5,"necessary":13,"ensure":18,"evolving":5,"reaches":4,"policy":11,"makers":3,"microsystems":1,"gov":34,"ernmental":1,"agencies":1,"gether":1,"stakeholders":1,"where":11,"coordi":3,"nates":1,"practices":10,"tablish":1,"enhanced":4,"ogy":2,"governance":1,"arrangements":1,"spe":2,"accountability":2,"professionals":18,"ection":1,"facility":3,"workers":2,"aligned":2,"mendations":4,"outlined":1,"lancet":79,"commission":5,"mem":4,"bers":4,"coordination":4,"disci":2,"plines":2,"dietitians":2,"psych":1,"etc":3,"specialties":1,"ophthalmol":1,"nephrology":4,"quires":1,"gaps":3,"call":4,"100th":1,"discovery":3,"partial":3,"puri":1,"remember":1,"remarkable":3,"speed":1,"distributed":4,"saving":3,"few":5,"quickly":4,"governments":1,"industry":5,"sys":8,"tems":4,"academic":1,"institutions":6,"spond":1,"global":13,"syndrome":13,"sars":1,"cov":1,"virus":1,"preventive":4,"products":17,"tested":3,"massive":2,"scale":9,"annual":4,"approximately":19,"million":2,"ive":2,"spectacular":1,"soci":1,"ety":3,"steady":3,"prevalence":13,"mor":6,"bidity":1,"centuries":1,"investigation":10,"extraordinary":1,"decades":4,"encouraging":2,"represent":4,"erous":1,"banting":1,"censing":1,"patent":1,"canadian":21,"dollar":2,"readily":1,"avail":4,"contribution":3,"disparate":2,"unfavorable":2,"opportunities":4,"imple":6,"orga":2,"nization":2,"ck":10,"reader":5,"play":2,"cision":2,"organizing":1,"mini":2,"mize":2,"payors":1,"companies":2,"marketed":2,"ensuring":7,"equitable":2,"parities":1,"priority":6,"basic":3,"science":5,"nec":1,"essary":1,"bring":5,"generation":4,"area":4,"internal":3,"precision":4,"initiatives":2,"omics":2,"optimally":6,"hete":1,"tre":4,"mendous":1,"unrealized":1,"world":12,"causal":1,"inference":1,"create":3,"sights":1,"understanding":12,"consen":4,"insights":9,"standing":4,"investiga":1,"eld":6,"upwards":1,"enormous":3,"attendant":2,"fo":3,"cus":2,"individualizing":2,"right":5,"getting":2,"overcome":1,"regu":4,"latory":1,"reform":1,"duct":1,"coordinated":3,"ning":3,"col":2,"lection":2,"instruments":1,"sharing":1,"explora":1,"forms":7,"underserved":1,"accel":1,"erate":2,"progress":5,"implement":5,"conduct":1,"paying":1,"vulnerable":1,"much":9,"larger":1,"numbers":5,"essen":2,"tial":9,"describe":1,"inadequate":11,"maximize":4,"dimension":1,"fail":4,"repre":1,"sentative":1,"recruitment":4,"reten":1,"his":6,"torically":1,"suffering":1,"inequities":1,"nationality":1,"emer":1,"gence":1,"explic":1,"itly":1,"examine":4,"centric":19,"prioritizing":1,"aggressive":7,"induce":6,"unclear":3,"quired":2,"select":8,"fully":6,"validate":2,"targe":1,"ction":3,"uncertainty":3,"fac":2,"tors":5,"variabil":3,"ne":6,"bet":1,"ter":1,"plementation":3,"episodic":3,"underway":1,"society":27,"pathophys":1,"iology":1,"challenging":1,"reward":1,"vanced":2,"hope":1,"avenues":2,"na":19,"comprehensively":1,"incentives":1,"natural":2,"deca":2,"des":8,"ago":2,"exploded":2,"wh":10,"why":1,"application":4,"chronotype":2,"clearly":3,"interventional":4,"responses":2,"recommend":17,"empathic":1,"nutri":3,"foundation":7,"attainment":9,"mu":4,"nce":2,"establish":3,"equitably":1,"zaccardi":8,"literature":14,"bonar":1,"franklin":2,"jamal":1,"assisted":2,"ception":4,"execution":1,"gures":1,"tables":3,"yates":3,"henson":4,"produc":2,"karagiannis":11,"uni":3,"versity":2,"interpretation":3,"contributed":1,"applying":1,"respective":3,"bradley":4,"ohio":4,"state":29,"cine":2,"columbus":3,"oh":2,"home":27,"newcastle":1,"kirkman":2,"dinneen":1,"galway":1,"gal":1,"ireland":1,"rodbard":10,"adventis":1,"shady":1,"grove":1,"rockville":1,"sesti":1,"sapienza":1,"newland":1,"jones":9,"southampton":1,"montanya":1,"barcelona":2,"spain":2,"nauck":8,"st":12,"josef":1,"ruhr":1,"bochum":1,"germany":3,"el":8,"sayed":1,"bannuru":3,"sar":1,"aco":1,"nie":2,"mann":5,"buckley":1,"uhge":1,"dusseldorf":1,"list":11,"funding":11,"funded":4,"euro":2,"pean":2,"duality":3,"acted":1,"sultant":1,"advisory":9,"member":6,"speaker":7,"boehringer":9,"ingelheim":9,"eli":7,"lilly":7,"novo":15,"nordisk":10,"sano":6,"astrazeneca":8,"janssen":4,"lexicon":1,"zer":5,"shouti":1,"pharma":13,"napp":1,"ceuticals":1,"novartis":6,"takeda":3,"pharmaceuticals":5,"international":10,"her":5,"institution":5,"grants":1,"consultant":6,"therapeutics":5,"fractyl":2,"spouse":1,"employee":1,"merck":8,"employer":4,"stitution":1,"investigator":7,"plied":1,"medpace":1,"premier":1,"nominating":2,"academy":4,"assistants":3,"advisor":2,"vida":2,"lark":2,"bayer":5,"anji":4,"ver":2,"vertex":1,"icon":1,"valo":1,"she":1,"conducts":1,"roche":3,"agreement":1,"healthcare":6,"solutions":6,"entitled":1,"royalty":1,"distributions":1,"ticipated":1,"traverse":1,"receives":4,"astra":3,"zeneca":3,"visory":1,"abbott":3,"hengrui":1,"menarini":1,"pant":1,"bureau":3,"boeh":2,"ringer":2,"msd":3,"boheringer":2,"serves":3,"advi":3,"sory":3,"medtronic":4,"actobio":2,"insulet":3,"zealand":3,"pha":1,"strazeneca":1,"financial":6,"compen":1,"sation":2,"sa":23,"disk":1,"compensation":1,"cor":6,"keyron":1,"metadeq":1,"scienti":12,"dustry":1,"consultancy":1,"fees":2,"gilead":1,"lecture":1,"astellas":1,"serv":3,"ngelheim":1,"ingel":1,"heim":1,"fortress":1,"biotech":1,"moderna":1,"pendulum":1,"apeutics":1,"praetego":1,"reachmd":1,"stability":1,"vtv":1,"ceives":1,"dexcom":6,"novatarg":1,"tolerion":1,"investor":1,"phasebio":1,"contributions":3,"sponsible":1,"drafting":1,"revising":1,"critically":21,"intellectual":2,"version":8,"references":8,"rodriguez":5,"gutierrez":3,"gionfriddo":2,"ospina":2,"ns":5,"directions":2,"lly":1,"endocrinol":64,"draznin":10,"vr":19,"bakris":15,"suppl":25,"s83":1,"s96":1,"inzucchi":14,"bergenstal":16,"rm":25,"jb":23,"hyperglycaemia":9,"centred":3,"position":11,"mj":34,"alessio":3,"fradkin":2,"wexler":3,"dj":17,"hyperglycae":1,"schandelmaier":1,"briel":1,"varadhan":1,"instrument":1,"iceman":1,"randomized":141,"cmaj":2,"e901":1,"e906":1,"sun":8,"ioannidis":1,"jpa":1,"agoritsas":1,"alba":3,"guyatt":3,"jama":62,"andrews":2,"oxman":1,"going":2,"presentation":4,"clin":87,"epidemiol":5,"santesso":1,"glenton":1,"dahm":1,"informative":1,"communicate":1,"hisland":2,"grenet":2,"reappraisal":2,"glycaemic":33,"analysi":1,"ystematic":1,"randomised":71,"therapie":1,"agrawal":1,"azad":1,"bahn":1,"gd":2,"vadt":1,"veterans":3,"lind":1,"imberg":1,"coleman":5,"rl":10,"nerman":1,"holman":11,"rr":23,"historical":3,"explain":4,"legacy":1,"riddle":10,"mc":24,"gerstein":16,"hc":17,"a1c":112,"limiting":2,"sargeant":2,"ja":22,"brady":2,"em":6,"severely":4,"s125":2,"s143":2,"crabtree":2,"ogendo":2,"jj":18,"vinogradova":2,"gordon":2,"idris":2,"macrovascu":1,"60years":1,"observation":1,"rev":36,"metab":103,"dickinson":1,"jk":11,"guzman":2,"sj":13,"maryniuk":1,"powers":3,"bardsley":2,"cypress":1,"dietetics":1,"physicians":7,"pas":1,"nurse":15,"davis":11,"fischl":3,"ah":4,"beck":17,"excellence":5,"nice":7,"guideline":57,"ng28":3,"accessed":44,"chapter":2,"s60":2,"s82":2,"fessional":1,"s3":1,"structuredpatiented":1,"qs6":1,"chrvala":1,"sherr":3,"lipman":1,"rd":4,"educ":4,"couns":3,"pillay":1,"armstrong":4,"butalia":4,"ann":37,"intern":42,"zhao":4,"ff":2,"suhonen":2,"koskinen":2,"leino":2,"kilpi":2,"adv":3,"nurs":6,"odgers":2,"jewell":1,"ball":1,"kelly":1,"jt":9,"isenring":1,"ea":3,"reidlinger":1,"dp":1,"thomas":2,"regression":5,"diabet":21,"wang":21,"chatterjee":4,"heller":5,"speight":6,"snoek":1,"fj":11,"khunti":8,"programmes":1,"narrative":4,"innovations":1,"captieux":1,"pearce":1,"parke":1,"hl":1,"quantitative":2,"bmj":42,"e024262":1,"lindekilde":1,"scheuer":1,"sh":18,"rutters":1,"psychiatric":2,"umbrella":4,"dening":2,"islam":2,"sms":2,"george":3,"maddison":2,"internet":2,"res":72,"e16437":1,"nkhoma":1,"soko":1,"cj":8,"banda":1,"iqbal":2,"app":1,"e100291":1,"omar":1,"hasan":3,"palaian":1,"mahameed":1,"whatsapp":1,"pharm":11,"pract":60,"granada":2,"quinn":1,"lm":10,"northern":1,"mydesmond":1,"programme":1,"e14469":1,"gershkowitz":1,"bd":2,"hillert":1,"crotty":1,"bh":2,"e1513":2,"e1520":2,"lee":24,"mk":2,"ahn":2,"park":10,"cy":2,"user":3,"utility":6,"score":10,"jmir":2,"mhealth":2,"uhealth":2,"e17573":2,"ahlqvist":1,"storm":1,"aj":19,"am":63,"aki":2,"cluster":5,"pigeyre":1,"hess":3,"gomez":4,"mf":5,"validation":7,"classi":4,"origin":2,"s8":1,"s16":1,"kunneman":1,"montori":2,"vm":3,"castaneda":1,"guarderas":1,"ep":3,"acad":4,"emerg":5,"breslin":1,"mullan":2,"rj":25,"aid":20,"consultation":6,"shah":22,"arch":11,"stacey":2,"egar":2,"atients":1,"lewis":7,"facing":1,"cochrane":12,"database":16,"syst":16,"cd001431":1,"haire":1,"joshu":1,"briggs":2,"translation":3,"annu":1,"adler":3,"berkowitz":1,"ephraim":1,"pl":1,"vrany":1,"african":1,"americans":1,"exemplar":1,"curr":30,"diab":21,"rep":24,"hyman":1,"groot":1,"gonzalez":7,"js":4,"hood":4,"peyrot":2,"lingvay":8,"sumithran":2,"cohen":4,"rv":2,"roux":5,"cw":5,"reframe":3,"conversation":3,"cefalu":5,"wt":13,"evans":4,"ph":5,"nition":7,"s17":1,"s38":1,"s97":1,"s112":1,"mannucci":12,"antenore":1,"giorgino":5,"scavini":1,"unstructured":1,"sci":34,"weaver":1,"overview":11,"imary":1,"july":6,"lu":7,"zhou":12,"egede":1,"gebregziabher":1,"echols":1,"lynch":1,"cp":7,"longitudinal":4,"nonadherence":4,"huber":1,"reich":1,"dispensing":2,"claims":3,"switzerland":2,"iglay":1,"cartier":1,"rosen":1,"examining":2,"antihyperglycemic":39,"opin":8,"mcgovern":2,"tippu":2,"hinton":2,"munro":2,"whyte":2,"lusignan":2,"comparison":33,"obes":71,"seidu":2,"kunutsor":3,"polonsky":2,"henry":4,"recognizing":2,"contributors":2,"konstantinou":1,"kassianos":1,"georgiou":1,"facilitators":2,"scoping":2,"transl":1,"lasalvia":1,"barahona":1,"correa":4,"je":15,"romero":1,"alvernia":1,"dm":44,"needle":4,"reappraise":2,"terminology":2,"prim":5,"furler":2,"neal":11,"stepping":2,"pragmatic":3,"j783":2,"manski":2,"nankervis":2,"ginnivan":2,"thuraisingam":2,"blackberry":2,"overcoming":4,"tabesh":1,"magliano":1,"koye":1,"dn":1,"shaw":5,"prescribers":1,"int":20,"murphy":6,"me":20,"byrne":3,"galvin":1,"boland":1,"fahey":1,"smith":8,"sm":16,"community":9,"e015135":1,"s1":7,"s2":1,"sainsbury":1,"kizirian":1,"nv":1,"partridge":1,"sr":12,"gill":2,"colagiuri":3,"gibson":1,"aa":9,"snorgaard":2,"poulsen":2,"gm":13,"andersen":7,"hk":10,"astrup":3,"e000354":1,"van":16,"zuuren":1,"ej":9,"fedorowicz":1,"kuijpers":1,"pijl":1,"assessments":4,"nutr":11,"schwingshackl":1,"chaimani":1,"hoffmann":1,"schwedhelm":1,"boeing":1,"eur":12,"mart":1,"nez":1,"gonz":6,"alez":3,"gea":1,"ruiz":2,"canela":1,"circ":4,"estruch":2,"ros":2,"salas":2,"salvad":2,"predimed":2,"investigators":46,"supplemented":1,"extra":1,"virgin":1,"olive":2,"oil":5,"nuts":2,"engl":73,"e34":2,"papamichou":2,"panagiotakos":2,"db":7,"itsiopoulos":2,"cardiovasc":21,"liu":15,"jiang":6,"chen":15,"carter":1,"clifton":1,"pm":11,"keogh":1,"noninferiority":2,"netw":8,"e180756":1,"corley":1,"bt":2,"carroll":1,"rw":11,"hall":5,"weatherall":1,"parry":1,"krebs":1,"jd":13,"hypoglycaemia":11,"neil":5,"miller":7,"kovach":2,"tuerk":3,"pw":3,"nationally":2,"silver":6,"spring":6,"mottalib":2,"salsberg":1,"mohd":1,"yusof":1,"bn":2,"chee":1,"wss":1,"gilcharan":1,"singh":9,"hamdy":1,"trans":5,"algorithm":75,"tdna":1,"e000384":1,"hasbullah":1,"fy":1,"shahar":1,"ramadan":1,"espen":1,"wan":2,"zukiman":1,"wzhh":1,"abu":2,"zaid":1,"e813":2,"lean":8,"leslie":2,"ws":2,"barnes":2,"mej":1,"findings":6,"houston":1,"dk":17,"neiberg":1,"rh":5,"gerontol":1,"biol":4,"garvey":6,"wing":4,"bolin":1,"brancati":1,"gregg":4,"ew":6,"jakicic":3,"jm":34,"blackburn":2,"bray":5,"ga":8,"cassidy":1,"begay":1,"dc211805":1,"compre":1,"hensive":1,"s40":1,"s52":1,"swh":1,"ky":1,"chin":1,"wk":1,"amount":8,"schipper":1,"sbj":2,"veen":2,"mm":18,"elders":2,"pjm":2,"navarro":2,"alpert":2,"pt":5,"cross":7,"shift":7,"diabete":1,"dr":26,"rowlands":3,"av":7,"baldry":1,"codec":1,"e001375":1,"kanaley":1,"colberg":2,"corcoran":1,"mh":3,"sports":5,"exerc":1,"bull":2,"fc":4,"ansari":2,"biddle":1,"behaviour":4,"br":6,"homer":1,"taylor":2,"dempsey":2,"pc":3,"frequency":9,"interruptions":1,"metabolism":21,"larsen":3,"rn":3,"sethi":1,"interrupting":1,"brief":2,"bouts":1,"walking":1,"edwardson":1,"razieh":1,"wrist":1,"worn":2,"accelerometers":1,"recommending":1,"minimum":10,"mcid":1,"average":13,"acceleration":1,"inactive":1,"haffner":4,"schulte":1,"pj":9,"navigator":2,"saint":1,"maurice":1,"pf":1,"troiano":1,"rp":1,"bassett":2,"jr":16,"count":3,"jayedi":1,"emadi":1,"shab":1,"bidar":1,"supervised":2,"chudasama":1,"yv":1,"kk":7,"biobank":1,"bmc":4,"pan":7,"ge":20,"xun":1,"yq":1,"modalities":3,"act":5,"mickute":2,"physi":1,"e14393":1,"ahmad":4,"webb":2,"diabetology":2,"smyth":2,"jenkins":1,"dunham":1,"kutzer":1,"taheri":1,"whitehead":1,"zuraikat":1,"fm":4,"makarem":1,"redline":1,"aggarwal":1,"jelic":1,"onge":1,"mp":8,"regularity":1,"heath":1,"excess":3,"adiposity":5,"federation":1,"idf":3,"apnoea":2,"brussels":1,"advocacy":2,"awareness":5,"html":5,"fallahi":2,"jamil":2,"karimi":2,"eb":3,"baghi":2,"gheshlagh":2,"rg":14,"syndr":6,"sondrup":1,"termannsen":1,"eriksen":1,"jn":7,"manipulation":1,"markers":4,"delevatti":1,"rs":4,"bracht":1,"cg":4,"lisboa":1,"sdc":1,"naja":1,"pour":3,"mobasseri":1,"yavari":1,"hba1c":8,"vo":2,"max":6,"e000414":1,"borror":1,"zieff":1,"battaglini":1,"stoner":1,"guo":6,"xu":5,"qin":2,"chi":2,"composition":7,"revi":1,"ith":2,"rehabil":1,"jrm00165":1,"gupta":3,"jose":1,"yoga":1,"mello":1,"mb":9,"righi":1,"schuch":1,"fb":3,"signori":1,"silva":3,"amv":1,"protocols":10,"s46":1,"s59":1,"tasali":1,"wroblewski":1,"kahn":9,"kilkus":1,"schoeller":1,"extension":2,"objectively":2,"depner":2,"cm":24,"melanson":2,"eckel":4,"libitum":2,"fails":2,"repe":1,"repeating":2,"e4":2,"s113":1,"s124":2,"rch":2,"jeppesen":3,"ok":3,"double":30,"blind":29,"dummy":2,"wilding":5,"jph":3,"batterham":2,"calanna":2,"jastreboff":4,"aronne":2,"lj":8,"nn":6,"surmount":3,"rubino":4,"abrahamsson":4,"nathan":5,"delegates":1,"2nd":3,"summit":2,"joint":11,"organizations":3,"carmona":1,"mn":7,"santos":4,"sousa":2,"lindeza":1,"cri":3,"bariatric":13,"surgeries":5,"m2":2,"surg":9,"currie":1,"askari":2,"fangueiro":1,"mahawar":1,"procedures":18,"cresci":1,"cosentino":9,"monami":11,"rubio":2,"almanza":2,"herv":2,"mar":2,"amara":2,"omez":2,"caudet":2,"esteban":2,"merino":2,"torres":3,"jf":5,"khorgami":1,"shoar":1,"saber":1,"howard":1,"danaei":1,"sclabas":1,"fultang":1,"chinaka":1,"rankin":1,"bakhshi":1,"ali":4,"preoperative":10,"predictors":5,"panunzi":2,"gaetano":1,"conventional":10,"aminian":1,"kashyap":1,"wolski":1,"ke":4,"s144":2,"s174":2,"mcguire":15,"shih":7,"wj":16,"cardiol":26,"zinman":20,"wanner":6,"lachin":12,"empa":18,"reg":10,"perkovic":14,"mahaffey":5,"kw":7,"canvas":8,"collaborative":8,"wiviott":4,"sd":18,"raz":4,"bonaca":3,"cannon":6,"pratley":12,"dagogo":9,"jack":9,"bhatt":13,"szarek":4,"pitt":4,"dci2200":1,"gators":1,"mcmurray":9,"jjv":6,"solomon":6,"committees":5,"packer":7,"anker":7,"butler":6,"steg":4,"pg":9,"filippatos":5,"jardine":6,"nephropathy":7,"heerspink":7,"hjl":6,"stef":3,"ansson":1,"bv":3,"rotter":3,"jardiance":2,"rhein":2,"docs":9,"20information":2,"pis":2,"invokana":1,"beerse":1,"janssenlabels":1,"package":1,"insert":1,"product":18,"monograph":1,"pi":2,"farxiga":1,"wilmington":1,"den8dhaj6zs0e":1,"cloudfront":1,"50fd68b9":1,"106b":1,"b5d0":1,"12b045f8b184":1,"0be9cb1b":1,"3b33":1,"41c7":1,"bfc2":1,"04c9f718e442":1,"viewable":1,"rendition":1,"steglatro":1,"readington":1,"nj":12,"accessdata":8,"drugsatfda":7,"209803s000lbl":1,"mistry":1,"eschler":1,"dc":11,"euglycemic":9,"caused":6,"ketogenic":2,"case":13,"series":4,"aace":31,"kosiborod":5,"esterline":1,"furtado":1,"rhm":2,"hospitalised":7,"qian":2,"bb":2,"tado":1,"yan":1,"cf":2,"osteoporos":1,"dorsey":1,"trevi":1,"eg":27,"jg":8,"alvarez":1,"villalobos":1,"sglt":20,"invest":3,"barraclough":1,"jy":1,"yu":7,"figtree":1,"oshima":2,"zhang":13,"e1":4,"quast":2,"wefers":2,"meier":4,"art":2,"rybelsus":2,"plainsboro":2,"idney":3,"213051s000lbl":1,"frias":4,"jp":28,"bonora":3,"nevarez":1,"fr":7,"auerbach":1,"bajaj":6,"hs":6,"3b":4,"wharton":3,"dicker":1,"managing":9,"postgrad":3,"peng":5,"want":1,"ll":10,"utilizing":2,"vilsb":5,"bain":12,"sc":29,"leiter":8,"glycated":9,"haemoglobin":3,"bethel":6,"diaz":6,"castellana":2,"bhattacharya":1,"lakshmanan":2,"ping":3,"gallbladder":3,"crowley":3,"alexopoulos":3,"leader":12,"e108":2,"e110":1,"neuen":2,"bl":5,"arnott":1,"masson":3,"lavalle":3,"cobo":3,"lobo":4,"molinero":3,"antidiabetic":7,"prev":5,"matthews":11,"mohan":1,"lalau":1,"kajbaf":1,"bennis":1,"hurtel":1,"lemaire":1,"belpaire":1,"broe":1,"3a":6,"kooy":3,"lehert":3,"schalkwijk":2,"stehouwer":3,"cda":2,"methylmalonic":2,"3year":3,"edelstein":4,"sl":20,"goldberg":4,"rb":7,"b12":9,"ciency":9,"toto":2,"cooper":3,"umpierrez":22,"cardona":2,"chachkhiani":1,"dpp4":7,"facilities":5,"ltc":1,"dir":2,"assoc":11,"e3":2,"batule":1,"ramos":3,"erez":2,"montes":1,"oca":1,"hospitalized":47,"rosenstock":22,"wysham":4,"dahl":5,"onishi":5,"norwood":7,"mised":1,"ludvik":1,"odar":1,"pavo":4,"multicentre":17,"gastaldelli":2,"cusi":6,"fern":3,"andez":3,"land":4,"brouwers":2,"rodr":3,"guez":3,"mri":3,"substudy":3,"ersus":1,"avgerinos":4,"liakos":3,"sattar":9,"nat":8,"zoungas":1,"sulphonylureas":3,"vaccaro":1,"masulli":1,"nicolucci":3,"italian":2,"johansen":6,"oe":4,"heise":8,"adopt":4,"rosiglitazone":8,"glyburide":6,"dormandy":1,"charbonnel":6,"eckland":1,"dja":1,"kernan":1,"wn":2,"viscoli":7,"furie":1,"kl":9,"transient":11,"spence":3,"prediabetes":37,"neurol":3,"orsak":1,"bril":2,"della":1,"pepa":1,"russo":2,"vitale":1,"dosage":14,"pathophysiological":1,"pd":7,"pocock":7,"nielsen":1,"record":10,"hanefeld":6,"brunetti":1,"schernthaner":1,"gh":7,"quartet":1,"lh":6,"ylurea":1,"defronzo":6,"abdul":7,"ghani":7,"nissen":2,"forgotten":1,"cardioprotective":2,"vasc":3,"marso":9,"sp":11,"devote":3,"bosch":2,"dagenais":6,"gr":10,"dysglycemia":7,"lowe":3,"williams":6,"claus":1,"lw":1,"experiencing":6,"caiulo":5,"naletto":5,"madama":5,"analogues":16,"chan":10,"cheng":8,"lai":6,"inhaled":20,"dreon":1,"calibra":1,"heinemann":1,"parkin":1,"rethinking":1,"viability":1,"arulandu":1,"maiorino":6,"chiodini":3,"bellastella":7,"blonde":47,"inations":1,"lixilan":1,"linjawi":1,"bode":9,"bw":6,"chaykin":2,"lb":3,"titratable":1,"manghi":1,"garc":2,"hern":2,"uncontrolled":5,"jam":2,"thurman":1,"nn9068":1,"ii":4,"kasthuri":1,"poongothai":1,"anjana":1,"ash":2,"voglibose":1,"dalsgaard":1,"nb":3,"gasbjerg":1,"ls":3,"hansen":4,"acarbose":8,"kakotrichi":3,"puckett":6,"adams":4,"triple":6,"edict":4,"pald":5,"anius":4,"proot":3,"chiang":5,"stumvoll":5,"sequential":5,"galvez":2,"viii":2,"mantsiou":1,"luo":6,"pharmacol":11,"gu":2,"teng":1,"eng":3,"kramer":5,"retnakaran":4,"shi":4,"tang":3,"chenchula":1,"varthya":1,"sb":3,"padmavathi":1,"rationality":1,"e100921196392":2,"katsiki":2,"ofori":2,"asenso":2,"ferrannini":3,"mazidi":3,"rvational":1,"yoon":4,"jh":15,"moon":2,"hahn":4,"cho":4,"ym":4,"milder":2,"ty":2,"stocker":2,"abdel":2,"shaheed":2,"e45":1,"cignarelli":1,"brescia":1,"laviola":1,"e3082":1,"investig":8,"cai":3,"gao":7,"yang":7,"han":4,"ji":10,"dave":2,"kim":15,"gold":1,"ab":5,"glynn":4,"tong":2,"patorno":5,"1ra":30,"circulation":19,"lam":4,"csp":3,"ramasundarahettige":3,"branch":4,"krh":3,"concomitant":12,"inhibition":18,"wright":3,"ak":3,"carr":2,"kontopantelis":2,"clegg":2,"penland":2,"rc":6,"bachina":2,"sequentially":2,"diabetol":21,"press":5,"ruff":2,"ct":3,"baron":1,"donoghue":1,"fiedorek":1,"ft":1,"sabatine":3,"ms":12,"inferiority":6,"giugliano":4,"longo":4,"caruso":2,"esposito":3,"mmy":3,"kristensen":7,"freedom":2,"shaman":3,"tsai":3,"chuang":3,"subtypes":3,"strain":2,"wd":2,"frenkel":2,"james":7,"pioneer":6,"bekiari":2,"husain":3,"consoli":4,"remigis":1,"pettersson":2,"meyer":1,"rasmussen":2,"palmer":6,"tendal":3,"mustafa":3,"protein":11,"neer":1,"m4573":2,"dsh":1,"hung":4,"htoo":1,"bahour":1,"cortez":1,"doria":1,"aguayo":1,"mazzucato":1,"correlates":2,"biomarkers":4,"geroscience":1,"nguyen":4,"tn":1,"woodward":5,"medicinal":2,"treatmen":1,"amsterdam":1,"netherlands":1,"ema":1,"europa":1,"gb":7,"document":10,"library":5,"06":8,"wc500129256":1,"biologics":2,"regulations":1,"0118":1,"0003":3,"athanasiadou":2,"andes":1,"yj":1,"rolka":1,"imperatore":1,"united":10,"states":11,"pediatr":10,"e194498":2,"dabelea":2,"bell":2,"agostino":3,"youth":4,"rise":6,"consortium":5,"withdrawal":1,"hannon":1,"arslanian":1,"lessons":2,"learned":2,"jalaludin":1,"my":4,"deeb":1,"zeitler":1,"bjornstad":2,"drews":1,"caprio":1,"hora":1,"benoit":1,"resurgence":1,"jcn":5,"subanalysis":2,"019":2,"bhattarai":1,"salih":1,"regmi":1,"e2142078":1,"mishriky":2,"bm":12,"powell":3,"wittwer":1,"1ras":1,"2is":1,"diversity":4,"enrollment":2,"nformation":1,"isearch":1,"documents":3,"morrish":2,"stevens":2,"lk":5,"fuller":2,"keen":2,"multinational":4,"s14":1,"s21":1,"regensteiner":1,"golden":2,"huebschmann":1,"ag":6,"council":1,"epidemiology":3,"genomics":1,"translational":1,"biology":1,"consequences":1,"kannel":1,"wb":4,"wilson":4,"attenuate":1,"female":3,"coronary":19,"hu":4,"jousilahti":1,"qiao":3,"katoh":1,"tuomilehto":1,"peters":7,"sae":2,"huxley":2,"cohorts":4,"strokes":2,"corona":1,"clemens":1,"gender":3,"dholm":1,"lazarus":2,"jv":3,"mark":4,"anstee":2,"qm":2,"agenda":2,"gastroenterol":3,"hepatol":4,"kanwal":2,"shubrook":1,"pathway":5,"strati":1,"gastroenterology":2,"newsome":2,"pn":2,"buchholtz":2,"nn9931":2,"musso":1,"cassader":1,"paschetta":1,"gambino":1,"maltese":1,"verrastro":1,"alcoholic":5,"hierarchical":2,"mantovani":1,"cd":4,"scorletti":1,"mantzoros":1,"targher":1,"anti":29,"hyperglycaemic":1,"lassailly":2,"caiazzo":2,"ntandja":2,"wandji":2,"lc":7,"aemic":1,"resolution":8,"e5":2,"lembo":1,"mari":1,"reversal":1,"histologic":1,"hartman":2,"sanyal":2,"loomba":2,"ghosal":1,"datta":1,"sinha":2,"glp1":14,"coelho":1,"fds":1,"borges":1,"canha":1,"von":2,"hafe":1,"parameters":7,"steatosis":7,"e3413":2,"dwinata":2,"putera":2,"dd":3,"raharjo":2,"ers":2,"complicated":1,"exp":1,"shao":1,"kuo":1,"lt":1,"chien":2,"ecc":1,"e001956":1,"wojeck":1,"bs":4,"neeland":1,"ij":1,"breath":2,"eliasson":1,"kasai":1,"expl":1,"oratory":1,"levengood":2,"tw":4,"xiong":2,"kz":2,"task":16,"force":16,"e17":2,"e26":2,"chamnan":2,"simmons":2,"rk":4,"sharp":2,"grif":2,"wareham":4,"scores":2,"srikanth":1,"sinclair":1,"moran":1,"biessels":1,"gj":1,"towards":1,"palta":1,"schneider":3,"alc":1,"touradji":1,"neuropsychological":1,"tests":7,"neuropsychol":1,"soc":10,"evert":1,"dennison":1,"gardner":1,"objectives":2,"atlanta":3,"cdc":9,"dhdsp":2,"febru":1,"guides":1,"htm":2,"sunyer":1,"cahn":3,"declare":7,"timi":8,"daniels":3,"brown":14,"frandsen":5,"steering":5,"colhoun":6,"hm":14,"rewind":6,"kahl":1,"ofstad":1,"brownrigg":1,"jrw":1,"hughes":3,"burleigh":1,"mearns":4,"saulsberry":4,"antihyperglycaemic":5,"sulphonylurea":6,"dhalwani":1,"dales":1,"downes":1,"bettington":1,"ek":5,"gunton":1,"turkstra":1,"peerj":1,"e1461":1,"cmy":2,"lukashevich":1,"araga":1,"kothny":1,"hong":3,"moses":3,"kalra":1,"brook":1,"round":1,"shentu":2,"alexandria":2,"madenidou":1,"paschos":2,"monnier":2,"colette":2,"ceriello":1,"bartolo":1,"corcos":1,"orsini":1,"federici":1,"christiansen":2,"niskanen":3,"fulcher":5,"aspart":14,"biphasic":3,"gabler":1,"picker":1,"geier":1,"german":1,"mccarty":1,"olenik":1,"hangaard":2,"laursen":2,"telemedicine":2,"december":6,"epub":1,"print":1,"eberle":1,"stichling":1,"telemetric":1,"tematic":2,"e23252":1,"dicembrini":3,"pala":1,"welsh":2,"ells":1,"seibold":1,"martens":4,"bailey":6,"organisation":2,"taxonomy":2,"ju":4,"transform":1,"lives":1,"geneva":1,"news":5,"room":5,"sheets":1,"detail":2,"saeedi":1,"karuranga":1,"atlas":1,"regional":4,"projections":1,"falcetta":1,"aragona":1,"bertolotto":1,"pivotal":3,"beran":1,"lazo":1,"porras":1,"mba":3,"mbanya":1,"jc":11,"perspective":5,"issue":7,"horwitz":1,"kuznetsova":1,"creating":3,"mcginnis":2,"fineberg":2,"hv":2,"dzau":2,"vj":2,"sheikh":2,"netsova":1,"anderson":3,"albala":1,"innovation":3,"digit":3,"e383":1,"e396":1,"s183":34,"s215":2,"dc26":2,"s009":1,"sint":2,"contributor":2,"sdis":2,"citation":2,"noncommercial":2,"purposes":4,"unaltered":2,"linked":2,"party":2,"site":11,"platform":2,"publication":7,"contents":7,"reproduced":2,"mining":5,"machine":4,"written":8,"requests":4,"reuse":4,"distribute":4,"sent":6,"permissions":4,"interprofessional":4,"responsible":2,"updating":4,"descrip":1,"tem":2,"methodology":2,"read":3,"wish":6,"fusion":6,"injected":8,"match":2,"tein":2,"depending":11,"caregiver":2,"taught":3,"correction":21,"concurrent":4,"trends":8,"sick":8,"anticipated":5,"cific":1,"absent":4,"insulinopenia":3,"contri":1,"disturbances":2,"hypertriglyceridemia":7,"catabolism":3,"threatening":2,"decompensation":5,"prevented":3,"supplement":52,"dc26s009":33,"twice":18,"injec":4,"seven":3,"past":7,"accumulated":3,"placement":1,"fectiveness":4,"dcct":5,"carried":1,"landmark":4,"crovascular":1,"mac":2,"rovascular":2,"peri":4,"ears":1,"persistent":4,"beneficial":16,"ended":1,"sist":2,"via":11,"flatter":1,"constant":1,"profiles":6,"raa":11,"quicker":1,"peak":6,"shorter":3,"ultra":10,"uraa":7,"contain":4,"excipients":2,"celerate":2,"absorption":7,"first":25,"portion":3,"profile":9,"shortened":1,"subsection":1,"alterna":2,"cursions":1,"flexibility":7,"relation":8,"confer":3,"pr":12,"ttr":1,"ut":1,"sgo":1,"nsul":1,"ryg":1,"ppro":1,"sg":2,"ngp":1,"opl":1,"gw":9,"gtyp":1,"g0g":1,"alternative":12,"automated":21,"predictive":9,"suspend":7,"automation":2,"mdi":10,"laa":5,"emia":1,"infused":4,"symbols":1,"reflective":1,"insurance":8,"coverage":18,"discounts":2,"rebates":2,"price":7,"adjustments":18,"sales":2,"holt":7,"logs":3,"expense":6,"hibitive":1,"s184":1,"examples":2,"distribution":2,"disadvantages":3,"adjusting":7,"closely":5,"mimic":1,"sensor":2,"augmented":2,"tdd":7,"icr":5,"isf":4,"premeal":8,"adjust":13,"varying":2,"fractions":1,"integration":10,"tbr":2,"lowest":3,"continuously":4,"wear":1,"interruption":6,"adhesives":1,"technically":1,"harder":1,"numeracy":5,"skills":5,"counting":8,"accurate":5,"consistentl":1,"overnight":9,"outside":5,"manual":1,"mode":3,"flexible":3,"detemir":9,"costly":2,"smallest":3,"increment":1,"laas":4,"cover":7,"dawn":1,"phenomenon":1,"morning":18,"hours":4,"breakfast":6,"lunch":5,"dinner":6,"unable":5,"deficit":2,"mealtimes":4,"evening":11,"s186":2,"s185":1,"dosed":3,"syringe":4,"take":19,"covers":2,"raas":2,"orning":1,"split":2,"preference":11,"eliminates":1,"afternoon":4,"night":2,"difficult":2,"sen":4,"sitivity":1,"precept":1,"defined":6,"betic":2,"specific":22,"concluded":1,"02":11,"tress":1,"moni":7,"toring":7,"soon":7,"proves":2,"esearch":1,"sec":5,"sug":1,"gests":1,"percentage":2,"commercially":7,"source":5,"ic":5,"pendently":1,"capabilities":4,"der":3,"proportion":4,"pends":2,"puberty":2,"typical":4,"ranging":6,"amounts":4,"luteal":2,"menstrual":2,"menstruating":2,"asso":2,"ciation":2,"jdrf":3,"sourcebook":2,"notes":1,"metabolically":4,"stable":14,"proximately":2,"remaining":3,"periods":2,"absorp":2,"sufficient":2,"endog":1,"enous":1,"production":4,"honeymoon":3,"presenting":1,"vides":1,"informa":2,"intensification":12,"amer":2,"ican":2,"thorough":6,"multidose":5,"regulate":1,"inhala":1,"pharmacokinetics":8,"mulation":1,"fore":5,"physiologic":1,"varies":2,"size":3,"demand":5,"evolved":1,"ucation":2,"carbohydrates":6,"simplified":6,"nouncement":1,"method":9,"effectively":4,"egies":2,"iors":2,"reassessed":2,"reassess":8,"attain":6,"s187":1,"uptitrate":1,"downtitrate":1,"smbg":3,"adequacy":2,"modification":4,"switch":6,"overbasalization":9,"preprandial":5,"unaware":6,"deficiency":8,"emergent":3,"educate":4,"nutrient":1,"macronutrient":1,"done":2,"freq":1,"caregivers":4,"fitter":2,"forward":4,"ommendations":1,"else":1,"outlining":2,"proper":4,"admin":6,"istration":6,"insertion":2,"infu":2,"propriate":5,"inhalation":5,"rotation":3,"appropri":1,"sites":6,"infec":1,"avoidance":10,"intramuscular":4,"filling":1,"reservoir":1,"inhaler":1,"connected":4,"depend":3,"pleted":1,"exogenously":1,"intramuscularly":1,"abdomen":2,"thigh":1,"buttock":1,"upper":4,"differs":2,"influenced":2,"inadvertent":2,"predictable":2,"unexplaine":1,"ites":1,"needles":4,"ages":2,"types":5,"leaner":1,"limbs":1,"truncal":1,"s188":1,"buttocks":1,"lon":1,"ger":1,"lipohypertrophy":1,"accumulation":1,"sponse":1,"adipogenic":1,"actions":4,"lipohyper":1,"trophy":1,"soft":1,"smooth":1,"centimeters":1,"breadth":1,"erratic":1,"jection":1,"injecting":1,"vice":4,"tech":1,"nique":1,"holds":2,"noninsulin":23,"adjuncts":2,"naturally":1,"amylin":1,"sustainably":1,"residual":10,"preservation":5,"lir":3,"aglutide":3,"retrospective":16,"ries":3,"pilot":4,"revealed":3,"benefits":27,"tri":2,"als":9,"sglt1":4,"sotagliflozin":3,"sotagliflo":1,"zin":3,"eightfold":1,"indica":4,"excluded":2,"individu":10,"mitigation":13,"inhib":2,"itors":1,"adjunctive":6,"selec":1,"cautions":3,"pies":3,"prolon":2,"gation":2,"teplizumab":3,"verapamil":1,"menin":1,"janus":1,"kinase":12,"antithymocyte":1,"globulin":1,"monoclonal":1,"antibodies":3,"cur":3,"rently":2,"pancreas":9,"islet":4,"successful":7,"transplanta":1,"normalize":1,"miti":1,"gate":2,"receiving":27,"immunosup":2,"pression":2,"graft":3,"rejection":3,"recurrence":5,"autoimmune":4,"destruc":2,"immunosuppressive":4,"pancre":2,"ype":4,"reserved":11,"undergoing":14,"recurrent":8,"poglycemia":8,"optimized":3,"allogenic":1,"lated":3,"transplant":17,"regulated":2,"allogeneic":1,"donislecel":1,"jujn":1,"repeated":2,"epi":3,"sodes":2,"inten":2,"offers":2,"s189":1,"suffi":1,"shorten":2,"atheroscle":1,"rotic":1,"cotrans":1,"porter":3,"ir":5,"9a":2,"symptomatic":24,"ure":3,"pres":4,"9b":1,"irre":1,"spective":3,"confirmed":3,"filtration":4,"benefit":24,"slowing":3,"gly":17,"cemic":14,"tinued":1,"stea":2,"totic":2,"masld":7,"mash":15,"mpl":1,"view":1,"balancing":1,"incapacitating":2,"exogenous":2,"donor":2,"tr":10,"intact":1,"replace":5,"plantation":2,"gfr":5,"s190":1,"versa":2,"tailor":1,"significant":22,"identified":5,"measurement":13,"confirm":2,"symptom":2,"listed":11,"decompensated":6,"cirrhosis":3,"incorporating":3,"artery":7,"indicators":3,"definitions":2,"comprise":2,"recommendation":21,"weaker":2,"share":1,"sglt2is":5,"demonstrate":4,"repeat":1,"maximally":9,"mitigating":1,"differently":1,"variably":1,"diagnostic":10,"left":13,"prioritizes":2,"manag":2,"gure":1,"angiotensincon":1,"verting":1,"filtra":1,"steatotic":1,"s191":2,"diabetesjourna":1,"etermi":1,"multifaceted":3,"accounts":1,"modifications":5,"empha":2,"sized":4,"along":9,"ications":1,"efits":3,"13a":1,"biopsy":4,"fibrosis":9,"noninvasive":4,"ferred":6,"13b":2,"uated":1,"af":10,"deintensification":2,"sul":4,"fonylureas":4,"pep":2,"tidase":2,"alized":1,"tensification":1,"abolic":1,"ini":3,"tiation":1,"perglycemic":1,"crisis":2,"tiveness":6,"upon":9,"tinue":1,"unless":12,"fits":2,"cologic":3,"guided":5,"encounters":2,"aides":2,"sha":1,"discussions":3,"ele":1,"vated":1,"condi":4,"s192":1,"slow":5,"extended":15,"formula":1,"replete":1,"canagliflozin":8,"empagliflozin":8,"dapagliflozin":3,"ertugliflozin":4,"labels":7,"discontinue":8,"promptly":8,"pected":2,"predis":2,"posing":2,"presentations":3,"sched":2,"uled":2,"urosepsis":1,"pyelonephri":1,"tis":3,"tract":5,"necrotizing":1,"fasciitis":1,"perineum":1,"fournier":1,"gangrene":1,"intravascular":1,"deple":1,"ill":26,"fast":5,"contracting":1,"appli":1,"cable":1,"s194":2,"s193":1,"initiat":1,"escalating":1,"fied":1,"rele":2,"vance":1,"discon":2,"tinuation":2,"aspiration":6,"anesthesia":4,"deep":2,"sedation":2,"pancrea":2,"titis":2,"causality":4,"pancreati":2,"dise":1,"dation":2,"chole":1,"lithiasis":1,"cholecystitis":1,"ileus":1,"nonarteritic":1,"anterior":1,"ische":1,"optic":1,"naion":1,"inci":3,"examinations":2,"orally":2,"sorption":1,"includ":5,"contraceptives":1,"counsel":1,"stop":13,"esca":2,"lating":1,"s195":2,"titra":1,"gastroparesis":2,"postmarketing":1,"discontinuing":3,"debilitating":1,"bullous":1,"pemphigoid":1,"reversible":1,"fluid":7,"cumulative":3,"yes":2,"glipizide":3,"conservatively":1,"warning":3,"tolbutamide":1,"uals":7,"s196":2,"titrate":8,"instructions":2,"compatible":2,"patches":1,"gastro":1,"intestinal":1,"dys":2,"informing":1,"historically":1,"widely":2,"principal":7,"intolerance":7,"bloating":1,"discomfort":1,"diar":1,"rhea":1,"cleared":1,"circulating":1,"overdose":1,"lac":1,"tic":1,"acidosis":12,"occurrence":3,"glo":1,"merular":1,"heightens":1,"lactic":4,"vi":1,"tamin":1,"effi":3,"clas":1,"head":9,"lect":3,"sulted":2,"reductio":1,"compara":1,"si":3,"tagliptin":1,"significantly":5,"obser":1,"vational":1,"emulated":1,"agliflozin":1,"liptin":1,"cessibility":2,"catabolic":2,"polyuria":5,"polydipsia":4,"ev":5,"idence":4,"unexpected":2,"toxicity":4,"resolves":2,"hypergly":5,"specifically":1,"favor":1,"tra":1,"ditional":3,"called":2,"inhibi":5,"tor":3,"incorporation":4,"purposeful":1,"alignment":3,"deintensifi":2,"nonin":3,"efit":1,"potency":2,"log":1,"already":19,"inject":3,"analyzing":2,"addit":1,"effica":1,"cies":1,"s197":1,"conversion":3,"then":14,"proceed":2,"choose":1,"ppg":5,"signals":2,"ization":2,"reinforcement":1,"provision":1,"develops":4,"forgets":1,"steroid":7,"induced":16,"possibility":7,"polypep":2,"s198":1,"tensive":3,"intensified":2,"instan":1,"rea":1,"sons":5,"ineffectiveness":1,"intolerable":2,"velopment":2,"medicatio":1,"ffectiveness":1,"cussion":1,"optimization":4,"style":2,"logic":3,"ential":1,"deescalation":1,"tablished":1,"indivi":1,"ceiving":3,"preferential":1,"iabetes":7,"suggests":5,"slowed":2,"kidneys":3,"elimination":2,"clearance":5,"flozin":1,"documented":5,"anal":2,"ysis":3,"glime":2,"piride":2,"mono":4,"econdary":1,"s199":1,"declines":4,"hence":1,"accruing":1,"creasing":4,"resolu":1,"fit":1,"histological":1,"subsequently":1,"mod":1,"await":1,"confirmation":1,"thiazolidine":2,"diones":2,"judiciously":1,"semaglu":1,"dopamine":4,"bile":5,"sequestrants":2,"unavailable":2,"bypass":1,"sleeve":1,"gastrectomy":2,"leeve":1,"eventu":1,"plained":1,"threat":2,"describing":1,"sign":3,"sonal":4,"overcomes":1,"situa":1,"glucocorticoid":11,"emphasized":4,"educating":1,"volving":1,"instruction":2,"glucos":1,"contingency":1,"unavailabil":1,"convenient":8,"restrain":2,"limit":8,"gluc":2,"zed":1,"glar":1,"gine":1,"noctur":1,"nal":5,"convert":1,"natives":1,"removal":2,"market":1,"converted":2,"subse":1,"quently":1,"tight":11,"masking":1,"insufficient":4,"s200":1,"overbasali":1,"ferential":2,"basali":1,"reevaluation":3,"ceptable":1,"advancement":1,"intensificat":1,"entails":1,"pran":3,"dial":7,"natively":1,"desired":5,"administering":5,"feasi":2,"disadvan":1,"eat":4,"irregular":2,"schedules":5,"otherwise":2,"hand":2,"ility":1,"means":4,"spreading":1,"formu":1,"lations":1,"alternatives":1,"resistant":3,"meaningful":2,"additions":2,"tiating":1,"ication":1,"sulfo":3,"nylureas":1,"initi":2,"justments":1,"codynamic":4,"simplify":2,"deintensify":2,"comfortable":1,"effort":4,"concen":1,"trated":1,"defi":1,"blunted":1,"longed":1,"centrated":1,"lis":4,"lispro":11,"aabc":3,"cokinetics":1,"counterparts":1,"prefilled":6,"vials":3,"errors":13,"syrin":1,"ges":1,"cutaneous":5,"adminis":6,"tration":5,"variation":2,"yond":1,"programmable":1,"bo":1,"lus":1,"monomers":2,"faster":6,"thos":1,"orrection":1,"s201":1,"cline":1,"forced":1,"expi":1,"ratory":1,"fev":1,"asthma":1,"smoke":1,"spirometry":1,"vant":1,"preventing":16,"ilitating":1,"gluca":1,"gon":2,"iner":1,"tia":5,"anytime":1,"thereafter":2,"apies":1,"overbas":1,"alization":2,"occurrences":2,"lor":2,"giver":1,"fam":2,"ily":1,"personnel":2,"others":4,"location":1,"ister":1,"reconstitution":3,"routinely":6,"obstacles":1,"impede":1,"collabora":3,"tively":1,"thereby":3,"kidne":1,"vide":4,"landscape":1,"rapidly":3,"encounter":3,"determining":4,"guid":1,"reconstitu":1,"noninsu":1,"dramatically":1,"passed":1,"ilies":1,"infor":1,"mation":1,"prices":5,"wholesale":4,"awp":6,"acquisition":4,"nadac":7,"actual":2,"s202":1,"incurred":1,"median":8,"monthly":3,"maximum":7,"compound":1,"biguanides":1,"sol":3,"xl":4,"micronized":1,"miglitol":2,"meglit":1,"nateglinide":1,"repaglinide":2,"bexagliflozin":1,"tablet":1,"041":1,"sequestrant":3,"tabs":1,"suspension":1,"bromocriptine":2,"riptine":1,"solution":4,"calculated":10,"supply":3,"calculate":3,"generic":1,"caps":4,"pocket":3,"medicare":3,"commercial":4,"live":1,"district":1,"columbia":4,"legislation":1,"payment":3,"ditionally":3,"copayment":2,"assistance":4,"variab":1,"eligibil":1,"payments":1,"degrees":1,"deductible":1,"incur":2,"expenses":1,"exist":2,"equipment":5,"screen":3,"s203":1,"certified":1,"munity":1,"para":1,"medics":1,"31a":1,"compounded":4,"cerns":1,"31b":1,"shortage":3,"specified":2,"compounds":1,"cartridge":2,"biosimilars":1,"glulisine":4,"cartridges":2,"prefille":1,"073":1,"quisition":1,"unbranded":1,"box":1,"walmart":1,"pricing":1,"xjhz":1,"s204":1,"unavailability":1,"struggle":1,"plies":1,"recalls":1,"marked":7,"mand":1,"latter":3,"circumstance":4,"signaled":1,"inclusion":5,"shortages":3,"compounding":3,"pharmacies":1,"outsourcing":1,"copies":1,"essentially":1,"duplicates":1,"concerning":2,"incre":1,"tin":2,"emerged":2,"salt":1,"ingredient":1,"humans":1,"incorpora":1,"ingredients":1,"b6":2,"prod":2,"ucts":2,"nonstandard":2,"concentra":2,"labeling":3,"emergence":1,"coun":4,"terfeit":1,"pounded":1,"becomes":1,"reas":1,"resuming":1,"priorities":5,"31c":1,"unavail":1,"propriateness":1,"original":3,"32a":1,"childbearing":5,"counseled":7,"32b":2,"preconception":4,"frame":3,"preparation":1,"munotherapy":1,"l1":2,"nivolumab":2,"pembrolizumab":1,"avelumab":2,"ketoacido":2,"immunotherapy":2,"mtor":3,"35a":1,"phosphoinositide":3,"pi3k":8,"hibitors":8,"isoform":3,"alpelisib":6,"inavolisib":5,"35b":2,"cris":1,"posttransplantation":8,"ptdm":8,"preexisting":6,"38a":1,"preexist":1,"cotherapy":2,"transplanted":1,"38b":1,"preex":1,"38c":2,"ketone":4,"hydroxybutyrate":3,"discourage":1,"pregnant":4,"intention":1,"pregnancies":1,"unplanned":1,"formation":1,"traception":2,"diminishes":1,"contin":4,"ued":3,"s205":1,"lesser":3,"hypertensive":4,"sev":2,"chemotherapy":5,"transie":1,"permanent":2,"immune":3,"checkpoint":3,"icis":1,"immuno":1,"genic":1,"cells":4,"toxicities":1,"destruction":2,"programmed":1,"pem":1,"brolizumab":1,"grammed":1,"ligand":1,"durvalumab":1,"cytotoxic":1,"lymphocyte":1,"ctla":1,"ipilimumab":1,"implicated":1,"cornerstone":2,"py":1,"vent":4,"drastic":1,"takes":2,"ici":1,"irreversible":1,"phosphatidylinositol":4,"molecules":1,"intracellular":1,"signaling":2,"interfering":2,"proliferation":1,"survival":6,"isoforms":1,"panlisib":2,"duvelisib":2,"appr":1,"discontinua":1,"negatively":1,"hyperglyce":5,"uptitration":2,"toler":1,"resort":1,"reactivate":1,"teracting":1,"antitumor":2,"uncertain":4,"pi3":1,"nau":1,"sea":1,"everi":1,"lomus":1,"sistance":1,"refractory":3,"intol":2,"erance":2,"glucocorticoids":10,"prednisone":3,"dexamethasone":5,"inflam":1,"matory":1,"rheumatoid":2,"thritis":1,"inflammatory":1,"bowel":1,"counterregulatory":3,"epinephrine":1,"intravenous":20,"intraarticu":1,"starts":2,"rising":3,"trast":2,"dexametha":2,"sone":2,"elevations":2,"elevation":2,"ta":10,"pered":1,"s206":1,"solely":4,"miss":1,"cocorticoid":2,"glucocorti":2,"coid":1,"depends":4,"dura":1,"chronically":1,"cystic":3,"classification":4,"relies":1,"unique":1,"immunosuppressant":3,"ogtt":4,"3rd":1,"pretransplant":2,"waitlist":2,"nose":2,"onward":2,"mainstay":1,"passive":2,"allograft":5,"recipients":8,"caviar":1,"lifestyles":1,"statistically":4,"mass":4,"index":13,"halved":1,"find":1,"imme":5,"diate":2,"sta":3,"precau":2,"increas":1,"diately":3,"dergone":1,"sample":2,"sizes":1,"bias":5,"designs":1,"majority":9,"undergone":1,"pharmacotherapeutic":2,"physiology":2,"bu":1,"cau":1,"fluctu":1,"ating":2,"cardiac":21,"vasculopathy":2,"malig":1,"nancy":2,"infection":8,"tality":5,"posttrans":1,"plant":2,"concern":4,"interaction":2,"immunosuppressants":1,"cessitate":1,"additive":2,"immunosuppres":1,"sants":1,"recip":1,"ients":1,"gastroesophageal":3,"reflux":1,"dam":1,"ideal":3,"genitourinary":2,"fection":1,"immunosuppressed":1,"nate":2,"anatomical":2,"utis":2,"posttransplant":5,"ureteral":2,"stent":2,"s207":1,"endocri":2,"nologists":1,"collaboratively":1,"delete":1,"rious":1,"maturity":2,"hnf1a":2,"hnf4a":1,"mutations":1,"muta":1,"var":1,"iability":1,"neonatal":1,"kcnj22":1,"abcc8":1,"ins":1,"gata6":1,"eif2ak3":1,"foxp3":1,"deficient":1,"hibitor":7,"oc":2,"curs":2,"tha":1,"excessive":3,"alcohol":6,"precipitating":1,"accu":2,"guidan":1,"edic":3,"bebu":3,"memory":1,"influence":1,"rig":2,"devries":3,"tricco":1,"ashoor":1,"antony":1,"g5459":1,"bartley":1,"bogoev":1,"philotheou":1,"hagedorn":4,"little":1,"s53":1,"s64":2,"aronson":4,"biester":1,"leohr":1,"humalog":3,"pieber":7,"danne":4,"erichsen":2,"haahr":4,"pharmacology":2,"investigating":5,"pharmacokinet":3,"mcgill":4,"lorber":1,"gross":1,"jl":15,"chang":4,"bregman":1,"affinity":1,"technosphere":2,"russell":6,"block":1,"klaff":1,"cao":4,"dellva":1,"pronto":1,"lane":1,"gerety":3,"bolli":4,"edition":2,"yeh":1,"tt":2,"choudhary":3,"wilmot":1,"e14944":1,"tzivian":1,"sokolovska":1,"grike":1,"ae":6,"qualitative":1,"qual":6,"mulinacci":1,"alonso":2,"gt":3,"snell":5,"bergeon":5,"vn":3,"elbalshy":2,"haszard":2,"divergent":2,"e14854":1,"champakanath":1,"akturk":3,"hessler":1,"ruedy":2,"diamond":1,"klonoff":4,"garg":12,"sk":11,"aspire":1,"forlenza":2,"gp":6,"buckingham":2,"ba":3,"crossover":10,"prolog":2,"kovatchev":3,"raghinaru":5,"idcl":5,"collyns":1,"oj":3,"betts":1,"zl":1,"s208":1,"minimed":4,"breton":1,"iq":2,"peacock":1,"frizelle":1,"hussain":2,"kolassa":1,"keuthage":1,"arunachalum":1,"velado":1,"vigersky":4,"cordero":1,"tl":5,"grunberger":4,"weinstock":1,"pediatric":4,"hcl":1,"damiano":2,"bionic":2,"stahl":1,"pehe":1,"shokri":1,"mashhadi":1,"wirth":1,"outpatient":8,"eclinicalmedicine":3,"burnside":1,"crocket":1,"continuation":2,"lepore":2,"rossini":1,"bellante":1,"780g":4,"achieves":2,"acta":6,"matejko":3,"juza":2,"kie":3,"wilk":3,"transitioning":6,"isganaitis":1,"ambler":1,"osborn":1,"carlson":5,"galindo":11,"tandem":1,"medicaid":3,"lal":2,"maahs":1,"mitsui":1,"kuroda":1,"ishizu":1,"castellano":2,"attanasio":2,"giagulli":2,"associazione":2,"medici":2,"endocrinologi":2,"ame":2,"outpatients":2,"disord":7,"kuku":1,"ka":4,"klupa":1,"malecki":2,"mt":6,"glycaemia":3,"nightly":1,"lafell":1,"laffel":3,"lmb":1,"hlhauser":1,"bender":1,"hunger":1,"dathe":1,"kloos":1,"ller":2,"ua":2,"builes":2,"monta":2,"ortiz":4,"cano":2,"ramirez":2,"rinc":2,"rojas":2,"henao":2,"hum":2,"balwi":1,"madani":2,"ghamdi":1,"algorithms":9,"dafne":2,"enable":1,"lawrence":8,"mansell":2,"amiel":2,"bruttomesso":1,"boscari":1,"slide":2,"rule":1,"trend":3,"arrows":2,"silico":1,"aleppo":2,"ahmann":3,"g5":1,"endocr":38,"xing":1,"weinzimer":1,"direcnet":1,"freestyle":2,"parise":1,"molfetta":1,"graziano":1,"rt":3,"environ":2,"petrovski":2,"campbell":2,"pasha":2,"announcement":2,"precise":3,"turrin":1,"kb":5,"trujillo":2,"ro":2,"wolff":1,"cavanaugh":1,"rothman":1,"spectr":3,"sacks":4,"arnold":3,"e151":2,"e199":2,"berard":3,"franco":2,"mayo":5,"proc":3,"strock":2,"peremislov":2,"gibney":2,"parvu":2,"hirsch":7,"4mm":2,"ling":2,"oncotarget":1,"meng":2,"liang":1,"hao":1,"e2983":1,"petrie":2,"chaturvedi":1,"ford":1,"hemmingsson":1,"ahr":4,"ib":4,"capped":2,"subjects":11,"herrath":1,"il":1,"interleukin":1,"antibody":2,"kaur":2,"haider":1,"rodriquez":1,"beatson":2,"s209":1,"pasqua":1,"tsoukas":2,"kobayati":1,"aboznadah":1,"jafar":1,"haidar":1,"dong":3,"karakus":1,"proof":3,"concept":4,"kruger":2,"nejm":2,"evid":2,"evidoa2500173":1,"biotechnology":3,"clinicaltrials":5,"t1":1,"disco":1,"nct05819138":1,"tab":1,"rt1d":2,"nct05822609":2,"ional":1,"alleviating":1,"sma":1,"nct06387199":1,"complicating":1,"analogue":4,"nct06411210":1,"rao":4,"ren":2,"huang":7,"zheng":1,"adjuvant":1,"e20875":1,"introductory":1,"remarks":1,"endocrinologic":2,"wayback":1,"archive":1,"20190207212714":1,"downloads":1,"advisorycommittees":1,"committeesmeeting":1,"materials":1,"endocrinologicandmetabolicdrugs":1,"advisorycommittee":1,"ucm629782":1,"herold":1,"kc":2,"bundy":1,"trialnet":1,"cd3":1,"relatives":1,"mcgee":1,"kosheleva":1,"koshelev":1,"lagunas":1,"rangel":1,"levit":1,"rabinovitch":1,"schi":1,"hb":1,"molecular":1,"checkpoints":2,"combinatorial":1,"dean":2,"kukla":3,"stegall":1,"kudva":2,"yc":2,"j1321":1,"lantidra":1,"vaccines":8,"geta":2,"terefa":2,"hailu":2,"plos":5,"e0306296":2,"coll":12,"tidra":1,"lang":2,"wadden":3,"ai":5,"leal":1,"whiteley":1,"clarke":1,"balasubramanian":2,"vg":2,"paul":5,"haw":2,"bahardoust":1,"mousavi":1,"yariali":1,"nm":4,"tseng":2,"hutfless":1,"paletas":1,"e1369":2,"revises":3,"salpeter":1,"greyber":1,"pasternak":1,"ee":4,"fatal":1,"nonfatal":17,"cd002967":1,"lipska":4,"insufficiency":1,"outcom":5,"olled":1,"sorli":1,"harashima":1,"balasubramanyam":2,"babu":2,"mehta":6,"guerrero":2,"emergency":14,"discharge":24,"pete":1,"ring":1,"eagle":1,"s210":1,"s137":1,"s145":1,"triplitt":1,"lez":3,"bennett":3,"wl":3,"maloney":2,"fonseca":5,"nett":1,"lajthia":1,"bucheit":1,"nadpara":1,"pa":22,"violante":1,"oliveira":1,"jha":1,"e417":1,"e424":1,"kahle":2,"baranov":1,"deacon":1,"holst":2,"amod":2,"hoff":2,"liragluti":1,"ide":3,"kwan":2,"aym":1,"levin":1,"wittbrodt":1,"abd":1,"aziz":1,"benroubi":2,"zimmermann":2,"pechtner":2,"ffects":1,"cariou":3,"naive":4,"sreenan":1,"diamant":2,"gaal":1,"stranks":6,"zile":1,"borlaug":1,"tuttle":3,"kr":4,"flow":5,"deanfield":1,"mildly":3,"mccoy":8,"houten":2,"departme":1,"e1919099":1,"herrin":3,"swarna":1,"ks":3,"berg":2,"scirica":4,"stratification":1,"kdigo":6,"s127":1,"rth":3,"jhund":6,"ps":12,"friedman":2,"nephrol":10,"022200s026lbl":1,"sanofi":2,"soliqua100":2,"scheen":2,"chroni":1,"reyes":4,"farias":1,"reategui":1,"romani":1,"prokop":1,"e0295059":1,"herrington":2,"wg":2,"staplin":3,"cherney":5,"dzi":3,"ran":8,"e002484":1,"tikkanen":1,"contrasting":1,"influences":1,"boer":3,"ih":2,"ghosh":2,"s211":1,"belfort":1,"harrison":2,"kliers":1,"essence":1,"lawitz":1,"synergy":1,"ndez":2,"gaunt":2,"aithal":2,"sathyanarayana":1,"jogi":1,"muthupillai":1,"krishnamurthy":1,"samson":40,"migahid":1,"megahed":1,"ozairi":1,"jayyousi":1,"beta":6,"produces":1,"qatar":1,"lavynenko":1,"alatrach":1,"tria":1,"tinahones":3,"nn8022":1,"capehorn":1,"charpentier":1,"schauer":2,"kirwan":2,"merilainen":1,"karwe":1,"raskin":1,"lucidi":1,"candeloro":1,"cioli":1,"equivalent":3,"hedrington":1,"gogitidze":1,"joy":1,"semlitsch":1,"engler":1,"siebenhofer":3,"jeitler":3,"berghold":2,"horvath":2,"isophane":2,"cd005613":4,"contr":1,"rane":1,"niemeyer":1,"goldenberg":6,"katselnik":1,"kuritzky":2,"cowart":1,"hesitancy":1,"companions":2,"hw":12,"visco":3,"hiort":3,"shu":3,"dhw":2,"boluses":3,"fullstep":3,"mccall":2,"fullerton":1,"persons":61,"cd013228":1,"morrow":3,"pharmacodynamics":2,"borra":1,"fan":1,"pollom":1,"humulin":1,"becker":1,"rha":1,"dahmen":1,"bergmann":1,"lehmann":1,"jax":1,"yki":6,"rvinen":3,"yea":2,"ziemen":1,"korsatko":1,"deller":1,"koehler":1,"seger":1,"bio":1,"equivalence":1,"pharmacodyna":1,"mics":2,"dev":2,"gentile":4,"fusco":2,"colarusso":2,"effic":1,"armacodyna":1,"saf":5,"grant":5,"baughman":1,"rewers":1,"stat":1,"hoogwerf":2,"bj":7,"pantalone":1,"km":3,"basina":1,"kendall":1,"deng":3,"kipnes":2,"chesser":2,"srinivasan":2,"gitelm":1,"gitelman":1,"wong":4,"willis":1,"hj":5,"df":1,"karslioglu":1,"french":1,"steenkamp":1,"dw":3,"rando":1,"s212":1,"battelino":1,"lalic":1,"chu":2,"flash":6,"agarwal":5,"varghese":1,"savian":1,"cc":1,"moving":1,"dijk":2,"bouma":2,"landman":2,"elderly":4,"tamborlane":1,"wv":1,"juvenile":1,"bibby":1,"diurnal":1,"urakami":1,"yoshida":2,"kuwabara":1,"scanning":3,"contributes":3,"kanapka":1,"lg":2,"teens":1,"city":1,"ajjan":4,"pfeiffer":2,"afh":2,"freckmann":2,"gladis":2,"gubitosi":1,"klug":1,"braffett":1,"teo":3,"hassan":1,"tam":1,"koh":1,"phillip":1,"nimri":1,"clc":3,"plgs":2,"gies":1,"pasquel":6,"huffman":1,"omnipod":1,"secure":1,"e2459348":1,"bhargava":2,"warren":3,"impact2d":1,"minimedtm":1,"lum":1,"jw":6,"2iqp":1,"valentine":1,"newswanger":2,"prestrelski":2,"andre":2,"garibaldi":2,"usability":2,"autoinjector":3,"simulated":2,"rescue":2,"settles":2,"gf":2,"spaepen":2,"suico":2,"child":2,"nasal":2,"herges":3,"neumiller":4,"heien":2,"benning":1,"tj":3,"creo":1,"nofal":1,"fill":1,"herman":3,"elephant":1,"merative":1,"redbook":1,"electronic":8,"micromedexsolutions":2,"healthdata":2,"dataset":2,"3tha":2,"57c6":2,"kang":1,"sohn":1,"patel":7,"piette":1,"resnicow":1,"kowalski":1,"dobson":1,"heisler":1,"interview":1,"survey":5,"senior":4,"savings":2,"cms":1,"models":6,"baig":1,"fry":1,"buntin":1,"dusetzina":1,"spending":1,"sponsored":1,"e14656":1,"copay":2,"suran":2,"cutting":2,"here":4,"essed":1,"easing":1,"dps":1,"drugshortages":1,"ashraf":1,"mackey":1,"tk":3,"schmidt":1,"purchases":1,"e2428280":1,"alerts":6,"compounders":2,"lambson":2,"flegal":2,"johnson":5,"poi":1,"poison":1,"warns":1,"consumers":1,"counterfeit":1,"ozempic":2,"chain":1,"whitley":1,"hp":1,"urva":1,"coskun":1,"loghin":1,"transiently":2,"delays":2,"selective":4,"skelley":2,"swearengin":2,"york":6,"glover":4,"hormonal":1,"e204":1,"s213":1,"handles":1,"birth":1,"pills":2,"nct04172987":1,"215866s000lbl":1,"barroso":1,"tolaney":1,"hodi":1,"fs":1,"kaiser":2,"ub":1,"xue":1,"immunol":2,"barry":1,"garrido":1,"castro":1,"oncol":4,"e79":2,"e80":2,"mulla":2,"farag":2,"moore":3,"aetiology":2,"assessme":1,"e15053":1,"byun":1,"braunstein":1,"flynn":1,"naidoo":1,"santomasso":1,"asco":1,"goncalves":2,"cantley":1,"growth":1,"andr":2,"ciruelos":1,"rubovszky":1,"solar":3,"pik3ca":2,"mutated":2,"hormone":2,"breast":3,"juric":1,"fulvestrant":2,"epidermal":1,"final":2,"rugo":2,"yamashita":2,"alpel":1,"jhaveri":1,"saura":1,"weintraub":1,"garcia":1,"characterization":1,"akt":2,"gallagher":1,"lacouture":1,"rash":1,"delphi":5,"npj":1,"ihle":1,"lemos":1,"schwartz":3,"peroxisome":1,"proliferator":1,"activated":1,"gamma":1,"prevents":2,"px":1,"affecting":1,"borrego":2,"cosmelli":2,"animal":2,"bylieve":2,"farooki":1,"integr":1,"15347354211073163":1,"cheung":1,"mcdonnell":1,"hamnvik":1,"mammalian":3,"rapamycin":3,"probl":1,"khan":8,"kh":1,"rihawi":1,"oncologist":1,"busaidy":2,"nl":5,"dowlati":1,"anticancer":1,"nowak":1,"rdzanek":1,"pikus":1,"romanowska":1,"chnicka":1,"nowakowska":1,"aza":1,"papierska":1,"rheumatology":2,"kulkarni":2,"systemic":3,"corticosteroid":2,"e061476":1,"perez":3,"jansen":1,"chaparro":1,"saigi":1,"bernal":1,"lopez":2,"ambres":1,"huelgas":2,"elena":2,"chiara":1,"angelica":1,"nondiabetic":1,"revision":1,"biotechnol":1,"burt":5,"roberts":6,"aguilar":5,"loza":5,"nr":10,"frith":3,"sn":7,"circadian":3,"prednisolone":6,"copd":3,"karam":1,"e930733":1,"wallace":1,"metzger":2,"limbachia":2,"nunney":2,"corticosteroids":3,"capillary":5,"hosp":5,"inpatients":3,"e59":1,"e63":1,"hydrocortisone":1,"lond":1,"dhatariya":3,"british":9,"societies":6,"jbds":5,"gerards":1,"maar":1,"steenbruggen":1,"tg":9,"hoekstra":1,"jbl":1,"vriesendorp":1,"tm":7,"gerdes":1,"vea":1,"sliding":4,"cyclic":1,"containing":6,"antineoplastic":1,"drake":3,"esterman":2,"protocol":20,"rossover":1,"joharatnam":1,"hogan":1,"chambers":1,"ukcb":1,"e14636":1,"pietruck":1,"dolff":1,"ode":1,"ballman":1,"battezzati":1,"ispad":2,"kurnikowski":2,"nordheim":1,"schwaiger":3,"accuracy":8,"sharif":2,"chakkera":2,"vries":2,"apj":2,"kuningas":2,"driscoll":2,"mair":2,"glycaemi":1,"ransplant":1,"hecking":1,"haidinger":1,"krenn":1,"chandra":1,"pooniya":1,"transpl":1,"bandur":1,"nuernberger":1,"gliquidone":1,"lo":3,"toyama":1,"treating":6,"cd009966":2,"chandran":2,"sweet":2,"syrup":2,"s214":1,"e14922":1,"munoz":2,"pena":1,"developments":2,"e11":1,"ram":1,"lavee":1,"tenenbaum":1,"vest":1,"koraishy":1,"registry":1,"pharmacy":6,"e13302":1,"abdelaziz":1,"ay":5,"fatthy":1,"thangavelu":1,"lyden":1,"shivaswamy":1,"merzkani":2,"glp1r":2,"ptor":1,"e524":1,"pesavento":1,"washburn":1,"walsh":1,"liou":1,"glucagonlike":1,"vigara":1,"villanego":1,"orellana":1,"e14633":1,"sweiss":1,"zeilmann":1,"zelada":1,"campana":1,"kawai":1,"e70144":2,"jung":3,"ch":5,"insul":2,"orandi":1,"wu":5,"diker":1,"rudman":1,"turjeman":1,"dotan":1,"e121":2,"e128":2,"sammour":2,"nassif":3,"magwire":2,"kwon":3,"jeon":1,"e404":1,"e412":1,"burghart":1,"signorini":1,"halden":1,"tas":1,"kvitne":1,"midtvedt":1,"mahling":1,"schork":1,"nadalin":1,"fritsche":1,"heyne":1,"guthoff":1,"virani":1,"rajput":1,"nchez":3,"fructuoso":2,"bedia":2,"raba":2,"banegas":4,"deras":2,"icacy":1,"greeley":1,"saw":1,"polak":1,"lstad":1,"christensen":3,"dersdal":1,"blinded":1,"glimlina":1,"elsayed":3,"wolfsdorf":1,"ratner":2,"extreme":5,"colacci":3,"fralick":6,"odutayo":3,"e2":3,"avogaro":1,"fadini":1,"blau":1,"tella":1,"rother":1,"ki":2,"faers":1,"dmrr":3,"s339":20,"s355":2,"s016":1,"nents":1,"description":1,"prac":6,"tice":5,"identification":2,"diagnosing":1,"perioperative":18,"transition":7,"scheduled":7,"appointments":4,"stays":2,"readmission":11,"perform":2,"dom":5,"admission":20,"puterized":2,"order":15,"entry":4,"sets":5,"gestational":1,"creatogenic":1,"enteral":11,"undiagnosed":4,"dc26s016":19,"pread":1,"mission":4,"stay":11,"recognition":3,"resid":1,"homes":2,"institutional":3,"tings":1,"obtained":1,"accordingly":7,"actionable":2,"computerized":5,"cpoe":2,"recommends":5,"spent":1,"fea":1,"sible":1,"specialty":4,"length":8,"attributed":2,"ined":1,"saved":1,"sectional":3,"vided":3,"virtual":2,"service":5,"chart":1,"ehr":9,"charge":1,"cess":1,"supplies":4,"nutritionists":2,"accreditation":2,"ciety":2,"workbook":2,"leapfrog":2,"brit":1,"ish":1,"inpa":3,"tient":6,"caring":3,"consult":3,"specialized":3,"abnormal":2,"preceded":1,"stratified":1,"gories":1,"concentration":4,"neuroglycopenic":2,"tioning":1,"signifi":1,"4a":1,"tensified":1,"firmed":1,"occasions":1,"icu":9,"4b":1,"noncritically":5,"5a":3,"ly":1,"5b":2,"berghe":2,"s340":1,"normoglycemia":1,"evalua":2,"regulation":1,"sugar":3,"icus":1,"failed":1,"replicate":1,"criti":1,"slightly":1,"intensively":1,"fold":3,"liberal":2,"parenteral":12,"separation":2,"remarkably":1,"necessitate":1,"lected":1,"terminally":1,"labile":1,"gressive":1,"judgment":5,"trajectory":1,"might":14,"corporated":1,"poc":9,"advised":8,"lucose":2,"calibrated":2,"monitors":1,"bedside":2,"curate":1,"analyzers":1,"cept":1,"instances":2,"compromised":7,"perfu":1,"edema":1,"ythrocytosis":1,"finger":1,"stick":1,"analytic":2,"interference":2,"simplicity":3,"uniformly":2,"solved":2,"arrived":2,"balanc":1,"etween":1,"workflow":2,"perfor":1,"mance":1,"reliability":1,"dictates":1,"correlate":3,"measuring":3,"hospitali":3,"confirmatory":2,"dos":3,"insti":2,"tutional":2,"couraged":2,"retrospec":1,"feasibility":4,"gration":2,"resulted":2,"satisfac":2,"modified":1,"teria":1,"criterion":1,"reading":2,"owned":2,"detecting":1,"recur":4,"rent":3,"coronaviru":1,"cularly":1,"s341":1,"enforcement":1,"cretion":1,"mote":1,"telemetry":2,"grown":1,"noncritical":7,"facilitation":1,"suc":1,"cessfully":1,"odic":2,"titrations":2,"hourly":2,"domized":6,"continua":1,"willing":1,"staff":4,"supervision":4,"chil":2,"dren":2,"satisfaction":9,"detection":5,"malfunction":1,"checking":1,"periodically":1,"valid":1,"dition":4,"velop":1,"knowl":1,"edge":1,"contingent":1,"neces":1,"competency":1,"indivdiuals":1,"sideration":1,"altering":2,"treatme":1,"emic":1,"infusions":2,"proto":1,"cols":1,"predefined":1,"fluctuations":1,"8a":1,"achiev":1,"8b":2,"noncriti":1,"sole":1,"supplemental":6,"formerly":2,"discouraged":2,"discontin":1,"rebound":4,"s342":1,"intra":4,"venous":5,"ularly":3,"meticulous":1,"supervi":1,"drawn":2,"ders":3,"correctional":7,"schedule":2,"formost":1,"culated":1,"sensi":1,"previ":2,"applies":2,"calculating":1,"glucotoxicity":1,"rectional":1,"scales":1,"propor":1,"medium":1,"code":4,"scan":1,"guar":1,"antee":1,"restart":1,"adoption":2,"admitted":3,"rection":1,"strongly":3,"exception":1,"mixture":1,"preadmis":1,"pharmacist":1,"correc":1,"caloric":4,"nothing":3,"mouth":3,"put":3,"prescriber":3,"pitalized":3,"ketonemia":2,"diuretic":7,"cardiology":23,"sultation":2,"s343":1,"ertu":1,"gliflozin":1,"safer":3,"discontinu":1,"worth":1,"noting":3,"medically":2,"acutely":3,"perience":3,"marker":3,"fatality":2,"conse":2,"quence":2,"dysregulated":2,"perative":2,"minimized":1,"preventable":3,"adopted":3,"immediately":4,"predicts":1,"sequent":2,"tracked":2,"orders":4,"talized":3,"missed":5,"incorrect":1,"tim":1,"iatrogenic":2,"improper":1,"inappropriate":1,"sode":2,"possibly":3,"ow":1,"sepsis":2,"malnutrition":1,"bundled":1,"ventive":1,"surveillance":2,"outliers":1,"aggregated":1,"sudden":1,"emesis":1,"inap":2,"dextrose":5,"paren":5,"teral":4,"feedings":4,"checks":1,"alert":3,"wearer":1,"impending":1,"offering":1,"opportunity":2,"happens":1,"swallow":2,"npo":1,"stabilized":4,"predicting":3,"episode":4,"terregulation":2,"preceding":4,"peaking":2,"midnight":1,"00":2,"dict":1,"valuable":2,"predictor":3,"s344":1,"calo":1,"demands":1,"creation":1,"dorse":1,"percentages":1,"macronutrients":1,"advise":2,"vidualization":2,"tray":1,"check":2,"triad":1,"creates":1,"possibil":1,"menu":2,"sat":2,"isfaction":2,"complicates":2,"stacking":2,"too":3,"nally":2,"pecially":1,"wearing":2,"successfully":1,"delirium":1,"agree":1,"dispensed":2,"ospitalization":1,"mined":1,"delineating":1,"sensors":1,"ferent":2,"ial":5,"tube":4,"feeds":1,"gorithm":2,"controlling":1,"tered":2,"interrupted":2,"feed":1,"feeding":3,"load":1,"ripheral":1,"justed":2,"bag":2,"safest":2,"glargi":1,"ously":1,"ingested":1,"s345":2,"febr":1,"steroids":4,"peaks":1,"concomitantly":2,"coids":1,"sometimes":3,"retro":2,"positively":3,"dosages":1,"predia":1,"postop":2,"erative":3,"somewhere":1,"preadmission":1,"elective":10,"preoperatively":1,"indicator":7,"lieu":1,"ade":2,"quate":2,"postponing":1,"denying":2,"perioper":2,"noncardiac":3,"stricter":3,"pol":2,"icies":1,"interprofes":1,"sional":1,"preopera":2,"sessment":1,"nonelective":1,"s346":1,"advises":1,"resolved":1,"reinitiating":1,"quiring":1,"justment":1,"covariates":3,"statisti":1,"agnosis":1,"icd":1,"anion":3,"gap":4,"abundance":1,"restarted":2,"resumed":2,"explained":2,"periop":1,"layed":2,"aspira":1,"chances":2,"holding":2,"wa":2,"pneumonia":2,"pneu":1,"monia":1,"anesthesiologists":4,"proce":1,"dure":1,"cieties":1,"stomach":2,"liquid":4,"tocol":2,"periopera":2,"indication":6,"urgency":1,"operative":2,"ultrasound":1,"quantify":1,"dyspepsia":1,"distension":1,"hold":5,"hyperosmolar":8,"hyperosmo":2,"hhs":10,"fluids":3,"electrolytes":3,"bridged":2,"su":10,"etic":1,"precipitat":1,"fected":1,"emergencies":4,"hospitaliza":4,"diagnoses":1,"vari":2,"inc":12,"concurrently":1,"21st":1,"century":1,"plateaued":1,"ranges":1,"s347":2,"countries":1,"discharged":4,"corrected":3,"pathways":2,"bohb":3,"considerable":2,"coma":1,"dks":1,"overlap":2,"yome":2,"withheld":2,"dropping":2,"alone0":2,"xefinitions":2,"meto6":1,"potassium":1,"nacl":2,"crystalloid":3,"osmolality":3,"drink":1,"transfer":1,"give":3,"05":7,"liter":2,"keep":2,"phosphate":3,"weakness":2,"compromise":1,"hemodynamic":1,"pressors":1,"hypovolemia":2,"hydration":3,"output":2,"naci":2,"alongside":3,"bicarbonate":3,"ketones":1,"mosm":2,"s348":1,"strip":1,"hyperosmolarity":1,"urea":1,"restora":1,"circulatory":1,"perfusion":1,"electrolyte":1,"aci":1,"dosis":1,"uous":1,"hyperketonemia":2,"disorder":2,"nous":3,"transi":1,"rises":1,"uncomplicated":1,"down":1,"icant":2,"nits":1,"depth":1,"reconciliation":2,"vir":1,"tual":1,"begin":6,"copresenting":1,"kussmaul":1,"respiration":1,"assis":2,"rehabilitation":2,"s349":1,"appointment":1,"usage":1,"summaries":2,"facilitates":2,"provid":2,"assist":5,"assume":2,"imum":1,"checked":1,"old":1,"prescriptions":3,"duplication":1,"brand":1,"names":1,"filled":1,"partners":2,"pending":2,"accurately":1,"mitted":1,"scheduling":2,"agreeing":2,"attend":2,"itted":1,"outpa":1,"injectables":1,"disposal":1,"ters":1,"lancets":1,"strips":2,"sors":2,"hiatus":2,"readmissions":4,"nearly":4,"implications":3,"male":1,"talizations":1,"readmis":1,"transitional":2,"laborative":1,"tiate":1,"just":5,"tate":2,"manageme":1,"lenging":1,"profes":1,"sionals":1,"advisories":1,"enhancements":1,"s350":1,"seisa":1,"mo":1,"saadi":1,"nayfeh":1,"isaacs":2,"bazargan":1,"you":3,"thaler":1,"kitabchi":2,"anzola":1,"e202":1,"e203":1,"smiley":3,"nanayakkara":1,"churilov":1,"e000113":2,"demidowich":3,"tschudy":2,"project":4,"sigma":2,"nassar":1,"montero":1,"magee":2,"davidson":5,"jain":2,"kazdan":1,"resnick":1,"scarabelli":1,"pandya":2,"kravchenko":1,"clerc":1,"aspden":1,"wolcott":1,"bootman":1,"cronenwett":1,"lr":3,"eds":1,"washington":2,"academies":1,"sly":1,"aw":2,"sullivan":4,"gianchandani":3,"wei":3,"itc177":2,"itc192":2,"aloi":2,"ullal":2,"nagement":1,"tanenberg":2,"hardee":1,"rothermel":1,"computer":1,"tertiary":2,"teaching":1,"akiboye":1,"sihre":1,"mulhem":1,"rayman":3,"nirantharakumar":1,"adderley":1,"e14573":1,"batty":1,"love":1,"haque":2,"wz":2,"sidhaye":1,"zilbermint":1,"bansal":1,"pawar":2,"e000460":2,"rushakoff":3,"alib":1,"macmaster":2,"baker":2,"wesley":1,"go":2,"enabled":1,"urban":1,"comm":3,"pinkhasova":3,"swami":2,"drincic":3,"akkireddy":2,"knezevich":2,"leapfroggroup":2,"hospitalists":2,"ww":1,"hospitalmedicine":1,"topics":4,"diabetologists":2,"abcd":12,"ip":1,"scheurer":1,"dake":1,"certification":1,"wouters":1,"weekers":1,"gunst":1,"debaveye":1,"iza":1,"tgc":1,"collaborators":1,"finfer":2,"chittock":2,"sy":3,"ors":1,"wiener":3,"larson":1,"adigbli":1,"hammond":1,"evidoa2400082":1,"furnary":1,"bookin":1,"portland":1,"magaji":1,"nayak":1,"donihi":1,"korytkowski":3,"muniyappa":1,"antinori":1,"lent":1,"murad":2,"coburn":2,"coto":2,"yglesias":2,"flory":1,"aleman":1,"jo":1,"furst":1,"seley":4,"inevitable":1,"dubois":1,"slingerland":1,"fokkert":1,"compliant":1,"crit":1,"isakow":1,"kollef":1,"scott":3,"performance":2,"modern":1,"meter":1,"paired":1,"misra":1,"avari":1,"lumb":1,"seav":2,"ongwela":2,"empowering":2,"fortmann":1,"spierling":1,"bagsic":1,"talavera":1,"fifth":1,"vital":2,"migdal":4,"libre":1,"satyarengga":1,"marcano":1,"wards":1,"s351":1,"spanakis":2,"urrutia":1,"olsen":1,"klarskov":1,"jensen":1,"diatec":1,"wallia":1,"prince":1,"touma":1,"muayed":1,"bridging":1,"elias":1,"g6":2,"faulds":1,"boutsicaris":1,"sumner":1,"e4007":1,"e4016":1,"giovannetti":1,"promotes":1,"efficiency":2,"enhances":1,"s1530":1,"ang":1,"yk":2,"schroeder":3,"lf":3,"jlv":1,"beach":2,"nnuru":1,"bally":1,"thabit":1,"hartnell":1,"owens":2,"courter":1,"schuler":1,"cl":4,"hornung":1,"lawson":3,"e2354595":1,"hamilton":2,"rajagopal":1,"ngo":1,"hendrix":1,"dicken":1,"mercer":1,"condren":1,"braithwaite":1,"clark":2,"lp":9,"idrees":1,"qureshi":1,"soetan":1,"ot":1,"kreider":1,"lien":1,"thammakosol":2,"sriphrapradang":2,"hsia":1,"seggelke":1,"gibbs":1,"ohn":1,"jeong":1,"seoul":1,"buehler":1,"zaw":1,"bena":1,"lansang":3,"bueno":1,"benitez":1,"rufinelli":1,"latin":2,"america":2,"xiang":2,"basa":1,"e001261":1,"veronesi":1,"poerio":1,"braus":1,"ismp":1,"default":2,"files":1,"attachments":1,"09":4,"ismp138d":1,"20guideline":1,"090718":1,"najmi":1,"waste":1,"maruoka":1,"wrong":2,"jacobs":2,"managemen":1,"rabbit":1,"fortin":1,"leung":2,"colunga":1,"lozano":2,"delgado":1,"figueroa":1,"cd011296":1,"bellido":1,"suarez":2,"vellanki":40,"khowaja":4,"u300":2,"carrasco":1,"gla":1,"insufficiently":1,"iv":4,"cobalta":1,"e001518":1,"tripathy":2,"palladino":2,"eberly":1,"emmons":1,"tannock":1,"mendez":1,"angermann":3,"empulse":3,"tamaki":2,"yamada":4,"watanabe":2,"toms":1,"decongestion":1,"e007048":1,"cunningham":1,"vaduganathan":2,"claggett":5,"salah":1,"aref":1,"voors":2,"teerlink":2,"ponikowski":1,"docherty":4,"kf":4,"s352":2,"apagliflozin":1,"pitalizations":1,"rasouli":1,"baldwin":1,"rubin":4,"sita":1,"schuman":3,"hurwitz":4,"bhandari":2,"e000394":2,"zger":1,"drugsafety":1,"ucm486096":1,"fushimi":1,"shibuya":1,"ito":1,"hachiya":1,"mori":1,"fayfman":1,"lake":1,"arthur":1,"davenport":1,"yamamoto":1,"turchin":2,"trivedi":2,"ilcewicz":2,"hn":2,"hennessey":2,"cb":5,"gregory":3,"gerber":2,"brillon":1,"lieb":1,"akirov":1,"grossman":1,"shochat":1,"shimon":1,"amori":1,"pittas":1,"siegel":1,"incidents":2,"voluntary":2,"error":3,"alwan":2,"chipps":2,"yen":2,"dungan":3,"administ":1,"heir":1,"siew":1,"od":3,"pratiwi":1,"mokoagow":1,"kshanti":1,"ia":2,"soewondo":1,"heliyon":1,"e03913":1,"maynard":1,"kulasa":1,"bundle":1,"milligan":1,"bocox":1,"pratt":1,"hoehner":1,"krettek":1,"dunagan":1,"wc":5,"rickels":2,"autonomic":2,"dendy":2,"chockalingam":2,"tirumalasetty":2,"ulmer":2,"kara":2,"mariash":2,"cn":2,"temporal":1,"walji":1,"kiss":1,"derivation":1,"prediction":2,"hydho":1,"mathioudakis":2,"everett":5,"routh":1,"e000499":1,"curll":1,"dinardo":1,"noschese":1,"mabrey":1,"setji":2,"flanagan":1,"kilvert":1,"kalangi":1,"bokka":1,"anand":3,"cd240103":2,"pb":2,"kohn":4,"rov":2,"ikpah":2,"olveira":1,"pez":1,"insupar":1,"aberer":1,"hochfellner":1,"sourij":1,"mader":1,"zale":1,"morgenlander":1,"wr":1,"abusamaan":1,"kleinhans":1,"albrecht":1,"benson":1,"fuhrer":1,"dissemond":1,"tan":1,"dermatologic":1,"alkhaddo":2,"rana":2,"fish":1,"hermayer":1,"thosani":1,"lavis":1,"cyclophosphamide":2,"doxorubicin":1,"vincristine":1,"guerra":1,"morkos":1,"exacerbated":1,"e0256682":1,"s353":1,"todd":1,"mil":1,"e867":1,"e872":1,"khalpey":1,"lipsitz":1,"boom":1,"manning":1,"mw":1,"fiestan":1,"dunson":1,"martin":3,"kaye":1,"knott":1,"infect":1,"goulet":1,"perkal":1,"rosenthal":2,"ata":1,"bestle":1,"desemone":1,"stain":1,"thompson":2,"dellinger":1,"yanez":1,"farrohki":1,"flum":1,"bader":2,"ycemic":1,"okabayashi":1,"shima":1,"sumiyoshi":1,"underwood":1,"chamarthi":1,"hallock":1,"mulvey":1,"cherian":1,"vt":2,"truong":1,"whitfield":1,"e15380":1,"tao":1,"matur":1,"palmisciano":1,"spine":2,"phila":2,"duggan":2,"anesthesiology":4,"bellon":1,"gimenez":1,"cd007315":1,"gibanica":1,"operating":1,"e50":1,"e52":1,"cruz":1,"mckee":1,"wearable":1,"anesth":2,"analg":1,"demma":1,"kt":3,"dixit":1,"bateman":1,"hawn":1,"odden":1,"ec":1,"tallarico":1,"jing":1,"steinhorn":2,"kronish":2,"retrospectiv":1,"odium":1,"anaesth":2,"kave":1,"mcilroy":1,"kyi":1,"colman":1,"fourlanos":1,"e7":1,"klein":3,"hobai":1,"intraoperative":1,"potnuru":1,"pp":1,"hernandez":6,"srlc":1,"scripts":1,"cder":1,"safetylabelingchanges":1,"cfm":1,"searchdetail":1,"drugnameid":1,"mizubuti":2,"esophagogastroduodenoscopy":2,"anest":1,"silveira":1,"campos":1,"vieira":1,"abib":1,"endoscopy":1,"zink":1,"e250081":1,"facciorusso":1,"ramai":1,"dhar":1,"e713":1,"asahq":1,"asa":2,"newsroom":2,"releases":2,"kindel":2,"wadhwa":2,"endoscopic":3,"surgeons":2,"multisociety":2,"relat":3,"oprea":1,"ostapenko":1,"sweitzer":1,"spaqi":1,"boghdadly":1,"dhesi":1,"fabb":1,"disciplinary":1,"anaesthetists":2,"royal":2,"anaesthesia":2,"hypergl":1,"desai":3,"mathias":1,"menon":1,"schubart":1,"utilization":2,"nationwide":4,"lentz":1,"koyfman":1,"gottlieb":1,"etiologies":3,"tsegka":1,"isolated":1,"e69":1,"e71":1,"zhong":2,"vw":1,"juhaeri":1,"mayer":1,"england":2,"copeland":2,"tp":2,"moin":2,"wisk":2,"endo":2,"crinol":2,"reilly":1,"jeyam":1,"caparrotta":2,"scottish":1,"widening":1,"scotland":1,"mohandes":1,"yee":1,"bhutta":1,"huecker":1,"statpearls":1,"treasure":1,"island":1,"ncbi":1,"nlm":1,"nih":1,"shaka":4,"wani":2,"amir":2,"s354":1,"propensity":1,"matched":1,"shand":1,"jad":1,"braatvedt":1,"anis":1,"boudreau":1,"thornton":1,"rustico":1,"ferrara":1,"hawkes":1,"keto":1,"kipnis":1,"e226417":1,"fisher":1,"stentz":2,"thirty":2,"alnuaimi":2,"mach":2,"reynier":3,"filion":3,"lipes":2,"ohy":2,"alves":1,"lannin":1,"clemson":1,"cameron":1,"id":1,"shepperd":1,"cd000313":1,"dargar":1,"galla":1,"interdisciplinary":2,"rinaldi":1,"snider":2,"disposition":2,"postdischarge":2,"e002722":1,"hames":1,"sandhu":1,"psnet":1,"ahrq":1,"primer":1,"aspx":3,"primerid":1,"stryer":1,"eq":1,"continuity":3,"maldonado":1,"amico":1,"iyer":1,"indigent":2,"prone":2,"aguilera":2,"aucar":2,"hirschman":1,"bixby":1,"sadusky":1,"roussel":1,"riveline":3,"vicaut":1,"drop":1,"france":1,"relief":2,"canada":22,"baiju":1,"frcpc":3,"phd":4,"harpreet":1,"mph":3,"sonia":1,"msc":4,"kaberi":1,"dasgupta":5,"eurich":1,"bsp":1,"rahul":1,"ccfp":1,"mscch":1,"karen":1,"coe":1,"kerry":1,"pharmd":1,"scot":1,"simpson":1,"messages":2,"lifetime":2,"dications":1,"introduced":2,"track":4,"anybody":1,"discuss":1,"pros":1,"cons":1,"decide":2,"kingdom":2,"spanned":1,"updates":2,"focusses":1,"chapters":1,"counselling":3,"sciencedirect":2,"journal":13,"owner":2,"name":1,"jcjd":1,"08":2,"002":6,"negligible":3,"superiority":1,"nosed":1,"gradually":2,"minimizes":2,"everyone":1,"uninten":1,"blurring":2,"taper":2,"decompen":1,"withdrawn":2,"outset":3,"submaximal":1,"maximal":2,"cipitants":1,"ischemia":3,"explore":2,"advantag":1,"desire":2,"sulfonyl":1,"ureas":1,"broadly":2,"incretins":3,"thia":1,"zolidinediones":1,"nancial":4,"preg":1,"contraceptive":2,"gnant":1,"retinal":1,"endpoint":2,"incon":1,"owing":1,"methodological":1,"footnotes":1,"nitions":4,"ranged":1,"ventricular":9,"systolic":9,"diastolic":6,"uced":1,"endpoints":2,"icodec":1,"separate":1,"secreta":1,"gogues":1,"introducing":4,"1a":3,"decom":2,"pensation":1,"unintentional":1,"dipsia":1,"substitutions":2,"precipitants":1,"adher":1,"secretagogues":9,"bed":1,"ejec":1,"hypogl":2,"wise":1,"ise":1,"external":2,"thankful":1,"insightful":1,"feedback":1,"lending":1,"expertise":4,"gamble":1,"ronald":2,"lorraine":1,"lipscombe":3,"ron":1,"sigal":3,"disclosures":3,"toronto":4,"chair":7,"amgen":1,"biomea":1,"glaxo":1,"smithkline":1,"ionis":1,"kowa":1,"icts":4,"disclose":3,"bacon":1,"boule":1,"kenny":1,"s54":1,"sievenpiper":1,"dworatzek":1,"freeze":1,"sherifali":2,"gucciardi":1,"macdonald":1,"macneill":1,"s36":2,"pedersen":3,"lau":2,"djr":2,"sharma":5,"imran":1,"ross":1,"s42":1,"siemens":2,"woo":5,"s47":1,"lega":1,"yale":2,"chadha":1,"paty":2,"roscoe":1,"steier":1,"mackay":1,"dominy":1,"gagner":1,"jin":2,"p854":2,"np":3,"kravitz":3,"bg":9,"neill":3,"viberti":2,"hut":1,"cuervo":1,"berger":3,"iyoha":1,"segal":1,"bolen":1,"lv":8,"cui":1,"zou":1,"shen":2,"zhu":1,"spread":1,"dimcad":1,"mavridis":2,"tonelli":1,"craig":2,"phung":2,"sobieraj":3,"engel":3,"rajpathak":2,"chuck":2,"merton":1,"capuano":3,"qiu":1,"mcgrath":1,"cadell":1,"samocha":1,"bonet":1,"nius":1,"rand":1,"omised":1,"zimmer":1,"rlh":1,"amorin":1,"ntabadde":1,"iredale":1,"composit":1,"hadjadj":1,"meinicke":2,"woerle":3,"broedl":3,"uc":3,"garber":6,"piper":1,"goldstein":1,"vinik":1,"dirani":1,"freed":1,"rood":2,"cobitz":2,"biswas":1,"chou":1,"bloomgarden":3,"zt":1,"dodis":1,"holmboe":1,"apparent":3,"nerenberg":1,"pullenayegum":1,"turner":1,"cull":1,"frighi":1,"nylurea":2,"rol":1,"thorsted":1,"wolden":1,"doleh":1,"zaccaro":1,"e0125879":1,"cummings":1,"foroutan":1,"muratov":1,"levine":1,"e48":2,"chubb":2,"nuhoho":2,"kallenbach":2,"orme":2,"clar":1,"court":1,"waugh":1,"e001007":1,"hartley":1,"betz":1,"schiff":1,"golm":1,"sisk":1,"shankar":2,"aging":1,"ye":3,"bai":2,"indirect":1,"tu":1,"lemieux":1,"sihabout":1,"ortega":1,"goring":1,"ha":2,"bergenheim":1,"sternhufvud":1,"mukherjee":1,"mel":4,"litus":3,"feig":2,"donovan":3,"godbout":2,"kader":2,"keely":2,"sanghera":2,"cli":2,"s255":1,"pais":1,"probst":2,"riesmeyer":1,"ryd":2,"xavier":1,"atisso":1,"dyal":1,"melacini":1,"avezum":1,"basile":1,"chung":2,"conget":1,"cushman":2,"franek":1,"hancu":1,"jansky":1,"keltai":1,"lanas":1,"jaramillo":1,"pirags":1,"pogosova":1,"raubenheimer":1,"sheu":1,"temelkova":1,"kurktschiev":1,"poulter":5,"ravn":1,"steinberg":1,"wm":3,"stockner":1,"eliaschewitz":3,"fg":3,"dar":3,"leit":1,"seufert":1,"fitchett":2,"bluhmki":1,"hantel":1,"mattheus":1,"devins":1,"mosenzon":3,"kato":1,"silverman":1,"zelniker":1,"kuder":1,"gause":1,"nilsson":2,"iam":1,"fredriksson":1,"johansson":1,"langkilde":3,"mancuso":2,"huyck":2,"masiukiewicz":2,"frederich":1,"gallo":1,"gantz":1,"terra":1,"khurmi":1,"preiss":3,"scappaticcio":2,"eight":2,"nreu":2,"ino":1,"andrea":1,"kesselheim":1,"eh":1,"hey":1,"het":1,"erogeneity":1,"dz":3,"rahman":2,"lone":1,"kunduru":1,"e030578":2,"pfeffer":3,"dickstein":2,"ber":4,"maggioni":2,"mcmurra":1,"ardiovascular":3,"tardif":1,"elixa":1,"mentz":1,"vp":1,"lokhnygina":1,"choi":2,"gustavson":1,"hman":1,"pagidipati":1,"ramachandran":1,"birkenfeld":2,"donsmark":2,"tack":1,"thomsen":1,"martinez":3,"carson":1,"zannad":5,"demets":1,"ferreira":4,"bocchi":1,"cardoso":2,"graffunder":2,"fp":2,"ternes":2,"fernandes":2,"rocha":2,"eclinicalm":1,"hiddo":1,"nsson":2,"bergur":1,"ricardo":1,"chertow":2,"glenn":1,"roddick":1,"emberson":1,"reith":1,"riding":1,"wonnacott":1,"wakabayashi":2,"bhalla":2,"chopra":2,"miyashita":2,"mikami":2,"dium":1,"jfe":2,"baeres":1,"fmm":1,"idorn":1,"traberg":1,"lausvig":1,"wolf":1,"kabadi":1,"um":1,"bination":1,"hemmingsen":2,"wetterslev":2,"vaag":2,"gluud":2,"lund":2,"almdal":2,"e1771":1,"kauppila":1,"kujansuu":1,"lahti":1,"marjanen":1,"philis":2,"tsimikas":2,"handelsman":7,"endahl":2,"nn1250":1,"donley":1,"edwards":1,"hoe":2,"emerson":2,"lange":2,"skibsted":2,"kvist":3,"glass":1,"heilmann":1,"cr":3,"arnolds":1,"dellweg":1,"clair":1,"dain":1,"rave":1,"kapitza":1,"barnett":1,"fleming":1,"sax":1,"agliptin":1,"vilsboll":1,"jarvinen":2,"musser":2,"neubacher":2,"woe":1,"zeeuw":1,"vercruysse":1,"meininger":1,"jelaska":1,"frappin":1,"salsali":1,"rohwedder":2,"sugg":2,"parikh":2,"006":3,"sarigianni":1,"mainou":1,"papatheodorou":1,"yg":2,"lahtela":1,"loredo":1,"torn":1,"boopalan":1,"nn2211":1,"guerci":2,"roy":4,"duval":2,"souhami":2,"wardecki":2,"perfetti":2,"getgoal":2,"duo":2,"huh":1,"tof":1,"sears":1,"ocampo":1,"francisco":2,"victoza":2,"pozzilli":1,"ivanyi":1,"reed":2,"rosa":3,"rose":2,"sugimoto":2,"kesavadev":1,"pillai":1,"pbs":1,"krishnan":1,"jothydev":1,"swim":1,"connect":1,"ledesma":1,"morley":1,"keller":1,"dh":2,"brunelle":1,"keohane":1,"koivisto":1,"trautmann":1,"vignati":1,"dimarchi":1,"marchionni":2,"ebrahim":2,"gratzer":1,"plank":1,"rys":2,"wojciechowski":2,"rogoz":2,"sitek":2,"niesyczy":2,"07":3,"nski":1,"syta":1,"metaanalysis":1,"gough":1,"mersebach":1,"planned":1,"troelsen":1,"ln":1,"mv":3,"frier":2,"clements":2,"bello":2,"zhuang":1,"jager":3,"wulffel":1,"kolk":1,"bets":1,"verburg":1,"donker":1,"pla":1,"cebo":1,"c2181":1,"knowler":2,"marcovina":1,"orchard":1,"schade":1,"ds":2,"temprosa":1,"nh":1,"crandall":1,"niafar":2,"hai":2,"porhomayon":2,"nader":2,"dailey":2,"jabbour":2,"reasner":2,"mills":2,"gastrointestina":1,"tablets":4,"ziring":1,"levy":2,"cobas":1,"gomes":2,"bala":1,"busse":1,"vandvik":3,"rios":1,"malaga":1,"sohani":1,"atitis":1,"g2366":2,"udell":2,"cavender":2,"farkouh":2,"domised":1,"i610":1,"templeton":1,"clay":1,"wild":1,"reynolds":3,"glp1ra":1,"xie":1,"fung":2,"mineral":3,"bilezikian":2,"watts":2,"usiskin":2,"polidori":2,"puckrin":1,"saltiel":1,"azoulay":1,"schneeweiss":2,"nong":1,"schnell":1,"marx":1,"e074068":1,"mancini":14,"eileen":1,"meara":2,"shelley":1,"zieroth":1,"bernier":1,"alice":1,"david":1,"connelly":2,"justin":1,"ezekowitz":1,"mbbch":1,"gihad":1,"nesrallah":1,"breay":1,"marie":1,"eve":1,"pich":1,"mbbs":1,"abhinav":1,"subodh":1,"verma":2,"vincent":1,"darras":1,"jonathan":3,"gabor":3,"jean":1,"egoire":1,"eva":1,"lonn":1,"stone":2,"fran":1,"ois":1,"colin":1,"yeung":1,"deborah":1,"zimmerman":2,"vancouver":3,"montreal":3,"montr":1,"eal":1,"quebec":3,"rady":1,"manitoba":4,"winnipeg":2,"institut":2,"universitaire":2,"cardiologie":2,"pneumologie":2,"qu":6,"ebec":2,"laval":2,"unity":2,"trillium":2,"ontario":2,"keenan":1,"michael":4,"alberta":2,"edmonton":1,"lmc":1,"vaughan":1,"shing":1,"humber":1,"river":1,"selkirk":3,"mcmaster":1,"libin":1,"calgary":1,"regina":1,"saskatchewan":1,"saskatoon":1,"ottawa":1,"abstract":1,"synthesizes":1,"esum":1,"esente":1,"ligne":1,"directrice":1,"synth":2,"etise":2,"donn":2,"ees":4,"essais":2,"cliniques":2,"rmant":2,"agonistes":2,"ecepteurs":2,"au":3,"arglp":3,"inhibiteurs":2,"cotransporteur":2,"isglt2":4,"dans":2,"traitement":2,"rice":1,"sance":1,"cardia":1,"que":3,"enale":3,"chronique":3,"ainsi":3,"march":1,"laurel":1,"street":1,"v5z":1,"1m9":1,"tel":1,"fax":1,"mail":1,"ubc":1,"disclosure":3,"ccs":16,"experts":4,"mandate":1,"formulate":1,"allied":2,"obliged":2,"duty":2,"bestowing":2,"evolve":1,"substitute":1,"judgement":2,"necessarily":1,"produce":2,"cjca":4,"04":6,"029":2,"0828":2,"282x":2,"elsevier":7,"rights":7,"ceptor":3,"purpose":1,"building":1,"concordant":3,"chfs":6,"glycosylated":7,"symp":1,"tomatic":1,"pensated":1,"assembled":1,"representation":2,"partner":1,"drawing":1,"aca":1,"demic":1,"geographic":1,"pico":11,"commissioned":3,"companion":3,"documentation":1,"lvef":11,"evalu":1,"integra":1,"albuminuric":1,"profound":2,"evention":2,"optimis":1,"morbidit":1,"mortalit":3,"cardior":3,"enales":1,"chez":3,"atteints":3,"elle":1,"repose":1,"une":3,"revue":1,"ematique":1,"eta":2,"analyse":2,"compl":2,"ementaires":2,"utilisant":2,"ensemble":2,"ecis":2,"paraison":2,"objectifs":2,"param":2,"tres":2,"enaux":3,"prioritaires":2,"devel":1,"opment":1,"ethode":1,"ont":2,"uti":1,"econisons":1,"maladies":1,"cardiovasculaires":1,"mesures":1,"ematiques":1,"ebit":1,"glom":1,"erulaire":1,"estim":1,"rapport":1,"albumine":1,"eatinine":1,"urinaire":1,"taux":1,"emoglobine":1,"glyqu":1,"ventriculaire":1,"gauche":1,"fevg":2,"devrait":1,"aussi":2,"lors":1,"sympt":1,"mes":1,"esence":2,"recommandons":2,"egrer":2,"autres":2,"pharmacoth":2,"erapies":2,"fond":2,"lignes":2,"directrices":2,"eduire":2,"equence":1,"pitalisations":1,"lorsque":1,"toutes":2,"confondues":2,"cardiovasculaire":1,"hospitalisations":2,"eserver":1,"fonction":2,"dont":2,"ephropathie":2,"avec":2,"albuminurie":2,"origine":1,"risque":1,"infarctus":1,"myocarde":1,"mortel":1,"esentons":1,"recommandations":1,"algorithmes":1,"election":1,"tients":10,"maladie":1,"ath":1,"eroscl":1,"ereuse":1,"etablie":1,"esentant":1,"facteurs":1,"avc":1,"mortels":1,"eclin":1,"offrons":1,"conseils":1,"pratiques":1,"utilisation":1,"ecuritaire":1,"qui":1,"profonds":1,"avantages":1,"question":3,"indirectness":1,"imprecision":1,"inconsistency":1,"extensive":3,"panelists":1,"voted":1,"nements":1,"declared":1,"voting":1,"surveying":1,"submitted":2,"peer":5,"undertaken":5,"simulta":2,"neously":2,"dertaken":1,"auspices":1,"pharmaceu":1,"tical":1,"synthesis":2,"glance":1,"summarizing":2,"ratios":7,"hrs":1,"vigilance":1,"commonplace":1,"fosters":1,"imaging":1,"biomarker":1,"phenotype":1,"antic":1,"ipation":1,"media":1,"consequently":2,"ent":2,"pts":2,"mul":3,"parentheses":1,"shaded":1,"pertaining":1,"darker":2,"shading":2,"ventricula":1,"apagli":3,"revention":3,"dverse":3,"eart":4,"ailure":4,"001":12,"ancillary":4,"aft":1,"hg":5,"ons":2,"73m":2,"dney":1,"preven":1,"monographs":1,"rounded":2,"statemen":1,"alphabetical":1,"harmony":5,"agli":6,"ascular":3,"ssessment":2,"tudy":2,"anagli":3,"enal":4,"vents":6,"stablished":2,"ephropathy":2,"linical":2,"valuation":3,"hronic":2,"isease":2,"ffect":2,"ardiovascu":1,"hrombolysis":1,"yocardial":1,"nfarction":1,"emoving":1,"xcess":1,"emp":5,"chr":4,"nic":4,"hea":4,"enatide":2,"owering":2,"iraglutide":1,"esults":1,"eptide":1,"vatio":1,"arly":1,"eatment":1,"esearching":2,"eekly":2,"cretin":2,"otagli":1,"ardi":1,"taglif":2,"card":2,"ova":2,"orsening":2,"emaglutide":2,"nabated":2,"aluation":1,"ert":1,"ugli":1,"ardio":1,"ects":5,"nondiabetes":1,"peror":1,"terminal":1,"hor":1,"mone":1,"natriuretic":1,"atrial":3,"brillation":3,"occurred":4,"excellent":3,"sacubitril":2,"valsartan":2,"renin":6,"concor":1,"resynchronization":1,"implantable":1,"cardioverter":1,"brillators":1,"shows":4,"worldwide":2,"endorse":1,"foundational":2,"neprilysin":2,"arni":4,"mineralo":2,"corticoid":2,"antagonist":5,"mra":8,"antagonists":4,"mrf":1,"dicates":1,"tip":6,"statins":4,"predominantly":1,"slope":2,"empag":1,"0001":1,"rospective":1,"lobal":1,"utcomes":1,"ejectio":1,"paragon":1,"tertiles":1,"sented":1,"alpha":3,"protected":1,"clari":2,"placed":1,"underscore":2,"multidrug":2,"acknowledges":1,"accessi":1,"sequence":1,"shortly":1,"hemodynamically":1,"fai":1,"tabilis":1,"pub":6,"win":2,"attached":2,"rehospitalization":1,"overwhelming":1,"00001":1,"markedly":3,"009":3,"004":1,"persistently":2,"inability":2,"hyperkalemia":2,"glomerulonephritis":2,"cosylated":1,"gmi":8,"qam":1,"sadmans":1,"diuretics":5,"nonsteroidal":3,"ammatory":3,"entities":2,"prognostic":1,"great":1,"samples":1,"oving":1,"dedi":1,"accompanying":3,"believe":1,"dimin":1,"ished":1,"minor":2,"efpeglena":1,"theoretically":1,"thoroughly":2,"substitution":1,"replacing":1,"aligns":1,"seem":1,"lyses":1,"strongest":1,"opinions":1,"attempted":2,"differentiate":2,"emphasizes":4,"recognizes":1,"weigh":1,"diminished":1,"tained":2,"integrating":2,"prominent":2,"redundant":1,"mechanism":1,"rinse":1,"wipe":1,"rarely":1,"ydration":1,"cautiously":2,"preventative":1,"foot":1,"tenderness":1,"sores":1,"ulcers":1,"legs":1,"feet":3,"ulcer":1,"antiemetics":1,"phe":1,"nomenon":1,"eyes":1,"far":1,"outweigh":1,"gmis":1,"uncircumcised":1,"giene":1,"antifungal":1,"secre":2,"tagogues":2,"ogly":1,"counselled":1,"secretagogue":1,"eskd":1,"shortness":1,"confusion":1,"anorexia":1,"thirst":1,"lethargy":1,"conceptually":1,"premature":2,"favourably":1,"reassurance":1,"arnis":1,"diuresis":1,"temporarily":1,"dehydrating":1,"extremely":3,"merits":1,"paradigm":4,"summarize":2,"mputation":1,"terventions":4,"administrative":1,"economic":1,"expeditious":1,"mandating":1,"tied":1,"predicated":2,"upholding":2,"principle":2,"judicious":2,"stewardship":2,"imperative":2,"advocate":2,"hurdles":2,"aspirational":1,"tailoring":1,"environment":1,"cardiologists":1,"nephrologists":1,"endocrinologists":9,"gbj":3,"cardiodiabetes":1,"competencies":1,"era":2,"apidly":1,"houlden":1,"mcdonald":1,"mitral":1,"regurgitation":1,"tafamidis":1,"amyloidosis":1,"fitzpatrick":2,"janmohamed":1,"overload":2,"whitelaw":1,"pellegrini":1,"mamas":1,"cowie":1,"spall":1,"hgc":1,"uptake":2,"serenelli":2,"nicolau":2,"iew":2,"jackson":2,"dewan":1,"cording":1,"nepr":1,"ly3298176":1,"sum":3,"mit":1,"ct2":2,"nct04847557":1,"investigate":2,"works":2,"nct04788511":2,"clinicaltria":1,"thrombolysis":1,"nct04363697":1,"multina":1,"spertus":1,"birmingham":1,"chief":3,"nct03819153":1,"hramiak":1,"ayy":1,"gilbert":1,"hopyan":1,"neurologists":1,"accord":2,"maron":1,"hartigan":1,"aboyans":1,"esc":1,"juri":1,"zen":1,"uenced":1,"onary":3,"duan":1,"xy":1,"yin":1,"dg":1,"e26431":2,"tcome":1,"s316":1,"heartfailure":1,"concerned":2,"databases":1,"m2812":1,"onlinecjc":1,"008":4,"errata":1,"erratum":4,"syncope":1,"aortic":1,"stenosis":1,"obstruction":1,"ste":1,"pascual":1,"incomplete":1,"liation":2,"jaume":1,"ignacio":1,"incorrectly":2,"universitat":1,"aut":1,"noma":1,"bellaterra":1,"versitat":1,"accidentally":2,"omitted":2,"gabo":1,"liated":1,"saline":1,"radiofrequency":1,"ablation":1,"tachycardia":1,"serf":1,"radio":1,"sanchez":1,"somonte":1,"surname":1,"misspelled":1,"dryda":1,"spelling":1,"dyrda":1,"007":3,"susan":2,"priyathama":1,"facp":1,"christo":1,"rodolfo":1,"irl":2,"kenneth":2,"izuora":2,"cecilia":1,"christine":1,"twining":1,"guillermo":2,"cdces":1,"macp":1,"willy":1,"marcos":1,"valencia":1,"jacksonville":2,"florida":2,"associate":3,"professor":3,"lipids":5,"emory":3,"grady":2,"memorial":2,"georgia":2,"director":2,"ochsner":2,"frank":1,"riddick":1,"orleans":1,"louisiana":1,"miami":2,"lennar":2,"umiami":2,"jackso":1,"docrinology":1,"seattle":1,"kirk":2,"kerkorian":2,"nevada":4,"las":2,"vegas":2,"colorado":3,"anschutz":1,"campus":1,"aurora":1,"maine":1,"scarborough":1,"cleveland":2,"revised":5,"words":2,"objective":3,"concise":2,"graphic":3,"correspondence":2,"parkwy":1,"suite":1,"email":1,"disclaimer":1,"matter":1,"participated":3,"meant":1,"prescriptive":1,"clinician":8,"apply":3,"endocrinepractice":4,"eprac":10,"891x":4,"vaccine":8,"immunization":7,"aligning":1,"pillars":3,"highlights":1,"theme":2,"iteration":2,"ace":7,"road":3,"maps":2,"navigate":1,"glinides":4,"4is":1,"hyperten":2,"htn":15,"revisions":1,"yearly":1,"grateful":2,"framework":3,"graded":2,"rationales":1,"builds":1,"versions":2,"align":1,"cpg":7,"algo":6,"rithm":6,"easily":1,"iterate":1,"behind":1,"algorithmic":1,"roadmap":1,"depictions":1,"meetings":1,"subsections":1,"intentional":2,"overlapped":2,"highlighted":2,"obvious":1,"barrier":1,"divided":5,"discrete":1,"outline":3,"abbreviations":2,"disea":1,"abi":5,"ankle":3,"brachial":3,"agi":1,"apo":7,"apolipoprotein":6,"atp":1,"beam":3,"minus":2,"prebreakfast":2,"brc":1,"qr":1,"cad":1,"ccb":1,"calcium":7,"channel":5,"chf":6,"creatine":2,"colsvl":1,"coq10":1,"coenzyme":3,"q10":3,"crcl":1,"dash":10,"ext":1,"fbg":6,"gerd":1,"ux":2,"gln":1,"glinide":2,"hcp":4,"hdl":8,"lipoprotein":9,"cholesterol":13,"ifg":2,"igt":3,"ipe":3,"icosapent":4,"ethyl":4,"lada":1,"latent":3,"ldl":10,"ventricle":1,"men2":1,"mineralocorticoid":2,"mtc":2,"carcinoma":2,"ncep":3,"oa":1,"osteoarthritis":3,"osa":4,"pcos":1,"polycystic":2,"ovary":2,"pcsk9":2,"proprotein":2,"convertase":2,"subtilisin":2,"kexin":2,"praml":1,"pvd":1,"rx":1,"sams":2,"statin":14,"scr":1,"triglyceride":4,"vldl":3,"underlies":1,"staging":4,"pillar":1,"biomechanical":2,"decr":1,"erapy":1,"coexistence":2,"impetus":1,"rizes":1,"armamen":1,"tarium":1,"evolution":1,"dictability":1,"formularies":2,"acknowledged":2,"outlin":1,"achievable":1,"microangiopathic":1,"epidemiologic":1,"uum":1,"word":2,"prohibitive":1,"individualize":1,"imprecise":1,"red":2,"lifespan":2,"hemoglobinopathies":2,"backgrounds":2,"generated":2,"recommende":1,"ltered":1,"generate":1,"surrogate":1,"escalate":1,"cians":1,"chosen":2,"discusses":1,"ave":1,"nues":1,"alarms":2,"mittently":2,"areness":1,"concomi":1,"phrase":2,"ifestyle":1,"moderation":1,"mood":1,"viewing":1,"existence":3,"hypogonadism":1,"fertility":1,"determination":1,"south":2,"east":3,"southeast":1,"utilized":1,"mends":1,"inviting":1,"incorporates":1,"alternatively":2,"manifested":2,"ubstantially":1,"encompasses":1,"activ":1,"deprivation":2,"vegetarian":2,"prepared":1,"replacements":1,"calorie":2,"disabilities":2,"itself":2,"ivity":1,"snoring":1,"choking":1,"sleepiness":1,"fatigue":1,"nonrestorative":1,"bang":1,"naire":1,"oximetry":1,"scription":2,"airway":1,"wellbeing":2,"questionaire":2,"inventory":2,"sarcopenia":1,"spite":1,"remedied":2,"compensate":2,"prediabete":1,"ingestion":1,"ample":1,"overt":1,"autoim":2,"mune":2,"merit":2,"ossibility":1,"exercises":1,"moderately":1,"intense":1,"consisting":1,"repetitions":1,"nonexercise":1,"incorpo":1,"rated":1,"phentermine":3,"topiramate":2,"linotropic":1,"naltrexone":2,"bupropion":1,"orlistat":1,"nonpharmacologic":1,"hydrogel":2,"capsules":1,"cellulose":1,"citric":1,"taken":4,"intragastric":3,"balloons":1,"transpyloric":1,"shuttle":1,"disruptions":1,"atherogenic":6,"particles":4,"rich":1,"remnant":3,"dense":3,"screened":2,"panels":1,"nonfasting":3,"compliance":1,"draws":1,"resolve":4,"counter":4,"supplements":4,"expose":2,"investigated":1,"familial":1,"hypercholesterolemia":1,"chylomicronemia":1,"thyroidism":1,"uria":1,"nephrotic":1,"cholestatic":1,"lipodystrophy":1,"paraproteinemia":1,"dysgammaglobulinemia":1,"myeloma":1,"arthritis":1,"lupus":1,"erythematosus":1,"exacerbate":1,"estrogens":1,"progestins":1,"anabolic":1,"estrogen":1,"modulators":1,"antiretroviral":1,"protease":2,"hiv":3,"cyclosporine":2,"retinoids":2,"interferon":2,"taxol":2,"rivatives":2,"asparaginase":2,"cyclophosph":1,"atypical":1,"antipsychotic":1,"thiazide":2,"antilipid":1,"lipoproteins":1,"predication":1,"dyslipi":3,"calculator":3,"sugars":3,"minimization":1,"demia":1,"healthful":2,"processed":1,"saturated":1,"starches":1,"meat":2,"skinless":2,"poultry":2,"determ":1,"males":1,"females":1,"category":1,"helps":1,"egf":1,"weighed":1,"persist":1,"attained":1,"manifest":3,"bilateral":1,"cramping":1,"stiff":1,"queries":1,"rechallenged":1,"acknowledging":1,"myopathy":4,"rhabdomyolysis":2,"heritage":1,"brates":3,"erythromycin":1,"uconazole":1,"hypothyroidism":1,"teractions":1,"pass":1,"metabolized":1,"cyp3a4":1,"simvastatin":2,"lovastatin":2,"rechallenge":1,"calculators":1,"reynoldsriskscore":1,"framingham":1,"framinghamheartstudy":1,"fhs":1,"functions":1,"cvriskcalculator":2,"atherosclerosis":5,"mesa":2,"nhlbi":2,"mesachdrisk":2,"mesariskscore":2,"riskscore":2,"stati":1,"gy":1,"pravastatin":1,"fluvastatin":1,"bid":1,"pitavastatin":2,"atorvastatin":1,"rosuvastatin":1,"hydrophilic":1,"uvastatin":1,"hydroxy":1,"omega":4,"supplementation":1,"ezetimibe":2,"colestipol":2,"cholestyramine":2,"bempedoic":2,"adenosine":2,"triphosphate":2,"lyase":2,"valu":1,"pcsk9i":1,"inclisiran":1,"sirna":1,"fruit":2,"juices":1,"feno":3,"brate":4,"nitively":1,"pema":2,"triglycerides":1,"voiced":1,"niacin":1,"worsen":2,"macro":2,"macroalbuminuria":2,"tolerate":1,"ie":3,"oor":2,"correctly":2,"cuff":2,"serial":2,"averaged":2,"ition":1,"lose":1,"endurance":1,"dynamic":1,"aceis":1,"angio":1,"tensin":1,"arbs":2,"coad":1,"ministration":1,"cough":2,"substituted":2,"outs":1,"antihy":1,"pertensive":1,"hydrochlorothiazide":1,"chlorthalidone":1,"indapamide":1,"antihyper":1,"dihydropyridine":3,"amlodipine":2,"nifedipine":2,"tiple":1,"antihypertensive":3,"blockade":1,"expenditure":1,"atenolol":1,"metoprolol":1,"carvedilol":1,"labetalol":1,"dilevalol":1,"nebivolol":1,"betaxolol":1,"sparing":1,"clonidine":1,"doxazosin":1,"prazosin":1,"terazosin":1,"hydralazine":1,"hyperaldosteronism":2,"underdiagnosed":2,"junct":1,"mineralocor":1,"ticoid":1,"eplerenone":1,"spironolactone":1,"rational":1,"potas":1,"sium":1,"nerenone":3,"microalbuminuria":1,"albu":1,"pretreatment":2,"endent":1,"contemporary":1,"antiplatelet":1,"belonging":1,"interna":1,"showing":2,"diseas":1,"yperglycemic":1,"maces":6,"proteinuria":1,"hypertrophy":1,"maglutide":1,"pitalization":2,"robustly":1,"hem":1,"orrhagic":1,"pooling":1,"hi":1,"longstanding":1,"cult":1,"shoul":1,"suggestive":3,"scenario":1,"contrain":1,"dication":1,"denotes":1,"hierarchy":1,"entially":1,"economical":1,"lastly":2,"ciated":1,"cognizant":1,"inef":1,"antihyperglyc":1,"deglu":1,"dec":1,"comparatively":1,"nonetheless":1,"midday":1,"relying":1,"70mg":1,"juice":1,"unresponsive":1,"soluble":3,"dasiglucagon":3,"ready":2,"top":1,"bottom":1,"medic":1,"ene":1,"approximate":1,"illnesses":1,"bacteria":1,"viruses":1,"vacci":1,"nations":1,"nesses":1,"vaccination":7,"acip":1,"maintains":1,"vaccinations":4,"hcps":2,"rely":2,"vaccinated":2,"clinics":1,"staying":1,"latest":1,"vac":1,"sending":1,"reminders":1,"highlight":2,"stock":4,"communicates":1,"bidirectional":1,"consolidate":1,"records":1,"documentations":1,"unnecessary":1,"culture":1,"entire":1,"engaged":1,"coadministration":1,"champions":1,"drafts":1,"oversight":3,"directors":4,"empaneled":3,"accordance":3,"ict":3,"coi":2,"subcommittee":2,"leadership":1,"relationships":3,"panies":2,"employment":2,"ownership":2,"consul":2,"auth":1,"ceding":1,"authorship":1,"paper":2,"overlapping":1,"serve":1,"noncon":1,"icted":1,"disquali":1,"serving":1,"reminded":1,"ships":1,"arose":1,"currency":1,"uence":2,"corcept":2,"chiasma":2,"abim":2,"mittee":1,"pharmaceutical":1,"company":2,"institutes":2,"k23":1,"01a1":1,"salix":1,"abbvie":1,"ascendis":1,"amryt":1,"glitter1":1,"medizen":1,"title":2,"watchers":1,"partially":1,"digestive":1,"eases":1,"niddk":1,"p30dk111024":1,"04s":1,"1k23dk123384":1,"boards":1,"bigfoot":1,"gwave":1,"bionics":1,"pay":1,"myovant":1,"madrigal":1,"jaeb":2,"coordinating":2,"treasurer":1,"secretary":1,"represented":1,"investi":1,"gator":1,"ident":1,"acknowledgment":1,"invaluable":1,"roadmaps":1,"laid":1,"abrahamson":5,"joshua":2,"barzilay":5,"zachary":2,"bush":2,"samuel":2,"jaime":2,"ralph":2,"daniel":2,"einhorn":2,"vivian":1,"alan":1,"jeffrey":1,"garvin":1,"timothy":1,"yehuda":1,"richard":1,"hellman":1,"edward":1,"horton":1,"jellinger":3,"harold":1,"lebovitz":1,"philip":1,"janet":1,"mechanick":3,"etie":1,"moghissi":1,"leigh":1,"perreault":1,"victor":1,"helena":1,"rosenblit":2,"stanley":1,"associa":1,"manuscript":1,"electronically":1,"video":1,"volunteer":1,"remuneration":1,"participation":1,"cipation":1,"credentialed":1,"retires":1,"ship":1,"expiration":1,"sociation":3,"map":2,"endp":1,"a38267720403k242":1,"ep151063":1,"ep151126":1,"0153":2,"0535":1,"0472":1,"reddy":1,"ander":1,"dcrm":1,"multispecialty":1,"jdiacomp":3,"ismail":2,"beigi":2,"craven":1,"banerji":1,"s0140":10,"macmahon":1,"chalmers":1,"nejmoa0802987":1,"nejmoa0802743":2,"khaw":2,"bingham":2,"luben":2,"welch":2,"norfolk":1,"00006":1,"zu":1,"niga":1,"i5887":1,"duckworth":1,"abraira":1,"moritz":1,"nejmoa0808431":1,"mcmahon":1,"0310":1,"1932296818822496":1,"allende":1,"estimating":2,"dc18":3,"beebe":2,"overcomin":1,"karter":1,"parker":1,"moffet":1,"hh":2,"gilliam":1,"dlott":1,"haak":2,"hanaire":2,"hermanns":2,"sensing":2,"multice":1,"s13300":1,"016":1,"0223":1,"hurley":3,"ep161688":1,"nadolsky":1,"addison":1,"stigmatization":1,"03":3,"yegneswaran":1,"liao":2,"questionnaire":1,"aln":2,"0b013e31816d83e4":2,"topp":2,"stergaard":2,"ndergaard":2,"bech":2,"dex":2,"psychother":2,"psychosom":2,"000376585":1,"kroenke":1,"spitzer":1,"phq":1,"validity":1,"016009606":1,"ward":1,"mendelson":1,"mock":1,"erbaugh":1,"psychiatry":1,"archpsyc":1,"01710120031004":1,"hyland":1,"chacra":1,"predict":1,"012":1,"vegt":1,"dekker":1,"postload":2,"dutch":2,"hoorn":2,"lakka":3,"laaksonen":3,"kaplan":1,"salonen":1,"aje":1,"kwf145":1,"barrett":1,"connor":2,"fowler":1,"nejmoa012512":1,"ryan":1,"dc13":2,"lindstr":2,"om":2,"finnish":2,"xr":1,"yh":1,"niddm":3,"qing":1,"diacare":3,"terranean":1,"m13":3,"babio":1,"reus":1,"er10":1,"svetkey":2,"simons":1,"morton":1,"vollmer":2,"archinte":3,"nejm200101043440101":1,"fernhall":1,"dc10":2,"e147":1,"e167":1,"dai":1,"zhai":3,"e3143":2,"aguiar":2,"morgan":2,"plotnikoff":2,"callister":2,"componen":1,"ard":1,"aha":2,"acc":2,"jacc":6,"003":3,"nejmoa2032183":1,"billings":1,"fujioka":1,"nejmoa2206038":1,"greenway":2,"raben":1,"gelesis100":1,"nonsystemic":1,"oby":1,"genco":1,"bruni":1,"doldi":1,"bioenterics":1,"balloon":2,"0960892055002202":2,"ponce":2,"woodman":3,"swain":2,"intragastri":1,"soard":1,"marinos":1,"eliades":1,"raman":1,"muthusamy":1,"005":5,"apovian":1,"brethauer":1,"dergoing":1,"cosponsored":1,"0406":1,"chiasson":2,"josse":2,"gomis":2,"karasik":2,"laakso":2,"08905":1,"schwenke":1,"nejmoa1010949":1,"flores":1,"comin":1,"pedro":1,"botet":1,"diovasc":1,"giraldez":1,"clare":1,"lopes":1,"ahj":1,"norhammar":1,"tenerz":1,"09089":2,"abeysuriya":2,"037":2,"s2213":7,"ritter":1,"sep":1,"sjs":1,"kallen":1,"cjh":1,"diometabolic":1,"maastricht":1,"e000787":1,"bmjdrc":5,"000787":1,"hashemi":1,"poustchi":1,"golestan":1,"s12872":2,"020":4,"01390":1,"taskinen":1,"dyslipidaemia":1,"halcox":2,"eurika":2,"017":1,"0591":1,"yx":2,"lipo":2,"s12933":1,"01015":1,"ep171764":1,"appgl":1,"guerin":1,"0490":2,"mora":2,"moorthy":2,"sever":2,"anglo":1,"scandinavian":1,"jamainternmed":1,"0392":1,"sathiyakumar":1,"quispe":1,"circulationaha":5,"032463":1,"sniderman":2,"pierre":1,"cantin":1,"despr":1,"lamarche":1,"concordance":1,"discordance":1,"indexes":1,"s0002":1,"00262":1,"johannesen":1,"cdl":1,"mortensen":1,"langsted":1,"nordestgaard":1,"apolipopro":1,"choles":2,"terol":2,"027":2,"valavoor":2,"2047487319871733":1,"thanassoulis":1,"glavinovic":1,"jamacardio":3,"contois":1,"circoutcomes":1,"ridker":1,"paynter":1,"rifai":2,"gaziano":1,"cook":1,"parental":1,"4p":2,"viney":2,"capelleveen":2,"geary":2,"antisense":2,"oligonucleotides":2,"hartaigh":1,"warranty":1,"zero":1,"korean":1,"circj":1,"0731":1,"pereira":1,"bittencourt":1,"percentiles":1,"brazilian":1,"elsa":1,"brasil":1,"mcevoy":1,"nasir":1,"calci":2,"clerosis":1,"fcvm":1,"diabres":3,"brunzell":1,"furberg":1,"conference":1,"034":1,"seshasai":1,"murray":2,"robinson":1,"lichtenstein":1,"newman":1,"tobert":1,"arte":1,"rioscler":1,"thromb":2,"e38":1,"e81":1,"atv":2,"0000000000000073":1,"arterioscler":2,"e158":2,"0000000000000081":2,"chai":2,"zy":2,"e009835":1,"jaha":4,"009835":1,"hlatky":1,"manson":1,"das":2,"pradhan":1,"fruchart":1,"nejmoa2210645":1,"brien":1,"field":1,"dc08":2,"bruckert":2,"labreuche":2,"deplanque":2,"touboul":2,"amarenco":2,"fibrates":2,"fjc":1,"0b013e318202709f":1,"saver":2,"tow":1,"ghi":1,"chow":1,"ovbiagele":2,"nejmoa1812792":1,"suh":1,"plauschinat":1,"barone":1,"hypertens":2,"hjh":1,"0b013e32832d4aee":1,"hypertensionaha":1,"stratton":1,"neter":1,"stam":1,"kok":1,"grobbee":1,"geleijnse":1,"hyp":3,"0000094221":1,"cornelissen":1,"e004473":1,"004473":1,"conlin":1,"00045415":2,"00013":2,"davi":1,"hodgson":1,"bryan":1,"endothelial":1,"medley":1,"ajcn":1,"saglimbene":1,"ruospo":1,"lirico":1,"asn":1,"fried":1,"emanuele":1,"nejmoa1303154":1,"navarese":1,"yusuf":2,"pogue":2,"telmisartan":2,"ramipril":2,"twork":1,"nejmoa0801317":1,"pressel":1,"allhat":1,"pischon":1,"789x":1,"00044":1,"hardt":1,"kunz":1,"luft":1,"hypothesis":1,"adrenergic":1,"carey":1,"calhoun":1,"e53":2,"e90":2,"0000000000000084":2,"reincke":2,"aldosteronism":1,"revisited":1,"r19":1,"r29":1,"eje":1,"0990":1,"nejmoa2025845":1,"fidelity":1,"eurheartj":1,"ehab777":1,"corrigendum":2,"ehab886":1,"nejmoa2110956":2,"kerendia":2,"nere":1,"ilippatos":1,"215341s000lbl":1,"rezaie":1,"kengne":1,"cotransport":1,"e004007":1,"004007":1,"riche":1,"bourret":1,"chamberlin":1,"e9":1,"jash":1,"015":2,"berra":2,"manfrini":2,"regazzoli":2,"phrs":1,"raghavan":1,"vassy":1,"ho":1,"yl":1,"e011295":1,"011295":1,"00203":1,"nejmoa1611925":1,"nejmoa1504720":2,"braunwald":1,"nejmoa1307684":1,"actos":1,"hydrochloride":1,"021073s043s044lbl":1,"curtis":2,"oung":1,"024863":1,"fu":1,"ijgm":1,"s327075":1,"grewal":1,"zaman":1,"borgatta":1,"nudy":1,"foy":2,"peterson":2,"usefulness":2,"amjcard":2,"043":1,"malhotra":1,"katsanos":1,"lambadiari":1,"s00415":1,"09813":1,"birtcher":1,"strokeaha":2,"013977":1,"jamaneurol":2,"0079":2,"031623":1,"s41598":1,"supreme":1,"nejmoa2022190":1,"051685":1,"jongs":1,"00242":1,"nejmoa2204233":1,"036418":1,"cjn":2,"dc20":2,"0978":1,"s12020":2,"02889":2,"arvinen":1,"juurinen":1,"alvarsson":1,"dc06":1,"gerich":1,"zisman":1,"morales":1,"stewart":1,"stuhr":1,"vlajnic":1,"e000171":2,"000171":2,"luzio":1,"sert":1,"langeron":1,"01459":1,"lankisch":1,"ferlinz":1,"leahy":1,"scherbaum":1,"simpli":1,"00967":1,"vora":1,"hockey":1,"whately":1,"lan":2,"scape":2,"schunder":2,"tatzber":2,"neilson":2,"rgine":1,"awake":1,"emermed":1,"ammons":1,"phadnis":1,"nonaqueous":1,"1932296814565131":1,"ovelmann":1,"bysted":1,"mouritzen":1,"dc17":1,"cummins":1,"junaidi":1,"kit":1,"e002137":2,"002137":2,"pontiroli":2,"promising":2,"1932296814557518":1,"foster":1,"dc15":1,"powder":1,"baqsimi":1,"210134s000lbl":1,"casanova":1,"gobin":1,"villani":1,"verger":1,"seasonal":2,"uenza":2,"pcd":2,"poland":2,"pneumococcal":2,"za":1,"slaughter":1,"duffus":1,"tripled":1,"tahrat":1,"bekkat":1,"berkani":1,"immunogenicity":1,"vaccin":1,"immunother":1,"srivastav":1,"mmwr":1,"surveill":1,"summ":1,"ss7003a1":1,"bridges":2,"harpaz":2,"jacobson":1,"vann":1,"coyne":1,"beasley":1,"asafu":1,"adjei":1,"szilagyi":1,"reminder":1,"recall":1,"cd003941":1,"pub3":1,"nichol":1,"lipczynski":1,"s28":1,"s35":1,"amjmed":1,"nowalk":1,"moehling":1,"raviotta":1,"contained":1,"inaccurate":1,"originally":1,"info":1,"pmid":1,"corrections":1,"sentence":2,"dihdropyridine":1,"deleted":1,"inadvertently":1,"877e886":2,"footnote":1,"intent":1,"vasodilatory":1,"dihydropyridines":1},"chunks":[{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":1,"chunkId":"ada-easd-2022-p1-c0","text":"Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, Robert A. Gabbay, Jennifer Green, Nisa M. Maruthur, Sylvia E. Rosas, Stefano Del Prato, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Tsvetalina Tankova, Apostolos Tsapas, and John B. Buse Diabetes Care 2022;45(11):2753  2786 | https://doi.org/10.2337/dci22-0034 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"10":1,"11":2,"17":1,"45":2,"2022":2,"2026":1,"2337":1,"2753":2,"2786":1,"691567":1,"management":1,"of":2,"hyperglycemia":1,"in":1,"type":1,"diabetes":4,"consensus":1,"report":1,"by":2,"the":3,"american":1,"association":2,"ada":1,"and":2,"european":1,"for":1,"study":1,"easd":1,"melanie":1,"davies":1,"vanita":1,"aroda":1,"billy":1,"collins":1,"robert":1,"gabbay":1,"jennifer":1,"green":1,"nisa":1,"maruthur":1,"sylvia":1,"rosas":1,"stefano":1,"del":1,"prato":1,"chantal":1,"mathieu":1,"geltrude":1,"mingrone":1,"peter":1,"rossing":1,"tsvetalina":1,"tankova":1,"apostolos":1,"tsapas":1,"john":1,"buse":1,"care":2,"https":1,"doi":1,"org":2,"dci22":1,"0034":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"article":1,"pdf":2,"dci220034":1,"guest":1,"on":1,"february":1},"len":89},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":2,"chunkId":"ada-easd-2022-p2-c0","text":"Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 2022;45:2753  2786 | https://doi.org/10.2337/dci22-0034 Melanie J. Davies, 1,2 Vanita R. Aroda, 3 Billy S. Collins, 4 Robert A. Gabbay, 5 Jennifer Green, 6 Nisa M. Maruthur, 7 Sylvia E. Rosas, 8 Stefano Del Prato, 9 Chantal Mathieu, 10 Geltrude Mingrone, 11,12,13 Peter Rossing, 14,15 Tsvetalina Tankova, 16 Apostolos Tsapas, 17,18 and John B. Buse 19 The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommenda- tions. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium  glucose cotransporter 2 inhibitors and glucagon-like peptide 1","tf":{"10":2,"11":1,"12":1,"13":1,"14":1,"15":1,"16":1,"17":1,"18":1,"19":1,"45":1,"2006":1,"2018":1,"2019":1,"2022":2,"2337":1,"2753":1,"2786":1,"management":4,"of":9,"hyperglycemia":2,"in":5,"type":2,"diabetes":9,"consensus":2,"report":1,"by":1,"the":15,"american":2,"association":4,"ada":1,"and":8,"european":2,"for":2,"study":2,"easd":1,"care":4,"https":1,"doi":1,"org":1,"dci22":1,"0034":1,"melanie":1,"davies":1,"vanita":1,"aroda":1,"billy":1,"collins":1,"robert":1,"gabbay":1,"jennifer":1,"green":1,"nisa":1,"maruthur":1,"sylvia":1,"rosas":1,"stefano":1,"del":1,"prato":1,"chantal":1,"mathieu":1,"geltrude":1,"mingrone":1,"peter":1,"rossing":1,"tsvetalina":1,"tankova":1,"apostolos":1,"tsapas":1,"john":1,"buse":1,"convened":1,"panel":1,"to":2,"update":1,"previous":1,"statements":1,"on":3,"adults":1,"published":1,"since":2,"last":1,"updated":1,"target":1,"audience":1,"is":2,"full":1,"spectrum":1,"professional":1,"health":3,"team":1,"providing":1,"europe":1,"systematic":1,"examination":1,"publications":1,"informed":1,"new":1,"recommenda":1,"tions":1,"these":1,"include":1,"additional":1,"focus":1,"social":1,"determinants":1,"system":1,"physical":1,"activity":1,"behaviors":1,"including":1,"sleep":1,"there":1,"greater":1,"emphasis":1,"weight":1,"as":1,"part":1,"holistic":1,"approach":1,"results":1,"cardiovascular":1,"kidney":1,"outcomes":1,"trials":1,"involving":1,"sodium":1,"glucose":1,"cotransporter":1,"inhibitors":1,"glucagon":1,"like":1,"peptide":1},"len":199},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":2,"chunkId":"ada-easd-2022-p2-c1","text":"leep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium  glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal dis- ease. After a summary listing of consensus recommendations, practical tips for implementation are provided. Type 2 diabetes is a chronic complex disease, and management requires multifacto- rial behavioral and pharmacological treatments to prevent or delay complications and maintain quality of life (Fig. 1). This includes management of blood glucose lev- els, weight, cardiovascular risk factors, comorbidities, and complications. This necessi- tates that care be delivered in an organized and structured way, such as described in the chronic care model, and includes a person-centered approach to enhance en- gagement in self-care activities (1). Careful consideration of social determinants of health and the preferences of people living with diabetes must inform individualiza- tion of treatment goals and strategies (2). This consensus report addresses the approaches to management of blood glucose levels in nonpregnant adults with type 2 diabetes. The principles and appro","tf":{"leep":1,"there":1,"is":2,"greater":1,"emphasis":1,"on":1,"weight":2,"management":5,"as":2,"part":1,"of":12,"the":6,"holistic":1,"approach":2,"to":4,"diabetes":5,"results":1,"cardiovascular":2,"and":11,"kidney":1,"outcomes":1,"trials":1,"involving":1,"sodium":1,"glucose":3,"cotransporter":1,"inhibitors":1,"glucagon":1,"like":1,"peptide":1,"receptor":1,"agonists":1,"including":1,"assessment":1,"subgroups":1,"inform":2,"broader":1,"recommendations":2,"for":2,"cardiorenal":2,"protection":1,"in":5,"people":2,"with":3,"at":1,"high":1,"risk":2,"dis":1,"ease":1,"after":1,"summary":1,"listing":1,"consensus":2,"practical":1,"tips":1,"implementation":1,"are":1,"provided":1,"type":2,"chronic":2,"complex":1,"disease":1,"requires":1,"multifacto":1,"rial":1,"behavioral":1,"pharmacological":1,"treatments":1,"prevent":1,"or":1,"delay":1,"complications":2,"maintain":1,"quality":1,"life":1,"fig":1,"this":3,"includes":2,"blood":2,"lev":1,"els":1,"factors":1,"comorbidities":1,"necessi":1,"tates":1,"that":1,"care":3,"be":1,"delivered":1,"an":1,"organized":1,"structured":1,"way":1,"such":1,"described":1,"model":1,"person":1,"centered":1,"enhance":1,"en":1,"gagement":1,"self":1,"activities":1,"careful":1,"consideration":1,"social":1,"determinants":1,"health":1,"preferences":1,"living":1,"must":1,"individualiza":1,"tion":1,"treatment":1,"goals":1,"strategies":1,"report":1,"addresses":1,"approaches":1,"levels":1,"nonpregnant":1,"adults":1,"principles":1,"appro":1},"len":190},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":2,"chunkId":"ada-easd-2022-p2-c2","text":"ople living with diabetes must inform individualiza- tion of treatment goals and strategies (2). This consensus report addresses the approaches to management of blood glucose levels in nonpregnant adults with type 2 diabetes. The principles and approach for achieving this are summarized in Fig. 1. These recommendations are not generally applicable to individuals with diabetes due to other causes, for example, monogenic diabetes, secondary diabetes, and type 1 diabetes, or to children. 1 Leicester Diabetes Research Centre, University of Leicester, Leicester, U.K. 2 Leicester National Institute for Health Research Biomedical Research Centre, University Hospitals of Leicester NHS Trust, Leicester, U.K. 3 Division of Endocrinology, Diabetes and Hypertension, Brigham and Women  s Hospital, Harvard Medical School, Boston, MA 4 National Heart, Lung, and Blood Institute, Bethesda, MD 5 American Diabetes Association, Arlington, VA 6 Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 7 Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 8 Kidney and Hypertension Unit, Joslin Diabetes Center, Harvard Medical School, Boston, MA 9 Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy 10 Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium 11 Universit \u0012 a Cattolica del Sacro Cuore, Rome,","tf":{"10":1,"11":1,"ople":1,"living":1,"with":3,"diabetes":10,"must":1,"inform":1,"individualiza":1,"tion":1,"of":10,"treatment":1,"goals":1,"and":9,"strategies":1,"this":2,"consensus":1,"report":1,"addresses":1,"the":2,"approaches":1,"to":4,"management":1,"blood":2,"glucose":1,"levels":1,"in":2,"nonpregnant":1,"adults":1,"type":2,"principles":1,"approach":1,"for":3,"achieving":1,"are":2,"summarized":1,"fig":1,"these":1,"recommendations":1,"not":1,"generally":1,"applicable":1,"individuals":1,"due":1,"other":1,"causes":1,"example":1,"monogenic":1,"secondary":1,"or":1,"children":1,"leicester":6,"research":4,"centre":2,"university":5,"national":2,"institute":3,"health":1,"biomedical":1,"hospitals":1,"nhs":1,"trust":1,"division":1,"endocrinology":2,"hypertension":2,"brigham":1,"women":1,"hospital":1,"harvard":2,"medical":2,"school":4,"boston":2,"ma":2,"heart":1,"lung":1,"bethesda":1,"md":2,"american":1,"association":1,"arlington":1,"va":1,"duke":2,"clinical":3,"medicine":4,"durham":1,"nc":1,"department":2,"johns":1,"hopkins":1,"baltimore":1,"kidney":1,"unit":1,"joslin":1,"center":1,"experimental":2,"pisa":2,"italy":1,"ku":1,"leuven":2,"belgium":1,"universit":1,"cattolica":1,"del":1,"sacro":1,"cuore":1,"rome":1},"len":181},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":2,"chunkId":"ada-easd-2022-p2-c3","text":"es Center, Harvard Medical School, Boston, MA 9 Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy 10 Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium 11 Universit \u0012 a Cattolica del Sacro Cuore, Rome, Italy 12 Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy 13 Division of Diabetes and Nutritional Sciences, School of Cardiovascular and Metabolic Medicine and Sciences, King  s College London, London, U.K. 14 Steno Diabetes Center Copenhagen, Herlev, Denmark 15 Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark 16 Department of Endocrinology, Medical University  So fi a, So fi a, Bulgaria CONSENSUS REPORT Diabetes Care Volume 45, November 2022 2753 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"10":1,"11":2,"12":1,"13":1,"14":1,"15":1,"16":1,"17":1,"45":2,"2022":1,"2026":1,"2753":2,"691567":1,"es":1,"center":2,"harvard":1,"medical":2,"school":2,"boston":1,"ma":1,"department":3,"of":7,"clinical":3,"and":5,"experimental":2,"medicine":3,"university":3,"pisa":2,"italy":3,"endocrinology":2,"ku":1,"leuven":2,"belgium":1,"universit":1,"cattolica":1,"del":1,"sacro":1,"cuore":1,"rome":2,"fondazione":1,"policlinico":1,"universitario":1,"gemelli":1,"irccs":1,"division":1,"diabetes":3,"nutritional":1,"sciences":2,"cardiovascular":1,"metabolic":1,"king":1,"college":1,"london":2,"steno":1,"copenhagen":3,"herlev":1,"denmark":2,"so":2,"fi":2,"bulgaria":1,"consensus":1,"report":1,"care":2,"volume":1,"november":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"february":1},"len":119},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":3,"chunkId":"ada-easd-2022-p3-c0","text":"DATA SOURCES, SEARCHES, AND STUDY SELECTION The writing group members were ap- pointed by the American Diabetes Associ- ation (ADA) and European Association for the Study of Diabetes (EASD). The group largely worked virtually, with regular tele- conferences from September 2021, a 3-day workshop in January 2022, and a face-to-face 2-day meeting in April 2022. The writing group accepted the 2012 (3), 2015 (4), 2018 (5), and 2019 (6) editions of this consensus report as a starting point. To identify newer evidence, a search was conducted on PubMed for random- ized control trials (RCTs), systematic re- views, and meta-analyses published in English between 28 January 2018 and 13 June 2022; eligible publications ex- amined the effectiveness or safety of pharmacological or nonpharmacological interventions in adults with type 2 dia- betes. Reference lists in eligible reports were scanned to identify additional rel- evant articles. Details of the keywords and the search strategy are available at https://data.mendeley.com/datasets/ h5rcnxpk8w/2. Papers were grouped according to subject, and the authors re- viewed this new evidence. Up-to-date meta-analyses evaluating the effects of therapeutic interventions across clinically important subgroup populations were assessed in terms of their credibility us- ing relevant guidance (7,8). Evidence ap- praisal was informed by the Grading of Recom","tf":{"13":1,"28":1,"2012":1,"2015":1,"2018":2,"2019":1,"2021":1,"2022":3,"data":2,"sources":1,"searches":1,"and":8,"study":2,"selection":1,"the":12,"writing":2,"group":3,"members":1,"were":4,"ap":2,"pointed":1,"by":2,"american":1,"diabetes":2,"associ":1,"ation":1,"ada":1,"european":1,"association":1,"for":2,"of":7,"easd":1,"largely":1,"worked":1,"virtually":1,"with":2,"regular":1,"tele":1,"conferences":1,"from":1,"september":1,"day":2,"workshop":1,"in":6,"january":2,"face":2,"to":5,"meeting":1,"april":1,"accepted":1,"editions":1,"this":2,"consensus":1,"report":1,"as":1,"starting":1,"point":1,"identify":2,"newer":1,"evidence":3,"search":2,"was":2,"conducted":1,"on":1,"pubmed":1,"random":1,"ized":1,"control":1,"trials":1,"rcts":1,"systematic":1,"re":2,"views":1,"meta":2,"analyses":2,"published":1,"english":1,"between":1,"june":1,"eligible":2,"publications":1,"ex":1,"amined":1,"effectiveness":1,"or":2,"safety":1,"pharmacological":1,"nonpharmacological":1,"interventions":2,"adults":1,"type":1,"dia":1,"betes":1,"reference":1,"lists":1,"reports":1,"scanned":1,"additional":1,"rel":1,"evant":1,"articles":1,"details":1,"keywords":1,"strategy":1,"are":1,"available":1,"at":1,"https":1,"mendeley":1,"com":1,"datasets":1,"h5rcnxpk8w":1,"papers":1,"grouped":1,"according":1,"subject":1,"authors":1,"viewed":1,"new":1,"up":1,"date":1,"evaluating":1,"effects":1,"therapeutic":1,"across":1,"clinically":1,"important":1,"subgroup":1,"populations":1,"assessed":1,"terms":1,"their":1,"credibility":1,"us":1,"ing":1,"relevant":1,"guidance":1,"praisal":1,"informed":1,"grading":1,"recom":1},"len":205},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":3,"chunkId":"ada-easd-2022-p3-c1","text":" meta-analyses evaluating the effects of therapeutic interventions across clinically important subgroup populations were assessed in terms of their credibility us- ing relevant guidance (7,8). Evidence ap- praisal was informed by the Grading of Recommendations Assessment, Develop- ment and Evaluation (GRADE) guidelines on the formulation of clinical practice recommendations (9,10). The draft con- sensus recommendations were evaluated by invited reviewers and presented for public comment. Suggestions were incor- porated as deemed appropriate by the authors (see Acknowledgments ). Never- theless, although evidence based with stakeholder input, the recommendations presented herein re fl ect the values and preferences of the consensus group. THE RATIONALE, IMPORTANCE, AND CONTEXT OF GLUCOSE- LOWERING TREATMENT Fundamental aspects of diabetes care in- clude promoting healthy behaviors through medical nutrition therapy (MNT), physical activity, and psychological support, as well as weight management and tobacco/sub- stance abuse counseling as needed. This is often delivered in the context of dia- betes self-management education and support (DSMES). The expanding number of glucose-lowering interventions  from behavioral interventions to pharmacolog- ical interventions, devices, and surgery  and growing information about their ben- e fi ts and risks provide more options for people wi","tf":{"10":1,"meta":1,"analyses":1,"evaluating":1,"the":11,"effects":1,"of":9,"therapeutic":1,"interventions":4,"across":1,"clinically":1,"important":1,"subgroup":1,"populations":1,"were":3,"assessed":1,"in":3,"terms":1,"their":2,"credibility":1,"us":1,"ing":1,"relevant":1,"guidance":1,"evidence":2,"ap":1,"praisal":1,"was":1,"informed":1,"by":3,"grading":1,"recommendations":4,"assessment":1,"develop":1,"ment":1,"and":10,"evaluation":1,"grade":1,"guidelines":1,"on":1,"formulation":1,"clinical":1,"practice":1,"draft":1,"con":1,"sensus":1,"evaluated":1,"invited":1,"reviewers":1,"presented":2,"for":2,"public":1,"comment":1,"suggestions":1,"incor":1,"porated":1,"as":4,"deemed":1,"appropriate":1,"authors":1,"see":1,"acknowledgments":1,"never":1,"theless":1,"although":1,"based":1,"with":1,"stakeholder":1,"input":1,"herein":1,"re":1,"fl":1,"ect":1,"values":1,"preferences":1,"consensus":1,"group":1,"rationale":1,"importance":1,"context":2,"glucose":2,"lowering":2,"treatment":1,"fundamental":1,"aspects":1,"diabetes":1,"care":1,"clude":1,"promoting":1,"healthy":1,"behaviors":1,"through":1,"medical":1,"nutrition":1,"therapy":1,"mnt":1,"physical":1,"activity":1,"psychological":1,"support":2,"well":1,"weight":1,"management":2,"tobacco":1,"sub":1,"stance":1,"abuse":1,"counseling":1,"needed":1,"this":1,"is":1,"often":1,"delivered":1,"dia":1,"betes":1,"self":1,"education":1,"dsmes":1,"expanding":1,"number":1,"from":1,"behavioral":1,"to":1,"pharmacolog":1,"ical":1,"devices":1,"surgery":1,"growing":1,"information":1,"about":1,"ben":1,"fi":1,"ts":1,"risks":1,"provide":1,"more":1,"options":1,"people":1,"wi":1},"len":190},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":3,"chunkId":"ada-easd-2022-p3-c2","text":"t (DSMES). The expanding number of glucose-lowering interventions  from behavioral interventions to pharmacolog- ical interventions, devices, and surgery  and growing information about their ben- e fi ts and risks provide more options for people with diabetes and providers but complicate decision-making. The demon- strated bene fi ts for high-risk individuals with atherosclerotic cardiovascular disease (CVD), heart failure (HF), or chronic kidney disease (CKD) afforded by the glucagon- like peptide 1 receptor agonists (GLP-1 RA) and sodium  glucose cotransporter 2 inhibitors (SGLT2i) provide important prog- ress in treatment aimed at reducing the progression and burden of diabetes and its complications. These bene fi ts are largely independent of their glucose-lowering ef- fects. These treatments were initially in- troduced as glucose-lowering agents but are now also prescribed for organ protec- tion. In this consensus report, we summa- rize a large body of recent evidence for practitioners in the U.S. and Europe with the aim of simplifying clinical decision- making and focusing our efforts on pro- viding holistic person-centered care. Attaining recommended glycemic tar- gets yields substantial and enduring re- ductions in the onset and progression of microvascular complications (11,12), and early intervention is essential (13). The greatest absolute risk reduction comes fro","tf":{"11":1,"12":1,"13":1,"dsmes":1,"the":8,"expanding":1,"number":1,"of":6,"glucose":4,"lowering":3,"interventions":3,"from":1,"behavioral":1,"to":1,"pharmacolog":1,"ical":1,"devices":1,"and":12,"surgery":1,"growing":1,"information":1,"about":1,"their":2,"ben":1,"fi":3,"ts":3,"risks":1,"provide":2,"more":1,"options":1,"for":4,"people":1,"with":3,"diabetes":2,"providers":1,"but":2,"complicate":1,"decision":2,"making":2,"demon":1,"strated":1,"bene":2,"high":1,"risk":2,"individuals":1,"atherosclerotic":1,"cardiovascular":1,"disease":2,"cvd":1,"heart":1,"failure":1,"hf":1,"or":1,"chronic":1,"kidney":1,"ckd":1,"afforded":1,"by":1,"glucagon":1,"like":1,"peptide":1,"receptor":1,"agonists":1,"glp":1,"ra":1,"sodium":1,"cotransporter":1,"inhibitors":1,"sglt2i":1,"important":1,"prog":1,"ress":1,"in":5,"treatment":1,"aimed":1,"at":1,"reducing":1,"progression":2,"burden":1,"its":1,"complications":2,"these":2,"are":2,"largely":1,"independent":1,"ef":1,"fects":1,"treatments":1,"were":1,"initially":1,"troduced":1,"as":1,"agents":1,"now":1,"also":1,"prescribed":1,"organ":1,"protec":1,"tion":1,"this":1,"consensus":1,"report":1,"we":1,"summa":1,"rize":1,"large":1,"body":1,"recent":1,"evidence":1,"practitioners":1,"europe":1,"aim":1,"simplifying":1,"clinical":1,"focusing":1,"our":1,"efforts":1,"on":1,"pro":1,"viding":1,"holistic":1,"person":1,"centered":1,"care":1,"attaining":1,"recommended":1,"glycemic":1,"tar":1,"gets":1,"yields":1,"substantial":1,"enduring":1,"re":1,"ductions":1,"onset":1,"microvascular":1,"early":1,"intervention":1,"is":1,"essential":1,"greatest":1,"absolute":1,"reduction":1,"comes":1,"fro":1},"len":201},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":3,"chunkId":"ada-easd-2022-p3-c3","text":" care. Attaining recommended glycemic tar- gets yields substantial and enduring re- ductions in the onset and progression of microvascular complications (11,12), and early intervention is essential (13). The greatest absolute risk reduction comes from improving very elevated glycemic lev- els, and a more modest reduction results from near normalization of plasma glucose levels (2,14). The impact of glucose control on macrovascular complications is less certain but is supported by multiple meta- analyses and epidemiological studies. Be- cause the bene fi ts of intensive glucose control emerge slowly while the harms can be immediate, people with longer life expectancy have more to gain from early intensive glycemic management. A reason- able HbA 1c target for most nonpregnant adults with suf fi cient life expectancy to see microvascular bene fi ts (generally \u0018 10 years) is around 53 mmol/mol (7%) or less (2). Aiming for a lower HbA 1c level than this may have value if it can be achieved safely without signi fi cant hypogly- cemia or other adverse treatment effects. A lower target may be reasonable, particu- larly when using pharmacological agents that are not associated with hypoglycemic risk. Higher targets can be appropriate in cases of limited life expectancy, advanced complications, or poor tolerability or if other factors such as frailty are present. Thus, glycemic treatment","tf":{"10":1,"11":1,"12":1,"13":1,"14":1,"53":1,"care":1,"attaining":1,"recommended":1,"glycemic":4,"tar":1,"gets":1,"yields":1,"substantial":1,"and":5,"enduring":1,"re":1,"ductions":1,"in":2,"the":5,"onset":1,"progression":1,"of":5,"microvascular":2,"complications":3,"early":2,"intervention":1,"is":4,"essential":1,"greatest":1,"absolute":1,"risk":2,"reduction":2,"comes":1,"from":3,"improving":1,"very":1,"elevated":1,"lev":1,"els":1,"more":2,"modest":1,"results":1,"near":1,"normalization":1,"plasma":1,"glucose":3,"levels":1,"impact":1,"control":2,"on":1,"macrovascular":1,"less":2,"certain":1,"but":1,"supported":1,"by":1,"multiple":1,"meta":1,"analyses":1,"epidemiological":1,"studies":1,"be":5,"cause":1,"bene":2,"fi":4,"ts":2,"intensive":2,"emerge":1,"slowly":1,"while":1,"harms":1,"can":3,"immediate":1,"people":1,"with":3,"longer":1,"life":3,"expectancy":3,"have":2,"to":2,"gain":1,"management":1,"reason":1,"able":1,"hba":2,"1c":2,"target":2,"for":2,"most":1,"nonpregnant":1,"adults":1,"suf":1,"cient":1,"see":1,"generally":1,"years":1,"around":1,"mmol":1,"mol":1,"or":4,"aiming":1,"lower":2,"level":1,"than":1,"this":1,"may":2,"value":1,"if":2,"it":1,"achieved":1,"safely":1,"without":1,"signi":1,"cant":1,"hypogly":1,"cemia":1,"other":2,"adverse":1,"treatment":2,"effects":1,"reasonable":1,"particu":1,"larly":1,"when":1,"using":1,"pharmacological":1,"agents":1,"that":1,"are":2,"not":1,"associated":1,"hypoglycemic":1,"higher":1,"targets":1,"appropriate":1,"cases":1,"limited":1,"advanced":1,"poor":1,"tolerability":1,"factors":1,"such":1,"as":1,"frailty":1,"present":1,"thus":1},"len":212},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":3,"chunkId":"ada-easd-2022-p3-c4","text":"gical agents that are not associated with hypoglycemic risk. Higher targets can be appropriate in cases of limited life expectancy, advanced complications, or poor tolerability or if other factors such as frailty are present. Thus, glycemic treatment targets should be tailored based on an individual  s preferen- ces and characteristics, including younger age (i.e., age < 40 years), risk of compli- cations, frailty and comorbid conditions (2,15  17), and the impact of these features on the risk of adverse effects of therapy (e.g., hypoglycemia and weight gain). PRINCIPLES OF CARE Language Matters Communication between people living with type 2 diabetes and health care team members is at the core of inte- grated care, and clinicians must recognize 17 Diabetes Centre, Clinical Research and Evidence- Based Medicine Unit, Aristotle University Thessaloniki, Thessaloniki, Greece 18 Harris Manchester College, University of Oxford, Oxford, U.K. 19 University of North Carolina School of Medicine, Chapel Hill, NC Corresponding author: John B. Buse, jbuse@ med.unc.edu Received 2 August 2022 and accepted 4 August 2022 This article is being simultaneously published in Diabetologia (https://doi.org/10.1007/s00125-022- 05787-2) and Diabetes Care (https://doi.org/10.2337/ dci22-0034) by the European Association for the Study of Diabetes and American Diabetes Association. A consensus report of","tf":{"10":2,"15":1,"17":2,"18":1,"19":1,"40":1,"1007":1,"2022":2,"2337":1,"gical":1,"agents":1,"that":1,"are":2,"not":1,"associated":1,"with":2,"hypoglycemic":1,"risk":3,"higher":1,"targets":2,"can":1,"be":2,"appropriate":1,"in":2,"cases":1,"of":12,"limited":1,"life":1,"expectancy":1,"advanced":1,"complications":1,"or":2,"poor":1,"tolerability":1,"if":1,"other":1,"factors":1,"such":1,"as":1,"frailty":2,"present":1,"thus":1,"glycemic":1,"treatment":1,"should":1,"tailored":1,"based":2,"on":2,"an":1,"individual":1,"preferen":1,"ces":1,"and":10,"characteristics":1,"including":1,"younger":1,"age":2,"years":1,"compli":1,"cations":1,"comorbid":1,"conditions":1,"the":5,"impact":1,"these":1,"features":1,"adverse":1,"effects":1,"therapy":1,"hypoglycemia":1,"weight":1,"gain":1,"principles":1,"care":4,"language":1,"matters":1,"communication":1,"between":1,"people":1,"living":1,"type":1,"diabetes":5,"health":1,"team":1,"members":1,"is":2,"at":1,"core":1,"inte":1,"grated":1,"clinicians":1,"must":1,"recognize":1,"centre":1,"clinical":1,"research":1,"evidence":1,"medicine":2,"unit":1,"aristotle":1,"university":3,"thessaloniki":2,"greece":1,"harris":1,"manchester":1,"college":1,"oxford":2,"north":1,"carolina":1,"school":1,"chapel":1,"hill":1,"nc":1,"corresponding":1,"author":1,"john":1,"buse":1,"jbuse":1,"med":1,"unc":1,"edu":1,"received":1,"august":2,"accepted":1,"this":1,"article":1,"being":1,"simultaneously":1,"published":1,"diabetologia":1,"https":2,"doi":2,"org":2,"s00125":1,"022":1,"05787":1,"dci22":1,"0034":1,"by":1,"european":1,"association":2,"for":1,"study":1,"american":1,"consensus":1,"report":1},"len":203},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":3,"chunkId":"ada-easd-2022-p3-c5","text":"ultaneously published in Diabetologia (https://doi.org/10.1007/s00125-022- 05787-2) and Diabetes Care (https://doi.org/10.2337/ dci22-0034) by the European Association for the Study of Diabetes and American Diabetes Association. A consensus report of a particular topic contains a comprehensive examination and is authored by an expert panel and represents the panel  s collective analysis, evaluation and opinion. M.J.D. and J.B.B. were co-chairs for the Consensus Report Writing Group. V.R.A., B.S.C., R.A.G., J.G., N.M.M., and S.E.R. were the writing group members for ADA. S.D.P., C.M., G.M., P.R., T.T., and A.T. were the writing group members for EASD. The article was reviewed for EASD by its Committee on Clinical Affairs and approved by its Executive Board. The article was reviewed for ADA by its Professional Practice Committee. This article contains supplementary material online at https://doi.org/10.2337/ fi gshare.20800537.  2022 by the American Diabetes Association and the European Association for the Study of Diabetes. Readers may use this article as long as the work is properly cited, the use is educational and not for pro fi t, and the work is not altered. More information is available at https://www. diabetesjournals.org/journals/pages/license. 2754 Consensus Report Diabetes Care Volume 45, November 2022 Downloaded from http://diabetesjournals.org/care/article-pdf/45/1","tf":{"10":3,"45":2,"1007":1,"2022":2,"2337":2,"2754":1,"20800537":1,"ultaneously":1,"published":1,"in":1,"diabetologia":1,"https":4,"doi":3,"org":5,"s00125":1,"022":1,"05787":1,"and":12,"diabetes":6,"care":3,"dci22":1,"0034":1,"by":6,"the":14,"european":2,"association":4,"for":8,"study":2,"of":3,"american":2,"consensus":3,"report":3,"particular":1,"topic":1,"contains":2,"comprehensive":1,"examination":1,"is":5,"authored":1,"an":1,"expert":1,"panel":2,"represents":1,"collective":1,"analysis":1,"evaluation":1,"opinion":1,"were":3,"co":1,"chairs":1,"writing":3,"group":3,"members":2,"ada":2,"easd":2,"article":5,"was":2,"reviewed":2,"its":3,"committee":2,"on":1,"clinical":1,"affairs":1,"approved":1,"executive":1,"board":1,"professional":1,"practice":1,"this":2,"supplementary":1,"material":1,"online":1,"at":2,"fi":2,"gshare":1,"readers":1,"may":1,"use":2,"as":2,"long":1,"work":2,"properly":1,"cited":1,"educational":1,"not":2,"pro":1,"altered":1,"more":1,"information":1,"available":1,"www":1,"diabetesjournals":2,"journals":1,"pages":1,"license":1,"volume":1,"november":1,"downloaded":1,"from":1,"http":1,"pdf":1},"len":202},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":3,"chunkId":"ada-easd-2022-p3-c6","text":" t, and the work is not altered. More information is available at https://www. diabetesjournals.org/journals/pages/license. 2754 Consensus Report Diabetes Care Volume 45, November 2022 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"45":2,"2022":1,"2026":1,"2753":1,"2754":1,"691567":1,"and":1,"the":1,"work":1,"is":2,"not":1,"altered":1,"more":1,"information":1,"available":1,"at":1,"https":1,"www":1,"diabetesjournals":2,"org":2,"journals":1,"pages":1,"license":1,"consensus":1,"report":1,"diabetes":1,"care":2,"volume":1,"november":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"february":1},"len":47},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":4,"chunkId":"ada-easd-2022-p4-c0","text":"Figure 1  Decision cycle for person-centered glycemic management in type 2 diabetes. Adapted from Davies et al. (5) with permission. BGM, blood glucose monitoring; BP, blood pressure; CGM, continuous glucose monitoring; CKD, chronic kidney disease; CVD, atherosclerotic cardiovascular disease; DSMES, diabetes self-management education and support; HF, heart failure. diabetesjournals.org/care Davies and Associates 2755 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"45":1,"2026":1,"2753":1,"2755":1,"691567":1,"figure":1,"decision":1,"cycle":1,"for":1,"person":1,"centered":1,"glycemic":1,"management":2,"in":1,"type":1,"diabetes":2,"adapted":1,"from":2,"davies":2,"et":1,"al":1,"with":1,"permission":1,"bgm":1,"blood":2,"glucose":2,"monitoring":2,"bp":1,"pressure":1,"cgm":1,"continuous":1,"ckd":1,"chronic":1,"kidney":1,"disease":2,"cvd":1,"atherosclerotic":1,"cardiovascular":1,"dsmes":1,"self":1,"education":1,"and":2,"support":1,"hf":1,"heart":1,"failure":1,"diabetesjournals":2,"org":2,"care":2,"associates":1,"downloaded":1,"http":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"february":1},"len":74},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":5,"chunkId":"ada-easd-2022-p5-c0","text":"how language matters. Language in dia- betes care should be neutral, free of stigma, and based on facts; be strength- based (focus on what is working), respect- ful, and inclusive; encourage collaboration; and be person-centered (18). People living with diabetes should not be referred to as  diabetics  or described as  noncompliant  or blamed for their health condition. Diabetes Self-Management Education and Support DSMES is a key intervention, as important to the treatment plan as the selection of pharmacotherapy (19  21). DSMES is cen- tral to establishing and implementing the principles of care (Fig. 1). DSMES pro- grams usually involve face-to-face contact in group or individual sessions with trained educators, and key components of DSMES are shown in Supplementary Table 1 (19  24). Given the ever-changing nature of type 2 diabetes, DSMES should be of- fered on an ongoing basis. Critical junc- tures when DSMES should be provided include at diagnosis, annually, when com- plications arise, and during transitions in life and care (Supplementary Table 1) (22). High-quality evidence has consistently shown that DSMES signi fi cantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hos- pital admissions and all-cause mortality, and is cost-effective (22,25  30). DSMES is delivered through structured educational programs provided by train","tf":{"18":1,"19":2,"21":1,"22":2,"24":1,"25":1,"30":1,"how":1,"language":2,"matters":1,"in":4,"dia":1,"betes":1,"care":3,"should":4,"be":6,"neutral":1,"free":1,"of":6,"stigma":1,"and":12,"based":2,"on":3,"facts":1,"strength":1,"focus":1,"what":1,"is":5,"working":1,"respect":1,"ful":1,"inclusive":1,"encourage":1,"collaboration":1,"person":1,"centered":1,"people":1,"living":1,"with":2,"diabetes":3,"not":1,"referred":1,"to":4,"as":4,"diabetics":1,"or":3,"described":1,"noncompliant":1,"blamed":1,"for":1,"their":1,"health":1,"condition":1,"self":1,"management":1,"education":1,"support":1,"dsmes":8,"key":2,"intervention":1,"important":1,"the":4,"treatment":1,"plan":1,"selection":1,"pharmacotherapy":1,"cen":1,"tral":1,"establishing":1,"implementing":1,"principles":1,"fig":1,"pro":1,"grams":1,"usually":1,"involve":1,"face":2,"contact":1,"group":1,"individual":1,"sessions":1,"trained":1,"educators":1,"components":1,"are":1,"shown":2,"supplementary":2,"table":2,"given":1,"ever":1,"changing":1,"nature":1,"type":1,"fered":1,"an":1,"ongoing":1,"basis":1,"critical":1,"junc":1,"tures":1,"when":2,"provided":2,"include":1,"at":1,"diagnosis":1,"annually":1,"com":1,"plications":1,"arise":1,"during":1,"transitions":1,"life":1,"high":1,"quality":1,"evidence":1,"has":1,"consistently":1,"that":1,"signi":1,"fi":1,"cantly":1,"improves":1,"knowledge":1,"glycemic":1,"levels":1,"clinical":1,"psychological":1,"outcomes":1,"reduces":1,"hos":1,"pital":1,"admissions":1,"all":1,"cause":1,"mortality":1,"cost":1,"effective":1,"delivered":1,"through":1,"structured":1,"educational":1,"programs":1,"by":1,"train":1},"len":211},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":5,"chunkId":"ada-easd-2022-p5-c1","text":"ntly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hos- pital admissions and all-cause mortality, and is cost-effective (22,25  30). DSMES is delivered through structured educational programs provided by trained diabetes care and education specialists (termed DCES in the U.S.; hereafter referred to as diabetes educators) that focus particularly on the following: lifestyle behaviors (healthy eating, physical activity, and weight man- agement), medication-taking behavior, self- monitoring when needed, self-ef fi cacy, cop- ing, and problem solving. Importantly, DSMES is tailored to the individual  s context, which includes their beliefs and preferences. DSMES can be provided using multiple approaches and in a variety of settings (20,31), and it is im- portant for the care team to know how to access local DSMES resources. DSMES supports the psychosocial care of people with diabetes but is not a replacement for referral for mental health services when they are warranted, for example, when di- abetes distress remains after DSMES. Psy- chiatric disorders, including disordered eating behaviors, are common, often un- recognized, and contribute to poor out- comes in diabetes (32). The best outcomes from DSMES are achieved through programs with a theory- based and structured curriculum and with contact time of over 10 h (26). While on- line progr","tf":{"10":1,"20":1,"22":1,"25":1,"26":1,"30":1,"31":1,"32":1,"ntly":1,"improves":1,"knowledge":1,"glycemic":1,"levels":1,"and":13,"clinical":1,"psychological":1,"outcomes":2,"reduces":1,"hos":1,"pital":1,"admissions":1,"all":1,"cause":1,"mortality":1,"is":5,"cost":1,"effective":1,"dsmes":7,"delivered":1,"through":2,"structured":2,"educational":1,"programs":2,"provided":2,"by":1,"trained":1,"diabetes":4,"care":3,"education":1,"specialists":1,"termed":1,"dces":1,"in":3,"the":6,"hereafter":1,"referred":1,"to":5,"as":1,"educators":1,"that":1,"focus":1,"particularly":1,"on":2,"following":1,"lifestyle":1,"behaviors":2,"healthy":1,"eating":2,"physical":1,"activity":1,"weight":1,"man":1,"agement":1,"medication":1,"taking":1,"behavior":1,"self":2,"monitoring":1,"when":3,"needed":1,"ef":1,"fi":1,"cacy":1,"cop":1,"ing":1,"problem":1,"solving":1,"importantly":1,"tailored":1,"individual":1,"context":1,"which":1,"includes":1,"their":1,"beliefs":1,"preferences":1,"can":1,"be":1,"using":1,"multiple":1,"approaches":1,"variety":1,"of":3,"settings":1,"it":1,"im":1,"portant":1,"for":4,"team":1,"know":1,"how":1,"access":1,"local":1,"resources":1,"supports":1,"psychosocial":1,"people":1,"with":3,"but":1,"not":1,"replacement":1,"referral":1,"mental":1,"health":1,"services":1,"they":1,"are":3,"warranted":1,"example":1,"di":1,"abetes":1,"distress":1,"remains":1,"after":1,"psy":1,"chiatric":1,"disorders":1,"including":1,"disordered":1,"common":1,"often":1,"un":1,"recognized":1,"contribute":1,"poor":1,"out":1,"comes":1,"best":1,"from":1,"achieved":1,"theory":1,"based":1,"curriculum":1,"contact":1,"time":1,"over":1,"while":1,"line":1,"progr":1},"len":207},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":5,"chunkId":"ada-easd-2022-p5-c2","text":" common, often un- recognized, and contribute to poor out- comes in diabetes (32). The best outcomes from DSMES are achieved through programs with a theory- based and structured curriculum and with contact time of over 10 h (26). While on- line programs may reinforce learning, a comprehensive approach to education us- ing multiple methods may be more effec- tive (26). Emerging evidence demonstrates the bene fi ts of telehealth or web-based DSMES programs (33), and these were used with success during the coronavirus disease 2019 (COVID-19) pandemic (34  36). Technologies such as mobile apps, simula- tion tools, digital coaching, and digital self- management interventions can be used to deliver DSMES and extend its reach to a broader segment of the population with diabetes and provide comparable or even better outcomes (37). Greater HbA 1c re- ductions are demonstrated with increased engagement of people with diabetes (35,38). However, data from trials of digi- tal strategies to support behavior change are still preliminary in nature and quite heterogeneous (22,37). Individualized and Personalized Approach Type 2 diabetes is a very heterogeneous disease with variable age at onset, related degree of obesity, insulin resistance, and tendency to develop complications (39,40). Providing person-centered care that ad- dresses multimorbidity and is respectful of and responsive to indiv","tf":{"10":1,"19":1,"22":1,"26":2,"32":1,"33":1,"34":1,"35":1,"36":1,"37":2,"38":1,"39":1,"40":1,"2019":1,"common":1,"often":1,"un":1,"recognized":1,"and":12,"contribute":1,"to":7,"poor":1,"out":1,"comes":1,"in":2,"diabetes":4,"the":4,"best":1,"outcomes":2,"from":2,"dsmes":3,"are":3,"achieved":1,"through":1,"programs":3,"with":7,"theory":1,"based":2,"structured":1,"curriculum":1,"contact":1,"time":1,"of":7,"over":1,"while":1,"on":1,"line":1,"may":2,"reinforce":1,"learning":1,"comprehensive":1,"approach":2,"education":1,"us":1,"ing":1,"multiple":1,"methods":1,"be":2,"more":1,"effec":1,"tive":1,"emerging":1,"evidence":1,"demonstrates":1,"bene":1,"fi":1,"ts":1,"telehealth":1,"or":2,"web":1,"these":1,"were":1,"used":2,"success":1,"during":1,"coronavirus":1,"disease":2,"covid":1,"pandemic":1,"technologies":1,"such":1,"as":1,"mobile":1,"apps":1,"simula":1,"tion":1,"tools":1,"digital":2,"coaching":1,"self":1,"management":1,"interventions":1,"can":1,"deliver":1,"extend":1,"its":1,"reach":1,"broader":1,"segment":1,"population":1,"provide":1,"comparable":1,"even":1,"better":1,"greater":1,"hba":1,"1c":1,"re":1,"ductions":1,"demonstrated":1,"increased":1,"engagement":1,"people":1,"however":1,"data":1,"trials":1,"digi":1,"tal":1,"strategies":1,"support":1,"behavior":1,"change":1,"still":1,"preliminary":1,"nature":1,"quite":1,"heterogeneous":2,"individualized":1,"personalized":1,"type":1,"is":2,"very":1,"variable":1,"age":1,"at":1,"onset":1,"related":1,"degree":1,"obesity":1,"insulin":1,"resistance":1,"tendency":1,"develop":1,"complications":1,"providing":1,"person":1,"centered":1,"care":1,"that":1,"ad":1,"dresses":1,"multimorbidity":1,"respectful":1,"responsive":1,"indiv":1},"len":211},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":5,"chunkId":"ada-easd-2022-p5-c3","text":"eterogeneous disease with variable age at onset, related degree of obesity, insulin resistance, and tendency to develop complications (39,40). Providing person-centered care that ad- dresses multimorbidity and is respectful of and responsive to individual preferences and barriers, including the differential costs of therapies, is essential for effective diabe- tes management (41). Shared decision- making, facilitated by decision aids that show the absolute bene fi t and risk of alter- native treatment options, is a useful strat- egy to determine the best treatment course for an individual (42  45). With compelling indications for therapies such as SGLT2i and GLP-1 RA for high-risk indi- viduals with CVD, HF, or CKD, shared decision-making is essential to contextualize the evidence on bene fi ts, safety, and risks. Providers should evaluate the impact of any suggested intervention in the context of cognitive impairment, limited literacy, distinct cultural beliefs, and individual fears or health concerns. The health care system is an important factor in the implementa- tion, evaluation, and development of the personalized approach. Furthermore, social determinants of health  often out of di- rect control of the individual and poten- tially representing lifelong risk  contribute to medical and psychosocial outcomes and must be addressed to improve health out- comes. Five social","tf":{"39":1,"40":1,"41":1,"42":1,"45":1,"eterogeneous":1,"disease":1,"with":3,"variable":1,"age":1,"at":1,"onset":1,"related":1,"degree":1,"of":10,"obesity":1,"insulin":1,"resistance":1,"and":12,"tendency":1,"to":6,"develop":1,"complications":1,"providing":1,"person":1,"centered":1,"care":2,"that":2,"ad":1,"dresses":1,"multimorbidity":1,"is":5,"respectful":1,"responsive":1,"individual":4,"preferences":1,"barriers":1,"including":1,"the":10,"differential":1,"costs":1,"therapies":2,"essential":2,"for":4,"effective":1,"diabe":1,"tes":1,"management":1,"shared":2,"decision":3,"making":2,"facilitated":1,"by":1,"aids":1,"show":1,"absolute":1,"bene":2,"fi":2,"risk":3,"alter":1,"native":1,"treatment":2,"options":1,"useful":1,"strat":1,"egy":1,"determine":1,"best":1,"course":1,"an":2,"compelling":1,"indications":1,"such":1,"as":1,"sglt2i":1,"glp":1,"ra":1,"high":1,"indi":1,"viduals":1,"cvd":1,"hf":1,"or":2,"ckd":1,"contextualize":1,"evidence":1,"on":1,"ts":1,"safety":1,"risks":1,"providers":1,"should":1,"evaluate":1,"impact":1,"any":1,"suggested":1,"intervention":1,"in":2,"context":1,"cognitive":1,"impairment":1,"limited":1,"literacy":1,"distinct":1,"cultural":1,"beliefs":1,"fears":1,"health":4,"concerns":1,"system":1,"important":1,"factor":1,"implementa":1,"tion":1,"evaluation":1,"development":1,"personalized":1,"approach":1,"furthermore":1,"social":2,"determinants":1,"often":1,"out":2,"di":1,"rect":1,"control":1,"poten":1,"tially":1,"representing":1,"lifelong":1,"contribute":1,"medical":1,"psychosocial":1,"outcomes":1,"must":1,"be":1,"addressed":1,"improve":1,"comes":1,"five":1},"len":207},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":5,"chunkId":"ada-easd-2022-p5-c4","text":"urthermore, social determinants of health  often out of di- rect control of the individual and poten- tially representing lifelong risk  contribute to medical and psychosocial outcomes and must be addressed to improve health out- comes. Five social determinants of health areas have been identi fi ed: socioeconomic status (education, income, and occupa- tion), living and working conditions, multi- sector domains (e.g., housing, education, and criminal justice system), sociocultural context (e.g., shared cultural values, practi- ces, and experiences), and sociopolitical context (e.g., societal and political norms that are root-cause ideologies and policies underlying health disparities) (46). More granularity on social determinants of health as they pertain to diabetes is provided in a recent ADA review (47), with a particu- lar focus on the issues faced in the Afri- can American population provided in a subsequent report (48). Environmental, social, behavioral, and emotional factors, known as psychosocial factors, also in fl u- ence living with diabetes and achieving satisfactory medical outcomes and psy- chological well-being. Thus, these multi- faceted domains (heterogeneity across individual characteristics, social determi- nants of health, and psychosocial factors) challenge individuals with diabetes, their families, and their providers when at- tempting to integrate diabe","tf":{"46":1,"47":1,"48":1,"urthermore":1,"social":5,"determinants":3,"of":6,"health":6,"often":1,"out":2,"di":1,"rect":1,"control":1,"the":3,"individual":2,"and":15,"poten":1,"tially":1,"representing":1,"lifelong":1,"risk":1,"contribute":1,"to":4,"medical":2,"psychosocial":3,"outcomes":2,"must":1,"be":1,"addressed":1,"improve":1,"comes":1,"five":1,"areas":1,"have":1,"been":1,"identi":1,"fi":1,"ed":1,"socioeconomic":1,"status":1,"education":2,"income":1,"occupa":1,"tion":1,"living":2,"working":1,"conditions":1,"multi":2,"sector":1,"domains":2,"housing":1,"criminal":1,"justice":1,"system":1,"sociocultural":1,"context":2,"shared":1,"cultural":1,"values":1,"practi":1,"ces":1,"experiences":1,"sociopolitical":1,"societal":1,"political":1,"norms":1,"that":1,"are":1,"root":1,"cause":1,"ideologies":1,"policies":1,"underlying":1,"disparities":1,"more":1,"granularity":1,"on":2,"as":2,"they":1,"pertain":1,"diabetes":3,"is":1,"provided":2,"in":4,"recent":1,"ada":1,"review":1,"with":3,"particu":1,"lar":1,"focus":1,"issues":1,"faced":1,"afri":1,"can":1,"american":1,"population":1,"subsequent":1,"report":1,"environmental":1,"behavioral":1,"emotional":1,"factors":3,"known":1,"also":1,"fl":1,"ence":1,"achieving":1,"satisfactory":1,"psy":1,"chological":1,"well":1,"being":1,"thus":1,"these":1,"faceted":1,"heterogeneity":1,"across":1,"characteristics":1,"determi":1,"nants":1,"challenge":1,"individuals":1,"their":2,"families":1,"providers":1,"when":1,"at":1,"tempting":1,"integrate":1,"diabe":1},"len":190},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":5,"chunkId":"ada-easd-2022-p5-c5","text":"s, these multi- faceted domains (heterogeneity across individual characteristics, social determi- nants of health, and psychosocial factors) challenge individuals with diabetes, their families, and their providers when at- tempting to integrate diabetes care into daily life (49). Current principles of, and approaches to, person-centered care in diabetes (Fig. 1) include assessing key characteristics and preferences to determine individualized treatment goals and strategies. Such char- acteristics include comorbidities, clinical characteristics, and compelling indications for GLP-1 RA or SGLT2i for organ protec- tion (6). Weight Reduction as a Targeted Intervention Weight reduction has mostly been seen as a strategy to improve HbA 1c and re- duce the risk for weight-related complica- tions. However, it was recently suggested that weight loss of 5  15% should be a primary target of management for many people living with type 2 diabetes (50). A higher magnitude of weight loss confers better outcomes. Weight loss of 5  10% confers metabolic improvement; weight loss of 10  15% or more can have a dis- ease-modifying effect and lead to remis- sion of diabetes (50), de fi ned as normal blood glucose levels for 3 months or more in the absence of pharmacological therapy in a 2021 consensus report (51). Weight loss may exert bene fi ts that ex- tend beyond glycemic management to 2756 C","tf":{"10":2,"15":2,"49":1,"50":2,"51":1,"2021":1,"2756":1,"these":1,"multi":1,"faceted":1,"domains":1,"heterogeneity":1,"across":1,"individual":1,"characteristics":3,"social":1,"determi":1,"nants":1,"of":9,"health":1,"and":8,"psychosocial":1,"factors":1,"challenge":1,"individuals":1,"with":2,"diabetes":5,"their":2,"families":1,"providers":1,"when":1,"at":1,"tempting":1,"to":6,"integrate":1,"care":2,"into":1,"daily":1,"life":1,"current":1,"principles":1,"approaches":1,"person":1,"centered":1,"in":3,"fig":1,"include":2,"assessing":1,"key":1,"preferences":1,"determine":1,"individualized":1,"treatment":1,"goals":1,"strategies":1,"such":1,"char":1,"acteristics":1,"comorbidities":1,"clinical":1,"compelling":1,"indications":1,"for":5,"glp":1,"ra":1,"or":3,"sglt2i":1,"organ":1,"protec":1,"tion":1,"weight":8,"reduction":2,"as":3,"targeted":1,"intervention":1,"has":1,"mostly":1,"been":1,"seen":1,"strategy":1,"improve":1,"hba":1,"1c":1,"re":1,"duce":1,"the":2,"risk":1,"related":1,"complica":1,"tions":1,"however":1,"it":1,"was":1,"recently":1,"suggested":1,"that":2,"loss":5,"should":1,"be":1,"primary":1,"target":1,"management":2,"many":1,"people":1,"living":1,"type":1,"higher":1,"magnitude":1,"confers":2,"better":1,"outcomes":1,"metabolic":1,"improvement":1,"more":2,"can":1,"have":1,"dis":1,"ease":1,"modifying":1,"effect":1,"lead":1,"remis":1,"sion":1,"de":1,"fi":2,"ned":1,"normal":1,"blood":1,"glucose":1,"levels":1,"months":1,"absence":1,"pharmacological":1,"therapy":1,"consensus":1,"report":1,"may":1,"exert":1,"bene":1,"ts":1,"ex":1,"tend":1,"beyond":1,"glycemic":1},"len":205},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":5,"chunkId":"ada-easd-2022-p5-c6","text":"remis- sion of diabetes (50), de fi ned as normal blood glucose levels for 3 months or more in the absence of pharmacological therapy in a 2021 consensus report (51). Weight loss may exert bene fi ts that ex- tend beyond glycemic management to 2756 Consensus Report Diabetes Care Volume 45, November 2022 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"45":2,"50":1,"51":1,"2021":1,"2022":1,"2026":1,"2753":1,"2756":1,"691567":1,"remis":1,"sion":1,"of":2,"diabetes":2,"de":1,"fi":2,"ned":1,"as":1,"normal":1,"blood":1,"glucose":1,"levels":1,"for":1,"months":1,"or":1,"more":1,"in":2,"the":1,"absence":1,"pharmacological":1,"therapy":1,"consensus":2,"report":2,"weight":1,"loss":1,"may":1,"exert":1,"bene":1,"ts":1,"that":1,"ex":1,"tend":1,"beyond":1,"glycemic":1,"management":1,"to":1,"care":2,"volume":1,"november":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"february":1},"len":71},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":6,"chunkId":"ada-easd-2022-p6-c0","text":"improve risk factors for cardiometabolic disease and quality of life (50). Glucose Management: Monitoring Glycemic management is primarily as- sessed with the HbA 1c test, which was the measure used in trials demonstrating the bene fi ts of glucose lowering (2,52). As with any laboratory test, HbA 1c mea- surement has limitations (2,52). There may be discrepancies between HbA 1c re- sults and an individual  s true mean blood glucose levels, particularly in certain ra- cial and ethnic groups and in conditions that alter erythrocyte turnover, such as anemia, end-stage kidney disease (espe- cially with erythropoietin therapy), and pregnancy, or if an HbA 1c assay insensi- tive to hemoglobin variants is used in someone with a hemoglobinopathy. Dis- crepancies between measured HbA 1c lev- els and measured or reported glucose levels should prompt consideration that one of these may not be reliable (52,53). Regular blood glucose monitoring (BGM) may help with self-management and medication adjustment, particularly in in- dividuals taking insulin. BGM plans should be individualized. People with type 2 dia- betes and the health care team should use the monitoring data in an effective and timely manner. In people with type 2 diabetes not using insulin, routine glucose monitoring is of limited additional clinical bene fi t while adding burden and cost (54,55). However, for some individua","tf":{"50":1,"52":3,"53":1,"54":1,"55":1,"improve":1,"risk":1,"factors":1,"for":2,"cardiometabolic":1,"disease":2,"and":10,"quality":1,"of":4,"life":1,"glucose":6,"management":3,"monitoring":4,"glycemic":1,"is":3,"primarily":1,"as":3,"sessed":1,"with":7,"the":5,"hba":5,"1c":5,"test":2,"which":1,"was":1,"measure":1,"used":2,"in":8,"trials":1,"demonstrating":1,"bene":2,"fi":2,"ts":1,"lowering":1,"any":1,"laboratory":1,"mea":1,"surement":1,"has":1,"limitations":1,"there":1,"may":3,"be":3,"discrepancies":1,"between":2,"re":1,"sults":1,"an":3,"individual":1,"true":1,"mean":1,"blood":2,"levels":2,"particularly":2,"certain":1,"ra":1,"cial":1,"ethnic":1,"groups":1,"conditions":1,"that":2,"alter":1,"erythrocyte":1,"turnover":1,"such":1,"anemia":1,"end":1,"stage":1,"kidney":1,"espe":1,"cially":1,"erythropoietin":1,"therapy":1,"pregnancy":1,"or":2,"if":1,"assay":1,"insensi":1,"tive":1,"to":1,"hemoglobin":1,"variants":1,"someone":1,"hemoglobinopathy":1,"dis":1,"crepancies":1,"measured":2,"lev":1,"els":1,"reported":1,"should":3,"prompt":1,"consideration":1,"one":1,"these":1,"not":2,"reliable":1,"regular":1,"bgm":2,"help":1,"self":1,"medication":1,"adjustment":1,"dividuals":1,"taking":1,"insulin":2,"plans":1,"individualized":1,"people":2,"type":2,"dia":1,"betes":1,"health":1,"care":1,"team":1,"use":1,"data":1,"effective":1,"timely":1,"manner":1,"diabetes":1,"using":1,"routine":1,"limited":1,"additional":1,"clinical":1,"while":1,"adding":1,"burden":1,"cost":1,"however":1,"some":1,"individua":1},"len":217},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":6,"chunkId":"ada-easd-2022-p6-c1","text":"ould use the monitoring data in an effective and timely manner. In people with type 2 diabetes not using insulin, routine glucose monitoring is of limited additional clinical bene fi t while adding burden and cost (54,55). However, for some individuals, glucose monitoring can provide insight into the impact of lifestyle and medica- tion management on blood glucose and symptoms, particularly when combined with education and support (53). Technol- ogies such as intermittently scanned or real-time continuous glucose monitoring (CGM) provide more information and may be useful for people with type 2 dia- betes, particularly in those treated with insulin (53,56). When using CGM, standardized, single- page glucose reports, such as the ambula- tory glucose pro fi le, can be uploaded from CGM devices. They should be considered standard metrics for all CGM devices and provide visual cues for management oppor- tunities. Time in range is de fi ned as the per- centage of time that CGM readings are in the range 3.9  10.0 mmol/L (70  180 mg/dL). Time in range is associated with the risk of microvascular complications and can be used for assessment of glycemic management (57). Additionally, time above and below range are useful varia- bles for the evaluation of treatment regi- mens. Particular attention to minimizing the time below range in those with hypo- glycemia unawareness may convey be","tf":{"10":1,"53":2,"54":1,"55":1,"56":1,"57":1,"70":1,"180":1,"ould":1,"use":1,"the":8,"monitoring":4,"data":1,"in":7,"an":1,"effective":1,"and":9,"timely":1,"manner":1,"people":2,"with":6,"type":2,"diabetes":1,"not":1,"using":2,"insulin":2,"routine":1,"glucose":6,"is":3,"of":6,"limited":1,"additional":1,"clinical":1,"bene":1,"fi":3,"while":1,"adding":1,"burden":1,"cost":1,"however":1,"for":6,"some":1,"individuals":1,"can":3,"provide":3,"insight":1,"into":1,"impact":1,"lifestyle":1,"medica":1,"tion":1,"management":3,"on":1,"blood":1,"symptoms":1,"particularly":2,"when":2,"combined":1,"education":1,"support":1,"technol":1,"ogies":1,"such":2,"as":3,"intermittently":1,"scanned":1,"or":1,"real":1,"time":6,"continuous":1,"cgm":5,"more":1,"information":1,"may":2,"be":5,"useful":2,"dia":1,"betes":1,"those":2,"treated":1,"standardized":1,"single":1,"page":1,"reports":1,"ambula":1,"tory":1,"pro":1,"le":1,"uploaded":1,"from":1,"devices":2,"they":1,"should":1,"considered":1,"standard":1,"metrics":1,"all":1,"visual":1,"cues":1,"oppor":1,"tunities":1,"range":5,"de":1,"ned":1,"per":1,"centage":1,"that":1,"readings":1,"are":2,"mmol":1,"mg":1,"dl":1,"associated":1,"risk":1,"microvascular":1,"complications":1,"used":1,"assessment":1,"glycemic":1,"additionally":1,"above":1,"below":2,"varia":1,"bles":1,"evaluation":1,"treatment":1,"regi":1,"mens":1,"particular":1,"attention":1,"to":1,"minimizing":1,"hypo":1,"glycemia":1,"unawareness":1,"convey":1},"len":223},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":6,"chunkId":"ada-easd-2022-p6-c2","text":"nt of glycemic management (57). Additionally, time above and below range are useful varia- bles for the evaluation of treatment regi- mens. Particular attention to minimizing the time below range in those with hypo- glycemia unawareness may convey bene- fi t. If using the ambulatory glucose pro fi le to assess glycemic management, a goal parallel to an HbA 1c level of < 53 mmol/ mol ( < 7%) for many is time in range of > 70%, with additional recommendations to aim for time below range of < 4% and time at < 3.0 mmol/L ( < 54 mg/dL) of < 1% (2). Treatment Behaviors, Persistence, and Adherence Suboptimal medication-taking behavior and low rates of continued medication use, or what is termed  persistence to ther- apy plans,  affects almost half of people with type 2 diabetes, leading to subopti- mal glycemic and CVD risk factor control as well as increased risks of diabetes complications, mortality, and hospital ad- missions and increased health care costs (58  62). Although this consensus report focuses on medication-taking behavior, the principles are pertinent to all aspects of diabetes care. Multiple factors contrib- ute to inconsistent medication use and treatment discontinuation among people with diabetes, including perceived lack of medication ef fi cacy, fear of hypoglycemia, lack of access to medication, and adverse effects of medication (63). Focusing on fa- cilitators","tf":{"53":1,"54":1,"57":1,"58":1,"62":1,"63":1,"70":1,"nt":1,"of":14,"glycemic":3,"management":2,"additionally":1,"time":5,"above":1,"and":9,"below":3,"range":4,"are":2,"useful":1,"varia":1,"bles":1,"for":3,"the":4,"evaluation":1,"treatment":3,"regi":1,"mens":1,"particular":1,"attention":1,"to":9,"minimizing":1,"in":2,"those":1,"with":4,"hypo":1,"glycemia":1,"unawareness":1,"may":1,"convey":1,"bene":1,"fi":3,"if":1,"using":1,"ambulatory":1,"glucose":1,"pro":1,"le":1,"assess":1,"goal":1,"parallel":1,"an":1,"hba":1,"1c":1,"level":1,"mmol":2,"mol":1,"many":1,"is":2,"additional":1,"recommendations":1,"aim":1,"at":1,"mg":1,"dl":1,"behaviors":1,"persistence":2,"adherence":1,"suboptimal":1,"medication":7,"taking":2,"behavior":2,"low":1,"rates":1,"continued":1,"use":2,"or":1,"what":1,"termed":1,"ther":1,"apy":1,"plans":1,"affects":1,"almost":1,"half":1,"people":2,"type":1,"diabetes":4,"leading":1,"subopti":1,"mal":1,"cvd":1,"risk":1,"factor":1,"control":1,"as":2,"well":1,"increased":2,"risks":1,"complications":1,"mortality":1,"hospital":1,"ad":1,"missions":1,"health":1,"care":2,"costs":1,"although":1,"this":1,"consensus":1,"report":1,"focuses":1,"on":2,"principles":1,"pertinent":1,"all":1,"aspects":1,"multiple":1,"factors":1,"contrib":1,"ute":1,"inconsistent":1,"discontinuation":1,"among":1,"including":1,"perceived":1,"lack":2,"ef":1,"cacy":1,"fear":1,"hypoglycemia":1,"access":1,"adverse":1,"effects":1,"focusing":1,"fa":1,"cilitators":1},"len":212},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":6,"chunkId":"ada-easd-2022-p6-c3","text":"sistent medication use and treatment discontinuation among people with diabetes, including perceived lack of medication ef fi cacy, fear of hypoglycemia, lack of access to medication, and adverse effects of medication (63). Focusing on fa- cilitators of adherence, such as social/ family/provider support, motivation, edu- cation, and access to medications/foods, can provide bene fi ts (64). Observed rates of medication adherence and persistence vary across medication classes and be- tween agents; careful consideration of these differences may help improve out- comes (61). Ultimately, individual prefer- ences are major factors driving the choice of medications. Even when clinical charac- teristics suggest the use of a particular medication based on the available evi- dence from clinical trials, preferences re- garding route of administration, injection devices, side effects, or cost may prevent use by some individuals (65). Therapeutic Inertia Therapeutic (or clinical) inertia describes a lack of treatment intensi fi cation when targets or goals are not met. It also in- cludes failure to de-intensify manage- ment when people are overtreated. The causes of therapeutic inertia are multi- factorial, occurring at the levels of the practitioner, person with diabetes, and/ or health care system (66). Interventions targeting therapeutic inertia have facili- tated improvements in glycemi","tf":{"61":1,"63":1,"64":1,"65":1,"66":1,"sistent":1,"medication":7,"use":3,"and":6,"treatment":2,"discontinuation":1,"among":1,"people":2,"with":2,"diabetes":2,"including":1,"perceived":1,"lack":3,"of":13,"ef":1,"fi":3,"cacy":1,"fear":1,"hypoglycemia":1,"access":2,"to":3,"adverse":1,"effects":2,"focusing":1,"on":2,"fa":1,"cilitators":1,"adherence":2,"such":1,"as":1,"social":1,"family":1,"provider":1,"support":1,"motivation":1,"edu":1,"cation":2,"medications":2,"foods":1,"can":1,"provide":1,"bene":1,"ts":1,"observed":1,"rates":1,"persistence":1,"vary":1,"across":1,"classes":1,"be":1,"tween":1,"agents":1,"careful":1,"consideration":1,"these":1,"differences":1,"may":2,"help":1,"improve":1,"out":1,"comes":1,"ultimately":1,"individual":1,"prefer":1,"ences":1,"are":4,"major":1,"factors":1,"driving":1,"the":6,"choice":1,"even":1,"when":3,"clinical":3,"charac":1,"teristics":1,"suggest":1,"particular":1,"based":1,"available":1,"evi":1,"dence":1,"from":1,"trials":1,"preferences":1,"re":1,"garding":1,"route":1,"administration":1,"injection":1,"devices":1,"side":1,"or":4,"cost":1,"prevent":1,"by":1,"some":1,"individuals":1,"therapeutic":4,"inertia":4,"describes":1,"intensi":1,"targets":1,"goals":1,"not":1,"met":1,"it":1,"also":1,"in":2,"cludes":1,"failure":1,"de":1,"intensify":1,"manage":1,"ment":1,"overtreated":1,"causes":1,"multi":1,"factorial":1,"occurring":1,"at":1,"levels":1,"practitioner":1,"person":1,"health":1,"care":1,"system":1,"interventions":1,"targeting":1,"have":1,"facili":1,"tated":1,"improvements":1,"glycemi":1},"len":203},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":6,"chunkId":"ada-easd-2022-p6-c4","text":"reated. The causes of therapeutic inertia are multi- factorial, occurring at the levels of the practitioner, person with diabetes, and/ or health care system (66). Interventions targeting therapeutic inertia have facili- tated improvements in glycemic manage- ment and timely insulin intensi fi cation (67,68). For example, the involvement of multidisciplinary teams that include non- physician providers with authorization to prescribe (e.g., pharmacists, specialist nurses, and advanced practice providers) may reduce therapeutic inertia (69,70). Therapeutic Options: Lifestyle and Healthy Behavior, Weight Management, and Pharmacotherapy for the Treatment of Type 2 Diabetes This section summarizes the lifestyle and behavioral therapy, weight management interventions, and pharmacotherapy that support glycemic management in people with type 2 diabetes. Speci fi c pharmaco- logical treatment options are summarized in Table 1. Additional details are available in the previous ADA/EASD consensus re- port and update (5,6) and the ADA  s 2022 Standards of Medical Care in Diabetes (71). Nutrition Therapy Nutrition therapy is integral to diabetes management, with goals of promoting and supporting healthy eating patterns, addressing individual nutrition needs, maintaining the pleasure of eating, and providing the person with diabetes with the tools for developing healthy eating (22). MNT prov","tf":{"22":1,"66":1,"67":1,"68":1,"69":1,"70":1,"71":1,"2022":1,"reated":1,"the":11,"causes":1,"of":7,"therapeutic":4,"inertia":3,"are":3,"multi":1,"factorial":1,"occurring":1,"at":1,"levels":1,"practitioner":1,"person":2,"with":6,"diabetes":6,"and":11,"or":1,"health":1,"care":2,"system":1,"interventions":2,"targeting":1,"have":1,"facili":1,"tated":1,"improvements":1,"in":5,"glycemic":2,"manage":1,"ment":1,"timely":1,"insulin":1,"intensi":1,"fi":2,"cation":1,"for":3,"example":1,"involvement":1,"multidisciplinary":1,"teams":1,"that":2,"include":1,"non":1,"physician":1,"providers":2,"authorization":1,"to":2,"prescribe":1,"pharmacists":1,"specialist":1,"nurses":1,"advanced":1,"practice":1,"may":1,"reduce":1,"options":2,"lifestyle":2,"healthy":3,"behavior":1,"weight":2,"management":4,"pharmacotherapy":2,"treatment":2,"type":2,"this":1,"section":1,"summarizes":1,"behavioral":1,"therapy":3,"support":1,"people":1,"speci":1,"pharmaco":1,"logical":1,"summarized":1,"table":1,"additional":1,"details":1,"available":1,"previous":1,"ada":2,"easd":1,"consensus":1,"re":1,"port":1,"update":1,"standards":1,"medical":1,"nutrition":3,"is":1,"integral":1,"goals":1,"promoting":1,"supporting":1,"eating":3,"patterns":1,"addressing":1,"individual":1,"needs":1,"maintaining":1,"pleasure":1,"providing":1,"tools":1,"developing":1,"mnt":1,"prov":1},"len":190},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":6,"chunkId":"ada-easd-2022-p6-c5","text":" management, with goals of promoting and supporting healthy eating patterns, addressing individual nutrition needs, maintaining the pleasure of eating, and providing the person with diabetes with the tools for developing healthy eating (22). MNT provided by a registered dieti- tian/registered dietitian nutritionist com- plements DSMES, can signi fi cantly reduce HbA 1c , and can help prevent, delay, and treat comorbidities related to diabetes (19). Two core dimensions of MNT that can improve glycemic management include dietary quality and energy restriction. Dietary Quality and Eating Patterns There is no single ratio of carbohydrate, proteins, and fat intake that is optimal for every person with type 2 diabetes. Instead, individually selected eating pat- terns that emphasize foods with demon- strated health bene fi ts, minimize foods shown to be harmful, and accommodate individual preferences with the goal of identifying healthy dietary habits that are feasible and sustainable are recom- mended. A net energy de fi cit that can be diabetesjournals.org/care Davies and Associates 2757 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"19":1,"22":1,"45":1,"2026":1,"2753":1,"2757":1,"691567":1,"management":2,"with":6,"goals":1,"of":5,"promoting":1,"and":10,"supporting":1,"healthy":3,"eating":5,"patterns":2,"addressing":1,"individual":2,"nutrition":1,"needs":1,"maintaining":1,"the":4,"pleasure":1,"providing":1,"person":2,"diabetes":3,"tools":1,"for":2,"developing":1,"mnt":2,"provided":1,"by":2,"registered":2,"dieti":1,"tian":1,"dietitian":1,"nutritionist":1,"com":1,"plements":1,"dsmes":1,"can":4,"signi":1,"fi":3,"cantly":1,"reduce":1,"hba":1,"1c":1,"help":1,"prevent":1,"delay":1,"treat":1,"comorbidities":1,"related":1,"to":2,"two":1,"core":1,"dimensions":1,"that":5,"improve":1,"glycemic":1,"include":1,"dietary":3,"quality":2,"energy":2,"restriction":1,"there":1,"is":2,"no":1,"single":1,"ratio":1,"carbohydrate":1,"proteins":1,"fat":1,"intake":1,"optimal":1,"every":1,"type":1,"instead":1,"individually":1,"selected":1,"pat":1,"terns":1,"emphasize":1,"foods":2,"demon":1,"strated":1,"health":1,"bene":1,"ts":1,"minimize":1,"shown":1,"be":2,"harmful":1,"accommodate":1,"preferences":1,"goal":1,"identifying":1,"habits":1,"are":2,"feasible":1,"sustainable":1,"recom":1,"mended":1,"net":1,"de":1,"cit":1,"diabetesjournals":2,"org":2,"care":2,"davies":1,"associates":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"dci220034":1,"guest":1,"on":1,"february":1},"len":182},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":7,"chunkId":"ada-easd-2022-p7-c0","text":"Table 1  Medications for lowering glucose, summary of characteristics CV, cardiovascular; CVOT, cardiovascular outcomes trial; DKA, diabetic ketoacidosis; DKD, diabetic kidney disease; DPP-4, dipeptidyl peptidase 4; eGFR, estimated glomerular fi ltration rate; GI, gastroin- testinal; GIP, gastric inhibitory polypeptide; GLP-1 RA, glucagon-like peptide 1 receptor agonist; HF, heart failure; NASH, nonalcoholic steatohepatitis; MACE, major adverse cardiovascular events; SGLT2, sodium-glucose cotransporter 2; SQ, subcutaneous; T2DM, type 2 diabetes mellitus. *For agent-speci fi c dosing recommendations, please refer to manufacturers  prescribing information. 1 Tsapas et al. (223). 2 Tsapas et al. (224). 2758 Consensus Report Diabetes Care Volume 45, November 2022 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"45":2,"223":1,"224":1,"2022":1,"2026":1,"2753":1,"2758":1,"691567":1,"table":1,"medications":1,"for":2,"lowering":1,"glucose":2,"summary":1,"of":1,"characteristics":1,"cv":1,"cardiovascular":3,"cvot":1,"outcomes":1,"trial":1,"dka":1,"diabetic":2,"ketoacidosis":1,"dkd":1,"kidney":1,"disease":1,"dpp":1,"dipeptidyl":1,"peptidase":1,"egfr":1,"estimated":1,"glomerular":1,"fi":2,"ltration":1,"rate":1,"gi":1,"gastroin":1,"testinal":1,"gip":1,"gastric":1,"inhibitory":1,"polypeptide":1,"glp":1,"ra":1,"glucagon":1,"like":1,"peptide":1,"receptor":1,"agonist":1,"hf":1,"heart":1,"failure":1,"nash":1,"nonalcoholic":1,"steatohepatitis":1,"mace":1,"major":1,"adverse":1,"events":1,"sglt2":1,"sodium":1,"cotransporter":1,"sq":1,"subcutaneous":1,"t2dm":1,"type":1,"diabetes":2,"mellitus":1,"agent":1,"speci":1,"dosing":1,"recommendations":1,"please":1,"refer":1,"to":1,"manufacturers":1,"prescribing":1,"information":1,"tsapas":2,"et":2,"al":2,"consensus":1,"report":1,"care":2,"volume":1,"november":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"february":1},"len":114},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":8,"chunkId":"ada-easd-2022-p8-c0","text":"maintained is important for weight loss (5,6,22,72  74). A network analysis comparing trials of nine dietary approaches of > 12 weeks  du- ration demonstrated reductions in HbA 1c from  9 to  5.1 mmol/mol (  0.82% to  0.47%) with all approaches compared with a control diet. Greater glycemic ben- e fi ts were seen with the Mediterranean diet and low-carbohydrate diet (75). The greater glycemic bene fi ts of low-carbohy- drate diets ( < 26% of energy) at 3 and 6 months are not evident with longer follow-up (72). In a systematic review of trials of > 6 months  duration, compared with a low-fat diet, the Mediterranean diet demonstrated greater reductions in body weight and HbA 1c levels, delayed the requirement for diabetes medica- tion, and provided bene fi ts for cardio- vascular health (76,77). Similar bene fi ts have been ascribed to vegan and vege- tarian diets (78). There has been increased interest in time-restricted eating and intermittent fasting to improve metabolic variables, al- though with mixed, and modest, results. In a meta-analysis there were no differ- ences in the effect of intermittent fasting and continuous energy restriction on HbA 1c , with intermittent fasting having a modest effect on weight (  1.70 kg) (79). In a 12-month RCT in adults with type 2 diabetes comparing intermittent energy restriction (2,092  2,510 kJ [500  600 kcal] diet for 2 nonco","tf":{"12":2,"22":1,"26":1,"47":1,"70":1,"72":2,"74":1,"75":1,"76":1,"77":1,"78":1,"79":1,"82":1,"500":1,"510":1,"600":1,"maintained":1,"is":1,"important":1,"for":4,"weight":3,"loss":1,"network":1,"analysis":2,"comparing":2,"trials":2,"of":7,"nine":1,"dietary":1,"approaches":2,"weeks":1,"du":1,"ration":1,"demonstrated":2,"reductions":2,"in":8,"hba":3,"1c":3,"from":1,"to":4,"mmol":1,"mol":1,"with":8,"all":1,"compared":2,"control":1,"diet":6,"greater":3,"glycemic":2,"ben":1,"fi":4,"ts":4,"were":2,"seen":1,"the":5,"mediterranean":2,"and":8,"low":3,"carbohydrate":1,"bene":3,"carbohy":1,"drate":1,"diets":2,"energy":3,"at":1,"months":2,"are":1,"not":1,"evident":1,"longer":1,"follow":1,"up":1,"systematic":1,"review":1,"duration":1,"fat":1,"body":1,"levels":1,"delayed":1,"requirement":1,"diabetes":2,"medica":1,"tion":1,"provided":1,"cardio":1,"vascular":1,"health":1,"similar":1,"have":1,"been":2,"ascribed":1,"vegan":1,"vege":1,"tarian":1,"there":2,"has":1,"increased":1,"interest":1,"time":1,"restricted":1,"eating":1,"intermittent":4,"fasting":3,"improve":1,"metabolic":1,"variables":1,"al":1,"though":1,"mixed":1,"modest":2,"results":1,"meta":1,"no":1,"differ":1,"ences":1,"effect":2,"continuous":1,"restriction":2,"on":2,"having":1,"kg":1,"month":1,"rct":1,"adults":1,"type":1,"092":1,"kj":1,"kcal":1,"nonco":1},"len":217},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":8,"chunkId":"ada-easd-2022-p8-c1","text":"nergy restriction on HbA 1c , with intermittent fasting having a modest effect on weight (  1.70 kg) (79). In a 12-month RCT in adults with type 2 diabetes comparing intermittent energy restriction (2,092  2,510 kJ [500  600 kcal] diet for 2 nonconsecutive days/week fol- lowed by the usual diet for 5 days/week) with continuous energy restriction (5,021  6,276 kJ [1,200  1,500 kcal] diet for 7 days/ week), glycemic improvements were com- parable between the two groups. At 24 months  follow-up, HbA 1c increased in both groups to above baseline (80), while weight loss (  3.9 kg) was maintained in both groups (81). Fasting may increase the rates of hypoglycemia in those treated with insulin and sulfonylureas, highlighting the need for individualized education and proactive medication management during signi fi cant dietary changes (82). Nonsurgical Energy Restriction for Weight Loss An overall healthy eating plan that results in an energy de fi cit, in conjunction with medications and/or metabolic surgery as individually appropriate, should be consid- ered to support glycemic and weight management goals in adults with type 2 diabetes (5,22). Structured nutrition and lifestyle programs may be considered for glycemic bene fi t and can be adapted for speci fi c cultural indications (83  87). The Diabetes Remission Clinical Trial (DiRECT) demonstrated greater remis- sion of dia","tf":{"12":1,"22":1,"24":1,"70":1,"79":1,"80":1,"81":1,"82":1,"83":1,"87":1,"200":1,"276":1,"500":2,"510":1,"600":1,"nergy":1,"restriction":4,"on":2,"hba":2,"1c":2,"with":6,"intermittent":2,"fasting":2,"having":1,"modest":1,"effect":1,"weight":4,"kg":2,"in":8,"month":1,"rct":1,"adults":2,"type":2,"diabetes":3,"comparing":1,"energy":4,"092":1,"kj":2,"kcal":2,"diet":3,"for":7,"nonconsecutive":1,"days":3,"week":3,"fol":1,"lowed":1,"by":1,"the":5,"usual":1,"continuous":1,"021":1,"glycemic":3,"improvements":1,"were":1,"com":1,"parable":1,"between":1,"two":1,"groups":3,"at":1,"months":1,"follow":1,"up":1,"increased":1,"both":2,"to":2,"above":1,"baseline":1,"while":1,"loss":2,"was":1,"maintained":1,"may":2,"increase":1,"rates":1,"of":2,"hypoglycemia":1,"those":1,"treated":1,"insulin":1,"and":6,"sulfonylureas":1,"highlighting":1,"need":1,"individualized":1,"education":1,"proactive":1,"medication":1,"management":2,"during":1,"signi":1,"fi":4,"cant":1,"dietary":1,"changes":1,"nonsurgical":1,"an":2,"overall":1,"healthy":1,"eating":1,"plan":1,"that":1,"results":1,"de":1,"cit":1,"conjunction":1,"medications":1,"or":1,"metabolic":1,"surgery":1,"as":1,"individually":1,"appropriate":1,"should":1,"be":3,"consid":1,"ered":1,"support":1,"goals":1,"structured":1,"nutrition":1,"lifestyle":1,"programs":1,"considered":1,"bene":1,"can":1,"adapted":1,"speci":1,"cultural":1,"indications":1,"remission":1,"clinical":1,"trial":1,"direct":1,"demonstrated":1,"greater":1,"remis":1,"sion":1,"dia":1},"len":210},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":8,"chunkId":"ada-easd-2022-p8-c2","text":"etes (5,22). Structured nutrition and lifestyle programs may be considered for glycemic bene fi t and can be adapted for speci fi c cultural indications (83  87). The Diabetes Remission Clinical Trial (DiRECT) demonstrated greater remis- sion of diabetes with a weight manage- ment program than with usual best practice care in adults with type 2 dia- betes within 6 years of diagnosis. The structured, primary care-led intensive weight management program involved to- tal diet replacement (3,452  3,569 kJ/day [825  853 kcal/day] for 3  5 months) fol- lowed by stepped food reintroduction and structured support for long-term weight loss maintenance. In the whole study pop- ulation, remission directly varied with de- gree of weight loss (88). At the 2-year follow-up, sustained remission correlated with extent of sustained weight loss. In the whole study population, of those maintaining at least 10 kg weight loss, 64% achieved diabetes remission. How- ever, only 24% of the participants in the intervention group maintained at least 10 kg weight loss, highlighting both the potential and the challenges of long- term durability of weight loss (89). The Look AHEAD: Action for Health in Diabetes (Look AHEAD) trial on the longer- term effects of an intensive lifestyle inter- vention in adults who were overweight/ obese with type 2 diabetes showed im- provements in diabetes control and com","tf":{"10":2,"22":1,"24":1,"64":1,"83":1,"87":1,"88":1,"89":1,"452":1,"569":1,"825":1,"853":1,"etes":1,"structured":3,"nutrition":1,"and":5,"lifestyle":2,"programs":1,"may":1,"be":2,"considered":1,"for":5,"glycemic":1,"bene":1,"fi":2,"can":1,"adapted":1,"speci":1,"cultural":1,"indications":1,"the":11,"diabetes":6,"remission":4,"clinical":1,"trial":2,"direct":1,"demonstrated":1,"greater":1,"remis":1,"sion":1,"of":9,"with":6,"weight":8,"manage":1,"ment":1,"program":2,"than":1,"usual":1,"best":1,"practice":1,"care":2,"in":7,"adults":2,"type":2,"dia":1,"betes":1,"within":1,"years":1,"diagnosis":1,"primary":1,"led":1,"intensive":2,"management":1,"involved":1,"to":1,"tal":1,"diet":1,"replacement":1,"kj":1,"day":2,"kcal":1,"months":1,"fol":1,"lowed":1,"by":1,"stepped":1,"food":1,"reintroduction":1,"support":1,"long":2,"term":3,"loss":6,"maintenance":1,"whole":2,"study":2,"pop":1,"ulation":1,"directly":1,"varied":1,"de":1,"gree":1,"at":3,"year":1,"follow":1,"up":1,"sustained":2,"correlated":1,"extent":1,"population":1,"those":1,"maintaining":1,"least":2,"kg":2,"achieved":1,"how":1,"ever":1,"only":1,"participants":1,"intervention":1,"group":1,"maintained":1,"highlighting":1,"both":1,"potential":1,"challenges":1,"durability":1,"look":2,"ahead":2,"action":1,"health":1,"on":1,"longer":1,"effects":1,"an":1,"inter":1,"vention":1,"who":1,"were":1,"overweight":1,"obese":1,"showed":1,"im":1,"provements":1,"control":1,"com":1},"len":217},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":8,"chunkId":"ada-easd-2022-p8-c3","text":"ss (89). The Look AHEAD: Action for Health in Diabetes (Look AHEAD) trial on the longer- term effects of an intensive lifestyle inter- vention in adults who were overweight/ obese with type 2 diabetes showed im- provements in diabetes control and com- plications, depression, physical function, health-related quality of life, sleep apnea, incontinence, brain structure, and health care use and costs, with positive impacts on composite indices of multimorbidity, geriatric syndromes, and disability-free life- years. This should be balanced against po- tential negative effects on body composi- tion, bone density, and frailty fractures (90,91). Although there was no difference in the primary cardiovascular outcome or mortality rate between the intervention and the control groups, post hoc explor- atory analyses suggested potential bene fi ts in certain groups (e.g., in those who achieved at least 10% weight loss in the fi rst year of the study). Progressive meta- bolic bene fi ts were seen with greater de- grees of weight loss from > 5% to $ 15%, with an overall suggestion that $ 10% weight loss may be required to see bene- fi ts for CVD events and mortality rate and other complications, such as nonalcoholic steatohepatitis (50,90,92  95). Physical Activity Behaviors, Including Sleep Physical activity behaviors signi fi cantly impact cardiometabolic health in type 2 diabetes (Fig. 2","tf":{"10":2,"15":1,"50":1,"89":1,"90":2,"91":1,"92":1,"95":1,"ss":1,"the":7,"look":2,"ahead":2,"action":1,"for":2,"health":4,"in":8,"diabetes":4,"trial":1,"on":3,"longer":1,"term":1,"effects":2,"of":5,"an":2,"intensive":1,"lifestyle":1,"inter":1,"vention":1,"adults":1,"who":2,"were":2,"overweight":1,"obese":1,"with":4,"type":2,"showed":1,"im":1,"provements":1,"control":2,"and":8,"com":1,"plications":1,"depression":1,"physical":3,"function":1,"related":1,"quality":1,"life":2,"sleep":2,"apnea":1,"incontinence":1,"brain":1,"structure":1,"care":1,"use":1,"costs":1,"positive":1,"impacts":1,"composite":1,"indices":1,"multimorbidity":1,"geriatric":1,"syndromes":1,"disability":1,"free":1,"years":1,"this":1,"should":1,"be":2,"balanced":1,"against":1,"po":1,"tential":1,"negative":1,"body":1,"composi":1,"tion":1,"bone":1,"density":1,"frailty":1,"fractures":1,"although":1,"there":1,"was":1,"no":1,"difference":1,"primary":1,"cardiovascular":1,"outcome":1,"or":1,"mortality":2,"rate":2,"between":1,"intervention":1,"groups":2,"post":1,"hoc":1,"explor":1,"atory":1,"analyses":1,"suggested":1,"potential":1,"bene":3,"fi":5,"ts":3,"certain":1,"those":1,"achieved":1,"at":1,"least":1,"weight":3,"loss":3,"rst":1,"year":1,"study":1,"progressive":1,"meta":1,"bolic":1,"seen":1,"greater":1,"de":1,"grees":1,"from":1,"to":2,"overall":1,"suggestion":1,"that":1,"may":1,"required":1,"see":1,"cvd":1,"events":1,"other":1,"complications":1,"such":1,"as":1,"nonalcoholic":1,"steatohepatitis":1,"activity":2,"behaviors":2,"including":1,"signi":1,"cantly":1,"impact":1,"cardiometabolic":1,"fig":1},"len":215},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":8,"chunkId":"ada-easd-2022-p8-c4","text":"events and mortality rate and other complications, such as nonalcoholic steatohepatitis (50,90,92  95). Physical Activity Behaviors, Including Sleep Physical activity behaviors signi fi cantly impact cardiometabolic health in type 2 diabetes (Fig. 2) (96  117). Regular aero- bic exercise (i.e., involving large muscle groups and rhythmic in nature) improves glycemic management in adults with type 2 diabetes, resulting in less daily time in hyper- glycemia and reductions of \u0018 7 mmol/mol ( \u0018 0.6%) in HbA 1c (118), and induces clini- cally signi fi cant bene fi ts in cardiorespira- tory fi tness (101,110,119). These glycemic effects can be maximized by under- taking activity during the postprandial period and engaging in activities for $ 45 min (101,120). Resistance exercise (i.e., using your own body weight or working against a resistance) also improves blood glucose levels, fl exibility, and balance (101,110). This is important given the in- creased risk of impaired physical function at an earlier age in type 2 diabetes (112). A wide range of physical activities, in- cluding leisure time activities, can signi fi - cantly reduce HbA 1c levels (5,22,121,122). Even small, regular changes can make a difference to long-term health, with an in- crease of only 500 steps/day associated with 2  9% decreased risk of cardiovascu- lar morbidity and all-cause mortality rates (105  107). B","tf":{"22":1,"45":1,"50":1,"90":1,"92":1,"95":1,"96":1,"101":3,"105":1,"107":1,"110":2,"112":1,"117":1,"118":1,"119":1,"120":1,"121":1,"122":1,"500":1,"events":1,"and":8,"mortality":2,"rate":1,"other":1,"complications":1,"such":1,"as":1,"nonalcoholic":1,"steatohepatitis":1,"physical":4,"activity":3,"behaviors":2,"including":1,"sleep":1,"signi":3,"fi":5,"cantly":2,"impact":1,"cardiometabolic":1,"health":2,"in":12,"type":3,"diabetes":3,"fig":1,"regular":2,"aero":1,"bic":1,"exercise":2,"involving":1,"large":1,"muscle":1,"groups":1,"rhythmic":1,"nature":1,"improves":2,"glycemic":2,"management":1,"adults":1,"with":3,"resulting":1,"less":1,"daily":1,"time":2,"hyper":1,"glycemia":1,"reductions":1,"of":5,"mmol":1,"mol":1,"hba":2,"1c":2,"induces":1,"clini":1,"cally":1,"cant":1,"bene":1,"ts":1,"cardiorespira":1,"tory":1,"tness":1,"these":1,"effects":1,"can":3,"be":1,"maximized":1,"by":1,"under":1,"taking":1,"during":1,"the":2,"postprandial":1,"period":1,"engaging":1,"activities":3,"for":1,"min":1,"resistance":2,"using":1,"your":1,"own":1,"body":1,"weight":1,"or":1,"working":1,"against":1,"also":1,"blood":1,"glucose":1,"levels":2,"fl":1,"exibility":1,"balance":1,"this":1,"is":1,"important":1,"given":1,"creased":1,"risk":2,"impaired":1,"function":1,"at":1,"an":2,"earlier":1,"age":1,"wide":1,"range":1,"cluding":1,"leisure":1,"reduce":1,"even":1,"small":1,"changes":1,"make":1,"difference":1,"to":1,"long":1,"term":1,"crease":1,"only":1,"steps":1,"day":1,"associated":1,"decreased":1,"cardiovascu":1,"lar":1,"morbidity":1,"all":1,"cause":1,"rates":1},"len":211},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":8,"chunkId":"ada-easd-2022-p8-c5","text":"1c levels (5,22,121,122). Even small, regular changes can make a difference to long-term health, with an in- crease of only 500 steps/day associated with 2  9% decreased risk of cardiovascu- lar morbidity and all-cause mortality rates (105  107). Bene fi cial effects are evident across the continuum of human move- ment, from breaking prolonged sitting with light activity (103) to high-intensity interval training (123). Sleep Healthy sleep is considered a key lifestyle component in the management of type 2 diabetes (124), with clinical practice guide- lines promoting the importance of sleep hygiene (113). Sleep disorders are com- mon in type 2 diabetes and cause distur- bances in the quantity, quality, and timing of sleep and are associated with an in- creased risk of obesity and impairments in daytime functioning and glucose metabo- lism (114,115). Additionally, obstructive sleep apnea affects over half of people with type 2 diabetes, and its severity is associated with blood glucose levels (115,116). The quantity of sleep is known to be associated (in a U-shaped manner) with health outcomes (e.g., obesity and HbA 1c ), with both long ( > 8 h) and short ( < 6 h) sleep durations having negative impacts (97). By extending the sleep duration of short sleepers, it is possible to improve diabetesjournals.org/care Davies and Associates 2759 Downloaded from http://diabetesjournals.o","tf":{"22":1,"97":1,"103":1,"105":1,"107":1,"113":1,"114":1,"115":2,"116":1,"121":1,"122":1,"123":1,"124":1,"500":1,"2759":1,"1c":2,"levels":2,"even":1,"small":1,"regular":1,"changes":1,"can":1,"make":1,"difference":1,"to":4,"long":2,"term":1,"health":2,"with":9,"an":2,"in":7,"crease":1,"of":10,"only":1,"steps":1,"day":1,"associated":4,"decreased":1,"risk":2,"cardiovascu":1,"lar":1,"morbidity":1,"and":10,"all":1,"cause":2,"mortality":1,"rates":1,"bene":1,"fi":1,"cial":1,"effects":1,"are":3,"evident":1,"across":1,"the":6,"continuum":1,"human":1,"move":1,"ment":1,"from":2,"breaking":1,"prolonged":1,"sitting":1,"light":1,"activity":1,"high":1,"intensity":1,"interval":1,"training":1,"sleep":9,"healthy":1,"is":4,"considered":1,"key":1,"lifestyle":1,"component":1,"management":1,"type":3,"diabetes":3,"clinical":1,"practice":1,"guide":1,"lines":1,"promoting":1,"importance":1,"hygiene":1,"disorders":1,"com":1,"mon":1,"distur":1,"bances":1,"quantity":2,"quality":1,"timing":1,"creased":1,"obesity":2,"impairments":1,"daytime":1,"functioning":1,"glucose":2,"metabo":1,"lism":1,"additionally":1,"obstructive":1,"apnea":1,"affects":1,"over":1,"half":1,"people":1,"its":1,"severity":1,"blood":1,"known":1,"be":1,"shaped":1,"manner":1,"outcomes":1,"hba":1,"both":1,"short":2,"durations":1,"having":1,"negative":1,"impacts":1,"by":1,"extending":1,"duration":1,"sleepers":1,"it":1,"possible":1,"improve":1,"diabetesjournals":2,"org":1,"care":1,"davies":1,"associates":1,"downloaded":1,"http":1},"len":212},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":8,"chunkId":"ada-easd-2022-p8-c6","text":"long ( > 8 h) and short ( < 6 h) sleep durations having negative impacts (97). By extending the sleep duration of short sleepers, it is possible to improve diabetesjournals.org/care Davies and Associates 2759 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"45":1,"97":1,"2026":1,"2753":1,"2759":1,"691567":1,"long":1,"and":2,"short":2,"sleep":2,"durations":1,"having":1,"negative":1,"impacts":1,"by":2,"extending":1,"the":1,"duration":1,"of":1,"sleepers":1,"it":1,"is":1,"possible":1,"to":1,"improve":1,"diabetesjournals":2,"org":2,"care":2,"davies":1,"associates":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"dci220034":1,"guest":1,"on":1,"february":1},"len":49},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":9,"chunkId":"ada-easd-2022-p9-c0","text":"Figure 2  Importance of 24-h physical behaviors for type 2 diabetes. 2760 Consensus Report Diabetes Care Volume 45, November 2022 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"24":1,"45":2,"2022":1,"2026":1,"2753":1,"2760":1,"691567":1,"figure":1,"importance":1,"of":1,"physical":1,"behaviors":1,"for":1,"type":1,"diabetes":2,"consensus":1,"report":1,"care":2,"volume":1,"november":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"february":1},"len":38},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":10,"chunkId":"ada-easd-2022-p10-c0","text":"insulin sensitivity and reduce energy intake (117,125). However,  catch-up  weekend sleep alone is not enough to reverse the impact of insuf fi cient sleep (126). Weight Management Beyond Lifestyle Interventions Medications for Weight Loss in Type 2 Diabetes Weight loss medications are effective ad- juncts to lifestyle interventions and healthy behaviors for management of weight and have also been found to improve glucose control in people with diabetes (127). Newer therapies have demonstrated very high ef fi cacy for weight manage- ment in people with type 2 diabetes. In the Semaglutide Treatment Effect in Peo- ple with Obesity 2 (STEP 2) trial, subcuta- neous semaglutide 2.4 mg once a week as an adjunct to a lifestyle intervention performed better than either semaglutide 1.0 mg or placebo, with weight loss of 9.6% (6.2% more than with placebo and 2.7% more than with semaglutide 1.0 mg). More than two-thirds of participants in the semaglutide 2.4-mg arm achieved an HbA 1c level of # 48 mmol/mol ( # 6.5%) (128). However, the weight loss was less pro- nounced than the 14.9% weight loss (vs. 2.4% with placebo) seen in the STEP 1 trial in adults with overweight or obesity without diabetes (129). Tirzepatide, a novel glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA, at weekly doses of 5 mg, 10 mg, and 15 mg, re- duced body weight by 15%, 19.5%, and 20.9%, respectiv","tf":{"10":1,"14":1,"15":2,"19":1,"20":1,"48":1,"117":1,"125":1,"126":1,"127":1,"128":1,"129":1,"insulin":1,"sensitivity":1,"and":7,"reduce":1,"energy":1,"intake":1,"however":2,"catch":1,"up":1,"weekend":1,"sleep":2,"alone":1,"is":1,"not":1,"enough":1,"to":4,"reverse":1,"the":6,"impact":1,"of":6,"insuf":1,"fi":2,"cient":1,"weight":9,"management":2,"beyond":1,"lifestyle":3,"interventions":2,"medications":2,"for":3,"loss":5,"in":8,"type":2,"diabetes":4,"are":1,"effective":1,"ad":1,"juncts":1,"healthy":1,"behaviors":1,"have":2,"also":1,"been":1,"found":1,"improve":1,"glucose":2,"control":1,"people":2,"with":8,"newer":1,"therapies":1,"demonstrated":1,"very":1,"high":1,"ef":1,"cacy":1,"manage":1,"ment":1,"semaglutide":5,"treatment":1,"effect":1,"peo":1,"ple":1,"obesity":2,"step":2,"trial":2,"subcuta":1,"neous":1,"mg":7,"once":1,"week":1,"as":1,"an":2,"adjunct":1,"intervention":1,"performed":1,"better":1,"than":5,"either":1,"or":2,"placebo":3,"more":3,"two":1,"thirds":1,"participants":1,"arm":1,"achieved":1,"hba":1,"1c":1,"level":1,"mmol":1,"mol":1,"was":1,"less":1,"pro":1,"nounced":1,"vs":1,"seen":1,"adults":1,"overweight":1,"without":1,"tirzepatide":1,"novel":1,"dependent":1,"insulinotropic":1,"polypeptide":1,"gip":1,"glp":1,"ra":1,"at":1,"weekly":1,"doses":1,"re":1,"duced":1,"body":1,"by":1,"respectiv":1},"len":215},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":10,"chunkId":"ada-easd-2022-p10-c1","text":"al in adults with overweight or obesity without diabetes (129). Tirzepatide, a novel glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA, at weekly doses of 5 mg, 10 mg, and 15 mg, re- duced body weight by 15%, 19.5%, and 20.9%, respectively, compared with 3.1% with placebo at 72 weeks in people with obesity but without diabetes; however, tir- zepatide has not yet been approved for weight management by regulatory author- ities (130). Studies in adults with over- weight or obesity suggest that withdrawing treatment with semaglutide leads to in- creases in body weight (131), highlighting the chronic nature of, and need for, obe- sity/weight management. Metabolic Surgery Metabolic surgery should be considered as a treatment option in adults with type 2 diabetes who are appropriate surgical can- didates (127,132). Metabolic surgery also appears to be effective for diabetes remis- sion in people with type 2 diabetes and a BMI $ 25 kg/m 2 , although ef fi cacy for both weight loss and diabetes remission appears to vary by surgical type (133  135). One mixed-effects meta-analysis model has estimated a 43% diabetes remission rate (95% CI 34%, 53%) following metabolic surgery in people with type 2 diabetes and a BMI < 30 kg/m 2 (136), signi fi cantly higher than that achieved with traditional medical management (137). However, there is a strong association between duration ","tf":{"10":1,"15":2,"19":1,"20":1,"25":1,"30":1,"34":1,"43":1,"53":1,"72":1,"95":1,"127":1,"129":1,"130":1,"131":1,"132":1,"133":1,"135":1,"136":1,"137":1,"al":1,"in":8,"adults":3,"with":10,"overweight":1,"or":2,"obesity":3,"without":2,"diabetes":8,"tirzepatide":1,"novel":1,"glucose":1,"dependent":1,"insulinotropic":1,"polypeptide":1,"gip":1,"and":7,"glp":1,"ra":1,"at":2,"weekly":1,"doses":1,"of":2,"mg":3,"re":1,"duced":1,"body":2,"weight":6,"by":3,"respectively":1,"compared":1,"placebo":1,"weeks":1,"people":3,"but":1,"however":2,"tir":1,"zepatide":1,"has":2,"not":1,"yet":1,"been":1,"approved":1,"for":4,"management":3,"regulatory":1,"author":1,"ities":1,"studies":1,"over":1,"suggest":1,"that":2,"withdrawing":1,"treatment":2,"semaglutide":1,"leads":1,"to":3,"creases":1,"highlighting":1,"the":1,"chronic":1,"nature":1,"need":1,"obe":1,"sity":1,"metabolic":4,"surgery":4,"should":1,"be":2,"considered":1,"as":1,"option":1,"type":4,"who":1,"are":1,"appropriate":1,"surgical":2,"can":1,"didates":1,"also":1,"appears":2,"effective":1,"remis":1,"sion":1,"bmi":2,"kg":2,"although":1,"ef":1,"fi":2,"cacy":1,"both":1,"loss":1,"remission":2,"vary":1,"one":1,"mixed":1,"effects":1,"meta":1,"analysis":1,"model":1,"estimated":1,"rate":1,"ci":1,"following":1,"signi":1,"cantly":1,"higher":1,"than":1,"achieved":1,"traditional":1,"medical":1,"there":1,"is":1,"strong":1,"association":1,"between":1,"duration":1},"len":214},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":10,"chunkId":"ada-easd-2022-p10-c2","text":"te (95% CI 34%, 53%) following metabolic surgery in people with type 2 diabetes and a BMI < 30 kg/m 2 (136), signi fi cantly higher than that achieved with traditional medical management (137). However, there is a strong association between duration of diabetes and the likelihood of postoperative diabetes remission. People with more re- cently diagnosed diabetes are more likely to experience remission after metabolic surgery, and the likelihood of remission decreases signi fi cantly with duration of di- abetes longer than about 5  8 years (138). Even in people with diabetes who do not achieve postoperative diabetes remission, or relapse after initial remission, metabolic surgery is associated with better metabolic control than medical management (137, 139). In the Surgical Treatment and Medi- cations Potentially Eradicate Diabetes Ef fi - ciently (STAMPEDE) trial, metabolic surgery was also associated with improvements in patient-reported outcomes related to phys- ical health; however, measures of social and psychological quality of life did not im- prove (140). It is important to note that many of these estimates of bene fi t in- cluded data from nonrandomized studies and compared outcomes with medical treatments for obesity that were less ef- fective than those available today. Medications For Lowering Glucose Cardiorenal-Protective Glucose-Lowering Medications SGLT2i. The S","tf":{"30":1,"34":1,"53":1,"95":1,"136":1,"137":2,"138":1,"139":1,"140":1,"te":1,"ci":1,"following":1,"metabolic":5,"surgery":4,"in":5,"people":3,"with":8,"type":1,"diabetes":7,"and":6,"bmi":1,"kg":1,"signi":2,"fi":4,"cantly":2,"higher":1,"than":4,"that":3,"achieved":1,"traditional":1,"medical":3,"management":2,"however":2,"there":1,"is":3,"strong":1,"association":1,"between":1,"duration":2,"of":8,"the":4,"likelihood":2,"postoperative":2,"remission":5,"more":2,"re":1,"cently":1,"diagnosed":1,"are":1,"likely":1,"to":3,"experience":1,"after":2,"decreases":1,"di":1,"abetes":1,"longer":1,"about":1,"years":1,"even":1,"who":1,"do":1,"not":2,"achieve":1,"or":1,"relapse":1,"initial":1,"associated":2,"better":1,"control":1,"surgical":1,"treatment":1,"medi":1,"cations":1,"potentially":1,"eradicate":1,"ef":2,"ciently":1,"stampede":1,"trial":1,"was":1,"also":1,"improvements":1,"patient":1,"reported":1,"outcomes":2,"related":1,"phys":1,"ical":1,"health":1,"measures":1,"social":1,"psychological":1,"quality":1,"life":1,"did":1,"im":1,"prove":1,"it":1,"important":1,"note":1,"many":1,"these":1,"estimates":1,"bene":1,"cluded":1,"data":1,"from":1,"nonrandomized":1,"studies":1,"compared":1,"treatments":1,"for":2,"obesity":1,"were":1,"less":1,"fective":1,"those":1,"available":1,"today":1,"medications":2,"lowering":2,"glucose":2,"cardiorenal":1,"protective":1,"sglt2i":1},"len":203},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":10,"chunkId":"ada-easd-2022-p10-c3","text":"cluded data from nonrandomized studies and compared outcomes with medical treatments for obesity that were less ef- fective than those available today. Medications For Lowering Glucose Cardiorenal-Protective Glucose-Lowering Medications SGLT2i. The SGLT2i are oral medications that reduce plasma glucose by enhanc- ing urinary excretion of glucose. They have intermediate-to-high glycemic ef fi cacy, with lower glycemic ef fi cacy at lower es- timated glomerular fi ltration rate (eGFR). However, their scope of use has signi fi - cantly expanded based on cardiovascular and renal outcome studies (5,141). Car- diorenal outcome trials have demon- strated their ef fi cacy in reducing the risk of composite major adverse cardiovascu- lar events (MACE), cardiovascular death, myocardial infarction, hospitalization for heart failure (HHF), and all-cause mortal- ity and improving renal outcomes in indi- viduals with type 2 diabetes with an established/high risk of CVD. This is dis- cussed in the section Personalized Ap- proach to Treatment Based on Individual Characteristics and Comorbidities: Rec- ommended Process for Glucose-Lowering Medication Selection . Evidence support- ing their use is summarized in Table 1 (141,142). Recent data have increased con fi dence in the safety of the SGLT2i drug class (141,142). Their use is associated with in- creased risk for mycotic genital infections, w","tf":{"141":3,"142":2,"cluded":1,"data":2,"from":1,"nonrandomized":1,"studies":2,"and":5,"compared":1,"outcomes":2,"with":5,"medical":1,"treatments":1,"for":5,"obesity":1,"that":2,"were":1,"less":1,"ef":4,"fective":1,"than":1,"those":1,"available":1,"today":1,"medications":3,"lowering":3,"glucose":5,"cardiorenal":1,"protective":1,"sglt2i":3,"the":5,"are":1,"oral":1,"reduce":1,"plasma":1,"by":1,"enhanc":1,"ing":2,"urinary":1,"excretion":1,"of":5,"they":1,"have":3,"intermediate":1,"to":2,"high":2,"glycemic":2,"fi":6,"cacy":3,"lower":2,"at":1,"es":1,"timated":1,"glomerular":1,"ltration":1,"rate":1,"egfr":1,"however":1,"their":4,"scope":1,"use":3,"has":1,"signi":1,"cantly":1,"expanded":1,"based":2,"on":2,"cardiovascular":2,"renal":2,"outcome":2,"car":1,"diorenal":1,"trials":1,"demon":1,"strated":1,"in":6,"reducing":1,"risk":3,"composite":1,"major":1,"adverse":1,"cardiovascu":1,"lar":1,"events":1,"mace":1,"death":1,"myocardial":1,"infarction":1,"hospitalization":1,"heart":1,"failure":1,"hhf":1,"all":1,"cause":1,"mortal":1,"ity":1,"improving":1,"indi":1,"viduals":1,"type":1,"diabetes":1,"an":1,"established":1,"cvd":1,"this":1,"is":3,"dis":1,"cussed":1,"section":1,"personalized":1,"ap":1,"proach":1,"treatment":1,"individual":1,"characteristics":1,"comorbidities":1,"rec":1,"ommended":1,"process":1,"medication":1,"selection":1,"evidence":1,"support":1,"summarized":1,"table":1,"recent":1,"increased":1,"con":1,"dence":1,"safety":1,"drug":1,"class":1,"associated":1,"creased":1,"mycotic":1,"genital":1,"infections":1},"len":210},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":10,"chunkId":"ada-easd-2022-p10-c4","text":" Selection . Evidence support- ing their use is summarized in Table 1 (141,142). Recent data have increased con fi dence in the safety of the SGLT2i drug class (141,142). Their use is associated with in- creased risk for mycotic genital infections, which are reported to be typically mild and treatable. While SGLT2i use can in- crease the risk of diabetic ketoacidosis (DKA), the incidence is low, with a modest incremental absolute risk (142). The SGLT2i cardiovascular outcome trials (CVOTs) have reported DKA rates of 0.1  0.6% compared with rates of < 0.1  0.3% with placebo (143  147), with very low rates in the HF (148  151) and CKD (152,153) outcome studies. Risk can be mitigated with edu- cation and guidance, including education on signs and symptoms of DKA that should prompt medical attention, and temporary discontinuation of the medica- tion in clinical situations that predispose to ketoacidosis (e.g., during prolonged fasting and acute illness and perioperatively, i.e., 3 days prior to surgery) (154  158). The Da- pagli fl ozin in Respiratory Failure in Patients With COVID-19 (DARE-19) RCT demon- strated a low risk of DKA (0.3% vs. 0% in dapagli fl ozin-treated vs. placebo-treated participants) with structured monitoring of acid  base balance and kidney func- tion during inpatient use in adults admit- ted with COVID-19 and at least one cardiometabolic risk factor wit","tf":{"19":3,"141":2,"142":3,"143":1,"147":1,"148":1,"151":1,"152":1,"153":1,"154":1,"158":1,"selection":1,"evidence":1,"support":1,"ing":1,"their":2,"use":4,"is":3,"summarized":1,"in":10,"table":1,"recent":1,"data":1,"have":2,"increased":1,"con":1,"fi":1,"dence":1,"the":8,"safety":1,"of":8,"sglt2i":3,"drug":1,"class":1,"associated":1,"with":9,"creased":1,"risk":6,"for":1,"mycotic":1,"genital":1,"infections":1,"which":1,"are":1,"reported":2,"to":3,"be":2,"typically":1,"mild":1,"and":9,"treatable":1,"while":1,"can":2,"crease":1,"diabetic":1,"ketoacidosis":2,"dka":4,"incidence":1,"low":3,"modest":1,"incremental":1,"absolute":1,"cardiovascular":1,"outcome":2,"trials":1,"cvots":1,"rates":3,"compared":1,"placebo":2,"very":1,"hf":1,"ckd":1,"studies":1,"mitigated":1,"edu":1,"cation":1,"guidance":1,"including":1,"education":1,"on":1,"signs":1,"symptoms":1,"that":2,"should":1,"prompt":1,"medical":1,"attention":1,"temporary":1,"discontinuation":1,"medica":1,"tion":2,"clinical":1,"situations":1,"predispose":1,"during":2,"prolonged":1,"fasting":1,"acute":1,"illness":1,"perioperatively":1,"days":1,"prior":1,"surgery":1,"da":1,"pagli":1,"fl":2,"ozin":2,"respiratory":1,"failure":1,"patients":1,"covid":2,"dare":1,"rct":1,"demon":1,"strated":1,"vs":2,"dapagli":1,"treated":2,"participants":1,"structured":1,"monitoring":1,"acid":1,"base":1,"balance":1,"kidney":1,"func":1,"inpatient":1,"adults":1,"admit":1,"ted":1,"at":1,"least":1,"one":1,"cardiometabolic":1,"factor":1,"wit":1},"len":217},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":10,"chunkId":"ada-easd-2022-p10-c5","text":"(0.3% vs. 0% in dapagli fl ozin-treated vs. placebo-treated participants) with structured monitoring of acid  base balance and kidney func- tion during inpatient use in adults admit- ted with COVID-19 and at least one cardiometabolic risk factor without evi- dence of critical illness (159). While early studies brought attention to several safety areas of interest (acute kidney injury, dehydration, orthostatic hypotension, amputation, and fractures) (5,6), longer-term studies that have pro- spectively assessed and monitored these events (160,161) have not seen a signi fi - cant imbalance in risks. Analyses of SGLT2i outcome trial data also suggest that peo- ple with type 2 diabetes and peripheral arterial disease derive greater absolute outcome bene fi ts from SGLT2i therapy than those without peripheral arterial dis- ease, without an increase in risk of major adverse limb events (162). In post hoc analyses, SGLT2i use has been associated with reduced incidence of serious and nonserious kidney-related adverse events in people with type 2 diabetes and CKD and greater full recovery from acute kid- ney injury (163). GLP-1 RA. GLP-1 RA augment glucose- dependent insulin secretion and glucagon suppression, decelerate gastric emptying, curb postmeal glycemic increments, and reduce appetite, energy intake, and body diabetesjournals.org/care Davies and Associates 2761 Downloaded from h","tf":{"19":1,"159":1,"160":1,"161":1,"162":1,"163":1,"2761":1,"vs":2,"in":6,"dapagli":1,"fl":1,"ozin":1,"treated":2,"placebo":1,"participants":1,"with":5,"structured":1,"monitoring":1,"of":6,"acid":1,"base":1,"balance":1,"and":12,"kidney":3,"func":1,"tion":1,"during":1,"inpatient":1,"use":2,"adults":1,"admit":1,"ted":1,"covid":1,"at":1,"least":1,"one":1,"cardiometabolic":1,"risk":2,"factor":1,"without":3,"evi":1,"dence":1,"critical":1,"illness":1,"while":1,"early":1,"studies":2,"brought":1,"attention":1,"to":1,"several":1,"safety":1,"areas":1,"interest":1,"acute":2,"injury":2,"dehydration":1,"orthostatic":1,"hypotension":1,"amputation":1,"fractures":1,"longer":1,"term":1,"that":2,"have":2,"pro":1,"spectively":1,"assessed":1,"monitored":1,"these":1,"events":3,"not":1,"seen":1,"signi":1,"fi":2,"cant":1,"imbalance":1,"risks":1,"analyses":2,"sglt2i":3,"outcome":2,"trial":1,"data":1,"also":1,"suggest":1,"peo":1,"ple":1,"type":2,"diabetes":2,"peripheral":2,"arterial":2,"disease":1,"derive":1,"greater":2,"absolute":1,"bene":1,"ts":1,"from":3,"therapy":1,"than":1,"those":1,"dis":1,"ease":1,"an":1,"increase":1,"major":1,"adverse":2,"limb":1,"post":1,"hoc":1,"has":1,"been":1,"associated":1,"reduced":1,"incidence":1,"serious":1,"nonserious":1,"related":1,"people":1,"ckd":1,"full":1,"recovery":1,"kid":1,"ney":1,"glp":2,"ra":2,"augment":1,"glucose":1,"dependent":1,"insulin":1,"secretion":1,"glucagon":1,"suppression":1,"decelerate":1,"gastric":1,"emptying":1,"curb":1,"postmeal":1,"glycemic":1,"increments":1,"reduce":1,"appetite":1,"energy":1,"intake":1,"body":1,"diabetesjournals":1,"org":1,"care":1,"davies":1,"associates":1,"downloaded":1},"len":206},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":10,"chunkId":"ada-easd-2022-p10-c6","text":"augment glucose- dependent insulin secretion and glucagon suppression, decelerate gastric emptying, curb postmeal glycemic increments, and reduce appetite, energy intake, and body diabetesjournals.org/care Davies and Associates 2761 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"45":1,"2026":1,"2753":1,"2761":1,"691567":1,"augment":1,"glucose":1,"dependent":1,"insulin":1,"secretion":1,"and":4,"glucagon":1,"suppression":1,"decelerate":1,"gastric":1,"emptying":1,"curb":1,"postmeal":1,"glycemic":1,"increments":1,"reduce":1,"appetite":1,"energy":1,"intake":1,"body":1,"diabetesjournals":2,"org":2,"care":2,"davies":1,"associates":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"february":1},"len":49},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":11,"chunkId":"ada-easd-2022-p11-c0","text":"weight (5,6,164). Beyond improving HbA 1c in adults with type 2 diabetes, speci fi c GLP-1 RA have also been approved for re- ducing risk of MACE in adults with type 2 diabetes with established CVD (dulaglu- tide, liraglutide, and subcutaneous sema- glutide) or multiple cardiovascular risk factors (dulaglutide) (Table 1) and for chronic weight management (subcutane- ous liraglutide titrated to 3.0 mg once daily; subcutaneous semaglutide titrated to 2.4 mg once weekly). This is discussed in the sections Medications for Weight Loss in Type 2 Diabetes and Personalized Approach to Treatment Based on Individ- ual Characteristics and Comorbidities: Recommended Process for Glucose- Lowering Medication Selection . GLP-1 RA are primarily available as injectable therapies (subcutaneous administration), with one oral GLP-1 RA now available (oral semaglutide) (165). The recent higher-dose GLP-1 RA stud- ies have indicated incremental bene fi ts for glucose and weight at higher doses of GLP-1 RA, with greater proportions of people achieving glycemic targets and the ability of stepwise dose escalation to improve gastrointestinal tolerability. The Assessment of Weekly Administration of LY2189265 (dulaglutide) in Diabetes 11 (AWARD-11) trial evaluated higher doses of dulaglutide (3.0 mg and 4.5 mg weekly) compared with 1.5 mg weekly, demonstrat- ing superior HbA 1c reductions ( \u0003 19.4 vs. \u0003 16","tf":{"11":2,"16":1,"19":1,"164":1,"165":1,"weight":4,"beyond":1,"improving":1,"hba":2,"1c":2,"in":5,"adults":2,"with":6,"type":3,"diabetes":4,"speci":1,"fi":2,"glp":5,"ra":5,"have":2,"also":1,"been":1,"approved":1,"for":5,"re":1,"ducing":1,"risk":2,"of":7,"mace":1,"established":1,"cvd":1,"dulaglu":1,"tide":1,"liraglutide":2,"and":7,"subcutaneous":3,"sema":1,"glutide":1,"or":1,"multiple":1,"cardiovascular":1,"factors":1,"dulaglutide":3,"table":1,"chronic":1,"management":1,"subcutane":1,"ous":1,"titrated":2,"to":4,"mg":5,"once":2,"daily":1,"semaglutide":2,"weekly":4,"this":1,"is":1,"discussed":1,"the":4,"sections":1,"medications":1,"loss":1,"personalized":1,"approach":1,"treatment":1,"based":1,"on":1,"individ":1,"ual":1,"characteristics":1,"comorbidities":1,"recommended":1,"process":1,"glucose":2,"lowering":1,"medication":1,"selection":1,"are":1,"primarily":1,"available":2,"as":1,"injectable":1,"therapies":1,"administration":2,"one":1,"oral":2,"now":1,"recent":1,"higher":3,"dose":2,"stud":1,"ies":1,"indicated":1,"incremental":1,"bene":1,"ts":1,"at":1,"doses":2,"greater":1,"proportions":1,"people":1,"achieving":1,"glycemic":1,"targets":1,"ability":1,"stepwise":1,"escalation":1,"improve":1,"gastrointestinal":1,"tolerability":1,"assessment":1,"ly2189265":1,"award":1,"trial":1,"evaluated":1,"compared":1,"demonstrat":1,"ing":1,"superior":1,"reductions":1,"vs":1},"len":198},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":11,"chunkId":"ada-easd-2022-p11-c1","text":" Assessment of Weekly Administration of LY2189265 (dulaglutide) in Diabetes 11 (AWARD-11) trial evaluated higher doses of dulaglutide (3.0 mg and 4.5 mg weekly) compared with 1.5 mg weekly, demonstrat- ing superior HbA 1c reductions ( \u0003 19.4 vs. \u0003 16.8 mmol/mol [  1.77 vs. \u0003 1.54%], esti- mated treatment difference [ETD]  2.6 mmol/mol [ \u0003 0.24%]) and weight loss (  4.6 vs.  3.0 kg, ETD  1.6 kg) with dulaglutide 4.5 mg compared with 1.5 mg at 36 weeks in people with type 2 diabetes inadequately controlled with metformin (166). Likewise, the SUSTAIN FORTE trial studied higher doses of once-weekly subcutaneous semaglutide (2.0 mg) compared with the previously approved 1.0 mg dose, reporting a mean change in HbA 1c from baseline to week 40 of \u0003 23 vs. \u0003 21 mmol/mol (  2.1 vs. \u0003 1.9%, ETD  2 mmol/mol [ \u0003 0.18%]) and weight change of  6.4 kg with sema- glutide 2.0 mg and  5.6 kg with sema- glutide 1.0 mg (ETD  0.77 kg [95% CI  1.55, 0.01]) (167). The most common side effects of GLP-1 RA are gastrointestinal in nature (nausea, vomiting, and diarrhea) and tend to occur during initiation and dose escalation and diminish over time. Gradual up-titration is recommended to mitigate gastrointestinal effects (164,168,169). Education should be provided when initiating GLP-1 RA therapy. GLP-1 RA promote a sense of satiety, facili- tating reduction in food intake. It is impor- tant to","tf":{"11":2,"16":1,"18":1,"19":1,"21":1,"23":1,"24":1,"36":1,"40":1,"54":1,"55":1,"77":2,"95":1,"164":1,"166":1,"167":1,"168":1,"169":1,"assessment":1,"of":8,"weekly":4,"administration":1,"ly2189265":1,"dulaglutide":3,"in":5,"diabetes":2,"award":1,"trial":2,"evaluated":1,"higher":2,"doses":2,"mg":9,"and":8,"compared":3,"with":8,"demonstrat":1,"ing":1,"superior":1,"hba":2,"1c":2,"reductions":1,"vs":5,"mmol":4,"mol":4,"esti":1,"mated":1,"treatment":1,"difference":1,"etd":4,"weight":2,"loss":1,"kg":5,"at":1,"weeks":1,"people":1,"type":1,"inadequately":1,"controlled":1,"metformin":1,"likewise":1,"the":3,"sustain":1,"forte":1,"studied":1,"once":1,"subcutaneous":1,"semaglutide":1,"previously":1,"approved":1,"dose":2,"reporting":1,"mean":1,"change":2,"from":1,"baseline":1,"to":4,"week":1,"sema":2,"glutide":2,"ci":1,"01":1,"most":1,"common":1,"side":1,"effects":2,"glp":3,"ra":3,"are":1,"gastrointestinal":2,"nature":1,"nausea":1,"vomiting":1,"diarrhea":1,"tend":1,"occur":1,"during":1,"initiation":1,"escalation":1,"diminish":1,"over":1,"time":1,"gradual":1,"up":1,"titration":1,"is":2,"recommended":1,"mitigate":1,"education":1,"should":1,"be":1,"provided":1,"when":1,"initiating":1,"therapy":1,"promote":1,"sense":1,"satiety":1,"facili":1,"tating":1,"reduction":1,"food":1,"intake":1,"it":1,"impor":1,"tant":1},"len":207},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":11,"chunkId":"ada-easd-2022-p11-c2","text":" Gradual up-titration is recommended to mitigate gastrointestinal effects (164,168,169). Education should be provided when initiating GLP-1 RA therapy. GLP-1 RA promote a sense of satiety, facili- tating reduction in food intake. It is impor- tant to help people distinguish between nausea, a negative sensation, and satiety, a positive sensation that supports weight loss. Mindful eating should be encouraged: eating slowly, stopping eating when full and not eating when not hungry. Smaller meals or snacks, decreasing intake of high-fat and spicy foods, moderating al- cohol intake, and increasing water intake are also recommended. Slower or fl exi- ble dose escalations can be considered in the setting of gastrointestinal intoler- ance (168,169). Data from CVOTs on other safety areas of interest (pancreatitis, pancreatic cancer, and medullary thyroid cancer) indicate that there is no increase in these risks with GLP-1 RA. GLP-1 RA are contraindi- cated in people at risk for the rare medul- lary thyroid cancer (164), that is, those with a history or family history of medul- lary thyroid cancer or multiple endocrine neoplasia type 2, due to thyroid C-cell tumors seen in rodents treated with GLP-1 RA in preclinical studies. Increased retinopathy complications seen in the SUSTAIN 6 CVOT appear attributable to the magnitude and rapidity of HbA 1c re- ductions in individuals with pre-exis","tf":{"164":2,"168":2,"169":2,"gradual":1,"up":1,"titration":1,"is":4,"recommended":2,"to":4,"mitigate":1,"gastrointestinal":2,"effects":1,"education":1,"should":2,"be":3,"provided":1,"when":3,"initiating":1,"glp":5,"ra":5,"therapy":1,"promote":1,"sense":1,"of":6,"satiety":2,"facili":1,"tating":1,"reduction":1,"in":8,"food":1,"intake":4,"it":1,"impor":1,"tant":1,"help":1,"people":2,"distinguish":1,"between":1,"nausea":1,"negative":1,"sensation":2,"and":6,"positive":1,"that":3,"supports":1,"weight":1,"loss":1,"mindful":1,"eating":4,"encouraged":1,"slowly":1,"stopping":1,"full":1,"not":2,"hungry":1,"smaller":1,"meals":1,"or":4,"snacks":1,"decreasing":1,"high":1,"fat":1,"spicy":1,"foods":1,"moderating":1,"al":1,"cohol":1,"increasing":1,"water":1,"are":2,"also":1,"slower":1,"fl":1,"exi":1,"ble":1,"dose":1,"escalations":1,"can":1,"considered":1,"the":4,"setting":1,"intoler":1,"ance":1,"data":1,"from":1,"cvots":1,"on":1,"other":1,"safety":1,"areas":1,"interest":1,"pancreatitis":1,"pancreatic":1,"cancer":4,"medullary":1,"thyroid":4,"indicate":1,"there":1,"no":1,"increase":1,"these":1,"risks":1,"with":4,"contraindi":1,"cated":1,"at":1,"risk":1,"for":1,"rare":1,"medul":2,"lary":2,"those":1,"history":2,"family":1,"multiple":1,"endocrine":1,"neoplasia":1,"type":1,"due":1,"cell":1,"tumors":1,"seen":2,"rodents":1,"treated":1,"preclinical":1,"studies":1,"increased":1,"retinopathy":1,"complications":1,"sustain":1,"cvot":1,"appear":1,"attributable":1,"magnitude":1,"rapidity":1,"hba":1,"1c":1,"re":1,"ductions":1,"individuals":1,"pre":1,"exis":1},"len":215},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":11,"chunkId":"ada-easd-2022-p11-c3","text":"o thyroid C-cell tumors seen in rodents treated with GLP-1 RA in preclinical studies. Increased retinopathy complications seen in the SUSTAIN 6 CVOT appear attributable to the magnitude and rapidity of HbA 1c re- ductions in individuals with pre-existing diabetic retinopathy and high glycemic levels, as has been seen in previous stud- ies with insulin (170,171). GLP-1 RA are also associated with higher risks of gall- bladder and biliary diseases (172). Other Glucose-Lowering Medications Metformin. Because of its high ef fi cacy in lowering HbA 1c , minimal hypoglyce- mia risk when used as monotherapy, weight neutrality with the potential for modest weight loss, good safety pro fi le, and low cost, metformin has traditionally been recommended as fi rst-line glucose- lowering therapy for the management of type 2 diabetes. However, there is ongo- ing acceptance that other approaches may be appropriate. Notably, the bene- fi ts of GLP-1 RA and SGLT2i for cardio- vascular and renal outcomes have been found to be independent of metformin use, and thus these agents should be considered in people with established or high risk of CVD, HF, or CKD, indepen- dent of metformin use (173  175). Early combination therapy based on the per- ceived need for additional glycemic ef fi cacy or cardiorenal protection can be considered at treatment initiation to ex- tend the time to treatment failure","tf":{"170":1,"171":1,"172":1,"173":1,"175":1,"thyroid":1,"cell":1,"tumors":1,"seen":3,"in":7,"rodents":1,"treated":1,"with":6,"glp":3,"ra":3,"preclinical":1,"studies":1,"increased":1,"retinopathy":2,"complications":1,"the":7,"sustain":1,"cvot":1,"appear":1,"attributable":1,"to":4,"magnitude":1,"and":7,"rapidity":1,"of":8,"hba":2,"1c":2,"re":1,"ductions":1,"individuals":1,"pre":1,"existing":1,"diabetic":1,"high":3,"glycemic":2,"levels":1,"as":3,"has":2,"been":3,"previous":1,"stud":1,"ies":1,"insulin":1,"are":1,"also":1,"associated":1,"higher":1,"risks":1,"gall":1,"bladder":1,"biliary":1,"diseases":1,"other":2,"glucose":2,"lowering":3,"medications":1,"metformin":4,"because":1,"its":1,"ef":2,"fi":5,"cacy":2,"minimal":1,"hypoglyce":1,"mia":1,"risk":2,"when":1,"used":1,"monotherapy":1,"weight":2,"neutrality":1,"potential":1,"for":4,"modest":1,"loss":1,"good":1,"safety":1,"pro":1,"le":1,"low":1,"cost":1,"traditionally":1,"recommended":1,"rst":1,"line":1,"therapy":2,"management":1,"type":1,"diabetes":1,"however":1,"there":1,"is":1,"ongo":1,"ing":1,"acceptance":1,"that":1,"approaches":1,"may":1,"be":4,"appropriate":1,"notably":1,"bene":1,"ts":1,"sglt2i":1,"cardio":1,"vascular":1,"renal":1,"outcomes":1,"have":1,"found":1,"independent":1,"use":2,"thus":1,"these":1,"agents":1,"should":1,"considered":2,"people":1,"established":1,"or":3,"cvd":1,"hf":1,"ckd":1,"indepen":1,"dent":1,"early":1,"combination":1,"based":1,"on":1,"per":1,"ceived":1,"need":1,"additional":1,"cardiorenal":1,"protection":1,"can":1,"at":1,"treatment":2,"initiation":1,"ex":1,"tend":1,"time":1,"failure":1},"len":225},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":11,"chunkId":"ada-easd-2022-p11-c4","text":" CKD, indepen- dent of metformin use (173  175). Early combination therapy based on the per- ceived need for additional glycemic ef fi cacy or cardiorenal protection can be considered at treatment initiation to ex- tend the time to treatment failure (176). Metformin should not be used in people with an eGFR < 30 ml/min per 1.73 m 2 , and dose reduction should be considered when the eGFR is < 45 ml/min per 1.73 m 2 (177). Metformin use may result in lower serum vitamin B 12 concentrations and worsening of symptoms of neuropathy; therefore, periodic monitoring and supple- mentation are generally recommended if levels are de fi cient, particularly in those with anemia or neuropathy (178,179). Dipeptidyl Peptidase 4 Inhibitors. Dipep- tidyl peptidase 4 inhibitors (DPP-4i) are oral medications that inhibit the enzy- matic inactivation of endogenous incretin hormones, resulting in glucose-dependent insulin release and a decrease in glucagon secretion. They have a more modest glu- cose-lowering ef fi cacy and a neutral ef- fect on weight and are well tolerated with minimal risk of hypoglycemia. CVOTs have demonstrated the cardiovascular safety without cardiovascular risk reduc- tion of four DPP-4i (saxagliptin, alogliptin, sitagliptin, and linagliptin) (141). Reduc- tions in risk of albuminuria progression were noted with linagliptin in the Cardio- vascular and Renal Microvascular Ou","tf":{"12":1,"30":1,"45":1,"73":2,"141":1,"173":1,"175":1,"176":1,"177":1,"178":1,"179":1,"ckd":1,"indepen":1,"dent":1,"of":7,"metformin":3,"use":2,"early":1,"combination":1,"therapy":1,"based":1,"on":2,"the":6,"per":3,"ceived":1,"need":1,"for":1,"additional":1,"glycemic":1,"ef":3,"fi":3,"cacy":2,"or":2,"cardiorenal":1,"protection":1,"can":1,"be":3,"considered":2,"at":1,"treatment":2,"initiation":1,"to":2,"ex":1,"tend":1,"time":1,"failure":1,"should":2,"not":1,"used":1,"in":7,"people":1,"with":4,"an":1,"egfr":2,"ml":2,"min":2,"and":8,"dose":1,"reduction":1,"when":1,"is":1,"may":1,"result":1,"lower":1,"serum":1,"vitamin":1,"concentrations":1,"worsening":1,"symptoms":1,"neuropathy":2,"therefore":1,"periodic":1,"monitoring":1,"supple":1,"mentation":1,"are":4,"generally":1,"recommended":1,"if":1,"levels":1,"de":1,"cient":1,"particularly":1,"those":1,"anemia":1,"dipeptidyl":1,"peptidase":2,"inhibitors":2,"dipep":1,"tidyl":1,"dpp":2,"4i":2,"oral":1,"medications":1,"that":1,"inhibit":1,"enzy":1,"matic":1,"inactivation":1,"endogenous":1,"incretin":1,"hormones":1,"resulting":1,"glucose":1,"dependent":1,"insulin":1,"release":1,"decrease":1,"glucagon":1,"secretion":1,"they":1,"have":2,"more":1,"modest":1,"glu":1,"cose":1,"lowering":1,"neutral":1,"fect":1,"weight":1,"well":1,"tolerated":1,"minimal":1,"risk":3,"hypoglycemia":1,"cvots":1,"demonstrated":1,"cardiovascular":2,"safety":1,"without":1,"reduc":2,"tion":1,"four":1,"saxagliptin":1,"alogliptin":1,"sitagliptin":1,"linagliptin":2,"tions":1,"albuminuria":1,"progression":1,"were":1,"noted":1,"cardio":1,"vascular":1,"renal":1,"microvascular":1,"ou":1},"len":210},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":11,"chunkId":"ada-easd-2022-p11-c5","text":"afety without cardiovascular risk reduc- tion of four DPP-4i (saxagliptin, alogliptin, sitagliptin, and linagliptin) (141). Reduc- tions in risk of albuminuria progression were noted with linagliptin in the Cardio- vascular and Renal Microvascular Out- come Study With Linagliptin (CARMELINA) trial (180). While generally well tolerated, an increased risk of HHF was found with saxagliptin, which is re fl ected in its label, and there have been rare reports of ar- thralgia and hypersensitivity reactions with the DPP-4i class (16). The high tolerability and modest ef fi - cacy of DPP-4i may mean that they are suitable for speci fi c populations and con- siderations. For example, in a 6-month open-label RCT comparing a DPP-4i (lina- gliptin) with basal insulin (glargine) in long-term care and skilled nursing facili- ties, mean daily blood glucose was simi- lar, with fewer hypoglycemic events with linagliptin compared with insulin (181). Treatment of inpatient hyperglycemia with basal insulin plus DPP-4i has been demon- strated to be effective and safe in older adults with type 2 diabetes, with similar mean daily blood glucose but lower glyce- mic variability and fewer hypoglycemic episodes compared with the basal  bolus insulin regimen (182). Glucose-Dependent Insulinotropic Poly- peptide and GLP-1 RA. In May 2022, the 2762 Consensus Report Diabetes Care Volume 45, November 2022 Do","tf":{"16":1,"45":1,"141":1,"180":1,"181":1,"182":1,"2022":2,"2762":1,"afety":1,"without":1,"cardiovascular":1,"risk":3,"reduc":2,"tion":1,"of":6,"four":1,"dpp":5,"4i":5,"saxagliptin":2,"alogliptin":1,"sitagliptin":1,"and":10,"linagliptin":4,"tions":1,"in":7,"albuminuria":1,"progression":1,"were":1,"noted":1,"with":12,"the":5,"cardio":1,"vascular":1,"renal":1,"microvascular":1,"out":1,"come":1,"study":1,"carmelina":1,"trial":1,"while":1,"generally":1,"well":1,"tolerated":1,"an":1,"increased":1,"hhf":1,"was":2,"found":1,"which":1,"is":1,"re":1,"fl":1,"ected":1,"its":1,"label":2,"there":1,"have":1,"been":2,"rare":1,"reports":1,"ar":1,"thralgia":1,"hypersensitivity":1,"reactions":1,"class":1,"high":1,"tolerability":1,"modest":1,"ef":1,"fi":2,"cacy":1,"may":2,"mean":3,"that":1,"they":1,"are":1,"suitable":1,"for":2,"speci":1,"populations":1,"con":1,"siderations":1,"example":1,"month":1,"open":1,"rct":1,"comparing":1,"lina":1,"gliptin":1,"basal":3,"insulin":4,"glargine":1,"long":1,"term":1,"care":2,"skilled":1,"nursing":1,"facili":1,"ties":1,"daily":2,"blood":2,"glucose":3,"simi":1,"lar":1,"fewer":2,"hypoglycemic":2,"events":1,"compared":2,"treatment":1,"inpatient":1,"hyperglycemia":1,"plus":1,"has":1,"demon":1,"strated":1,"to":1,"be":1,"effective":1,"safe":1,"older":1,"adults":1,"type":1,"diabetes":2,"similar":1,"but":1,"lower":1,"glyce":1,"mic":1,"variability":1,"episodes":1,"bolus":1,"regimen":1,"dependent":1,"insulinotropic":1,"poly":1,"peptide":1,"glp":1,"ra":1,"consensus":1,"report":1,"volume":1,"november":1,"do":1},"len":217},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":11,"chunkId":"ada-easd-2022-p11-c6","text":"lyce- mic variability and fewer hypoglycemic episodes compared with the basal  bolus insulin regimen (182). Glucose-Dependent Insulinotropic Poly- peptide and GLP-1 RA. In May 2022, the 2762 Consensus Report Diabetes Care Volume 45, November 2022 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"45":2,"182":1,"2022":2,"2026":1,"2753":1,"2762":1,"691567":1,"lyce":1,"mic":1,"variability":1,"and":2,"fewer":1,"hypoglycemic":1,"episodes":1,"compared":1,"with":1,"the":2,"basal":1,"bolus":1,"insulin":1,"regimen":1,"glucose":1,"dependent":1,"insulinotropic":1,"poly":1,"peptide":1,"glp":1,"ra":1,"in":1,"may":1,"consensus":1,"report":1,"diabetes":1,"care":2,"volume":1,"november":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"february":1},"len":56},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":12,"chunkId":"ada-easd-2022-p12-c0","text":"U.S. Food and Drug Administration (FDA) approved tirzepatide, a GIP and GLP-1 RA, for once-weekly subcutaneous administra- tion to improve glucose control in adults with type 2 diabetes as an addition to healthy eating and exercise. In the Phase III clinical trial program, tirzepatide dem- onstrated superior glycemic ef fi cacy to placebo (183,184), subcutaneous sema- glutide 1.0 mg weekly (185), insulin de- gludec (186), and insulin glargine (187). For HbA 1c , placebo-adjusted reductions of 21 mmol/mol (1.91%), 21 mmol/mol (1.93%), and 23 mmol/mol (2.11%) were demonstrated with tirzepatide 5, 10, and 15 mg weekly, respectively, and mean weight reductions of 7  9.5 kg were seen (183). Additional metabolic bene fi ts in- cluded improvements in liver fat content and reduced visceral and subcutaneous abdominal adipose tissue volume (188). Based on meta-analysis fi ndings, tirzepa- tide was superior to its comparators, in- cluding other long-acting GLP-1 RA, in reducing glucose and body weight, but was associated with increased odds for gastrointestinal adverse events, in partic- ular nausea (189). Similar warnings and precautions are included in the prescrib- ing information for tirzepatide as for agents in the GLP-1 RA class. Addition- ally, current short-term data from RCTs suggest that tirzepatide does not increase the risk of MACE versus comparators; however, robust data on ","tf":{"10":1,"11":1,"15":1,"21":2,"23":1,"91":1,"93":1,"183":2,"184":1,"185":1,"186":1,"187":1,"188":1,"189":1,"food":1,"and":11,"drug":1,"administration":1,"fda":1,"approved":1,"tirzepatide":5,"gip":1,"glp":3,"ra":3,"for":5,"once":1,"weekly":3,"subcutaneous":3,"administra":1,"tion":1,"to":4,"improve":1,"glucose":2,"control":1,"in":9,"adults":1,"with":3,"type":1,"diabetes":1,"as":2,"an":1,"addition":2,"healthy":1,"eating":1,"exercise":1,"the":4,"phase":1,"iii":1,"clinical":1,"trial":1,"program":1,"dem":1,"onstrated":1,"superior":2,"glycemic":1,"ef":1,"fi":3,"cacy":1,"placebo":2,"sema":1,"glutide":1,"mg":2,"insulin":2,"de":1,"gludec":1,"glargine":1,"hba":1,"1c":1,"adjusted":1,"reductions":2,"of":3,"mmol":3,"mol":3,"were":2,"demonstrated":1,"respectively":1,"mean":1,"weight":2,"kg":1,"seen":1,"additional":1,"metabolic":1,"bene":1,"ts":1,"cluded":1,"improvements":1,"liver":1,"fat":1,"content":1,"reduced":1,"visceral":1,"abdominal":1,"adipose":1,"tissue":1,"volume":1,"based":1,"on":2,"meta":1,"analysis":1,"ndings":1,"tirzepa":1,"tide":1,"was":2,"its":1,"comparators":2,"cluding":1,"other":1,"long":1,"acting":1,"reducing":1,"body":1,"but":1,"associated":1,"increased":1,"odds":1,"gastrointestinal":1,"adverse":1,"events":1,"partic":1,"ular":1,"nausea":1,"similar":1,"warnings":1,"precautions":1,"are":1,"included":1,"prescrib":1,"ing":1,"information":1,"agents":1,"class":1,"ally":1,"current":1,"short":1,"term":1,"data":2,"from":1,"rcts":1,"suggest":1,"that":1,"does":1,"not":1,"increase":1,"risk":1,"mace":1,"versus":1,"however":1,"robust":1},"len":214},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":12,"chunkId":"ada-easd-2022-p12-c1","text":" included in the prescrib- ing information for tirzepatide as for agents in the GLP-1 RA class. Addition- ally, current short-term data from RCTs suggest that tirzepatide does not increase the risk of MACE versus comparators; however, robust data on its long-term car- diovascular pro fi le will be available after completion of the SURPASS-CVOT trial (190). Tirzepatide has received a positive opinion in the European Union (EU). Sulfonylureas. As per the previous con- sensus report and update, sulfonylureas are assessed as having high glucose- lowering ef fi cacy, but with a lack of du- rable effect, and the advantages of be- ing inexpensive and accessible (5,6). However, due to their glucose-indepen- dent stimulation of insulin secretion, they are associated with an increased risk for hypoglycemia. Sulfonylureas are also associated with weight gain, which is relatively modest in large cohort stud- ies (191). Use of sulfonylureas or insulin for early intensive blood glucose control in the UK Prospective Diabetes Study (UKPDS) signi fi cantly decreased the risk of microvascular complications, under- scoring the importance of early and continued glycemic management (192). Adverse cardiovascular outcomes with sulfonylureas in some observational stud- ies have raised concerns, although fi nd- ings from systematic reviews have found no increase in all-cause mortality rates compared wi","tf":{"190":1,"191":1,"192":1,"included":1,"in":7,"the":10,"prescrib":1,"ing":2,"information":1,"for":4,"tirzepatide":3,"as":3,"agents":1,"glp":1,"ra":1,"class":1,"addition":1,"ally":1,"current":1,"short":1,"term":2,"data":2,"from":2,"rcts":1,"suggest":1,"that":1,"does":1,"not":1,"increase":2,"risk":3,"of":8,"mace":1,"versus":1,"comparators":1,"however":2,"robust":1,"on":1,"its":1,"long":1,"car":1,"diovascular":1,"pro":1,"fi":4,"le":1,"will":1,"be":2,"available":1,"after":1,"completion":1,"surpass":1,"cvot":1,"trial":1,"has":1,"received":1,"positive":1,"opinion":1,"european":1,"union":1,"eu":1,"sulfonylureas":5,"per":1,"previous":1,"con":1,"sensus":1,"report":1,"and":4,"update":1,"are":3,"assessed":1,"having":1,"high":1,"glucose":3,"lowering":1,"ef":1,"cacy":1,"but":1,"with":4,"lack":1,"du":1,"rable":1,"effect":1,"advantages":1,"inexpensive":1,"accessible":1,"due":1,"to":1,"their":1,"indepen":1,"dent":1,"stimulation":1,"insulin":2,"secretion":1,"they":1,"associated":2,"an":1,"increased":1,"hypoglycemia":1,"also":1,"weight":1,"gain":1,"which":1,"is":1,"relatively":1,"modest":1,"large":1,"cohort":1,"stud":2,"ies":2,"use":1,"or":1,"early":2,"intensive":1,"blood":1,"control":1,"uk":1,"prospective":1,"diabetes":1,"study":1,"ukpds":1,"signi":1,"cantly":1,"decreased":1,"microvascular":1,"complications":1,"under":1,"scoring":1,"importance":1,"continued":1,"glycemic":1,"management":1,"adverse":1,"cardiovascular":1,"outcomes":1,"some":1,"observational":1,"have":2,"raised":1,"concerns":1,"although":1,"nd":1,"ings":1,"systematic":1,"reviews":1,"found":1,"no":1,"all":1,"cause":1,"mortality":1,"rates":1,"compared":1,"wi":1},"len":212},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":12,"chunkId":"ada-easd-2022-p12-c2","text":"continued glycemic management (192). Adverse cardiovascular outcomes with sulfonylureas in some observational stud- ies have raised concerns, although fi nd- ings from systematic reviews have found no increase in all-cause mortality rates compared with other active treatments (191). The incidence of cardiovascular events was comparable in those treated with a sulfonylurea or pioglitazone in the Thiazolidinediones or Sulfonylureas and Cardiovascular Accidents Intervention Trial (TOSCA.IT) (193), and no difference in the incidence of MACE was found in people at high cardiovascular risk treated with gli- mepiride or linagliptin (194), a medication whose cardiovascular safety was demon- strated in a population at high cardiovas- cular and renal risk (195). Thiazolidinediones. Thiazolidinediones (TZDs) are oral medications that increase insulin sensitivity and are of high glu- cose-lowering ef fi cacy (5,6). TZDs have a high durability of glycemic response, most likely through a potent effect on preserving b -cell function (196). In the Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive) in adults with type 2 diabetes and macrovascular disease, a reduction in secondary cardio- vascular end points was seen, although signi fi cance was not achieved for the pri- mary outcome (197). In the Insulin Resis- tance Intervention After Stroke (IRIS) study in adults with","tf":{"191":1,"192":1,"193":1,"194":1,"195":1,"196":1,"197":1,"continued":1,"glycemic":2,"management":1,"adverse":1,"cardiovascular":5,"outcomes":1,"with":6,"sulfonylureas":2,"in":13,"some":1,"observational":1,"stud":1,"ies":1,"have":3,"raised":1,"concerns":1,"although":2,"fi":3,"nd":1,"ings":1,"from":1,"systematic":1,"reviews":1,"found":2,"no":2,"increase":2,"all":1,"cause":1,"mortality":1,"rates":1,"compared":1,"other":1,"active":1,"treatments":1,"the":6,"incidence":2,"of":4,"events":2,"was":5,"comparable":1,"those":1,"treated":2,"sulfonylurea":1,"or":3,"pioglitazone":2,"thiazolidinediones":3,"and":5,"accidents":1,"intervention":2,"trial":2,"tosca":1,"it":1,"difference":1,"mace":1,"people":1,"at":2,"high":4,"risk":2,"gli":1,"mepiride":1,"linagliptin":1,"medication":1,"whose":1,"safety":1,"demon":1,"strated":1,"population":1,"cardiovas":1,"cular":1,"renal":1,"tzds":2,"are":2,"oral":1,"medications":1,"that":1,"insulin":2,"sensitivity":1,"glu":1,"cose":1,"lowering":1,"ef":1,"cacy":1,"durability":1,"response":1,"most":1,"likely":1,"through":1,"potent":1,"effect":1,"on":1,"preserving":1,"cell":1,"function":1,"prospective":1,"clinical":1,"macrovascular":2,"proactive":1,"adults":2,"type":1,"diabetes":1,"disease":1,"reduction":1,"secondary":1,"cardio":1,"vascular":1,"end":1,"points":1,"seen":1,"signi":1,"cance":1,"not":1,"achieved":1,"for":1,"pri":1,"mary":1,"outcome":1,"resis":1,"tance":1,"after":1,"stroke":1,"iris":1,"study":1},"len":196},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":12,"chunkId":"ada-easd-2022-p12-c3","text":"etes and macrovascular disease, a reduction in secondary cardio- vascular end points was seen, although signi fi cance was not achieved for the pri- mary outcome (197). In the Insulin Resis- tance Intervention After Stroke (IRIS) study in adults without diabetes but with insulin resistance (HOMA of insulin resistance > 3.0) and recent history of stroke or tran- sient ischemic attack, there was a lower risk of stroke or myocardial infarction with pioglitazone versus placebo (198,199). Bene fi cial effects on nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) have been seen with pioglitazone (200,201). However, these bene fi ts must be balanced against possible side effects of fl uid retention and congestive HF (196,197,202), weight gain (196  198,202,203), and bone fracture (204,205). Side effects can be mitigated by using lower doses and combining TZD therapy with other medications (SGLT2i and GLP-1 RA) that promote weight loss and sodium excretion (199,206). Insulin. The previous consensus report and update provide detailed descriptions of the different insulins (5,6). The pri- mary advantage of insulin therapy is that it lowers glucose in a dose-dependent manner and thus can address almost any level of blood glucose. However, its ef fi cacy and safety are largely dependent on the education and support provided to facilitate self-management (5,6)","tf":{"196":2,"197":2,"198":2,"199":2,"200":1,"201":1,"202":2,"203":1,"204":1,"205":1,"206":1,"etes":1,"and":12,"macrovascular":1,"disease":2,"reduction":1,"in":4,"secondary":1,"cardio":1,"vascular":1,"end":1,"points":1,"was":3,"seen":2,"although":1,"signi":1,"fi":4,"cance":1,"not":1,"achieved":1,"for":1,"the":6,"pri":2,"mary":2,"outcome":1,"insulin":5,"resis":1,"tance":1,"intervention":1,"after":1,"stroke":3,"iris":1,"study":1,"adults":1,"without":1,"diabetes":1,"but":1,"with":4,"resistance":2,"homa":1,"of":7,"recent":1,"history":1,"or":2,"tran":1,"sient":1,"ischemic":1,"attack":1,"there":1,"lower":2,"risk":1,"myocardial":1,"infarction":1,"pioglitazone":2,"versus":1,"placebo":1,"bene":2,"cial":1,"effects":3,"on":2,"nonalcoholic":2,"fatty":1,"liver":1,"nafld":1,"steatohepatitis":1,"nash":1,"have":1,"been":1,"however":2,"these":1,"ts":1,"must":1,"be":2,"balanced":1,"against":1,"possible":1,"side":2,"fl":1,"uid":1,"retention":1,"congestive":1,"hf":1,"weight":2,"gain":1,"bone":1,"fracture":1,"can":2,"mitigated":1,"by":1,"using":1,"doses":1,"combining":1,"tzd":1,"therapy":2,"other":1,"medications":1,"sglt2i":1,"glp":1,"ra":1,"that":2,"promote":1,"loss":1,"sodium":1,"excretion":1,"previous":1,"consensus":1,"report":1,"update":1,"provide":1,"detailed":1,"descriptions":1,"different":1,"insulins":1,"advantage":1,"is":1,"it":1,"lowers":1,"glucose":2,"dose":1,"dependent":2,"manner":1,"thus":1,"address":1,"almost":1,"any":1,"level":1,"blood":1,"its":1,"ef":1,"cacy":1,"safety":1,"are":1,"largely":1,"education":1,"support":1,"provided":1,"to":1,"facilitate":1,"self":1,"management":1},"len":216},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":12,"chunkId":"ada-easd-2022-p12-c4","text":"in therapy is that it lowers glucose in a dose-dependent manner and thus can address almost any level of blood glucose. However, its ef fi cacy and safety are largely dependent on the education and support provided to facilitate self-management (5,6). Care- ful consideration should be given to the pharmacokinetic and pharmacodynamic pro fi les of the available insulins as well as the matching of the dose and timing to an individual  s physiological require- ments. Numerous formulations of insulin are available, with advances in therapy geared toward better mimicking physio- logical insulin release patterns. Chal- lenges of insulin therapy include weight gain, the need for education and titration for optimal ef fi cacy, risk of hypoglycemia, the need for regular glucose monitoring, and cost. The approval of biosimilar insu- lins may improve accessibility at lower treatment costs. Both insulin glargine U100 and insulin degludec have demon- strated cardiovascular safety in dedicated CVOTs (207,208). Comprehensive educa- tion on self-monitoring of blood glucose, diet, injection technique, self-titration of in- sulin, and prevention and adequate treat- ment of hypoglycemia are of utmost importance when initiating and intensifying insulin therapy (5,6). Novel formulations and devices, including pre fi lled syringes, auto- injectors, and intranasal insuf fl ators, are now available t","tf":{"207":1,"208":1,"in":5,"therapy":4,"is":1,"that":1,"it":1,"lowers":1,"glucose":4,"dose":2,"dependent":2,"manner":1,"and":13,"thus":1,"can":1,"address":1,"almost":1,"any":1,"level":1,"of":11,"blood":2,"however":1,"its":1,"ef":2,"fi":4,"cacy":2,"safety":2,"are":4,"largely":1,"on":2,"the":8,"education":2,"support":1,"provided":1,"to":3,"facilitate":1,"self":3,"management":1,"care":1,"ful":1,"consideration":1,"should":1,"be":1,"given":1,"pharmacokinetic":1,"pharmacodynamic":1,"pro":1,"les":1,"available":3,"insulins":1,"as":2,"well":1,"matching":1,"timing":1,"an":1,"individual":1,"physiological":1,"require":1,"ments":1,"numerous":1,"formulations":2,"insulin":6,"with":1,"advances":1,"geared":1,"toward":1,"better":1,"mimicking":1,"physio":1,"logical":1,"release":1,"patterns":1,"chal":1,"lenges":1,"include":1,"weight":1,"gain":1,"need":2,"for":3,"titration":2,"optimal":1,"risk":1,"hypoglycemia":2,"regular":1,"monitoring":2,"cost":1,"approval":1,"biosimilar":1,"insu":1,"lins":1,"may":1,"improve":1,"accessibility":1,"at":1,"lower":1,"treatment":1,"costs":1,"both":1,"glargine":1,"u100":1,"degludec":1,"have":1,"demon":1,"strated":1,"cardiovascular":1,"dedicated":1,"cvots":1,"comprehensive":1,"educa":1,"tion":1,"diet":1,"injection":1,"technique":1,"sulin":1,"prevention":1,"adequate":1,"treat":1,"ment":1,"utmost":1,"importance":1,"when":1,"initiating":1,"intensifying":1,"novel":1,"devices":1,"including":1,"pre":1,"lled":1,"syringes":1,"auto":1,"injectors":1,"intranasal":1,"insuf":1,"fl":1,"ators":1,"now":1},"len":208},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":12,"chunkId":"ada-easd-2022-p12-c5","text":" adequate treat- ment of hypoglycemia are of utmost importance when initiating and intensifying insulin therapy (5,6). Novel formulations and devices, including pre fi lled syringes, auto- injectors, and intranasal insuf fl ators, are now available to administer glucagon in the setting of severe hypoglycemia and should be considered for those at risk (209). Starting doses of basal insulin (NPH or analog) are estimated based on body weight (0.1  0.2 units/kg per day) and the degree of hyperglycemia, with indi- vidualized titration as needed. A modest but signi fi cant reduction in HbA 1c and the risk of total and nocturnal hypogly- cemia has been observed for basal insu- lin analogs versus NPH insulin (210). Longer-acting basal insulin analogs have a lower risk of hypoglycemia than earlier generations of basal insulin, although they may cost more. Concentrated insu- lins allow injection of a reduced volume (5). Cost and access are important consid- erations and can contribute to treatment discontinuation. Short- and rapid-acting insulin can be added to basal insulin to intensify therapy to address prandial blood glucose levels. Premixed insulins combine basal insulin with mealtime insu- lin (short- or rapid-acting) in the same vial or pen, retaining the pharmacokinetic properties of the individual components. Premixed insulin may offer convenience for some but reduces treatment","tf":{"209":1,"210":1,"adequate":1,"treat":1,"ment":1,"of":10,"hypoglycemia":3,"are":4,"utmost":1,"importance":1,"when":1,"initiating":1,"and":10,"intensifying":1,"insulin":9,"therapy":2,"novel":1,"formulations":1,"devices":1,"including":1,"pre":1,"fi":2,"lled":1,"syringes":1,"auto":1,"injectors":1,"intranasal":1,"insuf":1,"fl":1,"ators":1,"now":1,"available":1,"to":5,"administer":1,"glucagon":1,"in":3,"the":6,"setting":1,"severe":1,"should":1,"be":2,"considered":1,"for":3,"those":1,"at":1,"risk":3,"starting":1,"doses":1,"basal":6,"nph":2,"or":3,"analog":1,"estimated":1,"based":1,"on":1,"body":1,"weight":1,"units":1,"kg":1,"per":1,"day":1,"degree":1,"hyperglycemia":1,"with":2,"indi":1,"vidualized":1,"titration":1,"as":1,"needed":1,"modest":1,"but":2,"signi":1,"cant":1,"reduction":1,"hba":1,"1c":1,"total":1,"nocturnal":1,"hypogly":1,"cemia":1,"has":1,"been":1,"observed":1,"insu":3,"lin":2,"analogs":2,"versus":1,"longer":1,"acting":3,"have":1,"lower":1,"than":1,"earlier":1,"generations":1,"although":1,"they":1,"may":2,"cost":2,"more":1,"concentrated":1,"lins":1,"allow":1,"injection":1,"reduced":1,"volume":1,"access":1,"important":1,"consid":1,"erations":1,"can":2,"contribute":1,"treatment":2,"discontinuation":1,"short":2,"rapid":2,"added":1,"intensify":1,"address":1,"prandial":1,"blood":1,"glucose":1,"levels":1,"premixed":2,"insulins":1,"combine":1,"mealtime":1,"same":1,"vial":1,"pen":1,"retaining":1,"pharmacokinetic":1,"properties":1,"individual":1,"components":1,"offer":1,"convenience":1,"some":1,"reduces":1},"len":210},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":12,"chunkId":"ada-easd-2022-p12-c6","text":"ixed insulins combine basal insulin with mealtime insu- lin (short- or rapid-acting) in the same vial or pen, retaining the pharmacokinetic properties of the individual components. Premixed insulin may offer convenience for some but reduces treatment fl exibility. Rapid-acting insulin analogs are also diabetesjournals.org/care Davies and Associates 2763 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"45":1,"2026":1,"2753":1,"2763":1,"691567":1,"ixed":1,"insulins":1,"combine":1,"basal":1,"insulin":3,"with":1,"mealtime":1,"insu":1,"lin":1,"short":1,"or":2,"rapid":2,"acting":2,"in":1,"the":3,"same":1,"vial":1,"pen":1,"retaining":1,"pharmacokinetic":1,"properties":1,"of":1,"individual":1,"components":1,"premixed":1,"may":1,"offer":1,"convenience":1,"for":1,"some":1,"but":1,"reduces":1,"treatment":1,"fl":1,"exibility":1,"analogs":1,"are":1,"also":1,"diabetesjournals":2,"org":2,"care":2,"davies":1,"and":1,"associates":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"february":1},"len":72},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":13,"chunkId":"ada-easd-2022-p13-c0","text":"formulated as premixes, combining mix- tures of the insulin with protamine sus- pension and the rapid-acting insulin. Analog-based mixtures may be timed in closer proximity to meals. Education on the impact of dietary nutrients on glucose levels to reduce the risk of hypoglycemia while using mixed insulin is important. Insulins with different routes of administration (in- haled, bolus-only insulin delivery patch pump) are also available (211  213). Combination GLP-1  Insulin Therapy. Two fi xed-ratio combinations of GLP-1 RA with basal insulin analogs are available: insulin degludec plus liraglutide (IDegLira) and in- sulin glargine plus lixisenatide (iGlarLixi). The combination of basal insulin with GLP-1 RA results in greater glycemic low- ering ef fi cacy than the monocomponents, with less weight gain and lower rates of hypoglycemia than with intensi fi ed insulin regimens, and better gastrointestinal tolerability than with GLP-1 RA alone (214,215). In studies of people with type 2 diabetes inadequately controlled on basal insulin or GLP-1 RA, switching to a fi xed- ratio combination of basal insulin and GLP-1 RA demonstrated signi fi cant im- provements in blood glucose levels and achievement of glycemic goals with fewer hypoglycemic events than with basal insulin alone (216  220). Less Commonly Used Glucose-Lowering Medications. a -Glucosidase inhibitors im- prove glyce","tf":{"211":1,"213":1,"214":1,"215":1,"216":1,"220":1,"formulated":1,"as":1,"premixes":1,"combining":1,"mix":1,"tures":1,"of":10,"the":6,"insulin":12,"with":10,"protamine":1,"sus":1,"pension":1,"and":6,"rapid":1,"acting":1,"analog":1,"based":1,"mixtures":1,"may":1,"be":1,"timed":1,"in":6,"closer":1,"proximity":1,"to":3,"meals":1,"education":1,"on":3,"impact":1,"dietary":1,"nutrients":1,"glucose":3,"levels":2,"reduce":1,"risk":1,"hypoglycemia":2,"while":1,"using":1,"mixed":1,"is":1,"important":1,"insulins":1,"different":1,"routes":1,"administration":1,"haled":1,"bolus":1,"only":1,"delivery":1,"patch":1,"pump":1,"are":2,"also":1,"available":2,"combination":3,"glp":6,"therapy":1,"two":1,"fi":5,"xed":2,"ratio":2,"combinations":1,"ra":5,"basal":5,"analogs":1,"degludec":1,"plus":2,"liraglutide":1,"ideglira":1,"sulin":1,"glargine":1,"lixisenatide":1,"iglarlixi":1,"results":1,"greater":1,"glycemic":2,"low":1,"ering":1,"ef":1,"cacy":1,"than":4,"monocomponents":1,"less":2,"weight":1,"gain":1,"lower":1,"rates":1,"intensi":1,"ed":1,"regimens":1,"better":1,"gastrointestinal":1,"tolerability":1,"alone":2,"studies":1,"people":1,"type":1,"diabetes":1,"inadequately":1,"controlled":1,"or":1,"switching":1,"demonstrated":1,"signi":1,"cant":1,"im":2,"provements":1,"blood":1,"achievement":1,"goals":1,"fewer":1,"hypoglycemic":1,"events":1,"commonly":1,"used":1,"lowering":1,"medications":1,"glucosidase":1,"inhibitors":1,"prove":1,"glyce":1},"len":211},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":13,"chunkId":"ada-easd-2022-p13-c1","text":"igni fi cant im- provements in blood glucose levels and achievement of glycemic goals with fewer hypoglycemic events than with basal insulin alone (216  220). Less Commonly Used Glucose-Lowering Medications. a -Glucosidase inhibitors im- prove glycemic control by reducing post- prandial glycemic excursions and glycemic variability and may provide speci fi c bene- fi ts in cultures and settings with high carbohydrate consumption or reactive hypoglycemia (221,222). Other glucose- lowering medications (i.e., meglitinides, colesevelam, quick-release bromocrip- tine, and pramlintide) are not commonly used in the U.S., and most are not li- censed in Europe. There was no new evi- dence that impacts clinical practice. Comparative Efficacy of Glucose-Lowering Agents In a network meta-analysis of 453 trials assessing glucose-lowering medications from nine drug classes, the greatest re- ductions in HbA 1c were seen with insulin regimens and GLP-1 RA (223). A network meta-analysis comparing the effects of glucose-lowering therapy on body weight and blood pressure indicates that the greatest ef fi cacy for reducing body weight is seen with subcutaneous semaglutide followed by the other GLP-1 RA and SGLT2i, and the greatest reduction in blood pressure is seen with the SGLT2i and GLP-1 RA classes (224). As discussed above, the novel GIP and GLP-1 RA tir- zepatide was associated with greater ","tf":{"216":1,"220":1,"221":1,"222":1,"223":1,"224":1,"453":1,"igni":1,"fi":4,"cant":1,"im":2,"provements":1,"in":7,"blood":3,"glucose":6,"levels":1,"and":12,"achievement":1,"of":4,"glycemic":4,"goals":1,"with":7,"fewer":1,"hypoglycemic":1,"events":1,"than":1,"basal":1,"insulin":2,"alone":1,"less":1,"commonly":2,"used":2,"lowering":5,"medications":3,"glucosidase":1,"inhibitors":1,"prove":1,"control":1,"by":2,"reducing":2,"post":1,"prandial":1,"excursions":1,"variability":1,"may":1,"provide":1,"speci":1,"bene":1,"ts":1,"cultures":1,"settings":1,"high":1,"carbohydrate":1,"consumption":1,"or":1,"reactive":1,"hypoglycemia":1,"other":2,"meglitinides":1,"colesevelam":1,"quick":1,"release":1,"bromocrip":1,"tine":1,"pramlintide":1,"are":2,"not":2,"the":8,"most":1,"li":1,"censed":1,"europe":1,"there":1,"was":2,"no":1,"new":1,"evi":1,"dence":1,"that":2,"impacts":1,"clinical":1,"practice":1,"comparative":1,"efficacy":1,"agents":1,"network":2,"meta":2,"analysis":2,"trials":1,"assessing":1,"from":1,"nine":1,"drug":1,"classes":2,"greatest":3,"re":1,"ductions":1,"hba":1,"1c":1,"were":1,"seen":3,"regimens":1,"glp":4,"ra":4,"comparing":1,"effects":1,"therapy":1,"on":1,"body":2,"weight":2,"pressure":2,"indicates":1,"ef":1,"cacy":1,"for":1,"is":2,"subcutaneous":1,"semaglutide":1,"followed":1,"sglt2i":2,"reduction":1,"as":1,"discussed":1,"above":1,"novel":1,"gip":1,"tir":1,"zepatide":1,"associated":1,"greater":1},"len":212},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":13,"chunkId":"ada-easd-2022-p13-c2","text":"utaneous semaglutide followed by the other GLP-1 RA and SGLT2i, and the greatest reduction in blood pressure is seen with the SGLT2i and GLP-1 RA classes (224). As discussed above, the novel GIP and GLP-1 RA tir- zepatide was associated with greater glycemic and weight loss ef fi cacy than semaglutide 1 mg weekly (185). Combination Therapy The underlying pathophysiology of type 2 diabetes is complex, with multiple con- tributing abnormalities resulting in a natu- rally progressive disease and increasing HbA 1c over time in many. While tradi- tional recommendations have focused on the stepwise addition of therapy, allowing for clear delineation of positive and nega- tive effects of new drugs, there are data to suggest bene fi ts of combination ap- proaches in diabetes care. Combination therapy has several potential advan- tages, including 1 ) increased durability of the glycemic effect (225  227), address- ing therapeutic inertia, 2 ) simultaneous targeting of the multiple pathophysiolog- ical processes characterized by type 2 di- abetes, and 3 ) impacts on medication burden, medication-taking behavior, and treatment persistence, and 4 ) comple- mentary clinical bene fi ts (e.g., on glyce- mic control, weight and cardiovascular risk pro fi les) (215,228  244). The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) was a multicenter open-la- be","tf":{"185":1,"215":1,"224":1,"225":1,"227":1,"228":1,"244":1,"utaneous":1,"semaglutide":2,"followed":1,"by":2,"the":9,"other":1,"glp":3,"ra":3,"and":11,"sglt2i":2,"greatest":1,"reduction":2,"in":5,"blood":1,"pressure":1,"is":2,"seen":1,"with":3,"classes":1,"as":1,"discussed":1,"above":1,"novel":1,"gip":1,"tir":1,"zepatide":1,"was":2,"associated":1,"greater":1,"glycemic":2,"weight":2,"loss":1,"ef":1,"fi":4,"cacy":1,"than":1,"mg":1,"weekly":1,"combination":3,"therapy":3,"underlying":1,"pathophysiology":1,"of":7,"type":2,"diabetes":3,"complex":1,"multiple":2,"con":1,"tributing":1,"abnormalities":1,"resulting":1,"natu":1,"rally":1,"progressive":1,"disease":1,"increasing":1,"hba":1,"1c":1,"over":1,"time":1,"many":1,"while":1,"tradi":1,"tional":1,"recommendations":1,"have":1,"focused":1,"on":3,"stepwise":1,"addition":1,"allowing":1,"for":1,"clear":1,"delineation":1,"positive":1,"nega":1,"tive":1,"effects":1,"new":1,"drugs":1,"there":1,"are":1,"data":1,"to":1,"suggest":1,"bene":2,"ts":2,"ap":1,"proaches":1,"care":1,"has":1,"several":1,"potential":1,"advan":1,"tages":1,"including":1,"increased":1,"durability":1,"effect":1,"address":1,"ing":1,"therapeutic":1,"inertia":1,"simultaneous":1,"targeting":1,"pathophysiolog":1,"ical":1,"processes":1,"characterized":1,"di":1,"abetes":1,"impacts":1,"medication":2,"burden":1,"taking":1,"behavior":1,"treatment":1,"persistence":1,"comple":1,"mentary":1,"clinical":1,"glyce":1,"mic":1,"control":1,"cardiovascular":1,"risk":1,"pro":1,"les":1,"glycemia":1,"approaches":1,"comparative":1,"effectiveness":1,"study":1,"grade":1,"multicenter":1,"open":1,"la":1,"be":1},"len":203},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":13,"chunkId":"ada-easd-2022-p13-c3","text":"d 4 ) comple- mentary clinical bene fi ts (e.g., on glyce- mic control, weight and cardiovascular risk pro fi les) (215,228  244). The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) was a multicenter open-la- bel RCT designed to test four different di- abetes medication classes in people with type 2 diabetes and compare their ability to achieve and maintain HbA 1c levels < 53 mmol/mol ( < 7%). Eligible partici- pants had their metformin therapy opti- mized and were randomly assigned to receive a sulfonylurea (glimepiride), a DPP-4i (sitagliptin), a GLP-1 RA (liraglu- tide), or basal insulin (insulin glargine), with the primary outcome being the time to metabolic failure, de fi ned as the time to an initial HbA 1c level $ 53 mmol/mol ( $ 7%) if it was con fi rmed at the next visit to remain above that threshold. Starting with a mean baseline HbA 1c level of 58 mmol/mol (7.5%) before the addi- tion of one of the four medications, over 5 years of follow-up, 71% of the cohort reached the primary metabolic outcome. Insulin glargine and liraglutide were signif- icantly, albeit modestly, more effective at achieving and maintaining HbA 1c targets. Liraglutide exhibited a lower risk than the pooled effect of the other three medica- tions on a composite cardiovascular out- come comprising MACE, revascularization, or HF or unstable angina requiring h","tf":{"53":2,"58":1,"71":1,"215":1,"228":1,"244":1,"comple":1,"mentary":1,"clinical":1,"bene":1,"fi":4,"ts":1,"on":2,"glyce":1,"mic":1,"control":1,"weight":1,"and":6,"cardiovascular":2,"risk":2,"pro":1,"les":1,"the":11,"glycemia":1,"reduction":1,"approaches":1,"in":2,"diabetes":2,"comparative":1,"effectiveness":1,"study":1,"grade":1,"was":2,"multicenter":1,"open":1,"la":1,"bel":1,"rct":1,"designed":1,"to":6,"test":1,"four":2,"different":1,"di":1,"abetes":1,"medication":1,"classes":1,"people":1,"with":3,"type":1,"compare":1,"their":2,"ability":1,"achieve":1,"maintain":1,"hba":4,"1c":4,"levels":1,"mmol":3,"mol":3,"eligible":1,"partici":1,"pants":1,"had":1,"metformin":1,"therapy":1,"opti":1,"mized":1,"were":2,"randomly":1,"assigned":1,"receive":1,"sulfonylurea":1,"glimepiride":1,"dpp":1,"4i":1,"sitagliptin":1,"glp":1,"ra":1,"liraglu":1,"tide":1,"or":3,"basal":1,"insulin":3,"glargine":2,"primary":2,"outcome":2,"being":1,"time":2,"metabolic":2,"failure":1,"de":1,"ned":1,"as":1,"an":1,"initial":1,"level":2,"if":1,"it":1,"con":1,"rmed":1,"at":2,"next":1,"visit":1,"remain":1,"above":1,"that":1,"threshold":1,"starting":1,"mean":1,"baseline":1,"of":6,"before":1,"addi":1,"tion":1,"one":1,"medications":1,"over":1,"years":1,"follow":1,"up":1,"cohort":1,"reached":1,"liraglutide":2,"signif":1,"icantly":1,"albeit":1,"modestly":1,"more":1,"effective":1,"achieving":1,"maintaining":1,"targets":1,"exhibited":1,"lower":1,"than":1,"pooled":1,"effect":1,"other":1,"three":1,"medica":1,"tions":1,"composite":1,"out":1,"come":1,"comprising":1,"mace":1,"revascularization":1,"hf":1,"unstable":1,"angina":1,"requiring":1},"len":214},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":13,"chunkId":"ada-easd-2022-p13-c4","text":"e at achieving and maintaining HbA 1c targets. Liraglutide exhibited a lower risk than the pooled effect of the other three medica- tions on a composite cardiovascular out- come comprising MACE, revascularization, or HF or unstable angina requiring hospi- talization (245,246). PERSONALIZED APPROACH TO TREATMENT BASED ON INDIVIDUAL CHARACTERISTICS AND COMORBIDITIES: RECOMMENDED PROCESS FOR GLUCOSE-LOWERING MEDICATION SELECTION People With Cardiorenal Comorbidities The 2018 ADA/EASD consensus report and 2019 update focused on the consid- eration of clinically important factors when choosing glucose-lowering ther- apy. In people with established CVD or with a high risk for CVD, GLP-1 RA were prioritized over SGLT2i. Given their fa- vorable drug class effect in reducing HHF and progression of CKD, SGLT2i were prioritized in people with HF, par- ticularly those with a reduced ejection fraction, or CKD. Since 2019, additional cardiovascular, kidney, and HF outcome trials have been completed, particularly with SGLT2i. In addition, updated meta- analyses have been published that com- pare subgroup populations based on clinically relevant characteristics, such as presence of CVD, use of background ther- apy with metformin, stage of CKD, history of HF, and age. Collectively, this new evi- dence was systematically retrieved and appraised to be incorporated into these clinical practice rec","tf":{"245":1,"246":1,"2018":1,"2019":2,"at":1,"achieving":1,"and":7,"maintaining":1,"hba":1,"1c":1,"targets":1,"liraglutide":1,"exhibited":1,"lower":1,"risk":2,"than":1,"the":4,"pooled":1,"effect":2,"of":7,"other":1,"three":1,"medica":1,"tions":1,"on":4,"composite":1,"cardiovascular":2,"out":1,"come":1,"comprising":1,"mace":1,"revascularization":1,"or":4,"hf":4,"unstable":1,"angina":1,"requiring":1,"hospi":1,"talization":1,"personalized":1,"approach":1,"to":2,"treatment":1,"based":2,"individual":1,"characteristics":2,"comorbidities":2,"recommended":1,"process":1,"for":2,"glucose":2,"lowering":2,"medication":1,"selection":1,"people":3,"with":7,"cardiorenal":1,"ada":1,"easd":1,"consensus":1,"report":1,"update":1,"focused":1,"consid":1,"eration":1,"clinically":2,"important":1,"factors":1,"when":1,"choosing":1,"ther":2,"apy":2,"in":4,"established":1,"cvd":3,"high":1,"glp":1,"ra":1,"were":2,"prioritized":2,"over":1,"sglt2i":3,"given":1,"their":1,"fa":1,"vorable":1,"drug":1,"class":1,"reducing":1,"hhf":1,"progression":1,"ckd":3,"par":1,"ticularly":1,"those":1,"reduced":1,"ejection":1,"fraction":1,"since":1,"additional":1,"kidney":1,"outcome":1,"trials":1,"have":2,"been":2,"completed":1,"particularly":1,"addition":1,"updated":1,"meta":1,"analyses":1,"published":1,"that":1,"com":1,"pare":1,"subgroup":1,"populations":1,"relevant":1,"such":1,"as":1,"presence":1,"use":1,"background":1,"metformin":1,"stage":1,"history":1,"age":1,"collectively":1,"this":1,"new":1,"evi":1,"dence":1,"was":1,"systematically":1,"retrieved":1,"appraised":1,"be":1,"incorporated":1,"into":1,"these":1,"clinical":1,"practice":1,"rec":1},"len":202},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":13,"chunkId":"ada-easd-2022-p13-c5","text":"aracteristics, such as presence of CVD, use of background ther- apy with metformin, stage of CKD, history of HF, and age. Collectively, this new evi- dence was systematically retrieved and appraised to be incorporated into these clinical practice recommendations (Fig. 3). New Evidence From Cardiorenal Outcomes Studies Since the Last Consensus Report In the Evaluation of Ertugli fl ozin Ef fi cacy and Safety CVOT (VERTIS CV), which re- cruited exclusively people with established CVD and type 2 diabetes, ertugli fl ozin was similar to placebo with respect to the pri- mary MACE outcome and all key second- ary outcomes (including a composite kidney outcome) except for HHF (146). The Canagli fl ozin and Renal End points in Diabetes with Established Nephropa- thy Clinical Evaluation (CREDENCE) study included adults with type 2 diabetes with an eGFR from 30 to < 90 ml/min per 1.73 m 2 and albuminuria (30  500 mg/mmol [300  5,000 mg/g] creatinine) (152). In CREDENCE, canagli fl ozin treat- ment signi fi cantly reduced the risk of a 2764 Consensus Report Diabetes Care Volume 45, November 2022 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"30":2,"45":2,"73":1,"90":1,"146":1,"152":1,"300":1,"500":1,"2022":1,"2026":1,"2753":1,"2764":1,"691567":1,"aracteristics":1,"such":1,"as":1,"presence":1,"of":6,"cvd":2,"use":1,"background":1,"ther":1,"apy":1,"with":6,"metformin":1,"stage":1,"ckd":1,"history":1,"hf":1,"and":7,"age":1,"collectively":1,"this":1,"new":2,"evi":1,"dence":1,"was":2,"systematically":1,"retrieved":1,"appraised":1,"to":4,"be":1,"incorporated":1,"into":1,"these":1,"clinical":2,"practice":1,"recommendations":1,"fig":1,"evidence":1,"from":3,"cardiorenal":1,"outcomes":2,"studies":1,"since":1,"the":5,"last":1,"consensus":2,"report":2,"in":3,"evaluation":2,"ertugli":2,"fl":4,"ozin":4,"ef":1,"fi":2,"cacy":1,"safety":1,"cvot":1,"vertis":1,"cv":1,"which":1,"re":1,"cruited":1,"exclusively":1,"people":1,"established":2,"type":2,"diabetes":4,"similar":1,"placebo":1,"respect":1,"pri":1,"mary":1,"mace":1,"outcome":2,"all":1,"key":1,"second":1,"ary":1,"including":1,"composite":1,"kidney":1,"except":1,"for":1,"hhf":1,"canagli":2,"renal":1,"end":1,"points":1,"nephropa":1,"thy":1,"credence":2,"study":1,"included":1,"adults":1,"an":1,"egfr":1,"ml":1,"min":1,"per":1,"albuminuria":1,"mg":2,"mmol":1,"000":1,"creatinine":1,"treat":1,"ment":1,"signi":1,"cantly":1,"reduced":1,"risk":1,"care":2,"volume":1,"november":1,"downloaded":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"february":1},"len":194},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":14,"chunkId":"ada-easd-2022-p14-c0","text":"Figure 3  Use of glucose-lowering medications in the management of type 2 diabetes. ACEi, angiotensin-converting enzyme inhibitor; ACR, albumin/creatinine ratio; ARB, angiotensin receptor blocker; ASCVD, atherosclerotic cardiovascular disease; CGM, continuous glucose monitoring; CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease; CVOT, cardiovascular outcomes trial; DPP-4i, dipep- tidyl peptidase 4 inhibitor; eGFR, estimated glomerular fi ltration rate; GLP-1 RA, glucagon-like peptide 1 receptor agonist; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HHF, hospitalization for heart failure; MACE, major adverse cardiovascular events; MI, myocardial infarction; SDOH, social determinants of health; SGLT2i, sodium-glucose co- transporter 2 inhibitor; T2D, type 2 diabetes; TZD, thiazolidinedione. diabetesjournals.org/care Davies and Associates 2765 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"45":1,"2026":1,"2753":1,"2765":1,"691567":1,"figure":1,"use":1,"of":3,"glucose":3,"lowering":1,"medications":1,"in":1,"the":1,"management":1,"type":2,"diabetes":2,"acei":1,"angiotensin":2,"converting":1,"enzyme":1,"inhibitor":3,"acr":1,"albumin":1,"creatinine":1,"ratio":1,"arb":1,"receptor":2,"blocker":1,"ascvd":1,"atherosclerotic":1,"cardiovascular":5,"disease":3,"cgm":1,"continuous":1,"monitoring":1,"ckd":1,"chronic":1,"kidney":1,"cv":1,"cvd":1,"cvot":1,"outcomes":1,"trial":1,"dpp":1,"4i":1,"dipep":1,"tidyl":1,"peptidase":1,"egfr":1,"estimated":1,"glomerular":1,"fi":1,"ltration":1,"rate":1,"glp":1,"ra":1,"glucagon":1,"like":1,"peptide":1,"agonist":1,"hf":1,"heart":4,"failure":4,"hfpef":1,"with":2,"preserved":1,"ejection":2,"fraction":2,"hfref":1,"reduced":1,"hhf":1,"hospitalization":1,"for":1,"mace":1,"major":1,"adverse":1,"events":1,"mi":1,"myocardial":1,"infarction":1,"sdoh":1,"social":1,"determinants":1,"health":1,"sglt2i":1,"sodium":1,"co":1,"transporter":1,"t2d":1,"tzd":1,"thiazolidinedione":1,"diabetesjournals":2,"org":2,"care":2,"davies":1,"and":1,"associates":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"february":1},"len":138},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":15,"chunkId":"ada-easd-2022-p15-c0","text":"composite primary outcome of progres- sion to renal replacement therapy, eGFR of < 15 ml/min per 1.73 m 2 , a doubling of serum creatinine level, or death from cardiovascular or kidney causes. The Da- pagli fl ozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial recruited participants with and without type 2 diabetes with an eGFR of 25  75 ml/min per 1.73 m 2 and a urinary albumin/creatinine ratio (UACR) of 20  500 mg/mmol [200  5,000 mg/g] (153). Results of the trial demon- strated a clear bene fi t of dapagli fl ozin on a composite kidney outcome, on individ- ual kidney-speci fi c outcomes, and on car- diovascular death or HHF, both in the overall population and in the subgroup of people with diabetes (68% of partici- pants). In CREDENCE, the SGTL2i was continued until initiation of dialysis or transplantation. The Effect of Sotagli fl ozin on Cardiovas- cular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Im- pairment Who Are at Cardiovascular Risk (SCORED) trial assessed sotagli fl ozin (a dual SGLT1i/SGLT2i, currently not ap- proved for type 2 diabetes in the U.S. or the EU) in people with type 2 diabetes who had CKD and additional cardiovascu- lar risk factors (147). Sotagli fl ozin reduced the composite end point of cardiovascular mortality, HHF, or urgent visits for HF compared with placebo but had no effect on the ","tf":{"15":1,"20":1,"25":1,"68":1,"73":2,"75":1,"147":1,"153":1,"200":1,"500":1,"composite":3,"primary":1,"outcome":2,"of":13,"progres":1,"sion":1,"to":1,"renal":3,"replacement":1,"therapy":1,"egfr":2,"ml":2,"min":2,"per":2,"doubling":1,"serum":1,"creatinine":2,"level":1,"or":6,"death":2,"from":1,"cardiovascular":3,"kidney":4,"causes":1,"the":10,"da":1,"pagli":1,"fl":5,"ozin":5,"and":8,"prevention":1,"adverse":1,"outcomes":2,"in":7,"chronic":1,"disease":1,"dapa":1,"ckd":2,"trial":3,"recruited":1,"participants":1,"with":6,"without":1,"type":4,"diabetes":5,"an":1,"urinary":1,"albumin":1,"ratio":1,"uacr":1,"mg":2,"mmol":1,"000":1,"results":1,"demon":1,"strated":1,"clear":1,"bene":1,"fi":2,"dapagli":1,"on":5,"individ":1,"ual":1,"speci":1,"car":1,"diovascular":1,"hhf":2,"both":1,"overall":1,"population":1,"subgroup":1,"people":2,"partici":1,"pants":1,"credence":1,"sgtl2i":1,"was":1,"continued":1,"until":1,"initiation":1,"dialysis":1,"transplantation":1,"effect":2,"sotagli":3,"cardiovas":1,"cular":1,"events":1,"patients":1,"moderate":1,"im":1,"pairment":1,"who":2,"are":1,"at":1,"risk":2,"scored":1,"assessed":1,"dual":1,"sglt1i":1,"sglt2i":1,"currently":1,"not":1,"ap":1,"proved":1,"for":2,"eu":1,"had":2,"additional":1,"cardiovascu":1,"lar":1,"factors":1,"reduced":1,"end":1,"point":1,"mortality":1,"urgent":1,"visits":1,"hf":1,"compared":1,"placebo":1,"but":1,"no":1},"len":227},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":15,"chunkId":"ada-easd-2022-p15-c1","text":") in people with type 2 diabetes who had CKD and additional cardiovascu- lar risk factors (147). Sotagli fl ozin reduced the composite end point of cardiovascular mortality, HHF, or urgent visits for HF compared with placebo but had no effect on the composite kidney end point. SGLT2i have been recently assessed in people with HF in dedicated HF out- come trials. In the Empagli fl ozin Out- come Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction (EMPEROR-Reduced), empagli- fl ozin reduced the primary composite end point of cardiovascular mortality or HHF in people with HF and a reduced ejection fraction, irrespective of the presence of type 2 diabetes (50% of participants) (149). Notably, this bene fi - cial effect of empagli fl ozin regardless of diabetes status was consistently evident in those with a preserved ejection frac- tion ( > 40%), as demonstrated in the Empagli fl ozin Outcome Trial in Patients With Chronic Heart Failure With Pre- served Ejection Fraction (EMPEROR-Pre- served) (151). Additionally, the Effect of Sotagli fl ozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Wors- ening Heart Failure (SOLOIST-WHF) trial showed that, in people with type 2 diabetes and worsening HF, sotagli fl ozin reduced the total number of cardiovascu- lar deaths or hospitalizations or urgent visits for HF compared with placebo re- gardless of ","tf":{"40":1,"50":1,"147":1,"149":1,"151":1,"in":11,"people":4,"with":12,"type":4,"diabetes":5,"who":1,"had":2,"ckd":1,"and":3,"additional":1,"cardiovascu":2,"lar":2,"risk":1,"factors":1,"sotagli":3,"fl":7,"ozin":7,"reduced":6,"the":8,"composite":3,"end":3,"point":3,"of":10,"cardiovascular":3,"mortality":2,"hhf":2,"or":4,"urgent":2,"visits":2,"for":2,"hf":6,"compared":2,"placebo":2,"but":1,"no":1,"effect":3,"on":2,"kidney":1,"sglt2i":1,"have":1,"been":1,"recently":1,"assessed":1,"dedicated":1,"out":2,"come":2,"trials":1,"empagli":4,"trial":3,"patients":3,"chronic":2,"heart":3,"failure":3,"ejection":4,"fraction":3,"emperor":2,"primary":1,"irrespective":1,"presence":1,"participants":1,"notably":1,"this":1,"bene":1,"fi":1,"cial":1,"regardless":1,"status":1,"was":1,"consistently":1,"evident":1,"those":1,"preserved":1,"frac":1,"tion":1,"as":1,"demonstrated":1,"outcome":1,"pre":2,"served":2,"additionally":1,"events":1,"post":1,"wors":1,"ening":1,"soloist":1,"whf":1,"showed":1,"that":1,"worsening":1,"total":1,"number":1,"deaths":1,"hospitalizations":1,"re":1,"gardless":1},"len":219},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":15,"chunkId":"ada-easd-2022-p15-c2","text":"ing Heart Failure (SOLOIST-WHF) trial showed that, in people with type 2 diabetes and worsening HF, sotagli fl ozin reduced the total number of cardiovascu- lar deaths or hospitalizations or urgent visits for HF compared with placebo re- gardless of ejection fraction (150). All these data corroborate the salutary drug class effects of SGLT2i on HF-related out- comes in the setting of HF, irrespective of ejection fraction or diabetes status. Finally, among GLP-1 RA, the Effect of Efpeglenatide on Cardiovascular Out- comes (AMPLITUDE-O) trial demonstrated a bene fi cial effect of weekly efpeglenatide on MACE and on a composite kidney out- come (decrease in kidney function or se- vere albuminuria) (247). Of note, an exploratory analysis suggested a possible dose  response effect of efpeglenatide on MACE. In a CVOT of an osmotic minipump delivering exenatide subcutaneously (ITCA 650) over 3  6 months, ITCA 650 had a neutral effect on MACE compared with placebo over 16 months (248). Both trials recruited individuals with type 2 diabetes with an established, or high, risk for CVD. Neither efpeglenatide nor ITCA 650 has received marketing authorization by the FDA or European Medicines Agency. As mentioned previously, the cardiovascular effects of tirzepatide are being assessed in the ongoing SURPASS-CVOT trial, with du- laglutide as an active comparator. Evidence is emerging regardi","tf":{"16":1,"150":1,"247":1,"248":1,"650":3,"ing":1,"heart":1,"failure":1,"soloist":1,"whf":1,"trial":3,"showed":1,"that":1,"in":5,"people":1,"with":6,"type":2,"diabetes":3,"and":2,"worsening":1,"hf":4,"sotagli":1,"fl":1,"ozin":1,"reduced":1,"the":7,"total":1,"number":1,"of":11,"cardiovascu":1,"lar":1,"deaths":1,"or":6,"hospitalizations":1,"urgent":1,"visits":1,"for":2,"compared":2,"placebo":2,"re":1,"gardless":1,"ejection":2,"fraction":2,"all":1,"these":1,"data":1,"corroborate":1,"salutary":1,"drug":1,"class":1,"effects":2,"sglt2i":1,"on":6,"related":1,"out":3,"comes":2,"setting":1,"irrespective":1,"status":1,"finally":1,"among":1,"glp":1,"ra":1,"effect":4,"efpeglenatide":4,"cardiovascular":2,"amplitude":1,"demonstrated":1,"bene":1,"fi":1,"cial":1,"weekly":1,"mace":3,"composite":1,"kidney":2,"come":1,"decrease":1,"function":1,"se":1,"vere":1,"albuminuria":1,"note":1,"an":4,"exploratory":1,"analysis":1,"suggested":1,"possible":1,"dose":1,"response":1,"cvot":2,"osmotic":1,"minipump":1,"delivering":1,"exenatide":1,"subcutaneously":1,"itca":3,"over":2,"months":2,"had":1,"neutral":1,"both":1,"trials":1,"recruited":1,"individuals":1,"established":1,"high":1,"risk":1,"cvd":1,"neither":1,"nor":1,"has":1,"received":1,"marketing":1,"authorization":1,"by":1,"fda":1,"european":1,"medicines":1,"agency":1,"as":2,"mentioned":1,"previously":1,"tirzepatide":1,"are":1,"being":1,"assessed":1,"ongoing":1,"surpass":1,"du":1,"laglutide":1,"active":1,"comparator":1,"evidence":1,"is":1,"emerging":1,"regardi":1},"len":210},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":15,"chunkId":"ada-easd-2022-p15-c3","text":"g authorization by the FDA or European Medicines Agency. As mentioned previously, the cardiovascular effects of tirzepatide are being assessed in the ongoing SURPASS-CVOT trial, with du- laglutide as an active comparator. Evidence is emerging regarding the potential bene fi ts of combined treat- ment with both an SGLT2i and a GLP-1 RA on outcomes. A post hoc analysis of data from the Exenatide Study of Cardio- vascular Event Lowering (EXSCEL) has suggested that the combination of exe- natide once weekly (EQW) plus open- label SGLT2i reduces all-cause mortality rates and attenuates the decline in eGFR compared with treatment with EQW alone (244). Importantly, a prespeci fi ed explor- atory analysis of the AMPLITUDE-O trial found comparable bene fi ts of GLP-1 RA treatment in participants who were receiv- ing an SGLT2i as background therapy (15% of the total trial population) and those who were not (241). Results From Evidence Syntheses Recent cardiovascular, kidney, and HF out- come trials have been incorporated in up- dated meta-analyses assessing SGLT2i or GLP-1 RA, both in the overall trial popula- tions and in clinically relevant subgroups. Pairwise meta-analyses of SGLT2i CVOTs veri fi ed that SGLT2i reduced MACE, HHF, and a composite kidney outcome in the overall population versus placebo (142,249). Regarding GLP-1 RA, a meta- analysis of relevant CVOTs demonstrated the fa","tf":{"15":1,"142":1,"241":1,"244":1,"249":1,"authorization":1,"by":1,"the":12,"fda":1,"or":2,"european":1,"medicines":1,"agency":1,"as":3,"mentioned":1,"previously":1,"cardiovascular":2,"effects":1,"of":10,"tirzepatide":1,"are":1,"being":1,"assessed":1,"in":7,"ongoing":1,"surpass":1,"cvot":1,"trial":4,"with":4,"du":1,"laglutide":1,"an":3,"active":1,"comparator":1,"evidence":2,"is":1,"emerging":1,"regarding":2,"potential":1,"bene":2,"fi":4,"ts":2,"combined":1,"treat":1,"ment":1,"both":2,"sglt2i":6,"and":6,"glp":4,"ra":4,"on":1,"outcomes":1,"post":1,"hoc":1,"analysis":3,"data":1,"from":2,"exenatide":1,"study":1,"cardio":1,"vascular":1,"event":1,"lowering":1,"exscel":1,"has":1,"suggested":1,"that":2,"combination":1,"exe":1,"natide":1,"once":1,"weekly":1,"eqw":2,"plus":1,"open":1,"label":1,"reduces":1,"all":1,"cause":1,"mortality":1,"rates":1,"attenuates":1,"decline":1,"egfr":1,"compared":1,"treatment":2,"alone":1,"importantly":1,"prespeci":1,"ed":2,"explor":1,"atory":1,"amplitude":1,"found":1,"comparable":1,"participants":1,"who":2,"were":2,"receiv":1,"ing":1,"background":1,"therapy":1,"total":1,"population":2,"those":1,"not":1,"results":1,"syntheses":1,"recent":1,"kidney":2,"hf":1,"out":1,"come":1,"trials":1,"have":1,"been":1,"incorporated":1,"up":1,"dated":1,"meta":3,"analyses":2,"assessing":1,"overall":2,"popula":1,"tions":1,"clinically":1,"relevant":2,"subgroups":1,"pairwise":1,"cvots":2,"veri":1,"reduced":1,"mace":1,"hhf":1,"composite":1,"outcome":1,"versus":1,"placebo":1,"demonstrated":1,"fa":1},"len":219},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":15,"chunkId":"ada-easd-2022-p15-c4","text":" subgroups. Pairwise meta-analyses of SGLT2i CVOTs veri fi ed that SGLT2i reduced MACE, HHF, and a composite kidney outcome in the overall population versus placebo (142,249). Regarding GLP-1 RA, a meta- analysis of relevant CVOTs demonstrated the favorable effect of GLP-1 RA versus placebo on MACE and its individual com- ponents, including stroke, HHF, and a composite kidney outcome including se- vere albuminuria (250,251). It should be noted, however, that the overall effect estimate for HHF seems to have been driven by CVOTs of albiglutide and efpe- glenatide, which are not available for clinical use. Similarly, the overall effect estimate for the composite kidney out- come was most likely driven by the ef- fect of GLP-1 RA on severe albuminuria only and not on hard kidney end points. Of note, the bene fi cial kidney effects of canagli fl ozin, dapagli fl ozin, and empagli- fl ozin were also evident for hard kidney outcomes, including chronic dialysis and kidney transplantation (252). When indi- vidual components of MACE were ana- lyzed separately, GLP-1 RA reduced all three outcomes, with a more pronounced effect on stroke followed by cardiovascular death and myocardial infarction (253,254). Conversely, SGLT2i, albeit reducing cardio- vascular death, had a neutral effect on stroke (142,255). The applicability of data to support selection of subgroups has been ques- tioned b","tf":{"142":2,"249":1,"250":1,"251":1,"252":1,"253":1,"254":1,"255":1,"subgroups":2,"pairwise":1,"meta":2,"analyses":1,"of":10,"sglt2i":3,"cvots":3,"veri":1,"fi":2,"ed":1,"that":2,"reduced":2,"mace":3,"hhf":3,"and":8,"composite":3,"kidney":7,"outcome":2,"in":1,"the":8,"overall":3,"population":1,"versus":2,"placebo":2,"regarding":1,"glp":4,"ra":4,"analysis":1,"relevant":1,"demonstrated":1,"favorable":1,"effect":5,"on":5,"its":1,"individual":1,"com":1,"ponents":1,"including":3,"stroke":3,"se":1,"vere":1,"albuminuria":2,"it":1,"should":1,"be":1,"noted":1,"however":1,"estimate":2,"for":4,"seems":1,"to":2,"have":1,"been":2,"driven":2,"by":3,"albiglutide":1,"efpe":1,"glenatide":1,"which":1,"are":1,"not":2,"available":1,"clinical":1,"use":1,"similarly":1,"out":1,"come":1,"was":1,"most":1,"likely":1,"ef":1,"fect":1,"severe":1,"only":1,"hard":2,"end":1,"points":1,"note":1,"bene":1,"cial":1,"effects":1,"canagli":1,"fl":3,"ozin":3,"dapagli":1,"empagli":1,"were":2,"also":1,"evident":1,"outcomes":2,"chronic":1,"dialysis":1,"transplantation":1,"when":1,"indi":1,"vidual":1,"components":1,"ana":1,"lyzed":1,"separately":1,"all":1,"three":1,"with":1,"more":1,"pronounced":1,"followed":1,"cardiovascular":1,"death":2,"myocardial":1,"infarction":1,"conversely":1,"albeit":1,"reducing":1,"cardio":1,"vascular":1,"had":1,"neutral":1,"applicability":1,"data":1,"support":1,"selection":1,"has":1,"ques":1,"tioned":1},"len":219},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":15,"chunkId":"ada-easd-2022-p15-c5","text":"wed by cardiovascular death and myocardial infarction (253,254). Conversely, SGLT2i, albeit reducing cardio- vascular death, had a neutral effect on stroke (142,255). The applicability of data to support selection of subgroups has been ques- tioned because of a lack of RCTs focus- ing on speci fi c populations, such as those using versus those not using met- formin. This has been examined in sub- group analyses of recent meta-analyses (6). It should be noted that fi ndings of subgroup analyses should not be re- garded as conclusive, their credibility should always be formally assessed, and ideally they should be complemented by fi ndings from relevant RCTs (7,8). Re- cently published subgroup analyses have explored the role of background use of metformin as a potential effect modi fi er of cardiovascular bene fi t. For SGLT2i, no differences were observed in MACE, car- diovascular death or HHF, major kidney outcomes, and mortality rates in those using versus those not using metformin (174). Further, for GLP-1 RA, no differ- ences were shown in MACE and mortal- ity outcomes (256  258) in metformin users compared with nonusers. The simi- larity of the direction and magnitude of the effect estimates between individual trials, the number of trials that contrib- uted data, mostly to within-trial com- parisons, and the statistical analyses 2766 Consensus Report Diabetes Care Volume ","tf":{"142":1,"174":1,"253":1,"254":1,"255":1,"256":1,"258":1,"2766":1,"wed":1,"by":2,"cardiovascular":2,"death":3,"and":6,"myocardial":1,"infarction":1,"conversely":1,"sglt2i":2,"albeit":1,"reducing":1,"cardio":1,"vascular":1,"had":1,"neutral":1,"effect":3,"on":2,"stroke":1,"the":7,"applicability":1,"of":12,"data":2,"to":2,"support":1,"selection":1,"subgroups":1,"has":2,"been":2,"ques":1,"tioned":1,"because":1,"lack":1,"rcts":2,"focus":1,"ing":1,"speci":1,"fi":5,"populations":1,"such":1,"as":3,"those":4,"using":4,"versus":2,"not":3,"met":1,"formin":1,"this":1,"examined":1,"in":5,"sub":1,"group":1,"analyses":5,"recent":1,"meta":1,"it":1,"should":4,"be":4,"noted":1,"that":2,"ndings":2,"subgroup":2,"re":2,"garded":1,"conclusive":1,"their":1,"credibility":1,"always":1,"formally":1,"assessed":1,"ideally":1,"they":1,"complemented":1,"from":1,"relevant":1,"cently":1,"published":1,"have":1,"explored":1,"role":1,"background":1,"use":1,"metformin":3,"potential":1,"modi":1,"er":1,"bene":1,"for":2,"no":2,"differences":1,"were":2,"observed":1,"mace":2,"car":1,"diovascular":1,"or":1,"hhf":1,"major":1,"kidney":1,"outcomes":2,"mortality":1,"rates":1,"further":1,"glp":1,"ra":1,"differ":1,"ences":1,"shown":1,"mortal":1,"ity":1,"users":1,"compared":1,"with":1,"nonusers":1,"simi":1,"larity":1,"direction":1,"magnitude":1,"estimates":1,"between":1,"individual":1,"trials":2,"number":1,"contrib":1,"uted":1,"mostly":1,"within":1,"trial":1,"com":1,"parisons":1,"statistical":1,"consensus":1,"report":1,"diabetes":1,"care":1,"volume":1},"len":219},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":15,"chunkId":"ada-easd-2022-p15-c6","text":"imi- larity of the direction and magnitude of the effect estimates between individual trials, the number of trials that contrib- uted data, mostly to within-trial com- parisons, and the statistical analyses 2766 Consensus Report Diabetes Care Volume 45, November 2022 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"45":2,"2022":1,"2026":1,"2753":1,"2766":1,"691567":1,"imi":1,"larity":1,"of":3,"the":4,"direction":1,"and":2,"magnitude":1,"effect":1,"estimates":1,"between":1,"individual":1,"trials":2,"number":1,"that":1,"contrib":1,"uted":1,"data":1,"mostly":1,"to":1,"within":1,"trial":1,"com":1,"parisons":1,"statistical":1,"analyses":1,"consensus":1,"report":1,"diabetes":1,"care":2,"volume":1,"november":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"february":1},"len":61},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":16,"chunkId":"ada-easd-2022-p16-c0","text":"implemented support the credibility of the conclusions favoring use of SGLT2i or GLP-1 RA in individuals with compelling indications independent of the use of metformin. Similarly, other subgroup analyses have explored the role of baseline cardiovascu- lar risk as a potential effect modi fi er re- garding the effect of treatment on MACE, HHF, or kidney outcomes. Consistency of fi ndings from between-trial and within- trial comparisons, formal statistical testing verifying the absence of a subgroup effect, and the similarity of baseline cardiovascular risk across different car- diovascular risk categories between indi- vidual CVOTs despite the use of seemingly different enrolment criteria suggest the bene fi ts of the use of SGLT2i or GLP-1 RA in people with type 2 diabetes and estab- lished CVD and in those at high cardiovas- cular and/or kidney risk (142,253). Of note, the level of certainty in this recom- mendation is higher for the former sub- group, because some CVOTs recruited exclusively people with established CVD, while fewer events were recorded for par- ticipants with cardiovascular risk factors only in CVOTs that recruited both sub- group populations. In addition, the de fi ni- tion used for risk factors was not identical among CVOTs. However, in general it comprised age $ 55 years plus two or more additional risk factors (including obesity, hypertension, smoking, dy","tf":{"55":1,"142":1,"253":1,"implemented":1,"support":1,"the":13,"credibility":1,"of":14,"conclusions":1,"favoring":1,"use":4,"sglt2i":2,"or":5,"glp":2,"ra":2,"in":7,"individuals":1,"with":4,"compelling":1,"indications":1,"independent":1,"metformin":1,"similarly":1,"other":1,"subgroup":2,"analyses":1,"have":1,"explored":1,"role":1,"baseline":2,"cardiovascu":1,"lar":1,"risk":7,"as":1,"potential":1,"effect":3,"modi":1,"fi":4,"er":1,"re":1,"garding":1,"treatment":1,"on":1,"mace":1,"hhf":1,"kidney":2,"outcomes":1,"consistency":1,"ndings":1,"from":1,"between":2,"trial":2,"and":5,"within":1,"comparisons":1,"formal":1,"statistical":1,"testing":1,"verifying":1,"absence":1,"similarity":1,"cardiovascular":2,"across":1,"different":2,"car":1,"diovascular":1,"categories":1,"indi":1,"vidual":1,"cvots":4,"despite":1,"seemingly":1,"enrolment":1,"criteria":1,"suggest":1,"bene":1,"ts":1,"people":2,"type":1,"diabetes":1,"estab":1,"lished":1,"cvd":2,"those":1,"at":1,"high":1,"cardiovas":1,"cular":1,"note":1,"level":1,"certainty":1,"this":1,"recom":1,"mendation":1,"is":1,"higher":1,"for":3,"former":1,"sub":2,"group":2,"because":1,"some":1,"recruited":2,"exclusively":1,"established":1,"while":1,"fewer":1,"events":1,"were":1,"recorded":1,"par":1,"ticipants":1,"factors":3,"only":1,"that":1,"both":1,"populations":1,"addition":1,"de":1,"ni":1,"tion":1,"used":1,"was":1,"not":1,"identical":1,"among":1,"however":1,"general":1,"it":1,"comprised":1,"age":1,"years":1,"plus":1,"two":1,"more":1,"additional":1,"including":1,"obesity":1,"hypertension":1,"smoking":1,"dy":1},"len":219},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":16,"chunkId":"ada-easd-2022-p16-c1","text":"d both sub- group populations. In addition, the de fi ni- tion used for risk factors was not identical among CVOTs. However, in general it comprised age $ 55 years plus two or more additional risk factors (including obesity, hypertension, smoking, dyslipide- mia, or albuminuria). Furthermore, in terms of absolute effects, the cardiovascu- lar bene fi ts of GLP-1 RA and SGLT2i were less pronounced in people with three or more cardiovascular risk factors than in those with established CVD. This was shown in a network meta-analysis that es- timated the absolute effects of treatment with GLP-1 RA or SGLT2i on cardiovascu- lar and kidney outcomes for different categories of baseline cardiovascular risk by combining relative effect estimates with baseline risk estimates (259). Subgroup meta-analyses based on par- ticipants  kidney function indicated that the salutary effects of SGLT2i on MACE, cardiovascular death or HHF, and a com- posite kidney outcome (substantial loss of kidney function, end-stage kidney disease, or death due to kidney disease) do not sig- ni fi cantly differ among subgroups based on eGFR (142,252). Moreover, the over- all effect on MACE and the kidney out- come seemed to be consistent across the three subgroups (normal urine albumin excretion rate [UACR < 3.0 mg/ mmol ( < 30 mg/g)], moderate albuminuria [UACR 3.0  30 mg/mmol (30  300 mg/g)], and severe albumi","tf":{"30":3,"55":1,"142":1,"252":1,"259":1,"300":1,"both":1,"sub":1,"group":1,"populations":1,"in":6,"addition":1,"the":7,"de":1,"fi":3,"ni":2,"tion":1,"used":1,"for":2,"risk":5,"factors":3,"was":2,"not":2,"identical":1,"among":2,"cvots":1,"however":1,"general":1,"it":1,"comprised":1,"age":1,"years":1,"plus":1,"two":1,"or":6,"more":2,"additional":1,"including":1,"obesity":1,"hypertension":1,"smoking":1,"dyslipide":1,"mia":1,"albuminuria":2,"furthermore":1,"terms":1,"of":6,"absolute":2,"effects":3,"cardiovascu":2,"lar":2,"bene":1,"ts":1,"glp":2,"ra":2,"and":5,"sglt2i":3,"were":1,"less":1,"pronounced":1,"people":1,"with":4,"three":2,"cardiovascular":3,"than":1,"those":1,"established":1,"cvd":1,"this":1,"shown":1,"network":1,"meta":2,"analysis":1,"that":2,"es":1,"timated":1,"treatment":1,"on":5,"kidney":7,"outcomes":1,"different":1,"categories":1,"baseline":2,"by":1,"combining":1,"relative":1,"effect":2,"estimates":2,"subgroup":1,"analyses":1,"based":2,"par":1,"ticipants":1,"function":2,"indicated":1,"salutary":1,"mace":2,"death":2,"hhf":1,"com":1,"posite":1,"outcome":1,"substantial":1,"loss":1,"end":1,"stage":1,"disease":2,"due":1,"to":2,"do":1,"sig":1,"cantly":1,"differ":1,"subgroups":2,"egfr":1,"moreover":1,"over":1,"all":1,"out":1,"come":1,"seemed":1,"be":1,"consistent":1,"across":1,"normal":1,"urine":1,"albumin":1,"excretion":1,"rate":1,"uacr":2,"mg":4,"mmol":2,"moderate":1,"severe":1,"albumi":1},"len":219},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":16,"chunkId":"ada-easd-2022-p16-c2","text":"r- all effect on MACE and the kidney out- come seemed to be consistent across the three subgroups (normal urine albumin excretion rate [UACR < 3.0 mg/ mmol ( < 30 mg/g)], moderate albuminuria [UACR 3.0  30 mg/mmol (30  300 mg/g)], and severe albuminuria [UACR $ 30 mg/ mmol ( $ 300 mg/g)]) (252). In addition, no modi fi cation of the effect estimates for MACE, cardiovascular death or HHF, and the composite kidney outcome was ob- served for SGLT2i in subgroup meta- analyses based on history of HF (142). Regarding GLP-1 RA, a subgroup meta- analysis found that their effect on MACE did not signi fi cantly differ between peo- ple with an eGFR < 60 ml/min per 1.73 m 2 and those with an eGFR $ 60 ml/min per 1.73 m 2 (253). Moreover, the effect on MACE did not appear to differ be- tween people with lower and higher HbA 1c at baseline, both for SGLT2i and for GLP-1 RA (142,253). Nevertheless, the conclusions of all subgroup analyses should be regarded with increased caution because of the small number of trials contributing data to within-trial comparisons, heterogeneity between in- dividual trials, or lack of formal statistical testing. Comparative Effectiveness Data While CVOTs and pairwise meta-analy- ses allow inferences about the overall ef fi cacy and safety of novel glucose-low- ering therapies, none of them directly compared SGLT2i with GLP-1 RA. How- ever, the comparative eff","tf":{"30":4,"60":2,"73":2,"142":2,"252":1,"253":2,"300":2,"all":2,"effect":4,"on":4,"mace":4,"and":8,"the":9,"kidney":2,"out":1,"come":1,"seemed":1,"to":3,"be":3,"consistent":1,"across":1,"three":1,"subgroups":1,"normal":1,"urine":1,"albumin":1,"excretion":1,"rate":1,"uacr":3,"mg":6,"mmol":3,"moderate":1,"albuminuria":2,"severe":1,"in":3,"addition":1,"no":1,"modi":1,"fi":3,"cation":1,"of":8,"estimates":1,"for":4,"cardiovascular":1,"death":1,"or":2,"hhf":1,"composite":1,"outcome":1,"was":1,"ob":1,"served":1,"sglt2i":3,"subgroup":3,"meta":3,"analyses":2,"based":1,"history":1,"hf":1,"regarding":1,"glp":3,"ra":3,"analysis":1,"found":1,"that":1,"their":1,"did":2,"not":2,"signi":1,"cantly":1,"differ":2,"between":2,"peo":1,"ple":1,"with":5,"an":2,"egfr":2,"ml":2,"min":2,"per":2,"those":1,"moreover":1,"appear":1,"tween":1,"people":1,"lower":1,"higher":1,"hba":1,"1c":1,"at":1,"baseline":1,"both":1,"nevertheless":1,"conclusions":1,"should":1,"regarded":1,"increased":1,"caution":1,"because":1,"small":1,"number":1,"trials":2,"contributing":1,"data":2,"within":1,"trial":1,"comparisons":1,"heterogeneity":1,"dividual":1,"lack":1,"formal":1,"statistical":1,"testing":1,"comparative":2,"effectiveness":1,"while":1,"cvots":1,"pairwise":1,"analy":1,"ses":1,"allow":1,"inferences":1,"about":1,"overall":1,"ef":1,"cacy":1,"safety":1,"novel":1,"glucose":1,"low":1,"ering":1,"therapies":1,"none":1,"them":1,"directly":1,"compared":1,"how":1,"ever":1,"eff":1},"len":229},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":16,"chunkId":"ada-easd-2022-p16-c3","text":"omparative Effectiveness Data While CVOTs and pairwise meta-analy- ses allow inferences about the overall ef fi cacy and safety of novel glucose-low- ering therapies, none of them directly compared SGLT2i with GLP-1 RA. How- ever, the comparative effectiveness of the two drug classes has been assessed in three recent network meta-analyses, which found that, in people with type 2 diabetes, SGLT2i were superior to GLP-1 RA in reducing HHF and a composite kidney outcome, while GLP-1 RA seemed more ef fi cacious in reducing the risk of stroke (223,259,260). No important dif- ferences between the two drug classes were evident in terms of mortality rates and other cardiovascular outcomes. These conclusions are further supported by ob- servational data from a large population- based cohort study in the U.S., which showed that SGLT2i reduced HHF com- pared with GLP-1 RA in people both with CVD (hazard ratio [HR] 0.71; 95% CI 0.64, 0.79) and without CVD (HR 0.69; 95% CI 0.56, 0.81). Differences between the two drug classes with regard to mortality rates and other cardiovascular outcomes were not clinically important (261). In terms of differences among individual SGLT2i and GLP-1 RA, choice should be based on country-speci fi c label indications and data on ef fi cacy, safety, and outcome bene fi ts considering within-class heteroge- neity. No CVOT is available that focuses on people wi","tf":{"56":1,"64":1,"69":1,"71":1,"79":1,"81":1,"95":2,"223":1,"259":1,"260":1,"261":1,"omparative":1,"effectiveness":2,"data":3,"while":2,"cvots":1,"and":9,"pairwise":1,"meta":2,"analy":1,"ses":1,"allow":1,"inferences":1,"about":1,"the":7,"overall":1,"ef":3,"fi":5,"cacy":2,"safety":2,"of":6,"novel":1,"glucose":1,"low":1,"ering":1,"therapies":1,"none":1,"them":1,"directly":1,"compared":1,"sglt2i":4,"with":5,"glp":5,"ra":5,"how":1,"ever":1,"comparative":1,"two":3,"drug":3,"classes":3,"has":1,"been":1,"assessed":1,"in":8,"three":1,"recent":1,"network":1,"analyses":1,"which":2,"found":1,"that":3,"people":3,"type":1,"diabetes":1,"were":3,"superior":1,"to":2,"reducing":2,"hhf":2,"composite":1,"kidney":1,"outcome":2,"seemed":1,"more":1,"cacious":1,"risk":1,"stroke":1,"no":2,"important":2,"dif":1,"ferences":1,"between":2,"evident":1,"terms":2,"mortality":2,"rates":2,"other":2,"cardiovascular":2,"outcomes":2,"these":1,"conclusions":1,"are":1,"further":1,"supported":1,"by":1,"ob":1,"servational":1,"from":1,"large":1,"population":1,"based":2,"cohort":1,"study":1,"showed":1,"reduced":1,"com":1,"pared":1,"both":1,"cvd":2,"hazard":1,"ratio":1,"hr":2,"ci":2,"without":1,"differences":2,"regard":1,"not":1,"clinically":1,"among":1,"individual":1,"choice":1,"should":1,"be":1,"on":3,"country":1,"speci":1,"label":1,"indications":1,"bene":1,"ts":1,"considering":1,"within":1,"class":1,"heteroge":1,"neity":1,"cvot":1,"is":1,"available":1,"focuses":1,"wi":1},"len":228},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":16,"chunkId":"ada-easd-2022-p16-c4","text":"ences among individual SGLT2i and GLP-1 RA, choice should be based on country-speci fi c label indications and data on ef fi cacy, safety, and outcome bene fi ts considering within-class heteroge- neity. No CVOT is available that focuses on people with type 2 diabetes who are at low cardiovascular risk. Some infer- ences about the effect of glucose-lower- ing medications as primary cardiovascular prevention in populations with low car- diovascular risk can be made from net- work meta-analyses, suggesting that no agent or drug class has a notable bene fi - cial effect on cardiovascular events in low- risk individuals with diabetes (223,259). Additional Clinical Considerations Age: Older People With Diabetes Type 2 diabetes represents a model of accelerated biological ageing. As such, type 2 diabetes is associated with de- clines in physical capacity, underpinned by dysfunction within skeletal muscle. The ability of people with type 2 diabe- tes to undertake simple functional exer- cises in middle age has been shown to be like those at least a decade older within the general population. Impor- tantly, this places people living with type 2 diabetes at a high risk of impaired physical function and frailty, which in turn reduces quality of life and increases health care use. As such, frailty is increasingly recog- nized as a major complication of type 2 diabetes and an important tar","tf":{"223":1,"259":1,"ences":2,"among":1,"individual":1,"sglt2i":1,"and":6,"glp":1,"ra":1,"choice":1,"should":1,"be":3,"based":1,"on":4,"country":1,"speci":1,"fi":4,"label":1,"indications":1,"data":1,"ef":1,"cacy":1,"safety":1,"outcome":1,"bene":2,"ts":1,"considering":1,"within":3,"class":2,"heteroge":1,"neity":1,"no":2,"cvot":1,"is":3,"available":1,"that":2,"focuses":1,"people":4,"with":7,"type":6,"diabetes":7,"who":1,"are":1,"at":3,"low":3,"cardiovascular":3,"risk":4,"some":1,"infer":1,"about":1,"the":3,"effect":2,"of":6,"glucose":1,"lower":1,"ing":1,"medications":1,"as":4,"primary":1,"prevention":1,"in":5,"populations":1,"car":1,"diovascular":1,"can":1,"made":1,"from":1,"net":1,"work":1,"meta":1,"analyses":1,"suggesting":1,"agent":1,"or":1,"drug":1,"has":2,"notable":1,"cial":1,"events":1,"individuals":1,"additional":1,"clinical":1,"considerations":1,"age":2,"older":2,"represents":1,"model":1,"accelerated":1,"biological":1,"ageing":1,"such":2,"associated":1,"de":1,"clines":1,"physical":2,"capacity":1,"underpinned":1,"by":1,"dysfunction":1,"skeletal":1,"muscle":1,"ability":1,"diabe":1,"tes":1,"to":2,"undertake":1,"simple":1,"functional":1,"exer":1,"cises":1,"middle":1,"been":1,"shown":1,"like":1,"those":1,"least":1,"decade":1,"general":1,"population":1,"impor":1,"tantly":1,"this":1,"places":1,"living":1,"high":1,"impaired":1,"function":1,"frailty":2,"which":1,"turn":1,"reduces":1,"quality":1,"life":1,"increases":1,"health":1,"care":1,"use":1,"increasingly":1,"recog":1,"nized":1,"major":1,"complication":1,"an":1,"important":1,"tar":1},"len":218},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":16,"chunkId":"ada-easd-2022-p16-c5","text":"pe 2 diabetes at a high risk of impaired physical function and frailty, which in turn reduces quality of life and increases health care use. As such, frailty is increasingly recog- nized as a major complication of type 2 diabetes and an important target for treatment (112,262). Informed decisions regarding treat- ment of older ( > 65 years) adults with diabetes are limited by the underrepre- sentation of such participants in clinical trials. When older individuals have been studied, analyses from trials such as Ac- tion in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) suggested that more frail individuals have worse out- comes and bene fi t less from intensive control of blood glucose levels and blood pressure (263). However, our con- fi dence in selecting medications to im- prove outcomes has improved, in part because of regulatory requirements to include older people in trials to deter- mine the ef fi cacy and safety of new drugs for diabetes (264,265). For exam- ple, a recent meta-analysis of 11 large outcome trials found that, in those aged 65 years or older, the cardiovascular and/ or kidney outcome bene fi ts of GLP-1 RA or SGLT2i therapy were consistent with the effects seen in the overall trial diabetesjournals.org/care Davies and Associates 2767 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci","tf":{"11":2,"45":1,"65":2,"112":1,"262":1,"263":1,"264":1,"265":1,"2753":1,"2767":1,"691567":1,"pe":1,"diabetes":5,"at":1,"high":1,"risk":1,"of":10,"impaired":1,"physical":1,"function":1,"and":10,"frailty":2,"which":1,"in":8,"turn":1,"reduces":1,"quality":1,"life":1,"increases":1,"health":1,"care":3,"use":1,"as":3,"such":3,"is":1,"increasingly":1,"recog":1,"nized":1,"major":1,"complication":1,"type":1,"an":1,"important":1,"target":1,"for":3,"treatment":1,"informed":1,"decisions":1,"regarding":1,"treat":1,"ment":1,"older":4,"years":2,"adults":1,"with":2,"are":1,"limited":1,"by":1,"the":5,"underrepre":1,"sentation":1,"participants":1,"clinical":1,"trials":4,"when":1,"individuals":2,"have":2,"been":1,"studied":1,"analyses":1,"from":3,"ac":1,"tion":1,"vascular":1,"disease":1,"preterax":1,"diamicron":1,"mr":1,"controlled":1,"evaluation":1,"advance":1,"suggested":1,"that":2,"more":1,"frail":1,"worse":1,"out":1,"comes":1,"bene":2,"fi":4,"less":1,"intensive":1,"control":1,"blood":2,"glucose":1,"levels":1,"pressure":1,"however":1,"our":1,"con":1,"dence":1,"selecting":1,"medications":1,"to":3,"im":1,"prove":1,"outcomes":1,"has":1,"improved":1,"part":1,"because":1,"regulatory":1,"requirements":1,"include":1,"people":1,"deter":1,"mine":1,"ef":1,"cacy":1,"safety":1,"new":1,"drugs":1,"exam":1,"ple":1,"recent":1,"meta":1,"analysis":1,"large":1,"outcome":2,"found":1,"those":1,"aged":1,"or":3,"cardiovascular":1,"kidney":1,"ts":1,"glp":1,"ra":1,"sglt2i":1,"therapy":1,"were":1,"consistent":1,"effects":1,"seen":1,"overall":1,"trial":1,"diabetesjournals":2,"org":2,"davies":1,"associates":1,"downloaded":1,"http":1,"article":1,"pdf":1,"dci":1},"len":224},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":16,"chunkId":"ada-easd-2022-p16-c6","text":"kidney outcome bene fi ts of GLP-1 RA or SGLT2i therapy were consistent with the effects seen in the overall trial diabetesjournals.org/care Davies and Associates 2767 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"45":1,"2026":1,"2753":1,"2767":1,"691567":1,"kidney":1,"outcome":1,"bene":1,"fi":1,"ts":1,"of":1,"glp":1,"ra":1,"or":1,"sglt2i":1,"therapy":1,"were":1,"consistent":1,"with":1,"the":2,"effects":1,"seen":1,"in":1,"overall":1,"trial":1,"diabetesjournals":2,"org":2,"care":2,"davies":1,"and":1,"associates":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"february":1},"len":48},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":17,"chunkId":"ada-easd-2022-p17-c0","text":"population (266). Therefore, recommen- dations for the selection of medications to improve cardiovascular and kidney outcomes do not differ for older people. Older age should not be an obstacle to treatment of individuals with established or high risk for CVD. However, medica- tion choices for people who are frail or who have multiple comorbidities may re- quire modi fi cation for safety and tolera- bility. People with diabetes should also understand and be able to appropriately modify use of their prescribed medica- tions during times of illness. Frailty is as- sociated with poorer prognosis, and some attenuation of bene fi t from intensive glu- cose-lowering and blood pressure-lower- ing treatments has been demonstrated in frail individuals (263). Consideration of de- prescribing medication to avoid unneces- sary medication or medication associated with harm, such as hypoglycemia and hypo- tension, is important in such populations. Age: Younger People With Diabetes Rates of impaired glucose tolerance and/ or impaired fasting glucose and type 2 di- abetes have increased signi fi cantly in the adolescent and young adult population, in concert with increases in obesity (267). It is estimated that one in fi ve adoles- cents and one in four young adults now have impaired glucose tolerance and/or impaired fasting glucose in the U.S., which in turn increases the risks of pro- gressi","tf":{"263":1,"266":1,"267":1,"population":2,"therefore":1,"recommen":1,"dations":1,"for":5,"the":4,"selection":1,"of":8,"medications":1,"to":4,"improve":1,"cardiovascular":1,"and":11,"kidney":1,"outcomes":1,"do":1,"not":2,"differ":1,"older":2,"people":4,"age":2,"should":2,"be":2,"an":1,"obstacle":1,"treatment":1,"individuals":2,"with":6,"established":1,"or":5,"high":1,"risk":1,"cvd":1,"however":1,"medica":2,"tion":1,"choices":1,"who":2,"are":1,"frail":2,"have":3,"multiple":1,"comorbidities":1,"may":1,"re":1,"quire":1,"modi":1,"fi":4,"cation":1,"safety":1,"tolera":1,"bility":1,"diabetes":2,"also":1,"understand":1,"able":1,"appropriately":1,"modify":1,"use":1,"their":1,"prescribed":1,"tions":1,"during":1,"times":1,"illness":1,"frailty":1,"is":3,"as":2,"sociated":1,"poorer":1,"prognosis":1,"some":1,"attenuation":1,"bene":1,"from":1,"intensive":1,"glu":1,"cose":1,"lowering":1,"blood":1,"pressure":1,"lower":1,"ing":1,"treatments":1,"has":1,"been":1,"demonstrated":1,"in":9,"consideration":1,"de":1,"prescribing":1,"medication":3,"avoid":1,"unneces":1,"sary":1,"associated":1,"harm":1,"such":2,"hypoglycemia":1,"hypo":1,"tension":1,"important":1,"populations":1,"younger":1,"rates":1,"impaired":4,"glucose":4,"tolerance":2,"fasting":2,"type":1,"di":1,"abetes":1,"increased":1,"signi":1,"cantly":1,"adolescent":1,"young":2,"adult":1,"concert":1,"increases":2,"obesity":1,"it":1,"estimated":1,"that":1,"one":2,"ve":1,"adoles":1,"cents":1,"four":1,"adults":1,"now":1,"which":1,"turn":1,"risks":1,"pro":1,"gressi":1},"len":219},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":17,"chunkId":"ada-easd-2022-p17-c1","text":"in concert with increases in obesity (267). It is estimated that one in fi ve adoles- cents and one in four young adults now have impaired glucose tolerance and/or impaired fasting glucose in the U.S., which in turn increases the risks of pro- gression to type 2 diabetes, CKD, and car- diovascular complications (267). Minority populations are particularly affected, with half or more of newly diagnosed cases of type 2 diabetes in childhood and adoles- cence occurring in Hispanic, non-Hispanic Black, Asian/Paci fi c Islander, and Ameri- can Indian populations (268). Affected young people have a more rapid deterio- ration in blood glucose levels, an attenu- ated response to diabetes medication, and more rapid development of diabetes complications (269  273). Early disease onset, higher levels of hyperglycemia, and the multiple cardiometabolic risk factors found in adolescents and young adults with impaired glucose tolerance and/or impaired fasting glucose and diabetes all contribute to an increase in risk of ad- verse outcomes (267). Most children and adolescents who develop type 2 diabetes will have microvascular complications by young adulthood (274); in addition, a re- cently identi fi ed 25% increase in the risks of hyperglycemic crises, acute myocardial infarction, stroke, and lower extremity amputation over a 5-year period was most notable in people with diabetes aged 18  ","tf":{"18":1,"25":1,"267":3,"268":1,"269":1,"273":1,"274":1,"in":14,"concert":1,"with":4,"increases":2,"obesity":1,"it":1,"is":1,"estimated":1,"that":1,"one":2,"fi":3,"ve":1,"adoles":2,"cents":1,"and":12,"four":1,"young":4,"adults":2,"now":1,"have":3,"impaired":4,"glucose":5,"tolerance":2,"or":3,"fasting":2,"the":4,"which":1,"turn":1,"risks":2,"of":7,"pro":1,"gression":1,"to":3,"type":3,"diabetes":7,"ckd":1,"car":1,"diovascular":1,"complications":3,"minority":1,"populations":2,"are":1,"particularly":1,"affected":2,"half":1,"more":3,"newly":1,"diagnosed":1,"cases":1,"childhood":1,"cence":1,"occurring":1,"hispanic":2,"non":1,"black":1,"asian":1,"paci":1,"islander":1,"ameri":1,"can":1,"indian":1,"people":2,"rapid":2,"deterio":1,"ration":1,"blood":1,"levels":2,"an":2,"attenu":1,"ated":1,"response":1,"medication":1,"development":1,"early":1,"disease":1,"onset":1,"higher":1,"hyperglycemia":1,"multiple":1,"cardiometabolic":1,"risk":2,"factors":1,"found":1,"adolescents":2,"all":1,"contribute":1,"increase":2,"ad":1,"verse":1,"outcomes":1,"most":2,"children":1,"who":1,"develop":1,"will":1,"microvascular":1,"by":1,"adulthood":1,"addition":1,"re":1,"cently":1,"identi":1,"ed":1,"hyperglycemic":1,"crises":1,"acute":1,"myocardial":1,"infarction":1,"stroke":1,"lower":1,"extremity":1,"amputation":1,"over":1,"year":1,"period":1,"was":1,"notable":1,"aged":1},"len":211},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":17,"chunkId":"ada-easd-2022-p17-c2","text":"ng adulthood (274); in addition, a re- cently identi fi ed 25% increase in the risks of hyperglycemic crises, acute myocardial infarction, stroke, and lower extremity amputation over a 5-year period was most notable in people with diabetes aged 18  44 years (275). Younger people with type 2 diabetes should be consid- ered at very high risk for complications and treated correspondingly. Early use of combination therapy may be consid- ered, as the Vildagliptin Ef fi cacy in Combi- nation with Metformin for Early Treatment of Type 2 Diabetes (VERIFY) trial fi ndings suggest that this approach provides supe- rior and more durable effects on blood glucose levels than metformin monother- apy in people with both early-onset (age < 40 years) and later-onset diabetes (276). Most of the evidence for health behavior interventions, glucose-lowering approaches, and the effectiveness of medications to im- prove cardiovascular and kidney outcomes in younger people with diabetes is poorly understood because of the very limited en- rollment of this group in completed trials (15). Beyond the scope of this statement, there are data emerging on the use of GLP-1 RA and SGLT2i in children that suggest glycemic bene fi t; however, the durability of this effect and any impact on cardiorenal outcomes in children and young adults remain unknown. Race and Ethnicity Although speci fi c populations are di","tf":{"15":1,"18":1,"25":1,"40":1,"44":1,"274":1,"275":1,"276":1,"ng":1,"adulthood":1,"in":9,"addition":1,"re":1,"cently":1,"identi":1,"fi":5,"ed":1,"increase":1,"the":8,"risks":1,"of":10,"hyperglycemic":1,"crises":1,"acute":1,"myocardial":1,"infarction":1,"stroke":1,"and":10,"lower":1,"extremity":1,"amputation":1,"over":1,"year":1,"period":1,"was":1,"most":2,"notable":1,"people":4,"with":5,"diabetes":5,"aged":1,"years":2,"younger":2,"type":2,"should":1,"be":2,"consid":2,"ered":2,"at":1,"very":2,"high":1,"risk":1,"for":3,"complications":1,"treated":1,"correspondingly":1,"early":3,"use":2,"combination":1,"therapy":1,"may":1,"as":1,"vildagliptin":1,"ef":1,"cacy":1,"combi":1,"nation":1,"metformin":2,"treatment":1,"verify":1,"trial":1,"ndings":1,"suggest":2,"that":2,"this":4,"approach":1,"provides":1,"supe":1,"rior":1,"more":1,"durable":1,"effects":1,"on":3,"blood":1,"glucose":2,"levels":1,"than":1,"monother":1,"apy":1,"both":1,"onset":2,"age":1,"later":1,"evidence":1,"health":1,"behavior":1,"interventions":1,"lowering":1,"approaches":1,"effectiveness":1,"medications":1,"to":1,"im":1,"prove":1,"cardiovascular":1,"kidney":1,"outcomes":2,"is":1,"poorly":1,"understood":1,"because":1,"limited":1,"en":1,"rollment":1,"group":1,"completed":1,"trials":1,"beyond":1,"scope":1,"statement":1,"there":1,"are":2,"data":1,"emerging":1,"glp":1,"ra":1,"sglt2i":1,"children":2,"glycemic":1,"bene":1,"however":1,"durability":1,"effect":1,"any":1,"impact":1,"cardiorenal":1,"young":1,"adults":1,"remain":1,"unknown":1,"race":1,"ethnicity":1,"although":1,"speci":1,"populations":1,"di":1},"len":220},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":17,"chunkId":"ada-easd-2022-p17-c3","text":"e of GLP-1 RA and SGLT2i in children that suggest glycemic bene fi t; however, the durability of this effect and any impact on cardiorenal outcomes in children and young adults remain unknown. Race and Ethnicity Although speci fi c populations are dispro- portionately affected by diabetes, they are consistently underrepresented in out- comes and other trials. A meta-analysis of six large cardiovascular and kidney out- come trials found that non-White partici- pants had higher rates of cardiovascular and other comorbidities than the White cohort but comprised only about 21% of the overall enrolled trial populations. Im- portantly, both non-White and White sub- groups had signi fi cant reductions in the risk of cardiovascular death or HHF with SGLT2i therapy compared with placebo (odds ratio 0.66 and 0.82, respectively) (277). The increased burden of complica- tions in underrepresented populations with diabetes should be factored into per- sonalized treatment plans, and bene fi cial medications should be used irrespective of race or ethnicity. Ongoing and future trials should recruit to be representative of the overall population of people with diabetes so that the effects of interven- tions in understudied subgroups may be better ascertained (278,279). Sex Differences In women with reproductive potential, the use of highly effective contraception should be ensured, such as long-","tf":{"21":1,"66":1,"82":1,"277":1,"278":1,"279":1,"of":12,"glp":1,"ra":1,"and":11,"sglt2i":2,"in":7,"children":2,"that":3,"suggest":1,"glycemic":1,"bene":2,"fi":4,"however":1,"the":8,"durability":1,"this":1,"effect":1,"any":1,"impact":1,"on":1,"cardiorenal":1,"outcomes":1,"young":1,"adults":1,"remain":1,"unknown":1,"race":2,"ethnicity":2,"although":1,"speci":1,"populations":3,"are":2,"dispro":1,"portionately":1,"affected":1,"by":1,"diabetes":3,"they":1,"consistently":1,"underrepresented":2,"out":2,"comes":1,"other":2,"trials":3,"meta":1,"analysis":1,"six":1,"large":1,"cardiovascular":3,"kidney":1,"come":1,"found":1,"non":2,"white":4,"partici":1,"pants":1,"had":2,"higher":1,"rates":1,"comorbidities":1,"than":1,"cohort":1,"but":1,"comprised":1,"only":1,"about":1,"overall":2,"enrolled":1,"trial":1,"im":1,"portantly":1,"both":1,"sub":1,"groups":1,"signi":1,"cant":1,"reductions":1,"risk":1,"death":1,"or":2,"hhf":1,"with":5,"therapy":1,"compared":1,"placebo":1,"odds":1,"ratio":1,"respectively":1,"increased":1,"burden":1,"complica":1,"tions":2,"should":4,"be":5,"factored":1,"into":1,"per":1,"sonalized":1,"treatment":1,"plans":1,"cial":1,"medications":1,"used":1,"irrespective":1,"ongoing":1,"future":1,"recruit":1,"to":1,"representative":1,"population":1,"people":1,"so":1,"effects":1,"interven":1,"understudied":1,"subgroups":1,"may":1,"better":1,"ascertained":1,"sex":1,"differences":1,"women":1,"reproductive":1,"potential":1,"use":1,"highly":1,"effective":1,"contraception":1,"ensured":1,"such":1,"as":1,"long":1},"len":213},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":17,"chunkId":"ada-easd-2022-p17-c4","text":"eople with diabetes so that the effects of interven- tions in understudied subgroups may be better ascertained (278,279). Sex Differences In women with reproductive potential, the use of highly effective contraception should be ensured, such as long-acting re- versible contraception (intrauterine device or progesterone implant), prior to pre- scribing medications that may adversely affect a fetus. Diabetes signi fi cantly in- creases the risk of cardiovascular compli- cations in both sexes, and CVD causes most hospitalizations and deaths in women and men with diabetes (280,281). In the general population, women are at lower risk for cardiovascular events than men of the same age; however, this vas- cular protection or advantage is reduced in women who develop type 2 diabetes (282,283). In fact, the increase in relative risk of CVD due to type 2 diabetes is greater in women than in men (284  286). Despite this, women have been underrep- resented in recent CVOTs in diabetes, com- prising between 28.5 and 35.8% of participants (287). This analysis also de- scribed differing patterns of cardiovascular complications in women compared with men and poorer management of cardio- vascular risk factors in women (287). Within-trial analyses and meta-analyses suggest that there are likely no between- sex differences in outcomes achieved with SGLT2i and GLP-1 RA therapy (288,289). Continued","tf":{"28":1,"35":1,"278":1,"279":1,"280":1,"281":1,"282":1,"283":1,"284":1,"286":1,"287":2,"288":1,"289":1,"eople":1,"with":5,"diabetes":6,"so":1,"that":3,"the":6,"effects":1,"of":8,"interven":1,"tions":1,"in":16,"understudied":1,"subgroups":1,"may":2,"be":2,"better":1,"ascertained":1,"sex":2,"differences":2,"women":8,"reproductive":1,"potential":1,"use":1,"highly":1,"effective":1,"contraception":2,"should":1,"ensured":1,"such":1,"as":1,"long":1,"acting":1,"re":1,"versible":1,"intrauterine":1,"device":1,"or":2,"progesterone":1,"implant":1,"prior":1,"to":2,"pre":1,"scribing":1,"medications":1,"adversely":1,"affect":1,"fetus":1,"signi":1,"fi":1,"cantly":1,"creases":1,"risk":4,"cardiovascular":3,"compli":1,"cations":1,"both":1,"sexes":1,"and":7,"cvd":2,"causes":1,"most":1,"hospitalizations":1,"deaths":1,"men":4,"general":1,"population":1,"are":2,"at":1,"lower":1,"for":1,"events":1,"than":2,"same":1,"age":1,"however":1,"this":3,"vas":1,"cular":1,"protection":1,"advantage":1,"is":2,"reduced":1,"who":1,"develop":1,"type":2,"fact":1,"increase":1,"relative":1,"due":1,"greater":1,"despite":1,"have":1,"been":1,"underrep":1,"resented":1,"recent":1,"cvots":1,"com":1,"prising":1,"between":2,"participants":1,"analysis":1,"also":1,"de":1,"scribed":1,"differing":1,"patterns":1,"complications":1,"compared":1,"poorer":1,"management":1,"cardio":1,"vascular":1,"factors":1,"within":1,"trial":1,"analyses":2,"meta":1,"suggest":1,"there":1,"likely":1,"no":1,"outcomes":1,"achieved":1,"sglt2i":1,"glp":1,"ra":1,"therapy":1,"continued":1},"len":218},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":17,"chunkId":"ada-easd-2022-p17-c5","text":"th men and poorer management of cardio- vascular risk factors in women (287). Within-trial analyses and meta-analyses suggest that there are likely no between- sex differences in outcomes achieved with SGLT2i and GLP-1 RA therapy (288,289). Continued efforts should be made to en- roll women in outcomes trials and to iden- tify and address modi fi able cardiovascular risk factors in women with diabetes. OBESITY AND WEIGHT-RELATED COMORBIDITIES, PARTICULARLY NAFLD AND NASH The care of people with diabetes who have weight-related comorbidities such as NAFLD, HF with preserved ejection fraction, or obstructive sleep apnea should include strategies intended to re- sult in weight loss. People with type 2 diabetes frequently have NAFLD and are at increased risk for progression to more severe stages of liver disease, in- cluding NASH, hepatic fi brosis, and cir- rhosis (290). The management of type 2 diabetes in people with NASH should in- clude lifestyle modi fi cation with a goal of weight loss, including strong consider- ation of medical and/or surgical ap- proaches to weight loss in those at higher risk of hepatic fi brosis (291). Pio- glitazone therapy, GLP-1 RA therapy, and metabolic surgery have all been shown 2768 Consensus Report Diabetes Care Volume 45, November 2022 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 Fe","tf":{"11":1,"17":1,"45":2,"287":1,"288":1,"289":1,"290":1,"291":1,"2022":1,"2753":1,"2768":1,"691567":1,"th":1,"men":1,"and":11,"poorer":1,"management":2,"of":7,"cardio":1,"vascular":1,"risk":4,"factors":2,"in":9,"women":3,"within":1,"trial":1,"analyses":2,"meta":1,"suggest":1,"that":1,"there":1,"are":2,"likely":1,"no":1,"between":1,"sex":1,"differences":1,"outcomes":2,"achieved":1,"with":7,"sglt2i":1,"glp":2,"ra":2,"therapy":3,"continued":1,"efforts":1,"should":3,"be":1,"made":1,"to":5,"en":1,"roll":1,"trials":1,"iden":1,"tify":1,"address":1,"modi":2,"fi":4,"able":1,"cardiovascular":1,"diabetes":5,"obesity":1,"weight":5,"related":2,"comorbidities":2,"particularly":1,"nafld":3,"nash":3,"the":2,"care":3,"people":3,"who":1,"have":3,"such":1,"as":1,"hf":1,"preserved":1,"ejection":1,"fraction":1,"or":2,"obstructive":1,"sleep":1,"apnea":1,"include":1,"strategies":1,"intended":1,"re":1,"sult":1,"loss":3,"type":2,"frequently":1,"at":2,"increased":1,"for":1,"progression":1,"more":1,"severe":1,"stages":1,"liver":1,"disease":1,"cluding":1,"hepatic":2,"brosis":2,"cir":1,"rhosis":1,"clude":1,"lifestyle":1,"cation":1,"goal":1,"including":1,"strong":1,"consider":1,"ation":1,"medical":1,"surgical":1,"ap":1,"proaches":1,"those":1,"higher":1,"pio":1,"glitazone":1,"metabolic":1,"surgery":1,"all":1,"been":1,"shown":1,"consensus":1,"report":1,"volume":1,"november":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"fe":1},"len":226},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":17,"chunkId":"ada-easd-2022-p17-c6","text":"glitazone therapy, GLP-1 RA therapy, and metabolic surgery have all been shown 2768 Consensus Report Diabetes Care Volume 45, November 2022 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"45":2,"2022":1,"2026":1,"2753":1,"2768":1,"691567":1,"glitazone":1,"therapy":2,"glp":1,"ra":1,"and":1,"metabolic":1,"surgery":1,"have":1,"all":1,"been":1,"shown":1,"consensus":1,"report":1,"diabetes":1,"care":2,"volume":1,"november":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"february":1},"len":41},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":18,"chunkId":"ada-easd-2022-p18-c0","text":"to reduce NASH activity; pioglitazone therapy and metabolic surgery may also improve hepatic fi brosis (188,292  298). Although not licensed for this pur- pose, it has therefore been suggested that people with type 2 diabetes at in- termediate to high risk of fi brosis should be considered for treatment with piogli- tazone and/or a GLP-1 RA with evidence of bene fi t (291,299). Although SGLT2i therapy has also been shown to reduce elevated levels of liver enzymes and he- patic fat content in people with NAFLD, at this time there is less evidence to support use of this class of drug as treatment for NASH (300  302). NAFLD, and in particular NASH, is also associ- ated with an increased risk of cardiovas- cular complications; therefore, people with NAFLD should have their cardiovas- cular risk factors assessed and managed to minimize this risk (303). SGLT2i have been shown to reduce incident obstructive sleep apnea in two SGLT2i CVOTs based on adverse event reporting (304,305). However, it is not clear that the data collected on incident obstructive sleep apnea in these trials were complete or that the bene fi t is mediated through changes in weight. Consensus Recommendations  All people with type 2 diabetes should be offered access to ongoing DSMES programs.  Providers and health care systems should prioritize the delivery of person- centered care.  Optimizing medication adh","tf":{"188":1,"291":1,"292":1,"298":1,"299":1,"300":1,"302":1,"303":1,"304":1,"305":1,"to":7,"reduce":3,"nash":3,"activity":1,"pioglitazone":1,"therapy":2,"and":6,"metabolic":1,"surgery":1,"may":1,"also":3,"improve":1,"hepatic":1,"fi":4,"brosis":2,"although":2,"not":2,"licensed":1,"for":3,"this":4,"pur":1,"pose":1,"it":2,"has":2,"therefore":2,"been":3,"suggested":1,"that":3,"people":4,"with":7,"type":2,"diabetes":2,"at":2,"in":6,"termediate":1,"high":1,"risk":4,"of":7,"should":4,"be":2,"considered":1,"treatment":2,"piogli":1,"tazone":1,"or":2,"glp":1,"ra":1,"evidence":2,"bene":2,"sglt2i":3,"shown":2,"elevated":1,"levels":1,"liver":1,"enzymes":1,"he":1,"patic":1,"fat":1,"content":1,"nafld":3,"time":1,"there":1,"is":4,"less":1,"support":1,"use":1,"class":1,"drug":1,"as":1,"particular":1,"associ":1,"ated":1,"an":1,"increased":1,"cardiovas":2,"cular":2,"complications":1,"have":2,"their":1,"factors":1,"assessed":1,"managed":1,"minimize":1,"incident":2,"obstructive":2,"sleep":2,"apnea":2,"two":1,"cvots":1,"based":1,"on":2,"adverse":1,"event":1,"reporting":1,"however":1,"clear":1,"the":3,"data":1,"collected":1,"these":1,"trials":1,"were":1,"complete":1,"mediated":1,"through":1,"changes":1,"weight":1,"consensus":1,"recommendations":1,"all":1,"offered":1,"access":1,"ongoing":1,"dsmes":1,"programs":1,"providers":1,"health":1,"care":2,"systems":1,"prioritize":1,"delivery":1,"person":1,"centered":1,"optimizing":1,"medication":1,"adh":1},"len":225},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":18,"chunkId":"ada-easd-2022-p18-c1","text":"hanges in weight. Consensus Recommendations  All people with type 2 diabetes should be offered access to ongoing DSMES programs.  Providers and health care systems should prioritize the delivery of person- centered care.  Optimizing medication adherence should be speci fi cally considered when selecting glucose-lowering medications.  MNT focused on identifying healthy dietary habits that are feasible and sustainable is recommended in sup- port of reaching metabolic and weight goals.  Physical activity improves glycemic con- trol and should be an essential compo- nent of type 2 diabetes management.  Adults with type 2 diabetes should engage in physical activity regularly ( > 150 min/week of moderate- to vig- orous-intensity aerobic activity) and be encouraged to reduce sedentary time and break up sitting time with frequent activity breaks.  Aerobic activity should be supple- mented with two to three resistance, fl exibility, and/or balance training sessions/week. Balance training ses- sions are particularly encouraged for older individuals or those with limited mobility/poor physical function.  Metabolic surgery should be consid- ered as a treatment option in adults with type 2 diabetes who are appro- priate surgical candidates with a BMI $ 40.0 kg/m 2 (BMI $ 37.5 kg/m 2 in people of Asian ancestry) or a BMI of 35.0  39.9 kg/m 2 (32.5  37.4 kg/m 2 in people of Asian an","tf":{"32":1,"35":1,"37":2,"39":1,"40":1,"150":1,"hanges":1,"in":6,"weight":2,"consensus":1,"recommendations":1,"all":1,"people":3,"with":7,"type":4,"diabetes":4,"should":7,"be":6,"offered":1,"access":1,"to":4,"ongoing":1,"dsmes":1,"programs":1,"providers":1,"and":7,"health":1,"care":2,"systems":1,"prioritize":1,"the":1,"delivery":1,"of":7,"person":1,"centered":1,"optimizing":1,"medication":1,"adherence":1,"speci":1,"fi":1,"cally":1,"considered":1,"when":1,"selecting":1,"glucose":1,"lowering":1,"medications":1,"mnt":1,"focused":1,"on":1,"identifying":1,"healthy":1,"dietary":1,"habits":1,"that":1,"are":3,"feasible":1,"sustainable":1,"is":1,"recommended":1,"sup":1,"port":1,"reaching":1,"metabolic":2,"goals":1,"physical":3,"activity":5,"improves":1,"glycemic":1,"con":1,"trol":1,"an":2,"essential":1,"compo":1,"nent":1,"management":1,"adults":2,"engage":1,"regularly":1,"min":1,"week":2,"moderate":1,"vig":1,"orous":1,"intensity":1,"aerobic":2,"encouraged":2,"reduce":1,"sedentary":1,"time":2,"break":1,"up":1,"sitting":1,"frequent":1,"breaks":1,"supple":1,"mented":1,"two":1,"three":1,"resistance":1,"fl":1,"exibility":1,"or":3,"balance":2,"training":2,"sessions":1,"ses":1,"sions":1,"particularly":1,"for":1,"older":1,"individuals":1,"those":1,"limited":1,"mobility":1,"poor":1,"function":1,"surgery":1,"consid":1,"ered":1,"as":1,"treatment":1,"option":1,"who":1,"appro":1,"priate":1,"surgical":1,"candidates":1,"bmi":3,"kg":4,"asian":2,"ancestry":1},"len":205},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":18,"chunkId":"ada-easd-2022-p18-c2","text":"sid- ered as a treatment option in adults with type 2 diabetes who are appro- priate surgical candidates with a BMI $ 40.0 kg/m 2 (BMI $ 37.5 kg/m 2 in people of Asian ancestry) or a BMI of 35.0  39.9 kg/m 2 (32.5  37.4 kg/m 2 in people of Asian ancestry) who do not achieve durable weight loss and im- provement in comorbidities (including hy- perglycemia) with nonsurgical methods.  In people with established CVD, a GLP-1 RA with proven bene fi t should be used to reduce MACE, or an SGLT2i with proven bene fi t should be used to re- duce MACE and HF and improve kidney outcomes.  In people with CKD and an eGFR $ 20 ml/min per 1.73 m 2 and a UACR > 3.0 mg/mmol ( > 30 mg/g), an SGLT2i with proven bene fi t should be initiated to reduce MACE and HF and improve kidney outcomes. Indications and eGFR thresholds may vary by region. If such treatment is not tolerated or is contra- indicated, a GLP-1 RA with proven car- diovascular outcome bene fi t could be considered to reduce MACE and should be continued until kidney replacement therapy is indicated.  In people with HF, SGLT2i should be used because they improve HF and kidney outcomes.  In individuals without established CVD but with multiple cardiovascular risk factors (such as age $ 55 years, obe- sity, hypertension, smoking, dyslipide- mia, or albuminuria), a GLP-1 RA with proven bene fi t could be used to re- duce MACE, or an","tf":{"20":1,"30":1,"32":1,"35":1,"37":2,"39":1,"40":1,"55":1,"73":1,"sid":1,"ered":1,"as":2,"treatment":2,"option":1,"in":8,"adults":1,"with":12,"type":1,"diabetes":1,"who":2,"are":1,"appro":1,"priate":1,"surgical":1,"candidates":1,"bmi":3,"kg":4,"people":5,"of":3,"asian":2,"ancestry":2,"or":5,"do":1,"not":2,"achieve":1,"durable":1,"weight":1,"loss":1,"and":10,"im":1,"provement":1,"comorbidities":1,"including":1,"hy":1,"perglycemia":1,"nonsurgical":1,"methods":1,"established":2,"cvd":2,"glp":3,"ra":3,"proven":5,"bene":5,"fi":5,"should":5,"be":7,"used":4,"to":5,"reduce":3,"mace":5,"an":4,"sglt2i":3,"re":2,"duce":2,"hf":4,"improve":3,"kidney":4,"outcomes":3,"ckd":1,"egfr":2,"ml":1,"min":1,"per":1,"uacr":1,"mg":2,"mmol":1,"initiated":1,"indications":1,"thresholds":1,"may":1,"vary":1,"by":1,"region":1,"if":1,"such":2,"is":3,"tolerated":1,"contra":1,"indicated":2,"car":1,"diovascular":1,"outcome":1,"could":2,"considered":1,"continued":1,"until":1,"replacement":1,"therapy":1,"because":1,"they":1,"individuals":1,"without":1,"but":1,"multiple":1,"cardiovascular":1,"risk":1,"factors":1,"age":1,"years":1,"obe":1,"sity":1,"hypertension":1,"smoking":1,"dyslipide":1,"mia":1,"albuminuria":1},"len":230},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":18,"chunkId":"ada-easd-2022-p18-c3","text":"  In individuals without established CVD but with multiple cardiovascular risk factors (such as age $ 55 years, obe- sity, hypertension, smoking, dyslipide- mia, or albuminuria), a GLP-1 RA with proven bene fi t could be used to re- duce MACE, or an SGLT2i with proven bene fi t could be used to reduce MACE and HF and improve kidney outcomes.  In people with HF, CKD, established CVD, or multiple risk factors for CVD, the decision to use a GLP-1 RA or SGLT2i with proven bene fi t should be independent of background use of metformin.  SGLT2i and GLP-1 RA reduce MACE, which is likely to be independent of baseline HbA 1c . In people with HF, CKD, established CVD, or multiple risk factors for CVD, the decision to use a GLP-1 RA or an SGLT2i with proven bene fi t should be indepen- dent of baseline HbA 1c .  In general, selection of medications to improve cardiovascular and kidney out- comes should not differ for older people.  In younger people with diabetes ( < 40 years), consider early combina- tion therapy.  In women with reproductive potential, counseling regarding contraception and taking care to avoid exposure to medi- cations that may adversely affect a fe- tus are important. PUTTING IT ALL TOGETHER: STRATEGIES FOR IMPLEMENTATION Importance of Integrated Care The overall goal of the management of type 2 diabetes is to maintain quality of life and avoid complications. The","tf":{"40":1,"55":1,"in":6,"individuals":1,"without":1,"established":3,"cvd":5,"but":1,"with":9,"multiple":3,"cardiovascular":2,"risk":3,"factors":3,"such":1,"as":1,"age":1,"years":2,"obe":1,"sity":1,"hypertension":1,"smoking":1,"dyslipide":1,"mia":1,"or":6,"albuminuria":1,"glp":4,"ra":4,"proven":4,"bene":4,"fi":4,"could":2,"be":5,"used":2,"to":9,"re":1,"duce":1,"mace":3,"an":2,"sglt2i":4,"reduce":2,"and":6,"hf":3,"improve":2,"kidney":2,"outcomes":1,"people":4,"ckd":2,"for":4,"the":5,"decision":2,"use":3,"should":3,"independent":2,"of":9,"background":1,"metformin":1,"which":1,"is":2,"likely":1,"baseline":2,"hba":2,"1c":2,"indepen":1,"dent":1,"general":1,"selection":1,"medications":1,"out":1,"comes":1,"not":1,"differ":1,"older":1,"younger":1,"diabetes":2,"consider":1,"early":1,"combina":1,"tion":1,"therapy":1,"women":1,"reproductive":1,"potential":1,"counseling":1,"regarding":1,"contraception":1,"taking":1,"care":2,"avoid":2,"exposure":1,"medi":1,"cations":1,"that":1,"may":1,"adversely":1,"affect":1,"fe":1,"tus":1,"are":1,"important":1,"putting":1,"it":1,"all":1,"together":1,"strategies":1,"implementation":1,"importance":1,"integrated":1,"overall":1,"goal":1,"management":1,"type":1,"maintain":1,"quality":1,"life":1,"complications":1},"len":224},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":18,"chunkId":"ada-easd-2022-p18-c4","text":" that may adversely affect a fe- tus are important. PUTTING IT ALL TOGETHER: STRATEGIES FOR IMPLEMENTATION Importance of Integrated Care The overall goal of the management of type 2 diabetes is to maintain quality of life and avoid complications. The man- agement approach must be holistic and multifactorial and account for the life- long nature of type 2 diabetes (Figs. 1, 3, and 4). The person living with type 2 diabetes should be at the center of care. The structure and organization of the health care team will vary across systems but generally involves multiple disciplines, including the primary care provider, diabetologist, diabetes care and education specialist, registered die- titian/nutritionist, pharmacists, nurses, and other specialists as needed (e.g., den- tist, eye care professional, podiatrist, mental health provider, cardiologist, nephrologist, neurologist, hepatologist, sleep medicine specialist, and pain management specialist) (306). Technology is now an important tool to enhance communication, support, and monitoring. Communication between peo- ple living with type 2 diabetes and health care team members is at the core of in- tegrated care, and clinicians must recog- nize the importance of language in this communication. Practical Tips for Clinicians  Acknowledge the lifelong and evolv- ing nature of type 2 diabetes.  Identify and coordinate with the team.  ","tf":{"306":1,"that":1,"may":1,"adversely":1,"affect":1,"fe":1,"tus":1,"are":1,"important":2,"putting":1,"it":1,"all":1,"together":1,"strategies":1,"for":3,"implementation":1,"importance":2,"of":10,"integrated":1,"care":8,"the":13,"overall":1,"goal":1,"management":2,"type":5,"diabetes":6,"is":3,"to":2,"maintain":1,"quality":1,"life":2,"and":13,"avoid":1,"complications":1,"man":1,"agement":1,"approach":1,"must":2,"be":2,"holistic":1,"multifactorial":1,"account":1,"long":1,"nature":2,"figs":1,"person":1,"living":2,"with":3,"should":1,"at":2,"center":1,"structure":1,"organization":1,"health":3,"team":3,"will":1,"vary":1,"across":1,"systems":1,"but":1,"generally":1,"involves":1,"multiple":1,"disciplines":1,"including":1,"primary":1,"provider":2,"diabetologist":1,"education":1,"specialist":3,"registered":1,"die":1,"titian":1,"nutritionist":1,"pharmacists":1,"nurses":1,"other":1,"specialists":1,"as":1,"needed":1,"den":1,"tist":1,"eye":1,"professional":1,"podiatrist":1,"mental":1,"cardiologist":1,"nephrologist":1,"neurologist":1,"hepatologist":1,"sleep":1,"medicine":1,"pain":1,"technology":1,"now":1,"an":1,"tool":1,"enhance":1,"communication":3,"support":1,"monitoring":1,"between":1,"peo":1,"ple":1,"members":1,"core":1,"in":2,"tegrated":1,"clinicians":2,"recog":1,"nize":1,"language":1,"this":1,"practical":1,"tips":1,"acknowledge":1,"lifelong":1,"evolv":1,"ing":1,"identify":1,"coordinate":1},"len":197},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":18,"chunkId":"ada-easd-2022-p18-c5","text":"ore of in- tegrated care, and clinicians must recog- nize the importance of language in this communication. Practical Tips for Clinicians  Acknowledge the lifelong and evolv- ing nature of type 2 diabetes.  Identify and coordinate with the team.  Know your local resources.  Language matters in diabetes care. See Supplementary Fig. 1. Individualization of Care The integrated care of type 2 diabetes must consider the person with diabetes as an individual (Figs. 1, 3, and 4) with re- spect to speci fi c preferences and values, social determinants of health, barriers to diabetesjournals.org/care Davies and Associates 2769 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"45":1,"2026":1,"2753":1,"2769":1,"691567":1,"ore":1,"of":6,"in":3,"tegrated":1,"care":6,"and":6,"clinicians":2,"must":2,"recog":1,"nize":1,"the":5,"importance":1,"language":2,"this":1,"communication":1,"practical":1,"tips":1,"for":1,"acknowledge":1,"lifelong":1,"evolv":1,"ing":1,"nature":1,"type":2,"diabetes":4,"identify":1,"coordinate":1,"with":3,"team":1,"know":1,"your":1,"local":1,"resources":1,"matters":1,"see":1,"supplementary":1,"fig":1,"individualization":1,"integrated":1,"consider":1,"person":1,"as":1,"an":1,"individual":1,"figs":1,"re":1,"spect":1,"to":2,"speci":1,"fi":1,"preferences":1,"values":1,"social":1,"determinants":1,"health":1,"barriers":1,"diabetesjournals":2,"org":2,"davies":1,"associates":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"february":1},"len":111},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":19,"chunkId":"ada-easd-2022-p19-c0","text":"Figure 4  Holistic person-centered approach to T2DM management. 1  Cardiovascular Disease and Risk Management  in Standards of Medical Care in Diabetes  2022 (141). ACEi, angiotensin-converting en- zyme inhibitor; ARB, angiotensin receptor blockers; ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; CKD, chronic kidney disease; CV, cardiovascular; eGFR, estimated glomerular fi ltration rate; GLP-1 RA, glucagon-like peptide 1 receptor agonist; HF, heart failure; SGLT2i, sodium-glucose cotransporter 2 inhibitor; T2D, type 2 diabetes. 2770 Consensus Report Diabetes Care Volume 45, November 2022 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"45":2,"141":1,"2022":2,"2026":1,"2753":1,"2770":1,"691567":1,"figure":1,"holistic":1,"person":1,"centered":1,"approach":1,"to":1,"t2dm":1,"management":2,"cardiovascular":3,"disease":3,"and":1,"risk":1,"in":2,"standards":1,"of":1,"medical":1,"care":3,"diabetes":3,"acei":1,"angiotensin":2,"converting":1,"en":1,"zyme":1,"inhibitor":2,"arb":1,"receptor":2,"blockers":1,"ascvd":1,"atherosclerotic":1,"bp":1,"blood":1,"pressure":1,"ckd":1,"chronic":1,"kidney":1,"cv":1,"egfr":1,"estimated":1,"glomerular":1,"fi":1,"ltration":1,"rate":1,"glp":1,"ra":1,"glucagon":1,"like":1,"peptide":1,"agonist":1,"hf":1,"heart":1,"failure":1,"sglt2i":1,"sodium":1,"glucose":1,"cotransporter":1,"t2d":1,"type":1,"consensus":1,"report":1,"volume":1,"november":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"february":1},"len":98},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":20,"chunkId":"ada-easd-2022-p20-c0","text":"care, comorbid conditions, degree of hy- perglycemia, risks of complications, and susceptibility to medication side effects. Attention should be given to how the bal- ance of risks and bene fi ts of each inter- vention is communicated to each person living with diabetes. Risk estimator tools, especially for CVD risk, may also be help- ful, but when using these tools one must be aware that they work best when they are derived from and/or are validated in a population similar to the population in which they are applied (307). These risk estimator tools are often developed in populations that exclude younger and older people and underrepresent women and various minority populations. Finally, shared decision-making is essential to in- corporating an individual  s preferences and values when formulating a manage- ment plan. Social determinants of health must be as- sessed and addressed (47) to achieve health equity in diabetes. Health systems must en- sure equity in the delivery of all diabetes care, including access to the more expen- sive, organ-protecting pharmacotherapies (SGLT2i and GLP-1 RAs) and technologies (e.g., CGM). Many people living with type 2 diabe- tes have multiple comorbidities, some related to diabetes, such as obesity, hy- pertension, dyslipidemia, cardiorenal dis- ease, NASH/NAFLD, and mental health problems. Other important conditions whose relationship to di","tf":{"47":1,"307":1,"care":2,"comorbid":1,"conditions":2,"degree":1,"of":6,"hy":2,"perglycemia":1,"risks":2,"complications":1,"and":11,"susceptibility":1,"to":9,"medication":1,"side":1,"effects":1,"attention":1,"should":1,"be":4,"given":1,"how":1,"the":4,"bal":1,"ance":1,"bene":1,"fi":1,"ts":1,"each":2,"inter":1,"vention":1,"is":2,"communicated":1,"person":1,"living":2,"with":2,"diabetes":4,"risk":3,"estimator":2,"tools":3,"especially":1,"for":1,"cvd":1,"may":1,"also":1,"help":1,"ful":1,"but":1,"when":3,"using":1,"these":2,"one":1,"must":3,"aware":1,"that":2,"they":3,"work":1,"best":1,"are":4,"derived":1,"from":1,"or":1,"validated":1,"in":6,"population":2,"similar":1,"which":1,"applied":1,"often":1,"developed":1,"populations":2,"exclude":1,"younger":1,"older":1,"people":2,"underrepresent":1,"women":1,"various":1,"minority":1,"finally":1,"shared":1,"decision":1,"making":1,"essential":1,"corporating":1,"an":1,"individual":1,"preferences":1,"values":1,"formulating":1,"manage":1,"ment":1,"plan":1,"social":1,"determinants":1,"health":4,"as":2,"sessed":1,"addressed":1,"achieve":1,"equity":2,"systems":1,"en":1,"sure":1,"delivery":1,"all":1,"including":1,"access":1,"more":1,"expen":1,"sive":1,"organ":1,"protecting":1,"pharmacotherapies":1,"sglt2i":1,"glp":1,"ras":1,"technologies":1,"cgm":1,"many":1,"type":1,"diabe":1,"tes":1,"have":1,"multiple":1,"comorbidities":1,"some":1,"related":1,"such":1,"obesity":1,"pertension":1,"dyslipidemia":1,"cardiorenal":1,"dis":1,"ease":1,"nash":1,"nafld":1,"mental":1,"problems":1,"other":1,"important":1,"whose":1,"relationship":1,"di":1},"len":213},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":20,"chunkId":"ada-easd-2022-p20-c1","text":"ple living with type 2 diabe- tes have multiple comorbidities, some related to diabetes, such as obesity, hy- pertension, dyslipidemia, cardiorenal dis- ease, NASH/NAFLD, and mental health problems. Other important conditions whose relationship to diabetes is not as well established, such as chronic obstruc- tive pulmonary disease and cancer, are prevalent. Attention to these comorbid- ities should be paid throughout the life span of the person living with diabetes, as such comorbidities may impact the tai- loring and implementation of the holistic plan for diabetes management, including choice of glucose-lowering medication. Importantly, diabetes is associated with cognitive decrements, which can substan- tially impact management (308,309). Fur- ther, long-term hyperglycemia is associated with worsening cognitive decline. Screening for cognitive impairment should be per- formed when risk factors are identi fi ed, such as frequent hypoglycemia, dif fi - culty with diabetes self-management, or unexplained falls. People with cognitive impairment should be referred for addi- tional support. Other conditions, such as serious mental illness and substance use disorders, must also be identi fi ed and managed appropriately in the holistic approach to diabetes. Mental illness, in- cluding depression, is associated with an increased risk of diabetes and with poorer prognosis but may also","tf":{"308":1,"309":1,"ple":1,"living":2,"with":8,"type":1,"diabe":1,"tes":1,"have":1,"multiple":1,"comorbidities":2,"some":1,"related":1,"to":4,"diabetes":8,"such":5,"as":6,"obesity":1,"hy":1,"pertension":1,"dyslipidemia":1,"cardiorenal":1,"dis":1,"ease":1,"nash":1,"nafld":1,"and":6,"mental":3,"health":1,"problems":1,"other":2,"important":1,"conditions":2,"whose":1,"relationship":1,"is":4,"not":1,"well":1,"established":1,"chronic":1,"obstruc":1,"tive":1,"pulmonary":1,"disease":1,"cancer":1,"are":2,"prevalent":1,"attention":1,"these":1,"comorbid":1,"ities":1,"should":3,"be":4,"paid":1,"throughout":1,"the":5,"life":1,"span":1,"of":4,"person":1,"may":2,"impact":2,"tai":1,"loring":1,"implementation":1,"holistic":2,"plan":1,"for":3,"management":3,"including":1,"choice":1,"glucose":1,"lowering":1,"medication":1,"importantly":1,"associated":3,"cognitive":4,"decrements":1,"which":1,"can":1,"substan":1,"tially":1,"fur":1,"ther":1,"long":1,"term":1,"hyperglycemia":1,"worsening":1,"decline":1,"screening":1,"impairment":2,"per":1,"formed":1,"when":1,"risk":2,"factors":1,"identi":2,"fi":3,"ed":2,"frequent":1,"hypoglycemia":1,"dif":1,"culty":1,"self":1,"or":1,"unexplained":1,"falls":1,"people":1,"referred":1,"addi":1,"tional":1,"support":1,"serious":1,"illness":2,"substance":1,"use":1,"disorders":1,"must":1,"also":2,"managed":1,"appropriately":1,"in":2,"approach":1,"cluding":1,"depression":1,"an":1,"increased":1,"poorer":1,"prognosis":1,"but":1},"len":204},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":20,"chunkId":"ada-easd-2022-p20-c2","text":"ess and substance use disorders, must also be identi fi ed and managed appropriately in the holistic approach to diabetes. Mental illness, in- cluding depression, is associated with an increased risk of diabetes and with poorer prognosis but may also compli- cate diabetes management and be a bar- rier to self-management. Practical Tips for Clinicians  Consider each person living with dia- betes an individual with speci fi c con- text, risks, and preferences.  Health care systems should monitor and address inequity in the delivery of evidence-based interventions for type 2 diabetes.  Assess and address social determi- nants of health for each individual liv- ing with diabetes, particularly in those not achieving goals.  Incorporate comorbidities when de- veloping and implementing the man- agement plan. See Supplementary Fig. 1. Diabetes Self-Management Education and Support DSMES is critical to integrated, holistic, person-centered care in type 2 diabetes (19  21,23) and is as important to the management plan as the selection of medication. DSMES should be offered on an ongoing basis, should be provided by trained diabetes care and education specialists, and can be delivered using multiple approaches and in a variety of settings (Supplementary Table 1) (20,31). The care team must be aware of the available local DSMES resources and how to access them. Importantly, DSMES is c","tf":{"19":1,"20":1,"21":1,"23":1,"31":1,"ess":1,"and":14,"substance":1,"use":1,"disorders":1,"must":2,"also":2,"be":6,"identi":1,"fi":2,"ed":1,"managed":1,"appropriately":1,"in":6,"the":7,"holistic":2,"approach":1,"to":5,"diabetes":8,"mental":1,"illness":1,"cluding":1,"depression":1,"is":4,"associated":1,"with":5,"an":3,"increased":1,"risk":1,"of":6,"poorer":1,"prognosis":1,"but":1,"may":1,"compli":1,"cate":1,"management":4,"bar":1,"rier":1,"self":2,"practical":1,"tips":1,"for":3,"clinicians":1,"consider":1,"each":2,"person":2,"living":1,"dia":1,"betes":1,"individual":2,"speci":1,"con":1,"text":1,"risks":1,"preferences":1,"health":2,"care":4,"systems":1,"should":3,"monitor":1,"address":2,"inequity":1,"delivery":1,"evidence":1,"based":1,"interventions":1,"type":2,"assess":1,"social":1,"determi":1,"nants":1,"liv":1,"ing":1,"particularly":1,"those":1,"not":1,"achieving":1,"goals":1,"incorporate":1,"comorbidities":1,"when":1,"de":1,"veloping":1,"implementing":1,"man":1,"agement":1,"plan":2,"see":1,"supplementary":2,"fig":1,"education":2,"support":1,"dsmes":4,"critical":1,"integrated":1,"centered":1,"as":2,"important":1,"selection":1,"medication":1,"offered":1,"on":1,"ongoing":1,"basis":1,"provided":1,"by":1,"trained":1,"specialists":1,"can":1,"delivered":1,"using":1,"multiple":1,"approaches":1,"variety":1,"settings":1,"table":1,"team":1,"aware":1,"available":1,"local":1,"resources":1,"how":1,"access":1,"them":1,"importantly":1},"len":213},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":20,"chunkId":"ada-easd-2022-p20-c3","text":"and education specialists, and can be delivered using multiple approaches and in a variety of settings (Supplementary Table 1) (20,31). The care team must be aware of the available local DSMES resources and how to access them. Importantly, DSMES is complementary to but does not re- place MNT (see below) (310) or referral for mental health services when they are warranted (49). Practical Tips for Clinicians  Embrace DSMES as being as impor- tant as other aspects of diabetes care, such as pharmacotherapy.  Identify and know how to access your local DSMES resources.  Impress on the person and the health care team the importance of DSMES in the ongoing holistic approach to the management of type 2 diabetes.  Initiate or refer for DSMES at diagno- sis, annually, with changes in social or health status, and with transitions of care or life situation. See Supplementary Fig. 1. Facilitating Healthy Behaviors and Weight Management Promotion of healthy behaviors is central to the holistic management of type 2 di- abetes and should be addressed at the time of diagnosis and throughout the course of diabetes. Healthy behaviors in- clude healthy nutrition, regular physical activity, adequate sleep, and smoking cessation. Health behaviors should al- ways be assessed and addressed when glycemic targets are not met and when new pharmacotherapy or interventions (e.g., metabolic surgery) are ","tf":{"20":1,"31":1,"49":1,"310":1,"and":13,"education":1,"specialists":1,"can":1,"be":4,"delivered":1,"using":1,"multiple":1,"approaches":1,"in":4,"variety":1,"of":10,"settings":1,"supplementary":2,"table":1,"the":10,"care":4,"team":2,"must":1,"aware":1,"available":1,"local":2,"dsmes":6,"resources":2,"how":2,"to":5,"access":2,"them":1,"importantly":1,"is":2,"complementary":1,"but":1,"does":1,"not":2,"re":1,"place":1,"mnt":1,"see":2,"below":1,"or":5,"referral":1,"for":3,"mental":1,"health":4,"services":1,"when":3,"they":1,"are":3,"warranted":1,"practical":1,"tips":1,"clinicians":1,"embrace":1,"as":4,"being":1,"impor":1,"tant":1,"other":1,"aspects":1,"diabetes":3,"such":1,"pharmacotherapy":2,"identify":1,"know":1,"your":1,"impress":1,"on":1,"person":1,"importance":1,"ongoing":1,"holistic":2,"approach":1,"management":3,"type":2,"initiate":1,"refer":1,"at":2,"diagno":1,"sis":1,"annually":1,"with":2,"changes":1,"social":1,"status":1,"transitions":1,"life":1,"situation":1,"fig":1,"facilitating":1,"healthy":4,"behaviors":4,"weight":1,"promotion":1,"central":1,"di":1,"abetes":1,"should":2,"addressed":2,"time":1,"diagnosis":1,"throughout":1,"course":1,"clude":1,"nutrition":1,"regular":1,"physical":1,"activity":1,"adequate":1,"sleep":1,"smoking":1,"cessation":1,"al":1,"ways":1,"assessed":1,"glycemic":1,"targets":1,"met":1,"new":1,"interventions":1,"metabolic":1,"surgery":1},"len":215},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":20,"chunkId":"ada-easd-2022-p20-c4","text":"thy nutrition, regular physical activity, adequate sleep, and smoking cessation. Health behaviors should al- ways be assessed and addressed when glycemic targets are not met and when new pharmacotherapy or interventions (e.g., metabolic surgery) are initiated. All individuals with type 2 diabetes should be offered MNT to develop a personal food plan in the context of dia- betes. The need for additional dietary advice should be reevaluated over time (310). There is no single dietary pattern recommended for all individuals with type 2 diabetes; many dietary patterns can be effective for achieving treatment goals, and a structured food plan should be based on an individual person  s pref- erences and context. Explicit physical activity and minimi- zation of sedentary time should be the focus of the physical activity regimen for people living with type 2 diabetes (Fig. 2). Individual preferences and cir- cumstances should inform the speci fi c activity regimen. A reasonable target for physical activity is at least 150 min/week. In addition to these activity minutes, breaking up sedentary time with activity breaks (e.g., 5-min activity break every hour) can be bene fi cial (101). A gradual increase in overall volume and intensity of activity does not require medical clear- ance (101). Additional clinical assessment may be warranted in those with moder- ate-to-severe diabetic retino","tf":{"101":2,"150":1,"310":1,"thy":1,"nutrition":1,"regular":1,"physical":4,"activity":9,"adequate":1,"sleep":1,"and":8,"smoking":1,"cessation":1,"health":1,"behaviors":1,"should":6,"al":1,"ways":1,"be":8,"assessed":1,"addressed":1,"when":2,"glycemic":1,"targets":1,"are":2,"not":2,"met":1,"new":1,"pharmacotherapy":1,"or":1,"interventions":1,"metabolic":1,"surgery":1,"initiated":1,"all":2,"individuals":2,"with":5,"type":3,"diabetes":3,"offered":1,"mnt":1,"to":3,"develop":1,"personal":1,"food":2,"plan":2,"in":4,"the":5,"context":2,"of":4,"dia":1,"betes":1,"need":1,"for":5,"additional":2,"dietary":3,"advice":1,"reevaluated":1,"over":1,"time":3,"there":1,"is":2,"no":1,"single":1,"pattern":1,"recommended":1,"many":1,"patterns":1,"can":2,"effective":1,"achieving":1,"treatment":1,"goals":1,"structured":1,"based":1,"on":1,"an":1,"individual":2,"person":1,"pref":1,"erences":1,"explicit":1,"minimi":1,"zation":1,"sedentary":2,"focus":1,"regimen":2,"people":1,"living":1,"fig":1,"preferences":1,"cir":1,"cumstances":1,"inform":1,"speci":1,"fi":2,"reasonable":1,"target":1,"at":1,"least":1,"min":2,"week":1,"addition":1,"these":1,"minutes":1,"breaking":1,"up":1,"breaks":1,"break":1,"every":1,"hour":1,"bene":1,"cial":1,"gradual":1,"increase":1,"overall":1,"volume":1,"intensity":1,"does":1,"require":1,"medical":1,"clear":1,"ance":1,"clinical":1,"assessment":1,"may":1,"warranted":1,"those":1,"moder":1,"ate":1,"severe":1,"diabetic":1,"retino":1},"len":208},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":20,"chunkId":"ada-easd-2022-p20-c5","text":"break every hour) can be bene fi cial (101). A gradual increase in overall volume and intensity of activity does not require medical clear- ance (101). Additional clinical assessment may be warranted in those with moder- ate-to-severe diabetic retinopathy, diabetic kidney disease, peripheral neuropathy, and unstable HF and for those prescribed insu- lin or with a history of hypoglycemia (101). Individual preferences, motivations, and circumstances should inform choice. Weight management should be a cen- tral focus for individuals with type 2 dia- betes with overweight or obesity, with individualized weight loss goals. For most people, a target of at least 5% weight loss is reasonable and can be expected to have clinical bene fi ts. Substantial ( > 10%) weight loss and weight loss early in the course of type 2 diabetes in- crease the chance of remission of dis- ease (50). The use of glucose-lowering agents that provide signi fi cant weight diabetesjournals.org/care Davies and Associates 2771 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"10":1,"11":1,"17":1,"45":1,"50":1,"101":3,"2026":1,"2753":1,"2771":1,"691567":1,"break":1,"every":1,"hour":1,"can":2,"be":4,"bene":2,"fi":3,"cial":1,"gradual":1,"increase":1,"in":4,"overall":1,"volume":1,"and":7,"intensity":1,"of":7,"activity":1,"does":1,"not":1,"require":1,"medical":1,"clear":1,"ance":1,"additional":1,"clinical":2,"assessment":1,"may":1,"warranted":1,"those":2,"with":5,"moder":1,"ate":1,"to":2,"severe":1,"diabetic":2,"retinopathy":1,"kidney":1,"disease":1,"peripheral":1,"neuropathy":1,"unstable":1,"hf":1,"for":3,"prescribed":1,"insu":1,"lin":1,"or":2,"history":1,"hypoglycemia":1,"individual":1,"preferences":1,"motivations":1,"circumstances":1,"should":2,"inform":1,"choice":1,"weight":6,"management":1,"cen":1,"tral":1,"focus":1,"individuals":1,"type":2,"dia":1,"betes":1,"overweight":1,"obesity":1,"individualized":1,"loss":4,"goals":1,"most":1,"people":1,"target":1,"at":1,"least":1,"is":1,"reasonable":1,"expected":1,"have":1,"ts":1,"substantial":1,"early":1,"the":3,"course":1,"diabetes":1,"crease":1,"chance":1,"remission":1,"dis":1,"ease":1,"use":1,"glucose":1,"lowering":1,"agents":1,"that":1,"provide":1,"signi":1,"cant":1,"diabetesjournals":2,"org":2,"care":2,"davies":1,"associates":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"february":1},"len":174},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":21,"chunkId":"ada-easd-2022-p21-c0","text":"loss, particularly GLP-1 RA with high weight loss ef fi cacy, should be considered, as they can often provide 10  15% weight loss or more. Metabolic surgery, which is most effective when performed early dur- ing diabetes, can be considered in those without a suf fi cient response to nonsurgi- cal weight loss interventions based on the speci fi c context and preferences and should be accompanied by health behav- ior interventions. The bene fi ts of meta- bolic surgery need to be balanced against its potential adverse effects, which vary by procedure and include surgical compli- cations, late metabolic or nutritional com- plications, and impact on psychological health (5,6,127). People being consid- ered for metabolic surgery should be evaluated for comorbid psychological conditions and social and situational cir- cumstances that may interfere with sur- gery outcomes. People who undergo metabolic surgery should receive long- term medical and behavioral support. Metabolic surgery should be performed in high-volume centers with experienced multidisciplinary teams (127). SMART (speci fi c, measurable, attainable, relevant, time-based) goals are more effec- tive for achieving behavior change than nonspeci fi c recommendations (311). An  all or none  approach related to behav- ioral goals should be avoided, as any im- provement in healthy behaviors can have a positive impact in dia","tf":{"10":1,"15":1,"127":2,"311":1,"loss":4,"particularly":1,"glp":1,"ra":1,"with":3,"high":2,"weight":3,"ef":1,"fi":6,"cacy":1,"should":6,"be":7,"considered":2,"as":2,"they":1,"can":3,"often":1,"provide":1,"or":3,"more":2,"metabolic":5,"surgery":5,"which":2,"is":1,"most":1,"effective":1,"when":1,"performed":2,"early":1,"dur":1,"ing":1,"diabetes":1,"in":4,"those":1,"without":1,"suf":1,"cient":1,"response":1,"to":3,"nonsurgi":1,"cal":1,"interventions":2,"based":2,"on":2,"the":2,"speci":2,"context":1,"and":7,"preferences":1,"accompanied":1,"by":2,"health":2,"behav":2,"ior":1,"bene":1,"ts":1,"of":1,"meta":1,"bolic":1,"need":1,"balanced":1,"against":1,"its":1,"potential":1,"adverse":1,"effects":1,"vary":1,"procedure":1,"include":1,"surgical":1,"compli":1,"cations":1,"late":1,"nutritional":1,"com":1,"plications":1,"impact":2,"psychological":2,"people":2,"being":1,"consid":1,"ered":1,"for":3,"evaluated":1,"comorbid":1,"conditions":1,"social":1,"situational":1,"cir":1,"cumstances":1,"that":1,"may":1,"interfere":1,"sur":1,"gery":1,"outcomes":1,"who":1,"undergo":1,"receive":1,"long":1,"term":1,"medical":1,"behavioral":1,"support":1,"volume":1,"centers":1,"experienced":1,"multidisciplinary":1,"teams":1,"smart":1,"measurable":1,"attainable":1,"relevant":1,"time":1,"goals":2,"are":1,"effec":1,"tive":1,"achieving":1,"behavior":1,"change":1,"than":1,"nonspeci":1,"recommendations":1,"an":1,"all":1,"none":1,"approach":1,"related":1,"ioral":1,"avoided":1,"any":1,"im":1,"provement":1,"healthy":1,"behaviors":1,"have":1,"positive":1,"dia":1},"len":210},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":21,"chunkId":"ada-easd-2022-p21-c1","text":"oals are more effec- tive for achieving behavior change than nonspeci fi c recommendations (311). An  all or none  approach related to behav- ioral goals should be avoided, as any im- provement in healthy behaviors can have a positive impact in diabetes (93,312). Self- monitoring of achievements (e.g., physical activity monitoring and weight measure- ment) is crucial to the achievement of health behavior goals (Fig. 1). Behavioral health specialists or psychologists with speci fi c training in behavior change inter- ventions can be of particular value as members of the team to help the person with type 2 diabetes achieve goals. Practical Tips for Clinicians  Speci fi c health behavior and weight management goals should be agreed on between the person with type 2 dia- betes and the care team; shared deci- sion-making is an important component of this discussion.  Emphasize self-monitoring behaviors and review data collected (e.g., glu- cose monitoring, weight, tracking phys- ical activity) in clinical visits to convey their importance in achieving the de- sired health behavior goals.  People taking insulin or a sulfonylurea should be educated about the risk, symptoms, and treatment of hypogly- cemia when undertaking physical ac- tivity or adopting a speci fi c nutritional plan; prescribe glucagon in people at risk for severe hypoglycemia.  DSMES and MNT can help the person","tf":{"93":1,"311":1,"312":1,"oals":1,"are":1,"more":1,"effec":1,"tive":1,"for":3,"achieving":2,"behavior":5,"change":2,"than":1,"nonspeci":1,"fi":4,"recommendations":1,"an":2,"all":1,"or":4,"none":1,"approach":1,"related":1,"to":4,"behav":1,"ioral":1,"goals":5,"should":3,"be":4,"avoided":1,"as":2,"any":1,"im":1,"provement":1,"in":6,"healthy":1,"behaviors":2,"can":3,"have":1,"positive":1,"impact":1,"diabetes":2,"self":2,"monitoring":4,"of":6,"achievements":1,"physical":2,"activity":2,"and":6,"weight":3,"measure":1,"ment":1,"is":2,"crucial":1,"the":8,"achievement":1,"health":4,"fig":1,"behavioral":1,"specialists":1,"psychologists":1,"with":3,"speci":3,"training":1,"inter":1,"ventions":1,"particular":1,"value":1,"members":1,"team":2,"help":2,"person":3,"type":2,"achieve":1,"practical":1,"tips":1,"clinicians":1,"management":1,"agreed":1,"on":1,"between":1,"dia":1,"betes":1,"care":1,"shared":1,"deci":1,"sion":1,"making":1,"important":1,"component":1,"this":1,"discussion":1,"emphasize":1,"review":1,"data":1,"collected":1,"glu":1,"cose":1,"tracking":1,"phys":1,"ical":1,"clinical":1,"visits":1,"convey":1,"their":1,"importance":1,"de":1,"sired":1,"people":2,"taking":1,"insulin":1,"sulfonylurea":1,"educated":1,"about":1,"risk":2,"symptoms":1,"treatment":1,"hypogly":1,"cemia":1,"when":1,"undertaking":1,"ac":1,"tivity":1,"adopting":1,"nutritional":1,"plan":1,"prescribe":1,"glucagon":1,"at":1,"severe":1,"hypoglycemia":1,"dsmes":1,"mnt":1},"len":209},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":21,"chunkId":"ada-easd-2022-p21-c2","text":"ld be educated about the risk, symptoms, and treatment of hypogly- cemia when undertaking physical ac- tivity or adopting a speci fi c nutritional plan; prescribe glucagon in people at risk for severe hypoglycemia.  DSMES and MNT can help the person living with diabetes to identify and ad- dress barriers to implementing health- ier behaviors. See Supplementary Fig. 2. Choice of Glucose-Lowering Medication The choice of glucose-lowering agents should be directed by the individual pro fi le of the person with type 2 diabe- tes, in particular the presence of comor- bidities, risk of side effects, preferences, and context (Figs. 3 and 4). Pharmaco- logical treatment of hyperglycemia must be integrated in DSMES and accompa- nied by a focus on healthy behaviors from diagnosis onwards. This should be integrated as part of a holistic, multifac- torial approach to type 2 diabetes that includes weight, blood pressure, and lipid management (Fig. 4). Whereas the pursuit of glycemic con- trol and the pursuit of organ-speci fi c (e.g., heart and kidney) protection are complementary and not mutually exclu- sive, clinicians should not confuse the discussion of choice of agents for their glucose-lowering effect with the discus- sion of choice of speci fi c agents for their direct organ-protecting effect. Some agents, in particular SGLT2i, have been shown to protect organs (heart, kidney) partl","tf":{"ld":1,"be":4,"educated":1,"about":1,"the":10,"risk":3,"symptoms":1,"and":10,"treatment":2,"of":14,"hypogly":1,"cemia":1,"when":1,"undertaking":1,"physical":1,"ac":1,"tivity":1,"or":1,"adopting":1,"speci":3,"fi":4,"nutritional":1,"plan":1,"prescribe":1,"glucagon":1,"in":4,"people":1,"at":1,"for":3,"severe":1,"hypoglycemia":1,"dsmes":2,"mnt":1,"can":1,"help":1,"person":2,"living":1,"with":3,"diabetes":2,"to":4,"identify":1,"ad":1,"dress":1,"barriers":1,"implementing":1,"health":1,"ier":1,"behaviors":2,"see":1,"supplementary":1,"fig":2,"choice":4,"glucose":3,"lowering":3,"medication":1,"agents":4,"should":3,"directed":1,"by":2,"individual":1,"pro":1,"le":1,"type":2,"diabe":1,"tes":1,"particular":2,"presence":1,"comor":1,"bidities":1,"side":1,"effects":1,"preferences":1,"context":1,"figs":1,"pharmaco":1,"logical":1,"hyperglycemia":1,"must":1,"integrated":2,"accompa":1,"nied":1,"focus":1,"on":1,"healthy":1,"from":1,"diagnosis":1,"onwards":1,"this":1,"as":1,"part":1,"holistic":1,"multifac":1,"torial":1,"approach":1,"that":1,"includes":1,"weight":1,"blood":1,"pressure":1,"lipid":1,"management":1,"whereas":1,"pursuit":2,"glycemic":1,"con":1,"trol":1,"organ":2,"heart":2,"kidney":2,"protection":1,"are":1,"complementary":1,"not":2,"mutually":1,"exclu":1,"sive":1,"clinicians":1,"confuse":1,"discussion":1,"their":2,"effect":2,"discus":1,"sion":1,"direct":1,"protecting":1,"some":1,"sglt2i":1,"have":1,"been":1,"shown":1,"protect":1,"organs":1,"partl":1},"len":213},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":21,"chunkId":"ada-easd-2022-p21-c3","text":"discussion of choice of agents for their glucose-lowering effect with the discus- sion of choice of speci fi c agents for their direct organ-protecting effect. Some agents, in particular SGLT2i, have been shown to protect organs (heart, kidney) partly independently of their glucose- lowering effect, as this organ protection also occurs in those not affected by type 2 diabetes. Based on these principles, regardless of HbA 1c level or the presence of other glucose-lowering agents, all individuals with diabetes and established or sub- clinical CVD should be prescribed an agent with proven cardiovascular bene- fi t from the GLP-1 RA class or SGLT2i class (5,6). The evidence for cardiovascu- lar bene fi ts of GLP-1 RA and SGLT2i in those with only risk factors for CVD, based on MACE (myocardial infarction, stroke, or cardiovascular death), is less robust, as fewer people with lower event rates are included in studies (313  315). Furthermore, it is important to recognize that the predicted absolute bene fi t of an intervention is dependent on the abso- lute risk, and thus those with prior CVD events are more likely to experience a bene fi t over intermediate time frames than those with cardiovascular risk factors only. Through shared decision-making, considering an individual  s lifelong CVD risk, introduction of a GLP-1 RA or SGLT2i with proven cardiovascular bene fi t into the re","tf":{"313":1,"315":1,"discussion":1,"of":10,"choice":2,"agents":4,"for":4,"their":3,"glucose":3,"lowering":3,"effect":3,"with":8,"the":7,"discus":1,"sion":1,"speci":1,"fi":6,"direct":1,"organ":2,"protecting":1,"some":1,"in":4,"particular":1,"sglt2i":4,"have":1,"been":1,"shown":1,"to":3,"protect":1,"organs":1,"heart":1,"kidney":1,"partly":1,"independently":1,"as":2,"this":1,"protection":1,"also":1,"occurs":1,"those":4,"not":1,"affected":1,"by":1,"type":1,"diabetes":2,"based":2,"on":3,"these":1,"principles":1,"regardless":1,"hba":1,"1c":1,"level":1,"or":5,"presence":1,"other":1,"all":1,"individuals":1,"and":3,"established":1,"sub":1,"clinical":1,"cvd":4,"should":1,"be":1,"prescribed":1,"an":3,"agent":1,"proven":2,"cardiovascular":4,"bene":5,"from":1,"glp":3,"ra":3,"class":2,"evidence":1,"cardiovascu":1,"lar":1,"ts":1,"only":2,"risk":4,"factors":2,"mace":1,"myocardial":1,"infarction":1,"stroke":1,"death":1,"is":3,"less":1,"robust":1,"fewer":1,"people":1,"lower":1,"event":1,"rates":1,"are":2,"included":1,"studies":1,"furthermore":1,"it":1,"important":1,"recognize":1,"that":1,"predicted":1,"absolute":1,"intervention":1,"dependent":1,"abso":1,"lute":1,"thus":1,"prior":1,"events":1,"more":1,"likely":1,"experience":1,"over":1,"intermediate":1,"time":1,"frames":1,"than":1,"through":1,"shared":1,"decision":1,"making":1,"considering":1,"individual":1,"lifelong":1,"introduction":1,"into":1,"re":1},"len":221},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":21,"chunkId":"ada-easd-2022-p21-c4","text":"i t over intermediate time frames than those with cardiovascular risk factors only. Through shared decision-making, considering an individual  s lifelong CVD risk, introduction of a GLP-1 RA or SGLT2i with proven cardiovascular bene fi t into the regimen for a person with CVD risk factors can be considered in the context of increased treatment burden and po- tential side effects with lower absolute risk reduction. All individuals with diabetes and CKD (eGFR < 60 ml/min per 1.73 m 2 or UACR > 3.0 mg/mmol [ > 30 mg/g]) should re- ceive an agent with proven kidney bene- fi t from the SGLT2i class (or GLP-1 RA class if SGLT2i are contraindicated or not preferred or their use is not permitted under license). Likewise, those with HF (HF with reduced ejection fraction or HF with preserved ejection fraction) should receive an agent from the SGLT2i class with proven bene fi t for HF. In both in- stances, the goal of organ protection with SGLT2i or GLP-1 RA should be inde- pendent of background glucose-lowering therapies, current HbA 1c level, or target HbA 1c level (Figs. 3 and 4). While there is compelling evidence to support a place for SGLT2i and the GLP-1 RA class in the treatment of many peo- ple with type 2 diabetes based on their direct organ-protecting effects, it is ac- knowledged that to date these agents are expensive. In the setting of resource constraints, prioritization o","tf":{"30":1,"60":1,"73":1,"over":1,"intermediate":1,"time":1,"frames":1,"than":1,"those":2,"with":12,"cardiovascular":2,"risk":4,"factors":2,"only":1,"through":1,"shared":1,"decision":1,"making":1,"considering":1,"an":3,"individual":1,"lifelong":1,"cvd":2,"introduction":1,"of":6,"glp":4,"ra":4,"or":8,"sglt2i":6,"proven":3,"bene":3,"fi":3,"into":1,"the":8,"regimen":1,"for":3,"person":1,"can":1,"be":2,"considered":1,"in":5,"context":1,"increased":1,"treatment":2,"burden":1,"and":4,"po":1,"tential":1,"side":1,"effects":2,"lower":1,"absolute":1,"reduction":1,"all":1,"individuals":1,"diabetes":2,"ckd":1,"egfr":1,"ml":1,"min":1,"per":1,"uacr":1,"mg":2,"mmol":1,"should":3,"re":1,"ceive":1,"agent":2,"kidney":1,"from":2,"class":4,"if":1,"are":2,"contraindicated":1,"not":2,"preferred":1,"their":2,"use":1,"is":3,"permitted":1,"under":1,"license":1,"likewise":1,"hf":4,"reduced":1,"ejection":2,"fraction":2,"preserved":1,"receive":1,"both":1,"stances":1,"goal":1,"organ":2,"protection":1,"inde":1,"pendent":1,"background":1,"glucose":1,"lowering":1,"therapies":1,"current":1,"hba":2,"1c":2,"level":2,"target":1,"figs":1,"while":1,"there":1,"compelling":1,"evidence":1,"to":2,"support":1,"place":1,"many":1,"peo":1,"ple":1,"type":1,"based":1,"on":1,"direct":1,"protecting":1,"it":1,"ac":1,"knowledged":1,"that":1,"date":1,"these":1,"agents":1,"expensive":1,"setting":1,"resource":1,"constraints":1,"prioritization":1},"len":225},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":21,"chunkId":"ada-easd-2022-p21-c5","text":"GLT2i and the GLP-1 RA class in the treatment of many peo- ple with type 2 diabetes based on their direct organ-protecting effects, it is ac- knowledged that to date these agents are expensive. In the setting of resource constraints, prioritization of the highest risk groups for access to these agents may be needed, with consideration of absolute risk reduction in addition to rel- ative risk reductions. Evidence on speci fi c agents and their effects on other comorbidities, such as NAFLD, is emerging. For those with NAFLD/NASH at high risk of fi brosis, pio- glitazone could be considered. There is emerging evidence for bene fi ts of meta- bolic surgery and three classes of glu- cose-lowering therapy (GLP-1 RA, SGLT2i, and GIP and GLP-1 RA) (188,292  298, 316). Overall, for treatment of hyperglycemia, metformin remains the agent of choice in most people with diabetes, based on its glucose-lowering ef fi cacy, minimal risk of hypoglycemia, lack of weight increase, and affordability. Often, monotherapy with metformin will not suf fi ce to main- tain glucose levels at target. As proposed in the previous consensus report and 2772 Consensus Report Diabetes Care Volume 45, November 2022 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"45":2,"188":1,"292":1,"298":1,"316":1,"2022":1,"2026":1,"2753":1,"2772":1,"691567":1,"glt2i":1,"and":7,"the":6,"glp":3,"ra":3,"class":1,"in":5,"treatment":2,"of":11,"many":1,"peo":1,"ple":1,"with":5,"type":1,"diabetes":3,"based":2,"on":5,"their":2,"direct":1,"organ":1,"protecting":1,"effects":2,"it":1,"is":3,"ac":1,"knowledged":1,"that":1,"to":4,"date":1,"these":2,"agents":3,"are":1,"expensive":1,"setting":1,"resource":1,"constraints":1,"prioritization":1,"highest":1,"risk":5,"groups":1,"for":4,"access":1,"may":1,"be":2,"needed":1,"consideration":1,"absolute":1,"reduction":1,"addition":1,"rel":1,"ative":1,"reductions":1,"evidence":2,"speci":1,"fi":5,"other":1,"comorbidities":1,"such":1,"as":2,"nafld":2,"emerging":2,"those":1,"nash":1,"at":2,"high":1,"brosis":1,"pio":1,"glitazone":1,"could":1,"considered":1,"there":1,"bene":1,"ts":1,"meta":1,"bolic":1,"surgery":1,"three":1,"classes":1,"glu":1,"cose":1,"lowering":2,"therapy":1,"sglt2i":1,"gip":1,"overall":1,"hyperglycemia":1,"metformin":2,"remains":1,"agent":1,"choice":1,"most":1,"people":1,"its":1,"glucose":2,"ef":1,"cacy":1,"minimal":1,"hypoglycemia":1,"lack":1,"weight":1,"increase":1,"affordability":1,"often":1,"monotherapy":1,"will":1,"not":1,"suf":1,"ce":1,"main":1,"tain":1,"levels":1,"target":1,"proposed":1,"previous":1,"consensus":2,"report":2,"care":2,"volume":1,"november":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"february":1},"len":218},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":22,"chunkId":"ada-easd-2022-p22-c0","text":"update (5,6), other classes of agents are useful in combination with metformin or when metformin is contraindicated or not tolerated. Selection of other glucose- lowering agents will be determined by the balance between the glucose-lowering ef fi cacy and the side effect pro fi le of the individual agents (see Table 1). Special attention needs to be given to populations in which hypoglycemia is most dangerous, for example, people with frailty, in whom agents without risk of hypoglycemia need to be prioritized. If sulfonylureas or insulin are used, consid- eration of less stringent targets in such settings is prudent and deprescribing if asymptomatic or severe hypoglycemia ensues. Finally, it needs to be stated that the evidence on organ-protecting or glucose- lowering effects of speci fi c pharmaco- therapies in speci fi c subpopulations (e.g., younger and older people, women, and various racial/ethnic groups) continues to be limited. This lack of evidence is, however, not a reason to withhold these medications in these subpopulations, given their proven bene fi ts in large gen- eral populations. Practical Tips for Clinicians  Providers should continually update their knowledge on the ef fi cacy and side effects of diabetes pharmacother- apy (see Table 1).  Identify relevant comorbidities (e.g., obesity, CVD, HF, CKD, NAFLD).  Assess the pro fi le of the person with diabetes","tf":{"update":2,"other":2,"classes":1,"of":9,"agents":4,"are":2,"useful":1,"in":7,"combination":1,"with":3,"metformin":2,"or":5,"when":1,"is":4,"contraindicated":1,"not":2,"tolerated":1,"selection":1,"glucose":3,"lowering":3,"will":1,"be":5,"determined":1,"by":1,"the":8,"balance":1,"between":1,"ef":2,"fi":7,"cacy":2,"and":5,"side":2,"effect":1,"pro":2,"le":2,"individual":1,"see":2,"table":2,"special":1,"attention":1,"needs":2,"to":6,"given":2,"populations":2,"which":1,"hypoglycemia":3,"most":1,"dangerous":1,"for":2,"example":1,"people":2,"frailty":1,"whom":1,"without":1,"risk":1,"need":1,"prioritized":1,"if":2,"sulfonylureas":1,"insulin":1,"used":1,"consid":1,"eration":1,"less":1,"stringent":1,"targets":1,"such":1,"settings":1,"prudent":1,"deprescribing":1,"asymptomatic":1,"severe":1,"ensues":1,"finally":1,"it":1,"stated":1,"that":1,"evidence":2,"on":2,"organ":1,"protecting":1,"effects":2,"speci":2,"pharmaco":1,"therapies":1,"subpopulations":2,"younger":1,"older":1,"women":1,"various":1,"racial":1,"ethnic":1,"groups":1,"continues":1,"limited":1,"this":1,"lack":1,"however":1,"reason":1,"withhold":1,"these":2,"medications":1,"their":2,"proven":1,"bene":1,"ts":1,"large":1,"gen":1,"eral":1,"practical":1,"tips":1,"clinicians":1,"providers":1,"should":1,"continually":1,"knowledge":1,"diabetes":2,"pharmacother":1,"apy":1,"identify":1,"relevant":1,"comorbidities":1,"obesity":1,"cvd":1,"hf":1,"ckd":1,"nafld":1,"assess":1,"person":1},"len":213},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":22,"chunkId":"ada-easd-2022-p22-c1","text":"iders should continually update their knowledge on the ef fi cacy and side effects of diabetes pharmacother- apy (see Table 1).  Identify relevant comorbidities (e.g., obesity, CVD, HF, CKD, NAFLD).  Assess the pro fi le of the person with diabetes (e.g., younger age, frailty, lim- ited life expectancy, cognitive impair- ment, social determinants of health).  Consider risk factors for medication adverse events (e.g., hypoglycemia, volume depletion, genital infections, history of pancreatitis).  Prioritize the use of organ-protective medications (GLP-1 RA, SGLT2i, TZD) in those with cardiorenal disease or NASH or at high risk. See Supplementary Fig. 2. Proactive Care: Avoiding Inertia Reassessment of individual glycemic tar- gets and their achievement at regular intervals is key (Figs. 1, 3, and 4). When targets are not met, in addition to ad- dressing health behaviors and referral to DSMES, the intensi fi cation of glu- cose-lowering medication by combining agents with complementary mechanisms of action should be pursued. Tradition- ally, a stepwise approach was advocated, in which a new agent is added to the ex- isting regimen, but evidence is growing to support a more proactive approach in many by combining glucose-lowering agents from initial diagnosis (6). Early use of combinations of agents allows tighter glucose control than monotherapy with the individual agents, and","tf":{"iders":1,"should":2,"continually":1,"update":1,"their":2,"knowledge":1,"on":1,"the":7,"ef":1,"fi":3,"cacy":1,"and":5,"side":1,"effects":1,"of":10,"diabetes":2,"pharmacother":1,"apy":1,"see":2,"table":1,"identify":1,"relevant":1,"comorbidities":1,"obesity":1,"cvd":1,"hf":1,"ckd":1,"nafld":1,"assess":1,"pro":1,"le":1,"person":1,"with":4,"younger":1,"age":1,"frailty":1,"lim":1,"ited":1,"life":1,"expectancy":1,"cognitive":1,"impair":1,"ment":1,"social":1,"determinants":1,"health":2,"consider":1,"risk":2,"factors":1,"for":1,"medication":2,"adverse":1,"events":1,"hypoglycemia":1,"volume":1,"depletion":1,"genital":1,"infections":1,"history":1,"pancreatitis":1,"prioritize":1,"use":2,"organ":1,"protective":1,"medications":1,"glp":1,"ra":1,"sglt2i":1,"tzd":1,"in":4,"those":1,"cardiorenal":1,"disease":1,"or":2,"nash":1,"at":2,"high":1,"supplementary":1,"fig":1,"proactive":2,"care":1,"avoiding":1,"inertia":1,"reassessment":1,"individual":2,"glycemic":1,"tar":1,"gets":1,"achievement":1,"regular":1,"intervals":1,"is":3,"key":1,"figs":1,"when":1,"targets":1,"are":1,"not":1,"met":1,"addition":1,"to":4,"ad":1,"dressing":1,"behaviors":1,"referral":1,"dsmes":1,"intensi":1,"cation":1,"glu":1,"cose":1,"lowering":2,"by":2,"combining":2,"agents":4,"complementary":1,"mechanisms":1,"action":1,"be":1,"pursued":1,"tradition":1,"ally":1,"stepwise":1,"approach":2,"was":1,"advocated":1,"which":1,"new":1,"agent":1,"added":1,"ex":1,"isting":1,"regimen":1,"but":1,"evidence":1,"growing":1,"support":1,"more":1,"many":1,"glucose":2,"from":1,"initial":1,"diagnosis":1,"early":1,"combinations":1,"allows":1,"tighter":1,"control":1,"than":1,"monotherapy":1},"len":201},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":22,"chunkId":"ada-easd-2022-p22-c2","text":" but evidence is growing to support a more proactive approach in many by combining glucose-lowering agents from initial diagnosis (6). Early use of combinations of agents allows tighter glucose control than monotherapy with the individual agents, and thus combinations of agents are in- dicated in those who have HbA 1c levels > 16.3 mmol/mol ( > 1.5%) above their target at diagnosis (e.g., $ 70 mmol/mol [8.5%] in most) (6). In particular, among young adults with type 2 diabetes, im- mediate and sustained glycemic manage- ment should be pursued, aiming for HbA 1c < 53 mmol/mol (7%) (or even lower). This presents the best opportu- nity to avoid complications of diabetes across the life span. Moreover, the path- ophysiology of micro- and macrovascular damage shares more commonality than usually thought, suggesting that the pre- vention of microvascular disease may, in the long term, contribute to a reduction in macrovascular complications as well (317). The knowledge base guiding clinicians beyond dual therapy in type 2 diabetes is still limited. In general, intensi fi cation of treatment beyond two medications follows the same general principles as the addition of a second medication, with the assumption that the effective- ness of third and fourth medications will be generally less than when they are used alone. Whereas solid evidence exists for combining SGLT2i and GLP-1 RA for ","tf":{"16":1,"53":1,"70":1,"317":1,"but":1,"evidence":2,"is":2,"growing":1,"to":3,"support":1,"more":2,"proactive":1,"approach":1,"in":9,"many":1,"by":1,"combining":2,"glucose":2,"lowering":1,"agents":4,"from":1,"initial":1,"diagnosis":2,"early":1,"use":1,"of":9,"combinations":2,"allows":1,"tighter":1,"control":1,"than":3,"monotherapy":1,"with":3,"the":11,"individual":1,"and":5,"thus":1,"are":2,"dicated":1,"those":1,"who":1,"have":1,"hba":2,"1c":2,"levels":1,"mmol":3,"mol":3,"above":1,"their":1,"target":1,"at":1,"most":1,"particular":1,"among":1,"young":1,"adults":1,"type":2,"diabetes":3,"im":1,"mediate":1,"sustained":1,"glycemic":1,"manage":1,"ment":1,"should":1,"be":2,"pursued":1,"aiming":1,"for":3,"or":1,"even":1,"lower":1,"this":1,"presents":1,"best":1,"opportu":1,"nity":1,"avoid":1,"complications":2,"across":1,"life":1,"span":1,"moreover":1,"path":1,"ophysiology":1,"micro":1,"macrovascular":2,"damage":1,"shares":1,"commonality":1,"usually":1,"thought":1,"suggesting":1,"that":2,"pre":1,"vention":1,"microvascular":1,"disease":1,"may":1,"long":1,"term":1,"contribute":1,"reduction":1,"as":2,"well":1,"knowledge":1,"base":1,"guiding":1,"clinicians":1,"beyond":2,"dual":1,"therapy":1,"still":1,"limited":1,"general":2,"intensi":1,"fi":1,"cation":1,"treatment":1,"two":1,"medications":2,"follows":1,"same":1,"principles":1,"addition":1,"second":1,"medication":1,"assumption":1,"effective":1,"ness":1,"third":1,"fourth":1,"will":1,"generally":1,"less":1,"when":1,"they":1,"used":1,"alone":1,"whereas":1,"solid":1,"exists":1,"sglt2i":1,"glp":1,"ra":1},"len":211},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":22,"chunkId":"ada-easd-2022-p22-c3","text":"principles as the addition of a second medication, with the assumption that the effective- ness of third and fourth medications will be generally less than when they are used alone. Whereas solid evidence exists for combining SGLT2i and GLP-1 RA for weight and glucose lowering, emerging data suggest promise for com- bined effects on cardiorenal outcomes (228). As more medications are added, there is an increased treatment burden and risk of adverse effects. It is important to con- sider medication interactions and whether regimen complexity may become an obstacle to adherence. Fixed-dose combi- nation preparations can improve medica- tion-taking behaviors. Finally, with each additional medication comes increased costs, which can affect medication-taking behavior and medication effectiveness (318  326). Response to all therapies should be reviewed at regular intervals, including the impact on ef fi cacy (HbA 1c , weight), safety, and organ protection. While most people with diabetes require intensi fi ca- tion of glucose-lowering medications, some require medication reduction or discontinuation, particularly if the ther- apy is ineffective or associated with side effects such as hypoglycemia or when glycemic goals have changed because of a change in clinical circumstances (e.g., development of comorbidities or even healthy ageing). Medication should be stopped, or the dose redu","tf":{"228":1,"318":1,"326":1,"principles":1,"as":3,"the":6,"addition":1,"of":6,"second":1,"medication":7,"with":4,"assumption":1,"that":1,"effective":1,"ness":1,"third":1,"and":7,"fourth":1,"medications":3,"will":1,"be":3,"generally":1,"less":1,"than":1,"when":2,"they":1,"are":2,"used":1,"alone":1,"whereas":1,"solid":1,"evidence":1,"exists":1,"for":3,"combining":1,"sglt2i":1,"glp":1,"ra":1,"weight":2,"glucose":2,"lowering":2,"emerging":1,"data":1,"suggest":1,"promise":1,"com":1,"bined":1,"effects":3,"on":2,"cardiorenal":1,"outcomes":1,"more":1,"added":1,"there":1,"is":3,"an":2,"increased":2,"treatment":1,"burden":1,"risk":1,"adverse":1,"it":1,"important":1,"to":3,"con":1,"sider":1,"interactions":1,"whether":1,"regimen":1,"complexity":1,"may":1,"become":1,"obstacle":1,"adherence":1,"fixed":1,"dose":2,"combi":1,"nation":1,"preparations":1,"can":2,"improve":1,"medica":1,"tion":2,"taking":2,"behaviors":1,"finally":1,"each":1,"additional":1,"comes":1,"costs":1,"which":1,"affect":1,"behavior":1,"effectiveness":1,"response":1,"all":1,"therapies":1,"should":2,"reviewed":1,"at":1,"regular":1,"intervals":1,"including":1,"impact":1,"ef":1,"fi":2,"cacy":1,"hba":1,"1c":1,"safety":1,"organ":1,"protection":1,"while":1,"most":1,"people":1,"diabetes":1,"require":2,"intensi":1,"ca":1,"some":1,"reduction":1,"or":5,"discontinuation":1,"particularly":1,"if":1,"ther":1,"apy":1,"ineffective":1,"associated":1,"side":1,"such":1,"hypoglycemia":1,"glycemic":1,"goals":1,"have":1,"changed":1,"because":1,"change":1,"in":1,"clinical":1,"circumstances":1,"development":1,"comorbidities":1,"even":1,"healthy":1,"ageing":1,"stopped":1,"redu":1},"len":206},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":22,"chunkId":"ada-easd-2022-p22-c4","text":"fective or associated with side effects such as hypoglycemia or when glycemic goals have changed because of a change in clinical circumstances (e.g., development of comorbidities or even healthy ageing). Medication should be stopped, or the dose reduced, if there are minimal bene fi ts or if harm outweighs any bene fi t. Ceasing or reducing the dose of medications that have an increased risk of hypoglycemia is suggested when any new glucose-lowering treatment (behav- ioral or medication) is started and the in- dividual  s glycemic levels are close to target (66). HbA 1c levels below 48 mmol/ mol (6.5%) or substantially below the indi- vidualized glycemic target as well as any increased risk of hypoglycemia should prompt stopping or reducing the dose of medications associated with an increased risk of hypoglycemia. Practical Tips for Clinicians  Consider initial combination therapy with glucose-lowering agents, espe- cially in those with high HbA 1c at diag- nosis (i.e., > 70 mmol/mol [ > 8.5%]), in younger people with type 2 diabe- tes (regardless of HbA 1c ), and in those in whom a stepwise approach would delay access to agents that provide cardiorenal protection beyond their glucose-lowering effects.  Avoid therapeutic inertia and reeval- uate health behaviors, individuals  medication-taking behaviors, and side effects of agents at every clinic visit.  When additional gl","tf":{"48":1,"66":1,"70":1,"fective":1,"or":9,"associated":2,"with":5,"side":2,"effects":3,"such":1,"as":3,"hypoglycemia":4,"when":3,"glycemic":3,"goals":1,"have":2,"changed":1,"because":1,"of":9,"change":1,"in":6,"clinical":1,"circumstances":1,"development":1,"comorbidities":1,"even":1,"healthy":1,"ageing":1,"medication":3,"should":2,"be":1,"stopped":1,"the":5,"dose":3,"reduced":1,"if":2,"there":1,"are":2,"minimal":1,"bene":2,"fi":2,"ts":1,"harm":1,"outweighs":1,"any":3,"ceasing":1,"reducing":2,"medications":2,"that":2,"an":2,"increased":3,"risk":3,"is":2,"suggested":1,"new":1,"glucose":3,"lowering":3,"treatment":1,"behav":1,"ioral":1,"started":1,"and":4,"dividual":1,"levels":2,"close":1,"to":2,"target":2,"hba":3,"1c":3,"below":2,"mmol":2,"mol":2,"substantially":1,"indi":1,"vidualized":1,"well":1,"prompt":1,"stopping":1,"practical":1,"tips":1,"for":1,"clinicians":1,"consider":1,"initial":1,"combination":1,"therapy":1,"agents":3,"espe":1,"cially":1,"those":2,"high":1,"at":2,"diag":1,"nosis":1,"younger":1,"people":1,"type":1,"diabe":1,"tes":1,"regardless":1,"whom":1,"stepwise":1,"approach":1,"would":1,"delay":1,"access":1,"provide":1,"cardiorenal":1,"protection":1,"beyond":1,"their":1,"avoid":1,"therapeutic":1,"inertia":1,"reeval":1,"uate":1,"health":1,"behaviors":2,"individuals":1,"taking":1,"every":1,"clinic":1,"visit":1,"additional":1,"gl":1},"len":210},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":22,"chunkId":"ada-easd-2022-p22-c5","text":"hat provide cardiorenal protection beyond their glucose-lowering effects.  Avoid therapeutic inertia and reeval- uate health behaviors, individuals  medication-taking behaviors, and side effects of agents at every clinic visit.  When additional glycemic control is needed, incorporate, rather than sub- stitute, glucose-lowering therapies with complementary mechanisms of action.  Consider fi xed-dose combinations to reduce prescription burden.  Consider deintensi fi cation of therapy, e.g., in frail older adults and in the set- ting of hypoglycemia-causing medica- tions, in those with glycemic metrics substantially better than target. See Supplementary Fig. 2. Place of Insulin in Type 2 Diabetes Insulin is a useful and effective glucose- lowering agent (Fig. 5). When glycemic measurements do not reach targets, diabetesjournals.org/care Davies and Associates 2773 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"45":1,"2026":1,"2753":1,"2773":1,"691567":1,"hat":1,"provide":1,"cardiorenal":1,"protection":1,"beyond":1,"their":1,"glucose":3,"lowering":3,"effects":2,"avoid":1,"therapeutic":1,"inertia":1,"and":5,"reeval":1,"uate":1,"health":1,"behaviors":2,"individuals":1,"medication":1,"taking":1,"side":1,"of":5,"agents":1,"at":1,"every":1,"clinic":1,"visit":1,"when":2,"additional":1,"glycemic":3,"control":1,"is":2,"needed":1,"incorporate":1,"rather":1,"than":2,"sub":1,"stitute":1,"therapies":1,"with":2,"complementary":1,"mechanisms":1,"action":1,"consider":2,"fi":2,"xed":1,"dose":1,"combinations":1,"to":1,"reduce":1,"prescription":1,"burden":1,"deintensi":1,"cation":1,"therapy":1,"in":4,"frail":1,"older":1,"adults":1,"the":1,"set":1,"ting":1,"hypoglycemia":1,"causing":1,"medica":1,"tions":1,"those":1,"metrics":1,"substantially":1,"better":1,"target":1,"see":1,"supplementary":1,"fig":2,"place":1,"insulin":2,"type":1,"diabetes":1,"useful":1,"effective":1,"agent":1,"measurements":1,"do":1,"not":1,"reach":1,"targets":1,"diabetesjournals":2,"org":2,"care":2,"davies":1,"associates":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"february":1},"len":139},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":23,"chunkId":"ada-easd-2022-p23-c0","text":"and insulin is the best choice for the in- dividual, its introduction should not be delayed. When clinicians are not familiar with insulin use, referral to specialist care is indicated. However, with the growing evidence supporting use of particular agents in people with type 2 diabetes with speci fi c pro fi les (comorbidities, over- weight/obesity) and with the availability of multiple glucose-lowering agents with good ef fi cacy and acceptable side effect pro fi les, the initiation of insulin can be postponed in many to later stages of the disease. GLP-1 RA should be considered in all when no contraindications are Figure 5  Place of insulin. *NPH insulin or preferably analog to reduce nocturnal hypoglycemia risk. 1 More details can be found in Davies et al. (12) and  Pharmacologic Approaches to Glycemic Treatment  in Standards of Medical Care in Diabetes  2022 (16). CGM, continuous glucose monitor- ing; DSMES, diabetes self-management education and support; FPG, fasting plasma glucose; GLP-1 RA, glucagon-like peptide 1 receptor agonist; SGLT2i, sodium-glucose cotransporter 2 inhibitor; T1D, type 1 diabetes; TIR, time in range. 2774 Consensus Report Diabetes Care Volume 45, November 2022 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"12":1,"16":1,"17":1,"45":2,"2022":2,"2026":1,"2753":1,"2774":1,"691567":1,"and":5,"insulin":5,"is":2,"the":6,"best":1,"choice":1,"for":1,"in":8,"dividual":1,"its":1,"introduction":1,"should":2,"not":2,"be":4,"delayed":1,"when":2,"clinicians":1,"are":2,"familiar":1,"with":6,"use":2,"referral":1,"to":4,"specialist":1,"care":4,"indicated":1,"however":1,"growing":1,"evidence":1,"supporting":1,"of":6,"particular":1,"agents":2,"people":1,"type":2,"diabetes":5,"speci":1,"fi":4,"pro":2,"les":2,"comorbidities":1,"over":1,"weight":1,"obesity":1,"availability":1,"multiple":1,"glucose":4,"lowering":1,"good":1,"ef":1,"cacy":1,"acceptable":1,"side":1,"effect":1,"initiation":1,"can":2,"postponed":1,"many":1,"later":1,"stages":1,"disease":1,"glp":2,"ra":2,"considered":1,"all":1,"no":1,"contraindications":1,"figure":1,"place":1,"nph":1,"or":1,"preferably":1,"analog":1,"reduce":1,"nocturnal":1,"hypoglycemia":1,"risk":1,"more":1,"details":1,"found":1,"davies":1,"et":1,"al":1,"pharmacologic":1,"approaches":1,"glycemic":1,"treatment":1,"standards":1,"medical":1,"cgm":1,"continuous":1,"monitor":1,"ing":1,"dsmes":1,"self":1,"management":1,"education":1,"support":1,"fpg":1,"fasting":1,"plasma":1,"glucagon":1,"like":1,"peptide":1,"receptor":1,"agonist":1,"sglt2i":1,"sodium":1,"cotransporter":1,"inhibitor":1,"t1d":1,"tir":1,"time":1,"range":1,"consensus":1,"report":1,"volume":1,"november":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"february":1},"len":205},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":24,"chunkId":"ada-easd-2022-p24-c0","text":"present before initiation of insulin ther- apy, as they allow lower glycemic targets to be reached with a lower injection bur- den and lower risk of hypoglycemia and weight gain than with insulin alone. The preferred way of initiating insulin in people with type 2 diabetes is to add basal insulin to the existing pharmaco- logical therapy in conjunction with re- visiting health behaviors and rereferral to DSMES. However, agents that cause hypoglycemia in themselves, such as sulfonylureas, should be discontinued once insulin is started. Technologies al- lowing continuous monitoring of glucose levels without fi nger sticking have clear advantages in those on insulin. Other sup- port tools and systems, such as apps guiding insulin dose adaptation or phone- based guidance, can also be helpful. In speci fi c circumstances, insulin may be the preferred agent for glucose lowering, speci fi cally in the setting of severe hyper- glycemia (HbA 1c > 86 mmol/mol [ > 10%]), particularly when associated with weight loss or ketonuria/ketosis and with acute glycemic dysregulation (e.g., during hospi- talization, surgery, or acute illness), in un- derweight people, or when the diagnosis of type 1 diabetes is suspected. If affordable, basal insulin analog for- mulations are preferred to NPH insulin because of their reduced risk of hypogly- cemia, particularly nocturnal hypoglyce- mia, when titrat","tf":{"10":1,"86":1,"present":1,"before":1,"initiation":1,"of":8,"insulin":10,"ther":1,"apy":1,"as":3,"they":1,"allow":1,"lower":3,"glycemic":2,"targets":1,"to":5,"be":4,"reached":1,"with":6,"injection":1,"bur":1,"den":1,"and":5,"risk":2,"hypoglycemia":2,"weight":2,"gain":1,"than":1,"alone":1,"the":5,"preferred":3,"way":1,"initiating":1,"in":7,"people":2,"type":2,"diabetes":2,"is":3,"add":1,"basal":2,"existing":1,"pharmaco":1,"logical":1,"therapy":1,"conjunction":1,"re":1,"visiting":1,"health":1,"behaviors":1,"rereferral":1,"dsmes":1,"however":1,"agents":1,"that":1,"cause":1,"themselves":1,"such":2,"sulfonylureas":1,"should":1,"discontinued":1,"once":1,"started":1,"technologies":1,"al":1,"lowing":1,"continuous":1,"monitoring":1,"glucose":2,"levels":1,"without":1,"fi":3,"nger":1,"sticking":1,"have":1,"clear":1,"advantages":1,"those":1,"on":1,"other":1,"sup":1,"port":1,"tools":1,"systems":1,"apps":1,"guiding":1,"dose":1,"adaptation":1,"or":4,"phone":1,"based":1,"guidance":1,"can":1,"also":1,"helpful":1,"speci":2,"circumstances":1,"may":1,"agent":1,"for":2,"lowering":1,"cally":1,"setting":1,"severe":1,"hyper":1,"glycemia":1,"hba":1,"1c":1,"mmol":1,"mol":1,"particularly":2,"when":3,"associated":1,"loss":1,"ketonuria":1,"ketosis":1,"acute":2,"dysregulation":1,"during":1,"hospi":1,"talization":1,"surgery":1,"illness":1,"un":1,"derweight":1,"diagnosis":1,"suspected":1,"if":1,"affordable":1,"analog":1,"mulations":1,"are":1,"nph":1,"because":1,"their":1,"reduced":1,"hypogly":1,"cemia":1,"nocturnal":1,"hypoglyce":1,"mia":1,"titrat":1},"len":212},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":24,"chunkId":"ada-easd-2022-p24-c1","text":"rweight people, or when the diagnosis of type 1 diabetes is suspected. If affordable, basal insulin analog for- mulations are preferred to NPH insulin because of their reduced risk of hypogly- cemia, particularly nocturnal hypoglyce- mia, when titrated to the same fasting glucose target (327). Basal insulins are typically administered before bedtime, but, with newer analogs, more fl exibility in the timing of insulin injection is possi- ble (i.e., any time of the day). In some, as the disease progresses, despite titration of the basal insulin to correct fasting hyperglycemia (typically more than 0.5 U/kg), mealtime insulin may have to be added to meet glycemic targets, particularly postprandial glucose (328). Mealtime insulin may be required to enhance postprandial blood glucose levels and achieve HbA 1c targets. Thera- peutic inertia in intensi fi cation of insulin therapy should be avoided, and, when clinicians are not familiar with multiple daily injection therapy, referral to special- ist care and/or DSMES is warranted. A straightforward way to introduce meal- time insulin is to start with a short- or rapid-acting insulin injection before the meal associated with the largest glucose excursion. Adding mealtime rapid-acting insulin requires increased DSMES and self-monitoring of glucose levels and adds complexity and cost to the ther- apy. In contrast to basal insulin analogs","tf":{"327":1,"328":1,"rweight":1,"people":1,"or":3,"when":3,"the":9,"diagnosis":1,"of":8,"type":1,"diabetes":1,"is":4,"suspected":1,"if":1,"affordable":1,"basal":4,"insulin":11,"analog":1,"for":1,"mulations":1,"are":3,"preferred":1,"to":11,"nph":1,"because":1,"their":1,"reduced":1,"risk":1,"hypogly":1,"cemia":1,"particularly":2,"nocturnal":1,"hypoglyce":1,"mia":1,"titrated":1,"same":1,"fasting":2,"glucose":5,"target":1,"insulins":1,"typically":2,"administered":1,"before":2,"bedtime":1,"but":1,"with":4,"newer":1,"analogs":2,"more":2,"fl":1,"exibility":1,"in":4,"timing":1,"injection":3,"possi":1,"ble":1,"any":1,"time":2,"day":1,"some":1,"as":1,"disease":1,"progresses":1,"despite":1,"titration":1,"correct":1,"hyperglycemia":1,"than":1,"kg":1,"mealtime":3,"may":2,"have":1,"be":3,"added":1,"meet":1,"glycemic":1,"targets":2,"postprandial":2,"required":1,"enhance":1,"blood":1,"levels":2,"and":6,"achieve":1,"hba":1,"1c":1,"thera":1,"peutic":1,"inertia":1,"intensi":1,"fi":1,"cation":1,"therapy":2,"should":1,"avoided":1,"clinicians":1,"not":1,"familiar":1,"multiple":1,"daily":1,"referral":1,"special":1,"ist":1,"care":1,"dsmes":2,"warranted":1,"straightforward":1,"way":1,"introduce":1,"meal":2,"start":1,"short":1,"rapid":2,"acting":2,"associated":1,"largest":1,"excursion":1,"adding":1,"requires":1,"increased":1,"self":1,"monitoring":1,"adds":1,"complexity":1,"cost":1,"ther":1,"apy":1,"contrast":1},"len":212},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":24,"chunkId":"ada-easd-2022-p24-c2","text":"ion before the meal associated with the largest glucose excursion. Adding mealtime rapid-acting insulin requires increased DSMES and self-monitoring of glucose levels and adds complexity and cost to the ther- apy. In contrast to basal insulin analogs, the evidence supporting the choice of mealtime rapid-acting insulin analogs is less clear (329). Another simpler and still popular way of combining mealtime and basal insulin components is using premixed insulins. Insulin analog-based combinations have the advantage of re- sulting in fewer hypoglycemic events and weight gain than are typically ob- served with human premixed insulin (330). Finally, it needs to be reemphasized that, in all insulin-treated people with type 2 diabetes, agents associated with cardiorenal protection or weight reduction should be kept in the treatment regimen whenever possible (331). The combination of a basal insulin analog and GLP-1 RA in one injection may be a simple way to re- duce the burden and complexity of treat- ment (332). Practical Tips for Clinicians  The use of a GLP-1 RA should be con- sidered prior to initiation of insulin.  When initiating insulin, start with a basal insulin and intensify the dose in a timely fashion, titrating to achieve an individualized fasting glycemic tar- get set for every person.  When insulin is initiated, continue or- gan-protective glucose-lowering medi- cati","tf":{"329":1,"330":1,"331":1,"332":1,"ion":1,"before":1,"the":11,"meal":1,"associated":2,"with":5,"largest":1,"glucose":3,"excursion":1,"adding":1,"mealtime":3,"rapid":2,"acting":2,"insulin":12,"requires":1,"increased":1,"dsmes":1,"and":9,"self":1,"monitoring":1,"of":8,"levels":1,"adds":1,"complexity":2,"cost":1,"to":6,"ther":1,"apy":1,"in":6,"contrast":1,"basal":4,"analogs":2,"evidence":1,"supporting":1,"choice":1,"is":3,"less":1,"clear":1,"another":1,"simpler":1,"still":1,"popular":1,"way":2,"combining":1,"components":1,"using":1,"premixed":2,"insulins":1,"analog":2,"based":1,"combinations":1,"have":1,"advantage":1,"re":2,"sulting":1,"fewer":1,"hypoglycemic":1,"events":1,"weight":2,"gain":1,"than":1,"are":1,"typically":1,"ob":1,"served":1,"human":1,"finally":1,"it":1,"needs":1,"be":4,"reemphasized":1,"that":1,"all":1,"treated":1,"people":1,"type":1,"diabetes":1,"agents":1,"cardiorenal":1,"protection":1,"or":2,"reduction":1,"should":2,"kept":1,"treatment":1,"regimen":1,"whenever":1,"possible":1,"combination":1,"glp":2,"ra":2,"one":1,"injection":1,"may":1,"simple":1,"duce":1,"burden":1,"treat":1,"ment":1,"practical":1,"tips":1,"for":2,"clinicians":1,"use":1,"con":1,"sidered":1,"prior":1,"initiation":1,"when":2,"initiating":1,"start":1,"intensify":1,"dose":1,"timely":1,"fashion":1,"titrating":1,"achieve":1,"an":1,"individualized":1,"fasting":1,"glycemic":1,"tar":1,"get":1,"set":1,"every":1,"person":1,"initiated":1,"continue":1,"gan":1,"protective":1,"lowering":1,"medi":1,"cati":1},"len":215},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":24,"chunkId":"ada-easd-2022-p24-c3","text":"nsulin, start with a basal insulin and intensify the dose in a timely fashion, titrating to achieve an individualized fasting glycemic tar- get set for every person.  When insulin is initiated, continue or- gan-protective glucose-lowering medi- cations and metformin.  Refer for DSMES when initiating insulin or advancing to basal  bolus therapy. See Supplementary Fig. 3. Place of Technology The use of technology in the therapy of people with type 2 diabetes is increasing through a broad range of approaches, for example, telehealth, remote monitor- ing systems, CGM, and behavioral aids to support physical activity, meal planning and monitoring, medication-taking be- havior, mindfulness, and stress manage- ment. Evidence on the impact of these systems is variable and highly dependent on the embedding of the technology in a more comprehensive approach. Evidence for a bene fi cial impact of telehealth on achieving treatment goals in those living with type 2 diabetes is growing (333,334). During the COVID-19 pandemic, tele- health has proven to be an ef fi cient way of overseeing the treatment of people with type 2 diabetes. In particular, inter- ventions using apps as tools to support DSMES have been shown to have an im- pact on outcomes (34). For those needing insulin as part of their treatment, smart insulin pens and insulin pumps (continuous subcutane- ous insulin infusion [CS","tf":{"19":1,"34":1,"333":1,"334":1,"nsulin":1,"start":1,"with":4,"basal":2,"insulin":7,"and":7,"intensify":1,"the":8,"dose":1,"in":5,"timely":1,"fashion":1,"titrating":1,"to":6,"achieve":1,"an":3,"individualized":1,"fasting":1,"glycemic":1,"tar":1,"get":1,"set":1,"for":5,"every":1,"person":1,"when":2,"is":4,"initiated":1,"continue":1,"or":2,"gan":1,"protective":1,"glucose":1,"lowering":1,"medi":1,"cations":1,"metformin":1,"refer":1,"dsmes":2,"initiating":1,"advancing":1,"bolus":1,"therapy":2,"see":1,"supplementary":1,"fig":1,"place":1,"of":10,"technology":3,"use":1,"people":2,"type":3,"diabetes":3,"increasing":1,"through":1,"broad":1,"range":1,"approaches":1,"example":1,"telehealth":2,"remote":1,"monitor":1,"ing":1,"systems":2,"cgm":1,"behavioral":1,"aids":1,"support":2,"physical":1,"activity":1,"meal":1,"planning":1,"monitoring":1,"medication":1,"taking":1,"be":2,"havior":1,"mindfulness":1,"stress":1,"manage":1,"ment":1,"evidence":2,"on":4,"impact":2,"these":1,"variable":1,"highly":1,"dependent":1,"embedding":1,"more":1,"comprehensive":1,"approach":1,"bene":1,"fi":2,"cial":1,"achieving":1,"treatment":3,"goals":1,"those":2,"living":1,"growing":1,"during":1,"covid":1,"pandemic":1,"tele":1,"health":1,"has":1,"proven":1,"ef":1,"cient":1,"way":1,"overseeing":1,"particular":1,"inter":1,"ventions":1,"using":1,"apps":1,"as":2,"tools":1,"have":2,"been":1,"shown":1,"im":1,"pact":1,"outcomes":1,"needing":1,"part":1,"their":1,"smart":1,"pens":1,"pumps":1,"continuous":1,"subcutane":1,"ous":1,"infusion":1,"cs":1},"len":216},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":24,"chunkId":"ada-easd-2022-p24-c4","text":"lar, inter- ventions using apps as tools to support DSMES have been shown to have an im- pact on outcomes (34). For those needing insulin as part of their treatment, smart insulin pens and insulin pumps (continuous subcutane- ous insulin infusion [CSII]) are available. Speci fi c evidence on the bene fi t of smart pens in people with type 2 diabe- tes is still scarce. CSII use is associated with small improvements in HbA 1c and fewer hypoglycemic events, suggesting that CSII can be considered in people living with type 2 diabetes treated with multiple daily insulin injections and able to manage the device (71). Again, for optimal effect, this technology should be embedded in an integrated approach to type 2 diabetes therapy, speci fi cally to avoid weight gain (335). In individuals with type 2 diabetes treated with insulin, CGM, both intermit- tently scanned CGM and real-time CGM, has gained traction, with evidence that CGM results in better overall glucose con- trol as de fi ned by HbA 1c and time in range (3.9  10.0 mmol/L [70  180 mg/dL]), fewer hyperglycemic and hypoglycemic episodes, and improvements in diabetes distress (336,337). As with other wearables, for example, those collecting steps walked or monitor- ing dietary intake, medication dose ad- ministered, or sleep quality, use of CGM has also been proposed as a motivational tool for those with type 2 diabetes not o","tf":{"10":1,"34":1,"70":1,"71":1,"180":1,"335":1,"336":1,"337":1,"lar":1,"inter":1,"ventions":1,"using":1,"apps":1,"as":5,"tools":1,"to":5,"support":1,"dsmes":1,"have":2,"been":2,"shown":1,"an":2,"im":1,"pact":1,"on":2,"outcomes":1,"for":4,"those":3,"needing":1,"insulin":6,"part":1,"of":3,"their":1,"treatment":1,"smart":2,"pens":2,"and":7,"pumps":1,"continuous":1,"subcutane":1,"ous":1,"infusion":1,"csii":3,"are":1,"available":1,"speci":2,"fi":4,"evidence":2,"the":2,"bene":1,"in":8,"people":2,"with":9,"type":5,"diabe":1,"tes":1,"is":2,"still":1,"scarce":1,"use":2,"associated":1,"small":1,"improvements":2,"hba":2,"1c":2,"fewer":2,"hypoglycemic":2,"events":1,"suggesting":1,"that":2,"can":1,"be":2,"considered":1,"living":1,"diabetes":5,"treated":2,"multiple":1,"daily":1,"injections":1,"able":1,"manage":1,"device":1,"again":1,"optimal":1,"effect":1,"this":1,"technology":1,"should":1,"embedded":1,"integrated":1,"approach":1,"therapy":1,"cally":1,"avoid":1,"weight":1,"gain":1,"individuals":1,"cgm":5,"both":1,"intermit":1,"tently":1,"scanned":1,"real":1,"time":2,"has":2,"gained":1,"traction":1,"results":1,"better":1,"overall":1,"glucose":1,"con":1,"trol":1,"de":1,"ned":1,"by":1,"range":1,"mmol":1,"mg":1,"dl":1,"hyperglycemic":1,"episodes":1,"distress":1,"other":1,"wearables":1,"example":1,"collecting":1,"steps":1,"walked":1,"or":2,"monitor":1,"ing":1,"dietary":1,"intake":1,"medication":1,"dose":1,"ad":1,"ministered":1,"sleep":1,"quality":1,"also":1,"proposed":1,"motivational":1,"tool":1,"not":1},"len":226},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":24,"chunkId":"ada-easd-2022-p24-c5","text":",337). As with other wearables, for example, those collecting steps walked or monitor- ing dietary intake, medication dose ad- ministered, or sleep quality, use of CGM has also been proposed as a motivational tool for those with type 2 diabetes not on insulin therapy, but the evidence on this is modest (337). Finally, to date, no convincing evidence is available on the use of hybrid closed- loop systems speci fi cally in people with type 2 diabetes. Practical Tips for Clinicians  Technology can be useful in people with type 2 diabetes but needs to be part of a holistic plan of care and sup- ported by DSMES.  Consider CGM in people with type 2 diabetes on insulin.  Adapt the clinic/system to optimize ef- fective use of technology among peo- ple with type 2 diabetes, particularly to support behavior change through self-monitoring. See Supplementary Fig. 3. diabetesjournals.org/care Davies and Associates 2775 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"45":1,"337":2,"2026":1,"2753":1,"2775":1,"691567":1,"as":2,"with":6,"other":1,"wearables":1,"for":3,"example":1,"those":2,"collecting":1,"steps":1,"walked":1,"or":2,"monitor":1,"ing":1,"dietary":1,"intake":1,"medication":1,"dose":1,"ad":1,"ministered":1,"sleep":1,"quality":1,"use":3,"of":5,"cgm":2,"has":1,"also":1,"been":1,"proposed":1,"motivational":1,"tool":1,"type":5,"diabetes":5,"not":1,"on":5,"insulin":2,"therapy":1,"but":2,"the":3,"evidence":2,"this":1,"is":2,"modest":1,"finally":1,"to":4,"date":1,"no":1,"convincing":1,"available":1,"hybrid":1,"closed":1,"loop":1,"systems":1,"speci":1,"fi":1,"cally":1,"in":3,"people":3,"practical":1,"tips":1,"clinicians":1,"technology":2,"can":1,"be":2,"useful":1,"needs":1,"part":1,"holistic":1,"plan":1,"care":3,"and":2,"sup":1,"ported":1,"by":2,"dsmes":1,"consider":1,"adapt":1,"clinic":1,"system":1,"optimize":1,"ef":1,"fective":1,"among":1,"peo":1,"ple":1,"particularly":1,"support":1,"behavior":1,"change":1,"through":1,"self":1,"monitoring":1,"see":1,"supplementary":1,"fig":1,"diabetesjournals":2,"org":2,"davies":1,"associates":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"dci220034":1,"guest":1,"february":1},"len":166},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":25,"chunkId":"ada-easd-2022-p25-c0","text":"Working Within the System to Deliver Improved Care We are fortunate to have evidence on nu- merous effective interventions in type 2 diabetes, but translating this evidence into practice cannot rest only with front-line clinicians during individual clinic visits. The systems of care that support front-line clinicians have a signi fi cant role in improv- ing diabetes clinical management, out- comes, and experience for people living with diabetes. Front-line clinicians must in- form and drive the design of care, but the systems of care should be held account- able for implementation. Supplementary Table 2, informed by the Effective Practice and Organization of Care (EPOC) taxon- omy (338), outlines key domains and questions that must be answered to achieve the goal of better care and out- comes for people living with type 2 diabe- tes. All levels of the care delivery system have a role and responsibility in improving diabetes management. Clinic leaders have a responsibility to improve work fl ows to make it easy to provide evidence-based care and provide data to inform quality improvement efforts. Continuing education is necessary to ensure evolving evidence reaches people living with type 2 diabetes. Policy makers have a responsibility to en- sure that evidence-based interventions are available and affordable to all. Interven- tions to improve diabetes must also in- clude the he","tf":{"338":1,"working":1,"within":1,"the":8,"system":2,"to":11,"deliver":1,"improved":1,"care":8,"we":1,"are":2,"fortunate":1,"have":5,"evidence":5,"on":1,"nu":1,"merous":1,"effective":2,"interventions":2,"in":5,"type":3,"diabetes":6,"but":2,"translating":1,"this":1,"into":1,"practice":2,"cannot":1,"rest":1,"only":1,"with":4,"front":3,"line":3,"clinicians":3,"during":1,"individual":1,"clinic":2,"visits":1,"systems":2,"of":6,"that":3,"support":1,"signi":1,"fi":1,"cant":1,"role":2,"improv":1,"ing":1,"clinical":1,"management":2,"out":2,"comes":2,"and":8,"experience":1,"for":3,"people":3,"living":3,"must":3,"form":1,"drive":1,"design":1,"should":1,"be":2,"held":1,"account":1,"able":1,"implementation":1,"supplementary":1,"table":1,"informed":1,"by":1,"organization":1,"epoc":1,"taxon":1,"omy":1,"outlines":1,"key":1,"domains":1,"questions":1,"answered":1,"achieve":1,"goal":1,"better":1,"diabe":1,"tes":1,"all":2,"levels":1,"delivery":1,"responsibility":3,"improving":1,"leaders":1,"improve":2,"work":1,"fl":1,"ows":1,"make":1,"it":1,"easy":1,"provide":2,"based":2,"data":1,"inform":1,"quality":1,"improvement":1,"efforts":1,"continuing":1,"education":1,"is":1,"necessary":1,"ensure":1,"evolving":1,"reaches":1,"policy":1,"makers":1,"en":1,"sure":1,"available":1,"affordable":1,"interven":1,"tions":1,"also":1,"clude":1,"he":1},"len":216},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":25,"chunkId":"ada-easd-2022-p25-c1","text":"ensure evolving evidence reaches people living with type 2 diabetes. Policy makers have a responsibility to en- sure that evidence-based interventions are available and affordable to all. Interven- tions to improve diabetes must also in- clude the health system (including the microsystems within a system) and gov- ernmental agencies. Policy makers, to- gether with all stakeholders, should re fl ect on care delivery. How, where, and by whom is care delivered? Who coordi- nates care and the management of care processes? Practices and systems must es- tablish enhanced communication technol- ogy to improve engagement. Governance arrangements must be implemented spe- ci fi cally around accountability for health professionals, with a focus on training and evaluation of quality of practice. Finally, re fl ection is needed around implementa- tion strategies at the level of the system, facility, and individual health care workers. These principles are aligned with recom- mendations outlined in the recent Lancet Commission on diabetes (339). Practical Tips for Clinicians  Identify and incorporate continuing education activities on the manage- ment of type 2 diabetes for all mem- bers of the health care team.  Team-based care is required for inte- grated care of diabetes; this includes coordination between multiple disci- plines (diabetes care and education specialist, dietitians, psych","tf":{"339":1,"ensure":1,"evolving":1,"evidence":2,"reaches":1,"people":1,"living":1,"with":4,"type":2,"diabetes":6,"policy":2,"makers":2,"have":1,"responsibility":1,"to":5,"en":1,"sure":1,"that":1,"based":2,"interventions":1,"are":2,"available":1,"and":9,"affordable":1,"all":3,"interven":1,"tions":1,"improve":2,"must":3,"also":1,"in":2,"clude":1,"the":8,"health":4,"system":3,"including":1,"microsystems":1,"within":1,"gov":1,"ernmental":1,"agencies":1,"gether":1,"stakeholders":1,"should":1,"re":2,"fl":2,"ect":1,"on":4,"care":9,"delivery":1,"how":1,"where":1,"by":1,"whom":1,"is":3,"delivered":1,"who":1,"coordi":1,"nates":1,"management":1,"of":7,"processes":1,"practices":1,"systems":1,"es":1,"tablish":1,"enhanced":1,"communication":1,"technol":1,"ogy":1,"engagement":1,"governance":1,"arrangements":1,"be":1,"implemented":1,"spe":1,"ci":1,"fi":1,"cally":1,"around":2,"accountability":1,"for":4,"professionals":1,"focus":1,"training":1,"evaluation":1,"quality":1,"practice":1,"finally":1,"ection":1,"needed":1,"implementa":1,"tion":1,"strategies":1,"at":1,"level":1,"facility":1,"individual":1,"workers":1,"these":1,"principles":1,"aligned":1,"recom":1,"mendations":1,"outlined":1,"recent":1,"lancet":1,"commission":1,"practical":1,"tips":1,"clinicians":1,"identify":1,"incorporate":1,"continuing":1,"education":2,"activities":1,"manage":1,"ment":1,"mem":1,"bers":1,"team":2,"required":1,"inte":1,"grated":1,"this":1,"includes":1,"coordination":1,"between":1,"multiple":1,"disci":1,"plines":1,"specialist":1,"dietitians":1,"psych":1},"len":205},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":25,"chunkId":"ada-easd-2022-p25-c2","text":"- ment of type 2 diabetes for all mem- bers of the health care team.  Team-based care is required for inte- grated care of diabetes; this includes coordination between multiple disci- plines (diabetes care and education specialist, dietitians, psychologists, etc.) and often other medical specialties (pri- mary care, endocrinology, ophthalmol- ogy, nephrology, etc.).  Management of type 2 diabetes re- quires continuous quality improve- ment interventions tailored to the local setting. See Supplementary Fig. 3. Key Knowledge Gaps and a Call to Action In this 100th year since the discovery and partial puri fi cation of insulin, we should remember the remarkable speed at which this fi rst glucose-lowering medica- tion was developed and distributed as life-saving therapy for people with diabe- tes. Through our experience in the last few years with the COVID-19 pandemic, we have demonstrated how quickly many governments, industry, health care sys- tems, and academic institutions can re- spond to global health care crises. Within a year of identi fi cation of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, preventive and thera- peutic products were not only developed and tested but also administered on a massive scale. The annual global mortal- ity rate directly attributable to diabetes is approximately 1.5 million people, with 540 million people affected (34","tf":{"19":1,"34":1,"540":1,"ment":2,"of":7,"type":2,"diabetes":5,"for":3,"all":1,"mem":1,"bers":1,"the":8,"health":3,"care":7,"team":2,"based":1,"is":2,"required":1,"inte":1,"grated":1,"this":3,"includes":1,"coordination":1,"between":1,"multiple":1,"disci":1,"plines":1,"and":8,"education":1,"specialist":1,"dietitians":1,"psychologists":1,"etc":2,"often":1,"other":1,"medical":1,"specialties":1,"pri":1,"mary":1,"endocrinology":1,"ophthalmol":1,"ogy":1,"nephrology":1,"management":1,"re":2,"quires":1,"continuous":1,"quality":1,"improve":1,"interventions":1,"tailored":1,"to":4,"local":1,"setting":1,"see":1,"supplementary":1,"fig":1,"key":1,"knowledge":1,"gaps":1,"call":1,"action":1,"in":2,"100th":1,"year":2,"since":1,"discovery":1,"partial":1,"puri":1,"fi":3,"cation":2,"insulin":1,"we":2,"should":1,"remember":1,"remarkable":1,"speed":1,"at":1,"which":1,"rst":1,"glucose":1,"lowering":1,"medica":1,"tion":1,"was":1,"developed":2,"distributed":1,"as":1,"life":1,"saving":1,"therapy":1,"people":3,"with":3,"diabe":1,"tes":1,"through":1,"our":1,"experience":1,"last":1,"few":1,"years":1,"covid":1,"pandemic":1,"have":1,"demonstrated":1,"how":1,"quickly":1,"many":1,"governments":1,"industry":1,"sys":1,"tems":1,"academic":1,"institutions":1,"can":1,"spond":1,"global":2,"crises":1,"within":1,"identi":1,"severe":1,"acute":1,"respiratory":1,"syndrome":1,"coronavirus":1,"sars":1,"cov":1,"virus":1,"preventive":1,"thera":1,"peutic":1,"products":1,"were":1,"not":1,"only":1,"tested":1,"but":1,"also":1,"administered":1,"on":1,"massive":1,"scale":1,"annual":1,"mortal":1,"ity":1,"rate":1,"directly":1,"attributable":1,"approximately":1,"million":2,"affected":1},"len":209},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":25,"chunkId":"ada-easd-2022-p25-c3","text":"ive and thera- peutic products were not only developed and tested but also administered on a massive scale. The annual global mortal- ity rate directly attributable to diabetes is approximately 1.5 million people, with 540 million people affected (340,341). Although not as spectacular as the im- pact of COVID-19 on the health of soci- ety, diabetes is sure and steady in its burden, increasing in prevalence and with an increase in mortality and mor- bidity over time. Two centuries of investigation into the pathophysiology of diabetes have led to the extraordinary advances in treatment of the last two decades. As reviewed in this consensus report, encouraging healthy behaviors, DSMES, medications, devices, technologies, and organization of care all represent effective tools for the manage- ment of diabetes to reduce its morbidity and mortality. However, despite the gen- erous approach of Banting and Best in li- censing the patent for insulin for one Canadian dollar, it is not yet readily avail- able to all people with diabetes (342,343). Recent events have focused attention on the contribution of social determinants of health and a lack of equity in the delivery of care to disparate and unfavorable out- comes. Today, the major opportunities to improve diabetes outcomes in the near term come from more effective imple- mentation of best evidence through orga- nization of care at al","tf":{"19":1,"340":1,"341":1,"342":1,"343":1,"540":1,"ive":1,"and":10,"thera":1,"peutic":1,"products":1,"were":1,"not":3,"only":1,"developed":1,"tested":1,"but":1,"also":1,"administered":1,"on":3,"massive":1,"scale":1,"the":13,"annual":1,"global":1,"mortal":1,"ity":1,"rate":1,"directly":1,"attributable":1,"to":6,"diabetes":6,"is":3,"approximately":1,"million":2,"people":3,"with":3,"affected":1,"although":1,"as":3,"spectacular":1,"im":1,"pact":1,"of":14,"covid":1,"health":2,"soci":1,"ety":1,"sure":1,"steady":1,"in":8,"its":2,"burden":1,"increasing":1,"prevalence":1,"an":1,"increase":1,"mortality":2,"mor":1,"bidity":1,"over":1,"time":1,"two":2,"centuries":1,"investigation":1,"into":1,"pathophysiology":1,"have":2,"led":1,"extraordinary":1,"advances":1,"treatment":1,"last":1,"decades":1,"reviewed":1,"this":1,"consensus":1,"report":1,"encouraging":1,"healthy":1,"behaviors":1,"dsmes":1,"medications":1,"devices":1,"technologies":1,"organization":1,"care":3,"all":2,"represent":1,"effective":2,"tools":1,"for":3,"manage":1,"ment":1,"reduce":1,"morbidity":1,"however":1,"despite":1,"gen":1,"erous":1,"approach":1,"banting":1,"best":2,"li":1,"censing":1,"patent":1,"insulin":1,"one":1,"canadian":1,"dollar":1,"it":1,"yet":1,"readily":1,"avail":1,"able":1,"recent":1,"events":1,"focused":1,"attention":1,"contribution":1,"social":1,"determinants":1,"lack":1,"equity":1,"delivery":1,"disparate":1,"unfavorable":1,"out":1,"comes":1,"today":1,"major":1,"opportunities":1,"improve":1,"outcomes":1,"near":1,"term":1,"come":1,"from":1,"more":1,"imple":1,"mentation":1,"evidence":1,"through":1,"orga":1,"nization":1,"at":1,"al":1},"len":223},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":25,"chunkId":"ada-easd-2022-p25-c4","text":"ck of equity in the delivery of care to disparate and unfavorable out- comes. Today, the major opportunities to improve diabetes outcomes in the near term come from more effective imple- mentation of best evidence through orga- nization of care at all levels (national to individual practices) and from addressing social determinants of health. Every reader of this consensus report has a role to play in better implementation with a focus on equity. For providers, that could involve a focus on shared de- cision-making to improve adherence to behavioral and medication interventions as well as organizing practice to mini- mize therapeutic inertia and enhance en- gagement and support for all people with diabetes. For policy makers, health care systems, payors, and companies with marketed products or services, ensuring equitable access to minimize health dis- parities should be a priority. Broad support for basic science is nec- essary to bring about the next generation of interventions. Implementation science is an essential area for future work, par- ticularly in the context of  learning health care systems,  in which internal data are systematically integrated with published evidence to drive quality improvement (344  346). Precision medicine initiatives, whether omics-based or focused on social determinants of health, aim to optimally target interventions based on the wide hete","tf":{"344":1,"346":1,"ck":1,"of":9,"equity":2,"in":5,"the":6,"delivery":1,"care":4,"to":11,"disparate":1,"and":6,"unfavorable":1,"out":1,"comes":1,"today":1,"major":1,"opportunities":1,"improve":2,"diabetes":2,"outcomes":1,"near":1,"term":1,"come":1,"from":2,"more":1,"effective":1,"imple":1,"mentation":1,"best":1,"evidence":2,"through":1,"orga":1,"nization":1,"at":1,"all":2,"levels":1,"national":1,"individual":1,"practices":1,"addressing":1,"social":2,"determinants":2,"health":5,"every":1,"reader":1,"this":1,"consensus":1,"report":1,"has":1,"role":1,"play":1,"better":1,"implementation":2,"with":4,"focus":2,"on":4,"for":5,"providers":1,"that":1,"could":1,"involve":1,"shared":1,"de":1,"cision":1,"making":1,"adherence":1,"behavioral":1,"medication":1,"interventions":3,"as":2,"well":1,"organizing":1,"practice":1,"mini":1,"mize":1,"therapeutic":1,"inertia":1,"enhance":1,"en":1,"gagement":1,"support":2,"people":1,"policy":1,"makers":1,"systems":2,"payors":1,"companies":1,"marketed":1,"products":1,"or":2,"services":1,"ensuring":1,"equitable":1,"access":1,"minimize":1,"dis":1,"parities":1,"should":1,"be":1,"priority":1,"broad":1,"basic":1,"science":2,"is":2,"nec":1,"essary":1,"bring":1,"about":1,"next":1,"generation":1,"an":1,"essential":1,"area":1,"future":1,"work":1,"par":1,"ticularly":1,"context":1,"learning":1,"which":1,"internal":1,"data":1,"are":1,"systematically":1,"integrated":1,"published":1,"drive":1,"quality":1,"improvement":1,"precision":1,"medicine":1,"initiatives":1,"whether":1,"omics":1,"based":2,"focused":1,"aim":1,"optimally":1,"target":1,"wide":1,"hete":1},"len":210},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":25,"chunkId":"ada-easd-2022-p25-c5","text":" systematically integrated with published evidence to drive quality improvement (344  346). Precision medicine initiatives, whether omics-based or focused on social determinants of health, aim to optimally target interventions based on the wide heterogeneity of the population affected by diabetes. Precision medicine has tre- mendous but largely unrealized promise. When these efforts are driven by real- world data, causal inference study design and analysis create greater con fi dence in the implementation and evaluation of in- sights. Studies should be conducted to support the better understanding of pre- cision medicine approaches to the full spectrum of diabetes interventions, from medications to behavioral treatments and diabetes support. Several key areas where further re- search could better inform future consen- sus reports were of particular interest to the writing group. For each area, one could add the need for more precision medicine insights and a better under- standing of the full spectrum of investiga- tions that are supporting efforts to advance the fi eld from basic to imple- mentation science. With upwards of 10% of the population affected by diabetes and the enormous attendant costs, a fo- cus on individualizing care to make sure 2776 Consensus Report Diabetes Care Volume 45, November 2022 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753","tf":{"10":1,"11":1,"45":2,"344":1,"346":1,"2022":1,"2753":1,"2776":1,"systematically":1,"integrated":1,"with":2,"published":1,"evidence":1,"to":9,"drive":1,"quality":1,"improvement":1,"precision":3,"medicine":4,"initiatives":1,"whether":1,"omics":1,"based":2,"or":1,"focused":1,"on":3,"social":1,"determinants":1,"of":10,"health":1,"aim":1,"optimally":1,"target":1,"interventions":2,"the":11,"wide":1,"heterogeneity":1,"population":2,"affected":2,"by":3,"diabetes":5,"has":1,"tre":1,"mendous":1,"but":1,"largely":1,"unrealized":1,"promise":1,"when":1,"these":1,"efforts":2,"are":2,"driven":1,"real":1,"world":1,"data":1,"causal":1,"inference":1,"study":1,"design":1,"and":5,"analysis":1,"create":1,"greater":1,"con":1,"fi":2,"dence":1,"in":2,"implementation":1,"evaluation":1,"sights":1,"studies":1,"should":1,"be":1,"conducted":1,"support":2,"better":3,"understanding":1,"pre":1,"cision":1,"approaches":1,"full":2,"spectrum":2,"from":3,"medications":1,"behavioral":1,"treatments":1,"several":1,"key":1,"areas":1,"where":1,"further":1,"re":1,"search":1,"could":2,"inform":1,"future":1,"consen":1,"sus":1,"reports":1,"were":1,"particular":1,"interest":1,"writing":1,"group":1,"for":2,"each":1,"area":1,"one":1,"add":1,"need":1,"more":1,"insights":1,"under":1,"standing":1,"investiga":1,"tions":1,"that":1,"supporting":1,"advance":1,"eld":1,"basic":1,"imple":1,"mentation":1,"science":1,"upwards":1,"enormous":1,"attendant":1,"costs":1,"fo":1,"cus":1,"individualizing":1,"care":3,"make":1,"sure":1,"consensus":1,"report":1,"volume":1,"november":1,"downloaded":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":1},"len":210},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":25,"chunkId":"ada-easd-2022-p25-c6","text":" the population affected by diabetes and the enormous attendant costs, a fo- cus on individualizing care to make sure 2776 Consensus Report Diabetes Care Volume 45, November 2022 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"45":2,"2022":1,"2026":1,"2753":1,"2776":1,"691567":1,"the":2,"population":1,"affected":1,"by":2,"diabetes":2,"and":1,"enormous":1,"attendant":1,"costs":1,"fo":1,"cus":1,"on":2,"individualizing":1,"care":3,"to":1,"make":1,"sure":1,"consensus":1,"report":1,"volume":1,"november":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"dci220034":1,"guest":1,"february":1},"len":47},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":26,"chunkId":"ada-easd-2022-p26-c0","text":"that the right person is getting the right therapy at the right time while working to overcome barriers dependent on social determinants of health is essential. Regu- latory reform, more ef fi cient study con- duct and analysis, coordinated global efforts in de fi ning outcomes and data col- lection instruments, data sharing, explora- tion of new forms of health care delivery (e.g., telehealth), and increased efforts to reach underserved populations, as were made to address COVID-19, would accel- erate progress in de fi ning and implement- ing optimal approaches for diabetes care.  Study conduct. Across the spectrum from highly controlled trials to ob- servational studies, paying greater attention to subgroups, in particular vulnerable populations, is essential. Dedicated studies in young adults with type 2 diabetes, or including much larger numbers of younger adults in broader studies, are essen- tial to better understand how to mitigate their high risk of early dis- ability. As more younger adults are being treated with therapies that have been inadequately studied in pregnancy, it is essential to describe the reproductive safety of recom- mended approaches. Similarly, there have been inadequate studies of frail older people and those aged > 75 years with regard to under- standing both appropriate targets and interventions to minimize harms and maximize quality of life. Sex ","tf":{"19":1,"75":1,"that":2,"the":5,"right":3,"person":1,"is":4,"getting":1,"therapy":1,"at":1,"time":1,"while":1,"working":1,"to":10,"overcome":1,"barriers":1,"dependent":1,"on":1,"social":1,"determinants":1,"of":8,"health":2,"essential":3,"regu":1,"latory":1,"reform":1,"more":2,"ef":1,"fi":3,"cient":1,"study":2,"con":1,"duct":1,"and":7,"analysis":1,"coordinated":1,"global":1,"efforts":2,"in":6,"de":2,"ning":2,"outcomes":1,"data":2,"col":1,"lection":1,"instruments":1,"sharing":1,"explora":1,"tion":1,"new":1,"forms":1,"care":2,"delivery":1,"telehealth":1,"increased":1,"reach":1,"underserved":1,"populations":2,"as":2,"were":1,"made":1,"address":1,"covid":1,"would":1,"accel":1,"erate":1,"progress":1,"implement":1,"ing":1,"optimal":1,"approaches":2,"for":1,"diabetes":2,"conduct":1,"across":1,"spectrum":1,"from":1,"highly":1,"controlled":1,"trials":1,"ob":1,"servational":1,"studies":4,"paying":1,"greater":1,"attention":1,"subgroups":1,"particular":1,"vulnerable":1,"dedicated":1,"young":1,"adults":3,"with":3,"type":1,"or":1,"including":1,"much":1,"larger":1,"numbers":1,"younger":2,"broader":1,"are":2,"essen":1,"tial":1,"better":1,"understand":1,"how":1,"mitigate":1,"their":1,"high":1,"risk":1,"early":1,"dis":1,"ability":1,"being":1,"treated":1,"therapies":1,"have":2,"been":2,"inadequately":1,"studied":1,"pregnancy":1,"it":1,"describe":1,"reproductive":1,"safety":1,"recom":1,"mended":1,"similarly":1,"there":1,"inadequate":1,"frail":1,"older":1,"people":1,"those":1,"aged":1,"years":1,"regard":1,"under":1,"standing":1,"both":1,"appropriate":1,"targets":1,"interventions":1,"minimize":1,"harms":1,"maximize":1,"quality":1,"life":1,"sex":1},"len":214},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":26,"chunkId":"ada-easd-2022-p26-c1","text":" of recom- mended approaches. Similarly, there have been inadequate studies of frail older people and those aged > 75 years with regard to under- standing both appropriate targets and interventions to minimize harms and maximize quality of life. Sex bal- ance is another dimension where our present studies fail to be repre- sentative. Better recruitment, reten- tion, and analysis to ensure safety and effectiveness in populations his- torically underrepresented in studies and generally suffering from health inequities is a minimal fi rst step to enhance health justice by sex, race/ ethnicity, nationality, etc.  Weight management. With the emer- gence of more effective behavioral and medical therapies and novel surgical approaches for the treatment of peo- ple who are overweight with diabetes, more direct comparisons are required to better target interventions based on impact and cost-effectiveness.  Targets. Studies designed to explic- itly examine glucose-centric versus weight-centric approaches to diabetes management are needed. The impact of prioritizing early aggressive therapy to induce remission is unclear.  Cardiorenal protection. Data are re- quired to better inform when to select a GLP-1 RA and/or an SGLT2i in the setting of CVD but without HF or CKD and to fully validate the recommenda- tion for combination therapy in those at high risk who do not meet glycemic targe","tf":{"75":1,"of":7,"recom":1,"mended":1,"approaches":3,"similarly":1,"there":1,"have":1,"been":1,"inadequate":1,"studies":4,"frail":1,"older":1,"people":1,"and":11,"those":2,"aged":1,"years":1,"with":3,"regard":1,"to":12,"under":1,"standing":1,"both":1,"appropriate":1,"targets":2,"interventions":2,"minimize":1,"harms":1,"maximize":1,"quality":1,"life":1,"sex":2,"bal":1,"ance":1,"is":3,"another":1,"dimension":1,"where":1,"our":1,"present":1,"fail":1,"be":1,"repre":1,"sentative":1,"better":3,"recruitment":1,"reten":1,"tion":2,"analysis":1,"ensure":1,"safety":1,"effectiveness":2,"in":4,"populations":1,"his":1,"torically":1,"underrepresented":1,"generally":1,"suffering":1,"from":1,"health":2,"inequities":1,"minimal":1,"fi":1,"rst":1,"step":1,"enhance":1,"justice":1,"by":1,"race":1,"ethnicity":1,"nationality":1,"etc":1,"weight":2,"management":2,"the":5,"emer":1,"gence":1,"more":2,"effective":1,"behavioral":1,"medical":1,"therapies":1,"novel":1,"surgical":1,"for":2,"treatment":1,"peo":1,"ple":1,"who":2,"are":4,"overweight":1,"diabetes":2,"direct":1,"comparisons":1,"required":1,"target":1,"based":1,"on":1,"impact":2,"cost":1,"designed":1,"explic":1,"itly":1,"examine":1,"glucose":1,"centric":2,"versus":1,"needed":1,"prioritizing":1,"early":1,"aggressive":1,"therapy":2,"induce":1,"remission":1,"unclear":1,"cardiorenal":1,"protection":1,"data":1,"re":1,"quired":1,"inform":1,"when":1,"select":1,"glp":1,"ra":1,"or":2,"an":1,"sglt2i":1,"setting":1,"cvd":1,"but":1,"without":1,"hf":1,"ckd":1,"fully":1,"validate":1,"recommenda":1,"combination":1,"at":1,"high":1,"risk":1,"do":1,"not":1,"meet":1,"glycemic":1,"targe":1},"len":213},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":26,"chunkId":"ada-easd-2022-p26-c2","text":"ction. Data are re- quired to better inform when to select a GLP-1 RA and/or an SGLT2i in the setting of CVD but without HF or CKD and to fully validate the recommenda- tion for combination therapy in those at high risk who do not meet glycemic targets. As discussed, there is consider- able uncertainty about the absolute bene fi ts of GLP-1 RA and SGLT2i for CVD outcomes in those with risk fac- tors only. As a result, there is variabil- ity in the recommendations on how to de fi ne high-risk people with diabetes, to whom these disease-modifying agents should be prescribed to have the greatest bene fi t/impact. As all people with diabetes are at high risk of CVD, HF, and CKD over time, real- world evidence and cost-effectiveness studies of GLP-1 RA and SGLT2i in broad populations would help to bet- ter target interventions to have the greatest impact on outcomes.  Glucose monitoring. Further studies to understand the role and optimal im- plementation of CGM and/or episodic CGM in type 2 diabetes are needed.  Comorbidities. There are numerous studies underway to understand the role of interventions in the setting of NAFLD and cognitive impairment. NAFLD is highly prevalent, and thus understanding the impact of interven- tions on person-centered outcomes and costs is essential. Cognitive impair- ment is a major burden to people with diabetes, their families, and society; better ","tf":{"ction":1,"data":1,"are":4,"re":1,"quired":1,"to":11,"better":2,"inform":1,"when":1,"select":1,"glp":3,"ra":3,"and":12,"or":3,"an":1,"sglt2i":3,"in":7,"the":10,"setting":2,"of":8,"cvd":3,"but":1,"without":1,"hf":2,"ckd":2,"fully":1,"validate":1,"recommenda":1,"tion":1,"for":2,"combination":1,"therapy":1,"those":2,"at":2,"high":3,"risk":4,"who":1,"do":1,"not":1,"meet":1,"glycemic":1,"targets":1,"as":3,"discussed":1,"there":3,"is":5,"consider":1,"able":1,"uncertainty":1,"about":1,"absolute":1,"bene":2,"fi":3,"ts":1,"outcomes":3,"with":4,"fac":1,"tors":1,"only":1,"result":1,"variabil":1,"ity":1,"recommendations":1,"on":3,"how":1,"de":1,"ne":1,"people":3,"diabetes":4,"whom":1,"these":1,"disease":1,"modifying":1,"agents":1,"should":1,"be":1,"prescribed":1,"have":2,"greatest":2,"impact":3,"all":1,"over":1,"time":1,"real":1,"world":1,"evidence":1,"cost":1,"effectiveness":1,"studies":3,"broad":1,"populations":1,"would":1,"help":1,"bet":1,"ter":1,"target":1,"interventions":2,"glucose":1,"monitoring":1,"further":1,"understand":2,"role":2,"optimal":1,"im":1,"plementation":1,"cgm":2,"episodic":1,"type":1,"needed":1,"comorbidities":1,"numerous":1,"underway":1,"nafld":2,"cognitive":2,"impairment":1,"highly":1,"prevalent":1,"thus":1,"understanding":1,"interven":1,"tions":1,"person":1,"centered":1,"costs":1,"essential":1,"impair":1,"ment":1,"major":1,"burden":1,"their":1,"families":1,"society":1},"len":235},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":26,"chunkId":"ada-easd-2022-p26-c3","text":"ive impairment. NAFLD is highly prevalent, and thus understanding the impact of interven- tions on person-centered outcomes and costs is essential. Cognitive impair- ment is a major burden to people with diabetes, their families, and society; better understanding of the pathophys- iology and the impact of interventions is a challenging but high-reward area for investigation. There are virtually no data to inform best practice in the care of people with diabetes and ad- vanced CKD, particularly in dialysis- dependent kidney disease. Additional studies, particularly of GLP-1 RA, GIP and GLP-1 RA, and SGLT2i, will hope- fully provide new avenues to reduce mortality in this population, in which there are enormous health disparities.  Screening and prevention. Screening for diabetes and its complications and comorbidities remains inadequate. Early intervention to prevent progres- sion is also generally suboptimal. Na- tional health care systems should comprehensively assess the imple- mentation of recommendations and create incentives for effective pro- grams. To optimally target resources, additional studies may be required on natural history and subpopulations, as much of the rationale for screening is based on studies conducted deca- des ago.  Technology. Remote care, wearables, apps, and decision support aids have exploded in availability, and a clear rationale exists as to wh","tf":{"ive":1,"impairment":1,"nafld":1,"is":6,"highly":1,"prevalent":1,"and":14,"thus":1,"understanding":2,"the":6,"impact":2,"of":7,"interven":1,"tions":1,"on":3,"person":1,"centered":1,"outcomes":1,"costs":1,"essential":1,"cognitive":1,"impair":1,"ment":1,"major":1,"burden":1,"to":6,"people":2,"with":2,"diabetes":3,"their":1,"families":1,"society":1,"better":1,"pathophys":1,"iology":1,"interventions":1,"challenging":1,"but":1,"high":1,"reward":1,"area":1,"for":4,"investigation":1,"there":2,"are":2,"virtually":1,"no":1,"data":1,"inform":1,"best":1,"practice":1,"in":5,"care":3,"ad":1,"vanced":1,"ckd":1,"particularly":2,"dialysis":1,"dependent":1,"kidney":1,"disease":1,"additional":2,"studies":3,"glp":2,"ra":2,"gip":1,"sglt2i":1,"will":1,"hope":1,"fully":1,"provide":1,"new":1,"avenues":1,"reduce":1,"mortality":1,"this":1,"population":1,"which":1,"enormous":1,"health":2,"disparities":1,"screening":3,"prevention":1,"its":1,"complications":1,"comorbidities":1,"remains":1,"inadequate":1,"early":1,"intervention":1,"prevent":1,"progres":1,"sion":1,"also":1,"generally":1,"suboptimal":1,"na":1,"tional":1,"systems":1,"should":1,"comprehensively":1,"assess":1,"imple":1,"mentation":1,"recommendations":1,"create":1,"incentives":1,"effective":1,"pro":1,"grams":1,"optimally":1,"target":1,"resources":1,"may":1,"be":1,"required":1,"natural":1,"history":1,"subpopulations":1,"as":2,"much":1,"rationale":2,"based":1,"conducted":1,"deca":1,"des":1,"ago":1,"technology":1,"remote":1,"wearables":1,"apps":1,"decision":1,"support":1,"aids":1,"have":1,"exploded":1,"availability":1,"clear":1,"exists":1,"wh":1},"len":204},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":26,"chunkId":"ada-easd-2022-p26-c4","text":"history and subpopulations, as much of the rationale for screening is based on studies conducted deca- des ago.  Technology. Remote care, wearables, apps, and decision support aids have exploded in availability, and a clear rationale exists as to why they may be of bene fi t. However, their optimal application is poorly understood.  Sleep and chronotype. Poor sleep is common and clearly associated with poor outcomes. Further studies are needed to understand behavioral sleep therapy and its bene fi ts more fully as well as the bene fi ts of medication and device aids. As chronotype is poten- tially modi fi able, future research should focus on social and lifestyle factors to optimize interventional responses. Until science and medicine bring us fur- ther insights, we recommend empathic, person-centered decision-making and sup- port informed by an understanding of local resources and individual social determi- nants of health. Combined with consistent efforts to improve health behaviors (nutri- tion, activity, sleep, and self-monitoring) and to provide DSMES, these form the foundation of diabetes management. In this context, acceptance of, adherence to, and persistence with medical and behav- ioral interventions to support cardiorenal health, cardiovascular risk reduction, and attainment of glycemic and weight goals will prevent complications and optimize quality of life. We mu","tf":{"history":1,"and":18,"subpopulations":1,"as":5,"much":1,"of":9,"the":3,"rationale":2,"for":1,"screening":1,"is":4,"based":1,"on":2,"studies":2,"conducted":1,"deca":1,"des":1,"ago":1,"technology":1,"remote":1,"care":1,"wearables":1,"apps":1,"decision":2,"support":2,"aids":2,"have":1,"exploded":1,"in":2,"availability":1,"clear":1,"exists":1,"to":7,"why":1,"they":1,"may":1,"be":1,"bene":3,"fi":4,"however":1,"their":1,"optimal":1,"application":1,"poorly":1,"understood":1,"sleep":4,"chronotype":2,"poor":2,"common":1,"clearly":1,"associated":1,"with":3,"outcomes":1,"further":1,"are":1,"needed":1,"understand":1,"behavioral":1,"therapy":1,"its":1,"ts":2,"more":1,"fully":1,"well":1,"medication":1,"device":1,"poten":1,"tially":1,"modi":1,"able":1,"future":1,"research":1,"should":1,"focus":1,"social":2,"lifestyle":1,"factors":1,"optimize":2,"interventional":1,"responses":1,"until":1,"science":1,"medicine":1,"bring":1,"us":1,"fur":1,"ther":1,"insights":1,"we":2,"recommend":1,"empathic":1,"person":1,"centered":1,"making":1,"sup":1,"port":1,"informed":1,"by":1,"an":1,"understanding":1,"local":1,"resources":1,"individual":1,"determi":1,"nants":1,"health":3,"combined":1,"consistent":1,"efforts":1,"improve":1,"behaviors":1,"nutri":1,"tion":1,"activity":1,"self":1,"monitoring":1,"provide":1,"dsmes":1,"these":1,"form":1,"foundation":1,"diabetes":1,"management":1,"this":1,"context":1,"acceptance":1,"adherence":1,"persistence":1,"medical":1,"behav":1,"ioral":1,"interventions":1,"cardiorenal":1,"cardiovascular":1,"risk":1,"reduction":1,"attainment":1,"glycemic":1,"weight":1,"goals":1,"will":1,"prevent":1,"complications":1,"quality":1,"life":1,"mu":1},"len":211},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":26,"chunkId":"ada-easd-2022-p26-c5","text":"nce of, adherence to, and persistence with medical and behav- ioral interventions to support cardiorenal health, cardiovascular risk reduction, and attainment of glycemic and weight goals will prevent complications and optimize quality of life. We must establish and re- fi ne quality improvement efforts in diabe- tes care at the local level to equitably implement evidence-based interventions for the bene fi t of all people with type 2 diabetes. Acknowledgments. F. Zaccardi performed the literature searches and M. Bonar, C. Franklin, and S. Jamal assisted with the con- ception and execution of fi gures and tables; T. Yates and J. Henson supported the produc- tion and content of Fig. 2 (all from Leicester Diabetes Centre, University of Leicester and the University Hospitals of Leicester NHS Trust). T. Karagiannis (Clinical Research and Evidence-Based Medicine Unit, Aristotle Uni- versity of Thessaloniki, Thessaloniki, Greece) assisted in the credibility assessment and diabetesjournals.org/care Davies and Associates 2777 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"45":1,"2026":1,"2753":1,"2777":1,"691567":1,"nce":1,"of":9,"adherence":1,"to":3,"and":16,"persistence":1,"with":3,"medical":1,"behav":1,"ioral":1,"interventions":2,"support":1,"cardiorenal":1,"health":1,"cardiovascular":1,"risk":1,"reduction":1,"attainment":1,"glycemic":1,"weight":1,"goals":1,"will":1,"prevent":1,"complications":1,"optimize":1,"quality":2,"life":1,"we":1,"must":1,"establish":1,"re":1,"fi":3,"ne":1,"improvement":1,"efforts":1,"in":2,"diabe":1,"tes":1,"care":3,"at":1,"the":7,"local":1,"level":1,"equitably":1,"implement":1,"evidence":2,"based":2,"for":1,"bene":1,"all":2,"people":1,"type":1,"diabetes":2,"acknowledgments":1,"zaccardi":1,"performed":1,"literature":1,"searches":1,"bonar":1,"franklin":1,"jamal":1,"assisted":2,"con":1,"ception":1,"execution":1,"gures":1,"tables":1,"yates":1,"henson":1,"supported":1,"produc":1,"tion":1,"content":1,"fig":1,"from":2,"leicester":3,"centre":1,"university":2,"hospitals":1,"nhs":1,"trust":1,"karagiannis":1,"clinical":1,"research":1,"medicine":1,"unit":1,"aristotle":1,"uni":1,"versity":1,"thessaloniki":2,"greece":1,"credibility":1,"assessment":1,"diabetesjournals":2,"org":2,"davies":1,"associates":1,"downloaded":1,"http":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"february":1},"len":166},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":27,"chunkId":"ada-easd-2022-p27-c0","text":"interpretation of meta-analyses evaluating the effects of glucose-lowering medications across subgroup populations and contributed in applying GRADE guidance in the formulation of respective practice recommendations. D. Bradley (Ohio State University College of Medi- cine, Columbus, OH), P. Home (Newcastle Uni- versity, Newcastle, U.K.), M.S. Kirkman (University of North Carolina, Chapel Hill, NC), S. Dinneen (Galway University Hospitals, Gal- way, Ireland), H.W. Rodbard (Adventis Health- Care Shady Grove Medical Center, Rockville, MD), G. Sesti (Sapienza University of Rome, Rome, Italy), P. Newland-Jones (University of Southampton, Southampton, U.K.), E. Montanya (University of Barcelona, Barcelona, Spain), and M. Nauck (Medical Department I, St. Josef-Hospi- tal [Ruhr-University Bochum], Bochum, Germany) all served as invited reviewers. We acknowledge the support of N.A. El Sayed, R.R. Bannuru, M. Sar- aco, and M.I. Hill (all ADA, Arlington, VA), P. Nie- mann and N. Buckley-M  uhge (both EASD, Dusseldorf, Germany), the Committee for Clinical Affairs of the EASD, and the Professional Practice Committee of the ADA. Data Availability. Details of the search strategy and list of identi fi ed articles can be found at https://data.mendeley.com/datasets/h5rcnxpk8w/2. Funding. This activity was funded by the American Diabetes Association and the Euro- pean Association for the Study o","tf":{"interpretation":1,"of":13,"meta":1,"analyses":1,"evaluating":1,"the":11,"effects":1,"glucose":1,"lowering":1,"medications":1,"across":1,"subgroup":1,"populations":1,"and":7,"contributed":1,"in":2,"applying":1,"grade":1,"guidance":1,"formulation":1,"respective":1,"practice":2,"recommendations":1,"bradley":1,"ohio":1,"state":1,"university":7,"college":1,"medi":1,"cine":1,"columbus":1,"oh":1,"home":1,"newcastle":2,"uni":1,"versity":1,"kirkman":1,"north":1,"carolina":1,"chapel":1,"hill":2,"nc":1,"dinneen":1,"galway":1,"hospitals":1,"gal":1,"way":1,"ireland":1,"rodbard":1,"adventis":1,"health":1,"care":1,"shady":1,"grove":1,"medical":2,"center":1,"rockville":1,"md":1,"sesti":1,"sapienza":1,"rome":2,"italy":1,"newland":1,"jones":1,"southampton":2,"montanya":1,"barcelona":2,"spain":1,"nauck":1,"department":1,"st":1,"josef":1,"hospi":1,"tal":1,"ruhr":1,"bochum":2,"germany":2,"all":2,"served":1,"as":1,"invited":1,"reviewers":1,"we":1,"acknowledge":1,"support":1,"el":1,"sayed":1,"bannuru":1,"sar":1,"aco":1,"ada":2,"arlington":1,"va":1,"nie":1,"mann":1,"buckley":1,"uhge":1,"both":1,"easd":2,"dusseldorf":1,"committee":2,"for":2,"clinical":1,"affairs":1,"professional":1,"data":2,"availability":1,"details":1,"search":1,"strategy":1,"list":1,"identi":1,"fi":1,"ed":1,"articles":1,"can":1,"be":1,"found":1,"at":1,"https":1,"mendeley":1,"com":1,"datasets":1,"h5rcnxpk8w":1,"funding":1,"this":1,"activity":1,"was":1,"funded":1,"by":1,"american":1,"diabetes":1,"association":2,"euro":1,"pean":1,"study":1},"len":187},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":27,"chunkId":"ada-easd-2022-p27-c1","text":"y. Details of the search strategy and list of identi fi ed articles can be found at https://data.mendeley.com/datasets/h5rcnxpk8w/2. Funding. This activity was funded by the American Diabetes Association and the Euro- pean Association for the Study of Diabetes. Duality of Interest. M.J.D. has acted as a con- sultant, advisory board member, and speaker for Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Sano fi , an advisory board member and speaker for AstraZeneca, an advisory board member for Janssen, Lexicon, P fi zer, and ShouTi Pharma, and as a speaker for Napp Pharma- ceuticals, Novartis, and Takeda Pharmaceuticals International. Her institution has received grants from Novo Nordisk, Sano fi , Eli Lilly, Boehringer Ingelheim, AstraZeneca, and Janssen. V.R.A. has served as a consultant for Applied Therapeutics, Duke, Fractyl, Novo Nordisk, P fi zer, and Sano fi . V.R.A.  s spouse is an employee of Janssen and a former employee of Merck. V.R.A.  s employer in- stitution has received research funding for her role as investigator on clinical trials from Ap- plied Therapeutics, Medpace, Eli Lilly, Fractyl, Premier, Novo Nordisk, and Sano fi . B.S.C. is a nominating work group member of the Ameri- can Academy of Physician Assistants. R.A.G. is an advisor to Vida and Lark. J.G. is a consultant for AstraZeneca, P fi zer, Boehringer Ingelheim/ Lilly, Bayer, Sano fi , Anji, Ver","tf":{"details":1,"of":8,"the":5,"search":1,"strategy":1,"and":13,"list":1,"identi":1,"fi":9,"ed":1,"articles":1,"can":2,"be":1,"found":1,"at":1,"https":1,"data":1,"mendeley":1,"com":1,"datasets":1,"h5rcnxpk8w":1,"funding":2,"this":1,"activity":1,"was":1,"funded":1,"by":1,"american":1,"diabetes":2,"association":2,"euro":1,"pean":1,"for":8,"study":1,"duality":1,"interest":1,"has":4,"acted":1,"as":4,"con":1,"sultant":1,"advisory":3,"board":3,"member":4,"speaker":3,"boehringer":3,"ingelheim":3,"eli":3,"lilly":4,"novo":4,"nordisk":4,"sano":5,"an":4,"astrazeneca":3,"janssen":3,"lexicon":1,"zer":3,"shouti":1,"pharma":2,"napp":1,"ceuticals":1,"novartis":1,"takeda":1,"pharmaceuticals":1,"international":1,"her":2,"institution":1,"received":2,"grants":1,"from":2,"served":1,"consultant":2,"applied":1,"therapeutics":2,"duke":1,"fractyl":2,"spouse":1,"is":4,"employee":2,"former":1,"merck":1,"employer":1,"in":1,"stitution":1,"research":1,"role":1,"investigator":1,"on":1,"clinical":1,"trials":1,"ap":1,"plied":1,"medpace":1,"premier":1,"nominating":1,"work":1,"group":1,"ameri":1,"academy":1,"physician":1,"assistants":1,"advisor":1,"to":1,"vida":1,"lark":1,"bayer":1,"anji":1,"ver":1},"len":204},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":27,"chunkId":"ada-easd-2022-p27-c2","text":", and Sano fi . B.S.C. is a nominating work group member of the Ameri- can Academy of Physician Assistants. R.A.G. is an advisor to Vida and Lark. J.G. is a consultant for AstraZeneca, P fi zer, Boehringer Ingelheim/ Lilly, Bayer, Sano fi , Anji, Vertex/ICON, and Valo. She conducts research at her institution for Boehringer Ingelheim/Lilly, Merck, and Roche. N.M.M. is under a license agreement between Johns Hopkins HealthCare Solutions and Johns Hopkins University. She and the university are entitled to royalty distributions related to an online diabetes prevention program. S.E.R. par- ticipated in at least one advisory board for Bayer, Traverse, and AstraZeneca. Her employer receives industry research support from Bayer and Astra Zeneca. S.D.P. is a member of the ad- visory board for Abbott, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Hengrui Pharmaceuticals, Menarini International, Novo Nordisk, Sano fi , and Vertex. He is a partici- pant in a speaker  s bureau for AstraZeneca, Boeh- ringer Ingelheim, Eli Lilly, MSD, Novo Nordisk, Sano fi , and Takeda. His employer receives re- search funding from AstraZeneca and Boheringer Ingelheim. C.M. serves or has served on the advi- sory panel for Novo Nordisk, Sano fi , MSD, Eli Lilly, Novartis, AstraZeneca, Boehringer Ingelheim, Roche, Medtronic, ActoBio Therapeutics, P fi zer, Insulet, and Zealand Pha","tf":{"and":12,"sano":5,"fi":7,"is":6,"nominating":1,"work":1,"group":1,"member":2,"of":3,"the":4,"ameri":1,"can":1,"academy":1,"physician":1,"assistants":1,"an":2,"advisor":1,"to":3,"vida":1,"lark":1,"consultant":1,"for":6,"astrazeneca":6,"zer":2,"boehringer":4,"ingelheim":6,"lilly":5,"bayer":4,"anji":1,"vertex":2,"icon":1,"valo":1,"she":2,"conducts":1,"research":2,"at":2,"her":2,"institution":1,"merck":1,"roche":2,"under":1,"license":1,"agreement":1,"between":1,"johns":2,"hopkins":2,"healthcare":1,"solutions":1,"university":2,"are":1,"entitled":1,"royalty":1,"distributions":1,"related":1,"online":1,"diabetes":1,"prevention":1,"program":1,"par":1,"ticipated":1,"in":2,"least":1,"one":1,"advisory":1,"board":2,"traverse":1,"employer":2,"receives":2,"industry":1,"support":1,"from":2,"astra":1,"zeneca":1,"ad":1,"visory":1,"abbott":1,"applied":1,"therapeutics":2,"eli":3,"hengrui":1,"pharmaceuticals":1,"menarini":1,"international":1,"novo":3,"nordisk":3,"he":1,"partici":1,"pant":1,"speaker":1,"bureau":1,"boeh":1,"ringer":1,"msd":2,"takeda":1,"his":1,"re":1,"search":1,"funding":1,"boheringer":1,"serves":1,"or":1,"has":1,"served":1,"on":1,"advi":1,"sory":1,"panel":1,"novartis":1,"medtronic":1,"actobio":1,"insulet":1,"zealand":1,"pha":1},"len":196},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":27,"chunkId":"ada-easd-2022-p27-c3","text":"straZeneca and Boheringer Ingelheim. C.M. serves or has served on the advi- sory panel for Novo Nordisk, Sano fi , MSD, Eli Lilly, Novartis, AstraZeneca, Boehringer Ingelheim, Roche, Medtronic, ActoBio Therapeutics, P fi zer, Insulet, and Zealand Pharma. Financial compen- sation for these activities has been received by KU Leuven. KU Leuven has received research sup- port for C.M. from Medtronic, Novo Nordisk, Sa- no fi , and ActoBio Therapeutics. C.M. serves or has served on the speaker  s bureau for Novo Nor- disk, Sano fi , Eli Lilly, Boehringer Ingelheim, Astra- Zeneca, and Novartis. Financial compensation for these activities has been received by KU Leuven. G.M. is a consultant to Novo Nordisk, Fractyl, Re- cor, Keyron, and Metadeq and is on the scienti fi c board of Fractyl. P.R.  s institution has received in- dustry research funding from AstraZeneca and Novo Nordisk. Her institution has also received consultancy fees from AstraZeneca, Bayer, Boeh- ringer Ingelheim, Novo Nordisk, Gilead, and MSD and lecture fees from Sano fi , Astellas, Novo Nor- disk, Bayer, and AstraZeneca. T.T. is on the advi- sory board for Boehringer Ingelheim, AstraZeneca, Sano fi , Novo Nordisk, and Eli Lilly and in the speaker  s bureau for Boehringer Ingelheim, Astra- Zeneca, Sano fi , Novo Nordisk, Eli Lilly, MSD, Serv- ier, and Merck. A.T. has served on the advisory board for Novo Nordisk a","tf":{"strazeneca":1,"and":13,"boheringer":1,"ingelheim":6,"serves":2,"or":2,"has":8,"served":3,"on":5,"the":6,"advi":2,"sory":2,"panel":1,"for":8,"novo":10,"nordisk":8,"sano":5,"fi":8,"msd":3,"eli":4,"lilly":4,"novartis":2,"astrazeneca":5,"boehringer":4,"roche":1,"medtronic":2,"actobio":2,"therapeutics":2,"zer":1,"insulet":1,"zealand":1,"pharma":1,"financial":2,"compen":1,"sation":1,"these":2,"activities":2,"been":2,"received":5,"by":2,"ku":3,"leuven":3,"research":2,"sup":1,"port":1,"from":4,"sa":1,"no":1,"speaker":2,"bureau":2,"nor":2,"disk":2,"astra":2,"zeneca":2,"compensation":1,"is":3,"consultant":1,"to":1,"fractyl":2,"re":1,"cor":1,"keyron":1,"metadeq":1,"scienti":1,"board":3,"of":1,"institution":2,"in":2,"dustry":1,"funding":1,"her":1,"also":1,"consultancy":1,"fees":2,"bayer":2,"boeh":1,"ringer":1,"gilead":1,"lecture":1,"astellas":1,"serv":1,"ier":1,"merck":1,"advisory":1},"len":208},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":27,"chunkId":"ada-easd-2022-p27-c4","text":"ngelheim, AstraZeneca, Sano fi , Novo Nordisk, and Eli Lilly and in the speaker  s bureau for Boehringer Ingelheim, Astra- Zeneca, Sano fi , Novo Nordisk, Eli Lilly, MSD, Serv- ier, and Merck. A.T. has served on the advisory board for Novo Nordisk and Boehringer Ingel- heim, and his university has received research funding. His university also receives funding for educational and research support from Eli Lilly. J.B.B. is a paid consultant to Anji Pharmaceuticals, Boehringer Ingelheim, Eli Lilly, Fortress Biotech, Janssen, Mellitus Health, Moderna, Pendulum Ther- apeutics, Praetego, ReachMD, Stability Health, and Zealand Pharma. He is a member of the advisory board for Boehringer Ingelheim, Eli Lilly, Mellitus Health, Moderna, Novo Nordisk, Pendulum Therapeutics, Praetego, Stability Health, vTv Ther- apeutics, and Zealand Pharma. His employer re- ceives research funding from Dexcom, Eli Lilly, NovaTarg, Novo Nordisk, Sano fi , Tolerion, and vTv Therapeutics. He is an investor in Mellitus Health, Pendulum Therapeutics, and PhaseBio. Author Contributions. All authors were re- sponsible for drafting the article and revising it critically for important intellectual content. All authors approved the version to be published. References 1. Rodriguez-Gutierrez R, Gionfriddo MR, Ospina NS, et al. Shared decision making in endocrinology: present and future directions. Lancet Diabetes En","tf":{"ngelheim":1,"astrazeneca":1,"sano":3,"fi":3,"novo":5,"nordisk":5,"and":12,"eli":6,"lilly":6,"in":3,"the":5,"speaker":1,"bureau":1,"for":6,"boehringer":4,"ingelheim":3,"astra":1,"zeneca":1,"msd":1,"serv":1,"ier":1,"merck":1,"has":2,"served":1,"on":1,"advisory":2,"board":2,"ingel":1,"heim":1,"his":3,"university":2,"received":1,"research":3,"funding":3,"also":1,"receives":1,"educational":1,"support":1,"from":2,"is":3,"paid":1,"consultant":1,"to":2,"anji":1,"pharmaceuticals":1,"fortress":1,"biotech":1,"janssen":1,"mellitus":3,"health":5,"moderna":2,"pendulum":3,"ther":2,"apeutics":2,"praetego":2,"reachmd":1,"stability":2,"zealand":2,"pharma":2,"he":2,"member":1,"of":1,"therapeutics":3,"vtv":2,"employer":1,"re":2,"ceives":1,"dexcom":1,"novatarg":1,"tolerion":1,"an":1,"investor":1,"phasebio":1,"author":1,"contributions":1,"all":2,"authors":2,"were":1,"sponsible":1,"drafting":1,"article":1,"revising":1,"it":1,"critically":1,"important":1,"intellectual":1,"content":1,"approved":1,"version":1,"be":1,"published":1,"references":1,"rodriguez":1,"gutierrez":1,"gionfriddo":1,"mr":1,"ospina":1,"ns":1,"et":1,"al":1,"shared":1,"decision":1,"making":1,"endocrinology":1,"present":1,"future":1,"directions":1,"lancet":1,"diabetes":1,"en":1},"len":195},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":27,"chunkId":"ada-easd-2022-p27-c5","text":"lly for important intellectual content. All authors approved the version to be published. References 1. Rodriguez-Gutierrez R, Gionfriddo MR, Ospina NS, et al. Shared decision making in endocrinology: present and future directions. Lancet Diabetes Endocrinol 2016;4:706  716 2. Draznin B, Aroda VR, Bakris G, et al.; American Diabetes Association Professional Practice Committee. 6. Glycemic targets: Standards of Medical Care in Diabetes  2022 . Diabetes Care 2022;45(Suppl. 1):S83  S96 3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centred approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577  1596 4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015;58:429  442 5. Davies MJ, D  Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018;61:2461  2498 6. Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of hyperglycae","tf":{"45":1,"55":1,"58":1,"61":1,"429":1,"442":1,"706":1,"716":1,"1577":1,"1596":1,"2012":1,"2015":2,"2016":1,"2018":2,"2019":1,"2022":2,"2461":1,"2498":1,"lly":1,"for":4,"important":1,"intellectual":1,"content":1,"all":1,"authors":1,"approved":1,"the":10,"version":1,"to":3,"be":1,"published":1,"references":1,"rodriguez":1,"gutierrez":1,"gionfriddo":1,"mr":1,"ospina":1,"ns":1,"et":6,"al":6,"shared":1,"decision":1,"making":1,"in":5,"endocrinology":1,"present":1,"and":4,"future":1,"directions":1,"lancet":1,"diabetes":13,"endocrinol":1,"draznin":1,"aroda":1,"vr":1,"bakris":1,"american":4,"association":7,"professional":1,"practice":1,"committee":1,"glycemic":1,"targets":1,"standards":1,"of":10,"medical":1,"care":2,"suppl":1,"s83":1,"s96":1,"inzucchi":2,"se":2,"bergenstal":2,"rm":2,"buse":3,"jb":3,"management":4,"hyperglycaemia":3,"type":3,"patient":2,"centred":2,"approach":2,"position":2,"statement":2,"ada":2,"european":3,"study":3,"easd":2,"diabetologia":3,"update":2,"davies":1,"mj":1,"alessio":1,"da":1,"fradkin":1,"consensus":1,"report":1,"by":1,"wexler":1,"dj":1,"tsapas":1,"hyperglycae":1},"len":196},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":27,"chunkId":"ada-easd-2022-p27-c6","text":"tes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018;61:2461  2498 6. Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2020;63:221  228 7. Schandelmaier S, Briel M, Varadhan R, et al. Development of the instrument to assess the credibility of effect modi fi cation analyses (ICEMAN) in randomized controlled trials and meta-analyses. CMAJ 2020;192:E901  E906 8. Sun X, Ioannidis JPA, Agoritsas T, Alba AC, Guyatt G. How to use a subgroup analysis: users  guide to the medical literature. JAMA 2014;311: 405  411 9. Andrews J, Guyatt G, Oxman AD, et al. GRADE guidelines: 14. Going from evidence to recommendations: the signi fi cance and presentation of recommendations. J Clin Epidemiol 2013;66:719  725 10. Santesso N, Glenton C, Dahm P, et al.; GRADE Working Group. GRADE guidelines 26: informative statements to communicate the fi ndings of systematic reviews of interventions. J Clin Epidemiol 2020;119:126  135 11. Sun S, Hisland L, Grenet G et al. Reappraisal of the ef fi cacy of intensive glycaemic control on microvascular complications in patients with type 2 diabetes: a meta-analysi","tf":{"10":1,"11":1,"14":1,"26":1,"61":1,"63":1,"66":1,"119":1,"126":1,"135":1,"192":1,"221":1,"228":1,"311":1,"405":1,"411":1,"719":1,"725":1,"2013":1,"2014":1,"2018":3,"2019":1,"2020":3,"2461":1,"2498":1,"tes":1,"consensus":2,"report":2,"by":2,"the":12,"american":2,"diabetes":6,"association":4,"ada":2,"and":4,"european":2,"for":2,"study":2,"of":10,"easd":2,"diabetologia":2,"buse":1,"jb":1,"wexler":1,"dj":1,"tsapas":1,"et":5,"al":5,"update":1,"to":6,"management":1,"hyperglycaemia":1,"in":3,"type":2,"schandelmaier":1,"briel":1,"varadhan":1,"development":1,"instrument":1,"assess":1,"credibility":1,"effect":1,"modi":1,"fi":4,"cation":1,"analyses":2,"iceman":1,"randomized":1,"controlled":1,"trials":1,"meta":2,"cmaj":1,"e901":1,"e906":1,"sun":2,"ioannidis":1,"jpa":1,"agoritsas":1,"alba":1,"ac":1,"guyatt":2,"how":1,"use":1,"subgroup":1,"analysis":1,"users":1,"guide":1,"medical":1,"literature":1,"jama":1,"andrews":1,"oxman":1,"ad":1,"grade":3,"guidelines":2,"going":1,"from":1,"evidence":1,"recommendations":2,"signi":1,"cance":1,"presentation":1,"clin":2,"epidemiol":2,"santesso":1,"glenton":1,"dahm":1,"working":1,"group":1,"informative":1,"statements":1,"communicate":1,"ndings":1,"systematic":1,"reviews":1,"interventions":1,"hisland":1,"grenet":1,"reappraisal":1,"ef":1,"cacy":1,"intensive":1,"glycaemic":1,"control":1,"on":1,"microvascular":1,"complications":1,"patients":1,"with":1,"analysi":1},"len":204},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":27,"chunkId":"ada-easd-2022-p27-c7","text":"ystematic reviews of interventions. J Clin Epidemiol 2020;119:126  135 11. Sun S, Hisland L, Grenet G et al. Reappraisal of the ef fi cacy of intensive glycaemic control on microvascular complications in patients with type 2 diabetes: a meta-analysis of randomised control- trials.Therapie 2021;77:413  423 12. Agrawal L, Azad N, Bahn GD, et al.; VADT Study Group. Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetologia 2018;61:295  299 13. Lind M, Imberg H, Coleman RL, Nerman O, Holman RR. Historical HbA 1c values may explain the type 2 diabetes legacy effect: UKPDS 88. Diabetes Care 2021;44:2231  2237 14. Riddle MC, Gerstein HC, Holman RR, et al. A1C targets should be personalized to maximize bene fi ts while limiting risks. Diabetes Care 2018;41:1121  1124 15. Sargeant JA, Brady EM, Zaccardi F, et al. Adults with early-onset type 2 diabetes (aged 18-39 years) are severely underrepresented in diabetes clinical research trials. Diabetologia 2020;63:1516  1520 16. American Diabetes Association Professional Practice Committee; Draznin B, Aroda VR, Bakris G, et al. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes  2022 . Diabetes Care 2022;45(Suppl. 1):S125  S143 17. Crabtree T, Ogendo JJ, Vinogradova Y, Gordon J, Idris I. Intensive glycemic control and macrovascu","tf":{"11":1,"12":1,"13":1,"14":1,"15":1,"16":1,"17":1,"18":1,"39":1,"41":1,"44":1,"45":1,"61":1,"63":1,"77":1,"88":1,"119":1,"126":1,"135":1,"295":1,"299":1,"413":1,"423":1,"1121":1,"1124":1,"1516":1,"1520":1,"2018":2,"2020":2,"2021":2,"2022":2,"2231":1,"2237":1,"ystematic":1,"reviews":1,"of":6,"interventions":1,"clin":1,"epidemiol":1,"sun":1,"hisland":1,"grenet":1,"et":5,"al":5,"reappraisal":1,"the":3,"ef":1,"fi":2,"cacy":1,"intensive":3,"glycaemic":2,"control":4,"on":2,"microvascular":1,"complications":1,"in":4,"patients":1,"with":2,"type":3,"diabetes":10,"meta":1,"analysis":1,"randomised":1,"trials":2,"therapie":1,"agrawal":1,"azad":1,"bahn":1,"gd":1,"vadt":2,"study":1,"group":1,"long":1,"term":1,"follow":1,"up":1,"renal":1,"outcomes":1,"veterans":1,"affairs":1,"trial":1,"diabetologia":2,"lind":1,"imberg":1,"coleman":1,"rl":1,"nerman":1,"holman":2,"rr":2,"historical":1,"hba":1,"1c":1,"values":1,"may":1,"explain":1,"legacy":1,"effect":1,"ukpds":1,"care":4,"riddle":1,"mc":1,"gerstein":1,"hc":1,"a1c":1,"targets":1,"should":1,"be":1,"personalized":1,"to":2,"maximize":1,"bene":1,"ts":1,"while":1,"limiting":1,"risks":1,"sargeant":1,"ja":1,"brady":1,"em":1,"zaccardi":1,"adults":1,"early":1,"onset":1,"aged":1,"years":1,"are":1,"severely":1,"underrepresented":1,"clinical":1,"research":1,"american":1,"association":1,"professional":1,"practice":1,"committee":1,"draznin":1,"aroda":1,"vr":1,"bakris":1,"pharmacologic":1,"approaches":1,"glycemic":2,"treatment":1,"standards":1,"medical":1,"suppl":1,"s125":1,"s143":1,"crabtree":1,"ogendo":1,"jj":1,"vinogradova":1,"gordon":1,"idris":1,"and":1,"macrovascu":1},"len":208},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":27,"chunkId":"ada-easd-2022-p27-c8","text":"t al. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes  2022 . Diabetes Care 2022;45(Suppl. 1):S125  S143 17. Crabtree T, Ogendo JJ, Vinogradova Y, Gordon J, Idris I. Intensive glycemic control and macrovascular, microvascular, hypoglycemia complications and mortality in older (age $ 60years) or frail adults with type 2 diabetes: a systematic review and meta-analysis from randomized controlled trial and observation studies. Expert Rev Endocrinol Metab 2022;17: 255  267 2778 Consensus Report Diabetes Care Volume 45, November 2022 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":3,"45":3,"255":1,"267":1,"2022":4,"2026":1,"2753":1,"2778":1,"691567":1,"al":1,"pharmacologic":1,"approaches":1,"to":1,"glycemic":2,"treatment":1,"standards":1,"of":1,"medical":1,"care":4,"in":2,"diabetes":4,"suppl":1,"s125":1,"s143":1,"crabtree":1,"ogendo":1,"jj":1,"vinogradova":1,"gordon":1,"idris":1,"intensive":1,"control":1,"and":4,"macrovascular":1,"microvascular":1,"hypoglycemia":1,"complications":1,"mortality":1,"older":1,"age":1,"60years":1,"or":1,"frail":1,"adults":1,"with":1,"type":1,"systematic":1,"review":1,"meta":1,"analysis":1,"from":2,"randomized":1,"controlled":1,"trial":1,"observation":1,"studies":1,"expert":1,"rev":1,"endocrinol":1,"metab":1,"consensus":1,"report":1,"volume":1,"november":1,"downloaded":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"february":1},"len":96},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":28,"chunkId":"ada-easd-2022-p28-c0","text":"18. Dickinson JK, Guzman SJ, Maryniuk MD, et al. The use of language in diabetes care and education. Diabetes Care 2017;40:1790  1799 19. Powers MA, Bardsley JK, Cypress M, et al. Diabetes self-management education and support in adults with type 2 diabetes: a consensus report of the American Diabetes Association, the Association of Diabetes Care & Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association. Diabetes Care 2020;43:1636  1649 20. Davis J, Fischl AH, Beck J, et al. 2022 National standards for diabetes self-management education and support. Diabetes Care 2022;45:484  494 21. National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. Recommendations. NICE guideline [NG28]. London, U.K., National Institute for Health and Care Excellence, 2022. Accessed 4 June 2022. Available from www.nice.org.uk/guidance/ng28/chapter/ Recommendations#patient-education 22. Draznin B, Aroda VR, Bakris G, et al.; American Diabetes Association Professional Practice Committee. 5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes  2022 . Diabetes Care 2022;45(Suppl. 1):S60  S82 23. Department of Health and Diabetes UK. Structured pat","tf":{"18":1,"19":1,"20":1,"21":1,"22":1,"23":1,"40":1,"43":1,"45":2,"484":1,"494":1,"1636":1,"1649":1,"1790":1,"1799":1,"2017":1,"2020":1,"2022":6,"dickinson":1,"jk":2,"guzman":1,"sj":1,"maryniuk":1,"md":1,"et":4,"al":4,"the":8,"use":1,"of":9,"language":1,"in":4,"diabetes":14,"care":9,"and":9,"education":5,"powers":1,"ma":1,"bardsley":1,"cypress":1,"self":2,"management":3,"support":2,"adults":2,"with":1,"type":2,"consensus":1,"report":1,"american":6,"association":5,"specialists":1,"academy":3,"nutrition":1,"dietetics":1,"family":1,"physicians":1,"pas":1,"nurse":1,"practitioners":1,"pharmacists":1,"davis":1,"fischl":1,"ah":1,"beck":1,"national":3,"standards":2,"for":3,"institute":2,"health":4,"excellence":2,"recommendations":2,"nice":2,"guideline":1,"ng28":2,"london":1,"accessed":1,"june":1,"available":1,"from":1,"www":1,"org":1,"uk":2,"guidance":1,"chapter":1,"patient":1,"draznin":1,"aroda":1,"vr":1,"bakris":1,"professional":1,"practice":1,"committee":1,"facilitating":1,"behavior":1,"change":1,"well":1,"being":1,"to":1,"improve":1,"outcomes":1,"medical":1,"suppl":1,"s60":1,"s82":1,"department":1,"structured":1,"pat":1},"len":201},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":28,"chunkId":"ada-easd-2022-p28-c1","text":"fessional Practice Committee. 5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes  2022 . Diabetes Care 2022;45(Suppl. 1):S60  S82 23. Department of Health and Diabetes UK. Structured patient education in diabetes: report from the Patient Education Working Group. London, U.K., Department of Health and Diabetes UK, 2005. Accessed 5 August 2022. Available from www.diabetes.org.uk/resources-s3/2017-11/ structuredpatiented.pdf 24. National Institute for Health and Clinical Excellence. Diabetes in adults. Quality statements 2 and 3. Quality standard [QS6]. London, U.K., National Institute for Health and Clinical Excellence, 2016. Accessed 18 August 2022. Available from www.nice.org.uk/guidance/qs6 25. Chrvala CA, Sherr D, Lipman RD. Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control. Patient Educ Couns 2016;99: 926  943 26. Pillay J, Armstrong MJ, Butalia S, et al. Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis. Ann Intern Med 2015;163:848  860 27. Zhao FF, Suhonen R, Koskinen S, Leino-Kilpi H. Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. J Adv Nurs 2017; 73:812  833 28. Odgers-","tf":{"11":1,"18":1,"23":1,"24":1,"25":1,"26":1,"27":1,"28":1,"45":1,"73":1,"99":1,"163":1,"812":1,"833":1,"848":1,"860":1,"926":1,"943":1,"2005":1,"2015":1,"2016":2,"2017":2,"2022":4,"fessional":1,"practice":1,"committee":1,"facilitating":1,"behavior":1,"change":1,"and":8,"well":1,"being":1,"to":1,"improve":1,"health":5,"outcomes":1,"standards":1,"of":5,"medical":1,"care":2,"in":3,"diabetes":11,"suppl":1,"s60":1,"s82":1,"department":2,"uk":4,"structured":1,"patient":3,"education":3,"report":1,"from":3,"the":2,"working":1,"group":1,"london":2,"accessed":2,"august":2,"available":2,"www":2,"org":2,"resources":1,"s3":1,"structuredpatiented":1,"pdf":1,"national":2,"institute":2,"for":4,"clinical":2,"excellence":2,"adults":2,"quality":2,"statements":1,"standard":1,"qs6":2,"nice":1,"guidance":1,"chrvala":1,"ca":1,"sherr":1,"lipman":1,"rd":1,"self":2,"management":2,"with":2,"type":3,"mellitus":2,"systematic":3,"review":3,"effect":1,"on":2,"glycemic":1,"control":1,"educ":1,"couns":1,"pillay":1,"armstrong":1,"mj":1,"butalia":1,"et":1,"al":1,"behavioral":1,"programs":1,"network":1,"meta":2,"analysis":2,"ann":1,"intern":1,"med":1,"zhao":1,"ff":1,"suhonen":1,"koskinen":1,"leino":1,"kilpi":1,"theory":1,"based":1,"educational":1,"interventions":1,"patients":1,"randomized":1,"controlled":1,"trials":1,"adv":1,"nurs":1,"odgers":1},"len":199},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":28,"chunkId":"ada-easd-2022-p28-c2","text":". Zhao FF, Suhonen R, Koskinen S, Leino-Kilpi H. Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. J Adv Nurs 2017; 73:812  833 28. Odgers-Jewell K, Ball LE, Kelly JT, Isenring EA, Reidlinger DP, Thomas R. Effectiveness of group- based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression. Diabet Med 2017;34:1027  1039 29. He X, Li J, Wang B, et al. Diabetes self- management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis. Endocrine 2017;55: 712  731 30. Chatterjee S, Davies MJ, Heller S, Speight J, Snoek FJ, Khunti K. Diabetes structured self- management education programmes: a narrative review and current innovations. Lancet Diabetes Endocrinol 2018;6:130  142 31. Captieux M, Pearce G, Parke HL, et al. Supported self-management for people with type 2 diabetes: a meta-review of quantitative systematic reviews. BMJ Open 2018;8:e024262 32. Lindekilde N, Scheuer SH, Rutters F, et al. Prevalence of type 2 diabetes in psychiatric disorders: an umbrella review with meta-analysis of 245 observational studies from 32 systematic reviews. Diabetologia 2022;65:440  456 33. Dening J, Islam SMS, George E, Maddison R. Web-based interventions for ","tf":{"28":1,"29":1,"30":1,"31":1,"32":2,"33":1,"34":1,"55":1,"65":1,"73":1,"130":1,"142":1,"245":1,"440":1,"456":1,"712":1,"731":1,"812":1,"833":1,"1027":1,"1039":1,"2017":3,"2018":2,"2022":1,"zhao":1,"ff":1,"suhonen":1,"koskinen":1,"leino":1,"kilpi":1,"theory":1,"based":3,"self":5,"management":5,"educational":1,"interventions":2,"on":1,"patients":2,"with":5,"type":5,"diabetes":8,"systematic":5,"review":6,"and":4,"meta":6,"analysis":3,"of":6,"randomized":1,"controlled":1,"trials":1,"adv":1,"nurs":1,"odgers":1,"jewell":1,"ball":1,"le":1,"kelly":1,"jt":1,"isenring":1,"ea":1,"reidlinger":1,"dp":1,"thomas":1,"effectiveness":1,"group":1,"education":3,"for":3,"individuals":1,"analyses":1,"regression":1,"diabet":1,"med":1,"he":1,"li":1,"wang":1,"et":3,"al":3,"reduces":1,"risk":1,"all":1,"cause":1,"mortality":1,"in":2,"endocrine":1,"chatterjee":1,"davies":1,"mj":1,"heller":1,"speight":1,"snoek":1,"fj":1,"khunti":1,"structured":1,"programmes":1,"narrative":1,"current":1,"innovations":1,"lancet":1,"endocrinol":1,"captieux":1,"pearce":1,"parke":1,"hl":1,"supported":1,"people":1,"quantitative":1,"reviews":2,"bmj":1,"open":1,"e024262":1,"lindekilde":1,"scheuer":1,"sh":1,"rutters":1,"prevalence":1,"psychiatric":1,"disorders":1,"an":1,"umbrella":1,"observational":1,"studies":1,"from":1,"diabetologia":1,"dening":1,"islam":1,"sms":1,"george":1,"maddison":1,"web":1},"len":194},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":28,"chunkId":"ada-easd-2022-p28-c3","text":"nce of type 2 diabetes in psychiatric disorders: an umbrella review with meta-analysis of 245 observational studies from 32 systematic reviews. Diabetologia 2022;65:440  456 33. Dening J, Islam SMS, George E, Maddison R. Web-based interventions for dietary behavior in adults with type 2 diabetes: systematic review of randomized controlled trials. J Med Internet Res 2020;22:e16437 34. Nkhoma DE, Soko CJ, Banda KJ, Green fi eld D, Li Y-CJ, Iqbal U. Impact of DSMES app interventions on medication adherence in type 2 diabetes mellitus: systematic review and meta-analysis. BMJ Health Care Inform 2021;28:e100291 35. Omar MA, Hasan S, Palaian S, Mahameed S. The impact of a self-management educational program coordinated through WhatsApp on diabetes control. Pharm Pract (Granada) 2020; 18:1841 36. Quinn LM, Davies MJ, Northern A, et al. Use of MyDesmond digital education programme to support self-management in people with type 2 diabetes during the COVID-19 pandemic. Diabet Med 2021;38:e14469 37. Gershkowitz BD, Hillert CJ, Crotty BH. Digital coaching strategies to facilitate behavioral change in type 2 diabetes: a systematic review. J Clin Endocrinol Metab 2021;106:e1513  e1520 38. Lee MK, Lee DY, Ahn HY, Park CY. A novel user utility score for diabetes management using tailored mobile coaching: secondary analysis of a randomized controlled trial. JMIR Mhealth Uhealth 2021;9:e17573 ","tf":{"18":1,"19":1,"22":1,"28":1,"32":1,"33":1,"34":1,"35":1,"36":1,"37":1,"38":2,"65":1,"106":1,"245":1,"440":1,"456":1,"1841":1,"2020":2,"2021":4,"2022":1,"nce":1,"of":7,"type":5,"diabetes":7,"in":5,"psychiatric":1,"disorders":1,"an":1,"umbrella":1,"review":4,"with":3,"meta":2,"analysis":3,"observational":1,"studies":1,"from":1,"systematic":4,"reviews":1,"diabetologia":1,"dening":1,"islam":1,"sms":1,"george":1,"maddison":1,"web":1,"based":1,"interventions":2,"for":2,"dietary":1,"behavior":1,"adults":1,"randomized":2,"controlled":2,"trials":1,"med":2,"internet":1,"res":1,"e16437":1,"nkhoma":1,"de":1,"soko":1,"cj":3,"banda":1,"kj":1,"green":1,"fi":1,"eld":1,"li":1,"iqbal":1,"impact":2,"dsmes":1,"app":1,"on":2,"medication":1,"adherence":1,"mellitus":1,"and":1,"bmj":1,"health":1,"care":1,"inform":1,"e100291":1,"omar":1,"ma":1,"hasan":1,"palaian":1,"mahameed":1,"the":2,"self":2,"management":3,"educational":1,"program":1,"coordinated":1,"through":1,"whatsapp":1,"control":1,"pharm":1,"pract":1,"granada":1,"quinn":1,"lm":1,"davies":1,"mj":1,"northern":1,"et":1,"al":1,"use":1,"mydesmond":1,"digital":2,"education":1,"programme":1,"to":2,"support":1,"people":1,"during":1,"covid":1,"pandemic":1,"diabet":1,"e14469":1,"gershkowitz":1,"bd":1,"hillert":1,"crotty":1,"bh":1,"coaching":2,"strategies":1,"facilitate":1,"behavioral":1,"change":1,"clin":1,"endocrinol":1,"metab":1,"e1513":1,"e1520":1,"lee":2,"mk":1,"dy":1,"ahn":1,"hy":1,"park":1,"cy":1,"novel":1,"user":1,"utility":1,"score":1,"using":1,"tailored":1,"mobile":1,"secondary":1,"trial":1,"jmir":1,"mhealth":1,"uhealth":1,"e17573":1},"len":207},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":28,"chunkId":"ada-easd-2022-p28-c4","text":"n Endocrinol Metab 2021;106:e1513  e1520 38. Lee MK, Lee DY, Ahn HY, Park CY. A novel user utility score for diabetes management using tailored mobile coaching: secondary analysis of a randomized controlled trial. JMIR Mhealth Uhealth 2021;9:e17573 39. Ahlqvist E, Storm P, K  ar  aj  am  aki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 2018;6:361  369 40. Pigeyre M, Hess S, Gomez MF, et al. Validation of the classi fi cation for type 2 diabetes into fi ve subgroups: a report from the ORIGIN trial. Diabetologia 2022;65:206  215 41. American Diabetes Association Professional Practice Committee. 1. Improving care and promoting health in populations: Standards of Medical Care in Diabetes  2022 . Diabetes Care 2022;45(Suppl. 1):S8  S16 42. Kunneman M, Montori VM, Castaneda- Guarderas A, Hess EP. What is shared decision making? (And what it is not). Acad Emerg Med 2016;23:1320  1324 43. Breslin M, Mullan RJ, Montori VM. The design of a decision aid about diabetes medications for use during the consultation with patients with type 2 diabetes. Patient Educ Couns 2008;73: 465  472 44. Mullan RJ, Montori VM, Shah ND, et al. The diabetes mellitus medication choice decision aid: a randomized trial. Arch Intern Med 2009;169: 1560  1568 45. Stacey D, L \u0013 egar \u0013 e ","tf":{"23":1,"38":1,"39":1,"40":1,"41":1,"42":1,"43":1,"44":1,"45":2,"65":1,"73":1,"106":1,"169":1,"206":1,"215":1,"361":1,"369":1,"465":1,"472":1,"1320":1,"1324":1,"1560":1,"1568":1,"2008":1,"2009":1,"2016":1,"2018":1,"2021":2,"2022":3,"endocrinol":2,"metab":1,"e1513":1,"e1520":1,"lee":2,"mk":1,"dy":1,"ahn":1,"hy":1,"park":1,"cy":1,"novel":2,"user":1,"utility":1,"score":1,"for":3,"diabetes":10,"management":1,"using":1,"tailored":1,"mobile":1,"coaching":1,"secondary":1,"analysis":2,"of":6,"randomized":2,"controlled":1,"trial":3,"jmir":1,"mhealth":1,"uhealth":1,"e17573":1,"ahlqvist":1,"storm":1,"ar":1,"aj":1,"am":1,"aki":1,"et":3,"al":3,"subgroups":2,"adult":1,"onset":1,"and":3,"their":1,"association":2,"with":3,"outcomes":1,"data":1,"driven":1,"cluster":1,"six":1,"variables":1,"lancet":1,"pigeyre":1,"hess":2,"gomez":1,"mf":1,"validation":1,"the":5,"classi":1,"fi":2,"cation":1,"type":2,"into":1,"ve":1,"report":1,"from":1,"origin":1,"diabetologia":1,"american":1,"professional":1,"practice":1,"committee":1,"improving":1,"care":3,"promoting":1,"health":1,"in":2,"populations":1,"standards":1,"medical":1,"suppl":1,"s8":1,"s16":1,"kunneman":1,"montori":3,"vm":3,"castaneda":1,"guarderas":1,"ep":1,"what":2,"is":2,"shared":1,"decision":3,"making":1,"it":1,"not":1,"acad":1,"emerg":1,"med":2,"breslin":1,"mullan":2,"rj":2,"design":1,"aid":2,"about":1,"medications":1,"use":1,"during":1,"consultation":1,"patients":1,"patient":1,"educ":1,"couns":1,"shah":1,"nd":1,"mellitus":1,"medication":1,"choice":1,"arch":1,"intern":1,"stacey":1,"egar":1},"len":212},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":28,"chunkId":"ada-easd-2022-p28-c5","text":"atients with type 2 diabetes. Patient Educ Couns 2008;73: 465  472 44. Mullan RJ, Montori VM, Shah ND, et al. The diabetes mellitus medication choice decision aid: a randomized trial. Arch Intern Med 2009;169: 1560  1568 45. Stacey D, L \u0013 egar \u0013 e F, Lewis K et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2017;4:CD001431 46. Haire-Joshu D, Hill-Briggs F. The next generation of diabetes translation: a path to health equity. Annu Rev Public Health 2019;40:391  410 47. Hill-Briggs F, Adler NE, Berkowitz SA, et al. Social determinants of health and diabetes: a scienti fi c review. Diabetes Care 2020;44:258  279 48. Hill-Briggs F, Ephraim PL, Vrany EA, et al. Social determinants of health, race, and diabetes population health improvement: Black/African Americans as a population exemplar. Curr Diab Rep 2022;22:117  128 49. Young-Hyman D, de Groot M, Hill-Briggs F, Gonzalez JS, Hood K, Peyrot M. Psychosocial care for people with diabetes: a position statement of the American Diabetes Association. Diabetes Care 2016;39:2126  2140 50. Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet 2022;399:394  405 51. Riddle MC, Cefalu WT, Evans PH, et al. Consensus report: de fi nition and interpretation of remission in type 2 dia","tf":{"22":1,"39":1,"40":1,"44":2,"45":1,"46":1,"47":1,"48":1,"49":1,"50":1,"51":1,"73":1,"117":1,"128":1,"169":1,"258":1,"279":1,"391":1,"394":1,"399":1,"405":1,"410":1,"465":1,"472":1,"1560":1,"1568":1,"2008":1,"2009":1,"2016":1,"2017":1,"2019":1,"2020":1,"2022":2,"2126":1,"2140":1,"atients":1,"with":2,"type":3,"diabetes":10,"patient":1,"educ":1,"couns":1,"mullan":1,"rj":1,"montori":1,"vm":1,"shah":1,"nd":1,"et":5,"al":5,"the":4,"mellitus":1,"medication":1,"choice":1,"decision":2,"aid":1,"randomized":1,"trial":1,"arch":1,"intern":1,"med":1,"stacey":1,"egar":1,"lewis":1,"aids":1,"for":3,"people":2,"facing":1,"health":6,"treatment":2,"or":1,"screening":1,"decisions":1,"cochrane":1,"database":1,"syst":1,"rev":2,"cd001431":1,"haire":1,"joshu":1,"hill":4,"briggs":4,"next":1,"generation":1,"of":5,"translation":1,"path":1,"to":2,"equity":1,"annu":1,"public":1,"adler":1,"ne":1,"berkowitz":1,"sa":1,"social":2,"determinants":2,"and":3,"scienti":1,"fi":2,"review":1,"care":3,"ephraim":1,"pl":1,"vrany":1,"ea":1,"race":1,"population":2,"improvement":1,"black":1,"african":1,"americans":1,"as":2,"exemplar":1,"curr":1,"diab":1,"rep":1,"young":1,"hyman":1,"de":2,"groot":1,"gonzalez":1,"js":1,"hood":1,"peyrot":1,"psychosocial":1,"position":1,"statement":1,"american":1,"association":1,"lingvay":1,"sumithran":1,"cohen":1,"rv":1,"le":1,"roux":1,"cw":1,"obesity":1,"management":1,"primary":1,"goal":1,"time":1,"reframe":1,"conversation":1,"lancet":1,"riddle":1,"mc":1,"cefalu":1,"wt":1,"evans":1,"ph":1,"consensus":1,"report":1,"nition":1,"interpretation":1,"remission":1,"in":1,"dia":1},"len":215},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":28,"chunkId":"ada-easd-2022-p28-c6","text":"W. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet 2022;399:394  405 51. Riddle MC, Cefalu WT, Evans PH, et al. Consensus report: de fi nition and interpretation of remission in type 2 diabetes. Diabetes Care 2021;44:2438  2444 52. American Diabetes Association Professional Practice Committee. 2. Classi fi cation and diagnosis of diabetes: Standards of Medical Care in Diabetes  2022 . Diabetes Care 2022;45(Suppl. 1): S17  S38 53. Draznin B, Aroda VR, Bakris G, et al.; American Diabetes Association Professional Practice Committee. 7. Diabetes technology: Standards of Medical Care in Diabetes  2022 . Diabetes Care 2022;45(Suppl. 1):S97  S112 54. Mannucci E, Antenore A, Giorgino F, Scavini M. Effects of structured versus unstructured self- monitoring of blood glucose on glucose control in patients with non-insulin-treated type 2 diabetes: a meta-analysis of randomized controlled trials. J Diabetes Sci Technol 2018;12:183  189 55. Young LA, Buse JB, Weaver MA, et al.; Monitor Trial Group. Glucose self-monitoring in non-insulin-treated patients with type 2 diabetes in primary care settings: a randomized trial. JAMA Intern Med 2017;177:920  929 56. National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. Overview. NICE guideline [NG28]. London, U.K., National Institute for Health and","tf":{"12":1,"44":1,"45":2,"51":1,"52":1,"53":1,"54":1,"55":1,"56":1,"177":1,"183":1,"189":1,"394":1,"399":1,"405":1,"920":1,"929":1,"2017":1,"2018":1,"2021":1,"2022":5,"2438":1,"2444":1,"obesity":1,"management":2,"as":1,"primary":2,"treatment":1,"goal":1,"for":3,"type":5,"diabetes":15,"time":1,"to":1,"reframe":1,"the":1,"conversation":1,"lancet":1,"riddle":1,"mc":1,"cefalu":1,"wt":1,"evans":1,"ph":1,"et":3,"al":3,"consensus":1,"report":1,"de":1,"fi":2,"nition":1,"and":4,"interpretation":1,"of":7,"remission":1,"in":7,"care":7,"american":2,"association":2,"professional":2,"practice":2,"committee":2,"classi":1,"cation":1,"diagnosis":1,"standards":2,"medical":2,"suppl":2,"s17":1,"s38":1,"draznin":1,"aroda":1,"vr":1,"bakris":1,"technology":1,"s97":1,"s112":1,"mannucci":1,"antenore":1,"giorgino":1,"scavini":1,"effects":1,"structured":1,"versus":1,"unstructured":1,"self":2,"monitoring":2,"blood":1,"glucose":3,"on":1,"control":1,"patients":2,"with":2,"non":2,"insulin":2,"treated":2,"meta":1,"analysis":1,"randomized":2,"controlled":1,"trials":1,"sci":1,"technol":1,"young":1,"la":1,"buse":1,"jb":1,"weaver":1,"ma":1,"monitor":1,"trial":2,"group":1,"settings":1,"jama":1,"intern":1,"med":1,"national":2,"institute":2,"health":2,"excellence":1,"adults":1,"overview":1,"nice":1,"guideline":1,"ng28":1,"london":1},"len":201},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":28,"chunkId":"ada-easd-2022-p28-c7","text":"imary care settings: a randomized trial. JAMA Intern Med 2017;177:920  929 56. National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. Overview. NICE guideline [NG28]. London, U.K., National Institute for Health and Clinical Excellence. Accessed 28 July 2022. Available from www.nice.org.uk/guidance/ng28 57. Lu J, Ma X, Zhou J, et al. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. Diabetes Care 2018;41:2370  2376 58. Egede LE, Gebregziabher M, Echols C, Lynch CP. Longitudinal effects of medication nonadherence on glycemic control. Ann Pharmacother 2014;48: 562  570 59. Huber CA, Reich O. Medication adherence in patients with diabetes mellitus: does physician drug dispensing enhance quality of care? Evidence from a large health claims database in Switzerland. Patient Prefer Adherence 2016;10: 1803  1809 60. Iglay K, Cartier SE, Rosen VM, et al. Meta- analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes. Curr Med Res Opin 2015;31:1283  1296 61. McGovern A, Tippu Z, Hinton W, Munro N, Whyte M, de Lusignan S. Comparison of medication adherence and persistence in type 2 diabetes: A diabetesjournals.org/care Davies and Associates 2779 Downloaded from http://diabetesjournals.org/care/article","tf":{"10":1,"28":1,"31":1,"41":1,"48":1,"56":1,"57":1,"58":1,"59":1,"60":1,"61":1,"177":1,"562":1,"570":1,"920":1,"929":1,"1283":1,"1296":1,"1803":1,"1809":1,"2014":1,"2015":1,"2016":1,"2017":1,"2018":1,"2022":1,"2370":1,"2376":1,"2779":1,"imary":1,"care":6,"settings":1,"randomized":1,"trial":1,"jama":1,"intern":1,"med":2,"national":2,"institute":2,"for":2,"health":3,"and":5,"excellence":2,"type":4,"diabetes":6,"in":7,"adults":1,"management":1,"overview":1,"nice":2,"guideline":1,"ng28":2,"london":1,"clinical":1,"accessed":1,"july":1,"available":1,"from":3,"www":1,"org":3,"uk":1,"guidance":1,"lu":1,"ma":1,"zhou":1,"et":2,"al":2,"association":1,"of":6,"time":1,"range":1,"as":1,"assessed":1,"by":1,"continuous":1,"glucose":1,"monitoring":1,"with":2,"diabetic":1,"retinopathy":1,"egede":1,"le":1,"gebregziabher":1,"echols":1,"lynch":1,"cp":1,"longitudinal":1,"effects":1,"medication":4,"nonadherence":1,"on":1,"glycemic":1,"control":1,"ann":1,"pharmacother":1,"huber":1,"ca":1,"reich":1,"adherence":4,"patients":1,"mellitus":1,"does":1,"physician":1,"drug":1,"dispensing":1,"enhance":1,"quality":1,"evidence":1,"large":1,"claims":1,"database":1,"switzerland":1,"patient":1,"prefer":1,"iglay":1,"cartier":1,"se":1,"rosen":1,"vm":1,"meta":1,"analysis":1,"studies":1,"examining":1,"persistence":2,"discontinuation":1,"oral":1,"antihyperglycemic":1,"agents":1,"curr":1,"res":1,"opin":1,"mcgovern":1,"tippu":1,"hinton":1,"munro":1,"whyte":1,"de":1,"lusignan":1,"comparison":1,"diabetesjournals":2,"davies":1,"associates":1,"downloaded":1,"http":1,"article":1},"len":197},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":28,"chunkId":"ada-easd-2022-p28-c8","text":"61. McGovern A, Tippu Z, Hinton W, Munro N, Whyte M, de Lusignan S. Comparison of medication adherence and persistence in type 2 diabetes: A diabetesjournals.org/care Davies and Associates 2779 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"45":1,"61":1,"2026":1,"2753":1,"2779":1,"691567":1,"mcgovern":1,"tippu":1,"hinton":1,"munro":1,"whyte":1,"de":1,"lusignan":1,"comparison":1,"of":1,"medication":1,"adherence":1,"and":2,"persistence":1,"in":1,"type":1,"diabetes":1,"diabetesjournals":2,"org":2,"care":2,"davies":1,"associates":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"february":1},"len":44},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":29,"chunkId":"ada-easd-2022-p29-c0","text":"systematic review and meta-analysis. Diabetes Obes Metab 2018;20:1040  1043 62. Khunti K, Seidu S, Kunutsor S, Davies M. Association between adherence to pharmacotherapy and outcomes in type 2 diabetes: a meta-analysis. Diabetes Care 2017;40:1588  1596 63. Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence 2016;10:1299  1307 64. Konstantinou P, Kassianos AP, Georgiou G, et al. Barriers, facilitators, and interventions for medication adherence across chronic conditions with the highest non-adherence rates: a scoping review with recommendations for intervention development. Transl Behav Med 2020;10:1390  1398 65. Lasalvia P, Barahona-Correa JE, Romero- Alvernia DM, et al. Pen devices for insulin self- administration compared with needle and vial: systematic review of the literature and meta- analysis. J Diabetes Sci Technol 2016;10:959  966 66. Khunti K, Davies MJ. Clinical inertia  time to reappraise the terminology? Prim Care Diabetes 2017;11:105  106 67. Furler J, O  Neal D, Speight J, et al. Supporting insulin initiation in type 2 diabetes in primary care: results of the Stepping Up pragmatic cluster randomised controlled clinical trial. BMJ 2017;356:j783 68. Manski-Nankervis JA, Furler J, O  Neal D, Ginnivan L, Thuraisingam S, Blackberry I. Overcoming clinical i","tf":{"10":3,"11":1,"20":1,"40":1,"62":1,"63":1,"64":1,"65":1,"66":1,"67":1,"68":1,"105":1,"106":1,"356":1,"959":1,"966":1,"1040":1,"1043":1,"1299":1,"1307":1,"1390":1,"1398":1,"1588":1,"1596":1,"2016":2,"2017":3,"2018":1,"2020":1,"systematic":2,"review":3,"and":6,"meta":3,"analysis":3,"diabetes":7,"obes":1,"metab":1,"khunti":2,"seidu":1,"kunutsor":1,"davies":2,"association":1,"between":1,"adherence":5,"to":2,"pharmacotherapy":1,"outcomes":1,"in":4,"type":3,"care":3,"polonsky":1,"wh":1,"henry":1,"rr":1,"poor":1,"medication":2,"recognizing":1,"the":6,"scope":1,"of":3,"problem":1,"its":1,"key":1,"contributors":1,"patient":1,"prefer":1,"konstantinou":1,"kassianos":1,"ap":1,"georgiou":1,"et":3,"al":3,"barriers":1,"facilitators":1,"interventions":1,"for":3,"across":1,"chronic":1,"conditions":1,"with":3,"highest":1,"non":1,"rates":1,"scoping":1,"recommendations":1,"intervention":1,"development":1,"transl":1,"behav":1,"med":1,"lasalvia":1,"barahona":1,"correa":1,"je":1,"romero":1,"alvernia":1,"dm":1,"pen":1,"devices":1,"insulin":2,"self":1,"administration":1,"compared":1,"needle":1,"vial":1,"literature":1,"sci":1,"technol":1,"mj":1,"clinical":3,"inertia":1,"time":1,"reappraise":1,"terminology":1,"prim":1,"furler":2,"neal":2,"speight":1,"supporting":1,"initiation":1,"primary":1,"results":1,"stepping":1,"up":1,"pragmatic":1,"cluster":1,"randomised":1,"controlled":1,"trial":1,"bmj":1,"j783":1,"manski":1,"nankervis":1,"ja":1,"ginnivan":1,"thuraisingam":1,"blackberry":1,"overcoming":1},"len":195},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":29,"chunkId":"ada-easd-2022-p29-c1","text":"on in type 2 diabetes in primary care: results of the Stepping Up pragmatic cluster randomised controlled clinical trial. BMJ 2017;356:j783 68. Manski-Nankervis JA, Furler J, O  Neal D, Ginnivan L, Thuraisingam S, Blackberry I. Overcoming clinical inertia in insulin initiation in primary care for patients with type 2 diabetes: 24-month follow-up of the Stepping Up cluster randomised controlled trial. Prim Care Diabetes 2017;11:474  481 69. Tabesh M, Magliano DJ, Koye DN, Shaw JE. The effect of nurse prescribers on glycaemic control in type 2 diabetes: a systematic review and meta-analysis. Int J Nurs Stud 2018;78:37  43 70. Murphy ME, Byrne M, Galvin R, Boland F, Fahey T, Smith SM. Improving risk factor management for patients with poorly controlled type 2 diabetes: a systematic review of healthcare interventions in primary care and community settings. BMJ Open 2017;7:e015135 71. American Diabetes Association. Introduction: Standards of Medical Care in Diabetes  2022 . Diabetes Care 2022;45(Suppl. 1):S1  S2 72. Sainsbury E, Kizirian NV, Partridge SR, Gill T, Colagiuri S, Gibson AA. Effect of dietary carbohydrate restriction on glycemic control in adults with diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract 2018;139: 239  252 73. Snorgaard O, Poulsen GM, Andersen HK, Astrup A. Systematic review and meta-analysis of dietary carbohydrate restriction i","tf":{"11":1,"24":1,"37":1,"43":1,"45":1,"68":1,"69":1,"70":1,"71":1,"72":1,"73":1,"78":1,"139":1,"239":1,"252":1,"356":1,"474":1,"481":1,"2017":3,"2018":2,"2022":2,"on":3,"in":8,"type":4,"diabetes":10,"primary":3,"care":6,"results":1,"of":7,"the":3,"stepping":2,"up":3,"pragmatic":1,"cluster":2,"randomised":2,"controlled":3,"clinical":2,"trial":2,"bmj":2,"j783":1,"manski":1,"nankervis":1,"ja":1,"furler":1,"neal":1,"ginnivan":1,"thuraisingam":1,"blackberry":1,"overcoming":1,"inertia":1,"insulin":1,"initiation":1,"for":2,"patients":2,"with":3,"month":1,"follow":1,"prim":1,"tabesh":1,"magliano":1,"dj":1,"koye":1,"dn":1,"shaw":1,"je":1,"effect":2,"nurse":1,"prescribers":1,"glycaemic":1,"control":2,"systematic":4,"review":4,"and":4,"meta":3,"analysis":3,"int":1,"nurs":1,"stud":1,"murphy":1,"me":1,"byrne":1,"galvin":1,"boland":1,"fahey":1,"smith":1,"sm":1,"improving":1,"risk":1,"factor":1,"management":1,"poorly":1,"healthcare":1,"interventions":1,"community":1,"settings":1,"open":1,"e015135":1,"american":1,"association":1,"introduction":1,"standards":1,"medical":1,"suppl":1,"s1":1,"s2":1,"sainsbury":1,"kizirian":1,"nv":1,"partridge":1,"sr":1,"gill":1,"colagiuri":1,"gibson":1,"aa":1,"dietary":2,"carbohydrate":2,"restriction":2,"glycemic":1,"adults":1,"res":1,"clin":1,"pract":1,"snorgaard":1,"poulsen":1,"gm":1,"andersen":1,"hk":1,"astrup":1},"len":200},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":29,"chunkId":"ada-easd-2022-p29-c2","text":"glycemic control in adults with diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract 2018;139: 239  252 73. Snorgaard O, Poulsen GM, Andersen HK, Astrup A. Systematic review and meta-analysis of dietary carbohydrate restriction in patients with type 2 diabetes. BMJ Open Diabetes Res Care 2017;5:e000354 74. van Zuuren EJ, Fedorowicz Z, Kuijpers T, Pijl H. Effects of low-carbohydrate- compared with low-fat-diet interventions on metabolic control in people with type 2 diabetes: a systematic review including GRADE assessments. Am J Clin Nutr 2018;108:300  331 75. Schwingshackl L, Chaimani A, Hoffmann G, Schwedhelm C, Boeing H. A network meta-analysis on the comparative ef fi cacy of different dietary approaches on glycaemic control in patients with type 2 diabetes mellitus. Eur J Epidemiol 2018;33: 157  170 76. Mart \u0013  nez-Gonz \u0013 alez MA, Gea A, Ruiz-Canela M. The Mediterranean diet and cardiovascular health. Circ Res 2019;124:779  798 77. Estruch R, Ros E, Salas-Salvad \u0013 o J, et al.; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med 2018;378:e34 78. Papamichou D, Panagiotakos DB, Itsiopoulos C. Dietary patterns and management of type 2 diabetes: a systematic review of randomised clinical trials. Nutr Metab Cardiovasc Dis 2019;29: 531  543 79. ","tf":{"29":1,"33":1,"73":1,"74":1,"75":1,"76":1,"77":1,"78":1,"79":1,"108":1,"124":1,"139":1,"157":1,"170":1,"239":1,"252":1,"300":1,"331":1,"378":1,"531":1,"543":1,"779":1,"798":1,"2017":1,"2018":4,"2019":2,"glycemic":1,"control":3,"in":4,"adults":1,"with":7,"diabetes":7,"systematic":4,"review":4,"and":4,"meta":3,"analysis":3,"res":3,"clin":2,"pract":1,"snorgaard":1,"poulsen":1,"gm":1,"andersen":1,"hk":1,"astrup":1,"of":6,"dietary":3,"carbohydrate":2,"restriction":1,"patients":2,"type":4,"bmj":1,"open":1,"care":1,"e000354":1,"van":1,"zuuren":1,"ej":1,"fedorowicz":1,"kuijpers":1,"pijl":1,"effects":1,"low":2,"compared":1,"fat":1,"diet":3,"interventions":1,"on":3,"metabolic":1,"people":1,"including":1,"grade":1,"assessments":1,"am":1,"nutr":2,"schwingshackl":1,"chaimani":1,"hoffmann":1,"schwedhelm":1,"boeing":1,"network":1,"the":2,"comparative":1,"ef":1,"fi":1,"cacy":1,"different":1,"approaches":1,"glycaemic":1,"mellitus":1,"eur":1,"epidemiol":1,"mart":1,"nez":1,"gonz":1,"alez":1,"ma":1,"gea":1,"ruiz":1,"canela":1,"mediterranean":2,"cardiovascular":2,"health":1,"circ":1,"estruch":1,"ros":1,"salas":1,"salvad":1,"et":1,"al":1,"predimed":1,"study":1,"investigators":1,"primary":1,"prevention":1,"disease":1,"supplemented":1,"extra":1,"virgin":1,"olive":1,"oil":1,"or":1,"nuts":1,"engl":1,"med":1,"e34":1,"papamichou":1,"panagiotakos":1,"db":1,"itsiopoulos":1,"patterns":1,"management":1,"randomised":1,"clinical":1,"trials":1,"metab":1,"cardiovasc":1,"dis":1},"len":197},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":29,"chunkId":"ada-easd-2022-p29-c3","text":"in olive oil or nuts. N Engl J Med 2018;378:e34 78. Papamichou D, Panagiotakos DB, Itsiopoulos C. Dietary patterns and management of type 2 diabetes: a systematic review of randomised clinical trials. Nutr Metab Cardiovasc Dis 2019;29: 531  543 79. Wang X, Li Q, Liu Y, Jiang H, Chen W. Intermittent fasting versus continuous energy- restricted diet for patients with type 2 diabetes mellitus and metabolic syndrome for glycemic control: a systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 2021;179:109003 80. Carter S, Clifton PM, Keogh JB. Effect of intermittent compared with continuous energy restricted diet on glycemic control in patients with type 2 diabetes: a randomized noninferiority trial. JAMA Netw Open 2018;1:e180756 81. Carter S, Clifton PM, Keogh JB. The effect of intermittent compared with continuous energy restriction on glycaemic control in patients with type 2 diabetes: 24-month follow-up of a randomised noninferiority trial. Diabetes Res Clin Pract 2019;151:11  19 82. Corley BT, Carroll RW, Hall RM, Weatherall M, Parry-Strong A, Krebs JD. Intermittent fasting in type 2 diabetes mellitus and the risk of hypoglycaemia: a randomized controlled trial. Diabet Med 2018;35:588  594 83. O  Neil PM, Miller-Kovach K, Tuerk PW, et al. Randomized controlled trial of a nationally available weight control program tailored for adults ","tf":{"11":1,"19":1,"24":1,"29":1,"35":1,"78":1,"79":1,"80":1,"81":1,"82":1,"83":1,"151":1,"179":1,"378":1,"531":1,"543":1,"588":1,"594":1,"2018":3,"2019":2,"2021":1,"109003":1,"in":4,"olive":1,"oil":1,"or":1,"nuts":1,"engl":1,"med":2,"e34":1,"papamichou":1,"panagiotakos":1,"db":1,"itsiopoulos":1,"dietary":1,"patterns":1,"and":4,"management":1,"of":8,"type":5,"diabetes":7,"systematic":2,"review":2,"randomised":2,"clinical":1,"trials":2,"nutr":1,"metab":1,"cardiovasc":1,"dis":1,"wang":1,"li":1,"liu":1,"jiang":1,"chen":1,"intermittent":4,"fasting":2,"versus":1,"continuous":3,"energy":3,"restricted":2,"diet":2,"for":3,"patients":3,"with":5,"mellitus":2,"metabolic":1,"syndrome":1,"glycemic":2,"control":4,"meta":1,"analysis":1,"randomized":4,"controlled":3,"res":2,"clin":2,"pract":2,"carter":2,"clifton":2,"pm":3,"keogh":2,"jb":2,"effect":2,"compared":2,"on":2,"noninferiority":2,"trial":4,"jama":1,"netw":1,"open":1,"e180756":1,"the":2,"restriction":1,"glycaemic":1,"month":1,"follow":1,"up":1,"corley":1,"bt":1,"carroll":1,"rw":1,"hall":1,"rm":1,"weatherall":1,"parry":1,"strong":1,"krebs":1,"jd":1,"risk":1,"hypoglycaemia":1,"diabet":1,"neil":1,"miller":1,"kovach":1,"tuerk":1,"pw":1,"et":1,"al":1,"nationally":1,"available":1,"weight":1,"program":1,"tailored":1,"adults":1},"len":200},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":29,"chunkId":"ada-easd-2022-p29-c4","text":"s mellitus and the risk of hypoglycaemia: a randomized controlled trial. Diabet Med 2018;35:588  594 83. O  Neil PM, Miller-Kovach K, Tuerk PW, et al. Randomized controlled trial of a nationally available weight control program tailored for adults with type 2 diabetes. Obesity (Silver Spring) 2016;24:2269  2277 84. Mottalib A, Salsberg V, Mohd-Yusof BN, et al. Effects of nutrition therapy on HbA 1c and cardiovascular disease risk factors in overweight and obese patients with type 2 diabetes. Nutr J 2018;17:42 85. Chee WSS, Gilcharan Singh HK, Hamdy O, et al. Structured lifestyle intervention based on a trans-cultural diabetes-speci fi c nutrition algorithm (tDNA) in individuals with type 2 diabetes: a randomized controlled trial. BMJ Open Diabetes Res Care 2017;5:e000384 86. Mohd Yusof BN, Hasbullah FY, Mohd Shahar AS, et al. Changes in dietary intake improve glycemic control following a structured nutrition therapy during Ramadan in individuals with type 2 diabetes. Clin Nutr ESPEN 2021;46:314  324 87. Mohd Yusof BN, Wan Zukiman WZHH, Abu Zaid Z, et al. Comparison of structured nutrition therapy for Ramadan with standard care in type 2 diabetes patients. Nutrients 2020;12:E813 88. Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster- randomised trial. Lancet 2018;391:541  551 89. Lean ME","tf":{"12":1,"17":1,"24":1,"35":1,"42":1,"46":1,"83":1,"84":1,"85":1,"86":1,"87":1,"88":1,"89":1,"314":1,"324":1,"391":1,"541":1,"551":1,"588":1,"594":1,"2016":1,"2017":1,"2018":3,"2020":1,"2021":1,"2269":1,"2277":1,"mellitus":1,"and":3,"the":1,"risk":2,"of":5,"hypoglycaemia":1,"randomized":3,"controlled":3,"trial":4,"diabet":1,"med":1,"neil":1,"pm":1,"miller":1,"kovach":1,"tuerk":1,"pw":1,"et":6,"al":6,"nationally":1,"available":1,"weight":2,"control":2,"program":1,"tailored":1,"for":3,"adults":1,"with":5,"type":6,"diabetes":8,"obesity":1,"silver":1,"spring":1,"mottalib":1,"salsberg":1,"mohd":4,"yusof":3,"bn":3,"effects":1,"nutrition":4,"therapy":3,"on":2,"hba":1,"1c":1,"cardiovascular":1,"disease":1,"factors":1,"in":5,"overweight":1,"obese":1,"patients":2,"nutr":2,"chee":1,"wss":1,"gilcharan":1,"singh":1,"hk":1,"hamdy":1,"structured":3,"lifestyle":1,"intervention":1,"based":1,"trans":1,"cultural":1,"speci":1,"fi":1,"algorithm":1,"tdna":1,"individuals":2,"bmj":1,"open":2,"res":1,"care":3,"e000384":1,"hasbullah":1,"fy":1,"shahar":1,"as":1,"changes":1,"dietary":1,"intake":1,"improve":1,"glycemic":1,"following":1,"during":1,"ramadan":2,"clin":1,"espen":1,"wan":1,"zukiman":1,"wzhh":1,"abu":1,"zaid":1,"comparison":1,"standard":1,"nutrients":1,"e813":1,"lean":2,"me":2,"leslie":1,"ws":1,"barnes":1,"ac":1,"primary":1,"led":1,"management":1,"remission":1,"direct":1,"an":1,"label":1,"cluster":1,"randomised":1,"lancet":1},"len":214},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":29,"chunkId":"ada-easd-2022-p29-c5","text":"n type 2 diabetes patients. Nutrients 2020;12:E813 88. Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster- randomised trial. Lancet 2018;391:541  551 89. Lean MEJ, Leslie WS, Barnes AC, et al. Durability of a primary care-led weight- management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol 2019;7:344  355 90. Look AHEAD Research Group. Does lifestyle intervention improve health of adults with overweight/obesity and type 2 diabetes? Findings from the Look AHEAD randomized trial. Obesity (Silver Spring) 2021;29:1246  1258 91. Houston DK, Neiberg RH, Miller ME, et al. Physical function following a long-term lifestyle intervention among middle aged and older adults with type 2 diabetes: the Look AHEAD study. J Gerontol A Biol Sci Med Sci 2018;73:1552  1559 92. Garvey WT. Long-term health bene fi ts of intensive lifestyle intervention in the Look AHEAD study. Obesity (Silver Spring) 2021;29:1242  1243 93. Wing RR, Bolin P, Brancati FL, et al.; Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369:145  154 94. Gregg EW, Jakicic JM, Blackburn G, et al.; Look AHEAD Research Group. Association of the magnitude of weight loss and","tf":{"12":1,"29":2,"73":1,"88":1,"89":1,"90":1,"91":1,"92":1,"93":1,"94":1,"145":1,"154":1,"344":1,"355":1,"369":1,"391":1,"541":1,"551":1,"1242":1,"1243":1,"1246":1,"1258":1,"1552":1,"1559":1,"2013":1,"2018":2,"2019":1,"2020":1,"2021":2,"type":6,"diabetes":7,"patients":1,"nutrients":1,"e813":1,"lean":2,"me":2,"leslie":2,"ws":2,"barnes":2,"ac":2,"et":5,"al":5,"primary":2,"care":2,"led":2,"weight":3,"management":2,"for":2,"remission":2,"of":9,"direct":2,"an":1,"open":2,"label":2,"cluster":2,"randomised":2,"trial":3,"lancet":2,"mej":1,"durability":1,"intervention":5,"year":1,"results":1,"the":5,"endocrinol":1,"look":6,"ahead":6,"research":3,"group":3,"does":1,"lifestyle":4,"improve":1,"health":2,"adults":2,"with":2,"overweight":1,"obesity":3,"and":3,"findings":1,"from":1,"randomized":1,"silver":2,"spring":2,"houston":1,"dk":1,"neiberg":1,"rh":1,"miller":1,"physical":1,"function":1,"following":1,"long":2,"term":2,"among":1,"middle":1,"aged":1,"older":1,"study":2,"gerontol":1,"biol":1,"sci":2,"med":2,"garvey":1,"wt":1,"bene":1,"fi":1,"ts":1,"intensive":2,"in":2,"wing":1,"rr":1,"bolin":1,"brancati":1,"fl":1,"cardiovascular":1,"effects":1,"engl":1,"gregg":1,"ew":1,"jakicic":1,"jm":1,"blackburn":1,"association":1,"magnitude":1,"loss":1},"len":218},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":29,"chunkId":"ada-easd-2022-p29-c6","text":"D Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369:145  154 94. Gregg EW, Jakicic JM, Blackburn G, et al.; Look AHEAD Research Group. Association of the magnitude of weight loss and changes in physical fi tness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2016;4:913  921 95. Wing RR, Bray GA, Cassidy-Begay M, et al.; Look AHEAD Research Group. Effects of intensive lifestyle intervention on all-cause mortality in older adults with type 2 diabetes and overweight/ obesity: results from the Look AHEAD study. Diabetes Care 2022;45:dc211805 96. American Diabetes Association. 4. Compre- hensive medical evaluation and assessment of comorbidities: Standards of Medical Care in Diabetes  2021 . Diabetes Care 2021;44(Suppl. 1): S40  S52 97. Lee SWH, Ng KY, Chin WK. The impact of sleep amount and sleep quality on glycemic control in type 2 diabetes: a systematic review and meta-analysis. Sleep Med Rev 2017;31: 91  101 98. Schipper SBJ, Van Veen MM, Elders PJM, et al. Sleep disorders in people with type 2 diabetes and associated health outcomes: a review of the literature. Diabetologia 2021;64: 2367  2377 99. Navarro DJ, Alpert PT, Cross C. The impact of shift work on diabete","tf":{"31":1,"44":1,"45":1,"64":1,"91":1,"94":1,"95":1,"96":1,"97":1,"98":1,"99":1,"101":1,"145":1,"154":1,"369":1,"913":1,"921":1,"2013":1,"2016":1,"2017":1,"2021":3,"2022":1,"2367":1,"2377":1,"research":3,"group":3,"cardiovascular":2,"effects":2,"of":10,"intensive":2,"lifestyle":2,"intervention":2,"in":7,"type":5,"diabetes":10,"engl":1,"med":2,"gregg":1,"ew":1,"jakicic":1,"jm":1,"blackburn":1,"et":3,"al":3,"look":4,"ahead":4,"association":2,"the":6,"magnitude":1,"weight":1,"loss":1,"and":6,"changes":1,"physical":1,"fi":1,"tness":1,"with":4,"long":1,"term":1,"disease":1,"outcomes":2,"overweight":2,"or":1,"obese":1,"people":2,"post":1,"hoc":1,"analysis":2,"randomised":1,"clinical":1,"trial":1,"lancet":1,"endocrinol":1,"wing":1,"rr":1,"bray":1,"ga":1,"cassidy":1,"begay":1,"on":3,"all":1,"cause":1,"mortality":1,"older":1,"adults":1,"obesity":1,"results":1,"from":1,"study":1,"care":3,"dc211805":1,"american":1,"compre":1,"hensive":1,"medical":2,"evaluation":1,"assessment":1,"comorbidities":1,"standards":1,"suppl":1,"s40":1,"s52":1,"lee":1,"swh":1,"ng":1,"ky":1,"chin":1,"wk":1,"impact":2,"sleep":4,"amount":1,"quality":1,"glycemic":1,"control":1,"systematic":1,"review":2,"meta":1,"rev":1,"schipper":1,"sbj":1,"van":1,"veen":1,"mm":1,"elders":1,"pjm":1,"disorders":1,"associated":1,"health":1,"literature":1,"diabetologia":1,"navarro":1,"dj":1,"alpert":1,"pt":1,"cross":1,"shift":1,"work":1,"diabete":1},"len":216},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":29,"chunkId":"ada-easd-2022-p29-c7","text":" SBJ, Van Veen MM, Elders PJM, et al. Sleep disorders in people with type 2 diabetes and associated health outcomes: a review of the literature. Diabetologia 2021;64: 2367  2377 99. Navarro DJ, Alpert PT, Cross C. The impact of shift work on diabetes self-management activities. J Dr Nurs Pract 2019;12:66  72 100. Henson J, Rowlands AV, Baldry E, et al.; CODEC Investigators. Physical behaviors and chronotype in people with type 2 diabetes. BMJ Open Diabetes Res Care 2020;8:e001375 101. Kanaley JA, Colberg SR, Corcoran MH, et al. Exercise/physical activity in individuals with type 2 diabetes: a consensus statement from the American College of Sports Medicine. Med Sci Sports Exerc 2022;54:353  368 102. Bull FC, Al-Ansari SS, Biddle S, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med 2020;54:1451  1462 103. Homer AR, Taylor FC, Dempsey PC, et al. Frequency of interruptions to sitting time: bene fi ts for postprandial metabolism in type 2 diabetes. Diabetes Care 2021;44:1254  1263 104. Dempsey PC, Larsen RN, Sethi P, et al. Bene fi ts for type 2 diabetes of interrupting prolonged sitting with brief bouts of light walking 2780 Consensus Report Diabetes Care Volume 45, November 2022 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"12":1,"17":1,"44":1,"45":2,"54":2,"64":1,"66":1,"72":1,"99":1,"100":1,"101":1,"102":1,"103":1,"104":1,"353":1,"368":1,"1254":1,"1263":1,"1451":1,"1462":1,"2019":1,"2020":3,"2021":2,"2022":2,"2026":1,"2367":1,"2377":1,"2753":1,"2780":1,"691567":1,"sbj":1,"van":1,"veen":1,"mm":1,"elders":1,"pjm":1,"et":6,"al":7,"sleep":1,"disorders":1,"in":4,"people":2,"with":4,"type":5,"diabetes":9,"and":3,"associated":1,"health":2,"outcomes":1,"review":1,"of":6,"the":3,"literature":1,"diabetologia":1,"navarro":1,"dj":1,"alpert":1,"pt":1,"cross":1,"impact":1,"shift":1,"work":1,"on":3,"self":1,"management":1,"activities":1,"dr":1,"nurs":1,"pract":1,"henson":1,"rowlands":1,"av":1,"baldry":1,"codec":1,"investigators":1,"physical":3,"behaviors":1,"chronotype":1,"bmj":1,"open":1,"res":1,"care":4,"e001375":1,"kanaley":1,"ja":1,"colberg":1,"sr":1,"corcoran":1,"mh":1,"exercise":1,"activity":2,"individuals":1,"consensus":2,"statement":1,"from":2,"american":1,"college":1,"sports":3,"medicine":1,"med":2,"sci":1,"exerc":1,"bull":1,"fc":2,"ansari":1,"ss":1,"biddle":1,"world":1,"organization":1,"guidelines":1,"sedentary":1,"behaviour":1,"br":1,"homer":1,"ar":1,"taylor":1,"dempsey":2,"pc":2,"frequency":1,"interruptions":1,"to":1,"sitting":2,"time":1,"bene":2,"fi":2,"ts":2,"for":2,"postprandial":1,"metabolism":1,"larsen":1,"rn":1,"sethi":1,"interrupting":1,"prolonged":1,"brief":1,"bouts":1,"light":1,"walking":1,"report":1,"volume":1,"november":1,"downloaded":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"february":1},"len":220},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":30,"chunkId":"ada-easd-2022-p30-c0","text":"or simple resistance activities. Diabetes Care 2016;39:964  972 105. Rowlands A, Davies M, Dempsey P, Edwardson C, Razieh C, Yates T. Wrist-worn accelerometers: recommending \u0018 1.0 m g as the minimum clinically important difference (MCID) in daily average acceleration for inactive adults. Br J Sports Med 2021;55:814  815 106. Yates T, Haffner SM, Schulte PJ, et al. Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis. Lancet 2014;383:1059  1066 107. Saint-Maurice PF, Troiano RP, Bassett DR Jr, et al. Association of daily step count and step intensity with mortality among US adults. JAMA 2020;323:1151  1160 108. Jayedi A, Emadi A, Shab-Bidar S. Dose- dependent effect of supervised aerobic exercise on HbA 1c in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Sports Med 2022;52:1919  1938 109. Chudasama YV, Khunti KK, Zaccardi F, et al. Physical activity, multimorbidity, and life expectancy: a UK Biobank longitudinal study. BMC Med 2019; 17:108 110. Pan B, Ge L, Xun YQ, et al. Exercise training modalities in patients with type 2 diabetes mellitus: a systematic review and network meta- analysis. Int J Behav Nutr Phys Act 2018;15:72 111. Mickute M, Henson J, Rowlands AV, et al. Device-measured physical activity and its association with physi","tf":{"15":1,"17":1,"39":1,"52":1,"55":1,"72":1,"105":1,"106":1,"107":1,"108":2,"109":1,"110":1,"111":1,"323":1,"383":1,"814":1,"815":1,"964":1,"972":1,"1059":1,"1066":1,"1151":1,"1160":1,"1919":1,"1938":1,"2014":1,"2016":1,"2018":1,"2019":1,"2020":1,"2021":1,"2022":1,"or":1,"simple":1,"resistance":1,"activities":1,"diabetes":3,"care":1,"rowlands":2,"davies":1,"dempsey":1,"edwardson":1,"razieh":1,"yates":2,"wrist":1,"worn":1,"accelerometers":1,"recommending":1,"as":1,"the":1,"minimum":1,"clinically":1,"important":1,"difference":1,"mcid":1,"in":5,"daily":3,"average":1,"acceleration":1,"for":1,"inactive":1,"adults":2,"br":1,"sports":2,"med":3,"haffner":1,"sm":1,"schulte":1,"pj":1,"et":5,"al":5,"association":3,"between":1,"change":1,"ambulatory":1,"activity":3,"and":5,"cardiovascular":1,"events":1,"people":1,"with":5,"impaired":1,"glucose":1,"tolerance":1,"navigator":1,"trial":1,"cohort":1,"analysis":3,"lancet":1,"saint":1,"maurice":1,"pf":1,"troiano":1,"rp":1,"bassett":1,"dr":1,"jr":1,"of":3,"step":2,"count":1,"intensity":1,"mortality":1,"among":1,"us":1,"jama":1,"jayedi":1,"emadi":1,"shab":1,"bidar":1,"dose":1,"dependent":1,"effect":1,"supervised":1,"aerobic":1,"exercise":2,"on":1,"hba":1,"1c":1,"patients":2,"type":2,"meta":2,"randomized":1,"controlled":1,"trials":1,"chudasama":1,"yv":1,"khunti":1,"kk":1,"zaccardi":1,"physical":2,"multimorbidity":1,"life":1,"expectancy":1,"uk":1,"biobank":1,"longitudinal":1,"study":1,"bmc":1,"pan":1,"ge":1,"xun":1,"yq":1,"training":1,"modalities":1,"mellitus":1,"systematic":1,"review":1,"network":1,"int":1,"behav":1,"nutr":1,"phys":1,"act":1,"mickute":1,"henson":1,"av":1,"device":1,"measured":1,"its":1,"physi":1},"len":205},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":30,"chunkId":"ada-easd-2022-p30-c1","text":" modalities in patients with type 2 diabetes mellitus: a systematic review and network meta- analysis. Int J Behav Nutr Phys Act 2018;15:72 111. Mickute M, Henson J, Rowlands AV, et al. Device-measured physical activity and its association with physical function in adults with type 2 diabetes mellitus. Diabet Med 2021;38: e14393 112. Ahmad E, Sargeant JA, Yates T, Webb DR, Davies MJ. Type 2 diabetes and impaired physical function: a growing problem. Diabetology 2022; 3:30  45 113. Smyth A, Jenkins M, Dunham M, Kutzer Y, Taheri S, Whitehead L. Systematic review of clinical practice guidelines to identify recommendations for sleep in type 2 diabetes mellitus management. Diabetes Res Clin Pract 2020;170:108532 114. Zuraikat FM, Makarem N, Redline S, Aggarwal B, Jelic S, St-Onge MP. Sleep regularity and cardiometabolic heath: is variability in sleep patterns a risk factor for excess adiposity and glycemic dysregulation? Curr Diab Rep 2020;20:38 115. International Diabetes Federation. (2017) The IDF Consensus Statement on sleep apnoea and type 2 diabetes. Brussels, Belgium, International Diabetes Federation, 2017. Accessed 5 June 2022. Available from www.idf.org/our-activities/advocacy- awareness/resources-and-tools/62-idf-consensus- statement-on-sleep-apnoea-and-type-2-diabetes. html 116. Fallahi A, Jamil DI, Karimi EB, Baghi V, Gheshlagh RG. Prevalence of obstructive sleep apnea ","tf":{"15":1,"20":1,"30":1,"38":2,"45":1,"62":1,"72":1,"111":1,"112":1,"113":1,"114":1,"115":1,"116":1,"170":1,"2017":2,"2018":1,"2020":2,"2021":1,"2022":2,"108532":1,"modalities":1,"in":4,"patients":1,"with":3,"type":6,"diabetes":9,"mellitus":3,"systematic":2,"review":2,"and":8,"network":1,"meta":1,"analysis":1,"int":1,"behav":1,"nutr":1,"phys":1,"act":1,"mickute":1,"henson":1,"rowlands":1,"av":1,"et":1,"al":1,"device":1,"measured":1,"physical":3,"activity":1,"its":1,"association":1,"function":2,"adults":1,"diabet":1,"med":1,"e14393":1,"ahmad":1,"sargeant":1,"ja":1,"yates":1,"webb":1,"dr":1,"davies":1,"mj":1,"impaired":1,"growing":1,"problem":1,"diabetology":1,"smyth":1,"jenkins":1,"dunham":1,"kutzer":1,"taheri":1,"whitehead":1,"of":2,"clinical":1,"practice":1,"guidelines":1,"to":1,"identify":1,"recommendations":1,"for":2,"sleep":6,"management":1,"res":1,"clin":1,"pract":1,"zuraikat":1,"fm":1,"makarem":1,"redline":1,"aggarwal":1,"jelic":1,"st":1,"onge":1,"mp":1,"regularity":1,"cardiometabolic":1,"heath":1,"is":1,"variability":1,"patterns":1,"risk":1,"factor":1,"excess":1,"adiposity":1,"glycemic":1,"dysregulation":1,"curr":1,"diab":1,"rep":1,"international":2,"federation":2,"the":1,"idf":3,"consensus":2,"statement":2,"on":2,"apnoea":2,"brussels":1,"belgium":1,"accessed":1,"june":1,"available":1,"from":1,"www":1,"org":1,"our":1,"activities":1,"advocacy":1,"awareness":1,"resources":1,"tools":1,"html":1,"fallahi":1,"jamil":1,"di":1,"karimi":1,"eb":1,"baghi":1,"gheshlagh":1,"rg":1,"prevalence":1,"obstructive":1,"apnea":1},"len":195},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":30,"chunkId":"ada-easd-2022-p30-c2","text":"Available from www.idf.org/our-activities/advocacy- awareness/resources-and-tools/62-idf-consensus- statement-on-sleep-apnoea-and-type-2-diabetes. html 116. Fallahi A, Jamil DI, Karimi EB, Baghi V, Gheshlagh RG. Prevalence of obstructive sleep apnea in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab Syndr 2019;13:2463  2468 117. Sondrup N, Termannsen AD, Eriksen JN, et al. Effects of sleep manipulation on markers of insulin sensitivity: a systematic review and meta- analysis of randomized controlled trials. Sleep Med Rev 2022;62:101594 118. Delevatti RS, Bracht CG, Lisboa SDC, et al. The role of aerobic training variables progression on glycemic control of patients with type 2 diabetes: a systematic review with meta-analysis. Sports Med Open 2019;5:22 119. Naja fi pour F, Mobasseri M, Yavari A, et al. Effect of regular exercise training on changes in HbA1c, BMI and VO 2 max among patients with type 2 diabetes mellitus: an 8-year trial. BMJ Open Diabetes Res Care 2017;5:e000414 120. Borror A, Zieff G, Battaglini C, Stoner L. The effects of postprandial exercise on glucose control in individuals with type 2 diabetes: a systematic review. Sports Med 2018;48:1479  1491 121. Guo S, Xu Y, Qin J, et al. Effect of tai chi on glycaemic control, lipid metabolism and body composition in adults with type 2 diabetes: a meta-analysis and systematic revi","tf":{"13":1,"22":1,"48":1,"62":2,"116":1,"117":1,"118":1,"119":1,"120":1,"121":1,"1479":1,"1491":1,"2017":1,"2018":1,"2019":2,"2022":1,"2463":1,"2468":1,"101594":1,"available":1,"from":1,"www":1,"idf":2,"org":1,"our":1,"activities":1,"advocacy":1,"awareness":1,"resources":1,"and":7,"tools":1,"consensus":1,"statement":1,"on":6,"sleep":4,"apnoea":1,"type":6,"diabetes":8,"html":1,"fallahi":1,"jamil":1,"di":1,"karimi":1,"eb":1,"baghi":1,"gheshlagh":1,"rg":1,"prevalence":1,"of":9,"obstructive":1,"apnea":1,"in":4,"patients":3,"with":6,"systematic":5,"review":4,"meta":4,"analysis":4,"metab":1,"syndr":1,"sondrup":1,"termannsen":1,"ad":1,"eriksen":1,"jn":1,"et":4,"al":4,"effects":2,"manipulation":1,"markers":1,"insulin":1,"sensitivity":1,"randomized":1,"controlled":1,"trials":1,"med":3,"rev":1,"delevatti":1,"rs":1,"bracht":1,"cg":1,"lisboa":1,"sdc":1,"the":2,"role":1,"aerobic":1,"training":2,"variables":1,"progression":1,"glycemic":1,"control":3,"sports":2,"open":2,"naja":1,"fi":1,"pour":1,"mobasseri":1,"yavari":1,"effect":2,"regular":1,"exercise":2,"changes":1,"hba1c":1,"bmi":1,"vo":1,"max":1,"among":1,"mellitus":1,"an":1,"year":1,"trial":1,"bmj":1,"res":1,"care":1,"e000414":1,"borror":1,"zieff":1,"battaglini":1,"stoner":1,"postprandial":1,"glucose":1,"individuals":1,"guo":1,"xu":1,"qin":1,"tai":1,"chi":1,"glycaemic":1,"lipid":1,"metabolism":1,"body":1,"composition":1,"adults":1,"revi":1},"len":211},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":30,"chunkId":"ada-easd-2022-p30-c3","text":"ith type 2 diabetes: a systematic review. Sports Med 2018;48:1479  1491 121. Guo S, Xu Y, Qin J, et al. Effect of tai chi on glycaemic control, lipid metabolism and body composition in adults with type 2 diabetes: a meta-analysis and systematic review. J Rehabil Med 2021;53:jrm00165 122. Gupta U, Gupta Y, Jose D, et al. Effectiveness of yoga-based exercise program compared to usual care, in improving HbA 1c in individuals with type 2 diabetes: a randomized control trial. Int J Yoga 2020;13:233  238 123. de Mello MB, Righi NC, Schuch FB, Signori LU, da Silva AMV. Effect of high-intensity interval training protocols on VO 2 max and HbA1c level in people with type 2 diabetes: a systematic review and meta-analysis. Ann Phys Rehabil Med 2022; 65:101586 124. Draznin B, Aroda VR, Bakris G, et al.; American Diabetes Association Professional Practice Committee. 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Medical Care in Diabetes  2022 . Diabetes Care 2022;45(Suppl. 1):S46  S59 125. Tasali E, Wroblewski K, Kahn E, Kilkus J, Schoeller DA. Effect of sleep extension on objectively assessed energy intake among adults with overweight in real-life settings: a randomized clinical trial. JAMA Intern Med 2022;182:365  374 126. Depner CM, Melanson EL, Eckel RH, et al. Ad libitum weekend recovery sleep fails to prevent metabolic dysregulation during a repe","tf":{"13":1,"45":1,"48":1,"53":1,"65":1,"121":1,"122":1,"123":1,"124":1,"125":1,"126":1,"182":1,"233":1,"238":1,"365":1,"374":1,"1479":1,"1491":1,"2018":1,"2020":1,"2021":1,"2022":4,"101586":1,"ith":1,"type":4,"diabetes":7,"systematic":3,"review":3,"sports":1,"med":4,"guo":1,"xu":1,"qin":1,"et":4,"al":4,"effect":3,"of":6,"tai":1,"chi":1,"on":3,"glycaemic":1,"control":2,"lipid":1,"metabolism":1,"and":5,"body":1,"composition":1,"in":6,"adults":2,"with":4,"meta":2,"analysis":2,"rehabil":2,"jrm00165":1,"gupta":2,"jose":1,"effectiveness":1,"yoga":2,"based":1,"exercise":1,"program":1,"compared":1,"to":2,"usual":1,"care":3,"improving":1,"hba":1,"1c":1,"individuals":1,"randomized":2,"trial":2,"int":1,"de":1,"mello":1,"mb":1,"righi":1,"nc":1,"schuch":1,"fb":1,"signori":1,"lu":1,"da":2,"silva":1,"amv":1,"high":1,"intensity":1,"interval":1,"training":1,"protocols":1,"vo":1,"max":1,"hba1c":1,"level":1,"people":1,"ann":1,"phys":1,"draznin":1,"aroda":1,"vr":1,"bakris":1,"american":1,"association":1,"professional":1,"practice":1,"committee":1,"comprehensive":1,"medical":2,"evaluation":1,"assessment":1,"comorbidities":1,"standards":1,"suppl":1,"s46":1,"s59":1,"tasali":1,"wroblewski":1,"kahn":1,"kilkus":1,"schoeller":1,"sleep":2,"extension":1,"objectively":1,"assessed":1,"energy":1,"intake":1,"among":1,"overweight":1,"real":1,"life":1,"settings":1,"clinical":1,"jama":1,"intern":1,"depner":1,"cm":1,"melanson":1,"el":1,"eckel":1,"rh":1,"ad":1,"libitum":1,"weekend":1,"recovery":1,"fails":1,"prevent":1,"metabolic":1,"dysregulation":1,"during":1,"repe":1},"len":210},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":30,"chunkId":"ada-easd-2022-p30-c4","text":"among adults with overweight in real-life settings: a randomized clinical trial. JAMA Intern Med 2022;182:365  374 126. Depner CM, Melanson EL, Eckel RH, et al. Ad libitum weekend recovery sleep fails to prevent metabolic dysregulation during a repeating pattern of insuf fi cient sleep and weekend recovery sleep. Curr Biol 2019;29:957  967.e4 127. Draznin B, Aroda VR, Bakris G, et al.; American Diabetes Association Professional Practice Committee. 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of Medical Care in Diabetes  2022 . Diabetes Care 2022;45(Suppl. 1):S113  S124 128. Davies M, Frch L, Jeppesen OK, et al.; STEP 2 Study Group. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double- blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021;397:971  984 129. Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989  1002 130. Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205  216 131. Rubino D, Abrahamsson N, Davies M, et al.; STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with","tf":{"29":1,"45":1,"126":1,"127":1,"128":1,"129":1,"130":1,"131":1,"182":1,"205":1,"216":1,"365":1,"374":1,"384":1,"387":1,"397":1,"957":1,"967":1,"971":1,"984":1,"989":1,"1002":1,"2019":1,"2021":2,"2022":4,"among":1,"adults":4,"with":4,"overweight":3,"in":5,"real":1,"life":1,"settings":1,"randomized":1,"clinical":1,"trial":2,"jama":1,"intern":1,"med":3,"depner":1,"cm":1,"melanson":1,"el":1,"eckel":1,"rh":1,"et":6,"al":6,"ad":1,"libitum":1,"weekend":2,"recovery":2,"sleep":3,"fails":1,"to":1,"prevent":1,"metabolic":1,"dysregulation":1,"during":1,"repeating":1,"pattern":1,"of":5,"insuf":1,"fi":1,"cient":1,"and":4,"curr":1,"biol":1,"e4":1,"draznin":1,"aroda":1,"vr":1,"bakris":1,"american":1,"diabetes":5,"association":1,"professional":1,"practice":1,"committee":1,"obesity":4,"weight":2,"management":1,"for":2,"the":2,"prevention":1,"treatment":2,"type":2,"standards":1,"medical":1,"care":2,"suppl":1,"s113":1,"s124":1,"davies":2,"rch":1,"jeppesen":1,"ok":1,"step":4,"study":2,"group":2,"semaglutide":3,"mg":1,"once":3,"week":1,"or":2,"randomised":1,"double":2,"blind":1,"dummy":1,"placebo":2,"controlled":1,"phase":1,"lancet":1,"wilding":1,"jph":1,"batterham":1,"rl":1,"calanna":1,"weekly":3,"engl":2,"jastreboff":1,"am":1,"aronne":1,"lj":1,"ahmad":1,"nn":1,"surmount":1,"investigators":2,"tirzepatide":1,"rubino":1,"abrahamsson":1,"effect":1,"continued":1,"subcutaneous":1,"vs":1,"on":1,"loss":1,"maintenance":1},"len":207},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":30,"chunkId":"ada-easd-2022-p30-c5","text":"e once weekly for the treatment of obesity. N Engl J Med 2022;387:205  216 131. Rubino D, Abrahamsson N, Davies M, et al.; STEP 4 Investigators. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 2021;325:1414  1425 132. Rubino F, Nathan DM, Eckel RH, et al.; Delegates of the 2nd Diabetes Surgery Summit. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by International Diabetes Organizations. Diabetes Care 2016;39: 861  877 133. Carmona MN, Santos-Sousa H, Lindeza L, et al.; CRI-O group. Comparative effectiveness of bariatric surgeries in patients with type 2 diabetes mellitus and BMI $ 25 kg/m2: a systematic review and network meta-analysis. Obes Surg 2021;31: 5312  5321 134. Currie AC, Askari A, Fangueiro A, Mahawar K. Network meta-analysis of metabolic surgery procedures for the treatment of obesity and diabetes. Obes Surg 2021;31:4528  4541 135. Cresci B, Cosentino C, Monami M, Mannucci E. Metabolic surgery for the treatment of type 2 diabetes: a network meta-analysis of randomized controlled trials. Diabetes Obes Metab 2020;22: 1378  1387 136. Rubio-Almanza M, Herv \u0013 as-Mar \u0013  n D, C \u0013 amara- G \u0013 omez R, Caudet-Esteban J, Merino-Torres JF. Does metabolic surgery lead to diabetes remission in patients with BMI < 30","tf":{"22":1,"25":1,"30":1,"31":2,"39":1,"131":1,"132":1,"133":1,"134":1,"135":1,"136":1,"205":1,"216":1,"325":1,"387":1,"861":1,"877":1,"1378":1,"1387":1,"1414":1,"1425":1,"2016":1,"2020":1,"2021":3,"2022":1,"4528":1,"4541":1,"5312":1,"5321":1,"once":1,"weekly":2,"for":4,"the":6,"treatment":4,"of":8,"obesity":3,"engl":1,"med":1,"rubino":2,"abrahamsson":1,"davies":1,"et":3,"al":3,"step":2,"investigators":1,"effect":1,"continued":1,"subcutaneous":1,"semaglutide":1,"vs":1,"placebo":1,"on":1,"weight":1,"loss":1,"maintenance":1,"in":4,"adults":1,"with":3,"overweight":1,"or":1,"randomized":2,"clinical":1,"trial":1,"jama":1,"nathan":1,"dm":1,"eckel":1,"rh":1,"delegates":1,"2nd":1,"diabetes":9,"surgery":5,"summit":1,"metabolic":4,"algorithm":1,"type":3,"joint":1,"statement":1,"by":1,"international":1,"organizations":1,"care":1,"carmona":1,"mn":1,"santos":1,"sousa":1,"lindeza":1,"cri":1,"group":1,"comparative":1,"effectiveness":1,"bariatric":1,"surgeries":1,"patients":2,"mellitus":1,"and":3,"bmi":2,"kg":1,"m2":1,"systematic":1,"review":1,"network":3,"meta":3,"analysis":3,"obes":3,"surg":2,"currie":1,"ac":1,"askari":1,"fangueiro":1,"mahawar":1,"procedures":1,"cresci":1,"cosentino":1,"monami":1,"mannucci":1,"controlled":1,"trials":1,"metab":1,"rubio":1,"almanza":1,"herv":1,"as":1,"mar":1,"amara":1,"omez":1,"caudet":1,"esteban":1,"merino":1,"torres":1,"jf":1,"does":1,"lead":1,"to":1,"remission":1},"len":201},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":30,"chunkId":"ada-easd-2022-p30-c6","text":"randomized controlled trials. Diabetes Obes Metab 2020;22: 1378  1387 136. Rubio-Almanza M, Herv \u0013 as-Mar \u0013  n D, C \u0013 amara- G \u0013 omez R, Caudet-Esteban J, Merino-Torres JF. Does metabolic surgery lead to diabetes remission in patients with BMI < 30 kg/m2?: A meta- analysis. Obes Surg 2019;29:1105  1116 137. Khorgami Z, Shoar S, Saber AA, Howard CA, Danaei G, Sclabas GM. Outcomes of bariatric surgery versus medical management for type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Obes Surg 2019;29:964  974 138. Fultang J, Chinaka U, Rankin J, Bakhshi A, Ali A. Preoperative bariatric surgery predictors of type 2 diabetes remission. J Obes Metab Syndr 2021;30:104  114 139. Mingrone G, Panunzi S, De Gaetano A, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 2021;397: 293  304 140. Aminian A, Kashyap SR, Wolski KE, et al. Patient-reported outcomes after metabolic surgery versus medical therapy for diabetes: insights from the STAMPEDE randomized trial. Ann Surg 2021; 274:524  532 141. American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes  2022 . Diabetes Care 2022;45(Suppl. 1): S144  S174 142. McGuire DK, Shih WJ, Cosentino F,","tf":{"10":2,"22":1,"29":2,"30":2,"45":1,"104":1,"114":1,"136":1,"137":1,"138":1,"139":1,"140":1,"141":1,"142":1,"274":1,"293":1,"304":1,"397":1,"524":1,"532":1,"964":1,"974":1,"1105":1,"1116":1,"1378":1,"1387":1,"2019":2,"2020":1,"2021":3,"2022":2,"randomized":3,"controlled":3,"trials":2,"diabetes":9,"obes":4,"metab":2,"rubio":1,"almanza":1,"herv":1,"as":1,"mar":1,"amara":1,"omez":1,"caudet":1,"esteban":1,"merino":1,"torres":1,"jf":1,"does":1,"metabolic":3,"surgery":5,"lead":1,"to":1,"remission":2,"in":3,"patients":2,"with":2,"bmi":1,"kg":1,"m2":1,"meta":2,"analysis":2,"surg":3,"khorgami":1,"shoar":1,"saber":1,"aa":1,"howard":1,"ca":1,"danaei":1,"sclabas":1,"gm":1,"outcomes":2,"of":5,"bariatric":2,"versus":3,"medical":4,"management":2,"for":2,"type":3,"mellitus":1,"fultang":1,"chinaka":1,"rankin":1,"bakhshi":1,"ali":1,"preoperative":1,"predictors":1,"syndr":1,"mingrone":1,"panunzi":1,"de":1,"gaetano":1,"et":2,"al":2,"conventional":1,"therapy":2,"year":1,"follow":1,"up":1,"an":1,"open":1,"label":1,"single":1,"centre":1,"randomised":1,"trial":2,"lancet":1,"aminian":1,"kashyap":1,"sr":1,"wolski":1,"ke":1,"patient":1,"reported":1,"after":1,"insights":1,"from":1,"the":1,"stampede":1,"ann":1,"american":1,"association":1,"professional":1,"practice":1,"committee":1,"cardiovascular":1,"disease":1,"and":1,"risk":1,"standards":1,"care":2,"suppl":1,"s144":1,"s174":1,"mcguire":1,"dk":1,"shih":1,"wj":1,"cosentino":1},"len":199},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":30,"chunkId":"ada-easd-2022-p30-c7","text":"532 141. American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes  2022 . Diabetes Care 2022;45(Suppl. 1): S144  S174 142. McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol 2021;6: 148  158 143. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagli fl ozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117  2128 144. Neal B, Perkovic V, Mahaffey KW, et al.; CANVAS Program Collaborative Group. Canagli fl ozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644  657 145. Wiviott SD, Raz I, Bonaca MP et al. Dapagli fl ozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347  357 146. Cannon CP, Pratley R, Dagogo-Jack S, et al.; VERTIS CV Investigators. Cardiovascular outcomes with ertugli fl ozin in type 2 diabetes. N Engl J Med 2020;383:1425  1435 147. Bhatt DL, Szarek M, Pitt B, et al.; SCORED Investigators. Sotagli fl ozin in patients with diabetes and chronic kidney disease. N Engl J Med 2021; 384:129  139 diabetesjournals.org/care Davies and Associates 2781 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci2200","tf":{"10":1,"11":1,"45":2,"129":1,"139":1,"141":1,"142":1,"143":1,"144":1,"145":1,"146":1,"147":1,"148":1,"158":1,"347":1,"357":1,"373":1,"377":1,"380":1,"383":1,"384":1,"532":1,"644":1,"657":1,"1425":1,"1435":1,"2015":1,"2017":1,"2019":1,"2020":1,"2021":2,"2022":2,"2117":1,"2128":1,"2753":1,"2781":1,"691567":1,"american":1,"diabetes":9,"association":2,"professional":1,"practice":1,"committee":1,"cardiovascular":6,"disease":2,"and":8,"risk":1,"management":1,"standards":1,"of":2,"medical":1,"care":4,"in":7,"suppl":1,"s144":1,"s174":1,"mcguire":1,"dk":1,"shih":1,"wj":1,"cosentino":1,"et":6,"al":6,"sglt2":1,"inhibitors":1,"with":4,"kidney":2,"outcomes":4,"patients":2,"type":5,"meta":1,"analysis":1,"jama":1,"cardiol":1,"zinman":1,"wanner":1,"lachin":1,"jm":1,"empa":1,"reg":1,"outcome":1,"investigators":3,"empagli":1,"fl":5,"ozin":5,"mortality":1,"engl":5,"med":5,"neal":1,"perkovic":1,"mahaffey":1,"kw":1,"canvas":1,"program":1,"collaborative":1,"group":1,"canagli":1,"renal":1,"events":1,"wiviott":1,"sd":1,"raz":1,"bonaca":1,"mp":1,"dapagli":1,"cannon":1,"cp":1,"pratley":1,"dagogo":1,"jack":1,"vertis":1,"cv":1,"ertugli":1,"bhatt":1,"dl":1,"szarek":1,"pitt":1,"scored":1,"sotagli":1,"chronic":1,"diabetesjournals":2,"org":2,"davies":1,"associates":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":1,"dci2200":1},"len":207},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":30,"chunkId":"ada-easd-2022-p30-c8","text":"gators. Sotagli fl ozin in patients with diabetes and chronic kidney disease. N Engl J Med 2021; 384:129  139 diabetesjournals.org/care Davies and Associates 2781 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"45":1,"129":1,"139":1,"384":1,"2021":1,"2026":1,"2753":1,"2781":1,"691567":1,"gators":1,"sotagli":1,"fl":1,"ozin":1,"in":1,"patients":1,"with":1,"diabetes":1,"and":2,"chronic":1,"kidney":1,"disease":1,"engl":1,"med":1,"diabetesjournals":2,"org":2,"care":2,"davies":1,"associates":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"february":1},"len":45},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":31,"chunkId":"ada-easd-2022-p31-c0","text":"148. McMurray JJV, Solomon SD, Inzucchi SE, et al.; DAPA-HF Trial Committees and Investigators. Dapagli fl ozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381:1995  2008 149. Packer M, Anker SD, Butler J, et al.; EMPEROR- Reduced Trial Investigators. Cardiovascular and renal outcomes with empagli fl ozin in heart failure. N Engl J Med 2020;383:1413  1424 150. Bhatt DL, Szarek M, Steg PG, et al.; SOLOIST-WHF Trial Investigators. Sotagli fl ozin in patients with diabetes and recent worsening heart failure. N Engl J Med 2021;384:117  128 151. Anker SD, Butler J, Filippatos G, et al.; EMPEROR-Preserved Trial Investigators. Empagli fl ozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451  1461 152. Perkovic V, Jardine MJ, Neal B, et al.; CREDENCE Trial Investigators. Canagli fl ozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295  2306 153. Heerspink HJL, Stef \u0013 ansson BV, Correa- Rotter R, et al.; DAPA-CKD Trial Committees and Investigators. Dapagli fl ozin in patients with chronic kidney disease. N Engl J Med 2020;383:1436  1446 154. Boehringer Ingelheim. Prescribing information for JARDIANCE. Ingelheim am Rhein, Germany, 2022. Accessed 20 June 2022. Available from https://docs.boehringer-ingelheim.com/Prescribing% 20Information/PIs/Jardiance/jardiance.pdf 155. Janssen. Pre","tf":{"20":1,"117":1,"128":1,"148":1,"149":1,"150":1,"151":1,"152":1,"153":1,"154":1,"155":1,"380":1,"381":1,"383":2,"384":1,"385":1,"1413":1,"1424":1,"1436":1,"1446":1,"1451":1,"1461":1,"1995":1,"2008":1,"2019":2,"2020":2,"2021":2,"2022":2,"2295":1,"2306":1,"mcmurray":1,"jjv":1,"solomon":1,"sd":3,"inzucchi":1,"se":1,"et":6,"al":6,"dapa":2,"hf":1,"trial":6,"committees":2,"and":7,"investigators":6,"dapagli":2,"fl":6,"ozin":6,"in":6,"patients":3,"with":5,"heart":4,"failure":4,"reduced":2,"ejection":2,"fraction":2,"engl":6,"med":6,"packer":1,"anker":2,"butler":2,"emperor":2,"cardiovascular":1,"renal":2,"outcomes":2,"empagli":2,"bhatt":1,"dl":1,"szarek":1,"steg":1,"pg":1,"soloist":1,"whf":1,"sotagli":1,"diabetes":2,"recent":1,"worsening":1,"filippatos":1,"preserved":2,"perkovic":1,"jardine":1,"mj":1,"neal":1,"credence":1,"canagli":1,"type":1,"nephropathy":1,"heerspink":1,"hjl":1,"stef":1,"ansson":1,"bv":1,"correa":1,"rotter":1,"ckd":1,"chronic":1,"kidney":1,"disease":1,"boehringer":2,"ingelheim":3,"prescribing":2,"information":1,"for":1,"jardiance":3,"am":1,"rhein":1,"germany":1,"accessed":1,"june":1,"available":1,"from":1,"https":1,"docs":1,"com":1,"20information":1,"pis":1,"pdf":1,"janssen":1,"pre":1},"len":208},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":31,"chunkId":"ada-easd-2022-p31-c1","text":" 154. Boehringer Ingelheim. Prescribing information for JARDIANCE. Ingelheim am Rhein, Germany, 2022. Accessed 20 June 2022. Available from https://docs.boehringer-ingelheim.com/Prescribing% 20Information/PIs/Jardiance/jardiance.pdf 155. Janssen. Prescribing information for INVOKANA. Beerse, Belgium, Janssen, 2020. Accessed 20 June 2022. Available from www.janssenlabels.com/ package-insert/product-monograph/prescribing- information/INVOKANA-pi.pdf 156. AstraZeneca. Prescribing information for FARXIGA. Wilmington, DE, 2021. Accessed 20 June 2022. Available from https://den8dhaj6zs0e. cloudfront.net/50fd68b9-106b-4550-b5d0- 12b045f8b184/0be9cb1b-3b33-41c7-bfc2- 04c9f718e442/0be9cb1b-3b33-41c7-bfc2- 04c9f718e442_viewable_rendition__v.pdf 157. Merck. Prescribing information for STEGLATRO. Readington, NJ, Merck, 2017. Accessed 20 June 2022. Available from www.accessdata.fda.gov/drugsatfda_ docs/label/2017/209803s000lbl.pdf 158. Mistry S, Eschler DC. Euglycemic diabetic ketoacidosis caused by SGLT2 inhibitors and a ketogenic diet: a case series and review of literature. AACE Clin Case Rep 2020;7:17  19 159. Kosiborod MN, Esterline R, Furtado RHM, et al. Dapagli fl ozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2021;9:586  594 160. Qian BB, Chen Q, Li L","tf":{"17":1,"19":3,"20":4,"154":1,"155":1,"156":1,"157":1,"158":1,"159":1,"160":1,"586":1,"594":1,"2017":2,"2020":2,"2021":2,"2022":5,"4550":1,"boehringer":2,"ingelheim":3,"prescribing":6,"information":5,"for":4,"jardiance":3,"am":1,"rhein":1,"germany":1,"accessed":4,"june":4,"available":4,"from":4,"https":2,"docs":2,"com":2,"20information":1,"pis":1,"pdf":4,"janssen":2,"invokana":2,"beerse":1,"belgium":1,"www":2,"janssenlabels":1,"package":1,"insert":1,"product":1,"monograph":1,"pi":1,"astrazeneca":1,"farxiga":1,"wilmington":1,"de":1,"den8dhaj6zs0e":1,"cloudfront":1,"net":1,"50fd68b9":1,"106b":1,"b5d0":1,"12b045f8b184":1,"0be9cb1b":2,"3b33":2,"41c7":2,"bfc2":2,"04c9f718e442":2,"viewable":1,"rendition":1,"merck":2,"steglatro":1,"readington":1,"nj":1,"accessdata":1,"fda":1,"gov":1,"drugsatfda":1,"label":1,"209803s000lbl":1,"mistry":1,"eschler":1,"dc":1,"euglycemic":1,"diabetic":1,"ketoacidosis":1,"caused":1,"by":1,"sglt2":1,"inhibitors":1,"and":2,"ketogenic":1,"diet":1,"case":2,"series":1,"review":1,"of":1,"literature":1,"aace":1,"clin":1,"rep":1,"kosiborod":1,"mn":1,"esterline":1,"furtado":1,"rhm":1,"et":1,"al":1,"dapagli":1,"fl":1,"ozin":1,"in":1,"patients":1,"with":2,"cardiometabolic":1,"risk":1,"factors":1,"hospitalised":1,"covid":1,"dare":1,"randomised":1,"double":1,"blind":1,"placebo":1,"controlled":1,"phase":1,"trial":1,"lancet":1,"diabetes":1,"endocrinol":1,"qian":1,"bb":1,"chen":1,"li":1},"len":188},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":31,"chunkId":"ada-easd-2022-p31-c2","text":"tado RHM, et al. Dapagli fl ozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2021;9:586  594 160. Qian BB, Chen Q, Li L, Yan CF. Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials. Osteoporos Int 2020;31:2313  2320 161. Dorsey-Trevi ~ no EG, Gonz \u0013 alez-Gonz \u0013 alez JG, Alvarez-Villalobos N, et al. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis. J Endocrinol Invest 2020;43:289  304 162. Barraclough JY, Yu J, Figtree GA, et al. Cardiovascular and renal outcomes with canagli fl ozin in patients with peripheral arterial disease: data from the CANVAS Program and CREDENCE trial. Diabetes Obes Metab 2022;24: 1072  1083 163. Heerspink HJL, Oshima M, Zhang H, et al. Canagli fl ozin and kidney-related adverse events in type 2 diabetes and CKD: fi ndings from the randomized CREDENCE trial. Am J Kidney Dis 2022;79:244  256.e1 164. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes  state-of-the-art. Mol Metab 2021;46: 101102 165. Novo Nordisk. Prescribing information for RYBELSUS. Plainsboro,","tf":{"19":2,"24":1,"31":1,"43":1,"46":1,"79":1,"160":1,"161":1,"162":1,"163":1,"164":1,"165":1,"244":1,"256":1,"289":1,"304":1,"586":1,"594":1,"1072":1,"1083":1,"2020":2,"2021":2,"2022":2,"2313":1,"2320":1,"101102":1,"tado":1,"rhm":1,"et":4,"al":4,"dapagli":1,"fl":3,"ozin":3,"in":5,"patients":3,"with":6,"cardiometabolic":1,"risk":2,"factors":1,"hospitalised":1,"covid":1,"dare":1,"randomised":1,"double":1,"blind":1,"placebo":1,"controlled":2,"phase":1,"trial":3,"lancet":1,"diabetes":6,"endocrinol":2,"qian":1,"bb":1,"chen":1,"li":1,"yan":1,"cf":1,"association":1,"between":1,"combined":1,"treatment":2,"sglt2":1,"inhibitors":2,"and":7,"metformin":1,"for":2,"type":4,"mellitus":1,"on":1,"fracture":1,"meta":2,"analysis":2,"of":3,"randomized":2,"trials":1,"osteoporos":1,"int":1,"dorsey":1,"trevi":1,"no":1,"eg":1,"gonz":2,"alez":2,"jg":1,"alvarez":1,"villalobos":1,"sodium":1,"glucose":1,"cotransporter":1,"sglt":1,"microvascular":1,"outcomes":2,"systematic":1,"review":1,"invest":1,"barraclough":1,"jy":1,"yu":1,"figtree":1,"ga":1,"cardiovascular":1,"renal":1,"canagli":2,"peripheral":1,"arterial":1,"disease":1,"data":1,"from":2,"the":4,"canvas":1,"program":1,"credence":2,"obes":1,"metab":2,"heerspink":1,"hjl":1,"oshima":1,"zhang":1,"kidney":2,"related":1,"adverse":1,"events":1,"ckd":1,"fi":1,"ndings":1,"am":1,"dis":1,"e1":1,"nauck":1,"ma":1,"quast":1,"dr":1,"wefers":1,"meier":1,"jj":1,"glp":1,"receptor":1,"agonists":1,"state":1,"art":1,"mol":1,"novo":1,"nordisk":1,"prescribing":1,"information":1,"rybelsus":1,"plainsboro":1},"len":211},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":31,"chunkId":"ada-easd-2022-p31-c3","text":"idney Dis 2022;79:244  256.e1 164. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes  state-of-the-art. Mol Metab 2021;46: 101102 165. Novo Nordisk. Prescribing information for RYBELSUS. Plainsboro, NJ, Novo Nordisk, 2019. Accessed 20 June 2022. Available from www. accessdata.fda.gov/drugsatfda_docs/label/2019/ 213051s000lbl.pdf 166. Frias JP, Bonora E, Nevarez Ruiz L, et al. Ef fi cacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin- treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care 2021;44:765  773 167. Fr \u0013  as JP, Auerbach P, Bajaj HS, et al. Ef fi cacy and safety of once-weekly semaglutide 20 mg versus 10 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol 2021; 9:563  574 168. Wharton S, Davies M, Dicker D, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med 2022;134:14  19 169. Peng H, Want LL, Aroda VR. Safety and tolerability of glucagon-like peptide-1 receptor agonists utilizing data from the exenatide clinical trial development program. Curr Diab Rep 2016; 16:44 170. Vilsbll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diab","tf":{"11":1,"14":1,"16":1,"19":1,"20":1,"44":2,"46":1,"79":1,"134":1,"164":1,"165":1,"166":1,"167":1,"168":1,"169":1,"170":1,"244":1,"256":1,"563":1,"574":1,"765":1,"773":1,"2016":1,"2019":2,"2021":3,"2022":3,"101102":1,"idney":1,"dis":1,"e1":1,"nauck":1,"ma":1,"quast":1,"dr":1,"wefers":1,"meier":1,"jj":1,"glp":2,"receptor":3,"agonists":3,"in":6,"the":5,"treatment":1,"of":7,"type":3,"diabetes":5,"state":1,"art":1,"mol":1,"metab":1,"novo":2,"nordisk":2,"prescribing":1,"information":1,"for":2,"rybelsus":1,"plainsboro":1,"nj":1,"accessed":1,"june":1,"available":1,"from":2,"www":1,"accessdata":1,"fda":1,"gov":1,"drugsatfda":1,"docs":1,"label":1,"213051s000lbl":1,"pdf":1,"frias":1,"jp":2,"bonora":1,"nevarez":1,"ruiz":1,"et":4,"al":4,"ef":2,"fi":2,"cacy":2,"and":5,"safety":3,"dulaglutide":2,"mg":5,"versus":2,"metformin":1,"treated":1,"patients":2,"with":2,"randomized":1,"controlled":1,"trial":3,"award":1,"care":1,"fr":1,"as":1,"auerbach":1,"bajaj":1,"hs":1,"once":1,"weekly":1,"semaglutide":2,"sustain":1,"forte":1,"double":1,"blind":1,"randomised":1,"phase":1,"3b":1,"lancet":1,"endocrinol":1,"wharton":1,"davies":1,"dicker":1,"managing":1,"gastrointestinal":1,"side":1,"effects":1,"obesity":1,"recommendations":1,"clinical":2,"practice":1,"postgrad":1,"med":1,"peng":1,"want":1,"ll":2,"aroda":1,"vr":1,"tolerability":1,"glucagon":1,"like":1,"peptide":1,"utilizing":1,"data":1,"exenatide":1,"development":1,"program":1,"curr":1,"diab":2,"rep":1,"vilsb":1,"bain":1,"sc":1,"leiter":1,"la":1,"reduction":1,"glycated":1,"haemoglobin":1,"risk":1},"len":217},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":31,"chunkId":"ada-easd-2022-p31-c4","text":" glucagon-like peptide-1 receptor agonists utilizing data from the exenatide clinical trial development program. Curr Diab Rep 2016; 16:44 170. Vilsbll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab 2018;20:889  897 171. Bethel MA, Diaz R, Castellana N, Bhattacharya I, Gerstein HC, Lakshmanan MC. HbA1c change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression. Diabetes Care 2021;44:290  296 172. He L, Wang J, Ping F, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med 2022;182:513  519 173. Crowley MJ, McGuire DK, Alexopoulos AS, et al. Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use: post hoc analyses of the LEADER trial. Diabetes Care 2020;43: e108  e110 174. Neuen BL, Arnott C, Perkovic V, et al. Sodium-glucose co-transporter-2 inhibitors with and without metformin: a meta-analysis of cardiovascular, kidney and mortality outcomes. Diabetes Obes Metab 2021;23:382  390 175. Masson W, Lavalle-Cobo A, Lobo M, Masson G, Molinero G. Novel antidiabetic drugs and risk of cardiovascular events in patients wit","tf":{"16":1,"20":1,"23":1,"43":1,"44":2,"170":1,"171":1,"172":1,"173":1,"174":1,"175":1,"182":1,"290":1,"296":1,"382":1,"390":1,"513":1,"519":1,"889":1,"897":1,"2016":1,"2018":1,"2020":1,"2021":2,"2022":1,"glucagon":2,"like":2,"peptide":2,"receptor":3,"agonists":1,"utilizing":1,"data":1,"from":1,"the":3,"exenatide":1,"clinical":2,"trial":2,"development":1,"program":1,"curr":1,"diab":1,"rep":1,"vilsb":1,"ll":1,"bain":1,"sc":1,"leiter":1,"la":1,"et":4,"al":4,"semaglutide":1,"reduction":1,"in":3,"glycated":1,"haemoglobin":1,"and":9,"risk":3,"of":8,"diabetic":2,"retinopathy":2,"diabetes":5,"obes":2,"metab":2,"bethel":1,"ma":1,"diaz":1,"castellana":1,"bhattacharya":1,"gerstein":1,"hc":1,"lakshmanan":1,"mc":1,"hba1c":1,"change":1,"during":1,"glp":1,"agonist":2,"cardiovascular":4,"outcome":1,"trials":2,"meta":4,"analysis":3,"regression":1,"care":2,"he":1,"wang":1,"ping":1,"association":1,"use":2,"with":3,"gallbladder":1,"biliary":1,"diseases":1,"systematic":1,"review":1,"randomized":1,"jama":1,"intern":1,"med":1,"crowley":1,"mj":1,"mcguire":1,"dk":1,"alexopoulos":1,"as":1,"effects":1,"liraglutide":1,"on":1,"outcomes":2,"type":1,"patients":2,"without":2,"baseline":1,"metformin":2,"post":1,"hoc":1,"analyses":1,"leader":1,"e108":1,"e110":1,"neuen":1,"bl":1,"arnott":1,"perkovic":1,"sodium":1,"glucose":1,"co":1,"transporter":1,"inhibitors":1,"kidney":1,"mortality":1,"masson":2,"lavalle":1,"cobo":1,"lobo":1,"molinero":1,"novel":1,"antidiabetic":1,"drugs":1,"events":1,"wit":1},"len":204},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":31,"chunkId":"ada-easd-2022-p31-c5","text":"metformin: a meta-analysis of cardiovascular, kidney and mortality outcomes. Diabetes Obes Metab 2021;23:382  390 175. Masson W, Lavalle-Cobo A, Lobo M, Masson G, Molinero G. Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis. Eur J Prev Cardiol 2021;28:69  75 176. Matthews D, Del Prato S, Mohan V, et al. Insights from VERIFY: early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed type 2 diabetes. Diabetes Ther 2020;11:2465  2476 177. Lalau JD, Kajbaf F, Bennis Y, Hurtel-Lemaire AS, Belpaire F, De Broe ME. Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4. Diabetes Care 2018;41:547  553 178. Out M, Kooy A, Lehert P, Schalkwijk CA, Stehouwer CDA. Long-term treatment with metformin in type 2 diabetes and methylmalonic acid: post hoc analysis of a randomized controlled 4.3year trial. J Diabetes Complications 2018;32: 171  178 179. Aroda VR, Edelstein SL, Goldberg RB, et al.; Diabetes Prevention Program Research Group. Long-term metformin use and vitamin B12 de fi ciency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab 2016; 101:1754  1761 180. Perkovic V, Toto R, Cooper ME, et al.; CARMELINA investigators. Effects of linagliptin on cardiovascular and kidney outcomes in people with n","tf":{"11":1,"23":1,"28":1,"32":1,"41":1,"69":1,"75":1,"101":1,"171":1,"175":1,"176":1,"177":1,"178":2,"179":1,"180":1,"382":1,"390":1,"547":1,"553":1,"1754":1,"1761":1,"2016":1,"2018":2,"2020":1,"2021":2,"2465":1,"2476":1,"metformin":5,"meta":2,"analysis":3,"of":4,"cardiovascular":3,"kidney":3,"and":6,"mortality":1,"outcomes":3,"diabetes":9,"obes":1,"metab":2,"masson":2,"lavalle":1,"cobo":1,"lobo":1,"molinero":1,"novel":1,"antidiabetic":1,"drugs":1,"risk":1,"events":1,"in":6,"patients":2,"without":1,"baseline":1,"use":2,"eur":1,"prev":1,"cardiol":1,"matthews":1,"del":1,"prato":1,"mohan":1,"et":3,"al":3,"insights":1,"from":1,"verify":1,"early":1,"combination":1,"therapy":1,"provides":1,"better":1,"glycaemic":1,"durability":1,"than":1,"stepwise":1,"approach":1,"newly":1,"diagnosed":1,"type":3,"ther":1,"lalau":1,"jd":1,"kajbaf":1,"bennis":1,"hurtel":1,"lemaire":1,"as":1,"belpaire":1,"de":2,"broe":1,"me":2,"treatment":2,"with":3,"chronic":1,"disease":1,"stages":1,"3a":1,"3b":1,"or":1,"care":1,"out":1,"kooy":1,"lehert":1,"schalkwijk":1,"ca":1,"stehouwer":1,"cda":1,"long":2,"term":2,"methylmalonic":1,"acid":1,"post":1,"hoc":1,"randomized":1,"controlled":1,"3year":1,"trial":1,"complications":1,"aroda":1,"vr":1,"edelstein":1,"sl":1,"goldberg":1,"rb":1,"prevention":2,"program":2,"research":1,"group":1,"vitamin":1,"b12":1,"fi":1,"ciency":1,"the":1,"study":1,"clin":1,"endocrinol":1,"perkovic":1,"toto":1,"cooper":1,"carmelina":1,"investigators":1,"effects":1,"linagliptin":1,"on":1,"people":1},"len":201},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":31,"chunkId":"ada-easd-2022-p31-c6","text":"ciency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab 2016; 101:1754  1761 180. Perkovic V, Toto R, Cooper ME, et al.; CARMELINA investigators. Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: secondary analysis of the CARMELINA randomized trial. Diabetes Care 2020;43:1803  1812 181. Umpierrez GE, Cardona S, Chachkhiani D, et al. A randomized controlled study comparing a DPP4 inhibitor (linagliptin) and basal insulin (glargine) in patients with type 2 diabetes in long- term care and skilled nursing facilities: linagliptin- LTC trial. J Am Med Dir Assoc 2018;19:399  404.e3 182. Batule S, Ramos A, P \u0013 erez-Montes de Oca A, et al. Comparison of glycemic variability and hypoglycemic events in hospitalized older adults treated with basal insulin plus vildagliptin and basal-bolus insulin regimen: a prospective randomized study. J Clin Med 2022;11:2813 183. Rosenstock J, Wysham C, Fr \u0013  as JP, et al. Ef fi cacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 2021;398:143  155 184. Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized c","tf":{"11":1,"19":1,"43":1,"101":1,"143":1,"155":1,"180":1,"181":1,"182":1,"183":1,"184":1,"398":1,"399":1,"404":1,"1754":1,"1761":1,"1803":1,"1812":1,"2016":1,"2018":1,"2020":1,"2021":1,"2022":1,"2813":1,"ciency":1,"in":7,"the":3,"diabetes":5,"prevention":1,"program":1,"outcomes":2,"study":3,"clin":2,"endocrinol":1,"metab":1,"perkovic":1,"toto":1,"cooper":1,"me":1,"et":5,"al":5,"carmelina":2,"investigators":1,"effects":1,"of":5,"linagliptin":3,"on":2,"cardiovascular":1,"and":8,"kidney":2,"people":1,"with":5,"normal":1,"reduced":1,"function":1,"secondary":1,"analysis":1,"randomized":4,"trial":3,"care":2,"umpierrez":1,"ge":1,"cardona":1,"chachkhiani":1,"controlled":1,"comparing":1,"dpp4":1,"inhibitor":1,"basal":3,"insulin":4,"glargine":2,"patients":3,"type":3,"long":1,"term":1,"skilled":1,"nursing":1,"facilities":1,"ltc":1,"am":1,"med":2,"dir":1,"assoc":1,"e3":1,"batule":1,"ramos":1,"erez":1,"montes":1,"de":1,"oca":1,"comparison":1,"glycemic":2,"variability":1,"hypoglycemic":1,"events":1,"hospitalized":1,"older":1,"adults":1,"treated":1,"plus":1,"vildagliptin":1,"bolus":1,"regimen":1,"prospective":1,"rosenstock":1,"wysham":1,"fr":1,"as":1,"jp":1,"ef":1,"fi":1,"cacy":1,"safety":1,"novel":1,"dual":1,"gip":1,"glp":1,"receptor":1,"agonist":1,"tirzepatide":2,"surpass":2,"double":1,"blind":1,"randomised":1,"phase":1,"lancet":1,"dahl":1,"onishi":1,"norwood":1,"effect":1,"subcutaneous":1,"vs":1,"placebo":1,"added":1,"to":1,"titrated":1,"control":1},"len":201},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":31,"chunkId":"ada-easd-2022-p31-c7","text":"mised, phase 3 trial. Lancet 2021;398:143  155 184. Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA 2022;327:534  545 185. Fr \u0013  as JP, Davies MJ, Rosenstock J, et al.; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021;385:503  515 186. Ludvik B, Giorgino F, J \u0013 odar E, et al. Once- weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet 2021;398: 583  598 187. Del Prato S, Kahn SE, Pavo I, et al.; SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 2021;398:1811  1824 188. Gastaldelli A, Cusi K, Fern \u0013 andez Land \u0013 o L, Bray R, Brouwers B, Rodr \u0013  guez \u0013 A. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel- group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 2022;10:393  406 ","tf":{"10":1,"143":1,"155":1,"184":1,"185":1,"186":1,"187":1,"188":1,"327":1,"385":1,"393":1,"398":3,"406":1,"503":1,"515":1,"534":1,"545":1,"583":1,"598":1,"1811":1,"1824":1,"2021":4,"2022":2,"mised":1,"phase":4,"trial":5,"lancet":4,"dahl":1,"onishi":1,"norwood":1,"et":4,"al":4,"effect":2,"of":3,"subcutaneous":1,"tirzepatide":5,"vs":1,"placebo":1,"added":1,"to":2,"titrated":1,"insulin":4,"glargine":2,"on":3,"glycemic":1,"control":1,"in":5,"patients":3,"with":5,"type":5,"diabetes":6,"the":2,"surpass":7,"randomized":1,"clinical":1,"jama":1,"fr":1,"as":2,"jp":1,"davies":1,"mj":1,"rosenstock":1,"investigators":2,"versus":4,"semaglutide":1,"once":3,"weekly":2,"engl":1,"med":1,"ludvik":1,"giorgino":1,"odar":1,"daily":1,"degludec":2,"add":1,"metformin":1,"or":1,"without":1,"sglt2":1,"inhibitors":1,"randomised":3,"open":3,"label":3,"parallel":3,"group":3,"del":1,"prato":1,"kahn":1,"se":1,"pavo":1,"and":2,"increased":1,"cardiovascular":1,"risk":1,"multicentre":1,"gastaldelli":1,"cusi":1,"fern":1,"andez":1,"land":1,"bray":1,"brouwers":1,"rodr":1,"guez":1,"liver":1,"fat":1,"content":1,"abdominal":1,"adipose":1,"tissue":1,"people":1,"mri":1,"substudy":1,"endocrinol":1},"len":196},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":31,"chunkId":"ada-easd-2022-p31-c8","text":"ersus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel- group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 2022;10:393  406 2782 Consensus Report Diabetes Care Volume 45, November 2022 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"10":1,"11":1,"17":1,"45":2,"393":1,"406":1,"2022":2,"2026":1,"2753":1,"2782":1,"691567":1,"ersus":1,"insulin":1,"degludec":1,"on":2,"liver":1,"fat":1,"content":1,"and":1,"abdominal":1,"adipose":1,"tissue":1,"in":1,"people":1,"with":1,"type":1,"diabetes":3,"surpass":2,"mri":1,"substudy":1,"of":1,"the":1,"randomised":1,"open":1,"label":1,"parallel":1,"group":1,"phase":1,"trial":1,"lancet":1,"endocrinol":1,"consensus":1,"report":1,"care":2,"volume":1,"november":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"february":1},"len":65},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":32,"chunkId":"ada-easd-2022-p32-c0","text":"189. Karagiannis T, Avgerinos I, Liakos A, et al. Management of type 2 diabetes with the dual GIP/ GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia 2022;65: 1251  1261 190. Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre-speci fi ed meta-analysis. Nat Med 2022;28: 591  598 191. Khunti K, Chatterjee S, Gerstein HC, Zoungas S, Davies MJ. Do sulphonylureas still have a place in clinical practice? Lancet Diabetes Endocrinol 2018;6:821  832 192. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837  853 193. Vaccaro O, Masulli M, Nicolucci A, et al.; Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group; Italian Diabetes Society. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol 2017;5:887  897 194. Rosenstock J, Kahn SE, Johansen OE, et al.; CAROLINA Investigators. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes","tf":{"28":1,"33":1,"65":1,"189":1,"190":1,"191":1,"192":1,"193":1,"194":1,"352":1,"591":1,"598":1,"821":1,"832":1,"837":1,"853":1,"887":1,"897":1,"1251":1,"1261":1,"1998":1,"2017":1,"2018":1,"2022":2,"karagiannis":1,"avgerinos":1,"liakos":1,"et":4,"al":4,"management":1,"of":6,"type":4,"diabetes":8,"with":7,"the":3,"dual":1,"gip":1,"glp":1,"receptor":1,"agonist":1,"tirzepatide":2,"systematic":1,"review":1,"and":2,"meta":2,"analysis":2,"diabetologia":1,"sattar":1,"mcguire":1,"dk":1,"pavo":1,"cardiovascular":4,"event":1,"risk":2,"assessment":1,"pre":1,"speci":1,"fi":1,"ed":1,"nat":1,"med":1,"khunti":1,"chatterjee":1,"gerstein":1,"hc":1,"zoungas":1,"davies":1,"mj":1,"do":1,"sulphonylureas":2,"still":1,"have":1,"place":1,"in":4,"clinical":1,"practice":1,"lancet":3,"endocrinol":2,"uk":1,"prospective":1,"study":2,"ukpds":2,"group":2,"intensive":1,"blood":1,"glucose":1,"control":1,"or":2,"insulin":1,"compared":1,"conventional":1,"treatment":1,"complications":1,"patients":3,"vaccaro":1,"masulli":1,"nicolucci":1,"thiazolidinediones":1,"sulfonylureas":2,"accidents":1,"intervention":1,"trial":2,"tosca":2,"it":2,"italian":1,"society":1,"effects":1,"on":2,"incidence":1,"events":1,"addition":1,"pioglitazone":1,"versus":1,"inadequately":1,"controlled":1,"metformin":1,"randomised":1,"multicentre":1,"rosenstock":1,"kahn":1,"se":1,"johansen":1,"oe":1,"carolina":1,"investigators":1,"effect":1,"linagliptin":1,"vs":1,"glimepiride":1,"major":1,"adverse":1,"outcomes":1},"len":188},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":32,"chunkId":"ada-easd-2022-p32-c1","text":"ed, multicentre trial. Lancet Diabetes Endocrinol 2017;5:887  897 194. Rosenstock J, Kahn SE, Johansen OE, et al.; CAROLINA Investigators. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA 2019; 322:1155  1166 195. Rosenstock J, Perkovic V, Johansen OE, et al.; CARMELINA Investigators. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 2019;321:69  79 196. Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427  2443 197. Dormandy JA, Charbonnel B, Eckland DJA, et al.; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366: 1279  1289 198. Kernan WN, Viscoli CM, Furie KL, et al.; IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016;374:1321  1331 199. Spence JD, Viscoli CM, Inzucchi SE, et al.; IRIS Investigators. Pioglitazone therapy in patients with stroke and prediabetes: a post hoc analysis of the","tf":{"69":1,"79":1,"194":1,"195":1,"196":1,"197":1,"198":1,"199":1,"321":1,"322":1,"355":1,"366":1,"374":1,"887":1,"897":1,"1155":1,"1166":1,"1279":1,"1289":1,"1321":1,"1331":1,"2005":1,"2006":1,"2016":1,"2017":1,"2019":2,"2427":1,"2443":1,"ed":1,"multicentre":1,"trial":6,"lancet":2,"diabetes":4,"endocrinol":1,"rosenstock":2,"kahn":2,"se":3,"johansen":2,"oe":2,"et":6,"al":6,"carolina":2,"investigators":5,"effect":2,"of":5,"linagliptin":2,"vs":2,"glimepiride":1,"on":2,"major":2,"adverse":1,"cardiovascular":3,"outcomes":1,"in":6,"patients":3,"with":4,"type":3,"the":4,"randomized":2,"clinical":3,"jama":2,"perkovic":1,"carmelina":2,"placebo":1,"events":3,"adults":1,"and":3,"high":1,"renal":1,"risk":1,"haffner":1,"sm":1,"heise":1,"ma":1,"adopt":1,"study":2,"group":1,"glycemic":1,"durability":1,"rosiglitazone":1,"metformin":1,"or":2,"glyburide":1,"monotherapy":1,"engl":2,"med":2,"dormandy":1,"ja":1,"charbonnel":1,"eckland":1,"dja":1,"proactive":2,"secondary":1,"prevention":1,"macrovascular":2,"prospective":1,"pioglitazone":3,"randomised":1,"controlled":1,"kernan":1,"wn":1,"viscoli":2,"cm":2,"furie":1,"kl":1,"iris":2,"after":1,"ischemic":2,"stroke":2,"transient":1,"attack":1,"spence":1,"jd":1,"inzucchi":1,"therapy":1,"prediabetes":1,"post":1,"hoc":1,"analysis":1},"len":198},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":32,"chunkId":"ada-easd-2022-p32-c2","text":"tazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016;374:1321  1331 199. Spence JD, Viscoli CM, Inzucchi SE, et al.; IRIS Investigators. Pioglitazone therapy in patients with stroke and prediabetes: a post hoc analysis of the IRIS randomized clinical trial. JAMA Neurol 2019;76:526  535 200. Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med 2016; 165:305  315 201. Della Pepa G, Russo M, Vitale M, et al. Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial. Diabetes Res Clin Pract 2021; 178:108984 202. Home PD, Pocock SJ, Beck-Nielsen H, et al.; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125  2135 203. Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR; QUARTET Study Group. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004;27:141  147 204. Viscoli CM, Inzucchi SE, Young LH, et al.; IRIS Trial Investigators. Pioglitazone and risk for bone fracture: safety ","tf":{"27":1,"76":1,"141":1,"147":1,"165":1,"178":1,"199":1,"200":1,"201":1,"202":1,"203":1,"204":1,"305":1,"315":1,"373":1,"374":1,"526":1,"535":1,"1321":1,"1331":1,"2004":1,"2009":1,"2016":2,"2019":1,"2021":1,"2125":1,"2135":1,"108984":1,"tazone":1,"after":1,"ischemic":2,"stroke":2,"or":2,"transient":1,"attack":1,"engl":1,"med":2,"spence":1,"jd":1,"viscoli":2,"cm":2,"inzucchi":2,"se":2,"et":5,"al":5,"iris":3,"investigators":2,"pioglitazone":5,"therapy":2,"in":4,"patients":3,"with":4,"and":4,"prediabetes":2,"post":1,"hoc":1,"analysis":1,"of":2,"the":2,"randomized":2,"clinical":2,"trial":5,"jama":1,"neurol":1,"cusi":1,"orsak":1,"bril":1,"long":1,"term":1,"treatment":1,"for":4,"nonalcoholic":1,"steatohepatitis":1,"type":4,"diabetes":6,"mellitus":1,"ann":1,"intern":1,"della":1,"pepa":1,"russo":1,"vitale":1,"even":1,"at":1,"low":1,"dosage":1,"improves":1,"nafld":1,"pathophysiological":1,"insights":1,"from":1,"subgroup":1,"tosca":1,"it":1,"randomised":2,"res":1,"clin":1,"pract":1,"home":1,"pd":1,"pocock":1,"sj":1,"beck":1,"nielsen":1,"record":2,"study":2,"team":1,"rosiglitazone":1,"evaluated":1,"cardiovascular":1,"outcomes":1,"oral":1,"agent":1,"combination":1,"multicentre":1,"open":1,"label":1,"lancet":1,"hanefeld":1,"brunetti":1,"schernthaner":1,"gh":1,"matthews":1,"dr":1,"quartet":1,"group":1,"one":1,"year":1,"glycemic":1,"control":1,"sulfonylurea":2,"plus":2,"versus":1,"metformin":1,"care":1,"young":1,"lh":1,"risk":1,"bone":1,"fracture":1,"safety":1},"len":202},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":32,"chunkId":"ada-easd-2022-p32-c3","text":"ylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004;27:141  147 204. Viscoli CM, Inzucchi SE, Young LH, et al.; IRIS Trial Investigators. Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial. J Clin Endocrinol Metab 2017;102:914  922 205. Kahn SE, Zinman B, Lachin JM, et al.; Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008;31:845  851 206. DeFronzo RA, Inzucchi S, Abdul-Ghani M, Nissen SE. Pioglitazone: the forgotten, cost- effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res 2019;16:133  143 207. Marso SP, McGuire DK, Zinman B, et al.; DEVOTE Study Group. Ef fi cacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 2017;377:723  732 208. Gerstein HC, Bosch J, Dagenais GR, et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319  328 209. Lowe RN, Williams B, Claus LW. Diabetes: how to manage patients experiencing hypoglycaemia. Drugs Context 2022;11:2021-9-11 210. Mannucci E, Caiulo C, Naletto L, Madama G, Monami M. Ef fi cacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes:","tf":{"11":2,"16":1,"27":1,"31":1,"102":1,"133":1,"141":1,"143":1,"147":1,"204":1,"205":1,"206":1,"207":1,"208":1,"209":1,"210":1,"319":1,"328":1,"367":1,"377":1,"723":1,"732":1,"845":1,"851":1,"914":1,"922":1,"2004":1,"2008":1,"2012":1,"2017":2,"2019":1,"2021":1,"2022":1,"ylurea":1,"plus":2,"pioglitazone":3,"versus":2,"sulfonylurea":1,"metformin":1,"in":4,"patients":2,"with":1,"type":5,"diabetes":10,"care":2,"viscoli":1,"cm":1,"inzucchi":2,"se":3,"young":1,"lh":1,"et":4,"al":4,"iris":1,"trial":5,"investigators":2,"and":6,"risk":1,"for":3,"bone":1,"fracture":1,"safety":3,"data":1,"from":2,"randomized":1,"clinical":1,"clin":1,"endocrinol":1,"metab":1,"kahn":1,"zinman":2,"lachin":1,"jm":1,"outcome":2,"progression":2,"adopt":2,"study":2,"group":2,"rosiglitazone":1,"associated":1,"fractures":1,"an":1,"analysis":1,"defronzo":1,"ra":1,"abdul":1,"ghani":1,"nissen":1,"the":2,"forgotten":1,"cost":1,"effective":1,"cardioprotective":1,"drug":1,"diab":1,"vasc":1,"dis":1,"res":1,"marso":1,"sp":1,"mcguire":1,"dk":1,"devote":1,"ef":2,"fi":2,"cacy":2,"of":3,"degludec":1,"glargine":1,"engl":2,"med":2,"gerstein":1,"hc":1,"bosch":1,"dagenais":1,"gr":1,"origin":1,"basal":2,"insulin":2,"cardiovascular":1,"other":1,"outcomes":1,"dysglycemia":1,"lowe":1,"rn":1,"williams":1,"claus":1,"lw":1,"how":1,"to":1,"manage":1,"experiencing":1,"hypoglycaemia":1,"drugs":1,"context":1,"mannucci":1,"caiulo":1,"naletto":1,"madama":1,"monami":1,"different":1,"prandial":1,"analogues":1,"treatment":1},"len":208},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":32,"chunkId":"ada-easd-2022-p32-c4","text":"how to manage patients experiencing hypoglycaemia. Drugs Context 2022;11:2021-9-11 210. Mannucci E, Caiulo C, Naletto L, Madama G, Monami M. Ef fi cacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes: a network meta- analysis of randomized controlled trials. Endocrine 2021;74:508  517 211. Chan J, Cheng-Lai A. Inhaled insulin: a clinical and historical review. Cardiol Rev 2017; 25:140  146 212. Bergenstal RM, Peyrot M, Dreon DM, et al.; Calibra Study Group. Implementation of basal- bolus therapy in type 2 diabetes: a randomized controlled trial comparing bolus insulin delivery using an insulin patch with an insulin pen. Diabetes Technol Ther 2019;21:273  285 213. Heinemann L, Parkin CG. Rethinking the viability and utility of inhaled insulin in clinical practice. J Diabetes Res 2018;2018:4568903 214. Aroda VR, Arulandu JR, Cannon AJ. Insulin/ glucagon-like peptide-1 receptor agonist combination therapy for the treatment of type 2 diabetes: are two agents better than one? Clin Diabetes 2018; 36:138  147 215. Maiorino MI, Chiodini P, Bellastella G, et al. Free and fi xed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensi fi cation in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 2018;20:2309  2313 216. Blonde L, Rosenstock ","tf":{"11":2,"20":1,"21":1,"25":1,"36":1,"74":1,"138":1,"140":1,"146":1,"147":1,"210":1,"211":1,"212":1,"213":1,"214":1,"215":1,"216":1,"273":1,"285":1,"508":1,"517":1,"2017":1,"2018":4,"2019":1,"2021":2,"2022":1,"2309":1,"2313":1,"4568903":1,"how":1,"to":1,"manage":1,"patients":1,"experiencing":1,"hypoglycaemia":1,"drugs":1,"context":1,"mannucci":1,"caiulo":1,"naletto":1,"madama":1,"monami":1,"ef":1,"fi":3,"cacy":1,"and":7,"safety":1,"of":8,"different":1,"basal":4,"prandial":1,"insulin":9,"analogues":1,"for":2,"the":3,"treatment":2,"type":4,"diabetes":8,"network":1,"meta":2,"analysis":2,"randomized":3,"controlled":3,"trials":2,"endocrine":1,"chan":1,"cheng":1,"lai":1,"inhaled":2,"clinical":2,"historical":1,"review":2,"cardiol":1,"rev":1,"bergenstal":1,"rm":1,"peyrot":1,"dreon":1,"dm":1,"et":2,"al":2,"calibra":1,"study":1,"group":1,"implementation":1,"bolus":2,"therapy":2,"in":3,"trial":1,"comparing":1,"delivery":1,"using":1,"an":2,"patch":1,"with":1,"pen":1,"technol":1,"ther":1,"heinemann":1,"parkin":1,"cg":1,"rethinking":1,"viability":1,"utility":1,"practice":1,"res":1,"aroda":1,"vr":1,"arulandu":1,"jr":1,"cannon":1,"aj":1,"glucagon":1,"like":1,"peptide":1,"receptor":2,"agonist":1,"combination":1,"are":1,"two":1,"agents":1,"better":1,"than":1,"one":1,"clin":1,"maiorino":1,"mi":1,"chiodini":1,"bellastella":1,"free":1,"xed":1,"ratio":1,"combinations":1,"glp":1,"agonists":1,"versus":1,"intensi":1,"cation":1,"systematic":1,"obes":1,"metab":1,"blonde":1,"rosenstock":1},"len":206},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":32,"chunkId":"ada-easd-2022-p32-c5","text":"inations of basal insulin and GLP-1 receptor agonists versus basal insulin intensi fi cation in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 2018;20:2309  2313 216. Blonde L, Rosenstock J, Del Prato S, et al. Switching to iGlarLixi versus continuing daily or weekly GLP-1 RA in type 2 diabetes inadequately controlled by GLP-1 RA and oral antihyperglycemic therapy: the LixiLan-G randomized clinical trial. Diabetes Care 2019;42:2108  2116 217. Linjawi S, Bode BW, Chaykin LB, et al. The ef fi cacy of IDegLira (insulin degludec/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III randomized clinical trial. Diabetes Ther 2017;8:101  114 218. Aroda VR, Rosenstock J, Wysham C, et al.; LixiLan-L Trial Investigators. Ef fi cacy and safety of LixiLan, a titratable fi xed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial. Diabetes Care 2016;39:1972  1980 219. Lingvay I, P \u0013 erez Manghi F, Garc \u0013  a-Hern \u0013 andez P, et al.; DUAL V Investigators. Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial. JAM","tf":{"20":1,"39":1,"42":1,"101":1,"114":1,"216":1,"217":1,"218":1,"219":1,"1972":1,"1980":1,"2016":1,"2017":1,"2018":1,"2019":1,"2108":1,"2116":1,"2309":1,"2313":1,"inations":1,"of":6,"basal":3,"insulin":7,"and":6,"glp":4,"receptor":2,"agonists":1,"versus":2,"intensi":1,"fi":4,"cation":1,"in":5,"type":5,"diabetes":9,"systematic":1,"review":1,"meta":1,"analysis":1,"randomized":5,"controlled":4,"trials":1,"obes":1,"metab":1,"blonde":1,"rosenstock":2,"del":1,"prato":1,"et":4,"al":4,"switching":1,"to":1,"iglarlixi":1,"continuing":1,"daily":1,"or":1,"weekly":1,"ra":2,"inadequately":3,"by":1,"oral":2,"antihyperglycemic":1,"therapy":2,"the":4,"lixilan":4,"clinical":3,"trial":5,"care":2,"linjawi":1,"bode":1,"bw":1,"chaykin":1,"lb":1,"ef":2,"cacy":2,"ideglira":1,"degludec":2,"liraglutide":2,"combination":2,"adults":1,"with":3,"agonist":1,"dual":3,"iii":1,"ther":1,"aroda":1,"vr":1,"wysham":1,"investigators":2,"safety":1,"titratable":1,"xed":1,"ratio":1,"glargine":2,"plus":1,"lixisenatide":1,"on":2,"metformin":1,"lingvay":1,"erez":1,"manghi":1,"garc":1,"hern":1,"andez":1,"effect":1,"up":1,"titration":1,"vs":1,"glycated":1,"hemoglobin":1,"levels":1,"patients":1,"uncontrolled":1,"jam":1},"len":199},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":32,"chunkId":"ada-easd-2022-p32-c6","text":"F, Garc \u0013  a-Hern \u0013 andez P, et al.; DUAL V Investigators. Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial. JAMA 2016;315:898  907 220. Buse JB, Vilsbll T, Thurman J, et al.; NN9068-3912 (DUAL-II) Trial Investigators. Contribution of liraglutide in the fi xed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care 2014;37:2926  2933 221. Kasthuri S, Poongothai S, Anjana RM, et al. Comparison of glycemic excursion using fl ash continuous glucose monitoring in patients with type 2 diabetes mellitus before and after treatment with voglibose. Diabetes Technol Ther 2021;23: 213  220 222. Dalsgaard NB, Gasbjerg LS, Hansen LS, et al. The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes. Eur J Endocrinol 2021;184:383  394 223. Tsapas A, Avgerinos I, Karagiannis T, et al. Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. Ann Intern Med 2020;173:278  286 224. Tsapas A, Karagiannis T, Kakotrichi P, et al. Comparative ef fi cacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Obes Metab 2021;23:2116  2124 225. Abdul-Ghani M,","tf":{"23":2,"37":1,"173":1,"184":1,"213":1,"220":2,"221":1,"222":1,"223":1,"224":1,"225":1,"278":1,"286":1,"315":1,"383":1,"394":1,"898":1,"907":1,"2014":1,"2016":1,"2020":1,"2021":3,"2116":1,"2124":1,"2926":1,"2933":1,"3912":1,"garc":1,"hern":1,"andez":1,"et":6,"al":6,"dual":3,"investigators":2,"effect":1,"of":8,"insulin":3,"glargine":1,"up":1,"titration":1,"vs":1,"degludec":2,"liraglutide":3,"on":2,"glycated":1,"hemoglobin":1,"levels":1,"in":6,"patients":3,"with":4,"uncontrolled":1,"type":5,"diabetes":8,"the":4,"randomized":1,"clinical":1,"trial":2,"jama":1,"buse":1,"jb":1,"vilsb":1,"ll":1,"thurman":1,"nn9068":1,"ii":1,"contribution":1,"fi":2,"xed":1,"ratio":1,"combination":1,"and":5,"ideglira":1,"care":1,"kasthuri":1,"poongothai":1,"anjana":1,"rm":1,"comparison":1,"glycemic":1,"excursion":1,"using":1,"fl":1,"ash":1,"continuous":1,"glucose":3,"monitoring":1,"mellitus":1,"before":1,"after":1,"treatment":1,"voglibose":1,"technol":1,"ther":1,"dalsgaard":1,"nb":1,"gasbjerg":1,"ls":2,"hansen":1,"role":1,"glp":1,"postprandial":1,"effects":1,"acarbose":1,"eur":1,"endocrinol":1,"tsapas":2,"avgerinos":1,"karagiannis":2,"comparative":2,"effectiveness":1,"lowering":2,"drugs":1,"for":1,"systematic":2,"review":2,"network":2,"meta":2,"analysis":2,"ann":1,"intern":1,"med":1,"kakotrichi":1,"ef":1,"cacy":1,"medications":1,"body":1,"weight":1,"blood":1,"pressure":1,"obes":1,"metab":1,"abdul":1,"ghani":1},"len":205},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":32,"chunkId":"ada-easd-2022-p32-c7","text":"Kakotrichi P, et al. Comparative ef fi cacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Obes Metab 2021;23:2116  2124 225. Abdul-Ghani M, Puckett C, Adams J, et al. Durability of triple combination therapy versus stepwise addition therapy in patients with new- onset T2DM: 3-year follow-up of EDICT. Diabetes Care 2021;44:433  439 226. Matthews DR, Pald \u0013 anius PM, Proot P, Chiang Y, Stumvoll M; VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet 2019;394:1519  1529 227. Aroda VR, Gonz \u0013 alez-Galvez G, Grn R, et al. Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol 2019;7:596  605 228. Mantsiou C, Karagiannis T, Kakotrichi P, et al. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2020;22:1857  1868 diabetesjournals.org/care Davies and Associates 27","tf":{"22":1,"23":1,"27":1,"44":1,"225":1,"226":1,"227":1,"228":1,"394":1,"433":1,"439":1,"596":1,"605":1,"1519":1,"1529":1,"1857":1,"1868":1,"2019":2,"2020":1,"2021":2,"2116":1,"2124":1,"kakotrichi":2,"et":4,"al":4,"comparative":1,"ef":1,"fi":1,"cacy":1,"of":5,"glucose":2,"lowering":1,"medications":1,"on":1,"body":1,"weight":1,"and":6,"blood":1,"pressure":1,"in":4,"patients":2,"with":3,"type":4,"diabetes":8,"systematic":2,"review":2,"network":1,"meta":2,"analysis":2,"obes":2,"metab":2,"abdul":1,"ghani":1,"puckett":1,"adams":1,"durability":3,"triple":1,"combination":3,"therapy":5,"versus":3,"stepwise":1,"addition":1,"new":1,"onset":1,"t2dm":1,"year":2,"follow":1,"up":1,"edict":1,"care":2,"matthews":1,"dr":1,"pald":1,"anius":1,"pm":1,"proot":1,"chiang":1,"stumvoll":1,"verify":2,"study":1,"group":1,"glycaemic":1,"an":1,"early":1,"vildagliptin":1,"metformin":2,"sequential":1,"monotherapy":1,"newly":1,"diagnosed":1,"multicentre":2,"randomised":2,"double":1,"blind":1,"trial":2,"lancet":2,"aroda":1,"vr":1,"gonz":1,"alez":1,"galvez":1,"gr":1,"insulin":2,"degludec":1,"plus":1,"liraglutide":1,"glargine":1,"u100":1,"as":2,"initial":1,"injectable":1,"dual":1,"viii":1,"open":1,"label":1,"phase":1,"3b":1,"controlled":1,"endocrinol":1,"mantsiou":1,"karagiannis":1,"glucagon":1,"like":1,"peptide":1,"receptor":1,"agonists":1,"sodium":1,"co":1,"transporter":1,"inhibitors":1,"for":1,"diabetesjournals":1,"org":1,"davies":1,"associates":1},"len":196},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":32,"chunkId":"ada-easd-2022-p32-c8","text":"e peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2020;22:1857  1868 diabetesjournals.org/care Davies and Associates 2783 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"22":1,"45":1,"1857":1,"1868":1,"2020":1,"2026":1,"2753":1,"2783":1,"691567":1,"peptide":1,"receptor":1,"agonists":1,"and":3,"sodium":1,"glucose":1,"co":1,"transporter":1,"inhibitors":1,"as":1,"combination":1,"therapy":1,"for":1,"type":1,"diabetes":2,"systematic":1,"review":1,"meta":1,"analysis":1,"obes":1,"metab":1,"diabetesjournals":2,"org":2,"care":2,"davies":1,"associates":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"february":1},"len":54},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":33,"chunkId":"ada-easd-2022-p33-c0","text":"229. Li C, Luo J, Jiang M, Wang K. The ef fi cacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: a systematic review and meta- analysis. Front Pharmacol 2022;13:838277 230. Guo M, Gu J, Teng F, et al. The ef fi cacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis. Endocrine 2020;67:294  304 231. Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 2014;384: 2228  2234 232. Li D, Shi W, Wang T, Tang H. SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: a systematic review and meta- analysis. Diabetes Obes Metab 2018;20:1972  1976 233. Chenchula S, Varthya SB, Padmavathi R. Rationality, ef fi cacy, tolerability of empagli fl ozin plus linagliptin combination for the management of type 2 diabetes mellitus: a systematic review of randomized controlled trials and observational studies. Curr Diabetes Rev 2022;18:e100921196392 234. Katsiki N, Ofori-Asenso R, Ferrannini E, Mazidi M. Fixed-dose combination of empagli fl ozin and linagliptin for the treatment of patients with type 2 diabetes mellitus: a systematic rev","tf":{"13":1,"18":1,"20":1,"67":1,"229":1,"230":1,"231":1,"232":1,"233":1,"234":1,"294":1,"304":1,"384":1,"1972":1,"1976":1,"2014":1,"2018":1,"2020":1,"2022":2,"2228":1,"2234":1,"838277":1,"li":2,"luo":1,"jiang":1,"wang":2,"the":7,"ef":3,"fi":3,"cacy":3,"and":11,"safety":2,"of":10,"combination":5,"therapy":2,"with":2,"glp":2,"receptor":3,"agonists":2,"sglt":1,"inhibitors":2,"in":2,"type":6,"diabetes":8,"mellitus":3,"systematic":6,"review":5,"meta":4,"analysis":4,"front":1,"pharmacol":1,"guo":1,"gu":1,"teng":1,"et":1,"al":1,"combinations":1,"sglt2":2,"treatment":3,"or":1,"obese":1,"adults":1,"endocrine":1,"eng":1,"kramer":1,"ck":1,"zinman":1,"retnakaran":1,"glucagon":1,"like":1,"peptide":1,"agonist":1,"basal":1,"insulin":1,"for":4,"management":2,"lancet":1,"shi":1,"tang":1,"inhibitor":2,"plus":2,"dpp":1,"as":1,"obes":1,"metab":1,"chenchula":1,"varthya":1,"sb":1,"padmavathi":1,"rationality":1,"tolerability":1,"empagli":2,"fl":2,"ozin":2,"linagliptin":2,"randomized":1,"controlled":1,"trials":1,"observational":1,"studies":1,"curr":1,"rev":2,"e100921196392":1,"katsiki":1,"ofori":1,"asenso":1,"ferrannini":1,"mazidi":1,"fixed":1,"dose":1,"patients":1},"len":201},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":33,"chunkId":"ada-easd-2022-p33-c1","text":"rvational studies. Curr Diabetes Rev 2022;18:e100921196392 234. Katsiki N, Ofori-Asenso R, Ferrannini E, Mazidi M. Fixed-dose combination of empagli fl ozin and linagliptin for the treatment of patients with type 2 diabetes mellitus: a systematic review and meta- analysis. Diabetes Obes Metab 2020;22:1001  1005 235. Min SH, Yoon JH, Moon SJ, Hahn S, Cho YM. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta- analysis. Sci Rep 2018;8:4466 236. Milder TY, Stocker SL, Abdel Shaheed C, et al. Combination therapy with an SGLT2 inhibitor as initial treatment for type 2 diabetes: a systematic review and meta-analysis. J Clin Med 2019;8:E45 237. Castellana M, Cignarelli A, Brescia F, Laviola L, Giorgino F. GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab Res Rev 2019;35:e3082 238. Min SH, Yoon JH, Hahn S, Cho YM. Ef fi cacy and safety of combination therapy with an a -glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: a systematic review with meta-analysis. J Diabetes Investig 2018;9:893  902 239. Cai X, Gao X, Yang W, Han X, Ji L. Ef fi cacy and safety of initial combination therapy in treatment-nave type 2 diabetes patients: a","tf":{"18":1,"22":1,"35":1,"234":1,"235":1,"236":1,"237":1,"238":1,"239":1,"893":1,"902":1,"1001":1,"1005":1,"2018":2,"2019":2,"2020":1,"2022":1,"4466":1,"rvational":1,"studies":1,"curr":1,"diabetes":10,"rev":2,"e100921196392":1,"katsiki":1,"ofori":1,"asenso":1,"ferrannini":1,"mazidi":1,"fixed":1,"dose":1,"combination":5,"of":5,"empagli":1,"fl":1,"ozin":1,"and":8,"linagliptin":1,"for":2,"the":1,"treatment":3,"patients":3,"with":6,"type":6,"mellitus":2,"systematic":5,"review":5,"meta":5,"analysis":5,"obes":1,"metab":2,"min":2,"sh":2,"yoon":2,"jh":2,"moon":1,"sj":1,"hahn":2,"cho":2,"ym":2,"sodium":1,"glucose":1,"cotransporter":1,"inhibitor":5,"dipeptidyl":2,"peptidase":2,"in":4,"sci":1,"rep":1,"milder":1,"ty":1,"stocker":1,"sl":1,"abdel":1,"shaheed":1,"et":1,"al":1,"therapy":4,"an":2,"sglt2":1,"as":1,"initial":2,"clin":1,"med":1,"e45":1,"castellana":1,"cignarelli":1,"brescia":1,"laviola":1,"giorgino":1,"glp":1,"receptor":1,"agonist":1,"added":1,"to":1,"insulin":2,"versus":1,"basal":2,"plus":1,"or":1,"bolus":1,"res":1,"e3082":1,"ef":2,"fi":2,"cacy":2,"safety":2,"glucosidase":1,"investig":1,"cai":1,"gao":1,"yang":1,"han":1,"ji":1,"na":1,"ve":1},"len":203},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":33,"chunkId":"ada-easd-2022-p33-c2","text":"ts with type 2 diabetes mellitus: a systematic review with meta-analysis. J Diabetes Investig 2018;9:893  902 239. Cai X, Gao X, Yang W, Han X, Ji L. Ef fi cacy and safety of initial combination therapy in treatment-nave type 2 diabetes patients: a systematic review and meta-analysis. Diabetes Ther 2018;9:1995  2014 240. Dave CV, Kim SC, Gold fi ne AB, Glynn RJ, Tong A, Patorno E. Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA Therapy. Circulation 2021;143:770  779 241. Lam CSP, Ramasundarahettige C, Branch KRH, et al. Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial. Circulation 2022;145:565  574 242. DeFronzo RA. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes Metab 2017;19:1353  1362 243. Wright AK, Carr MJ, Kontopantelis E, et al. Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes. Diabetes Care 2022;45:909  918 244. Clegg LE, Penland RC, Bachina S, et al. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diab","tf":{"19":1,"45":1,"143":1,"145":1,"239":1,"240":1,"241":1,"242":1,"243":1,"244":1,"565":1,"574":1,"770":1,"779":1,"893":1,"902":1,"909":1,"918":1,"1353":1,"1362":1,"1995":1,"2014":1,"2017":1,"2018":2,"2021":1,"2022":2,"ts":1,"with":6,"type":6,"diabetes":9,"mellitus":1,"systematic":2,"review":2,"meta":2,"analysis":3,"investig":1,"cai":1,"gao":1,"yang":1,"han":1,"ji":1,"ef":1,"fi":2,"cacy":1,"and":10,"safety":1,"of":6,"initial":1,"combination":3,"therapy":3,"in":6,"treatment":2,"na":1,"ve":1,"patients":2,"ther":1,"dave":1,"cv":1,"kim":1,"sc":1,"gold":1,"ne":1,"ab":1,"glynn":1,"rj":1,"tong":1,"patorno":1,"risk":1,"cardiovascular":3,"outcomes":3,"after":1,"addition":1,"sglt2":4,"inhibitors":2,"versus":1,"sulfonylureas":1,"to":1,"baseline":1,"glp":3,"1ra":1,"circulation":2,"lam":1,"csp":1,"ramasundarahettige":1,"branch":1,"krh":1,"et":3,"al":3,"efpeglenatide":1,"clinical":1,"without":1,"concomitant":1,"sodium":1,"glucose":1,"cotransporter":1,"inhibition":1,"use":1,"exploratory":1,"the":1,"amplitude":1,"trial":1,"defronzo":1,"ra":1,"receptor":2,"agonist":1,"inhibitor":2,"obes":1,"metab":1,"wright":1,"ak":1,"carr":1,"mj":1,"kontopantelis":1,"primary":1,"prevention":1,"heart":1,"failure":1,"events":1,"agonists":1,"their":1,"care":1,"clegg":1,"le":1,"penland":1,"rc":1,"bachina":1,"effects":1,"exenatide":1,"open":1,"label":1,"given":1,"parallel":1,"or":1,"sequentially":1,"on":1,"mortality":1,"renal":1,"diab":1},"len":206},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":33,"chunkId":"ada-easd-2022-p33-c3","text":"diabetes. Diabetes Care 2022;45:909  918 244. Clegg LE, Penland RC, Bachina S, et al. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. Cardiovasc Diabetol 2019;18:138 245. Nathan DM. Glycemic outcomes in the glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study. N Engl J Med. In press. 246. Nathan DM. Glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study microvascular and cardiovascular outcomes. N Engl J Med. In press. 247. Gerstein HC, Sattar N, Rosenstock J, et al.; AMPLITUDE-O Trial Investigators. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med 2021;385:896  907 248. Ruff CT, Baron M, Im K, O  Donoghue ML, Fiedorek FT, Sabatine MS. Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. Nat Med 2022;28:89  95 249. Giugliano D, Longo M, Caruso P, Maiorino MI, Bellastella G, Esposito K. Sodium-glucose co- transporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis. Diabetes Obes Metab 2021;23:1672  1676 250. Lee MMY, Kristensen SL, Gerstein HC, McMurray JJV, Sattar N. Cardiovascular an","tf":{"18":1,"23":1,"28":1,"45":1,"89":1,"95":1,"138":1,"244":1,"245":1,"246":1,"247":1,"248":1,"249":1,"250":1,"385":1,"896":1,"907":1,"909":1,"918":1,"1672":1,"1676":1,"2019":1,"2021":2,"2022":2,"diabetes":9,"care":1,"clegg":1,"le":1,"penland":1,"rc":1,"bachina":1,"et":2,"al":2,"effects":1,"of":3,"exenatide":2,"and":6,"open":1,"label":1,"sglt2":1,"inhibitor":1,"treatment":1,"given":1,"in":10,"parallel":1,"or":1,"sequentially":1,"on":1,"mortality":1,"cardiovascular":5,"renal":2,"outcomes":6,"type":6,"insights":1,"from":1,"the":3,"exscel":1,"trial":3,"cardiovasc":1,"diabetol":1,"nathan":2,"dm":2,"glycemic":1,"glycemia":2,"reduction":2,"approaches":2,"comparative":2,"effectiveness":2,"grade":2,"study":2,"engl":3,"med":4,"press":2,"microvascular":1,"gerstein":2,"hc":2,"sattar":2,"rosenstock":1,"amplitude":1,"investigators":1,"with":1,"efpeglenatide":1,"ruff":1,"ct":1,"baron":1,"im":1,"donoghue":1,"ml":1,"fiedorek":1,"ft":1,"sabatine":1,"ms":1,"subcutaneous":1,"infusion":1,"non":1,"inferiority":1,"randomized":1,"controlled":1,"nat":1,"giugliano":1,"longo":1,"caruso":1,"maiorino":1,"mi":1,"bellastella":1,"esposito":1,"sodium":1,"glucose":1,"co":1,"transporter":1,"inhibitors":1,"for":1,"prevention":1,"cardiorenal":1,"an":2,"updated":1,"meta":1,"analysis":1,"obes":1,"metab":1,"lee":1,"mmy":1,"kristensen":1,"sl":1,"mcmurray":1,"jjv":1},"len":193},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":33,"chunkId":"ada-easd-2022-p33-c4","text":"-glucose co- transporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis. Diabetes Obes Metab 2021;23:1672  1676 250. Lee MMY, Kristensen SL, Gerstein HC, McMurray JJV, Sattar N. Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a meta-analysis with the FREEDOM cardiovascular outcomes trial. Diabetes Metab Syndr 2022;16:102382 251. Shaman AM, Bain SC, Bakris GL, et al. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation 2022; 145:575  585 252. Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2019;7:845  854 253. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta- analysis of randomised trials. Lancet Diabetes Endocrinol 2021;9:653  662 254. Tsai WH, Chuang SM, Liu SC, et al. Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis. Sci Rep 2021;11:15364 255. Strain WD, Frenkel O, James MA et al. Ef","tf":{"11":1,"16":1,"23":1,"145":1,"250":1,"251":1,"252":1,"253":1,"254":1,"255":1,"575":1,"585":1,"653":1,"662":1,"845":1,"854":1,"1672":1,"1676":1,"2019":1,"2021":3,"2022":2,"15364":1,"102382":1,"glucose":1,"co":1,"transporter":1,"inhibitors":3,"for":2,"the":4,"prevention":2,"of":6,"cardiorenal":1,"outcomes":5,"in":6,"type":6,"diabetes":10,"an":1,"updated":1,"meta":5,"analysis":6,"obes":1,"metab":2,"lee":2,"mmy":2,"kristensen":2,"sl":2,"gerstein":1,"hc":1,"mcmurray":1,"jjv":1,"sattar":2,"cardiovascular":3,"and":8,"mortality":2,"with":8,"glp":2,"receptor":3,"agonists":3,"patients":5,"freedom":1,"trial":1,"syndr":1,"shaman":1,"am":1,"bain":1,"sc":2,"bakris":1,"gl":1,"et":5,"al":5,"effect":1,"glucagon":1,"like":1,"peptide":1,"semaglutide":1,"liraglutide":1,"on":2,"kidney":3,"pooled":1,"sustain":1,"leader":1,"circulation":1,"neuen":1,"bl":1,"young":1,"heerspink":1,"hjl":1,"sglt2":2,"failure":1,"systematic":3,"review":3,"lancet":2,"endocrinol":2,"randomised":1,"trials":1,"tsai":1,"wh":1,"chuang":1,"sm":1,"liu":1,"effects":1,"stroke":1,"its":1,"subtypes":1,"sci":1,"rep":1,"strain":1,"wd":1,"frenkel":1,"james":1,"ma":1,"ef":1},"len":210},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":33,"chunkId":"ada-easd-2022-p33-c5","text":"21;9:653  662 254. Tsai WH, Chuang SM, Liu SC, et al. Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis. Sci Rep 2021;11:15364 255. Strain WD, Frenkel O, James MA et al. Effects of semaglutide on stroke subtypes in type 2 diabetes: post hoc analysis of the randomized SUSTAIN 6 and PIONEER 6. Stroke 2022;53: 2749  2757 256. Tsapas A, Karagiannis T, Avgerinos I, Liakos A, Bekiari E. GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials. Diabetes Res Clin Pract 2021;177:108921 257. Lavalle-Cobo A, Masson W, Lobo M, Masson G, Molinero G. Glucagon-like peptide-1 receptor agonists and cardioprotective bene fi t in patients with type 2 diabetes without baseline metformin: a systematic review and update meta-analysis. High Blood Press Cardiovasc Prev 2021;28:605  612 258. Husain M, Consoli A, De Remigis A, Pettersson Meyer AS, Rasmussen S, Bain S. Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6. Cardiovasc Diabetol 2022;21:64 259. Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network me","tf":{"11":1,"21":2,"28":1,"53":1,"64":1,"177":1,"254":1,"255":1,"256":1,"257":1,"258":1,"259":1,"605":1,"612":1,"653":1,"662":1,"2021":3,"2022":2,"2749":1,"2757":1,"15364":1,"108921":1,"tsai":1,"wh":1,"chuang":1,"sm":1,"liu":1,"sc":2,"et":3,"al":3,"effects":2,"of":6,"sglt2":1,"inhibitors":2,"on":2,"stroke":3,"and":10,"its":1,"subtypes":2,"in":3,"patients":2,"with":3,"type":4,"diabetes":5,"systematic":4,"review":4,"meta":3,"analysis":5,"sci":1,"rep":1,"strain":1,"wd":1,"frenkel":1,"james":1,"ma":1,"semaglutide":2,"post":2,"hoc":2,"the":1,"randomized":1,"sustain":2,"pioneer":2,"tsapas":1,"karagiannis":1,"avgerinos":1,"liakos":1,"bekiari":1,"glp":2,"receptor":3,"agonists":3,"for":2,"cardiovascular":3,"outcomes":2,"without":2,"metformin":3,"trials":1,"res":1,"clin":1,"pract":1,"lavalle":1,"cobo":1,"masson":2,"lobo":1,"molinero":1,"glucagon":2,"like":2,"peptide":2,"cardioprotective":1,"bene":1,"fi":1,"baseline":1,"update":1,"high":1,"blood":1,"press":1,"cardiovasc":2,"prev":1,"husain":1,"consoli":1,"de":1,"remigis":1,"pettersson":1,"meyer":1,"as":1,"rasmussen":1,"bain":1,"reduces":1,"events":1,"regardless":1,"use":1,"subgroup":1,"diabetol":1,"palmer":1,"tendal":1,"mustafa":1,"ra":1,"sodium":1,"glucose":1,"cotransporter":1,"protein":1,"sglt":1,"network":1,"me":1},"len":198},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":33,"chunkId":"ada-easd-2022-p33-c6","text":"NEER 6. Cardiovasc Diabetol 2022;21:64 259. Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2021;372:m4573 260. Lin DSH, Lee JK, Hung CS, Chen WJ. The ef fi cacy and safety of novel classes of glucose- lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials. Diabetologia 2021;64:2676  2686 261. Patorno E, Htoo PT, Glynn RJ, et al. Sodium- glucose cotransporter-2 inhibitors versus glucagon- like peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with diabetes across categories of cardiovascular disease. Ann Intern Med 2021;174:1528  1541 262. Bahour N, Cortez B, Pan H, Shah H, Doria A, Aguayo-Mazzucato C. Diabetes mellitus correlates with increased biological age as indicated by clinical biomarkers. Geroscience 2022;44:415  427 263. Nguyen TN, Harris K, Woodward M, et al. The impact of frailty on the effectiveness and safety of intensive glucose control and blood pressure-lowering therapy for people with type 2 diabetes: results from the ADVANCE trial. Diabetes Care 2021;44:1622  1629 264. European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatmen","tf":{"21":1,"44":2,"64":2,"174":1,"259":1,"260":1,"261":1,"262":1,"263":1,"264":1,"372":1,"415":1,"427":1,"1528":1,"1541":1,"1622":1,"1629":1,"2021":4,"2022":2,"2676":1,"2686":1,"neer":1,"cardiovasc":1,"diabetol":1,"palmer":1,"sc":1,"tendal":1,"mustafa":1,"ra":1,"et":3,"al":3,"sodium":2,"glucose":4,"cotransporter":2,"protein":1,"sglt":1,"inhibitors":2,"and":6,"glucagon":2,"like":2,"peptide":2,"glp":1,"receptor":2,"agonists":2,"for":4,"type":2,"diabetes":5,"systematic":1,"review":1,"network":2,"meta":2,"analysis":2,"of":8,"randomised":2,"controlled":1,"trials":2,"bmj":1,"m4573":1,"lin":1,"dsh":1,"lee":1,"jk":1,"hung":1,"cs":1,"chen":1,"wj":1,"the":6,"ef":1,"fi":1,"cacy":1,"safety":2,"novel":1,"classes":1,"lowering":2,"drugs":1,"cardiovascular":3,"outcomes":2,"clinical":3,"diabetologia":1,"patorno":1,"htoo":1,"pt":1,"glynn":1,"rj":1,"versus":1,"risk":1,"in":2,"routine":1,"care":2,"patients":1,"with":3,"across":1,"categories":1,"disease":1,"ann":1,"intern":1,"med":1,"bahour":1,"cortez":1,"pan":1,"shah":1,"doria":1,"aguayo":1,"mazzucato":1,"mellitus":1,"correlates":1,"increased":1,"biological":1,"age":1,"as":1,"indicated":1,"by":1,"biomarkers":1,"geroscience":1,"nguyen":1,"tn":1,"harris":1,"woodward":1,"impact":1,"frailty":1,"on":2,"effectiveness":1,"intensive":1,"control":1,"blood":1,"pressure":1,"therapy":1,"people":1,"results":1,"from":1,"advance":1,"trial":1,"european":1,"medicines":1,"agency":1,"guideline":1,"investigation":1,"medicinal":1,"products":1,"treatmen":1},"len":203},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":33,"chunkId":"ada-easd-2022-p33-c7","text":"e control and blood pressure-lowering therapy for people with type 2 diabetes: results from the ADVANCE trial. Diabetes Care 2021;44:1622  1629 264. European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. Amsterdam, Netherlands, European Medicines Agency, 2012. Accessed 18 August 2022. Available from www.ema.europa.eu/docs/en_GB/document_ library/Scienti fi c_guideline/2012/06/WC500129256. pdf 265. Food and Drug Administration. Draft guidance for industry on diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention  guidance document. Silver Spring, MD, Food and Drug Administration, 2008. Accessed 22 June 2022. Available from www.regulations.gov/document/FDA-2008-D-0118- 0003 266. Karagiannis T, Tsapas A, Athanasiadou E, et al. GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract 2021;174:108737 267. Andes LJ, Cheng YJ, Rolka DB, Gregg EW, Imperatore G. Prevalence of prediabetes among adolescents and young adults in the United States, 2005-2016. JAMA Pediatr 2020;174:e194498 268. Dabelea D, Bell RA, D  Agostino RB Jr, et al.; Writing Group for the SEARCH for Diabetes in Youth Study Group. Incidence of diabetes in youth in the United States. JAMA 2007;297:2716  2724 269","tf":{"18":1,"22":1,"44":1,"174":2,"264":1,"265":1,"266":1,"267":1,"268":1,"269":1,"297":1,"1622":1,"1629":1,"2005":1,"2007":1,"2008":2,"2012":2,"2016":1,"2020":1,"2021":2,"2022":2,"2716":1,"2724":1,"108737":1,"control":1,"and":8,"blood":1,"pressure":1,"lowering":1,"therapy":1,"for":6,"people":2,"with":2,"type":2,"diabetes":8,"results":1,"from":3,"the":5,"advance":1,"trial":1,"care":1,"european":2,"medicines":2,"agency":2,"guideline":2,"on":2,"clinical":1,"investigation":1,"of":4,"medicinal":1,"products":1,"in":5,"treatment":2,"or":1,"prevention":2,"mellitus":2,"amsterdam":1,"netherlands":1,"accessed":2,"august":1,"available":2,"www":2,"ema":1,"europa":1,"eu":1,"docs":1,"en":1,"gb":1,"document":3,"library":1,"scienti":1,"fi":1,"06":1,"wc500129256":1,"pdf":1,"food":2,"drug":2,"administration":2,"draft":1,"guidance":2,"industry":1,"developing":1,"drugs":1,"therapeutic":1,"biologics":1,"silver":1,"spring":1,"md":1,"june":1,"regulations":1,"gov":1,"fda":1,"0118":1,"0003":1,"karagiannis":1,"tsapas":1,"athanasiadou":1,"et":2,"al":2,"glp":1,"receptor":1,"agonists":1,"sglt2":1,"inhibitors":1,"older":1,"systematic":1,"review":1,"meta":1,"analysis":1,"res":1,"clin":1,"pract":1,"andes":1,"lj":1,"cheng":1,"yj":1,"rolka":1,"db":1,"gregg":1,"ew":1,"imperatore":1,"prevalence":1,"prediabetes":1,"among":1,"adolescents":1,"young":1,"adults":1,"united":2,"states":2,"jama":2,"pediatr":1,"e194498":1,"dabelea":1,"bell":1,"ra":1,"agostino":1,"rb":1,"jr":1,"writing":1,"group":2,"search":1,"youth":2,"study":1,"incidence":1},"len":208},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":33,"chunkId":"ada-easd-2022-p33-c8","text":"d States, 2005-2016. JAMA Pediatr 2020;174:e194498 268. Dabelea D, Bell RA, D  Agostino RB Jr, et al.; Writing Group for the SEARCH for Diabetes in Youth Study Group. Incidence of diabetes in youth in the United States. JAMA 2007;297:2716  2724 269. RISE Consortium. Impact of insulin and metformin versus metformin alone on b -cell function in youth with impaired glucose tolerance 2784 Consensus Report Diabetes Care Volume 45, November 2022 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"45":2,"174":1,"268":1,"269":1,"297":1,"2005":1,"2007":1,"2016":1,"2020":1,"2022":1,"2026":1,"2716":1,"2724":1,"2753":1,"2784":1,"691567":1,"states":2,"jama":2,"pediatr":1,"e194498":1,"dabelea":1,"bell":1,"ra":1,"agostino":1,"rb":1,"jr":1,"et":1,"al":1,"writing":1,"group":2,"for":2,"the":2,"search":1,"diabetes":3,"in":4,"youth":3,"study":1,"incidence":1,"of":2,"united":1,"rise":1,"consortium":1,"impact":1,"insulin":1,"and":1,"metformin":2,"versus":1,"alone":1,"on":2,"cell":1,"function":1,"with":1,"impaired":1,"glucose":1,"tolerance":1,"consensus":1,"report":1,"care":2,"volume":1,"november":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"february":1},"len":91},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":34,"chunkId":"ada-easd-2022-p34-c0","text":"or recently diagnosed type 2 diabetes. Diabetes Care 2018;41:1717  1725 270. RISE Consortium. Lack of durable improve- ments in b -cell function following withdrawal of pharmacological interventions in adults with impaired glucose tolerance or recently diagnosed type 2 diabetes. Diabetes Care 2019;42:1742  1751 271. Hannon TS, Arslanian SA. The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes. Ann N Y Acad Sci 2015;1353:113  137 272. TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and b -cell function in TODAY. Diabetes Care 2013;36:1749  1757 273. Jalaludin MY, Deeb A, Zeitler P, et al. Ef fi cacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin. Pediatr Diabetes 2022; 23:183  193 274. Bjornstad P, Drews KL, Caprio S, et al.; TODAY Study Group. Long-term complications in youth-onset type 2 diabetes. N Engl J Med 2021;385:416  426 275. Gregg EW, Hora I, Benoit SR. Resurgence in diabetes-related complications. JAMA 2019;321: 1867  1868 276. Chan JCN, Pald \u0013 anius PM, Mathieu C, Stumvoll M, Matthews DR, Del Prato S. Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: a subanalysis of the VERIFY study. Diabetes O","tf":{"23":1,"36":1,"41":1,"42":1,"113":1,"137":1,"183":1,"193":1,"270":1,"271":1,"272":1,"273":1,"274":1,"275":1,"276":1,"321":1,"385":1,"416":1,"426":1,"1353":1,"1717":1,"1725":1,"1742":1,"1749":1,"1751":1,"1757":1,"1867":1,"1868":1,"2013":1,"2015":1,"2018":1,"2019":2,"2021":1,"2022":1,"or":3,"recently":2,"diagnosed":3,"type":6,"diabetes":13,"care":3,"rise":1,"consortium":1,"lack":1,"of":9,"durable":1,"improve":1,"ments":1,"in":7,"cell":2,"function":2,"following":1,"withdrawal":1,"pharmacological":1,"interventions":1,"adults":1,"with":3,"impaired":1,"glucose":1,"tolerance":1,"hannon":1,"ts":1,"arslanian":1,"sa":1,"the":3,"changing":1,"face":1,"youth":3,"lessons":1,"learned":1,"from":1,"studies":1,"ann":1,"acad":1,"sci":1,"today":3,"study":3,"group":2,"effects":1,"metformin":4,"plus":2,"rosiglitazone":1,"and":4,"lifestyle":1,"on":2,"insulin":2,"sensitivity":1,"jalaludin":1,"my":1,"deeb":1,"zeitler":1,"et":2,"al":2,"ef":1,"fi":1,"cacy":1,"safety":1,"addition":1,"sitagliptin":1,"to":1,"treatment":2,"inadequate":1,"glycemic":1,"control":1,"without":1,"pediatr":1,"bjornstad":1,"drews":1,"kl":1,"caprio":1,"long":1,"term":1,"complications":2,"onset":2,"engl":1,"med":1,"gregg":1,"ew":1,"hora":1,"benoit":1,"sr":1,"resurgence":1,"related":1,"jama":1,"chan":1,"jcn":1,"pald":1,"anius":1,"pm":1,"mathieu":1,"stumvoll":1,"matthews":1,"dr":1,"del":1,"prato":1,"early":1,"combination":1,"therapy":1,"delayed":1,"escalation":1,"newly":1,"young":1,"subanalysis":1,"verify":1},"len":209},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":34,"chunkId":"ada-easd-2022-p34-c1","text":"019;321: 1867  1868 276. Chan JCN, Pald \u0013 anius PM, Mathieu C, Stumvoll M, Matthews DR, Del Prato S. Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: a subanalysis of the VERIFY study. Diabetes Obes Metab 2021;23:245  251 277. Bhattarai M, Salih M, Regmi M, et al. Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in patients with type 2 diabetes and other risk factors for cardiovascular disease: a meta-analysis. JAMA Netw Open 2022;5:e2142078 278. Mishriky BM, Powell JR, Wittwer JA, et al. Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis. Diabetes Obes Metab 2019;21:2274  2283 279. Food and Drug Administration. Diversity plans to improve enrollment of participants from underrepresented racial and ethnic populations in clinical trials; draft guidance for industry; availability. Silver Spring, MD, Food and Drug Administration, 2022. Accessed 22 June 2022. Available from www.fda.gov/regulatory-nformation/ isearch-fda-guidance-documents/diversity-plans- improve-enrollment-participants-underrepresented- racial-and-ethnic-populations 280. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001;44(Suppl. 2","tf":{"21":1,"22":1,"23":1,"44":1,"245":1,"251":1,"276":1,"277":1,"278":1,"279":1,"280":1,"321":1,"1867":1,"1868":1,"2001":1,"2019":1,"2021":1,"2022":3,"2274":1,"2283":1,"019":1,"chan":1,"jcn":1,"pald":1,"anius":1,"pm":1,"mathieu":1,"stumvoll":1,"matthews":1,"dr":1,"del":1,"prato":1,"early":1,"combination":1,"therapy":1,"delayed":1,"treatment":1,"escalation":1,"in":6,"newly":1,"diagnosed":1,"young":1,"onset":1,"type":3,"diabetes":6,"subanalysis":1,"of":5,"the":2,"verify":1,"study":2,"obes":2,"metab":2,"bhattarai":1,"salih":1,"regmi":1,"et":2,"al":2,"association":1,"sodium":1,"glucose":1,"cotransporter":1,"inhibitors":1,"with":3,"cardiovascular":3,"outcomes":1,"patients":2,"and":8,"other":1,"risk":1,"factors":1,"for":2,"disease":2,"meta":2,"analysis":2,"jama":1,"netw":1,"open":1,"e2142078":1,"mishriky":1,"bm":1,"powell":1,"jr":1,"wittwer":1,"ja":1,"do":1,"glp":1,"1ras":1,"sglt":1,"2is":1,"reduce":1,"events":1,"black":1,"systematic":1,"review":1,"food":2,"drug":2,"administration":2,"diversity":2,"plans":2,"to":1,"improve":2,"enrollment":2,"participants":2,"from":2,"underrepresented":2,"racial":2,"ethnic":2,"populations":2,"clinical":1,"trials":1,"draft":1,"guidance":2,"industry":1,"availability":1,"silver":1,"spring":1,"md":1,"accessed":1,"june":1,"available":1,"www":1,"fda":2,"gov":1,"regulatory":1,"nformation":1,"isearch":1,"documents":1,"morrish":1,"nj":1,"wang":1,"sl":1,"stevens":1,"lk":1,"fuller":1,"jh":1,"keen":1,"mortality":1,"causes":1,"death":1,"who":1,"multinational":1,"vascular":1,"diabetologia":1,"suppl":1},"len":199},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":34,"chunkId":"ada-easd-2022-p34-c2","text":"rollment-participants-underrepresented- racial-and-ethnic-populations 280. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001;44(Suppl. 2):S14  S21 281. Regensteiner JG, Golden S, Huebschmann AG, et al.; American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health, Council on Epidemiology and Prevention, Council on Functional Genomics and Translational Biology, and Council on Hypertension. Sex differences in the cardiovascular consequences of diabetes mellitus: a scienti fi c statement from the American Heart Association. Circulation 2015;132: 2424  2447 282. Kannel WB, Wilson PW. Risk factors that attenuate the female coronary disease advantage. Arch Intern Med 1995;155:57  61 283. Hu G, Jousilahti P, Qiao Q, Katoh S, Tuomilehto J. Sex differences in cardiovascular and total mortality among diabetic and non- diabetic individuals with or without history of myocardial infarction. Diabetologia 2005;48: 856  861 284. Peters SAE, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet 2014;383: 1973  1980 285. Peters SAE, Huxley RR, Woodward M. Diabetes as risk factor for incident corona","tf":{"12":1,"44":1,"48":1,"57":1,"61":1,"64":1,"132":1,"155":1,"280":1,"281":1,"282":1,"283":1,"284":1,"285":1,"383":1,"385":1,"539":1,"775":1,"856":1,"861":1,"1973":1,"1980":1,"1995":1,"2001":1,"2005":1,"2014":1,"2015":1,"2424":1,"2447":1,"rollment":1,"participants":1,"underrepresented":1,"racial":1,"and":10,"ethnic":1,"populations":1,"morrish":1,"nj":1,"wang":1,"sl":1,"stevens":1,"lk":1,"fuller":1,"jh":1,"keen":1,"mortality":2,"causes":1,"of":6,"death":1,"in":5,"the":5,"who":1,"multinational":1,"study":1,"vascular":1,"disease":2,"diabetes":5,"diabetologia":2,"suppl":1,"s14":1,"s21":1,"regensteiner":1,"jg":1,"golden":1,"huebschmann":1,"ag":1,"et":1,"al":1,"american":2,"heart":2,"association":2,"committee":1,"council":4,"on":4,"lifestyle":1,"cardiometabolic":1,"health":1,"epidemiology":1,"prevention":1,"functional":1,"genomics":1,"translational":1,"biology":1,"hypertension":1,"sex":2,"differences":2,"cardiovascular":2,"consequences":1,"mellitus":1,"scienti":1,"fi":1,"statement":1,"from":1,"circulation":1,"kannel":1,"wb":1,"wilson":1,"pw":1,"risk":3,"factors":1,"that":1,"attenuate":1,"female":1,"coronary":1,"advantage":1,"arch":1,"intern":1,"med":1,"hu":1,"jousilahti":1,"qiao":1,"katoh":1,"tuomilehto":1,"total":1,"among":1,"diabetic":2,"non":1,"individuals":2,"with":2,"or":1,"without":1,"history":1,"myocardial":1,"infarction":1,"peters":2,"sae":2,"huxley":2,"rr":2,"woodward":2,"as":2,"factor":2,"for":2,"stroke":1,"women":1,"compared":1,"men":1,"systematic":1,"review":1,"meta":1,"analysis":1,"cohorts":1,"including":1,"strokes":1,"lancet":1,"incident":1,"corona":1},"len":200},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":34,"chunkId":"ada-easd-2022-p34-c3","text":"stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet 2014;383: 1973  1980 285. Peters SAE, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia 2014;57:1542  1551 286. Peters SAE, Woodward M. Sex differences in the burden and complications of diabetes. Curr Diab Rep 2018;18:33 287. Clemens KK, Woodward M, Neal B, Zinman B. Sex disparities in cardiovascular outcome trials of populations with diabetes: a systematic review and meta-analysis. Diabetes Care 2020;43:1157  1163 288. Singh AK, Singh R. Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: a systematic review and meta-analysis of cardio- vascular outcome trials. Diabetes Metab Syndr 2020;14:181  187 289. Rdholm K, Zhou Z, Clemens K, Neal B, Woodward M. Effects of sodium-glucose co- transporter-2 inhibitors in type 2 diabetes in women versus men. Diabetes Obes Metab 2020; 22:263  266 290. Lazarus JV, Mark HE, Anstee QM, et al.; NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol 2022;19:60  78 291. Kanwal ","tf":{"12":1,"14":1,"18":1,"19":1,"22":1,"28":1,"33":1,"43":1,"57":1,"60":1,"64":2,"78":1,"181":1,"187":1,"203":1,"263":1,"266":1,"285":1,"286":1,"287":1,"288":1,"289":1,"290":1,"291":1,"383":1,"385":1,"507":1,"539":1,"775":1,"858":1,"1157":1,"1163":1,"1542":1,"1551":1,"1973":1,"1980":1,"2014":2,"2018":1,"2020":3,"2022":1,"stroke":1,"in":8,"women":3,"compared":2,"with":4,"men":3,"systematic":4,"review":4,"and":8,"meta":4,"analysis":4,"of":6,"cohorts":2,"including":2,"individuals":2,"strokes":1,"lancet":1,"peters":2,"sae":2,"huxley":1,"rr":1,"woodward":4,"diabetes":8,"as":1,"risk":1,"factor":1,"for":2,"incident":1,"coronary":2,"heart":1,"disease":1,"events":1,"diabetologia":1,"sex":2,"differences":1,"the":2,"burden":1,"complications":1,"curr":1,"diab":1,"rep":1,"clemens":2,"kk":1,"neal":2,"zinman":1,"disparities":1,"cardiovascular":2,"outcome":2,"trials":2,"populations":1,"care":1,"singh":2,"ak":1,"gender":1,"difference":1,"outcomes":1,"sglt":1,"inhibitors":2,"glp":1,"receptor":1,"agonist":1,"type":2,"cardio":1,"vascular":1,"metab":2,"syndr":1,"dholm":1,"zhou":1,"effects":1,"sodium":1,"glucose":1,"co":1,"transporter":1,"versus":1,"obes":1,"lazarus":1,"jv":1,"mark":1,"he":1,"anstee":1,"qm":1,"et":1,"al":1,"nafld":2,"consensus":2,"consortium":1,"advancing":1,"global":1,"public":1,"health":1,"agenda":1,"statement":1,"nat":1,"rev":1,"gastroenterol":1,"hepatol":1,"kanwal":1},"len":210},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":34,"chunkId":"ada-easd-2022-p34-c4","text":"en. Diabetes Obes Metab 2020; 22:263  266 290. Lazarus JV, Mark HE, Anstee QM, et al.; NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol 2022;19:60  78 291. Kanwal F, Shubrook JH, Adams LA, et al. Clinical care pathway for the risk strati fi cation and management of patients with nonalcoholic fatty liver disease. Gastroenterology 2021;161: 1657  1669 292. Newsome PN, Buchholtz K, Cusi K, et al.; NN9931-4296 Investigators. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021;384:1113  1124 293. Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and advanced liver fi brosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med 2017;177:633  640 294. Panunzi S, Maltese S, Verrastro O, et al. Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: a hierarchical network meta-analysis. Diabetes Obes Metab 2021;23:980  990 295. Mantovani A, Byrne CD, Scorletti E, Mantzoros CS, Targher G. Ef fi cacy and safety of anti-hyperglycaemic drugs in patients with non- alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. Diabetes Metab 2020;46:427  441 296. Lassailly G, Caiazzo R, Ntandja-Wandji LC, et al. Bariatric ","tf":{"19":1,"22":1,"23":1,"46":1,"60":1,"78":1,"161":1,"177":1,"263":1,"266":1,"290":1,"291":1,"292":1,"293":1,"294":1,"295":1,"296":1,"384":1,"427":1,"441":1,"633":1,"640":1,"980":1,"990":1,"1113":1,"1124":1,"1657":1,"1669":1,"2017":1,"2020":2,"2021":3,"2022":1,"4296":1,"en":1,"diabetes":4,"obes":2,"metab":3,"lazarus":1,"jv":1,"mark":1,"he":1,"anstee":1,"qm":1,"et":5,"al":5,"nafld":2,"consensus":2,"consortium":1,"advancing":1,"the":3,"global":1,"public":1,"health":1,"agenda":1,"for":3,"statement":1,"nat":1,"rev":1,"gastroenterol":1,"hepatol":1,"kanwal":1,"shubrook":1,"jh":1,"adams":1,"la":1,"clinical":1,"care":1,"pathway":1,"risk":1,"strati":1,"fi":3,"cation":1,"and":4,"management":1,"of":4,"patients":2,"with":3,"nonalcoholic":3,"fatty":2,"liver":3,"disease":2,"gastroenterology":1,"newsome":1,"pn":1,"buchholtz":1,"cusi":1,"nn9931":1,"investigators":1,"placebo":1,"controlled":2,"trial":1,"subcutaneous":1,"semaglutide":1,"in":3,"steatohepatitis":3,"engl":1,"med":2,"musso":1,"cassader":1,"paschetta":1,"gambino":1,"thiazolidinediones":1,"advanced":1,"brosis":1,"meta":2,"analysis":2,"jama":1,"intern":1,"panunzi":1,"maltese":1,"verrastro":1,"pioglitazone":1,"bariatric":2,"surgery":1,"are":1,"most":1,"effective":1,"treatments":1,"non":2,"alcoholic":2,"hierarchical":1,"network":1,"mantovani":1,"byrne":1,"cd":1,"scorletti":1,"mantzoros":1,"cs":1,"targher":1,"ef":1,"cacy":1,"safety":1,"anti":1,"hyperglycaemic":1,"drugs":1,"or":1,"without":1,"an":1,"updated":1,"systematic":1,"review":1,"randomized":1,"trials":1,"lassailly":1,"caiazzo":1,"ntandja":1,"wandji":1,"lc":1},"len":199},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":34,"chunkId":"ada-easd-2022-p34-c5","text":"aemic drugs in patients with non- alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. Diabetes Metab 2020;46:427  441 296. Lassailly G, Caiazzo R, Ntandja-Wandji LC, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fi brosis. Gastroenterology 2020;159:1290  1301.e5 297. Russo MF, Lembo E, Mari A, et al. Insulin resistance is central to long-term reversal of histologic nonalcoholic steatohepatitis after metabolic surgery. J Clin Endocrinol Metab 2021;106:750  761 298. Hartman ML, Sanyal AJ, Loomba R, et al. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care 2020;43:1352  1355 299. Ghosal S, Datta D, Sinha B. A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D). Sci Rep 2021;11:22063 300. Coelho FDS, Borges-Canha M, von Hafe M, et al. Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: a meta-analysis of randomized clinical trials. Diabetes Metab Res Rev 2021;37:e3413 301. Dwinata M, Putera DD, Hasan I, Raharjo M. SGLT2 inhibitors for improving hepatic fi brosis and steatosis in non-alcoholic fatty liver disease ","tf":{"11":1,"37":1,"43":1,"46":1,"106":1,"159":1,"296":1,"297":1,"298":1,"299":1,"300":1,"301":1,"427":1,"441":1,"750":1,"761":1,"1290":1,"1301":1,"1352":1,"1355":1,"2020":3,"2021":3,"22063":1,"aemic":1,"drugs":1,"in":4,"patients":2,"with":4,"non":2,"alcoholic":2,"fatty":3,"liver":4,"disease":3,"or":1,"without":1,"diabetes":6,"an":1,"updated":1,"systematic":1,"review":1,"of":10,"randomized":2,"controlled":1,"trials":2,"metab":3,"lassailly":1,"caiazzo":1,"ntandja":1,"wandji":1,"lc":1,"et":4,"al":4,"bariatric":1,"surgery":2,"provides":1,"long":2,"term":2,"resolution":1,"nonalcoholic":4,"steatohepatitis":3,"and":4,"regression":1,"fi":2,"brosis":2,"gastroenterology":1,"e5":1,"russo":1,"mf":1,"lembo":1,"mari":1,"insulin":1,"resistance":1,"is":1,"central":1,"to":1,"reversal":1,"histologic":1,"after":1,"metabolic":1,"clin":1,"endocrinol":1,"hartman":1,"ml":1,"sanyal":1,"aj":1,"loomba":1,"effects":3,"novel":1,"dual":1,"gip":1,"glp":1,"receptor":2,"agonist":2,"tirzepatide":1,"on":2,"biomarkers":1,"type":2,"care":1,"ghosal":1,"datta":1,"sinha":1,"meta":2,"analysis":2,"the":1,"glucagon":1,"like":1,"peptide":1,"glp1":1,"ra":1,"nafld":1,"t2d":1,"sci":1,"rep":1,"coelho":1,"fds":1,"borges":1,"canha":1,"von":1,"hafe":1,"sodium":1,"glucose":1,"co":1,"transporter":1,"inhibitors":2,"parameters":1,"steatosis":2,"clinical":1,"res":1,"rev":1,"e3413":1,"dwinata":1,"putera":1,"dd":1,"hasan":1,"raharjo":1,"sglt2":1,"for":1,"improving":1,"hepatic":1},"len":206},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":34,"chunkId":"ada-easd-2022-p34-c6","text":"ers and steatosis: a meta-analysis of randomized clinical trials. Diabetes Metab Res Rev 2021;37:e3413 301. Dwinata M, Putera DD, Hasan I, Raharjo M. SGLT2 inhibitors for improving hepatic fi brosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review. Clin Exp Hepatol 2020;6:339  346 302. Shao SC, Kuo LT, Chien RN, Hung MJ, Lai ECC. SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews. BMJ Open Diabetes Res Care 2020;8:e001956 303. Bril F, Cusi K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action. Diabetes Care 2017;40: 419  430 304. Wojeck BS, Inzucchi SE, Neeland IJ, et al. Ertugli fl ozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial. Sleep Breath 2022 305. Neeland IJ, Eliasson B, Kasai T, et al.; EMPA- REG OUTCOME Investigators. The impact of empagli fl ozin on obstructive sleep apnea and cardiovascular and renal outcomes: an expl- oratory analysis of the EMPA-REG OUTCOME trial. Diabetes Care 2020;43:3007  3015 306. Levengood TW, Peng Y, Xiong KZ, et al.; Community Preventive Services Task Force. Team- based care to improve diabetes management: a community guide meta-analysis. Am J Prev Med 2019;57:e17  e26 307. Chamnan P, Simmons RK, Sharp SJ, Grif fi n S","tf":{"37":1,"40":1,"43":1,"57":1,"301":1,"302":1,"303":1,"304":1,"305":1,"306":1,"307":1,"339":1,"346":1,"419":1,"430":1,"2017":1,"2019":1,"2020":3,"2021":1,"2022":1,"3007":1,"3015":1,"ers":1,"and":5,"steatosis":2,"meta":2,"analysis":4,"of":5,"randomized":1,"clinical":1,"trials":1,"diabetes":8,"metab":1,"res":2,"rev":1,"e3413":1,"dwinata":1,"putera":1,"dd":1,"hasan":1,"raharjo":1,"sglt2":2,"inhibitors":2,"for":1,"improving":1,"hepatic":1,"fi":2,"brosis":1,"in":3,"non":2,"alcoholic":2,"fatty":3,"liver":3,"disease":2,"complicated":1,"with":4,"type":3,"mellitus":1,"systematic":2,"review":2,"clin":1,"exp":1,"hepatol":1,"shao":1,"sc":1,"kuo":1,"lt":1,"chien":1,"rn":1,"hung":1,"mj":1,"lai":1,"ecc":1,"patients":2,"diseases":1,"an":3,"umbrella":1,"reviews":1,"bmj":1,"open":1,"care":4,"e001956":1,"bril":1,"cusi":1,"management":2,"nonalcoholic":1,"call":1,"to":2,"action":1,"wojeck":1,"bs":1,"inzucchi":1,"se":1,"neeland":2,"ij":2,"et":3,"al":3,"ertugli":1,"fl":2,"ozin":2,"incident":1,"obstructive":2,"sleep":3,"apnea":2,"from":1,"the":3,"vertis":1,"cv":1,"trial":2,"breath":1,"eliasson":1,"kasai":1,"empa":2,"reg":2,"outcome":2,"investigators":1,"impact":1,"empagli":1,"on":1,"cardiovascular":1,"renal":1,"outcomes":1,"expl":1,"oratory":1,"levengood":1,"tw":1,"peng":1,"xiong":1,"kz":1,"community":2,"preventive":1,"services":1,"task":1,"force":1,"team":1,"based":1,"improve":1,"guide":1,"am":1,"prev":1,"med":1,"e17":1,"e26":1,"chamnan":1,"simmons":1,"rk":1,"sharp":1,"sj":1,"grif":1},"len":218},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":34,"chunkId":"ada-easd-2022-p34-c7","text":"306. Levengood TW, Peng Y, Xiong KZ, et al.; Community Preventive Services Task Force. Team- based care to improve diabetes management: a community guide meta-analysis. Am J Prev Med 2019;57:e17  e26 307. Chamnan P, Simmons RK, Sharp SJ, Grif fi n SJ, Wareham NJ. Cardiovascular risk assessment scores for people with diabetes: a systematic review. Diabetologia 2009;52:2001  2014 308. Srikanth V, Sinclair AJ, Hill-Briggs F, Moran C, Biessels GJ. Type 2 diabetes and cognitive dysfunction  towards effective management of both comorbidities. Lancet Diabetes Endocrinol 2020;8:535  545 309. Palta P, Schneider ALC, Biessels GJ, Touradji P, Hill-Briggs F. Magnitude of cognitive dysfunction in adults with type 2 diabetes: a meta-analysis of six cognitive domains and the most frequently reported neuropsychological tests within domains. J Int Neuropsychol Soc 2014;20:278  291 310. Evert AB, Dennison M, Gardner CD, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care 2019;42:731  754 311. Centers for Disease Control and Prevention. Writing SMART objectives. Atlanta, GA, Centers for Disease Control and Prevention, 2019. Accessed 22 June 2022. Available from www.cdc.gov/dhdsp/ diabetesjournals.org/care Davies and Associates 2785 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 Febru","tf":{"11":1,"17":1,"20":1,"22":1,"42":1,"45":1,"52":1,"57":1,"278":1,"291":1,"306":1,"307":1,"308":1,"309":1,"310":1,"311":1,"535":1,"545":1,"731":1,"754":1,"2001":1,"2009":1,"2014":2,"2019":3,"2020":1,"2022":1,"2753":1,"2785":1,"691567":1,"levengood":1,"tw":1,"peng":1,"xiong":1,"kz":1,"et":2,"al":2,"community":2,"preventive":1,"services":1,"task":1,"force":1,"team":1,"based":1,"care":4,"to":1,"improve":1,"diabetes":7,"management":2,"guide":1,"meta":2,"analysis":2,"am":1,"prev":1,"med":1,"e17":1,"e26":1,"chamnan":1,"simmons":1,"rk":1,"sharp":1,"sj":2,"grif":1,"fi":1,"wareham":1,"nj":1,"cardiovascular":1,"risk":1,"assessment":1,"scores":1,"for":4,"people":1,"with":3,"systematic":1,"review":1,"diabetologia":1,"srikanth":1,"sinclair":1,"aj":1,"hill":2,"briggs":2,"moran":1,"biessels":2,"gj":2,"type":2,"and":5,"cognitive":3,"dysfunction":2,"towards":1,"effective":1,"of":3,"both":1,"comorbidities":1,"lancet":1,"endocrinol":1,"palta":1,"schneider":1,"alc":1,"touradji":1,"magnitude":1,"in":1,"adults":2,"six":1,"domains":2,"the":1,"most":1,"frequently":1,"reported":1,"neuropsychological":1,"tests":1,"within":1,"int":1,"neuropsychol":1,"soc":1,"evert":1,"ab":1,"dennison":1,"gardner":1,"cd":1,"nutrition":1,"therapy":1,"or":1,"prediabetes":1,"consensus":1,"report":1,"centers":2,"disease":2,"control":2,"prevention":2,"writing":1,"smart":1,"objectives":1,"atlanta":1,"ga":1,"accessed":1,"june":1,"available":1,"from":2,"www":1,"cdc":1,"gov":1,"dhdsp":1,"diabetesjournals":2,"org":2,"davies":1,"associates":1,"downloaded":1,"http":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"febru":1},"len":202},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":34,"chunkId":"ada-easd-2022-p34-c8","text":"trol and Prevention, 2019. Accessed 22 June 2022. Available from www.cdc.gov/dhdsp/ diabetesjournals.org/care Davies and Associates 2785 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"22":1,"45":1,"2019":1,"2022":1,"2026":1,"2753":1,"2785":1,"691567":1,"trol":1,"and":2,"prevention":1,"accessed":1,"june":1,"available":1,"from":2,"www":1,"cdc":1,"gov":1,"dhdsp":1,"diabetesjournals":2,"org":2,"care":2,"davies":1,"associates":1,"downloaded":1,"http":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"february":1},"len":41},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":35,"chunkId":"ada-easd-2022-p35-c0","text":"evaluation_resources/guides/writing-smart- objectives.htm 312. Pi-Sunyer X. The Look AHEAD trial: a review and discussion of its outcomes. Curr Nutr Rep 2014;3:387  391 313. Cahn A, Raz I, Leiter LA, et al. Cardiovascular, renal, and metabolic outcomes of dapagli fl ozin versus placebo in a primary cardiovascular prevention cohort: analyses from DECLARE- TIMI 58. Diabetes Care 2021;44:1159  1167 314. Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311  322 315. Gerstein HC, Colhoun HM, Dagenais GR, et al.; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo- controlled trial. Lancet 2019;394:121  130 316. Kahl S, Ofstad AP, Zinman B, et al. Effects of empagli fl ozin on markers of liver steatosis and fi brosis and their relationship to cardiorenal outcomes. Diabetes Obes Metab 2022;24:1061  1071 317. Brownrigg JRW, Hughes CO, Burleigh D, et al. Microvascular disease and risk of cardio- vascular events among individuals with type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol 2016;4:588  597 318. Mearns ES, Saulsberry WJ, White CM, et al. Ef fi cacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy i","tf":{"24":1,"44":1,"58":1,"121":1,"130":1,"311":1,"312":1,"313":1,"314":1,"315":1,"316":1,"317":1,"318":1,"322":1,"375":1,"387":1,"391":1,"394":1,"588":1,"597":1,"1061":1,"1071":1,"1159":1,"1167":1,"2014":1,"2016":2,"2019":1,"2021":1,"2022":1,"evaluation":1,"resources":1,"guides":1,"writing":1,"smart":1,"objectives":1,"htm":1,"pi":1,"sunyer":1,"the":1,"look":1,"ahead":1,"trial":3,"review":1,"and":9,"discussion":1,"of":6,"its":1,"outcomes":5,"curr":1,"nutr":1,"rep":1,"cahn":1,"raz":1,"leiter":1,"la":1,"et":6,"al":6,"cardiovascular":4,"renal":1,"metabolic":1,"dapagli":1,"fl":2,"ozin":2,"versus":1,"placebo":2,"in":3,"primary":1,"prevention":1,"cohort":2,"analyses":1,"from":1,"declare":1,"timi":1,"diabetes":6,"care":1,"marso":1,"sp":1,"daniels":1,"gh":1,"brown":1,"frandsen":1,"leader":2,"steering":1,"committee":1,"investigators":2,"liraglutide":1,"type":3,"engl":1,"med":1,"gerstein":1,"hc":1,"colhoun":1,"hm":1,"dagenais":1,"gr":1,"rewind":2,"dulaglutide":1,"double":1,"blind":1,"randomised":1,"controlled":1,"lancet":2,"kahl":1,"ofstad":1,"ap":1,"zinman":1,"effects":1,"empagli":1,"on":1,"markers":1,"liver":1,"steatosis":1,"fi":2,"brosis":1,"their":1,"relationship":1,"to":2,"cardiorenal":1,"obes":1,"metab":1,"brownrigg":1,"jrw":1,"hughes":1,"co":1,"burleigh":1,"microvascular":1,"disease":1,"risk":1,"cardio":1,"vascular":1,"events":1,"among":1,"individuals":1,"with":1,"population":1,"level":1,"study":1,"endocrinol":1,"mearns":1,"es":1,"saulsberry":1,"wj":1,"white":1,"cm":1,"ef":1,"cacy":1,"safety":1,"antihyperglycaemic":1,"drug":1,"regimens":1,"added":1,"metformin":1,"sulphonylurea":1,"therapy":1},"len":206},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":35,"chunkId":"ada-easd-2022-p35-c1","text":"ith type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol 2016;4:588  597 318. Mearns ES, Saulsberry WJ, White CM, et al. Ef fi cacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in type 2 diabetes: a network meta- analysis. Diabet Med 2015;32:1530  1540 319. Zaccardi F, Dhalwani NN, Dales J, et al. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials. Diabetes Obes Metab 2018;20:985  997 320. Downes MJ, Bettington EK, Gunton JE, Turkstra E. Triple therapy in type 2 diabetes; a systematic review and network meta-analysis. PeerJ 2015;3:e1461 321. Lee CMY, Woodward M, Colagiuri S. Triple therapy combinations for the treatment of type 2 diabetes  a network meta-analysis. Diabetes Res Clin Pract 2016;116:149  158 322. Lukashevich V, Del Prato S, Araga M, Kothny W. Ef fi cacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes Obes Metab 2014;16: 403  409 323. Hong AR, Lee J, Ku EJ, et al. Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): a randomized trial","tf":{"16":1,"20":1,"32":1,"116":1,"149":1,"158":1,"318":1,"319":1,"320":1,"321":1,"322":1,"323":1,"403":1,"409":1,"588":1,"597":1,"985":1,"997":1,"1530":1,"1540":1,"2014":1,"2015":2,"2016":2,"2018":1,"ith":1,"type":7,"diabetes":11,"population":1,"level":1,"cohort":1,"study":2,"lancet":1,"endocrinol":1,"mearns":1,"es":1,"saulsberry":1,"wj":1,"white":1,"cm":1,"et":3,"al":3,"ef":2,"fi":2,"cacy":2,"and":8,"safety":2,"of":7,"antihyperglycaemic":1,"drug":1,"regimens":1,"added":1,"to":1,"metformin":3,"sulphonylurea":2,"therapy":6,"in":5,"network":4,"meta":4,"analysis":4,"diabet":1,"med":1,"zaccardi":1,"dhalwani":1,"nn":1,"dales":1,"comparison":2,"glucose":1,"lowering":1,"agents":1,"after":1,"dual":2,"failure":1,"systematic":2,"review":2,"randomized":2,"controlled":3,"trials":1,"obes":2,"metab":2,"downes":1,"mj":1,"bettington":1,"ek":1,"gunton":1,"je":1,"turkstra":1,"triple":2,"peerj":1,"e1461":1,"lee":2,"cmy":1,"woodward":1,"colagiuri":1,"combinations":1,"for":1,"the":1,"treatment":1,"res":1,"clin":1,"pract":1,"lukashevich":1,"del":1,"prato":1,"araga":1,"kothny":1,"vildagliptin":2,"patients":2,"with":3,"mellitus":1,"inadequately":2,"combination":1,"hong":1,"ar":1,"ku":1,"ej":1,"as":1,"an":1,"add":1,"on":1,"sulfonylurea":2,"dose":1,"increasing":1,"using":1,"visual":1,"trial":1},"len":203},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":35,"chunkId":"ada-easd-2022-p35-c2","text":"9 323. Hong AR, Lee J, Ku EJ, et al. Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): a randomized trial. Diabetes Res Clin Pract 2015;109:141  148 324. Moses RG, Kalra S, Brook D, et al. A randomized controlled trial of the ef fi cacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. Diabetes Obes Metab 2014;16:443  450 325. Moses RG, Round E, Shentu Y, et al. A randomized clinical trial evaluating the safety and ef fi cacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. J Diabetes 2016;8:701  711 326. American Diabetes Association. Overcoming therapeutic inertia. Alexandria, VA, American Diabetes Association. Accessed 3 September 2019. Available from https://professional.diabetes.org/ meeting/other/overcoming-therapeutic-inertia 327. Madenidou AV, Paschos P, Karagiannis T, et al. Comparative bene fi ts and harms of basal insulin analogues for type 2 diabetes: a systematic review and network meta-analysis. Ann Intern Med 2018;169:165  174 328. Monnier, L, Colette, C. Addition of rapid- acting insulin to basal insulin therapy in type 2 diabet","tf":{"16":1,"109":1,"141":1,"148":1,"165":1,"169":1,"174":1,"323":1,"324":1,"325":1,"326":1,"327":1,"328":1,"443":1,"450":1,"701":1,"711":1,"2014":1,"2015":1,"2016":1,"2018":1,"2019":1,"hong":1,"ar":1,"lee":1,"ku":1,"ej":1,"et":4,"al":4,"comparison":1,"of":7,"vildagliptin":1,"as":2,"an":1,"add":2,"on":3,"therapy":4,"and":9,"sulfonylurea":3,"dose":1,"increasing":1,"in":4,"patients":3,"with":3,"inadequately":1,"controlled":2,"type":5,"diabetes":10,"using":1,"metformin":3,"visual":1,"study":1,"randomized":3,"trial":3,"res":1,"clin":1,"pract":1,"moses":2,"rg":2,"kalra":1,"brook":1,"the":3,"ef":2,"fi":3,"cacy":2,"safety":2,"saxagliptin":1,"inadequate":2,"glycaemic":1,"control":2,"plus":1,"sulphonylurea":1,"obes":1,"metab":1,"round":1,"shentu":1,"clinical":1,"evaluating":1,"sitagliptin":1,"added":1,"to":2,"combination":1,"mellitus":1,"glycemic":1,"american":2,"association":2,"overcoming":2,"therapeutic":2,"inertia":2,"alexandria":1,"va":1,"accessed":1,"september":1,"available":1,"from":1,"https":1,"professional":1,"org":1,"meeting":1,"other":1,"madenidou":1,"av":1,"paschos":1,"karagiannis":1,"comparative":1,"bene":1,"ts":1,"harms":1,"basal":2,"insulin":3,"analogues":1,"for":1,"systematic":1,"review":1,"network":1,"meta":1,"analysis":1,"ann":1,"intern":1,"med":1,"monnier":1,"colette":1,"addition":1,"rapid":1,"acting":1,"diabet":1},"len":202},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":35,"chunkId":"ada-easd-2022-p35-c3","text":" fi ts and harms of basal insulin analogues for type 2 diabetes: a systematic review and network meta-analysis. Ann Intern Med 2018;169:165  174 328. Monnier, L, Colette, C. Addition of rapid- acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities. Diabetes Metab 2006;32:7  13 329. Nicolucci A, Ceriello A, Di Bartolo P, Corcos A, Orsini Federici M. Rapid-acting insulin analogues versus regular human insulin: a meta-analysis of effects on glycemic control in patients with diabetes. Diabetes Ther 2020;11:573  584 330. Christiansen JS, Niskanen L, Rasmussen S, Johansen T, Fulcher G. Lower rates of hypoglycemia during maintenance treatment with insulin degludec/ insulin aspart versus biphasic insulin aspart 30: a combined analysis of two phase 3a studies in type 2 diabetes. J Diabetes 2016;8:720  728 331. Gabler M, Picker N, Geier S, et al. Real- world clinical outcomes and costs in type 2 diabetes mellitus patients after initiation of insulin therapy: a German claims data analysis. Diabetes Res Clin Pract 2021;174:108734 332. McCarty D, Olenik A, McCarty BP. Ef fi cacy and safety of basal insulin/GLP-1 receptor agonist used in combination for type 2 diabetes management. J Pharm Pract 2019;32:671  678 333. Hangaard S, Laursen SH, Andersen JD, et al. The effectiveness of telemedicine solutions for the management of type 2 diabetes: a systematic r","tf":{"11":1,"13":1,"30":1,"32":2,"165":1,"169":1,"174":2,"328":1,"329":1,"330":1,"331":1,"332":1,"333":1,"573":1,"584":1,"671":1,"678":1,"720":1,"728":1,"2006":1,"2016":1,"2018":1,"2019":1,"2020":1,"2021":1,"108734":1,"fi":2,"ts":1,"and":5,"harms":1,"of":9,"basal":3,"insulin":10,"analogues":2,"for":3,"type":6,"diabetes":11,"systematic":2,"review":1,"network":1,"meta":2,"analysis":4,"ann":1,"intern":1,"med":1,"monnier":1,"colette":1,"addition":1,"rapid":2,"acting":2,"to":1,"therapy":2,"in":5,"indications":1,"modalities":1,"metab":1,"nicolucci":1,"ceriello":1,"di":1,"bartolo":1,"corcos":1,"orsini":1,"federici":1,"versus":2,"regular":1,"human":1,"effects":1,"on":1,"glycemic":1,"control":1,"patients":2,"with":2,"ther":1,"christiansen":1,"js":1,"niskanen":1,"rasmussen":1,"johansen":1,"fulcher":1,"lower":1,"rates":1,"hypoglycemia":1,"during":1,"maintenance":1,"treatment":1,"degludec":1,"aspart":2,"biphasic":1,"combined":1,"two":1,"phase":1,"3a":1,"studies":1,"gabler":1,"picker":1,"geier":1,"et":2,"al":2,"real":1,"world":1,"clinical":1,"outcomes":1,"costs":1,"mellitus":1,"after":1,"initiation":1,"german":1,"claims":1,"data":1,"res":1,"clin":1,"pract":2,"mccarty":2,"olenik":1,"bp":1,"ef":1,"cacy":1,"safety":1,"glp":1,"receptor":1,"agonist":1,"used":1,"combination":1,"management":2,"pharm":1,"hangaard":1,"laursen":1,"sh":1,"andersen":1,"jd":1,"the":2,"effectiveness":1,"telemedicine":1,"solutions":1},"len":200},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":35,"chunkId":"ada-easd-2022-p35-c4","text":"-1 receptor agonist used in combination for type 2 diabetes management. J Pharm Pract 2019;32:671  678 333. Hangaard S, Laursen SH, Andersen JD, et al. The effectiveness of telemedicine solutions for the management of type 2 diabetes: a systematic review, meta-analysis, and meta-regression. J Diabetes Sci Technol. 26 December 2021 [Epub ahead of print]. 334. Eberle C, Stichling S. Effect of telemetric interventions on glycated hemoglobin A1c and management of type 2 diabetes mellitus: sys- tematic meta-review. J Med Internet Res 2021; 23:e23252 335. Dicembrini I, Mannucci E, Monami M, Pala L. Impact of technology on glycaemic control in type 2 diabetes: A meta-analysis of randomized trials on continuous glucose monitoring and continuous subcutaneous insulin infusion. Diabetes Obes Metab 2019;21:2619  2625 336. Evans M, Welsh Z, Ells S, Seibold A. The impact of fl ash glucose monitoring on glycaemic control as measured by HbA1c: a meta-analysis of clinical trials and real-world observational studies. Diabetes Ther 2020;11:83  95 337. Martens T, Beck RW, Bailey R, et al.; MOBILE Study Group. Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. JAMA 2021; 325:2262  2272 338. Effective Practice and Organisation of Care (EPOC). (2015) EPOC taxonomy. London, U.K., 2015. Accessed 29 Ju","tf":{"11":1,"21":1,"23":1,"26":1,"29":1,"32":1,"83":1,"95":1,"325":1,"333":1,"334":1,"335":1,"336":1,"337":1,"338":1,"671":1,"678":1,"2015":2,"2019":2,"2020":1,"2021":3,"2262":1,"2272":1,"2619":1,"2625":1,"receptor":1,"agonist":1,"used":1,"in":3,"combination":1,"for":2,"type":5,"diabetes":8,"management":3,"pharm":1,"pract":1,"hangaard":1,"laursen":1,"sh":1,"andersen":1,"jd":1,"et":2,"al":2,"the":3,"effectiveness":1,"of":11,"telemedicine":1,"solutions":1,"systematic":1,"review":2,"meta":5,"analysis":3,"and":5,"regression":1,"sci":1,"technol":1,"december":1,"epub":1,"ahead":1,"print":1,"eberle":1,"stichling":1,"effect":2,"telemetric":1,"interventions":1,"on":5,"glycated":1,"hemoglobin":1,"a1c":1,"mellitus":1,"sys":1,"tematic":1,"med":1,"internet":1,"res":1,"e23252":1,"dicembrini":1,"mannucci":1,"monami":1,"pala":1,"impact":2,"technology":1,"glycaemic":2,"control":3,"randomized":2,"trials":2,"continuous":3,"glucose":3,"monitoring":3,"subcutaneous":1,"insulin":2,"infusion":1,"obes":1,"metab":1,"evans":1,"welsh":1,"ells":1,"seibold":1,"fl":1,"ash":1,"as":1,"measured":1,"by":1,"hba1c":1,"clinical":2,"real":1,"world":1,"observational":1,"studies":1,"ther":1,"martens":1,"beck":1,"rw":1,"bailey":1,"mobile":1,"study":1,"group":1,"glycemic":1,"patients":1,"with":2,"treated":1,"basal":1,"trial":1,"jama":1,"effective":1,"practice":1,"organisation":1,"care":1,"epoc":2,"taxonomy":1,"london":1,"accessed":1,"ju":1},"len":199},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":35,"chunkId":"ada-easd-2022-p35-c5","text":"on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. JAMA 2021; 325:2262  2272 338. Effective Practice and Organisation of Care (EPOC). (2015) EPOC taxonomy. London, U.K., 2015. Accessed 29 July 2022. Available from https://epoc.Cochrane.org/epoc-taxonomy 339. Chan JCN, Lim LL, Wareham NJ, et al. The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. Lancet 2021;396:2019  2082 340. World Health Organization. Diabetes. Geneva, Switzerland, World Health Organization, 2021. Accessed 1 August 2022. Available from www.who.int/news-room/fact-sheets/detail/ diabetes 341. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 2022;183:109119 342. Falcetta P, Aragona M, Bertolotto A, et al. Insulin discovery: a pivotal point in medical history. Metabolism 2022;127:154941 343. Beran D, Lazo-Porras M, Mba CM, Mbanya JC. A global perspective on the issue of access to insulin. Diabetologia 2021;64:954  962 344. Horwitz LI, Kuznetsova M, Jones SA. Creating a learning health system through rapid- cycle, randomized testing. N Engl J Med 2019; 381:1175  1179 345. McGinnis JM, Fineberg HV, Dzau VJ. Advancing the learning health system. N Engl J Med 2021;385:1  5 346. Sheikh ","tf":{"29":1,"64":1,"127":1,"183":1,"325":1,"338":1,"339":1,"340":1,"341":1,"342":1,"343":1,"344":1,"345":1,"346":1,"381":1,"385":1,"396":1,"954":1,"962":1,"1175":1,"1179":1,"2015":2,"2019":2,"2021":6,"2022":4,"2045":1,"2082":1,"2262":1,"2272":1,"109119":1,"154941":1,"on":3,"glycemic":1,"control":1,"in":2,"patients":1,"with":2,"type":1,"diabetes":8,"treated":1,"basal":1,"insulin":3,"randomized":2,"clinical":1,"trial":1,"jama":1,"effective":1,"practice":1,"and":4,"organisation":1,"of":2,"care":2,"epoc":4,"taxonomy":2,"london":1,"accessed":2,"july":1,"available":2,"from":2,"https":1,"cochrane":1,"org":1,"chan":1,"jcn":1,"lim":1,"ll":1,"wareham":1,"nj":1,"et":3,"al":3,"the":3,"lancet":2,"commission":1,"using":1,"data":1,"to":2,"transform":1,"patient":1,"lives":1,"world":2,"health":4,"organization":2,"geneva":1,"switzerland":1,"august":1,"www":1,"who":1,"int":1,"news":1,"room":1,"fact":1,"sheets":1,"detail":1,"sun":1,"saeedi":1,"karuranga":1,"idf":1,"atlas":1,"global":2,"regional":1,"country":1,"level":1,"prevalence":1,"estimates":1,"for":2,"projections":1,"res":1,"clin":1,"pract":1,"falcetta":1,"aragona":1,"bertolotto":1,"discovery":1,"pivotal":1,"point":1,"medical":1,"history":1,"metabolism":1,"beran":1,"lazo":1,"porras":1,"mba":1,"cm":1,"mbanya":1,"jc":1,"perspective":1,"issue":1,"access":1,"diabetologia":1,"horwitz":1,"li":1,"kuznetsova":1,"jones":1,"sa":1,"creating":1,"learning":2,"system":2,"through":1,"rapid":1,"cycle":1,"testing":1,"engl":2,"med":2,"mcginnis":1,"jm":1,"fineberg":1,"hv":1,"dzau":1,"vj":1,"advancing":1,"sheikh":1},"len":206},{"docId":"ada-easd-2022","docTitle":"ADA/EASD Consensus 2022","file":"ada-easd-2022.pdf","page":35,"chunkId":"ada-easd-2022-p35-c6","text":"netsova M, Jones SA. Creating a learning health system through rapid- cycle, randomized testing. N Engl J Med 2019; 381:1175  1179 345. McGinnis JM, Fineberg HV, Dzau VJ. Advancing the learning health system. N Engl J Med 2021;385:1  5 346. Sheikh A, Anderson M, Albala S, et al. Health information technology and digital innovation for national learning health and care systems. Lancet Digit Health 2021;3:e383  e396 2786 Consensus Report Diabetes Care Volume 45, November 2022 Downloaded from http://diabetesjournals.org/care/article-pdf/45/11/2753/691567/dci220034.pdf by guest on 17 February 2026","tf":{"11":1,"17":1,"45":2,"345":1,"346":1,"381":1,"385":1,"1175":1,"1179":1,"2019":1,"2021":2,"2022":1,"2026":1,"2753":1,"2786":1,"691567":1,"netsova":1,"jones":1,"sa":1,"creating":1,"learning":3,"health":5,"system":2,"through":1,"rapid":1,"cycle":1,"randomized":1,"testing":1,"engl":2,"med":2,"mcginnis":1,"jm":1,"fineberg":1,"hv":1,"dzau":1,"vj":1,"advancing":1,"the":1,"sheikh":1,"anderson":1,"albala":1,"et":1,"al":1,"information":1,"technology":1,"and":2,"digital":1,"innovation":1,"for":1,"national":1,"care":3,"systems":1,"lancet":1,"digit":1,"e383":1,"e396":1,"consensus":1,"report":1,"diabetes":1,"volume":1,"november":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"dci220034":1,"by":1,"guest":1,"on":1,"february":1},"len":88},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":1,"chunkId":"ada-2026-pharm-p1-c0","text":"9. PHARMACOLOGIC APPROACHES TO GLYCEMIC TREATMENT 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes2026 Diabetes Care 2026;49(Suppl. 1):S183  S215 | https://doi.org/10.2337/dc26-S009 American Diabetes Association Professional Practice Committee for Diabetes * * A complete list of members of the American Diabetes Association Professional Practice Committee for Diabetes can be found at https://doi.org/ 10.2337/dc26-SINT . Duality of interest information for each contributor is available at https://doi.org/10.2337/dc26-SDIS . Suggested citation: American Diabetes Association Professional Practice Committee for Diabetes. 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes2026. Diabetes Care 2026;49(Suppl. 1):S183  S215  2025 by the American Diabetes Association. Readers may use this work for educational, noncommercial purposes if properly cited and unaltered. The version of record may be linked at https://diabetesjournals.org/care , but ADA permission is required to post this work on any third-party site or platform. This publication and its contents may not be reproduced, distributed, or used for text or data mining, machine learning, or similar technologies without prior written permission. Requests to reuse, adapt, or distribute this work may be sent to permissions@diabetes .org . More information is available at h","tf":{"10":3,"49":2,"2025":1,"2026":4,"2337":3,"pharmacologic":3,"approaches":3,"to":6,"glycemic":3,"treatment":3,"standards":2,"of":6,"care":5,"in":2,"diabetes":12,"suppl":2,"s183":2,"s215":2,"https":4,"doi":3,"org":5,"dc26":3,"s009":1,"american":4,"association":4,"professional":3,"practice":3,"committee":3,"for":6,"complete":1,"list":1,"members":1,"the":3,"can":1,"be":4,"found":1,"at":4,"sint":1,"duality":1,"interest":1,"information":2,"each":1,"contributor":1,"is":3,"available":2,"sdis":1,"suggested":1,"citation":1,"by":1,"readers":1,"may":4,"use":1,"this":4,"work":3,"educational":1,"noncommercial":1,"purposes":1,"if":1,"properly":1,"cited":1,"and":2,"unaltered":1,"version":1,"record":1,"linked":1,"diabetesjournals":1,"but":1,"ada":1,"permission":2,"required":1,"post":1,"on":1,"any":1,"third":1,"party":1,"site":1,"or":5,"platform":1,"publication":1,"its":1,"contents":1,"not":1,"reproduced":1,"distributed":1,"used":1,"text":1,"data":1,"mining":1,"machine":1,"learning":1,"similar":1,"technologies":1,"without":1,"prior":1,"written":1,"requests":1,"reuse":1,"adapt":1,"distribute":1,"sent":1,"permissions":1,"more":1},"len":202},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":1,"chunkId":"ada-2026-pharm-p1-c1","text":" distributed, or used for text or data mining, machine learning, or similar technologies without prior written permission. Requests to reuse, adapt, or distribute this work may be sent to permissions@diabetes .org . More information is available at https:// diabetesjournals.org/journals/pages/license . The American Diabetes Association (ADA) Standards of Care in Diabetes includes the ADAs current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee for Diabetes , an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed descrip - tion of ADA standards, statements, and reports, as well as the evidence-grading sys - tem for ADAs clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology . Read - ers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC . PHARMACOLOGIC THERAPY FOR ADULTS WITH TYPE 1 DIABETES Recommendations 9.1 Treat most adults with type 1 diabetes with continuous subcutaneous insulin in - fusion or multiple daily doses of prandial (injected or inhaled) and basal insulin. A 9.2 Fo","tf":{"distributed":1,"or":7,"used":1,"for":6,"text":1,"data":1,"mining":1,"machine":1,"learning":1,"similar":1,"technologies":1,"without":1,"prior":1,"written":1,"permission":1,"requests":1,"to":7,"reuse":1,"adapt":1,"distribute":1,"this":1,"work":1,"may":1,"be":1,"sent":1,"permissions":1,"diabetes":8,"org":3,"more":2,"information":1,"is":2,"available":1,"at":2,"https":1,"diabetesjournals":1,"journals":1,"pages":1,"license":1,"the":7,"american":1,"association":1,"ada":5,"standards":4,"of":9,"care":5,"in":2,"includes":1,"current":1,"clinical":2,"practice":4,"recommendations":3,"and":7,"intended":1,"provide":1,"components":1,"general":1,"treatment":1,"goals":1,"guidelines":1,"tools":1,"evaluate":1,"quality":1,"members":2,"professional":3,"committee":3,"an":1,"interprofessional":1,"expert":1,"are":2,"responsible":1,"updating":1,"annually":1,"frequently":1,"as":3,"warranted":1,"detailed":1,"descrip":1,"tion":1,"statements":1,"reports":1,"well":1,"evidence":1,"grading":1,"sys":1,"tem":1,"full":1,"list":1,"please":1,"refer":1,"introduction":1,"methodology":1,"read":1,"ers":1,"who":1,"wish":1,"comment":1,"on":1,"invited":1,"do":1,"so":1,"soc":1,"pharmacologic":1,"therapy":1,"adults":2,"with":3,"type":2,"treat":1,"most":1,"continuous":1,"subcutaneous":1,"insulin":2,"fusion":1,"multiple":1,"daily":1,"doses":1,"prandial":1,"injected":1,"inhaled":1,"basal":1,"fo":1},"len":200},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":1,"chunkId":"ada-2026-pharm-p1-c2","text":" . PHARMACOLOGIC THERAPY FOR ADULTS WITH TYPE 1 DIABETES Recommendations 9.1 Treat most adults with type 1 diabetes with continuous subcutaneous insulin in - fusion or multiple daily doses of prandial (injected or inhaled) and basal insulin. A 9.2 For most adults with type 1 diabetes, insulin analogs (or inhaled insulin) are preferred over injectable human insulins to minimize hypoglycemia risk. A 9.3 To improve glycemic outcomes and quality of life and to minimize hypo - glycemia risk, most adults with type 1 diabetes should receive education on how to match mealtime insulin doses to carbohydrate intake and fat and pro - tein intake depending on the persons or caregivers needs or preferences. They should also be taught how to modify the insulin dose (correction dose) based on concurrent glycemia, glycemic trends (if available), sick-day manage - ment, and anticipated physical activity. B 9.4 Insulin treatment plans and insulin-taking behaviors should be reevaluated at regular intervals (e.g., every 3  6 months) and adjusted to incorporate spe - cific factors that affect choice of treatment and ensure achievement of indi - vidualized glycemic goals. E Insulin Therapy Insulin treatment is essential for individuals with type 1 diabetes because the hall - mark of type 1 diabetes is absent or near-absent  -cell function. In addition to hy - perglycemia, insulinopenia can contri","tf":{"pharmacologic":1,"therapy":2,"for":3,"adults":4,"with":6,"type":6,"diabetes":6,"recommendations":1,"treat":1,"most":3,"continuous":1,"subcutaneous":1,"insulin":10,"in":2,"fusion":1,"or":6,"multiple":1,"daily":1,"doses":2,"of":5,"prandial":1,"injected":1,"inhaled":2,"and":9,"basal":1,"analogs":1,"are":1,"preferred":1,"over":1,"injectable":1,"human":1,"insulins":1,"to":8,"minimize":2,"hypoglycemia":1,"risk":2,"improve":1,"glycemic":3,"outcomes":1,"quality":1,"life":1,"hypo":1,"glycemia":2,"should":3,"receive":1,"education":1,"on":3,"how":2,"match":1,"mealtime":1,"carbohydrate":1,"intake":2,"fat":1,"pro":1,"tein":1,"depending":1,"the":3,"person":1,"caregiver":1,"needs":1,"preferences":1,"they":1,"also":1,"be":2,"taught":1,"modify":1,"dose":2,"correction":1,"based":1,"concurrent":1,"trends":1,"if":1,"available":1,"sick":1,"day":1,"manage":1,"ment":1,"anticipated":1,"physical":1,"activity":1,"treatment":3,"plans":1,"taking":1,"behaviors":1,"reevaluated":1,"at":1,"regular":1,"intervals":1,"every":1,"months":1,"adjusted":1,"incorporate":1,"spe":1,"cific":1,"factors":1,"that":1,"affect":1,"choice":1,"ensure":1,"achievement":1,"indi":1,"vidualized":1,"goals":1,"is":2,"essential":1,"individuals":1,"because":1,"hall":1,"mark":1,"absent":2,"near":1,"cell":1,"function":1,"addition":1,"hy":1,"perglycemia":1,"insulinopenia":1,"can":1,"contri":1},"len":197},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":1,"chunkId":"ada-2026-pharm-p1-c3","text":"ized glycemic goals. E Insulin Therapy Insulin treatment is essential for individuals with type 1 diabetes because the hall - mark of type 1 diabetes is absent or near-absent  -cell function. In addition to hy - perglycemia, insulinopenia can contribute to other metabolic disturbances like hypertriglyceridemia and ketoacidosis as well as tissue catabolism that can be life threatening. Severe metabolic decompensation can be, and was, mostly prevented Diabetes Care Volume 49, Supplement 1, January 2026 S183 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"49":2,"2026":2,"848878":1,"ized":1,"glycemic":1,"goals":1,"insulin":2,"therapy":1,"treatment":1,"is":2,"essential":1,"for":1,"individuals":1,"with":1,"type":2,"diabetes":3,"because":1,"the":1,"hall":1,"mark":1,"of":1,"absent":2,"or":1,"near":1,"cell":1,"function":1,"in":1,"addition":1,"to":2,"hy":1,"perglycemia":1,"insulinopenia":1,"can":3,"contribute":1,"other":1,"metabolic":2,"disturbances":1,"like":1,"hypertriglyceridemia":1,"and":2,"ketoacidosis":1,"as":2,"well":1,"tissue":1,"catabolism":1,"that":1,"be":2,"life":1,"threatening":1,"severe":1,"decompensation":1,"was":1,"mostly":1,"prevented":1,"care":2,"volume":1,"supplement":2,"january":1,"s183":2,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"dc26s009":1,"by":1,"guest":1,"on":1,"february":1},"len":91},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":2,"chunkId":"ada-2026-pharm-p2-c0","text":"with once- or twice-daily insulin injec - tions for the six or seven decades after the discovery of insulin. Over the past four decades, evidence has accumulated supporting more intensive insulin re - placement, using multiple daily injec - tions of insulin or continuous subcutaneous administration through an insulin pump, as providing the best combination of ef - fectiveness and safety for people with type 1 diabetes. The Diabetes Control and Complications Trial (DCCT) demonstrated that intensive therapy with multiple daily injections or continuous subcutaneous insulin infusion (CSII) reduced A1C and was associated with improved long-term outcomes ( 1  3 ). The study was carried out with short- acting (regular) and intermediate-acting (NPH) human insulins. In this landmark trial, lower A1C with intensive manage - ment (7.3%) led to  50% reductions in mi - crovascular complications compared with 9.1% mean A1C in the conventional treat - ment arm over 6 years of treatment. How - ever, intensive therapy was associated with a higher rate of severe hypoglycemia than conventional treatment (62 compared with 19 episodes per 100 person-years of therapy) ( 1 ). Follow-up of participants from the DCCT demonstrated fewer mac - rovascular and microvascular complica - tions in the group that received intensive treatment. Achieving intensive glycemic goals during the active treatment peri","tf":{"19":1,"50":1,"62":1,"100":1,"with":9,"once":1,"or":4,"twice":1,"daily":3,"insulin":6,"injec":2,"tions":3,"for":2,"the":10,"six":1,"seven":1,"decades":2,"after":1,"discovery":1,"of":7,"over":2,"past":1,"four":1,"evidence":1,"has":1,"accumulated":1,"supporting":1,"more":1,"intensive":6,"re":1,"placement":1,"using":1,"multiple":2,"continuous":2,"subcutaneous":2,"administration":1,"through":1,"an":1,"pump":1,"as":1,"providing":1,"best":1,"combination":1,"ef":1,"fectiveness":1,"and":5,"safety":1,"people":1,"type":1,"diabetes":2,"control":1,"complications":2,"trial":2,"dcct":2,"demonstrated":2,"that":2,"therapy":3,"injections":1,"infusion":1,"csii":1,"reduced":1,"a1c":3,"was":3,"associated":2,"improved":1,"long":1,"term":1,"outcomes":1,"study":1,"carried":1,"out":1,"short":1,"acting":2,"regular":1,"intermediate":1,"nph":1,"human":1,"insulins":1,"in":4,"this":1,"landmark":1,"lower":1,"manage":1,"ment":2,"led":1,"to":1,"reductions":1,"mi":1,"crovascular":1,"compared":2,"mean":1,"conventional":2,"treat":1,"arm":1,"years":2,"treatment":4,"how":1,"ever":1,"higher":1,"rate":1,"severe":1,"hypoglycemia":1,"than":1,"episodes":1,"per":1,"person":1,"follow":1,"up":1,"participants":1,"from":1,"fewer":1,"mac":1,"rovascular":1,"microvascular":1,"complica":1,"group":1,"received":1,"achieving":1,"glycemic":1,"goals":1,"during":1,"active":1,"peri":1},"len":198},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":2,"chunkId":"ada-2026-pharm-p2-c1","text":"ears of therapy) ( 1 ). Follow-up of participants from the DCCT demonstrated fewer mac - rovascular and microvascular complica - tions in the group that received intensive treatment. Achieving intensive glycemic goals during the active treatment period of the study had a persistent beneficial im - pact over the 20 years after the active treat - ment component of the study ended ( 1  3 ). Insulin replacement plans typically con - sist of basal insulin, mealtime insulin, and correction insulin ( Fig. 9.1 ) ( 4 ). Basal insu - lin includes NPH insulin, long-acting insu - lin analogs, and continuous delivery of rapid-acting insulin via an insulin pump. Basal insulin analogs have longer duration of action with flatter, more constant and consistent plasma concentrations and ac - tivity profiles than NPH insulin; rapid-acting analogs (RAA) have a quicker onset and peak and shorter duration of action than regular human insulin. In people with type 1 diabetes, treatment with analog insulins is associated with less hypoglyce - mia and weight gain and lower A1C compared with injectable human insulins ( 5  7 ). Two injectable ultra-rapid-acting analog (URAA) insulin formulations are available that contain excipients that ac - celerate absorption and provide more ac - tivity in the first portion of their profile compared with the other RAA ( 8 , 9 ). In - haled human insulin has a rapid p","tf":{"20":1,"ears":1,"of":9,"therapy":1,"follow":1,"up":1,"participants":1,"from":1,"the":9,"dcct":1,"demonstrated":1,"fewer":1,"mac":1,"rovascular":1,"and":10,"microvascular":1,"complica":1,"tions":1,"in":4,"group":1,"that":3,"received":1,"intensive":2,"treatment":3,"achieving":1,"glycemic":1,"goals":1,"during":1,"active":2,"period":1,"study":2,"had":1,"persistent":1,"beneficial":1,"im":1,"pact":1,"over":1,"years":1,"after":1,"treat":1,"ment":1,"component":1,"ended":1,"insulin":12,"replacement":1,"plans":1,"typically":1,"con":1,"sist":1,"basal":3,"mealtime":1,"correction":1,"fig":1,"insu":2,"lin":2,"includes":1,"nph":2,"long":1,"acting":4,"analogs":3,"continuous":1,"delivery":1,"rapid":4,"via":1,"an":1,"pump":1,"have":2,"longer":1,"duration":2,"action":2,"with":6,"flatter":1,"more":2,"constant":1,"consistent":1,"plasma":1,"concentrations":1,"ac":3,"tivity":2,"profiles":1,"than":2,"raa":2,"quicker":1,"onset":1,"peak":1,"shorter":1,"regular":1,"human":3,"people":1,"type":1,"diabetes":1,"analog":2,"insulins":2,"is":1,"associated":1,"less":1,"hypoglyce":1,"mia":1,"weight":1,"gain":1,"lower":1,"a1c":1,"compared":2,"injectable":2,"two":1,"ultra":1,"uraa":1,"formulations":1,"are":1,"available":1,"contain":1,"excipients":1,"celerate":1,"absorption":1,"provide":1,"first":1,"portion":1,"their":1,"profile":1,"other":1,"haled":1,"has":1},"len":201},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":2,"chunkId":"ada-2026-pharm-p2-c2","text":"ng analog (URAA) insulin formulations are available that contain excipients that ac - celerate absorption and provide more ac - tivity in the first portion of their profile compared with the other RAA ( 8 , 9 ). In - haled human insulin has a rapid peak and shortened duration of action compared with RAA ( 10 ) (see also subsection ALTERNA - TIVE INSULIN ROUTES IN PHARMACOLOGIC THERAPY FOR ADULTS WITH TYPE 2 DIABETES ). These newer for - mulations may cause less hypoglycemia while improving postprandial glucose ex - cursions and administration flexibility (in relation to prandial intake) compared with RAA ( 10  12 ). In addition, longer- acting basal analogs (U-300 glargine or de - gludec) may confer a lower hypoglycemia risk compared with U-100 glargine in indi - viduals with type 1 diabetes ( 13 , 14 ). Qprsnt=tvgrl=tvg=ttrutsgognsulnglvryg =ppro=&_sgngpoplgwt_gtypg0g=ts Insulin plans Greater flexibility Lower risk of hypoglycemia Higher costs +++ +++ $$$ Less-preferred, alternative injected insulin plans ++ ++ $$ ++ + $ + + $ Continuous insulin infusion plans Greater flexibility Lower risk of hypoglycemia Higher costs Automated insulin delivery systems +++++ +++++ $$$$$ Insulin pump with threshold/ predictive low-glucose suspend ++++ ++++ $$$$$ Insulin pump therapy without automation +++ +++ $$$$ MDI with LAA + RAA or URAA MDI with NPH + RAA or U","tf":{"10":2,"12":1,"13":1,"14":1,"100":1,"300":1,"ng":2,"analog":1,"uraa":2,"insulin":9,"formulations":1,"are":1,"available":1,"that":2,"contain":1,"excipients":1,"ac":2,"celerate":1,"absorption":1,"and":3,"provide":1,"more":1,"tivity":1,"in":6,"the":2,"first":1,"portion":1,"of":4,"their":1,"profile":1,"compared":4,"with":9,"other":1,"raa":5,"haled":1,"human":1,"has":1,"rapid":1,"peak":1,"shortened":1,"duration":1,"action":1,"see":1,"also":1,"subsection":1,"alterna":1,"tive":1,"routes":1,"pharmacologic":1,"therapy":2,"for":2,"adults":1,"type":2,"diabetes":2,"these":1,"newer":1,"mulations":1,"may":2,"cause":1,"less":2,"hypoglycemia":4,"while":1,"improving":1,"postprandial":1,"glucose":2,"ex":1,"cursions":1,"administration":1,"flexibility":3,"relation":1,"to":1,"prandial":1,"intake":1,"addition":1,"longer":1,"acting":1,"basal":1,"analogs":1,"glargine":2,"or":3,"de":1,"gludec":1,"confer":1,"lower":3,"risk":3,"indi":1,"viduals":1,"pr":1,"nt":1,"gr":1,"ttr":1,"ut":1,"sgo":1,"nsul":1,"ryg":1,"ppro":1,"sg":1,"ngp":1,"opl":1,"gw":1,"gtyp":1,"g0g":1,"plans":3,"greater":2,"higher":2,"costs":2,"preferred":1,"alternative":1,"injected":1,"continuous":1,"infusion":1,"automated":1,"delivery":1,"systems":1,"pump":2,"threshold":1,"predictive":1,"low":1,"suspend":1,"without":1,"automation":1,"mdi":2,"laa":1,"nph":1},"len":189},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":2,"chunkId":"ada-2026-pharm-p2-c3","text":"emia Higher costs Automated insulin delivery systems +++++ +++++ $$$$$ Insulin pump with threshold/ predictive low-glucose suspend ++++ ++++ $$$$$ Insulin pump therapy without automation +++ +++ $$$$ MDI with LAA + RAA or URAA MDI with NPH + RAA or URAA MDI with NPH + short-acting (regular) insulin Two daily injections with NPH + short- acting (regular) insulin or premixed Figure 9.1 Choices of insulin plans in people with type 1 diabetes. Continuous glucose monitoring improves outcomes with injected or infused in - sulin and is superior to blood glucose monitoring. Inhaled insulin may be used in place of injectable prandial insulin in the U.S. The number of plus or dollar signs is an estimate of relative association of the plan with greater flexibility, lower risk of hypoglycemia, and higher costs between the different plans. Cost symbols are reflective of general costs, which may vary for individuals based on various circumstances: insurance coverage, discounts, rebates, and other price adjustments involved in prescription sales. LAA, long-acting insulin analog; MDI, multiple daily injections; RAA, rapid-acting insulin analog; URAA, injectable ultra-rapid-acting insulin analog or inhaled insulin. Adapted from Holt et al. ( 4 ). Despite the advantages of insulin ana - logs in individuals with type 1 diabetes, the expense and/or complexity of treat - ment required for their us","tf":{"emia":1,"higher":2,"costs":3,"automated":1,"insulin":13,"delivery":1,"systems":1,"pump":2,"with":9,"threshold":1,"predictive":1,"low":1,"glucose":3,"suspend":1,"therapy":1,"without":1,"automation":1,"mdi":4,"laa":2,"raa":3,"or":7,"uraa":3,"nph":3,"short":2,"acting":5,"regular":2,"two":1,"daily":2,"injections":2,"premixed":1,"figure":1,"choices":1,"of":9,"plans":2,"in":6,"people":1,"type":2,"diabetes":2,"continuous":1,"monitoring":2,"improves":1,"outcomes":1,"injected":1,"infused":1,"sulin":1,"and":4,"is":2,"superior":1,"to":1,"blood":1,"inhaled":2,"may":2,"be":1,"used":1,"place":1,"injectable":2,"prandial":1,"the":6,"number":1,"plus":1,"dollar":1,"signs":1,"an":1,"estimate":1,"relative":1,"association":1,"plan":1,"greater":1,"flexibility":1,"lower":1,"risk":1,"hypoglycemia":1,"between":1,"different":1,"cost":1,"symbols":1,"are":1,"reflective":1,"general":1,"which":1,"vary":1,"for":2,"individuals":2,"based":1,"on":1,"various":1,"circumstances":1,"insurance":1,"coverage":1,"discounts":1,"rebates":1,"other":1,"price":1,"adjustments":1,"involved":1,"prescription":1,"sales":1,"long":1,"analog":3,"multiple":1,"rapid":2,"ultra":1,"adapted":1,"from":1,"holt":1,"et":1,"al":1,"despite":1,"advantages":1,"ana":1,"logs":1,"expense":1,"complexity":1,"treat":1,"ment":1,"required":1,"their":1,"us":1},"len":202},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":2,"chunkId":"ada-2026-pharm-p2-c4","text":"AA, injectable ultra-rapid-acting insulin analog or inhaled insulin. Adapted from Holt et al. ( 4 ). Despite the advantages of insulin ana - logs in individuals with type 1 diabetes, the expense and/or complexity of treat - ment required for their use may be pro - hibitive ( Table 9.1 ). There are multiple approaches to insulin treatment. The S184 Pharmacologic Approaches to Glycemic Treatment Diabetes Care Volume 49, Supplement 1, January 2026 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"49":2,"2026":2,"848878":1,"aa":1,"injectable":1,"ultra":1,"rapid":1,"acting":1,"insulin":4,"analog":1,"or":2,"inhaled":1,"adapted":1,"from":2,"holt":1,"et":1,"al":1,"despite":1,"the":3,"advantages":1,"of":2,"ana":1,"logs":1,"in":1,"individuals":1,"with":1,"type":1,"diabetes":2,"expense":1,"and":1,"complexity":1,"treat":1,"ment":1,"required":1,"for":1,"their":1,"use":1,"may":1,"be":1,"pro":1,"hibitive":1,"table":1,"there":1,"are":1,"multiple":1,"approaches":2,"to":2,"treatment":2,"s184":1,"pharmacologic":1,"glycemic":1,"care":2,"volume":1,"supplement":2,"january":1,"downloaded":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"s183":1,"dc26s009":1,"by":1,"guest":1,"on":1,"february":1},"len":85},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":3,"chunkId":"ada-2026-pharm-p3-c0","text":"Table 9.1Examples of subcutaneous insulin treatment plans Plans Timing and distribution Advantages Disadvantages Adjusting doses Plans that more closely mimic normal insulin secretion Insulin pump therapy, including conventional CSII, sensor-augmented pump, low-glucose suspend; AID systems such as hybrid closed loop Basal delivery of URAA or RAA; generally 30  50% of TDD. Mealtime and correction: URAA or RAA by bolus based on ICR and/or ISF and target glucose, with premeal insulin  15 min before eating. Can adjust basal rates for varying insulin sensitivity by time of day, for exercise, and for sick days. Flexibility in meal timing and content. Pump can deliver insulin in increments of fractions of units. Potential for integration with CGM for AID systems. TIR % highest and TBR % lowest with: hybrid closed-loop > low- glucose suspend > sensor- augmented open-loop > conventional CSII. Most expensive plan. Must continuously wear one or more devices. Risk of rapid development of ketosis or DKA with interruption of insulin delivery. Potential reactions to adhesives and site infections. Most technically complex approach (harder for people with lower numeracy or literacy skills). Mealtime insulin: if carbohydrate counting is accurate, change ICR if glucose after meal consistently out of target. Correction insulin: adjust ISF and/or target glucose if correction does not consistentl","tf":{"15":1,"30":1,"50":1,"table":1,"examples":1,"of":10,"subcutaneous":1,"insulin":9,"treatment":1,"plans":3,"timing":2,"and":9,"distribution":1,"advantages":1,"disadvantages":1,"adjusting":1,"doses":1,"that":1,"more":2,"closely":1,"mimic":1,"normal":1,"secretion":1,"pump":3,"therapy":1,"including":1,"conventional":2,"csii":2,"sensor":2,"augmented":2,"low":2,"glucose":5,"suspend":2,"aid":2,"systems":2,"such":1,"as":1,"hybrid":2,"closed":2,"loop":3,"basal":2,"delivery":2,"uraa":2,"or":7,"raa":2,"generally":1,"tdd":1,"mealtime":2,"correction":3,"by":2,"bolus":1,"based":1,"on":1,"icr":2,"isf":2,"target":3,"with":5,"premeal":1,"min":1,"before":1,"eating":1,"can":2,"adjust":2,"rates":1,"for":6,"varying":1,"sensitivity":1,"time":1,"day":1,"exercise":1,"sick":1,"days":1,"flexibility":1,"in":2,"meal":2,"content":1,"deliver":1,"increments":1,"fractions":1,"units":1,"potential":2,"integration":1,"cgm":1,"tir":1,"highest":1,"tbr":1,"lowest":1,"open":1,"most":2,"expensive":1,"plan":1,"must":1,"continuously":1,"wear":1,"one":1,"devices":1,"risk":1,"rapid":1,"development":1,"ketosis":1,"dka":1,"interruption":1,"reactions":1,"to":1,"adhesives":1,"site":1,"infections":1,"technically":1,"complex":1,"approach":1,"harder":1,"people":1,"lower":1,"numeracy":1,"literacy":1,"skills":1,"if":3,"carbohydrate":1,"counting":1,"is":1,"accurate":1,"change":1,"after":1,"consistently":1,"out":1,"does":1,"not":1,"consistentl":1},"len":210},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":3,"chunkId":"ada-2026-pharm-p3-c1","text":"ople with lower numeracy or literacy skills). Mealtime insulin: if carbohydrate counting is accurate, change ICR if glucose after meal consistently out of target. Correction insulin: adjust ISF and/or target glucose if correction does not consistently bring glucose into range. Basal rates: adjust based on overnight, fasting or daytime glucose outside of activity of URAA/RAA bolus. AID systems: carbohydrate ratio, insulin on board, targets, and/or ISF may be adjusted, depending on the system; make sure to review and adjust manual mode settings, if available. MDI: LAA + flexible doses of URAA or RAA at meals LAA once daily (insulin detemir or insulin glargine may require twice-daily dosing); generally 30  50% of TDD. Mealtime and correction: URAA or RAA based on ICR and/or ISF and target glucose. Can use pens for all components. Flexibility in meal timing and content. Insulin analogs cause less hypoglycemia than human insulins. At least four daily injections. Most costly insulins. Smallest increment of insulin is 1 unit (0.5 unit with some pens). LAAs may not cover strong dawn phenomenon (rise in glucose in early morning hours) as well as pump therapy. Mealtime insulin: if carbohydrate counting is accurate, change ICR if glucose after meal consistently out of target. Correction insulin: adjust ISF and/or target glucose if correction does not consistently bring glucose into range","tf":{"30":1,"50":1,"ople":1,"with":2,"lower":1,"numeracy":1,"or":9,"literacy":1,"skills":1,"mealtime":3,"insulin":9,"if":7,"carbohydrate":3,"counting":2,"is":3,"accurate":2,"change":2,"icr":3,"glucose":9,"after":2,"meal":3,"consistently":4,"out":2,"of":7,"target":5,"correction":5,"adjust":4,"isf":4,"and":8,"does":2,"not":3,"bring":2,"into":2,"range":2,"basal":1,"rates":1,"based":2,"on":4,"overnight":1,"fasting":1,"daytime":1,"outside":1,"activity":1,"uraa":3,"raa":3,"bolus":1,"aid":1,"systems":1,"ratio":1,"board":1,"targets":1,"may":3,"be":1,"adjusted":1,"depending":1,"the":1,"system":1,"make":1,"sure":1,"to":1,"review":1,"manual":1,"mode":1,"settings":1,"available":1,"mdi":1,"laa":2,"flexible":1,"doses":1,"at":2,"meals":1,"once":1,"daily":3,"detemir":1,"glargine":1,"require":1,"twice":1,"dosing":1,"generally":1,"tdd":1,"can":1,"use":1,"pens":2,"for":1,"all":1,"components":1,"flexibility":1,"in":3,"timing":1,"content":1,"analogs":1,"cause":1,"less":1,"hypoglycemia":1,"than":1,"human":1,"insulins":2,"least":1,"four":1,"injections":1,"most":1,"costly":1,"smallest":1,"increment":1,"unit":2,"some":1,"laas":1,"cover":1,"strong":1,"dawn":1,"phenomenon":1,"rise":1,"early":1,"morning":1,"hours":1,"as":2,"well":1,"pump":1,"therapy":1},"len":221},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":3,"chunkId":"ada-2026-pharm-p3-c2","text":"ll as pump therapy. Mealtime insulin: if carbohydrate counting is accurate, change ICR if glucose after meal consistently out of target. Correction insulin: adjust ISF and/or target glucose if correction does not consistently bring glucose into range. LAA: based on overnight or fasting glucose or daytime glucose outside of activity time course, or URAA or RAA injections. MDI plans with less flexibility Four injections daily with fixed doses of N and RAA Pre-breakfast: RAA  20% of TDD. Pre-lunch: RAA  10% of TDD. Pre-dinner: RAA  10% of TDD. Bedtime: N  50% of TDD. May be feasible if unable to carbohydrate count. All meals have RAA coverage. N is less expensive than LAAs. Shorter duration RAA may lead to basal deficit during day; may need twice-daily N. Greater risk of nocturnal hypoglycemia with N. Requires relatively consistent mealtimes and carbohydrate intake. Pre-breakfast RAA: based on BGM after breakfast or before lunch. Pre-lunch RAA: based on BGM after lunch or before dinner. Pre-dinner RAA: based on BGM after dinner or at bedtime. Evening N: based on fasting or overnight BGM. Continued on p. S186 diabetesjournals.org/care Pharmacologic Approaches to Glycemic Treatment S185 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"10":2,"17":1,"20":1,"49":1,"50":1,"2026":1,"848878":1,"ll":1,"as":1,"pump":1,"therapy":1,"mealtime":1,"insulin":2,"if":4,"carbohydrate":3,"counting":1,"is":2,"accurate":1,"change":1,"icr":1,"glucose":5,"after":4,"meal":1,"consistently":2,"out":1,"of":8,"target":2,"correction":2,"adjust":1,"isf":1,"and":3,"or":9,"does":1,"not":1,"bring":1,"into":1,"range":1,"laa":1,"based":5,"on":7,"overnight":2,"fasting":2,"daytime":1,"outside":1,"activity":1,"time":1,"course":1,"uraa":1,"raa":10,"injections":2,"mdi":1,"plans":1,"with":3,"less":2,"flexibility":1,"four":1,"daily":2,"fixed":1,"doses":1,"pre":6,"breakfast":3,"tdd":4,"lunch":4,"dinner":4,"bedtime":2,"may":3,"be":1,"feasible":1,"unable":1,"to":3,"count":1,"all":1,"meals":1,"have":1,"coverage":1,"expensive":1,"than":1,"laas":1,"shorter":1,"duration":1,"lead":1,"basal":1,"deficit":1,"during":1,"day":1,"need":1,"twice":1,"greater":1,"risk":1,"nocturnal":1,"hypoglycemia":1,"requires":1,"relatively":1,"consistent":1,"mealtimes":1,"intake":1,"bgm":4,"before":2,"at":1,"evening":1,"continued":1,"s186":1,"diabetesjournals":2,"org":2,"care":2,"pharmacologic":1,"approaches":1,"glycemic":1,"treatment":1,"s185":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"supplement":1,"s183":1,"dc26s009":1,"by":1,"guest":1,"february":1},"len":211},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":4,"chunkId":"ada-2026-pharm-p4-c0","text":"Table 9.1Continued Plans Timing and distribution Advantages Disadvantages Adjusting doses Four injections daily with fixed doses of N and R Pre-breakfast: R  20% of TDD. Pre-lunch: R  10% of TDD. Pre-dinner: R  10% of TDD. Bedtime: N  50% of TDD. May be feasible if unable to carbohydrate count. R can be dosed based on ICR and correction. All meals have R coverage. Least expensive insulins. Greater risk of nocturnal hypoglycemia with N. Greater risk of delayed post-meal hypoglycemia with R. Requires relatively consistent mealtimes and carbohydrate intake. R must be injected at least 30 min before meal for better effect. Pre-breakfast R: based on BGM after breakfast or before lunch. Pre-lunch R: based on BGM after lunch or before dinner. Pre-dinner R: based on BGM after dinner or at bedtime. Evening N: based on fasting or overnight BGM. Plans with fewer daily injections Three injections daily: N + R or N + RAA Pre-breakfast: N  40% TDD + R or RAA  15% TDD. Pre-dinner: R or RAA  15% TDD. Bedtime: N  30% TDD. Morning insulins can be mixed in one syringe. May be appropriate for those who cannot take injection in middle of day. Morning N covers lunch to some extent. Same advantages of RAAs over R. Least (N + R) or less expensive insulins than MDI with analogs. Greater risk of nocturnal hypoglycemia with N than LAAs. Greater risk of delayed post-meal hypoglycemia with R than ","tf":{"10":2,"15":2,"20":1,"30":2,"40":1,"50":1,"table":1,"continued":1,"plans":2,"timing":1,"and":4,"distribution":1,"advantages":2,"disadvantages":1,"adjusting":1,"doses":2,"four":1,"injections":3,"daily":3,"with":7,"fixed":1,"of":11,"pre":8,"breakfast":4,"tdd":8,"lunch":5,"dinner":5,"bedtime":3,"may":2,"be":5,"feasible":1,"if":1,"unable":1,"to":2,"carbohydrate":2,"count":1,"can":2,"dosed":1,"based":5,"on":5,"icr":1,"correction":1,"all":1,"meals":1,"have":1,"coverage":1,"least":3,"expensive":2,"insulins":3,"greater":4,"risk":4,"nocturnal":2,"hypoglycemia":4,"delayed":2,"post":2,"meal":3,"requires":1,"relatively":1,"consistent":1,"mealtimes":1,"intake":1,"must":1,"injected":1,"at":2,"min":1,"before":3,"for":2,"better":1,"effect":1,"bgm":4,"after":3,"or":8,"evening":1,"fasting":1,"overnight":1,"fewer":1,"three":1,"raa":3,"morning":2,"mixed":1,"in":2,"one":1,"syringe":1,"appropriate":1,"those":1,"who":1,"cannot":1,"take":1,"injection":1,"middle":1,"day":1,"covers":1,"some":1,"extent":1,"same":1,"raas":1,"over":1,"less":1,"than":3,"mdi":1,"analogs":1,"laas":1},"len":215},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":4,"chunkId":"ada-2026-pharm-p4-c1","text":"orning N covers lunch to some extent. Same advantages of RAAs over R. Least (N + R) or less expensive insulins than MDI with analogs. Greater risk of nocturnal hypoglycemia with N than LAAs. Greater risk of delayed post-meal hypoglycemia with R than RAAs. Requires relatively consistent mealtimes and carbohydrate intake. Coverage of post-lunch glucose often suboptimal. R must be injected at least 30 min before meal for better effect. Morning N: based on pre-dinner BGM. Morning R: based on pre-lunch BGM. Morning RAA: based on post- breakfast or pre-lunch BGM. Pre-dinner R: based on bedtime BGM. Pre-dinner RAA: based on post- dinner or bedtime BGM. Evening N: based on fasting BGM. Twice-daily split-mixed: N + R or N + RAA Pre-breakfast: N  40% TDD + R or RAA  15% TDD. Pre-dinner: N  30% TDD + R or RAA  15% TDD. Least number of injections for people with strong preference for this. Insulins can be mixed in one syringe. Least (N + R) or less (N + RAA) expensive insulins vs. analogs. Eliminates need for doses during the day. Risk of hypoglycemia in afternoon or middle of night from N. Fixed mealtimes and meal content. Coverage of post-lunch glucose often suboptimal. Difficult to reach targets for blood glucose without hypoglycemia. Morning N: based on pre-dinner BGM. Morning R: based on pre-lunch BGM. Morning RAA: based on post- breakfast or pre-lunch BGM. Evening R: based on b","tf":{"15":2,"30":2,"40":1,"orning":1,"covers":1,"lunch":7,"to":2,"some":1,"extent":1,"same":1,"advantages":1,"of":8,"raas":2,"over":1,"least":4,"or":9,"less":2,"expensive":2,"insulins":3,"than":3,"mdi":1,"with":4,"analogs":2,"greater":2,"risk":3,"nocturnal":1,"hypoglycemia":4,"laas":1,"delayed":1,"post":6,"meal":3,"requires":1,"relatively":1,"consistent":1,"mealtimes":2,"and":2,"carbohydrate":1,"intake":1,"coverage":2,"glucose":3,"often":2,"suboptimal":2,"must":1,"be":2,"injected":1,"at":1,"min":1,"before":1,"for":5,"better":1,"effect":1,"morning":6,"based":10,"on":10,"pre":10,"dinner":6,"bgm":9,"raa":7,"breakfast":3,"bedtime":2,"evening":2,"fasting":1,"twice":1,"daily":1,"split":1,"mixed":2,"tdd":4,"number":1,"injections":1,"people":1,"strong":1,"preference":1,"this":1,"can":1,"in":2,"one":1,"syringe":1,"vs":1,"eliminates":1,"need":1,"doses":1,"during":1,"the":1,"day":1,"afternoon":1,"middle":1,"night":1,"from":1,"fixed":1,"content":1,"difficult":1,"reach":1,"targets":1,"blood":1,"without":1},"len":218},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":4,"chunkId":"ada-2026-pharm-p4-c2","text":"st-lunch glucose often suboptimal. Difficult to reach targets for blood glucose without hypoglycemia. Morning N: based on pre-dinner BGM. Morning R: based on pre-lunch BGM. Morning RAA: based on post- breakfast or pre-lunch BGM. Evening R: based on bedtime BGM. Evening RAA: based on post-dinner or bedtime BGM. Evening N: based on fasting BGM. AID, automated insulin delivery; BGM, blood glucose monitoring; CGM, continuous glucose monitoring; CSII, continuous subcutaneous insulin infusion; ICR, insulin-to-carbohydrate ratio; ISF, insulin sen - sitivity factor; LAA, long-acting analog; MDI, multiple daily injections; N, NPH insulin; R, short-acting (regular) insulin; RAA, rapid-acting analog; TBR, time below range; TDD, total daily insulin dose; TIR, time in range; URAA, ultra-rapid-acting analog (inhaled insulin may be considered if appropriate). Adapted from Holt et al. ( 4 ). S186 Pharmacologic Approaches to Glycemic Treatment Diabetes Care Volume 49, Supplement 1, January 2026 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"49":2,"2026":2,"848878":1,"st":1,"lunch":3,"glucose":4,"often":1,"suboptimal":1,"difficult":1,"to":3,"reach":1,"targets":1,"for":1,"blood":2,"without":1,"hypoglycemia":1,"morning":3,"based":6,"on":7,"pre":3,"dinner":2,"bgm":7,"raa":3,"post":2,"breakfast":1,"or":2,"evening":3,"bedtime":2,"fasting":1,"aid":1,"automated":1,"insulin":8,"delivery":1,"monitoring":2,"cgm":1,"continuous":2,"csii":1,"subcutaneous":1,"infusion":1,"icr":1,"carbohydrate":1,"ratio":1,"isf":1,"sen":1,"sitivity":1,"factor":1,"laa":1,"long":1,"acting":4,"analog":3,"mdi":1,"multiple":1,"daily":2,"injections":1,"nph":1,"short":1,"regular":1,"rapid":2,"tbr":1,"time":2,"below":1,"range":2,"tdd":1,"total":1,"dose":1,"tir":1,"in":1,"uraa":1,"ultra":1,"inhaled":1,"may":1,"be":1,"considered":1,"if":1,"appropriate":1,"adapted":1,"from":2,"holt":1,"et":1,"al":1,"s186":1,"pharmacologic":1,"approaches":1,"glycemic":1,"treatment":1,"diabetes":1,"care":2,"volume":1,"supplement":2,"january":1,"downloaded":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"s183":1,"dc26s009":1,"by":1,"guest":1,"february":1},"len":163},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":5,"chunkId":"ada-2026-pharm-p5-c0","text":"central precept in the management of type 1 diabetes is that some form of insu - lin be given in a defined treatment plan tailored to the individual to prevent dia - betic ketoacidosis (DKA) and minimize clinically relevant hypoglycemia while achieving the individuals glycemic goals. Reassessment of insulin-taking behavior and adjustment of treatment plans to account for specific factors, including cost, that affect choice of treatment is recommended at reg - ular intervals (every 3  6 months). Most studies comparing multiple daily injections with CSII have been relatively small and of short duration. A systematic review and meta-analysis concluded that CSII via pump therapy has modest advan - tages for lowering A1C (  0.30% [95% CI  0.58 to  0.02]) and for reducing severe hypoglycemia rates in adults ( 15 ). Use of CSII is associated with improvement in quality of life, particularly in areas related to fear of hypoglycemia and diabetes dis - tress, compared with multiple daily injec - tions of insulin ( 16 , 17 ). However, there is no consensus to guide the choice of injec - tion or pump therapy in a given individ - ual, and research to guide this decision- making is needed ( 4 ). Integration of continuous glucose moni - toring (CGM) into the treatment plan soon after diagnosis improves glycemic outcomes, decreases hypoglycemic events, and im - proves quality of life for ","tf":{"15":1,"16":1,"17":1,"30":1,"58":1,"95":1,"central":1,"precept":1,"in":6,"the":5,"management":1,"of":13,"type":1,"diabetes":2,"is":5,"that":3,"some":1,"form":1,"insu":1,"lin":1,"be":1,"given":2,"defined":1,"treatment":4,"plan":2,"tailored":1,"to":7,"individual":2,"prevent":1,"dia":1,"betic":1,"ketoacidosis":1,"dka":1,"and":8,"minimize":1,"clinically":1,"relevant":1,"hypoglycemia":3,"while":1,"achieving":1,"glycemic":2,"goals":1,"reassessment":1,"insulin":2,"taking":1,"behavior":1,"adjustment":1,"plans":1,"account":1,"for":4,"specific":1,"factors":1,"including":1,"cost":1,"affect":1,"choice":2,"recommended":1,"at":1,"reg":1,"ular":1,"intervals":1,"every":1,"months":1,"most":1,"studies":1,"comparing":1,"multiple":2,"daily":2,"injections":1,"with":3,"csii":3,"have":1,"been":1,"relatively":1,"small":1,"short":1,"duration":1,"systematic":1,"review":1,"meta":1,"analysis":1,"concluded":1,"via":1,"pump":2,"therapy":2,"has":1,"modest":1,"advan":1,"tages":1,"lowering":1,"a1c":1,"ci":1,"02":1,"reducing":1,"severe":1,"rates":1,"adults":1,"use":1,"associated":1,"improvement":1,"quality":2,"life":2,"particularly":1,"areas":1,"related":1,"fear":1,"dis":1,"tress":1,"compared":1,"injec":2,"tions":1,"however":1,"there":1,"no":1,"consensus":1,"guide":2,"tion":1,"or":1,"individ":1,"ual":1,"research":1,"this":1,"decision":1,"making":1,"needed":1,"integration":1,"continuous":1,"glucose":1,"moni":1,"toring":1,"cgm":1,"into":1,"soon":1,"after":1,"diagnosis":1,"improves":1,"outcomes":1,"decreases":1,"hypoglycemic":1,"events":1,"im":1,"proves":1},"len":209},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":5,"chunkId":"ada-2026-pharm-p5-c1","text":"esearch to guide this decision- making is needed ( 4 ). Integration of continuous glucose moni - toring (CGM) into the treatment plan soon after diagnosis improves glycemic outcomes, decreases hypoglycemic events, and im - proves quality of life for individuals with type 1 diabetes ( 18  21 ). Its use is now considered standard of care for most people with type 1 diabetes ( 4 ) (see sec - tion 7,  Diabetes Technology ). Although nocturnal hypoglycemia is reduced in individuals with type 1 diabetes using sensor-augmented pump therapy with low-glucose suspend and predictive low- glucose suspend ( 22 , 23 ), evidence sug - gests that automated insulin delivery (AID) systems are superior for increasing percentage of time in range and reduc - ing hypoglycemia ( 24  26 ). AID systems, which integrate CSII via an insulin pump, a CGM, and a control algorithm to adjust insulin delivery in real time based on glu - cose levels, are safe and effective for people with type 1 diabetes. Random - ized controlled trials (RCTs) and real- world studies have demonstrated the ability of commercially available systems to improve achievement of glycemic goals while reducing the risk of hypogly - cemia ( 27  32 ). Data are emerging on the safety and effectiveness of open-source AID systems ( 33 , 34 ). Intensive insulin management with CSII and CGM should be considered in individuals with type 1 ","tf":{"18":1,"21":1,"22":1,"23":1,"24":1,"26":1,"27":1,"32":1,"33":1,"34":1,"esearch":1,"to":3,"guide":1,"this":1,"decision":1,"making":1,"is":3,"needed":1,"integration":1,"of":8,"continuous":1,"glucose":3,"moni":1,"toring":1,"cgm":3,"into":1,"the":4,"treatment":1,"plan":1,"soon":1,"after":1,"diagnosis":1,"improves":1,"glycemic":2,"outcomes":1,"decreases":1,"hypoglycemic":1,"events":1,"and":8,"im":1,"proves":1,"quality":1,"life":1,"for":4,"individuals":3,"with":7,"type":5,"diabetes":5,"its":1,"use":1,"now":1,"considered":2,"standard":1,"care":1,"most":1,"people":2,"see":1,"sec":1,"tion":1,"technology":1,"although":1,"nocturnal":1,"hypoglycemia":2,"reduced":1,"in":4,"using":1,"sensor":1,"augmented":1,"pump":2,"therapy":1,"low":2,"suspend":2,"predictive":1,"evidence":1,"sug":1,"gests":1,"that":1,"automated":1,"insulin":4,"delivery":2,"aid":3,"systems":4,"are":3,"superior":1,"increasing":1,"percentage":1,"time":2,"range":1,"reduc":1,"ing":1,"which":1,"integrate":1,"csii":2,"via":1,"an":1,"control":1,"algorithm":1,"adjust":1,"real":2,"based":1,"on":2,"glu":1,"cose":1,"levels":1,"safe":1,"effective":1,"random":1,"ized":1,"controlled":1,"trials":1,"rcts":1,"world":1,"studies":1,"have":1,"demonstrated":1,"ability":1,"commercially":1,"available":1,"improve":1,"achievement":1,"goals":1,"while":1,"reducing":1,"risk":1,"hypogly":1,"cemia":1,"data":1,"emerging":1,"safety":1,"effectiveness":1,"open":1,"source":1,"intensive":1,"management":1,"should":1,"be":1},"len":205},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":5,"chunkId":"ada-2026-pharm-p5-c2","text":"ic goals while reducing the risk of hypogly - cemia ( 27  32 ). Data are emerging on the safety and effectiveness of open-source AID systems ( 33 , 34 ). Intensive insulin management with CSII and CGM should be considered in individuals with type 1 diabetes whenever feasible. AID systems are preferred for individuals with type 1 diabetes who can use them safely (inde - pendently or with caregiver support), as they consistently improve time in range, lower A1C, and reduce hypoglycemia ( 26 , 28  31 , 35  38 ). When choosing among insulin delivery systems, individual pref - erences, cost, insulin type, dosing plan, and self-management capabilities should be considered. See section 7,  Diabetes Technology , for a full discussion of insu - lin delivery devices. In general, individuals with type 1 dia - betes require approximately 30  50% of their daily insulin as basal and the remain - der as prandial ( 39 ). This proportion de - pends on several factors, including but not limited to carbohydrate consumption, age, pregnancy status, and puberty stage ( 4 , 40  43 ). Total daily insulin requirements can be estimated based on weight, with typical doses ranging from 0.4 to 1 unit/ kg/day. Higher amounts may be required during puberty, the late luteal phase (pre - menstrual) in menstruating individuals, and illness. The American Diabetes Asso - ciation/JDRF Type 1 Diabetes Source","tf":{"26":1,"27":1,"28":1,"30":1,"31":1,"32":1,"33":1,"34":1,"35":1,"38":1,"39":1,"40":1,"43":1,"50":1,"ic":1,"goals":1,"while":1,"reducing":1,"the":5,"risk":1,"of":4,"hypogly":1,"cemia":1,"data":1,"are":2,"emerging":1,"on":3,"safety":1,"and":7,"effectiveness":1,"open":1,"source":2,"aid":2,"systems":3,"intensive":1,"insulin":5,"management":2,"with":6,"csii":1,"cgm":1,"should":2,"be":4,"considered":2,"in":4,"individuals":4,"type":5,"diabetes":5,"whenever":1,"feasible":1,"preferred":1,"for":2,"who":1,"can":2,"use":1,"them":1,"safely":1,"inde":1,"pendently":1,"or":1,"caregiver":1,"support":1,"as":3,"they":1,"consistently":1,"improve":1,"time":1,"range":1,"lower":1,"a1c":1,"reduce":1,"hypoglycemia":1,"when":1,"choosing":1,"among":1,"delivery":2,"individual":1,"pref":1,"erences":1,"cost":1,"dosing":1,"plan":1,"self":1,"capabilities":1,"see":1,"section":1,"technology":1,"full":1,"discussion":1,"insu":1,"lin":1,"devices":1,"general":1,"dia":1,"betes":1,"require":1,"approximately":1,"their":1,"daily":2,"basal":1,"remain":1,"der":1,"prandial":1,"this":1,"proportion":1,"de":1,"pends":1,"several":1,"factors":1,"including":1,"but":1,"not":1,"limited":1,"to":2,"carbohydrate":1,"consumption":1,"age":1,"pregnancy":1,"status":1,"puberty":2,"stage":1,"total":1,"requirements":1,"estimated":1,"based":1,"weight":1,"typical":1,"doses":1,"ranging":1,"from":1,"unit":1,"kg":1,"day":1,"higher":1,"amounts":1,"may":1,"required":1,"during":1,"late":1,"luteal":1,"phase":1,"pre":1,"menstrual":1,"menstruating":1,"illness":1,"american":1,"asso":1,"ciation":1,"jdrf":1},"len":205},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":5,"chunkId":"ada-2026-pharm-p5-c3","text":", with typical doses ranging from 0.4 to 1 unit/ kg/day. Higher amounts may be required during puberty, the late luteal phase (pre - menstrual) in menstruating individuals, and illness. The American Diabetes Asso - ciation/JDRF Type 1 Diabetes Sourcebook notes 0.5 units/kg/day as a typical start - ing dose in adults with type 1 diabetes who are metabolically stable, with ap - proximately one-half administered as prandial insulin given to manage blood glucose after meals and the remaining portion as basal insulin to manage glyce - mia in the periods between meal absorp - tion ( 44 ). In adults newly diagnosed with type 1 diabetes, insulin requirements at initiation typically range from 0.2 to 0.6 units/kg/day, with lower doses often sufficient in those with continued endog - enous insulin production (during the par - tial remission phase or honeymoon period, or in people presenting outside of ketoacidosis) ( 44 ). This guideline pro - vides an algorithm for insulin use for indi - viduals with type 1 diabetes using insulin injections ( Fig. 9.2 ) and detailed informa - tion on intensification of therapy to meet individualized needs. In addition, the Amer - ican Diabetes Association (ADA) position statement Type 1 Diabetes Management Through the Life Span provides a thorough overview of type 1 diabetes treatment ( 45 ). Typical multidose insulin treatment plans for adults with","tf":{"44":2,"45":1,"with":8,"typical":3,"doses":2,"ranging":1,"from":2,"to":5,"unit":1,"kg":3,"day":3,"higher":1,"amounts":1,"may":1,"be":1,"required":1,"during":2,"puberty":1,"the":7,"late":1,"luteal":1,"phase":2,"pre":1,"menstrual":1,"in":7,"menstruating":1,"individuals":1,"and":3,"illness":1,"american":1,"diabetes":8,"asso":1,"ciation":1,"jdrf":1,"type":6,"sourcebook":1,"notes":1,"units":2,"as":3,"start":1,"ing":1,"dose":1,"adults":3,"who":1,"are":1,"metabolically":1,"stable":1,"ap":1,"proximately":1,"one":1,"half":1,"administered":1,"prandial":1,"insulin":7,"given":1,"manage":2,"blood":1,"glucose":1,"after":1,"meals":1,"remaining":1,"portion":1,"basal":1,"glyce":1,"mia":1,"periods":1,"between":1,"meal":1,"absorp":1,"tion":2,"newly":1,"diagnosed":1,"requirements":1,"at":1,"initiation":1,"typically":1,"range":1,"lower":1,"often":1,"sufficient":1,"those":1,"continued":1,"endog":1,"enous":1,"production":1,"par":1,"tial":1,"remission":1,"or":2,"honeymoon":1,"period":1,"people":1,"presenting":1,"outside":1,"of":3,"ketoacidosis":1,"this":1,"guideline":1,"pro":1,"vides":1,"an":1,"algorithm":1,"for":3,"use":1,"indi":1,"viduals":1,"using":1,"injections":1,"fig":1,"detailed":1,"informa":1,"on":1,"intensification":1,"therapy":1,"meet":1,"individualized":1,"needs":1,"addition":1,"amer":1,"ican":1,"association":1,"ada":1,"position":1,"statement":1,"management":1,"through":1,"life":1,"span":1,"provides":1,"thorough":1,"overview":1,"treatment":2,"multidose":1,"plans":1},"len":201},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":5,"chunkId":"ada-2026-pharm-p5-c4","text":" In addition, the Amer - ican Diabetes Association (ADA) position statement Type 1 Diabetes Management Through the Life Span provides a thorough overview of type 1 diabetes treatment ( 45 ). Typical multidose insulin treatment plans for adults with type 1 diabetes combine premeal prandial insulin with a longer- acting basal insulin. The long-acting basal dose is titrated to regulate overnight and fasting glucose. Postprandial glucose excursions are best managed by an appropriately timed injection or inhala - tion of prandial insulin. Prandial insulin should ideally be administered before meals, although the optimal timing de - pends on the pharmacokinetics of the for - mulation (regular, rapid-acting analog, or inhaled), the premeal blood glucose level, and the anticipated carbohydrate intake. Dosing recommendations should there - fore be individualized. Because physiologic insulin secretion varies with glycemia, meal size and composition, and tissue demand, strategies have evolved to adjust prandial doses based on predicted needs. Thus, ed - ucation on how to adjust prandial insulin to account for nutritional intake and the correction dose based on premeal glucose levels, anticipated activity, and sick-day management can be effective and should be offered to most individuals ( 46  51 ). Ed - ucation regarding adjustment of prandial insulin dose for glycemic trends should be","tf":{"45":1,"46":1,"51":1,"in":1,"addition":1,"the":9,"amer":1,"ican":1,"diabetes":4,"association":1,"ada":1,"position":1,"statement":1,"type":3,"management":2,"through":1,"life":1,"span":1,"provides":1,"thorough":1,"overview":1,"of":4,"treatment":2,"typical":1,"multidose":1,"insulin":8,"plans":1,"for":4,"adults":1,"with":3,"combine":1,"premeal":3,"prandial":6,"longer":1,"acting":3,"basal":2,"long":1,"dose":3,"is":1,"titrated":1,"to":5,"regulate":1,"overnight":1,"and":7,"fasting":1,"glucose":4,"postprandial":1,"excursions":1,"are":1,"best":1,"managed":1,"by":1,"an":1,"appropriately":1,"timed":1,"injection":1,"or":2,"inhala":1,"tion":1,"should":4,"ideally":1,"be":5,"administered":1,"before":1,"meals":1,"although":1,"optimal":1,"timing":1,"de":1,"pends":1,"on":4,"pharmacokinetics":1,"mulation":1,"regular":1,"rapid":1,"analog":1,"inhaled":1,"blood":1,"level":1,"anticipated":2,"carbohydrate":1,"intake":2,"dosing":1,"recommendations":1,"there":1,"fore":1,"individualized":1,"because":1,"physiologic":1,"secretion":1,"varies":1,"glycemia":1,"meal":1,"size":1,"composition":1,"tissue":1,"demand":1,"strategies":1,"have":1,"evolved":1,"adjust":2,"doses":1,"based":2,"predicted":1,"needs":1,"thus":1,"ed":2,"ucation":2,"how":1,"account":1,"nutritional":1,"correction":1,"levels":1,"activity":1,"sick":1,"day":1,"can":1,"effective":1,"offered":1,"most":1,"individuals":1,"regarding":1,"adjustment":1,"glycemic":1,"trends":1},"len":197},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":5,"chunkId":"ada-2026-pharm-p5-c5","text":"ction dose based on premeal glucose levels, anticipated activity, and sick-day management can be effective and should be offered to most individuals ( 46  51 ). Ed - ucation regarding adjustment of prandial insulin dose for glycemic trends should be provided to individuals who are using CGM alone or an AID system ( 52  55 ). Fur - ther adjustment of prandial insulin doses for nutritional intake of protein and fat, in addition to carbohydrates, is recom - mended but may be more feasible for in - dividuals using CSII than for those using multiple daily injections ( 48 ). With some AID systems, use of a simplified meal an - nouncement method may be an alterna - tive for prandial insulin dosing ( 31 , 56 ). Assessment and education tailored to im - prove health literacy and numeracy may be necessary for individuals to effectively use various insulin dosing strategies and tools ( 57 , 58 ) (see section 5,  Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes , and section 7,  Diabetes Technology ). The 2021 ADA/European Association for the Study of Diabetes (EASD) consen - sus report on the management of type 1 diabetes in adults summarizes different insulin plans and glucose monitoring strat - egies in individuals with type 1 diabetes ( Fig. 9.1 and Table 9.1 ) ( 4 ). An individuals treatment plan and insulin-taking behav - iors should be frequent","tf":{"31":1,"46":1,"48":1,"51":1,"52":1,"55":1,"56":1,"57":1,"58":1,"2021":1,"ction":1,"dose":2,"based":1,"on":2,"premeal":1,"glucose":2,"levels":1,"anticipated":1,"activity":1,"and":11,"sick":1,"day":1,"management":2,"can":1,"be":7,"effective":1,"should":3,"offered":1,"to":6,"most":1,"individuals":4,"ed":1,"ucation":1,"regarding":1,"adjustment":2,"of":6,"prandial":3,"insulin":6,"for":7,"glycemic":1,"trends":1,"provided":1,"who":1,"are":1,"using":3,"cgm":1,"alone":1,"or":1,"an":4,"aid":2,"system":1,"fur":1,"ther":1,"doses":1,"nutritional":1,"intake":1,"protein":1,"fat":1,"in":4,"addition":1,"carbohydrates":1,"is":1,"recom":1,"mended":1,"but":1,"may":3,"more":1,"feasible":1,"dividuals":1,"csii":1,"than":1,"those":1,"multiple":1,"daily":1,"injections":1,"with":2,"some":1,"systems":1,"use":2,"simplified":1,"meal":1,"nouncement":1,"method":1,"alterna":1,"tive":1,"dosing":2,"assessment":1,"education":1,"tailored":1,"im":1,"prove":1,"health":3,"literacy":1,"numeracy":1,"necessary":1,"effectively":1,"various":1,"strategies":1,"tools":1,"see":1,"section":2,"facilitating":1,"positive":1,"behaviors":1,"well":1,"being":1,"improve":1,"outcomes":1,"diabetes":4,"technology":1,"the":3,"ada":1,"european":1,"association":1,"study":1,"easd":1,"consen":1,"sus":1,"report":1,"type":2,"adults":1,"summarizes":1,"different":1,"plans":1,"monitoring":1,"strat":1,"egies":1,"fig":1,"table":1,"individual":1,"treatment":1,"plan":1,"taking":1,"behav":1,"iors":1,"frequent":1},"len":208},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":5,"chunkId":"ada-2026-pharm-p5-c6","text":" type 1 diabetes in adults summarizes different insulin plans and glucose monitoring strat - egies in individuals with type 1 diabetes ( Fig. 9.1 and Table 9.1 ) ( 4 ). An individuals treatment plan and insulin-taking behav - iors should be frequently reassessed to at - tain individualized treatment goals and assess risk or progression of complications and comorbidities. The timing of reassess - ment may vary based on time since diag - nosis, ability to attain/maintain treatment goals, health status, comorbidities, and in - dividual needs ( 4 , 45 , 59 ). diabetesjournals.org/care Pharmacologic Approaches to Glycemic Treatment S187 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"45":1,"49":1,"59":1,"2026":1,"848878":1,"type":2,"diabetes":2,"in":3,"adults":1,"summarizes":1,"different":1,"insulin":2,"plans":1,"and":6,"glucose":1,"monitoring":1,"strat":1,"egies":1,"individuals":1,"with":1,"fig":1,"table":1,"an":1,"individual":1,"treatment":4,"plan":1,"taking":1,"behav":1,"iors":1,"should":1,"be":1,"frequently":1,"reassessed":1,"to":3,"at":1,"tain":1,"individualized":1,"goals":2,"assess":1,"risk":1,"or":1,"progression":1,"of":2,"complications":1,"comorbidities":2,"the":1,"timing":1,"reassess":1,"ment":1,"may":1,"vary":1,"based":1,"on":2,"time":1,"since":1,"diag":1,"nosis":1,"ability":1,"attain":1,"maintain":1,"health":1,"status":1,"dividual":1,"needs":1,"diabetesjournals":2,"org":2,"care":2,"pharmacologic":1,"approaches":1,"glycemic":1,"s187":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"supplement":1,"s183":1,"dc26s009":1,"by":1,"guest":1,"february":1},"len":106},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":6,"chunkId":"ada-2026-pharm-p6-c0","text":"Initiation and titration of insulin INITIATION 2 coverage TITRATION Uptitrate or downtitrate as necessary, adjusting basal and prandial doses based on individualized goals for A1C, CGM, and SMBG Assess adequacy of insulin dose and insulin-taking behaviors at every visit Consider person-specific considerations and clinical signs to evaluate for need for modification of administration method (switch to or from MDI, AID, inhaled insulin) and for overbasalization (e.g., elevated bedtime-to-morning and/or postprandial- to-preprandial differential, hypoglycemia [aware or unaware], high glucose variability) Considerations for starting insulin Choice of insulin(s) and administration method should be based on person-specific considerations including progression and severity of insulin deficiency, initial presentation with DKA, 1 and/or concomitant overweight or obesity Glucagon should be prescribed for emergent hypoglycemia If hypoglycemia is present , adjust basal and/or prandial insulin based on the timing of 3,4 If hyperglycemia is present, adjust basal and/or prandial insulin based on the timing and extent of hyperglycemia (e.g., 1 units or 10% dosage adjustments) 3,4 If fasting hyperglycemia is present, review overnight glucose pattern (using CGM, if available) and adjust basal insulin, if appropriate If postprandial hyperglycemia is present, assess and educate to ensure prandial a","tf":{"10":1,"initiation":2,"and":15,"titration":2,"of":7,"insulin":10,"coverage":1,"uptitrate":1,"or":9,"downtitrate":1,"as":1,"necessary":1,"adjusting":1,"basal":4,"prandial":4,"doses":1,"based":4,"on":4,"individualized":1,"goals":1,"for":6,"a1c":1,"cgm":2,"smbg":1,"assess":2,"adequacy":1,"dose":1,"taking":1,"behaviors":1,"at":1,"every":1,"visit":1,"consider":1,"person":2,"specific":2,"considerations":3,"clinical":1,"signs":1,"to":5,"evaluate":1,"need":1,"modification":1,"administration":2,"method":2,"switch":1,"from":1,"mdi":1,"aid":1,"inhaled":1,"overbasalization":1,"elevated":1,"bedtime":1,"morning":1,"postprandial":2,"preprandial":1,"differential":1,"hypoglycemia":3,"aware":1,"unaware":1,"high":1,"glucose":2,"variability":1,"starting":1,"choice":1,"should":2,"be":2,"including":1,"progression":1,"severity":1,"deficiency":1,"initial":1,"presentation":1,"with":1,"dka":1,"concomitant":1,"overweight":1,"obesity":1,"glucagon":1,"prescribed":1,"emergent":1,"if":6,"is":4,"present":4,"adjust":3,"the":2,"timing":2,"hyperglycemia":4,"extent":1,"units":1,"dosage":1,"adjustments":1,"fasting":1,"review":1,"overnight":1,"pattern":1,"using":1,"available":1,"appropriate":1,"educate":1,"ensure":1},"len":192},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":6,"chunkId":"ada-2026-pharm-p6-c1","text":" or 10% dosage adjustments) 3,4 If fasting hyperglycemia is present, review overnight glucose pattern (using CGM, if available) and adjust basal insulin, if appropriate If postprandial hyperglycemia is present, assess and educate to ensure prandial administration is appropriately timed and adjusted for nutrient intake (dosing may be fixed based on general intake or variable based on macronutrient and/or glycemic trends, depending on individual preference and ability) If A1C, CGM metrics, or SMBG not at goal Reassess frequently using CGM and/or SMBG to determine individual needs for prandial and basal dosing balance Support healthy lifestyle behaviors, deliver diabetes self-management education and support, and address social determinants of health to meet individualized treatment goals To avoid therapeutic inertia, reassess and modify treatment regularly 1. Refer to section 16, \"Diabetes Care in the Hospital,\" for information on care during hospitalizations. 2. Prandial insulin options include: injectable rapid-acting and ultra-rapid-acting analog insulins, injectable short-acting human insulin, and inhaled human insulin. 3. Amount of dosage adjustment may vary between individuals depending on their severity of insulin deficiency and/or insulin re 4. Adjustment may be done by their diabetes care team or by individuals, with guidance provided by their diabetes care team, as freq","tf":{"10":1,"16":1,"or":7,"dosage":2,"adjustments":1,"if":5,"fasting":1,"hyperglycemia":2,"is":3,"present":2,"review":1,"overnight":1,"glucose":1,"pattern":1,"using":2,"cgm":3,"available":1,"and":13,"adjust":1,"basal":2,"insulin":6,"appropriate":1,"postprandial":1,"assess":1,"educate":1,"to":5,"ensure":1,"prandial":3,"administration":1,"appropriately":1,"timed":1,"adjusted":1,"for":3,"nutrient":1,"intake":2,"dosing":2,"may":3,"be":2,"fixed":1,"based":2,"on":5,"general":1,"variable":1,"macronutrient":1,"glycemic":1,"trends":1,"depending":2,"individual":2,"preference":1,"ability":1,"a1c":1,"metrics":1,"smbg":2,"not":1,"at":1,"goal":1,"reassess":2,"frequently":1,"determine":1,"needs":1,"balance":1,"support":2,"healthy":1,"lifestyle":1,"behaviors":1,"deliver":1,"diabetes":4,"self":1,"management":1,"education":1,"address":1,"social":1,"determinants":1,"of":3,"health":1,"meet":1,"individualized":1,"treatment":2,"goals":1,"avoid":1,"therapeutic":1,"inertia":1,"modify":1,"regularly":1,"refer":1,"section":1,"care":4,"in":1,"the":1,"hospital":1,"information":1,"during":1,"hospitalizations":1,"options":1,"include":1,"injectable":2,"rapid":2,"acting":3,"ultra":1,"analog":1,"insulins":1,"short":1,"human":2,"inhaled":1,"amount":1,"adjustment":2,"vary":1,"between":1,"individuals":2,"their":3,"severity":1,"deficiency":1,"re":1,"done":1,"by":3,"team":2,"with":1,"guidance":1,"provided":1,"as":1,"freq":1},"len":201},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":6,"chunkId":"ada-2026-pharm-p6-c2","text":"of dosage adjustment may vary between individuals depending on their severity of insulin deficiency and/or insulin re 4. Adjustment may be done by their diabetes care team or by individuals, with guidance provided by their diabetes care team, as frequently as once to twice weekly using the lowest levels or average of the Initiation and adjustment of insulin using multiple daily dosing in individuals with type 1 diabetes Figure 9.2 Insulin initiation and adjustment for people with type 1 diabetes using multiple daily dosing. AID, automated insulin delivery; CGM, continuous glucose monitoring; DKA, diabetic ketoacidosis; MDI, multiple daily injections; SMBG, self-monitoring of blood glucose. Insulin Administration Technique Ensuring that individuals and/or caregivers understand correct insulin administration technique is important to optimize glyce - mic management and insulin use safety. Advanced insulin injection technique and education with FITTER Forward expert rec - ommendations have been published else - where outlining best practices for insulin administration ( 60 ). Proper insulin admin - istration technique includes the following: injection, insertion of patch (for bolus patch or fixed-rate patch pump) or infu - sion set (for CSII or AID systems) into ap - propriate body areas, or oral inhalation (inhaled human insulin); injection or infu - sion site rotation; appropri","tf":{"60":1,"of":6,"dosage":1,"adjustment":4,"may":2,"vary":1,"between":1,"individuals":4,"depending":1,"on":1,"their":3,"severity":1,"insulin":12,"deficiency":1,"and":6,"or":9,"re":1,"be":1,"done":1,"by":3,"diabetes":4,"care":2,"team":2,"with":4,"guidance":1,"provided":1,"as":2,"frequently":1,"once":1,"to":2,"twice":1,"weekly":1,"using":3,"the":3,"lowest":1,"levels":1,"average":1,"initiation":2,"multiple":3,"daily":3,"dosing":2,"in":1,"type":2,"figure":1,"for":4,"people":1,"aid":2,"automated":1,"delivery":1,"cgm":1,"continuous":1,"glucose":2,"monitoring":2,"dka":1,"diabetic":1,"ketoacidosis":1,"mdi":1,"injections":1,"smbg":1,"self":1,"blood":1,"administration":3,"technique":4,"ensuring":1,"that":1,"caregivers":1,"understand":1,"correct":1,"is":1,"important":1,"optimize":1,"glyce":1,"mic":1,"management":1,"use":1,"safety":1,"advanced":1,"injection":3,"education":1,"fitter":1,"forward":1,"expert":1,"rec":1,"ommendations":1,"have":1,"been":1,"published":1,"else":1,"where":1,"outlining":1,"best":1,"practices":1,"proper":1,"admin":1,"istration":1,"includes":1,"following":1,"insertion":1,"patch":3,"bolus":1,"fixed":1,"rate":1,"pump":1,"infu":2,"sion":2,"set":1,"csii":1,"systems":1,"into":1,"ap":1,"propriate":1,"body":1,"areas":1,"oral":1,"inhalation":1,"inhaled":1,"human":1,"site":1,"rotation":1,"appropri":1},"len":198},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":6,"chunkId":"ada-2026-pharm-p6-c3","text":"lowing: injection, insertion of patch (for bolus patch or fixed-rate patch pump) or infu - sion set (for CSII or AID systems) into ap - propriate body areas, or oral inhalation (inhaled human insulin); injection or infu - sion site rotation; appropriate care of injection or infusion sites to avoid infec - tion or other complications; avoidance of intramuscular (IM) insulin delivery; and filling of the reservoir (for bolus patch, CSII, or AID systems) or inhaler (for in - haled human insulin) depending on the method of administration. Selection of method of administration (vial and syringe, insulin pen, insulin patch, inhaled insulin, connected insulin pens/devices, or insulin pumps) will depend on a variety of indi - vidual-specific factors and needs, cost and coverage, and individual preferen - ces. Reassessment of the appropriate administration technique should be com - pleted during routine follow-up. Exogenously delivered insulin should be injected or infused into subcutaneous tissue, not intramuscularly. Recommended sites for insulin administration include the abdomen, thigh, buttock, and upper arm. Insulin absorption from IM sites differs from that in subcutaneous sites and is also influenced by the activity of the muscle. Inadvertent IM injection can lead to un - predictable insulin absorption and variable effects on glucose and is associated with frequent and unexplaine","tf":{"lowing":1,"injection":4,"insertion":1,"of":10,"patch":5,"for":5,"bolus":2,"or":11,"fixed":1,"rate":1,"pump":1,"infu":2,"sion":2,"set":1,"csii":2,"aid":2,"systems":2,"into":2,"ap":1,"propriate":1,"body":1,"areas":1,"oral":1,"inhalation":1,"inhaled":2,"human":2,"insulin":12,"site":1,"rotation":1,"appropriate":2,"care":1,"infusion":1,"sites":4,"to":2,"avoid":1,"infec":1,"tion":1,"other":1,"complications":1,"avoidance":1,"intramuscular":1,"im":3,"delivery":1,"and":10,"filling":1,"the":6,"reservoir":1,"inhaler":1,"in":2,"haled":1,"depending":1,"on":3,"method":2,"administration":4,"selection":1,"vial":1,"syringe":1,"pen":1,"connected":1,"pens":1,"devices":1,"pumps":1,"will":1,"depend":1,"variety":1,"indi":1,"vidual":1,"specific":1,"factors":1,"needs":1,"cost":1,"coverage":1,"individual":1,"preferen":1,"ces":1,"reassessment":1,"technique":1,"should":2,"be":2,"com":1,"pleted":1,"during":1,"routine":1,"follow":1,"up":1,"exogenously":1,"delivered":1,"injected":1,"infused":1,"subcutaneous":2,"tissue":1,"not":1,"intramuscularly":1,"recommended":1,"include":1,"abdomen":1,"thigh":1,"buttock":1,"upper":1,"arm":1,"absorption":2,"from":2,"differs":1,"that":1,"is":2,"also":1,"influenced":1,"by":1,"activity":1,"muscle":1,"inadvertent":1,"can":1,"lead":1,"un":1,"predictable":1,"variable":1,"effects":1,"glucose":1,"associated":1,"with":1,"frequent":1,"unexplaine":1},"len":206},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":6,"chunkId":"ada-2026-pharm-p6-c4","text":"ites differs from that in subcutaneous sites and is also influenced by the activity of the muscle. Inadvertent IM injection can lead to un - predictable insulin absorption and variable effects on glucose and is associated with frequent and unexplained hypoglycemia. Size 4-mm pen needles should be used to reduce inadvertent IM insulin delivery across ages and body types. IM risk is higher in younger, leaner individuals, with injections into limbs rather than truncal S188 Pharmacologic Approaches to Glycemic Treatment Diabetes Care Volume 49, Supplement 1, January 2026 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"49":2,"2026":2,"848878":1,"ites":1,"differs":1,"from":2,"that":1,"in":2,"subcutaneous":1,"sites":1,"and":5,"is":3,"also":1,"influenced":1,"by":2,"the":2,"activity":1,"of":1,"muscle":1,"inadvertent":2,"im":3,"injection":1,"can":1,"lead":1,"to":3,"un":1,"predictable":1,"insulin":2,"absorption":1,"variable":1,"effects":1,"on":2,"glucose":1,"associated":1,"with":2,"frequent":1,"unexplained":1,"hypoglycemia":1,"size":1,"mm":1,"pen":1,"needles":1,"should":1,"be":1,"used":1,"reduce":1,"delivery":1,"across":1,"ages":1,"body":1,"types":1,"risk":1,"higher":1,"younger":1,"leaner":1,"individuals":1,"injections":1,"into":1,"limbs":1,"rather":1,"than":1,"truncal":1,"s188":1,"pharmacologic":1,"approaches":1,"glycemic":1,"treatment":1,"diabetes":1,"care":2,"volume":1,"supplement":2,"january":1,"downloaded":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"s183":1,"dc26s009":1,"guest":1,"february":1},"len":106},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":7,"chunkId":"ada-2026-pharm-p7-c0","text":"sites (abdomen, buttocks), and with lon - ger needles. Short needles (e.g., 4-mm) are effective and well tolerated compared with longer needles, including in adults with obesity ( 61 ). Injection or infusion site rotation is necessary to avoid lipohypertrophy, an accumulation of subcutaneous fat in re - sponse to the adipogenic actions of insulin at a site of multiple injections. Lipohyper - trophy appears as soft, smooth raised areas several centimeters in breadth and can contribute to erratic insulin absorp - tion, increased glycemic variability, and unexplained hypoglycemic episodes. Peo - ple treated with insulin and/or caregivers should receive education about proper in - jection or infusion site rotation and how to recognize and avoid injecting in areas of lipohypertrophy ( 60 ). As noted in Table 4.1 , examination of insulin administration sites for the presence of lipohypertrophy, as well as assessment of administration de - vice use and injection technique, are key components of a comprehensive diabetes evaluation and treatment plan. Proper in - sulin injection, infusion, or inhalation tech - nique may lead to more effective use of this therapy and, as such, holds the po - tential for improved clinical outcomes. Noninsulin Treatments for Type 1 Diabetes Injectable and oral noninsulin glucose- lowering medications have been studied for their efficacy as adjuncts to insu","tf":{"60":1,"61":1,"sites":2,"abdomen":1,"buttocks":1,"and":11,"with":4,"lon":1,"ger":1,"needles":3,"short":1,"mm":1,"are":2,"effective":2,"well":2,"tolerated":1,"compared":1,"longer":1,"including":1,"in":7,"adults":1,"obesity":1,"injection":3,"or":4,"infusion":3,"site":3,"rotation":2,"is":1,"necessary":1,"to":6,"avoid":2,"lipohypertrophy":3,"an":1,"accumulation":1,"of":9,"subcutaneous":1,"fat":1,"re":1,"sponse":1,"the":3,"adipogenic":1,"actions":1,"insulin":4,"at":1,"multiple":1,"injections":1,"lipohyper":1,"trophy":1,"appears":1,"as":6,"soft":1,"smooth":1,"raised":1,"areas":2,"several":1,"centimeters":1,"breadth":1,"can":1,"contribute":1,"erratic":1,"absorp":1,"tion":1,"increased":1,"glycemic":1,"variability":1,"unexplained":1,"hypoglycemic":1,"episodes":1,"peo":1,"ple":1,"treated":1,"caregivers":1,"should":1,"receive":1,"education":1,"about":1,"proper":2,"jection":1,"how":1,"recognize":1,"injecting":1,"noted":1,"table":1,"examination":1,"administration":2,"for":4,"presence":1,"assessment":1,"de":1,"vice":1,"use":2,"technique":1,"key":1,"components":1,"comprehensive":1,"diabetes":2,"evaluation":1,"treatment":1,"plan":1,"sulin":1,"inhalation":1,"tech":1,"nique":1,"may":1,"lead":1,"more":1,"this":1,"therapy":1,"such":1,"holds":1,"po":1,"tential":1,"improved":1,"clinical":1,"outcomes":1,"noninsulin":2,"treatments":1,"type":1,"injectable":1,"oral":1,"glucose":1,"lowering":1,"medications":1,"have":1,"been":1,"studied":1,"their":1,"efficacy":1,"adjuncts":1,"insu":1},"len":200},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":7,"chunkId":"ada-2026-pharm-p7-c1","text":"e use of this therapy and, as such, holds the po - tential for improved clinical outcomes. Noninsulin Treatments for Type 1 Diabetes Injectable and oral noninsulin glucose- lowering medications have been studied for their efficacy as adjuncts to insulin treatment of type 1 diabetes. Pramlintide is based on the naturally occurring  -cell peptide amylin and is approved for use in adults with type 1 diabetes. Clinical trials have demonstrated a modest reduction in A1C (0.3  0.4%) and modest weight loss (  1  2 kg) with pramlintide ( 62 ). Similar results have been reported for several agents currently approved for the treat - ment of type 2 diabetes. The addition of metformin in adults with type 1 diabetes was associated with small reductions in body weight, insulin dose, and lipid levels but did not sustainably improve A1C ( 63 , 64 ). The largest clinical trials of glucagon- like peptide 1 receptor agonists (GLP-1 RAs) in type 1 diabetes have been conducted with liraglutide 1.8 mg daily, and results showed modest A1C reductions (  0.4%), decreases in weight (  5 kg), and reduc - tions in insulin doses ( 65 , 66 ). Higher rates of DKA and gastrointestinal side effects have limited their use in type 1 diabetes. Liraglutide was also assessed for impact on C-peptide in individuals with type 1 diabetes and residual  -cell function. Dur - ing treatment there was no impact on pr","tf":{"62":1,"63":1,"64":1,"65":1,"66":1,"use":3,"of":6,"this":1,"therapy":1,"and":9,"as":2,"such":1,"holds":1,"the":5,"po":1,"tential":1,"for":7,"improved":1,"clinical":3,"outcomes":1,"noninsulin":2,"treatments":1,"type":8,"diabetes":8,"injectable":1,"oral":1,"glucose":1,"lowering":1,"medications":1,"have":5,"been":3,"studied":1,"their":2,"efficacy":1,"adjuncts":1,"to":1,"insulin":3,"treatment":2,"pramlintide":2,"is":2,"based":1,"on":3,"naturally":1,"occurring":1,"cell":2,"peptide":3,"amylin":1,"approved":2,"in":9,"adults":2,"with":6,"trials":2,"demonstrated":1,"modest":3,"reduction":1,"a1c":3,"weight":3,"loss":1,"kg":2,"similar":1,"results":2,"reported":1,"several":1,"agents":1,"currently":1,"treat":1,"ment":1,"addition":1,"metformin":1,"was":3,"associated":1,"small":1,"reductions":2,"body":1,"dose":1,"lipid":1,"levels":1,"but":1,"did":1,"not":1,"sustainably":1,"improve":1,"largest":1,"glucagon":1,"like":1,"receptor":1,"agonists":1,"glp":1,"ras":1,"conducted":1,"liraglutide":2,"mg":1,"daily":1,"showed":1,"decreases":1,"reduc":1,"tions":1,"doses":1,"higher":1,"rates":1,"dka":1,"gastrointestinal":1,"side":1,"effects":1,"limited":1,"also":1,"assessed":1,"impact":2,"individuals":1,"residual":1,"function":1,"dur":1,"ing":1,"there":1,"no":1,"pr":1},"len":205},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":7,"chunkId":"ada-2026-pharm-p7-c2","text":"of DKA and gastrointestinal side effects have limited their use in type 1 diabetes. Liraglutide was also assessed for impact on C-peptide in individuals with type 1 diabetes and residual  -cell function. Dur - ing treatment there was no impact on preservation of  -cell function, but with lir - aglutide discontinuation there was wors - ening of C-peptide loss compared with placebo ( 67 ). Small retrospective case se - ries and pilot studies have revealed poten - tial benefits on body weight and glycemic metrics with addition of semaglutide or tirzepatide for individuals with type 1 dia - betes and obesity ( 68  72 ). Prospective studies on use of incretin medications (i.e., GLP-1 RAs or a dual glucose-dependent insulinotropic polypeptide [GIP] and GLP-1 RA) for individuals with type 1 diabetes are ongoing and include evaluation of cardio - vascular and kidney outcomes and other aspects of care ( 73  76 ). Sodium  glucose cotransporter 2 (SGLT2) inhibitors have been studied in clinical tri - als in people with type 1 diabetes, and results showed improvements in A1C, re - duced body weight, and improved blood pressure ( 77 ); however, SGLT2 inhibitor use in type 1 diabetes was associated with an increased rate of DKA ( 78 ). The SGLT1/2 inhibitor sotagliflozin has been studied in clinical trials in people with type 1 diabetes, and results showed improvements in A1C and body w","tf":{"67":1,"68":1,"72":1,"73":1,"76":1,"77":1,"78":1,"of":8,"dka":2,"and":13,"gastrointestinal":1,"side":1,"effects":1,"have":3,"limited":1,"their":1,"use":3,"in":9,"type":7,"diabetes":6,"liraglutide":1,"was":4,"also":1,"assessed":1,"for":3,"impact":2,"on":4,"peptide":2,"individuals":3,"with":9,"residual":1,"cell":2,"function":2,"dur":1,"ing":1,"treatment":1,"there":2,"no":1,"preservation":1,"but":1,"lir":1,"aglutide":1,"discontinuation":1,"wors":1,"ening":1,"loss":1,"compared":1,"placebo":1,"small":1,"retrospective":1,"case":1,"se":1,"ries":1,"pilot":1,"studies":2,"revealed":1,"poten":1,"tial":1,"benefits":1,"body":3,"weight":2,"glycemic":1,"metrics":1,"addition":1,"semaglutide":1,"or":2,"tirzepatide":1,"dia":1,"betes":1,"obesity":1,"prospective":1,"incretin":1,"medications":1,"glp":2,"ras":1,"dual":1,"glucose":2,"dependent":1,"insulinotropic":1,"polypeptide":1,"gip":1,"ra":1,"are":1,"ongoing":1,"include":1,"evaluation":1,"cardio":1,"vascular":1,"kidney":1,"outcomes":1,"other":1,"aspects":1,"care":1,"sodium":1,"cotransporter":1,"sglt2":2,"inhibitors":1,"been":2,"studied":2,"clinical":2,"tri":1,"als":1,"people":2,"results":2,"showed":2,"improvements":2,"a1c":2,"re":1,"duced":1,"improved":1,"blood":1,"pressure":1,"however":1,"inhibitor":2,"associated":1,"an":1,"increased":1,"rate":1,"the":1,"sglt1":1,"sotagliflozin":1,"has":1,"trials":1},"len":206},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":7,"chunkId":"ada-2026-pharm-p7-c3","text":"ver, SGLT2 inhibitor use in type 1 diabetes was associated with an increased rate of DKA ( 78 ). The SGLT1/2 inhibitor sotagliflozin has been studied in clinical trials in people with type 1 diabetes, and results showed improvements in A1C and body weight ( 79 ); however, sotagliflo - zin use was associated with an eightfold in - crease in DKA compared with placebo ( 80 ). The studies that led to the approved indica - tion for heart failure (HF) excluded individu - als with type 1 diabetes or a history of DKA ( 81 , 82 ). Sotagliflozin is therefore ap - proved for HF and chronic kidney disease (CKD) but contraindicated in type 1 dia - betes due to DKA risk. See SGLT INHIBITION AND RISK OF KETOSIS , later in this section, and PREVENTION AND TREATMENT OF HEART FAILURE in section 10,  Cardiovascular Disease and Risk Management , for information on risk mitigation with the use of SGLT inhib - itors in those with type 1 diabetes. The risks and benefits of adjunctive agents continue to be evaluated, with consensus statements providing guidance on selec - tion of candidates for treatment and pre - cautions ( 83 ). There are currently no approved thera - pies for preservation of C-peptide or prolon - gation of the partial remission (honeymoon) phase in individuals with established stage 3 type 1 diabetes. Teplizumab was approved by the U.S. Food and Drug Administration. (FDA) in 2022","tf":{"10":1,"78":1,"79":1,"80":1,"81":1,"82":1,"83":1,"2022":1,"ver":1,"sglt2":1,"inhibitor":2,"use":3,"in":12,"type":6,"diabetes":5,"was":3,"associated":2,"with":9,"an":2,"increased":1,"rate":1,"of":9,"dka":4,"the":7,"sglt1":1,"sotagliflozin":2,"has":1,"been":1,"studied":1,"clinical":1,"trials":1,"people":1,"and":10,"results":1,"showed":1,"improvements":1,"a1c":1,"body":1,"weight":1,"however":1,"sotagliflo":1,"zin":1,"eightfold":1,"crease":1,"compared":1,"placebo":1,"studies":1,"that":1,"led":1,"to":3,"approved":3,"indica":1,"tion":2,"for":5,"heart":2,"failure":2,"hf":2,"excluded":1,"individu":1,"als":1,"or":2,"history":1,"is":1,"therefore":1,"ap":1,"proved":1,"chronic":1,"kidney":1,"disease":2,"ckd":1,"but":1,"contraindicated":1,"dia":1,"betes":1,"due":1,"risk":4,"see":1,"sglt":2,"inhibition":1,"ketosis":1,"later":1,"this":1,"section":2,"prevention":1,"treatment":2,"cardiovascular":1,"management":1,"information":1,"on":2,"mitigation":1,"inhib":1,"itors":1,"those":1,"risks":1,"benefits":1,"adjunctive":1,"agents":1,"continue":1,"be":1,"evaluated":1,"consensus":1,"statements":1,"providing":1,"guidance":1,"selec":1,"candidates":1,"pre":1,"cautions":1,"there":1,"are":1,"currently":1,"no":1,"thera":1,"pies":1,"preservation":1,"peptide":1,"prolon":1,"gation":1,"partial":1,"remission":1,"honeymoon":1,"phase":1,"individuals":1,"established":1,"stage":1,"teplizumab":1,"by":1,"food":1,"drug":1,"administration":1,"fda":1},"len":214},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":7,"chunkId":"ada-2026-pharm-p7-c4","text":"approved thera - pies for preservation of C-peptide or prolon - gation of the partial remission (honeymoon) phase in individuals with established stage 3 type 1 diabetes. Teplizumab was approved by the U.S. Food and Drug Administration. (FDA) in 2022 for delay of the progression from stage 2 to stage 3 type 1 diabetes (for additional guidance for use in early stage type 1 diabetes, refer to section 3,  Prevention or Delay of Diabetes and Associated Comorbidities ), but it is not indicated for those with established stage 3 type 1 diabetes ( 84 ). Higher C-peptide levels have been associated with better A1C, lower risk of retinopathy, lower risk of nephropathy, and lower risk of severe hypoglycemia ( 85 ). Various therapies, in - cluding verapamil, menin inhibitors, Janus kinase inhibitors, antithymocyte globulin, several monoclonal antibodies including teplizumab, and cell therapies, are cur - rently under active investigation ( 86 ). SURGICAL TREATMENT OF TYPE 1 DIABETES Pancreas and Islet Transplantation Successful pancreas and islet transplanta - tion can normalize glucose levels and miti - gate microvascular complications of type 1 diabetes. However, people receiving these treatments require lifelong immunosup - pression to prevent graft rejection and/or recurrence of autoimmune islet destruc - tion. Given the potential adverse effects of immunosuppressive therapy, pancre","tf":{"84":1,"85":1,"86":1,"2022":1,"approved":2,"thera":1,"pies":1,"for":5,"preservation":1,"of":11,"peptide":2,"or":3,"prolon":1,"gation":1,"the":4,"partial":1,"remission":1,"honeymoon":1,"phase":1,"in":4,"individuals":1,"with":3,"established":2,"stage":5,"type":6,"diabetes":7,"teplizumab":2,"was":1,"by":1,"food":1,"and":8,"drug":1,"administration":1,"fda":1,"delay":2,"progression":1,"from":1,"to":3,"additional":1,"guidance":1,"use":1,"early":1,"refer":1,"section":1,"prevention":1,"associated":2,"comorbidities":1,"but":1,"it":1,"is":1,"not":1,"indicated":1,"those":1,"higher":1,"levels":2,"have":1,"been":1,"better":1,"a1c":1,"lower":3,"risk":3,"retinopathy":1,"nephropathy":1,"severe":1,"hypoglycemia":1,"various":1,"therapies":2,"cluding":1,"verapamil":1,"menin":1,"inhibitors":2,"janus":1,"kinase":1,"antithymocyte":1,"globulin":1,"several":1,"monoclonal":1,"antibodies":1,"including":1,"cell":1,"are":1,"cur":1,"rently":1,"under":1,"active":1,"investigation":1,"surgical":1,"treatment":1,"pancreas":2,"islet":3,"transplantation":1,"successful":1,"transplanta":1,"tion":2,"can":1,"normalize":1,"glucose":1,"miti":1,"gate":1,"microvascular":1,"complications":1,"however":1,"people":1,"receiving":1,"these":1,"treatments":1,"require":1,"lifelong":1,"immunosup":1,"pression":1,"prevent":1,"graft":1,"rejection":1,"recurrence":1,"autoimmune":1,"destruc":1,"given":1,"potential":1,"adverse":1,"effects":1,"immunosuppressive":1,"therapy":1,"pancre":1},"len":188},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":7,"chunkId":"ada-2026-pharm-p7-c5","text":"ype 1 diabetes. However, people receiving these treatments require lifelong immunosup - pression to prevent graft rejection and/or recurrence of autoimmune islet destruc - tion. Given the potential adverse effects of immunosuppressive therapy, pancreas transplantation should be reserved for people with type 1 diabetes undergoing simultaneous kidney transplantation, fol - lowing kidney transplantation, or for those with recurrent ketoacidosis or severe hy - poglycemia despite optimized glycemic management ( 87 ). In much of the world, allogenic islet transplantation is regu - lated as an organ transplant. However, in the U.S., allogenic islet transplantation is regulated as a cell therapy, and the first such allogeneic islet cell therapy, donislecel- jujn, was approved in 2023. Donislecel is in - dicated for the treatment of adults with type 1 diabetes who are unable to reach their A1C goals because of repeated epi - sodes of severe hypoglycemia despite inten - sive diabetes management and education ( 88 ). Alternative islet sources are currently under active investigation. The 2021 ADA/EASD consensus report on the management of type 1 diabetes in adults offers a simplified overview of indi - cations for  -cell replacement therapy in people with type 1 diabetes ( Fig. 9.3 ) ( 4 ). PHARMACOLOGIC THERAPY FOR ADULTS WITH TYPE 2 DIABETES Recommendations 9.5 A person-centered shared","tf":{"87":1,"88":1,"2021":1,"2023":1,"ype":1,"diabetes":7,"however":2,"people":3,"receiving":1,"these":1,"treatments":1,"require":1,"lifelong":1,"immunosup":1,"pression":1,"to":2,"prevent":1,"graft":1,"rejection":1,"and":3,"or":3,"recurrence":1,"of":8,"autoimmune":1,"islet":5,"destruc":1,"tion":1,"given":1,"the":7,"potential":1,"adverse":1,"effects":1,"immunosuppressive":1,"therapy":5,"pancreas":1,"transplantation":5,"should":1,"be":1,"reserved":1,"for":5,"with":5,"type":5,"undergoing":1,"simultaneous":1,"kidney":2,"fol":1,"lowing":1,"those":1,"recurrent":1,"ketoacidosis":1,"severe":2,"hy":1,"poglycemia":1,"despite":2,"optimized":1,"glycemic":1,"management":3,"in":6,"much":1,"world":1,"allogenic":2,"is":3,"regu":1,"lated":1,"as":2,"an":1,"organ":1,"transplant":1,"regulated":1,"cell":3,"first":1,"such":1,"allogeneic":1,"donislecel":2,"jujn":1,"was":1,"approved":1,"dicated":1,"treatment":1,"adults":3,"who":1,"are":2,"unable":1,"reach":1,"their":1,"a1c":1,"goals":1,"because":1,"repeated":1,"epi":1,"sodes":1,"hypoglycemia":1,"inten":1,"sive":1,"education":1,"alternative":1,"sources":1,"currently":1,"under":1,"active":1,"investigation":1,"ada":1,"easd":1,"consensus":1,"report":1,"on":1,"offers":1,"simplified":1,"overview":1,"indi":1,"cations":1,"replacement":1,"fig":1,"pharmacologic":1,"recommendations":1,"person":1,"centered":1,"shared":1},"len":189},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":7,"chunkId":"ada-2026-pharm-p7-c6","text":" 1 diabetes in adults offers a simplified overview of indi - cations for  -cell replacement therapy in people with type 1 diabetes ( Fig. 9.3 ) ( 4 ). PHARMACOLOGIC THERAPY FOR ADULTS WITH TYPE 2 DIABETES Recommendations 9.5 A person-centered shared decision- making approach should guide the diabetesjournals.org/care Pharmacologic Approaches to Glycemic Treatment S189 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"49":1,"2026":1,"848878":1,"diabetes":3,"in":2,"adults":2,"offers":1,"simplified":1,"overview":1,"of":1,"indi":1,"cations":1,"for":2,"cell":1,"replacement":1,"therapy":2,"people":1,"with":2,"type":2,"fig":1,"pharmacologic":2,"recommendations":1,"person":1,"centered":1,"shared":1,"decision":1,"making":1,"approach":1,"should":1,"guide":1,"the":1,"diabetesjournals":2,"org":2,"care":2,"approaches":1,"to":1,"glycemic":1,"treatment":1,"s189":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"supplement":1,"s183":1,"dc26s009":1,"by":1,"guest":1,"on":1,"february":1},"len":65},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":8,"chunkId":"ada-2026-pharm-p8-c0","text":"choice of glucose-lowering medica - tions for adults with type 2 diabetes. Use medications that provide suffi - cient effectiveness to achieve and maintain intended treatment goals with consideration of the effects on cardiovascular, kidney, weight, and other relevant comorbidities; hypogly - cemia risk; cost and access; risk for ad - verse reactions and tolerability; and individual preferences ( Fig. 9.4 and Table 9.2 ). E 9.6 Consider combination therapy in adults with type 2 diabetes for initial treatment to shorten time to attain - ment of individualized glycemic goals. A 9.7 In adults with type 2 diabetes and established or high risk of atheroscle - rotic cardiovascular disease, the treat - ment plan should include medications with demonstrated benefits to reduce cardiovascular events (e.g., glucagon- like peptide 1 receptor agonist [GLP-1 RA] and/or sodium  glucose cotrans - porter 2 [SGLT2] inhibitor) for glyce - mic management and comprehensive cardiovascular risk reduction (irrespective of A1C) ( Fig. 9.4 and Table 9.2 ). A 9.8 In adults with type 2 diabetes who have heart failure (HF) (with either re - duced or preserved ejection fraction), an SGLT2 inhibitor is recommended for both glycemic management and prevention of HF hospitalizations (ir - respective of A1C) ( Fig. 9.4 ). A 9.9a In adults with type 2 diabetes, obesity, and symptomatic heart fail - ure with pres","tf":{"choice":1,"of":7,"glucose":2,"lowering":1,"medica":1,"tions":1,"for":5,"adults":5,"with":9,"type":5,"diabetes":5,"use":1,"medications":2,"that":1,"provide":1,"suffi":1,"cient":1,"effectiveness":1,"to":4,"achieve":1,"and":12,"maintain":1,"intended":1,"treatment":2,"goals":2,"consideration":1,"the":2,"effects":1,"on":1,"cardiovascular":4,"kidney":1,"weight":1,"other":1,"relevant":1,"comorbidities":1,"hypogly":1,"cemia":1,"risk":4,"cost":1,"access":1,"ad":1,"verse":1,"reactions":1,"tolerability":1,"individual":1,"preferences":1,"fig":3,"table":2,"consider":1,"combination":1,"therapy":1,"in":4,"initial":1,"shorten":1,"time":1,"attain":1,"ment":2,"individualized":1,"glycemic":2,"established":1,"or":3,"high":1,"atheroscle":1,"rotic":1,"disease":1,"treat":1,"plan":1,"should":1,"include":1,"demonstrated":1,"benefits":1,"reduce":1,"events":1,"glucagon":1,"like":1,"peptide":1,"receptor":1,"agonist":1,"glp":1,"ra":1,"sodium":1,"cotrans":1,"porter":1,"sglt2":2,"inhibitor":2,"glyce":1,"mic":1,"management":2,"comprehensive":1,"reduction":1,"irrespective":1,"a1c":2,"who":1,"have":1,"heart":2,"failure":1,"hf":2,"either":1,"re":1,"duced":1,"preserved":1,"ejection":1,"fraction":1,"an":1,"is":1,"recommended":1,"both":1,"prevention":1,"hospitalizations":1,"ir":1,"respective":1,"9a":1,"obesity":1,"symptomatic":1,"fail":1,"ure":1,"pres":1},"len":188},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":8,"chunkId":"ada-2026-pharm-p8-c1","text":"ejection fraction), an SGLT2 inhibitor is recommended for both glycemic management and prevention of HF hospitalizations (ir - respective of A1C) ( Fig. 9.4 ). A 9.9a In adults with type 2 diabetes, obesity, and symptomatic heart fail - ure with preserved ejection fraction (HFpEF), the glucose-lowering treatment plan should include a dual glucose- dependent insulinotropic polypeptide (GIP) and GLP-1 RA with demonstrated benefits for HF-related symptoms and reduction in HF events (irrespective of A1C). A 9.9b In adults with type 2 diabetes, obesity, and symptomatic HFpEF, the glucose-lowering treatment plan should include a GLP-1 RA with demonstrated benefits for HF-related symptoms A and/or reduction in HF events (irre - spective of A1C). B 9.10 In adults with type 2 diabetes who have chronic kidney disease (CKD) (with confirmed estimated glomerular filtration rate [eGFR] 20  60 mL/min/ 1.73 m 2 and/or albuminuria), an SGLT2 inhibitor or GLP-1 RA with demonstrated benefit in this population should be used for both glycemic management and for slowing progression of CKD and reduction in cardiovascular events (ir - respective of A1C) ( Fig. 9.4 ). The gly - cemic benefits of SGLT2 inhibitors are reduced at eGFR < 45 mL/min/ 1.73 m 2 . A 9.11 In adults with type 2 diabetes and advanced CKD (eGFR < 30 mL/ min/1.73 m 2 ), a GLP-1 RA is preferred for glycemic management due to lower ","tf":{"10":1,"11":1,"20":1,"30":1,"45":1,"60":1,"73":3,"ejection":2,"fraction":2,"an":2,"sglt2":3,"inhibitor":2,"is":2,"recommended":1,"for":6,"both":2,"glycemic":3,"management":3,"and":10,"prevention":1,"of":7,"hf":5,"hospitalizations":1,"ir":2,"respective":2,"a1c":4,"fig":2,"9a":1,"in":8,"adults":4,"with":9,"type":4,"diabetes":4,"obesity":2,"symptomatic":2,"heart":1,"fail":1,"ure":1,"preserved":1,"hfpef":2,"the":3,"glucose":3,"lowering":2,"treatment":2,"plan":2,"should":3,"include":2,"dual":1,"dependent":1,"insulinotropic":1,"polypeptide":1,"gip":1,"glp":4,"ra":4,"demonstrated":3,"benefits":3,"related":2,"symptoms":2,"reduction":3,"events":3,"irrespective":1,"9b":1,"or":3,"irre":1,"spective":1,"who":1,"have":1,"chronic":1,"kidney":1,"disease":1,"ckd":3,"confirmed":1,"estimated":1,"glomerular":1,"filtration":1,"rate":1,"egfr":3,"ml":3,"min":3,"albuminuria":1,"benefit":1,"this":1,"population":1,"be":1,"used":1,"slowing":1,"progression":1,"cardiovascular":1,"gly":1,"cemic":1,"inhibitors":1,"are":1,"reduced":1,"at":1,"advanced":1,"preferred":1,"due":1,"to":1,"lower":1},"len":206},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":8,"chunkId":"ada-2026-pharm-p8-c2","text":"( Fig. 9.4 ). The gly - cemic benefits of SGLT2 inhibitors are reduced at eGFR < 45 mL/min/ 1.73 m 2 . A 9.11 In adults with type 2 diabetes and advanced CKD (eGFR < 30 mL/ min/1.73 m 2 ), a GLP-1 RA is preferred for glycemic management due to lower risk of hypoglycemia and for cardiovas - cular event reduction. B Individuals on dialysis can be safely initiated or con - tinued on GLP-1  based therapy (that is not dependent on kidney clear - ance) to reduce cardiovascular risk and mortality. C 9.12 In adults with type 2 diabetes, metabolic dysfunction  associated stea - totic liver disease (MASLD), and over - weight or obesity, consider using a GLP-1 RA with demonstrated benefits in metabolic dysfunction  associated steatohepatitis (MASH) A or a dual $mplgovr view of indications for -cell replacement therapy in people with type 1 diabetes Pancreas after kidney Islet after kidney Simultaneous islet and kidney Pancreas transplantation alone Simultaneous pancreas and kidney Islet transplantation alone Balancing surgical risk, metabolic need, and the choice of the individual with diabetes Severe chronic kidney disease 73 m 2 ) Severe metabolic complications  Hypoglycemia  Hypoglycemia unawareness  Ketoacidosis  Incapacitating problems with exogenous insulin therapy  Failure of insulin-based management to prevent acute complications Living donor kidney Simultaneous tr","tf":{"11":1,"12":1,"30":1,"45":1,"73":3,"fig":1,"the":3,"gly":1,"cemic":1,"benefits":2,"of":5,"sglt2":1,"inhibitors":1,"are":1,"reduced":1,"at":1,"egfr":2,"ml":2,"min":2,"in":4,"adults":2,"with":6,"type":3,"diabetes":4,"and":7,"advanced":1,"ckd":1,"glp":3,"ra":2,"is":2,"preferred":1,"for":3,"glycemic":1,"management":2,"due":1,"to":3,"lower":1,"risk":3,"hypoglycemia":3,"cardiovas":1,"cular":1,"event":1,"reduction":1,"individuals":1,"on":3,"dialysis":1,"can":1,"be":1,"safely":1,"initiated":1,"or":3,"con":1,"tinued":1,"based":2,"therapy":3,"that":1,"not":1,"dependent":1,"kidney":7,"clear":1,"ance":1,"reduce":1,"cardiovascular":1,"mortality":1,"metabolic":4,"dysfunction":2,"associated":2,"stea":1,"totic":1,"liver":1,"disease":2,"masld":1,"over":1,"weight":1,"obesity":1,"consider":1,"using":1,"demonstrated":1,"steatohepatitis":1,"mash":1,"dual":1,"mpl":1,"gov":1,"view":1,"indications":1,"cell":1,"replacement":1,"people":1,"pancreas":3,"after":2,"islet":3,"simultaneous":3,"transplantation":2,"alone":2,"balancing":1,"surgical":1,"need":1,"choice":1,"individual":1,"severe":2,"chronic":1,"complications":2,"unawareness":1,"ketoacidosis":1,"incapacitating":1,"problems":1,"exogenous":1,"insulin":2,"failure":1,"prevent":1,"acute":1,"living":1,"donor":1,"tr":1},"len":190},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":8,"chunkId":"ada-2026-pharm-p8-c3","text":" Severe metabolic complications  Hypoglycemia  Hypoglycemia unawareness  Ketoacidosis  Incapacitating problems with exogenous insulin therapy  Failure of insulin-based management to prevent acute complications Living donor kidney Simultaneous transplantation Impaired kidney function Intact/stable kidney function Figure 9.3 Simplified overview of indications for  -cell replacement therapy in people with type 1 diabetes. The two main forms of  -cell replace - ment therapy are whole-pancreas transplantation and islet cell transplantation.  -Cell replacement therapy can be combined with kidney trans - plantation if the individual has kidney failure, which may be performed simultaneously or after kidney transplantation. All decisions about transplantation must consider the surgical risk, metabolic need, and the choices of the individual with diabetes. GFR, glomerular filtration rate. Adapted from Holt et al. ( 4 ). S190 Pharmacologic Approaches to Glycemic Treatment Diabetes Care Volume 49, Supplement 1, January 2026 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"49":2,"2026":2,"848878":1,"severe":1,"metabolic":2,"complications":2,"hypoglycemia":2,"unawareness":1,"ketoacidosis":1,"incapacitating":1,"problems":1,"with":4,"exogenous":1,"insulin":2,"therapy":4,"failure":2,"of":4,"based":1,"management":1,"to":2,"prevent":1,"acute":1,"living":1,"donor":1,"kidney":6,"simultaneous":1,"transplantation":5,"impaired":1,"function":2,"intact":1,"stable":1,"figure":1,"simplified":1,"overview":1,"indications":1,"for":1,"cell":4,"replacement":2,"in":1,"people":1,"type":1,"diabetes":3,"the":5,"two":1,"main":1,"forms":1,"replace":1,"ment":1,"are":1,"whole":1,"pancreas":1,"and":2,"islet":1,"can":1,"be":2,"combined":1,"trans":1,"plantation":1,"if":1,"individual":2,"has":1,"which":1,"may":1,"performed":1,"simultaneously":1,"or":1,"after":1,"all":1,"decisions":1,"about":1,"must":1,"consider":1,"surgical":1,"risk":1,"need":1,"choices":1,"gfr":1,"glomerular":1,"filtration":1,"rate":1,"adapted":1,"from":2,"holt":1,"et":1,"al":1,"s190":1,"pharmacologic":1,"approaches":1,"glycemic":1,"treatment":1,"care":2,"volume":1,"supplement":2,"january":1,"downloaded":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"s183":1,"dc26s009":1,"by":1,"guest":1,"on":1,"february":1},"len":151},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":9,"chunkId":"ada-2026-pharm-p9-c0","text":"Efficacy for glucose lowering Very high: Dulaglutide (high dose), semaglutide, tirzepatide, insulin Combination oral, combination High: pioglitazone, SGLT2i, sulfonylurea Intermediate:   SGLT2i with proven CVD benefit or vice versa  Pioglitazone^  Refer to DSMES to support self-efficacy in achievement of treatment goal  identify therapeutic gaps and tailor therapy  Identify and address SDOH that affect achievement of treatment goals with proven CVD benefit If glycemia is above goal If additional cardiovascular and kidney risk reduction, management of other metabolic comorbidities, and/or glycemic lowering is needed If glycemia is above goal or significant hypoglycemia or hyperglycemia or barriers to care are identified SGLT2i  with proven CVD benefit measurement is required to confirm CKD SGLT2i  with proven HF benefit in current or prior symptom s of HFrEF or HFpEF SGLT2i and/or either proven benefit in symptomatic HFpEF and obesity Efficacy for weight loss Very high: Semaglutide, tirzepatide High: Dulaglutide, liraglutide Intermediate: listed above), SGLT2i Neutral: Metformin, Agents with proven or potential benefit in MASLD or MASH Use insulin in the setting of decompensated cirrhosis Metformin or other agent (including combination therapy) that provides adequate efficacy to achieve and maintain glycemic treatment goals. Prioritize avoidance of hypoglycemia in high r","tf":{"efficacy":4,"for":2,"glucose":1,"lowering":2,"very":2,"high":6,"dulaglutide":2,"dose":1,"semaglutide":2,"tirzepatide":2,"insulin":2,"combination":3,"oral":1,"pioglitazone":2,"sglt2i":6,"sulfonylurea":1,"intermediate":2,"with":5,"proven":6,"cvd":3,"benefit":6,"or":11,"vice":1,"versa":1,"refer":1,"to":5,"dsmes":1,"support":1,"self":1,"in":6,"achievement":2,"of":6,"treatment":3,"goal":3,"identify":2,"therapeutic":1,"gaps":1,"and":7,"tailor":1,"therapy":2,"address":1,"sdoh":1,"that":2,"affect":1,"goals":2,"if":3,"glycemia":2,"is":4,"above":3,"additional":1,"cardiovascular":1,"kidney":1,"risk":1,"reduction":1,"management":1,"other":2,"metabolic":1,"comorbidities":1,"glycemic":2,"needed":1,"significant":1,"hypoglycemia":2,"hyperglycemia":1,"barriers":1,"care":1,"are":1,"identified":1,"measurement":1,"required":1,"confirm":1,"ckd":1,"hf":1,"current":1,"prior":1,"symptom":1,"hfref":1,"hfpef":2,"either":1,"symptomatic":1,"obesity":1,"weight":1,"loss":1,"liraglutide":1,"listed":1,"neutral":1,"metformin":2,"agents":1,"potential":1,"masld":1,"mash":1,"use":1,"the":1,"setting":1,"decompensated":1,"cirrhosis":1,"agent":1,"including":1,"provides":1,"adequate":1,"achieve":1,"maintain":1,"prioritize":1,"avoidance":1},"len":195},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":9,"chunkId":"ada-2026-pharm-p9-c1","text":"LD or MASH Use insulin in the setting of decompensated cirrhosis Metformin or other agent (including combination therapy) that provides adequate efficacy to achieve and maintain glycemic treatment goals. Prioritize avoidance of hypoglycemia in high risk individuals Goal: cardiovascular and kidney risk reduction* Goal: achievement and maintenance of weight and glycemic goals To avoid therapeutic inertia, reassess and modify treatment regularly If glycemia is above goal, for individuals on SGLT2i, consider incorporating SGLT2i  with primary evidence of reducing CKD progression  SGLT2i can be started wit h eGFR 20 mL/min/1.73 m  Glucose-lowering efficacy is reduced GLP-1 RA # with proven CKD benefit OR   #  ^ Low-dose pioglitazone may be better tolerated and similarly effective as higher doses. ischemic attack, unstable angina, amputation, and symptomatic or asymptomatic coronary artery disease. Indicators of high risk: While definitions vary, most comprise 55 years of age with two or more additional risk factors (including obesity, hypertension, smoking, dyslipidemia, or albuminuria). A strong recommendation is warranted for people with CVD and a weaker recommendation for those with indicators of high risk CVD. Moreover, a higher absolute risk reduction and thus lower numbers needed to treat are seen at higher levels of baseline risk and should be factored into the share","tf":{"20":1,"55":1,"73":1,"ld":1,"or":6,"mash":1,"use":1,"insulin":1,"in":2,"the":2,"setting":1,"of":8,"decompensated":1,"cirrhosis":1,"metformin":1,"other":1,"agent":1,"including":2,"combination":1,"therapy":1,"that":1,"provides":1,"adequate":1,"efficacy":2,"to":3,"achieve":1,"and":10,"maintain":1,"glycemic":2,"treatment":2,"goals":2,"prioritize":1,"avoidance":1,"hypoglycemia":1,"high":3,"risk":7,"individuals":2,"goal":3,"cardiovascular":1,"kidney":1,"reduction":2,"achievement":1,"maintenance":1,"weight":1,"avoid":1,"therapeutic":1,"inertia":1,"reassess":1,"modify":1,"regularly":1,"if":1,"glycemia":1,"is":3,"above":1,"for":3,"on":1,"sglt2i":3,"consider":1,"incorporating":1,"with":5,"primary":1,"evidence":1,"reducing":1,"ckd":2,"progression":1,"can":1,"be":3,"started":1,"wit":1,"egfr":1,"ml":1,"min":1,"glucose":1,"lowering":1,"reduced":1,"glp":1,"ra":1,"proven":1,"benefit":1,"low":1,"dose":1,"pioglitazone":1,"may":1,"better":1,"tolerated":1,"similarly":1,"effective":1,"as":1,"higher":3,"doses":1,"ischemic":1,"attack":1,"unstable":1,"angina":1,"amputation":1,"symptomatic":1,"asymptomatic":1,"coronary":1,"artery":1,"disease":1,"indicators":2,"while":1,"definitions":1,"vary":1,"most":1,"comprise":1,"years":1,"age":1,"two":1,"more":1,"additional":1,"factors":1,"obesity":1,"hypertension":1,"smoking":1,"dyslipidemia":1,"albuminuria":1,"strong":1,"recommendation":2,"warranted":1,"people":1,"cvd":2,"weaker":1,"those":1,"moreover":1,"absolute":1,"thus":1,"lower":1,"numbers":1,"needed":1,"treat":1,"are":1,"seen":1,"at":1,"levels":1,"baseline":1,"should":1,"factored":1,"into":1,"share":1},"len":200},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":9,"chunkId":"ada-2026-pharm-p9-c2","text":"people with CVD and a weaker recommendation for those with indicators of high risk CVD. Moreover, a higher absolute risk reduction and thus lower numbers needed to treat are seen at higher levels of baseline risk and should be factored into the shared decision-making process. See text for details. For SGLT2is, CV and kidney outcomes trials demonstrate their efficacy in reducing the risks of composite MACE, CV death, all-cause mortality, MI, HHF, and kidney outcomes in individuals with T2D and established or high risk of CVD. (For recommendations for specific conditions, including non-glucose-lowering medications, refer to pertinent sections) Healthy lifestyle behaviors; diabetes self-management education and support; social determinants of health (36 months) +ASCVD  +Indicators of high CVD risk +HF +CKD eGFR <60 mL/min/1.73 m or albuminuria (ACR 3.0 mg/mmol [30 mg/g]). Repeat +ASCVD/indicators of high CVD risk  GLP-1 RA # +CKD (on maximally tolerated dose of ACEi or ARB) with eGFR <45 mL/min/1.73 m a GLP-1 RA or vice versa dual GIP/GLP-1 RA or GLP-1 RA with For individuals on a GLP-1 RA, consider adding +Mitigating risk of MASLD or MASH GLP-1 RA, dual GIP and GLP-1 RA, pioglitazone, or combination of GLP-1 RA with pioglitazone In people with HF, CKD, established CVD, or multiple risk factors for CVD, the decision to use a GLP-1 RA or SGLT2i with proven benefit should be m","tf":{"30":1,"45":1,"60":1,"73":2,"people":2,"with":8,"cvd":7,"and":8,"weaker":1,"recommendation":1,"for":7,"those":1,"indicators":3,"of":10,"high":4,"risk":8,"moreover":1,"higher":2,"absolute":1,"reduction":1,"thus":1,"lower":1,"numbers":1,"needed":1,"to":3,"treat":1,"are":1,"seen":1,"at":1,"levels":1,"baseline":1,"should":2,"be":2,"factored":1,"into":1,"the":3,"shared":1,"decision":2,"making":1,"process":1,"see":1,"text":1,"details":1,"sglt2is":1,"cv":2,"kidney":2,"outcomes":2,"trials":1,"demonstrate":1,"their":1,"efficacy":1,"in":3,"reducing":1,"risks":1,"composite":1,"mace":1,"death":1,"all":1,"cause":1,"mortality":1,"mi":1,"hhf":1,"individuals":2,"t2d":1,"established":2,"or":9,"recommendations":1,"specific":1,"conditions":1,"including":1,"non":1,"glucose":1,"lowering":1,"medications":1,"refer":1,"pertinent":1,"sections":1,"healthy":1,"lifestyle":1,"behaviors":1,"diabetes":1,"self":1,"management":1,"education":1,"support":1,"social":1,"determinants":1,"health":1,"months":1,"ascvd":2,"hf":2,"ckd":3,"egfr":2,"ml":2,"min":2,"albuminuria":1,"acr":1,"mg":2,"mmol":1,"repeat":1,"glp":9,"ra":9,"on":2,"maximally":1,"tolerated":1,"dose":1,"acei":1,"arb":1,"vice":1,"versa":1,"dual":2,"gip":2,"consider":1,"adding":1,"mitigating":1,"masld":1,"mash":1,"pioglitazone":2,"combination":1,"multiple":1,"factors":1,"use":1,"sglt2i":1,"proven":1,"benefit":1},"len":225},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":9,"chunkId":"ada-2026-pharm-p9-c3","text":"LD or MASH GLP-1 RA, dual GIP and GLP-1 RA, pioglitazone, or combination of GLP-1 RA with pioglitazone In people with HF, CKD, established CVD, or multiple risk factors for CVD, the decision to use a GLP-1 RA or SGLT2i with proven benefit should be made irrespective of attainment of glycemic goal. ASCVD: Defined differently across CVOTs but all included individuals with established CVD (e.g., MI, stroke, and arterial revascularization procedure) and variably included conditions such as transient For GLP-1 RAs, CVOTs demonstrate their efficacy in reducing composite MACE, CV death, all-cause mortality, MI, stroke, and kidney end points in individuals with T2D with established or high risk of CVD. One kidney outcome trial demonstrated benefit in reducing persistent eGFR reduction and CV death for a GLP-1 RA in individuals with CKD and T2D. +Weight management \"Achievement and maintenance of glycemic goals GLP-1 RA (not DPP-4i DPP-4i injectable (GLP-1 RA and insulin) GLP-1 RA (not listed above), metformin, Consider technology (e.g., diagnostic or personal CGM) to Use of glucose-lowering medications in the management of type 2 diabetes Figure 9.4 Use of glucose-lowering medications in the management of type 2 diabetes. The left side of the algorithm prioritizes mitigation of diabetes-related complications and end-organ effects, while the right side addresses weight and glucose manag","tf":{"ld":1,"or":6,"mash":1,"glp":9,"ra":8,"dual":1,"gip":1,"and":10,"pioglitazone":2,"combination":1,"of":11,"with":7,"in":7,"people":1,"hf":1,"ckd":2,"established":3,"cvd":4,"multiple":1,"risk":2,"factors":1,"for":3,"the":6,"decision":1,"to":2,"use":3,"sglt2i":1,"proven":1,"benefit":2,"should":1,"be":1,"made":1,"irrespective":1,"attainment":1,"glycemic":2,"goal":1,"ascvd":1,"defined":1,"differently":1,"across":1,"cvots":2,"but":1,"all":2,"included":2,"individuals":3,"mi":2,"stroke":2,"arterial":1,"revascularization":1,"procedure":1,"variably":1,"conditions":1,"such":1,"as":1,"transient":1,"ras":1,"demonstrate":1,"their":1,"efficacy":1,"reducing":2,"composite":1,"mace":1,"cv":2,"death":2,"cause":1,"mortality":1,"kidney":2,"end":2,"points":1,"t2d":2,"high":1,"one":1,"outcome":1,"trial":1,"demonstrated":1,"persistent":1,"egfr":1,"reduction":1,"weight":2,"management":3,"achievement":1,"maintenance":1,"goals":1,"not":2,"dpp":2,"4i":2,"injectable":1,"insulin":1,"listed":1,"above":1,"metformin":1,"consider":1,"technology":1,"diagnostic":1,"personal":1,"cgm":1,"glucose":3,"lowering":2,"medications":2,"type":2,"diabetes":3,"figure":1,"left":1,"side":2,"algorithm":1,"prioritizes":1,"mitigation":1,"related":1,"complications":1,"organ":1,"effects":1,"while":1,"right":1,"addresses":1,"manag":1},"len":213},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":9,"chunkId":"ada-2026-pharm-p9-c4","text":"gure 9.4 Use of glucose-lowering medications in the management of type 2 diabetes. The left side of the algorithm prioritizes mitigation of diabetes-related complications and end-organ effects, while the right side addresses weight and glucose management goals. ACEi, angiotensincon - verting enzyme inhibitor; ACR, albumin-to-creatinine ratio; ARB, angiotensin receptor blocker; ASCVD, atherosclerotic cardiovascular disease; CGM, continuous glucose monitoring; CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease; CVOT, cardiovascular out - comes trial; DPP-4i, dipeptidyl peptidase 4 inhibitor; DSMES, diabetes self-management education and support; eGFR, estimated glomerular filtra - tion rate; GLP-1 RA, glucagon-like peptide 1 receptor agonist; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HHF, hospitalization for heart failure; MACE, major adverse cardiovascular events; MASH, metabolic dysfunction-associated steatohepatitis; MASLD, metabolic dysfunction-associated steatotic liver disease; MI, myocardial infarction; SDOH, social determi - nants of health; SGLT2i, sodium  glucose cotransporter 2 inhibitor; T2D, type 2 diabetes. Adapted from Davies et al. ( 90 ). diabetesjournals.org/care Pharmacologic Approaches to Glycemic Treatment S191 Downloaded from http://diabetesjourna","tf":{"90":1,"gure":1,"use":1,"of":5,"glucose":4,"lowering":1,"medications":1,"in":1,"the":4,"management":3,"type":2,"diabetes":4,"left":1,"side":2,"algorithm":1,"prioritizes":1,"mitigation":1,"related":1,"complications":1,"and":3,"end":1,"organ":1,"effects":1,"while":1,"right":1,"addresses":1,"weight":1,"goals":1,"acei":1,"angiotensincon":1,"verting":1,"enzyme":1,"inhibitor":3,"acr":1,"albumin":1,"to":2,"creatinine":1,"ratio":1,"arb":1,"angiotensin":1,"receptor":2,"blocker":1,"ascvd":1,"atherosclerotic":1,"cardiovascular":5,"disease":4,"cgm":1,"continuous":1,"monitoring":1,"ckd":1,"chronic":1,"kidney":1,"cv":1,"cvd":1,"cvot":1,"out":1,"comes":1,"trial":1,"dpp":1,"4i":1,"dipeptidyl":1,"peptidase":1,"dsmes":1,"self":1,"education":1,"support":1,"egfr":1,"estimated":1,"glomerular":1,"filtra":1,"tion":1,"rate":1,"glp":1,"ra":1,"glucagon":1,"like":1,"peptide":1,"agonist":1,"hf":1,"heart":4,"failure":4,"hfpef":1,"with":2,"preserved":1,"ejection":2,"fraction":2,"hfref":1,"reduced":1,"hhf":1,"hospitalization":1,"for":1,"mace":1,"major":1,"adverse":1,"events":1,"mash":1,"metabolic":2,"dysfunction":2,"associated":2,"steatohepatitis":1,"masld":1,"steatotic":1,"liver":1,"mi":1,"myocardial":1,"infarction":1,"sdoh":1,"social":1,"determi":1,"nants":1,"health":1,"sglt2i":1,"sodium":1,"cotransporter":1,"t2d":1,"adapted":1,"from":2,"davies":1,"et":1,"al":1,"diabetesjournals":1,"org":1,"care":1,"pharmacologic":1,"approaches":1,"glycemic":1,"treatment":1,"s191":1,"downloaded":1,"http":1,"diabetesjourna":1},"len":174},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":9,"chunkId":"ada-2026-pharm-p9-c5","text":"etermi - nants of health; SGLT2i, sodium  glucose cotransporter 2 inhibitor; T2D, type 2 diabetes. Adapted from Davies et al. ( 90 ). diabetesjournals.org/care Pharmacologic Approaches to Glycemic Treatment S191 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"49":1,"90":1,"2026":1,"848878":1,"etermi":1,"nants":1,"of":1,"health":1,"sglt2i":1,"sodium":1,"glucose":1,"cotransporter":1,"inhibitor":1,"t2d":1,"type":1,"diabetes":1,"adapted":1,"from":2,"davies":1,"et":1,"al":1,"diabetesjournals":2,"org":2,"care":2,"pharmacologic":1,"approaches":1,"to":1,"glycemic":1,"treatment":1,"s191":1,"downloaded":1,"http":1,"article":1,"pdf":2,"supplement":1,"s183":1,"dc26s009":1,"by":1,"guest":1,"on":1,"february":1},"len":47},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":10,"chunkId":"ada-2026-pharm-p10-c0","text":"A holistic, multifaceted, person-centered approach that accounts for the complex - ity of managing type 2 diabetes and its complications across the life span is rec - ommended. Person-specific factors that affect choice of treatment include indi - vidualized glycemic goals (see section 6,  Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises ), individualized weight goals (see section 8,  Obesity and Weight Management for the Prevention and Treatment of Diabetes ), the indi - viduals risk for hypoglycemia, and the in - dividuals history of or risk factors for cardiovascular, kidney, liver, and other comorbidities and complications of dia - betes (see section 4,  Comprehensive Medical Evaluation and Assessment of Comorbidities , section 10,  Cardiovascular Disease and Risk Management , and sec - tion 11,  Chronic Kidney Disease and Risk Management ). In addition, treatment decisions must consider the tolerability and side effect profiles of medications, complexity of the medication plan and the individuals capacity to implement it given their specific situation and context, and the access, cost, and availability of medications. Lifestyle modifications and health behaviors that improve health (see section 5,  Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes ) should be empha - sized along with any pharmacologic therapy. Section 13,","tf":{"10":1,"11":1,"13":1,"holistic":1,"multifaceted":1,"person":2,"centered":1,"approach":1,"that":3,"accounts":1,"for":4,"the":9,"complex":1,"ity":1,"of":9,"managing":1,"type":1,"diabetes":2,"and":18,"its":1,"complications":2,"across":1,"life":1,"span":1,"is":1,"rec":1,"ommended":1,"specific":2,"factors":2,"affect":1,"choice":1,"treatment":3,"include":1,"indi":2,"vidualized":1,"glycemic":2,"goals":3,"see":4,"section":6,"hypoglycemia":2,"hyperglycemic":1,"crises":1,"individualized":1,"weight":2,"obesity":1,"management":3,"prevention":1,"vidual":1,"risk":4,"in":2,"dividual":1,"history":1,"or":1,"cardiovascular":2,"kidney":2,"liver":1,"other":1,"comorbidities":2,"dia":1,"betes":1,"comprehensive":1,"medical":1,"evaluation":1,"assessment":1,"disease":2,"sec":1,"tion":1,"chronic":1,"addition":1,"decisions":1,"must":1,"consider":1,"tolerability":1,"side":1,"effect":1,"profiles":1,"medications":2,"complexity":1,"medication":1,"plan":1,"individual":1,"capacity":1,"to":2,"implement":1,"it":1,"given":1,"their":1,"situation":1,"context":1,"access":1,"cost":1,"availability":1,"lifestyle":1,"modifications":1,"health":4,"behaviors":2,"improve":2,"facilitating":1,"positive":1,"well":1,"being":1,"outcomes":1,"should":1,"be":1,"empha":1,"sized":1,"along":1,"with":1,"any":1,"pharmacologic":1,"therapy":1},"len":187},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":10,"chunkId":"ada-2026-pharm-p10-c1","text":"ications. Lifestyle modifications and health behaviors that improve health (see section 5,  Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes ) should be empha - sized along with any pharmacologic therapy. Section 13,  Older Adults , and section 14,  Children and Adolescents , have recommendations specific for older adults and for children and adolescents with type 2 diabetes, respectively. Sec - tion 10,  Cardiovascular Disease and Risk Management , and section 11,  Chronic Kidney Disease and Risk Management , have recommendations for the use of glucose-lowering drugs in the management of cardiovascular disease and kidney dis - ease, respectively. GIP and GLP-1 RA with potential ben - efits in MASH B for glycemic manage - ment and as an adjunctive therapy to interventions for weight loss. 9.13a In adults with type 2 diabetes and biopsy-proven MASH or those at high risk for liver fibrosis (based on noninvasive tests), a GLP-1 RA is pre - ferred for glycemic management due to beneficial effects on MASH. A Pio - glitazone or a dual GIP and GLP-1 RA B can be considered for glycemic man - agement due to potential beneficial ef - fects on MASH. B 9.13b Combination therapy with pio - glitazone plus a GLP-1 RA can be considered for the treatment of hyper - glycemia in adults with type 2 diabetes with biopsy-proven MASH or those at high risk of ","tf":{"10":1,"11":1,"13":1,"14":1,"ications":1,"lifestyle":1,"modifications":1,"and":14,"health":4,"behaviors":2,"that":1,"improve":2,"see":1,"section":4,"facilitating":1,"positive":1,"well":1,"being":1,"to":4,"outcomes":1,"should":1,"be":3,"empha":1,"sized":1,"along":1,"with":7,"any":1,"pharmacologic":1,"therapy":3,"older":2,"adults":4,"children":2,"adolescents":2,"have":2,"recommendations":2,"specific":1,"for":9,"type":3,"diabetes":3,"respectively":2,"sec":1,"tion":1,"cardiovascular":2,"disease":3,"risk":4,"management":4,"chronic":1,"kidney":2,"the":3,"use":1,"of":4,"glucose":1,"lowering":1,"drugs":1,"in":4,"dis":1,"ease":1,"gip":2,"glp":4,"ra":4,"potential":2,"ben":1,"efits":1,"mash":5,"glycemic":3,"manage":1,"ment":1,"as":1,"an":1,"adjunctive":1,"interventions":1,"weight":1,"loss":1,"13a":1,"biopsy":2,"proven":2,"or":3,"those":2,"at":2,"high":2,"liver":1,"fibrosis":1,"based":1,"on":3,"noninvasive":1,"tests":1,"is":1,"pre":1,"ferred":1,"due":2,"beneficial":2,"effects":1,"pio":2,"glitazone":2,"dual":1,"can":2,"considered":2,"man":1,"agement":1,"ef":1,"fects":1,"13b":1,"combination":1,"plus":1,"treatment":1,"hyper":1,"glycemia":1},"len":209},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":10,"chunkId":"ada-2026-pharm-p10-c2","text":" due to potential beneficial ef - fects on MASH. B 9.13b Combination therapy with pio - glitazone plus a GLP-1 RA can be considered for the treatment of hyper - glycemia in adults with type 2 diabetes with biopsy-proven MASH or those at high risk of liver fibrosis (identified with noninvasive tests) due to poten - tial beneficial effects on MASH. B 9.14 Medication plan and medication- taking behavior should be reeval - uated at regular intervals (e.g., every 3  6 months) and adjusted as needed to incorporate specific factors that af - fect choice of treatment and ensure achievement of individualized glyce - mic goals ( Fig. 4.1 and Table 9.2 ). E 9.15 Treatment modification (including intensification or deintensification) for adults not meeting individualized treat - ment goals should not be delayed. A 9.16 Choice of glucose-lowering therapy modification should take into consideration individualized glycemic and weight goals, presence of comor - bidities (cardiovascular, kidney, liver, and other metabolic comorbidities), and the risk of hypoglycemia. A 9.17 When initiating a new glucose- lowering medication, reassess the need for and/or dose of medications with higher hypoglycemia risk (i.e., sul - fonylureas, meglitinides, and insulin) to minimize the risk of hypoglycemia and treatment burden. A 9.18 Concurrent use of dipeptidyl pep - tidase 4 (DPP-4) inhibitors with a GLP-1 ","tf":{"14":1,"15":1,"16":1,"17":1,"18":1,"due":2,"to":4,"potential":1,"beneficial":2,"ef":1,"fects":1,"on":2,"mash":3,"13b":1,"combination":1,"therapy":2,"with":6,"pio":1,"glitazone":1,"plus":1,"glp":2,"ra":1,"can":1,"be":3,"considered":1,"for":3,"the":4,"treatment":4,"of":10,"hyper":1,"glycemia":1,"in":1,"adults":2,"type":1,"diabetes":1,"biopsy":1,"proven":1,"or":3,"those":1,"at":2,"high":1,"risk":4,"liver":2,"fibrosis":1,"identified":1,"noninvasive":1,"tests":1,"poten":1,"tial":1,"effects":1,"medication":3,"plan":1,"and":10,"taking":1,"behavior":1,"should":3,"reeval":1,"uated":1,"regular":1,"intervals":1,"every":1,"months":1,"adjusted":1,"as":1,"needed":1,"incorporate":1,"specific":1,"factors":1,"that":1,"af":1,"fect":1,"choice":2,"ensure":1,"achievement":1,"individualized":3,"glyce":1,"mic":1,"goals":3,"fig":1,"table":1,"modification":2,"including":1,"intensification":1,"deintensification":1,"not":2,"meeting":1,"treat":1,"ment":1,"delayed":1,"glucose":2,"lowering":2,"take":1,"into":1,"consideration":1,"glycemic":1,"weight":1,"presence":1,"comor":1,"bidities":1,"cardiovascular":1,"kidney":1,"other":1,"metabolic":1,"comorbidities":1,"hypoglycemia":3,"when":1,"initiating":1,"new":1,"reassess":1,"need":1,"dose":1,"medications":1,"higher":1,"sul":1,"fonylureas":1,"meglitinides":1,"insulin":1,"minimize":1,"burden":1,"concurrent":1,"use":1,"dipeptidyl":1,"pep":1,"tidase":1,"dpp":1,"inhibitors":1},"len":192},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":10,"chunkId":"ada-2026-pharm-p10-c3","text":"nd/or dose of medications with higher hypoglycemia risk (i.e., sul - fonylureas, meglitinides, and insulin) to minimize the risk of hypoglycemia and treatment burden. A 9.18 Concurrent use of dipeptidyl pep - tidase 4 (DPP-4) inhibitors with a GLP-1 RA or a dual GIP and GLP-1 RA is not recommended due to lack of additional glucose lowering beyond that of a GLP-1  based therapy. B 9.19 In adults with type 2 diabetes who have not achieved their individu - alized weight goals, additional weight management interventions (e.g., in - tensification of lifestyle modifications, structured weight management pro - grams, pharmacologic agents, or met - abolic surgery, as appropriate) are recommended. A 9.20 In adults with type 2 diabetes, ini - tiation of insulin should be considered regardless of background glucose- lowering therapy or disease duration if symptoms of hyperglycemia are pre - sent or when A1C or blood glucose levels are very high (i.e., A1C > 10% [ > 86 mmol/mol] or blood glucose  300 mg/dL [  16.7 mmol/L]). E 9.21 In adults with type 2 diabetes without severe hyperglycemia or hy - perglycemic crisis, GLP-1  based ther - apy is preferred to insulin for initial or add-on glucose-lowering therapy ( Fig. 9.4 ). A 9.22 If insulin is used, combination therapy with a GLP-1 RA, including a dual GIP and GLP-1 RA, is recom - mended for greater glycemic effec - tiveness as well a","tf":{"10":1,"16":1,"18":1,"19":1,"20":1,"21":1,"22":1,"86":1,"300":1,"nd":1,"or":9,"dose":1,"of":9,"medications":1,"with":6,"higher":1,"hypoglycemia":2,"risk":2,"sul":1,"fonylureas":1,"meglitinides":1,"and":4,"insulin":4,"to":3,"minimize":1,"the":1,"treatment":1,"burden":1,"concurrent":1,"use":1,"dipeptidyl":1,"pep":1,"tidase":1,"dpp":1,"inhibitors":1,"glp":6,"ra":4,"dual":2,"gip":2,"is":4,"not":2,"recommended":2,"due":1,"lack":1,"additional":2,"glucose":5,"lowering":3,"beyond":1,"that":1,"based":2,"therapy":4,"in":4,"adults":3,"type":3,"diabetes":3,"who":1,"have":1,"achieved":1,"their":1,"individu":1,"alized":1,"weight":3,"goals":1,"management":2,"interventions":1,"tensification":1,"lifestyle":1,"modifications":1,"structured":1,"pro":1,"grams":1,"pharmacologic":1,"agents":1,"met":1,"abolic":1,"surgery":1,"as":2,"appropriate":1,"are":3,"ini":1,"tiation":1,"should":1,"be":1,"considered":1,"regardless":1,"background":1,"disease":1,"duration":1,"if":2,"symptoms":1,"hyperglycemia":2,"pre":1,"sent":1,"when":1,"a1c":2,"blood":2,"levels":1,"very":1,"high":1,"mmol":2,"mol":1,"mg":1,"dl":1,"without":1,"severe":1,"hy":1,"perglycemic":1,"crisis":1,"ther":1,"apy":1,"preferred":1,"for":2,"initial":1,"add":1,"on":1,"fig":1,"used":1,"combination":1,"including":1,"recom":1,"mended":1,"greater":1,"glycemic":1,"effec":1,"tiveness":1,"well":1},"len":204},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":10,"chunkId":"ada-2026-pharm-p10-c4","text":" is preferred to insulin for initial or add-on glucose-lowering therapy ( Fig. 9.4 ). A 9.22 If insulin is used, combination therapy with a GLP-1 RA, including a dual GIP and GLP-1 RA, is recom - mended for greater glycemic effec - tiveness as well as beneficial effects on weight and hypoglycemia risk for adults with type 2 diabetes. Insulin dosing should be reassessed upon addition or dose escalation of a GLP-1 RA or dual GIP and GLP-1 RA. A 9.23 In adults with type 2 diabetes who are initiating insulin therapy, con - tinue glucose-lowering agents (unless contraindicated or not tolerated) for ongoing glycemic and metabolic bene - fits (i.e., weight, cardiometabolic, or kidney benefits). A Choice of Glucose-Lowering Therapy Healthy lifestyle behaviors, diabetes self-management education and support (DSMES), avoidance of therapeutic inertia, and social determinants of health should be considered in the glucose-lowering management of type 2 diabetes. Pharma - cologic therapy should be guided by person- centered treatment factors, including comorbidities, considerations of ad - verse effects (including hypoglycemia), treatment burden, and treatment goals and preferences. Shared decision-making can be facilitated during clinical encounters through use of decision aides and has been shown to improve A1C in adults with type 2 diabetes, though in clinical trials the ben - efits of sha","tf":{"22":1,"23":1,"is":3,"preferred":1,"to":2,"insulin":4,"for":4,"initial":1,"or":5,"add":1,"on":2,"glucose":4,"lowering":4,"therapy":5,"fig":1,"if":1,"used":1,"combination":1,"with":4,"glp":4,"ra":4,"including":3,"dual":2,"gip":2,"and":9,"recom":1,"mended":1,"greater":1,"glycemic":2,"effec":1,"tiveness":1,"as":2,"well":1,"beneficial":1,"effects":2,"weight":2,"hypoglycemia":2,"risk":1,"adults":3,"type":4,"diabetes":5,"dosing":1,"should":3,"be":4,"reassessed":1,"upon":1,"addition":1,"dose":1,"escalation":1,"of":8,"in":4,"who":1,"are":1,"initiating":1,"con":1,"tinue":1,"agents":1,"unless":1,"contraindicated":1,"not":1,"tolerated":1,"ongoing":1,"metabolic":1,"bene":1,"fits":1,"cardiometabolic":1,"kidney":1,"benefits":1,"choice":1,"healthy":1,"lifestyle":1,"behaviors":1,"self":1,"management":2,"education":1,"support":1,"dsmes":1,"avoidance":1,"therapeutic":1,"inertia":1,"social":1,"determinants":1,"health":1,"considered":1,"the":2,"pharma":1,"cologic":1,"guided":1,"by":1,"person":1,"centered":1,"treatment":3,"factors":1,"comorbidities":1,"considerations":1,"ad":1,"verse":1,"burden":1,"goals":1,"preferences":1,"shared":1,"decision":2,"making":1,"can":1,"facilitated":1,"during":1,"clinical":2,"encounters":1,"through":1,"use":1,"aides":1,"has":1,"been":1,"shown":1,"improve":1,"a1c":1,"though":1,"trials":1,"ben":1,"efits":1,"sha":1},"len":201},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":10,"chunkId":"ada-2026-pharm-p10-c5","text":"and treatment goals and preferences. Shared decision-making can be facilitated during clinical encounters through use of decision aides and has been shown to improve A1C in adults with type 2 diabetes, though in clinical trials the ben - efits of shared decision-making were lim - ited to face-to-face discussions (not online encounters) and to individuals with ele - vated A1C ( > 8%) ( 89 ). Pharmacotherapy should be started at the time type 2 dia - betes is diagnosed, without delay, unless there are contraindications. Medication plans should have adequate efficacy to achieve and maintain individualized treat - ment goals with respect to glucose low - ering, reduction of cardiovascular and kidney disease risks, weight manage - ment, and effects on other health condi - tions and treatment burden. In adults with type 2 diabetes and established or high risk of atherosclerotic cardiovascular disease (ASCVD), HF, and/or CKD, the S192 Pharmacologic Approaches to Glycemic Treatment Diabetes Care Volume 49, Supplement 1, January 2026 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"49":2,"89":1,"2026":2,"848878":1,"and":10,"treatment":3,"goals":2,"preferences":1,"shared":2,"decision":3,"making":2,"can":1,"be":2,"facilitated":1,"during":1,"clinical":2,"encounters":2,"through":1,"use":1,"of":4,"aides":1,"has":1,"been":1,"shown":1,"to":7,"improve":1,"a1c":2,"in":3,"adults":2,"with":4,"type":3,"diabetes":3,"though":1,"trials":1,"the":3,"ben":1,"efits":1,"were":1,"lim":1,"ited":1,"face":2,"discussions":1,"not":1,"online":1,"individuals":1,"ele":1,"vated":1,"pharmacotherapy":1,"should":2,"started":1,"at":1,"time":1,"dia":1,"betes":1,"is":1,"diagnosed":1,"without":1,"delay":1,"unless":1,"there":1,"are":1,"contraindications":1,"medication":1,"plans":1,"have":1,"adequate":1,"efficacy":1,"achieve":1,"maintain":1,"individualized":1,"treat":1,"ment":2,"respect":1,"glucose":1,"low":1,"ering":1,"reduction":1,"cardiovascular":2,"kidney":1,"disease":2,"risks":1,"weight":1,"manage":1,"effects":1,"on":2,"other":1,"health":1,"condi":1,"tions":1,"burden":1,"established":1,"or":2,"high":1,"risk":1,"atherosclerotic":1,"ascvd":1,"hf":1,"ckd":1,"s192":1,"pharmacologic":1,"approaches":1,"glycemic":1,"care":2,"volume":1,"supplement":2,"january":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"s183":1,"dc26s009":1,"by":1,"guest":1,"february":1},"len":172},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":11,"chunkId":"ada-2026-pharm-p11-c0","text":"Table 9.2Features of medications for lowering glucose in type 2 diabetes Medication (route of administration) Glucose-lowering efficacy 1 Hypoglycemia risk Weight effects 2 CV effects Kidney effects MASH effects Clinical considerations and adverse effects Effect on MACE Effect on HF Progression of CKD Dosing/use considerations* Metformin (oral) High No Neutral (potential for modest loss) Potential benefit Neutral Neutral  Contraindicated with eGFR < 30 mL/min/ 1.73 m 2 Neutral  GI side effects: mitigate with slow dose titration, extended-release formula - tions, and administration with food  Potential for vitamin B12 deficiency: monitor and replete as appropriate SGLT2 inhibitors (oral) Intermediate to high No Loss (intermediate) Benefit: canagliflozin, empagliflozin Benefit: canagliflozin, dapagliflozin, empagliflozin, ertugliflozin Benefit: canagliflozin, empagliflozin, dapagliflozin  See labels of individ - ual agents for dosage considerations for kidney function  Glucose-lowering effect is minimal at eGFR < 45 mL/min/ 1.73 m 2 and lower; continue or start for cardiovascular and kidney benefit if eGFR > 20 mL/min/1.73 m 2 . May continue until dialysis or transplantation Unknown  DKA risk in individuals with insulin deficiency (rare in T2D): discontinue, evaluate, and treat promptly if sus - pected; be aware of predis - posing risk factors and clini - cal presentations","tf":{"20":1,"30":1,"45":1,"73":3,"table":1,"features":1,"of":5,"medications":1,"for":6,"lowering":3,"glucose":3,"in":3,"type":1,"diabetes":1,"medication":1,"route":1,"administration":2,"efficacy":1,"hypoglycemia":1,"risk":3,"weight":1,"effects":6,"cv":1,"kidney":3,"mash":1,"clinical":1,"considerations":3,"and":7,"adverse":1,"effect":3,"on":2,"mace":1,"hf":1,"progression":1,"ckd":1,"dosing":1,"use":1,"metformin":1,"oral":2,"high":2,"no":2,"neutral":4,"potential":3,"modest":1,"loss":2,"benefit":5,"contraindicated":1,"with":4,"egfr":3,"ml":3,"min":3,"gi":1,"side":1,"mitigate":1,"slow":1,"dose":1,"titration":1,"extended":1,"release":1,"formula":1,"tions":1,"food":1,"vitamin":1,"b12":1,"deficiency":2,"monitor":1,"replete":1,"as":1,"appropriate":1,"sglt2":1,"inhibitors":1,"intermediate":2,"to":1,"canagliflozin":3,"empagliflozin":3,"dapagliflozin":2,"ertugliflozin":1,"see":1,"labels":1,"individ":1,"ual":1,"agents":1,"dosage":1,"function":1,"is":1,"minimal":1,"at":1,"lower":1,"continue":2,"or":2,"start":1,"cardiovascular":1,"if":2,"may":1,"until":1,"dialysis":1,"transplantation":1,"unknown":1,"dka":1,"individuals":1,"insulin":1,"rare":1,"t2d":1,"discontinue":1,"evaluate":1,"treat":1,"promptly":1,"sus":1,"pected":1,"be":1,"aware":1,"predis":1,"posing":1,"factors":1,"clini":1,"cal":1,"presentations":1},"len":187},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":11,"chunkId":"ada-2026-pharm-p11-c1","text":" May continue until dialysis or transplantation Unknown  DKA risk in individuals with insulin deficiency (rare in T2D): discontinue, evaluate, and treat promptly if sus - pected; be aware of predis - posing risk factors and clini - cal presentations (including euglycemic DKA); mitigate risk with sick-day planning; discontinue before sched - uled surgery (e.g., 3  4 days), during critical illness, or during prolonged fasting  Genital mycotic infections: mitigate risk with genital hygiene and avoid use in high-risk individuals  Urosepsis and pyelonephri - tis: evaluate individuals for signs and symptoms of urinary tract infections and treat promptly  Necrotizing fasciitis in the perineum (Fournier gangrene): rare; prompt treatment if suspected  Intravascular volume deple - tion: attention to volume status and blood pressure, particularly when ill or fast - ing; adjust other volume- contracting agents as appli - cable; monitor kidney func - tion upon initiation Continued on p. S194 diabetesjournals.org/care Pharmacologic Approaches to Glycemic Treatment S193 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"49":1,"2026":1,"848878":1,"may":1,"continue":1,"until":1,"dialysis":1,"or":3,"transplantation":1,"unknown":1,"dka":2,"risk":5,"in":4,"individuals":3,"with":3,"insulin":1,"deficiency":1,"rare":2,"t2d":1,"discontinue":2,"evaluate":2,"and":7,"treat":2,"promptly":2,"if":2,"sus":1,"pected":1,"be":1,"aware":1,"of":2,"predis":1,"posing":1,"factors":1,"clini":1,"cal":1,"presentations":1,"including":1,"euglycemic":1,"mitigate":2,"sick":1,"day":1,"planning":1,"before":1,"sched":1,"uled":1,"surgery":1,"days":1,"during":2,"critical":1,"illness":1,"prolonged":1,"fasting":1,"genital":2,"mycotic":1,"infections":2,"hygiene":1,"avoid":1,"use":1,"high":1,"urosepsis":1,"pyelonephri":1,"tis":1,"for":1,"signs":1,"symptoms":1,"urinary":1,"tract":1,"necrotizing":1,"fasciitis":1,"the":1,"perineum":1,"fournier":1,"gangrene":1,"prompt":1,"treatment":2,"suspected":1,"intravascular":1,"volume":3,"deple":1,"tion":2,"attention":1,"to":2,"status":1,"blood":1,"pressure":1,"particularly":1,"when":1,"ill":1,"fast":1,"ing":1,"adjust":1,"other":1,"contracting":1,"agents":1,"as":1,"appli":1,"cable":1,"monitor":1,"kidney":1,"func":1,"upon":1,"initiation":1,"continued":1,"on":2,"s194":1,"diabetesjournals":2,"org":2,"care":2,"pharmacologic":1,"approaches":1,"glycemic":1,"s193":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"supplement":1,"s183":1,"dc26s009":1,"by":1,"guest":1,"february":1},"len":165},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":12,"chunkId":"ada-2026-pharm-p12-c0","text":"Table 9.2Continued Medication (route of administration) Glucose-lowering efficacy 1 Hypoglycemia risk Weight effects 2 CV effects Kidney effects MASH effects Clinical considerations and adverse effects Effect on MACE Effect on HF Progression of CKD Dosing/use considerations* GLP-1 RAs (SQ; semaglutide also available in oral formulation) High to very high No Loss (intermediate to very high) Benefit: dulaglutide, liraglutide, semaglutide (SQ and oral) Benefit: semaglutide (SQ) Benefit for kidney end points in CVOTs, driven by albuminuria outcomes: dulaglutide, liraglutide, semaglutide (SQ)  See labels of individ - ual agents for dosage considerations for kidney function  No dose adjustment for dulaglutide, liraglutide, or semaglutide  Monitor kidney function when initiat - ing or escalating doses in individuals with kidney impair - ment reporting severe adverse GI reactions Benefit: semaglutide (SQ)  Thyroid C-cell tumors identi - fied in rodents; human rele - vance not determined  Provide guidance on discon - tinuation prior to surgical procedures to mitigate potential for pulmonary aspiration with general anesthesia or deep sedation  Pancreatitis: acute pancrea - titis has been reported, but causality has not been established; do not initiate if at high risk for pancreatitis, and discontinue if pancreati - tis is suspected  Biliary disease: evaluate for gallbladder dise","tf":{"table":1,"continued":1,"medication":1,"route":1,"of":3,"administration":1,"glucose":1,"lowering":1,"efficacy":1,"hypoglycemia":1,"risk":2,"weight":1,"effects":5,"cv":1,"kidney":5,"mash":1,"clinical":1,"considerations":3,"and":3,"adverse":2,"effect":2,"on":3,"mace":1,"hf":1,"progression":1,"ckd":1,"dosing":1,"use":1,"glp":1,"ras":1,"sq":5,"semaglutide":6,"also":1,"available":1,"in":4,"oral":2,"formulation":1,"high":4,"to":4,"very":2,"no":2,"loss":1,"intermediate":1,"benefit":4,"dulaglutide":3,"liraglutide":3,"for":7,"end":1,"points":1,"cvots":1,"driven":1,"by":1,"albuminuria":1,"outcomes":1,"see":1,"labels":1,"individ":1,"ual":1,"agents":1,"dosage":1,"function":2,"dose":1,"adjustment":1,"or":3,"monitor":1,"when":1,"initiat":1,"ing":1,"escalating":1,"doses":1,"individuals":1,"with":2,"impair":1,"ment":1,"reporting":1,"severe":1,"gi":1,"reactions":1,"thyroid":1,"cell":1,"tumors":1,"identi":1,"fied":1,"rodents":1,"human":1,"rele":1,"vance":1,"not":3,"determined":1,"provide":1,"guidance":1,"discon":1,"tinuation":1,"prior":1,"surgical":1,"procedures":1,"mitigate":1,"potential":1,"pulmonary":1,"aspiration":1,"general":1,"anesthesia":1,"deep":1,"sedation":1,"pancreatitis":2,"acute":1,"pancrea":1,"titis":1,"has":2,"been":2,"reported":1,"but":1,"causality":1,"established":1,"do":1,"initiate":1,"if":2,"at":1,"discontinue":1,"pancreati":1,"tis":1,"is":1,"suspected":1,"biliary":1,"disease":1,"evaluate":1,"gallbladder":1,"dise":1},"len":191},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":12,"chunkId":"ada-2026-pharm-p12-c1","text":"dation  Pancreatitis: acute pancrea - titis has been reported, but causality has not been established; do not initiate if at high risk for pancreatitis, and discontinue if pancreati - tis is suspected  Biliary disease: evaluate for gallbladder disease if chole - lithiasis or cholecystitis is suspected; avoid use in at-risk individuals  Ileus: reported, but risk level is not well established  Diabetic retinopathy: close monitoring of retinopathy in those at high risk (older individuals and those with longer duration of T2D [  10 years])  Nonarteritic anterior ische - mic optic neuropathy (NAION) reported (rare inci - dence); monitor for NAION during eye examinations  Impact on drug absorption: orally administered drug ab - sorption may be impaired during dose titration (includ - ing oral contraceptives)  GI side effects: counsel on potential for GI side effects; provide guidance on dietary modifications to mitigate GI side effects (reduction in meal size, mindful eating practices [e.g., stop eating Neutral: exenatide once weekly, lixisenatide Demonstrated benefit for progression of CKD for semaglutide (SQ) Dual GIP and GLP-1 RA (SQ) Very high No Loss (very high) Under investigation Benefit: tirzepatide Potential benefit  See labels of individ - ual agents for dosage considerations for kidney function  No dose adjustment  Monitor kidney function when initiating or esca","tf":{"10":1,"dation":1,"pancreatitis":2,"acute":1,"pancrea":1,"titis":1,"has":2,"been":2,"reported":3,"but":2,"causality":1,"not":3,"established":2,"do":1,"initiate":1,"if":3,"at":3,"high":4,"risk":4,"for":8,"and":3,"discontinue":1,"pancreati":1,"tis":1,"is":3,"suspected":2,"biliary":1,"disease":2,"evaluate":1,"gallbladder":1,"chole":1,"lithiasis":1,"or":2,"cholecystitis":1,"avoid":1,"use":1,"in":3,"individuals":2,"ileus":1,"level":1,"well":1,"diabetic":1,"retinopathy":2,"close":1,"monitoring":1,"of":4,"those":2,"older":1,"with":1,"longer":1,"duration":1,"t2d":1,"years":1,"nonarteritic":1,"anterior":1,"ische":1,"mic":1,"optic":1,"neuropathy":1,"naion":2,"rare":1,"inci":1,"dence":1,"monitor":2,"during":2,"eye":1,"examinations":1,"impact":1,"on":3,"drug":2,"absorption":1,"orally":1,"administered":1,"ab":1,"sorption":1,"may":1,"be":1,"impaired":1,"dose":2,"titration":1,"includ":1,"ing":1,"oral":1,"contraceptives":1,"gi":3,"side":3,"effects":3,"counsel":1,"potential":2,"provide":1,"guidance":1,"dietary":1,"modifications":1,"to":1,"mitigate":1,"reduction":1,"meal":1,"size":1,"mindful":1,"eating":2,"practices":1,"stop":1,"neutral":1,"exenatide":1,"once":1,"weekly":1,"lixisenatide":1,"demonstrated":1,"benefit":3,"progression":1,"ckd":1,"semaglutide":1,"sq":2,"dual":1,"gip":1,"glp":1,"ra":1,"very":2,"no":2,"loss":1,"under":1,"investigation":1,"tirzepatide":1,"see":1,"labels":1,"individ":1,"ual":1,"agents":1,"dosage":1,"considerations":1,"kidney":2,"function":2,"adjustment":1,"when":1,"initiating":1,"esca":1},"len":199},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":12,"chunkId":"ada-2026-pharm-p12-c2","text":"RA (SQ) Very high No Loss (very high) Under investigation Benefit: tirzepatide Potential benefit  See labels of individ - ual agents for dosage considerations for kidney function  No dose adjustment  Monitor kidney function when initiating or esca - lating doses in individu - als with kidney impair - ment reporting severe adverse GI reactions Potential benefit Continued on p. S195 S194 Pharmacologic Approaches to Glycemic Treatment Diabetes Care Volume 49, Supplement 1, January 2026 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"49":2,"2026":2,"848878":1,"ra":1,"sq":1,"very":2,"high":2,"no":2,"loss":1,"under":1,"investigation":1,"benefit":3,"tirzepatide":1,"potential":2,"see":1,"labels":1,"of":1,"individ":1,"ual":1,"agents":1,"for":2,"dosage":1,"considerations":1,"kidney":3,"function":2,"dose":1,"adjustment":1,"monitor":1,"when":1,"initiating":1,"or":1,"esca":1,"lating":1,"doses":1,"in":1,"individu":1,"als":1,"with":1,"impair":1,"ment":1,"reporting":1,"severe":1,"adverse":1,"gi":1,"reactions":1,"continued":1,"on":2,"s195":1,"s194":1,"pharmacologic":1,"approaches":1,"to":1,"glycemic":1,"treatment":1,"diabetes":1,"care":2,"volume":1,"supplement":2,"january":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"s183":1,"dc26s009":1,"by":1,"guest":1,"february":1},"len":88},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":13,"chunkId":"ada-2026-pharm-p13-c0","text":"Table 9.2Continued Medication (route of administration) Glucose-lowering efficacy 1 Hypoglycemia risk Weight effects 2 CV effects Kidney effects MASH effects Clinical considerations and adverse effects Effect on MACE Effect on HF Progression of CKD Dosing/use considerations* once full], decreasing intake of high-fat or spicy food); consider slower dose titra - tion for those experiencing GI challenges; not recom - mended for individuals with gastroparesis DPP-4 inhibitors (oral) Intermediate No Neutral Neutral Neutral (potential risk: saxagliptin) Neutral  Dose adjustment required based on kidney function (sitagliptin, saxagliptin, alogliptin)  No dose adjustment required for linagliptin Unknown  Pancreatitis has been reported but causality has not been established; discontinue if pancreatitis is suspected  Postmarketing concerns about joint pain (consider discontinuing if debilitating and other treatment options are feasible) and bullous pemphigoid (discontinue if suspected) reversible upon discontinuation Pioglitazone (oral) High No Gain Potential benefit Increased risk Neutral  No dose adjustment required  Generally not recom - mended in kidney impairment due to potential for fluid retention Potential benefit  Increased risk of HF and fluid retention; do not use in setting of HF  Risk of bone fractures  Bladder cancer: do not use in individuals with active bladder ","tf":{"table":1,"continued":1,"medication":1,"route":1,"of":6,"administration":1,"glucose":1,"lowering":1,"efficacy":1,"hypoglycemia":1,"risk":5,"weight":1,"effects":5,"cv":1,"kidney":3,"mash":1,"clinical":1,"considerations":2,"and":4,"adverse":1,"effect":2,"on":3,"mace":1,"hf":3,"progression":1,"ckd":1,"dosing":1,"use":3,"once":1,"full":1,"decreasing":1,"intake":1,"high":2,"fat":1,"or":1,"spicy":1,"food":1,"consider":2,"slower":1,"dose":4,"titra":1,"tion":1,"for":4,"those":1,"experiencing":1,"gi":1,"challenges":1,"not":5,"recom":2,"mended":2,"individuals":2,"with":2,"gastroparesis":1,"dpp":1,"inhibitors":1,"oral":2,"intermediate":1,"no":4,"neutral":5,"potential":4,"saxagliptin":2,"adjustment":3,"required":3,"based":1,"function":1,"sitagliptin":1,"alogliptin":1,"linagliptin":1,"unknown":1,"pancreatitis":2,"has":2,"been":2,"reported":1,"but":1,"causality":1,"established":1,"discontinue":2,"if":3,"is":1,"suspected":2,"postmarketing":1,"concerns":1,"about":1,"joint":1,"pain":1,"discontinuing":1,"debilitating":1,"other":1,"treatment":1,"options":1,"are":1,"feasible":1,"bullous":1,"pemphigoid":1,"reversible":1,"upon":1,"discontinuation":1,"pioglitazone":1,"gain":1,"benefit":2,"increased":2,"generally":1,"in":3,"impairment":1,"due":1,"to":1,"fluid":2,"retention":2,"do":2,"setting":1,"bone":1,"fractures":1,"bladder":2,"cancer":1,"active":1},"len":188},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":13,"chunkId":"ada-2026-pharm-p13-c1","text":"com - mended in kidney impairment due to potential for fluid retention Potential benefit  Increased risk of HF and fluid retention; do not use in setting of HF  Risk of bone fractures  Bladder cancer: do not use in individuals with active bladder cancer, and use caution in those with prior history of bladder cancer; association observed with higher cumulative exposure (e.g., longer duration, higher doses) Sulfonylureas (2nd generation) (oral) High Yes Gain Neutral Neutral Neutral  Glyburide: generally not recommended in CKD  Glipizide and glimepiride: initiate conservatively to avoid hypoglycemia Unknown  FDA Special Warning on in - creased risk of CV mortality based on studies of an older sulfonylurea (tolbutamide); glimepiride shown to be CV safe (see text)  Use with caution in individ - uals at risk for hypoglyce - mia, particularly if in combi - nation with insulin Continued on p. S196 diabetesjournals.org/care Pharmacologic Approaches to Glycemic Treatment S195 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"49":1,"2026":1,"848878":1,"com":1,"mended":1,"in":8,"kidney":1,"impairment":1,"due":1,"to":4,"potential":2,"for":2,"fluid":2,"retention":2,"benefit":1,"increased":1,"risk":4,"of":6,"hf":2,"and":3,"do":2,"not":3,"use":4,"setting":1,"bone":1,"fractures":1,"bladder":3,"cancer":3,"individuals":1,"with":5,"active":1,"caution":2,"those":1,"prior":1,"history":1,"association":1,"observed":1,"higher":2,"cumulative":1,"exposure":1,"longer":1,"duration":1,"doses":1,"sulfonylureas":1,"2nd":1,"generation":1,"oral":1,"high":1,"yes":1,"gain":1,"neutral":3,"glyburide":1,"generally":1,"recommended":1,"ckd":1,"glipizide":1,"glimepiride":2,"initiate":1,"conservatively":1,"avoid":1,"hypoglycemia":1,"unknown":1,"fda":1,"special":1,"warning":1,"on":4,"creased":1,"cv":2,"mortality":1,"based":1,"studies":1,"an":1,"older":1,"sulfonylurea":1,"tolbutamide":1,"shown":1,"be":1,"safe":1,"see":1,"text":1,"individ":1,"uals":1,"at":1,"hypoglyce":1,"mia":1,"particularly":1,"if":1,"combi":1,"nation":1,"insulin":1,"continued":1,"s196":1,"diabetesjournals":2,"org":2,"care":2,"pharmacologic":1,"approaches":1,"glycemic":1,"treatment":1,"s195":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"supplement":1,"s183":1,"dc26s009":1,"by":1,"guest":1,"february":1},"len":164},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":14,"chunkId":"ada-2026-pharm-p14-c0","text":"Table 9.2Continued Medication (route of administration) Glucose-lowering efficacy 1 Hypoglycemia risk Weight effects 2 CV effects Kidney effects MASH effects Clinical considerations and adverse effects Effect on MACE Effect on HF Progression of CKD Dosing/use considerations* Insulin (human) (SQ; regular insulin also available as inhaled formulation) High to very high Yes Gain Neutral Neutral Neutral  Lower insulin doses required with a decrease in eGFR; titrate per clinical response Unknown  Injection site reactions  Higher risk of hypoglycemia with human insulin (NPH or premixed formulations) vs. analogs  Risk of hypoglycemia and duration of activity increases with severity of impaired kidney function  Refer to device-specific instructions for insulins compatible with different delivery systems (i.e., pumps, connected insulin pens, insulin patches) Insulin (analogs) (SQ) CKD, chronic kidney disease; CV, cardiovascular; DKA, diabetic ketoacidosis; DPP-4, dipeptidyl peptidase 4; eGFR, estimated glomerular filtration rate; FDA, U.S. Food and Drug Administration; GI, gastro - intestinal; GIP, glucose-dependent insulinotropic polypeptide; GLP-1 RA, glucagon-like peptide 1 receptor agonist; HF, heart failure; MACE, major adverse cardiovascular events; MASH, metabolic dys - function-associated steatohepatitis; SGLT2, sodium  glucose cotransporter 2; SQ, subcutaneous; T2D, type","tf":{"table":1,"continued":1,"medication":1,"route":1,"of":6,"administration":2,"glucose":3,"lowering":1,"efficacy":1,"hypoglycemia":3,"risk":3,"weight":1,"effects":5,"cv":2,"kidney":3,"mash":2,"clinical":2,"considerations":2,"and":3,"adverse":2,"effect":2,"on":2,"mace":2,"hf":2,"progression":1,"ckd":2,"dosing":1,"use":1,"insulin":7,"human":2,"sq":3,"regular":1,"also":1,"available":1,"as":1,"inhaled":1,"formulation":1,"high":2,"to":2,"very":1,"yes":1,"gain":1,"neutral":3,"lower":1,"doses":1,"required":1,"with":4,"decrease":1,"in":1,"egfr":2,"titrate":1,"per":1,"response":1,"unknown":1,"injection":1,"site":1,"reactions":1,"higher":1,"nph":1,"or":1,"premixed":1,"formulations":1,"vs":1,"analogs":2,"duration":1,"activity":1,"increases":1,"severity":1,"impaired":1,"function":2,"refer":1,"device":1,"specific":1,"instructions":1,"for":1,"insulins":1,"compatible":1,"different":1,"delivery":1,"systems":1,"pumps":1,"connected":1,"pens":1,"patches":1,"chronic":1,"disease":1,"cardiovascular":2,"dka":1,"diabetic":1,"ketoacidosis":1,"dpp":1,"dipeptidyl":1,"peptidase":1,"estimated":1,"glomerular":1,"filtration":1,"rate":1,"fda":1,"food":1,"drug":1,"gi":1,"gastro":1,"intestinal":1,"gip":1,"dependent":1,"insulinotropic":1,"polypeptide":1,"glp":1,"ra":1,"glucagon":1,"like":1,"peptide":1,"receptor":1,"agonist":1,"heart":1,"failure":1,"major":1,"events":1,"metabolic":1,"dys":1,"associated":1,"steatohepatitis":1,"sglt2":1,"sodium":1,"cotransporter":1,"subcutaneous":1,"t2d":1,"type":1},"len":178},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":14,"chunkId":"ada-2026-pharm-p14-c1","text":"peptide; GLP-1 RA, glucagon-like peptide 1 receptor agonist; HF, heart failure; MACE, major adverse cardiovascular events; MASH, metabolic dys - function-associated steatohepatitis; SGLT2, sodium  glucose cotransporter 2; SQ, subcutaneous; T2D, type 2 diabetes. *For agent-specific dosing recommendations, please refer to manufacturers prescribing information. 1 Tsapas et al. ( 107 ). 2 Tsapas et al. ( 317 ). Adapted from Davies et al. ( 90 ). treatment plan should include agents that reduce cardiovascular and kidney disease risk ( Fig. 9.4 and Table 9.2 ) (see also section 10,  Cardiovascular Disease and Risk Management , and section 11,  Chronic Kidney Disease and Risk Management ). In individuals without ASCVD, HF, or CKD, choice of therapy should be in - formed by considerations of weight man - agement (see section 8,  Obesity and Weight Management for the Prevention and Treatment of Diabetes ), mitigation of metabolic dysfunction  associated stea - totic liver disease (MASLD) or metabolic dysfunction  associated steatohepatitis (MASH) risk (see section 4,  Comprehensive Medical Evaluation and Assessment of Comorbidities ), and achievement and maintenance of individualized glycemic goals. In general, higher-efficacy approaches, including combination therapy, have greater likelihood of achieving treatment goals. Weight management is a distinct treat - ment goal, al","tf":{"10":1,"11":1,"90":1,"107":1,"317":1,"peptide":2,"glp":1,"ra":1,"glucagon":1,"like":1,"receptor":1,"agonist":1,"hf":2,"heart":1,"failure":1,"mace":1,"major":1,"adverse":1,"cardiovascular":3,"events":1,"mash":2,"metabolic":3,"dys":1,"function":1,"associated":3,"steatohepatitis":2,"sglt2":1,"sodium":1,"glucose":1,"cotransporter":1,"sq":1,"subcutaneous":1,"t2d":1,"type":1,"diabetes":2,"for":2,"agent":1,"specific":1,"dosing":1,"recommendations":1,"please":1,"refer":1,"to":1,"manufacturers":1,"prescribing":1,"information":1,"tsapas":2,"et":3,"al":4,"adapted":1,"from":1,"davies":1,"treatment":3,"plan":1,"should":2,"include":1,"agents":1,"that":1,"reduce":1,"and":10,"kidney":2,"disease":4,"risk":4,"fig":1,"table":1,"see":3,"also":1,"section":4,"management":4,"chronic":1,"in":3,"individuals":1,"without":1,"ascvd":1,"or":2,"ckd":1,"choice":1,"of":7,"therapy":2,"be":1,"formed":1,"by":1,"considerations":1,"weight":3,"man":1,"agement":1,"obesity":1,"the":1,"prevention":1,"mitigation":1,"dysfunction":2,"stea":1,"totic":1,"liver":1,"masld":1,"comprehensive":1,"medical":1,"evaluation":1,"assessment":1,"comorbidities":1,"achievement":1,"maintenance":1,"individualized":1,"glycemic":1,"goals":2,"general":1,"higher":1,"efficacy":1,"approaches":1,"including":1,"combination":1,"have":1,"greater":1,"likelihood":1,"achieving":1,"is":1,"distinct":1,"treat":1,"ment":1,"goal":1},"len":179},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":14,"chunkId":"ada-2026-pharm-p14-c2","text":"s ), and achievement and maintenance of individualized glycemic goals. In general, higher-efficacy approaches, including combination therapy, have greater likelihood of achieving treatment goals. Weight management is a distinct treat - ment goal, along with glycemic manage - ment, as it has multifaceted benefits, including reduction of A1C, reduction in hepatic steatosis, and improvement in cardiovascular risk factors ( 90  92 ). For individuals with type 2 diabetes who re - quire initiation or intensification of glucose- lowering therapy to achieve and/or maintain individualized glycemic goals and who do not have additional consid - erations informing choice of therapy beyond need for glucose lowering, metformin is a commonly used medi - cation that historically has been the first-line treatment for type 2 diabetes ( 93 , 94 ). Metformin is effective and safe, is inexpensive and widely available, and reduces risks of microvascular complica - tions, cardiovascular events, and death ( 93 , 95 , 96 ). Metformin is available in an immediate-release form for twice-daily dosing or as an extended-release form that can be given once daily. Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglyce - mia, and reduces cardiovascular mortality ( 97 ). Metformin is also more effective than dipeptidyl peptidase ","tf":{"90":1,"92":1,"93":2,"94":1,"95":1,"96":1,"97":1,"and":10,"achievement":1,"maintenance":1,"of":6,"individualized":2,"glycemic":3,"goals":3,"in":4,"general":1,"higher":1,"efficacy":1,"approaches":1,"including":2,"combination":1,"therapy":4,"have":2,"greater":1,"likelihood":1,"achieving":1,"treatment":2,"weight":2,"management":1,"is":7,"distinct":1,"treat":1,"ment":2,"goal":1,"along":1,"with":3,"manage":1,"as":3,"it":1,"has":3,"multifaceted":1,"benefits":1,"reduction":2,"a1c":2,"hepatic":1,"steatosis":1,"improvement":1,"cardiovascular":3,"risk":1,"factors":1,"for":4,"individuals":1,"type":2,"diabetes":2,"who":2,"re":1,"quire":1,"initiation":1,"or":3,"intensification":1,"glucose":2,"lowering":2,"to":1,"achieve":1,"maintain":1,"do":1,"not":2,"additional":1,"consid":1,"erations":1,"informing":1,"choice":1,"beyond":1,"need":1,"metformin":5,"commonly":1,"used":1,"medi":1,"cation":1,"that":2,"historically":1,"been":1,"the":1,"first":2,"line":2,"effective":2,"safe":1,"inexpensive":1,"widely":1,"available":2,"reduces":2,"risks":1,"microvascular":1,"complica":1,"tions":1,"events":1,"death":1,"an":2,"immediate":1,"release":2,"form":2,"twice":1,"daily":2,"dosing":1,"extended":1,"can":1,"be":1,"given":1,"once":1,"compared":1,"sulfonylureas":1,"beneficial":1,"effects":1,"on":1,"neutral":1,"does":1,"cause":1,"hypoglyce":1,"mia":1,"mortality":1,"also":1,"more":1,"than":1,"dipeptidyl":1,"peptidase":1},"len":197},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":14,"chunkId":"ada-2026-pharm-p14-c3","text":"y. Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglyce - mia, and reduces cardiovascular mortality ( 97 ). Metformin is also more effective than dipeptidyl peptidase 4 (DPP-4) inhibitors in lowering A1C and weight when used as monotherapy ( 98 ). The principal side effects of metformin are gastrointestinal intolerance due to bloating, abdominal discomfort, and diar - rhea; these can be mitigated by gradual dose titration and/or using extended- S196 Pharmacologic Approaches to Glycemic Treatment Diabetes Care Volume 49, Supplement 1, January 2026 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"49":2,"97":1,"98":1,"2026":2,"848878":1,"compared":1,"with":1,"sulfonylureas":1,"metformin":3,"as":2,"first":1,"line":1,"therapy":1,"has":1,"beneficial":1,"effects":2,"on":2,"a1c":2,"is":2,"weight":2,"neutral":1,"does":1,"not":1,"cause":1,"hypoglyce":1,"mia":1,"and":4,"reduces":1,"cardiovascular":1,"mortality":1,"also":1,"more":1,"effective":1,"than":1,"dipeptidyl":1,"peptidase":1,"dpp":1,"inhibitors":1,"in":1,"lowering":1,"when":1,"used":1,"monotherapy":1,"the":1,"principal":1,"side":1,"of":1,"are":1,"gastrointestinal":1,"intolerance":1,"due":1,"to":2,"bloating":1,"abdominal":1,"discomfort":1,"diar":1,"rhea":1,"these":1,"can":1,"be":1,"mitigated":1,"by":2,"gradual":1,"dose":1,"titration":1,"or":1,"using":1,"extended":1,"s196":1,"pharmacologic":1,"approaches":1,"glycemic":1,"treatment":1,"diabetes":1,"care":2,"volume":1,"supplement":2,"january":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"s183":1,"dc26s009":1,"guest":1,"february":1},"len":108},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":15,"chunkId":"ada-2026-pharm-p15-c0","text":"release formulation. The drug is cleared by kidney filtration, and metformin may be safely used in people with estimated glomerular filtration rate  30 mL/min/ 1.73 m 2 ( 99 ). Very high circulating levels (e.g., as a result of overdose or acute kid - ney injury) have been associated with lac - tic acidosis ( 100 ). However, the occurrence of this complication is very rare ( 101 ) and primarily occurs when the estimated glo - merular filtration rate (eGFR) is < 30 mL/ min/1.73 m 2 ( 102 ). For people with an eGFR of 30  45 mL/min/1.73 m 2 , there is an increased risk for periodic decreases of eGFR to  30 mL/min/1.73 m 2 which heightens the risk of lactic acidosis. Met - formin use is also associated with in - creased risk of vitamin B12 deficiency and worsening of symptoms of neuropathy ( 103 , 104 ), suggesting periodic testing of vi - tamin B12 levels (see section 3,  Prevention or Delay of Diabetes and Associated Comorbidities ). The comparative glucose-lowering effi - cacy of different pharmacologic agents has been examined primarily in network meta-analyses, as few prospective clinical trials have compared multiple drug clas - ses head-to-head. In general, the largest reductions in A1C levels are achieved by treatment plans that include insulin, se - lect GLP-1 RAs (particularly semaglutide), and tirzepatide, while DPP-4 inhibitors re - sulted in the smallest reductio","tf":{"30":4,"45":1,"73":4,"99":1,"100":1,"101":1,"102":1,"103":1,"104":1,"release":1,"formulation":1,"the":7,"drug":2,"is":5,"cleared":1,"by":2,"kidney":1,"filtration":3,"and":5,"metformin":1,"may":1,"be":1,"safely":1,"used":1,"in":6,"people":2,"with":4,"estimated":2,"glomerular":1,"rate":2,"ml":4,"min":4,"very":2,"high":1,"circulating":1,"levels":3,"as":2,"result":1,"of":11,"overdose":1,"or":2,"acute":1,"kid":1,"ney":1,"injury":1,"have":2,"been":2,"associated":3,"lac":1,"tic":1,"acidosis":2,"however":1,"occurrence":1,"this":1,"complication":1,"rare":1,"primarily":2,"occurs":1,"when":1,"glo":1,"merular":1,"egfr":3,"for":2,"an":2,"there":1,"increased":1,"risk":3,"periodic":2,"decreases":1,"to":2,"which":1,"heightens":1,"lactic":1,"met":1,"formin":1,"use":1,"also":1,"creased":1,"vitamin":1,"b12":2,"deficiency":1,"worsening":1,"symptoms":1,"neuropathy":1,"suggesting":1,"testing":1,"vi":1,"tamin":1,"see":1,"section":1,"prevention":1,"delay":1,"diabetes":1,"comorbidities":1,"comparative":1,"glucose":1,"lowering":1,"effi":1,"cacy":1,"different":1,"pharmacologic":1,"agents":1,"has":1,"examined":1,"network":1,"meta":1,"analyses":1,"few":1,"prospective":1,"clinical":1,"trials":1,"compared":1,"multiple":1,"clas":1,"ses":1,"head":2,"general":1,"largest":1,"reductions":1,"a1c":1,"are":1,"achieved":1,"treatment":1,"plans":1,"that":1,"include":1,"insulin":1,"se":1,"lect":1,"glp":1,"ras":1,"particularly":1,"semaglutide":1,"tirzepatide":1,"while":1,"dpp":1,"inhibitors":1,"re":1,"sulted":1,"smallest":1,"reductio":1},"len":213},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":15,"chunkId":"ada-2026-pharm-p15-c1","text":"as - ses head-to-head. In general, the largest reductions in A1C levels are achieved by treatment plans that include insulin, se - lect GLP-1 RAs (particularly semaglutide), and tirzepatide, while DPP-4 inhibitors re - sulted in the smallest reductions in A1C ( 105  107 ). The Glycemia Reduction Ap - proaches in Type 2 Diabetes: A Compara - tive Effectiveness (GRADE) trial compared use of insulin glargine U-100, liraglutide, si - tagliptin, and glimepiride as add-on treat - ments to metformin monotherapy among individuals with type 2 diabetes and base - line A1C 6.8  8.5% ( 108 ). It found that at 5 years, all therapies decreased A1C levels but glargine and liraglutide were modestly more effective in achieving and maintain - ing A1C below 7%, while sitagliptin was least effective. Severe hypoglycemia was significantly more common in those pre - scribed glargine or glimepiride. An obser - vational study that emulated many of GRADEs design features and included can - agliflozin as a comparator arm, but did not include insulin glargine, found that liraglu - tide was more effective at achieving and maintaining A1C below 7% than sitagliptin, canagliflozin, or glimepiride, which all had comparable effectiveness ( 108 ). Thus, when choosing a glucose-lowering medication to achieve individualized gly - cemic goals, we recommend engaging in shared decision-making and considering fact","tf":{"100":1,"105":1,"107":1,"108":2,"as":3,"ses":1,"head":2,"to":3,"in":8,"general":1,"the":3,"largest":1,"reductions":2,"a1c":6,"levels":2,"are":1,"achieved":1,"by":1,"treatment":1,"plans":1,"that":4,"include":2,"insulin":3,"se":1,"lect":1,"glp":1,"ras":1,"particularly":1,"semaglutide":1,"and":8,"tirzepatide":1,"while":2,"dpp":1,"inhibitors":1,"re":1,"sulted":1,"smallest":1,"glycemia":1,"reduction":1,"ap":1,"proaches":1,"type":2,"diabetes":2,"compara":1,"tive":1,"effectiveness":2,"grade":2,"trial":1,"compared":1,"use":1,"of":2,"glargine":4,"liraglutide":2,"si":1,"tagliptin":1,"glimepiride":3,"add":1,"on":1,"treat":1,"ments":1,"metformin":1,"monotherapy":1,"among":1,"individuals":1,"with":1,"base":1,"line":1,"it":1,"found":2,"at":2,"years":1,"all":2,"therapies":1,"decreased":1,"but":2,"were":1,"modestly":1,"more":3,"effective":3,"achieving":2,"maintain":1,"ing":1,"below":2,"sitagliptin":2,"was":3,"least":1,"severe":1,"hypoglycemia":1,"significantly":1,"common":1,"those":1,"pre":1,"scribed":1,"or":2,"an":1,"obser":1,"vational":1,"study":1,"emulated":1,"many":1,"design":1,"features":1,"included":1,"can":1,"agliflozin":1,"comparator":1,"arm":1,"did":1,"not":1,"liraglu":1,"tide":1,"maintaining":1,"than":1,"canagliflozin":1,"which":1,"had":1,"comparable":1,"thus":1,"when":1,"choosing":1,"glucose":1,"lowering":1,"medication":1,"achieve":1,"individualized":1,"gly":1,"cemic":1,"goals":1,"we":1,"recommend":1,"engaging":1,"shared":1,"decision":1,"making":1,"considering":1,"fact":1},"len":197},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":15,"chunkId":"ada-2026-pharm-p15-c2","text":"liptin, canagliflozin, or glimepiride, which all had comparable effectiveness ( 108 ). Thus, when choosing a glucose-lowering medication to achieve individualized gly - cemic goals, we recommend engaging in shared decision-making and considering factors such as glucose-lowering efficacy, the side effect profile, and medication ac - cessibility and affordability ( 108 ). In all cases, treatment plans need to be continuously re - viewed for efficacy, side effects, hypoglyce - mia, and treatment burden ( Table 9.2 ). When A1C is  1.5% above the indi - vidualized glycemic goal (see section 6,  Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises , for appropriate goals), many individuals will require dual- combination therapy or a more potent glucose-lowering agent to achieve and maintain their goal A1C level ( 90 ) ( Fig. 9.4 and Table 9.2 ). Insulin should be consid - ered as part of any combination medica - tion plan when hyperglycemia is severe, especially if catabolic features (weight loss, hypertriglyceridemia, and ketosis) are pre - sent. It is common practice to initiate insu - lin therapy for people who present with blood glucose levels  300 mg/dL (  16.7 mmol/L) or A1C > 10% ( > 86 mmol/mol) or if the individual has symptoms of hyper - glycemia (i.e., polyuria or polydipsia) or ev - idence of catabolism (unexpected weight loss) ( Fig. 9.5 ). As glucose toxicity res","tf":{"10":1,"16":1,"86":1,"90":1,"108":2,"300":1,"liptin":1,"canagliflozin":1,"or":6,"glimepiride":1,"which":1,"all":2,"had":1,"comparable":1,"effectiveness":1,"thus":1,"when":3,"choosing":1,"glucose":5,"lowering":3,"medication":2,"to":4,"achieve":2,"individualized":1,"gly":1,"cemic":1,"goals":3,"we":1,"recommend":1,"engaging":1,"in":2,"shared":1,"decision":1,"making":1,"and":8,"considering":1,"factors":1,"such":1,"as":3,"efficacy":2,"the":3,"side":2,"effect":1,"profile":1,"ac":1,"cessibility":1,"affordability":1,"cases":1,"treatment":2,"plans":1,"need":1,"be":2,"continuously":1,"re":1,"viewed":1,"for":3,"effects":1,"hypoglyce":1,"mia":1,"burden":1,"table":2,"a1c":3,"is":3,"above":1,"indi":1,"vidualized":1,"glycemic":2,"goal":2,"see":1,"section":1,"hypoglycemia":1,"hyperglycemic":1,"crises":1,"appropriate":1,"many":1,"individuals":1,"will":1,"require":1,"dual":1,"combination":2,"therapy":2,"more":1,"potent":1,"agent":1,"maintain":1,"their":1,"level":1,"fig":2,"insulin":1,"should":1,"consid":1,"ered":1,"part":1,"of":3,"any":1,"medica":1,"tion":1,"plan":1,"hyperglycemia":1,"severe":1,"especially":1,"if":2,"catabolic":1,"features":1,"weight":2,"loss":2,"hypertriglyceridemia":1,"ketosis":1,"are":1,"pre":1,"sent":1,"it":1,"common":1,"practice":1,"initiate":1,"insu":1,"lin":1,"people":1,"who":1,"present":1,"with":1,"blood":1,"levels":1,"mg":1,"dl":1,"mmol":2,"mol":1,"individual":1,"has":1,"symptoms":1,"hyper":1,"glycemia":1,"polyuria":1,"polydipsia":1,"ev":1,"idence":1,"catabolism":1,"unexpected":1,"toxicity":1,"res":1},"len":196},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":15,"chunkId":"ada-2026-pharm-p15-c3","text":"glucose levels  300 mg/dL (  16.7 mmol/L) or A1C > 10% ( > 86 mmol/mol) or if the individual has symptoms of hyper - glycemia (i.e., polyuria or polydipsia) or ev - idence of catabolism (unexpected weight loss) ( Fig. 9.5 ). As glucose toxicity resolves, simplifying the medication plan and/or changing to noninsulin agents is possible. Additionally, there is evidence that people with type 2 diabetes and severe hypergly - cemia can also be effectively treated with a sulfonylurea, a GLP-1 RA, or a dual GIP and GLP-1 RA, though evidence is scarce for individuals with baseline A1C above 10  12% ( 105 , 109  111 ). GLP-1 RAs and tir - zepatide have additional benefits over in - sulin and sulfonylureas, specifically lower risks for hypoglycemia (both) and favor - able weight (both), cardiovascular (GLP-1 RAs), kidney (GLP-1 RAs), and liver (both) end points. Combination Therapy Because type 2 diabetes is a progressive disease, maintenance of glycemic goals often requires combination therapy. Tra - ditional recommendations have called for the use of stepwise addition of medica - tions to metformin to maintain A1C goals. The advantage of this is to provide a clear assessment of the positive and negative effects of new drugs and reduce potential side effects and expense ( 112 ). However, some data support initial combination therapy for more rapid attainment of glyce - mic goals ( 11","tf":{"10":2,"11":1,"12":1,"16":1,"86":1,"105":1,"109":1,"111":1,"112":1,"300":1,"glucose":2,"levels":1,"mg":1,"dl":1,"mmol":2,"or":6,"a1c":3,"mol":1,"if":1,"the":5,"individual":1,"has":1,"symptoms":1,"of":9,"hyper":1,"glycemia":1,"polyuria":1,"polydipsia":1,"ev":1,"idence":1,"catabolism":1,"unexpected":1,"weight":2,"loss":1,"fig":1,"as":1,"toxicity":1,"resolves":1,"simplifying":1,"medication":1,"plan":1,"and":10,"changing":1,"to":4,"noninsulin":1,"agents":1,"is":5,"possible":1,"additionally":1,"there":1,"evidence":2,"that":1,"people":1,"with":3,"type":2,"diabetes":2,"severe":1,"hypergly":1,"cemia":1,"can":1,"also":1,"be":1,"effectively":1,"treated":1,"sulfonylurea":1,"glp":5,"ra":2,"dual":1,"gip":1,"though":1,"scarce":1,"for":4,"individuals":1,"baseline":1,"above":1,"ras":3,"tir":1,"zepatide":1,"have":2,"additional":1,"benefits":1,"over":1,"in":1,"sulin":1,"sulfonylureas":1,"specifically":1,"lower":1,"risks":1,"hypoglycemia":1,"both":3,"favor":1,"able":1,"cardiovascular":1,"kidney":1,"liver":1,"end":1,"points":1,"combination":3,"therapy":3,"because":1,"progressive":1,"disease":1,"maintenance":1,"glycemic":1,"goals":3,"often":1,"requires":1,"tra":1,"ditional":1,"recommendations":1,"called":1,"use":1,"stepwise":1,"addition":1,"medica":1,"tions":1,"metformin":1,"maintain":1,"advantage":1,"this":1,"provide":1,"clear":1,"assessment":1,"positive":1,"negative":1,"effects":2,"new":1,"drugs":1,"reduce":1,"potential":1,"side":1,"expense":1,"however":1,"some":1,"data":1,"support":1,"initial":1,"more":1,"rapid":1,"attainment":1,"glyce":1,"mic":1},"len":206},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":15,"chunkId":"ada-2026-pharm-p15-c4","text":" this is to provide a clear assessment of the positive and negative effects of new drugs and reduce potential side effects and expense ( 112 ). However, some data support initial combination therapy for more rapid attainment of glyce - mic goals ( 113 , 114 ) and later combination therapy for longer durability of glycemic effect ( 115 ). Initial combination therapy should be considered in people present - ing with A1C levels 1.5  2.0% above their individualized goal or in those at high risk for cardiovascular disease (CVD) or with established CVD irrespective of A1C levels (GLP-1 RA and SGLT2 inhibi - tor combination therapy) (see section 10,  Cardiovascular Disease and Risk Management ). The incorporation of high-glycemic-efficacy therapies or thera - pies for cardiovascular and kidney disease risk reduction (e.g., GLP-1 RAs, a dual GIP and GLP-1 RA, and SGLT2 inhibitors) may reduce the need for agents that increase the risks of hypoglycemia and weight gain or are less well tolerated. Thus, treatment intensification requires purposeful se - lection of medications in alignment with multiple individualized person-centered treatment goals simultaneously ( Fig. 9.4 ). Treatment intensification, deintensifi - cation, or modification, as appropriate, for people not meeting individualized treatment goals should not be delayed (therapeutic inertia) ( 116 ). Results from comparative","tf":{"10":1,"112":1,"113":1,"114":1,"115":1,"116":1,"this":1,"is":1,"to":1,"provide":1,"clear":1,"assessment":1,"of":8,"the":4,"positive":1,"and":10,"negative":1,"effects":2,"new":1,"drugs":1,"reduce":2,"potential":1,"side":1,"expense":1,"however":1,"some":1,"data":1,"support":1,"initial":2,"combination":4,"therapy":4,"for":6,"more":1,"rapid":1,"attainment":1,"glyce":1,"mic":1,"goals":3,"later":1,"longer":1,"durability":1,"glycemic":2,"effect":1,"should":2,"be":2,"considered":1,"in":3,"people":2,"present":1,"ing":1,"with":3,"a1c":2,"levels":2,"above":1,"their":1,"individualized":3,"goal":1,"or":5,"those":1,"at":1,"high":2,"risk":3,"cardiovascular":3,"disease":3,"cvd":2,"established":1,"irrespective":1,"glp":3,"ra":2,"sglt2":2,"inhibi":1,"tor":1,"see":1,"section":1,"management":1,"incorporation":1,"efficacy":1,"therapies":1,"thera":1,"pies":1,"kidney":1,"reduction":1,"ras":1,"dual":1,"gip":1,"inhibitors":1,"may":1,"need":1,"agents":1,"that":1,"increase":1,"risks":1,"hypoglycemia":1,"weight":1,"gain":1,"are":1,"less":1,"well":1,"tolerated":1,"thus":1,"treatment":4,"intensification":2,"requires":1,"purposeful":1,"se":1,"lection":1,"medications":1,"alignment":1,"multiple":1,"person":1,"centered":1,"simultaneously":1,"fig":1,"deintensifi":1,"cation":1,"modification":1,"as":1,"appropriate":1,"not":2,"meeting":1,"delayed":1,"therapeutic":1,"inertia":1,"results":1,"from":1,"comparative":1},"len":194},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":15,"chunkId":"ada-2026-pharm-p15-c5","text":"t goals simultaneously ( Fig. 9.4 ). Treatment intensification, deintensifi - cation, or modification, as appropriate, for people not meeting individualized treatment goals should not be delayed (therapeutic inertia) ( 116 ). Results from comparative effectiveness meta-analyses suggest that each new class of oral nonin - sulin agents when added to metformin generally lowers A1C by approximately 0.7  1.0% (8  11 mmol/mol). Addition of GLP-1 RAs or the dual GIP and GLP-1 RA to metformin usually results in 1% to  2% lowering of A1C ( 105 , 117 , 118 ) ( Fig. 9.4 and Table 9.2 ). Use of GLP-1 RAs (or the dual GIP and GLP-1 RA) together with a DPP-4 inhibitor is not recommended, as there is no added glucose-lowering ben - efit beyond that of the GLP-1 RA alone ( 119  121 ). When even greater potency of glucose reduction is needed, basal insulin, either human NPH or a long-acting insulin ana - log, should be initiated. However, if the individual is not already receiving GLP-1 RA or dual GIP and GLP-1 RA therapy, an agent from these classes should be started first, as it may be sufficient for achieving individualized A1C goals but with lower risk of hypoglycemia and with favorable weight, cardiovascular, kidney, and liver profiles. While most GLP-1 RAs are inject - able medications, an oral formulation of semaglutide is commercially available ( 122 ). In trials analyzing the addit","tf":{"11":1,"105":1,"116":1,"117":1,"118":1,"119":1,"121":1,"122":1,"goals":3,"simultaneously":1,"fig":2,"treatment":2,"intensification":1,"deintensifi":1,"cation":1,"or":5,"modification":1,"as":3,"appropriate":1,"for":2,"people":1,"not":4,"meeting":1,"individualized":2,"should":3,"be":4,"delayed":1,"therapeutic":1,"inertia":1,"results":2,"from":2,"comparative":1,"effectiveness":1,"meta":1,"analyses":1,"suggest":1,"that":2,"each":1,"new":1,"class":1,"of":8,"oral":2,"nonin":1,"sulin":1,"agents":1,"when":2,"added":2,"to":3,"metformin":2,"generally":1,"lowers":1,"a1c":3,"by":1,"approximately":1,"mmol":1,"mol":1,"addition":1,"glp":8,"ras":3,"the":5,"dual":3,"gip":3,"and":6,"ra":5,"usually":1,"in":2,"lowering":2,"table":1,"use":1,"together":1,"with":3,"dpp":1,"inhibitor":1,"is":5,"recommended":1,"there":1,"no":1,"glucose":2,"ben":1,"efit":1,"beyond":1,"alone":1,"even":1,"greater":1,"potency":1,"reduction":1,"needed":1,"basal":1,"insulin":2,"either":1,"human":1,"nph":1,"long":1,"acting":1,"ana":1,"log":1,"initiated":1,"however":1,"if":1,"individual":1,"already":1,"receiving":1,"therapy":1,"an":2,"agent":1,"these":1,"classes":1,"started":1,"first":1,"it":1,"may":1,"sufficient":1,"achieving":1,"but":1,"lower":1,"risk":1,"hypoglycemia":1,"favorable":1,"weight":1,"cardiovascular":1,"kidney":1,"liver":1,"profiles":1,"while":1,"most":1,"are":1,"inject":1,"able":1,"medications":1,"formulation":1,"semaglutide":1,"commercially":1,"available":1,"trials":1,"analyzing":1,"addit":1},"len":211},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":15,"chunkId":"ada-2026-pharm-p15-c6","text":" lower risk of hypoglycemia and with favorable weight, cardiovascular, kidney, and liver profiles. While most GLP-1 RAs are inject - able medications, an oral formulation of semaglutide is commercially available ( 122 ). In trials analyzing the addition of an injectable GLP-1 RA, dual GIP and GLP-1 RA, or insulin in people needing further glucose lowering, glycemic effica - cies of GLP-1 RAs and the dual GIP and GLP-1 RA were similar to or greater than diabetesjournals.org/care Pharmacologic Approaches to Glycemic Treatment S197 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"49":1,"122":1,"2026":1,"848878":1,"lower":1,"risk":1,"of":4,"hypoglycemia":1,"and":5,"with":1,"favorable":1,"weight":1,"cardiovascular":1,"kidney":1,"liver":1,"profiles":1,"while":1,"most":1,"glp":5,"ras":2,"are":1,"inject":1,"able":1,"medications":1,"an":2,"oral":1,"formulation":1,"semaglutide":1,"is":1,"commercially":1,"available":1,"in":2,"trials":1,"analyzing":1,"the":2,"addition":1,"injectable":1,"ra":3,"dual":2,"gip":2,"or":2,"insulin":1,"people":1,"needing":1,"further":1,"glucose":1,"lowering":1,"glycemic":2,"effica":1,"cies":1,"were":1,"similar":1,"to":2,"greater":1,"than":1,"diabetesjournals":2,"org":2,"care":2,"pharmacologic":1,"approaches":1,"treatment":1,"s197":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"supplement":1,"s183":1,"dc26s009":1,"by":1,"guest":1,"on":1,"february":1},"len":101},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":16,"chunkId":"ada-2026-pharm-p16-c0","text":"INITIATION Initiate appropriate starting dose for agent selected (varies within class) TITRATION Titrate to maintenance dose (varies within class) appropriate, or if insulin is preferred If on bedtime NPH, consider converting to twice-daily NPH plan Conversion based on individual needs and current glycemic management. The following is one possible approach: INITIATION   2/3 given in the morning  1/3 given at bedtime TITRATION  Titrate based on individualized needs Considerations for adding basal insulin 3 Choice of basal insulin should be based on person-specific considerations, including cost. Refer to Table 9.4 for insulin cost information. Consider prescription of glucagon for emergent hypoglycemia. If not on CGM, consider adding CGM. Stepwise doses of prandial insulin (i.e., two, then three additional injections) Proceed to full basal-bolus plan (i.e., basal insulin and prandial insulin with each meal) Consider self-mixed/split insulin plan Can adjust NPH and short/rapid-acting insulins separately INITIATION   2/3 given before breakfast  1/3 given before dinner  Add 4 units of short/rapid-acting insulin to each injection or 10% of reduced NPH dose TITRATION  Titrate each component of the plan based on individualized needs Consider twice-daily premixed insulin plan INITIATION  Usually unit per unit at the same total insulin dose, but may require adjustment to indiv","tf":{"10":1,"initiation":4,"initiate":1,"appropriate":2,"starting":1,"dose":4,"for":4,"agent":1,"selected":1,"varies":2,"within":2,"class":2,"titration":3,"titrate":3,"to":6,"maintenance":1,"or":2,"if":3,"insulin":11,"is":2,"preferred":1,"on":6,"bedtime":2,"nph":4,"consider":5,"converting":1,"twice":2,"daily":2,"plan":5,"conversion":1,"based":4,"individual":1,"needs":3,"and":3,"current":1,"glycemic":1,"management":1,"the":4,"following":1,"one":1,"possible":1,"approach":1,"given":4,"in":1,"morning":1,"at":2,"individualized":2,"considerations":2,"adding":2,"basal":4,"choice":1,"of":6,"should":1,"be":1,"person":1,"specific":1,"including":1,"cost":2,"refer":1,"table":1,"information":1,"prescription":1,"glucagon":1,"emergent":1,"hypoglycemia":1,"not":1,"cgm":2,"stepwise":1,"doses":1,"prandial":2,"two":1,"then":1,"three":1,"additional":1,"injections":1,"proceed":1,"full":1,"bolus":1,"with":1,"each":3,"meal":1,"self":1,"mixed":1,"split":1,"can":1,"adjust":1,"short":2,"rapid":2,"acting":2,"insulins":1,"separately":1,"before":2,"breakfast":1,"dinner":1,"add":1,"units":1,"injection":1,"reduced":1,"component":1,"premixed":1,"usually":1,"unit":2,"per":1,"same":1,"total":1,"but":1,"may":1,"require":1,"adjustment":1,"indiv":1},"len":200},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":16,"chunkId":"ada-2026-pharm-p16-c1","text":" or 10% of reduced NPH dose TITRATION  Titrate each component of the plan based on individualized needs Consider twice-daily premixed insulin plan INITIATION  Usually unit per unit at the same total insulin dose, but may require adjustment to individual needs TITRATION  Titrate based on individualized needs Initiation and titration of basal analog or bedtime NPH insulin 4 INITIATION Start 10 units per day or kg per day TITRATION  Set FPG goal (see section 6, \"Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises\")  Choose evidence-based titration algorithm, e.g., increase 2 units every 3 days to reach fasting plasma glucose goal without hypoglycemia  Initiation and titration of prandial insulin 5,6 Usually one dose with the largest meal or meal with greatest PPG excursion; prandial insulin can be dosed individually or mixed with NPH as appropriate INITIATION  4 units per day or 10% of basal insulin dose  lowering the basal dose by 4 units per day or 10% of basal dose TITRATION   For hypoglycemia: determine cause; if no clear Assess adequacy of insulin dose at every visit Consider clinical signals to evaluate for overbasalization and need to consider adjunctive therapies (e.g., elevated bedtime-to-morning and/or postprandial-to-preprandial differential, hypoglycemia [aware or unaware], high glucose variability) If glycemia is above goal If glycemia is above goal If gl","tf":{"10":4,"or":9,"of":7,"reduced":1,"nph":3,"dose":7,"titration":7,"titrate":2,"each":1,"component":1,"the":4,"plan":2,"based":3,"on":2,"individualized":2,"needs":3,"consider":3,"twice":1,"daily":1,"premixed":1,"insulin":7,"initiation":5,"usually":2,"unit":2,"per":5,"at":2,"same":1,"total":1,"but":1,"may":1,"require":1,"adjustment":1,"to":6,"individual":1,"and":5,"basal":4,"analog":1,"bedtime":2,"start":1,"units":4,"day":4,"kg":1,"set":1,"fpg":1,"goal":4,"see":1,"section":1,"glycemic":1,"goals":1,"hypoglycemia":4,"hyperglycemic":1,"crises":1,"choose":1,"evidence":1,"algorithm":1,"increase":1,"every":2,"days":1,"reach":1,"fasting":1,"plasma":1,"glucose":2,"without":1,"prandial":2,"one":1,"with":3,"largest":1,"meal":2,"greatest":1,"ppg":1,"excursion":1,"can":1,"be":1,"dosed":1,"individually":1,"mixed":1,"as":1,"appropriate":1,"lowering":1,"by":1,"for":2,"determine":1,"cause":1,"if":4,"no":1,"clear":1,"assess":1,"adequacy":1,"visit":1,"clinical":1,"signals":1,"evaluate":1,"overbasalization":1,"need":1,"adjunctive":1,"therapies":1,"elevated":1,"morning":1,"postprandial":1,"preprandial":1,"differential":1,"aware":1,"unaware":1,"high":1,"variability":1,"glycemia":2,"is":2,"above":2,"gl":1},"len":208},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":16,"chunkId":"ada-2026-pharm-p16-c2","text":"ization and need to consider adjunctive therapies (e.g., elevated bedtime-to-morning and/or postprandial-to-preprandial differential, hypoglycemia [aware or unaware], high glucose variability) If glycemia is above goal If glycemia is above goal If glycemia is above goal  consider these classes in combination and with insulin (may use fixed-ratio product, if available and appropriate) 3  If glycemia remains above goal: Use principles in Figure 9.3, including reinforcement of behavioral interventions (weight management and physical activity) and provision of DSMES, to meet individualized treatment goals To avoid therapeutic inertia, reassess and modify treatment regularly 1. 2. 3. 4. Consider switching from evening NPH to a basal analog if the individual develops hypoglycemia and/or frequently forgets to administer NPH in the evening and would be better managed with a morning dose of a long-acting basal Insulin. Consider dosing NPH in the morning for steroid-induced hyperglycemia. 5. Prandial insulin options include injectable rapid- and ultra-rapid-acting analog insulins, injectable short-acting human insulin, or inhaled human insulin. 6. If adding prandial insulin to NPH, consider initiation of a self-mixed or premixed insulin plan to decrease the number of injections required. If injectable therapy is needed to attain glycemic goals 1 Consider GLP-1 RA or dual GIP and GLP-1 ","tf":{"ization":1,"and":11,"need":1,"to":10,"consider":6,"adjunctive":1,"therapies":1,"elevated":1,"bedtime":1,"morning":3,"or":6,"postprandial":1,"preprandial":1,"differential":1,"hypoglycemia":2,"aware":1,"unaware":1,"high":1,"glucose":1,"variability":1,"if":8,"glycemia":4,"is":4,"above":4,"goal":4,"these":1,"classes":1,"in":4,"combination":1,"with":2,"insulin":7,"may":1,"use":2,"fixed":1,"ratio":1,"product":1,"available":1,"appropriate":1,"remains":1,"principles":1,"figure":1,"including":1,"reinforcement":1,"of":5,"behavioral":1,"interventions":1,"weight":1,"management":1,"physical":1,"activity":1,"provision":1,"dsmes":1,"meet":1,"individualized":1,"treatment":2,"goals":2,"avoid":1,"therapeutic":1,"inertia":1,"reassess":1,"modify":1,"regularly":1,"switching":1,"from":1,"evening":2,"nph":4,"basal":2,"analog":2,"the":4,"individual":1,"develops":1,"frequently":1,"forgets":1,"administer":1,"would":1,"be":1,"better":1,"managed":1,"dose":1,"long":1,"acting":3,"dosing":1,"for":1,"steroid":1,"induced":1,"hyperglycemia":1,"prandial":2,"options":1,"include":1,"injectable":3,"rapid":2,"ultra":1,"insulins":1,"short":1,"human":2,"inhaled":1,"adding":1,"initiation":1,"self":1,"mixed":1,"premixed":1,"plan":1,"decrease":1,"number":1,"injections":1,"required":1,"therapy":1,"needed":1,"attain":1,"glycemic":1,"glp":2,"ra":1,"dual":1,"gip":1},"len":199},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":16,"chunkId":"ada-2026-pharm-p16-c3","text":"lin. 6. If adding prandial insulin to NPH, consider initiation of a self-mixed or premixed insulin plan to decrease the number of injections required. If injectable therapy is needed to attain glycemic goals 1 Consider GLP-1 RA or dual GIP and GLP-1 RA in most individuals prior to insulin 2 If already on GLP-1 RA or dual GIP and GLP-1 RA, or if these are not 0.10.2 units/ For hypoglycemia: determine cause; if no clear reason, lower dose by 1020% If A1C <8% (<64 mmol/mol), consider Increase dose by 12 units insulin dose or 1015% twice weekly reason, lower corresponding dose by 1020% Total dose = 80% of current bedtime NPH dose Total NPH dose = 80% of current NPH dose at the same total Consider insulin as the first injectable if symptoms of hyperglycemia are present, when A1C or blood glucose levels are very high (i.e., A1C >10% [>86 mmol/mol] or blood glucose 300 mg/dL [16.7 mmol/L]), or when a diagnosis of type 1 diabetes is a possibility. When selecting GLP-1 RAs, consider individual preference, glycemic lowering, weight-lowering effect, and frequency of injection. If CVD is present, consider GLP-1 RA with proven CVD benefit; oral or injectable GLP-1 RAs are appropriate. For people on GLP-1 RA and basal insulin combination, consider use of a fixed-ratio combination product (IDegLira or iGlarLixi). Figure 9.5 Intensifying to injectable therapies in type 2 diabetes. CGM,","tf":{"10":4,"15":1,"16":1,"20":2,"64":1,"80":2,"86":1,"300":1,"lin":1,"if":8,"adding":1,"prandial":1,"insulin":6,"to":5,"nph":4,"consider":7,"initiation":1,"of":8,"self":1,"mixed":1,"or":10,"premixed":1,"plan":1,"decrease":1,"the":3,"number":1,"injections":1,"required":1,"injectable":4,"therapy":1,"is":3,"needed":1,"attain":1,"glycemic":2,"goals":1,"glp":8,"ra":6,"dual":2,"gip":2,"and":4,"in":2,"most":1,"individuals":1,"prior":1,"already":1,"on":2,"these":1,"are":4,"not":1,"units":2,"for":2,"hypoglycemia":1,"determine":1,"cause":1,"no":1,"clear":1,"reason":2,"lower":2,"dose":8,"by":3,"a1c":3,"mmol":3,"mol":2,"increase":1,"twice":1,"weekly":1,"corresponding":1,"total":3,"current":2,"bedtime":1,"at":1,"same":1,"as":1,"first":1,"symptoms":1,"hyperglycemia":1,"present":2,"when":3,"blood":2,"glucose":2,"levels":1,"very":1,"high":1,"mg":1,"dl":1,"diagnosis":1,"type":2,"diabetes":2,"possibility":1,"selecting":1,"ras":2,"individual":1,"preference":1,"lowering":2,"weight":1,"effect":1,"frequency":1,"injection":1,"cvd":2,"with":1,"proven":1,"benefit":1,"oral":1,"appropriate":1,"people":1,"basal":1,"combination":2,"use":1,"fixed":1,"ratio":1,"product":1,"ideglira":1,"iglarlixi":1,"figure":1,"intensifying":1,"therapies":1,"cgm":1},"len":225},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":16,"chunkId":"ada-2026-pharm-p16-c4","text":"; oral or injectable GLP-1 RAs are appropriate. For people on GLP-1 RA and basal insulin combination, consider use of a fixed-ratio combination product (IDegLira or iGlarLixi). Figure 9.5 Intensifying to injectable therapies in type 2 diabetes. CGM, continuous glucose monitoring; DSMES, diabetes self-management educa - tion and support; FPG, fasting plasma glucose; GLP-1 RA, glucagon-like peptide 1 receptor agonist; GIP, glucose-dependent insulinotropic polypep - tide; PPG, postprandial glucose. Adapted from Davies et al. ( 318 ). S198 Pharmacologic Approaches to Glycemic Treatment Diabetes Care Volume 49, Supplement 1, January 2026 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"49":2,"318":1,"2026":2,"848878":1,"oral":1,"or":2,"injectable":2,"glp":3,"ras":1,"are":1,"appropriate":1,"for":1,"people":1,"on":2,"ra":2,"and":2,"basal":1,"insulin":1,"combination":2,"consider":1,"use":1,"of":1,"fixed":1,"ratio":1,"product":1,"ideglira":1,"iglarlixi":1,"figure":1,"intensifying":1,"to":2,"therapies":1,"in":1,"type":1,"diabetes":3,"cgm":1,"continuous":1,"glucose":4,"monitoring":1,"dsmes":1,"self":1,"management":1,"educa":1,"tion":1,"support":1,"fpg":1,"fasting":1,"plasma":1,"glucagon":1,"like":1,"peptide":1,"receptor":1,"agonist":1,"gip":1,"dependent":1,"insulinotropic":1,"polypep":1,"tide":1,"ppg":1,"postprandial":1,"adapted":1,"from":2,"davies":1,"et":1,"al":1,"s198":1,"pharmacologic":1,"approaches":1,"glycemic":1,"treatment":1,"care":2,"volume":1,"supplement":2,"january":1,"downloaded":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"s183":1,"dc26s009":1,"by":1,"guest":1,"february":1},"len":105},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":17,"chunkId":"ada-2026-pharm-p17-c0","text":"that of basal insulin ( 123  130 ). GLP-1 RAs and dual GIP and GLP-1 RA in these trials also had a lower risk of hypoglyce - mia and beneficial effects on body weight compared with insulin, albeit with greater gastrointestinal side effects. Thus, trial re - sults support high-potency GLP-1 RAs and dual GIP and GLP-1 RA as the preferred options for individuals requiring more in - tensive glucose management ( Fig. 9.5 ). In individuals who are intensified to in - sulin therapy, combination therapy with a GLP-1 RA or a dual GIP and GLP-1 RA has been shown to have greater efficacy and durability of glycemic treatment effects, as well as weight and hypoglycemia bene - fits, than treatment intensification with insulin alone ( 90 , 131 ). However, cost, ac - cessibility, and tolerability are important considerations for GLP-1 RA and dual GIP and GLP-1 RA use. In all cases, treatment plans need to be continuously reviewed for efficacy, side effects (including hypoglycemia), and treat - ment burden ( Table 9.2 ). In some instan - ces, the individual will require medication reduction or discontinuation. Common rea - sons for this include ineffectiveness, hypo - glycemia, intolerable side effects, new contraindications, expense, or a change in glycemic goals (e.g., in response to de - velopment of comorbidities). See below for cost considerations of glucose-lowering therapies ( MEDICATIO","tf":{"90":1,"123":1,"130":1,"131":1,"that":1,"of":5,"basal":1,"insulin":3,"glp":8,"ras":2,"and":12,"dual":4,"gip":4,"ra":6,"in":8,"these":1,"trials":1,"also":1,"had":1,"lower":1,"risk":1,"hypoglyce":1,"mia":1,"beneficial":1,"effects":5,"on":1,"body":1,"weight":2,"compared":1,"with":4,"albeit":1,"greater":2,"gastrointestinal":1,"side":3,"thus":1,"trial":1,"re":1,"sults":1,"support":1,"high":1,"potency":1,"as":3,"the":2,"preferred":1,"options":1,"for":5,"individuals":2,"requiring":1,"more":1,"tensive":1,"glucose":2,"management":1,"fig":1,"who":1,"are":2,"intensified":1,"to":4,"sulin":1,"therapy":2,"combination":1,"or":3,"has":1,"been":1,"shown":1,"have":1,"efficacy":2,"durability":1,"glycemic":2,"treatment":3,"well":1,"hypoglycemia":2,"bene":1,"fits":1,"than":1,"intensification":1,"alone":1,"however":1,"cost":2,"ac":1,"cessibility":1,"tolerability":1,"important":1,"considerations":2,"use":1,"all":1,"cases":1,"plans":1,"need":1,"be":1,"continuously":1,"reviewed":1,"including":1,"treat":1,"ment":1,"burden":1,"table":1,"some":1,"instan":1,"ces":1,"individual":1,"will":1,"require":1,"medication":1,"reduction":1,"discontinuation":1,"common":1,"rea":1,"sons":1,"this":1,"include":1,"ineffectiveness":1,"hypo":1,"glycemia":1,"intolerable":1,"new":1,"contraindications":1,"expense":1,"change":1,"goals":1,"response":1,"de":1,"velopment":1,"comorbidities":1,"see":1,"below":1,"lowering":1,"therapies":1,"medicatio":1},"len":205},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":17,"chunkId":"ada-2026-pharm-p17-c1","text":"ffectiveness, hypo - glycemia, intolerable side effects, new contraindications, expense, or a change in glycemic goals (e.g., in response to de - velopment of comorbidities). See below for cost considerations of glucose-lowering therapies ( MEDICATION COSTS AND AFFORDABILITY ). Section 13,  Older Adults , has a full dis - cussion of treatment considerations in older adults. Treatment deintensification may also be needed in the setting of weight loss and/or optimization of life - style behaviors, when fewer pharmaco - logic agents are needed to maintain A1C goals. In this case, we recommend prefer - ential deescalation of therapies that are most likely to cause side effects, hypogly - cemia, and/or treatment burden and do not have cardiovascular, kidney, or meta - bolic benefits for continued use. Glucose-Lowering Therapy for People With Cardiovascular Disease or Risk Factors for Cardiovascular Disease For people with type 2 diabetes and es - tablished ASCVD or indicators of high ASCVD risk, HF, or CKD, an SGLT2 inhibi - tor and/or GLP-1 RA with demonstrated cardiovascular benefit ( Table 9.2 ) is rec - ommended independent of A1C, with or without metformin use, and in consider - ation of person-specific factors ( Fig. 9.4 ). GLP-1 RAs or a dual GIP and GLP-1 RA with demonstrated benefits are recom - mended for people with type 2 diabetes, obesity, and symptomatic HF with pres","tf":{"13":1,"ffectiveness":1,"hypo":1,"glycemia":1,"intolerable":1,"side":2,"effects":2,"new":1,"contraindications":1,"expense":1,"or":10,"change":1,"in":6,"glycemic":1,"goals":2,"response":1,"to":3,"de":1,"velopment":1,"of":9,"comorbidities":1,"see":1,"below":1,"for":6,"cost":1,"considerations":2,"glucose":2,"lowering":2,"therapies":2,"medication":1,"costs":1,"and":9,"affordability":1,"section":1,"older":2,"adults":2,"has":1,"full":1,"dis":1,"cussion":1,"treatment":3,"deintensification":1,"may":1,"also":1,"be":1,"needed":2,"the":1,"setting":1,"weight":1,"loss":1,"optimization":1,"life":1,"style":1,"behaviors":1,"when":1,"fewer":1,"pharmaco":1,"logic":1,"agents":1,"are":3,"maintain":1,"a1c":2,"this":1,"case":1,"we":1,"recommend":1,"prefer":1,"ential":1,"deescalation":1,"that":1,"most":1,"likely":1,"cause":1,"hypogly":1,"cemia":1,"burden":1,"do":1,"not":1,"have":1,"cardiovascular":4,"kidney":1,"meta":1,"bolic":1,"benefits":2,"continued":1,"use":2,"therapy":1,"people":3,"with":7,"disease":2,"risk":2,"factors":2,"type":2,"diabetes":2,"es":1,"tablished":1,"ascvd":2,"indicators":1,"high":1,"hf":2,"ckd":1,"an":1,"sglt2":1,"inhibi":1,"tor":1,"glp":3,"ra":2,"demonstrated":2,"benefit":1,"table":1,"is":1,"rec":1,"ommended":1,"independent":1,"without":1,"metformin":1,"consider":1,"ation":1,"person":1,"specific":1,"fig":1,"ras":1,"dual":1,"gip":1,"recom":1,"mended":1,"obesity":1,"symptomatic":1,"pres":1},"len":205},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":17,"chunkId":"ada-2026-pharm-p17-c2","text":" with or without metformin use, and in consider - ation of person-specific factors ( Fig. 9.4 ). GLP-1 RAs or a dual GIP and GLP-1 RA with demonstrated benefits are recom - mended for people with type 2 diabetes, obesity, and symptomatic HF with preserved ejection fraction ( 132  135 ) ( Table 9.2 and Fig. 9.4 ). Individuals with these comorbid - ities already achieving their individualized glycemic goals with other medications may benefit from switching to these pre - ferred medications to reduce risk of ASCVD, HF, and/or CKD in addition to achieving gly - cemic goals (see section 10,  Cardiovascular Disease and Risk Management , and sec - tion 11,  Chronic Kidney Disease and Risk Management ). This is particularly impor - tant because SGLT2 inhibitors and GLP-1 RAs are associated with lower risk of hypo - glycemia and individuals with ASCVD, HF, and CKD have higher hypoglycemia risk than individuals without these conditions ( 136 ). Individuals at lower risk for ASCVD may still benefit from GLP-1 RA therapy to reduce their risk of future cardiovas - cular events. The GRADE trial, which was designed to examine the comparative ef - fectiveness of insulin glargine U-100, gli - mepiride, liraglutide, and sitagliptin in individuals with relatively short duration of diabetes (and without established CVD) with respect to achieving and maintaining A1C below 7%, found that indivi","tf":{"10":1,"11":1,"100":1,"132":1,"135":1,"136":1,"with":10,"or":3,"without":3,"metformin":1,"use":1,"and":14,"in":3,"consider":1,"ation":1,"of":6,"person":1,"specific":1,"factors":1,"fig":2,"glp":4,"ras":2,"dual":1,"gip":1,"ra":2,"demonstrated":1,"benefits":1,"are":2,"recom":1,"mended":1,"for":2,"people":1,"type":1,"diabetes":2,"obesity":1,"symptomatic":1,"hf":3,"preserved":1,"ejection":1,"fraction":1,"table":1,"individuals":5,"these":3,"comorbid":1,"ities":1,"already":1,"achieving":3,"their":2,"individualized":1,"glycemic":1,"goals":2,"other":1,"medications":2,"may":2,"benefit":2,"from":2,"switching":1,"to":6,"pre":1,"ferred":1,"reduce":2,"risk":7,"ascvd":3,"ckd":2,"addition":1,"gly":1,"cemic":1,"see":1,"section":1,"cardiovascular":1,"disease":2,"management":2,"sec":1,"tion":1,"chronic":1,"kidney":1,"this":1,"is":1,"particularly":1,"impor":1,"tant":1,"because":1,"sglt2":1,"inhibitors":1,"associated":1,"lower":2,"hypo":1,"glycemia":1,"have":1,"higher":1,"hypoglycemia":1,"than":1,"conditions":1,"at":1,"still":1,"therapy":1,"future":1,"cardiovas":1,"cular":1,"events":1,"the":2,"grade":1,"trial":1,"which":1,"was":1,"designed":1,"examine":1,"comparative":1,"ef":1,"fectiveness":1,"insulin":1,"glargine":1,"gli":1,"mepiride":1,"liraglutide":1,"sitagliptin":1,"relatively":1,"short":1,"duration":1,"established":1,"cvd":1,"respect":1,"maintaining":1,"a1c":1,"below":1,"found":1,"that":1,"indivi":1},"len":205},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":17,"chunkId":"ada-2026-pharm-p17-c3","text":"ef - fectiveness of insulin glargine U-100, gli - mepiride, liraglutide, and sitagliptin in individuals with relatively short duration of diabetes (and without established CVD) with respect to achieving and maintaining A1C below 7%, found that individuals treated with liraglutide had a lower risk of cardiovascular events than individuals re - ceiving the other three treatments (hazard ratio 0.7 [95% CI 0.6  0.9]), although no significant differences were found between individual treatment groups for major ad - verse cardiovascular events, hospitalization for HF, or cardiovascular death ( 137 ). Indi - viduals with type 2 diabetes and moderate levels of CVD risk appear to derive car - diovascular and mortality benefits with preferential use of GLP-1 RA and SGLT2 inhibitors compared with sulfonylurea or DPP-4 inhibitors ( 138 ). Similarly, while greater reductions in HF hospitalization risk are observed with SGLT2 inhibitor therapy in individuals with higher baseline HF risk, some benefit is observed across the full range of HF risk ( 139 ). Glucose-Lowering Therapy for People With Chronic Kidney Disease For individuals with type 2 diabetes and CKD, considerations for selection of glucose- lowering medications include their effec - tiveness and safety when eGFR is reduced as well as the potential to affect CKD progression, CVD risk, and hypoglycemia ( 140 ). Preferred medication","tf":{"95":1,"100":1,"137":1,"138":1,"139":1,"140":1,"ef":1,"fectiveness":1,"of":7,"insulin":1,"glargine":1,"gli":1,"mepiride":1,"liraglutide":2,"and":9,"sitagliptin":1,"in":3,"individuals":5,"with":10,"relatively":1,"short":1,"duration":1,"diabetes":3,"without":1,"established":1,"cvd":3,"respect":1,"to":3,"achieving":1,"maintaining":1,"a1c":1,"below":1,"found":2,"that":1,"treated":1,"had":1,"lower":1,"risk":6,"cardiovascular":3,"events":2,"than":1,"re":1,"ceiving":1,"the":3,"other":1,"three":1,"treatments":1,"hazard":1,"ratio":1,"ci":1,"although":1,"no":1,"significant":1,"differences":1,"were":1,"between":1,"individual":1,"treatment":1,"groups":1,"for":5,"major":1,"ad":1,"verse":1,"hospitalization":2,"hf":4,"or":2,"death":1,"indi":1,"viduals":1,"type":2,"moderate":1,"levels":1,"appear":1,"derive":1,"car":1,"diovascular":1,"mortality":1,"benefits":1,"preferential":1,"use":1,"glp":1,"ra":1,"sglt2":2,"inhibitors":2,"compared":1,"sulfonylurea":1,"dpp":1,"similarly":1,"while":1,"greater":1,"reductions":1,"are":1,"observed":2,"inhibitor":1,"therapy":2,"higher":1,"baseline":1,"some":1,"benefit":1,"is":2,"across":1,"full":1,"range":1,"glucose":2,"lowering":2,"people":1,"chronic":1,"kidney":1,"disease":1,"ckd":2,"considerations":1,"selection":1,"medications":1,"include":1,"their":1,"effec":1,"tiveness":1,"safety":1,"when":1,"egfr":1,"reduced":1,"as":2,"well":1,"potential":1,"affect":1,"progression":1,"hypoglycemia":1,"preferred":1,"medication":1},"len":195},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":17,"chunkId":"ada-2026-pharm-p17-c4","text":"iabetes and CKD, considerations for selection of glucose- lowering medications include their effec - tiveness and safety when eGFR is reduced as well as the potential to affect CKD progression, CVD risk, and hypoglycemia ( 140 ). Preferred medications for glucose management in individuals with CKD are GLP-1 RAs and SGLT2 inhibitors (can be initiated if eGFR is above 20 mL/min/ 1.73 m 2 ). GLP-1 RAs are effective in lower - ing glucose levels, regardless of kidney function, with a low risk for hypoglycemia, and a recent clinical trial suggests that the GLP-1 RA semaglutide has a beneficial ef - fect on CVD, mortality, and kidney out - comes among people with CKD, leading to the recommendation that semaglutide can be used as another first-line agent for people with CKD ( 141 , 142 ). Other GLP-1 RAs (liraglutide and dulaglutide) may also have CKD benefits, but no other dedicated kidney trials have been published. Similarly, no dedicated kidney outcomes studies for the dual GIP and GLP-1 RA (tirzepatide) have been published, although post hoc analyses of clinical trials in people with type 2 diabetes have shown that tirzepatide slowed the rate of eGFR decline and reduced albuminuria ( 143 , 144 ). The GLP-1 RAs lixisenatide and exenatide, which require the kidneys for elimination, should be avoided in individ - uals with eGFR  30 mL/min/1.73 m 2 or with creatinine clearance  30 ","tf":{"20":1,"30":2,"73":2,"140":1,"141":1,"142":1,"143":1,"144":1,"iabetes":1,"and":10,"ckd":6,"considerations":1,"for":6,"selection":1,"of":4,"glucose":3,"lowering":1,"medications":2,"include":1,"their":1,"effec":1,"tiveness":1,"safety":1,"when":1,"egfr":4,"is":2,"reduced":2,"as":3,"well":1,"the":7,"potential":1,"to":2,"affect":1,"progression":1,"cvd":2,"risk":2,"hypoglycemia":2,"preferred":1,"management":1,"in":4,"individuals":1,"with":7,"are":2,"glp":6,"ras":4,"sglt2":1,"inhibitors":1,"can":2,"be":3,"initiated":1,"if":1,"above":1,"ml":2,"min":2,"effective":1,"lower":1,"ing":1,"levels":1,"regardless":1,"kidney":4,"function":1,"low":1,"recent":1,"clinical":2,"trial":1,"suggests":1,"that":3,"ra":2,"semaglutide":2,"has":1,"beneficial":1,"ef":1,"fect":1,"on":1,"mortality":1,"out":1,"comes":1,"among":1,"people":3,"leading":1,"recommendation":1,"used":1,"another":1,"first":1,"line":1,"agent":1,"other":2,"liraglutide":1,"dulaglutide":1,"may":1,"also":1,"have":4,"benefits":1,"but":1,"no":2,"dedicated":2,"trials":2,"been":2,"published":2,"similarly":1,"outcomes":1,"studies":1,"dual":1,"gip":1,"tirzepatide":2,"although":1,"post":1,"hoc":1,"analyses":1,"type":1,"diabetes":1,"shown":1,"slowed":1,"rate":1,"decline":1,"albuminuria":1,"lixisenatide":1,"exenatide":1,"which":1,"require":1,"kidneys":1,"elimination":1,"should":1,"avoided":1,"individ":1,"uals":1,"or":1,"creatinine":1,"clearance":1},"len":216},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":17,"chunkId":"ada-2026-pharm-p17-c5","text":"the rate of eGFR decline and reduced albuminuria ( 143 , 144 ). The GLP-1 RAs lixisenatide and exenatide, which require the kidneys for elimination, should be avoided in individ - uals with eGFR  30 mL/min/1.73 m 2 or with creatinine clearance  30 mL/min, respectively ( 145  147 ). Dedicated kidney outcomes trials in people with CKD and type 2 diabetes have shown that the SGLT2 inhibitors empagliflozin, canagliflozin, and dapagli - flozin have beneficial effects on slowing progression of CKD and CV outcomes in this population ( 148  150 ). However, their ability to lower glucose levels de - clines when the eGFR falls below 45 mL/ min/1.73 m 2 ( 151  153 ). Metformin is also a therapeutic agent for those with CKD due to its well-documented efficacy and safety profile for people with type 2 dia - betes. However, there is no documented direct kidney benefit. Importantly, met - formin should not be started in those whose eGFR is < 45 mL/min/1.73 m 2 . For those already treated with metformin, the dose of metformin should be reduced once eGFR is < 45 mL/min/1.73 m 2 and should be stopped once eGFR is < 30 mL/min/1.73 m 2 ( 99 ). A secondary anal - ysis of the GRADE trial found that insulin glargine, liraglutide, sitagliptin, and glime - piride did not prevent the development of CKD when added to metformin mono - therapy in individuals without underlying CKD ( 154 ). Individuals","tf":{"30":3,"45":3,"73":5,"99":1,"143":1,"144":1,"145":1,"147":1,"148":1,"150":1,"151":1,"153":1,"154":1,"the":8,"rate":1,"of":5,"egfr":6,"decline":1,"and":8,"reduced":2,"albuminuria":1,"glp":1,"ras":1,"lixisenatide":1,"exenatide":1,"which":1,"require":1,"kidneys":1,"for":4,"elimination":1,"should":4,"be":4,"avoided":1,"in":5,"individ":1,"uals":1,"with":6,"ml":6,"min":6,"or":1,"creatinine":1,"clearance":1,"respectively":1,"dedicated":1,"kidney":2,"outcomes":2,"trials":1,"people":2,"ckd":5,"type":2,"diabetes":1,"have":2,"shown":1,"that":2,"sglt2":1,"inhibitors":1,"empagliflozin":1,"canagliflozin":1,"dapagli":1,"flozin":1,"beneficial":1,"effects":1,"on":1,"slowing":1,"progression":1,"cv":1,"this":1,"population":1,"however":2,"their":1,"ability":1,"to":3,"lower":1,"glucose":1,"levels":1,"de":1,"clines":1,"when":2,"falls":1,"below":1,"metformin":4,"is":5,"also":1,"therapeutic":1,"agent":1,"those":3,"due":1,"its":1,"well":1,"documented":2,"efficacy":1,"safety":1,"profile":1,"dia":1,"betes":1,"there":1,"no":1,"direct":1,"benefit":1,"importantly":1,"met":1,"formin":1,"not":2,"started":1,"whose":1,"already":1,"treated":1,"dose":1,"once":2,"stopped":1,"secondary":1,"anal":1,"ysis":1,"grade":1,"trial":1,"found":1,"insulin":1,"glargine":1,"liraglutide":1,"sitagliptin":1,"glime":1,"piride":1,"did":1,"prevent":1,"development":1,"added":1,"mono":1,"therapy":1,"individuals":2,"without":1,"underlying":1},"len":218},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":17,"chunkId":"ada-2026-pharm-p17-c6","text":"econdary anal - ysis of the GRADE trial found that insulin glargine, liraglutide, sitagliptin, and glime - piride did not prevent the development of CKD when added to metformin mono - therapy in individuals without underlying CKD ( 154 ). Individuals with CKD, particularly ad - vanced CKD and kidney failure, are at high risk for hypoglycemia ( 136 ). If treated with insulin and/or sulfonylureas, treatment needs diabetesjournals.org/care Pharmacologic Approaches to Glycemic Treatment S199 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"49":1,"136":1,"154":1,"2026":1,"848878":1,"econdary":1,"anal":1,"ysis":1,"of":2,"the":2,"grade":1,"trial":1,"found":1,"that":1,"insulin":2,"glargine":1,"liraglutide":1,"sitagliptin":1,"and":3,"glime":1,"piride":1,"did":1,"not":1,"prevent":1,"development":1,"ckd":4,"when":1,"added":1,"to":2,"metformin":1,"mono":1,"therapy":1,"in":1,"individuals":2,"without":1,"underlying":1,"with":2,"particularly":1,"ad":1,"vanced":1,"kidney":1,"failure":1,"are":1,"at":1,"high":1,"risk":1,"for":1,"hypoglycemia":1,"if":1,"treated":1,"or":1,"sulfonylureas":1,"treatment":2,"needs":1,"diabetesjournals":2,"org":2,"care":2,"pharmacologic":1,"approaches":1,"glycemic":1,"s199":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"supplement":1,"s183":1,"dc26s009":1,"by":1,"guest":1,"on":1,"february":1},"len":90},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":18,"chunkId":"ada-2026-pharm-p18-c0","text":"to be closely monitored and adjusted as eGFR declines and individuals need to be educated about and closely monitored for hypoglycemia occurrence ( 140 ). See section 11,  Chronic Kidney Disease and Risk Management , for more details about prevention and treatment of CKD in individ - uals with diabetes. Glucose-Lowering Therapy for People With Metabolic Comorbidities Many adults with diabetes, either type 2 diabetes or type 1 diabetes, with obesity are at high risk of developing MASLD or MASH as well as MASH cirrhosis. Hence, the presence of MASLD or MASH should be a consideration when choosing glucose- lowering therapies. Accruing randomized clinical trial data suggest that pioglitazone, GLP-1 RAs, and a dual GIP and GLP-1 RA have favorable outcomes in terms of de - creasing hepatic steatosis and in the resolu - tion of MASH without worsening of fibrosis in individuals with biopsy-proven MASH or those at higher risk of clinically significant liver fibrosis identified with noninvasive tests ( 155  160 ). Combination therapy with pioglitazone plus GLP-1 RA should also be considered for treatment of hyperglycemia in adults with type 2 diabetes with biopsy- proven MASH or those at higher risk of clinically significant liver fibrosis identified with noninvasive tests, as such therapy is safe and effective and has been shown to reduce hepatic steatosis ( 161  163 ). It is im - p","tf":{"11":1,"140":1,"155":1,"160":1,"161":1,"163":1,"to":3,"be":4,"closely":2,"monitored":2,"and":10,"adjusted":1,"as":4,"egfr":1,"declines":1,"individuals":2,"need":1,"educated":1,"about":2,"for":4,"hypoglycemia":1,"occurrence":1,"see":1,"section":1,"chronic":1,"kidney":1,"disease":1,"risk":4,"management":1,"more":1,"details":1,"prevention":1,"treatment":2,"of":9,"ckd":1,"in":5,"individ":1,"uals":1,"with":10,"diabetes":5,"glucose":2,"lowering":2,"therapy":3,"people":1,"metabolic":1,"comorbidities":1,"many":1,"adults":2,"either":1,"type":3,"or":5,"obesity":1,"are":1,"at":3,"high":1,"developing":1,"masld":2,"mash":6,"well":1,"cirrhosis":1,"hence":1,"the":2,"presence":1,"should":2,"consideration":1,"when":1,"choosing":1,"therapies":1,"accruing":1,"randomized":1,"clinical":1,"trial":1,"data":1,"suggest":1,"that":1,"pioglitazone":2,"glp":3,"ras":1,"dual":1,"gip":1,"ra":2,"have":1,"favorable":1,"outcomes":1,"terms":1,"de":1,"creasing":1,"hepatic":2,"steatosis":2,"resolu":1,"tion":1,"without":1,"worsening":1,"fibrosis":3,"biopsy":2,"proven":2,"those":2,"higher":2,"clinically":2,"significant":2,"liver":2,"identified":2,"noninvasive":2,"tests":2,"combination":1,"plus":1,"also":1,"considered":1,"hyperglycemia":1,"such":1,"is":2,"safe":1,"effective":1,"has":1,"been":1,"shown":1,"reduce":1,"it":1,"im":1},"len":212},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":18,"chunkId":"ada-2026-pharm-p18-c1","text":"e 2 diabetes with biopsy- proven MASH or those at higher risk of clinically significant liver fibrosis identified with noninvasive tests, as such therapy is safe and effective and has been shown to reduce hepatic steatosis ( 161  163 ). It is im - portant to note that these studies are based on phase 2 clinical trials and that only semaglutide has recently shown bene - fit in a phase 3 clinical trial with histological outcomes in MASH, including improve - ments in steatohepatitis and fibrosis ( 156 ); this subsequently led to its approval by the FDA for the treatment of MASH with mod - erate to advanced liver fibrosis, while the other therapies await further phase 3 confirmation of evidence. However, these plans are preferred as they offer potential benefit compared with lack of histological benefit (or clinical trial data) from other glucose-lowering therapies in MASLD. Fur - ther details regarding liver health in diabetes can be found in section 4,  Comprehensive Medical Evaluation and Assessment of Comorbidities . Obesity is present in over 90% of peo - ple with type 2 diabetes, and in these in - dividuals weight management is a key treatment goal, along with glucose lower - ing. In the setting of obesity, the choice of glucose-lowering medications should take into consideration their effects on weight. Insulins, sulfonylureas, and thiazolidine - diones can promote weight","tf":{"90":1,"156":1,"161":1,"163":1,"diabetes":3,"with":7,"biopsy":1,"proven":1,"mash":3,"or":2,"those":1,"at":1,"higher":1,"risk":1,"of":8,"clinically":1,"significant":1,"liver":3,"fibrosis":3,"identified":1,"noninvasive":1,"tests":1,"as":2,"such":1,"therapy":1,"is":4,"safe":1,"and":7,"effective":1,"has":2,"been":1,"shown":2,"to":4,"reduce":1,"hepatic":1,"steatosis":1,"it":1,"im":1,"portant":1,"note":1,"that":2,"these":3,"studies":1,"are":2,"based":1,"on":2,"phase":3,"clinical":3,"trials":1,"only":1,"semaglutide":1,"recently":1,"bene":1,"fit":1,"in":10,"trial":2,"histological":2,"outcomes":1,"including":1,"improve":1,"ments":1,"steatohepatitis":1,"this":1,"subsequently":1,"led":1,"its":1,"approval":1,"by":1,"the":5,"fda":1,"for":1,"treatment":2,"mod":1,"erate":1,"advanced":1,"while":1,"other":2,"therapies":2,"await":1,"further":1,"confirmation":1,"evidence":1,"however":1,"plans":1,"preferred":1,"they":1,"offer":1,"potential":1,"benefit":2,"compared":1,"lack":1,"data":1,"from":1,"glucose":3,"lowering":2,"masld":1,"fur":1,"ther":1,"details":1,"regarding":1,"health":1,"can":2,"be":1,"found":1,"section":1,"comprehensive":1,"medical":1,"evaluation":1,"assessment":1,"comorbidities":1,"obesity":2,"present":1,"over":1,"peo":1,"ple":1,"type":1,"dividuals":1,"weight":3,"management":1,"key":1,"goal":1,"along":1,"lower":1,"ing":1,"setting":1,"choice":1,"medications":1,"should":1,"take":1,"into":1,"consideration":1,"their":1,"effects":1,"insulins":1,"sulfonylureas":1,"thiazolidine":1,"diones":1,"promote":1},"len":210},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":18,"chunkId":"ada-2026-pharm-p18-c2","text":" a key treatment goal, along with glucose lower - ing. In the setting of obesity, the choice of glucose-lowering medications should take into consideration their effects on weight. Insulins, sulfonylureas, and thiazolidine - diones can promote weight gain and should be used judiciously and at the lowest possible dose. Glucose-lowering medications that promote weight loss should be prioritized. Of the currently available agents, tirzepatide and semaglu - tide have the highest efficacy in terms of glucose lowering as well as weight loss, followed by dulaglutide, liraglutide, and extended-release exenatide ( 164  168 ). Other glucose-lowering medications (met - formin, SGLT2 inhibitors, DPP-4 inhibitors, dopamine agonists, bile acid sequestrants, and  -glucosidase inhibitors) are weight neutral or have a modest beneficial effect on weight. These medications can be used as add-on therapies in people with type 2 diabetes and obesity who require addi - tional glucose lowering or if the more ef - fective medications are not tolerated, are contraindicated, or are unavailable. Meta - bolic surgery, especially Roux-en-Y gastric bypass and sleeve gastrectomy, are very effective interventions to achieve both weight and glycemic goals and have ad - ditional health benefits beyond improv - ing metabolism ( 169 ). Further details regarding treatment of obesity can be found in section 8,  O","tf":{"164":1,"168":1,"169":1,"key":1,"treatment":2,"goal":1,"along":1,"with":2,"glucose":6,"lower":1,"ing":2,"in":4,"the":6,"setting":1,"of":5,"obesity":3,"choice":1,"lowering":5,"medications":5,"should":3,"take":1,"into":1,"consideration":1,"their":1,"effects":1,"on":3,"weight":7,"insulins":1,"sulfonylureas":1,"and":10,"thiazolidine":1,"diones":1,"can":3,"promote":2,"gain":1,"be":4,"used":2,"judiciously":1,"at":1,"lowest":1,"possible":1,"dose":1,"that":1,"loss":2,"prioritized":1,"currently":1,"available":1,"agents":1,"tirzepatide":1,"semaglu":1,"tide":1,"have":3,"highest":1,"efficacy":1,"terms":1,"as":3,"well":1,"followed":1,"by":1,"dulaglutide":1,"liraglutide":1,"extended":1,"release":1,"exenatide":1,"other":1,"met":1,"formin":1,"sglt2":1,"inhibitors":3,"dpp":1,"dopamine":1,"agonists":1,"bile":1,"acid":1,"sequestrants":1,"glucosidase":1,"are":5,"neutral":1,"or":3,"modest":1,"beneficial":1,"effect":1,"these":1,"add":1,"therapies":1,"people":1,"type":1,"diabetes":1,"who":1,"require":1,"addi":1,"tional":1,"if":1,"more":1,"ef":1,"fective":1,"not":1,"tolerated":1,"contraindicated":1,"unavailable":1,"meta":1,"bolic":1,"surgery":1,"especially":1,"roux":1,"en":1,"gastric":1,"bypass":1,"sleeve":1,"gastrectomy":1,"very":1,"effective":1,"interventions":1,"to":1,"achieve":1,"both":1,"glycemic":1,"goals":1,"ad":1,"ditional":1,"health":1,"benefits":1,"beyond":1,"improv":1,"metabolism":1,"further":1,"details":1,"regarding":1,"found":1,"section":1},"len":199},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":18,"chunkId":"ada-2026-pharm-p18-c3","text":"leeve gastrectomy, are very effective interventions to achieve both weight and glycemic goals and have ad - ditional health benefits beyond improv - ing metabolism ( 169 ). Further details regarding treatment of obesity can be found in section 8,  Obesity and Weight Management for the Prevention and Treatment of Diabetes . Insulin Therapy Many adults with type 2 diabetes eventu - ally require and benefit from insulin ther - apy ( Fig. 9.5 ). See INSULIN ADMINISTRATION TECHNIQUE , above, for guidance on how to administer insulin safely and effectively. The progressive nature of type 2 diabetes should be regularly and objectively ex - plained to individuals with diabetes, and clinicians should avoid using insulin as a threat or describing it as a sign of per - sonal failure. The utility and importance of insulin to achieve and maintain glyce - mic goals once progression of the disease overcomes the effect of other agents as well as for temporary use for acute situa - tions (such as hospitalization, acute ill - ness, or high-dose glucocorticoid therapy) should be emphasized. Educating and in - volving people with diabetes in insulin management is beneficial. For example, instruction of individuals with type 2 dia - betes initiating insulin on self-titration of insulin doses based on glucose monitoring improves glycemic management ( 170 ). Comprehensive education regarding glucos","tf":{"169":1,"170":1,"leeve":1,"gastrectomy":1,"are":1,"very":1,"effective":1,"interventions":1,"to":4,"achieve":2,"both":1,"weight":2,"and":11,"glycemic":2,"goals":2,"have":1,"ad":1,"ditional":1,"health":1,"benefits":1,"beyond":1,"improv":1,"ing":1,"metabolism":1,"further":1,"details":1,"regarding":2,"treatment":2,"of":9,"obesity":2,"can":1,"be":3,"found":1,"in":3,"section":1,"management":3,"for":5,"the":5,"prevention":1,"diabetes":5,"insulin":9,"therapy":2,"many":1,"adults":1,"with":4,"type":3,"eventu":1,"ally":1,"require":1,"benefit":1,"from":1,"ther":1,"apy":1,"fig":1,"see":1,"administration":1,"technique":1,"above":1,"guidance":1,"on":3,"how":1,"administer":1,"safely":1,"effectively":1,"progressive":1,"nature":1,"should":3,"regularly":1,"objectively":1,"ex":1,"plained":1,"individuals":2,"clinicians":1,"avoid":1,"using":1,"as":5,"threat":1,"or":2,"describing":1,"it":1,"sign":1,"per":1,"sonal":1,"failure":1,"utility":1,"importance":1,"maintain":1,"glyce":1,"mic":1,"once":1,"progression":1,"disease":1,"overcomes":1,"effect":1,"other":1,"agents":1,"well":1,"temporary":1,"use":1,"acute":2,"situa":1,"tions":1,"such":1,"hospitalization":1,"ill":1,"ness":1,"high":1,"dose":1,"glucocorticoid":1,"emphasized":1,"educating":1,"volving":1,"people":1,"is":1,"beneficial":1,"example":1,"instruction":1,"dia":1,"betes":1,"initiating":1,"self":1,"titration":1,"doses":1,"based":1,"glucose":1,"monitoring":1,"improves":1,"comprehensive":1,"education":1,"glucos":1},"len":201},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":18,"chunkId":"ada-2026-pharm-p18-c4","text":"management is beneficial. For example, instruction of individuals with type 2 dia - betes initiating insulin on self-titration of insulin doses based on glucose monitoring improves glycemic management ( 170 ). Comprehensive education regarding glucose monitoring, nutrition, physical activity, contingency planning (for ill - ness, fasting, or medication unavailabil - ity), and the prevention and appropriate treatment of hypoglycemia are critically important for all individuals using insulin. Assessment and education tailored to im - prove health literacy and numeracy may be necessary for individuals to effectively use various insulin dosing strategies and tools ( 57 , 58 ). See section 5,  Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes , for guidance on diabetes self-management education. Basal Insulin Basal insulin alone is the most convenient initial insulin treatment and can be added to noninsulin glucose-lowering medica - tions. For individuals with type 2 diabetes, starting doses can be estimated based on body weight (0.1  0.2 units/kg/day) and the degree of hyperglycemia, with indi - vidualized titration over time as needed to achieve and maintain glycemic goals. The principal action of basal insulin is to restrain hepatic glucose production and limit hyperglycemia overnight and be - tween meals ( 171 , 172 ). Attainment of fasting gluc","tf":{"57":1,"58":1,"170":1,"171":1,"172":1,"management":3,"is":3,"beneficial":1,"for":6,"example":1,"instruction":1,"of":6,"individuals":4,"with":3,"type":2,"dia":1,"betes":1,"initiating":1,"insulin":8,"on":4,"self":2,"titration":2,"doses":2,"based":2,"glucose":4,"monitoring":2,"improves":1,"glycemic":2,"comprehensive":1,"education":3,"regarding":1,"nutrition":1,"physical":1,"activity":1,"contingency":1,"planning":1,"ill":1,"ness":1,"fasting":2,"or":1,"medication":1,"unavailabil":1,"ity":1,"and":11,"the":4,"prevention":1,"appropriate":1,"treatment":2,"hypoglycemia":1,"are":1,"critically":1,"important":1,"all":1,"using":1,"assessment":1,"tailored":1,"to":6,"im":1,"prove":1,"health":3,"literacy":1,"numeracy":1,"may":1,"be":4,"necessary":1,"effectively":1,"use":1,"various":1,"dosing":1,"strategies":1,"tools":1,"see":1,"section":1,"facilitating":1,"positive":1,"behaviors":1,"well":1,"being":1,"improve":1,"outcomes":1,"guidance":1,"diabetes":2,"basal":3,"alone":1,"most":1,"convenient":1,"initial":1,"can":2,"added":1,"noninsulin":1,"lowering":1,"medica":1,"tions":1,"starting":1,"estimated":1,"body":1,"weight":1,"units":1,"kg":1,"day":1,"degree":1,"hyperglycemia":2,"indi":1,"vidualized":1,"over":1,"time":1,"as":1,"needed":1,"achieve":1,"maintain":1,"goals":1,"principal":1,"action":1,"restrain":1,"hepatic":1,"production":1,"limit":1,"overnight":1,"tween":1,"meals":1,"attainment":1,"gluc":1},"len":193},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":18,"chunkId":"ada-2026-pharm-p18-c5","text":"zed titration over time as needed to achieve and maintain glycemic goals. The principal action of basal insulin is to restrain hepatic glucose production and limit hyperglycemia overnight and be - tween meals ( 171 , 172 ). Attainment of fasting glucose goals can be achieved with human NPH insulin or a long-acting insulin analog. In clinical trials, long-acting basal analogs (U-100 glargine) have been demonstrated to reduce the risk of level 2 hypoglycemia and nocturnal hypoglyce - mia compared with NPH insulin ( 173 ). Longer-acting basal analogs (U-300 glar - gine or degludec) convey a lower noctur - nal hypoglycemia risk than U-100 glargine ( 174 , 175 ). It is important to understand how to convert individuals from one basal insulin to another, as switching insulins may be required due to the availability of more clinically appropriate insulin alter - natives, removal of a product from the market (i.e., insulin detemir), or changes to insurance coverage. Often doses can be converted unit for unit and subse - quently adjusted based on glucose moni - toring; however, an initial dose reduction of 10  20% can be used for individuals in very tight management or at high risk for hypoglycemia and is typically needed when switching from human NPH insulin or U-300 glargine to another insulin ( 176 ). Clinicians should also be aware of the potential for overbasalization with insulin","tf":{"10":1,"20":1,"100":2,"171":1,"172":1,"173":1,"174":1,"175":1,"176":1,"300":2,"zed":1,"titration":1,"over":1,"time":1,"as":2,"needed":2,"to":9,"achieve":1,"and":6,"maintain":1,"glycemic":1,"goals":2,"the":5,"principal":1,"action":1,"of":7,"basal":4,"insulin":10,"is":3,"restrain":1,"hepatic":1,"glucose":3,"production":1,"limit":1,"hyperglycemia":1,"overnight":1,"be":6,"tween":1,"meals":1,"attainment":1,"fasting":1,"can":3,"achieved":1,"with":3,"human":2,"nph":3,"or":5,"long":2,"acting":3,"analog":1,"in":2,"clinical":1,"trials":1,"analogs":2,"glargine":3,"have":1,"been":1,"demonstrated":1,"reduce":1,"risk":3,"level":1,"hypoglycemia":3,"nocturnal":1,"hypoglyce":1,"mia":1,"compared":1,"longer":1,"glar":1,"gine":1,"degludec":1,"convey":1,"lower":1,"noctur":1,"nal":1,"than":1,"it":1,"important":1,"understand":1,"how":1,"convert":1,"individuals":2,"from":3,"one":1,"another":2,"switching":2,"insulins":1,"may":1,"required":1,"due":1,"availability":1,"more":1,"clinically":1,"appropriate":1,"alter":1,"natives":1,"removal":1,"product":1,"market":1,"detemir":1,"changes":1,"insurance":1,"coverage":1,"often":1,"doses":1,"converted":1,"unit":2,"for":4,"subse":1,"quently":1,"adjusted":1,"based":1,"on":1,"moni":1,"toring":1,"however":1,"an":1,"initial":1,"dose":1,"reduction":1,"used":1,"very":1,"tight":1,"management":1,"at":1,"high":1,"typically":1,"when":1,"clinicians":1,"should":1,"also":1,"aware":1,"potential":1,"overbasalization":1},"len":213},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":18,"chunkId":"ada-2026-pharm-p18-c6","text":"s in very tight management or at high risk for hypoglycemia and is typically needed when switching from human NPH insulin or U-300 glargine to another insulin ( 176 ). Clinicians should also be aware of the potential for overbasalization with insulin therapy (i.e., use of higher than clinically necessary and appropriate dose of basal insulin, typically masking insufficient S200 Pharmacologic Approaches to Glycemic Treatment Diabetes Care Volume 49, Supplement 1, January 2026 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"49":2,"176":1,"300":1,"2026":2,"848878":1,"in":1,"very":1,"tight":1,"management":1,"or":2,"at":1,"high":1,"risk":1,"for":2,"hypoglycemia":1,"and":2,"is":1,"typically":2,"needed":1,"when":1,"switching":1,"from":2,"human":1,"nph":1,"insulin":4,"glargine":1,"to":2,"another":1,"clinicians":1,"should":1,"also":1,"be":1,"aware":1,"of":3,"the":1,"potential":1,"overbasalization":1,"with":1,"therapy":1,"use":1,"higher":1,"than":1,"clinically":1,"necessary":1,"appropriate":1,"dose":1,"basal":1,"masking":1,"insufficient":1,"s200":1,"pharmacologic":1,"approaches":1,"glycemic":1,"treatment":1,"diabetes":1,"care":2,"volume":1,"supplement":2,"january":1,"downloaded":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"s183":1,"dc26s009":1,"by":1,"guest":1,"on":1,"february":1},"len":88},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":19,"chunkId":"ada-2026-pharm-p19-c0","text":"mealtime insulin). Clinical signals that should prompt evaluation for overbasali - zation include high bedtime-to-morning or postprandial-to-preprandial glucose dif - ferential (e.g., bedtime-to-morning glucose differential  50 mg/dL [  2.8 mmol/L]), hy - poglycemia (aware or unaware), and high glucose variability. Evidence of over-basali - zation should prompt reevaluation of the glucose-lowering treatment plan to better address postprandial hyperglycemia ( 177 ). Combination Injectable Therapy and Prandial Insulin If basal insulin has been titrated to an ac - ceptable fasting blood glucose level and A1C remains above goal, if there is evi - dence of significant postprandial hyper - glycemia, or if signs of overbasalization are present, advancement to combination injectable therapy is necessary ( Fig. 9.5 ). This approach can use a GLP-1 RA or dual GIP and GLP-1 RA added to basal in - sulin or multiple doses of prandial insulin ( 131 , 178 ). If an individual is not already being treated with a GLP-1 RA or dual GIP and GLP-1 RA, a GLP-1 RA (either as an in - dividual product or in a fixed-ratio combi - nation with a basal insulin product) or dual GIP and GLP-1 RA should be consid - ered prior to starting prandial insulin to ad - dress prandial management and to lower the risks of hypoglycemia and weight gain associated with insulin therapy ( 131 , 178 ). Further intensificat","tf":{"50":1,"131":2,"177":1,"178":2,"mealtime":1,"insulin":7,"clinical":1,"signals":1,"that":1,"should":3,"prompt":2,"evaluation":1,"for":1,"overbasali":1,"zation":2,"include":1,"high":2,"bedtime":2,"to":10,"morning":2,"or":8,"postprandial":3,"preprandial":1,"glucose":5,"dif":1,"ferential":1,"differential":1,"mg":1,"dl":1,"mmol":1,"hy":1,"poglycemia":1,"aware":1,"unaware":1,"and":8,"variability":1,"evidence":1,"of":6,"over":1,"basali":1,"reevaluation":1,"the":2,"lowering":1,"treatment":1,"plan":1,"better":1,"address":1,"hyperglycemia":1,"combination":2,"injectable":2,"therapy":3,"prandial":4,"if":4,"basal":3,"has":1,"been":1,"titrated":1,"an":3,"ac":1,"ceptable":1,"fasting":1,"blood":1,"level":1,"a1c":1,"remains":1,"above":1,"goal":1,"there":1,"is":3,"evi":1,"dence":1,"significant":1,"hyper":1,"glycemia":1,"signs":1,"overbasalization":1,"are":1,"present":1,"advancement":1,"necessary":1,"fig":1,"this":1,"approach":1,"can":1,"use":1,"glp":6,"ra":6,"dual":3,"gip":3,"added":1,"in":3,"sulin":1,"multiple":1,"doses":1,"individual":1,"not":1,"already":1,"being":1,"treated":1,"with":3,"either":1,"as":1,"dividual":1,"product":2,"fixed":1,"ratio":1,"combi":1,"nation":1,"be":1,"consid":1,"ered":1,"prior":1,"starting":1,"ad":1,"dress":1,"management":1,"lower":1,"risks":1,"hypoglycemia":1,"weight":1,"gain":1,"associated":1,"further":1,"intensificat":1},"len":209},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":19,"chunkId":"ada-2026-pharm-p19-c1","text":" product) or dual GIP and GLP-1 RA should be consid - ered prior to starting prandial insulin to ad - dress prandial management and to lower the risks of hypoglycemia and weight gain associated with insulin therapy ( 131 , 178 ). Further intensification of insulin ther - apy entails adding doses of prandial insu - lin to basal insulin. Starting with a single prandial dose with the largest meal of the day is simple and effective, and it can be advanced to a plan with multiple prandial doses if necessary ( 179 ). We suggest start - ing with a prandial insulin dose of 4 units or 10% of the amount of basal insulin at the largest meal or the meal with the greatest postprandial excursion. The pran - dial insulin plan can then be intensified based on individual needs ( Fig. 9.5 ). Alter - natively, for an individual treated with basal insulin in whom additional prandial coverage is desired but administering insu - lin prior to one or more meals is not feasi - ble, the medication plan can be converted to two doses of a premixed insulin. Each approach has advantages and disadvan - tages. For example, basal-prandial plans offer greater flexibility for individuals who eat on irregular schedules, have variable meal content, or otherwise benefit from greater individualization and flexibility in insulin administration. On the other hand, two doses of premixed insulin is a simple, convenient ","tf":{"10":1,"131":1,"178":1,"179":1,"product":1,"or":5,"dual":1,"gip":1,"and":7,"glp":1,"ra":1,"should":1,"be":4,"consid":1,"ered":1,"prior":2,"to":7,"starting":2,"prandial":8,"insulin":11,"ad":1,"dress":1,"management":1,"lower":1,"the":10,"risks":1,"of":9,"hypoglycemia":1,"weight":1,"gain":1,"associated":1,"with":7,"therapy":1,"further":1,"intensification":1,"ther":1,"apy":1,"entails":1,"adding":1,"doses":4,"insu":2,"lin":2,"basal":4,"single":1,"dose":2,"largest":2,"meal":4,"day":1,"is":4,"simple":2,"effective":1,"it":1,"can":3,"advanced":1,"plan":3,"multiple":1,"if":1,"necessary":1,"we":1,"suggest":1,"start":1,"ing":1,"units":1,"amount":1,"at":1,"greatest":1,"postprandial":1,"excursion":1,"pran":1,"dial":1,"then":1,"intensified":1,"based":1,"on":3,"individual":2,"needs":1,"fig":1,"alter":1,"natively":1,"for":3,"an":1,"treated":1,"in":2,"whom":1,"additional":1,"coverage":1,"desired":1,"but":1,"administering":1,"one":1,"more":1,"meals":1,"not":1,"feasi":1,"ble":1,"medication":1,"converted":1,"two":2,"premixed":2,"each":1,"approach":1,"has":1,"advantages":1,"disadvan":1,"tages":1,"example":1,"plans":1,"offer":1,"greater":2,"flexibility":2,"individuals":1,"who":1,"eat":1,"irregular":1,"schedules":1,"have":1,"variable":1,"content":1,"otherwise":1,"benefit":1,"from":1,"individualization":1,"administration":1,"other":1,"hand":1,"convenient":1},"len":218},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":19,"chunkId":"ada-2026-pharm-p19-c2","text":"ility for individuals who eat on irregular schedules, have variable meal content, or otherwise benefit from greater individualization and flexibility in insulin administration. On the other hand, two doses of premixed insulin is a simple, convenient means of spreading insulin across the day. Moreover, human insulins, separately, self-mixed, or as premixed NPH/regular (for example, 70/30) formu - lations, are often less costly alternatives to insulin analogs. Individuals with type 2 diabetes are generally more insulin resistant than those with type 1 diabetes, require higher daily doses (  1 unit/kg), and have lower rates of hypoglycemia ( 180 ). Meta-analyses of trials comparing rapid-acting insulin ana - logs with human regular insulin in type 2 diabetes have not reported meaningful differences in A1C or hypoglycemia ( 181 ). Titration of prandial insulin can be based on home self-monitored blood glucose or CGM. When significant additions to the prandial insulin dose are made, particu - larly with the evening meal, consideration should be given to decreasing basal insulin to reduce risk of hypoglycemia. When ini - tiating intensification of insulin therapy, metformin, SGLT2 inhibitors, and GLP-1 RAs (or a dual GIP and GLP-1 RA) should be maintained, unless adverse effects (in - cluding significant treatment burden) or contraindications are present. Use of sul - fonylureas, me","tf":{"30":1,"70":1,"180":1,"181":1,"ility":1,"for":2,"individuals":2,"who":1,"eat":1,"on":3,"irregular":1,"schedules":1,"have":3,"variable":1,"meal":2,"content":1,"or":6,"otherwise":1,"benefit":1,"from":1,"greater":1,"individualization":1,"and":4,"flexibility":1,"in":4,"insulin":11,"administration":1,"the":4,"other":1,"hand":1,"two":1,"doses":2,"of":8,"premixed":2,"is":1,"simple":1,"convenient":1,"means":1,"spreading":1,"across":1,"day":1,"moreover":1,"human":2,"insulins":1,"separately":1,"self":2,"mixed":1,"as":1,"nph":1,"regular":2,"example":1,"formu":1,"lations":1,"are":4,"often":1,"less":1,"costly":1,"alternatives":1,"to":4,"analogs":1,"with":4,"type":3,"diabetes":3,"generally":1,"more":1,"resistant":1,"than":1,"those":1,"require":1,"higher":1,"daily":1,"unit":1,"kg":1,"lower":1,"rates":1,"hypoglycemia":3,"meta":1,"analyses":1,"trials":1,"comparing":1,"rapid":1,"acting":1,"ana":1,"logs":1,"not":1,"reported":1,"meaningful":1,"differences":1,"a1c":1,"titration":1,"prandial":2,"can":1,"be":3,"based":1,"home":1,"monitored":1,"blood":1,"glucose":1,"cgm":1,"when":2,"significant":2,"additions":1,"dose":1,"made":1,"particu":1,"larly":1,"evening":1,"consideration":1,"should":2,"given":1,"decreasing":1,"basal":1,"reduce":1,"risk":1,"ini":1,"tiating":1,"intensification":1,"therapy":1,"metformin":1,"sglt2":1,"inhibitors":1,"glp":2,"ras":1,"dual":1,"gip":1,"ra":1,"maintained":1,"unless":1,"adverse":1,"effects":1,"cluding":1,"treatment":1,"burden":1,"contraindications":1,"present":1,"use":1,"sul":1,"fonylureas":1,"me":1},"len":204},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":19,"chunkId":"ada-2026-pharm-p19-c3","text":"ication of insulin therapy, metformin, SGLT2 inhibitors, and GLP-1 RAs (or a dual GIP and GLP-1 RA) should be maintained, unless adverse effects (in - cluding significant treatment burden) or contraindications are present. Use of sul - fonylureas, meglitinides, and DPP-4 inhibi - tors should be limited or discontinued, as these medications do not have additional beneficial effects on cardiovascular, kid - ney, weight, or liver outcomes, and sulfo - nylureas and meglitinides increase risk of hypoglycemia and weight gain. Adjunctive use of pioglitazone may help to improve glycemia and reduce the amount of insulin needed, although potential side effects should be considered and may limit its use. Once a basal-bolus insulin plan is initi - ated, dose titration is important, with ad - justments made in both prandial and basal insulins based on blood glucose lev - els and an understanding of the pharma - codynamic profile of each formulation (also known as pattern control or pattern management). In some people with type 2 diabetes with significant clinical complex - ity, multimorbidity, and/or treatment bur - den, it may become necessary to simplify or deintensify complex insulin plans to de - crease risk of hypoglycemia and improve quality of life (see section 13,  Older Adults ). Concentrated Insulins Concentrated preparations may be more convenient (fewer injections to achieve g","tf":{"13":1,"ication":1,"of":9,"insulin":4,"therapy":1,"metformin":1,"sglt2":1,"inhibitors":1,"and":12,"glp":2,"ras":1,"or":7,"dual":1,"gip":1,"ra":1,"should":3,"be":4,"maintained":1,"unless":1,"adverse":1,"effects":3,"in":3,"cluding":1,"significant":2,"treatment":2,"burden":1,"contraindications":1,"are":1,"present":1,"use":3,"sul":1,"fonylureas":1,"meglitinides":2,"dpp":1,"inhibi":1,"tors":1,"limited":1,"discontinued":1,"as":2,"these":1,"medications":1,"do":1,"not":1,"have":1,"additional":1,"beneficial":1,"on":2,"cardiovascular":1,"kid":1,"ney":1,"weight":2,"liver":1,"outcomes":1,"sulfo":1,"nylureas":1,"increase":1,"risk":2,"hypoglycemia":2,"gain":1,"adjunctive":1,"pioglitazone":1,"may":4,"help":1,"to":4,"improve":2,"glycemia":1,"reduce":1,"the":2,"amount":1,"needed":1,"although":1,"potential":1,"side":1,"considered":1,"limit":1,"its":1,"once":1,"basal":2,"bolus":1,"plan":1,"is":2,"initi":1,"ated":1,"dose":1,"titration":1,"important":1,"with":3,"ad":1,"justments":1,"made":1,"both":1,"prandial":1,"insulins":2,"based":1,"blood":1,"glucose":1,"lev":1,"els":1,"an":1,"understanding":1,"pharma":1,"codynamic":1,"profile":1,"each":1,"formulation":1,"also":1,"known":1,"pattern":2,"control":1,"management":1,"some":1,"people":1,"type":1,"diabetes":1,"clinical":1,"complex":2,"ity":1,"multimorbidity":1,"bur":1,"den":1,"it":1,"become":1,"necessary":1,"simplify":1,"deintensify":1,"plans":1,"de":1,"crease":1,"quality":1,"life":1,"see":1,"section":1,"older":1,"adults":1,"concentrated":2,"preparations":1,"more":1,"convenient":1,"fewer":1,"injections":1,"achieve":1},"len":205},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":19,"chunkId":"ada-2026-pharm-p19-c4","text":"to simplify or deintensify complex insulin plans to de - crease risk of hypoglycemia and improve quality of life (see section 13,  Older Adults ). Concentrated Insulins Concentrated preparations may be more convenient (fewer injections to achieve goal dose) and comfortable (less volume to inject the desired dose and/or less injection effort) for individuals and may improve treatment plan engagement in those with insulin resistance who require large doses of insulin. Several concen - trated insulin preparations are currently available. U-500 regular insulin is, by defi - nition, five times more concentrated than U-100 regular insulin. U-500 regular insulin has distinct pharmacokinetics with similar onset but a delayed, blunted, and pro - longed peak effect and longer duration of action compared with U-100 regular insu - lin; thus, it has characteristics more like a premixed intermediate-acting (NPH) and regular insulin product and can be used as two or three daily injections ( 182 , 183 ). U-300 glargine and U-200 degludec are three and two times, respectively, as con - centrated as their U-100 formulations and allow higher doses of basal insulin admin - istration per volume used. U-300 glargine has a longer duration of action than U-100 glargine but modestly lower efficacy per unit administered ( 184  186 ). The U-200 formulations of insulin degludec, insulin lis - pro, and ","tf":{"13":1,"100":4,"182":1,"183":1,"184":1,"186":1,"200":2,"300":2,"500":2,"to":4,"simplify":1,"or":3,"deintensify":1,"complex":1,"insulin":11,"plans":1,"de":1,"crease":1,"risk":1,"of":7,"hypoglycemia":1,"and":12,"improve":2,"quality":1,"life":1,"see":1,"section":1,"older":1,"adults":1,"concentrated":3,"insulins":1,"preparations":2,"may":2,"be":2,"more":3,"convenient":1,"fewer":1,"injections":2,"achieve":1,"goal":1,"dose":2,"comfortable":1,"less":2,"volume":2,"inject":1,"the":2,"desired":1,"injection":1,"effort":1,"for":1,"individuals":1,"treatment":1,"plan":1,"engagement":1,"in":1,"those":1,"with":3,"resistance":1,"who":1,"require":1,"large":1,"doses":2,"several":1,"concen":1,"trated":1,"are":2,"currently":1,"available":1,"regular":5,"is":1,"by":1,"defi":1,"nition":1,"five":1,"times":2,"than":2,"has":3,"distinct":1,"pharmacokinetics":1,"similar":1,"onset":1,"but":2,"delayed":1,"blunted":1,"pro":2,"longed":1,"peak":1,"effect":1,"longer":2,"duration":2,"action":2,"compared":1,"insu":1,"lin":1,"thus":1,"it":1,"characteristics":1,"like":1,"premixed":1,"intermediate":1,"acting":1,"nph":1,"product":1,"can":1,"used":2,"as":3,"two":2,"three":2,"daily":1,"glargine":3,"degludec":2,"respectively":1,"con":1,"centrated":1,"their":1,"formulations":2,"allow":1,"higher":1,"basal":1,"admin":1,"istration":1,"per":2,"modestly":1,"lower":1,"efficacy":1,"unit":1,"administered":1,"lis":1},"len":206},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":19,"chunkId":"ada-2026-pharm-p19-c5","text":"f basal insulin admin - istration per volume used. U-300 glargine has a longer duration of action than U-100 glargine but modestly lower efficacy per unit administered ( 184  186 ). The U-200 formulations of insulin degludec, insulin lis - pro, and insulin lispro-aabc have pharma - cokinetics similar to those of their U-100 counterparts ( 187  189 ). While U-500 reg - ular insulin is available in both prefilled pens and vials, other concentrated insulins are available only in prefilled pens to minimize the risk of dosing errors. If U-500 regular insulin vials are prescribed, the prescription should be accompanied by a specific prescription for U-500 syrin - ges to minimize the risk of dosing errors. Alternative Insulin Routes Insulin is primarily administered via sub - cutaneous injection or infusion. Adminis - tration devices provide some additional variation in the subcutaneous delivery be - yond vial and syringe versus insulin pen. Those devices include continuous insulin pumps (programmable or automated basal and bolus settings and fixed basal and bo - lus settings) and bolus-only insulin patch pump. In addition, prandial or correction insulin doses may be administered using inhaled human insulin. Inhaled insulin is available as monomers of regular human insulin; studies in individuals with type 1 diabetes suggest that inhaled insulin has pharmacokinetics faster than thos","tf":{"100":2,"184":1,"186":1,"187":1,"189":1,"200":1,"300":1,"500":3,"basal":3,"insulin":16,"admin":1,"istration":1,"per":2,"volume":1,"used":1,"glargine":2,"has":2,"longer":1,"duration":1,"of":6,"action":1,"than":2,"but":1,"modestly":1,"lower":1,"efficacy":1,"unit":1,"administered":3,"the":5,"formulations":1,"degludec":1,"lis":1,"pro":1,"and":7,"lispro":1,"aabc":1,"have":1,"pharma":1,"cokinetics":1,"similar":1,"to":3,"those":2,"their":1,"counterparts":1,"while":1,"reg":1,"ular":1,"is":3,"available":3,"in":5,"both":1,"prefilled":2,"pens":2,"vials":2,"other":1,"concentrated":1,"insulins":1,"are":2,"only":2,"minimize":2,"risk":2,"dosing":2,"errors":2,"if":1,"regular":2,"prescribed":1,"prescription":2,"should":1,"be":3,"accompanied":1,"by":1,"specific":1,"for":1,"syrin":1,"ges":1,"alternative":1,"routes":1,"primarily":1,"via":1,"sub":1,"cutaneous":1,"injection":1,"or":3,"infusion":1,"adminis":1,"tration":1,"devices":2,"provide":1,"some":1,"additional":1,"variation":1,"subcutaneous":1,"delivery":1,"yond":1,"vial":1,"syringe":1,"versus":1,"pen":1,"include":1,"continuous":1,"pumps":1,"programmable":1,"automated":1,"bolus":2,"settings":2,"fixed":1,"bo":1,"lus":1,"patch":1,"pump":1,"addition":1,"prandial":1,"correction":1,"doses":1,"may":1,"using":1,"inhaled":3,"human":2,"as":1,"monomers":1,"studies":1,"individuals":1,"with":1,"type":1,"diabetes":1,"suggest":1,"that":1,"pharmacokinetics":1,"faster":1,"thos":1},"len":203},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":19,"chunkId":"ada-2026-pharm-p19-c6","text":"orrection insulin doses may be administered using inhaled human insulin. Inhaled insulin is available as monomers of regular human insulin; studies in individuals with type 1 diabetes suggest that inhaled insulin has pharmacokinetics faster than those of RAA ( 190 ). Studies comparing inhaled insulin with injectable insulin have demonstrated its faster onset and shorter duration com - pared with the RAA insulin lispro as well as clinically meaningful A1C reductions and diabetesjournals.org/care Pharmacologic Approaches to Glycemic Treatment S201 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"49":1,"190":1,"2026":1,"848878":1,"orrection":1,"insulin":8,"doses":1,"may":1,"be":1,"administered":1,"using":1,"inhaled":4,"human":2,"is":1,"available":1,"as":3,"monomers":1,"of":2,"regular":1,"studies":2,"in":1,"individuals":1,"with":3,"type":1,"diabetes":1,"suggest":1,"that":1,"has":1,"pharmacokinetics":1,"faster":2,"than":1,"those":1,"raa":2,"comparing":1,"injectable":1,"have":1,"demonstrated":1,"its":1,"onset":1,"and":2,"shorter":1,"duration":1,"com":1,"pared":1,"the":1,"lispro":1,"well":1,"clinically":1,"meaningful":1,"a1c":1,"reductions":1,"diabetesjournals":2,"org":2,"care":2,"pharmacologic":1,"approaches":1,"to":1,"glycemic":1,"treatment":1,"s201":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"supplement":1,"s183":1,"dc26s009":1,"by":1,"guest":1,"on":1,"february":1},"len":97},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":20,"chunkId":"ada-2026-pharm-p20-c0","text":"weight reductions compared with the RAA insulin aspart over 24 weeks ( 190  192 ). Use of inhaled insulin may result in a de - cline in lung function (reduced forced expi - ratory volume in 1 s [FEV 1 ]). Inhaled insulin is contraindicated in individuals with chronic lung disease, such as asthma and chronic obstructive pulmonary disease, and is not recommended in individuals who smoke or who recently stopped smoking. All individu - als require spirometry (FEV 1 ) testing to iden - tify potential lung disease prior to and after starting inhaled insulin therapy. ADDITIONAL RECOMMENDATIONS FOR ALL INDIVIDUALS WITH DIABETES Several key aspects of insulin manage - ment that are relevant to all people with diabetes requiring insulin therapy, including available formulations, insulin plans and delivery systems, administration technique, and overbasalization, were dis - cussed earlier in this section. Additional essential components for the glucose- lowering management plan that are rele - vant to people with all types of diabetes include encouraging healthy behaviors and diabetes self-management education and support (see section 5,  Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes ), considering social determinants of health (see section 1,  Improving Care and Promoting Health in Populations ), avoiding and preventing therapeutic inertia, and pres","tf":{"24":1,"190":1,"192":1,"weight":1,"reductions":1,"compared":1,"with":5,"the":2,"raa":1,"insulin":7,"aspart":1,"over":1,"weeks":1,"use":1,"of":4,"inhaled":3,"may":1,"result":1,"in":7,"de":1,"cline":1,"lung":3,"function":1,"reduced":1,"forced":1,"expi":1,"ratory":1,"volume":1,"fev":2,"is":2,"contraindicated":1,"individuals":3,"chronic":2,"disease":3,"such":1,"as":1,"asthma":1,"and":11,"obstructive":1,"pulmonary":1,"not":1,"recommended":1,"who":2,"smoke":1,"or":1,"recently":1,"stopped":1,"smoking":1,"all":4,"individu":1,"als":1,"require":1,"spirometry":1,"testing":1,"to":5,"iden":1,"tify":1,"potential":1,"prior":1,"after":1,"starting":1,"therapy":2,"additional":2,"recommendations":1,"for":2,"diabetes":4,"several":1,"key":1,"aspects":1,"manage":1,"ment":1,"that":2,"are":2,"relevant":1,"people":2,"requiring":1,"including":1,"available":1,"formulations":1,"plans":1,"delivery":1,"systems":1,"administration":1,"technique":1,"overbasalization":1,"were":1,"dis":1,"cussed":1,"earlier":1,"this":1,"section":3,"essential":1,"components":1,"glucose":1,"lowering":1,"management":2,"plan":1,"rele":1,"vant":1,"types":1,"include":1,"encouraging":1,"healthy":1,"behaviors":2,"self":1,"education":1,"support":1,"see":2,"facilitating":1,"positive":1,"health":4,"well":1,"being":1,"improve":1,"outcomes":1,"considering":1,"social":1,"determinants":1,"improving":1,"care":1,"promoting":1,"populations":1,"avoiding":1,"preventing":1,"therapeutic":1,"inertia":1,"pres":1},"len":193},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":20,"chunkId":"ada-2026-pharm-p20-c1","text":"ilitating Positive Health Behaviors and Well-being to Improve Health Outcomes ), considering social determinants of health (see section 1,  Improving Care and Promoting Health in Populations ), avoiding and preventing therapeutic inertia, and prescribing gluca - gon and affordable diabetes treatments. Recommendations 9.24 Include healthy behaviors, diabe - tes self-management education and support, avoidance of therapeutic iner - tia, and social determinants of health as essential components of the glucose- lowering management of diabetes. A 9.25 Use of continuous glucose moni - toring (CGM) is recommended at dia - betes onset and anytime thereafter for adults with diabetes who are on insulin therapy, A on noninsulin ther - apies that can cause hypoglycemia, B and on any diabetes treatment where CGM aids in management. B The choice of CGM device and method for use should be made based on the in - dividuals circumstances, preferences, and needs. 9.26 Monitor for signs of overbas - alization during insulin therapy, such as significant bedtime-to-morning or postprandial-to-preprandial glucose dif - ferential, occurrences of hypoglycemia (aware or unaware), and high glycemic variability. When overbasalization is suspected, a thorough reevaluation should occur promptly to further tai - lor therapy to the individuals needs. E 9.27 Automated insulin delivery sys - tems should be ","tf":{"24":1,"25":1,"26":1,"27":1,"ilitating":1,"positive":1,"health":5,"behaviors":2,"and":12,"well":1,"being":1,"to":5,"improve":1,"outcomes":1,"considering":1,"social":2,"determinants":2,"of":9,"see":1,"section":1,"improving":1,"care":1,"promoting":1,"in":3,"populations":1,"avoiding":1,"preventing":1,"therapeutic":2,"inertia":1,"prescribing":1,"gluca":1,"gon":1,"affordable":1,"diabetes":4,"treatments":1,"recommendations":1,"include":1,"healthy":1,"diabe":1,"tes":1,"self":1,"management":3,"education":1,"support":1,"avoidance":1,"iner":1,"tia":1,"as":2,"essential":1,"components":1,"the":4,"glucose":3,"lowering":1,"use":2,"continuous":1,"moni":1,"toring":1,"cgm":3,"is":2,"recommended":1,"at":1,"dia":1,"betes":1,"onset":1,"anytime":1,"thereafter":1,"for":3,"adults":1,"with":1,"who":1,"are":1,"on":4,"insulin":3,"therapy":3,"noninsulin":1,"ther":1,"apies":1,"that":1,"can":1,"cause":1,"hypoglycemia":2,"any":1,"treatment":1,"where":1,"aids":1,"choice":1,"device":1,"method":1,"should":3,"be":2,"made":1,"based":1,"dividual":1,"circumstances":1,"preferences":1,"needs":2,"monitor":1,"signs":1,"overbas":1,"alization":1,"during":1,"such":1,"significant":1,"bedtime":1,"morning":1,"or":2,"postprandial":1,"preprandial":1,"dif":1,"ferential":1,"occurrences":1,"aware":1,"unaware":1,"high":1,"glycemic":1,"variability":1,"when":1,"overbasalization":1,"suspected":1,"thorough":1,"reevaluation":1,"occur":1,"promptly":1,"further":1,"tai":1,"lor":1,"individual":1,"automated":1,"delivery":1,"sys":1,"tems":1},"len":194},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":20,"chunkId":"ada-2026-pharm-p20-c2","text":"cemia (aware or unaware), and high glycemic variability. When overbasalization is suspected, a thorough reevaluation should occur promptly to further tai - lor therapy to the individuals needs. E 9.27 Automated insulin delivery sys - tems should be offered to all adults with type 1 and 2 diabetes on insulin depending on the persons or care - givers needs and preferences. A 9.28 Glucagon should be prescribed for all individuals taking insulin or at high risk for hypoglycemia. A Fam - ily, caregivers, school personnel, and others providing support to these individuals should know its location and be educated on how to admin - ister it. Glucagon preparations that do not require reconstitution are preferred. B 9.29 Routinely assess all people with diabetes for financial obstacles that could impede their diabetes manage - ment. Clinicians, members of the dia - betes care team, and social services professionals should work collabora - tively, as appropriate and feasible, to support these individuals by implement - ing strategies to reduce costs, thereby improving their access to evidence- based care. E 9.30 In adults with diabetes and cost-related barriers, consider use of lower-cost medications for gly - cemic management (i.e., metformin, sulfonylureas, thiazolidinediones, and human insulin) within the context of their risks for hypoglycemia, weight gain, cardiovascular and kidne","tf":{"27":1,"28":1,"29":1,"30":1,"cemia":1,"aware":1,"or":3,"unaware":1,"and":10,"high":2,"glycemic":1,"variability":1,"when":1,"overbasalization":1,"is":1,"suspected":1,"thorough":1,"reevaluation":1,"should":5,"occur":1,"promptly":1,"to":8,"further":1,"tai":1,"lor":1,"therapy":1,"the":4,"individual":1,"needs":2,"automated":1,"insulin":4,"delivery":1,"sys":1,"tems":1,"be":3,"offered":1,"all":3,"adults":2,"with":3,"type":1,"diabetes":4,"on":3,"depending":1,"person":1,"care":3,"giver":1,"preferences":1,"glucagon":2,"prescribed":1,"for":5,"individuals":3,"taking":1,"at":1,"risk":1,"hypoglycemia":2,"fam":1,"ily":1,"caregivers":1,"school":1,"personnel":1,"others":1,"providing":1,"support":2,"these":2,"know":1,"its":1,"location":1,"educated":1,"how":1,"admin":1,"ister":1,"it":1,"preparations":1,"that":2,"do":1,"not":1,"require":1,"reconstitution":1,"are":1,"preferred":1,"routinely":1,"assess":1,"people":1,"financial":1,"obstacles":1,"could":1,"impede":1,"their":3,"manage":1,"ment":1,"clinicians":1,"members":1,"of":3,"dia":1,"betes":1,"team":1,"social":1,"services":1,"professionals":1,"work":1,"collabora":1,"tively":1,"as":1,"appropriate":1,"feasible":1,"by":1,"implement":1,"ing":1,"strategies":1,"reduce":1,"costs":1,"thereby":1,"improving":1,"access":1,"evidence":1,"based":1,"in":1,"cost":2,"related":1,"barriers":1,"consider":1,"use":1,"lower":1,"medications":1,"gly":1,"cemic":1,"management":1,"metformin":1,"sulfonylureas":1,"thiazolidinediones":1,"human":1,"within":1,"context":1,"risks":1,"weight":1,"gain":1,"cardiovascular":1,"kidne":1},"len":198},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":20,"chunkId":"ada-2026-pharm-p20-c3","text":"cost-related barriers, consider use of lower-cost medications for gly - cemic management (i.e., metformin, sulfonylureas, thiazolidinediones, and human insulin) within the context of their risks for hypoglycemia, weight gain, cardiovascular and kidney events, and other adverse effects. E Diabetes Technology and Glycemic Management The use of continuous glucose monitoring (CGM) in adults with diabetes improves glycemic outcomes (e.g., A1C, time in range) and reduces episodes of hypogly - cemia in adults with diabetes who are on insulin therapy or other noninsulin therapies that can induce hypoglycemia ( 193  209 ). In addition, the use of AID systems should be offered to adults with type 1 or type 2 diabetes who are on insulin therapy to improve glycemic management and glycemic outcomes ( 26 , 28  32 , 35  37 , 210  215 ). The decision of which CGM and/or AID system to use should be based on the preference of the individual with diabetes and their caregivers, availability of resources to pro - vide the needed training and education, and available support. As the diabetes technology landscape is rapidly evolving and individuals require a tailored ap - proach, health care teams may encounter challenges with determining the best technology for people with diabetes. An ADA resource, which can be found at diabetes.org/living-with-diabetes/ treatment-care/diabetes-technology- guid","tf":{"26":1,"28":1,"32":1,"35":1,"37":1,"193":1,"209":1,"210":1,"215":1,"cost":2,"related":1,"barriers":1,"consider":1,"use":4,"of":8,"lower":1,"medications":1,"for":3,"gly":1,"cemic":1,"management":3,"metformin":1,"sulfonylureas":1,"thiazolidinediones":1,"and":11,"human":1,"insulin":3,"within":1,"the":9,"context":1,"their":2,"risks":1,"hypoglycemia":2,"weight":1,"gain":1,"cardiovascular":1,"kidney":1,"events":1,"other":2,"adverse":1,"effects":1,"diabetes":10,"technology":4,"glycemic":4,"continuous":1,"glucose":1,"monitoring":1,"cgm":2,"in":4,"adults":3,"with":7,"improves":1,"outcomes":2,"a1c":1,"time":1,"range":1,"reduces":1,"episodes":1,"hypogly":1,"cemia":1,"who":2,"are":2,"on":3,"therapy":2,"or":3,"noninsulin":1,"therapies":1,"that":1,"can":2,"induce":1,"addition":1,"aid":2,"systems":1,"should":2,"be":3,"offered":1,"to":4,"type":2,"improve":1,"decision":1,"which":2,"system":1,"based":1,"preference":1,"individual":1,"caregivers":1,"availability":1,"resources":1,"pro":1,"vide":1,"needed":1,"training":1,"education":1,"available":1,"support":1,"as":1,"landscape":1,"is":1,"rapidly":1,"evolving":1,"individuals":1,"require":1,"tailored":1,"ap":1,"proach":1,"health":1,"care":2,"teams":1,"may":1,"encounter":1,"challenges":1,"determining":1,"best":1,"people":1,"an":1,"ada":1,"resource":1,"found":1,"at":1,"org":1,"living":1,"treatment":1,"guid":1},"len":207},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":20,"chunkId":"ada-2026-pharm-p20-c4","text":"quire a tailored ap - proach, health care teams may encounter challenges with determining the best technology for people with diabetes. An ADA resource, which can be found at diabetes.org/living-with-diabetes/ treatment-care/diabetes-technology- guide , can provide helpful information for health care professionals and indi - viduals with diabetes in making decisions regarding technology. For more informa - tion on diabetes technology, see section 7,  Diabetes Technology . Glucagon Due to the risk of hypoglycemia with insu - lin treatment, all individuals treated with insulin or who are at high risk for hypogly - cemia should be prescribed glucagon. Indi - viduals with diabetes who are prescribed glucagon and those in close contact with them should be educated on the use and administration of the individuals pre - scribed glucagon product. The glucagon product available to individuals may differ based on coverage and cost; however, products that do not require reconstitu - tion are preferred for ease of administra - tion ( 216 , 217 ). Clinicians should routinely review the individuals access to glucagon, as appropriate glucagon prescribing is low ( 218  220 ). See section 6,  Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises , for additional information on hy - poglycemia and glucagon in individuals with diabetes. Medication Costs and Affordability Costs for noninsu","tf":{"216":1,"217":1,"218":1,"220":1,"quire":1,"tailored":1,"ap":1,"proach":1,"health":2,"care":3,"teams":1,"may":2,"encounter":1,"challenges":1,"with":9,"determining":1,"the":6,"best":1,"technology":5,"for":7,"people":1,"diabetes":9,"an":1,"ada":1,"resource":1,"which":1,"can":2,"be":3,"found":1,"at":2,"org":1,"living":1,"treatment":2,"guide":1,"provide":1,"helpful":1,"information":2,"professionals":1,"and":7,"indi":2,"viduals":2,"in":3,"making":1,"decisions":1,"regarding":1,"more":1,"informa":1,"tion":3,"on":4,"see":2,"section":2,"glucagon":8,"due":1,"to":3,"risk":2,"of":3,"hypoglycemia":2,"insu":1,"lin":1,"all":1,"individuals":3,"treated":1,"insulin":1,"or":1,"who":2,"are":3,"high":1,"hypogly":1,"cemia":1,"should":3,"prescribed":2,"those":1,"close":1,"contact":1,"them":1,"educated":1,"use":1,"administration":1,"individual":2,"pre":1,"scribed":1,"product":2,"available":1,"differ":1,"based":1,"coverage":1,"cost":1,"however":1,"products":1,"that":1,"do":1,"not":1,"require":1,"reconstitu":1,"preferred":1,"ease":1,"administra":1,"clinicians":1,"routinely":1,"review":1,"access":1,"as":1,"appropriate":1,"prescribing":1,"is":1,"low":1,"glycemic":1,"goals":1,"hyperglycemic":1,"crises":1,"additional":1,"hy":1,"poglycemia":1,"medication":1,"costs":2,"affordability":1,"noninsu":1},"len":199},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":20,"chunkId":"ada-2026-pharm-p20-c5","text":"prescribing is low ( 218  220 ). See section 6,  Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises , for additional information on hy - poglycemia and glucagon in individuals with diabetes. Medication Costs and Affordability Costs for noninsulin and insulin diabetes medications have increased dramatically over the past two decades, and an in - creasing proportion of cost is now passed on to people with diabetes and their fam - ilies ( 221 ). Table 9.3 provides cost infor - mation for currently approved noninsulin therapies, while Table 9.4 provides these data for insulin. Of note, prices listed are average wholesale prices (AWP) ( 222 ) and National Average Drug Acquisition Costs (NADAC) ( 223 ); these estimates al - low for a comparison of drug prices but do not represent the actual costs to S202 Pharmacologic Approaches to Glycemic Treatment Diabetes Care Volume 49, Supplement 1, January 2026 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"49":2,"218":1,"220":1,"221":1,"222":1,"223":1,"2026":2,"848878":1,"prescribing":1,"is":2,"low":2,"see":1,"section":1,"glycemic":2,"goals":1,"hypoglycemia":1,"and":7,"hyperglycemic":1,"crises":1,"for":5,"additional":1,"information":1,"on":3,"hy":1,"poglycemia":1,"glucagon":1,"in":2,"individuals":1,"with":2,"diabetes":4,"medication":1,"costs":4,"affordability":1,"noninsulin":2,"insulin":2,"medications":1,"have":1,"increased":1,"dramatically":1,"over":1,"the":2,"past":1,"two":1,"decades":1,"an":1,"creasing":1,"proportion":1,"of":3,"cost":2,"now":1,"passed":1,"to":3,"people":1,"their":1,"fam":1,"ilies":1,"table":2,"provides":2,"infor":1,"mation":1,"currently":1,"approved":1,"therapies":1,"while":1,"these":2,"data":1,"note":1,"prices":3,"listed":1,"are":1,"average":2,"wholesale":1,"awp":1,"national":1,"drug":2,"acquisition":1,"nadac":1,"estimates":1,"al":1,"comparison":1,"but":1,"do":1,"not":1,"represent":1,"actual":1,"s202":1,"pharmacologic":1,"approaches":1,"treatment":1,"care":2,"volume":1,"supplement":2,"january":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"s183":1,"dc26s009":1,"by":1,"guest":1,"february":1},"len":149},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":21,"chunkId":"ada-2026-pharm-p21-c0","text":"people with diabetes because they do not account for various discounts, rebates, and other price adjustments often involved in prescription sales that affect the actual cost incurred by the individual. Medication costs can be a major source of stress for people with diabetes and contribute to worse medication-taking behavior ( 224 ); cost-reducing strategies may improve medication-taking behavior in some cases ( 225 ). Table 9.3Median monthly (30-day) AWP and NADAC of maximum approved daily dose of noninsulin glucose-lowering agents in the U.S. Class Compound Dosage strength/ product (if applicable) Maximum approved daily dose Median AWP (min, max)* Median NADAC (min, max)* Biguanides  Metformin 500 mg (IR) 2,000 mg $85 ($3, $216) $2 500 mg (ER) 2,000 mg $89 ($5, $6,719) $3 850 mg (IR) 2,550 mg $108 ($3, $189) $2 1,000 mg (IR) 2,000 mg $87 ($2, $144) $1 1,000 mg (ER) 2,000 mg $1,884 ($242, $7,214) $26 ($24, $28) 500 mg (Sol) 2,000 mg $810 ($810, $1,478) $417 Sulfonylureas (2nd generation)  Glimepiride 4 mg 8 mg $73 ($71, $198) $2  Glipizide 10 mg (IR) 40 mg $72 ($67, $91) $6 10 mg (XL/ER) 20 mg $48 $9  Glyburide 6 mg (micronized) 12 mg $54 ($48, $71) $13 5 mg 20 mg $88 ($63, $432) $7 Thiazolidinedione  Pioglitazone 45 mg 45 mg $348 ($7, $349) $4  -Glucosidase inhibitors  Acarbose 100 mg 300 mg $106 ($104, $378) $22  Miglitol 100 mg 300 mg $294 ($241, $346) $183 Meglit","tf":{"10":2,"12":1,"13":1,"20":2,"22":1,"24":1,"26":1,"28":1,"30":1,"40":1,"45":2,"48":2,"54":1,"63":1,"67":1,"71":2,"72":1,"73":1,"85":1,"87":1,"88":1,"89":1,"91":1,"100":2,"104":1,"106":1,"108":1,"144":1,"183":1,"189":1,"198":1,"214":1,"216":1,"224":1,"225":1,"241":1,"242":1,"294":1,"300":2,"346":1,"348":1,"349":1,"378":1,"417":1,"432":1,"478":1,"500":3,"550":1,"719":1,"810":2,"850":1,"884":1,"people":2,"with":2,"diabetes":2,"because":1,"they":1,"do":1,"not":1,"account":1,"for":2,"various":1,"discounts":1,"rebates":1,"and":3,"other":1,"price":1,"adjustments":1,"often":1,"involved":1,"in":3,"prescription":1,"sales":1,"that":1,"affect":1,"the":3,"actual":1,"cost":2,"incurred":1,"by":1,"individual":1,"medication":3,"costs":1,"can":1,"be":1,"major":1,"source":1,"of":3,"stress":1,"contribute":1,"to":1,"worse":1,"taking":2,"behavior":2,"reducing":1,"strategies":1,"may":1,"improve":1,"some":1,"cases":1,"table":1,"median":3,"monthly":1,"day":1,"awp":2,"nadac":2,"maximum":2,"approved":2,"daily":2,"dose":2,"noninsulin":1,"glucose":1,"lowering":1,"agents":1,"class":1,"compound":1,"dosage":1,"strength":1,"product":1,"if":1,"applicable":1,"min":2,"max":2,"biguanides":1,"metformin":1,"mg":28,"ir":4,"000":7,"er":3,"sol":1,"sulfonylureas":1,"2nd":1,"generation":1,"glimepiride":1,"glipizide":1,"xl":1,"glyburide":1,"micronized":1,"thiazolidinedione":1,"pioglitazone":1,"glucosidase":1,"inhibitors":1,"acarbose":1,"miglitol":1,"meglit":1},"len":220},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":21,"chunkId":"ada-2026-pharm-p21-c1","text":"ed) 12 mg $54 ($48, $71) $13 5 mg 20 mg $88 ($63, $432) $7 Thiazolidinedione  Pioglitazone 45 mg 45 mg $348 ($7, $349) $4  -Glucosidase inhibitors  Acarbose 100 mg 300 mg $106 ($104, $378) $22  Miglitol 100 mg 300 mg $294 ($241, $346) $183 Meglitinides  Nateglinide 120 mg 360 mg $104 $16  Repaglinide 2 mg 16 mg $878 ($799, $1,728) $28 DPP-4 inhibitors  Alogliptin 25 mg 25 mg $234 $143  Linagliptin 5 mg 5 mg $630 $504  Saxagliptin 5 mg 5 mg $524 ($523, $524) $179  Sitagliptin 100 mg 100 mg $341 $303 25 mg/mL 100 mg $354 NA SGLT2 inhibitors  Bexagliflozin 20 mg 20 mg $47 NA  Canagliflozin 300 mg 300 mg $718 $575  Dapagliflozin 10 mg 10 mg $664 $345  Empagliflozin 25 mg 25 mg $629 $604  Ertugliflozin 15 mg 15 mg $428 $343 GLP-1 RAs  Dulaglutide 4.5 mg pen 4.5 mg $1,185 $953  Liraglutide 18 mg/3 mL pen 1.8 mg $929 ($845, $929) $577  Semaglutide 2 mg pen 2 mg $1,197 $966 14 mg (tablet) 14 mg $1,197 $965 Dual GIP and GLP-1 RA  Tirzepatide 15 mg pen 15 mg $1,296 $1,041 Bile acid sequestrant  Colesevelam 625 mg tabs 3.75 g $692 ($674, $712) $56 3.75 g suspension 3.75 g $674 ($673, $675) $93 Dopamine-2 agonist  Bromocriptine 0.8 mg 4.8 mg $1,188 $957 AWP, average wholesale price; DPP-4, dipeptidyl peptidase 4; ER and XL, extended release; GIP, glucose-dependent insulinotropic polypeptide; GLP-1 RA, glucagon-like peptide 1 receptor agonist; IR, immediate release; ","tf":{"10":2,"12":1,"13":1,"14":2,"15":4,"16":2,"18":1,"20":3,"22":1,"25":5,"28":1,"45":2,"47":1,"48":1,"54":1,"56":1,"63":1,"71":1,"75":3,"88":1,"93":1,"100":5,"104":2,"106":1,"120":1,"143":1,"179":1,"183":1,"185":1,"188":1,"197":2,"234":1,"241":1,"294":1,"296":1,"300":4,"303":1,"341":1,"343":1,"345":1,"346":1,"348":1,"349":1,"354":1,"360":1,"378":1,"428":1,"432":1,"504":1,"523":1,"524":2,"575":1,"577":1,"604":1,"625":1,"629":1,"630":1,"664":1,"673":1,"674":2,"675":1,"692":1,"712":1,"718":1,"728":1,"799":1,"845":1,"878":1,"929":2,"953":1,"957":1,"965":1,"966":1,"ed":1,"mg":46,"thiazolidinedione":1,"pioglitazone":1,"glucosidase":1,"inhibitors":3,"acarbose":1,"miglitol":1,"meglitinides":1,"nateglinide":1,"repaglinide":1,"dpp":2,"alogliptin":1,"linagliptin":1,"saxagliptin":1,"sitagliptin":1,"ml":2,"na":2,"sglt2":1,"bexagliflozin":1,"canagliflozin":1,"dapagliflozin":1,"empagliflozin":1,"ertugliflozin":1,"glp":3,"ras":1,"dulaglutide":1,"pen":4,"liraglutide":1,"semaglutide":1,"tablet":1,"dual":1,"gip":2,"and":2,"ra":2,"tirzepatide":1,"041":1,"bile":1,"acid":1,"sequestrant":1,"colesevelam":1,"tabs":1,"suspension":1,"dopamine":1,"agonist":2,"bromocriptine":1,"awp":1,"average":1,"wholesale":1,"price":1,"dipeptidyl":1,"peptidase":1,"er":1,"xl":1,"extended":1,"release":2,"glucose":1,"dependent":1,"insulinotropic":1,"polypeptide":1,"glucagon":1,"like":1,"peptide":1,"receptor":1,"ir":1,"immediate":1},"len":226},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":21,"chunkId":"ada-2026-pharm-p21-c2","text":"riptine 0.8 mg 4.8 mg $1,188 $957 AWP, average wholesale price; DPP-4, dipeptidyl peptidase 4; ER and XL, extended release; GIP, glucose-dependent insulinotropic polypeptide; GLP-1 RA, glucagon-like peptide 1 receptor agonist; IR, immediate release; max, maximum; min, minimum; NA, data not available; NADAC, Na - tional Average Drug Acquisition Cost; SGLT2, sodium  glucose cotransporter 2; Sol, solution. AWP and NADAC prices as of 15 July 2025. *Calculated for 30-day supply (AWP [ 222 ] or NADAC [ 223 ] unit price  number of doses required to provide maximum approved daily dose  30 days); median AWP or NADAC listed alone when only one product and/or price. Used to calculate median AWP and NADAC (min, max); generic prices used, if available commercially. Administered once weekly. Caps on out-of-pocket costs for insulin have been implemented for individuals with Medicare insurance (to $35 per insulin prescription per month) and indi - viduals with state-regulated commercial insurance plans who live in 26 states and the District of Columbia that implemented such legislation (to either $35 per insulin prescription per month or $100 per total monthly insulin payment) ( 226  228 ). Ad - ditionally, insulin manufacturers have in - troduced cost reductions and copayment assistance programs; however, these do not cover all insulins, and the copayment assistance programs have variab","tf":{"15":1,"26":1,"30":2,"35":2,"100":1,"188":1,"222":1,"223":1,"226":1,"228":1,"957":1,"2025":1,"riptine":1,"mg":2,"awp":5,"average":2,"wholesale":1,"price":3,"dpp":1,"dipeptidyl":1,"peptidase":1,"er":1,"and":8,"xl":1,"extended":1,"release":2,"gip":1,"glucose":2,"dependent":1,"insulinotropic":1,"polypeptide":1,"glp":1,"ra":1,"glucagon":1,"like":1,"peptide":1,"receptor":1,"agonist":1,"ir":1,"immediate":1,"max":2,"maximum":2,"min":2,"minimum":1,"na":2,"data":1,"not":2,"available":2,"nadac":5,"tional":1,"drug":1,"acquisition":1,"cost":2,"sglt2":1,"sodium":1,"cotransporter":1,"sol":1,"solution":1,"prices":2,"as":1,"of":4,"july":1,"calculated":1,"for":3,"day":1,"supply":1,"or":4,"unit":1,"number":1,"doses":1,"required":1,"to":4,"provide":1,"approved":1,"daily":1,"dose":1,"days":1,"median":2,"listed":1,"alone":1,"when":1,"only":1,"one":1,"product":1,"used":2,"calculate":1,"generic":1,"if":1,"commercially":1,"administered":1,"once":1,"weekly":1,"caps":1,"on":1,"out":1,"pocket":1,"costs":1,"insulin":5,"have":3,"been":1,"implemented":2,"individuals":1,"with":2,"medicare":1,"insurance":2,"per":5,"prescription":2,"month":2,"indi":1,"viduals":1,"state":1,"regulated":1,"commercial":1,"plans":1,"who":1,"live":1,"in":2,"states":1,"the":2,"district":1,"columbia":1,"that":1,"such":1,"legislation":1,"either":1,"total":1,"monthly":1,"payment":1,"ad":1,"ditionally":1,"manufacturers":1,"troduced":1,"reductions":1,"copayment":2,"assistance":2,"programs":2,"however":1,"these":1,"do":1,"cover":1,"all":1,"insulins":1,"variab":1},"len":207},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":21,"chunkId":"ada-2026-pharm-p21-c3","text":"per total monthly insulin payment) ( 226  228 ). Ad - ditionally, insulin manufacturers have in - troduced cost reductions and copayment assistance programs; however, these do not cover all insulins, and the copayment assistance programs have variable eligibil - ity requirements and reduce out-of-pocket payments to variable degrees ( 229 ) (see section 1,  Improving Care and Promoting Health in Populations ). Individuals with high-deductible health plans and those without insurance coverage can incur very high out-of-pocket expenses for glucose- lowering therapies. Moreover, no such caps exist for diabetes medical equipment (i.e., equipment for glucose monitoring and insulin administration) or for nonin - sulin medications. It is therefore essen - tial to screen all people with diabetes for financial concerns and cost-related barriers to care and to engage mem - bers of the health care team, including diabetesjournals.org/care Pharmacologic Approaches to Glycemic Treatment S203 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"49":1,"226":1,"228":1,"229":1,"2026":1,"848878":1,"per":1,"total":1,"monthly":1,"insulin":3,"payment":1,"ad":1,"ditionally":1,"manufacturers":1,"have":2,"in":2,"troduced":1,"cost":2,"reductions":1,"and":8,"copayment":2,"assistance":2,"programs":2,"however":1,"these":1,"do":1,"not":1,"cover":1,"all":2,"insulins":1,"the":2,"variable":2,"eligibil":1,"ity":1,"requirements":1,"reduce":1,"out":2,"of":3,"pocket":2,"payments":1,"to":5,"degrees":1,"see":1,"section":1,"improving":1,"care":5,"promoting":1,"health":3,"populations":1,"individuals":1,"with":2,"high":2,"deductible":1,"plans":1,"those":1,"without":1,"insurance":1,"coverage":1,"can":1,"incur":1,"very":1,"expenses":1,"for":5,"glucose":2,"lowering":1,"therapies":1,"moreover":1,"no":1,"such":1,"caps":1,"exist":1,"diabetes":2,"medical":1,"equipment":2,"monitoring":1,"administration":1,"or":1,"nonin":1,"sulin":1,"medications":1,"it":1,"is":1,"therefore":1,"essen":1,"tial":1,"screen":1,"people":1,"financial":1,"concerns":1,"related":1,"barriers":1,"engage":1,"mem":1,"bers":1,"team":1,"including":1,"diabetesjournals":2,"org":2,"pharmacologic":1,"approaches":1,"glycemic":1,"treatment":1,"s203":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"supplement":1,"s183":1,"dc26s009":1,"by":1,"guest":1,"on":1,"february":1},"len":160},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":22,"chunkId":"ada-2026-pharm-p22-c0","text":"pharmacists, certified diabetes care and education specialists, social workers, com - munity health workers, community para - medics, and others, to identify cost-saving opportunities for medications, diabetes durable medical equipment, and glucagon ( 230 ). Recommendations 9.31a Use of compounded products that are not approved by the U.S. Food and Drug Administration (FDA) is not recommended due to uncertainty about their content and resulting con - cerns about safety, quality, and effec - tiveness. C 9.31b If a glucose-lowering medication is unavailable (e.g., in shortage), it is Table 9.4Median cost of insulin products in the U.S. calculated as AWP and NADAC per 1,000 units of specified dosage form/product Insulins Compounds Dosage form/product Median AWP (min, max)* Median NADAC (min, max)* Rapid-acting  Aspart U-100 vial $87 $70 U-100 cartridge $107 $86 U-100 prefilled pen $112 $90  Aspart biosimilars# U-100 vial $83 NA U-100 prefilled pen $107 NA  Aspart (faster acting product) U-100 vial $347 $278 U-100 cartridge $430 $344 U-100 prefilled pen $447 $358  Glulisine U-100 vial $102 $82 U-100 prefilled pen $132 $105  Inhaled insulin Inhalation cartridges $1,578 $1,265  Lispro U-100 vial $30 $24 U-100 cartridge $123 $98 U-100 prefilled pen $127 $102 U-200 prefilled pen $424 $339  Lispro-aabc U-100 vial $330 $263 U-100 prefilled pen $424 $339 U-200 prefille","tf":{"24":1,"30":1,"70":1,"82":1,"83":1,"86":1,"87":1,"90":1,"98":1,"100":15,"102":2,"105":1,"107":2,"112":1,"123":1,"127":1,"132":1,"200":2,"230":1,"263":1,"265":1,"278":1,"330":1,"339":2,"344":1,"347":1,"358":1,"424":2,"430":1,"447":1,"578":1,"pharmacists":1,"certified":1,"diabetes":2,"care":1,"and":7,"education":1,"specialists":1,"social":1,"workers":2,"com":1,"munity":1,"health":1,"community":1,"para":1,"medics":1,"others":1,"to":2,"identify":1,"cost":2,"saving":1,"opportunities":1,"for":1,"medications":1,"durable":1,"medical":1,"equipment":1,"glucagon":1,"recommendations":1,"31a":1,"use":1,"of":3,"compounded":1,"products":2,"that":1,"are":1,"not":2,"approved":1,"by":1,"the":2,"food":1,"drug":1,"administration":1,"fda":1,"is":3,"recommended":1,"due":1,"uncertainty":1,"about":2,"their":1,"content":1,"resulting":1,"con":1,"cerns":1,"safety":1,"quality":1,"effec":1,"tiveness":1,"31b":1,"if":1,"glucose":1,"lowering":1,"medication":1,"unavailable":1,"in":2,"shortage":1,"it":1,"table":1,"median":3,"insulin":2,"calculated":1,"as":1,"awp":2,"nadac":2,"per":1,"000":1,"units":1,"specified":1,"dosage":2,"form":2,"product":3,"insulins":1,"compounds":1,"min":2,"max":2,"rapid":1,"acting":2,"aspart":3,"vial":6,"cartridge":3,"prefilled":7,"pen":7,"biosimilars":1,"na":2,"faster":1,"glulisine":1,"inhaled":1,"inhalation":1,"cartridges":1,"lispro":2,"aabc":1,"prefille":1},"len":205},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":22,"chunkId":"ada-2026-pharm-p22-c1","text":" Inhaled insulin Inhalation cartridges $1,578 $1,265  Lispro U-100 vial $30 $24 U-100 cartridge $123 $98 U-100 prefilled pen $127 $102 U-200 prefilled pen $424 $339  Lispro-aabc U-100 vial $330 $263 U-100 prefilled pen $424 $339 U-200 prefilled pen $424 $339  Lispro follow-on product U-100 vial $118 $110 U-100 prefilled pen $151 $121 Short-acting  Human regular U-100 vial $56 ($54, $58) $44 ($43, $46) U-100 prefilled pen $73 $58 Intermediate-acting  Human NPH U-100 vial $58 ($54, $58) $45 ($43, $46) U-100 prefilled pen $93 ($73, $113) $74 ($58, $91) Concentrated human regular insulin  U-500 human regular insulin U-500 vial $178 $143 U-500 prefilled pen $230 $183 Long-acting  Degludec U-100 vial $142 $114 U-100 prefilled pen $142 $114 U-200 prefilled pen $142 $114  Glargine U-100 vial U-100 prefilled pen $77 $77 $62 $62 U-300 prefilled pen $152 $122  Glargine biosimilar/follow-on products U-100 vial $76 $61 U-100 prefilled pen $74 ($74, $261) $59 ($59, $209) Premixed insulin products  Aspart 70/30 U-100 vial $87 $69 U-100 prefilled pen $112 $90  Lispro 50/50 U-100 vial $102 NA U-100 prefilled pen $127 $102  Lispro 75/25 U-100 vial $102 $82 U-100 prefilled pen $127 $102  NPH/regular 70/30 U-100 vial $56 ($54, $58) $45 ($43, $46) U-100 prefilled pen $93 ($73, $113) $74 ($58, $90) Premixed insulin/GLP-1 RA products  Degludec/liraglutide","tf":{"24":1,"25":1,"30":3,"43":3,"44":1,"45":2,"46":3,"50":2,"54":3,"56":2,"58":7,"59":2,"61":1,"62":2,"69":1,"70":2,"73":3,"74":4,"75":1,"76":1,"77":2,"82":1,"87":1,"90":2,"91":1,"93":2,"98":1,"100":25,"102":5,"110":1,"112":1,"113":2,"114":3,"118":1,"121":1,"122":1,"123":1,"127":3,"142":3,"143":1,"151":1,"152":1,"178":1,"183":1,"200":3,"209":1,"230":1,"261":1,"263":1,"265":1,"300":1,"330":1,"339":3,"424":3,"500":3,"578":1,"inhaled":1,"insulin":5,"inhalation":1,"cartridges":1,"lispro":5,"vial":13,"cartridge":1,"prefilled":17,"pen":17,"aabc":1,"follow":2,"on":2,"product":1,"short":1,"acting":3,"human":4,"regular":4,"intermediate":1,"nph":2,"concentrated":1,"long":1,"degludec":2,"glargine":2,"biosimilar":1,"products":3,"premixed":2,"aspart":1,"na":1,"glp":1,"ra":1,"liraglutide":1},"len":226},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":22,"chunkId":"ada-2026-pharm-p22-c2","text":"n $127 $102  Lispro 75/25 U-100 vial $102 $82 U-100 prefilled pen $127 $102  NPH/regular 70/30 U-100 vial $56 ($54, $58) $45 ($43, $46) U-100 prefilled pen $93 ($73, $113) $74 ($58, $90) Premixed insulin/GLP-1 RA products  Degludec/liraglutide 100/3.6 mg prefilled pen $1,073 $859  Glargine/lixisenatide 100/33 mg prefilled pen $713 $571 AWP, average wholesale price; GLP-1 RA, glucagon-like peptide 1 receptor agonist; NA, data not available; NADAC, National Average Drug Ac - quisition Cost. AWP ( 222 ) and NADAC ( 223 ) prices as of 15 July 2025. *AWP or NADAC calculated as in Table 9.3 . Unbranded product prices used when available. AWP and NADAC data presented do not include human insulins (approximately $25/vial or $43/box of 5 pens) or select analog insulins (approximately $73/vial or $86/box of 5 pens) available at Walmart; median listed alone when only one product and/or price. #Pricing for aspart-xjhz not available on 15 July 2025. SPECIAL CIRCUMSTANCES AND POPULATIONS S204 Pharmacologic Approaches to Glycemic Treatment Diabetes Care Volume 49, Supplement 1, January 2026 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"15":2,"17":1,"25":2,"30":1,"33":1,"43":2,"45":1,"46":1,"49":2,"54":1,"56":1,"58":2,"70":1,"73":2,"74":1,"75":1,"82":1,"86":1,"90":1,"93":1,"100":6,"102":3,"113":1,"127":2,"222":1,"223":1,"571":1,"713":1,"859":1,"2025":2,"2026":2,"848878":1,"lispro":1,"vial":4,"prefilled":4,"pen":4,"nph":1,"regular":1,"premixed":1,"insulin":1,"glp":2,"ra":2,"products":1,"degludec":1,"liraglutide":1,"mg":2,"073":1,"glargine":1,"lixisenatide":1,"awp":4,"average":2,"wholesale":1,"price":2,"glucagon":1,"like":1,"peptide":1,"receptor":1,"agonist":1,"na":1,"data":2,"not":3,"available":4,"nadac":4,"national":1,"drug":1,"ac":1,"quisition":1,"cost":1,"and":4,"prices":2,"as":2,"of":3,"july":2,"or":5,"calculated":1,"in":1,"table":1,"unbranded":1,"product":2,"used":1,"when":2,"presented":1,"do":1,"include":1,"human":1,"insulins":2,"approximately":2,"box":2,"pens":2,"select":1,"analog":1,"at":1,"walmart":1,"median":1,"listed":1,"alone":1,"only":1,"one":1,"pricing":1,"for":1,"aspart":1,"xjhz":1,"on":2,"special":1,"circumstances":1,"populations":1,"s204":1,"pharmacologic":1,"approaches":1,"to":1,"glycemic":1,"treatment":1,"diabetes":1,"care":2,"volume":1,"supplement":2,"january":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"s183":1,"dc26s009":1,"by":1,"guest":1,"february":1},"len":193},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":23,"chunkId":"ada-2026-pharm-p23-c0","text":"Therapeutic Strategies With Medication Unavailability Health care professionals and people with diabetes struggle when medication sup - plies are insufficient to meet the demand. Examples of such circumstances include recalls involving a number of metformin products and the marked increase in de - mand for agents from the GLP-1 RA and dual GIP and GLP-1 RA classes. The latter circumstance led to such a low level of availability that products were determined by the FDA to be in shortage ( 231 ). To as - sist with supply of medications during the time they are in shortage (as signaled by their inclusion on the FDA Drug Shortages Database), compounding pharmacies and outsourcing compounding facilities are al - lowed to make copies, or products that are essentially duplicates of the marketed FDA-approved product ( 232 ). A significant number of concerning reports regarding safety and efficacy of compounded incre - tin products have emerged, including using salt forms of the FDA-approved products active ingredient that are not proven safe or effective for use in humans, incorpora - tion of additional ingredients not clinically tested when mixed with incretin products (e.g., vitamin B12 and vitamin B6), prod - ucts provided in nonstandard concentra - tions and doses and/or multidose vials and prefilled syringes not accompanied by education or labeling to mitigate adminis - tration e","tf":{"231":1,"232":1,"therapeutic":1,"strategies":1,"with":4,"medication":2,"unavailability":1,"health":1,"care":1,"professionals":1,"and":10,"people":1,"diabetes":1,"struggle":1,"when":2,"sup":1,"plies":1,"are":5,"insufficient":1,"to":6,"meet":1,"the":9,"demand":1,"examples":1,"of":9,"such":2,"circumstances":1,"include":1,"recalls":1,"involving":1,"number":2,"metformin":1,"products":5,"marked":1,"increase":1,"in":5,"de":1,"mand":1,"for":2,"agents":1,"from":1,"glp":2,"ra":2,"dual":1,"gip":1,"classes":1,"latter":1,"circumstance":1,"led":1,"low":1,"level":1,"availability":1,"that":3,"were":1,"determined":1,"by":3,"fda":4,"be":1,"shortage":2,"as":2,"sist":1,"supply":1,"medications":1,"during":1,"time":1,"they":1,"signaled":1,"their":1,"inclusion":1,"on":1,"drug":1,"shortages":1,"database":1,"compounding":2,"pharmacies":1,"outsourcing":1,"facilities":1,"al":1,"lowed":1,"make":1,"copies":1,"or":4,"essentially":1,"duplicates":1,"marketed":1,"approved":2,"product":2,"significant":1,"concerning":1,"reports":1,"regarding":1,"safety":1,"efficacy":1,"compounded":1,"incre":1,"tin":1,"have":1,"emerged":1,"including":1,"using":1,"salt":1,"forms":1,"active":1,"ingredient":1,"not":3,"proven":1,"safe":1,"effective":1,"use":1,"humans":1,"incorpora":1,"tion":1,"additional":1,"ingredients":1,"clinically":1,"tested":1,"mixed":1,"incretin":1,"vitamin":2,"b12":1,"b6":1,"prod":1,"ucts":1,"provided":1,"nonstandard":1,"concentra":1,"tions":1,"doses":1,"multidose":1,"vials":1,"prefilled":1,"syringes":1,"accompanied":1,"education":1,"labeling":1,"mitigate":1,"adminis":1,"tration":1},"len":208},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":23,"chunkId":"ada-2026-pharm-p23-c1","text":"en mixed with incretin products (e.g., vitamin B12 and vitamin B6), prod - ucts provided in nonstandard concentra - tions and doses and/or multidose vials and prefilled syringes not accompanied by education or labeling to mitigate adminis - tration errors, and the emergence of coun - terfeit products that pose significant risk to individuals taking these products ( 233  236 ). Due to safety, quality, and effectiveness concerns, use of non-FDA-approved com - pounded products is not recommended ( 237 ). Instead, consider switching to a different FDA-approved medication as clinically appropriate ( 238 ). Once the de - sired FDA-approved product becomes available, individuals should be reas - sessed to determine the appropriate - ness of resuming the product based on their current care needs, preferences, and priorities. recommended to switch to a different FDA-approved medication with similar efficacy, as clinically appropriate. E 9.31c Upon resolution of the unavail - ability (e.g., shortage), reassess the ap - propriateness of resuming the original FDA-approved medication. E 9.32a Individuals of childbearing poten - tial with diabetes should be counseled on contraception options A and the im - pact of some glucose-lowering medica - tions on contraception efficacy. C 9.32b A person-centered shared deci - sion-making approach to preconception planning is essential for all individ","tf":{"233":1,"236":1,"237":1,"238":1,"en":1,"mixed":1,"with":3,"incretin":1,"products":4,"vitamin":2,"b12":1,"and":8,"b6":1,"prod":1,"ucts":1,"provided":1,"in":1,"nonstandard":1,"concentra":1,"tions":2,"doses":1,"or":2,"multidose":1,"vials":1,"prefilled":1,"syringes":1,"not":2,"accompanied":1,"by":1,"education":1,"labeling":1,"to":8,"mitigate":1,"adminis":1,"tration":1,"errors":1,"the":8,"emergence":1,"of":7,"coun":1,"terfeit":1,"that":1,"pose":1,"significant":1,"risk":1,"individuals":3,"taking":1,"these":1,"due":1,"safety":1,"quality":1,"effectiveness":1,"concerns":1,"use":1,"non":1,"fda":5,"approved":5,"com":1,"pounded":1,"is":2,"recommended":2,"instead":1,"consider":1,"switching":1,"different":2,"medication":3,"as":2,"clinically":2,"appropriate":3,"once":1,"de":1,"sired":1,"product":2,"becomes":1,"available":1,"should":2,"be":2,"reas":1,"sessed":1,"determine":1,"ness":1,"resuming":2,"based":1,"on":3,"their":1,"current":1,"care":1,"needs":1,"preferences":1,"priorities":1,"switch":1,"similar":1,"efficacy":2,"31c":1,"upon":1,"resolution":1,"unavail":1,"ability":1,"shortage":1,"reassess":1,"ap":1,"propriateness":1,"original":1,"32a":1,"childbearing":1,"poten":1,"tial":1,"diabetes":1,"counseled":1,"contraception":2,"options":1,"im":1,"pact":1,"some":1,"glucose":1,"lowering":1,"medica":1,"32b":1,"person":1,"centered":1,"shared":1,"deci":1,"sion":1,"making":1,"approach":1,"preconception":1,"planning":1,"essential":1,"for":1,"all":1,"individ":1},"len":194},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":23,"chunkId":"ada-2026-pharm-p23-c2","text":"es should be counseled on contraception options A and the im - pact of some glucose-lowering medica - tions on contraception efficacy. C 9.32b A person-centered shared deci - sion-making approach to preconception planning is essential for all individuals of childbearing potential with diabetes. A Preconception planning should ad - dress attainment of glycemic goals, A the time frame for discontinuing nonin - sulin glucose-lowering medications, E and optimal glycemic management in preparation for pregnancy. A 9.33 Individuals who develop hyper - glycemia during treatment with im - munotherapy (including anti-PD-1 or anti-PD-L1 therapy, e.g., nivolumab, pembrolizumab, or avelumab) should be assessed for the immediate need for initiation of insulin therapy due to the potential risk of diabetic ketoacido - sis while additional testing is completed to determine if the hyperglycemia is related to immunotherapy-associated diabetes. Close monitoring, education, and dose adjustment are needed if in - sulin is started. C 9.34 Consider metformin as the first- line treatment of hyperglycemia due to mTOR inhibitors. E 9.35a Consider metformin as the first- line treatment of hyperglycemia due to phosphoinositide 3-kinase (PI3K) in - hibitors that affect the  isoform (e.g., alpelisib and inavolisib). E 9.35b Use of insulin should be re - served for severe hyperglycemia and hyperglycemic cris","tf":{"33":1,"34":1,"es":1,"should":4,"be":3,"counseled":1,"on":2,"contraception":2,"options":1,"and":5,"the":8,"im":2,"pact":1,"of":8,"some":1,"glucose":2,"lowering":2,"medica":1,"tions":1,"efficacy":1,"32b":1,"person":1,"centered":1,"shared":1,"deci":1,"sion":1,"making":1,"approach":1,"to":6,"preconception":2,"planning":2,"is":4,"essential":1,"for":6,"all":1,"individuals":2,"childbearing":1,"potential":2,"with":2,"diabetes":2,"ad":1,"dress":1,"attainment":1,"glycemic":2,"goals":1,"time":1,"frame":1,"discontinuing":1,"nonin":1,"sulin":2,"medications":1,"optimal":1,"management":1,"in":3,"preparation":1,"pregnancy":1,"who":1,"develop":1,"hyper":1,"glycemia":1,"during":1,"treatment":3,"munotherapy":1,"including":1,"anti":2,"pd":2,"or":2,"l1":1,"therapy":2,"nivolumab":1,"pembrolizumab":1,"avelumab":1,"assessed":1,"immediate":1,"need":1,"initiation":1,"insulin":2,"due":3,"risk":1,"diabetic":1,"ketoacido":1,"sis":1,"while":1,"additional":1,"testing":1,"completed":1,"determine":1,"if":2,"hyperglycemia":4,"related":1,"immunotherapy":1,"associated":1,"close":1,"monitoring":1,"education":1,"dose":1,"adjustment":1,"are":1,"needed":1,"started":1,"consider":2,"metformin":2,"as":2,"first":2,"line":2,"mtor":1,"inhibitors":1,"35a":1,"phosphoinositide":1,"kinase":1,"pi3k":1,"hibitors":1,"that":1,"affect":1,"isoform":1,"alpelisib":1,"inavolisib":1,"35b":1,"use":1,"re":1,"served":1,"severe":1,"hyperglycemic":1,"cris":1},"len":193},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":23,"chunkId":"ada-2026-pharm-p23-c3","text":" the first- line treatment of hyperglycemia due to phosphoinositide 3-kinase (PI3K) in - hibitors that affect the  isoform (e.g., alpelisib and inavolisib). E 9.35b Use of insulin should be re - served for severe hyperglycemia and hyperglycemic crises due to its poten - tial impact on the efficacy of PI3K in - hibitors. E 9.36 Adjust or initiate additional glucose- lowering therapies to maintain indi - vidualized glycemic goals based on the specific glucocorticoid treatment plan, with frequent reassessment of glucose levels and glucocorticoid treat - ment plans. C 9.37 In adults with posttransplantation diabetes mellitus (PTDM) or preexisting type 2 diabetes, insulin is preferred for the management of hyperglycemia in the postoperative setting. A A DPP-4 inhibitor can be considered for mild hyperglycemia. A 9.38a In adults with PTDM or preexist - ing type 2 diabetes, noninsulin pharma - cotherapy can be used for long-term glycemic management, C and medi - cation selection may differ depending on the transplanted organ(s). E 9.38b In adults with PTDM or preex - isting type 2 diabetes, a GLP-1 RA can be considered for long-term gly - cemic management due to additional cardiometabolic benefits (e.g., car - diovascular, kidney, weight, and liver benefits). C 9.38c If long-term individualized gly - cemic goals cannot be achieved or maintained with noninsulin pharma - cotherapy in a","tf":{"36":1,"37":1,"the":7,"first":1,"line":1,"treatment":2,"of":5,"hyperglycemia":4,"due":3,"to":4,"phosphoinositide":1,"kinase":1,"pi3k":2,"in":7,"hibitors":2,"that":1,"affect":1,"isoform":1,"alpelisib":1,"and":5,"inavolisib":1,"35b":1,"use":1,"insulin":2,"should":1,"be":5,"re":1,"served":1,"for":5,"severe":1,"hyperglycemic":1,"crises":1,"its":1,"poten":1,"tial":1,"impact":1,"on":3,"efficacy":1,"adjust":1,"or":5,"initiate":1,"additional":2,"glucose":2,"lowering":1,"therapies":1,"maintain":1,"indi":1,"vidualized":1,"glycemic":2,"goals":2,"based":1,"specific":1,"glucocorticoid":2,"plan":1,"with":5,"frequent":1,"reassessment":1,"levels":1,"treat":1,"ment":1,"plans":1,"adults":3,"posttransplantation":1,"diabetes":4,"mellitus":1,"ptdm":3,"preexisting":1,"type":3,"is":1,"preferred":1,"management":3,"postoperative":1,"setting":1,"dpp":1,"inhibitor":1,"can":3,"considered":2,"mild":1,"38a":1,"preexist":1,"ing":1,"noninsulin":2,"pharma":2,"cotherapy":2,"used":1,"long":3,"term":3,"medi":1,"cation":1,"selection":1,"may":1,"differ":1,"depending":1,"transplanted":1,"organ":1,"38b":1,"preex":1,"isting":1,"glp":1,"ra":1,"gly":2,"cemic":2,"cardiometabolic":1,"benefits":2,"car":1,"diovascular":1,"kidney":1,"weight":1,"liver":1,"38c":1,"if":1,"individualized":1,"cannot":1,"achieved":1,"maintained":1},"len":194},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":23,"chunkId":"ada-2026-pharm-p23-c4","text":" cemic management due to additional cardiometabolic benefits (e.g., car - diovascular, kidney, weight, and liver benefits). C 9.38c If long-term individualized gly - cemic goals cannot be achieved or maintained with noninsulin pharma - cotherapy in adults with PTDM or preexisting type 2 diabetes, con - sider adding insulin. C 9.39 Educate individuals with diabe - tes who are at risk for developing dia - betic ketoacidosis and who are treated with SGLT inhibition on the risks and signs of ketoacidosis and methods of risk mitigation management, provide them with appropriate tools for ketone measurement (i.e., serum  -hydroxybutyrate), and discourage a ketogenic eating pattern. E Care Considerations for Individuals of Childbearing Potential The impact of glycemia during pregnancy is well understood; however, evidence for the safe use of noninsulin glucose-lowering medications is limited (see section 15,  Management of Diabetes in Pregnancy ). Studies on the efficacy and safety of glucose-lowering medications exclude indi - viduals who are pregnant and require indi - viduals of childbearing potential to use one or two forms of contraception. It is recom - mended that individuals of childbearing potential use a form of contraception when also taking glucose-lowering medi - cations with unknown risks, limited evi - dence on safety, or known risks during pregnancy, regardless of th","tf":{"15":1,"39":1,"cemic":2,"management":3,"due":1,"to":2,"additional":1,"cardiometabolic":1,"benefits":2,"car":1,"diovascular":1,"kidney":1,"weight":1,"and":7,"liver":1,"38c":1,"if":1,"long":1,"term":1,"individualized":1,"gly":1,"goals":1,"cannot":1,"be":1,"achieved":1,"or":4,"maintained":1,"with":6,"noninsulin":2,"pharma":1,"cotherapy":1,"in":2,"adults":1,"ptdm":1,"preexisting":1,"type":1,"diabetes":2,"con":1,"sider":1,"adding":1,"insulin":1,"educate":1,"individuals":3,"diabe":1,"tes":1,"who":3,"are":3,"at":1,"risk":2,"for":4,"developing":1,"dia":1,"betic":1,"ketoacidosis":2,"treated":1,"sglt":1,"inhibition":1,"on":3,"the":4,"risks":3,"signs":1,"of":12,"methods":1,"mitigation":1,"provide":1,"them":1,"appropriate":1,"tools":1,"ketone":1,"measurement":1,"serum":1,"hydroxybutyrate":1,"discourage":1,"ketogenic":1,"eating":1,"pattern":1,"care":1,"considerations":1,"childbearing":3,"potential":3,"impact":1,"glycemia":1,"during":2,"pregnancy":3,"is":3,"well":1,"understood":1,"however":1,"evidence":1,"safe":1,"use":3,"glucose":3,"lowering":3,"medications":2,"limited":2,"see":1,"section":1,"studies":1,"efficacy":1,"safety":2,"exclude":1,"indi":2,"viduals":2,"pregnant":1,"require":1,"one":1,"two":1,"forms":1,"contraception":2,"it":1,"recom":1,"mended":1,"that":1,"form":1,"when":1,"also":1,"taking":1,"medi":1,"cations":1,"unknown":1,"evi":1,"dence":1,"known":1,"regardless":1,"th":1},"len":197},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":23,"chunkId":"ada-2026-pharm-p23-c5","text":"ception. It is recom - mended that individuals of childbearing potential use a form of contraception when also taking glucose-lowering medi - cations with unknown risks, limited evi - dence on safety, or known risks during pregnancy, regardless of the individuals intention to become pregnant, as many pregnancies are unplanned. The options for contraception should be discussed with all individuals of childbearing poten - tial with diabetes and should include in - formation regarding the potential impact of glucose-lowering medications on the effectiveness of contraception. Medica - tions that affect gastrointestinal emptying time (e.g., GLP-1 RAs or dual GIP and GLP-1 RA) may affect the absorption of orally ad - ministered medications, including oral con - traception. The impact on gastric emptying with GLP-1 RAs and the dual GIP and GLP-1 RA is highest at initiation and with dosage increases and then diminishes with contin - ued administration ( 239 ). Tirzepatide, the diabetesjournals.org/care Pharmacologic Approaches to Glycemic Treatment S205 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"49":1,"239":1,"2026":1,"848878":1,"ception":1,"it":1,"is":2,"recom":1,"mended":1,"that":2,"individuals":2,"of":7,"childbearing":2,"potential":2,"use":1,"form":1,"contraception":3,"when":1,"also":1,"taking":1,"glucose":2,"lowering":2,"medi":1,"cations":1,"with":6,"unknown":1,"risks":2,"limited":1,"evi":1,"dence":1,"on":4,"safety":1,"or":2,"known":1,"during":1,"pregnancy":1,"regardless":1,"the":8,"individual":1,"intention":1,"to":2,"become":1,"pregnant":1,"as":1,"many":1,"pregnancies":1,"are":1,"unplanned":1,"options":1,"for":1,"should":2,"be":1,"discussed":1,"all":1,"poten":1,"tial":1,"diabetes":1,"and":6,"include":1,"in":1,"formation":1,"regarding":1,"impact":2,"medications":2,"effectiveness":1,"medica":1,"tions":1,"affect":2,"gastrointestinal":1,"emptying":2,"time":1,"glp":4,"ras":2,"dual":2,"gip":2,"ra":2,"may":1,"absorption":1,"orally":1,"ad":1,"ministered":1,"including":1,"oral":1,"con":1,"traception":1,"gastric":1,"highest":1,"at":1,"initiation":1,"dosage":1,"increases":1,"then":1,"diminishes":1,"contin":1,"ued":1,"administration":1,"tirzepatide":1,"diabetesjournals":2,"org":2,"care":2,"pharmacologic":1,"approaches":1,"glycemic":1,"treatment":1,"s205":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"supplement":1,"s183":1,"dc26s009":1,"by":1,"guest":1,"february":1},"len":171},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":24,"chunkId":"ada-2026-pharm-p24-c0","text":"dual GIP and GLP-1 RA, was shown to af - fect the levels of oral contraception during the time of its highest impact on gastric emptying; the GLP-1 RAs may affect the levels of oral contraception as well but to a lesser extent than tirzepatide ( 240 , 241 ). Thus, individuals starting or increasing doses of tirzepatide who also take oral contra - ception should use a second form of con - traception until the maintenance dose of tirzepatide is achieved and used for at least 4 weeks ( 242 ). Preconception counseling should be part of the routine care of individuals with diabetes who have childbearing potential. Counseling should include the known benefits and risks of glucose- lowering medications as well as other medications (e.g., lipid-lowering and anti - hypertensive therapies) during pregnancy and recommendations for when changes in medications should occur prior to pregnancy. Individuals planning pregnancy should be counseled that a period of sev - eral months is usually needed and adjust - ment of therapy approved for use in pregnancy to achieve preconception gly - cemic goals prior to pregnancy (see sec - tion 15,  Management of Diabetes in Pregnancy , for more information on preconception counseling and glucose- lowering treatment during pregnancy). Therapeutic Strategies for Individuals Receiving Cancer Treatment Hyperglycemia due to chemotherapy may either be transie","tf":{"15":1,"240":1,"241":1,"242":1,"dual":1,"gip":1,"and":7,"glp":2,"ra":1,"was":1,"shown":1,"to":6,"af":1,"fect":1,"the":7,"levels":2,"of":12,"oral":3,"contraception":2,"during":3,"time":1,"its":1,"highest":1,"impact":1,"on":2,"gastric":1,"emptying":1,"ras":1,"may":2,"affect":1,"as":3,"well":2,"but":1,"lesser":1,"extent":1,"than":1,"tirzepatide":3,"thus":1,"individuals":4,"starting":1,"or":1,"increasing":1,"doses":1,"who":2,"also":1,"take":1,"contra":1,"ception":1,"should":5,"use":2,"second":1,"form":1,"con":1,"traception":1,"until":1,"maintenance":1,"dose":1,"is":2,"achieved":1,"used":1,"for":5,"at":1,"least":1,"weeks":1,"preconception":3,"counseling":3,"be":3,"part":1,"routine":1,"care":1,"with":1,"diabetes":2,"have":1,"childbearing":1,"potential":1,"include":1,"known":1,"benefits":1,"risks":1,"glucose":2,"lowering":3,"medications":3,"other":1,"lipid":1,"anti":1,"hypertensive":1,"therapies":1,"pregnancy":7,"recommendations":1,"when":1,"changes":1,"in":3,"occur":1,"prior":2,"planning":1,"counseled":1,"that":1,"period":1,"sev":1,"eral":1,"months":1,"usually":1,"needed":1,"adjust":1,"ment":1,"therapy":1,"approved":1,"achieve":1,"gly":1,"cemic":1,"goals":1,"see":1,"sec":1,"tion":1,"management":1,"more":1,"information":1,"treatment":2,"therapeutic":1,"strategies":1,"receiving":1,"cancer":1,"hyperglycemia":1,"due":1,"chemotherapy":1,"either":1,"transie":1},"len":205},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":24,"chunkId":"ada-2026-pharm-p24-c1","text":" of Diabetes in Pregnancy , for more information on preconception counseling and glucose- lowering treatment during pregnancy). Therapeutic Strategies for Individuals Receiving Cancer Treatment Hyperglycemia due to chemotherapy may either be transient (improving upon treat - ment cessation) or represent permanent diabetes. Immune checkpoint inhibitors (ICIs) impair regulatory components of the immune system, allowing for immuno - genic response against cancer cells, which can result in autoimmune toxicities, includ - ing an autoimmune form of diabetes that results in  -cell destruction (incidence ap - proximately  1%) ( 243  246 ). This form of diabetes is most common after exposure to ICIs that target programmed cell death protein 1 (PD-1) (i.e., nivolumab and pem - brolizumab) and those that target pro - grammed cell death protein ligand 1 (PD-L1) (i.e., durvalumab and avelumab). ICIs that target cytotoxic T-lymphocyte  associated protein 4 (CTLA-4) (i.e., ipilimumab) have also been implicated in this process, but much less commonly ( 247 ). Hyperglycemia as a result of ICIs can occur at any time after the initiation of therapyas quickly as 1 week after the first dose to up to 12 months after. Insulin therapy is the cornerstone of manage - ment, as individuals typically present with rapid-onset, severe hyperglycemia or DKA ( 248 ). Early initiation of therapy can pre - ","tf":{"12":1,"243":1,"246":1,"247":1,"248":1,"of":8,"diabetes":4,"in":4,"pregnancy":2,"for":3,"more":1,"information":1,"on":1,"preconception":1,"counseling":1,"and":4,"glucose":1,"lowering":1,"treatment":2,"during":1,"therapeutic":1,"strategies":1,"individuals":2,"receiving":1,"cancer":2,"hyperglycemia":3,"due":1,"to":4,"chemotherapy":1,"may":1,"either":1,"be":1,"transient":1,"improving":1,"upon":1,"treat":1,"ment":2,"cessation":1,"or":2,"represent":1,"permanent":1,"immune":2,"checkpoint":1,"inhibitors":1,"icis":4,"impair":1,"regulatory":1,"components":1,"the":4,"system":1,"allowing":1,"immuno":1,"genic":1,"response":1,"against":1,"cells":1,"which":1,"can":3,"result":2,"autoimmune":2,"toxicities":1,"includ":1,"ing":1,"an":1,"form":2,"that":4,"results":1,"cell":3,"destruction":1,"incidence":1,"ap":1,"proximately":1,"this":2,"is":2,"most":1,"common":1,"after":4,"exposure":1,"target":3,"programmed":1,"death":2,"protein":3,"pd":2,"nivolumab":1,"pem":1,"brolizumab":1,"those":1,"pro":1,"grammed":1,"ligand":1,"l1":1,"durvalumab":1,"avelumab":1,"cytotoxic":1,"lymphocyte":1,"associated":1,"ctla":1,"ipilimumab":1,"have":1,"also":1,"been":1,"implicated":1,"process":1,"but":1,"much":1,"less":1,"commonly":1,"as":4,"occur":1,"at":1,"any":1,"time":1,"initiation":2,"therapy":3,"quickly":1,"week":1,"first":1,"dose":1,"up":1,"months":1,"insulin":1,"cornerstone":1,"manage":1,"typically":1,"present":1,"with":1,"rapid":1,"onset":1,"severe":1,"dka":1,"early":1,"pre":1},"len":195},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":24,"chunkId":"ada-2026-pharm-p24-c2","text":"pyas quickly as 1 week after the first dose to up to 12 months after. Insulin therapy is the cornerstone of manage - ment, as individuals typically present with rapid-onset, severe hyperglycemia or DKA ( 248 ). Early initiation of therapy can pre - vent these drastic presentations, and the initiation of basal insulin should be con - sidered in individuals with blood glucose > 250 mg/dL while further evaluation takes place. Prandial insulin is often required as well, if insulinopenia is confirmed. ICI treat - ment should not be discontinued in the event of severe hyperglycemia, as the  -cell destruction associated with this process is irreversible. Lifelong insulin therapy is generally required ( 249 ). Phosphatidylinositol 3-kinase (PI3K) inhibitors are small molecules that inhibit intracellular signaling, interfering with cancer cell proliferation and survival. Four isoforms have been identified as thera - peutic targets, with both pan-PI3K in - hibitors and isoform-specific inhibitors in clinical use. The  isoform of this en - zyme (PI3K  ) is also involved in insulin signaling, and the inhibition of this path - way by either pan-PI3K inhibitors (i.e., co - panlisib and duvelisib) or specific PI3K  inhibitors (i.e., alpelisib and inavolisib) can lead to hyperglycemia ( 250 ). Hyper - glycemia typically occurs within the first 2 weeks of therapy, with an incidence of appr","tf":{"12":1,"248":1,"249":1,"250":2,"py":1,"as":6,"quickly":1,"week":1,"after":2,"the":8,"first":2,"dose":1,"to":3,"up":1,"months":1,"insulin":5,"therapy":4,"is":6,"cornerstone":1,"of":8,"manage":1,"ment":2,"individuals":2,"typically":2,"present":1,"with":6,"rapid":1,"onset":1,"severe":2,"hyperglycemia":3,"or":2,"dka":1,"early":1,"initiation":2,"can":2,"pre":1,"vent":1,"these":1,"drastic":1,"presentations":1,"and":6,"basal":1,"should":2,"be":2,"con":1,"sidered":1,"in":5,"blood":1,"glucose":1,"mg":1,"dl":1,"while":1,"further":1,"evaluation":1,"takes":1,"place":1,"prandial":1,"often":1,"required":2,"well":1,"if":1,"insulinopenia":1,"confirmed":1,"ici":1,"treat":1,"not":1,"discontinued":1,"event":1,"cell":2,"destruction":1,"associated":1,"this":3,"process":1,"irreversible":1,"lifelong":1,"generally":1,"phosphatidylinositol":1,"kinase":1,"pi3k":5,"inhibitors":4,"are":1,"small":1,"molecules":1,"that":1,"inhibit":1,"intracellular":1,"signaling":2,"interfering":1,"cancer":1,"proliferation":1,"survival":1,"four":1,"isoforms":1,"have":1,"been":1,"identified":1,"thera":1,"peutic":1,"targets":1,"both":1,"pan":2,"hibitors":1,"isoform":2,"specific":2,"clinical":1,"use":1,"en":1,"zyme":1,"also":1,"involved":1,"inhibition":1,"path":1,"way":1,"by":1,"either":1,"co":1,"panlisib":1,"duvelisib":1,"alpelisib":1,"inavolisib":1,"lead":1,"hyper":1,"glycemia":1,"occurs":1,"within":1,"weeks":1,"an":1,"incidence":1,"appr":1},"len":205},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":24,"chunkId":"ada-2026-pharm-p24-c3","text":"pan-PI3K inhibitors (i.e., co - panlisib and duvelisib) or specific PI3K  inhibitors (i.e., alpelisib and inavolisib) can lead to hyperglycemia ( 250 ). Hyper - glycemia typically occurs within the first 2 weeks of therapy, with an incidence of approximately 60% ( 251  254 ). Risk fac - tors include preexisting dysglycemia, BMI > 25 kg/m 2 , and age > 65 years. Adequate management is crucial, as uncontrolled hyperglycemia can lead to discontinua - tion and/or reduction in medication dose, which can negatively affect the efficacy of the therapy ( 254  256 ). Metformin is the first-line oral agent to treat PI3K inhibitor  induced hyperglyce - mia, with uptitration of the dose as toler - ated ( 256 ). Pioglitazone is also an option as monotherapy or in combination with metformin, but its slow onset of action can limit its effectiveness ( 257 ). SGLT2 in - hibitors have also shown efficacy, but close monitoring is needed, as ketoacido - sis has been reported ( 258 ). Insulin and sulfonylureas should be considered only as a last resort, as increased insulin levels may reactivate the PI3K pathway, coun - teracting the antitumor effects of PI3K inhibition ( 256 , 259 ). There is no direct ev - idence for the use of GLP-1 RAs for PI3K inhibitor  induced hyperglycemia. They should not be considered for treatment in this circumstance at this time due to their uncertain effect on PI3","tf":{"25":1,"60":1,"65":1,"250":1,"251":1,"254":2,"256":3,"257":1,"258":1,"259":1,"pan":1,"pi3k":6,"inhibitors":2,"co":1,"panlisib":1,"and":5,"duvelisib":1,"or":3,"specific":1,"alpelisib":1,"inavolisib":1,"can":4,"lead":2,"to":4,"hyperglycemia":3,"hyper":1,"glycemia":1,"typically":1,"occurs":1,"within":1,"the":8,"first":2,"weeks":1,"of":7,"therapy":2,"with":3,"an":2,"incidence":1,"approximately":1,"risk":1,"fac":1,"tors":1,"include":1,"preexisting":1,"dysglycemia":1,"bmi":1,"kg":1,"age":1,"years":1,"adequate":1,"management":1,"is":5,"crucial":1,"as":6,"uncontrolled":1,"discontinua":1,"tion":1,"reduction":1,"in":4,"medication":1,"dose":2,"which":1,"negatively":1,"affect":1,"efficacy":2,"metformin":2,"line":1,"oral":1,"agent":1,"treat":1,"inhibitor":2,"induced":2,"hyperglyce":1,"mia":1,"uptitration":1,"toler":1,"ated":1,"pioglitazone":1,"also":2,"option":1,"monotherapy":1,"combination":1,"but":2,"its":2,"slow":1,"onset":1,"action":1,"limit":1,"effectiveness":1,"sglt2":1,"hibitors":1,"have":1,"shown":1,"close":1,"monitoring":1,"needed":1,"ketoacido":1,"sis":1,"has":1,"been":1,"reported":1,"insulin":2,"sulfonylureas":1,"should":2,"be":2,"considered":2,"only":1,"last":1,"resort":1,"increased":1,"levels":1,"may":1,"reactivate":1,"pathway":1,"coun":1,"teracting":1,"antitumor":1,"effects":1,"inhibition":1,"there":1,"no":1,"direct":1,"ev":1,"idence":1,"for":3,"use":1,"glp":1,"ras":1,"they":1,"not":1,"treatment":1,"this":2,"circumstance":1,"at":1,"time":1,"due":1,"their":1,"uncertain":1,"effect":1,"on":1,"pi3":1},"len":210},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":24,"chunkId":"ada-2026-pharm-p24-c4","text":"s of PI3K inhibition ( 256 , 259 ). There is no direct ev - idence for the use of GLP-1 RAs for PI3K inhibitor  induced hyperglycemia. They should not be considered for treatment in this circumstance at this time due to their uncertain effect on PI3K inhibitor efficacy (based on their increase in insulin secretion) and the potential to cause nau - sea and vomiting. mTOR kinase inhibitors, including everi - lomus, cause hyperglycemia by interfering with insulin signaling, leading to impaired insulin secretion and increased insulin re - sistance. Metformin is the first-line treat - ment of hyperglycemia secondary to mTOR inhibitor treatment because of its efficacy and safety profile. Due to its ability to reduce insulin resistance, pioglitazone may be considered as a second-line treatment, depending on the risks of its adverse effects to the individ - ual. There is no direct evidence regarding the efficacy of GLP-1 RAs or SGLT2 inhibi - tors for mTOR inhibitor  induced hypergly - cemia; however, there is also no evidence that they impair the efficacy of the mTOR inhibitor. Thus, evaluation of their use as second- or third-line treatments for this circumstance should be made based on their overall benefits and risks. Insulin is typically reserved for cases of refractory hyperglycemia after noninsulin treat - ments are used, in the presence of intol - erance or contraindications ","tf":{"256":1,"259":1,"of":10,"pi3k":3,"inhibition":1,"there":3,"is":5,"no":3,"direct":2,"ev":1,"idence":1,"for":6,"the":9,"use":2,"glp":2,"ras":2,"inhibitor":5,"induced":2,"hyperglycemia":4,"they":2,"should":2,"not":1,"be":3,"considered":2,"treatment":3,"in":3,"this":3,"circumstance":2,"at":1,"time":1,"due":2,"to":7,"their":4,"uncertain":1,"effect":1,"on":4,"efficacy":4,"based":2,"increase":1,"insulin":6,"secretion":2,"and":5,"potential":1,"cause":2,"nau":1,"sea":1,"vomiting":1,"mtor":4,"kinase":1,"inhibitors":1,"including":1,"everi":1,"lomus":1,"by":1,"interfering":1,"with":1,"signaling":1,"leading":1,"impaired":1,"increased":1,"re":1,"sistance":1,"metformin":1,"first":1,"line":3,"treat":2,"ment":1,"secondary":1,"because":1,"its":3,"safety":1,"profile":1,"ability":1,"reduce":1,"resistance":1,"pioglitazone":1,"may":1,"as":2,"second":2,"depending":1,"risks":2,"adverse":1,"effects":1,"individ":1,"ual":1,"evidence":2,"regarding":1,"or":3,"sglt2":1,"inhibi":1,"tors":1,"hypergly":1,"cemia":1,"however":1,"also":1,"that":1,"impair":1,"thus":1,"evaluation":1,"third":1,"treatments":1,"made":1,"overall":1,"benefits":1,"typically":1,"reserved":1,"cases":1,"refractory":1,"after":1,"noninsulin":1,"ments":1,"are":1,"used":1,"presence":1,"intol":1,"erance":1,"contraindications":1},"len":215},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":24,"chunkId":"ada-2026-pharm-p24-c5","text":"ments for this circumstance should be made based on their overall benefits and risks. Insulin is typically reserved for cases of refractory hyperglycemia after noninsulin treat - ments are used, in the presence of intol - erance or contraindications to noninsulin treatments, or for severe hyperglycemia ( 260  262 ). Glucocorticoids (including prednisone and dexamethasone), which are often used as part of acute, adjunctive, and chronic treatment of cancer and inflam - matory conditions (e.g., rheumatoid ar - thritis and inflammatory bowel disease) as well as posttransplantation, cause hy - perglycemia primarily by increased insulin resistance and hepatic glucose produc - tion. Other contributing effects include in - creased appetite, decreased production/ secretion of insulin, and enhanced effects of counterregulatory hormones (such as epinephrine) ( 263  266 ). The timing and extent of hyperglycemia vary based on the dose, duration, route of administra - tion (i.e., intravenous, oral, or intraarticu - lar) and the specific glucocorticoid used ( 265  271 ). For example, with morning administration of prednisone (with the first meal of the day), glucose starts rising after the first meal, with peak effects in the afternoon and evening, and declines to baseline by the next morning; in con - trast, with a single dose of dexametha - sone, glucose elevations may last more than 24 ","tf":{"24":1,"260":1,"262":1,"263":1,"265":1,"266":1,"271":1,"ments":2,"for":4,"this":1,"circumstance":1,"should":1,"be":1,"made":1,"based":2,"on":2,"their":1,"overall":1,"benefits":1,"and":11,"risks":1,"insulin":3,"is":1,"typically":1,"reserved":1,"cases":1,"of":11,"refractory":1,"hyperglycemia":3,"after":2,"noninsulin":2,"treat":1,"are":2,"used":3,"in":4,"the":9,"presence":1,"intol":1,"erance":1,"or":3,"contraindications":1,"to":2,"treatments":1,"severe":1,"glucocorticoids":1,"including":1,"prednisone":2,"dexamethasone":1,"which":1,"often":1,"as":4,"part":1,"acute":1,"adjunctive":1,"chronic":1,"treatment":1,"cancer":1,"inflam":1,"matory":1,"conditions":1,"rheumatoid":1,"ar":1,"thritis":1,"inflammatory":1,"bowel":1,"disease":1,"well":1,"posttransplantation":1,"cause":1,"hy":1,"perglycemia":1,"primarily":1,"by":2,"increased":1,"resistance":1,"hepatic":1,"glucose":3,"produc":1,"tion":2,"other":1,"contributing":1,"effects":3,"include":1,"creased":1,"appetite":1,"decreased":1,"production":1,"secretion":1,"enhanced":1,"counterregulatory":1,"hormones":1,"such":1,"epinephrine":1,"timing":1,"extent":1,"vary":1,"dose":2,"duration":1,"route":1,"administra":1,"intravenous":1,"oral":1,"intraarticu":1,"lar":1,"specific":1,"glucocorticoid":1,"example":1,"with":4,"morning":2,"administration":1,"first":2,"meal":2,"day":1,"starts":1,"rising":1,"peak":1,"afternoon":1,"evening":1,"declines":1,"baseline":1,"next":1,"con":1,"trast":1,"single":1,"dexametha":1,"sone":1,"elevations":1,"may":1,"last":1,"more":1,"than":1},"len":197},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":24,"chunkId":"ada-2026-pharm-p24-c6","text":"l of the day), glucose starts rising after the first meal, with peak effects in the afternoon and evening, and declines to baseline by the next morning; in con - trast, with a single dose of dexametha - sone, glucose elevations may last more than 24 h with some decline overnight. The extent of the elevation is dependent on the dose, so as the glucocorticoid is ta - pered, the extent of hyperglycemia will S206 Pharmacologic Approaches to Glycemic Treatment Diabetes Care Volume 49, Supplement 1, January 2026 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"24":1,"49":2,"2026":2,"848878":1,"of":4,"the":9,"day":1,"glucose":2,"starts":1,"rising":1,"after":1,"first":1,"meal":1,"with":3,"peak":1,"effects":1,"in":2,"afternoon":1,"and":2,"evening":1,"declines":1,"to":2,"baseline":1,"by":2,"next":1,"morning":1,"con":1,"trast":1,"single":1,"dose":2,"dexametha":1,"sone":1,"elevations":1,"may":1,"last":1,"more":1,"than":1,"some":1,"decline":1,"overnight":1,"extent":2,"elevation":1,"is":2,"dependent":1,"on":2,"so":1,"as":1,"glucocorticoid":1,"ta":1,"pered":1,"hyperglycemia":1,"will":1,"s206":1,"pharmacologic":1,"approaches":1,"glycemic":1,"treatment":1,"diabetes":1,"care":2,"volume":1,"supplement":2,"january":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"s183":1,"dc26s009":1,"guest":1,"february":1},"len":101},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":25,"chunkId":"ada-2026-pharm-p25-c0","text":"decline. Monitoring glucose levels solely in the morning may miss the extent of the hyperglycemia experienced due to glucocorticoid use and prevent appropriate management ( 263 , 265  267 , 272 ). Thus, glucose-lowering medication adjustments or additions should match the timing and extent of hyperglycemia and allow for rapid adjustment as the dose of the glu - cocorticoid dose changes to minimize the likelihood of hyperglycemia and hypogly - cemia. Insulin is the most frequently used glucose-lowering medication to manage hyperglycemia secondary to glucocorti - coid use. The selection of insulin type and dose depends on the dose and dura - tion of the glucocorticoid ( 265 , 266 , 269 , 272  275 ). Additions or dose adjustments of sulfonylureas, including meglitinides, have also been used for those with type 2 diabetes or no previous diagno - sis of diabetes. Due to lack of direct evi - dence and the time needed to achieve the glucose-lowering effect, additions or dose adjustments of other glucose- lowering medications are reserved for when stable doses of glucocorticoids are chronically administered and are not for acute management ( 265 , 266 , 269 , 272 , 275 , 276 ). Pancreatic Diabetes and Cystic Fibrosis  Related Diabetes Individuals with pancreatic diabetes may require early insulin initiation to achieve and maintain glycemic goals. In individu - als with a history of ","tf":{"263":1,"265":3,"266":2,"267":1,"269":2,"272":3,"275":2,"276":1,"decline":1,"monitoring":1,"glucose":5,"levels":1,"solely":1,"in":2,"the":13,"morning":1,"may":2,"miss":1,"extent":2,"of":12,"hyperglycemia":4,"experienced":1,"due":2,"to":7,"glucocorticoid":2,"use":2,"and":10,"prevent":1,"appropriate":1,"management":2,"thus":1,"lowering":4,"medication":2,"adjustments":3,"or":4,"additions":3,"should":1,"match":1,"timing":1,"allow":1,"for":4,"rapid":1,"adjustment":1,"as":1,"dose":6,"glu":1,"cocorticoid":1,"changes":1,"minimize":1,"likelihood":1,"hypogly":1,"cemia":1,"insulin":3,"is":1,"most":1,"frequently":1,"used":2,"manage":1,"secondary":1,"glucocorti":1,"coid":1,"selection":1,"type":2,"depends":1,"on":1,"dura":1,"tion":1,"sulfonylureas":1,"including":1,"meglitinides":1,"have":1,"also":1,"been":1,"those":1,"with":3,"diabetes":5,"no":1,"previous":1,"diagno":1,"sis":1,"lack":1,"direct":1,"evi":1,"dence":1,"time":1,"needed":1,"achieve":2,"effect":1,"other":1,"medications":1,"are":3,"reserved":1,"when":1,"stable":1,"doses":1,"glucocorticoids":1,"chronically":1,"administered":1,"not":1,"acute":1,"pancreatic":2,"cystic":1,"fibrosis":1,"related":1,"individuals":1,"require":1,"early":1,"initiation":1,"maintain":1,"glycemic":1,"goals":1,"individu":1,"als":1,"history":1},"len":206},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":25,"chunkId":"ada-2026-pharm-p25-c1","text":"t ( 265 , 266 , 269 , 272 , 275 , 276 ). Pancreatic Diabetes and Cystic Fibrosis  Related Diabetes Individuals with pancreatic diabetes may require early insulin initiation to achieve and maintain glycemic goals. In individu - als with a history of pancreatitis, use of incretin medications (i.e., GLP-1 RAs, a dual GIP and GLP-1 RA, and DPP-4 inhibi - tors) should be avoided (see section 2,  Diagnosis and Classification of Diabetes ). Individuals with cystic fibrosis  related dia - betes should be treated with insulin ther - apy; insulin pump therapy, including AID systems, should be considered when ap - propriate ( 277 ). Posttransplantation Diabetes Mellitus The diagnosis of posttransplantation dia - betes mellitus (PTDM) relies on the same glycemic characteristics as other forms of diabetes. However, due to the unique ef - fects of immunosuppressant drugs, an oral glucose tolerance test (OGTT) is the preferred and most accurate method for diagnosis (compared with A1C or fasting plasma glucose) ( 278 ). In 2024, an up - date from the 3rd International PTDM Consensus Meeting recommended screen - ing for diabetes risk factors with a pretransplant OGTT while the individual is on the waitlist, followed by early OGTT at 3 months posttransplantation to diag - nose PTDM and a late OGTT at 1 year and onward as appropriate ( 279 ). As with all strategies in metabolic man - agement,","tf":{"265":1,"266":1,"269":1,"272":1,"275":1,"276":1,"277":1,"278":1,"279":1,"2024":1,"pancreatic":2,"diabetes":7,"and":8,"cystic":2,"fibrosis":2,"related":2,"individuals":2,"with":7,"may":1,"require":1,"early":2,"insulin":3,"initiation":1,"to":3,"achieve":1,"maintain":1,"glycemic":2,"goals":1,"in":3,"individu":1,"als":1,"history":1,"of":6,"pancreatitis":1,"use":1,"incretin":1,"medications":1,"glp":2,"ras":1,"dual":1,"gip":1,"ra":1,"dpp":1,"inhibi":1,"tors":1,"should":3,"be":3,"avoided":1,"see":1,"section":1,"diagnosis":3,"classification":1,"dia":2,"betes":2,"treated":1,"ther":1,"apy":1,"pump":1,"therapy":1,"including":1,"aid":1,"systems":1,"considered":1,"when":1,"ap":1,"propriate":1,"posttransplantation":3,"mellitus":2,"the":7,"ptdm":3,"relies":1,"on":2,"same":1,"characteristics":1,"as":3,"other":1,"forms":1,"however":1,"due":1,"unique":1,"ef":1,"fects":1,"immunosuppressant":1,"drugs":1,"an":2,"oral":1,"glucose":2,"tolerance":1,"test":1,"ogtt":4,"is":2,"preferred":1,"most":1,"accurate":1,"method":1,"for":2,"compared":1,"a1c":1,"or":1,"fasting":1,"plasma":1,"up":1,"date":1,"from":1,"3rd":1,"international":1,"consensus":1,"meeting":1,"recommended":1,"screen":1,"ing":1,"risk":1,"factors":1,"pretransplant":1,"while":1,"individual":1,"waitlist":1,"followed":1,"by":1,"at":2,"months":1,"diag":1,"nose":1,"late":1,"year":1,"onward":1,"appropriate":1,"all":1,"strategies":1,"metabolic":1,"man":1,"agement":1},"len":200},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":25,"chunkId":"ada-2026-pharm-p25-c2","text":"h a pretransplant OGTT while the individual is on the waitlist, followed by early OGTT at 3 months posttransplantation to diag - nose PTDM and a late OGTT at 1 year and onward as appropriate ( 279 ). As with all strategies in metabolic man - agement, lifestyle modifications remain a mainstay of long-term management. The Comparing Glycaemic Benefits of Active Versus Passive Lifestyle Intervention in Kidney Allograft Recipients (CAVIAR) study compared active and passive lifestyles after kidney transplantation using be - havior therapy and found a statistically significant reduction in fat mass and weight loss with active lifestyle. However, there were no changes in the primary outcomes of glucose metabolism (i.e., in - sulin secretion, insulin sensitivity, or dis - position index). The rate of PTDM was halved in the active group, but this find - ing was not statistically significant ( 280 ). In early postoperative periods, insulin is the preferred drug for glycemic man - agement due to its lack of interactions with other transplant medications, imme - diate efficacy, and added potential to pre - vent PTDM, albeit with the expected risk of hypoglycemia ( 281  283 ). Sulfonylureas may also be used for individuals with sta - ble kidney function with similar precau - tions of hypoglycemia, but they may not confer any added metabolic benefits out - side of glucose management ( 284 ).","tf":{"279":1,"280":1,"281":1,"283":1,"284":1,"pretransplant":1,"ogtt":3,"while":1,"the":8,"individual":1,"is":2,"on":1,"waitlist":1,"followed":1,"by":1,"early":2,"at":2,"months":1,"posttransplantation":1,"to":3,"diag":1,"nose":1,"ptdm":3,"and":6,"late":1,"year":1,"onward":1,"as":2,"appropriate":1,"with":6,"all":1,"strategies":1,"in":7,"metabolic":2,"man":2,"agement":2,"lifestyle":3,"modifications":1,"remain":1,"mainstay":1,"of":8,"long":1,"term":1,"management":2,"comparing":1,"glycaemic":1,"benefits":2,"active":4,"versus":1,"passive":2,"intervention":1,"kidney":3,"allograft":1,"recipients":1,"caviar":1,"study":1,"compared":1,"lifestyles":1,"after":1,"transplantation":1,"using":1,"be":2,"havior":1,"therapy":1,"found":1,"statistically":2,"significant":2,"reduction":1,"fat":1,"mass":1,"weight":1,"loss":1,"however":1,"there":1,"were":1,"no":1,"changes":1,"primary":1,"outcomes":1,"glucose":2,"metabolism":1,"sulin":1,"secretion":1,"insulin":2,"sensitivity":1,"or":1,"dis":1,"position":1,"index":1,"rate":1,"was":2,"halved":1,"group":1,"but":2,"this":1,"find":1,"ing":1,"not":2,"postoperative":1,"periods":1,"preferred":1,"drug":1,"for":2,"glycemic":1,"due":1,"its":1,"lack":1,"interactions":1,"other":1,"transplant":1,"medications":1,"imme":1,"diate":1,"efficacy":1,"added":2,"potential":1,"pre":1,"vent":1,"albeit":1,"expected":1,"risk":1,"hypoglycemia":2,"sulfonylureas":1,"may":2,"also":1,"used":1,"individuals":1,"sta":1,"ble":1,"function":1,"similar":1,"precau":1,"tions":1,"they":1,"confer":1,"any":1,"out":1,"side":1},"len":203},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":25,"chunkId":"ada-2026-pharm-p25-c3","text":"k of hypoglycemia ( 281  283 ). Sulfonylureas may also be used for individuals with sta - ble kidney function with similar precau - tions of hypoglycemia, but they may not confer any added metabolic benefits out - side of glucose management ( 284 ). Although still limited, data are increas - ing to inform the optimal pharmacologic management of PTDM and preexisting type 2 diabetes at the time of transplant ( 285 , 286 ) (for diagnosis and classification of PTDM, see section 2,  Diagnosis and Classification of Diabetes ). While many in - dividuals require insulin therapy imme - diately posttransplantation, noninsulin therapies can be used for long-term man - agement. Studies of metformin, DPP-4 in - hibitors, SGLT2 inhibitors, GLP-1 RAs, and pioglitazone in individuals who have un - dergone solid organ transplantation have demonstrated effectiveness and safety but are limited by small sample sizes, short follow-up, and risk of bias due to retrospective, single-center, or single-arm prospective designs ( 287 ). The majority of studies are in individuals who have undergone kidney transplantation, but studies in liver and heart transplantation are available to a lesser degree as well. Selection of pharmacotherapeutic classes should take into account organ-specific physiology, immunosuppressant plan, and general metabolic and cardiovascular circumstances. Metformin can be used bu","tf":{"281":1,"283":1,"284":1,"285":1,"286":1,"287":1,"of":11,"hypoglycemia":2,"sulfonylureas":1,"may":2,"also":1,"be":3,"used":3,"for":3,"individuals":3,"with":2,"sta":1,"ble":1,"kidney":2,"function":1,"similar":1,"precau":1,"tions":1,"but":3,"they":1,"not":1,"confer":1,"any":1,"added":1,"metabolic":2,"benefits":1,"out":1,"side":1,"glucose":1,"management":2,"although":1,"still":1,"limited":2,"data":1,"are":4,"increas":1,"ing":1,"to":3,"inform":1,"the":3,"optimal":1,"pharmacologic":1,"ptdm":2,"and":9,"preexisting":1,"type":1,"diabetes":2,"at":1,"time":1,"transplant":1,"diagnosis":2,"classification":2,"see":1,"section":1,"while":1,"many":1,"in":5,"dividuals":1,"require":1,"insulin":1,"therapy":1,"imme":1,"diately":1,"posttransplantation":1,"noninsulin":1,"therapies":1,"can":2,"long":1,"term":1,"man":1,"agement":1,"studies":3,"metformin":2,"dpp":1,"hibitors":1,"sglt2":1,"inhibitors":1,"glp":1,"ras":1,"pioglitazone":1,"who":2,"have":3,"un":1,"dergone":1,"solid":1,"organ":2,"transplantation":3,"demonstrated":1,"effectiveness":1,"safety":1,"by":1,"small":1,"sample":1,"sizes":1,"short":1,"follow":1,"up":1,"risk":1,"bias":1,"due":1,"retrospective":1,"single":2,"center":1,"or":1,"arm":1,"prospective":1,"designs":1,"majority":1,"undergone":1,"liver":1,"heart":1,"available":1,"lesser":1,"degree":1,"as":1,"well":1,"selection":1,"pharmacotherapeutic":1,"classes":1,"should":1,"take":1,"into":1,"account":1,"specific":1,"physiology":1,"immunosuppressant":1,"plan":1,"general":1,"cardiovascular":1,"circumstances":1,"bu":1},"len":197},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":25,"chunkId":"ada-2026-pharm-p25-c4","text":"plantation are available to a lesser degree as well. Selection of pharmacotherapeutic classes should take into account organ-specific physiology, immunosuppressant plan, and general metabolic and cardiovascular circumstances. Metformin can be used but with cau - tion; it should not be initiated if eGFR is < 45 mL/min/1.73 m 2 , and it should be discontinued with eGFR < 30 mL/min/ 1.73 m 2 . Limitations in metformin use in - clude the risk of lactic acidosis with fluctu - ating kidney function, either with graft dysfunction or rejection in kidney trans - plantation or acute kidney injury in other solid organ transplantation. Metformin use may be associated with lower risks of cardiac allograft vasculopathy after heart transplantation ( 288 ) and all-cause, malig - nancy-related, and infection-related mor - tality after kidney transplantation ( 289 ). DPP-4 inhibitors have been shown to be safe and effective posttransplantation in RCTs, even in the immediate posttrans - plant period for mild hyperglycemia or impaired glucose tolerance, and have the potential to decrease progression to PTDM ( 290 ). GLP-1 RA therapy may be preferred for many individuals, as shown by increasing evidence from large retrospective studies on the benefits of GLP-1 RAs on cardio - vascular, kidney, weight loss, and glucose lowering outcomes. Studies have not found any concern for negative interaction wi","tf":{"30":1,"45":1,"73":2,"288":1,"289":1,"290":1,"plantation":2,"are":1,"available":1,"to":4,"lesser":1,"degree":1,"as":2,"well":1,"selection":1,"of":4,"pharmacotherapeutic":1,"classes":1,"should":3,"take":1,"into":1,"account":1,"organ":2,"specific":1,"physiology":1,"immunosuppressant":1,"plan":1,"and":8,"general":1,"metabolic":1,"cardiovascular":1,"circumstances":1,"metformin":3,"can":1,"be":6,"used":1,"but":1,"with":5,"cau":1,"tion":1,"it":2,"not":2,"initiated":1,"if":1,"egfr":2,"is":1,"ml":2,"min":2,"discontinued":1,"limitations":1,"in":6,"use":2,"clude":1,"the":4,"risk":1,"lactic":1,"acidosis":1,"fluctu":1,"ating":1,"kidney":5,"function":1,"either":1,"graft":1,"dysfunction":1,"or":3,"rejection":1,"trans":1,"acute":1,"injury":1,"other":1,"solid":1,"transplantation":3,"may":2,"associated":1,"lower":1,"risks":1,"cardiac":1,"allograft":1,"vasculopathy":1,"after":2,"heart":1,"all":1,"cause":1,"malig":1,"nancy":1,"related":2,"infection":1,"mor":1,"tality":1,"dpp":1,"inhibitors":1,"have":3,"been":1,"shown":2,"safe":1,"effective":1,"posttransplantation":1,"rcts":1,"even":1,"immediate":1,"posttrans":1,"plant":1,"period":1,"for":3,"mild":1,"hyperglycemia":1,"impaired":1,"glucose":2,"tolerance":1,"potential":1,"decrease":1,"progression":1,"ptdm":1,"glp":2,"ra":1,"therapy":1,"preferred":1,"many":1,"individuals":1,"by":1,"increasing":1,"evidence":1,"from":1,"large":1,"retrospective":1,"studies":2,"on":2,"benefits":1,"ras":1,"cardio":1,"vascular":1,"weight":1,"loss":1,"lowering":1,"outcomes":1,"found":1,"any":1,"concern":1,"negative":1,"interaction":1,"wi":1},"len":205},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":25,"chunkId":"ada-2026-pharm-p25-c5","text":"r many individuals, as shown by increasing evidence from large retrospective studies on the benefits of GLP-1 RAs on cardio - vascular, kidney, weight loss, and glucose lowering outcomes. Studies have not found any concern for negative interaction with immunosuppressants, which would ne - cessitate changes in in dosing ( 291  303 ). However, caution should be used when gastrointestinal side effects occur, particu - larly if individuals have this additive effect to the side effects of the immunosuppres - sants. Additionally, in lung transplant recip - ients, gastroparesis and gastroesophageal reflux are of particular concern, as these conditions may induce allograft lung dam - age and are frequent side effects of GLP-1 RAs. A gastric emptying study may be use - ful in identifying ideal candidates before initiation. SGLT2 inhibitors may be similarly pre - ferred for individuals with ASCVD, HF, and CKD and appear to be safe and effec - tive in PTDM ( 304  309 ). However, there is increased risk of genitourinary tract in - fection, which is of particular concern in immunosuppressed individuals. Of note, kidney transplant recipients have an in - nate anatomical increased risk of urinary tract infections (UTIs), particularly imme - diately posttransplant when the ureteral stent is still in place. Prior history of UTIs and individual risk of UTIs should be con - sidered when using t","tf":{"291":1,"303":1,"304":1,"309":1,"many":1,"individuals":4,"as":2,"shown":1,"by":1,"increasing":1,"evidence":1,"from":1,"large":1,"retrospective":1,"studies":2,"on":2,"the":4,"benefits":1,"of":10,"glp":2,"ras":2,"cardio":1,"vascular":1,"kidney":2,"weight":1,"loss":1,"and":7,"glucose":1,"lowering":1,"outcomes":1,"have":3,"not":1,"found":1,"any":1,"concern":3,"for":2,"negative":1,"interaction":1,"with":2,"immunosuppressants":1,"which":2,"would":1,"ne":1,"cessitate":1,"changes":1,"in":9,"dosing":1,"however":2,"caution":1,"should":2,"be":5,"used":1,"when":3,"gastrointestinal":1,"side":3,"effects":3,"occur":1,"particu":1,"larly":1,"if":1,"this":1,"additive":1,"effect":1,"to":2,"immunosuppres":1,"sants":1,"additionally":1,"lung":2,"transplant":2,"recip":1,"ients":1,"gastroparesis":1,"gastroesophageal":1,"reflux":1,"are":2,"particular":2,"these":1,"conditions":1,"may":3,"induce":1,"allograft":1,"dam":1,"age":1,"frequent":1,"gastric":1,"emptying":1,"study":1,"use":1,"ful":1,"identifying":1,"ideal":1,"candidates":1,"before":1,"initiation":1,"sglt2":1,"inhibitors":1,"similarly":1,"pre":1,"ferred":1,"ascvd":1,"hf":1,"ckd":1,"appear":1,"safe":1,"effec":1,"tive":1,"ptdm":1,"there":1,"is":3,"increased":2,"risk":3,"genitourinary":1,"tract":2,"fection":1,"immunosuppressed":1,"note":1,"recipients":1,"an":1,"nate":1,"anatomical":1,"urinary":1,"infections":1,"utis":3,"particularly":1,"imme":1,"diately":1,"posttransplant":1,"ureteral":1,"stent":1,"still":1,"place":1,"prior":1,"history":1,"individual":1,"con":1,"sidered":1,"using":1},"len":206},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":25,"chunkId":"ada-2026-pharm-p25-c6","text":"ve an in - nate anatomical increased risk of urinary tract infections (UTIs), particularly imme - diately posttransplant when the ureteral stent is still in place. Prior history of UTIs and individual risk of UTIs should be con - sidered when using this class after kidney transplant. diabetesjournals.org/care Pharmacologic Approaches to Glycemic Treatment S207 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"49":1,"2026":1,"848878":1,"ve":1,"an":1,"in":2,"nate":1,"anatomical":1,"increased":1,"risk":2,"of":3,"urinary":1,"tract":1,"infections":1,"utis":3,"particularly":1,"imme":1,"diately":1,"posttransplant":1,"when":2,"the":1,"ureteral":1,"stent":1,"is":1,"still":1,"place":1,"prior":1,"history":1,"and":1,"individual":1,"should":1,"be":1,"con":1,"sidered":1,"using":1,"this":1,"class":1,"after":1,"kidney":1,"transplant":1,"diabetesjournals":2,"org":2,"care":2,"pharmacologic":1,"approaches":1,"to":1,"glycemic":1,"treatment":1,"s207":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"supplement":1,"s183":1,"dc26s009":1,"by":1,"guest":1,"on":1,"february":1},"len":73},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":26,"chunkId":"ada-2026-pharm-p26-c0","text":"It is essential that diabetes manage - ment posttransplantation is implemented in the setting of an interprofessional team. The transplant physicians and the endocri - nologists should work collaboratively to monitor for medication toxicity and delete - rious side effects that may affect allograft function and to optimize cardiovascular and metabolic outcomes. Maturity-Onset Diabetes of the Young Individuals with maturity-onset diabetes of the young due to HNF1A and HNF4A mutations can be treated with low-dose sulfonylurea therapy but may ultimately re - quire insulin therapy ( 310 ) (see section 2,  Diagnosis and Classification of Diabetes ) ( Table 2.7 ). For those with HNF1A muta - tions, addition of a DPP-4 inhibitor to the sulfonylurea may help improve glycemic var - iability and attainment of glycemic goals ( 311 ). Individuals with neonatal diabetes due to KCNJ22 and ABCC8 mutations can be treated with high-dose sulfonylureas, while those with INS, GATA6, EIF2AK3, and FOXP3 mutations require insulin therapy ( 310 ). SGLT Inhibition and Risk of Ketosis Individuals with type 1 diabetes ( 83 , 312 ) and insulin-deficient type 2 diabetes are at increased risk for DKA with SGLT inhibitor therapy (SGLT2 inhibitors or the SGLT1/2 in - hibitor). SGLT inhibitor  associated DKA oc - curs in approximately 4% of people with type 1 diabetes; the risk can be 5  17 times higher tha","tf":{"17":1,"83":1,"310":2,"311":1,"312":1,"it":1,"is":2,"essential":1,"that":2,"diabetes":8,"manage":1,"ment":1,"posttransplantation":1,"implemented":1,"in":3,"the":8,"setting":1,"of":8,"an":1,"interprofessional":1,"team":1,"transplant":1,"physicians":1,"and":11,"endocri":1,"nologists":1,"should":1,"work":1,"collaboratively":1,"to":5,"monitor":1,"for":3,"medication":1,"toxicity":1,"delete":1,"rious":1,"side":1,"effects":1,"may":3,"affect":1,"allograft":1,"function":1,"optimize":1,"cardiovascular":1,"metabolic":1,"outcomes":1,"maturity":2,"onset":2,"young":2,"individuals":3,"with":9,"due":2,"hnf1a":2,"hnf4a":1,"mutations":3,"can":3,"be":3,"treated":2,"low":1,"dose":2,"sulfonylurea":2,"therapy":4,"but":1,"ultimately":1,"re":1,"quire":1,"insulin":3,"see":1,"section":1,"diagnosis":1,"classification":1,"table":1,"those":2,"muta":1,"tions":1,"addition":1,"dpp":1,"inhibitor":3,"help":1,"improve":1,"glycemic":2,"var":1,"iability":1,"attainment":1,"goals":1,"neonatal":1,"kcnj22":1,"abcc8":1,"high":1,"sulfonylureas":1,"while":1,"ins":1,"gata6":1,"eif2ak3":1,"foxp3":1,"require":1,"sglt":3,"inhibition":1,"risk":3,"ketosis":1,"type":3,"deficient":1,"are":1,"at":1,"increased":1,"dka":2,"sglt2":1,"inhibitors":1,"or":1,"sglt1":1,"hibitor":1,"associated":1,"oc":1,"curs":1,"approximately":1,"people":1,"times":1,"higher":1,"tha":1},"len":203},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":26,"chunkId":"ada-2026-pharm-p26-c1","text":"2 diabetes are at increased risk for DKA with SGLT inhibitor therapy (SGLT2 inhibitors or the SGLT1/2 in - hibitor). SGLT inhibitor  associated DKA oc - curs in approximately 4% of people with type 1 diabetes; the risk can be 5  17 times higher than that in people with type 1 diabetes not treated with SGLT inhibitors ( 313 ). It is important to note that SGLT2 in - hibitors are not approved for use in people with type 1 diabetes. In contrast, DKA is un - common in people with type 2 diabetes treated with SGLT inhibitors, with an esti - mated incidence of 0.6  4.9 events per 1,000 person-years ( 314 ). Risk factors for DKA in individuals with either type 1 or type 2 diabetes treated with SGLT in - hibitors include very-low-carbohydrate eat - ing patterns, prolonged fasting, dehydration, excessive alcohol intake, and other common precipitating factors ( 83 , 312 ). Up to a third of people treated with SGLT2 inhibitors who developed DKA present with glucose levels < 200 mg/dL ( < 11.1 mmol/L) ( 315 ), and in one study 71% presented with glucose levels  250 mg/dL (  13.9 mmol/L) ( 316 ); therefore, it is important to edu - cate at-risk individuals about the signs and symptoms of DKA and DKA mitigation and management and to prescribe accu - rate tools for ketone measurement. Indi - viduals who have experienced DKA should not be treated with SGLT inhibition. Addi - tional guidan","tf":{"11":1,"13":1,"17":1,"71":1,"83":1,"200":1,"250":1,"312":1,"313":1,"314":1,"315":1,"316":1,"diabetes":6,"are":2,"at":2,"increased":1,"risk":4,"for":4,"dka":8,"with":14,"sglt":6,"inhibitor":2,"therapy":1,"sglt2":3,"inhibitors":4,"or":2,"the":3,"sglt1":1,"in":10,"hibitor":1,"associated":1,"oc":1,"curs":1,"approximately":1,"of":4,"people":5,"type":6,"can":1,"be":2,"times":1,"higher":1,"than":1,"that":2,"not":3,"treated":5,"it":2,"is":3,"important":2,"to":4,"note":1,"hibitors":2,"approved":1,"use":1,"contrast":1,"un":1,"common":2,"an":1,"esti":1,"mated":1,"incidence":1,"events":1,"per":1,"000":1,"person":1,"years":1,"factors":2,"individuals":2,"either":1,"include":1,"very":1,"low":1,"carbohydrate":1,"eat":1,"ing":1,"patterns":1,"prolonged":1,"fasting":1,"dehydration":1,"excessive":1,"alcohol":1,"intake":1,"and":6,"other":1,"precipitating":1,"up":1,"third":1,"who":2,"developed":1,"present":1,"glucose":2,"levels":2,"mg":2,"dl":2,"mmol":2,"one":1,"study":1,"presented":1,"therefore":1,"edu":1,"cate":1,"about":1,"signs":1,"symptoms":1,"mitigation":1,"management":1,"prescribe":1,"accu":1,"rate":1,"tools":1,"ketone":1,"measurement":1,"indi":1,"viduals":1,"have":1,"experienced":1,"should":1,"inhibition":1,"addi":1,"tional":1,"guidan":1},"len":218},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":26,"chunkId":"ada-2026-pharm-p26-c2","text":"risk individuals about the signs and symptoms of DKA and DKA mitigation and management and to prescribe accu - rate tools for ketone measurement. Indi - viduals who have experienced DKA should not be treated with SGLT inhibition. Addi - tional guidance on DKA risk mitigation is available in section 6,  Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises . References 1. Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Mortality in type 1 diabetes in the DCCT/EDIC versus the general population. Diabetes Care 2016;39:1378  1383 2. Lachin JM, Bebu I, Nathan DM; DCCT/EDIC Research Group. The beneficial effects of earlier versus later implementation of intensive therapy in type 1 diabetes. Diabetes Care 2021;44:2225  2230 3. Lachin JM, Nathan DM; DCCT/EDIC Research Group. Understanding metabolic memory: the prolonged influence of glycemia during the Diabetes Control and Complications Trial (DCCT) on future risks of complications during the study of the Epidemiology of Diabetes Interventions and Complications (EDIC). Diabetes Care 2021;44: 2216  2224 4. Holt RIG, DeVries JH, Hess-Fischl A, et al. The management of type 1 diabetes in adults. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2021;44:2589  2","tf":{"39":1,"44":3,"1378":1,"1383":1,"2016":1,"2021":3,"2216":1,"2224":1,"2225":1,"2230":1,"2589":1,"risk":2,"individuals":1,"about":1,"the":12,"signs":1,"and":10,"symptoms":1,"of":10,"dka":4,"mitigation":2,"management":2,"to":1,"prescribe":1,"accu":1,"rate":1,"tools":1,"for":2,"ketone":1,"measurement":1,"indi":1,"viduals":1,"who":1,"have":1,"experienced":1,"should":1,"not":1,"be":1,"treated":1,"with":1,"sglt":1,"inhibition":1,"addi":1,"tional":1,"guidance":1,"on":2,"is":1,"available":1,"in":5,"section":1,"glycemic":1,"goals":1,"hypoglycemia":1,"hyperglycemic":1,"crises":1,"references":1,"diabetes":13,"control":2,"complications":5,"trial":2,"dcct":5,"epidemiology":2,"interventions":2,"edic":5,"study":3,"research":3,"group":3,"mortality":1,"type":3,"versus":2,"general":1,"population":1,"care":4,"lachin":2,"jm":2,"bebu":1,"nathan":2,"dm":2,"beneficial":1,"effects":1,"earlier":1,"later":1,"implementation":1,"intensive":1,"therapy":1,"understanding":1,"metabolic":1,"memory":1,"prolonged":1,"influence":1,"glycemia":1,"during":2,"future":1,"risks":1,"holt":1,"rig":1,"devries":1,"jh":1,"hess":1,"fischl":1,"et":1,"al":1,"adults":1,"consensus":1,"report":1,"by":1,"american":1,"association":2,"ada":1,"european":1,"easd":1},"len":202},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":26,"chunkId":"ada-2026-pharm-p26-c3","text":"24 4. Holt RIG, DeVries JH, Hess-Fischl A, et al. The management of type 1 diabetes in adults. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2021;44:2589  2625 5. Tricco AC, Ashoor HM, Antony J, et al. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis. BMJ 2014;349:g5459 6. Bartley PC, Bogoev M, Larsen J, Philotheou A. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to- target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med 2008;25:442  449 7. Little S, Shaw J, Home P. Hypoglycemia rates with basal insulin analogs. Diabetes Technol Ther 2011;13(Suppl. 1):S53  S64 8. Aronson R, Biester T, Leohr J, et al. Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus. Diabetes Obes Metab 2023;25:1964  1972 9. Heise T, Pieber TR, Danne T, Erichsen L, Haahr H. A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharma- codynamic characteristics of fast-acting insulin aspart in adults with type 1 dia","tf":{"13":1,"24":1,"25":2,"44":1,"349":1,"442":1,"449":1,"1964":1,"1972":1,"2008":1,"2011":1,"2014":1,"2021":1,"2023":1,"2589":1,"2625":1,"holt":1,"rig":1,"devries":1,"jh":1,"hess":1,"fischl":1,"et":3,"al":3,"the":5,"management":1,"of":6,"type":5,"diabetes":9,"in":5,"adults":3,"consensus":1,"report":1,"by":1,"american":1,"association":2,"ada":1,"and":6,"european":1,"for":2,"study":1,"easd":1,"care":1,"tricco":1,"ac":1,"ashoor":1,"hm":1,"antony":1,"safety":2,"effectiveness":2,"cost":1,"long":2,"acting":3,"versus":2,"intermediate":1,"insulin":6,"patients":2,"with":6,"systematic":1,"review":1,"network":1,"meta":1,"analysis":2,"bmj":1,"g5459":1,"bartley":1,"pc":1,"bogoev":1,"larsen":1,"philotheou":1,"term":1,"efficacy":1,"detemir":1,"compared":1,"to":2,"neutral":1,"protamine":1,"hagedorn":1,"using":1,"treat":1,"target":1,"basal":2,"bolus":1,"regimen":1,"aspart":2,"at":1,"meals":1,"year":1,"randomized":1,"controlled":1,"trial":1,"diabet":1,"med":1,"little":1,"shaw":1,"home":1,"hypoglycemia":1,"rates":1,"analogs":1,"technol":1,"ther":1,"suppl":1,"s53":1,"s64":1,"aronson":1,"biester":1,"leohr":1,"ultra":1,"rapid":1,"lispro":1,"showed":1,"greater":1,"reduction":1,"postprandial":1,"glucose":1,"humalog":1,"children":1,"adolescents":1,"mellitus":1,"obes":1,"metab":1,"heise":1,"pieber":1,"tr":1,"danne":1,"erichsen":1,"haahr":1,"pooled":1,"clinical":1,"pharmacology":1,"trials":1,"investigating":1,"pharmacokinetic":1,"pharma":1,"codynamic":1,"characteristics":1,"fast":1,"dia":1},"len":198},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":26,"chunkId":"ada-2026-pharm-p26-c4","text":"2023;25:1964  1972 9. Heise T, Pieber TR, Danne T, Erichsen L, Haahr H. A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharma- codynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes. Clin Pharmacokinet 2017;56:551  559 10. Bode BW, McGill JB, Lorber DL, Gross JL, Chang PC, Bregman DB; Affinity 1 Study Group. Inhaled Technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial. Diabetes Care 2015;38: 2266  2273 11. Russell-Jones D, Bode BW, De Block C, et al. Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1). Diabetes Care 2017;40:943  950 12. Klaff L, Cao D, Dellva MA, et al. Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: results from the 26-week PRONTO-T1D study. Diabetes Obes Metab 2020;22:1799  1807 13. Lane W, Bailey TS, Gerety G, et al.; SWITCH 1. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial. JAMA 2017;318:33  44 14. Home PD, Bergenstal RM, Bolli GB, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people wit","tf":{"10":1,"11":1,"12":1,"13":1,"14":1,"22":1,"24":1,"25":1,"26":2,"33":1,"38":1,"40":1,"44":1,"56":1,"100":1,"300":1,"318":1,"551":1,"559":1,"943":1,"950":1,"1799":1,"1807":1,"1964":1,"1972":1,"2015":1,"2017":3,"2020":1,"2023":1,"2266":1,"2273":1,"heise":1,"pieber":1,"tr":1,"danne":1,"erichsen":1,"haahr":1,"pooled":1,"analysis":1,"of":4,"clinical":2,"pharmacology":1,"trials":1,"investigating":1,"the":3,"pharmacokinetic":1,"and":1,"pharma":1,"codynamic":1,"characteristics":1,"fast":2,"acting":2,"insulin":7,"aspart":2,"in":6,"adults":1,"with":5,"type":5,"diabetes":8,"clin":1,"pharmacokinet":1,"bode":2,"bw":2,"mcgill":1,"jb":1,"lorber":1,"dl":1,"gross":1,"jl":1,"chang":1,"pc":1,"bregman":1,"db":1,"affinity":1,"study":2,"group":2,"inhaled":1,"technosphere":1,"compared":2,"injected":1,"prandial":1,"randomized":3,"week":3,"trial":3,"care":2,"russell":1,"jones":1,"de":1,"block":1,"et":4,"al":4,"improves":2,"glycemic":1,"control":2,"basal":1,"bolus":1,"treatment":1,"for":1,"results":2,"multicenter":1,"active":1,"controlled":1,"treat":1,"to":1,"target":1,"parallel":1,"onset":1,"klaff":1,"cao":1,"dellva":1,"ma":1,"ultra":1,"rapid":1,"lispro":2,"postprandial":1,"glucose":1,"patients":2,"from":1,"pronto":1,"t1d":1,"obes":1,"metab":1,"lane":1,"bailey":1,"ts":1,"gerety":1,"switch":2,"effect":1,"degludec":1,"vs":1,"glargine":3,"u100":1,"on":1,"hypoglycemia":1,"jama":1,"home":1,"pd":1,"bergenstal":1,"rm":1,"bolli":1,"gb":1,"new":1,"units":2,"ml":2,"versus":1,"people":1,"wit":1},"len":213},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":26,"chunkId":"ada-2026-pharm-p26-c5","text":"in glargine U100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial. JAMA 2017;318:33  44 14. Home PD, Bergenstal RM, Bolli GB, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care 2015;38:2217  2225 15. Yeh H-C, Brown TT, Maruthur N, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta- analysis. Ann Intern Med 2012;157:336  347 16. Speight J, Choudhary P, Wilmot EG, et al. Impact of glycaemic technologies on quality of life and related outcomes in adults with type 1 diabetes: a narrative review. Diabet Med 2023;40: e14944 17. Tzivian L, Sokolovska J, Grike AE, et al. Quantitative and qualitative analysis of the quality of life of type 1 diabetes patients using insulin pumps and of those receiving multiple daily insulin injections. Health Qual Life Outcomes 2022;20:120 18. Mulinacci G, Alonso GT, Snell-Bergeon JK, Shah VN. Glycemic outcomes with early initiation of continuous glucose monitoring system in recently diagnosed patients with type 1 diabetes. Diabetes Technol Ther 2019;21:6  10 19. Elbalshy M, Haszard J, Smith H, et al. Effect of divergent continuous glucose monitoring technologies on glycaemic control in ","tf":{"10":1,"14":1,"15":1,"16":1,"17":1,"18":1,"19":1,"20":1,"21":1,"33":1,"38":1,"40":1,"44":1,"100":1,"120":1,"157":1,"300":1,"318":1,"336":1,"347":1,"2012":1,"2015":1,"2017":1,"2019":1,"2022":1,"2023":1,"2217":1,"2225":1,"in":6,"glargine":3,"u100":1,"on":3,"hypoglycemia":1,"patients":3,"with":5,"type":5,"diabetes":8,"the":2,"switch":1,"randomized":2,"clinical":2,"trial":2,"jama":1,"home":1,"pd":1,"bergenstal":1,"rm":1,"bolli":1,"gb":1,"et":5,"al":5,"new":1,"insulin":4,"units":2,"ml":2,"versus":1,"people":1,"phase":1,"3a":1,"open":1,"label":1,"edition":1,"care":1,"yeh":1,"brown":1,"tt":1,"maruthur":1,"comparative":1,"effectiveness":1,"and":6,"safety":1,"of":10,"methods":1,"delivery":1,"glucose":3,"monitoring":3,"for":1,"mellitus":1,"systematic":1,"review":2,"meta":1,"analysis":2,"ann":1,"intern":1,"med":2,"speight":1,"choudhary":1,"wilmot":1,"eg":1,"impact":1,"glycaemic":2,"technologies":2,"quality":2,"life":3,"related":1,"outcomes":3,"adults":1,"narrative":1,"diabet":1,"e14944":1,"tzivian":1,"sokolovska":1,"grike":1,"ae":1,"quantitative":1,"qualitative":1,"using":1,"pumps":1,"those":1,"receiving":1,"multiple":1,"daily":1,"injections":1,"health":1,"qual":1,"mulinacci":1,"alonso":1,"gt":1,"snell":1,"bergeon":1,"jk":1,"shah":1,"vn":1,"glycemic":1,"early":1,"initiation":1,"continuous":2,"system":1,"recently":1,"diagnosed":1,"technol":1,"ther":1,"elbalshy":1,"haszard":1,"smith":1,"effect":1,"divergent":1,"control":1},"len":210},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":26,"chunkId":"ada-2026-pharm-p26-c6","text":"ous glucose monitoring system in recently diagnosed patients with type 1 diabetes. Diabetes Technol Ther 2019;21:6  10 19. Elbalshy M, Haszard J, Smith H, et al. Effect of divergent continuous glucose monitoring technologies on glycaemic control in type 1 diabetes mellitus: a systematic review and meta- analysis of randomised controlled trials. Diabet Med 2022;39:e14854 20. Champakanath A, Akturk HK, Alonso GT, Snell-Bergeon JK, Shah VN. Continuous glucose monitoring initiation within first year of type 1 diabetes diagnosis is associated with improved glycemic outcomes: 7-year follow-up study. Diabetes Care 2022;45:750  753 21. Polonsky WH, Hessler D, Ruedy KJ, Beck RW; DIAMOND Study Group. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial. Diabetes Care 2017;40:736  741 22. Bergenstal RM, Klonoff DC, Garg SK, et al.; ASPIRE In-Home Study Group. Threshold-based insulin-pump interruption for reduction of hypo- glycemia. N Engl J Med 2013;369:224  232 23. Forlenza GP, Li Z, Buckingham BA, et al. Predictive low-glucose suspend reduces hypo- glycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: results of the PROLOG trial. Diabetes Care 2018;41:2155  2161 24. Brown SA, Kovatchev BP, Raghinaru D, et al.; iDCL ","tf":{"10":1,"19":1,"20":1,"21":2,"22":1,"23":1,"24":1,"39":1,"40":1,"41":1,"45":1,"224":1,"232":1,"369":1,"736":1,"741":1,"750":1,"753":1,"2013":1,"2017":1,"2018":1,"2019":1,"2022":2,"2155":1,"2161":1,"ous":1,"glucose":5,"monitoring":4,"system":1,"in":6,"recently":1,"diagnosed":1,"patients":1,"with":4,"type":5,"diabetes":9,"technol":1,"ther":1,"elbalshy":1,"haszard":1,"smith":1,"et":4,"al":4,"effect":1,"of":8,"divergent":1,"continuous":3,"technologies":1,"on":2,"glycaemic":1,"control":1,"mellitus":1,"systematic":1,"review":1,"and":2,"meta":1,"analysis":1,"randomised":1,"controlled":1,"trials":1,"diabet":1,"med":2,"e14854":1,"champakanath":1,"akturk":1,"hk":1,"alonso":1,"gt":1,"snell":1,"bergeon":1,"jk":1,"shah":1,"vn":1,"initiation":1,"within":1,"first":1,"year":2,"diagnosis":1,"is":1,"associated":1,"improved":1,"glycemic":1,"outcomes":1,"follow":1,"up":1,"study":4,"care":3,"polonsky":1,"wh":1,"hessler":1,"ruedy":1,"kj":1,"beck":1,"rw":1,"diamond":2,"group":2,"the":3,"impact":1,"markers":1,"quality":1,"life":1,"adults":2,"further":1,"findings":1,"from":1,"randomized":2,"clinical":1,"trial":2,"bergenstal":1,"rm":1,"klonoff":1,"dc":1,"garg":1,"sk":1,"aspire":1,"home":2,"threshold":1,"based":1,"insulin":1,"pump":1,"interruption":1,"for":1,"reduction":1,"hypo":2,"glycemia":2,"engl":1,"forlenza":1,"gp":1,"li":1,"buckingham":1,"ba":1,"predictive":1,"low":1,"suspend":1,"reduces":1,"adolescents":1,"children":1,"an":1,"at":1,"crossover":1,"results":1,"prolog":1,"brown":1,"sa":1,"kovatchev":1,"bp":1,"raghinaru":1,"idcl":1},"len":211},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":26,"chunkId":"ada-2026-pharm-p26-c7","text":"e suspend reduces hypo- glycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: results of the PROLOG trial. Diabetes Care 2018;41:2155  2161 24. Brown SA, Kovatchev BP, Raghinaru D, et al.; iDCL Trial Research Group. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med 2019;381:1707  1717 25. Collyns OJ, Meier RA, Betts ZL, et al. Improved glycemic outcomes with Medtronic S208 Pharmacologic Approaches to Glycemic Treatment Diabetes Care Volume 49, Supplement 1, January 2026 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"24":1,"25":1,"41":1,"49":2,"381":1,"1707":1,"1717":1,"2018":1,"2019":1,"2026":2,"2155":1,"2161":1,"848878":1,"suspend":1,"reduces":1,"hypo":1,"glycemia":1,"in":3,"adults":1,"adolescents":1,"and":1,"children":1,"with":2,"type":2,"diabetes":4,"an":1,"at":1,"home":1,"randomized":2,"crossover":1,"study":1,"results":1,"of":2,"the":1,"prolog":1,"trial":3,"care":3,"brown":1,"sa":1,"kovatchev":1,"bp":1,"raghinaru":1,"et":2,"al":2,"idcl":1,"research":1,"group":1,"six":1,"month":1,"multicenter":1,"closed":1,"loop":1,"control":1,"engl":1,"med":1,"collyns":1,"oj":1,"meier":1,"ra":1,"betts":1,"zl":1,"improved":1,"glycemic":2,"outcomes":1,"medtronic":1,"s208":1,"pharmacologic":1,"approaches":1,"to":1,"treatment":1,"volume":1,"supplement":2,"january":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"s183":1,"dc26s009":1,"by":1,"guest":1,"on":1,"february":1},"len":107},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":27,"chunkId":"ada-2026-pharm-p27-c0","text":"MiniMed advanced hybrid closed-loop delivery: results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in people with type 1 diabetes. Diabetes Care 2021;44:969  975 26. Breton MD, Kovatchev BP. One year real-world use of the control-IQ advanced hybrid closed-loop technology. Diabetes Technol Ther 2021;23:601  608 27. Peacock S, Frizelle I, Hussain S. A systematic review of commercial hybrid closed-loop automated insulin delivery systems. Diabetes Ther 2023;14: 839  855 28. Choudhary P, Kolassa R, Keuthage W, et al.; ADAPT study Group. Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study. Lancet Diabetes Endocrinol 2022;10:720  731 29. Arunachalum S, Velado K, Vigersky RA, Cordero TL. Glycemic outcomes during real-world hybrid closed-loop system use by individuals with type 1 diabetes in the United States. J Diabetes Sci Technol 2023;17:951  958 30. Garg SK, Grunberger G, Weinstock R, et al.; Adult and Pediatric MiniMed HCL Outcomes 6- month RCT: HCL versus CSII Control Study Group. Improved glycemia with hybrid closed-loop versus continuous subcutaneous insulin infusion therapy: results from a randomized controlled trial. Diabetes Technol Ther 2023;25:1  12 31. Russell SJ, Beck RW, Damiano ER, et al.; Bionic Pancreas Research Group.","tf":{"10":1,"12":1,"14":1,"17":1,"23":1,"25":1,"26":1,"27":1,"28":1,"29":1,"30":1,"31":1,"44":1,"601":1,"608":1,"720":1,"731":1,"839":1,"855":1,"951":1,"958":1,"969":1,"975":1,"2021":2,"2022":1,"2023":3,"minimed":2,"advanced":3,"hybrid":6,"closed":6,"loop":6,"delivery":3,"results":2,"from":2,"randomized":2,"crossover":1,"trial":2,"comparing":1,"automated":2,"insulin":3,"with":5,"predictive":1,"low":1,"glucose":1,"suspend":1,"in":3,"people":1,"type":3,"diabetes":9,"care":1,"breton":1,"md":1,"kovatchev":1,"bp":1,"one":1,"year":1,"real":2,"world":2,"use":2,"of":2,"the":2,"control":2,"iq":1,"technology":1,"technol":3,"ther":3,"peacock":1,"frizelle":1,"hussain":1,"systematic":1,"review":1,"commercial":1,"systems":1,"choudhary":1,"kolassa":1,"keuthage":1,"et":3,"al":3,"adapt":2,"study":3,"group":3,"therapy":2,"versus":3,"conventional":1,"treatment":1,"adults":1,"randomised":1,"controlled":2,"lancet":1,"endocrinol":1,"arunachalum":1,"velado":1,"vigersky":1,"ra":1,"cordero":1,"tl":1,"glycemic":1,"outcomes":2,"during":1,"system":1,"by":1,"individuals":1,"united":1,"states":1,"sci":1,"garg":1,"sk":1,"grunberger":1,"weinstock":1,"adult":1,"and":1,"pediatric":1,"hcl":2,"month":1,"rct":1,"csii":1,"improved":1,"glycemia":1,"continuous":1,"subcutaneous":1,"infusion":1,"russell":1,"sj":1,"beck":1,"rw":1,"damiano":1,"er":1,"bionic":1,"pancreas":1,"research":1},"len":201},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":27,"chunkId":"ada-2026-pharm-p27-c1","text":"ed glycemia with hybrid closed-loop versus continuous subcutaneous insulin infusion therapy: results from a randomized controlled trial. Diabetes Technol Ther 2023;25:1  12 31. Russell SJ, Beck RW, Damiano ER, et al.; Bionic Pancreas Research Group. Multicenter, randomized trial of a bionic pancreas in type 1 diabetes. N Engl J Med 2022;387:1161  1172 32. Stahl-Pehe A, Shokri-Mashhadi N, Wirth M, et al. Efficacy of automated insulin delivery systems in people with type 1 diabetes: a systematic review and network meta-analysis of outpatient randomised controlled trials. EClinicalMedicine 2025;82:103190 33. Burnside MJ, Lewis DM, Crocket HR, et al. Open-source automated insulin delivery in type 1 diabetes. N Engl J Med 2022;387:869  881 34. Burnside MJ, Lewis DM, Crocket HR, et al. Extended use of an open-source automated insulin delivery system in children and adults with type 1 diabetes: the 24-week continuation phase following the CREATE randomized controlled trial. Diabetes Technol Ther 2023;25:250  259 35. Lepore G, Rossini A, Bellante R, et al. Switching to the Minimed 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose control. Acta Diabetol 2022;59:1309  1315 36. Matejko B, Juza A, Kie  c-Wilk B, et al. Transitioning of people with type 1 diabetes from multiple daily injections and","tf":{"12":1,"24":1,"25":2,"31":1,"32":1,"33":1,"34":1,"35":1,"36":1,"59":1,"82":1,"250":1,"259":1,"387":2,"869":1,"881":1,"1161":1,"1172":1,"1309":1,"1315":1,"2022":3,"2023":2,"2025":1,"103190":1,"ed":1,"glycemia":1,"with":5,"hybrid":1,"closed":1,"loop":1,"versus":1,"continuous":1,"subcutaneous":1,"insulin":5,"infusion":1,"therapy":1,"results":1,"from":2,"randomized":3,"controlled":3,"trial":3,"diabetes":8,"technol":2,"ther":2,"russell":1,"sj":1,"beck":1,"rw":1,"damiano":1,"er":1,"et":6,"al":6,"bionic":2,"pancreas":2,"research":1,"group":1,"multicenter":1,"of":6,"in":5,"type":6,"engl":2,"med":2,"stahl":1,"pehe":1,"shokri":1,"mashhadi":1,"wirth":1,"efficacy":1,"automated":3,"delivery":3,"systems":1,"people":2,"systematic":1,"review":1,"and":4,"network":1,"meta":1,"analysis":1,"outpatient":1,"randomised":1,"trials":1,"eclinicalmedicine":1,"burnside":2,"mj":2,"lewis":2,"dm":2,"crocket":2,"hr":2,"open":2,"source":2,"extended":1,"use":1,"an":1,"system":2,"children":1,"adults":2,"the":3,"week":1,"continuation":1,"phase":1,"following":1,"create":1,"lepore":1,"rossini":1,"bellante":1,"switching":1,"to":1,"minimed":1,"780g":1,"achieves":1,"clinical":1,"targets":1,"for":1,"cgm":1,"regardless":1,"previous":1,"strategy":1,"baseline":1,"glucose":1,"control":1,"acta":1,"diabetol":1,"matejko":1,"juza":1,"kie":1,"wilk":1,"transitioning":1,"multiple":1,"daily":1,"injections":1},"len":207},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":27,"chunkId":"ada-2026-pharm-p27-c2","text":"with type 1 diabetes regardless of previous insulin strategy and baseline glucose control. Acta Diabetol 2022;59:1309  1315 36. Matejko B, Juza A, Kie  c-Wilk B, et al. Transitioning of people with type 1 diabetes from multiple daily injections and self-monitoring of blood glucose directly to MiniMed 780G advanced hybrid closed-loop system: a two-center, randomized, controlled study. Diabetes Care 2022;45:2628  2635 37. Isganaitis E, Raghinaru D, Ambler-Osborn L, et al.; iDCL Trial Research Group. Closed-loop insulin therapy improves glycemic control in adolescents and young adults: outcomes from the international diabetes closed-loop trial. Diabetes Technol Ther 2021;23:342  349 38. Forlenza GP, Carlson AL, Galindo RJ, et al. Real-world evidence supporting tandem control- IQ hybrid closed-loop success in the Medicare and Medicaid type 1 and type 2 diabetes populations. Diabetes Technol Ther 2022;24:814  823 39. Lal RA, Maahs DM. Optimizing basal insulin dosing. J Pediatr 2019;215:7  8 40. Mitsui Y, Kuroda A, Ishizu M, et al. Basal insulin requirement in patients with type 1 diabetes depends on the age and body mass index. J Diabetes Investig 2022;13:292  298 41. Castellano E, Attanasio R, Giagulli VA, et al.; Associazione Medici Endocrinologi (AME). The basal to total insulin ratio in outpatients with diabetes on basal-bolus regimen. J Diabetes Metab Disord 2018; 17:393","tf":{"13":1,"17":1,"23":1,"24":1,"36":1,"37":1,"38":1,"39":1,"40":1,"41":1,"45":1,"59":1,"215":1,"292":1,"298":1,"342":1,"349":1,"393":1,"814":1,"823":1,"1309":1,"1315":1,"2018":1,"2019":1,"2021":1,"2022":4,"2628":1,"2635":1,"with":4,"type":5,"diabetes":11,"regardless":1,"of":3,"previous":1,"insulin":5,"strategy":1,"and":6,"baseline":1,"glucose":2,"control":3,"acta":1,"diabetol":1,"matejko":1,"juza":1,"kie":1,"wilk":1,"et":5,"al":6,"transitioning":1,"people":1,"from":2,"multiple":1,"daily":1,"injections":1,"self":1,"monitoring":1,"blood":1,"directly":1,"to":2,"minimed":1,"780g":1,"advanced":1,"hybrid":2,"closed":4,"loop":4,"system":1,"two":1,"center":1,"randomized":1,"controlled":1,"study":1,"care":1,"isganaitis":1,"raghinaru":1,"ambler":1,"osborn":1,"idcl":1,"trial":2,"research":1,"group":1,"therapy":1,"improves":1,"glycemic":1,"in":4,"adolescents":1,"young":1,"adults":1,"outcomes":1,"the":4,"international":1,"technol":2,"ther":2,"forlenza":1,"gp":1,"carlson":1,"galindo":1,"rj":1,"real":1,"world":1,"evidence":1,"supporting":1,"tandem":1,"iq":1,"success":1,"medicare":1,"medicaid":1,"populations":1,"lal":1,"ra":1,"maahs":1,"dm":1,"optimizing":1,"basal":4,"dosing":1,"pediatr":1,"mitsui":1,"kuroda":1,"ishizu":1,"requirement":1,"patients":1,"depends":1,"on":2,"age":1,"body":1,"mass":1,"index":1,"investig":1,"castellano":1,"attanasio":1,"giagulli":1,"va":1,"associazione":1,"medici":1,"endocrinologi":1,"ame":1,"total":1,"ratio":1,"outpatients":1,"bolus":1,"regimen":1,"metab":1,"disord":1},"len":207},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":27,"chunkId":"ada-2026-pharm-p27-c3","text":"iabetes Investig 2022;13:292  298 41. Castellano E, Attanasio R, Giagulli VA, et al.; Associazione Medici Endocrinologi (AME). The basal to total insulin ratio in outpatients with diabetes on basal-bolus regimen. J Diabetes Metab Disord 2018; 17:393  399 42. Matejko B, Kukuka A, Kie  c-Wilk B, Sta pr A, Klupa T, Malecki MT. Basal insulin dose in adults with type 1 diabetes mellitus on insulin pumps in real-life clinical practice: a single-center experience. Adv Med 2018;2018:1473160 43. King AB. Mean basal insulin dose is 0.2 U/kg/d at near normal glycaemia for type 1 or 2 diabetes on continuous subcutaneous insulin infusion or once- nightly basal insulin. Diabetes Obesity Metabolism 2021;23:866  869 44. Peters Al, Lafell L. The American Diabetes Association/JDRF Type 1 Diabetes Sourcebook. American Diabetes Association, 2013 45. Chiang JL, Kirkman MS, Laffel LMB, Peters AL, Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 2014; 37:2034  2054 46. Smann A, Mhlhauser I, Bender R, Hunger- Dathe W, Kloos C, Mller UA. Flexible intensive insulin therapy in adults with type 1 diabetes and high risk for severe hypoglycemia and diabetic ketoacidosis. Diabetes Care 2006;29:2196  2199 47. Builes-Montao CE, Ortiz-Cano NA, Ramirez- Rincn A, Rojas-Henao NA. Efficacy and safety of ","tf":{"13":1,"17":1,"23":1,"29":1,"37":1,"41":1,"42":1,"43":1,"44":1,"45":1,"46":1,"47":1,"292":1,"298":1,"393":1,"399":1,"866":1,"869":1,"2006":1,"2013":1,"2014":1,"2018":3,"2021":1,"2022":1,"2034":1,"2054":1,"2196":1,"2199":1,"1473160":1,"iabetes":1,"investig":1,"castellano":1,"attanasio":1,"giagulli":1,"va":1,"et":1,"al":3,"associazione":1,"medici":1,"endocrinologi":1,"ame":1,"the":4,"basal":5,"to":1,"total":1,"insulin":7,"ratio":1,"in":4,"outpatients":1,"with":3,"diabetes":14,"on":3,"bolus":1,"regimen":1,"metab":1,"disord":1,"matejko":1,"kuku":1,"ka":1,"kie":1,"wilk":1,"sta":1,"klupa":1,"malecki":1,"mt":1,"dose":2,"adults":2,"type":6,"mellitus":1,"pumps":1,"real":1,"life":2,"clinical":1,"practice":1,"single":1,"center":1,"experience":1,"adv":1,"med":1,"king":1,"ab":1,"mean":1,"is":1,"kg":1,"at":1,"near":1,"normal":1,"glycaemia":1,"for":2,"or":2,"continuous":1,"subcutaneous":1,"infusion":1,"once":1,"nightly":1,"obesity":1,"metabolism":1,"peters":2,"lafell":1,"american":3,"association":3,"jdrf":1,"sourcebook":2,"chiang":1,"jl":1,"kirkman":1,"ms":1,"laffel":1,"lmb":1,"authors":1,"through":1,"span":1,"position":1,"statement":1,"of":2,"care":2,"mann":1,"hlhauser":1,"bender":1,"hunger":1,"dathe":1,"kloos":1,"ller":1,"ua":1,"flexible":1,"intensive":1,"therapy":1,"and":3,"high":1,"risk":1,"severe":1,"hypoglycemia":1,"diabetic":1,"ketoacidosis":1,"builes":1,"monta":1,"ce":1,"ortiz":1,"cano":1,"na":2,"ramirez":1,"rinc":1,"rojas":1,"henao":1,"efficacy":1,"safety":1},"len":204},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":27,"chunkId":"ada-2026-pharm-p27-c4","text":"tensive insulin therapy in adults with type 1 diabetes and high risk for severe hypoglycemia and diabetic ketoacidosis. Diabetes Care 2006;29:2196  2199 47. Builes-Montao CE, Ortiz-Cano NA, Ramirez- Rincn A, Rojas-Henao NA. Efficacy and safety of carbohydrate counting versus other forms of dietary advice in patients with type 1 diabetes mellitus: a systematic review and meta-analysis of randomised clinical trials. J Hum Nutr Diet 2022;35:1030  1042 48. Al Balwi R, Al Madani W, Al Ghamdi A. Efficacy of insulin dosing algorithms for high-fat high-protein mixed meals to control postprandial glycemic excursions in people living with type 1 diabetes: a systematic review and meta-analysis. Pediatr Diabetes 2022;23:1635  1646 49. DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: Dose Adjustment For Normal Eating (DAFNE) randomised controlled trial. BMJ 2002;325:746 50. Hopkins D, Lawrence I, Mansell P, et al. Improved biomedical and psychological outcomes 1 year after structured education in flexible insulin therapy for people with type 1 diabetes: the U.K. DAFNE experience. Diabetes Care 2012;35:1638  1642 51. Speight J, Amiel SA, Bradley C, et al. Long- term biomedical and psychosocial outcomes following DAFNE (Dose Adjustment For Normal Eating) structured education to promote intensive insulin thera","tf":{"23":1,"29":1,"35":2,"47":1,"48":1,"49":1,"50":1,"51":1,"325":1,"746":1,"1030":1,"1042":1,"1635":1,"1638":1,"1642":1,"1646":1,"2002":1,"2006":1,"2012":1,"2022":2,"2196":1,"2199":1,"tensive":1,"insulin":5,"therapy":2,"in":6,"adults":1,"with":5,"type":5,"diabetes":8,"and":7,"high":3,"risk":1,"for":5,"severe":1,"hypoglycemia":1,"diabetic":1,"ketoacidosis":1,"care":2,"builes":1,"monta":1,"ce":1,"ortiz":1,"cano":1,"na":2,"ramirez":1,"rinc":1,"rojas":1,"henao":1,"efficacy":2,"safety":1,"of":4,"carbohydrate":1,"counting":1,"versus":1,"other":1,"forms":1,"dietary":2,"advice":1,"patients":1,"mellitus":1,"systematic":2,"review":2,"meta":2,"analysis":2,"randomised":2,"clinical":1,"trials":1,"hum":1,"nutr":1,"diet":1,"al":5,"balwi":1,"madani":1,"ghamdi":1,"dosing":1,"algorithms":1,"fat":1,"protein":1,"mixed":1,"meals":1,"to":3,"control":1,"postprandial":1,"glycemic":1,"excursions":1,"people":3,"living":1,"pediatr":1,"dafne":4,"study":1,"group":1,"training":1,"flexible":2,"intensive":2,"management":1,"enable":1,"freedom":1,"dose":2,"adjustment":2,"normal":2,"eating":2,"controlled":1,"trial":1,"bmj":1,"hopkins":1,"lawrence":1,"mansell":1,"et":2,"improved":1,"biomedical":2,"psychological":1,"outcomes":2,"year":1,"after":1,"structured":2,"education":2,"the":1,"experience":1,"speight":1,"amiel":1,"sa":1,"bradley":1,"long":1,"term":1,"psychosocial":1,"following":1,"promote":1,"thera":1},"len":202},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":27,"chunkId":"ada-2026-pharm-p27-c5","text":"DAFNE experience. Diabetes Care 2012;35:1638  1642 51. Speight J, Amiel SA, Bradley C, et al. Long- term biomedical and psychosocial outcomes following DAFNE (Dose Adjustment For Normal Eating) structured education to promote intensive insulin therapy in adults with sub-optimally controlled type 1 diabetes. Diabetes Res Clin Pract 2010;89:22  29 52. Bruttomesso D, Boscari F, Lepore G, et al. A slide rule to adjust insulin dose using trend arrows in adults with type 1 diabetes: test in silico and in real life. Diabetes Ther 2021;12:1313  1324 53. Aleppo G, Laffel LM, Ahmann AJ, et al. A practical approach to using trend arrows on the Dexcom G5 CGM system for the management of adults with diabetes. J Endocr Soc 2017;1:1445  1460 54. Buckingham B, Xing D, Weinzimer S, et al.; Diabetes Research In Children Network (DirecNet) Study Group. Use of the DirecNet Applied Treatment Algorithm (DATA) for diabetes management with a real-time continuous glucose monitor (the FreeStyle Navigator). Pediatr Diabetes 2008;9:142  147 55. Parise M, Di Molfetta S, Graziano RT, et al. A head-to-head comparison of two algorithms for adjusting mealtime insulin doses based on CGM trend arrows in adult patients with type 1 diabetes: results from an exploratory study. Int J Environ Res Public Health 2023;20:3945 56. Petrovski G, Campbell J, Pasha M, et al. Simplified meal announcement versus precise","tf":{"12":1,"20":1,"22":1,"29":1,"35":1,"51":1,"52":1,"53":1,"54":1,"55":1,"56":1,"89":1,"142":1,"147":1,"1313":1,"1324":1,"1445":1,"1460":1,"1638":1,"1642":1,"2008":1,"2010":1,"2012":1,"2017":1,"2021":1,"2023":1,"3945":1,"dafne":2,"experience":1,"diabetes":10,"care":1,"speight":1,"amiel":1,"sa":1,"bradley":1,"et":6,"al":6,"long":1,"term":1,"biomedical":1,"and":2,"psychosocial":1,"outcomes":1,"following":1,"dose":2,"adjustment":1,"for":4,"normal":1,"eating":1,"structured":1,"education":1,"to":4,"promote":1,"intensive":1,"insulin":3,"therapy":1,"in":6,"adults":3,"with":5,"sub":1,"optimally":1,"controlled":1,"type":3,"res":2,"clin":1,"pract":1,"bruttomesso":1,"boscari":1,"lepore":1,"slide":1,"rule":1,"adjust":1,"using":2,"trend":3,"arrows":3,"test":1,"silico":1,"real":2,"life":1,"ther":1,"aleppo":1,"laffel":1,"lm":1,"ahmann":1,"aj":1,"practical":1,"approach":1,"on":2,"the":4,"dexcom":1,"g5":1,"cgm":2,"system":1,"management":2,"of":3,"endocr":1,"soc":1,"buckingham":1,"xing":1,"weinzimer":1,"research":1,"children":1,"network":1,"direcnet":2,"study":2,"group":1,"use":1,"applied":1,"treatment":1,"algorithm":1,"data":1,"time":1,"continuous":1,"glucose":1,"monitor":1,"freestyle":1,"navigator":1,"pediatr":1,"parise":1,"di":1,"molfetta":1,"graziano":1,"rt":1,"head":2,"comparison":1,"two":1,"algorithms":1,"adjusting":1,"mealtime":1,"doses":1,"based":1,"adult":1,"patients":1,"results":1,"from":1,"an":1,"exploratory":1,"int":1,"environ":1,"public":1,"health":1,"petrovski":1,"campbell":1,"pasha":1,"simplified":1,"meal":1,"announcement":1,"versus":1,"precise":1},"len":210},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":27,"chunkId":"ada-2026-pharm-p27-c6","text":"e insulin doses based on CGM trend arrows in adult patients with type 1 diabetes: results from an exploratory study. Int J Environ Res Public Health 2023;20:3945 56. Petrovski G, Campbell J, Pasha M, et al. Simplified meal announcement versus precise carbohydrate counting in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed loop system: a randomized controlled trial comparing glucose control. Diabetes Care 2023; 46:544  550 57. Turrin KB, Trujillo JM. Effects of diabetes numeracy on glycemic control and diabetes self- management behaviors in patients on insulin pump therapy. Diabetes Ther 2019;10:1337  1346 58. White RO, Wolff K, Cavanaugh KL, Rothman R. Addressing health literacy and numeracy to improve diabetes education and care. Diabetes Spectr 2010;23:238  243 59. Sacks DB, Arnold M, Bakris GL, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2023;46:e151  e199 60. Klonoff DC, Berard L, Franco DR, et al. Advance insulin injection technique and education with FITTER forward expert recommendations. Mayo Clin Proc 2025;100:682  699 61. Bergenstal RM, Strock ES, Peremislov D, Gibney MA, Parvu V, Hirsch LJ. Safety and efficacy of insulin therapy delivered via a 4mm pen needle in obese patients with diabetes. Mayo Clin Proc 2015; 90:329  338 62. Qiao Y-C, Ling W, P","tf":{"10":1,"20":1,"23":1,"46":2,"56":1,"57":1,"58":1,"59":1,"60":1,"61":1,"62":1,"90":1,"100":1,"238":1,"243":1,"329":1,"338":1,"544":1,"550":1,"682":1,"699":1,"1337":1,"1346":1,"2010":1,"2015":1,"2019":1,"2023":3,"2025":1,"3945":1,"insulin":4,"doses":1,"based":1,"on":3,"cgm":1,"trend":1,"arrows":1,"in":5,"adult":1,"patients":3,"with":4,"type":2,"diabetes":11,"results":1,"from":1,"an":1,"exploratory":1,"study":1,"int":1,"environ":1,"res":1,"public":1,"health":2,"petrovski":1,"campbell":1,"pasha":1,"et":3,"al":3,"simplified":1,"meal":1,"announcement":1,"versus":1,"precise":1,"carbohydrate":1,"counting":1,"adolescents":1,"using":1,"the":2,"minimed":1,"780g":1,"advanced":1,"hybrid":1,"closed":1,"loop":1,"system":1,"randomized":1,"controlled":1,"trial":1,"comparing":1,"glucose":1,"control":2,"care":3,"turrin":1,"kb":1,"trujillo":1,"jm":1,"effects":1,"of":3,"numeracy":2,"glycemic":1,"and":7,"self":1,"management":2,"behaviors":1,"pump":1,"therapy":2,"ther":1,"white":1,"ro":1,"wolff":1,"cavanaugh":1,"kl":1,"rothman":1,"addressing":1,"literacy":1,"to":1,"improve":1,"education":2,"spectr":1,"sacks":1,"db":1,"arnold":1,"bakris":1,"gl":1,"guidelines":1,"recommendations":2,"for":1,"laboratory":1,"analysis":1,"diagnosis":1,"mellitus":1,"e151":1,"e199":1,"klonoff":1,"dc":1,"berard":1,"franco":1,"dr":1,"advance":1,"injection":1,"technique":1,"fitter":1,"forward":1,"expert":1,"mayo":2,"clin":2,"proc":2,"bergenstal":1,"rm":1,"strock":1,"es":1,"peremislov":1,"gibney":1,"ma":1,"parvu":1,"hirsch":1,"lj":1,"safety":1,"efficacy":1,"delivered":1,"via":1,"4mm":1,"pen":1,"needle":1,"obese":1,"qiao":1,"ling":1},"len":209},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":27,"chunkId":"ada-2026-pharm-p27-c7","text":";100:682  699 61. Bergenstal RM, Strock ES, Peremislov D, Gibney MA, Parvu V, Hirsch LJ. Safety and efficacy of insulin therapy delivered via a 4mm pen needle in obese patients with diabetes. Mayo Clin Proc 2015; 90:329  338 62. Qiao Y-C, Ling W, Pan Y-H, et al. Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysis. Oncotarget 2017;8:66504  66515 63. Meng H, Zhang A, Liang Y, Hao J, Zhang X, Lu J. Effect of metformin on glycaemic control in patients with type 1 diabetes: a meta-analysis of randomized controlled trials. Diabetes Metab Res Rev 2018;34:e2983 64. Petrie JR, Chaturvedi N, Ford I, et al.; REMOVAL Study Group. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo- controlled trial. Lancet Diabetes Endocrinol 2017;5: 597  609 65. Mathieu C, Zinman B, Hemmingsson JU, et al.; ADJUNCT ONE Investigators. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care 2016;39:1702  1710 66. Ahrn B, Hirsch IB, Pieber TR, et al.; ADJUNCT TWO Investigators. Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial. Diabetes Care 2016;39:1693 ","tf":{"34":1,"39":2,"61":1,"62":1,"63":1,"64":1,"65":1,"66":1,"90":1,"100":1,"329":1,"338":1,"597":1,"609":1,"682":1,"699":1,"1693":1,"1702":1,"1710":1,"2015":1,"2016":2,"2017":2,"2018":1,"66504":1,"66515":1,"bergenstal":1,"rm":1,"strock":1,"es":1,"peremislov":1,"gibney":1,"ma":1,"parvu":1,"hirsch":2,"lj":1,"safety":4,"and":6,"efficacy":4,"of":7,"insulin":4,"therapy":2,"delivered":1,"via":1,"4mm":1,"pen":1,"needle":1,"in":6,"obese":1,"patients":4,"with":5,"diabetes":10,"mayo":1,"clin":1,"proc":1,"qiao":1,"ling":1,"pan":1,"et":4,"al":4,"pramlintide":1,"injection":1,"adjunct":5,"to":4,"type":5,"mellitus":1,"systematic":1,"review":1,"meta":2,"analysis":2,"oncotarget":1,"meng":1,"zhang":2,"liang":1,"hao":1,"lu":1,"effect":1,"metformin":2,"on":1,"glycaemic":1,"control":1,"randomized":3,"controlled":2,"trials":1,"metab":1,"res":1,"rev":1,"e2983":1,"petrie":1,"jr":1,"chaturvedi":1,"ford":1,"removal":2,"study":1,"group":1,"cardiovascular":1,"metabolic":1,"effects":1,"double":1,"blind":1,"randomised":1,"placebo":1,"trial":3,"lancet":1,"endocrinol":1,"mathieu":1,"zinman":1,"hemmingsson":1,"ju":1,"one":2,"investigators":2,"liraglutide":2,"added":2,"treatment":2,"the":2,"treat":1,"target":1,"care":2,"ahr":1,"ib":1,"pieber":1,"tr":1,"two":2,"capped":1,"subjects":1},"len":205},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":27,"chunkId":"ada-2026-pharm-p27-c8","text":";39:1702  1710 66. Ahrn B, Hirsch IB, Pieber TR, et al.; ADJUNCT TWO Investigators. Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial. Diabetes Care 2016;39:1693  1701 67. von Herrath M, Bain SC, Bode B, et al.; Anti- IL-21  liraglutide Study Group investigators and contributors. Anti-interleukin-21 antibody and liraglutide for the preservation of  -cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 2021;9:212  224 68. Garg SK, Kaur G, Haider Z, Rodriquez E, Beatson C, Snell-Bergeon J. Efficacy of semaglutide in over- diabetesjournals.org/care Pharmacologic Approaches to Glycemic Treatment S209 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"21":2,"39":2,"49":1,"66":1,"67":1,"68":1,"212":1,"224":1,"1693":1,"1701":1,"1702":1,"1710":1,"2016":1,"2021":1,"2026":1,"848878":1,"ahr":1,"hirsch":1,"ib":1,"pieber":1,"tr":1,"et":2,"al":2,"adjunct":2,"two":2,"investigators":2,"efficacy":2,"and":3,"safety":1,"of":3,"liraglutide":3,"added":1,"to":2,"capped":1,"insulin":1,"treatment":2,"in":3,"subjects":1,"with":2,"type":2,"diabetes":4,"the":2,"randomized":1,"trial":2,"care":3,"von":1,"herrath":1,"bain":1,"sc":1,"bode":1,"anti":2,"il":1,"study":1,"group":1,"contributors":1,"interleukin":1,"antibody":1,"for":1,"preservation":1,"cell":1,"function":1,"adults":1,"recent":1,"onset":1,"randomised":1,"double":1,"blind":1,"placebo":1,"controlled":1,"phase":1,"lancet":1,"endocrinol":1,"garg":1,"sk":1,"kaur":1,"haider":1,"rodriquez":1,"beatson":1,"snell":1,"bergeon":1,"semaglutide":1,"over":1,"diabetesjournals":2,"org":2,"pharmacologic":1,"approaches":1,"glycemic":1,"s209":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"supplement":1,"s183":1,"dc26s009":1,"by":1,"guest":1,"on":1,"february":1},"len":132},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":28,"chunkId":"ada-2026-pharm-p28-c0","text":"weight and obese patients with type 1 diabetes. Diabetes Technol Ther 2024;26:184  189 69. Garg SK, Akturk HK, Kaur G, Beatson C, Snell- Bergeon J. Efficacy and safety of tirzepatide in overweight and obese adult patients with type 1 diabetes. Diabetes Technol Ther 2024;26:367  374 70. Pasqua M-R, Tsoukas MA, Kobayati A, Aboznadah W, Jafar A, Haidar A. Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial. Nat Med 2025;31:1239  1245 71. Akturk HK, Dong F, Snell-Bergeon JK, Karakus KE, Shah VN. Efficacy and safety of tirzepatide in adults with type 1 diabetes: a proof of concept observational study. J Diabetes Sci Technol 2025;19:292  296 72. Shah VN, Akturk HK, Kruger D, et al. Semaglutide in adults with type 1 diabetes and obesity. NEJM Evid 2025;4:EVIDoa2500173 73. National Library of Medicine. National Center for Biotechnology Information. ClinicalTrials.gov. Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes (T1-DISCO) (NCT05819138). Accessed 23 August 2025. Available from https://clinicaltrials.gov/ study/NCT05819138?tab=results 74. National Library of Medicine. National Center for Biotechnology Information. ClinicalTrials.gov. Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes (RT1D) (NCT05822609). Accessed 20 August 2025. Available from https://www.clinicaltrials","tf":{"19":1,"20":1,"23":1,"26":2,"31":1,"69":1,"70":1,"71":1,"72":1,"73":1,"74":1,"184":1,"189":1,"292":1,"296":1,"367":1,"374":1,"1239":1,"1245":1,"2024":2,"2025":5,"weight":1,"and":5,"obese":2,"patients":2,"with":5,"type":7,"diabetes":10,"technol":3,"ther":2,"garg":1,"sk":1,"akturk":3,"hk":3,"kaur":1,"beatson":1,"snell":2,"bergeon":2,"efficacy":2,"safety":2,"of":7,"tirzepatide":2,"in":5,"overweight":1,"adult":1,"pasqua":1,"tsoukas":1,"ma":1,"kobayati":1,"aboznadah":1,"jafar":1,"haidar":1,"subcutaneous":1,"weekly":1,"semaglutide":4,"automated":1,"insulin":1,"delivery":1,"double":1,"blind":1,"randomized":1,"crossover":1,"trial":2,"nat":1,"med":1,"dong":1,"jk":1,"karakus":1,"ke":1,"shah":2,"vn":2,"adults":2,"proof":1,"concept":1,"observational":1,"study":2,"sci":1,"kruger":1,"et":1,"al":1,"obesity":1,"nejm":1,"evid":1,"evidoa2500173":1,"national":4,"library":2,"medicine":2,"center":2,"for":3,"biotechnology":2,"information":2,"clinicaltrials":4,"gov":3,"impacts":1,"on":1,"cardiovascular":1,"outcomes":1,"t1":1,"disco":1,"nct05819138":2,"accessed":2,"august":2,"available":2,"from":2,"https":2,"tab":1,"results":1,"diabetic":1,"kidney":1,"disease":1,"rt1d":1,"nct05822609":1,"www":1},"len":195},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":28,"chunkId":"ada-2026-pharm-p28-c1","text":"ional Library of Medicine. National Center for Biotechnology Information. ClinicalTrials.gov. Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes (RT1D) (NCT05822609). Accessed 20 August 2025. Available from https://www.clinicaltrials. gov/study/NCT05822609 75. National Library of Medicine. National Center for Biotechnology Information. ClinicalTrials.gov. Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide (SEMA SMA) (NCT06387199). Accessed 20 August 2025. Available from https://clinicaltrials.gov/study/NCT06387199 76. National Library of Medicine. National Center for Biotechnology Information. ClinicalTrials.gov. Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment (NCT06411210). Accessed 20 August 2025. Available from https:// clinicaltrials.gov/study/NCT06411210 77. Rao L, Ren C, Luo S, Huang C, Li X. Sodium- glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: meta-analysis of randomized controlled trials. Acta Diabetol 2021;58:869  880 78. Li M, Liu Z, Yang X, et al. The effect of sodium-glucose cotransporter 2 inhibitors as an adjunct to insulin in patients with type 1 diabetes assessed by continuous glucose monitoring: a systematic review and meta-analysis. J Diabetes Complications 2023;37:108632 79. Chen M-B","tf":{"20":3,"37":1,"58":1,"75":1,"76":1,"77":1,"78":1,"79":1,"869":1,"880":1,"2021":1,"2023":1,"2025":3,"108632":1,"ional":1,"library":3,"of":6,"medicine":3,"national":5,"center":3,"for":6,"biotechnology":3,"information":3,"clinicaltrials":6,"gov":6,"trial":1,"semaglutide":2,"diabetic":1,"kidney":1,"disease":1,"in":2,"type":5,"diabetes":6,"rt1d":1,"nct05822609":2,"accessed":3,"august":3,"available":3,"from":3,"https":3,"www":1,"study":3,"alleviating":1,"carbohydrate":1,"counting":1,"patients":2,"with":3,"using":1,"closed":1,"loop":1,"system":1,"weekly":1,"subcutaneous":1,"sema":1,"sma":1,"nct06387199":2,"obesity":2,"complicating":1,"glp":1,"analogue":1,"anti":1,"treatment":1,"nct06411210":2,"rao":1,"ren":1,"luo":1,"huang":1,"li":2,"sodium":2,"glucose":3,"cotransporter":2,"inhibitors":2,"as":2,"an":2,"add":1,"on":1,"therapy":1,"to":2,"insulin":2,"mellitus":1,"meta":2,"analysis":2,"randomized":1,"controlled":1,"trials":1,"acta":1,"diabetol":1,"liu":1,"yang":1,"et":1,"al":1,"the":1,"effect":1,"adjunct":1,"assessed":1,"by":1,"continuous":1,"monitoring":1,"systematic":1,"review":1,"and":1,"complications":1,"chen":1},"len":183},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":28,"chunkId":"ada-2026-pharm-p28-c2","text":". The effect of sodium-glucose cotransporter 2 inhibitors as an adjunct to insulin in patients with type 1 diabetes assessed by continuous glucose monitoring: a systematic review and meta-analysis. J Diabetes Complications 2023;37:108632 79. Chen M-B, Xu R-J, Zheng Q-H, Zheng X-W, Wang H. Efficacy and safety of sotagliflozin adjuvant therapy for type 1 diabetes mellitus: a systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e20875 80. U.S. Food and Drug Administration. FDA Introductory Remarks: January 17, 2019: Endocrinologic and Metabolic Drugs Advisory Committee Meeting. 2019. Accessed 25 August 2025. Available from https://wayback.archive-it.org/ 7993/20190207212714/https://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeeting Materials/Drugs/EndocrinologicandMetabolicDrugs AdvisoryCommittee/UCM629782.pdf 81. Bhatt DL, Szarek M, Steg PG, et al.; SOLOIST- WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 2021;384:117  128 82. Bhatt DL, Szarek M, Pitt B, et al.; SCORED Investigators. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 2021;384: 129  139 83. Danne T, Garg S, Peters AL, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Car","tf":{"17":1,"25":1,"37":1,"79":1,"80":1,"81":1,"82":1,"83":1,"99":1,"117":1,"128":1,"129":1,"139":1,"384":2,"2019":2,"2020":1,"2021":2,"2023":1,"2025":1,"7993":1,"108632":1,"the":1,"effect":1,"of":3,"sodium":2,"glucose":3,"cotransporter":2,"inhibitors":2,"as":1,"an":1,"adjunct":1,"to":1,"insulin":1,"in":4,"patients":4,"with":5,"type":3,"diabetes":7,"assessed":1,"by":1,"continuous":1,"monitoring":1,"systematic":2,"review":2,"and":7,"meta":2,"analysis":2,"complications":1,"chen":1,"xu":1,"zheng":2,"wang":1,"efficacy":1,"safety":1,"sotagliflozin":3,"adjuvant":1,"therapy":1,"for":1,"mellitus":1,"medicine":1,"baltimore":1,"e20875":1,"food":1,"drug":1,"administration":1,"fda":2,"introductory":1,"remarks":1,"january":1,"endocrinologic":1,"metabolic":1,"drugs":2,"advisory":1,"committee":1,"meeting":1,"accessed":1,"august":1,"available":1,"from":1,"https":2,"wayback":1,"archive":1,"it":1,"org":1,"20190207212714":1,"www":1,"gov":1,"downloads":1,"advisorycommittees":1,"committeesmeeting":1,"materials":1,"endocrinologicandmetabolicdrugs":1,"advisorycommittee":1,"ucm629782":1,"pdf":1,"bhatt":2,"dl":2,"szarek":2,"steg":1,"pg":1,"et":3,"al":4,"soloist":1,"whf":1,"trial":1,"investigators":2,"recent":1,"worsening":1,"heart":1,"failure":1,"engl":2,"med":2,"pitt":1,"scored":1,"chronic":1,"kidney":1,"disease":1,"danne":1,"garg":1,"peters":1,"international":1,"consensus":1,"on":1,"risk":1,"management":1,"diabetic":1,"ketoacidosis":1,"treated":1,"sglt":1,"car":1},"len":185},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":28,"chunkId":"ada-2026-pharm-p28-c3","text":"se. N Engl J Med 2021;384: 129  139 83. Danne T, Garg S, Peters AL, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care 2019;42:1147  1154 84. Herold KC, Bundy BN, Long SA, et al.; Type 1 Diabetes TrialNet Study Group. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 2019;381:603  613 85. Lachin JM, McGee P, Palmer JP; DCCT/EDIC Research Group. Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes 2014;63: 739  748 86. Kosheleva L, Koshelev D, Lagunas-Rangel FA, Levit S, Rabinovitch A, Schith HB. Disease-modifying pharmacological treatments of type 1 diabetes: molecular mechanisms, target checkpoints, and possible combinatorial treatments. Pharmacol Rev 2025;77:100044 87. Dean PG, Kukla A, Stegall MD, Kudva YC. Pancreas transplantation. BMJ 2017;357:j1321 88. U.S. Food & Drug Administration. Lantidra. Accessed 25 August 2025. Available from https:// www.fda.gov/vaccines-blood-biologics/lantidra 89. Geta ET, Terefa DR, Hailu WB, et al. Effectiveness of shared decision-making for glycaemic control among type 2 diabetes mellitus adult patients: a systematic review and meta-analysis. PLoS One 2024;19:e0306296 90. Davies MJ, Aroda VR, Coll","tf":{"19":1,"25":1,"42":1,"63":1,"77":1,"83":1,"84":1,"85":1,"86":1,"87":1,"88":1,"89":1,"90":1,"129":1,"139":1,"357":1,"381":1,"384":1,"603":1,"613":1,"739":1,"748":1,"1147":1,"1154":1,"2014":1,"2017":1,"2019":2,"2021":1,"2024":1,"2025":2,"100044":1,"se":1,"engl":2,"med":2,"danne":1,"garg":1,"peters":1,"al":4,"et":4,"international":1,"consensus":1,"on":2,"risk":2,"management":1,"of":4,"diabetic":1,"ketoacidosis":1,"in":3,"patients":2,"with":2,"type":5,"diabetes":8,"treated":1,"sodium":1,"glucose":1,"cotransporter":1,"sglt":1,"inhibitors":1,"care":1,"herold":1,"kc":1,"bundy":1,"bn":1,"long":1,"sa":1,"trialnet":1,"study":1,"group":2,"an":1,"anti":1,"cd3":1,"antibody":1,"teplizumab":1,"relatives":1,"at":1,"for":2,"lachin":1,"jm":1,"mcgee":1,"palmer":1,"jp":1,"dcct":1,"edic":1,"research":1,"impact":1,"peptide":1,"preservation":1,"metabolic":1,"and":4,"clinical":1,"outcomes":1,"the":1,"control":2,"complications":1,"trial":1,"kosheleva":1,"koshelev":1,"lagunas":1,"rangel":1,"fa":1,"levit":1,"rabinovitch":1,"schi":1,"th":1,"hb":1,"disease":1,"modifying":1,"pharmacological":1,"treatments":2,"molecular":1,"mechanisms":1,"target":1,"checkpoints":1,"possible":1,"combinatorial":1,"pharmacol":1,"rev":1,"dean":1,"pg":1,"kukla":1,"stegall":1,"md":1,"kudva":1,"yc":1,"pancreas":1,"transplantation":1,"bmj":1,"j1321":1,"food":1,"drug":1,"administration":1,"lantidra":2,"accessed":1,"august":1,"available":1,"from":1,"https":1,"www":1,"fda":1,"gov":1,"vaccines":1,"blood":1,"biologics":1,"geta":1,"terefa":1,"dr":1,"hailu":1,"wb":1,"effectiveness":1,"shared":1,"decision":1,"making":1,"glycaemic":1,"among":1,"mellitus":1,"adult":1,"systematic":1,"review":1,"meta":1,"analysis":1,"plos":1,"one":1,"e0306296":1,"davies":1,"mj":1,"aroda":1,"vr":1,"coll":1},"len":206},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":28,"chunkId":"ada-2026-pharm-p28-c4","text":"tidra 89. Geta ET, Terefa DR, Hailu WB, et al. Effectiveness of shared decision-making for glycaemic control among type 2 diabetes mellitus adult patients: a systematic review and meta-analysis. PLoS One 2024;19:e0306296 90. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022;45: 2753  2786 91. Lingvay I, Sumithran P, Cohen RV, Le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet 2022;399:394  405 92. Wing RR, Lang W, Wadden TA, et al.; Look AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011;34:1481  1486 93. Adler AI, Coleman RL, Leal J, Whiteley WN, Clarke P, Holman RR. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet 2024;404:145  155 94. Kunutsor SK, Balasubramanian VG, Zaccardi F, et al. Glycaemic control and macrovascular and microvascular outcomes: a systematic review and meta-analysis of trials investigating intensive glucose-lowering strategies in people with type 2 diabetes. Diabetes Obes ","tf":{"10":1,"19":1,"24":1,"34":1,"45":1,"89":1,"90":1,"91":2,"92":1,"93":1,"94":1,"145":1,"155":1,"394":1,"399":1,"404":1,"405":1,"1481":1,"1486":1,"2011":1,"2022":3,"2024":2,"2753":1,"2786":1,"tidra":1,"geta":1,"et":5,"terefa":1,"dr":1,"hailu":1,"wb":1,"al":4,"effectiveness":1,"of":7,"shared":1,"decision":1,"making":1,"for":3,"glycaemic":3,"control":3,"among":1,"type":6,"diabetes":11,"mellitus":1,"adult":1,"patients":1,"systematic":2,"review":2,"and":6,"meta":2,"analysis":2,"plos":1,"one":1,"e0306296":1,"davies":1,"mj":1,"aroda":1,"vr":1,"collins":1,"bs":1,"management":2,"hyperglycemia":1,"in":5,"consensus":1,"report":1,"by":1,"the":4,"american":1,"association":2,"ada":1,"european":1,"study":1,"easd":1,"care":2,"lingvay":1,"sumithran":1,"cohen":1,"rv":1,"le":1,"roux":1,"cw":1,"obesity":1,"as":1,"primary":1,"treatment":1,"goal":1,"time":1,"to":2,"reframe":1,"conversation":1,"lancet":2,"wing":1,"rr":2,"lang":1,"wadden":1,"ta":1,"look":1,"ahead":1,"research":1,"group":1,"benefits":1,"modest":1,"weight":1,"loss":1,"improving":1,"cardiovascular":1,"risk":1,"factors":1,"overweight":1,"obese":1,"individuals":1,"with":2,"adler":1,"ai":1,"coleman":1,"rl":1,"leal":1,"whiteley":1,"wn":1,"clarke":1,"holman":1,"post":1,"trial":2,"monitoring":1,"randomised":1,"controlled":1,"intensive":2,"extended":1,"from":1,"years":2,"ukpds":1,"kunutsor":1,"sk":1,"balasubramanian":1,"vg":1,"zaccardi":1,"macrovascular":1,"microvascular":1,"outcomes":1,"trials":1,"investigating":1,"glucose":1,"lowering":1,"strategies":1,"people":1,"obes":1},"len":210},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":28,"chunkId":"ada-2026-pharm-p28-c5","text":" Balasubramanian VG, Zaccardi F, et al. Glycaemic control and macrovascular and microvascular outcomes: a systematic review and meta-analysis of trials investigating intensive glucose-lowering strategies in people with type 2 diabetes. Diabetes Obes Metab 2024;26:2069  2081 95. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577  1589 96. Bahardoust M, Mousavi S, Yariali M, et al. Effect of metformin (vs. placebo or sulfonylurea) on all- cause and cardiovascular mortality and incident cardiovascular events in patients with diabetes: an umbrella review of systematic reviews with meta- analysis. J Diabetes Metab Disord 2024;23:27  38 97. Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin- based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2016;164:740  751 98. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012;344:e1369 99. U.S. Food & Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. Accessed 25 August 2025. Available fr","tf":{"10":1,"23":1,"25":1,"26":1,"27":1,"38":1,"95":1,"96":1,"97":1,"98":1,"99":1,"164":1,"344":1,"359":1,"740":1,"751":1,"1577":1,"1589":1,"2008":1,"2012":1,"2016":1,"2024":2,"2025":1,"2069":1,"2081":1,"balasubramanian":1,"vg":1,"zaccardi":1,"et":3,"al":3,"glycaemic":1,"control":2,"and":7,"macrovascular":1,"microvascular":1,"outcomes":1,"systematic":4,"review":4,"meta":4,"analysis":4,"of":6,"trials":1,"investigating":1,"intensive":2,"glucose":2,"lowering":1,"strategies":1,"in":5,"people":1,"with":4,"type":4,"diabetes":9,"obes":1,"metab":2,"holman":1,"rr":1,"paul":1,"sk":1,"bethel":1,"ma":1,"matthews":2,"dr":2,"neil":1,"haw":1,"year":1,"follow":1,"up":1,"engl":1,"med":2,"bahardoust":1,"mousavi":1,"yariali":1,"effect":1,"metformin":3,"vs":1,"placebo":1,"or":2,"sulfonylurea":1,"on":1,"all":1,"cause":1,"cardiovascular":2,"mortality":1,"incident":1,"events":1,"patients":2,"an":1,"umbrella":1,"reviews":1,"disord":1,"maruthur":1,"nm":1,"tseng":1,"hutfless":1,"medications":1,"as":1,"monotherapy":1,"based":1,"combination":1,"therapy":1,"for":2,"ann":1,"intern":1,"karagiannis":1,"paschos":1,"paletas":1,"tsapas":1,"dipeptidyl":1,"peptidase":1,"inhibitors":1,"treatment":1,"mellitus":1,"the":2,"clinical":1,"setting":1,"bmj":1,"e1369":1,"food":1,"drug":2,"administration":1,"fda":2,"safety":1,"communication":1,"revises":1,"warnings":1,"regarding":1,"use":1,"medicine":1,"certain":1,"reduced":1,"kidney":1,"function":1,"accessed":1,"august":1,"available":1,"fr":1},"len":198},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":28,"chunkId":"ada-2026-pharm-p28-c6","text":"ysis. BMJ 2012;344:e1369 99. U.S. Food & Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. Accessed 25 August 2025. Available from https:// www.fda.gov/drugs/drug-safety-and-availability/fda- drug-safety-communication-fda-revises-warnings- regarding-use-diabetes-medicine-metformin-certain 100. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003;163:2594  2602 101. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010;2010:CD002967 102. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011;34:1431  1437 103. Out M, Kooy A, Lehert P, Schalkwijk CA, Stehouwer CDA. Long-term treatment with metformin in type 2 diabetes and methylmalonic acid: post hoc analysis of a randomized controlled 4.3year trial. J Diabetes Complications 2018;32:171  178 104. Aroda VR, Edelstein SL, Goldberg RB, et al.; Diabetes Prevention Program Research Group. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcom","tf":{"25":1,"32":1,"34":1,"99":1,"100":1,"101":1,"102":1,"103":1,"104":1,"163":1,"171":1,"178":1,"344":1,"1431":1,"1437":1,"2003":1,"2010":2,"2011":1,"2012":1,"2018":1,"2025":1,"2594":1,"2602":1,"ysis":1,"bmj":1,"e1369":1,"food":1,"drug":4,"administration":1,"fda":5,"safety":3,"communication":2,"revises":2,"warnings":2,"regarding":2,"use":6,"of":6,"the":3,"diabetes":9,"medicine":2,"metformin":7,"in":6,"certain":2,"patients":1,"with":4,"reduced":1,"kidney":1,"function":1,"accessed":1,"august":1,"available":1,"from":1,"https":1,"www":1,"gov":1,"drugs":1,"and":6,"availability":1,"salpeter":4,"sr":2,"greyber":2,"pasternak":2,"ga":2,"ee":2,"risk":2,"fatal":2,"nonfatal":2,"lactic":2,"acidosis":2,"type":3,"mellitus":2,"systematic":1,"review":1,"meta":1,"analysis":2,"arch":1,"intern":1,"med":1,"cochrane":1,"database":1,"syst":1,"rev":1,"cd002967":1,"lipska":1,"kj":1,"bailey":1,"cj":1,"inzucchi":1,"se":1,"setting":1,"mild":1,"to":1,"moderate":1,"renal":1,"insufficiency":1,"care":1,"out":1,"kooy":1,"lehert":1,"schalkwijk":1,"ca":1,"stehouwer":1,"cda":1,"long":2,"term":2,"treatment":1,"methylmalonic":1,"acid":1,"post":1,"hoc":1,"randomized":1,"controlled":1,"3year":1,"trial":1,"complications":1,"aroda":1,"vr":1,"edelstein":1,"sl":1,"goldberg":1,"rb":1,"et":1,"al":1,"prevention":2,"program":2,"research":1,"group":1,"vitamin":1,"b12":1,"deficiency":1,"outcom":1},"len":207},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":28,"chunkId":"ada-2026-pharm-p28-c7","text":"olled 4.3year trial. J Diabetes Complications 2018;32:171  178 104. Aroda VR, Edelstein SL, Goldberg RB, et al.; Diabetes Prevention Program Research Group. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab 2016;101:1754  1761 105. Fras JP, Davies MJ, Rosenstock J, et al.; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 2021;385:503  515 106. Sorli C, Harashima S-I, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol 2017;5:251  260 107. Tsapas A, Avgerinos I, Karagiannis T, et al. Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. Ann Intern Med 2020; 173:278  286 108. Nathan DM, Lachin JM, Balasubramanyam A, et al.; GRADE Study Research Group. Glycemia reduction in type 2 diabetes - glycemic outcomes. N Engl J Med 2022;387:1063  1074 109. Babu A, Mehta A, Guerrero P, et al. Safe and simple emergency department discharge therapy for patients with type 2 diabetes mellitus and severe hyperglycemia. Endocr Pract 2009;15:696  704 110. Buse JB, Pete","tf":{"15":1,"32":1,"101":1,"104":1,"105":1,"106":1,"107":1,"108":1,"109":1,"110":1,"171":1,"173":1,"178":1,"251":1,"260":1,"278":1,"286":1,"385":1,"387":1,"503":1,"515":1,"696":1,"704":1,"1063":1,"1074":1,"1754":1,"1761":1,"2009":1,"2016":1,"2017":1,"2018":1,"2020":1,"2021":1,"2022":1,"olled":1,"3year":1,"trial":2,"diabetes":9,"complications":1,"aroda":1,"vr":1,"edelstein":1,"sl":1,"goldberg":1,"rb":1,"et":6,"al":6,"prevention":2,"program":2,"research":2,"group":3,"long":1,"term":1,"metformin":1,"use":1,"and":5,"vitamin":1,"b12":1,"deficiency":1,"in":4,"the":1,"outcomes":2,"study":2,"clin":1,"endocrinol":2,"metab":1,"fr":1,"as":1,"jp":1,"davies":1,"mj":1,"rosenstock":1,"surpass":1,"investigators":1,"tirzepatide":1,"versus":2,"semaglutide":2,"once":2,"weekly":2,"patients":3,"with":3,"type":5,"engl":2,"med":3,"sorli":1,"harashima":1,"tsoukas":1,"gm":1,"efficacy":1,"safety":1,"of":2,"monotherapy":1,"placebo":2,"sustain":1,"double":1,"blind":1,"randomised":1,"controlled":1,"parallel":1,"multinational":1,"multicentre":1,"phase":1,"3a":1,"lancet":1,"tsapas":1,"avgerinos":1,"karagiannis":1,"comparative":1,"effectiveness":1,"glucose":1,"lowering":1,"drugs":1,"for":2,"systematic":1,"review":1,"network":1,"meta":1,"analysis":1,"ann":1,"intern":1,"nathan":1,"dm":1,"lachin":1,"jm":1,"balasubramanyam":1,"grade":1,"glycemia":1,"reduction":1,"glycemic":1,"babu":1,"mehta":1,"guerrero":1,"safe":1,"simple":1,"emergency":1,"department":1,"discharge":1,"therapy":1,"mellitus":1,"severe":1,"hyperglycemia":1,"endocr":1,"pract":1,"buse":1,"jb":1,"pete":1},"len":198},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":28,"chunkId":"ada-2026-pharm-p28-c8","text":". N Engl J Med 2022;387:1063  1074 109. Babu A, Mehta A, Guerrero P, et al. Safe and simple emergency department discharge therapy for patients with type 2 diabetes mellitus and severe hyperglycemia. Endocr Pract 2009;15:696  704 110. Buse JB, Peters A, Russell-Jones D, et al. Is insulin the most effective injectable antihyperglycaemic therapy? Diabetes Obes Metab 2015;17:145  151 111. DAlessio D, Hring H-U, Charbonnel B, et al.; EAGLE Investigators. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes. Diabetes Obes Metab 2015;17:170  178 S210 Pharmacologic Approaches to Glycemic Treatment Diabetes Care Volume 49, Supplement 1, January 2026 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"15":1,"17":3,"49":2,"109":1,"110":1,"111":1,"145":1,"151":1,"170":1,"178":1,"387":1,"696":1,"704":1,"1063":1,"1074":1,"2009":1,"2015":2,"2022":1,"2026":2,"848878":1,"engl":1,"med":1,"babu":1,"mehta":1,"guerrero":1,"et":3,"al":3,"safe":1,"and":3,"simple":1,"emergency":1,"department":1,"discharge":1,"therapy":2,"for":1,"patients":2,"with":2,"type":2,"diabetes":5,"mellitus":1,"severe":1,"hyperglycemia":1,"endocr":1,"pract":1,"buse":1,"jb":1,"peters":1,"russell":1,"jones":1,"is":1,"insulin":2,"the":1,"most":1,"effective":1,"injectable":1,"antihyperglycaemic":1,"obes":2,"metab":2,"alessio":1,"ring":1,"charbonnel":1,"eagle":1,"investigators":1,"comparison":1,"of":1,"glargine":1,"liraglutide":1,"added":1,"to":2,"oral":1,"agents":1,"in":1,"poorly":1,"controlled":1,"s210":1,"pharmacologic":1,"approaches":1,"glycemic":1,"treatment":1,"care":2,"volume":1,"supplement":2,"january":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"s183":1,"dc26s009":1,"by":1,"guest":1,"on":1,"february":1},"len":122},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":29,"chunkId":"ada-2026-pharm-p29-c0","text":"112. Cahn A, Cefalu WT. Clinical considerations for use of initial combination therapy in type 2 diabetes. Diabetes Care 2016;39(Suppl. 2):S137  S145 113. Abdul-Ghani MA, Puckett C, Triplitt C, et al. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new- onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. Diabetes Obes Metab 2015;17:268  275 114. Cai X, Gao X, Yang W, Han X, Ji L. Efficacy and safety of initial combination therapy in treatment- nave type 2 diabetes patients: a systematic review and meta-analysis. Diabetes Ther 2018;9:1995  2014 115. Aroda VR, Gonzlez-Galvez G, Grn R, et al. Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol 2019;7:596  605 116. Khunti K, Davies MJ. Clinical inertia-time to reappraise the terminology? Prim Care Diabetes 2017;11:105  106 117. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011;154: 602  613 118. Maloney A, Rosenstock J, Fonseca V. A model-","tf":{"11":1,"17":1,"39":1,"105":1,"106":1,"112":1,"113":1,"114":1,"115":1,"116":1,"117":1,"118":1,"154":1,"268":1,"275":1,"596":1,"602":1,"605":1,"613":1,"1995":1,"2011":1,"2014":1,"2015":1,"2016":1,"2017":1,"2018":1,"2019":1,"cahn":1,"cefalu":1,"wt":1,"clinical":2,"considerations":1,"for":3,"use":1,"of":5,"initial":5,"combination":4,"therapy":6,"in":4,"type":5,"diabetes":11,"care":2,"suppl":1,"s137":1,"s145":1,"abdul":1,"ghani":1,"ma":1,"puckett":1,"triplitt":1,"et":3,"al":3,"with":2,"metformin":1,"pioglitazone":1,"and":6,"exenatide":1,"is":1,"more":1,"effective":1,"than":1,"sequential":1,"add":1,"on":1,"subjects":1,"new":2,"onset":1,"results":1,"from":1,"the":2,"efficacy":2,"durability":2,"edict":1,"randomized":1,"trial":2,"obes":1,"metab":1,"cai":1,"gao":1,"yang":1,"han":1,"ji":1,"safety":2,"treatment":1,"na":1,"ve":1,"patients":1,"systematic":1,"review":1,"meta":1,"analysis":1,"ther":1,"aroda":1,"vr":1,"gonz":1,"lez":1,"galvez":1,"gr":1,"insulin":2,"degludec":1,"plus":1,"liraglutide":1,"versus":1,"glargine":1,"u100":1,"as":1,"injectable":1,"dual":1,"viii":1,"multicentre":1,"open":1,"label":1,"phase":1,"3b":1,"randomised":1,"controlled":1,"lancet":1,"endocrinol":1,"khunti":1,"davies":1,"mj":1,"inertia":1,"time":1,"to":1,"reappraise":1,"terminology":1,"prim":1,"bennett":1,"wl":1,"maruthur":1,"nm":1,"singh":1,"comparative":1,"effectiveness":1,"medications":1,"an":1,"update":1,"including":1,"drugs":1,"drug":1,"combinations":1,"ann":1,"intern":1,"med":1,"maloney":1,"rosenstock":1,"fonseca":1,"model":1},"len":202},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":29,"chunkId":"ada-2026-pharm-p29-c1","text":"nett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011;154: 602  613 118. Maloney A, Rosenstock J, Fonseca V. A model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes: comparison of treatment effects at therapeutic doses. Clin Pharmacol Ther 2019;105:1213  1223 119. Lajthia E, Bucheit JD, Nadpara PA, et al. Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series. Pharm Pract (Granada) 2019;17:1588 120. Violante R, Oliveira JHA, Yoon K-H, et al. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin. Diabet Med 2012;29:e417  e424 121. Nauck MA, Kahle M, Baranov O, Deacon CF, Holst JJ. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: a randomized controlled trial in patients with type 2 diabetes. Diabetes Obes Metab 2017;19:200  207 122. Pratley R, Amod A, Hoff ST, et al.; PIONEER 4 investigators. Oral semaglutide versus subcutaneous liragluti","tf":{"17":1,"19":1,"24":1,"29":1,"105":1,"118":1,"119":1,"120":1,"121":1,"122":1,"154":1,"200":1,"207":1,"602":1,"613":1,"1213":1,"1223":1,"1588":1,"2011":1,"2012":1,"2017":1,"2019":2,"nett":1,"wl":1,"maruthur":1,"nm":1,"singh":1,"et":4,"al":4,"comparative":1,"effectiveness":1,"and":4,"safety":1,"of":5,"medications":1,"for":2,"type":5,"diabetes":6,"an":1,"update":1,"including":1,"new":1,"drugs":2,"drug":1,"combinations":1,"ann":1,"intern":1,"med":2,"maloney":1,"rosenstock":1,"fonseca":1,"model":1,"based":1,"meta":1,"analysis":1,"antihyperglycemic":1,"comparison":1,"treatment":1,"effects":1,"at":1,"therapeutic":1,"doses":1,"clin":1,"pharmacol":1,"ther":1,"lajthia":1,"bucheit":1,"jd":1,"nadpara":1,"pa":1,"combination":1,"therapy":2,"with":4,"once":1,"weekly":1,"glucagon":2,"like":2,"peptide":2,"receptor":2,"agonists":1,"dipeptidyl":2,"peptidase":2,"inhibitors":1,"in":3,"case":1,"series":1,"pharm":1,"pract":1,"granada":1,"violante":1,"oliveira":1,"jha":1,"yoon":1,"randomized":2,"non":1,"inferiority":1,"study":1,"comparing":1,"the":2,"addition":2,"exenatide":2,"twice":2,"daily":2,"to":3,"sitagliptin":4,"or":1,"switching":1,"from":1,"patients":2,"experiencing":1,"inadequate":1,"glycaemic":1,"control":1,"on":1,"metformin":1,"diabet":1,"e417":1,"e424":1,"nauck":1,"ma":1,"kahle":1,"baranov":1,"deacon":1,"cf":1,"holst":1,"jj":1,"inhibitor":1,"ongoing":1,"agonist":1,"liraglutide":1,"controlled":1,"trial":1,"obes":1,"metab":1,"pratley":1,"amod":1,"hoff":1,"st":1,"pioneer":1,"investigators":1,"oral":1,"semaglutide":1,"versus":1,"subcutaneous":1,"liragluti":1},"len":195},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":29,"chunkId":"ada-2026-pharm-p29-c2","text":"ide-1 receptor agonist liraglutide: a randomized controlled trial in patients with type 2 diabetes. Diabetes Obes Metab 2017;19:200  207 122. Pratley R, Amod A, Hoff ST, et al.; PIONEER 4 investigators. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet 2019;394:39  50 123. Del Prato S, Kahn SE, Pavo I, et al.; SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 2021;398:1811  1824 124. Singh S, Wright EE, Kwan AYM, et al. Glucagon- like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab 2017;19:228  238 125. Levin PA, Nguyen H, Wittbrodt ET, Kim SC. Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes Metab Syndr Obes 2017;10:123  139 126. Abd El Aziz MS, Kahle M, Meier JJ, Nauck MA. A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab 2017;19:216  227 127. Giorgino F, Benroubi M, Sun J-H, Zimmermann AG, Pechtner V. Efficacy an","tf":{"10":1,"19":3,"39":1,"50":1,"122":1,"123":2,"124":1,"125":1,"126":1,"127":1,"139":1,"200":1,"207":1,"216":1,"227":1,"228":1,"238":1,"394":1,"398":1,"1811":1,"1824":1,"2017":4,"2019":1,"2021":1,"ide":1,"receptor":4,"agonist":1,"liraglutide":2,"randomized":1,"controlled":1,"trial":3,"in":4,"patients":2,"with":2,"type":5,"diabetes":8,"obes":4,"metab":4,"pratley":1,"amod":1,"hoff":1,"st":1,"et":4,"al":3,"pioneer":2,"investigators":2,"oral":1,"semaglutide":1,"versus":3,"subcutaneous":1,"and":3,"placebo":1,"randomised":2,"double":1,"blind":1,"phase":2,"3a":1,"lancet":2,"del":1,"prato":1,"kahn":1,"se":1,"pavo":1,"surpass":2,"tirzepatide":1,"insulin":2,"glargine":1,"increased":1,"cardiovascular":1,"risk":1,"open":1,"label":1,"parallel":1,"group":1,"multicentre":1,"singh":1,"wright":1,"ee":1,"kwan":1,"aym":1,"glucagon":2,"like":2,"peptide":2,"agonists":3,"compared":1,"basal":1,"insulins":1,"for":1,"the":1,"treatment":2,"of":3,"mellitus":1,"systematic":2,"review":2,"meta":2,"analysis":2,"levin":1,"pa":1,"nguyen":1,"wittbrodt":1,"kim":1,"sc":1,"comparative":1,"effectiveness":1,"research":1,"syndr":1,"abd":1,"el":1,"aziz":1,"ms":1,"kahle":1,"meier":1,"jj":1,"nauck":1,"ma":1,"comparing":1,"clinical":1,"effects":1,"short":1,"or":1,"long":1,"acting":1,"glp":1,"from":1,"head":2,"to":1,"studies":1,"diabetic":1,"giorgino":1,"benroubi":1,"sun":1,"zimmermann":1,"ag":1,"pechtner":1,"efficacy":1,"an":1},"len":199},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":29,"chunkId":"ada-2026-pharm-p29-c3","text":"ffects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab 2017;19:216  227 127. Giorgino F, Benroubi M, Sun J-H, Zimmermann AG, Pechtner V. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care 2015;38:2241  2249 128. Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once- daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open- label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol 2017;5:355  366 129. Davies M, Heller S, Sreenan S, et al. Once- weekly exenatide versus once- or twice-daily insulin detemir. Diabetes Care 2013;36:1368  1376 130. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010;375:2234  2243 131. Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA 2022;327:534  545 13","tf":{"13":1,"19":1,"36":1,"38":1,"127":1,"128":1,"129":1,"130":1,"131":1,"216":1,"227":1,"327":1,"355":1,"366":1,"375":1,"534":1,"545":1,"1368":1,"1376":1,"2010":1,"2013":1,"2015":1,"2017":2,"2022":1,"2234":1,"2241":1,"2243":1,"2249":1,"ffects":1,"of":4,"short":1,"or":3,"long":1,"acting":1,"glp":1,"receptor":1,"agonists":1,"versus":4,"insulin":7,"treatment":1,"from":1,"head":2,"to":4,"studies":1,"in":5,"type":5,"diabetic":1,"patients":5,"diabetes":8,"obes":1,"metab":1,"giorgino":1,"benroubi":1,"sun":1,"zimmermann":1,"ag":1,"pechtner":1,"efficacy":2,"and":3,"safety":2,"once":6,"weekly":4,"dulaglutide":1,"glargine":4,"with":6,"on":3,"metformin":2,"glimepiride":1,"award":1,"care":2,"aroda":1,"vr":1,"bain":1,"sc":1,"cariou":1,"et":4,"al":4,"semaglutide":1,"daily":2,"as":1,"add":1,"without":1,"sulfonylureas":1,"naive":1,"sustain":1,"randomised":2,"open":2,"label":2,"parallel":1,"group":1,"multicentre":1,"multinational":1,"phase":1,"3a":1,"trial":3,"lancet":2,"endocrinol":1,"davies":1,"heller":1,"sreenan":1,"exenatide":2,"twice":1,"detemir":1,"diamant":1,"van":1,"gaal":1,"stranks":1,"compared":1,"titrated":2,"target":1,"duration":1,"an":1,"dahl":1,"onishi":1,"norwood":1,"effect":1,"subcutaneous":1,"tirzepatide":1,"vs":1,"placebo":1,"added":1,"glycemic":1,"control":1,"the":1,"surpass":1,"randomized":1,"clinical":1,"jama":1},"len":205},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":29,"chunkId":"ada-2026-pharm-p29-c4","text":" 2243 131. Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA 2022;327:534  545 132. Packer M, Zile MR, Kramer CM, et al.; SUMMIT Trial Study Group. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 2025;392:427  437 133. Kosiborod MN, Petrie MC, Borlaug BA, et al.; STEP-HFpEF DM Trial Committees and Investigators. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med 2024;390:1394  1407 134. Pratley RE, Tuttle KR, Rossing P, et al.; FLOW Trial Committees and Investigators. Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial. J Am Coll Cardiol 2024;84:1615  1628 135. Kosiborod MN, Deanfield J, Pratley R, et al.; SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM Trial Committees and Investigators. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP- HFpEF, and STEP-HFpEF DM randomised trials. Lancet 2024;404:949  961 136. McCoy RG, Lipska KJ, Van Houten HK, Shah ND. Association of cumulative multimorbidity, glycemic control, and medication use with hypoglycemia-related emergency departme","tf":{"84":1,"131":1,"132":1,"133":1,"134":1,"135":1,"136":1,"327":1,"390":1,"392":1,"404":1,"427":1,"437":1,"534":1,"545":1,"949":1,"961":1,"1394":1,"1407":1,"1615":1,"1628":1,"2022":1,"2024":3,"2025":1,"2243":1,"dahl":1,"onishi":1,"norwood":1,"et":5,"al":5,"effect":1,"of":4,"subcutaneous":1,"tirzepatide":2,"vs":1,"placebo":2,"added":1,"to":1,"titrated":1,"insulin":1,"glargine":1,"on":2,"glycemic":2,"control":2,"in":5,"patients":3,"with":5,"type":2,"diabetes":3,"the":3,"surpass":1,"randomized":1,"clinical":1,"trial":6,"jama":1,"packer":1,"zile":1,"mr":1,"kramer":1,"cm":1,"summit":1,"study":1,"group":1,"for":1,"heart":4,"failure":4,"preserved":2,"ejection":2,"fraction":2,"and":10,"obesity":2,"engl":2,"med":2,"kosiborod":2,"mn":2,"petrie":1,"mc":1,"borlaug":1,"ba":1,"step":5,"hfpef":5,"dm":3,"committees":3,"investigators":3,"semaglutide":3,"related":2,"pratley":2,"re":1,"tuttle":1,"kr":1,"rossing":1,"flow":4,"effects":1,"outcomes":1,"chronic":1,"kidney":1,"disease":1,"am":1,"coll":1,"cardiol":1,"deanfield":1,"select":2,"versus":1,"mildly":1,"reduced":1,"or":1,"pooled":1,"analysis":1,"randomised":1,"trials":1,"lancet":1,"mccoy":1,"rg":1,"lipska":1,"kj":1,"van":1,"houten":1,"hk":1,"shah":1,"nd":1,"association":1,"cumulative":1,"multimorbidity":1,"medication":1,"use":1,"hypoglycemia":1,"emergency":1,"departme":1},"len":211},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":29,"chunkId":"ada-2026-pharm-p29-c5","text":" STEP- HFpEF, and STEP-HFpEF DM randomised trials. Lancet 2024;404:949  961 136. McCoy RG, Lipska KJ, Van Houten HK, Shah ND. Association of cumulative multimorbidity, glycemic control, and medication use with hypoglycemia-related emergency department visits and hospitalizations among adults with diabetes. JAMA Netw Open 2020;3:e1919099 137. Nathan DM, Lachin JM, Bebu I, et al.; GRADE Study Research Group. Glycemia reduction in type 2 diabetes - microvascular and cardiovascular outcomes. N Engl J Med 2022;387:1075  1088 138. McCoy RG, Herrin J, Swarna KS, et al. Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk. Nat Cardiovasc Res 2024;3:431  440 139. Berg DD, Wiviott SD, Scirica BM, et al. Heart failure risk stratification and efficacy of sodium- glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus. Circulation 2019;140: 1569  1577 140. Kidney Disease: improving Global Outcomes Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 2022;102:S1  S127 141. Kristensen SL, Rrth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta- analysis of cardiovascular outcome trials. Lancet Diabetes Endocr","tf":{"102":1,"136":1,"137":1,"138":1,"139":1,"140":2,"141":1,"387":1,"404":1,"431":1,"440":1,"949":1,"961":1,"1075":1,"1088":1,"1569":1,"1577":1,"2019":1,"2020":1,"2022":3,"2024":2,"step":2,"hfpef":2,"and":7,"dm":2,"randomised":1,"trials":2,"lancet":2,"mccoy":2,"rg":2,"lipska":1,"kj":1,"van":1,"houten":1,"hk":1,"shah":1,"nd":1,"association":1,"of":4,"cumulative":1,"multimorbidity":1,"glycemic":1,"control":1,"medication":1,"use":1,"with":6,"hypoglycemia":1,"related":1,"emergency":1,"department":1,"visits":1,"hospitalizations":1,"among":1,"adults":1,"diabetes":8,"jama":1,"netw":1,"open":1,"e1919099":1,"nathan":1,"lachin":1,"jm":1,"bebu":1,"et":4,"al":4,"grade":1,"study":1,"research":1,"group":2,"glycemia":1,"reduction":1,"in":5,"type":4,"microvascular":1,"cardiovascular":5,"outcomes":4,"engl":1,"med":1,"herrin":1,"swarna":1,"ks":1,"effectiveness":1,"glucose":2,"lowering":1,"medications":1,"on":1,"patients":3,"at":1,"moderate":1,"risk":2,"nat":1,"cardiovasc":1,"res":1,"berg":1,"dd":1,"wiviott":1,"sd":1,"scirica":1,"bm":1,"heart":1,"failure":1,"stratification":1,"efficacy":1,"sodium":1,"cotransporter":1,"inhibitors":1,"mellitus":1,"circulation":1,"kidney":4,"disease":2,"improving":1,"global":1,"work":1,"kdigo":1,"clinical":1,"practice":1,"guideline":1,"for":1,"management":1,"chronic":1,"int":1,"s1":1,"s127":1,"kristensen":1,"sl":1,"rth":1,"jhund":1,"ps":1,"mortality":1,"glp":1,"receptor":1,"agonists":1,"systematic":1,"review":1,"meta":1,"analysis":1,"outcome":1,"endocr":1},"len":199},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":29,"chunkId":"ada-2026-pharm-p29-c6","text":"41. Kristensen SL, Rrth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta- analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019;7:776  785 142. Perkovic V, Tuttle KR, Rossing P, et al.; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024;391: 109  121 143. Heerspink HJL, Sattar N, Pavo I, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open- label, randomised, phase 3 trial. Lancet Diabetes Endocrinol 2022;10:774  785 144. Heerspink HJL, Friedman AN, Bjornstad P, et al. Kidney parameters with tirzepatide in obesity with or without type 2 diabetes. J Am Soc Nephrol 2025; 36:2190  2200 145. U.S. Food & Drug Administration. Exenatide extended-release prescribing information. Accessed 20 September 2025. Available from https:// www.accessdata.fda.gov/drugsatfda_docs/label/2018/ 022200s026lbl.pdf 146. U.S. Food & Drug Administration. Lixisenatide prescribing information. Accessed 20 September 2025. Available from https://products.sanofi.us/ soliqua100-33/soliqua100-33.pdf 147. Scheen AJ. Pharmacokinetics and clinical use of incretin-based therapies in patients with chroni","tf":{"10":1,"20":2,"33":2,"36":1,"41":1,"109":1,"121":1,"142":1,"143":1,"144":1,"145":1,"146":1,"147":1,"391":1,"774":1,"776":1,"785":2,"2018":1,"2019":1,"2022":1,"2024":1,"2025":3,"2190":1,"2200":1,"kristensen":1,"sl":1,"rth":1,"jhund":1,"ps":1,"et":4,"al":4,"cardiovascular":2,"mortality":1,"and":4,"kidney":4,"outcomes":2,"with":6,"glp":1,"receptor":1,"agonists":1,"in":6,"patients":3,"type":4,"diabetes":6,"systematic":1,"review":1,"meta":1,"analysis":2,"of":5,"outcome":1,"trials":1,"lancet":2,"endocrinol":2,"perkovic":1,"tuttle":1,"kr":1,"rossing":1,"flow":1,"trial":3,"committees":1,"investigators":1,"effects":2,"semaglutide":1,"on":2,"chronic":1,"disease":1,"engl":1,"med":1,"heerspink":2,"hjl":2,"sattar":1,"pavo":1,"tirzepatide":2,"versus":1,"insulin":1,"glargine":1,"the":1,"surpass":1,"post":1,"hoc":1,"an":2,"open":1,"label":2,"randomised":1,"phase":1,"friedman":1,"bjornstad":1,"parameters":1,"obesity":1,"or":1,"without":1,"am":1,"soc":1,"nephrol":1,"food":2,"drug":2,"administration":2,"exenatide":1,"extended":1,"release":1,"prescribing":2,"information":2,"accessed":2,"september":2,"available":2,"from":2,"https":2,"www":1,"accessdata":1,"fda":1,"gov":1,"drugsatfda":1,"docs":1,"022200s026lbl":1,"pdf":2,"lixisenatide":1,"products":1,"sanofi":1,"us":1,"soliqua100":2,"scheen":1,"aj":1,"pharmacokinetics":1,"clinical":1,"use":1,"incretin":1,"based":1,"therapies":1,"chroni":1},"len":196},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":29,"chunkId":"ada-2026-pharm-p29-c7","text":"ration. Lixisenatide prescribing information. Accessed 20 September 2025. Available from https://products.sanofi.us/ soliqua100-33/soliqua100-33.pdf 147. Scheen AJ. Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet 2015;54:1  21 148. McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol 2021;6:148  158 149. Reyes-Farias CI, Reategui-Diaz M, Romani- Romani F, Prokop L. The effect of sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes mellitus on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLoS One 2023;18:e0295059 150. Herrington WG, Staplin N, Wanner C, et al.; The Empa-Kidney Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023;388:117  127 151. Perkovic V, Jardine MJ, Neal B, et al.; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295  2306 152. Dagogo-Jack S, Pratley RE, Cherney DZI, et al. Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV ran","tf":{"18":1,"20":1,"21":1,"33":2,"54":1,"117":1,"127":1,"147":1,"148":2,"149":1,"150":1,"151":1,"152":1,"158":1,"380":1,"388":1,"2015":1,"2019":1,"2021":1,"2023":2,"2025":1,"2295":1,"2306":1,"ration":1,"lixisenatide":1,"prescribing":1,"information":1,"accessed":1,"september":1,"available":1,"from":2,"https":1,"products":1,"sanofi":1,"us":1,"soliqua100":2,"pdf":1,"scheen":1,"aj":1,"pharmacokinetics":1,"and":9,"clinical":1,"use":1,"of":4,"incretin":1,"based":1,"therapies":1,"in":6,"patients":5,"with":7,"chronic":4,"kidney":6,"disease":4,"type":5,"diabetes":5,"clin":1,"pharmacokinet":1,"mcguire":1,"dk":1,"shih":1,"wj":1,"cosentino":1,"et":4,"al":4,"association":1,"sglt2":2,"inhibitors":2,"cardiovascular":2,"outcomes":3,"meta":2,"analysis":3,"jama":1,"cardiol":1,"reyes":1,"farias":1,"ci":1,"reategui":1,"diaz":1,"romani":2,"prokop":1,"the":4,"effect":1,"sodium":1,"glucose":1,"cotransporter":1,"or":1,"without":1,"mellitus":1,"on":1,"renal":2,"systematic":1,"review":1,"plos":1,"one":1,"e0295059":1,"herrington":1,"wg":1,"staplin":1,"wanner":1,"empa":1,"collaborative":1,"group":1,"empagliflozin":1,"engl":2,"med":2,"perkovic":1,"jardine":1,"mj":1,"neal":1,"credence":1,"trial":1,"investigators":1,"canagliflozin":1,"nephropathy":1,"dagogo":1,"jack":1,"pratley":1,"re":1,"cherney":1,"dzi":1,"glycemic":1,"efficacy":1,"safety":1,"inhibitor":1,"ertugliflozin":1,"stage":1,"an":1,"vertis":1,"cv":1,"ran":1},"len":201},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":29,"chunkId":"ada-2026-pharm-p29-c8","text":"l J Med 2019;380:2295  2306 152. Dagogo-Jack S, Pratley RE, Cherney DZI, et al. Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial. BMJ Open Diabetes Res Care 2021;9:e002484 153. Cherney DZI, Cooper ME, Tikkanen I, et al. Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int 2018;93:231  244 154. Wexler DJ, de Boer IH, Ghosh A, et al.; GRADE Research Group. Comparative effects of glucose-lowering medications on kidney outcomes in diabetesjournals.org/care Pharmacologic Approaches to Glycemic Treatment S211 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"49":1,"93":1,"152":1,"153":1,"154":1,"231":1,"244":1,"380":1,"2018":1,"2019":1,"2021":1,"2026":1,"2295":1,"2306":1,"848878":1,"med":1,"dagogo":1,"jack":1,"pratley":1,"re":1,"cherney":2,"dzi":2,"et":3,"al":3,"glycemic":2,"efficacy":1,"and":3,"safety":1,"of":4,"the":2,"sglt2":1,"inhibitor":1,"ertugliflozin":1,"in":2,"patients":1,"with":2,"type":1,"diabetes":2,"stage":1,"chronic":1,"kidney":3,"disease":1,"an":1,"analysis":2,"from":2,"vertis":1,"cv":1,"randomized":1,"trial":1,"bmj":1,"open":1,"res":1,"care":3,"e002484":1,"cooper":1,"me":1,"tikkanen":1,"pooled":1,"phase":1,"iii":1,"trials":1,"indicate":1,"contrasting":1,"influences":1,"renal":1,"function":1,"on":3,"blood":1,"pressure":1,"body":1,"weight":1,"hba1c":1,"reductions":1,"empagliflozin":1,"int":1,"wexler":1,"dj":1,"de":1,"boer":1,"ih":1,"ghosh":1,"grade":1,"research":1,"group":1,"comparative":1,"effects":1,"glucose":1,"lowering":1,"medications":1,"outcomes":1,"diabetesjournals":2,"org":2,"pharmacologic":1,"approaches":1,"to":1,"treatment":1,"s211":1,"downloaded":1,"http":1,"article":1,"pdf":2,"supplement":1,"s183":1,"dc26s009":1,"by":1,"guest":1,"february":1},"len":135},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":30,"chunkId":"ada-2026-pharm-p30-c0","text":"type 2 diabetes: the GRADE randomized clinical trial. JAMA Intern Med 2023;183:705  714 155. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297  2307 156. Sanyal AJ, Newsome PN, Kliers I, et al.; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med 2025;392:2089  2099 157. Newsome PN, Buchholtz K, Cusi K, et al.; NN9931-4296 Investigators. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021;384:1113  1124 158. Loomba R, Hartman ML, Lawitz EJ, et al.; SYNERGY-NASH Investigators. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med 2024;391:299  310 159. Gastaldelli A, Cusi K, Fernndez Land L, Bray R, Brouwers B, Rodrguez  A. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 2022;10:393  406 160. Armstrong MJ, Gaunt P, Aithal GP, et al.; LEAN trial team. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo- controlled phase ","tf":{"10":1,"155":1,"156":1,"157":1,"158":1,"159":1,"160":1,"183":1,"299":1,"310":1,"355":1,"384":1,"391":1,"392":1,"393":1,"406":1,"705":1,"714":1,"1113":1,"1124":1,"2006":1,"2021":1,"2022":1,"2023":1,"2024":1,"2025":1,"2089":1,"2099":1,"2297":1,"2307":1,"4296":1,"type":2,"diabetes":3,"the":2,"grade":1,"randomized":1,"clinical":1,"trial":6,"jama":1,"intern":1,"med":5,"belfort":1,"harrison":1,"sa":1,"brown":1,"et":5,"al":5,"placebo":3,"controlled":3,"of":5,"pioglitazone":1,"in":5,"subjects":1,"with":4,"nonalcoholic":2,"steatohepatitis":5,"engl":4,"sanyal":1,"aj":1,"newsome":2,"pn":2,"kliers":1,"essence":1,"study":1,"group":2,"phase":3,"semaglutide":2,"metabolic":2,"dysfunction":2,"associated":2,"buchholtz":1,"cusi":2,"nn9931":1,"investigators":2,"subcutaneous":1,"loomba":1,"hartman":1,"ml":1,"lawitz":1,"ej":1,"synergy":1,"nash":1,"tirzepatide":2,"for":1,"liver":2,"fibrosis":1,"gastaldelli":1,"fern":1,"ndez":1,"land":1,"bray":1,"brouwers":1,"rodr":1,"guez":1,"effect":1,"versus":1,"insulin":1,"degludec":1,"on":1,"fat":1,"content":1,"and":2,"abdominal":1,"adipose":1,"tissue":1,"people":1,"surpass":2,"mri":1,"substudy":1,"randomised":2,"open":1,"label":1,"parallel":1,"lancet":1,"endocrinol":1,"armstrong":1,"mj":1,"gaunt":1,"aithal":1,"gp":1,"lean":2,"team":1,"liraglutide":1,"safety":1,"efficacy":1,"patients":1,"non":1,"alcoholic":1,"multicentre":1,"double":1,"blind":1},"len":192},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":30,"chunkId":"ada-2026-pharm-p30-c1","text":"es Endocrinol 2022;10:393  406 160. Armstrong MJ, Gaunt P, Aithal GP, et al.; LEAN trial team. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo- controlled phase 2 study. Lancet 2016;387:679  690 161. Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity (Silver Spring) 2011;19:2310  2315 162. Abdul-Ghani M, Migahid O, Megahed A, DeFronzo RA, Al-Ozairi E, Jayyousi A. Combination therapy with pioglitazone/exenatide improves beta- cell function and produces superior glycaemic control compared with basal/bolus insulin in poorly controlled type 2 diabetes: a 3-year follow-up of the Qatar study. Diabetes Obes Metab 2020;22:2287  2294 163. Lavynenko O, Abdul-Ghani M, Alatrach M, et al. Combination therapy with pioglitazone/ exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: the efficacy and durability of initial combination therapy for type 2 diabetes (EDICT). Diabetes Obes Metab 2022;24: 899  907 164. Garvey WT, Frias JP, Jastreboff AM, et al.; SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 tria","tf":{"10":1,"19":1,"22":1,"24":1,"160":1,"161":1,"162":1,"163":1,"164":1,"387":1,"393":1,"406":1,"679":1,"690":1,"899":1,"907":1,"2011":1,"2016":1,"2020":1,"2022":2,"2287":1,"2294":1,"2310":1,"2315":1,"es":1,"endocrinol":1,"armstrong":1,"mj":1,"gaunt":1,"aithal":1,"gp":1,"et":3,"al":4,"lean":2,"trial":1,"team":1,"liraglutide":1,"safety":1,"and":5,"efficacy":2,"in":4,"patients":1,"with":5,"non":1,"alcoholic":1,"steatohepatitis":1,"multicentre":2,"double":2,"blind":2,"randomised":2,"placebo":2,"controlled":3,"phase":2,"study":2,"lancet":1,"sathyanarayana":1,"jogi":1,"muthupillai":1,"krishnamurthy":1,"samson":1,"sl":1,"bajaj":1,"effects":1,"of":5,"combined":1,"exenatide":3,"pioglitazone":3,"therapy":4,"on":1,"hepatic":2,"fat":1,"content":1,"type":4,"diabetes":6,"obesity":2,"silver":1,"spring":1,"abdul":2,"ghani":2,"migahid":1,"megahed":1,"defronzo":1,"ra":1,"ozairi":1,"jayyousi":1,"combination":3,"improves":1,"beta":1,"cell":1,"function":1,"produces":1,"superior":1,"glycaemic":1,"control":1,"compared":1,"basal":1,"bolus":1,"insulin":1,"poorly":1,"year":1,"follow":1,"up":1,"the":4,"qatar":1,"obes":2,"metab":2,"lavynenko":1,"alatrach":1,"metformin":1,"reduces":1,"prevalence":1,"fibrosis":1,"steatosis":1,"durability":1,"initial":1,"for":2,"edict":1,"garvey":1,"wt":1,"frias":1,"jp":1,"jastreboff":1,"am":1,"surmount":2,"investigators":1,"tirzepatide":1,"once":1,"weekly":1,"treatment":1,"people":1,"tria":1},"len":191},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":30,"chunkId":"ada-2026-pharm-p30-c2","text":"907 164. Garvey WT, Frias JP, Jastreboff AM, et al.; SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402:613  626 165. Davies M, Frch L, Jeppesen OK, et al.; STEP 2 Study Group. Semaglutide 24 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double- blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021;397:971  984 166. Bonora E, Frias JP, Tinahones FJ, et al. Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: exploratory analyses of AWARD- 11. Diabetes Obes Metab 2021;23:2242  2250 167. Davies MJ, Bergenstal R, Bode B, et al.; NN8022-1922 Study Group. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 2015;314:687  699 168. Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide er in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care 2018;41:258  266 169. Schauer PR, Bhatt DL, Kirwan JP, et al.; STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med 2017;376:641  651 170","tf":{"11":1,"23":1,"41":1,"56":1,"164":1,"165":1,"166":1,"167":1,"168":1,"169":1,"170":1,"258":1,"266":1,"314":1,"376":1,"397":1,"402":1,"613":1,"626":1,"641":1,"651":1,"687":1,"699":1,"907":1,"971":1,"984":1,"1922":1,"2015":1,"2017":1,"2018":1,"2021":2,"2023":1,"2242":1,"2250":1,"garvey":1,"wt":1,"frias":2,"jp":3,"jastreboff":1,"am":1,"et":6,"al":6,"surmount":2,"investigators":2,"tirzepatide":1,"once":3,"weekly":2,"for":3,"the":2,"treatment":1,"of":5,"obesity":2,"in":4,"people":1,"with":5,"type":5,"diabetes":9,"double":3,"blind":2,"randomised":2,"multicentre":1,"placebo":2,"controlled":2,"phase":2,"trial":4,"lancet":2,"davies":2,"rch":1,"jeppesen":1,"ok":1,"step":2,"study":2,"group":2,"semaglutide":2,"mg":2,"week":2,"adults":1,"overweight":1,"or":1,"and":3,"dummy":1,"bonora":1,"tinahones":1,"fj":1,"effect":1,"dulaglutide":1,"on":1,"weight":2,"patients":2,"exploratory":1,"analyses":1,"award":1,"obes":1,"metab":1,"mj":1,"bergenstal":1,"bode":1,"nn8022":1,"efficacy":2,"liraglutide":1,"loss":1,"among":1,"scale":1,"randomized":2,"clinical":2,"jama":1,"ahmann":1,"aj":1,"capehorn":1,"charpentier":1,"safety":1,"versus":2,"exenatide":1,"er":1,"subjects":1,"sustain":1,"open":1,"label":1,"care":1,"schauer":1,"pr":1,"bhatt":1,"dl":1,"kirwan":1,"stampede":1,"bariatric":1,"surgery":1,"intensive":1,"medical":1,"therapy":1,"year":1,"outcomes":1,"engl":1,"med":1},"len":206},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":30,"chunkId":"ada-2026-pharm-p30-c3","text":"l, randomized clinical trial. Diabetes Care 2018;41:258  266 169. Schauer PR, Bhatt DL, Kirwan JP, et al.; STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med 2017;376:641  651 170. Blonde L, Merilainen M, Karwe V, Raskin P, TITRATE Study Group. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study. Diabetes Obes Metab 2009;11:623  631 171. Lucidi P, Candeloro P, Cioli P, et al. Pharmacokinetic and pharmacodynamic head- to-head comparison of clinical, equivalent doses of insulin glargine 300 units  mL 1 and insulin degludec 100 unitsmL 1 in type 1 diabetes. Diabetes Care 2021;44:125  132 172. Wang Z, Hedrington MS, Gogitidze Joy N, et al. Dose-response effects of insulin glargine in type 2 diabetes. Diabetes Care 2010;33:1555  1560 173. Semlitsch T, Engler J, Siebenhofer A, Jeitler K, Berghold A, Horvath K. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev 2020;11:CD005613 174. Mannucci E, Caiulo C, Naletto L, Madama G, Monami M. Efficacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes: a network meta- analysis of randomized contr","tf":{"11":2,"33":1,"41":1,"44":1,"100":1,"125":1,"132":1,"169":1,"170":1,"171":1,"172":1,"173":1,"174":1,"258":1,"266":1,"300":1,"376":1,"623":1,"631":1,"641":1,"651":1,"1555":1,"1560":1,"2009":1,"2010":1,"2017":1,"2018":1,"2020":1,"2021":1,"randomized":2,"clinical":2,"trial":1,"diabetes":9,"care":3,"schauer":1,"pr":1,"bhatt":1,"dl":1,"kirwan":1,"jp":1,"et":3,"al":3,"stampede":1,"investigators":1,"bariatric":1,"surgery":1,"versus":2,"intensive":1,"medical":1,"therapy":1,"for":4,"year":1,"outcomes":1,"engl":1,"med":1,"blonde":1,"merilainen":1,"karwe":1,"raskin":1,"titrate":2,"study":2,"group":1,"patient":1,"directed":1,"titration":1,"achieving":1,"glycaemic":1,"goals":1,"using":1,"once":1,"daily":1,"basal":2,"insulin":8,"analogue":1,"an":1,"assessment":1,"of":7,"two":1,"different":2,"fasting":1,"plasma":1,"glucose":1,"targets":1,"the":2,"obes":1,"metab":1,"lucidi":1,"candeloro":1,"cioli":1,"pharmacokinetic":1,"and":4,"pharmacodynamic":1,"head":2,"to":1,"comparison":1,"equivalent":1,"doses":1,"glargine":2,"units":2,"ml":2,"degludec":1,"in":2,"type":4,"wang":1,"hedrington":1,"ms":1,"gogitidze":1,"joy":1,"dose":1,"response":1,"effects":1,"semlitsch":1,"engler":1,"siebenhofer":1,"jeitler":1,"berghold":1,"horvath":1,"ultra":1,"long":1,"acting":1,"analogues":2,"nph":1,"human":1,"isophane":1,"adults":1,"with":1,"mellitus":1,"cochrane":1,"database":1,"syst":1,"rev":1,"cd005613":1,"mannucci":1,"caiulo":1,"naletto":1,"madama":1,"monami":1,"efficacy":1,"safety":1,"prandial":1,"treatment":1,"network":1,"meta":1,"analysis":1,"contr":1},"len":196},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":30,"chunkId":"ada-2026-pharm-p30-c4","text":"rane Database Syst Rev 2020;11:CD005613 174. Mannucci E, Caiulo C, Naletto L, Madama G, Monami M. Efficacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes: a network meta- analysis of randomized controlled trials. Endocrine 2021;74:508  517 175. Russell-Jones D, Gall M-A, Niemeyer M, Diamant M, Del Prato S. Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: a meta-analysis of seven clinical trials. Nutr Metab Cardiovasc Dis 2015;25:898  905 176. Mehta R, Goldenberg R, Katselnik D, Kuritzky L. Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care. Ann Med 2021;53:998  1009 177. Cowart K. Overbasalization: addressing hesitancy in treatment intensification beyond basal insulin. Clin Diabetes 2020;38:304  310 178. Maiorino MI, Chiodini P, Bellastella G, et al. The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 2019;154: 101  115 179. Rodbard HW, Visco VE, Andersen H, Hiort LC, Shu DHW. Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical tri","tf":{"11":1,"25":1,"38":1,"53":1,"74":1,"101":1,"115":1,"154":1,"174":1,"175":1,"176":1,"177":1,"178":1,"179":1,"304":1,"310":1,"508":1,"517":1,"898":1,"905":1,"998":1,"1009":1,"2015":1,"2019":1,"2020":2,"2021":2,"rane":1,"database":1,"syst":1,"rev":1,"cd005613":1,"mannucci":1,"caiulo":1,"naletto":1,"madama":1,"monami":1,"efficacy":1,"and":6,"safety":1,"of":8,"different":1,"basal":4,"prandial":2,"insulin":6,"analogues":1,"for":2,"the":3,"treatment":3,"type":2,"diabetes":4,"network":1,"meta":3,"analysis":3,"randomized":2,"controlled":2,"trials":3,"endocrine":1,"russell":1,"jones":1,"gall":1,"niemeyer":1,"diamant":1,"del":1,"prato":1,"degludec":1,"results":1,"in":3,"lower":1,"rates":1,"nocturnal":1,"hypoglycaemia":1,"fasting":1,"plasma":1,"glucose":1,"vs":1,"glargine":1,"seven":1,"clinical":2,"nutr":1,"metab":1,"cardiovasc":1,"dis":1,"mehta":1,"goldenberg":1,"katselnik":1,"kuritzky":1,"practical":1,"guidance":1,"on":1,"initiation":1,"titration":1,"switching":1,"insulins":1,"narrative":1,"review":2,"primary":1,"care":1,"ann":1,"med":1,"cowart":1,"overbasalization":1,"addressing":1,"hesitancy":1,"intensification":2,"beyond":1,"clin":2,"maiorino":1,"mi":1,"chiodini":1,"bellastella":1,"et":1,"al":1,"good":1,"companions":1,"glucagon":1,"like":1,"peptide":1,"receptor":1,"agonist":1,"systematic":1,"res":1,"pract":1,"rodbard":1,"hw":1,"visco":1,"ve":1,"andersen":1,"hiort":1,"lc":1,"shu":1,"dhw":1,"with":2,"stepwise":1,"addition":1,"aspart":1,"boluses":1,"compared":1,"full":1,"bolus":1,"therapy":1,"fullstep":1,"study":1,"randomised":1,"treat":1,"to":1,"target":1,"tri":1},"len":194},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":30,"chunkId":"ada-2026-pharm-p30-c5","text":"01  115 179. Rodbard HW, Visco VE, Andersen H, Hiort LC, Shu DHW. Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial. Lancet Diabetes Endocrinol 2014;2:30  37 180. McCall AL. Insulin therapy and hypoglycemia. Endocrinol Metab Clin North Am 2012;41:57  87 181. Fullerton B, Siebenhofer A, Jeitler K, et al. Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus. Cochrane Database Syst Rev 2018;12:CD013228 182. de la Pea A, Riddle M, Morrow LA, et al. Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. Diabetes Care 2011;34:2496  2501 183. Hood RC, Borra S, Fan L, Pollom RD, Huang A, Chen J. Treatment patterns and outcomes, before and after humulin R U-500 initiation, among high- dose type 2 diabetes mellitus patients in the United States. Endocr Pract 2021;27:798  806 184. Becker RHA, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T. New insulin glargine 300 units  mL 1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units  mL 1 . Diabetes Care 2015;38:637  643 185. Riddle MC, Yki-Jrvinen H, Bolli GB, et al. One-yea","tf":{"12":1,"27":1,"30":1,"34":1,"37":1,"38":1,"41":1,"57":1,"87":1,"100":2,"115":1,"179":1,"180":1,"181":1,"182":1,"183":1,"184":1,"185":1,"300":1,"500":2,"637":1,"643":1,"798":1,"806":1,"2011":1,"2012":1,"2014":1,"2015":1,"2018":1,"2021":1,"2496":1,"2501":1,"01":1,"rodbard":1,"hw":1,"visco":1,"ve":1,"andersen":1,"hiort":1,"lc":1,"shu":1,"dhw":1,"treatment":2,"intensification":1,"with":4,"stepwise":1,"addition":1,"of":2,"prandial":1,"insulin":8,"aspart":1,"boluses":1,"compared":2,"full":1,"basal":1,"bolus":1,"therapy":2,"fullstep":1,"study":1,"randomised":1,"treat":1,"to":1,"target":1,"clinical":1,"trial":1,"lancet":1,"diabetes":5,"endocrinol":2,"mccall":1,"al":4,"and":5,"hypoglycemia":1,"metab":1,"clin":1,"north":1,"am":1,"fullerton":1,"siebenhofer":1,"jeitler":1,"et":3,"short":1,"acting":1,"analogues":1,"versus":2,"regular":3,"human":3,"for":1,"adult":1,"non":1,"pregnant":1,"persons":1,"type":2,"mellitus":2,"cochrane":1,"database":1,"syst":1,"rev":1,"cd013228":1,"de":1,"la":2,"pe":1,"riddle":2,"morrow":1,"pharmacokinetics":1,"pharmacodynamics":1,"high":2,"dose":2,"in":2,"healthy":1,"obese":1,"subjects":1,"care":2,"hood":1,"rc":1,"borra":1,"fan":1,"pollom":1,"rd":1,"huang":1,"chen":1,"patterns":1,"outcomes":1,"before":1,"after":1,"humulin":1,"initiation":1,"among":1,"patients":1,"the":1,"united":1,"states":1,"endocr":1,"pract":1,"becker":1,"rha":1,"dahmen":1,"bergmann":1,"lehmann":1,"jax":1,"heise":1,"new":1,"glargine":2,"units":2,"ml":2,"provides":1,"more":1,"even":1,"activity":1,"profile":1,"prolonged":1,"glycemic":1,"control":1,"at":1,"steady":1,"state":1,"mc":1,"yki":1,"rvinen":1,"bolli":1,"gb":1,"one":1,"yea":1},"len":208},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":30,"chunkId":"ada-2026-pharm-p30-c6","text":" glargine 300 units  mL 1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units  mL 1 . Diabetes Care 2015;38:637  643 185. Riddle MC, Yki-Jrvinen H, Bolli GB, et al. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension. Diabetes Obes Metab 2015;17:835  842 186. Yki-Jrvinen H, Bergenstal R, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care 2014;37:3235  3243 187. Korsatko S, Deller S, Koehler G, et al. A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec. Clin Drug Investig 2013;33:515  521 188. de la Pea A, Seger M, Soon D, et al. Bio- equivalence and comparative pharmacodyna- mics of insulin lispro 200 U/mL relative to insulin lispro (Humalog) 100 U/mL. Clin Pharmacol Drug Dev 2016;5:69  75 189. Gentile S, Fusco A, Colarusso S, et al. A randomized, open-label, comparative, crossover trial on preference, effic","tf":{"12":1,"17":1,"33":1,"37":1,"38":1,"69":1,"75":1,"100":5,"185":1,"186":1,"187":1,"188":1,"189":1,"200":2,"300":3,"515":1,"521":1,"637":1,"643":1,"835":1,"842":1,"2013":1,"2014":1,"2015":2,"2016":1,"3235":1,"3243":1,"glargine":5,"units":4,"ml":9,"provides":1,"more":1,"even":1,"activity":1,"profile":1,"and":7,"prolonged":1,"glycemic":1,"control":3,"at":1,"steady":2,"state":2,"compared":2,"with":5,"insulin":8,"diabetes":5,"care":2,"riddle":1,"mc":1,"yki":2,"rvinen":2,"bolli":1,"gb":1,"et":5,"al":5,"one":1,"year":1,"sustained":1,"glycaemic":1,"less":1,"hypoglycaemia":1,"new":2,"in":3,"people":2,"type":2,"using":2,"basal":2,"plus":1,"meal":1,"time":1,"the":2,"edition":2,"month":3,"randomized":3,"trial":3,"including":1,"extension":1,"obes":1,"metab":1,"bergenstal":1,"ziemen":1,"versus":1,"oral":1,"agents":1,"glucose":1,"hypoglycemia":1,"controlled":1,"korsatko":1,"deller":1,"koehler":1,"comparison":1,"of":4,"pharmacokinetic":1,"pharmacodynamic":1,"profiles":1,"formulations":1,"ultra":1,"long":1,"acting":1,"degludec":1,"clin":2,"drug":2,"investig":1,"de":1,"la":1,"pe":1,"seger":1,"soon":1,"bio":1,"equivalence":1,"comparative":2,"pharmacodyna":1,"mics":1,"lispro":2,"relative":1,"to":1,"humalog":1,"pharmacol":1,"dev":1,"gentile":1,"fusco":1,"colarusso":1,"open":1,"label":1,"crossover":1,"on":1,"preference":1,"effic":1},"len":210},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":30,"chunkId":"ada-2026-pharm-p30-c7","text":"armacodyna- mics of insulin lispro 200 U/mL relative to insulin lispro (Humalog) 100 U/mL. Clin Pharmacol Drug Dev 2016;5:69  75 189. Gentile S, Fusco A, Colarusso S, et al. A randomized, open-label, comparative, crossover trial on preference, efficacy, and safety profiles of lispro insulin u-100 versus concentrated lispro insulin u-200 in patients with type 2 diabetes mellitus: a possible contribution to greater treatment adherence. Expert Opin Drug Saf 2018;17:445  450 190. Grant M, Heise T, Baughman R. Comparison of pharmacokinetics and pharmacodynamics of inhaled technosphere insulin and subcutaneous insulin lispro in the treatment of type 1 diabetes mellitus. Clin Pharmacokinet 2022;61:413  422 191. Akturk HK, Snell-Bergeon JK, Rewers A, et al. Improved postprandial glucose with inhaled technosphere insulin compared with insulin aspart in patients with type 1 diabetes on multiple daily injections: the STAT study. Diabetes Technol Ther 2018;20:639  647 192. Hoogwerf BJ, Pantalone KM, Basina M, Jones MC, Grant M, Kendall DM. Results of a 24-week trial of Technosphere insulin versus insulin aspart in type 2 diabetes. Endocr Pract 2021;27:38  43 193. Price DA, Deng Q, Kipnes M, Beck SE. Episodic real-time CGM use in adults with type 2 diabetes: results of a pilot randomized controlled trial. Diabetes Ther 2021;12:2089  2099 194. Chesser H, Srinivasan S, Puckett C, Gitelm","tf":{"12":1,"17":1,"20":1,"24":1,"27":1,"38":1,"43":1,"61":1,"69":1,"75":1,"100":2,"189":1,"190":1,"191":1,"192":1,"193":1,"194":1,"200":2,"413":1,"422":1,"445":1,"450":1,"639":1,"647":1,"2016":1,"2018":2,"2021":2,"2022":1,"2089":1,"2099":1,"armacodyna":1,"mics":1,"of":8,"insulin":10,"lispro":5,"ml":2,"relative":1,"to":2,"humalog":1,"clin":2,"pharmacol":1,"drug":2,"dev":1,"gentile":1,"fusco":1,"colarusso":1,"et":2,"al":2,"randomized":2,"open":1,"label":1,"comparative":1,"crossover":1,"trial":3,"on":2,"preference":1,"efficacy":1,"and":3,"safety":1,"profiles":1,"versus":2,"concentrated":1,"in":5,"patients":2,"with":5,"type":5,"diabetes":7,"mellitus":2,"possible":1,"contribution":1,"greater":1,"treatment":2,"adherence":1,"expert":1,"opin":1,"saf":1,"grant":2,"heise":1,"baughman":1,"comparison":1,"pharmacokinetics":1,"pharmacodynamics":1,"inhaled":2,"technosphere":3,"subcutaneous":1,"the":2,"pharmacokinet":1,"akturk":1,"hk":1,"snell":1,"bergeon":1,"jk":1,"rewers":1,"improved":1,"postprandial":1,"glucose":1,"compared":1,"aspart":2,"multiple":1,"daily":1,"injections":1,"stat":1,"study":1,"technol":1,"ther":2,"hoogwerf":1,"bj":1,"pantalone":1,"km":1,"basina":1,"jones":1,"mc":1,"kendall":1,"dm":1,"results":2,"week":1,"endocr":1,"pract":1,"price":1,"da":1,"deng":1,"kipnes":1,"beck":1,"se":1,"episodic":1,"real":1,"time":1,"cgm":1,"use":1,"adults":1,"pilot":1,"controlled":1,"chesser":1,"srinivasan":1,"puckett":1,"gitelm":1},"len":202},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":30,"chunkId":"ada-2026-pharm-p30-c8","text":"act 2021;27:38  43 193. Price DA, Deng Q, Kipnes M, Beck SE. Episodic real-time CGM use in adults with type 2 diabetes: results of a pilot randomized controlled trial. Diabetes Ther 2021;12:2089  2099 194. Chesser H, Srinivasan S, Puckett C, Gitelman SE, Wong JC. Real-time continuous glucose monitoring in adolescents and young adults with type 2 diabetes can improve quality of life. J Diabetes Sci Technol 2024;18:911  919 195. Martens TW, Willis HJ, Bergenstal RM, Kruger DF, Karslioglu-French E, Steenkamp DW. A rando- mized controlled trial using continuous glucose monitoring to guide food choices and diabetes S212 Pharmacologic Approaches to Glycemic Treatment Diabetes Care Volume 49, Supplement 1, January 2026 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"12":1,"17":1,"18":1,"27":1,"38":1,"43":1,"49":2,"193":1,"194":1,"195":1,"911":1,"919":1,"2021":2,"2024":1,"2026":2,"2089":1,"2099":1,"848878":1,"act":1,"price":1,"da":1,"deng":1,"kipnes":1,"beck":1,"se":2,"episodic":1,"real":2,"time":2,"cgm":1,"use":1,"in":2,"adults":2,"with":2,"type":2,"diabetes":6,"results":1,"of":2,"pilot":1,"randomized":1,"controlled":2,"trial":2,"ther":1,"chesser":1,"srinivasan":1,"puckett":1,"gitelman":1,"wong":1,"jc":1,"continuous":2,"glucose":2,"monitoring":2,"adolescents":1,"and":2,"young":1,"can":1,"improve":1,"quality":1,"life":1,"sci":1,"technol":1,"martens":1,"tw":1,"willis":1,"hj":1,"bergenstal":1,"rm":1,"kruger":1,"df":1,"karslioglu":1,"french":1,"steenkamp":1,"dw":1,"rando":1,"mized":1,"using":1,"to":2,"guide":1,"food":1,"choices":1,"s212":1,"pharmacologic":1,"approaches":1,"glycemic":1,"treatment":1,"care":2,"volume":1,"supplement":2,"january":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"s183":1,"dc26s009":1,"by":1,"guest":1,"on":1,"february":1},"len":127},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":31,"chunkId":"ada-2026-pharm-p31-c0","text":"self-care in people with type 2 diabetes not taking insulin. Diabetes Technol Ther 2025;27:261  270 196. Battelino T, Lalic N, Hussain S, et al. The use of continuous glucose monitoring in people living with obesity, intermediate hyperglycemia or type 2 diabetes. Diabetes Res Clin Pract 2025;223:112111 197. Aronson R, Brown RE, Chu L, et al. Impact of flash glucose monitoring in people with type 2 diabetes inadequately controlled with non- insulin antihyperglycaemic therapy (IMMEDIATE): a randomized controlled trial. Diabetes Obes Metab 2023;25:1024  1031 198. Moon SJ, Kim K-S, Lee WJ, Lee MY, Vigersky R, Park C-Y. Efficacy of intermittent short-term use of a real-time continuous glucose monitoring system in non-insulin-treated patients with type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2023;25:110  120 199. Martens T, Beck RW, Bailey R, et al.; MOBILE Study Group. Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. JAMA 2021;325:2262  2272 200. Agarwal S, Varghese RT, Savian R, Low Wang CC, Galindo RJ. Moving beyond glycated hemoglobin to glucose patterns: newer indications for continuous glucose monitor use. Endocr Pract 2025;31:1046  1053 201. van Dijk P, Bouma A, Landman GW, et al. Hypoglycemia in frail elderly patients with type 2 diabetes mellitus t","tf":{"25":2,"27":1,"31":1,"110":1,"120":1,"196":1,"197":1,"198":1,"199":1,"200":1,"201":1,"223":1,"261":1,"270":1,"325":1,"1024":1,"1031":1,"1046":1,"1053":1,"2021":1,"2023":2,"2025":3,"2262":1,"2272":1,"112111":1,"self":1,"care":1,"in":6,"people":3,"with":8,"type":6,"diabetes":10,"not":1,"taking":1,"insulin":4,"technol":1,"ther":1,"battelino":1,"lalic":1,"hussain":1,"et":4,"al":4,"the":1,"use":3,"of":5,"continuous":4,"glucose":6,"monitoring":4,"living":1,"obesity":1,"intermediate":1,"hyperglycemia":1,"or":1,"res":1,"clin":1,"pract":2,"aronson":1,"brown":1,"re":1,"chu":1,"impact":1,"flash":1,"inadequately":1,"controlled":3,"non":2,"antihyperglycaemic":1,"therapy":1,"immediate":1,"randomized":3,"trial":3,"obes":2,"metab":2,"moon":1,"sj":1,"kim":1,"lee":2,"wj":1,"my":1,"vigersky":1,"park":1,"efficacy":1,"intermittent":1,"short":1,"term":1,"real":1,"time":1,"system":1,"treated":2,"patients":3,"martens":1,"beck":1,"rw":1,"bailey":1,"mobile":1,"study":1,"group":1,"effect":1,"on":1,"glycemic":1,"control":1,"basal":1,"clinical":1,"jama":1,"agarwal":1,"varghese":1,"rt":1,"savian":1,"low":1,"wang":1,"cc":1,"galindo":1,"rj":1,"moving":1,"beyond":1,"glycated":1,"hemoglobin":1,"to":1,"patterns":1,"newer":1,"indications":1,"for":1,"monitor":1,"endocr":1,"van":1,"dijk":1,"bouma":1,"landman":1,"gw":1,"hypoglycemia":1,"frail":1,"elderly":1,"mellitus":1},"len":204},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":31,"chunkId":"ada-2026-pharm-p31-c1","text":"beyond glycated hemoglobin to glucose patterns: newer indications for continuous glucose monitor use. Endocr Pract 2025;31:1046  1053 201. van Dijk P, Bouma A, Landman GW, et al. Hypoglycemia in frail elderly patients with type 2 diabetes mellitus treated with sulfonylurea. J Diabetes Sci Technol 2017;11:438  439 202. Tamborlane WV, Beck RW, Bode BW, et al.; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359:1464  1476 203. Hansen KW, Bibby BM. The frequency of intermittently scanned glucose and diurnal variation of glycemic metrics. J Diabetes Sci Technol 2022;16: 1461  1465 204. Urakami T, Yoshida K, Kuwabara R, et al. Frequent scanning using flash glucose monitoring contributes to better glycemic control in children and adolescents with type 1 diabetes. J Diabetes Investig 2022;13:185  190 205. Laffel LM, Kanapka LG, Beck RW, et al.; CGM Intervention in Teens and Young Adults with T1D (CITY) Study Group. Effect of continuous glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes: a randomized clinical trial. JAMA 2020;323:2388  2396 206. New JP, Ajjan R, Pfeiffer AFH, Freckmann G. Continuous glucose monitoring in people with diabetes: the randomized controlled Glucose Level Awareness in Diabetes Study (GLADIS","tf":{"11":1,"13":1,"16":1,"31":1,"185":1,"190":1,"201":1,"202":1,"203":1,"204":1,"205":1,"206":1,"323":1,"359":1,"438":1,"439":1,"1046":1,"1053":1,"1461":1,"1464":1,"1465":1,"1476":1,"2008":1,"2017":1,"2020":1,"2022":2,"2025":1,"2388":1,"2396":1,"beyond":1,"glycated":1,"hemoglobin":1,"to":2,"glucose":9,"patterns":1,"newer":1,"indications":1,"for":1,"continuous":5,"monitor":1,"use":1,"endocr":1,"pract":1,"van":1,"dijk":1,"bouma":1,"landman":1,"gw":1,"et":4,"al":4,"hypoglycemia":1,"in":6,"frail":1,"elderly":1,"patients":1,"with":6,"type":4,"diabetes":10,"mellitus":1,"treated":1,"sulfonylurea":1,"sci":2,"technol":2,"tamborlane":1,"wv":1,"beck":2,"rw":2,"bode":1,"bw":1,"juvenile":1,"research":1,"foundation":1,"monitoring":5,"study":3,"group":2,"and":5,"intensive":1,"treatment":1,"of":4,"engl":1,"med":1,"hansen":1,"kw":1,"bibby":1,"bm":1,"the":2,"frequency":1,"intermittently":1,"scanned":1,"diurnal":1,"variation":1,"glycemic":3,"metrics":1,"urakami":1,"yoshida":1,"kuwabara":1,"frequent":1,"scanning":1,"using":1,"flash":1,"contributes":1,"better":1,"control":2,"children":1,"adolescents":2,"investig":1,"laffel":1,"lm":1,"kanapka":1,"lg":1,"cgm":1,"intervention":1,"teens":1,"young":2,"adults":2,"t1d":1,"city":1,"effect":1,"on":1,"randomized":2,"clinical":1,"trial":1,"jama":1,"new":1,"jp":1,"ajjan":1,"pfeiffer":1,"afh":1,"freckmann":1,"people":1,"controlled":1,"level":1,"awareness":1,"gladis":1},"len":202},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":31,"chunkId":"ada-2026-pharm-p31-c2","text":"ype 1 diabetes: a randomized clinical trial. JAMA 2020;323:2388  2396 206. New JP, Ajjan R, Pfeiffer AFH, Freckmann G. Continuous glucose monitoring in people with diabetes: the randomized controlled Glucose Level Awareness in Diabetes Study (GLADIS). Diabet Med 2015;32:609  617 207. Gubitosi-Klug RA, Braffett BH, Bebu I, et al. Continuous glucose monitoring in adults with type 1 diabetes with 35 years duration from the DCCT/EDIC study. Diabetes Care 2022;45:659  665 208. Teo E, Hassan N, Tam W, Koh S. Effectiveness of continuous glucose monitoring in maintaining glycaemic control among people with type 1 diabetes mellitus: a systematic review of randomised controlled trials and meta-analysis. Diabetologia 2022;65:604  619 209. Seidu S, Kunutsor SK, Ajjan RA, Choudhary P. Efficacy and safety of continuous glucose monitoring and intermittently scanned continuous glucose monitoring in patients with type 2 diabetes: a systematic review and meta-analysis of interventional evidence. Diabetes Care 2024;47:169-179 210. Phillip M, Nimri R, Bergenstal RM, et al. Consensus recommendations for the use of automated insulin delivery technologies in clinical practice. Endocr Rev 2023;44:254  280 211. Brown SA, Beck RW, Raghinaru D, et al.; iDCL Trial Research Group. Glycemic outcomes of use of CLC versus PLGS in type 1 diabetes: a randomized controlled trial. Diabetes Care 2020; 43:1822","tf":{"32":1,"35":1,"43":1,"44":1,"45":1,"47":1,"65":1,"169":1,"179":1,"206":1,"207":1,"208":1,"209":1,"210":1,"211":1,"254":1,"280":1,"323":1,"604":1,"609":1,"617":1,"619":1,"659":1,"665":1,"1822":1,"2015":1,"2020":2,"2022":2,"2023":1,"2024":1,"2388":1,"2396":1,"ype":1,"diabetes":10,"randomized":3,"clinical":2,"trial":3,"jama":1,"new":1,"jp":1,"ajjan":2,"pfeiffer":1,"afh":1,"freckmann":1,"continuous":5,"glucose":6,"monitoring":5,"in":7,"people":2,"with":5,"the":3,"controlled":3,"level":1,"awareness":1,"study":2,"gladis":1,"diabet":1,"med":1,"gubitosi":1,"klug":1,"ra":2,"braffett":1,"bh":1,"bebu":1,"et":3,"al":3,"adults":1,"type":4,"years":1,"duration":1,"from":1,"dcct":1,"edic":1,"care":3,"teo":1,"hassan":1,"tam":1,"koh":1,"effectiveness":1,"of":7,"maintaining":1,"glycaemic":1,"control":1,"among":1,"mellitus":1,"systematic":2,"review":2,"randomised":1,"trials":1,"and":4,"meta":2,"analysis":2,"diabetologia":1,"seidu":1,"kunutsor":1,"sk":1,"choudhary":1,"efficacy":1,"safety":1,"intermittently":1,"scanned":1,"patients":1,"interventional":1,"evidence":1,"phillip":1,"nimri":1,"bergenstal":1,"rm":1,"consensus":1,"recommendations":1,"for":1,"use":2,"automated":1,"insulin":1,"delivery":1,"technologies":1,"practice":1,"endocr":1,"rev":1,"brown":1,"sa":1,"beck":1,"rw":1,"raghinaru":1,"idcl":1,"research":1,"group":1,"glycemic":1,"outcomes":1,"clc":1,"versus":1,"plgs":1},"len":202},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":31,"chunkId":"ada-2026-pharm-p31-c3","text":"gies in clinical practice. Endocr Rev 2023;44:254  280 211. Brown SA, Beck RW, Raghinaru D, et al.; iDCL Trial Research Group. Glycemic outcomes of use of CLC versus PLGS in type 1 diabetes: a randomized controlled trial. Diabetes Care 2020; 43:1822  1828 212. Pasquel FJ, Davis GM, Huffman DM, et al.; Omnipod 5 SECURE-T2D Consortium. Automated insulin delivery in adults with type 2 diabetes: a nonrandomized clinical trial. JAMA Netw Open 2025;8:e2459348 213. Bhargava A, Bergenstal RM, Warren ML, et al.; IMPACT2D Study Group. Safety and effectiveness of MiniMedTM 780G advanced hybrid closed-loop insulin intensification in adults with insulin-requiring type 2 diabetes. Diabetes Technol Ther 2025;27: 366  375 214. Davis GM, Peters AL, Bode BW, et al. Safety and efficacy of the Omnipod 5 automated insulin delivery system in adults with type 2 diabetes: from injections to hybrid closed-loop therapy. Diabetes Care 2023;46:742  750 215. Kudva YC, Raghinaru D, Lum JW, et al.; 2IQP Study Group. A randomized trial of automated insulin delivery in type 2 diabetes. N Engl J Med 2025;392:1801  1812 216. Valentine V, Newswanger B, Prestrelski S, Andre AD, Garibaldi M. Human factors usability and validation studies of a glucagon autoinjector in a simulated severe hypoglycemia rescue situation. Diabetes Technol Ther 2019;21:522  530 217. Settles JA, Gerety GF, Spaepen E, Suico JG, Child ","tf":{"21":1,"27":1,"43":1,"44":1,"46":1,"211":1,"212":1,"213":1,"214":1,"215":1,"216":1,"217":1,"254":1,"280":1,"366":1,"375":1,"392":1,"522":1,"530":1,"742":1,"750":1,"1801":1,"1812":1,"1822":1,"1828":1,"2019":1,"2020":1,"2023":2,"2025":3,"gies":1,"in":7,"clinical":2,"practice":1,"endocr":1,"rev":1,"brown":1,"sa":1,"beck":1,"rw":1,"raghinaru":2,"et":5,"al":6,"idcl":1,"trial":4,"research":1,"group":3,"glycemic":1,"outcomes":1,"of":6,"use":1,"clc":1,"versus":1,"plgs":1,"type":5,"diabetes":9,"randomized":2,"controlled":1,"care":2,"pasquel":1,"fj":1,"davis":2,"gm":2,"huffman":1,"dm":1,"omnipod":2,"secure":1,"t2d":1,"consortium":1,"automated":3,"insulin":5,"delivery":3,"adults":3,"with":3,"nonrandomized":1,"jama":1,"netw":1,"open":1,"e2459348":1,"bhargava":1,"bergenstal":1,"rm":1,"warren":1,"ml":1,"impact2d":1,"study":2,"safety":2,"and":3,"effectiveness":1,"minimedtm":1,"780g":1,"advanced":1,"hybrid":2,"closed":2,"loop":2,"intensification":1,"requiring":1,"technol":2,"ther":2,"peters":1,"bode":1,"bw":1,"efficacy":1,"the":1,"system":1,"from":1,"injections":1,"to":1,"therapy":1,"kudva":1,"yc":1,"lum":1,"jw":1,"2iqp":1,"engl":1,"med":1,"valentine":1,"newswanger":1,"prestrelski":1,"andre":1,"ad":1,"garibaldi":1,"human":1,"factors":1,"usability":1,"validation":1,"studies":1,"glucagon":1,"autoinjector":1,"simulated":1,"severe":1,"hypoglycemia":1,"rescue":1,"situation":1,"settles":1,"ja":1,"gerety":1,"gf":1,"spaepen":1,"suico":1,"jg":1,"child":1},"len":209},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":31,"chunkId":"ada-2026-pharm-p31-c4","text":"i S, Andre AD, Garibaldi M. Human factors usability and validation studies of a glucagon autoinjector in a simulated severe hypoglycemia rescue situation. Diabetes Technol Ther 2019;21:522  530 217. Settles JA, Gerety GF, Spaepen E, Suico JG, Child CJ. Nasal glucagon delivery is more successful than injectable delivery: a simulated severe hypoglycemia rescue. Endocr Pract 2020;26:407  415 218. Herges JR, Galindo RJ, Neumiller JJ, Heien HC, Umpierrez GE, McCoy RG. Glucagon prescribing and costs among U.S. adults with diabetes, 2011-2021. Diabetes Care 2023;46:620  627 219. Kahn PA, Liu S, McCoy R, Gabbay RA, Lipska K. Glucagon use by U.S. adults with type 1 and type 2 diabetes. J Diabetes Complications 2021;35:107882 220. Benning TJ, Heien HC, Herges JR, Creo AL, Al Nofal A, McCoy RG. Glucagon fill rates and cost among children and adolescents with type 1 diabetes in the United States, 2011  2021. Diabetes Res Clin Pract 2023;206:111026 221. Riddle MC, Herman WH. The cost of diabetes care-an elephant in the room. Diabetes Care 2018;41:929  932 222. Merative. Redbook (electronic version). Accessed 15 July 2025. Available from https:// www.micromedexsolutions.com 223. Data.Medicaid.gov. NADAC (National Average Drug Acquisition Cost). Accessed 15 July 2025. Available from https://healthdata.gov/dataset/NADAC-National- Average-Drug-Acquisition-Cost-2024/3tha-57c6/about _data 22","tf":{"15":2,"21":1,"22":1,"26":1,"35":1,"41":1,"46":1,"206":1,"217":1,"218":1,"219":1,"220":1,"221":1,"222":1,"223":1,"407":1,"415":1,"522":1,"530":1,"620":1,"627":1,"929":1,"932":1,"2011":2,"2018":1,"2019":1,"2020":1,"2021":3,"2023":2,"2024":1,"2025":2,"107882":1,"111026":1,"andre":1,"ad":1,"garibaldi":1,"human":1,"factors":1,"usability":1,"and":5,"validation":1,"studies":1,"of":2,"glucagon":5,"autoinjector":1,"in":3,"simulated":2,"severe":2,"hypoglycemia":2,"rescue":2,"situation":1,"diabetes":9,"technol":1,"ther":1,"settles":1,"ja":1,"gerety":1,"gf":1,"spaepen":1,"suico":1,"jg":1,"child":1,"cj":1,"nasal":1,"delivery":2,"is":1,"more":1,"successful":1,"than":1,"injectable":1,"endocr":1,"pract":2,"herges":2,"jr":2,"galindo":1,"rj":1,"neumiller":1,"jj":1,"heien":2,"hc":2,"umpierrez":1,"ge":1,"mccoy":3,"rg":2,"prescribing":1,"costs":1,"among":2,"adults":2,"with":3,"care":3,"kahn":1,"pa":1,"liu":1,"gabbay":1,"ra":1,"lipska":1,"use":1,"by":1,"type":3,"complications":1,"benning":1,"tj":1,"creo":1,"al":2,"nofal":1,"fill":1,"rates":1,"cost":4,"children":1,"adolescents":1,"the":3,"united":1,"states":1,"res":1,"clin":1,"riddle":1,"mc":1,"herman":1,"wh":1,"an":1,"elephant":1,"room":1,"merative":1,"redbook":1,"electronic":1,"version":1,"accessed":2,"july":2,"available":2,"from":2,"https":2,"www":1,"micromedexsolutions":1,"com":1,"data":2,"medicaid":1,"gov":2,"nadac":2,"national":2,"average":2,"drug":2,"acquisition":2,"healthdata":1,"dataset":1,"3tha":1,"57c6":1,"about":1},"len":211},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":31,"chunkId":"ada-2026-pharm-p31-c5","text":"ps:// www.micromedexsolutions.com 223. Data.Medicaid.gov. NADAC (National Average Drug Acquisition Cost). Accessed 15 July 2025. Available from https://healthdata.gov/dataset/NADAC-National- Average-Drug-Acquisition-Cost-2024/3tha-57c6/about _data 224. Kang H, Lobo JM, Kim S, Sohn M-W. Cost- related medication non-adherence among U.S. adults with diabetes. Diabetes Res Clin Pract 2018;143:24  33 225. Patel MR, Piette JD, Resnicow K, Kowalski- Dobson T, Heisler M. Social determinants of health, cost-related nonadherence, and cost-reducing behaviors among adults with diabetes: findings from the National Health Interview Survey. Med Care 2016;54:796  803 226. Centers for Medicare & Medicaid Services. Part D Senior Savings Model. Accessed 25 August 2025. Available from https://www.cms.gov/priorities/ innovation/innovation-models/part-d-savings-model 227. Baig KA, Fry CE, Buntin MB, Powers AC, Dusetzina SB. Insulin out-of-pocket spending caps and employer-sponsored insurance: changes in out-of-pocket and total costs for insulin and healthcare. Health Serv Res 2025:e14656 228. American Diabetes Association. State Insulin Copay Caps. Accessed 25 August 2025. Available from https://diabetes.org/tools-resources/affordable -insulin/state-insulin-copay-caps 229. Suran M. All 3 major insulin manufacturers are cutting their prices-heres what the news means for patients with diabetes. JAM","tf":{"15":1,"24":1,"25":2,"33":1,"54":1,"143":1,"223":1,"224":1,"225":1,"226":1,"227":1,"228":1,"229":1,"796":1,"803":1,"2016":1,"2018":1,"2024":1,"2025":4,"ps":1,"www":2,"micromedexsolutions":1,"com":1,"data":2,"medicaid":2,"gov":3,"nadac":2,"national":3,"average":2,"drug":2,"acquisition":2,"cost":5,"accessed":3,"july":1,"available":3,"from":4,"https":3,"healthdata":1,"dataset":1,"3tha":1,"57c6":1,"about":1,"kang":1,"lobo":1,"jm":1,"kim":1,"sohn":1,"related":2,"medication":1,"non":1,"adherence":1,"among":2,"adults":2,"with":3,"diabetes":6,"res":2,"clin":1,"pract":1,"patel":1,"mr":1,"piette":1,"jd":1,"resnicow":1,"kowalski":1,"dobson":1,"heisler":1,"social":1,"determinants":1,"of":3,"health":3,"nonadherence":1,"and":4,"reducing":1,"behaviors":1,"findings":1,"the":2,"interview":1,"survey":1,"med":1,"care":1,"centers":1,"for":3,"medicare":1,"services":1,"part":2,"senior":1,"savings":2,"model":2,"august":2,"cms":1,"priorities":1,"innovation":2,"models":1,"baig":1,"ka":1,"fry":1,"ce":1,"buntin":1,"mb":1,"powers":1,"ac":1,"dusetzina":1,"sb":1,"insulin":6,"out":2,"pocket":2,"spending":1,"caps":3,"employer":1,"sponsored":1,"insurance":1,"changes":1,"in":1,"total":1,"costs":1,"healthcare":1,"serv":1,"e14656":1,"american":1,"association":1,"state":2,"copay":2,"org":1,"tools":1,"resources":1,"affordable":1,"suran":1,"all":1,"major":1,"manufacturers":1,"are":1,"cutting":1,"their":1,"prices":1,"here":1,"what":1,"news":1,"means":1,"patients":1,"jam":1},"len":205},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":31,"chunkId":"ada-2026-pharm-p31-c6","text":"essed 25 August 2025. Available from https://diabetes.org/tools-resources/affordable -insulin/state-insulin-copay-caps 229. Suran M. All 3 major insulin manufacturers are cutting their prices-heres what the news means for patients with diabetes. JAMA 2023;329:1337  1339 230. Herges JR, Neumiller JJ, McCoy RG. Easing the financial burden of diabetes management: a guide for patients and primary care clinicians. Clin Diabetes 2021;39:427  436 231. U.S. Food & Drug Administration. FDA Drug Shortages. Accessed 17 August 2025. Available from https://dps.fda.gov/drugshortages 232. U.S. Food & Drug Administration. Drug Compounding and Drug Shortages. Accessed 25 August 2025. Available from https://www.fda .gov/drugs/human-drug-compounding/drug- compounding-and-drug-shortages 233. Ashraf AR, Mackey TK, Schmidt J, et al. Safety and risk assessment of no-prescription online semaglutide purchases. JAMA Netw Open 2024;7:e2428280 234. U.S. Food & Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. Accessed 25 August 2025. Available from https://www.fda.gov/drugs/human -drug-compounding/fda-alerts-health-care-providers -compounders-and-patients-dosing-errors-associated -compounded 235. Lambson JE, Flegal SC, Johnson AR. Admin- istration errors of compounded semaglutide reported to a poi","tf":{"17":1,"25":3,"39":1,"229":1,"230":1,"231":1,"232":1,"233":1,"234":1,"235":1,"329":1,"427":1,"436":1,"1337":1,"1339":1,"2021":1,"2023":1,"2024":1,"2025":4,"essed":1,"august":4,"available":4,"from":4,"https":4,"diabetes":4,"org":1,"tools":1,"resources":1,"affordable":1,"insulin":3,"state":1,"copay":1,"caps":1,"suran":1,"all":1,"major":1,"manufacturers":1,"are":1,"cutting":1,"their":1,"prices":1,"here":1,"what":1,"the":2,"news":1,"means":1,"for":2,"patients":4,"with":2,"jama":2,"herges":1,"jr":1,"neumiller":1,"jj":1,"mccoy":1,"rg":1,"easing":1,"financial":1,"burden":1,"of":4,"management":1,"guide":1,"and":6,"primary":1,"care":3,"clinicians":1,"clin":1,"food":3,"drug":10,"administration":3,"fda":6,"shortages":3,"accessed":3,"dps":1,"gov":3,"drugshortages":1,"compounding":4,"www":2,"drugs":2,"human":2,"ashraf":1,"ar":2,"mackey":1,"tk":1,"schmidt":1,"et":1,"al":1,"safety":1,"risk":1,"assessment":1,"no":1,"prescription":1,"online":1,"semaglutide":3,"purchases":1,"netw":1,"open":1,"e2428280":1,"alerts":2,"health":2,"providers":2,"compounders":2,"dosing":2,"errors":3,"associated":2,"compounded":3,"injectable":1,"products":1,"lambson":1,"je":1,"flegal":1,"sc":1,"johnson":1,"admin":1,"istration":1,"reported":1,"to":1,"poi":1},"len":200},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":31,"chunkId":"ada-2026-pharm-p31-c7","text":"ps://www.fda.gov/drugs/human -drug-compounding/fda-alerts-health-care-providers -compounders-and-patients-dosing-errors-associated -compounded 235. Lambson JE, Flegal SC, Johnson AR. Admin- istration errors of compounded semaglutide reported to a poison control center-case series. J Am Pharm Assoc (2003) 2023;63:1643  1645 236. U.S. Food & Drug Administration. FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain. Accessed 25 August 2025. Available from https:// www.fda.gov/drugs/drug-safety-and-availability/ fda-warns-consumers-not-use-counterfeit-ozempic -semaglutide-found-us-drug-supply-chain 237. Neumiller JJ, Bajaj M, Bannuru RR, et al. Compounded GLP-1 and dual GIP/GLP-1 receptor agonists: a statement from the American Diabetes Association. Diabetes Care 2025;48:177  181 238. Whitley HP, Trujillo JM, Neumiller JJ. Special report: potential strategies for addressing GLP-1 and dual GLP-1/GIP Receptor agonist shortages. Clin Diabetes 2023;41:467  473 239. Urva S, Coskun T, Loghin C, et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab 2020;22:1886  1891 240. Skelley JW, Swearengin K, York AL, Glover LH. The impact of tirzepatide and gluc","tf":{"22":1,"25":1,"41":1,"48":1,"63":1,"177":1,"181":1,"235":1,"236":1,"237":1,"238":1,"239":1,"240":1,"467":1,"473":1,"1643":1,"1645":1,"1886":1,"1891":1,"2003":1,"2020":1,"2023":2,"2025":2,"ps":1,"www":2,"fda":5,"gov":2,"drugs":2,"human":1,"drug":5,"compounding":1,"alerts":1,"health":1,"care":2,"providers":1,"compounders":1,"and":6,"patients":1,"dosing":1,"errors":2,"associated":1,"compounded":3,"lambson":1,"je":1,"flegal":1,"sc":1,"johnson":1,"ar":1,"admin":1,"istration":1,"of":2,"semaglutide":3,"reported":1,"to":3,"poison":1,"control":1,"center":1,"case":1,"series":1,"am":1,"pharm":1,"assoc":1,"food":1,"administration":1,"warns":2,"consumers":2,"not":2,"use":2,"counterfeit":2,"ozempic":2,"found":2,"in":1,"supply":2,"chain":2,"accessed":1,"august":1,"available":1,"from":2,"https":1,"safety":1,"availability":1,"us":1,"neumiller":2,"jj":2,"bajaj":1,"bannuru":1,"rr":1,"et":2,"al":3,"glp":6,"dual":3,"gip":2,"receptor":4,"agonists":2,"statement":1,"the":3,"american":1,"diabetes":4,"association":1,"whitley":1,"hp":1,"trujillo":1,"jm":1,"special":1,"report":1,"potential":1,"strategies":1,"for":1,"addressing":1,"agonist":2,"shortages":1,"clin":1,"urva":1,"coskun":1,"loghin":1,"novel":1,"glucose":1,"dependent":1,"insulinotropic":1,"polypeptide":1,"glucagon":1,"like":1,"peptide":1,"tirzepatide":2,"transiently":1,"delays":1,"gastric":1,"emptying":1,"similarly":1,"selective":1,"long":1,"acting":1,"obes":1,"metab":1,"skelley":1,"jw":1,"swearengin":1,"york":1,"glover":1,"lh":1,"impact":1,"gluc":1},"len":203},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":31,"chunkId":"ada-2026-pharm-p31-c8","text":"receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab 2020;22:1886  1891 240. Skelley JW, Swearengin K, York AL, Glover LH. The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception. J Am Pharm Assoc (2003) 2024;64:204  211.e4 e204 diabetesjournals.org/care Pharmacologic Approaches to Glycemic Treatment S213 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"22":1,"49":1,"64":1,"204":1,"211":1,"240":1,"1886":1,"1891":1,"2003":1,"2020":1,"2024":1,"2026":1,"848878":1,"receptor":3,"agonist":1,"tirzepatide":2,"transiently":1,"delays":1,"gastric":1,"emptying":1,"similarly":1,"to":2,"selective":1,"long":1,"acting":1,"glp":1,"agonists":2,"diabetes":1,"obes":1,"metab":1,"skelley":1,"jw":1,"swearengin":1,"york":1,"al":1,"glover":1,"lh":1,"the":1,"impact":1,"of":1,"and":1,"glucagon":1,"like":1,"peptide":1,"on":2,"oral":1,"hormonal":1,"contraception":1,"am":1,"pharm":1,"assoc":1,"e4":1,"e204":1,"diabetesjournals":2,"org":2,"care":2,"pharmacologic":1,"approaches":1,"glycemic":1,"treatment":1,"s213":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"supplement":1,"s183":1,"dc26s009":1,"by":1,"guest":1,"february":1},"len":83},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":32,"chunkId":"ada-2026-pharm-p32-c0","text":"241. National Library of Medicine. National Center for Biotechnology Information. ClinicalTrials.gov. A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants (NCT04172987). Accessed 12 June 2024. Available from https://clinicaltrials.gov/ study/NCT04172987 242. U.S. Food & Drug Administration. Tirzepatide prescribing information. Accessed 25 August 2025. Available from https://www.accessdata.fda.gov/ drugsatfda_docs/label/2022/215866s000lbl.pdf 243. Chang L-S, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev 2019;40:17  65 244. Zhou L, Yang S, Li Y, Xue C, Wan R. A comprehensive review of immune checkpoint inhibitor-related diabetes mellitus: incidence, clinical features, management, and prognosis. Front Immunol 2024;15:1448728 245. Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 2018;4:173  182 246. Liu J, Zhou H, Zhang Y, et al. Reporting of immune checkpoint inhibitor therapy-associated diabetes, 2015  2019. Diabetes Care 2020;43: e79  e80 247. Mulla K, Farag S, Moore B, et al. Hyperglycaemia following immune checkpoint inhibitor therapy-Incidence, aetiology and assessme","tf":{"12":1,"15":1,"17":1,"25":1,"40":1,"43":1,"65":1,"173":1,"182":1,"241":1,"242":1,"243":1,"244":1,"245":1,"246":1,"247":1,"2015":1,"2018":1,"2019":2,"2020":1,"2022":1,"2024":2,"2025":1,"1448728":1,"national":2,"library":1,"of":8,"medicine":1,"center":1,"for":1,"biotechnology":1,"information":2,"clinicaltrials":2,"gov":3,"study":2,"the":3,"effect":1,"tirzepatide":2,"on":1,"how":1,"body":1,"handles":1,"birth":1,"control":1,"pills":1,"in":1,"healthy":1,"female":1,"participants":1,"nct04172987":2,"accessed":2,"june":1,"available":2,"from":2,"https":2,"food":1,"drug":1,"administration":1,"prescribing":1,"august":1,"www":1,"accessdata":1,"fda":1,"drugsatfda":1,"docs":1,"label":1,"215866s000lbl":1,"pdf":1,"chang":1,"barroso":2,"sousa":2,"tolaney":1,"sm":1,"hodi":1,"fs":1,"kaiser":1,"ub":1,"min":1,"endocrine":2,"toxicity":1,"cancer":1,"immunotherapy":1,"targeting":1,"immune":5,"checkpoints":1,"endocr":1,"rev":1,"zhou":2,"yang":1,"li":1,"xue":1,"wan":1,"comprehensive":1,"review":2,"checkpoint":4,"inhibitor":4,"related":1,"diabetes":3,"mellitus":1,"incidence":3,"clinical":1,"features":1,"management":1,"and":3,"prognosis":1,"front":1,"immunol":1,"barry":1,"wt":1,"garrido":1,"castro":1,"ac":1,"et":3,"al":3,"dysfunction":1,"following":2,"use":1,"different":1,"regimens":1,"systematic":1,"meta":1,"analysis":1,"jama":1,"oncol":1,"liu":1,"zhang":1,"reporting":1,"therapy":2,"associated":1,"care":1,"e79":1,"e80":1,"mulla":1,"farag":1,"moore":1,"hyperglycaemia":1,"aetiology":1,"assessme":1},"len":188},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":32,"chunkId":"ada-2026-pharm-p32-c1","text":" Reporting of immune checkpoint inhibitor therapy-associated diabetes, 2015  2019. Diabetes Care 2020;43: e79  e80 247. Mulla K, Farag S, Moore B, et al. Hyperglycaemia following immune checkpoint inhibitor therapy-Incidence, aetiology and assessment. Diabet Med 2023;40:e15053 248. Byun DJ, Braunstein R, Flynn J, et al. Immune checkpoint inhibitor-associated diabetes: a single-institution experience. Diabetes Care 2020;43: 3106  3109 249. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 2021;39:4073  4126 250. Goncalves MD, Hopkins BD, Cantley LC. phosphatidylinositol 3-kinase, growth disorders, and cancer. N Engl J Med 2018;379:2052  2062 251. Andr F, Ciruelos E, Rubovszky G, et al.; SOLAR-1 Study Group. Alpelisib for PIK3CA- mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 2019;380:1929  1940 252. Andr F, Ciruelos EM, Juric D, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol 2021;32:208  217 253. Rugo HS, Andr F, Yamashita T, et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpel","tf":{"32":1,"39":1,"40":1,"43":2,"208":1,"217":1,"247":1,"248":1,"249":1,"250":1,"251":1,"252":1,"253":1,"379":1,"380":1,"1929":1,"1940":1,"2015":1,"2018":1,"2019":2,"2020":2,"2021":2,"2023":1,"2052":1,"2062":1,"3106":1,"3109":1,"4073":1,"4126":1,"reporting":1,"of":4,"immune":5,"checkpoint":4,"inhibitor":5,"therapy":3,"associated":2,"diabetes":4,"care":2,"e79":1,"e80":1,"mulla":1,"farag":1,"moore":1,"et":6,"al":6,"hyperglycaemia":1,"following":1,"incidence":1,"aetiology":1,"and":3,"assessment":1,"diabet":1,"med":3,"e15053":1,"byun":1,"dj":1,"braunstein":1,"flynn":1,"single":1,"institution":1,"experience":1,"schneider":1,"bj":1,"naidoo":1,"santomasso":1,"bd":2,"management":2,"related":1,"adverse":2,"events":2,"in":1,"patients":1,"treated":1,"with":1,"asco":1,"guideline":1,"update":1,"clin":1,"oncol":2,"goncalves":1,"md":1,"hopkins":1,"cantley":1,"lc":1,"phosphatidylinositol":1,"kinase":1,"growth":2,"disorders":1,"cancer":3,"engl":2,"andr":3,"ciruelos":2,"rubovszky":1,"solar":3,"study":2,"group":1,"alpelisib":2,"for":2,"pik3ca":2,"mutated":2,"hormone":2,"receptor":3,"positive":2,"advanced":2,"breast":2,"em":1,"juric":1,"plus":1,"fulvestrant":1,"human":1,"epidermal":1,"factor":1,"negative":1,"final":1,"overall":1,"survival":1,"results":1,"from":1,"ann":1,"rugo":1,"hs":1,"yamashita":1,"time":1,"course":1,"key":1,"during":1,"the":1,"randomized":1,"phase":1,"iii":1,"pi3k":1,"alpel":1},"len":196},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":32,"chunkId":"ada-2026-pharm-p32-c2","text":" breast cancer: final overall survival results from SOLAR-1. Ann Oncol 2021;32:208  217 253. Rugo HS, Andr F, Yamashita T, et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol 2020;31:1001  1010 254. Jhaveri KL, Im S-A, Saura C, et al. Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer. N Engl J Med 2025;393:151  161 255. Liu D, Weintraub MA, Garcia C, et al. Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment. Cancer Med 2022;11:1796  1804 256. Gallagher EJ, Moore H, Lacouture ME, et al. Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique. NPJ Breast Cancer 2024;10:12 257. Ihle NT, Lemos R, Schwartz D, et al. Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity. Mol Cancer Ther 2009;8:94  100 258. Borrego MR, Lu Y-S, Reyes-Cosmelli F, et al. SGLT2 inhibition improves PI3K  inhibitor- induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials. Breast Cancer Res Treat 2024;208:","tf":{"10":1,"11":1,"12":1,"31":1,"32":1,"94":1,"100":1,"151":1,"161":1,"208":2,"217":1,"253":1,"254":1,"255":1,"256":1,"257":1,"258":1,"393":1,"866":1,"1001":1,"1010":1,"1796":1,"1804":1,"2009":1,"2020":1,"2021":1,"2022":1,"2024":2,"2025":1,"breast":5,"cancer":7,"final":1,"overall":2,"survival":2,"results":1,"from":3,"solar":3,"ann":2,"oncol":2,"rugo":1,"hs":1,"andr":1,"yamashita":1,"et":6,"al":6,"time":1,"course":1,"and":5,"management":2,"of":3,"key":1,"adverse":1,"events":1,"during":2,"the":4,"randomized":1,"phase":1,"iii":1,"study":1,"pi3k":3,"inhibitor":3,"alpelisib":2,"plus":1,"fulvestrant":1,"in":3,"patients":2,"with":3,"hr":1,"positive":1,"advanced":2,"jhaveri":1,"kl":1,"im":1,"saura":1,"inavolisib":1,"pik3ca":1,"mutated":1,"engl":1,"med":2,"liu":1,"weintraub":1,"ma":1,"garcia":1,"characterization":1,"risk":1,"factors":1,"hyperglycemia":4,"or":1,"akt":1,"treatment":1,"gallagher":1,"ej":1,"moore":1,"lacouture":1,"me":1,"managing":1,"rash":1,"associated":1,"expert":1,"consensus":1,"recommendations":1,"using":1,"delphi":1,"technique":1,"npj":1,"ihle":1,"nt":1,"lemos":1,"schwartz":1,"peroxisome":1,"proliferator":1,"activated":1,"receptor":1,"gamma":1,"agonist":1,"pioglitazone":1,"prevents":1,"caused":1,"by":2,"phosphatidylinositol":1,"kinase":1,"pathway":1,"inhibition":2,"px":1,"without":1,"affecting":1,"antitumor":1,"activity":1,"mol":1,"ther":1,"borrego":1,"mr":1,"lu":1,"reyes":1,"cosmelli":1,"sglt2":1,"improves":1,"induced":1,"findings":1,"preclinical":1,"animal":1,"models":1,"bylieve":1,"trials":1,"res":1,"treat":1},"len":204},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":32,"chunkId":"ada-2026-pharm-p32-c3","text":"  100 258. Borrego MR, Lu Y-S, Reyes-Cosmelli F, et al. SGLT2 inhibition improves PI3K  inhibitor- induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials. Breast Cancer Res Treat 2024;208:111  121 259. Goncalves MD, Farooki A. Management of phosphatidylinositol-3-kinase inhibitor-associated hyperglycemia. Integr Cancer Ther 2022;21: 15347354211073163 260. Cheung Y-MM, McDonnell M, Hamnvik O-PR. A targeted approach to phosphoinositide-3-kinase/ Akt/mammalian target of rapamycin-induced hyperglycemia. Curr Probl Cancer 2022;46:100776 261. Khan KH, Wong M, Rihawi K, et al. Hyperglycemia and phosphatidylinositol 3-kinase/ protein kinase b/mammalian target of rapamycin (PI3K/AKT/mTOR) inhibitors in phase I trials: incidence, predictive factors, and management. Oncologist 2016;21:855  860 262. Busaidy NL, Farooki A, Dowlati A, et al. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt- mTOR pathway. J Clin Oncol 2012;30:2919  2928 263. Nowak KM, Rdzanek-Pikus M, Romanowska- Prchnicka K, Nowakowska-Paza A, Papierska L. High prevalence of steroid-induced glucose intolerance with normal fasting glycaemia during low-dose glucocorticoid therapy: an oral glucose tolerance test screening study. Rheumatology (Oxford) 2021;60:2842  2851 264. Kulkarni S, Durham H, Glover L, et al. Metabolic","tf":{"21":2,"30":1,"46":1,"60":1,"100":1,"111":1,"121":1,"208":1,"258":1,"259":1,"260":1,"261":1,"262":1,"263":1,"264":1,"855":1,"860":1,"2012":1,"2016":1,"2021":1,"2022":2,"2024":1,"2842":1,"2851":1,"2919":1,"2928":1,"100776":1,"borrego":1,"mr":1,"lu":1,"reyes":1,"cosmelli":1,"et":4,"al":4,"sglt2":1,"inhibition":1,"improves":1,"pi3k":3,"inhibitor":2,"induced":3,"hyperglycemia":4,"findings":1,"from":2,"preclinical":1,"animal":1,"models":1,"and":4,"patients":1,"in":2,"the":2,"bylieve":1,"solar":1,"trials":2,"breast":1,"cancer":3,"res":1,"treat":1,"goncalves":1,"md":1,"farooki":2,"management":3,"of":5,"phosphatidylinositol":2,"kinase":4,"associated":2,"integr":1,"ther":1,"15347354211073163":1,"cheung":1,"mm":1,"mcdonnell":1,"hamnvik":1,"pr":2,"targeted":1,"approach":1,"to":1,"phosphoinositide":1,"akt":3,"mammalian":2,"target":2,"rapamycin":2,"curr":1,"probl":1,"khan":1,"kh":1,"wong":1,"rihawi":1,"protein":1,"mtor":2,"inhibitors":1,"phase":1,"incidence":1,"predictive":1,"factors":1,"oncologist":1,"busaidy":1,"nl":1,"dowlati":1,"metabolic":2,"effects":1,"with":2,"anticancer":1,"agents":1,"targeting":1,"pathway":1,"clin":1,"oncol":1,"nowak":1,"km":1,"rdzanek":1,"pikus":1,"romanowska":1,"chnicka":1,"nowakowska":1,"aza":1,"papierska":1,"high":1,"prevalence":1,"steroid":1,"glucose":2,"intolerance":1,"normal":1,"fasting":1,"glycaemia":1,"during":1,"low":1,"dose":1,"glucocorticoid":1,"therapy":1,"an":1,"oral":1,"tolerance":1,"test":1,"screening":1,"study":1,"rheumatology":1,"oxford":1,"kulkarni":1,"durham":1,"glover":1},"len":187},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":32,"chunkId":"ada-2026-pharm-p32-c4","text":" steroid-induced glucose intolerance with normal fasting glycaemia during low-dose glucocorticoid therapy: an oral glucose tolerance test screening study. Rheumatology (Oxford) 2021;60:2842  2851 264. Kulkarni S, Durham H, Glover L, et al. Metabolic adverse events associated with systemic corticosteroid therapy-a systematic review and meta-analysis. BMJ Open 2022;12:e061476 265. Perez A, Jansen-Chaparro S, Saigi I, Bernal-Lopez MR, Miambres I, Gomez-Huelgas R. Glucocorticoid- induced hyperglycemia. J Diabetes 2014;6:9  20 266. Elena C, Chiara M, Angelica B, et al. Hyperglycemia and diabetes induced by glucocorticoids in nondiabetic and diabetic patients: revision of literature and personal considerations. Curr Pharm Biotechnol 2018;19:1210  1220 267. Burt MG, Roberts GW, Aguilar-Loza NR, Frith P, Stranks SN. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab 2011;96:1789  1796 268. Zhang F, Karam JG. Glycemic profile of intravenous dexamethasone-induced hyperglycemia using continuous glucose monitoring. Am J Case Rep 2021;22:e930733 269. Wallace MD, Metzger NL. Optimizing the treatment of steroid-induced hyperglycemia. Ann Pharmacother 2018;52:86  90 270. Limbachia V, Nunney I, Page DJ, et al. The effect of different types of oral or intravenous corticosteroids on capillary blood glucose levels in hosp","tf":{"12":1,"19":1,"20":1,"22":1,"52":1,"60":1,"86":1,"90":1,"96":1,"264":1,"265":1,"266":1,"267":1,"268":1,"269":1,"270":1,"1210":1,"1220":1,"1789":1,"1796":1,"2011":1,"2014":1,"2018":2,"2021":2,"2022":1,"2842":1,"2851":1,"steroid":2,"induced":5,"glucose":4,"intolerance":1,"with":2,"normal":1,"fasting":1,"glycaemia":1,"during":1,"low":1,"dose":1,"glucocorticoid":2,"therapy":2,"an":1,"oral":2,"tolerance":1,"test":1,"screening":1,"study":1,"rheumatology":1,"oxford":1,"kulkarni":1,"durham":1,"glover":1,"et":3,"al":3,"metabolic":1,"adverse":1,"events":1,"associated":1,"systemic":1,"corticosteroid":1,"systematic":1,"review":1,"and":4,"meta":1,"analysis":1,"bmj":1,"open":1,"e061476":1,"perez":1,"jansen":1,"chaparro":1,"saigi":1,"bernal":1,"lopez":1,"mr":1,"mi":1,"ambres":1,"gomez":1,"huelgas":1,"hyperglycemia":4,"diabetes":2,"elena":1,"chiara":1,"angelica":1,"by":1,"glucocorticoids":1,"in":3,"nondiabetic":1,"diabetic":1,"patients":2,"revision":1,"of":6,"literature":1,"personal":1,"considerations":1,"curr":1,"pharm":1,"biotechnol":1,"burt":1,"mg":1,"roberts":1,"gw":1,"aguilar":1,"loza":1,"nr":1,"frith":1,"stranks":1,"sn":1,"continuous":2,"monitoring":2,"circadian":1,"glycemic":2,"patterns":1,"receiving":1,"prednisolone":1,"for":1,"copd":1,"clin":1,"endocrinol":1,"metab":1,"zhang":1,"karam":1,"jg":1,"profile":1,"intravenous":2,"dexamethasone":1,"using":1,"am":1,"case":1,"rep":1,"e930733":1,"wallace":1,"md":1,"metzger":1,"nl":1,"optimizing":1,"the":2,"treatment":1,"ann":1,"pharmacother":1,"limbachia":1,"nunney":1,"page":1,"dj":1,"effect":1,"different":1,"types":1,"or":1,"corticosteroids":1,"on":1,"capillary":1,"blood":1,"levels":1,"hosp":1},"len":191},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":32,"chunkId":"ada-2026-pharm-p32-c5","text":"NL. Optimizing the treatment of steroid-induced hyperglycemia. Ann Pharmacother 2018;52:86  90 270. Limbachia V, Nunney I, Page DJ, et al. The effect of different types of oral or intravenous corticosteroids on capillary blood glucose levels in hospitalized inpatients with and without diabetes. Clin Ther 2024;46:e59  e63 271. Limbachia V, Nunney I, Page DJ, et al. Differential effects of oral versus intravenous hydrocortisone and dexamethasone on capillary blood glucose levels in adult inpatients - a single centre study. Clin Med (Lond) 2024;24:100249 272. Roberts A, James J, Dhatariya K, Joint British Diabetes Societies (JBDS) for Inpatient Care. Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabet Med 2018;35:1011  1017 273. Gerards MC, de Maar JS, Steenbruggen TG, Hoekstra JBL, Vriesendorp TM, Gerdes VEA. Add-on treatment with intermediate-acting insulin versus sliding-scale insulin for patients with type 2 diabetes or insulin resistance during cyclic glucocorticoid- containing antineoplastic chemotherapy: a randomized crossover study. Diabetes Obes Metab 2016;18:1041  1044 274. Burt MG, Drake SM, Aguilar-Loza NR, Esterman A, Stranks SN, Roberts GW. Efficacy of a basal bolus insulin protocol to treat prednisolone-induced hyperglycaemia in hospitalised patients. Int","tf":{"18":1,"24":1,"35":1,"46":1,"52":1,"86":1,"90":1,"270":1,"271":1,"272":1,"273":1,"274":1,"1011":1,"1017":1,"1041":1,"1044":1,"2016":1,"2018":2,"2024":2,"100249":1,"nl":1,"optimizing":1,"the":3,"treatment":2,"of":6,"steroid":2,"induced":2,"hyperglycemia":1,"ann":1,"pharmacother":1,"limbachia":2,"nunney":2,"page":2,"dj":2,"et":2,"al":2,"effect":1,"different":1,"types":1,"oral":2,"or":2,"intravenous":2,"corticosteroids":1,"on":3,"capillary":2,"blood":2,"glucose":2,"levels":2,"in":3,"hospitalized":1,"inpatients":2,"with":3,"and":3,"without":1,"diabetes":5,"clin":2,"ther":1,"e59":1,"e63":1,"differential":1,"effects":1,"versus":2,"hydrocortisone":1,"dexamethasone":1,"adult":1,"single":1,"centre":1,"study":2,"med":2,"lond":1,"roberts":2,"james":1,"dhatariya":1,"joint":2,"british":2,"societies":2,"jbds":2,"for":3,"inpatient":2,"care":2,"management":1,"hyperglycaemia":2,"glucocorticoid":2,"therapy":1,"guideline":1,"from":1,"group":1,"diabet":1,"gerards":1,"mc":1,"de":1,"maar":1,"js":1,"steenbruggen":1,"tg":1,"hoekstra":1,"jbl":1,"vriesendorp":1,"tm":1,"gerdes":1,"vea":1,"add":1,"intermediate":1,"acting":1,"insulin":4,"sliding":1,"scale":1,"patients":2,"type":1,"resistance":1,"during":1,"cyclic":1,"containing":1,"antineoplastic":1,"chemotherapy":1,"randomized":1,"crossover":1,"obes":1,"metab":1,"burt":1,"mg":1,"drake":1,"sm":1,"aguilar":1,"loza":1,"nr":1,"esterman":1,"stranks":1,"sn":1,"gw":1,"efficacy":1,"basal":1,"bolus":1,"protocol":1,"to":1,"treat":1,"prednisolone":1,"hospitalised":1,"int":1},"len":196},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":32,"chunkId":"ada-2026-pharm-p32-c6","text":"rossover study. Diabetes Obes Metab 2016;18:1041  1044 274. Burt MG, Drake SM, Aguilar-Loza NR, Esterman A, Stranks SN, Roberts GW. Efficacy of a basal bolus insulin protocol to treat prednisolone-induced hyperglycaemia in hospitalised patients. Intern Med J 2015;45:261  266 275. Joharatnam-Hogan N, Chambers P, Dhatariya K, Board R; Joint British Diabetes Society for Inpatient Care (JBDS), UK Chemotherapy Board (UKCB) . A guideline for the outpatient management of glycaemic control in people with cancer. Diabet Med 2022;39:e14636 276. Trk T, Pietruck F, Dolff S, et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant 2006;6: 842  846 277. Ode KL, Ballman M, Battezzati A, et al. ISPAD clinical practice consensus guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes 2022;23: 1212  1228 278. Kurnikowski A, Nordheim E, Schwaiger E, et al. Criteria for prediabetes and posttransplant diabetes mellitus after kidney transplantation: a 2-year diagnostic accuracy study of participants from a randomized controlled trial. Am J Transplant 2022;22:2880  2891 279. Sharif A, Chakkera H, de Vries APJ, et al. International consensus on post-transplantation diabetes mellitus. Nephrol Dial Transplant 2024;39: 531  549 280. Kuningas K, Driscoll J, Mair R, et al. Comparing glycaemi","tf":{"18":1,"22":1,"23":1,"39":2,"45":1,"261":1,"266":1,"274":1,"275":1,"276":1,"277":1,"278":1,"279":1,"280":1,"531":1,"549":1,"842":1,"846":1,"1041":1,"1044":1,"1212":1,"1228":1,"2006":1,"2015":1,"2016":1,"2022":4,"2024":1,"2880":1,"2891":1,"rossover":1,"study":2,"diabetes":7,"obes":1,"metab":1,"burt":1,"mg":1,"drake":1,"sm":1,"aguilar":1,"loza":1,"nr":1,"esterman":1,"stranks":1,"sn":1,"roberts":1,"gw":1,"efficacy":1,"of":5,"basal":1,"bolus":1,"insulin":1,"protocol":1,"to":1,"treat":1,"prednisolone":1,"induced":1,"hyperglycaemia":1,"in":4,"hospitalised":1,"patients":1,"intern":1,"med":2,"joharatnam":1,"hogan":1,"chambers":1,"dhatariya":1,"board":2,"joint":1,"british":1,"society":1,"for":3,"inpatient":1,"care":1,"jbds":1,"uk":1,"chemotherapy":1,"ukcb":1,"guideline":1,"the":2,"outpatient":1,"management":3,"glycaemic":1,"control":1,"people":1,"with":1,"cancer":1,"diabet":1,"e14636":1,"rk":1,"pietruck":1,"dolff":1,"et":5,"al":5,"repaglinide":1,"new":1,"onset":1,"mellitus":3,"after":2,"renal":1,"transplantation":3,"am":2,"transplant":3,"ode":1,"kl":1,"ballman":1,"battezzati":1,"ispad":1,"clinical":1,"practice":1,"consensus":2,"guidelines":1,"cystic":1,"fibrosis":1,"related":1,"children":1,"and":2,"adolescents":1,"pediatr":1,"kurnikowski":1,"nordheim":1,"schwaiger":1,"criteria":1,"prediabetes":1,"posttransplant":1,"kidney":1,"year":1,"diagnostic":1,"accuracy":1,"participants":1,"from":1,"randomized":1,"controlled":1,"trial":1,"sharif":1,"chakkera":1,"de":1,"vries":1,"apj":1,"international":1,"on":1,"post":1,"nephrol":1,"dial":1,"kuningas":1,"driscoll":1,"mair":1,"comparing":1,"glycaemi":1},"len":191},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":32,"chunkId":"ada-2026-pharm-p32-c7","text":"ransplant 2022;22:2880  2891 279. Sharif A, Chakkera H, de Vries APJ, et al. International consensus on post-transplantation diabetes mellitus. Nephrol Dial Transplant 2024;39: 531  549 280. Kuningas K, Driscoll J, Mair R, et al. Comparing glycaemic benefits of active versus passive lifestyle intervention in kidney allograft recipients: a randomized controlled trial. Transplantation 2020;104:1491  1499 281. Hecking M, Haidinger M, Dller D, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol 2012;23:739  749 282. Schwaiger E, Krenn S, Kurnikowski A, et al. Early postoperative basal insulin therapy versus standard of care for the prevention of diabetes mellitus after kidney transplantation: a multicenter randomized trial. J Am Soc Nephrol 2021;32:2083  2098 283. Chandra A, Rao N, Pooniya V, Singh A. Hypoglycemia with insulin in post-transplant diabetes mellitus. Transpl Immunol 2023;78:101833 284. Tuerk TR, Bandur S, Nuernberger J, et al. Gliquidone therapy of new-onset diabetes mellitus after kidney transplantation. Clin Nephrol 2008;70:26  32 285. Lo C, Toyama T, Oshima M, et al. Glucose- lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. Cochrane Database Syst Rev 2020;8:CD009966 286. Lawrence SE, Chandran MM, Park JM, et al. Sweet and simple as syrup: a review and g","tf":{"22":1,"23":1,"26":1,"32":2,"39":1,"70":1,"78":1,"104":1,"279":1,"280":1,"281":1,"282":1,"283":1,"284":1,"285":1,"286":1,"531":1,"549":1,"739":1,"749":1,"1491":1,"1499":1,"2008":1,"2012":1,"2020":2,"2021":1,"2022":1,"2023":1,"2024":1,"2083":1,"2098":1,"2880":1,"2891":1,"101833":1,"ransplant":1,"sharif":1,"chakkera":1,"de":1,"vries":1,"apj":1,"et":7,"al":7,"international":1,"consensus":1,"on":1,"post":2,"transplantation":5,"diabetes":6,"mellitus":4,"nephrol":4,"dial":1,"transplant":3,"kuningas":1,"driscoll":1,"mair":1,"comparing":1,"glycaemic":1,"benefits":1,"of":4,"active":1,"versus":2,"passive":1,"lifestyle":1,"intervention":1,"in":3,"kidney":4,"allograft":1,"recipients":2,"randomized":2,"controlled":1,"trial":2,"hecking":1,"haidinger":1,"ller":1,"early":2,"basal":2,"insulin":3,"therapy":3,"decreases":1,"new":3,"onset":3,"after":3,"renal":1,"am":2,"soc":2,"schwaiger":1,"krenn":1,"kurnikowski":1,"postoperative":1,"standard":1,"care":1,"for":2,"the":1,"prevention":1,"multicenter":1,"chandra":1,"rao":1,"pooniya":1,"singh":1,"hypoglycemia":1,"with":1,"transpl":1,"immunol":1,"tuerk":1,"tr":1,"bandur":1,"nuernberger":1,"gliquidone":1,"clin":1,"lo":1,"toyama":1,"oshima":1,"glucose":1,"lowering":1,"agents":1,"treating":1,"pre":1,"existing":1,"and":3,"cochrane":1,"database":1,"syst":1,"rev":1,"cd009966":1,"lawrence":1,"se":1,"chandran":1,"mm":1,"park":1,"jm":1,"sweet":1,"simple":1,"as":1,"syrup":1,"review":1},"len":196},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":32,"chunkId":"ada-2026-pharm-p32-c8","text":"a M, et al. Glucose- lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. Cochrane Database Syst Rev 2020;8:CD009966 286. Lawrence SE, Chandran MM, Park JM, et al. Sweet and simple as syrup: a review and guidance for use of novel antihyperglycemic agents for S214 Pharmacologic Approaches to Glycemic Treatment Diabetes Care Volume 49, Supplement 1, January 2026 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"17":1,"49":2,"286":1,"2020":1,"2026":2,"848878":1,"et":2,"al":2,"glucose":1,"lowering":1,"agents":2,"for":3,"treating":1,"pre":1,"existing":1,"and":3,"new":1,"onset":1,"diabetes":2,"in":1,"kidney":1,"transplant":1,"recipients":1,"cochrane":1,"database":1,"syst":1,"rev":1,"cd009966":1,"lawrence":1,"se":1,"chandran":1,"mm":1,"park":1,"jm":1,"sweet":1,"simple":1,"as":1,"syrup":1,"review":1,"guidance":1,"use":1,"of":1,"novel":1,"antihyperglycemic":1,"s214":1,"pharmacologic":1,"approaches":1,"to":1,"glycemic":1,"treatment":1,"care":2,"volume":1,"supplement":2,"january":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"s183":1,"dc26s009":1,"by":1,"guest":1,"on":1,"february":1},"len":80},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":33,"chunkId":"ada-2026-pharm-p33-c0","text":"post-transplant diabetes mellitus and type 2 diabetes mellitus after kidney transplantation. Clin Transplant 2023;37:e14922 287. Munoz Pena JM, Cusi K. Posttransplant diabetes mellitus: recent developments in pharmacological management of hyperglycemia. J Clin Endocrinol Metab 2023;109:e1  e11 288. Ram E, Lavee J, Tenenbaum A, et al. Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantation. Cardiovasc Diabetol 2019;18:118 289. Vest LS, Koraishy FM, Zhang Z, et al. Metformin use in the first year after kidney transplant, correlates, and associated outcomes in diabetic transplant recipients: a retrospective analysis of integrated registry and pharmacy claims data. Clin Transplant 2018;32:e13302 290. Abdelaziz TS, Ali AY, Fatthy M. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in kidney transplant recipients with post-transplant diabetes mellitus (PTDM)- a systematic review and meta- analysis. Curr Diabetes Rev 2020;16:580  585 291. Thangavelu T, Lyden E, Shivaswamy V. A retrospective study of glucagon-like peptide 1 receptor agonists for the management of diabetes after transplantation. Diabetes Ther 2020;11: 987  994 292. Kukla A, Hill J, Merzkani M, et al. The use of GLP1R agonists for the treatment of type 2 diabetes in kidney transplant recipients. Transplant D","tf":{"11":1,"16":1,"18":1,"32":1,"37":1,"109":1,"118":1,"287":1,"288":1,"289":1,"290":1,"291":1,"292":1,"580":1,"585":1,"987":1,"994":1,"2018":1,"2019":1,"2020":2,"2023":2,"post":2,"transplant":9,"diabetes":9,"mellitus":5,"and":6,"type":2,"after":4,"kidney":4,"transplantation":3,"clin":3,"e14922":1,"munoz":1,"pena":1,"jm":1,"cusi":1,"posttransplant":1,"recent":1,"developments":1,"in":6,"pharmacological":1,"management":2,"of":8,"hyperglycemia":1,"endocrinol":1,"metab":1,"e1":1,"e11":1,"ram":1,"lavee":1,"tenenbaum":1,"et":3,"al":3,"metformin":2,"therapy":1,"patients":1,"with":3,"is":1,"associated":2,"reduced":1,"risk":1,"vasculopathy":1,"cardiovascular":1,"mortality":1,"heart":1,"cardiovasc":1,"diabetol":1,"vest":1,"ls":1,"koraishy":1,"fm":1,"zhang":1,"use":2,"the":4,"first":1,"year":1,"correlates":1,"outcomes":1,"diabetic":1,"recipients":3,"retrospective":2,"analysis":2,"integrated":1,"registry":1,"pharmacy":1,"claims":1,"data":1,"e13302":1,"abdelaziz":1,"ts":1,"ali":1,"ay":1,"fatthy":1,"efficacy":1,"safety":1,"dipeptidyl":1,"peptidase":1,"inhibitors":1,"ptdm":1,"systematic":1,"review":1,"meta":1,"curr":1,"rev":1,"thangavelu":1,"lyden":1,"shivaswamy":1,"study":1,"glucagon":1,"like":1,"peptide":1,"receptor":1,"agonists":2,"for":2,"ther":1,"kukla":1,"hill":1,"merzkani":1,"glp1r":1,"treatment":1},"len":190},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":33,"chunkId":"ada-2026-pharm-p33-c1","text":"ptor agonists for the management of diabetes after transplantation. Diabetes Ther 2020;11: 987  994 292. Kukla A, Hill J, Merzkani M, et al. The use of GLP1R agonists for the treatment of type 2 diabetes in kidney transplant recipients. Transplant Direct 2020;6:e524 293. Singh P, Pesavento TE, Washburn K, Walsh D, Meng S. Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients. Diabetes Obes Metab 2019;21:1061  1065 294. Liou J-H, Liu Y-M, Chen C-H. Management of diabetes mellitus with glucagonlike peptide-1 agonist liraglutide in renal transplant recipients: a retrospective study. Transplant Proc 2018;50:2502  2505 295. Vigara LA, Villanego F, Orellana C, et al. Effectiveness and safety of glucagon-like peptide-1 receptor agonist in a cohort of kidney transplant recipients. Clin Transplant 2022;36:e14633 296. Sweiss H, Hall R, Zeilmann D, et al. Single- center evaluation of safety & efficacy of glucagon-like peptide-1 receptor agonists in solid organ transplantation. Prog Transplant 2022;32:357  362 297. Zelada H, Campana M, Kawai K, et al. Efficacy, tolerability, and safety of glucagon-like peptide 1 receptor agonists (GLP1-RA) in kidney transplant recipients with diabetes. Clin Transplant 2025;39:e70144 298. Kim HS, Lee J, Jung CH, Park J-Y, Lee WJ. Dulaglutide as an effective replacement for prandial insul","tf":{"11":1,"21":1,"32":1,"36":1,"39":1,"50":1,"292":1,"293":1,"294":1,"295":1,"296":1,"297":1,"298":1,"357":1,"362":1,"987":1,"994":1,"1061":1,"1065":1,"2018":1,"2019":1,"2020":2,"2022":2,"2025":1,"2502":1,"2505":1,"ptor":1,"agonists":4,"for":4,"the":3,"management":3,"of":11,"diabetes":7,"after":1,"transplantation":2,"ther":1,"kukla":1,"hill":1,"merzkani":1,"et":4,"al":4,"use":1,"glp1r":1,"treatment":1,"type":1,"in":6,"kidney":3,"transplant":10,"recipients":5,"direct":1,"e524":1,"singh":1,"pesavento":1,"te":1,"washburn":1,"walsh":1,"meng":1,"largest":1,"single":2,"centre":1,"experience":1,"dulaglutide":2,"mellitus":2,"solid":2,"organ":2,"obes":1,"metab":1,"liou":1,"liu":1,"chen":1,"with":2,"glucagonlike":1,"peptide":4,"agonist":2,"liraglutide":1,"renal":1,"retrospective":1,"study":1,"proc":1,"vigara":1,"la":1,"villanego":1,"orellana":1,"effectiveness":1,"and":2,"safety":3,"glucagon":3,"like":3,"receptor":3,"cohort":1,"clin":2,"e14633":1,"sweiss":1,"hall":1,"zeilmann":1,"center":1,"evaluation":1,"efficacy":2,"prog":1,"zelada":1,"campana":1,"kawai":1,"tolerability":1,"glp1":1,"ra":1,"e70144":1,"kim":1,"hs":1,"lee":2,"jung":1,"ch":1,"park":1,"wj":1,"as":1,"an":1,"effective":1,"replacement":1,"prandial":1,"insul":1},"len":196},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":33,"chunkId":"ada-2026-pharm-p33-c2","text":" and safety of glucagon-like peptide 1 receptor agonists (GLP1-RA) in kidney transplant recipients with diabetes. Clin Transplant 2025;39:e70144 298. Kim HS, Lee J, Jung CH, Park J-Y, Lee WJ. Dulaglutide as an effective replacement for prandial insulin in kidney transplant recipients with type 2 diabetes mellitus: a retrospective review. Diabetes Metab J 2021;45:948  953 299. Orandi BJ, Chen Y, Li Y, et al. GLP-1 receptor agonists in kidney transplant recipients with pre- existing diabetes: a retrospective cohort study. Lancet Diabetes Endocrinol 2025;13:374  383 300. Lin L-C, Chen J-Y, Huang TT-M, Wu V-C. Association of glucagon-like peptide-1 receptor agonists with cardiovascular and kidney outcomes in type 2 diabetic kidney transplant recipients. Cardiovasc Diabetol 2025;24:87 301. Diker Cohen T, Rudman Y, Turjeman A, et al. Glucagon-like peptide 1 receptor agonists and renal outcomes in kidney transplant recipients with diabetes mellitus. Diabetes Metab 2025;51:101624 302. Dotan I, Rudman Y, Turjeman A, et al. Glucagon-like peptide 1 receptor agonists and cardiovascular outcomes in solid organ transplant recipients with diabetes mellitus. Transplantation 2024;108:e121  e128 303. Sammour Y, Nassif M, Magwire M, et al. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors in heart transplant patients with type 2 diabetes: initial report from a cardiometabolic center of ","tf":{"13":1,"24":1,"39":1,"45":1,"51":1,"87":1,"108":1,"298":1,"299":1,"300":1,"301":1,"302":1,"303":1,"374":1,"383":1,"948":1,"953":1,"2021":1,"2024":1,"2025":4,"101624":1,"and":5,"safety":1,"of":4,"glucagon":4,"like":4,"peptide":4,"receptor":6,"agonists":6,"glp1":1,"ra":1,"in":7,"kidney":6,"transplant":8,"recipients":6,"with":7,"diabetes":9,"clin":1,"e70144":1,"kim":1,"hs":1,"lee":2,"jung":1,"ch":1,"park":1,"wj":1,"dulaglutide":1,"as":1,"an":1,"effective":1,"replacement":1,"for":1,"prandial":1,"insulin":1,"type":3,"mellitus":3,"retrospective":2,"review":1,"metab":2,"orandi":1,"bj":1,"chen":2,"li":1,"et":4,"al":4,"glp":2,"pre":1,"existing":1,"cohort":1,"study":1,"lancet":1,"endocrinol":1,"lin":1,"huang":1,"tt":1,"wu":1,"association":1,"cardiovascular":2,"outcomes":3,"diabetic":1,"cardiovasc":1,"diabetol":1,"diker":1,"cohen":1,"rudman":2,"turjeman":2,"renal":1,"dotan":1,"solid":1,"organ":1,"transplantation":1,"e121":1,"e128":1,"sammour":1,"nassif":1,"magwire":1,"effects":1,"sglt":1,"inhibitors":1,"heart":1,"patients":1,"initial":1,"report":1,"from":1,"cardiometabolic":1,"center":1},"len":192},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":33,"chunkId":"ada-2026-pharm-p33-c3","text":"es mellitus. Transplantation 2024;108:e121  e128 303. Sammour Y, Nassif M, Magwire M, et al. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors in heart transplant patients with type 2 diabetes: initial report from a cardiometabolic center of excellence. J Heart Lung Transplant 2021;40:426  429 304. Lim J-H, Kwon S, Jeon Y, et al. The efficacy and safety of SGLT2 inhibitor in diabetic kidney transplant recipients. Transplantation 2022;106:e404  e412 305. Schwaiger E, Burghart L, Signorini L, et al. Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. Am J Transplant 2019;19:907  919 306. Halden TAS, Kvitne KE, Midtvedt K, et al. Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus. Diabetes Care 2019;42:1067  1074 307. Mahling M, Schork A, Nadalin S, Fritsche A, Heyne N, Guthoff M. Sodium-glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus. Kidney Blood Press Res 2019;44:984  992 308. Shah M, Virani Z, Rajput P, Shah B. Efficacy and safety of canagliflozin in kidney transplant patients. Indian J Nephrol 2019;29:278  281 309. Snchez Fructuoso AI, Bedia Raba A, Banegas Deras E, et al. Sodium-glucose cotransporter-2 inhibitor therapy in kidney transplant patients with t","tf":{"19":1,"29":1,"40":1,"42":1,"44":1,"106":1,"108":1,"278":1,"281":1,"303":1,"304":1,"305":1,"306":1,"307":1,"308":1,"309":1,"426":1,"429":1,"907":1,"919":1,"984":1,"992":1,"1067":1,"1074":1,"2019":4,"2021":1,"2022":1,"2024":1,"es":1,"mellitus":4,"transplantation":2,"e121":1,"e128":1,"sammour":1,"nassif":1,"magwire":1,"et":5,"al":5,"effects":1,"of":5,"glp":1,"receptor":1,"agonists":1,"and":5,"sglt":1,"inhibitors":1,"in":7,"heart":2,"transplant":8,"patients":3,"with":4,"type":1,"diabetes":5,"initial":1,"report":1,"from":1,"cardiometabolic":1,"center":1,"excellence":1,"lung":1,"lim":1,"kwon":1,"jeon":1,"the":1,"efficacy":3,"safety":4,"sglt2":2,"inhibitor":2,"diabetic":1,"kidney":5,"recipients":3,"e404":1,"e412":1,"schwaiger":1,"burghart":1,"signorini":1,"empagliflozin":2,"posttransplantation":1,"prospective":1,"interventional":1,"pilot":1,"study":1,"on":1,"glucose":3,"metabolism":1,"fluid":1,"volume":1,"patient":1,"am":1,"halden":1,"tas":1,"kvitne":1,"ke":1,"midtvedt":1,"renal":1,"posttransplant":1,"care":1,"mahling":1,"schork":1,"nadalin":1,"fritsche":1,"heyne":1,"guthoff":1,"sodium":2,"cotransporter":2,"inhibition":1,"blood":1,"press":1,"res":1,"shah":2,"virani":1,"rajput":1,"canagliflozin":1,"indian":1,"nephrol":1,"nchez":1,"fructuoso":1,"ai":1,"bedia":1,"raba":1,"banegas":1,"deras":1,"therapy":1},"len":188},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":33,"chunkId":"ada-2026-pharm-p33-c4","text":"icacy and safety of canagliflozin in kidney transplant patients. Indian J Nephrol 2019;29:278  281 309. Snchez Fructuoso AI, Bedia Raba A, Banegas Deras E, et al. Sodium-glucose cotransporter-2 inhibitor therapy in kidney transplant patients with type 2 or post-transplant diabetes: an observational multicentre study. Clin Kidney J 2023;16:1022  1034 310. Greeley SAW, Polak M, Njlstad PR, et al. ISPAD clinical practice consensus guidelines 2022: the diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes 2022;23:1188  1211 311. Christensen AS, Hdersdal S, Sty J, et al. Efficacy and safety of glimepiride with or without linagliptin treatment in patients with HNF1A diabetes (maturity-onset diabetes of the young type 3): a randomized, double-blinded, placebo- controlled, crossover trial (GLIMLINA). Diabetes Care 2020;43:2025  2033 312. Umpierrez GE, Davis GM, ElSayed NA, et al. Hyperglycemic crises in adults with diabetes: a consensus report. Diabetes Care 2024;47:1257  1275 313. Wolfsdorf JI, Ratner RE. SGLT inhibitors for type 1 diabetes: proceed with extreme caution. Diabetes Care 2019;42:991  993 314. Colacci M, Fralick J, Odutayo A, Fralick M. Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type 2 diabetes: a systematic review and meta- analysis. Can J Diabetes 2022;46:10  15.e2 315. ","tf":{"10":1,"15":1,"16":1,"23":1,"29":1,"42":1,"43":1,"46":1,"47":1,"278":1,"281":1,"309":1,"310":1,"311":1,"312":1,"313":1,"314":1,"315":1,"991":1,"993":1,"1022":1,"1034":1,"1188":1,"1211":1,"1257":1,"1275":1,"2019":2,"2020":1,"2022":3,"2023":1,"2024":1,"2025":1,"2033":1,"icacy":1,"and":6,"safety":2,"of":5,"canagliflozin":1,"in":5,"kidney":3,"transplant":3,"patients":3,"indian":1,"nephrol":1,"nchez":1,"fructuoso":1,"ai":1,"bedia":1,"raba":1,"banegas":1,"deras":1,"et":4,"al":4,"sodium":2,"glucose":2,"cotransporter":2,"inhibitor":1,"therapy":1,"with":6,"type":4,"or":2,"post":1,"diabetes":12,"an":1,"observational":1,"multicentre":1,"study":1,"clin":1,"greeley":1,"saw":1,"polak":1,"nj":1,"lstad":1,"pr":1,"ispad":1,"clinical":1,"practice":1,"consensus":2,"guidelines":1,"the":2,"diagnosis":1,"management":1,"monogenic":1,"children":1,"adolescents":1,"pediatr":1,"christensen":1,"as":1,"dersdal":1,"st":1,"efficacy":1,"glimepiride":1,"without":1,"linagliptin":1,"treatment":1,"hnf1a":1,"maturity":1,"onset":1,"young":1,"randomized":1,"double":1,"blinded":1,"placebo":1,"controlled":1,"crossover":1,"trial":1,"glimlina":1,"care":3,"umpierrez":1,"ge":1,"davis":1,"gm":1,"elsayed":1,"na":1,"hyperglycemic":1,"crises":1,"adults":2,"report":1,"wolfsdorf":1,"ji":1,"ratner":1,"re":1,"sglt":1,"inhibitors":2,"for":1,"proceed":1,"extreme":1,"caution":1,"colacci":1,"fralick":2,"odutayo":1,"risk":1,"diabetic":1,"ketoacidosis":1,"among":1,"systematic":1,"review":1,"meta":1,"analysis":1,"can":1,"e2":1},"len":200},{"docId":"ada-2026-pharm","docTitle":"ADA Standards 2026  Pharmacologic Approaches","file":"ada-2026-pharm.pdf","page":33,"chunkId":"ada-2026-pharm-p33-c5","text":":991  993 314. Colacci M, Fralick J, Odutayo A, Fralick M. Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type 2 diabetes: a systematic review and meta- analysis. Can J Diabetes 2022;46:10  15.e2 315. Bonora BM, Avogaro A, Fadini GP. Sodium- glucose co-transporter-2 inhibitors and diabetic ketoacidosis: an updated review of the literature. Diabetes Obes Metab 2018;20:25  33 316. Blau JE, Tella SH, Taylor SI, Rother KI. Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data. Diabetes Metab Res Rev 2017;33:10.1002/dmrr.2924 317. Tsapas A, Karagiannis T, Kakotrichi P, et al. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Obes Metab 2021;23:2116  2124 318. Davies MJ, DAlessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41:2669  2701 diabetesjournals.org/care Pharmacologic Approaches to Glycemic Treatment S215 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S183/848878/dc26s009.pdf by guest on 17 February 2026","tf":{"10":2,"15":1,"17":1,"20":1,"23":1,"25":1,"33":2,"41":1,"46":1,"49":1,"314":1,"315":1,"316":1,"317":1,"318":1,"991":1,"993":1,"1002":1,"2017":1,"2018":3,"2021":1,"2022":1,"2026":1,"2116":1,"2124":1,"2669":1,"2701":1,"2924":1,"848878":1,"colacci":1,"fralick":2,"odutayo":1,"sodium":2,"glucose":3,"cotransporter":1,"inhibitors":2,"and":6,"risk":1,"of":6,"diabetic":2,"ketoacidosis":3,"among":1,"adults":1,"with":3,"type":3,"diabetes":10,"systematic":2,"review":3,"meta":2,"analysis":3,"can":1,"e2":1,"bonora":1,"bm":1,"avogaro":1,"fadini":1,"gp":1,"co":1,"transporter":1,"an":1,"updated":1,"the":4,"literature":1,"obes":2,"metab":3,"blau":1,"je":1,"tella":1,"sh":1,"taylor":1,"si":1,"rother":1,"ki":1,"associated":1,"sglt2":1,"inhibitor":1,"treatment":2,"faers":1,"data":1,"res":1,"rev":1,"dmrr":1,"tsapas":1,"karagiannis":1,"kakotrichi":1,"et":2,"al":2,"comparative":1,"efficacy":1,"lowering":1,"medications":1,"on":2,"body":1,"weight":1,"blood":1,"pressure":1,"in":2,"patients":1,"network":1,"davies":1,"mj":1,"alessio":1,"da":1,"fradkin":1,"management":1,"hyperglycemia":1,"consensus":1,"report":1,"by":2,"american":1,"association":2,"ada":1,"european":1,"for":1,"study":1,"easd":1,"care":3,"diabetesjournals":2,"org":2,"pharmacologic":1,"approaches":1,"to":1,"glycemic":1,"s215":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"supplement":1,"s183":1,"dc26s009":1,"guest":1,"february":1},"len":193},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":1,"chunkId":"ada-2026-hosp-p1-c0","text":"16. DIABETES CARE IN THE HOSPITAL 16. Diabetes Care in the Hospital: Standards of Care in Diabetes 2026 Diabetes Care 2026;49(Suppl. 1):S339  S355 | https://doi.org/10.2337/dc26-S016 American Diabetes Association Professional Practice Committee for Diabetes * * A complete list of members of the American Diabetes Association Professional Practice Committee for Diabetes can be found at https://doi.org/ 10.2337/dc26-SINT . Duality of interest information for each contributor is available at https://doi.org/10.2337/dc26-SDIS . Suggested citation: American Diabetes Association Professional Practice Committee for Diabetes. 16. Diabetes care in the hospital: Standards of Care in Diabetes2026. Diabetes Care 2026;49(Suppl. 1): S339  S355  2025 by the American Diabetes Association. Readers may use this work for educational, noncommercial purposes if properly cited and unaltered. The version of record may be linked at https://diabetesjournals.org/care , but ADA permission is required to post this work on any third-party site or platform. This publication and its contents may not be reproduced, distributed, or used for text or data mining, machine learning, or similar technologies without prior written permission. Requests to reuse, adapt, or distribute this work may be sent to permissions@diabetes .org . More information is available at https:// diabetesjournals.org/journals/pages/li","tf":{"10":3,"16":3,"49":2,"2025":1,"2026":4,"2337":3,"diabetes":15,"care":8,"in":5,"the":6,"hospital":3,"standards":2,"of":6,"suppl":2,"s339":2,"s355":2,"https":5,"doi":3,"org":6,"dc26":3,"s016":1,"american":4,"association":4,"professional":3,"practice":3,"committee":3,"for":6,"complete":1,"list":1,"members":1,"can":1,"be":4,"found":1,"at":4,"sint":1,"duality":1,"interest":1,"information":2,"each":1,"contributor":1,"is":3,"available":2,"sdis":1,"suggested":1,"citation":1,"by":1,"readers":1,"may":4,"use":1,"this":4,"work":3,"educational":1,"noncommercial":1,"purposes":1,"if":1,"properly":1,"cited":1,"and":2,"unaltered":1,"version":1,"record":1,"linked":1,"diabetesjournals":2,"but":1,"ada":1,"permission":2,"required":1,"to":3,"post":1,"on":1,"any":1,"third":1,"party":1,"site":1,"or":5,"platform":1,"publication":1,"its":1,"contents":1,"not":1,"reproduced":1,"distributed":1,"used":1,"text":1,"data":1,"mining":1,"machine":1,"learning":1,"similar":1,"technologies":1,"without":1,"prior":1,"written":1,"requests":1,"reuse":1,"adapt":1,"distribute":1,"sent":1,"permissions":1,"more":1,"journals":1,"pages":1,"li":1},"len":211},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":1,"chunkId":"ada-2026-hosp-p1-c1","text":" machine learning, or similar technologies without prior written permission. Requests to reuse, adapt, or distribute this work may be sent to permissions@diabetes .org . More information is available at https:// diabetesjournals.org/journals/pages/license . The American Diabetes Association (ADA) Standards of Care in Diabetes includes the ADAs current clinical practice recommendations and is intended to provide the compo - nents of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee for Diabetes , an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADAs clinical prac - tice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology . Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC . Among hospitalized individuals, hyperglycemia, hypoglycemia, and glucose variabil - ity are associated with adverse outcomes, including increased morbidity and mor - tality ( 1 , 2 ). Identification and careful management of people with diabetes and dysglycemia during hospitalization has direct ","tf":{"machine":1,"learning":1,"or":3,"similar":1,"technologies":1,"without":1,"prior":1,"written":1,"permission":1,"requests":1,"to":7,"reuse":1,"adapt":1,"distribute":1,"this":1,"work":1,"may":1,"be":1,"sent":1,"permissions":1,"diabetes":7,"org":3,"more":2,"information":1,"is":2,"available":1,"at":2,"https":1,"diabetesjournals":1,"journals":1,"pages":1,"license":1,"the":7,"american":1,"association":1,"ada":5,"standards":4,"of":9,"care":5,"in":1,"includes":1,"current":1,"clinical":2,"practice":3,"recommendations":2,"and":10,"intended":1,"provide":1,"compo":1,"nents":1,"general":1,"treatment":1,"goals":1,"guidelines":1,"tools":1,"evaluate":1,"quality":1,"members":2,"professional":3,"committee":3,"for":4,"an":1,"interprofessional":1,"expert":1,"are":3,"responsible":1,"updating":1,"annually":1,"frequently":1,"as":3,"warranted":1,"detailed":1,"description":1,"statements":1,"reports":1,"well":1,"evidence":1,"grading":1,"system":1,"prac":1,"tice":1,"full":1,"list":1,"please":1,"refer":1,"introduction":1,"methodology":1,"readers":1,"who":1,"wish":1,"comment":1,"on":1,"invited":1,"do":1,"so":1,"soc":1,"among":1,"hospitalized":1,"individuals":1,"hyperglycemia":1,"hypoglycemia":1,"glucose":1,"variabil":1,"ity":1,"associated":1,"with":2,"adverse":1,"outcomes":1,"including":1,"increased":1,"morbidity":1,"mor":1,"tality":1,"identification":1,"careful":1,"management":1,"people":1,"dysglycemia":1,"during":1,"hospitalization":1,"has":1,"direct":1},"len":192},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":1,"chunkId":"ada-2026-hosp-p1-c2","text":" hypoglycemia, and glucose variabil - ity are associated with adverse outcomes, including increased morbidity and mor - tality ( 1 , 2 ). Identification and careful management of people with diabetes and dysglycemia during hospitalization has direct and immediate benefits. Diabetes management in the inpatient setting includes identification and treatment of hy - perglycemia and hypoglycemia, diagnosing and managing hyperglycemic crises, perioperative care planning, and a proactive transition plan for outpatient diabetes care with timely scheduled follow-up appointments. These steps can improve out - comes, shorten hospital stays, and reduce the need for readmission and emergency department visits. For older individuals or for people with diabetes in post-acute and long-term care settings, please see section 13,  Older Adults . HOSPITAL CARE DELIVERY STANDARDS Recommendations 16.1 Perform an A1C test on all people with diabetes or hyperglycemia (ran - dom blood glucose > 140 mg/dL [ > 7.8 mmol/L]) at the time of admission to the hospital if no A1C test result is available from the prior 3 months. B 16.2 Institutions should implement protocols using validated written or com - puterized provider order entry sets for management of dysglycemia in the hospital that allow for a personalized approach. B Considerations on Admission Initial evaluation should state the type of diabetes ","tf":{"13":1,"16":2,"140":1,"hypoglycemia":2,"and":12,"glucose":2,"variabil":1,"ity":1,"are":1,"associated":1,"with":5,"adverse":1,"outcomes":1,"including":1,"increased":1,"morbidity":1,"mor":1,"tality":1,"identification":2,"careful":1,"management":3,"of":5,"people":3,"diabetes":6,"dysglycemia":2,"during":1,"hospitalization":1,"has":1,"direct":1,"immediate":1,"benefits":1,"in":3,"the":7,"inpatient":1,"setting":1,"includes":1,"treatment":1,"hy":1,"perglycemia":1,"diagnosing":1,"managing":1,"hyperglycemic":1,"crises":1,"perioperative":1,"care":4,"planning":1,"proactive":1,"transition":1,"plan":1,"for":6,"outpatient":1,"timely":1,"scheduled":1,"follow":1,"up":1,"appointments":1,"these":1,"steps":1,"can":1,"improve":1,"out":1,"comes":1,"shorten":1,"hospital":4,"stays":1,"reduce":1,"need":1,"readmission":1,"emergency":1,"department":1,"visits":1,"older":2,"individuals":1,"or":3,"post":1,"acute":1,"long":1,"term":1,"settings":1,"please":1,"see":1,"section":1,"adults":1,"delivery":1,"standards":1,"recommendations":1,"perform":1,"an":1,"a1c":2,"test":2,"on":2,"all":1,"hyperglycemia":1,"ran":1,"dom":1,"blood":1,"mg":1,"dl":1,"mmol":1,"at":1,"time":1,"admission":2,"to":1,"if":1,"no":1,"result":1,"is":1,"available":1,"from":1,"prior":1,"months":1,"institutions":1,"should":2,"implement":1,"protocols":1,"using":1,"validated":1,"written":1,"com":1,"puterized":1,"provider":1,"order":1,"entry":1,"sets":1,"that":1,"allow":1,"personalized":1,"approach":1,"considerations":1,"initial":1,"evaluation":1,"state":1,"type":1},"len":193},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":1,"chunkId":"ada-2026-hosp-p1-c3","text":"t protocols using validated written or com - puterized provider order entry sets for management of dysglycemia in the hospital that allow for a personalized approach. B Considerations on Admission Initial evaluation should state the type of diabetes (i.e., type 1, type 2, gestational, pan - creatogenic, stress hyperglycemia, drug related, or nutrition related [e.g., enteral or par - enteral nutrition]) when it is known. To identify people with undiagnosed diabetes, and Diabetes Care Volume 49, Supplement 1, January 2026 S339 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S339/848851/dc26s016.pdf by guest on 17 February 2026","tf":{"17":1,"49":2,"2026":2,"848851":1,"protocols":1,"using":1,"validated":1,"written":1,"or":3,"com":1,"puterized":1,"provider":1,"order":1,"entry":1,"sets":1,"for":2,"management":1,"of":2,"dysglycemia":1,"in":1,"the":2,"hospital":1,"that":1,"allow":1,"personalized":1,"approach":1,"considerations":1,"on":2,"admission":1,"initial":1,"evaluation":1,"should":1,"state":1,"type":3,"diabetes":3,"gestational":1,"pan":1,"creatogenic":1,"stress":1,"hyperglycemia":1,"drug":1,"related":2,"nutrition":2,"enteral":2,"par":1,"when":1,"it":1,"is":1,"known":1,"to":1,"identify":1,"people":1,"with":1,"undiagnosed":1,"and":1,"care":2,"volume":1,"supplement":2,"january":1,"s339":2,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"dc26s016":1,"by":1,"guest":1,"february":1},"len":90},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":2,"chunkId":"ada-2026-hosp-p2-c0","text":"because inpatient treatment and discharge planning are more effective when pread - mission glycemia is considered, A1C should be measured for all people with diabetes or dysglycemia at the time of admission to the hospital or soon after if no A1C test result is available from the previous 3 months ( 3  5 ). Incorporating A1C into the glucose management order set may help increase frequency of A1C testing ( 6 ). In addition, diabetes self-management knowledge and behaviors should be as - sessed on admission, and diabetes self- management education should be provided throughout the hospital stay, especially if a new treatment plan is being considered. Diabetes self-management education should include the knowledge and skills needed after discharge, such as medication dosing and administration, meal planning, glucose monitoring, and recognition and treatment of hypoglycemia ( 7 ). For individuals resid - ing in group homes or institutional set - tings ( 8 ), information on site capabilities related to diabetes management should be obtained and the therapeutic plan should be adjusted accordingly. High-quality hospital care for diabetes requires clear and actionable standards for care delivery, which are best imple - mented using structured order sets with computerized provider order entry (CPOE) as well as quality improvement strategies for process improvement ( 9 ). The National ","tf":{"because":1,"inpatient":1,"treatment":3,"and":9,"discharge":2,"planning":2,"are":2,"more":1,"effective":1,"when":1,"pread":1,"mission":1,"glycemia":1,"is":3,"considered":2,"a1c":4,"should":6,"be":5,"measured":1,"for":5,"all":1,"people":1,"with":2,"diabetes":6,"or":3,"dysglycemia":1,"at":1,"the":8,"time":1,"of":3,"admission":2,"to":2,"hospital":3,"soon":1,"after":2,"if":2,"no":1,"test":1,"result":1,"available":1,"from":1,"previous":1,"months":1,"incorporating":1,"into":1,"glucose":2,"management":5,"order":3,"set":2,"may":1,"help":1,"increase":1,"frequency":1,"testing":1,"in":2,"addition":1,"self":3,"knowledge":2,"behaviors":1,"as":4,"sessed":1,"on":2,"education":2,"provided":1,"throughout":1,"stay":1,"especially":1,"new":1,"plan":2,"being":1,"include":1,"skills":1,"needed":1,"such":1,"medication":1,"dosing":1,"administration":1,"meal":1,"monitoring":1,"recognition":1,"hypoglycemia":1,"individuals":1,"resid":1,"ing":1,"group":1,"homes":1,"institutional":1,"tings":1,"information":1,"site":1,"capabilities":1,"related":1,"obtained":1,"therapeutic":1,"adjusted":1,"accordingly":1,"high":1,"quality":2,"care":2,"requires":1,"clear":1,"actionable":1,"standards":1,"delivery":1,"which":1,"best":1,"imple":1,"mented":1,"using":1,"structured":1,"sets":1,"computerized":1,"provider":1,"entry":1,"cpoe":1,"well":1,"improvement":2,"strategies":1,"process":1,"national":1},"len":196},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":2,"chunkId":"ada-2026-hosp-p2-c1","text":" requires clear and actionable standards for care delivery, which are best imple - mented using structured order sets with computerized provider order entry (CPOE) as well as quality improvement strategies for process improvement ( 9 ). The National Academy of Medicine recommends CPOE to prevent medication-related errors and to increase medication administration effi - ciency ( 10 ). Systematic reviews of random - ized controlled trials using computerized assistance to improve glycemic outcomes in the hospital found significant improve - ment in the percentage of time individu - als spent in the glycemic goal range, lower mean blood glucose levels, and no increase in hypoglycemia ( 11 ). Where fea - sible, the structured order set should pro - vide computerized guidance for glycemic management, including initial weight-based insulin dosing guidance and insulin titration guidance during the hospital stay ( 12 ). Cur - rently available commercial electronic glu - cose management systems may facilitate implementation of insulin protocols in the hospital ( 13 , 14 ). Diabetes Care Teams in the Hospital Care provided by appropriately trained specialists or specialty teams may reduce the length of stay and improve glycemic and other clinical outcomes ( 15  17 ). In addition, the increased risk of 30-day re - admission following hospitalization that has been attributed to diabetes ca","tf":{"10":1,"11":1,"12":1,"13":1,"14":1,"15":1,"17":1,"30":1,"requires":1,"clear":1,"and":6,"actionable":1,"standards":1,"for":3,"care":3,"delivery":1,"which":1,"are":1,"best":1,"imple":1,"mented":1,"using":2,"structured":2,"order":3,"sets":1,"with":1,"computerized":3,"provider":1,"entry":1,"cpoe":2,"as":2,"well":1,"quality":1,"improvement":2,"strategies":1,"process":1,"the":10,"national":1,"academy":1,"of":6,"medicine":1,"recommends":1,"to":4,"prevent":1,"medication":2,"related":1,"errors":1,"increase":2,"administration":1,"effi":1,"ciency":1,"systematic":1,"reviews":1,"random":1,"ized":1,"controlled":1,"trials":1,"assistance":1,"improve":3,"glycemic":4,"outcomes":2,"in":7,"hospital":4,"found":1,"significant":1,"ment":1,"percentage":1,"time":1,"individu":1,"als":1,"spent":1,"goal":1,"range":1,"lower":1,"mean":1,"blood":1,"glucose":1,"levels":1,"no":1,"hypoglycemia":1,"where":1,"fea":1,"sible":1,"set":1,"should":1,"pro":1,"vide":1,"guidance":3,"management":2,"including":1,"initial":1,"weight":1,"based":1,"insulin":3,"dosing":1,"titration":1,"during":1,"stay":2,"cur":1,"rently":1,"available":1,"commercial":1,"electronic":1,"glu":1,"cose":1,"systems":1,"may":2,"facilitate":1,"implementation":1,"protocols":1,"diabetes":2,"teams":2,"provided":1,"by":1,"appropriately":1,"trained":1,"specialists":1,"or":1,"specialty":1,"reduce":1,"length":1,"other":1,"clinical":1,"addition":1,"increased":1,"risk":1,"day":1,"re":1,"admission":1,"following":1,"hospitalization":1,"that":1,"has":1,"been":1,"attributed":1,"ca":1},"len":197},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":2,"chunkId":"ada-2026-hosp-p2-c2","text":"ined specialists or specialty teams may reduce the length of stay and improve glycemic and other clinical outcomes ( 15  17 ). In addition, the increased risk of 30-day re - admission following hospitalization that has been attributed to diabetes can be reduced, and costs saved, when inpatient care is provided by a diabetes manage - ment team ( 15 , 18 ). In a cross-sectional study comparing usual care to care pro - vided by a virtual glucose management service based on the daily chart review and making recommendations through the electronic health record (EHR), rates of both hyperglycemia and hypoglycemia were reduced by 30  40% ( 19 ). In addi - tion, providing diabetes self-management education and developing a diabetes dis - charge plan that includes continued ac - cess to diabetes medications and supplies and ongoing education and support are key strategies to improve long-term out - comes ( 20 , 21 ). Hospital diabetes care teams may include and be led by physicians or other health care professionals trained in diabetes care and education such as nurse practitioners or physician assistants/ associates, nurses, registered dietitian nutritionists, or pharmacists ( 22 ). Details of diabetes care team composition and other resources are available from the Joint Commission accreditation program for the hospital care of diabetes, the So - ciety of Hospital Medicine workbook, ","tf":{"15":2,"17":1,"18":1,"19":1,"20":1,"21":1,"22":1,"30":2,"40":1,"ined":1,"specialists":1,"or":4,"specialty":1,"teams":2,"may":2,"reduce":1,"the":7,"length":1,"of":6,"stay":1,"and":12,"improve":2,"glycemic":1,"other":3,"clinical":1,"outcomes":1,"in":4,"addition":1,"increased":1,"risk":1,"day":1,"re":1,"admission":1,"following":1,"hospitalization":1,"that":2,"has":1,"been":1,"attributed":1,"to":4,"diabetes":9,"can":1,"be":2,"reduced":2,"costs":1,"saved":1,"when":1,"inpatient":1,"care":8,"is":1,"provided":1,"by":4,"manage":1,"ment":1,"team":2,"cross":1,"sectional":1,"study":1,"comparing":1,"usual":1,"pro":1,"vided":1,"virtual":1,"glucose":1,"management":2,"service":1,"based":1,"on":1,"daily":1,"chart":1,"review":1,"making":1,"recommendations":1,"through":1,"electronic":1,"health":2,"record":1,"ehr":1,"rates":1,"both":1,"hyperglycemia":1,"hypoglycemia":1,"were":1,"addi":1,"tion":1,"providing":1,"self":1,"education":3,"developing":1,"dis":1,"charge":1,"plan":1,"includes":1,"continued":1,"ac":1,"cess":1,"medications":1,"supplies":1,"ongoing":1,"support":1,"are":2,"key":1,"strategies":1,"long":1,"term":1,"out":1,"comes":1,"hospital":3,"include":1,"led":1,"physicians":1,"professionals":1,"trained":1,"such":1,"as":1,"nurse":1,"practitioners":1,"physician":1,"assistants":1,"associates":1,"nurses":1,"registered":1,"dietitian":1,"nutritionists":1,"pharmacists":1,"details":1,"composition":1,"resources":1,"available":1,"from":1,"joint":1,"commission":1,"accreditation":1,"program":1,"for":1,"so":1,"ciety":1,"medicine":1,"workbook":1},"len":206},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":2,"chunkId":"ada-2026-hosp-p2-c3","text":"titian nutritionists, or pharmacists ( 22 ). Details of diabetes care team composition and other resources are available from the Joint Commission accreditation program for the hospital care of diabetes, the So - ciety of Hospital Medicine workbook, The Leapfrog Group, and the Joint Brit - ish Diabetes Societies (JBDS) for Inpa - tient Care Group ( 23  26 ). Recommendation 16.3 When caring for hospitalized people with diabetes (with an existing or new diagnosis) or stress hypergly - cemia, consult with a specialized dia - betes or glucose management team when available. B GLYCEMIC GOALS IN HOSPITALIZED ADULTS Standard Definitions of Glucose Abnormalities Hyperglycemia in hospitalized individuals is defined as any blood glucose level > 140 mg/dL ( > 7.8 mmol/L) based on the threshold for an abnormal glucose level ( 27 ). An admission A1C value  6.5% (  48 mmol/mol) suggests that the onset of diabetes preceded hospitalization (see section 2,  Diagnosis and Classification of Diabetes ). Hypoglycemia is defined as blood glucose < 70 mg/dL ( < 3.9 mmol/L) and is further stratified into three cate - gories: level 1 (glucose concentration of 54  69 mg/dL [3.0  3.8 mmol/L]), level 2 (glucose concentration < 54 mg/dL [ < 3.0 mmol/L], which is typically the threshold for neuroglycopenic symptoms), and level 3 (a clinical event characterized by altered mental and/or physical func -","tf":{"16":1,"22":1,"23":1,"26":1,"27":1,"48":1,"54":2,"69":1,"70":1,"140":1,"titian":1,"nutritionists":1,"or":5,"pharmacists":1,"details":1,"of":7,"diabetes":6,"care":3,"team":2,"composition":1,"and":6,"other":1,"resources":1,"are":1,"available":2,"from":1,"the":8,"joint":2,"commission":1,"accreditation":1,"program":1,"for":5,"hospital":2,"so":1,"ciety":1,"medicine":1,"workbook":1,"leapfrog":1,"group":2,"brit":1,"ish":1,"societies":1,"jbds":1,"inpa":1,"tient":1,"recommendation":1,"when":2,"caring":1,"hospitalized":3,"people":1,"with":3,"an":3,"existing":1,"new":1,"diagnosis":2,"stress":1,"hypergly":1,"cemia":1,"consult":1,"specialized":1,"dia":1,"betes":1,"glucose":7,"management":1,"glycemic":1,"goals":1,"in":2,"adults":1,"standard":1,"definitions":1,"abnormalities":1,"hyperglycemia":1,"individuals":1,"is":4,"defined":2,"as":2,"any":1,"blood":2,"level":5,"mg":4,"dl":4,"mmol":5,"based":1,"on":1,"threshold":2,"abnormal":1,"admission":1,"a1c":1,"value":1,"mol":1,"suggests":1,"that":1,"onset":1,"preceded":1,"hospitalization":1,"see":1,"section":1,"classification":1,"hypoglycemia":1,"further":1,"stratified":1,"into":1,"three":1,"cate":1,"gories":1,"concentration":2,"which":1,"typically":1,"neuroglycopenic":1,"symptoms":1,"clinical":1,"event":1,"characterized":1,"by":1,"altered":1,"mental":1,"physical":1,"func":1},"len":194},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":2,"chunkId":"ada-2026-hosp-p2-c4","text":"tion of 54  69 mg/dL [3.0  3.8 mmol/L]), level 2 (glucose concentration < 54 mg/dL [ < 3.0 mmol/L], which is typically the threshold for neuroglycopenic symptoms), and level 3 (a clinical event characterized by altered mental and/or physical func - tioning that requires assistance from an - other person for recovery) ( Table 6.4 ). Levels 2 and 3 hypoglycemia require im - mediate intervention and correction of low blood glucose. Prompt treatment of level 1 hypoglycemia is recommended for prevention of progression to more signifi - cant level 2 and level 3 hypoglycemia. Recommendations 16.4a Insulin should be initiated or in - tensified for treatment of persistent hyperglycemia starting at a threshold of  180 mg/dL (  10.0 mmol/L) (con - firmed on two occasions within 24 h) for the majority of critically ill individu - als (those in the intensive care unit [ICU]). A 16.4b Insulin and/or other glucose low - ering therapies should be initiated or in - tensified for treatment of persistent hyperglycemia starting at a threshold of  180 mg/dL (  10.0 mmol/L) (con - firmed on two occasions within 24 h) for the majority of noncritically ill indi - viduals (those not in the ICU). B 16.5a Once therapy is initiated, a glycemic goal of 140  180 mg/dL (7.8  10.0 mmol/L) is recommended for most critically ill individuals (those in the ICU) with hyperglycemia. A More stringent individ","tf":{"10":3,"16":3,"24":2,"54":2,"69":1,"140":1,"180":3,"tion":1,"of":11,"mg":5,"dl":5,"mmol":5,"level":5,"glucose":3,"concentration":1,"which":1,"is":4,"typically":1,"the":6,"threshold":3,"for":8,"neuroglycopenic":1,"symptoms":1,"and":6,"clinical":1,"event":1,"characterized":1,"by":1,"altered":1,"mental":1,"or":4,"physical":1,"func":1,"tioning":1,"that":1,"requires":1,"assistance":1,"from":1,"an":1,"other":2,"person":1,"recovery":1,"table":1,"levels":1,"hypoglycemia":3,"require":1,"im":1,"mediate":1,"intervention":1,"correction":1,"low":2,"blood":1,"prompt":1,"treatment":3,"recommended":2,"prevention":1,"progression":1,"to":1,"more":2,"signifi":1,"cant":1,"recommendations":1,"4a":1,"insulin":2,"should":2,"be":2,"initiated":3,"in":5,"tensified":2,"persistent":2,"hyperglycemia":3,"starting":2,"at":2,"con":2,"firmed":2,"on":2,"two":2,"occasions":2,"within":2,"majority":2,"critically":2,"ill":3,"individu":1,"als":1,"those":3,"intensive":1,"care":1,"unit":1,"icu":3,"4b":1,"ering":1,"therapies":1,"noncritically":1,"indi":1,"viduals":1,"not":1,"5a":1,"once":1,"therapy":1,"glycemic":1,"goal":1,"most":1,"individuals":1,"with":1,"stringent":1,"individ":1},"len":204},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":2,"chunkId":"ada-2026-hosp-p2-c5","text":"ly ill indi - viduals (those not in the ICU). B 16.5a Once therapy is initiated, a glycemic goal of 140  180 mg/dL (7.8  10.0 mmol/L) is recommended for most critically ill individuals (those in the ICU) with hyperglycemia. A More stringent individualized glycemic goals may be appropriate for selected critically ill individuals if they can be achieved without significant hypogly - cemia. B 16.5b For noncritically ill individuals (those not in the ICU), a glycemic goal of 100  180 mg/dL (5.6  10.0 mmol/L) is recommended if it can be achieved without significant hypoglycemia. B Glycemic Goals In a landmark clinical trial conducted in a surgical intensive care unit (ICU), Van den Berghe et al. ( 28 ) demonstrated that an intensive intravenous insulin protocol with a glycemic goal of 80  110 mg/dL (4.4  6.1 mmol/L) reduced mortality by 40% compared with a standard approach S340 Diabetes Care in the Hospital Diabetes Care Volume 49, Supplement 1, January 2026 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S339/848851/dc26s016.pdf by guest on 17 February 2026","tf":{"10":2,"16":2,"17":1,"28":1,"40":1,"49":2,"80":1,"100":1,"110":1,"140":1,"180":2,"2026":2,"848851":1,"ly":1,"ill":4,"indi":1,"viduals":1,"those":3,"not":2,"in":6,"the":4,"icu":4,"5a":1,"once":1,"therapy":1,"is":3,"initiated":1,"glycemic":5,"goal":3,"of":3,"mg":3,"dl":3,"mmol":3,"recommended":2,"for":3,"most":1,"critically":2,"individuals":3,"with":3,"hyperglycemia":1,"more":1,"stringent":1,"individualized":1,"goals":2,"may":1,"be":3,"appropriate":1,"selected":1,"if":2,"they":1,"can":2,"achieved":2,"without":2,"significant":2,"hypogly":1,"cemia":1,"5b":1,"noncritically":1,"it":1,"hypoglycemia":1,"landmark":1,"clinical":1,"trial":1,"conducted":1,"surgical":1,"intensive":2,"care":4,"unit":1,"van":1,"den":1,"berghe":1,"et":1,"al":1,"demonstrated":1,"that":1,"an":1,"intravenous":1,"insulin":1,"protocol":1,"reduced":1,"mortality":1,"by":2,"compared":1,"standard":1,"approach":1,"s340":1,"diabetes":2,"hospital":1,"volume":1,"supplement":2,"january":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"s339":1,"dc26s016":1,"guest":1,"on":1,"february":1},"len":165},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":3,"chunkId":"ada-2026-hosp-p3-c0","text":"of a glycemic goal of 180  215 mg/dL (10  12 mmol/L) in critically ill hospitalized individuals with diabetes and/or stress hy - perglycemia and recent surgery. However, several multicenter studies, including the Normoglycemia in Intensive Care Evalua - tion and Survival Using Glucose Algorithm Regulation (NICE-SUGAR) trial, in critically ill hospitalized individuals in medical and surgical ICUs ( 29  31 ) failed to replicate these data. In the NICE-SUGAR trial, criti - cally ill individuals randomized to inten - sive glycemic management (80  110 mg/dL [4.4  6.1 mmol/L]) derived no significant treatment advantage compared with a group with more moderate glycemic goals (140  180 mg/dL [7.8  10.0 mmol/L]) and had slightly but significantly higher mor - tality (27.5% vs. 25%). The intensively treated group had 10- to 15-fold greater rates of hypoglycemia. The findings from the NICE-SUGAR trial, supported by sev - eral meta-analyses showed higher rates of hypoglycemia and an increase in mortality with more aggressive glycemic manage - ment goals compared with moderate gly - cemic goals ( 29 , 32 , 33 ). More recently, a multicenter randomized controlled trial comparing tight and liberal glucose man - agement in critically ill individuals not re - ceiving early parenteral nutrition showed no benefit of tight glycemic management despite effective glucose separation be - tween ","tf":{"10":3,"12":1,"15":1,"25":1,"27":1,"29":2,"31":1,"32":1,"33":1,"80":1,"110":1,"140":1,"180":2,"215":1,"of":5,"glycemic":5,"goal":1,"mg":3,"dl":3,"mmol":3,"in":7,"critically":3,"ill":4,"hospitalized":2,"individuals":4,"with":5,"diabetes":1,"and":7,"or":1,"stress":1,"hy":1,"perglycemia":1,"recent":1,"surgery":1,"however":1,"several":1,"multicenter":2,"studies":1,"including":1,"the":5,"normoglycemia":1,"intensive":1,"care":1,"evalua":1,"tion":1,"survival":1,"using":1,"glucose":3,"algorithm":1,"regulation":1,"nice":3,"sugar":3,"trial":4,"medical":1,"surgical":1,"icus":1,"failed":1,"to":3,"replicate":1,"these":1,"data":1,"criti":1,"cally":1,"randomized":2,"inten":1,"sive":1,"management":2,"derived":1,"no":2,"significant":1,"treatment":1,"advantage":1,"compared":2,"group":2,"more":3,"moderate":2,"goals":3,"had":2,"slightly":1,"but":1,"significantly":1,"higher":2,"mor":1,"tality":1,"vs":1,"intensively":1,"treated":1,"fold":1,"greater":1,"rates":2,"hypoglycemia":2,"findings":1,"from":1,"supported":1,"by":1,"sev":1,"eral":1,"meta":1,"analyses":1,"showed":2,"an":1,"increase":1,"mortality":1,"aggressive":1,"manage":1,"ment":1,"gly":1,"cemic":1,"recently":1,"controlled":1,"comparing":1,"tight":2,"liberal":1,"man":1,"agement":1,"not":1,"re":1,"ceiving":1,"early":1,"parenteral":1,"nutrition":1,"benefit":1,"despite":1,"effective":1,"separation":1,"be":1,"tween":1},"len":202},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":3,"chunkId":"ada-2026-hosp-p3-c1","text":"er randomized controlled trial comparing tight and liberal glucose man - agement in critically ill individuals not re - ceiving early parenteral nutrition showed no benefit of tight glycemic management despite effective glucose separation be - tween the groups and remarkably low rates of hypoglycemia in both groups (1.0% in tight group vs. 0.7% in liberal group) ( 30 ). Based on these clinical trials and results of other observational studies, insulin and/or other therapies should be initiated for the treatment of persistent hy - perglycemia  180 mg/dL (  10.0 mmol/L). Once therapy is initiated, a glycemic goal of 140  180 mg/dL (7.8  10.0 mmol/L) is recommended for most critically ill individu - als. More stringent glycemic goals, such as 110  140 mg/dL (6.1  7.8 mmol/L), may be appropriate for selected individuals (e.g., critically ill individuals undergoing cardiac surgery) if they can be achieved without significant hypoglycemia ( 34 , 35 ). For hospitalized individuals without critical illness, a glycemic goal of 100  180 mg/dL (5.6  10.0 mmol/L) is recommended, whether it is hyperglycemia due to newly diagnosed diabetes or stress hyperglyce - mia or hyperglycemia related to diabetes prior to admission ( 36 , 37 ). It has been found that fasting glucose levels < 100 mg/dL ( < 5.6 mmol/L) are predictors of hypoglyce - mia within the next 24 h ( 38 ) and therefore ne","tf":{"10":3,"24":1,"30":1,"34":1,"35":1,"36":1,"37":1,"38":1,"100":2,"110":1,"140":2,"180":3,"er":1,"randomized":1,"controlled":1,"trial":1,"comparing":1,"tight":3,"and":5,"liberal":2,"glucose":3,"man":1,"agement":1,"in":4,"critically":3,"ill":3,"individuals":4,"not":1,"re":1,"ceiving":1,"early":1,"parenteral":1,"nutrition":1,"showed":1,"no":1,"benefit":1,"of":7,"glycemic":4,"management":1,"despite":1,"effective":1,"separation":1,"be":4,"tween":1,"the":3,"groups":2,"remarkably":1,"low":1,"rates":1,"hypoglycemia":2,"both":1,"group":2,"vs":1,"based":1,"on":1,"these":1,"clinical":1,"trials":1,"results":1,"other":2,"observational":1,"studies":1,"insulin":1,"or":3,"therapies":1,"should":1,"initiated":2,"for":4,"treatment":1,"persistent":1,"hy":1,"perglycemia":1,"mg":5,"dl":5,"mmol":5,"once":1,"therapy":1,"is":4,"goal":2,"recommended":2,"most":1,"individu":1,"als":1,"more":1,"stringent":1,"goals":1,"such":1,"as":1,"may":1,"appropriate":1,"selected":1,"undergoing":1,"cardiac":1,"surgery":1,"if":1,"they":1,"can":1,"achieved":1,"without":2,"significant":1,"hospitalized":1,"critical":1,"illness":1,"whether":1,"it":2,"hyperglycemia":2,"due":1,"to":3,"newly":1,"diagnosed":1,"diabetes":2,"stress":1,"hyperglyce":1,"mia":2,"related":1,"prior":1,"admission":1,"has":1,"been":1,"found":1,"that":1,"fasting":1,"levels":1,"are":1,"predictors":1,"hypoglyce":1,"within":1,"next":1,"therefore":1,"ne":1},"len":203},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":3,"chunkId":"ada-2026-hosp-p3-c2","text":"s or stress hyperglyce - mia or hyperglycemia related to diabetes prior to admission ( 36 , 37 ). It has been found that fasting glucose levels < 100 mg/dL ( < 5.6 mmol/L) are predictors of hypoglyce - mia within the next 24 h ( 38 ) and therefore necessitate basal insulin dose adjustments. Higher glycemic levels (up to 250 mg/dL [13.9 mmol/L]) may be acceptable in se - lected populations (terminally ill individuals with short life expectancy, advanced kid - ney failure [and/or on dialysis], high risk for hypoglycemia, and/or labile glycemic excursions). In these individuals, less ag - gressive treatment goals that would help avoid symptomatic hypoglycemia and/or hyperglycemia are often appropriate. Clinical judgment combined with ongoing assess - ment of clinical status, including changes in the trajectory of glucose measures, illness severity, nutritional status, or concomitant medications that might affect glucose levels (e.g., glucocorticoids), should be in - corporated into the day-to-day decisions regarding treatment goals. GLUCOSE MONITORING In hospitalized individuals with diabetes who are eating, point-of-care (POC) blood glucose monitoring should be performed before meals; in those not eating, glucose monitoring is advised every 4  6 h ( 36 ). More frequent POC blood glucose moni - toring typically ranging from every 30 min to every 2 h is recommended for safe use of","tf":{"13":1,"24":1,"30":1,"36":2,"37":1,"38":1,"100":1,"250":1,"or":6,"stress":1,"hyperglyce":1,"mia":2,"hyperglycemia":2,"related":1,"to":5,"diabetes":2,"prior":1,"admission":1,"it":1,"has":1,"been":1,"found":1,"that":3,"fasting":1,"glucose":7,"levels":3,"mg":2,"dl":2,"mmol":2,"are":3,"predictors":1,"of":5,"hypoglyce":1,"within":1,"the":3,"next":1,"and":4,"therefore":1,"necessitate":1,"basal":1,"insulin":1,"dose":1,"adjustments":1,"higher":1,"glycemic":2,"up":1,"may":1,"be":3,"acceptable":1,"in":6,"se":1,"lected":1,"populations":1,"terminally":1,"ill":1,"individuals":3,"with":3,"short":1,"life":1,"expectancy":1,"advanced":1,"kid":1,"ney":1,"failure":1,"on":1,"dialysis":1,"high":1,"risk":1,"for":2,"hypoglycemia":2,"labile":1,"excursions":1,"these":1,"less":1,"ag":1,"gressive":1,"treatment":2,"goals":2,"would":1,"help":1,"avoid":1,"symptomatic":1,"often":1,"appropriate":1,"clinical":2,"judgment":1,"combined":1,"ongoing":1,"assess":1,"ment":1,"status":2,"including":1,"changes":1,"trajectory":1,"measures":1,"illness":1,"severity":1,"nutritional":1,"concomitant":1,"medications":1,"might":1,"affect":1,"glucocorticoids":1,"should":2,"corporated":1,"into":1,"day":2,"decisions":1,"regarding":1,"monitoring":3,"hospitalized":1,"who":1,"eating":2,"point":1,"care":1,"poc":2,"blood":2,"performed":1,"before":1,"meals":1,"those":1,"not":1,"is":2,"advised":1,"every":3,"more":1,"frequent":1,"moni":1,"toring":1,"typically":1,"ranging":1,"from":1,"min":1,"recommended":1,"safe":1,"use":1},"len":201},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":3,"chunkId":"ada-2026-hosp-p3-c3","text":"lucose monitoring should be performed before meals; in those not eating, glucose monitoring is advised every 4  6 h ( 36 ). More frequent POC blood glucose moni - toring typically ranging from every 30 min to every 2 h is recommended for safe use of intravenous insulin therapy. Hospital blood glucose monitoring should be performed with U.S. Food and Drug Administration (FDA)-approved POC hospital-calibrated glucose monitoring sys - tems ( 39 ) ( Table 7.1 ). POC blood glucose monitors provide the advantage of imme - diate bedside results, and studies suggest that while POC measurements are less ac - curate and less precise than those from laboratory glucose analyzers, they provide adequate information for usual practice ex - cept in rare instances where care has been compromised ( 40 , 41 ). Particular attention should be given to factors that may cause errors in POC measurement such as perfu - sion abnormalities, edema, anemia or er - ythrocytosis, and several medications commonly used in the hospital ( 39 ). The FDA has established standards for capillary (finger-stick) POC glucose monitoring in the hospital ( 39 ). The balance between analytic requirements (e.g., accuracy, precision, and interference) and clinical requirements (e.g., rapidity, simplicity, and POC) has not been uniformly re - solved ( 39  42 ), and most hospitals have arrived at their own policies to balanc","tf":{"30":1,"36":1,"39":4,"40":1,"41":1,"42":1,"lucose":1,"monitoring":5,"should":3,"be":3,"performed":2,"before":1,"meals":1,"in":5,"those":2,"not":2,"eating":1,"glucose":7,"is":2,"advised":1,"every":3,"more":1,"frequent":1,"poc":7,"blood":3,"moni":1,"toring":1,"typically":1,"ranging":1,"from":2,"min":1,"to":3,"recommended":1,"for":3,"safe":1,"use":1,"of":2,"intravenous":1,"insulin":1,"therapy":1,"hospital":4,"with":1,"food":1,"and":8,"drug":1,"administration":1,"fda":2,"approved":1,"calibrated":1,"sys":1,"tems":1,"table":1,"monitors":1,"provide":2,"the":5,"advantage":1,"imme":1,"diate":1,"bedside":1,"results":1,"studies":1,"suggest":1,"that":2,"while":1,"measurements":1,"are":1,"less":2,"ac":1,"curate":1,"precise":1,"than":1,"laboratory":1,"analyzers":1,"they":1,"adequate":1,"information":1,"usual":1,"practice":1,"ex":1,"cept":1,"rare":1,"instances":1,"where":1,"care":1,"has":3,"been":2,"compromised":1,"particular":1,"attention":1,"given":1,"factors":1,"may":1,"cause":1,"errors":1,"measurement":1,"such":1,"as":1,"perfu":1,"sion":1,"abnormalities":1,"edema":1,"anemia":1,"or":1,"er":1,"ythrocytosis":1,"several":1,"medications":1,"commonly":1,"used":1,"established":1,"standards":1,"capillary":1,"finger":1,"stick":1,"balance":1,"between":1,"analytic":1,"requirements":2,"accuracy":1,"precision":1,"interference":1,"clinical":1,"rapidity":1,"simplicity":1,"uniformly":1,"re":1,"solved":1,"most":1,"hospitals":1,"have":1,"arrived":1,"at":1,"their":1,"own":1,"policies":1,"balanc":1},"len":199},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":3,"chunkId":"ada-2026-hosp-p3-c4","text":"etween analytic requirements (e.g., accuracy, precision, and interference) and clinical requirements (e.g., rapidity, simplicity, and POC) has not been uniformly re - solved ( 39  42 ), and most hospitals have arrived at their own policies to balance these parameters. It is critically important that devices selected for in-hospital use, and the workflow through which they are applied, undergo careful analysis of perfor - mance and reliability and ongoing quality assessments ( 42 ). Best practice dictates that any POC glucose result that does not correlate with the individuals clinical status should be confirmed by repeating the test first and measuring a sample in the clinical laboratory if the second result is similar, particularly for asymptomatic hypoglycemic events. Continuous Glucose Monitoring Recommendations 16.6 In people with diabetes using a personal continuous glucose monitor - ing (CGM) device, the use of CGM should be continued during hospitali - zation if clinically appropriate, with confirmatory point-of-care (POC) blood glucose measurements for insulin dos - ing decisions and hypoglycemia assess - ment, if resources and training are available, and according to an insti - tutional protocol. B While supporting individuals who wish to continue use of personal continuous glu - cose monitoring (CGM) devices is en - couraged, currently it is recommended that confirm","tf":{"16":1,"39":1,"42":2,"etween":1,"analytic":1,"requirements":2,"accuracy":1,"precision":1,"and":11,"interference":1,"clinical":3,"rapidity":1,"simplicity":1,"poc":3,"has":1,"not":2,"been":1,"uniformly":1,"re":1,"solved":1,"most":1,"hospitals":1,"have":1,"arrived":1,"at":1,"their":1,"own":1,"policies":1,"to":3,"balance":1,"these":1,"parameters":1,"it":2,"is":4,"critically":1,"important":1,"that":4,"devices":2,"selected":1,"for":3,"in":3,"hospital":1,"use":3,"the":6,"workflow":1,"through":1,"which":1,"they":1,"are":2,"applied":1,"undergo":1,"careful":1,"analysis":1,"of":4,"perfor":1,"mance":1,"reliability":1,"ongoing":1,"quality":1,"assessments":1,"best":1,"practice":1,"dictates":1,"any":1,"glucose":4,"result":2,"does":1,"correlate":1,"with":3,"individual":1,"status":1,"should":2,"be":2,"confirmed":1,"by":1,"repeating":1,"test":1,"first":1,"measuring":1,"sample":1,"laboratory":1,"if":3,"second":1,"similar":1,"particularly":1,"asymptomatic":1,"hypoglycemic":1,"events":1,"continuous":3,"monitoring":2,"recommendations":1,"people":1,"diabetes":1,"using":1,"personal":2,"monitor":1,"ing":2,"cgm":3,"device":1,"continued":1,"during":1,"hospitali":1,"zation":1,"clinically":1,"appropriate":1,"confirmatory":1,"point":1,"care":1,"blood":1,"measurements":1,"insulin":1,"dos":1,"decisions":1,"hypoglycemia":1,"assess":1,"ment":1,"resources":1,"training":1,"available":1,"according":1,"an":1,"insti":1,"tutional":1,"protocol":1,"while":1,"supporting":1,"individuals":1,"who":1,"wish":1,"continue":1,"glu":1,"cose":1,"en":1,"couraged":1,"currently":1,"recommended":1,"confirm":1},"len":196},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":3,"chunkId":"ada-2026-hosp-p3-c5","text":"s and training are available, and according to an insti - tutional protocol. B While supporting individuals who wish to continue use of personal continuous glu - cose monitoring (CGM) devices is en - couraged, currently it is recommended that confirmatory POC be used for insu - lin dosing. However, a recent retrospec - tive study demonstrated the feasibility of implementation of a hospital-wide per - sonal CGM policy that included EHR inte - gration and CGM validation for insulin dosing; the policy resulted in favorable hospitalized individual and nurse satisfac - tion ( 43 ). Validation criteria to ensure adequate accuracy of CGM have been based on a modified version of FDA cri - teria for integrated CGM devices. Known as the 20/20 criterion, it requires a CGM reading to be within  20% of the POC measurement when blood glucose is  70 mg/dL or within  20 mg/dL of the POC measurement when blood glucose is < 70 mg/dL. Several other studies have demonstrated that inpatient use of hospital-owned CGM devices is feasi - ble and has advantages over POC glucose monitoring in improving glycemic manage - ment, detecting hypoglycemia (particularly nocturnal, prolonged and/or asymptomatic hypoglycemia [ 44 , 45 ]), and reducing recur - rent hypoglycemia ( 43 , 46  48 ). However, at this time, none of the CGM devices have been approved by the FDA for inpatient use. During the coronaviru","tf":{"20":4,"43":2,"44":1,"45":1,"46":1,"48":1,"70":2,"and":7,"training":1,"are":1,"available":1,"according":1,"to":4,"an":1,"insti":1,"tutional":1,"protocol":1,"while":1,"supporting":1,"individuals":1,"who":1,"wish":1,"continue":1,"use":3,"of":9,"personal":1,"continuous":1,"glu":1,"cose":1,"monitoring":2,"cgm":8,"devices":4,"is":5,"en":1,"couraged":1,"currently":1,"it":2,"recommended":1,"that":3,"confirmatory":1,"poc":4,"be":2,"used":1,"for":4,"insu":1,"lin":1,"dosing":2,"however":2,"recent":1,"retrospec":1,"tive":1,"study":1,"demonstrated":2,"the":8,"feasibility":1,"implementation":1,"hospital":2,"wide":1,"per":1,"sonal":1,"policy":2,"included":1,"ehr":1,"inte":1,"gration":1,"validation":2,"insulin":1,"resulted":1,"in":2,"favorable":1,"hospitalized":1,"individual":1,"nurse":1,"satisfac":1,"tion":1,"criteria":1,"ensure":1,"adequate":1,"accuracy":1,"have":3,"been":2,"based":1,"on":1,"modified":1,"version":1,"fda":2,"cri":1,"teria":1,"integrated":1,"known":1,"as":1,"criterion":1,"requires":1,"reading":1,"within":2,"measurement":2,"when":2,"blood":2,"glucose":3,"mg":3,"dl":3,"or":2,"several":1,"other":1,"studies":1,"inpatient":2,"owned":1,"feasi":1,"ble":1,"has":1,"advantages":1,"over":1,"improving":1,"glycemic":1,"manage":1,"ment":1,"detecting":1,"hypoglycemia":3,"particularly":1,"nocturnal":1,"prolonged":1,"asymptomatic":1,"reducing":1,"recur":1,"rent":1,"at":1,"this":1,"time":1,"none":1,"approved":1,"by":1,"during":1,"coronaviru":1},"len":214},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":3,"chunkId":"ada-2026-hosp-p3-c6","text":"cularly nocturnal, prolonged and/or asymptomatic hypoglycemia [ 44 , 45 ]), and reducing recur - rent hypoglycemia ( 43 , 46  48 ). However, at this time, none of the CGM devices have been approved by the FDA for inpatient use. During the coronavirus disease 2019 diabetesjournals.org/care Diabetes Care in the Hospital S341 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S339/848851/dc26s016.pdf by guest on 17 February 2026","tf":{"17":1,"43":1,"44":1,"45":1,"46":1,"48":1,"49":1,"2019":1,"2026":1,"848851":1,"cularly":1,"nocturnal":1,"prolonged":1,"and":2,"or":1,"asymptomatic":1,"hypoglycemia":2,"reducing":1,"recur":1,"rent":1,"however":1,"at":1,"this":1,"time":1,"none":1,"of":1,"the":4,"cgm":1,"devices":1,"have":1,"been":1,"approved":1,"by":2,"fda":1,"for":1,"inpatient":1,"use":1,"during":1,"coronavirus":1,"disease":1,"diabetesjournals":2,"org":2,"care":3,"diabetes":1,"in":1,"hospital":1,"s341":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"supplement":1,"s339":1,"dc26s016":1,"guest":1,"on":1,"february":1},"len":69},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":4,"chunkId":"ada-2026-hosp-p4-c0","text":"(COVID-19) pandemic, many institutions used CGM in ICU and non-ICU settings, with the aim of minimizing exposure time and saving personal protective equipment, under an FDA policy of enforcement dis - cretion ( 49 , 50 ). Data on the safety and effi - cacy of real-time CGM use in the hospital, particularly with implementation of re - mote monitoring (e.g., a glucose telemetry system), has grown ( 47 , 50  52 ). However, a recent multicenter randomized clinical trial did not show a benefit of using CGM over POC monitoring for insulin adjustment in individuals with type 2 diabetes hospital - ized for noncritical illness ( 53 ). Both groups achieved similar mean blood glucose levels (170  32 vs. 175  33 [ P = 0.25]) with similarly low levels of hypoglycemia. The discrepancies in the results of clinical trials may be related to treatment algorithms rather than the method of glucose moni - toring. Before the COVID-19 pandemic, the use of hospital CGM was mostly restricted to remote monitoring and facilitation of insulin adjustment based on daily CGM data, rather than as a replacement for POC. However, hospital CGM was suc - cessfully used in conjunction with peri - odic POC monitoring in hybrid protocols used for intravenous insulin titrations, decreasing the burden of hourly POC test - ing ( 54  56 ). Due to an ongoing interest in use of hospital CGM systems, a recent consen - ","tf":{"19":2,"25":1,"32":1,"33":1,"47":1,"49":1,"50":2,"52":1,"53":1,"54":1,"56":1,"170":1,"175":1,"covid":2,"pandemic":2,"many":1,"institutions":1,"used":3,"cgm":7,"in":7,"icu":2,"and":4,"non":1,"settings":1,"with":5,"the":9,"aim":1,"of":12,"minimizing":1,"exposure":1,"time":2,"saving":1,"personal":1,"protective":1,"equipment":1,"under":1,"an":2,"fda":1,"policy":1,"enforcement":1,"dis":1,"cretion":1,"data":2,"on":2,"safety":1,"effi":1,"cacy":1,"real":1,"use":3,"hospital":5,"particularly":1,"implementation":1,"re":1,"mote":1,"monitoring":4,"glucose":3,"telemetry":1,"system":1,"has":1,"grown":1,"however":2,"recent":2,"multicenter":1,"randomized":1,"clinical":2,"trial":1,"did":1,"not":1,"show":1,"benefit":1,"using":1,"over":1,"poc":4,"for":4,"insulin":3,"adjustment":2,"individuals":1,"type":1,"diabetes":1,"ized":1,"noncritical":1,"illness":1,"both":1,"groups":1,"achieved":1,"similar":1,"mean":1,"blood":1,"levels":2,"vs":1,"similarly":1,"low":1,"hypoglycemia":1,"discrepancies":1,"results":1,"trials":1,"may":1,"be":1,"related":1,"to":3,"treatment":1,"algorithms":1,"rather":2,"than":2,"method":1,"moni":1,"toring":1,"before":1,"was":2,"mostly":1,"restricted":1,"remote":1,"facilitation":1,"based":1,"daily":1,"as":1,"replacement":1,"suc":1,"cessfully":1,"conjunction":1,"peri":1,"odic":1,"hybrid":1,"protocols":1,"intravenous":1,"titrations":1,"decreasing":1,"burden":1,"hourly":1,"test":1,"ing":1,"due":1,"ongoing":1,"interest":1,"systems":1,"consen":1},"len":214},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":4,"chunkId":"ada-2026-hosp-p4-c1","text":"used in conjunction with peri - odic POC monitoring in hybrid protocols used for intravenous insulin titrations, decreasing the burden of hourly POC test - ing ( 54  56 ). Due to an ongoing interest in use of hospital CGM systems, a recent consen - sus on good practice points for use of CGM devices in hospital settings has been published ( 57 ). For more general information on CGM, see section 7,  Diabetes Technology . Insulin Pump Use in the Hospital Data on inpatient use of hybrid closed-loop systems (currently commercially available automated insulin delivery [AID] devices) are limited to feasibility trials ( 58 ). In a ran - domized controlled trial, people with type 2 diabetes receiving noncritical care had significantly better glycemia with the use of an automated, fully closed-loop in - sulin delivery system than with conventional subcutaneous insulin therapy, without a higher risk of hypoglycemia ( 59 ). Continua - tion of insulin pump or AID system use should be supported during hospitalization when clinically appropriate in individuals who are willing and able to self-manage their devices, with proper staff training and supervision. An observational study in chil - dren demonstrated improvement in individ - ual satisfaction and improved detection of glycemic excursions with continued use of personal devices ( 60 ). Consultation with the endocrinology/diabetes care ","tf":{"54":1,"56":1,"57":1,"58":1,"59":1,"60":1,"used":2,"in":10,"conjunction":1,"with":7,"peri":1,"odic":1,"poc":2,"monitoring":1,"hybrid":2,"protocols":1,"for":3,"intravenous":1,"insulin":5,"titrations":1,"decreasing":1,"the":4,"burden":1,"of":9,"hourly":1,"test":1,"ing":1,"due":1,"to":3,"an":3,"ongoing":1,"interest":1,"use":7,"hospital":3,"cgm":3,"systems":2,"recent":1,"consen":1,"sus":1,"on":3,"good":1,"practice":1,"points":1,"devices":4,"settings":1,"has":1,"been":1,"published":1,"more":1,"general":1,"information":1,"see":1,"section":1,"diabetes":3,"technology":1,"pump":2,"data":1,"inpatient":1,"closed":2,"loop":2,"currently":1,"commercially":1,"available":1,"automated":2,"delivery":2,"aid":2,"are":2,"limited":1,"feasibility":1,"trials":1,"ran":1,"domized":1,"controlled":1,"trial":1,"people":1,"type":1,"receiving":1,"noncritical":1,"care":2,"had":1,"significantly":1,"better":1,"glycemia":1,"fully":1,"sulin":1,"system":2,"than":1,"conventional":1,"subcutaneous":1,"therapy":1,"without":1,"higher":1,"risk":1,"hypoglycemia":1,"continua":1,"tion":1,"or":1,"should":1,"be":1,"supported":1,"during":1,"hospitalization":1,"when":1,"clinically":1,"appropriate":1,"individuals":1,"who":1,"willing":1,"and":3,"able":1,"self":1,"manage":1,"their":1,"proper":1,"staff":1,"training":1,"supervision":1,"observational":1,"study":1,"chil":1,"dren":1,"demonstrated":1,"improvement":1,"individ":1,"ual":1,"satisfaction":1,"improved":1,"detection":1,"glycemic":1,"excursions":1,"continued":1,"personal":1,"consultation":1,"endocrinology":1},"len":202},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":4,"chunkId":"ada-2026-hosp-p4-c2","text":" supervision. An observational study in chil - dren demonstrated improvement in individ - ual satisfaction and improved detection of glycemic excursions with continued use of personal devices ( 60 ). Consultation with the endocrinology/diabetes care team or diabe - tes care and education specialists, if avail - able, is recommended, especially if the reason for admission is suspected to be re - lated to device malfunction or lack of adequate education, training, or use. Best practices ensuring safe use of AID systems in the hospital setting are evolv - ing. Many institutions still require POC blood glucose monitoring with variable frequency (1  6 times daily) for individuals continuing insulin pump or AID system use. Since AID systems cannot function without using CGM data, it is important to ensure and document CGM accuracy by cross-checking CGM readings with POC or blood glucose readings periodically (at least once daily) or when clinically appropriate. To consider CGM readings valid, cur - rent criteria require a CGM reading to be within  20% of POC or laboratory blood glucose measurement or within  20 mg/dL when POC or laboratory blood glucose is  70 mg/dL ( 43 ). In ad - dition, CGM and AID data should be re - viewed and documented daily (e.g., before meals and at bedtime) and pump settings should be adjusted as needed to ensure that the individual is meeting treatment","tf":{"20":2,"43":1,"60":1,"70":1,"supervision":1,"an":1,"observational":1,"study":1,"in":4,"chil":1,"dren":1,"demonstrated":1,"improvement":1,"individ":1,"ual":1,"satisfaction":1,"and":7,"improved":1,"detection":1,"of":5,"glycemic":1,"excursions":1,"with":4,"continued":1,"use":4,"personal":1,"devices":1,"consultation":1,"the":4,"endocrinology":1,"diabetes":1,"care":2,"team":1,"or":9,"diabe":1,"tes":1,"education":2,"specialists":1,"if":2,"avail":1,"able":1,"is":5,"recommended":1,"especially":1,"reason":1,"for":2,"admission":1,"suspected":1,"to":6,"be":4,"re":2,"lated":1,"device":1,"malfunction":1,"lack":1,"adequate":1,"training":1,"best":1,"practices":1,"ensuring":1,"safe":1,"aid":4,"systems":2,"hospital":1,"setting":1,"are":1,"evolv":1,"ing":1,"many":1,"institutions":1,"still":1,"require":2,"poc":4,"blood":4,"glucose":4,"monitoring":1,"variable":1,"frequency":1,"times":1,"daily":3,"individuals":1,"continuing":1,"insulin":1,"pump":2,"system":1,"since":1,"cannot":1,"function":1,"without":1,"using":1,"cgm":6,"data":2,"it":1,"important":1,"ensure":2,"document":1,"accuracy":1,"by":1,"cross":1,"checking":1,"readings":3,"periodically":1,"at":2,"least":1,"once":1,"when":2,"clinically":1,"appropriate":1,"consider":1,"valid":1,"cur":1,"rent":1,"criteria":1,"reading":1,"within":2,"laboratory":2,"measurement":1,"mg":2,"dl":2,"ad":1,"dition":1,"should":2,"viewed":1,"documented":1,"before":1,"meals":1,"bedtime":1,"settings":1,"adjusted":1,"as":1,"needed":1,"that":1,"individual":1,"meeting":1,"treatment":1},"len":216},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":4,"chunkId":"ada-2026-hosp-p4-c3","text":"tory blood glucose is  70 mg/dL ( 43 ). In ad - dition, CGM and AID data should be re - viewed and documented daily (e.g., before meals and at bedtime) and pump settings should be adjusted as needed to ensure that the individual is meeting treatment goals. Hospitals are encouraged to de - velop institutional policies and have available trained personnel with knowl - edge of diabetes technology. In a recent survey, less than half the hospitals had these policies in place ( 61 ). For more general information on AID, see section 7,  Diabetes Technology . Recommendation 16.7 Continue use of insulin pump in - cluding automated insulin delivery in people with diabetes who are hospital - ized when clinically appropriate. This is contingent upon availability of neces - sary supplies, resources, training, on - going competency assessments, and implementation of institutional diabe - tes technology protocols. C GLUCOSE-LOWERING TREATMENT IN HOSPITALIZED INDIVDIUALS An individualized approach for glycemic management is encouraged throughout the hospital stay and should take into con - sideration several predictive factors for achieving glycemic goals, such as prior home use and doses of insulin or noninsulin therapy, expected level of insulin resis - tance, prior A1C, current glucose levels, nutritional intake, duration of diabetes, glucose altering medications, and the goal of treatme","tf":{"16":1,"43":1,"61":1,"70":1,"tory":1,"blood":1,"glucose":4,"is":4,"mg":1,"dl":1,"in":6,"ad":1,"dition":1,"cgm":1,"and":9,"aid":2,"data":1,"should":3,"be":2,"re":1,"viewed":1,"documented":1,"daily":1,"before":1,"meals":1,"at":1,"bedtime":1,"pump":2,"settings":1,"adjusted":1,"as":2,"needed":1,"to":2,"ensure":1,"that":1,"the":4,"individual":1,"meeting":1,"treatment":2,"goals":2,"hospitals":2,"are":2,"encouraged":2,"de":1,"velop":1,"institutional":2,"policies":2,"have":1,"available":1,"trained":1,"personnel":1,"with":2,"knowl":1,"edge":1,"of":8,"diabetes":4,"technology":3,"recent":1,"survey":1,"less":1,"than":1,"half":1,"had":1,"these":1,"place":1,"for":3,"more":1,"general":1,"information":1,"on":2,"see":1,"section":1,"recommendation":1,"continue":1,"use":2,"insulin":4,"cluding":1,"automated":1,"delivery":1,"people":1,"who":1,"hospital":2,"ized":1,"when":1,"clinically":1,"appropriate":1,"this":1,"contingent":1,"upon":1,"availability":1,"neces":1,"sary":1,"supplies":1,"resources":1,"training":1,"going":1,"competency":1,"assessments":1,"implementation":1,"diabe":1,"tes":1,"protocols":1,"lowering":1,"hospitalized":1,"indivdiuals":1,"an":1,"individualized":1,"approach":1,"glycemic":2,"management":1,"throughout":1,"stay":1,"take":1,"into":1,"con":1,"sideration":1,"several":1,"predictive":1,"factors":1,"achieving":1,"such":1,"prior":2,"home":1,"doses":1,"or":1,"noninsulin":1,"therapy":1,"expected":1,"level":1,"resis":1,"tance":1,"a1c":1,"current":1,"levels":1,"nutritional":1,"intake":1,"duration":1,"altering":1,"medications":1,"goal":1,"treatme":1},"len":200},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":4,"chunkId":"ada-2026-hosp-p4-c4","text":"emic goals, such as prior home use and doses of insulin or noninsulin therapy, expected level of insulin resis - tance, prior A1C, current glucose levels, nutritional intake, duration of diabetes, glucose altering medications, and the goal of treatment for primary disease. Insulin Therapy Critical Care Setting Continuous intravenous insulin infusion is the most effective method for achieving specific glycemic goals and avoiding hypogly - cemia in the critical care setting. Intravenous insulin infusions should be administered us - ing validated written or computerized proto - cols that allow for predefined adjustments in the insulin infusion rate based on glyce - mic fluctuations and immediate past and current insulin infusion rates ( 62 ). For indi - viduals who are eating but continue to need intravenous insulin infusion, prandial cover - age may be provided as rapid-acting insulin administered subcutaneously, as this would prevent large fluctuations in intravenous in - sulin requirement and subsequent hypogly - cemia risk ( 63 ). Recommendations 16.8a Continuous intravenous insulin infusion is recommended for achiev - ing glycemic goals and avoiding hypo - glycemia in critically ill individuals. A 16.8b Basal insulin or a basal plus correction insulin plan is the pre - ferred treatment for noncritically ill hospitalized individuals with poor or no oral intake. A 16.9 An insul","tf":{"16":3,"62":1,"63":1,"emic":1,"goals":3,"such":1,"as":3,"prior":2,"home":1,"use":1,"and":7,"doses":1,"of":4,"insulin":12,"or":4,"noninsulin":1,"therapy":2,"expected":1,"level":1,"resis":1,"tance":1,"a1c":1,"current":2,"glucose":2,"levels":1,"nutritional":1,"intake":2,"duration":1,"diabetes":1,"altering":1,"medications":1,"the":5,"goal":1,"treatment":2,"for":6,"primary":1,"disease":1,"critical":2,"care":2,"setting":2,"continuous":2,"intravenous":5,"infusion":5,"is":3,"most":1,"effective":1,"method":1,"achieving":1,"specific":1,"glycemic":2,"avoiding":2,"hypogly":2,"cemia":2,"in":5,"infusions":1,"should":1,"be":2,"administered":2,"us":1,"ing":2,"validated":1,"written":1,"computerized":1,"proto":1,"cols":1,"that":1,"allow":1,"predefined":1,"adjustments":1,"rate":1,"based":1,"on":1,"glyce":1,"mic":1,"fluctuations":2,"immediate":1,"past":1,"rates":1,"indi":1,"viduals":1,"who":1,"are":1,"eating":1,"but":1,"continue":1,"to":1,"need":1,"prandial":1,"cover":1,"age":1,"may":1,"provided":1,"rapid":1,"acting":1,"subcutaneously":1,"this":1,"would":1,"prevent":1,"large":1,"sulin":1,"requirement":1,"subsequent":1,"risk":1,"recommendations":1,"8a":1,"recommended":1,"achiev":1,"hypo":1,"glycemia":1,"critically":1,"ill":2,"individuals":2,"8b":1,"basal":2,"plus":1,"correction":1,"plan":1,"pre":1,"ferred":1,"noncritically":1,"hospitalized":1,"with":1,"poor":1,"no":1,"oral":1,"an":1,"insul":1},"len":200},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":4,"chunkId":"ada-2026-hosp-p4-c5","text":" goals and avoiding hypo - glycemia in critically ill individuals. A 16.8b Basal insulin or a basal plus correction insulin plan is the pre - ferred treatment for noncritically ill hospitalized individuals with poor or no oral intake. A 16.9 An insulin plan with basal, pran - dial, and correction components is the preferred treatment for most noncriti - cally ill hospitalized individuals with adequate nutritional intake. A 16.10 For most individuals, sole use of a correction or supplemental in - sulin without basal insulin (formerly referred to as a sliding scale) in the inpatient setting is discouraged. A Transitioning From Intravenous to Subcuta - neous Insulin When discontinuing intravenous insulin, a transition protocol should be used. Sub - cutaneous basal insulin should be given 2 h before intravenous infusion is discontin - ued, with the aim of minimizing rebound hyperglycemia while the subcutaneous in - sulin achieves its effect ( 63 ). Emerging data from studies in people with hyperglycemia with and without diabetic S342 Diabetes Care in the Hospital Diabetes Care Volume 49, Supplement 1, January 2026 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S339/848851/dc26s016.pdf by guest on 17 February 2026","tf":{"10":1,"16":3,"17":1,"49":2,"63":1,"2026":2,"848851":1,"goals":1,"and":3,"avoiding":1,"hypo":1,"glycemia":1,"in":6,"critically":1,"ill":3,"individuals":4,"8b":1,"basal":5,"insulin":7,"or":3,"plus":1,"correction":3,"plan":2,"is":4,"the":6,"pre":1,"ferred":1,"treatment":2,"for":3,"noncritically":1,"hospitalized":2,"with":6,"poor":1,"no":1,"oral":1,"intake":2,"an":1,"pran":1,"dial":1,"components":1,"preferred":1,"most":2,"noncriti":1,"cally":1,"adequate":1,"nutritional":1,"sole":1,"use":1,"of":2,"supplemental":1,"sulin":2,"without":2,"formerly":1,"referred":1,"to":2,"as":1,"sliding":1,"scale":1,"inpatient":1,"setting":1,"discouraged":1,"transitioning":1,"from":3,"intravenous":3,"subcuta":1,"neous":1,"when":1,"discontinuing":1,"transition":1,"protocol":1,"should":2,"be":2,"used":1,"sub":1,"cutaneous":1,"given":1,"before":1,"infusion":1,"discontin":1,"ued":1,"aim":1,"minimizing":1,"rebound":1,"hyperglycemia":2,"while":1,"subcutaneous":1,"achieves":1,"its":1,"effect":1,"emerging":1,"data":1,"studies":1,"people":1,"diabetic":1,"s342":1,"diabetes":2,"care":3,"hospital":1,"volume":1,"supplement":2,"january":1,"downloaded":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"s339":1,"dc26s016":1,"by":1,"guest":1,"on":1,"february":1},"len":179},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":5,"chunkId":"ada-2026-hosp-p5-c0","text":"ketoacidosis (DKA) show that the adminis - tration of a low dose (0.15  0.3 units/kg) of basal insulin analog in addition to intra - venous insulin infusion may reduce the duration of insulin infusion and length of hospital stay and prevent rebound hy - perglycemia without increased risk of hypoglycemia ( 64  67 ). This may be partic - ularly beneficial for people with type 1 diabetes to minimize the risk for DKA should insulin infusion be stopped for a prolonged period of time. For transitioning, the total daily dose of subcutaneous insulin may be calculated using a weight-based approach, based on prior home insulin dose or based on the insulin infusion rate during the prior 6  8 h when stable glycemic goals were achieved ( 12 ). It is important to ensure correct dos - ing either by either using an insulin pen or meticulous pharmacy and nursing supervi - sion of the dose drawn from a vial. Noncritical Care Setting In most instances, insulin is the preferred treatment for hyperglycemia in hospitalized individuals. In certain circumstances, it may be appropriate to continue home oral glucose-lowering medications or initiate use of agents such as dipeptidyl peptidase 4 inhibitors (DPP-4i) for mild hyperglycemia. Scheduled subcutaneous insulin or - ders are recommended for the manage - ment of hyperglycemia in people with diabetes and hyperglycemia. Use of in - sulin analogs or","tf":{"12":1,"15":1,"64":1,"67":1,"ketoacidosis":1,"dka":2,"show":1,"that":1,"the":9,"adminis":1,"tration":1,"of":11,"low":1,"dose":4,"units":1,"kg":1,"basal":1,"insulin":10,"analog":1,"in":6,"addition":1,"to":4,"intra":1,"venous":1,"infusion":4,"may":4,"reduce":1,"duration":1,"and":4,"length":1,"hospital":1,"stay":1,"prevent":1,"rebound":1,"hy":1,"perglycemia":1,"without":1,"increased":1,"risk":2,"hypoglycemia":1,"this":1,"be":4,"partic":1,"ularly":1,"beneficial":1,"for":7,"people":2,"with":2,"type":1,"diabetes":2,"minimize":1,"should":1,"stopped":1,"prolonged":1,"period":1,"time":1,"transitioning":1,"total":1,"daily":1,"subcutaneous":2,"calculated":1,"using":2,"weight":1,"based":3,"approach":1,"on":2,"prior":2,"home":2,"or":5,"rate":1,"during":1,"when":1,"stable":1,"glycemic":1,"goals":1,"were":1,"achieved":1,"it":2,"is":2,"important":1,"ensure":1,"correct":1,"dos":1,"ing":1,"either":2,"by":1,"an":1,"pen":1,"meticulous":1,"pharmacy":1,"nursing":1,"supervi":1,"sion":1,"drawn":1,"from":1,"vial":1,"noncritical":1,"care":1,"setting":1,"most":1,"instances":1,"preferred":1,"treatment":1,"hyperglycemia":4,"hospitalized":1,"individuals":1,"certain":1,"circumstances":1,"appropriate":1,"continue":1,"oral":1,"glucose":1,"lowering":1,"medications":1,"initiate":1,"use":2,"agents":1,"such":1,"as":1,"dipeptidyl":1,"peptidase":1,"inhibitors":1,"dpp":1,"4i":1,"mild":1,"scheduled":1,"ders":1,"are":1,"recommended":1,"manage":1,"ment":1,"sulin":1,"analogs":1},"len":212},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":5,"chunkId":"ada-2026-hosp-p5-c1","text":" agents such as dipeptidyl peptidase 4 inhibitors (DPP-4i) for mild hyperglycemia. Scheduled subcutaneous insulin or - ders are recommended for the manage - ment of hyperglycemia in people with diabetes and hyperglycemia. Use of in - sulin analogs or human insulin results in similar glycemic outcomes in the hospi - tal setting, but human insulin may in - crease the risk of hypoglycemic events ( 68 ). The use of subcutaneous rapid- or short-acting correctional insulin before meals, or every 4  6 h if no meals are given or if the individual is receiving continuous enteral or parenteral nutrition, is indicated to correct or prevent hyperglycemia. Basal insulin, or a basal plus bolus correction schedule, is the preferred treatment for noncritically ill hospitalized individuals with inadequate or restricted oral intake. An in - sulin schedule with basal, prandial, and correction components is the preferred treatment formost noncritically ill hospital - ized people with diabetes with adequate nutritional intake. Typically, total daily insulin dose is cal - culated based on body weight and sensi - tivity to insulin, with 0.3  0.6 units/kg/day as the usual starting dose ( 69 ). Initial total daily insulin dose may also be estimated from the last 6  8 h of insulin infusion rate or the insulin dose received in previ - ous hospitalization or calculated as 80% of the home insulin dose, ","tf":{"68":1,"69":1,"80":1,"agents":1,"such":1,"as":3,"dipeptidyl":1,"peptidase":1,"inhibitors":1,"dpp":1,"4i":1,"for":3,"mild":1,"hyperglycemia":4,"scheduled":1,"subcutaneous":2,"insulin":11,"or":11,"ders":1,"are":2,"recommended":1,"the":11,"manage":1,"ment":1,"of":6,"in":7,"people":2,"with":6,"diabetes":2,"and":3,"use":2,"sulin":2,"analogs":1,"human":2,"results":1,"similar":1,"glycemic":1,"outcomes":1,"hospi":1,"tal":1,"setting":1,"but":1,"may":2,"crease":1,"risk":1,"hypoglycemic":1,"events":1,"rapid":1,"short":1,"acting":1,"correctional":1,"before":1,"meals":2,"every":1,"if":2,"no":1,"given":1,"individual":1,"is":5,"receiving":1,"continuous":1,"enteral":1,"parenteral":1,"nutrition":1,"indicated":1,"to":2,"correct":1,"prevent":1,"basal":3,"plus":1,"bolus":1,"correction":2,"schedule":2,"preferred":2,"treatment":2,"noncritically":2,"ill":2,"hospitalized":1,"individuals":1,"inadequate":1,"restricted":1,"oral":1,"intake":2,"an":1,"prandial":1,"components":1,"formost":1,"hospital":1,"ized":1,"adequate":1,"nutritional":1,"typically":1,"total":2,"daily":2,"dose":5,"cal":1,"culated":1,"based":1,"on":1,"body":1,"weight":1,"sensi":1,"tivity":1,"units":1,"kg":1,"day":1,"usual":1,"starting":1,"initial":1,"also":1,"be":1,"estimated":1,"from":1,"last":1,"infusion":1,"rate":1,"received":1,"previ":1,"ous":1,"hospitalization":1,"calculated":1,"home":1},"len":207},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":5,"chunkId":"ada-2026-hosp-p5-c2","text":"g/day as the usual starting dose ( 69 ). Initial total daily insulin dose may also be estimated from the last 6  8 h of insulin infusion rate or the insulin dose received in previ - ous hospitalization or calculated as 80% of the home insulin dose, as the situation applies. If calculating from the insulin in - fusion rate, about 60% of the calculated total daily dose should be used to account for glucotoxicity. Half of the estimated to - tal daily insulin should be given as basal insulin and half as nutritional insulin. Cor - rectional insulin scales should be propor - tional to the total daily dose of insulin e.g., low scale for insulin dose < 40 units/day, medium for 40  80 units/day, and high for > 80 units/day. Correctional insulin dosing should typically start at 140 or 150 mg/dL (7.8 or 8.3 mmol/L) for adequate glycemic management. Several reports indicate that inpatient use of insulin pens is safe and may improve nurse satisfac - tion when safety protocols, including nursing education and bar code scan - ning procedures, are in place to guar - antee single-person use ( 70  73 ). The decision to restart a home insulin plan upon hospitalization should take into account the individuals adoption of their insulin plan while at home as well as the change in their clinical status, in - cluding nutrition and kidney function. A randomized controlled trial has shown that basal","tf":{"40":2,"60":1,"69":1,"70":1,"73":1,"80":3,"140":1,"150":1,"day":4,"as":7,"the":12,"usual":1,"starting":1,"dose":7,"initial":1,"total":3,"daily":4,"insulin":15,"may":2,"also":1,"be":4,"estimated":2,"from":2,"last":1,"of":7,"infusion":1,"rate":2,"or":4,"received":1,"in":5,"previ":1,"ous":1,"hospitalization":2,"calculated":2,"home":3,"situation":1,"applies":1,"if":1,"calculating":1,"fusion":1,"about":1,"should":5,"used":1,"to":5,"account":2,"for":5,"glucotoxicity":1,"half":2,"tal":1,"given":1,"basal":2,"and":5,"nutritional":1,"cor":1,"rectional":1,"scales":1,"propor":1,"tional":1,"low":1,"scale":1,"units":3,"medium":1,"high":1,"correctional":1,"dosing":1,"typically":1,"start":1,"at":2,"mg":1,"dl":1,"mmol":1,"adequate":1,"glycemic":1,"management":1,"several":1,"reports":1,"indicate":1,"that":2,"inpatient":1,"use":2,"pens":1,"is":1,"safe":1,"improve":1,"nurse":1,"satisfac":1,"tion":1,"when":1,"safety":1,"protocols":1,"including":1,"nursing":1,"education":1,"bar":1,"code":1,"scan":1,"ning":1,"procedures":1,"are":1,"place":1,"guar":1,"antee":1,"single":1,"person":1,"decision":1,"restart":1,"plan":2,"upon":1,"take":1,"into":1,"individual":1,"adoption":1,"their":2,"while":1,"well":1,"change":1,"clinical":1,"status":1,"cluding":1,"nutrition":1,"kidney":1,"function":1,"randomized":1,"controlled":1,"trial":1,"has":1,"shown":1},"len":225},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":5,"chunkId":"ada-2026-hosp-p5-c3","text":"upon hospitalization should take into account the individuals adoption of their insulin plan while at home as well as the change in their clinical status, in - cluding nutrition and kidney function. A randomized controlled trial has shown that basal plus bolus insulin plan improved glycemic outcomes and reduced hospital complications compared with a correction or supplemental insulin without basal insu - lin (formerly known as sliding scale) for people with type 2 diabetes admitted for general surgery ( 74 ). Prolonged use of cor - rection or supplemental insulin without basal insulin is strongly discouraged in the inpatient setting, with the exception of people with type 2 diabetes in noncritical care with mild hyperglycemia or stress hy - perglycemia who maintain blood glucose < 180 mg/dL ( 75 , 76 ). A prospective randomized inpatient study of 70/30 intermediate-acting (NPH)/ regular insulin mixture versus basal-bolus therapy showed comparable glycemic out - comes but significantly increased hypogly - cemia in the group receiving the insulin mixture ( 77 ). Therefore, insulin mixtures such as 75/25, 70/30, or 50/50 insulins are not routinely recommended for in-hospital use. Data on the use of concentrated insulins such as glargine U-300, degludec U-200, and U-500 regular insulin in the inpatient and perioperative settings are limited and have shown variable results ( 78  8","tf":{"25":1,"30":2,"50":2,"70":2,"74":1,"75":2,"76":1,"77":1,"78":1,"180":1,"200":1,"300":1,"500":1,"upon":1,"hospitalization":1,"should":1,"take":1,"into":1,"account":1,"the":8,"individual":1,"adoption":1,"of":5,"their":2,"insulin":9,"plan":2,"while":1,"at":1,"home":1,"as":5,"well":1,"change":1,"in":7,"clinical":1,"status":1,"cluding":1,"nutrition":1,"and":5,"kidney":1,"function":1,"randomized":2,"controlled":1,"trial":1,"has":1,"shown":2,"that":1,"basal":4,"plus":1,"bolus":2,"improved":1,"glycemic":2,"outcomes":1,"reduced":1,"hospital":2,"complications":1,"compared":1,"with":5,"correction":1,"or":4,"supplemental":2,"without":2,"insu":1,"lin":1,"formerly":1,"known":1,"sliding":1,"scale":1,"for":3,"people":2,"type":2,"diabetes":2,"admitted":1,"general":1,"surgery":1,"prolonged":1,"use":3,"cor":1,"rection":1,"is":1,"strongly":1,"discouraged":1,"inpatient":3,"setting":1,"exception":1,"noncritical":1,"care":1,"mild":1,"hyperglycemia":1,"stress":1,"hy":1,"perglycemia":1,"who":1,"maintain":1,"blood":1,"glucose":1,"mg":1,"dl":1,"prospective":1,"study":1,"intermediate":1,"acting":1,"nph":1,"regular":2,"mixture":2,"versus":1,"therapy":1,"showed":1,"comparable":1,"out":1,"comes":1,"but":1,"significantly":1,"increased":1,"hypogly":1,"cemia":1,"group":1,"receiving":1,"therefore":1,"mixtures":1,"such":2,"insulins":2,"are":2,"not":1,"routinely":1,"recommended":1,"data":1,"on":1,"concentrated":1,"glargine":1,"degludec":1,"perioperative":1,"settings":1,"limited":1,"have":1,"variable":1,"results":1},"len":206},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":5,"chunkId":"ada-2026-hosp-p5-c4","text":"not routinely recommended for in-hospital use. Data on the use of concentrated insulins such as glargine U-300, degludec U-200, and U-500 regular insulin in the inpatient and perioperative settings are limited and have shown variable results ( 78  81 ). Hypoglycemia and dosing errors are a particular concern for individuals using U-500 insulin whose inpatient insulin needs are reduced up to 75% compared with home dosing regardless of preadmis - sion glycemia ( 82 ). If concentrated insulin must be used in a specific situation, the risk of dosing errors can be reduced by us - ing a pen device or having the dose drawn by a pharmacist. Consultation with a dia - betes care team should be considered in this situation. Type 1 Diabetes For people with type 1 diabetes, correc - tional insulin alone is contraindicated because insulin dosing based solely on premeal glucose levels does not account for basal insulin requirements or caloric intake and increases the risk of both hypo - glycemia and hyperglycemia ( 83 ). An insu - lin schedule with basal and correction components is necessary for all hospital - ized individuals with type 1 diabetes, even for those taking nothing by mouth, with the addition of prandial insulin when individuals are eating. Policies and prac - tice alerts in the EHR should be put in place to ensure that basal insulin (given subcutaneously, via insulin pump or b","tf":{"75":1,"78":1,"81":1,"82":1,"83":1,"200":1,"300":1,"500":2,"not":2,"routinely":1,"recommended":1,"for":6,"in":6,"hospital":2,"use":2,"data":1,"on":2,"the":7,"of":5,"concentrated":2,"insulins":1,"such":1,"as":1,"glargine":1,"degludec":1,"and":8,"regular":1,"insulin":10,"inpatient":2,"perioperative":1,"settings":1,"are":4,"limited":1,"have":1,"shown":1,"variable":1,"results":1,"hypoglycemia":1,"dosing":4,"errors":2,"particular":1,"concern":1,"individuals":3,"using":1,"whose":1,"needs":1,"reduced":2,"up":1,"to":2,"compared":1,"with":6,"home":1,"regardless":1,"preadmis":1,"sion":1,"glycemia":2,"if":1,"must":1,"be":4,"used":1,"specific":1,"situation":2,"risk":2,"can":1,"by":3,"us":1,"ing":1,"pen":1,"device":1,"or":3,"having":1,"dose":1,"drawn":1,"pharmacist":1,"consultation":1,"dia":1,"betes":1,"care":1,"team":1,"should":2,"considered":1,"this":1,"type":3,"diabetes":3,"people":1,"correc":1,"tional":1,"alone":1,"is":2,"contraindicated":1,"because":1,"based":1,"solely":1,"premeal":1,"glucose":1,"levels":1,"does":1,"account":1,"basal":3,"requirements":1,"caloric":1,"intake":1,"increases":1,"both":1,"hypo":1,"hyperglycemia":1,"an":1,"insu":1,"lin":1,"schedule":1,"correction":1,"components":1,"necessary":1,"all":1,"ized":1,"even":1,"those":1,"taking":1,"nothing":1,"mouth":1,"addition":1,"prandial":1,"when":1,"eating":1,"policies":1,"prac":1,"tice":1,"alerts":1,"ehr":1,"put":1,"place":1,"ensure":1,"that":1,"given":1,"subcutaneously":1,"via":1,"pump":1},"len":214},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":5,"chunkId":"ada-2026-hosp-p5-c5","text":"es, even for those taking nothing by mouth, with the addition of prandial insulin when individuals are eating. Policies and prac - tice alerts in the EHR should be put in place to ensure that basal insulin (given subcutaneously, via insulin pump or by in - sulin infusion) is not held for people with type 1 diabetes, especially during care transitions, and that ongoing prescriber and nursing education is provided ( 71 ). Noninsulin Therapies Recommendation 16.11 It is recommended that use of a sodium  glucose cotransporter 2 in - hibitor be initiated or continued during hospitalization if indicated for heart failure, providing there are no contra - indications. A While sodium  glucose cotransporter 2 (SGLT2) inhibitors are not recommended for glycemic management in the hospital setting, they may be initiated or contin - ued for people with type 2 diabetes hos - pitalized with heart failure if there are no contraindications and after recovery from the acute illness ( 84  89 ). SGLT2 in - hibitors should be avoided in cases of se - vere illness, in people with ketonemia or ketonuria, and during prolonged fasting and surgical procedures ( 90 ). Proactive adjustment of insulin and diuretic dosing is recommended during hospitalization and/or discharge, especially in collabora - tion with a cardiology/heart failure con - sultation team. It is recommended that diabetesjournals.org/c","tf":{"11":1,"16":1,"71":1,"84":1,"89":1,"90":1,"es":1,"even":1,"for":5,"those":1,"taking":1,"nothing":1,"by":2,"mouth":1,"with":6,"the":4,"addition":1,"of":4,"prandial":1,"insulin":4,"when":1,"individuals":1,"are":4,"eating":1,"policies":1,"and":8,"prac":1,"tice":1,"alerts":1,"in":9,"ehr":1,"should":2,"be":4,"put":1,"place":1,"to":1,"ensure":1,"that":4,"basal":1,"given":1,"subcutaneously":1,"via":1,"pump":1,"or":5,"sulin":1,"infusion":1,"is":5,"not":2,"held":1,"people":3,"type":2,"diabetes":2,"especially":2,"during":4,"care":1,"transitions":1,"ongoing":1,"prescriber":1,"nursing":1,"education":1,"provided":1,"noninsulin":1,"therapies":1,"recommendation":1,"it":2,"recommended":4,"use":1,"sodium":2,"glucose":2,"cotransporter":2,"hibitor":1,"initiated":2,"continued":1,"hospitalization":2,"if":2,"indicated":1,"heart":3,"failure":3,"providing":1,"there":2,"no":2,"contra":1,"indications":1,"while":1,"sglt2":2,"inhibitors":1,"glycemic":1,"management":1,"hospital":1,"setting":1,"they":1,"may":1,"contin":1,"ued":1,"hos":1,"pitalized":1,"contraindications":1,"after":1,"recovery":1,"from":1,"acute":1,"illness":2,"hibitors":1,"avoided":1,"cases":1,"se":1,"vere":1,"ketonemia":1,"ketonuria":1,"prolonged":1,"fasting":1,"surgical":1,"procedures":1,"proactive":1,"adjustment":1,"diuretic":1,"dosing":1,"discharge":1,"collabora":1,"tion":1,"cardiology":1,"con":1,"sultation":1,"team":1,"diabetesjournals":1,"org":1},"len":205},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":5,"chunkId":"ada-2026-hosp-p5-c6","text":"res ( 90 ). Proactive adjustment of insulin and diuretic dosing is recommended during hospitalization and/or discharge, especially in collabora - tion with a cardiology/heart failure con - sultation team. It is recommended that diabetesjournals.org/care Diabetes Care in the Hospital S343 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S339/848851/dc26s016.pdf by guest on 17 February 2026","tf":{"17":1,"49":1,"90":1,"2026":1,"848851":1,"res":1,"proactive":1,"adjustment":1,"of":1,"insulin":1,"and":2,"diuretic":1,"dosing":1,"is":2,"recommended":2,"during":1,"hospitalization":1,"or":1,"discharge":1,"especially":1,"in":2,"collabora":1,"tion":1,"with":1,"cardiology":1,"heart":1,"failure":1,"con":1,"sultation":1,"team":1,"it":1,"that":1,"diabetesjournals":2,"org":2,"care":3,"diabetes":1,"the":1,"hospital":1,"s343":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"supplement":1,"s339":1,"dc26s016":1,"by":1,"guest":1,"on":1,"february":1},"len":60},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":6,"chunkId":"ada-2026-hosp-p6-c0","text":"SGLT2 inhibitors be stopped 3 days be - fore scheduled surgeries (4 days for ertu - gliflozin) ( 90 ). A few randomized trials demonstrated the safety and efficacy of DPP-4i in specific groups of hospitalized people with diabe - tes ( 91  93 ). The use of DPP-4i with or without basal insulin may be a safer and simpler plan for people with mild to moderate hyperglycemia on admission (e.g., admission glucose < 180  200 mg/dL), with reduced risk of hypoglycemia ( 91 , 92 ). However, the FDA states that health care professionals should consider discontinu - ing saxagliptin and alogliptin in people who develop heart failure ( 94 ). It is worth noting that in the case of linagliptin, no re - nal dose adjustment is required. Data on the inpatient use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are still mostly limited to research studies and se - lect populations that are medically stable ( 95 , 96 ). Therefore, GLP-1 RA drugs should be held for acutely ill individuals in the hospital setting. HYPOGLYCEMIA People with or without diabetes may ex - perience hypoglycemia in the hospital set - ting. While hypoglycemia is associated with increased mortality ( 97 , 98 ), in many cases, it is a marker of an underlying dis - ease rather than the cause of fatality. However, hypoglycemia is a severe conse - quence of dysregulated metabolism and/or diabetes treatment, and it is im","tf":{"90":1,"91":2,"92":1,"93":1,"94":1,"95":1,"96":1,"97":1,"98":1,"180":1,"200":1,"sglt2":1,"inhibitors":1,"be":4,"stopped":1,"days":2,"fore":1,"scheduled":1,"surgeries":1,"for":3,"ertu":1,"gliflozin":1,"few":1,"randomized":1,"trials":1,"demonstrated":1,"the":8,"safety":1,"and":6,"efficacy":1,"of":9,"dpp":2,"4i":2,"in":6,"specific":1,"groups":1,"hospitalized":1,"people":4,"with":6,"diabe":1,"tes":1,"use":2,"or":3,"without":2,"basal":1,"insulin":1,"may":2,"safer":1,"simpler":1,"plan":1,"mild":1,"to":2,"moderate":1,"hyperglycemia":1,"on":2,"admission":2,"glucose":1,"mg":1,"dl":1,"reduced":1,"risk":1,"hypoglycemia":5,"however":2,"fda":1,"states":1,"that":3,"health":1,"care":1,"professionals":1,"should":2,"consider":1,"discontinu":1,"ing":1,"saxagliptin":1,"alogliptin":1,"who":1,"develop":1,"heart":1,"failure":1,"it":3,"is":6,"worth":1,"noting":1,"case":1,"linagliptin":1,"no":1,"re":1,"nal":1,"dose":1,"adjustment":1,"required":1,"data":1,"inpatient":1,"glucagon":1,"like":1,"peptide":1,"receptor":1,"agonists":1,"glp":2,"ras":1,"are":2,"still":1,"mostly":1,"limited":1,"research":1,"studies":1,"se":1,"lect":1,"populations":1,"medically":1,"stable":1,"therefore":1,"ra":1,"drugs":1,"held":1,"acutely":1,"ill":1,"individuals":1,"hospital":2,"setting":1,"diabetes":2,"ex":1,"perience":1,"set":1,"ting":1,"while":1,"associated":1,"increased":1,"mortality":1,"many":1,"cases":1,"marker":1,"an":1,"underlying":1,"dis":1,"ease":1,"rather":1,"than":1,"cause":1,"fatality":1,"severe":1,"conse":1,"quence":1,"dysregulated":1,"metabolism":1,"treatment":1,"im":1},"len":216},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":6,"chunkId":"ada-2026-hosp-p6-c1","text":"ted with increased mortality ( 97 , 98 ), in many cases, it is a marker of an underlying dis - ease rather than the cause of fatality. However, hypoglycemia is a severe conse - quence of dysregulated metabolism and/or diabetes treatment, and it is im - perative that it be minimized during hospitalization. Many episodes of inpa - tient hypoglycemia are preventable. A hypoglycemia prevention and manage - ment protocol should be adopted and implemented by each hospital or hospital system. A standardized hospital-wide, nurse-initiated hypoglycemia treatment protocol should be in place to immediately address blood glucose levels < 70 mg/dL ( < 3.9 mmol/L) ( 99 , 100 ). In addition, indi - vidualized plans for preventing and treat - ing hypoglycemia for each person should also be developed. The treatment plan should be reviewed any time a blood glu - cose value of < 70 mg/dL ( < 3.9 mmol/L) occurs, as this level often predicts sub - sequent level 3 hypoglycemia. Episodes of hypoglycemia in the hospital should be documented in the EHR and tracked ( 101 ). A key strategy is embedding hypo - glycemia treatment into all insulin and insulin infusion orders. Recommendations 16.12 A hypoglycemia management protocol should be adopted by all health systems. A plan for identify - ing, treating, and preventing hypo - glycemia should be established for each individual. Episodes of hypo - glycemi","tf":{"12":1,"16":1,"70":2,"97":1,"98":1,"99":1,"100":1,"101":1,"ted":1,"with":1,"increased":1,"mortality":1,"in":5,"many":2,"cases":1,"it":3,"is":4,"marker":1,"of":7,"an":1,"underlying":1,"dis":1,"ease":1,"rather":1,"than":1,"the":4,"cause":1,"fatality":1,"however":1,"hypoglycemia":8,"severe":1,"conse":1,"quence":1,"dysregulated":1,"metabolism":1,"and":8,"or":2,"diabetes":1,"treatment":4,"im":1,"perative":1,"that":1,"be":8,"minimized":1,"during":1,"hospitalization":1,"episodes":3,"inpa":1,"tient":1,"are":1,"preventable":1,"prevention":1,"manage":1,"ment":1,"protocol":3,"should":7,"adopted":2,"implemented":1,"by":2,"each":3,"hospital":4,"system":1,"standardized":1,"wide":1,"nurse":1,"initiated":1,"place":1,"to":1,"immediately":1,"address":1,"blood":2,"glucose":1,"levels":1,"mg":2,"dl":2,"mmol":2,"addition":1,"indi":1,"vidualized":1,"plans":1,"for":4,"preventing":2,"treat":1,"ing":2,"person":1,"also":1,"developed":1,"plan":2,"reviewed":1,"any":1,"time":1,"glu":1,"cose":1,"value":1,"occurs":1,"as":1,"this":1,"level":2,"often":1,"predicts":1,"sub":1,"sequent":1,"documented":1,"ehr":1,"tracked":1,"key":1,"strategy":1,"embedding":1,"hypo":3,"glycemia":2,"into":1,"all":2,"insulin":2,"infusion":1,"orders":1,"recommendations":1,"management":1,"health":1,"systems":1,"identify":1,"treating":1,"established":1,"individual":1,"glycemi":1},"len":202},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":6,"chunkId":"ada-2026-hosp-p6-c2","text":"fusion orders. Recommendations 16.12 A hypoglycemia management protocol should be adopted by all health systems. A plan for identify - ing, treating, and preventing hypo - glycemia should be established for each individual. Episodes of hypo - glycemia in the hospital should be documented in the health record and tracked to inform quality im - provements. C 16.13 Treatment plans should be re - viewed and changed as necessary to prevent hypoglycemia and recurrent hypoglycemia when a blood glucose value of < 70 mg/dL ( < 3.9 mmol/L) is documented. C Inpatient Hypoglycemia: Risk Factors, Treatment, and Prevention Insulin is one of the most common medica - tions that causes adverse events in hospi - talized individuals. Errors in insulin dosing, missed doses, and/or administration errors including incorrect insulin type and/or tim - ing of dose occur relatively frequently ( 102  104 ) and include prescriber (order - ing), pharmacy (dispensing), and nursing (administration) errors. Common prevent - able sources of iatrogenic hypoglycemia are improper prescribing of other glucose- lowering medications and inappropriate management and follow-up of the first epi - sode of hypoglycemia . Kidney failure is an important risk factor for hypoglycemia in the hospital ( 105 ), possibly as a result of decreased insulin clearance. Other related factors for hypoglycemia include advanced age, com","tf":{"12":1,"13":1,"16":2,"70":1,"102":1,"104":1,"105":1,"fusion":1,"orders":1,"recommendations":1,"hypoglycemia":8,"management":2,"protocol":1,"should":4,"be":4,"adopted":1,"by":1,"all":1,"health":2,"systems":1,"plan":1,"for":4,"identify":1,"ing":3,"treating":1,"and":11,"preventing":1,"hypo":2,"glycemia":2,"established":1,"each":1,"individual":1,"episodes":1,"of":9,"in":5,"the":5,"hospital":2,"documented":2,"record":1,"tracked":1,"to":2,"inform":1,"quality":1,"im":1,"provements":1,"treatment":2,"plans":1,"re":1,"viewed":1,"changed":1,"as":2,"necessary":1,"prevent":2,"recurrent":1,"when":1,"blood":1,"glucose":2,"value":1,"mg":1,"dl":1,"mmol":1,"is":3,"inpatient":1,"risk":2,"factors":2,"prevention":1,"insulin":4,"one":1,"most":1,"common":2,"medica":1,"tions":1,"that":1,"causes":1,"adverse":1,"events":1,"hospi":1,"talized":1,"individuals":1,"errors":3,"dosing":1,"missed":1,"doses":1,"or":2,"administration":2,"including":1,"incorrect":1,"type":1,"tim":1,"dose":1,"occur":1,"relatively":1,"frequently":1,"include":2,"prescriber":1,"order":1,"pharmacy":1,"dispensing":1,"nursing":1,"able":1,"sources":1,"iatrogenic":1,"are":1,"improper":1,"prescribing":1,"other":2,"lowering":1,"medications":1,"inappropriate":1,"follow":1,"up":1,"first":1,"epi":1,"sode":1,"kidney":1,"failure":1,"an":1,"important":1,"factor":1,"possibly":1,"result":1,"decreased":1,"clearance":1,"related":1,"advanced":1,"age":1,"com":1},"len":197},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":6,"chunkId":"ada-2026-hosp-p6-c3","text":"ow-up of the first epi - sode of hypoglycemia . Kidney failure is an important risk factor for hypoglycemia in the hospital ( 105 ), possibly as a result of decreased insulin clearance. Other related factors for hypoglycemia include advanced age, comorbidities including heart and liver failure, sepsis, and malnutrition, among others ( 106 ). Studies of bundled pre - ventive therapies, including proactive surveillance of glycemic outliers and an interprofessional data-driven approach to glycemic management, showed that hypoglycemic episodes in the hospital could be reduced or prevented ( 107 , 108 ). Compared with baseline, studies found that hypoglycemic events decreased by 56  80% ( 100 , 107 , 108 ). The Joint Com - mission, a quality improvement and pa - tient safety in health care organization, recommends that all hypoglycemic epi - sodes be evaluated for a root cause and the episodes be aggregated and reviewed to address systemic issues and possible solutions ( 26 ). In addition to errors with insulin treat - ment, iatrogenic hypoglycemia may occur after a sudden reduction of corticosteroid dose, reduced oral intake, emesis, inap - propriate timing of short- or rapid-acting insulin doses in relation to meals, reduced infusion rate of intravenous dextrose, un - expected interruption of enteral or paren - teral feedings, prolonged procedures or surgery, delayed or missed ","tf":{"26":1,"56":1,"80":1,"100":1,"105":1,"106":1,"107":2,"108":2,"ow":1,"up":1,"of":9,"the":5,"first":1,"epi":2,"sode":1,"hypoglycemia":4,"kidney":1,"failure":2,"is":1,"an":2,"important":1,"risk":1,"factor":1,"for":3,"in":5,"hospital":2,"possibly":1,"as":1,"result":1,"decreased":2,"insulin":3,"clearance":1,"other":1,"related":1,"factors":1,"include":1,"advanced":1,"age":1,"comorbidities":1,"including":2,"heart":1,"and":7,"liver":1,"sepsis":1,"malnutrition":1,"among":1,"others":1,"studies":2,"bundled":1,"pre":1,"ventive":1,"therapies":1,"proactive":1,"surveillance":1,"glycemic":2,"outliers":1,"interprofessional":1,"data":1,"driven":1,"approach":1,"to":4,"management":1,"showed":1,"that":3,"hypoglycemic":3,"episodes":2,"could":1,"be":3,"reduced":3,"or":5,"prevented":1,"compared":1,"with":2,"baseline":1,"found":1,"events":1,"by":1,"joint":1,"com":1,"mission":1,"quality":1,"improvement":1,"pa":1,"tient":1,"safety":1,"health":1,"care":1,"organization":1,"recommends":1,"all":1,"sodes":1,"evaluated":1,"root":1,"cause":1,"aggregated":1,"reviewed":1,"address":1,"systemic":1,"issues":1,"possible":1,"solutions":1,"addition":1,"errors":1,"treat":1,"ment":1,"iatrogenic":1,"may":1,"occur":1,"after":1,"sudden":1,"reduction":1,"corticosteroid":1,"dose":1,"oral":1,"intake":1,"emesis":1,"inap":1,"propriate":1,"timing":1,"short":1,"rapid":1,"acting":1,"doses":1,"relation":1,"meals":1,"infusion":1,"rate":1,"intravenous":1,"dextrose":1,"un":1,"expected":1,"interruption":1,"enteral":1,"paren":1,"teral":1,"feedings":1,"prolonged":1,"procedures":1,"surgery":1,"delayed":1,"missed":1},"len":197},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":6,"chunkId":"ada-2026-hosp-p6-c4","text":" inap - propriate timing of short- or rapid-acting insulin doses in relation to meals, reduced infusion rate of intravenous dextrose, un - expected interruption of enteral or paren - teral feedings, prolonged procedures or surgery, delayed or missed blood glucose checks, and altered ability of the individ - ual to report symptoms. Studies show promise for CGM to alert the wearer or care staff of impending hy - poglycemia, offering an opportunity to mitigate it before it happens ( 46 , 48 ). The use of personal CGM and AID devices may also help avoid hypoglycemia. Thus, the use of diabetes technology may help reduce the risk of hypoglycemia in future. Treatment of hypoglycemia includes administering 15 g of fast-acting carbohy - drate (to those who can swallow and do not have NPO status) or administering intravenous glucose or glucagon. Blood glucose should be monitored every 15 min and treatment hypoglycemia repeated until it is stabilized above 70 mg/dL (3.9 mmol/L). Predicting and Preventing Severe Hypoglycemia In people with diabetes, it is well estab - lished that an episode of severe hypogly - cemia increases the risk for a subsequent event, partly because of impaired coun - terregulation ( 109 ). In a study of hospi - talized individuals, 84% of people who had an episode of severe hypoglycemia (defined as < 40 mg/dL [ < 2.2 mmol/L]) had a preceding episode of hypoglycemia","tf":{"15":2,"40":1,"46":1,"48":1,"70":1,"84":1,"109":1,"inap":1,"propriate":1,"timing":1,"of":16,"short":1,"or":7,"rapid":1,"acting":2,"insulin":1,"doses":1,"in":4,"relation":1,"to":5,"meals":1,"reduced":1,"infusion":1,"rate":1,"intravenous":2,"dextrose":1,"un":1,"expected":1,"interruption":1,"enteral":1,"paren":1,"teral":1,"feedings":1,"prolonged":1,"procedures":1,"surgery":1,"delayed":1,"missed":1,"blood":2,"glucose":3,"checks":1,"and":5,"altered":1,"ability":1,"the":6,"individ":1,"ual":1,"report":1,"symptoms":1,"studies":1,"show":1,"promise":1,"for":2,"cgm":2,"alert":1,"wearer":1,"care":1,"staff":1,"impending":1,"hy":1,"poglycemia":1,"offering":1,"an":3,"opportunity":1,"mitigate":1,"it":4,"before":1,"happens":1,"use":2,"personal":1,"aid":1,"devices":1,"may":2,"also":1,"help":2,"avoid":1,"hypoglycemia":7,"thus":1,"diabetes":2,"technology":1,"reduce":1,"risk":2,"future":1,"treatment":2,"includes":1,"administering":2,"fast":1,"carbohy":1,"drate":1,"those":1,"who":2,"can":1,"swallow":1,"do":1,"not":1,"have":1,"npo":1,"status":1,"glucagon":1,"should":1,"be":1,"monitored":1,"every":1,"min":1,"repeated":1,"until":1,"is":2,"stabilized":1,"above":1,"mg":2,"dl":2,"mmol":2,"predicting":1,"preventing":1,"severe":3,"people":2,"with":1,"well":1,"estab":1,"lished":1,"that":1,"episode":3,"hypogly":1,"cemia":1,"increases":1,"subsequent":1,"event":1,"partly":1,"because":1,"impaired":1,"coun":1,"terregulation":1,"study":1,"hospi":1,"talized":1,"individuals":1,"had":2,"defined":1,"as":1,"preceding":1},"len":214},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":6,"chunkId":"ada-2026-hosp-p6-c5","text":"sequent event, partly because of impaired coun - terregulation ( 109 ). In a study of hospi - talized individuals, 84% of people who had an episode of severe hypoglycemia (defined as < 40 mg/dL [ < 2.2 mmol/L]) had a preceding episode of hypoglycemia ( < 70 mg/dL [ < 3.9 mmol/L]) during the same admission ( 110 ). In another study of hypoglycemic episodes (defined as < 50 mg/dL [ < 2.8 mmol/L]), 78% of indi - viduals were taking basal insulin, with the incidence of hypoglycemia peaking between midnight and 6:00 A . M . ( 111 ). Despite recognition of hypoglycemia, 75% of individuals did not have their dose of basal insulin changed before the next basal insulin administration ( 111 ). Several groups have developed algorithms to pre - dict episodes of hypoglycemia in the inpa - tient setting ( 112 , 113 ). Models such as these are potentially important and, once validated for general use, could provide a valuable tool to reduce rates of hypogly - cemia in the hospital. In one retrospective cohort study, a fasting blood glucose of < 100 mg/dL was shown to be a predictor of next-day hypoglycemia ( 38 ). S344 Diabetes Care in the Hospital Diabetes Care Volume 49, Supplement 1, January 2026 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S339/848851/dc26s016.pdf by guest on 17 February 2026","tf":{"17":1,"38":1,"40":1,"49":2,"50":1,"70":1,"75":1,"78":1,"84":1,"100":1,"109":1,"110":1,"111":2,"112":1,"113":1,"2026":2,"848851":1,"sequent":1,"event":1,"partly":1,"because":1,"of":15,"impaired":1,"coun":1,"terregulation":1,"in":6,"study":3,"hospi":1,"talized":1,"individuals":2,"people":1,"who":1,"had":2,"an":1,"episode":2,"severe":1,"hypoglycemia":6,"defined":2,"as":3,"mg":4,"dl":4,"mmol":3,"preceding":1,"during":1,"the":6,"same":1,"admission":1,"another":1,"hypoglycemic":1,"episodes":2,"indi":1,"viduals":1,"were":1,"taking":1,"basal":3,"insulin":3,"with":1,"incidence":1,"peaking":1,"between":1,"midnight":1,"and":2,"00":1,"despite":1,"recognition":1,"did":1,"not":1,"have":2,"their":1,"dose":1,"changed":1,"before":1,"next":2,"administration":1,"several":1,"groups":1,"developed":1,"algorithms":1,"to":3,"pre":1,"dict":1,"inpa":1,"tient":1,"setting":1,"models":1,"such":1,"these":1,"are":1,"potentially":1,"important":1,"once":1,"validated":1,"for":1,"general":1,"use":1,"could":1,"provide":1,"valuable":1,"tool":1,"reduce":1,"rates":1,"hypogly":1,"cemia":1,"hospital":2,"one":1,"retrospective":1,"cohort":1,"fasting":1,"blood":1,"glucose":1,"was":1,"shown":1,"be":1,"predictor":1,"day":1,"s344":1,"diabetes":2,"care":3,"volume":1,"supplement":2,"january":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"s339":1,"dc26s016":1,"by":1,"guest":1,"on":1,"february":1},"len":198},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":7,"chunkId":"ada-2026-hosp-p7-c0","text":"MEDICAL NUTRITION THERAPY IN THE HOSPITAL The goals of medical nutrition therapy in the hospital are to provide adequate calo - ries to meet metabolic demands, optimize glycemic outcomes, address personal food preferences, and facilitate the creation of a discharge plan. The ADA does not en - dorse any single meal plan or specified percentages of macronutrients. Current nutrition recommendations advise indi - vidualization based on treatment goals, physiological parameters, and medication use. Controlled carbohydrate meal plans, where the amount of carbohydrate on each meal tray is calculated, are pre - ferred by many hospitals, as they facilitate matching the prandial insulin dose to the amount of carbohydrate given ( 114 ). Or - ders should also indicate that the glucose check, meal delivery, and nutritional insu - lin coverage should be coordinateda concept also known as a meal triadas their variability often creates the possibil - ity of hyperglycemic and hypoglycemic events ( 20 ). Some hospitals offer meals on demand, where individuals may order meals from the menu at any time during the day. This option improves patient sat - isfaction with hospital but complicates glucose monitoring  insulin  meal coordi - nation and can lead to insulin stacking if meals are too close together ( 115 ). Fi - nally, if the hospital food service supports carbohydrate counting, this","tf":{"20":1,"114":1,"115":1,"medical":2,"nutrition":3,"therapy":2,"in":2,"the":13,"hospital":4,"goals":2,"of":6,"are":3,"to":4,"provide":1,"adequate":1,"calo":1,"ries":1,"meet":1,"metabolic":1,"demands":1,"optimize":1,"glycemic":1,"outcomes":1,"address":1,"personal":1,"food":2,"preferences":1,"and":5,"facilitate":2,"creation":1,"discharge":1,"plan":2,"ada":1,"does":1,"not":1,"en":1,"dorse":1,"any":2,"single":1,"meal":6,"or":2,"specified":1,"percentages":1,"macronutrients":1,"current":1,"recommendations":1,"advise":1,"indi":1,"vidualization":1,"based":1,"on":3,"treatment":1,"physiological":1,"parameters":1,"medication":1,"use":1,"controlled":1,"carbohydrate":4,"plans":1,"where":2,"amount":2,"each":1,"tray":1,"is":1,"calculated":1,"pre":1,"ferred":1,"by":1,"many":1,"hospitals":2,"as":3,"they":1,"matching":1,"prandial":1,"insulin":3,"dose":1,"given":1,"ders":1,"should":2,"also":2,"indicate":1,"that":1,"glucose":2,"check":1,"delivery":1,"nutritional":1,"insu":1,"lin":1,"coverage":1,"be":1,"coordinated":1,"concept":1,"known":1,"triad":1,"their":1,"variability":1,"often":1,"creates":1,"possibil":1,"ity":1,"hyperglycemic":1,"hypoglycemic":1,"events":1,"some":1,"offer":1,"meals":3,"demand":1,"individuals":1,"may":1,"order":1,"from":1,"menu":1,"at":1,"time":1,"during":1,"day":1,"this":2,"option":1,"improves":1,"patient":1,"sat":1,"isfaction":1,"with":1,"but":1,"complicates":1,"monitoring":1,"coordi":1,"nation":1,"can":1,"lead":1,"stacking":1,"if":2,"too":1,"close":1,"together":1,"fi":1,"nally":1,"service":1,"supports":1,"counting":1},"len":204},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":7,"chunkId":"ada-2026-hosp-p7-c1","text":" sat - isfaction with hospital but complicates glucose monitoring  insulin  meal coordi - nation and can lead to insulin stacking if meals are too close together ( 115 ). Fi - nally, if the hospital food service supports carbohydrate counting, this option should be made available to people with diabe - tes counting carbohydrates at home, es - pecially people wearing insulin pumps ( 115 , 116 ). SELF-MANAGEMENT IN THE HOSPITAL Diabetes self-management in the hospi - tal may be appropriate for select indi - viduals who wish to continue to perform self-care while acutely ill ( 117  119 ). Candidates include children with paren - tal supervision, adolescents, and adults who successfully perform diabetes self- management at home and whose cognitive and physical skills needed to successfully self-administer insulin and perform glu - cose monitoring are not compromised by acute illness or delirium ( 7 ). In addition, they should have adequate oral intake and have stable insulin requirements. If self- management is supported, a policy should include a requirement that people with diabetes and the care team agree on a daily basis during hospitalization that self- management is appropriate. Hospital per - sonal medication policies may include guidance for people with diabetes who wish to take their own or hospital-dispensed insu - lin and noninsulin medications during their hospital s","tf":{"115":2,"116":1,"117":1,"119":1,"sat":1,"isfaction":1,"with":5,"hospital":6,"but":1,"complicates":1,"glucose":1,"monitoring":2,"insulin":5,"meal":1,"coordi":1,"nation":1,"and":8,"can":1,"lead":1,"to":6,"stacking":1,"if":3,"meals":1,"are":2,"too":1,"close":1,"together":1,"fi":1,"nally":1,"the":4,"food":1,"service":1,"supports":1,"carbohydrate":1,"counting":2,"this":1,"option":1,"should":3,"be":2,"made":1,"available":1,"people":4,"diabe":1,"tes":1,"carbohydrates":1,"at":2,"home":2,"es":1,"pecially":1,"wearing":1,"pumps":1,"self":7,"management":5,"in":3,"diabetes":4,"hospi":1,"tal":2,"may":2,"appropriate":2,"for":2,"select":1,"indi":1,"viduals":1,"who":3,"wish":2,"continue":1,"perform":3,"care":2,"while":1,"acutely":1,"ill":1,"candidates":1,"include":3,"children":1,"paren":1,"supervision":1,"adolescents":1,"adults":1,"successfully":2,"whose":1,"cognitive":1,"physical":1,"skills":1,"needed":1,"administer":1,"glu":1,"cose":1,"not":1,"compromised":1,"by":1,"acute":1,"illness":1,"or":2,"delirium":1,"addition":1,"they":1,"have":2,"adequate":1,"oral":1,"intake":1,"stable":1,"requirements":1,"is":2,"supported":1,"policy":1,"requirement":1,"that":2,"team":1,"agree":1,"on":1,"daily":1,"basis":1,"during":2,"hospitalization":1,"per":1,"sonal":1,"medication":1,"policies":1,"guidance":1,"take":1,"their":2,"own":1,"dispensed":1,"insu":1,"lin":1,"noninsulin":1,"medications":1},"len":203},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":7,"chunkId":"ada-2026-hosp-p7-c2","text":"ospitalization that self- management is appropriate. Hospital per - sonal medication policies may include guidance for people with diabetes who wish to take their own or hospital-dispensed insu - lin and noninsulin medications during their hospital stay. A hospital policy for personal medication may include a pharmacy ex - ception on a case-by-case basis as deter - mined in consultation with the care team. Pharmacy must verify any home medica - tion and require a prescriber order for the individual to self-administer home or hospital-dispensed medication under the supervision of the registered nurse. If an insulin pump or CGM device is worn, hos - pital policy and procedures delineating guidelines for wearing an insulin pump and/or CGM device should be developed according to consensus guidelines, includ - ing the changing of insulin infusion sites and CGM glucose sensors ( 120 ). STANDARDS FOR SPECIAL SITUATIONS Enteral and Parenteral Feedings For individuals receiving enteral or par - enteral nutrition who require insulin, the insulin orders should include cover - age of basal, prandial, and correctional needs ( 115 ). It is essential that people with type 1 diabetes continue to re - ceive basal insulin even if feedings are discontinued. Commercially available enteral nutrition preparations contain variable amounts of carbohydrates and may be infused at dif - ferent rates ( 11","tf":{"11":1,"115":1,"120":1,"ospitalization":1,"that":2,"self":2,"management":1,"is":3,"appropriate":1,"hospital":5,"per":1,"sonal":1,"medication":3,"policies":1,"may":3,"include":3,"guidance":1,"for":6,"people":2,"with":3,"diabetes":2,"who":2,"wish":1,"to":4,"take":1,"their":2,"own":1,"or":5,"dispensed":2,"insu":1,"lin":1,"and":8,"noninsulin":1,"medications":1,"during":1,"stay":1,"policy":2,"personal":1,"pharmacy":2,"ex":1,"ception":1,"on":1,"case":2,"by":1,"basis":1,"as":1,"deter":1,"mined":1,"in":1,"consultation":1,"the":6,"care":1,"team":1,"must":1,"verify":1,"any":1,"home":2,"medica":1,"tion":1,"require":2,"prescriber":1,"order":1,"individual":1,"administer":1,"under":1,"supervision":1,"of":4,"registered":1,"nurse":1,"if":2,"an":2,"insulin":6,"pump":2,"cgm":3,"device":2,"worn":1,"hos":1,"pital":1,"procedures":1,"delineating":1,"guidelines":2,"wearing":1,"should":2,"be":2,"developed":1,"according":1,"consensus":1,"includ":1,"ing":1,"changing":1,"infusion":1,"sites":1,"glucose":1,"sensors":1,"standards":1,"special":1,"situations":1,"enteral":4,"parenteral":1,"feedings":2,"individuals":1,"receiving":1,"par":1,"nutrition":2,"orders":1,"cover":1,"age":1,"basal":2,"prandial":1,"correctional":1,"needs":1,"it":1,"essential":1,"type":1,"continue":1,"re":1,"ceive":1,"even":1,"are":1,"discontinued":1,"commercially":1,"available":1,"preparations":1,"contain":1,"variable":1,"amounts":1,"carbohydrates":1,"infused":1,"at":1,"dif":1,"ferent":1,"rates":1},"len":205},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":7,"chunkId":"ada-2026-hosp-p7-c3","text":"ial that people with type 1 diabetes continue to re - ceive basal insulin even if feedings are discontinued. Commercially available enteral nutrition preparations contain variable amounts of carbohydrates and may be infused at dif - ferent rates ( 116 ) that may affect nutri - tional insulin needs. Most adults receiving basal insulin should continue with their basal dose, while the insulin dose for the total daily nutritional component may be calculated as 1 unit of insulin for every 10  15 g of carbohydrate in the enteral and parenteral formulations. To avoid hy - poglycemia, it is important not to cover all insulin needs using basal insulin only. Rapid-acting insulin every 4 h, regular insulin every 6 h, or NPH insulin every 8  12 h are options for coverage of nutri - tional needs during continuous adminis - tration of enteral tube feeds. However, a regular insulin  based plan has been associ - ated with better glycemic management with fewer daily injections in individuals receiving continuous tube feeds ( 121 ). An automated self-adjusting insulin al - gorithm was shown to be safe and ef - fective in controlling hyperglycemia in hospitalized individuals receiving enteral nutrition or total parenteral nutrition ( 122 ). Correctional insulin should also be adminis - tered subcutaneously every 6 h with regu - lar human insulin or rapid-acting insulin every 4 h. If enteral nu","tf":{"10":1,"12":1,"15":1,"116":1,"121":1,"122":1,"ial":1,"that":2,"people":1,"with":5,"type":1,"diabetes":1,"continue":2,"to":4,"re":1,"ceive":1,"basal":4,"insulin":15,"even":1,"if":2,"feedings":1,"are":2,"discontinued":1,"commercially":1,"available":1,"enteral":5,"nutrition":3,"preparations":1,"contain":1,"variable":1,"amounts":1,"of":5,"carbohydrates":1,"and":3,"may":3,"be":4,"infused":1,"at":1,"dif":1,"ferent":1,"rates":1,"affect":1,"nutri":2,"tional":2,"needs":3,"most":1,"adults":1,"receiving":3,"should":2,"their":1,"dose":2,"while":1,"the":3,"for":3,"total":2,"daily":2,"nutritional":1,"component":1,"calculated":1,"as":1,"unit":1,"every":6,"carbohydrate":1,"in":4,"parenteral":2,"formulations":1,"avoid":1,"hy":1,"poglycemia":1,"it":1,"is":1,"important":1,"not":1,"cover":1,"all":1,"using":1,"only":1,"rapid":2,"acting":2,"regular":2,"or":3,"nph":1,"options":1,"coverage":1,"during":1,"continuous":2,"adminis":2,"tration":1,"tube":2,"feeds":2,"however":1,"based":1,"plan":1,"has":1,"been":1,"associ":1,"ated":1,"better":1,"glycemic":1,"management":1,"fewer":1,"injections":1,"individuals":2,"an":1,"automated":1,"self":1,"adjusting":1,"al":1,"gorithm":1,"was":1,"shown":1,"safe":1,"ef":1,"fective":1,"controlling":1,"hyperglycemia":1,"hospitalized":1,"correctional":1,"also":1,"tered":1,"subcutaneously":1,"regu":1,"lar":1,"human":1,"nu":1},"len":203},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":7,"chunkId":"ada-2026-hosp-p7-c4","text":"in hospitalized individuals receiving enteral nutrition or total parenteral nutrition ( 122 ). Correctional insulin should also be adminis - tered subcutaneously every 6 h with regu - lar human insulin or rapid-acting insulin every 4 h. If enteral nutrition is interrupted, intravenous dextrose may be given for du - ration of active insulin time. For adults receiving enteral bolus feed - ings, approximately 1 unit of rapid-acting insulin per every 10  15 g of carbohydrate should be given subcutaneously before each feeding. To mitigate any hyperglyce - mia, correctional insulin should be added as needed before each feeding. In individuals receiving nocturnal tube feeding, NPH insulin administered along with the initiation of the feeding to cover this nutritional load is a reasonable approach. For individuals receiving continuous pe - ripheral or central parenteral nutrition, hu - man regular insulin may be added to the total parenteral nutrition solution, particu - larly if > 20 units of correctional insulin have been required in the past 24 h. A starting dose of 1 unit of regular human in - sulin for every 10 g of dextrose has been recommended ( 115 ) and should be ad - justed daily in the solution. Adding insulin to the parenteral nutrition bag is the safest way to prevent hypoglycemia if the paren - teral nutrition is stopped or interrupted, though subcutaneous insulin glargi","tf":{"10":2,"15":1,"20":1,"24":1,"115":1,"122":1,"in":5,"hospitalized":1,"individuals":3,"receiving":4,"enteral":3,"nutrition":7,"or":4,"total":2,"parenteral":4,"correctional":3,"insulin":11,"should":4,"also":1,"be":6,"adminis":1,"tered":1,"subcutaneously":2,"every":4,"with":2,"regu":1,"lar":1,"human":2,"rapid":2,"acting":2,"if":3,"is":4,"interrupted":2,"intravenous":1,"dextrose":2,"may":2,"given":2,"for":4,"du":1,"ration":1,"of":8,"active":1,"time":1,"adults":1,"bolus":1,"feed":1,"ings":1,"approximately":1,"unit":2,"per":1,"carbohydrate":1,"before":2,"each":2,"feeding":4,"to":5,"mitigate":1,"any":1,"hyperglyce":1,"mia":1,"added":2,"as":1,"needed":1,"nocturnal":1,"tube":1,"nph":1,"administered":1,"along":1,"the":8,"initiation":1,"cover":1,"this":1,"nutritional":1,"load":1,"reasonable":1,"approach":1,"continuous":1,"pe":1,"ripheral":1,"central":1,"hu":1,"man":1,"regular":2,"solution":2,"particu":1,"larly":1,"units":1,"have":1,"been":2,"required":1,"past":1,"starting":1,"dose":1,"sulin":1,"has":1,"recommended":1,"and":1,"ad":1,"justed":1,"daily":1,"adding":1,"bag":1,"safest":1,"way":1,"prevent":1,"hypoglycemia":1,"paren":1,"teral":1,"stopped":1,"though":1,"subcutaneous":1,"glargi":1},"len":204},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":7,"chunkId":"ada-2026-hosp-p7-c5","text":"recommended ( 115 ) and should be ad - justed daily in the solution. Adding insulin to the parenteral nutrition bag is the safest way to prevent hypoglycemia if the paren - teral nutrition is stopped or interrupted, though subcutaneous insulin glargine has been shown to achieve equivalent man - agement of glycemia ( 123 ). Correctional insulin should be administered subcutane - ously to address any hyperglycemia. Because continuous enteral or par - enteral nutrition results in a continuous postprandial state, efforts to bring blood glucose levels to below 140 mg/dL (7.8 mmol/L) substantially increase the risk of hypoglycemia in these individuals. Glucocorticoid Therapy The prevalence of consistent use of glu - cocorticoid therapy in hospitalized indi - viduals can approach 10  15%, and these medications can induce hyperglycemia in 56  86% of these individuals with and without preexisting diabetes ( 124  126 ). Glucocorticoid type and duration of action must be considered in determining appro - priate insulin treatments. Daily-ingested in - termediate-acting glucocorticoids such as prednisone reach peak plasma levels in 4  6 h but have pharmacologic actions that can last throughout the day. When diabetesjournals.org/care Diabetes Care in the Hospital S345 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S339/848851/dc26s016.pdf by guest on 17 Febr","tf":{"10":1,"15":1,"17":1,"49":1,"56":1,"86":1,"115":1,"123":1,"124":1,"126":1,"140":1,"848851":1,"recommended":1,"and":4,"should":2,"be":3,"ad":1,"justed":1,"daily":2,"in":9,"the":8,"solution":1,"adding":1,"insulin":4,"to":6,"parenteral":1,"nutrition":3,"bag":1,"is":2,"safest":1,"way":1,"prevent":1,"hypoglycemia":2,"if":1,"paren":1,"teral":1,"stopped":1,"or":2,"interrupted":1,"though":1,"subcutaneous":1,"glargine":1,"has":1,"been":1,"shown":1,"achieve":1,"equivalent":1,"man":1,"agement":1,"of":6,"glycemia":1,"correctional":1,"administered":1,"subcutane":1,"ously":1,"address":1,"any":1,"hyperglycemia":2,"because":1,"continuous":2,"enteral":2,"par":1,"results":1,"postprandial":1,"state":1,"efforts":1,"bring":1,"blood":1,"glucose":1,"levels":2,"below":1,"mg":1,"dl":1,"mmol":1,"substantially":1,"increase":1,"risk":1,"these":3,"individuals":2,"glucocorticoid":2,"therapy":2,"prevalence":1,"consistent":1,"use":1,"glu":1,"cocorticoid":1,"hospitalized":1,"indi":1,"viduals":1,"can":3,"approach":1,"medications":1,"induce":1,"with":1,"without":1,"preexisting":1,"diabetes":2,"type":1,"duration":1,"action":1,"must":1,"considered":1,"determining":1,"appro":1,"priate":1,"treatments":1,"ingested":1,"termediate":1,"acting":1,"glucocorticoids":1,"such":1,"as":1,"prednisone":1,"reach":1,"peak":1,"plasma":1,"but":1,"have":1,"pharmacologic":1,"actions":1,"that":1,"last":1,"throughout":1,"day":1,"when":1,"diabetesjournals":2,"org":2,"care":3,"hospital":1,"s345":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"supplement":1,"s339":1,"dc26s016":1,"by":1,"guest":1,"on":1,"febr":1},"len":199},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":7,"chunkId":"ada-2026-hosp-p7-c6","text":"t have pharmacologic actions that can last throughout the day. When diabetesjournals.org/care Diabetes Care in the Hospital S345 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S339/848851/dc26s016.pdf by guest on 17 February 2026","tf":{"17":1,"49":1,"2026":1,"848851":1,"have":1,"pharmacologic":1,"actions":1,"that":1,"can":1,"last":1,"throughout":1,"the":2,"day":1,"when":1,"diabetesjournals":2,"org":2,"care":3,"diabetes":1,"in":1,"hospital":1,"s345":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"supplement":1,"s339":1,"dc26s016":1,"by":1,"guest":1,"on":1,"february":1},"len":39},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":8,"chunkId":"ada-2026-hosp-p8-c0","text":"monitored by CGM, the typical glycemic pattern for individuals treated with daily prednisone or prednisolone, administered in the morning, is characterized by normal or mild fasting hyperglycemia, with trends of increasing hyperglycemia during the afternoon, and peaking in the evening. These hyperglycemic excursions are more pronounced in individuals with type 2 diabetes than in those without diabetes ( 127 ). For individuals treated with once- or twice-daily steroids, administering NPH insulin with prednisone or prednisolone dosing is a frequently used approach, aimed at matching the NPH actions with the steroid-induced hyperglycemic response. NPH may be administered in addition to daily basal-bolus insulin or in addition to oral glucose-lowering medica - tions, depending on the type of diabetes and recent diabetes medication prior to starting steroids ( 128 ). Because NPH action peaks about 4  6 h after administration, it is recommended that it be administered concomitantly with intermediate-acting steroids ( 129 ). For long-acting glucocorti - coids such as dexamethasone and multi - dose or continuous glucocorticoid use, long-acting basal insulin may be required to manage fasting blood glucose levels. For higher doses of glucocorticoids, in - creasing doses of prandial (if eating) and correction insulin, sometimes as much as 40  60% or more, are often needed in ad - dition","tf":{"40":1,"60":1,"127":1,"128":1,"129":1,"monitored":1,"by":2,"cgm":1,"the":7,"typical":1,"glycemic":1,"pattern":1,"for":4,"individuals":3,"treated":2,"with":7,"daily":3,"prednisone":2,"or":7,"prednisolone":2,"administered":3,"in":8,"morning":1,"is":3,"characterized":1,"normal":1,"mild":1,"fasting":2,"hyperglycemia":2,"trends":1,"of":4,"increasing":1,"during":1,"afternoon":1,"and":4,"peaking":1,"evening":1,"these":1,"hyperglycemic":2,"excursions":1,"are":2,"more":2,"pronounced":1,"type":2,"diabetes":4,"than":1,"those":1,"without":1,"once":1,"twice":1,"steroids":3,"administering":1,"nph":4,"insulin":4,"dosing":1,"frequently":1,"used":1,"approach":1,"aimed":1,"at":1,"matching":1,"actions":1,"steroid":1,"induced":1,"response":1,"may":2,"be":3,"addition":2,"to":4,"basal":2,"bolus":1,"oral":1,"glucose":2,"lowering":1,"medica":1,"tions":1,"depending":1,"on":1,"recent":1,"medication":1,"prior":1,"starting":1,"because":1,"action":1,"peaks":1,"about":1,"after":1,"administration":1,"it":2,"recommended":1,"that":1,"concomitantly":1,"intermediate":1,"acting":3,"long":2,"glucocorti":1,"coids":1,"such":1,"as":3,"dexamethasone":1,"multi":1,"dose":1,"continuous":1,"glucocorticoid":1,"use":1,"required":1,"manage":1,"blood":1,"levels":1,"higher":1,"doses":2,"glucocorticoids":1,"creasing":1,"prandial":1,"if":1,"eating":1,"correction":1,"sometimes":1,"much":1,"often":1,"needed":1,"ad":1,"dition":1},"len":202},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":8,"chunkId":"ada-2026-hosp-p8-c1","text":"ting basal insulin may be required to manage fasting blood glucose levels. For higher doses of glucocorticoids, in - creasing doses of prandial (if eating) and correction insulin, sometimes as much as 40  60% or more, are often needed in ad - dition to basal insulin ( 130 , 131 ). A retro - spective study found that increasing the ratio of insulin to steroids was positively associated with improved time in range (70  180 mg/dL [3.9  10.0 mmol/L]); how - ever, there was an increase in hypoglyce - mia ( 125 ). If insulin orders are initiated, daily adjustments based on levels of gly - cemia and anticipated changes in type, dosages, and duration of glucocorticoids, along with POC blood glucose monitoring, are critical to reducing hypoglycemia and hyperglycemia. Perioperative Care It is estimated that up to 20% of indi - viduals undergoing major general surgery have diabetes, and 23  60% have predia - betes or undiagnosed diabetes. Surgical stress and counterregulatory hormone release increase the risk of hyperglyce - mia as well as mortality, infection, and length of stay ( 131 , 132 ). Perioperative hyperglycemia is a risk factor for postop - erative infections and other complications ( 133 , 134 ). A meta-analysis showed that preoperative and perioperative hypergly - cemia were associated with surgical site infections ( 135 ). The glycemic threshold for an increase in compli","tf":{"10":1,"20":1,"23":1,"40":1,"60":2,"70":1,"125":1,"130":1,"131":2,"132":1,"133":1,"134":1,"135":1,"180":1,"ting":1,"basal":2,"insulin":5,"may":1,"be":1,"required":1,"to":5,"manage":1,"fasting":1,"blood":2,"glucose":2,"levels":2,"for":3,"higher":1,"doses":2,"of":8,"glucocorticoids":2,"in":6,"creasing":1,"prandial":1,"if":2,"eating":1,"and":9,"correction":1,"sometimes":1,"as":4,"much":1,"or":2,"more":1,"are":3,"often":1,"needed":1,"ad":1,"dition":1,"retro":1,"spective":1,"study":1,"found":1,"that":3,"increasing":1,"the":3,"ratio":1,"steroids":1,"was":2,"positively":1,"associated":2,"with":3,"improved":1,"time":1,"range":1,"mg":1,"dl":1,"mmol":1,"how":1,"ever":1,"there":1,"an":2,"increase":3,"hypoglyce":1,"mia":2,"orders":1,"initiated":1,"daily":1,"adjustments":1,"based":1,"on":1,"gly":1,"cemia":2,"anticipated":1,"changes":1,"type":1,"dosages":1,"duration":1,"along":1,"poc":1,"monitoring":1,"critical":1,"reducing":1,"hypoglycemia":1,"hyperglycemia":2,"perioperative":3,"care":1,"it":1,"is":2,"estimated":1,"up":1,"indi":1,"viduals":1,"undergoing":1,"major":1,"general":1,"surgery":1,"have":2,"diabetes":2,"predia":1,"betes":1,"undiagnosed":1,"surgical":2,"stress":1,"counterregulatory":1,"hormone":1,"release":1,"risk":2,"hyperglyce":1,"well":1,"mortality":1,"infection":1,"length":1,"stay":1,"factor":1,"postop":1,"erative":1,"infections":2,"other":1,"complications":1,"meta":1,"analysis":1,"showed":1,"preoperative":1,"hypergly":1,"were":1,"site":1,"glycemic":1,"threshold":1,"compli":1},"len":206},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":8,"chunkId":"ada-2026-hosp-p8-c2","text":"for postop - erative infections and other complications ( 133 , 134 ). A meta-analysis showed that preoperative and perioperative hypergly - cemia were associated with surgical site infections ( 135 ). The glycemic threshold for an increase in complications is esti - mated to be somewhere between 100 and 180 mg/dL (5.5 and 10 mmol/L) in most of these studies ( 135  138 ). Overall evidence supports preadmission treat - ment of hyperglycemia in people sched - uled for elective surgery as an effective means of reducing adverse outcomes ( 139 , 140 ). Current data also suggest an optimal A1C goal between 7% and 8% preoperatively, as it is associated with better glycemic management in the perioperative period and decreased length of hospital stay ( 139 , 141  144 ). If available, 14-day CGM data with a glucose manage - ment indicator < 8% or time in range > 50% before elective surgery may be used in lieu of A1C as evidence of ade - quate preoperative glycemic management. However, due to lack of interventional data, postponing surgery based on A1C or glucose management indicator alone is not recommended, as it may lead to un - necessary delay or denying of required sur - gery. Some institutions have developed optimization programs to lower A1C prior to elective surgery. These programs have been shown to result in improved perioper - ative glycemic management and decreased length of","tf":{"10":1,"14":1,"50":1,"100":1,"133":1,"134":1,"135":2,"138":1,"139":2,"140":1,"141":1,"144":1,"180":1,"for":3,"postop":1,"erative":1,"infections":2,"and":7,"other":1,"complications":2,"meta":1,"analysis":1,"showed":1,"that":1,"preoperative":2,"perioperative":2,"hypergly":1,"cemia":1,"were":1,"associated":2,"with":3,"surgical":1,"site":1,"the":2,"glycemic":4,"threshold":1,"an":3,"increase":1,"in":7,"is":3,"esti":1,"mated":1,"to":6,"be":2,"somewhere":1,"between":2,"mg":1,"dl":1,"mmol":1,"most":1,"of":9,"these":2,"studies":1,"overall":1,"evidence":2,"supports":1,"preadmission":1,"treat":1,"ment":2,"hyperglycemia":1,"people":1,"sched":1,"uled":1,"elective":3,"surgery":4,"as":4,"effective":1,"means":1,"reducing":1,"adverse":1,"outcomes":1,"current":1,"data":3,"also":1,"suggest":1,"optimal":1,"a1c":4,"goal":1,"preoperatively":1,"it":2,"better":1,"management":4,"period":1,"decreased":2,"length":2,"hospital":1,"stay":1,"if":1,"available":1,"day":1,"cgm":1,"glucose":2,"manage":1,"indicator":2,"or":3,"time":1,"range":1,"before":1,"may":2,"used":1,"lieu":1,"ade":1,"quate":1,"however":1,"due":1,"lack":1,"interventional":1,"postponing":1,"based":1,"on":1,"alone":1,"not":1,"recommended":1,"lead":1,"un":1,"necessary":1,"delay":1,"denying":1,"required":1,"sur":1,"gery":1,"some":1,"institutions":1,"have":2,"developed":1,"optimization":1,"programs":2,"lower":1,"prior":1,"been":1,"shown":1,"result":1,"improved":1,"perioper":1,"ative":1},"len":210},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":8,"chunkId":"ada-2026-hosp-p8-c3","text":" delay or denying of required sur - gery. Some institutions have developed optimization programs to lower A1C prior to elective surgery. These programs have been shown to result in improved perioper - ative glycemic management and decreased length of hospital stay after surgery ( 139 ). In individuals undergoing noncardiac gen - eral surgery, basal insulin plus premeal short- or rapid-acting insulin (basal-bolus) coverage has been associated with im - proved glycemic outcomes and lower rates of perioperative complications compared with the reactive, correction-only short- or rapid-acting insulin coverage alone with no basal insulin dosing ( 74 , 145 ). In addition to glycemic goals, the following points need attention: 1. Stricter perioperative glycemic goals are not advised because they may not improve outcomes and are associated with increased hypoglycemia ( 146 ). 2. Blood glucose should be monitored at least every 2  4 h while the indi - vidual takes nothing by mouth, and insulin should be administered as needed. Insulin is the only recom - mended glucose-lowering medica - tion in the perioperative period. 3. CGM should not be used alone for glucose monitoring during surgery ( 147 ). 4. Metformin and other oral glucose- lowering agents should be held on the day of surgery or procedure. See below for SGLT2 inhibitor and GLP-1 RA use in the perioperative period. 5. Individua","tf":{"74":1,"139":1,"145":1,"146":1,"147":1,"delay":1,"or":4,"denying":1,"of":4,"required":1,"sur":1,"gery":1,"some":1,"institutions":1,"have":2,"developed":1,"optimization":1,"programs":2,"to":4,"lower":2,"a1c":1,"prior":1,"elective":1,"surgery":5,"these":1,"been":2,"shown":1,"result":1,"in":5,"improved":1,"perioper":1,"ative":1,"glycemic":4,"management":1,"and":6,"decreased":1,"length":1,"hospital":1,"stay":1,"after":1,"individuals":1,"undergoing":1,"noncardiac":1,"gen":1,"eral":1,"basal":3,"insulin":6,"plus":1,"premeal":1,"short":2,"rapid":2,"acting":2,"bolus":1,"coverage":2,"has":1,"associated":2,"with":4,"im":1,"proved":1,"outcomes":2,"rates":1,"perioperative":4,"complications":1,"compared":1,"the":7,"reactive":1,"correction":1,"only":2,"alone":2,"no":1,"dosing":1,"addition":1,"goals":2,"following":1,"points":1,"need":1,"attention":1,"stricter":1,"are":2,"not":3,"advised":1,"because":1,"they":1,"may":1,"improve":1,"increased":1,"hypoglycemia":1,"blood":1,"glucose":4,"should":4,"be":4,"monitored":1,"at":1,"least":1,"every":1,"while":1,"indi":1,"vidual":1,"takes":1,"nothing":1,"by":1,"mouth":1,"administered":1,"as":1,"needed":1,"is":1,"recom":1,"mended":1,"lowering":2,"medica":1,"tion":1,"period":2,"cgm":1,"used":1,"for":2,"monitoring":1,"during":1,"metformin":1,"other":1,"oral":1,"agents":1,"held":1,"on":1,"day":1,"procedure":1,"see":1,"below":1,"sglt2":1,"inhibitor":1,"glp":1,"ra":1,"use":1,"individua":1},"len":205},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":8,"chunkId":"ada-2026-hosp-p8-c4","text":"used alone for glucose monitoring during surgery ( 147 ). 4. Metformin and other oral glucose- lowering agents should be held on the day of surgery or procedure. See below for SGLT2 inhibitor and GLP-1 RA use in the perioperative period. 5. Individuals using an insulin pump may continue pump use during surgery if this is consistent with institutional pol - icies and surgical procedures ( 148 ). This would require an interprofes - sional approach and adequate sup - port systems in the hospital. If an insulin pump cannot be used during surgery, an alternative plan (insulin in - fusion or basal plus correctional insu - lin) should be initiated before surgery. Compared with usual dosing, a reduc - tion of 25% of basal insulin dose given the evening before surgery is more likely to achieve perioperative blood glucose goals with a lower risk for hypoglycemia ( 149 ). Insulin dose reductions also include NPH insulin to one-half of the dose or long-acting basal insulin analogs to 75  80% of the dose or adjustment of insulin pump (if not in automated mode) basal rates based on the type of dia - betes and clinical judgment. However, the decision needs to be individual - ized, as the dose reduction may not be appropriate for some people with type 1 diabetes. Recommendations 16.14 To improve postoperative out - comes after elective surgery, a preopera - tive A1C goal < 8% ( < 64 mmol/mol)","tf":{"14":1,"16":1,"25":1,"64":1,"75":1,"80":1,"147":1,"148":1,"149":1,"used":2,"alone":1,"for":4,"glucose":3,"monitoring":1,"during":3,"surgery":7,"metformin":1,"and":5,"other":1,"oral":1,"lowering":1,"agents":1,"should":2,"be":5,"held":1,"on":2,"the":9,"day":1,"of":7,"or":4,"procedure":1,"see":1,"below":1,"sglt2":1,"inhibitor":1,"glp":1,"ra":1,"use":2,"in":4,"perioperative":2,"period":1,"individuals":1,"using":1,"an":4,"insulin":8,"pump":4,"may":2,"continue":1,"if":3,"this":2,"is":2,"consistent":1,"with":4,"institutional":1,"pol":1,"icies":1,"surgical":1,"procedures":1,"would":1,"require":1,"interprofes":1,"sional":1,"approach":1,"adequate":1,"sup":1,"port":1,"systems":1,"hospital":1,"cannot":1,"alternative":1,"plan":1,"fusion":1,"basal":4,"plus":1,"correctional":1,"insu":1,"lin":1,"initiated":1,"before":2,"compared":1,"usual":1,"dosing":1,"reduc":1,"tion":1,"dose":5,"given":1,"evening":1,"more":1,"likely":1,"to":5,"achieve":1,"blood":1,"goals":1,"lower":1,"risk":1,"hypoglycemia":1,"reductions":1,"also":1,"include":1,"nph":1,"one":1,"half":1,"long":1,"acting":1,"analogs":1,"adjustment":1,"not":2,"automated":1,"mode":1,"rates":1,"based":1,"type":2,"dia":1,"betes":1,"clinical":1,"judgment":1,"however":1,"decision":1,"needs":1,"individual":1,"ized":1,"as":1,"reduction":1,"appropriate":1,"some":1,"people":1,"diabetes":1,"recommendations":1,"improve":1,"postoperative":1,"out":1,"comes":1,"after":1,"elective":1,"preopera":1,"tive":1,"a1c":1,"goal":1,"mmol":1,"mol":1},"len":221},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":8,"chunkId":"ada-2026-hosp-p8-c5","text":"sion needs to be individual - ized, as the dose reduction may not be appropriate for some people with type 1 diabetes. Recommendations 16.14 To improve postoperative out - comes after elective surgery, a preopera - tive A1C goal < 8% ( < 64 mmol/mol) is recommended within 3 months, with individualized risk-to-benefit ratio as - sessment. C The 14-day glucose man - agement indicator goal < 8% and/or time in range > 50% can also be used. E 16.15 Blood glucose before, during, and after surgery should be monitored and maintained between 100 and 180 mg/dL (5.6 and 10.0 mmol/L). Goals may differ depending on the surgery, risk for hypoglycemia, and glucose-lowering therapy. E SGLT2 Inhibitors in the Perioperative Period SGLT2 inhibitors should be held for 3  4 days before elective surgery. Individ - uals using SGLT2 inhibitors who undergo nonelective surgeries should be closely S346 Diabetes Care in the Hospital Diabetes Care Volume 49, Supplement 1, January 2026 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S339/848851/dc26s016.pdf by guest on 17 February 2026","tf":{"10":1,"14":2,"15":1,"16":2,"17":1,"49":2,"50":1,"64":1,"100":1,"180":1,"2026":2,"848851":1,"sion":1,"needs":1,"to":3,"be":6,"individual":1,"ized":1,"as":2,"the":5,"dose":1,"reduction":1,"may":2,"not":1,"appropriate":1,"for":3,"some":1,"people":1,"with":2,"type":1,"diabetes":3,"recommendations":1,"improve":1,"postoperative":1,"out":1,"comes":1,"after":2,"elective":2,"surgery":4,"preopera":1,"tive":1,"a1c":1,"goal":2,"mmol":2,"mol":1,"is":1,"recommended":1,"within":1,"months":1,"individualized":1,"risk":2,"benefit":1,"ratio":1,"sessment":1,"day":1,"glucose":3,"man":1,"agement":1,"indicator":1,"and":6,"or":1,"time":1,"in":3,"range":1,"can":1,"also":1,"used":1,"blood":1,"before":2,"during":1,"should":3,"monitored":1,"maintained":1,"between":1,"mg":1,"dl":1,"goals":1,"differ":1,"depending":1,"on":2,"hypoglycemia":1,"lowering":1,"therapy":1,"sglt2":3,"inhibitors":3,"perioperative":1,"period":1,"held":1,"days":1,"individ":1,"uals":1,"using":1,"who":1,"undergo":1,"nonelective":1,"surgeries":1,"closely":1,"s346":1,"care":3,"hospital":1,"volume":1,"supplement":2,"january":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"s339":1,"dc26s016":1,"by":1,"guest":1,"february":1},"len":166},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":9,"chunkId":"ada-2026-hosp-p9-c0","text":"monitored for DKA after surgery; the possibility of euglycemic DKA should be considered. The FDA advises considering temporary discontinuation of SGLT2 inhibitors at least 3 days prior to surgery and ensuring risk factors for ketoacidosis are resolved prior to reinitiating therapy. In a retro - spective study of individuals with type 2 diabetes using SGLT2 inhibitors and re - quiring emergency surgery, the incidence of DKA was 4.9% for individuals using SGLT2 inhibitors and 3.5% for individuals not using SGLT2 inhibitors ( 150 ). After ad - justment for covariates, the differences between the two groups were not statisti - cally significant. However, because the di - agnosis of DKA was based on an ICD-10 code, it is possible that some cases of DKA were missed in the SGLT2 inhibitor group, especially cases of euglycemic DKA. Other studies have shown a higher risk of DKA or anion gap acidosis associated with SGLT2 inhibitor use in the perioperative period ( 151  153 ). Therefore, until further prospective studies are conducted, as an abundance of caution, SGLT2 inhibitors should be held for 3  4 days before sur - gery. The medication may be restarted in the hospital setting for heart failure indica - tion when nutritional intake is resumed, as explained above. GLP-1 or Dual GIP and GLP-1 RAs and the Perioperative Period With increasing use of GLP-1  based medi - cations, there","tf":{"10":1,"150":1,"151":1,"153":1,"monitored":1,"for":7,"dka":7,"after":2,"surgery":3,"the":11,"possibility":1,"of":10,"euglycemic":2,"should":2,"be":3,"considered":1,"fda":1,"advises":1,"considering":1,"temporary":1,"discontinuation":1,"sglt2":7,"inhibitors":5,"at":1,"least":1,"days":2,"prior":2,"to":2,"and":5,"ensuring":1,"risk":2,"factors":1,"ketoacidosis":1,"are":2,"resolved":1,"reinitiating":1,"therapy":1,"in":4,"retro":1,"spective":1,"study":1,"individuals":3,"with":3,"type":1,"diabetes":1,"using":3,"re":1,"quiring":1,"emergency":1,"incidence":1,"was":2,"not":2,"ad":1,"justment":1,"covariates":1,"differences":1,"between":1,"two":1,"groups":1,"were":2,"statisti":1,"cally":1,"significant":1,"however":1,"because":1,"di":1,"agnosis":1,"based":2,"on":1,"an":2,"icd":1,"code":1,"it":1,"is":2,"possible":1,"that":1,"some":1,"cases":2,"missed":1,"inhibitor":2,"group":1,"especially":1,"other":1,"studies":2,"have":1,"shown":1,"higher":1,"or":2,"anion":1,"gap":1,"acidosis":1,"associated":1,"use":2,"perioperative":2,"period":2,"therefore":1,"until":1,"further":1,"prospective":1,"conducted":1,"as":2,"abundance":1,"caution":1,"held":1,"before":1,"sur":1,"gery":1,"medication":1,"may":1,"restarted":1,"hospital":1,"setting":1,"heart":1,"failure":1,"indica":1,"tion":1,"when":1,"nutritional":1,"intake":1,"resumed":1,"explained":1,"above":1,"glp":3,"dual":1,"gip":1,"ras":1,"increasing":1,"medi":1,"cations":1,"there":1},"len":212},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":9,"chunkId":"ada-2026-hosp-p9-c1","text":"n may be restarted in the hospital setting for heart failure indica - tion when nutritional intake is resumed, as explained above. GLP-1 or Dual GIP and GLP-1 RAs and the Perioperative Period With increasing use of GLP-1  based medi - cations, there are concerns about the safety of these medications in the periop - erative period. These medications may be associated with nausea, vomiting, and de - layed gastric emptying, and there have been case reports of pulmonary aspira - tion during general anesthesia and deep sedation ( 154 ). Individuals taking a GLP-1 RA medication have higher chances of in - creased residual gastric content despite fasting for the procedure as needed ( 155 ). Based on these reports, FDA added a warning to the label of all GLP-1 RA or dual glucose-dependent insulinotropic polypep - tide (GIP) and GLP-1 RA medications about the possibility of pulmonary aspiration dur - ing surgeries or procedures requiring gen - eral anesthesia or deep sedation ( 156 ). However, there is insufficient information on how to mitigate the risk of pulmonary aspiration in this situation. Even if the medication is held, the duration required to withhold the medication is unknown because 1 week of holding a once-weekly medication is likely insufficient to mitigate the risk ( 157 ). In a retrospective study, with - holding semaglutide up to 30 days (with an average of 10 days) wa","tf":{"10":1,"30":1,"154":1,"155":1,"156":1,"157":1,"may":2,"be":2,"restarted":1,"in":5,"the":12,"hospital":1,"setting":1,"for":2,"heart":1,"failure":1,"indica":1,"tion":2,"when":1,"nutritional":1,"intake":1,"is":5,"resumed":1,"as":2,"explained":1,"above":1,"glp":6,"or":4,"dual":2,"gip":2,"and":6,"ras":1,"perioperative":1,"period":2,"with":4,"increasing":1,"use":1,"of":9,"based":2,"medi":1,"cations":1,"there":3,"are":1,"concerns":1,"about":2,"safety":1,"these":3,"medications":3,"periop":1,"erative":1,"associated":1,"nausea":1,"vomiting":1,"de":1,"layed":1,"gastric":2,"emptying":1,"have":2,"been":1,"case":1,"reports":2,"pulmonary":3,"aspira":1,"during":1,"general":1,"anesthesia":2,"deep":2,"sedation":2,"individuals":1,"taking":1,"ra":3,"medication":4,"higher":1,"chances":1,"creased":1,"residual":1,"content":1,"despite":1,"fasting":1,"procedure":1,"needed":1,"on":2,"fda":1,"added":1,"warning":1,"to":5,"label":1,"all":1,"glucose":1,"dependent":1,"insulinotropic":1,"polypep":1,"tide":1,"possibility":1,"aspiration":2,"dur":1,"ing":1,"surgeries":1,"procedures":1,"requiring":1,"gen":1,"eral":1,"however":1,"insufficient":2,"information":1,"how":1,"mitigate":2,"risk":2,"this":1,"situation":1,"even":1,"if":1,"held":1,"duration":1,"required":1,"withhold":1,"unknown":1,"because":1,"week":1,"holding":2,"once":1,"weekly":1,"likely":1,"retrospective":1,"study":1,"semaglutide":1,"up":1,"days":2,"an":1,"average":1,"wa":1},"len":214},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":9,"chunkId":"ada-2026-hosp-p9-c2","text":" required to withhold the medication is unknown because 1 week of holding a once-weekly medication is likely insufficient to mitigate the risk ( 157 ). In a retrospective study, with - holding semaglutide up to 30 days (with an average of 10 days) was still associated with increased residual gastric content ( 158 ). The risk of aspiration pneumonia with increased gastric content in this setting is still unknown. In some retrospective stud - ies, no increase in risk of aspiration pneu - monia was found in association with GLP-1 RAs ( 159 , 160 ). The American Society of Anesthesiologists initially recommended holding GLP-1 RAs on the day of the proce - dure or surgery for daily dose agents and for at least 7 days prior to the procedure or surgery for once-weekly dose agents ( 161 ). However, more recently, multiple so - cieties and expert groups have advised a more personalized approach, allowing in - dividuals at low risk for delayed stomach emptying who undergo elective surgery to continue taking their GLP-1 RA medica - tions and suggesting a liquid nutrition pro - tocol for 24 h before the procedure or other measures for those at higher risk for significant gastrointestinal side effects ( 162  164 ). A personalized approach for periopera - tive management of individuals taking a GLP-1 RA or a dual GIP and GLP-1 RA is rec - ommended. Factors such as the primary indication of ","tf":{"10":1,"24":1,"30":1,"157":1,"158":1,"159":1,"160":1,"161":1,"162":1,"164":1,"required":1,"to":5,"withhold":1,"the":9,"medication":2,"is":4,"unknown":2,"because":1,"week":1,"of":8,"holding":3,"once":2,"weekly":2,"likely":1,"insufficient":1,"mitigate":1,"risk":5,"in":6,"retrospective":2,"study":1,"with":5,"semaglutide":1,"up":1,"days":3,"an":1,"average":1,"was":2,"still":2,"associated":1,"increased":2,"residual":1,"gastric":2,"content":2,"aspiration":2,"pneumonia":1,"this":1,"setting":1,"some":1,"stud":1,"ies":1,"no":1,"increase":1,"pneu":1,"monia":1,"found":1,"association":1,"glp":5,"ras":2,"american":1,"society":1,"anesthesiologists":1,"initially":1,"recommended":1,"on":1,"day":1,"proce":1,"dure":1,"or":4,"surgery":3,"for":8,"daily":1,"dose":2,"agents":2,"and":4,"at":3,"least":1,"prior":1,"procedure":2,"however":1,"more":2,"recently":1,"multiple":1,"so":1,"cieties":1,"expert":1,"groups":1,"have":1,"advised":1,"personalized":2,"approach":2,"allowing":1,"dividuals":1,"low":1,"delayed":1,"stomach":1,"emptying":1,"who":1,"undergo":1,"elective":1,"continue":1,"taking":2,"their":1,"ra":3,"medica":1,"tions":1,"suggesting":1,"liquid":1,"nutrition":1,"pro":1,"tocol":1,"before":1,"other":1,"measures":1,"those":1,"higher":1,"significant":1,"gastrointestinal":1,"side":1,"effects":1,"periopera":1,"tive":1,"management":1,"individuals":1,"dual":1,"gip":1,"rec":1,"ommended":1,"factors":1,"such":1,"as":1,"primary":1,"indication":1},"len":213},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":9,"chunkId":"ada-2026-hosp-p9-c3","text":"higher risk for significant gastrointestinal side effects ( 162  164 ). A personalized approach for periopera - tive management of individuals taking a GLP-1 RA or a dual GIP and GLP-1 RA is rec - ommended. Factors such as the primary indication of these medications (e.g., dia - betes or obesity treatment); current gly - cemic management; dose, duration, and characteristics of the drug; gastrointestinal symptoms; type of surgery or procedure and its urgency; and type of anesthesia should be considered. In addition, a pre - operative gastric ultrasound may be con - sidered to quantify gastric contents. In individuals with symptoms suggesting de - layed gastric emptying (nausea, vomiting, dyspepsia, or abdominal distension), im - plementation of full stomach precautions may be considered. A liquid nutrition pro - tocol for 24 h before the procedure may be helpful. If a decision is made to hold the drug and worsening of glycemia is anticipated, an alternative strategy for perioperative glycemic management (e.g., insulin) should be implemented. Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State Recommendations 16.16 Manage diabetic ketoacidosis (DKA) and hyperglycemic hyperosmo - lar state (HHS) by administering intra - venous fluids, insulin, and electrolytes ( Fig. 16.1 ) and by closely monitoring during treatment, ensuring timely and bridged transition to maintenance su","tf":{"16":3,"24":1,"162":1,"164":1,"higher":1,"risk":1,"for":4,"significant":1,"gastrointestinal":2,"side":1,"effects":1,"personalized":1,"approach":1,"periopera":1,"tive":1,"management":3,"of":7,"individuals":2,"taking":1,"glp":2,"ra":2,"or":4,"dual":1,"gip":1,"and":10,"is":3,"rec":1,"ommended":1,"factors":1,"such":1,"as":1,"the":4,"primary":1,"indication":1,"these":1,"medications":1,"dia":1,"betes":1,"obesity":1,"treatment":2,"current":1,"gly":1,"cemic":1,"dose":1,"duration":1,"characteristics":1,"drug":2,"symptoms":2,"type":2,"surgery":1,"procedure":2,"its":1,"urgency":1,"anesthesia":1,"should":2,"be":5,"considered":2,"in":2,"addition":1,"pre":1,"operative":1,"gastric":3,"ultrasound":1,"may":3,"con":1,"sidered":1,"to":3,"quantify":1,"contents":1,"with":1,"suggesting":1,"de":1,"layed":1,"emptying":1,"nausea":1,"vomiting":1,"dyspepsia":1,"abdominal":1,"distension":1,"im":1,"plementation":1,"full":1,"stomach":1,"precautions":1,"liquid":1,"nutrition":1,"pro":1,"tocol":1,"before":1,"helpful":1,"if":1,"decision":1,"made":1,"hold":1,"worsening":1,"glycemia":1,"anticipated":1,"an":1,"alternative":1,"strategy":1,"perioperative":1,"glycemic":1,"insulin":2,"implemented":1,"diabetic":2,"ketoacidosis":2,"hyperglycemic":2,"hyperosmolar":1,"state":2,"recommendations":1,"manage":1,"dka":1,"hyperosmo":1,"lar":1,"hhs":1,"by":2,"administering":1,"intra":1,"venous":1,"fluids":1,"electrolytes":1,"fig":1,"closely":1,"monitoring":1,"during":1,"ensuring":1,"timely":1,"bridged":1,"transition":1,"maintenance":1,"su":1},"len":189},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":9,"chunkId":"ada-2026-hosp-p9-c4","text":"etic ketoacidosis (DKA) and hyperglycemic hyperosmo - lar state (HHS) by administering intra - venous fluids, insulin, and electrolytes ( Fig. 16.1 ) and by closely monitoring during treatment, ensuring timely and bridged transition to maintenance sub - cutaneous insulin administration, and identifying and treating the precipitat - ing cause. A 16.17 The discharge planning process should include education on the recog - nition, prevention, and management of DKA and/or HHS for all individuals af - fected by or at high risk for these events to prevent recurrence and read - mission. B DKA and the hyperglycemic hyperosmolar state (HHS) are serious, acute, and life- threatening hyperglycemic emergencies in individuals with diabetes ( 165 ) that incur substantial morbidity, mortality, and costs ( 166 ). Approximately 1% of all hospitaliza - tions in people with diabetes are for hyper - glycemic crises. The diagnostic criteria for DKA and HHS are summarized in Table 16.1 ; all criteria must be met to establish these diagnoses. Importantly, approximately 10% of people experiencing DKA present with euglycemic DKA (plasma glucose < 200 mg/dL [ < 11.1 mmol/L]); there - fore, DKA diagnosis requires either the presence of hyperglycemia or prior his - tory of diabetes ( 165 ). Euglycemic DKA develops in the presence of low insulin levels and can be associated with a vari - ety of factors inc","tf":{"10":1,"11":1,"16":3,"17":1,"165":2,"166":1,"200":1,"etic":1,"ketoacidosis":1,"dka":8,"and":14,"hyperglycemic":3,"hyperosmo":1,"lar":1,"state":2,"hhs":4,"by":3,"administering":1,"intra":1,"venous":1,"fluids":1,"insulin":3,"electrolytes":1,"fig":1,"closely":1,"monitoring":1,"during":1,"treatment":1,"ensuring":1,"timely":1,"bridged":1,"transition":1,"to":3,"maintenance":1,"sub":1,"cutaneous":1,"administration":1,"identifying":1,"treating":1,"the":7,"precipitat":1,"ing":1,"cause":1,"discharge":1,"planning":1,"process":1,"should":1,"include":1,"education":1,"on":1,"recog":1,"nition":1,"prevention":1,"management":1,"of":7,"or":3,"for":4,"all":3,"individuals":2,"af":1,"fected":1,"at":1,"high":1,"risk":1,"these":2,"events":1,"prevent":1,"recurrence":1,"read":1,"mission":1,"hyperosmolar":1,"are":3,"serious":1,"acute":1,"life":1,"threatening":1,"emergencies":1,"in":4,"with":4,"diabetes":3,"that":1,"incur":1,"substantial":1,"morbidity":1,"mortality":1,"costs":1,"approximately":2,"hospitaliza":1,"tions":1,"people":2,"hyper":1,"glycemic":1,"crises":1,"diagnostic":1,"criteria":2,"summarized":1,"table":1,"must":1,"be":2,"met":1,"establish":1,"diagnoses":1,"importantly":1,"experiencing":1,"present":1,"euglycemic":2,"plasma":1,"glucose":1,"mg":1,"dl":1,"mmol":1,"there":1,"fore":1,"diagnosis":1,"requires":1,"either":1,"presence":2,"hyperglycemia":1,"prior":1,"his":1,"tory":1,"develops":1,"low":1,"levels":1,"can":1,"associated":1,"vari":1,"ety":1,"factors":1,"inc":1},"len":202},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":9,"chunkId":"ada-2026-hosp-p9-c5","text":"[ < 11.1 mmol/L]); there - fore, DKA diagnosis requires either the presence of hyperglycemia or prior his - tory of diabetes ( 165 ). Euglycemic DKA develops in the presence of low insulin levels and can be associated with a vari - ety of factors including reduced food in - take, pregnancy, alcohol use, liver failure, and/or SGLT2 inhibitor therapy ( 167 ). Ad - ditionally, DKA and HHS often present concurrently ( 168 ), though few studies have examined mixed DKA-HHS events. There has been a concerning rise in the rate of hyperglycemic crises in people with both type 1 diabetes and type 2 diabetes over the past decade ( 169  171 ). Recent data suggest hyperglycemic crisis rates of up to 44.5  82.6 per 1,000 person-years among people with type 1 diabetes ( 169 , 172 ) and up to 3.2 per 1,000 person- years among people with type 2 diabetes ( 169 ). While DKA mortality decreased in the first decade of the 21st century ( 166 ), these improvements have plateaued in the past decade ( 170 , 172 , 173 ). Most re - cently available data for inpatient mortality during hospital admission for DKA ranges from 0.2% in type 1 diabetes ( 174 ) to 1.0% in type 2 diabetes ( 166 , 175 ). Inpatient mortality among people with type 2 diabe - tes hospitalized for HHS decreased from diabetesjournals.org/care Diabetes Care in the Hospital S347 Downloaded from http://diabetesjournals.org/care/article","tf":{"11":1,"44":1,"82":1,"165":1,"166":2,"167":1,"168":1,"169":3,"170":1,"171":1,"172":2,"173":1,"174":1,"175":1,"mmol":1,"there":2,"fore":1,"dka":6,"diagnosis":1,"requires":1,"either":1,"the":8,"presence":2,"of":7,"hyperglycemia":1,"or":2,"prior":1,"his":1,"tory":1,"diabetes":8,"euglycemic":1,"develops":1,"in":9,"low":1,"insulin":1,"levels":1,"and":5,"can":1,"be":1,"associated":1,"with":5,"vari":1,"ety":1,"factors":1,"including":1,"reduced":1,"food":1,"take":1,"pregnancy":1,"alcohol":1,"use":1,"liver":1,"failure":1,"sglt2":1,"inhibitor":1,"therapy":1,"ad":1,"ditionally":1,"hhs":3,"often":1,"present":1,"concurrently":1,"though":1,"few":1,"studies":1,"have":2,"examined":1,"mixed":1,"events":1,"has":1,"been":1,"concerning":1,"rise":1,"rate":1,"hyperglycemic":2,"crises":1,"people":4,"both":1,"type":7,"over":1,"past":2,"decade":3,"recent":1,"data":2,"suggest":1,"crisis":1,"rates":1,"up":2,"to":3,"per":2,"000":2,"person":2,"years":2,"among":3,"while":1,"mortality":3,"decreased":2,"first":1,"21st":1,"century":1,"these":1,"improvements":1,"plateaued":1,"most":1,"re":1,"cently":1,"available":1,"for":3,"inpatient":2,"during":1,"hospital":2,"admission":1,"ranges":1,"from":3,"diabe":1,"tes":1,"hospitalized":1,"diabetesjournals":2,"org":2,"care":3,"s347":1,"downloaded":1,"http":1,"article":1},"len":211},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":9,"chunkId":"ada-2026-hosp-p9-c6","text":" 1.0% in type 2 diabetes ( 166 , 175 ). Inpatient mortality among people with type 2 diabe - tes hospitalized for HHS decreased from diabetesjournals.org/care Diabetes Care in the Hospital S347 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S339/848851/dc26s016.pdf by guest on 17 February 2026","tf":{"17":1,"49":1,"166":1,"175":1,"2026":1,"848851":1,"in":2,"type":2,"diabetes":2,"inpatient":1,"mortality":1,"among":1,"people":1,"with":1,"diabe":1,"tes":1,"hospitalized":1,"for":1,"hhs":1,"decreased":1,"from":2,"diabetesjournals":2,"org":2,"care":3,"the":1,"hospital":1,"s347":1,"downloaded":1,"http":1,"article":1,"pdf":2,"supplement":1,"s339":1,"dc26s016":1,"by":1,"guest":1,"on":1,"february":1},"len":47},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":10,"chunkId":"ada-2026-hosp-p10-c0","text":"1.44% in 2008 to 0.77% in 2018 ( 176 ). The only study to have examined inpatient mortality for mixed DKA-HHS found it to be higher than mortality for HHS or DKA alone ( 168 ). Mortality rates reported in low- and middle-income countries are much higher than those in developed countries, potentially because of delayed diagnosis and treatment ( 165 ). People discharged after an episode of DKA have a 1-year age-corrected mortality rate that is 13 times higher than the gen - eral population ( 177 ). Figure 16.1 Treatment pathways for diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS). BOHB,  -hydroxybutyrate. Adapted from Umpierrez et al. (165). There is considerable variability in the presentation of DKA and HHS, includ - ing euglycemic DKA (defined as plasma glucose levels < 200 mg/dL [ < 11.1 mmol/L] in the presence of ketosis and metabolic acidosis), mild to moderate hyperglycemia and acidosis, or severe hyperglycemia, dehydration, and coma; therefore, indi - vidualization of treatment based on a careful clinical and laboratory assess - ment is needed ( 165 ). Differences in the clinical presentation of DKS and HHS are shown in Table 16.2 , though there is a considerable overlap.  . Yome.have.recommended.that.insulin.be.withheld.until.glucose.has.stopped.dropping.with.fluid.administration.alone0 . xefinitions.of.resolution.use.clinical.judgment.and.do.","tf":{"11":1,"13":1,"16":2,"44":1,"77":1,"165":3,"168":1,"176":1,"177":1,"200":1,"2008":1,"2018":1,"in":8,"to":4,"the":5,"only":1,"study":1,"have":3,"examined":1,"inpatient":1,"mortality":4,"for":3,"mixed":1,"dka":6,"hhs":5,"found":1,"it":1,"be":2,"higher":3,"than":3,"or":2,"alone":1,"rates":1,"reported":1,"low":1,"and":10,"middle":1,"income":1,"countries":2,"are":2,"much":1,"those":1,"developed":1,"potentially":1,"because":1,"of":7,"delayed":1,"diagnosis":1,"treatment":3,"people":1,"discharged":1,"after":1,"an":1,"episode":1,"year":1,"age":1,"corrected":1,"rate":1,"that":2,"is":4,"times":1,"gen":1,"eral":1,"population":1,"figure":1,"pathways":1,"diabetic":1,"ketoacidosis":1,"hyperglycemic":1,"hyperosmolar":1,"state":1,"bohb":1,"hydroxybutyrate":1,"adapted":1,"from":1,"umpierrez":1,"et":1,"al":1,"there":2,"considerable":2,"variability":1,"presentation":2,"includ":1,"ing":1,"euglycemic":1,"defined":1,"as":1,"plasma":1,"glucose":2,"levels":1,"mg":1,"dl":1,"mmol":1,"presence":1,"ketosis":1,"metabolic":1,"acidosis":2,"mild":1,"moderate":1,"hyperglycemia":2,"severe":1,"dehydration":1,"coma":1,"therefore":1,"indi":1,"vidualization":1,"based":1,"on":1,"careful":1,"clinical":3,"laboratory":1,"assess":1,"ment":1,"needed":1,"differences":1,"dks":1,"shown":1,"table":1,"though":1,"overlap":1,"yome":1,"recommended":1,"insulin":1,"withheld":1,"until":1,"has":1,"stopped":1,"dropping":1,"with":1,"fluid":1,"administration":1,"alone0":1,"xefinitions":1,"resolution":1,"use":1,"judgment":1,"do":1},"len":207},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":10,"chunkId":"ada-2026-hosp-p10-c1","text":"d HHS are shown in Table 16.2 , though there is a considerable overlap.  . Yome.have.recommended.that.insulin.be.withheld.until.glucose.has.stopped.dropping.with.fluid.administration.alone0 . xefinitions.of.resolution.use.clinical.judgment.and.do.not.delay.discharge.or.level.of.care.if.these.are.not.metO6   K + >5.0 mmol/L I.V. Fluids Insulin Potassium 0.9% NaCl or other crystalloid at a clinically appropriate rate aiming to replace 50% of the estimated fluid deficit in the first 812 h Check electrolytes, kidney function, venous pH, osmolality, and glucose every 24 h until stable. After resolution of DKA or HHS and when individual is able to eat and drink, initiate s.c. multidose insulin plan. To transfer from i.v. to maintenance s.c. insulin, continue i.v. insulin infusion for 12 h after s.c. insulin. 1020 mmol/L/h until K + >3.5 mmol/L (faster K + replacement will require central venous access) Moderate or severe DKA 0.9% NaCl or other crystalloid K + 3.55.0 mmol/L Start insulin, but do not give K + ; check serum K + every 2 h acting insulin dose to 0.05 units/kg/h i.v. (or 0.05 units/kg/h or 0.1 units/kg every 2 h s.c. or nurse-driven protocol with a variable rate based on glucose values HHS Target glucose to between 200 and 250 mg/dL until resolution* mmol/L K + in each liter of i.v. fluid as needed to keep serum K + between 4 and 5 mmol/L Phosphate should not be ","tf":{"10":1,"12":1,"16":1,"20":1,"50":1,"200":1,"250":1,"hhs":3,"are":2,"shown":1,"in":3,"table":1,"though":1,"there":1,"is":2,"considerable":1,"overlap":1,"yome":1,"have":1,"recommended":1,"that":1,"insulin":8,"be":2,"withheld":1,"until":4,"glucose":4,"has":1,"stopped":1,"dropping":1,"with":2,"fluid":3,"administration":1,"alone0":1,"xefinitions":1,"of":5,"resolution":3,"use":1,"clinical":1,"judgment":1,"and":6,"do":2,"not":4,"delay":1,"discharge":1,"or":8,"level":1,"care":1,"if":1,"these":1,"meto6":1,"mmol":6,"fluids":1,"potassium":1,"nacl":2,"other":2,"crystalloid":2,"at":1,"clinically":1,"appropriate":1,"rate":2,"aiming":1,"to":7,"replace":1,"the":2,"estimated":1,"deficit":1,"first":1,"check":2,"electrolytes":1,"kidney":1,"function":1,"venous":2,"ph":1,"osmolality":1,"every":3,"stable":1,"after":2,"dka":2,"when":1,"individual":1,"able":1,"eat":1,"drink":1,"initiate":1,"multidose":1,"plan":1,"transfer":1,"from":1,"maintenance":1,"continue":1,"infusion":1,"for":1,"faster":1,"replacement":1,"will":1,"require":1,"central":1,"access":1,"moderate":1,"severe":1,"start":1,"but":1,"give":1,"serum":2,"acting":1,"dose":1,"05":2,"units":3,"kg":3,"nurse":1,"driven":1,"protocol":1,"variable":1,"based":1,"on":1,"values":1,"target":1,"between":2,"mg":1,"dl":1,"each":1,"liter":1,"as":1,"needed":1,"keep":1,"phosphate":1,"should":1},"len":201},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":10,"chunkId":"ada-2026-hosp-p10-c2","text":"or nurse-driven protocol with a variable rate based on glucose values HHS Target glucose to between 200 and 250 mg/dL until resolution* mmol/L K + in each liter of i.v. fluid as needed to keep serum K + between 4 and 5 mmol/L Phosphate should not be given unless there is muscle weakness, respiratory compromise, and a DKA Keep glucose between 150 and 200 mg/dL until resolution* Mild DKA Start 0.05 units/kg/h short-acting insulin as fixed-rate i.v. infusion  or nurse-driven protocol with a variable rate based on glucose values HHS i.v. insulin Hemodynamic monitoring/ pressors K + <3.5 mmol/L Severe hypovolemia Mild hypovolemia Cardiac compromise 0.1 units/kg rapid-acting insulin analog as s.c. bolus 0.1 units/kg rapid-acting insulin analog every 1 h or 0.2 units/kg every 2 h s.c. insulin Consider 0.1 units/kg short- acting insulin as i.v. bolus if there is a delay in setting up the infusion 0.1 units/kg/h short-acting insulin fixed- rate i.v. insulin infusion or nurse-driven protocol with a variable rate based on glucose values i.v. insulin Establish adequate kidney function Determine hydration status (1.0 L/h) (urine output ~0.5 mL/kg/h) Give 1020 = When glucose reaches <250 mg/dL, reduce short- in \"mild\" DKA) When glucose reaches <250 mg/dL, add 5% or 10% dextrose to the 0.9% NaCI/crystalloid In euglycemic DKA (glucose <200 mg/dL and positive BOHB), 5% or 10% dextrose needs t","tf":{"10":3,"20":1,"150":1,"200":3,"250":3,"or":6,"nurse":3,"driven":3,"protocol":3,"with":3,"variable":3,"rate":5,"based":3,"on":3,"glucose":8,"values":3,"hhs":2,"target":1,"to":3,"between":3,"and":5,"mg":5,"dl":5,"until":2,"resolution":2,"mmol":3,"in":4,"each":1,"liter":1,"of":1,"fluid":1,"as":4,"needed":1,"keep":2,"serum":1,"phosphate":1,"should":1,"not":1,"be":1,"given":1,"unless":1,"there":2,"is":2,"muscle":1,"weakness":1,"respiratory":1,"compromise":2,"dka":4,"mild":3,"start":1,"05":1,"units":6,"kg":7,"short":4,"acting":5,"insulin":9,"fixed":2,"infusion":3,"hemodynamic":1,"monitoring":1,"pressors":1,"severe":1,"hypovolemia":2,"cardiac":1,"rapid":2,"analog":2,"bolus":2,"every":2,"consider":1,"if":1,"delay":1,"setting":1,"up":1,"the":2,"establish":1,"adequate":1,"kidney":1,"function":1,"determine":1,"hydration":1,"status":1,"urine":1,"output":1,"ml":1,"give":1,"when":2,"reaches":2,"reduce":1,"add":1,"dextrose":2,"naci":1,"crystalloid":1,"euglycemic":1,"positive":1,"bohb":1,"needs":1},"len":208},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":10,"chunkId":"ada-2026-hosp-p10-c3","text":"kg/h) Give 1020 = When glucose reaches <250 mg/dL, reduce short- in \"mild\" DKA) When glucose reaches <250 mg/dL, add 5% or 10% dextrose to the 0.9% NaCI/crystalloid In euglycemic DKA (glucose <200 mg/dL and positive BOHB), 5% or 10% dextrose needs to be started alongside 0.9% NaCl/crystalloid at the start of the insulin treatment DKA: Venous pH >7.3 or bicarbonate >18 mmol/L and plasma/capillary ketones <0.6 mmol/L HHS: Calculated serum osmolality falls to <300 mOsm/kg and urine output is >0.5 mL/kg/h and glucose is <250 mg/dL Bicarbonate should only be considered if pH is <7.0 phosphate <1.0 mmol/L or <0.32 mmol/L 150 mg/dL = 8.3 mmol/L 200 mg/dL = 11.0 mmol/L 250 mg/dL = 13.9 mmol/L 300 mg/dL = 16.6 mmol/L S348 Diabetes Care in the Hospital Diabetes Care Volume 49, Supplement 1, January 2026 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S339/848851/dc26s016.pdf by guest on 17 February 2026","tf":{"10":3,"11":1,"13":1,"16":1,"17":1,"18":1,"20":1,"32":1,"49":2,"150":1,"200":2,"250":4,"300":2,"2026":2,"848851":1,"kg":3,"give":1,"when":2,"glucose":4,"reaches":2,"mg":8,"dl":8,"reduce":1,"short":1,"in":3,"mild":1,"dka":3,"add":1,"or":4,"dextrose":2,"to":3,"the":4,"naci":1,"crystalloid":2,"euglycemic":1,"and":4,"positive":1,"bohb":1,"needs":1,"be":2,"started":1,"alongside":1,"nacl":1,"at":1,"start":1,"of":1,"insulin":1,"treatment":1,"venous":1,"ph":2,"bicarbonate":2,"mmol":8,"plasma":1,"capillary":1,"ketones":1,"hhs":1,"calculated":1,"serum":1,"osmolality":1,"falls":1,"mosm":1,"urine":1,"output":1,"is":3,"ml":1,"should":1,"only":1,"considered":1,"if":1,"phosphate":1,"s348":1,"diabetes":2,"care":3,"hospital":1,"volume":1,"supplement":2,"january":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"s339":1,"dc26s016":1,"by":1,"guest":1,"on":1,"february":1},"len":154},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":11,"chunkId":"ada-2026-hosp-p11-c0","text":"Table 16.1Diagnostic criteria for DKA and HHS DKA Diabetes/hyperglycemia Glucose  200 mg/dL (11.1 mmol/L) or prior history of diabetes Ketosis  -Hydroxybutyrate concentration  3.0 mmol/L or urine ketone strip 2 + or greater Metabolic acidosis pH < 7.3 and/or bicarbonate concentration < 18 mmol/L HHS Hyperglycemia Plasma glucose  600 mg/dL (33.3 mmol/L) Hyperosmolarity Calculated effective serum osmolality > 300 mOsm/kg (calculated as [2  Na + (mmol/L) + glucose (mmol/L)] or total serum osmolality > 320 mOsm/kg [2  Na + (mmol/L) + glucose (mmol/L) + urea (mmol/L)] Absence of significant ketonemia  -Hydroxybutyrate concentration < 3.0 mmol/L OR urine ketone strip less than 2 + Absence of acidosis pH  7.3 and bicarbonate concentration  15 mmol/L Adapted from Umpierrez et al. ( 165 ). Management goals include restora - tion of circulatory volume and tissue perfusion, resolution of ketoacidosis, and correction of electrolyte imbalance and aci - dosis. It is also essential to treat and man - age any underlying cause of DKA, such as sepsis, myocardial infarction, or stroke. For severe DKA and HHS management, contin - uous intravenous insulin infusion should be given for correction of hyperglycemia, hyperketonemia, and acid-base disorder following a fixed-rate intravenous insulin infusion ( 165 ) or nurse-driven protocol with a variable rate based on glucose values ( 178 ). I","tf":{"11":1,"15":1,"16":1,"18":1,"33":1,"165":2,"178":1,"200":1,"300":1,"320":1,"600":1,"table":1,"diagnostic":1,"criteria":1,"for":3,"dka":4,"and":9,"hhs":3,"diabetes":2,"hyperglycemia":3,"glucose":5,"mg":2,"dl":2,"mmol":11,"or":8,"prior":1,"history":1,"of":8,"ketosis":1,"hydroxybutyrate":2,"concentration":4,"urine":2,"ketone":2,"strip":2,"greater":1,"metabolic":1,"acidosis":2,"ph":2,"bicarbonate":2,"plasma":1,"hyperosmolarity":1,"calculated":2,"effective":1,"serum":2,"osmolality":2,"mosm":2,"kg":2,"as":2,"na":2,"total":1,"urea":1,"absence":2,"significant":1,"ketonemia":1,"less":1,"than":1,"adapted":1,"from":1,"umpierrez":1,"et":1,"al":1,"management":2,"goals":1,"include":1,"restora":1,"tion":1,"circulatory":1,"volume":1,"tissue":1,"perfusion":1,"resolution":1,"ketoacidosis":1,"correction":2,"electrolyte":1,"imbalance":1,"aci":1,"dosis":1,"it":1,"is":1,"also":1,"essential":1,"to":1,"treat":1,"man":1,"age":1,"any":1,"underlying":1,"cause":1,"such":1,"sepsis":1,"myocardial":1,"infarction":1,"stroke":1,"severe":1,"contin":1,"uous":1,"intravenous":2,"insulin":2,"infusion":2,"should":1,"be":1,"given":1,"hyperketonemia":1,"acid":1,"base":1,"disorder":1,"following":1,"fixed":1,"rate":2,"nurse":1,"driven":1,"protocol":1,"with":1,"variable":1,"based":1,"on":1,"values":1},"len":190},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":11,"chunkId":"ada-2026-hosp-p11-c1","text":"nous insulin infusion should be given for correction of hyperglycemia, hyperketonemia, and acid-base disorder following a fixed-rate intravenous insulin infusion ( 165 ) or nurse-driven protocol with a variable rate based on glucose values ( 178 ). If a nurse-driven insulin in - fusion protocol is used, the infusion rate should be no less than 1 unit/h to allow for acidosis resolution. Successful transi - tion from intravenous to subcutaneous insulin requires administration of basal insulin 2  4 h before the intravenous in - sulin is stopped to prevent recurrence of ketoacidosis and rebound hyperglycemia while the subcutaneous insulin action rises ( 63 , 179 ). Studies have reported that the administration of a low dose of basal insulin analog in addition to intravenous insulin infusion early in the course of treatment may prevent rebound hyper - glycemia without increased risk of hypo - glycemia ( 64  66 , 179 ). Individuals with mild and uncomplicated DKA can be man - aged with subcutaneous rapid-acting insu - lin doses given every 1  2 h ( 180 ), and this treatment may be administered in the emergency department or step-down units ( 181 ). This approach may be safer and more cost-effective than treatment with intravenous insulin. There is no signif - icant difference in outcomes for intravenous human regular insulin versus subcutaneous rapid-acting analogs when combined w","tf":{"63":1,"64":1,"66":1,"165":1,"178":1,"179":2,"180":1,"181":1,"nous":1,"insulin":10,"infusion":4,"should":2,"be":5,"given":2,"for":3,"correction":1,"of":7,"hyperglycemia":2,"hyperketonemia":1,"and":5,"acid":1,"base":1,"disorder":1,"following":1,"fixed":1,"rate":3,"intravenous":6,"or":2,"nurse":2,"driven":2,"protocol":2,"with":4,"variable":1,"based":1,"on":1,"glucose":1,"values":1,"if":1,"in":6,"fusion":1,"is":3,"used":1,"the":6,"no":2,"less":1,"than":2,"unit":1,"to":4,"allow":1,"acidosis":1,"resolution":1,"successful":1,"transi":1,"tion":1,"from":1,"subcutaneous":4,"requires":1,"administration":2,"basal":2,"before":1,"sulin":1,"stopped":1,"prevent":2,"recurrence":1,"ketoacidosis":1,"rebound":2,"while":1,"action":1,"rises":1,"studies":1,"have":1,"reported":1,"that":1,"low":1,"dose":1,"analog":1,"addition":1,"early":1,"course":1,"treatment":3,"may":3,"hyper":1,"glycemia":2,"without":1,"increased":1,"risk":1,"hypo":1,"individuals":1,"mild":1,"uncomplicated":1,"dka":1,"can":1,"man":1,"aged":1,"rapid":2,"acting":2,"insu":1,"lin":1,"doses":1,"every":1,"this":2,"administered":1,"emergency":1,"department":1,"step":1,"down":1,"units":1,"approach":1,"safer":1,"more":1,"cost":1,"effective":1,"there":1,"signif":1,"icant":1,"difference":1,"outcomes":1,"human":1,"regular":1,"versus":1,"analogs":1,"when":1,"combined":1},"len":201},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":11,"chunkId":"ada-2026-hosp-p11-c2","text":"nits ( 181 ). This approach may be safer and more cost-effective than treatment with intravenous insulin. There is no signif - icant difference in outcomes for intravenous human regular insulin versus subcutaneous rapid-acting analogs when combined with aggressive fluid management for treating mild or moderate DKA ( 182 ). Therefore, if subcutaneous insulin administration is used, it is important to provide an ade - quate fluid replacement, frequent POC blood glucose monitoring, treatment of any concurrent infections, and appro - priate follow-up to avoid recurrent DKA. Several studies have shown that the use of bicarbonate in people with DKA made no difference in the resolution of acidosis or time to discharge, and its use is generally not recommended. For further treatment information and in-depth review, refer to the ADA consensus report Hyperglycemic Crises in Adults With Diabetes ( 165 ). TRANSITION FROM THE HOSPITAL TO THE AMBULATORY SETTING Recommendation 16.18 A structured discharge plan should be tailored to the individual with diabetes. B For those not be - ing discharged to home, consider the capabilities of the facility for di - abetes management. E A structured discharge plan tailored to the individual may reduce the length of hospital stay and readmission rates and increase satisfaction with the hospital ex - perience ( 183 ). Multiple strategies are key, includ","tf":{"16":1,"18":1,"165":1,"181":1,"182":1,"183":1,"nits":1,"this":1,"approach":1,"may":2,"be":3,"safer":1,"and":6,"more":1,"cost":1,"effective":1,"than":1,"treatment":3,"with":6,"intravenous":2,"insulin":3,"there":1,"is":4,"no":2,"signif":1,"icant":1,"difference":2,"in":5,"outcomes":1,"for":5,"human":1,"regular":1,"versus":1,"subcutaneous":2,"rapid":1,"acting":1,"analogs":1,"when":1,"combined":1,"aggressive":1,"fluid":2,"management":2,"treating":1,"mild":1,"or":2,"moderate":1,"dka":3,"therefore":1,"if":1,"administration":1,"used":1,"it":1,"important":1,"to":8,"provide":1,"an":1,"ade":1,"quate":1,"replacement":1,"frequent":1,"poc":1,"blood":1,"glucose":1,"monitoring":1,"of":5,"any":1,"concurrent":1,"infections":1,"appro":1,"priate":1,"follow":1,"up":1,"avoid":1,"recurrent":1,"several":1,"studies":1,"have":1,"shown":1,"that":1,"the":11,"use":2,"bicarbonate":1,"people":1,"made":1,"resolution":1,"acidosis":1,"time":1,"discharge":3,"its":1,"generally":1,"not":2,"recommended":1,"further":1,"information":1,"depth":1,"review":1,"refer":1,"ada":1,"consensus":1,"report":1,"hyperglycemic":1,"crises":1,"adults":1,"diabetes":2,"transition":1,"from":1,"hospital":3,"ambulatory":1,"setting":1,"recommendation":1,"structured":2,"plan":2,"should":1,"tailored":2,"individual":2,"those":1,"ing":1,"discharged":1,"home":1,"consider":1,"capabilities":1,"facility":1,"di":1,"abetes":1,"reduce":1,"length":1,"stay":1,"readmission":1,"rates":1,"increase":1,"satisfaction":1,"ex":1,"perience":1,"multiple":1,"strategies":1,"are":1,"key":1,"includ":1},"len":207},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":11,"chunkId":"ada-2026-hosp-p11-c3","text":"y for di - abetes management. E A structured discharge plan tailored to the individual may reduce the length of hospital stay and readmission rates and increase satisfaction with the hospital ex - perience ( 183 ). Multiple strategies are key, including diabetes self-management education prior to discharge, diabetes medication reconciliation with attention to access, affordability, and scheduled vir - tual and/or face-to-face follow-up visits after discharge. Discharge planning should begin at admission and be updated as in - dividual needs change ( 184 , 185 ). Individu - alization and shared decision-making is key when creating a safe and effective discharge plan. Table 16.2Clinical presentation in people with diabetes with DKA and HHS DKA HHS Develops over hours to days Develops over days to a week Usually alert Change in cognitive state common Polyuria, polydipsia, weight loss, and dehydration Nausea, vomiting, and abdominal pain Often copresenting with other acute illness Kussmaul respiration - One-third of hyperglycemic emergencies have a hybrid DKA-HHS presentation Adapted from Umpierrez et al. ( 165 ). The transition from the acute care setting presents risks for all people with diabetes. Individuals may be discharged to varied settings, including home (with or without visiting nurse services), assis - ted living, rehabilitation, or skilled nurs - ing facilities. For i","tf":{"16":1,"165":1,"183":1,"184":1,"185":1,"for":3,"di":1,"abetes":1,"management":2,"structured":1,"discharge":5,"plan":2,"tailored":1,"to":7,"the":5,"individual":1,"may":2,"reduce":1,"length":1,"of":2,"hospital":2,"stay":1,"and":10,"readmission":1,"rates":1,"increase":1,"satisfaction":1,"with":7,"ex":1,"perience":1,"multiple":1,"strategies":1,"are":1,"key":2,"including":2,"diabetes":4,"self":1,"education":1,"prior":1,"medication":1,"reconciliation":1,"attention":1,"access":1,"affordability":1,"scheduled":1,"vir":1,"tual":1,"or":3,"face":2,"follow":1,"up":1,"visits":1,"after":1,"planning":1,"should":1,"begin":1,"at":1,"admission":1,"be":2,"updated":1,"as":1,"in":3,"dividual":1,"needs":1,"change":2,"individu":1,"alization":1,"shared":1,"decision":1,"making":1,"is":1,"when":1,"creating":1,"safe":1,"effective":1,"table":1,"clinical":1,"presentation":2,"people":2,"dka":3,"hhs":3,"develops":2,"over":2,"hours":1,"days":2,"week":1,"usually":1,"alert":1,"cognitive":1,"state":1,"common":1,"polyuria":1,"polydipsia":1,"weight":1,"loss":1,"dehydration":1,"nausea":1,"vomiting":1,"abdominal":1,"pain":1,"often":1,"copresenting":1,"other":1,"acute":2,"illness":1,"kussmaul":1,"respiration":1,"one":1,"third":1,"hyperglycemic":1,"emergencies":1,"have":1,"hybrid":1,"adapted":1,"from":2,"umpierrez":1,"et":1,"al":1,"transition":1,"care":1,"setting":1,"presents":1,"risks":1,"all":1,"individuals":1,"discharged":1,"varied":1,"settings":1,"home":1,"without":1,"visiting":1,"nurse":1,"services":1,"assis":1,"ted":1,"living":1,"rehabilitation":1,"skilled":1,"nurs":1,"ing":1,"facilities":1},"len":200},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":11,"chunkId":"ada-2026-hosp-p11-c4","text":"he acute care setting presents risks for all people with diabetes. Individuals may be discharged to varied settings, including home (with or without visiting nurse services), assis - ted living, rehabilitation, or skilled nurs - ing facilities. For individuals discharged to home or assisted living, the optimal discharge plan will need to consider dia - betes type and severity, effects of the diabetesjournals.org/care Diabetes Care in the Hospital S349 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S339/848851/dc26s016.pdf by guest on 17 February 2026","tf":{"17":1,"49":1,"2026":1,"848851":1,"he":1,"acute":1,"care":4,"setting":1,"presents":1,"risks":1,"for":2,"all":1,"people":1,"with":2,"diabetes":2,"individuals":2,"may":1,"be":1,"discharged":2,"to":3,"varied":1,"settings":1,"including":1,"home":2,"or":3,"without":1,"visiting":1,"nurse":1,"services":1,"assis":1,"ted":1,"living":2,"rehabilitation":1,"skilled":1,"nurs":1,"ing":1,"facilities":1,"assisted":1,"the":3,"optimal":1,"discharge":1,"plan":1,"will":1,"need":1,"consider":1,"dia":1,"betes":1,"type":1,"and":1,"severity":1,"effects":1,"of":1,"diabetesjournals":2,"org":2,"in":1,"hospital":1,"s349":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"supplement":1,"s339":1,"dc26s016":1,"by":1,"guest":1,"on":1,"february":1},"len":88},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":12,"chunkId":"ada-2026-hosp-p12-c0","text":"illness on blood glucose levels, and the individuals circumstances, capabilities, and preferences as well as the facility- related capabilities to manage diabetes ( 21 , 186  188 ). See section 13,  Older Adults , for more information. An outpatient follow-up visit with primary care, endocrinology, or a diabetes care and education specialist within 1 month of discharge is advised for all individuals experiencing hyperglycemia and/or hypo - glycemia in the hospital. If glycemic man - agement medications are changed or glucose management is not optimal at discharge, an earlier appointment (in 1  2 weeks) is preferred, and frequent contact to consider therapy adjustments may be needed to avoid hyperglycemia and hypoglycemia. A discharge algorithm for glycemic medication adjustment, based on admission A1C, diabetes medications before admission, and insulin usage during hospitalization was found useful to guide treatment decisions and significantly im - proved A1C after discharge ( 4 ). Clear communication with outpatient health care professionals directly or via hospital discharge summaries facilitates safe transitions to outpatient care. Provid - ing information regarding the root cause of hyperglycemia (or the plan for deter - mining the cause), related complications and comorbidities, and recommended treatments can assist outpatient health care professionals as they assume ","tf":{"13":1,"21":1,"186":1,"188":1,"illness":1,"on":2,"blood":1,"glucose":2,"levels":1,"and":10,"the":6,"individual":1,"circumstances":1,"capabilities":2,"preferences":1,"as":3,"well":1,"facility":1,"related":2,"to":5,"manage":1,"diabetes":3,"see":1,"section":1,"older":1,"adults":1,"for":4,"more":1,"information":2,"an":2,"outpatient":4,"follow":1,"up":1,"visit":1,"with":2,"primary":1,"care":5,"endocrinology":1,"or":5,"education":1,"specialist":1,"within":1,"month":1,"of":2,"discharge":5,"is":3,"advised":1,"all":1,"individuals":1,"experiencing":1,"hyperglycemia":3,"hypo":1,"glycemia":1,"in":2,"hospital":2,"if":1,"glycemic":2,"man":1,"agement":1,"medications":2,"are":1,"changed":1,"management":1,"not":1,"optimal":1,"at":1,"earlier":1,"appointment":1,"weeks":1,"preferred":1,"frequent":1,"contact":1,"consider":1,"therapy":1,"adjustments":1,"may":1,"be":1,"needed":1,"avoid":1,"hypoglycemia":1,"algorithm":1,"medication":1,"adjustment":1,"based":1,"admission":2,"a1c":2,"before":1,"insulin":1,"usage":1,"during":1,"hospitalization":1,"was":1,"found":1,"useful":1,"guide":1,"treatment":1,"decisions":1,"significantly":1,"im":1,"proved":1,"after":1,"clear":1,"communication":1,"health":2,"professionals":2,"directly":1,"via":1,"summaries":1,"facilitates":1,"safe":1,"transitions":1,"provid":1,"ing":1,"regarding":1,"root":1,"cause":2,"plan":1,"deter":1,"mining":1,"complications":1,"comorbidities":1,"recommended":1,"treatments":1,"can":1,"assist":1,"they":1,"assume":1},"len":188},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":12,"chunkId":"ada-2026-hosp-p12-c1","text":"t care. Provid - ing information regarding the root cause of hyperglycemia (or the plan for deter - mining the cause), related complications and comorbidities, and recommended treatments can assist outpatient health care professionals as they assume ongoing care. The Agency for Healthcare Research and Quality recommends that, at a min - imum, discharge plans include medica - tion reconciliation, structured discharge communication, and education for the individual with diabetes ( 189 ). Medication Reconciliation  Home and hospital medications must be cross-checked to ensure the safety of new and old prescriptions, that no chronic medications are stopped, and that there is no duplication of medica - tions under different brand names.  Prescriptions for new or changed medi - cations should be filled and reviewed with the individual and care partners at or before discharge whenever possible. Structured Discharge Communication  Information on medication changes, pending tests and studies, and follow- up needs must be accurately and promptly communicated to outpatient health care professionals.  Discharge summaries should be trans - mitted to the primary care health care professional as soon as possible after discharge.  Scheduling follow-up appointments prior to discharge with people with diabetes agreeing to the time and place increases the likelihood that they will attend. Ed","tf":{"189":1,"care":7,"provid":1,"ing":1,"information":2,"regarding":1,"the":10,"root":1,"cause":2,"of":3,"hyperglycemia":1,"or":3,"plan":1,"for":4,"deter":1,"mining":1,"related":1,"complications":1,"and":13,"comorbidities":1,"recommended":1,"treatments":1,"can":1,"assist":1,"outpatient":2,"health":3,"professionals":2,"as":3,"they":2,"assume":1,"ongoing":1,"agency":1,"healthcare":1,"research":1,"quality":1,"recommends":1,"that":4,"at":2,"min":1,"imum":1,"discharge":7,"plans":1,"include":1,"medica":2,"tion":1,"reconciliation":2,"structured":2,"communication":2,"education":1,"individual":2,"with":4,"diabetes":2,"medication":2,"home":1,"hospital":1,"medications":2,"must":2,"be":4,"cross":1,"checked":1,"to":5,"ensure":1,"safety":1,"new":2,"old":1,"prescriptions":2,"no":2,"chronic":1,"are":1,"stopped":1,"there":1,"is":1,"duplication":1,"tions":1,"under":1,"different":1,"brand":1,"names":1,"changed":1,"medi":1,"cations":1,"should":2,"filled":1,"reviewed":1,"partners":1,"before":1,"whenever":1,"possible":2,"on":1,"changes":1,"pending":1,"tests":1,"studies":1,"follow":2,"up":2,"needs":1,"accurately":1,"promptly":1,"communicated":1,"summaries":1,"trans":1,"mitted":1,"primary":1,"professional":1,"soon":1,"after":1,"scheduling":1,"appointments":1,"prior":1,"people":1,"agreeing":1,"time":1,"place":1,"increases":1,"likelihood":1,"will":1,"attend":1,"ed":1},"len":197},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":12,"chunkId":"ada-2026-hosp-p12-c2","text":"itted to the primary care health care professional as soon as possible after discharge.  Scheduling follow-up appointments prior to discharge with people with diabetes agreeing to the time and place increases the likelihood that they will attend. Education for the Person With Diabetes  Identify the health care professionals who will provide follow-up and dia - betes care after discharge.  Assess the level of understanding re - lated to diabetes diagnosis, glucose monitoring, home glucose goals, and when to call a health care professional.  Provide information on choosing healthy food at home and referral to an outpa - tient registered dietitian nutritionist or diabetes care and education specialist to guide individualization of the meal plan, if needed.  Review when and how to take blood glucose-lowering medications, including insulin administration and noninsulin injectables.  Review sick-day management ( 21 , 187 ).  Review proper use and disposal of diabetes supplies, e.g., insulin pens, pen needles, syringes, glucose me - ters, and lancets. People with diabetes must be pro - vided with appropriate durable medical equipment, medications, supplies (e.g., blood glucose test strips or CGM sen - sors), prescriptions, and appropriate education at the time of discharge to avoid a potentially dangerous hiatus in care. PREVENTING ADMISSIONS AND READMISSIONS For people with di","tf":{"21":1,"187":1,"itted":1,"to":9,"the":8,"primary":1,"care":7,"health":3,"professional":2,"as":2,"soon":1,"possible":1,"after":2,"discharge":4,"scheduling":1,"follow":2,"up":2,"appointments":1,"prior":1,"with":6,"people":3,"diabetes":6,"agreeing":1,"time":2,"and":11,"place":1,"increases":1,"likelihood":1,"that":1,"they":1,"will":2,"attend":1,"education":3,"for":2,"person":1,"identify":1,"professionals":1,"who":1,"provide":2,"dia":1,"betes":1,"assess":1,"level":1,"of":4,"understanding":1,"re":1,"lated":1,"diagnosis":1,"glucose":5,"monitoring":1,"home":2,"goals":1,"when":2,"call":1,"information":1,"on":1,"choosing":1,"healthy":1,"food":1,"at":2,"referral":1,"an":1,"outpa":1,"tient":1,"registered":1,"dietitian":1,"nutritionist":1,"or":2,"specialist":1,"guide":1,"individualization":1,"meal":1,"plan":1,"if":1,"needed":1,"review":3,"how":1,"take":1,"blood":2,"lowering":1,"medications":2,"including":1,"insulin":2,"administration":1,"noninsulin":1,"injectables":1,"sick":1,"day":1,"management":1,"proper":1,"use":1,"disposal":1,"supplies":2,"pens":1,"pen":1,"needles":1,"syringes":1,"me":1,"ters":1,"lancets":1,"must":1,"be":1,"pro":1,"vided":1,"appropriate":2,"durable":1,"medical":1,"equipment":1,"test":1,"strips":1,"cgm":1,"sen":1,"sors":1,"prescriptions":1,"avoid":1,"potentially":1,"dangerous":1,"hiatus":1,"in":1,"preventing":1,"admissions":1,"readmissions":1,"di":1},"len":200},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":12,"chunkId":"ada-2026-hosp-p12-c3","text":"t, medications, supplies (e.g., blood glucose test strips or CGM sen - sors), prescriptions, and appropriate education at the time of discharge to avoid a potentially dangerous hiatus in care. PREVENTING ADMISSIONS AND READMISSIONS For people with diabetes, the hospital re - admission rate is between 14% and 20%, which is nearly twice that for people without diabetes ( 184 , 190 ). This may re - sult in increased diabetes distress and has significant financial implications. Of peo - ple with diabetes who are hospitalized, 30% have two or more days of hospital stays, and these admissions account for over 50% of hospital costs for diabetes ( 191 ). Factors contributing to readmission include male sex, longer duration of prior hospitalization, number of previous hospi - talizations, number and severity of comor - bidities, and lower socioeconomic and/or educational status; factors that may re - duce readmission rates include scheduled home health visits and timely ambulatory follow-up care ( 184 , 190 ). While there is no standardized protocol to prevent readmis - sions, several successful strategies have been reported that identify high-risk indi - viduals and offer some possible solutions ( 184 ). To prevent readmissions, monitor in - sulin adjustments for individuals admitted with A1C > 9% ( > 75 mmol/mol) ( 192 ) or DKA ( 193 , 194 ) and follow a transitional care model ( 195 ","tf":{"14":1,"20":1,"30":1,"50":1,"75":1,"184":3,"190":2,"191":1,"192":1,"193":1,"194":1,"195":1,"medications":1,"supplies":1,"blood":1,"glucose":1,"test":1,"strips":1,"or":4,"cgm":1,"sen":1,"sors":1,"prescriptions":1,"and":11,"appropriate":1,"education":1,"at":1,"the":2,"time":1,"of":7,"discharge":1,"to":4,"avoid":1,"potentially":1,"dangerous":1,"hiatus":1,"in":3,"care":3,"preventing":1,"admissions":2,"readmissions":2,"for":5,"people":2,"with":3,"diabetes":5,"hospital":3,"re":3,"admission":1,"rate":1,"is":3,"between":1,"which":1,"nearly":1,"twice":1,"that":3,"without":1,"this":1,"may":2,"sult":1,"increased":1,"distress":1,"has":1,"significant":1,"financial":1,"implications":1,"peo":1,"ple":1,"who":1,"are":1,"hospitalized":1,"have":2,"two":1,"more":1,"days":1,"stays":1,"these":1,"account":1,"over":1,"costs":1,"factors":2,"contributing":1,"readmission":2,"include":2,"male":1,"sex":1,"longer":1,"duration":1,"prior":1,"hospitalization":1,"number":2,"previous":1,"hospi":1,"talizations":1,"severity":1,"comor":1,"bidities":1,"lower":1,"socioeconomic":1,"educational":1,"status":1,"duce":1,"rates":1,"scheduled":1,"home":1,"health":1,"visits":1,"timely":1,"ambulatory":1,"follow":2,"up":1,"while":1,"there":1,"no":1,"standardized":1,"protocol":1,"prevent":2,"readmis":1,"sions":1,"several":1,"successful":1,"strategies":1,"been":1,"reported":1,"identify":1,"high":1,"risk":1,"indi":1,"viduals":1,"offer":1,"some":1,"possible":1,"solutions":1,"monitor":1,"sulin":1,"adjustments":1,"individuals":1,"admitted":1,"a1c":1,"mmol":1,"mol":1,"dka":1,"transitional":1,"model":1},"len":202},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":12,"chunkId":"ada-2026-hosp-p12-c4","text":"gh-risk indi - viduals and offer some possible solutions ( 184 ). To prevent readmissions, monitor in - sulin adjustments for individuals admitted with A1C > 9% ( > 75 mmol/mol) ( 192 ) or DKA ( 193 , 194 ) and follow a transitional care model ( 195 ). For individuals hospital - ized with severe hypoglycemia, impaired awareness of hypoglycemia, or high risk for hypoglycemia (kidney failure, intensive insulin management, frailty, inadequate support system, etc.), consider prescribing glucagon to treat any future severe hypo - glycemia events ( 196 ). For people with diabetes and chronic kidney disease, col - laborative person-centered medical homes may decrease risk-adjusted readmission rates ( 197 ). Since recent studies have shown that use of CGM may prevent emergency department visits and hospital admission in people with type 1 and type 2 diabetes, it may be beneficial to ini - tiate CGM just prior to discharge to facili - tate follow-up and possibly prevent acute diabetes-related complications and read - mission ( 198 ). Age is also an important risk factor in hospitalization and readmission among people with diabetes (refer to section 13,  Older Adults , for detailed information). Successful proactive care transitions from inpatient to outpatient settings are key strategies for preventing readmission and emergency department visits. THE FUTURE Inpatient diabetes manageme","tf":{"13":1,"75":1,"184":1,"192":1,"193":1,"194":1,"195":1,"196":1,"197":1,"198":1,"gh":1,"risk":4,"indi":1,"viduals":1,"and":9,"offer":1,"some":1,"possible":1,"solutions":1,"to":7,"prevent":3,"readmissions":1,"monitor":1,"in":3,"sulin":1,"adjustments":1,"for":6,"individuals":2,"admitted":1,"with":5,"a1c":1,"mmol":1,"mol":1,"or":2,"dka":1,"follow":2,"transitional":1,"care":2,"model":1,"hospital":2,"ized":1,"severe":2,"hypoglycemia":3,"impaired":1,"awareness":1,"of":2,"high":1,"kidney":2,"failure":1,"intensive":1,"insulin":1,"management":1,"frailty":1,"inadequate":1,"support":1,"system":1,"etc":1,"consider":1,"prescribing":1,"glucagon":1,"treat":1,"any":1,"future":2,"hypo":1,"glycemia":1,"events":1,"people":3,"diabetes":5,"chronic":1,"disease":1,"col":1,"laborative":1,"person":1,"centered":1,"medical":1,"homes":1,"may":3,"decrease":1,"adjusted":1,"readmission":3,"rates":1,"since":1,"recent":1,"studies":1,"have":1,"shown":1,"that":1,"use":1,"cgm":2,"emergency":2,"department":2,"visits":2,"admission":1,"type":2,"it":1,"be":1,"beneficial":1,"ini":1,"tiate":1,"just":1,"prior":1,"discharge":1,"facili":1,"tate":1,"up":1,"possibly":1,"acute":1,"related":1,"complications":1,"read":1,"mission":1,"age":1,"is":1,"also":1,"an":1,"important":1,"factor":1,"hospitalization":1,"among":1,"refer":1,"section":1,"older":1,"adults":1,"detailed":1,"information":1,"successful":1,"proactive":1,"transitions":1,"from":1,"inpatient":2,"outpatient":1,"settings":1,"are":1,"key":1,"strategies":1,"preventing":1,"the":1,"manageme":1},"len":195},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":12,"chunkId":"ada-2026-hosp-p12-c5","text":"section 13,  Older Adults , for detailed information). Successful proactive care transitions from inpatient to outpatient settings are key strategies for preventing readmission and emergency department visits. THE FUTURE Inpatient diabetes management is chal - lenging for hospitals, health care profes - sionals, and people with diabetes, as acute illness increases the risk of both hypoglycemia and hyperglycemia. The use of decision support tools and prac - tice advisories in the EHR has facilitated health care professionals following the recommendations in this standard of care. In addition, personal and hospital- owned diabetes devices and dosing algorithms are changing the way we pro - vide care. Future enhancements will likely continue to improve the quality of care S350 Diabetes Care in the Hospital Diabetes Care Volume 49, Supplement 1, January 2026 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S339/848851/dc26s016.pdf by guest on 17 February 2026","tf":{"13":1,"17":1,"49":2,"2026":2,"848851":1,"section":1,"older":1,"adults":1,"for":3,"detailed":1,"information":1,"successful":1,"proactive":1,"care":9,"transitions":1,"from":2,"inpatient":2,"to":2,"outpatient":1,"settings":1,"are":2,"key":1,"strategies":1,"preventing":1,"readmission":1,"and":6,"emergency":1,"department":1,"visits":1,"the":8,"future":2,"diabetes":5,"management":1,"is":1,"chal":1,"lenging":1,"hospitals":1,"health":2,"profes":1,"sionals":1,"people":1,"with":1,"as":1,"acute":1,"illness":1,"increases":1,"risk":1,"of":4,"both":1,"hypoglycemia":1,"hyperglycemia":1,"use":1,"decision":1,"support":1,"tools":1,"prac":1,"tice":1,"advisories":1,"in":4,"ehr":1,"has":1,"facilitated":1,"professionals":1,"following":1,"recommendations":1,"this":1,"standard":1,"addition":1,"personal":1,"hospital":2,"owned":1,"devices":1,"dosing":1,"algorithms":1,"changing":1,"way":1,"we":1,"pro":1,"vide":1,"enhancements":1,"will":1,"likely":1,"continue":1,"improve":1,"quality":1,"s350":1,"volume":1,"supplement":2,"january":1,"downloaded":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"s339":1,"dc26s016":1,"by":1,"guest":1,"on":1,"february":1},"len":144},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":13,"chunkId":"ada-2026-hosp-p13-c0","text":"we deliver in hospitals and in transitions from inpatient to outpatient. References 1. Seisa MO, Saadi S, Nayfeh T, et al. A systematic review supporting the endocrine society clinical practice guideline for the management of hyperglycemia in adults hospitalized for noncritical illness or undergoing elective surgical procedures. J Clin Endocrinol Metab 2022;107:2139  2147 2. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002;87:978  982 3. Pasquel FJ, Gomez-Huelgas R, Anzola I, et al. Predictive value of admission hemoglobin A1c on inpatient glycemic control and response to insulin therapy in medicine and surgery patients with type 2 diabetes. Diabetes Care 2015;38:e202-203  e203 4. Umpierrez GE, Reyes D, Smiley D, et al. Hospital discharge algorithm based on admission HbA1c for the management of patients with type 2 diabetes. Diabetes Care 2014;37:2934  2939 5. Nanayakkara N, Nguyen H, Churilov L, et al. Inpatient HbA1c testing: a prospective observational study. BMJ Open Diabetes Res Care 2015;3:e000113 6. Khan SA, Demidowich AP, Tschudy MM, et al. Increasing frequency of hemoglobin A1c measurements in hospitalized patients with diabetes: a quality improvement project using Lean Six Sigma. J Diabetes Sci Technol 2024;18: 866  ","tf":{"18":1,"37":1,"38":1,"87":1,"107":1,"203":1,"866":1,"978":1,"982":1,"2002":1,"2014":1,"2015":2,"2022":1,"2024":1,"2139":1,"2147":1,"2934":1,"2939":1,"we":1,"deliver":1,"in":7,"hospitals":1,"and":3,"transitions":1,"from":1,"inpatient":3,"to":2,"outpatient":1,"references":1,"seisa":1,"mo":1,"saadi":1,"nayfeh":1,"et":5,"al":5,"systematic":1,"review":1,"supporting":1,"the":3,"endocrine":1,"society":1,"clinical":1,"practice":1,"guideline":1,"for":3,"management":2,"of":5,"hyperglycemia":2,"adults":1,"hospitalized":2,"noncritical":1,"illness":1,"or":1,"undergoing":1,"elective":1,"surgical":1,"procedures":1,"clin":2,"endocrinol":2,"metab":2,"umpierrez":2,"ge":2,"isaacs":1,"sd":1,"bazargan":1,"you":1,"thaler":1,"lm":1,"kitabchi":1,"ae":1,"an":1,"independent":1,"marker":1,"hospital":2,"mortality":1,"patients":4,"with":4,"undiagnosed":1,"diabetes":8,"pasquel":1,"fj":1,"gomez":1,"huelgas":1,"anzola":1,"predictive":1,"value":1,"admission":2,"hemoglobin":2,"a1c":2,"on":2,"glycemic":1,"control":1,"response":1,"insulin":1,"therapy":1,"medicine":1,"surgery":1,"type":2,"care":3,"e202":1,"e203":1,"reyes":1,"smiley":1,"discharge":1,"algorithm":1,"based":1,"hba1c":2,"nanayakkara":1,"nguyen":1,"churilov":1,"testing":1,"prospective":1,"observational":1,"study":1,"bmj":1,"open":1,"res":1,"e000113":1,"khan":1,"sa":1,"demidowich":1,"ap":1,"tschudy":1,"mm":1,"increasing":1,"frequency":1,"measurements":1,"quality":1,"improvement":1,"project":1,"using":1,"lean":1,"six":1,"sigma":1,"sci":1,"technol":1},"len":194},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":13,"chunkId":"ada-2026-hosp-p13-c1","text":"s Care 2015;3:e000113 6. Khan SA, Demidowich AP, Tschudy MM, et al. Increasing frequency of hemoglobin A1c measurements in hospitalized patients with diabetes: a quality improvement project using Lean Six Sigma. J Diabetes Sci Technol 2024;18: 866  873 7. Nassar CM, Montero A, Magee MF. Inpatient diabetes education in the real world: an overview of guidelines and delivery models. Curr Diab Rep 2019;19:103 8. Davidson HE, Jain S, Kazdan C, Resnick B, Scarabelli T, Pandya N. Clinical practice guideline for diabetes management in the post-acute and long-term care setting. J Am Med Dir Assoc 2024;25:105342 9. Kravchenko MI, Tate JM, Clerc PG, et al. Impact of structured insulin order sets on inpatient hypoglycemia and glycemic control. Endocr Pract 2020;26:523  528 10. Institute of Medicine. Preventing Medication Errors Aspden P, Wolcott J, Bootman JL, Cronenwett LR, Eds. Washington, DC, National Academies Press, 2007 11. Sly B, Russell AW, Sullivan C. Digital inter- ventions to improve safety and quality of inpatient diabetes management: a systematic review. Int J Med Inform 2022;157:104596 12. Gianchandani R, Wei M, Demidowich A. Management of hyperglycemia in hospitalized patients. Ann Intern Med 2024;177:ITC177  ITC192 13. Aloi J, Bode BW, Ullal J, et al. Comparison of an electronic glycemic management system versus provider-managed subcutaneous basal bolus insulin therapy i","tf":{"10":1,"11":1,"12":1,"13":1,"18":1,"19":1,"25":1,"26":1,"103":1,"157":1,"177":1,"523":1,"528":1,"866":1,"873":1,"2007":1,"2015":1,"2019":1,"2020":1,"2022":1,"2024":3,"104596":1,"105342":1,"care":2,"e000113":1,"khan":1,"sa":1,"demidowich":2,"ap":1,"tschudy":1,"mm":1,"et":3,"al":3,"increasing":1,"frequency":1,"of":7,"hemoglobin":1,"a1c":1,"measurements":1,"in":4,"hospitalized":2,"patients":2,"with":1,"diabetes":5,"quality":2,"improvement":1,"project":1,"using":1,"lean":1,"six":1,"sigma":1,"sci":1,"technol":1,"nassar":1,"cm":1,"montero":1,"magee":1,"mf":1,"inpatient":3,"education":1,"the":2,"real":1,"world":1,"an":2,"overview":1,"guidelines":1,"and":4,"delivery":1,"models":1,"curr":1,"diab":1,"rep":1,"davidson":1,"he":1,"jain":1,"kazdan":1,"resnick":1,"scarabelli":1,"pandya":1,"clinical":1,"practice":1,"guideline":1,"for":1,"management":4,"post":1,"acute":1,"long":1,"term":1,"setting":1,"am":1,"med":3,"dir":1,"assoc":1,"kravchenko":1,"mi":1,"tate":1,"jm":1,"clerc":1,"pg":1,"impact":1,"structured":1,"insulin":2,"order":1,"sets":1,"on":1,"hypoglycemia":1,"glycemic":2,"control":1,"endocr":1,"pract":1,"institute":1,"medicine":1,"preventing":1,"medication":1,"errors":1,"aspden":1,"wolcott":1,"bootman":1,"jl":1,"cronenwett":1,"lr":1,"eds":1,"washington":1,"dc":1,"national":1,"academies":1,"press":1,"sly":1,"russell":1,"aw":1,"sullivan":1,"digital":1,"inter":1,"ventions":1,"to":1,"improve":1,"safety":1,"systematic":1,"review":1,"int":1,"inform":1,"gianchandani":1,"wei":1,"hyperglycemia":1,"ann":1,"intern":1,"itc177":1,"itc192":1,"aloi":1,"bode":1,"bw":1,"ullal":1,"comparison":1,"electronic":1,"system":1,"versus":1,"provider":1,"managed":1,"subcutaneous":1,"basal":1,"bolus":1,"therapy":1},"len":200},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":13,"chunkId":"ada-2026-hosp-p13-c2","text":"nagement of hyperglycemia in hospitalized patients. Ann Intern Med 2024;177:ITC177  ITC192 13. Aloi J, Bode BW, Ullal J, et al. Comparison of an electronic glycemic management system versus provider-managed subcutaneous basal bolus insulin therapy in the hospital setting. J Diabetes Sci Technol 2017;11:12  16 14. Tanenberg RJ, Hardee S, Rothermel C, Drake AJ. Use of a computer-guided glucose management system to improve glycemic control and address national quality measures: a 7-year, retrospective observational study at a tertiary care teaching hospital. Endocr Pract 2017;23:331  341 15. Akiboye F, Sihre HK, Al Mulhem M, Rayman G, Nirantharakumar K, Adderley NJ. Impact of diabetes specialist nurses on inpatient care: a systematic review. Diabet Med 2021;38:e14573 16. Demidowich AP, Batty K, Love T, et al. Effects of a dedicated inpatient diabetes management service on glycemic control in a community hospital setting. J Diabetes Sci Technol 2021; 15:546  552 17. Haque WZ, Demidowich AP, Sidhaye A, Golden SH, Zilbermint M. The financial impact of an inpatient diabetes management service. Curr Diab Rep 2021;21:5 18. Bansal V, Mottalib A, Pawar TK, et al. Inpatient diabetes management by specialized diabetes team versus primary service team in non-critical care units: impact on 30-day readmission rate and hospital cost. BMJ Open Diabetes Res Care 2018;6:e000460 19. Rushakoff R","tf":{"11":1,"12":1,"13":1,"14":1,"15":2,"16":2,"17":1,"18":1,"19":1,"21":1,"23":1,"30":1,"38":1,"177":1,"331":1,"341":1,"546":1,"552":1,"2017":2,"2018":1,"2021":3,"2024":1,"nagement":1,"of":6,"hyperglycemia":1,"in":4,"hospitalized":1,"patients":1,"ann":1,"intern":1,"med":2,"itc177":1,"itc192":1,"aloi":1,"bode":1,"bw":1,"ullal":1,"et":3,"al":4,"comparison":1,"an":2,"electronic":1,"glycemic":3,"management":5,"system":2,"versus":2,"provider":1,"managed":1,"subcutaneous":1,"basal":1,"bolus":1,"insulin":1,"therapy":1,"the":2,"hospital":4,"setting":2,"diabetes":8,"sci":2,"technol":2,"tanenberg":1,"rj":1,"hardee":1,"rothermel":1,"drake":1,"aj":1,"use":1,"computer":1,"guided":1,"glucose":1,"to":1,"improve":1,"control":2,"and":2,"address":1,"national":1,"quality":1,"measures":1,"year":1,"retrospective":1,"observational":1,"study":1,"at":1,"tertiary":1,"care":4,"teaching":1,"endocr":1,"pract":1,"akiboye":1,"sihre":1,"hk":1,"mulhem":1,"rayman":1,"nirantharakumar":1,"adderley":1,"nj":1,"impact":3,"specialist":1,"nurses":1,"on":3,"inpatient":4,"systematic":1,"review":1,"diabet":1,"e14573":1,"demidowich":2,"ap":2,"batty":1,"love":1,"effects":1,"dedicated":1,"service":3,"community":1,"haque":1,"wz":1,"sidhaye":1,"golden":1,"sh":1,"zilbermint":1,"financial":1,"curr":1,"diab":1,"rep":1,"bansal":1,"mottalib":1,"pawar":1,"tk":1,"by":1,"specialized":1,"team":2,"primary":1,"non":1,"critical":1,"units":1,"day":1,"readmission":1,"rate":1,"cost":1,"bmj":1,"open":1,"res":1,"e000460":1,"rushakoff":1},"len":201},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":13,"chunkId":"ada-2026-hosp-p13-c3","text":"alib A, Pawar TK, et al. Inpatient diabetes management by specialized diabetes team versus primary service team in non-critical care units: impact on 30-day readmission rate and hospital cost. BMJ Open Diabetes Res Care 2018;6:e000460 19. Rushakoff RJ, Sullivan MM, MacMaster HW, et al. Association between a virtual glucose management service and glycemic control in hospitalized adult patients: an observational study. Ann Intern Med 2017;166:621  627 20. Magee MF, Baker KM, Bardsley JK, Wesley D, Smith KM. Diabetes to go-inpatient: pragmatic lessons learned from implementation of technology- enabled diabetes survival skills education within nursing unit workflow in an urban, tertiary care hospital. Jt Comm J Qual Patient Saf 2021;47: 107  119 21. Pinkhasova D, Swami JB, Patel N, et al. Patient understanding of discharge instructions for home diabetes self-management and risk for hospital readmission and emergency department visits. Endocr Pract 2021;27:561  566 22. Drincic AT, Akkireddy P, Knezevich JT. Common models used for inpatient diabetes management. Curr Diab Rep 2018;18:10 23. The Leapfrog Group. Recognized leader in caring for people living with diabetes. Accessed 4 August 2025. Available from https://www .leapfroggroup.org/recognized-leader-diabetes 24. Society of Hospital Medicine. Glycemic control for hospitalists. Accessed 4 August 2025. Available from https://ww","tf":{"10":1,"18":1,"19":1,"20":1,"21":1,"22":1,"23":1,"24":1,"27":1,"30":1,"47":1,"107":1,"119":1,"166":1,"561":1,"566":1,"621":1,"627":1,"2017":1,"2018":2,"2021":2,"2025":2,"alib":1,"pawar":1,"tk":1,"et":3,"al":3,"inpatient":3,"diabetes":9,"management":4,"by":1,"specialized":1,"team":2,"versus":1,"primary":1,"service":2,"in":4,"non":1,"critical":1,"care":3,"units":1,"impact":1,"on":1,"day":1,"readmission":2,"rate":1,"and":4,"hospital":4,"cost":1,"bmj":1,"open":1,"res":1,"e000460":1,"rushakoff":1,"rj":1,"sullivan":1,"mm":1,"macmaster":1,"hw":1,"association":1,"between":1,"virtual":1,"glucose":1,"glycemic":2,"control":2,"hospitalized":1,"adult":1,"patients":1,"an":2,"observational":1,"study":1,"ann":1,"intern":1,"med":1,"magee":1,"mf":1,"baker":1,"km":2,"bardsley":1,"jk":1,"wesley":1,"smith":1,"to":1,"go":1,"pragmatic":1,"lessons":1,"learned":1,"from":3,"implementation":1,"of":3,"technology":1,"enabled":1,"survival":1,"skills":1,"education":1,"within":1,"nursing":1,"unit":1,"workflow":1,"urban":1,"tertiary":1,"jt":2,"comm":1,"qual":1,"patient":2,"saf":1,"pinkhasova":1,"swami":1,"jb":1,"patel":1,"understanding":1,"discharge":1,"instructions":1,"for":5,"home":1,"self":1,"risk":1,"emergency":1,"department":1,"visits":1,"endocr":1,"pract":1,"drincic":1,"at":1,"akkireddy":1,"knezevich":1,"common":1,"models":1,"used":1,"curr":1,"diab":1,"rep":1,"the":1,"leapfrog":1,"group":1,"recognized":2,"leader":2,"caring":1,"people":1,"living":1,"with":1,"accessed":2,"august":2,"available":2,"https":2,"www":1,"leapfroggroup":1,"org":1,"society":1,"medicine":1,"hospitalists":1,"ww":1},"len":206},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":13,"chunkId":"ada-2026-hosp-p13-c4","text":"g for people living with diabetes. Accessed 4 August 2025. Available from https://www .leapfroggroup.org/recognized-leader-diabetes 24. Society of Hospital Medicine. Glycemic control for hospitalists. Accessed 4 August 2025. Available from https://www.hospitalmedicine.org/ clinical-topics/glycemic-control/ 25. Association of British Clinical Diabetologists. Joint British Diabetes Societies (JBDS) for Inpatient Care Group. Accessed 4 August 2025. Available from https://abcd.care/jbds-ip 26. Arnold P, Scheurer D, Dake AW, et al. Hospital guidelines for diabetes management and the Joint Commission-American Diabetes Association Inpatient Diabetes Certification. Am J Med Sci 2016;351:333  341 27. U.S. Centers for Disease Control and Prevention. Testing for diabetes. Accessed 4 August 2025. Available from https://www.cdc .gov/diabetes/diabetes-testing/index.html 28. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359  1367 29. Umpierrez GE. Glucose control in the ICU. N Engl J Med 2023;389:1234  1237 30. Gunst J, Debaveye Y, Giza F, et al.; TGC-Fast Collaborators. Tight blood-glucose control without early parenteral nutrition in the ICU. N Engl J Med 2023;389:1180  1190 31. Finfer S, Chittock DR, Su SY-S, et al.; NICE- SUGAR Study Investigators. Intensive versus conventional glucose control in critically","tf":{"24":1,"25":1,"26":1,"27":1,"28":1,"29":1,"30":1,"31":1,"333":1,"341":1,"345":1,"351":1,"389":2,"1180":1,"1190":1,"1234":1,"1237":1,"1359":1,"1367":1,"2001":1,"2016":1,"2023":2,"2025":4,"for":6,"people":1,"living":1,"with":1,"diabetes":9,"accessed":4,"august":4,"available":4,"from":4,"https":4,"www":3,"leapfroggroup":1,"org":2,"recognized":1,"leader":1,"society":1,"of":2,"hospital":2,"medicine":1,"glycemic":2,"control":6,"hospitalists":1,"hospitalmedicine":1,"clinical":2,"topics":1,"association":2,"british":2,"diabetologists":1,"joint":2,"societies":1,"jbds":2,"inpatient":2,"care":2,"group":1,"abcd":1,"ip":1,"arnold":1,"scheurer":1,"dake":1,"aw":1,"et":4,"al":4,"guidelines":1,"management":1,"and":2,"the":3,"commission":1,"american":1,"certification":1,"am":1,"med":4,"sci":1,"centers":1,"disease":1,"prevention":1,"testing":2,"cdc":1,"gov":1,"index":1,"html":1,"van":1,"den":1,"berghe":1,"wouters":1,"weekers":1,"intensive":2,"insulin":1,"therapy":1,"in":4,"critically":2,"ill":1,"patients":1,"engl":3,"umpierrez":1,"ge":1,"glucose":3,"icu":2,"gunst":1,"debaveye":1,"iza":1,"tgc":1,"fast":1,"collaborators":1,"tight":1,"blood":1,"without":1,"early":1,"parenteral":1,"nutrition":1,"finfer":1,"chittock":1,"dr":1,"su":1,"sy":1,"nice":1,"sugar":1,"study":1,"investigators":1,"versus":1,"conventional":1},"len":197},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":13,"chunkId":"ada-2026-hosp-p13-c5","text":"ors. Tight blood-glucose control without early parenteral nutrition in the ICU. N Engl J Med 2023;389:1180  1190 31. Finfer S, Chittock DR, Su SY-S, et al.; NICE- SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283  1297 32. Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA 2008;300:933  944 33. Adigbli D, Li Y, Hammond N, et al. A patient-level meta-analysis of intensive glucose control in critically ill adults. NEJM Evid 2024;3: EVIDoa2400082 34. Furnary AP, Wu Y, Bookin SO. Effect of hyperglycemia and continuous intravenous insulin infusions on outcomes of cardiac surgical procedures: the Portland Diabetic Project. Endocr Pract 2004;10(Suppl. 2):21  33 35. Magaji V, Nayak S, Donihi AC, et al. Comparison of insulin infusion protocols targeting 110  140 mg/dL in patients after cardiac surgery. Diabetes Technol Ther 2012;14:1013  1017 36. Korytkowski MT, Muniyappa R, Antinori-Lent K, et al. Management of hyperglycemia in hospitalized adult patients in non-critical care settings: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2022;107: 2101  2128 37. Murad MH, Coburn JA, Coto-Yglesias F, et al. Glycemic control in non-critically ill hospitalized patients: a systematic review and meta-analysis. J C","tf":{"10":1,"14":1,"21":1,"31":1,"32":1,"33":2,"34":1,"35":1,"36":1,"37":1,"107":1,"110":1,"140":1,"300":1,"360":1,"389":1,"933":1,"944":1,"1013":1,"1017":1,"1180":1,"1190":1,"1283":1,"1297":1,"2004":1,"2008":1,"2009":1,"2012":1,"2022":1,"2023":1,"2024":1,"2101":1,"2128":1,"ors":1,"tight":2,"blood":1,"glucose":4,"control":5,"without":1,"early":1,"parenteral":1,"nutrition":1,"in":8,"the":2,"icu":1,"engl":2,"med":2,"finfer":1,"chittock":1,"dr":1,"su":1,"sy":1,"et":5,"al":5,"nice":1,"sugar":1,"study":1,"investigators":1,"intensive":2,"versus":1,"conventional":1,"critically":4,"ill":4,"patients":4,"wiener":2,"rs":1,"dc":1,"larson":1,"rj":1,"benefits":1,"and":3,"risks":1,"of":6,"adults":2,"meta":3,"analysis":3,"jama":1,"adigbli":1,"li":1,"hammond":1,"patient":1,"level":1,"nejm":1,"evid":1,"evidoa2400082":1,"furnary":1,"ap":1,"wu":1,"bookin":1,"so":1,"effect":1,"hyperglycemia":2,"continuous":1,"intravenous":1,"insulin":2,"infusions":1,"on":1,"outcomes":1,"cardiac":2,"surgical":1,"procedures":1,"portland":1,"diabetic":1,"project":1,"endocr":1,"pract":1,"suppl":1,"magaji":1,"nayak":1,"donihi":1,"ac":1,"comparison":1,"infusion":1,"protocols":1,"targeting":1,"mg":1,"dl":1,"after":1,"surgery":1,"diabetes":1,"technol":1,"ther":1,"korytkowski":1,"mt":1,"muniyappa":1,"antinori":1,"lent":1,"management":1,"hospitalized":2,"adult":1,"non":2,"critical":1,"care":1,"settings":1,"an":1,"endocrine":1,"society":1,"clinical":1,"practice":1,"guideline":1,"clin":1,"endocrinol":1,"metab":1,"murad":1,"mh":1,"coburn":1,"ja":1,"coto":1,"yglesias":1,"glycemic":1,"systematic":1,"review":1},"len":207},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":13,"chunkId":"ada-2026-hosp-p13-c6","text":" an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2022;107: 2101  2128 37. Murad MH, Coburn JA, Coto-Yglesias F, et al. Glycemic control in non-critically ill hospitalized patients: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012;97:49  58 38. Flory JH, Aleman JO, Furst J, Seley JJ. Basal insulin use in the non-critical care setting: is fasting hypoglycemia inevitable or preventable? J Diabetes Sci Technol 2014;8:427  428 39. Sacks DB, Arnold M, Bakris GL, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2023;46:e151  e199 40. DuBois JA, Slingerland RJ, Fokkert M, et al. Bedside glucose monitoring-is it safe? A new, regulatory-compliant risk assessment evaluation protocol in critically ill patient care settings. Crit Care Med 2017;45:567  574 41. Zhang R, Isakow W, Kollef MH, Scott MG. Performance of a modern glucose meter in ICU and general hospital inpatients: 3 years of real- world paired meter and central laboratory results. Crit Care Med 2017;45:1509  1514 42. Misra S, Avari P, Lumb A, et al. How can point-of-care technologies support in-hospital diabetes care? J Diabetes Sci Technol 2023;17: 509  516 43. Lee MY, Seav SM, Ongwela L, et al. Empowering hospitalized patients with diabetes: implementation of a hospital-wide CGM policy with EHR-in","tf":{"17":1,"37":1,"38":1,"39":1,"40":1,"41":1,"42":1,"43":1,"45":2,"46":1,"49":1,"58":1,"97":1,"107":1,"427":1,"428":1,"509":1,"516":1,"567":1,"574":1,"1509":1,"1514":1,"2012":1,"2014":1,"2017":2,"2022":1,"2023":2,"2101":1,"2128":1,"an":1,"endocrine":1,"society":1,"clinical":1,"practice":1,"guideline":1,"clin":2,"endocrinol":2,"metab":2,"murad":1,"mh":2,"coburn":1,"ja":2,"coto":1,"yglesias":1,"et":5,"al":5,"glycemic":1,"control":1,"in":7,"non":2,"critically":2,"ill":2,"hospitalized":2,"patients":2,"systematic":1,"review":1,"and":5,"meta":1,"analysis":2,"flory":1,"jh":1,"aleman":1,"jo":1,"furst":1,"seley":1,"jj":1,"basal":1,"insulin":1,"use":1,"the":2,"critical":1,"care":7,"setting":1,"is":2,"fasting":1,"hypoglycemia":1,"inevitable":1,"or":1,"preventable":1,"diabetes":6,"sci":2,"technol":2,"sacks":1,"db":1,"arnold":1,"bakris":1,"gl":1,"guidelines":1,"recommendations":1,"for":1,"laboratory":2,"diagnosis":1,"management":1,"of":5,"mellitus":1,"e151":1,"e199":1,"dubois":1,"slingerland":1,"rj":1,"fokkert":1,"bedside":1,"glucose":2,"monitoring":1,"it":1,"safe":1,"new":1,"regulatory":1,"compliant":1,"risk":1,"assessment":1,"evaluation":1,"protocol":1,"patient":1,"settings":1,"crit":2,"med":2,"zhang":1,"isakow":1,"kollef":1,"scott":1,"mg":1,"performance":1,"modern":1,"meter":2,"icu":1,"general":1,"hospital":3,"inpatients":1,"years":1,"real":1,"world":1,"paired":1,"central":1,"results":1,"misra":1,"avari":1,"lumb":1,"how":1,"can":1,"point":1,"technologies":1,"support":1,"lee":1,"my":1,"seav":1,"sm":1,"ongwela":1,"empowering":1,"with":2,"implementation":1,"wide":1,"cgm":1,"policy":1,"ehr":1},"len":214},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":13,"chunkId":"ada-2026-hosp-p13-c7","text":"an point-of-care technologies support in-hospital diabetes care? J Diabetes Sci Technol 2023;17: 509  516 43. Lee MY, Seav SM, Ongwela L, et al. Empowering hospitalized patients with diabetes: implementation of a hospital-wide CGM policy with EHR-integrated validation for dosing insulin. Diabetes Care 2024;47:1838  1845 44. Fortmann AL, Spierling Bagsic SR, Talavera L, et al. Glucose as the fifth vital sign: a randomized controlled trial of continuous glucose monitoring in a non-ICU hospital setting. Diabetes Care 2020;43:2873  2877 45. Galindo RJ, Migdal AL, Davis GM, et al. Comparison of the FreeStyle Libre Pro flash continuous glucose monitoring (CGM) system and point-of-care capillary glucose testing in hospitalized patients with type 2 diabetes treated with basal-bolus insulin regimen. Diabetes Care 2020;43:2730  2735 46. Singh LG, Satyarengga M, Marcano I, et al. Reducing inpatient hypoglycemia in the general wards using real-time continuous glucose monitoring: the glucose telemetry system, a randomized clinical trial. Diabetes Care 2020;43: 2736  2743 diabetesjournals.org/care Diabetes Care in the Hospital S351 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S339/848851/dc26s016.pdf by guest on 17 February 2026","tf":{"17":2,"43":4,"44":1,"45":1,"46":1,"47":1,"49":1,"509":1,"516":1,"1838":1,"1845":1,"2020":3,"2023":1,"2024":1,"2026":1,"2730":1,"2735":1,"2736":1,"2743":1,"2873":1,"2877":1,"848851":1,"an":1,"point":2,"of":5,"care":10,"technologies":1,"support":1,"in":5,"hospital":4,"diabetes":9,"sci":1,"technol":1,"lee":1,"my":1,"seav":1,"sm":1,"ongwela":1,"et":4,"al":6,"empowering":1,"hospitalized":2,"patients":2,"with":4,"implementation":1,"wide":1,"cgm":2,"policy":1,"ehr":1,"integrated":1,"validation":1,"for":1,"dosing":1,"insulin":2,"fortmann":1,"spierling":1,"bagsic":1,"sr":1,"talavera":1,"glucose":6,"as":1,"the":5,"fifth":1,"vital":1,"sign":1,"randomized":2,"controlled":1,"trial":2,"continuous":3,"monitoring":3,"non":1,"icu":1,"setting":1,"galindo":1,"rj":1,"migdal":1,"davis":1,"gm":1,"comparison":1,"freestyle":1,"libre":1,"pro":1,"flash":1,"system":2,"and":1,"capillary":1,"testing":1,"type":1,"treated":1,"basal":1,"bolus":1,"regimen":1,"singh":1,"lg":1,"satyarengga":1,"marcano":1,"reducing":1,"inpatient":1,"hypoglycemia":1,"general":1,"wards":1,"using":1,"real":1,"time":1,"telemetry":1,"clinical":1,"diabetesjournals":2,"org":2,"s351":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"supplement":1,"s339":1,"dc26s016":1,"by":1,"guest":1,"on":1,"february":1},"len":190},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":14,"chunkId":"ada-2026-hosp-p14-c0","text":"47. Spanakis EK, Urrutia A, Galindo RJ, et al. Continuous glucose monitoring-guided insulin administration in hospitalized patients with diabetes: a randomized clinical trial. Diabetes Care 2022;45:2369  2375 48. Olsen MT, Klarskov CK, Jensen SH, et al. In- hospital diabetes management by a diabetes team and insulin titration algorithms based on continuous glucose monitoring or point-of-care glucose testing in patients with type 2 diabetes (DIATEC): a randomized controlled trial. Diabetes Care 2025;48:569  578 49. Wallia A, Prince G, Touma E, El Muayed M, Seley JJ. Caring for hospitalized patients with diabetes mellitus, hyperglycemia, and COVID-19: bridging the remaining knowledge gaps. Curr Diab Rep 2020;20:77 50. Galindo RJ, Aleppo G, Klonoff DC, et al. Implementation of continuous glucose monitoring in the hospital: emergent considerations for remote glucose monitoring during the COVID-19 pandemic. J Diabetes Sci Technol 2020;14:822  832 51. Longo RR, Elias H, Khan M, Seley JJ. Use and accuracy of inpatient CGM during the COVID-19 pandemic: an observational study of general medicine and ICU patients. J Diabetes Sci Technol 2022;16:1136  1143 52. Davis GM, Spanakis EK, Migdal AL, et al. Accuracy of Dexcom G6 continuous glucose monitoring in non-critically ill hospitalized patients with diabetes. Diabetes Care 2021;44:1641  1646 53. Hirsch IB, Draznin B, Buse JB, et al.;","tf":{"14":1,"16":1,"19":3,"20":1,"44":1,"45":1,"47":1,"48":2,"49":1,"50":1,"51":1,"52":1,"53":1,"77":1,"569":1,"578":1,"822":1,"832":1,"1136":1,"1143":1,"1641":1,"1646":1,"2020":2,"2021":1,"2022":2,"2025":1,"2369":1,"2375":1,"spanakis":2,"ek":2,"urrutia":1,"galindo":2,"rj":2,"et":5,"al":6,"continuous":4,"glucose":6,"monitoring":5,"guided":1,"insulin":2,"administration":1,"in":5,"hospitalized":3,"patients":5,"with":4,"diabetes":11,"randomized":2,"clinical":1,"trial":2,"care":4,"olsen":1,"mt":1,"klarskov":1,"ck":1,"jensen":1,"sh":1,"hospital":2,"management":1,"by":1,"team":1,"and":4,"titration":1,"algorithms":1,"based":1,"on":1,"or":1,"point":1,"of":5,"testing":1,"type":1,"diatec":1,"controlled":1,"wallia":1,"prince":1,"touma":1,"el":1,"muayed":1,"seley":2,"jj":2,"caring":1,"for":2,"mellitus":1,"hyperglycemia":1,"covid":3,"bridging":1,"the":4,"remaining":1,"knowledge":1,"gaps":1,"curr":1,"diab":1,"rep":1,"aleppo":1,"klonoff":1,"dc":1,"implementation":1,"emergent":1,"considerations":1,"remote":1,"during":2,"pandemic":2,"sci":2,"technol":2,"longo":1,"rr":1,"elias":1,"khan":1,"use":1,"accuracy":2,"inpatient":1,"cgm":1,"an":1,"observational":1,"study":1,"general":1,"medicine":1,"icu":1,"davis":1,"gm":1,"migdal":1,"dexcom":1,"g6":1,"non":1,"critically":1,"ill":1,"hirsch":1,"ib":1,"draznin":1,"buse":1,"jb":1},"len":210},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":14,"chunkId":"ada-2026-hosp-p14-c1","text":"22;16:1136  1143 52. Davis GM, Spanakis EK, Migdal AL, et al. Accuracy of Dexcom G6 continuous glucose monitoring in non-critically ill hospitalized patients with diabetes. Diabetes Care 2021;44:1641  1646 53. Hirsch IB, Draznin B, Buse JB, et al.; TIGHT RCT Study Group. Results from a randomized trial of intensive glucose management using CGM versus usual care in hospitalized adults with type 2 diabetes: the TIGHT study. Diabetes Care 2025;48:118  124 54. Faulds ER, Boutsicaris A, Sumner L, et al. Use of continuous glucose monitor in critically ill COVID-19 patients requiring insulin infusion: an observational study. J Clin Endocrinol Metab 2021;106:e4007  e4016 55. Giovannetti ER, Lee RO, Thomas RL, et al. Continuous glucose monitoring-guided insulin infusion in critically ill patients promotes safety, improves time efficiency, and enhances provider satisfaction. Endocr Pract 2025:S1530 56. Ang L, Lin YK, Schroeder LF, et al. Feasibility and performance of continuous glucose monitoring to guide computerized insulin infusion therapy in cardiovascular intensive care unit. J Diabetes Sci Technol 2024;18:562  569 57. Shaw JLV, Bannuru RR, Beach L, et al. Consensus considerations and good practice points for use of continuous glucose monitoring systems in hospital settings. Diabetes Care 2024; 47:2062  2075 58. Davis GM, Hughes MS, Brown SA, et al. Automated insulin delivery","tf":{"16":1,"18":1,"19":1,"22":1,"44":1,"47":1,"48":1,"52":1,"53":1,"54":1,"55":1,"56":1,"57":1,"58":1,"106":1,"118":1,"124":1,"562":1,"569":1,"1136":1,"1143":1,"1641":1,"1646":1,"2021":2,"2024":2,"2025":2,"2062":1,"2075":1,"davis":2,"gm":2,"spanakis":1,"ek":1,"migdal":1,"al":8,"et":7,"accuracy":1,"of":5,"dexcom":1,"g6":1,"continuous":5,"glucose":6,"monitoring":4,"in":6,"non":1,"critically":3,"ill":3,"hospitalized":2,"patients":3,"with":2,"diabetes":6,"care":5,"hirsch":1,"ib":1,"draznin":1,"buse":1,"jb":1,"tight":2,"rct":1,"study":3,"group":1,"results":1,"from":1,"randomized":1,"trial":1,"intensive":2,"management":1,"using":1,"cgm":1,"versus":1,"usual":1,"adults":1,"type":1,"the":1,"faulds":1,"er":2,"boutsicaris":1,"sumner":1,"use":2,"monitor":1,"covid":1,"requiring":1,"insulin":4,"infusion":3,"an":1,"observational":1,"clin":1,"endocrinol":1,"metab":1,"e4007":1,"e4016":1,"giovannetti":1,"lee":1,"ro":1,"thomas":1,"rl":1,"guided":1,"promotes":1,"safety":1,"improves":1,"time":1,"efficiency":1,"and":3,"enhances":1,"provider":1,"satisfaction":1,"endocr":1,"pract":1,"s1530":1,"ang":1,"lin":1,"yk":1,"schroeder":1,"lf":1,"feasibility":1,"performance":1,"to":1,"guide":1,"computerized":1,"therapy":1,"cardiovascular":1,"unit":1,"sci":1,"technol":1,"shaw":1,"jlv":1,"bannuru":1,"rr":1,"beach":1,"consensus":1,"considerations":1,"good":1,"practice":1,"points":1,"for":1,"systems":1,"hospital":1,"settings":1,"hughes":1,"ms":1,"brown":1,"sa":1,"automated":1,"delivery":1},"len":212},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":14,"chunkId":"ada-2026-hosp-p14-c2","text":"nnuru RR, Beach L, et al. Consensus considerations and good practice points for use of continuous glucose monitoring systems in hospital settings. Diabetes Care 2024; 47:2062  2075 58. Davis GM, Hughes MS, Brown SA, et al. Automated insulin delivery with remote real-time continuous glucose monitoring for hospitalized patients with diabetes: a multicenter, single-arm, feasibility trial. Diabetes Technol Ther 2023;25: 677  688 59. Bally L, Thabit H, Hartnell S, et al. Closed- loop insulin delivery for glycemic control in noncritical care. N Engl J Med 2018;379:547  556 60. Owens J, Courter J, Schuler CL, Lawrence M, Hornung L, Lawson S. Home insulin pump use in hospitalized children with type 1 diabetes. JAMA Netw Open 2024;7:e2354595 61. Hamilton AB, Rajagopal N, Ngo C, Hendrix- Dicken AD, Mercer S, Condren M. Survey of diabetes technology in the pediatric inpatient setting. J Pediatr Pharmacol Ther 2025;30:123  128 62. Braithwaite SS, Clark LP, Idrees T, Qureshi F, Soetan OT. Hypoglycemia prevention by algorithm design during intravenous insulin infusion. Curr Diab Rep 2018;18:26 63. Kreider KE, Lien LF. Transitioning safely from intravenous to subcutaneous insulin. Curr Diab Rep 2015;15:23 64. Thammakosol K, Sriphrapradang C. Effectiveness and safety of early insulin glargine administration in combination with continuous intravenous insulin infusion in the management of di","tf":{"15":1,"18":1,"23":1,"25":1,"26":1,"30":1,"47":1,"58":1,"59":1,"60":1,"61":1,"62":1,"63":1,"64":1,"123":1,"128":1,"379":1,"547":1,"556":1,"677":1,"688":1,"2015":1,"2018":2,"2023":1,"2024":2,"2025":1,"2062":1,"2075":1,"nnuru":1,"rr":1,"beach":1,"et":3,"al":3,"consensus":1,"considerations":1,"and":2,"good":1,"practice":1,"points":1,"for":3,"use":2,"of":4,"continuous":3,"glucose":2,"monitoring":2,"systems":1,"in":6,"hospital":1,"settings":1,"diabetes":5,"care":2,"davis":1,"gm":1,"hughes":1,"ms":1,"brown":1,"sa":1,"automated":1,"insulin":7,"delivery":2,"with":4,"remote":1,"real":1,"time":1,"hospitalized":2,"patients":1,"multicenter":1,"single":1,"arm":1,"feasibility":1,"trial":1,"technol":1,"ther":2,"bally":1,"thabit":1,"hartnell":1,"closed":1,"loop":1,"glycemic":1,"control":1,"noncritical":1,"engl":1,"med":1,"owens":1,"courter":1,"schuler":1,"cl":1,"lawrence":1,"hornung":1,"lawson":1,"home":1,"pump":1,"children":1,"type":1,"jama":1,"netw":1,"open":1,"e2354595":1,"hamilton":1,"ab":1,"rajagopal":1,"ngo":1,"hendrix":1,"dicken":1,"ad":1,"mercer":1,"condren":1,"survey":1,"technology":1,"the":2,"pediatric":1,"inpatient":1,"setting":1,"pediatr":1,"pharmacol":1,"braithwaite":1,"ss":1,"clark":1,"lp":1,"idrees":1,"qureshi":1,"soetan":1,"ot":1,"hypoglycemia":1,"prevention":1,"by":1,"algorithm":1,"design":1,"during":1,"intravenous":3,"infusion":2,"curr":2,"diab":2,"rep":2,"kreider":1,"ke":1,"lien":1,"lf":1,"transitioning":1,"safely":1,"from":1,"to":1,"subcutaneous":1,"thammakosol":1,"sriphrapradang":1,"effectiveness":1,"safety":1,"early":1,"glargine":1,"administration":1,"combination":1,"management":1,"di":1},"len":199},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":14,"chunkId":"ada-2026-hosp-p14-c3","text":"m intravenous to subcutaneous insulin. Curr Diab Rep 2015;15:23 64. Thammakosol K, Sriphrapradang C. Effectiveness and safety of early insulin glargine administration in combination with continuous intravenous insulin infusion in the management of diabetic ketoacidosis: a randomized controlled trial. Diabetes Obes Metab 2023;25:815  822 65. Hsia E, Seggelke S, Gibbs J, et al. Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia. J Clin Endocrinol Metab 2012;97: 3132  3137 66. Lim Y, Ohn JH, Jeong J, et al. Effect of the concomitant use of subcutaneous basal insulin and intravenous insulin infusion in the treatment of severe hyperglycemic patients. Endocrinol Metab (Seoul) 2022;37:444  454 67. Zhou K, Buehler LA, Zaw T, Bena J, Lansang MC. Weight-based insulin during and after intravenous insulin infusion reduces rates of rebound hyperglycemia when transitioning to subcutaneous insulin in the medical intensive care unit. Endocr Pract 2022;28:173  178 68. Bueno E, Benitez A, Rufinelli JV, et al. Basal- bolus regimen with insulin analogues versus human insulin in medical patients with type 2 diabetes: a randomized controlled trial in Latin America. Endocr Pract 2015;21:807  813 69. Zhang X, Zhang T, Xiang G, et al. Comparison of weight-based insulin titration (WIT) and glucose-based insulin titration using basa","tf":{"15":1,"21":1,"23":1,"25":1,"28":1,"37":1,"64":1,"65":1,"66":1,"67":1,"68":1,"69":1,"97":1,"173":1,"178":1,"444":1,"454":1,"807":1,"813":1,"815":1,"822":1,"2012":1,"2015":2,"2022":2,"2023":1,"3132":1,"3137":1,"intravenous":4,"to":3,"subcutaneous":4,"insulin":13,"curr":1,"diab":1,"rep":1,"thammakosol":1,"sriphrapradang":1,"effectiveness":1,"and":4,"safety":1,"of":8,"early":1,"glargine":2,"administration":2,"in":6,"combination":1,"with":3,"continuous":1,"infusion":4,"the":4,"management":1,"diabetic":2,"ketoacidosis":1,"randomized":2,"controlled":2,"trial":2,"diabetes":2,"obes":1,"metab":3,"hsia":1,"seggelke":1,"gibbs":1,"et":4,"al":4,"patients":3,"receiving":1,"prevents":1,"rebound":2,"hyperglycemia":2,"clin":1,"endocrinol":2,"lim":1,"ohn":1,"jh":1,"jeong":1,"effect":1,"concomitant":1,"use":1,"basal":2,"treatment":1,"severe":1,"hyperglycemic":1,"seoul":1,"zhou":1,"buehler":1,"la":1,"zaw":1,"bena":1,"lansang":1,"mc":1,"weight":2,"based":3,"during":1,"after":1,"reduces":1,"rates":1,"when":1,"transitioning":1,"medical":2,"intensive":1,"care":1,"unit":1,"endocr":2,"pract":2,"bueno":1,"benitez":1,"rufinelli":1,"jv":1,"bolus":1,"regimen":1,"analogues":1,"versus":1,"human":1,"type":1,"latin":1,"america":1,"zhang":2,"xiang":1,"comparison":1,"titration":2,"wit":1,"glucose":1,"using":1,"basa":1},"len":197},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":14,"chunkId":"ada-2026-hosp-p14-c4","text":"ical patients with type 2 diabetes: a randomized controlled trial in Latin America. Endocr Pract 2015;21:807  813 69. Zhang X, Zhang T, Xiang G, et al. Comparison of weight-based insulin titration (WIT) and glucose-based insulin titration using basal-bolus algorithm in hospitalized patients with type 2 diabetes: a multicenter, randomized, clinical study. BMJ Open Diabetes Res Care 2020;8: e001261 70. Veronesi G, Poerio CS, Braus A, et al. Determinants of nurse satisfaction using insulin pen devices with safety needles: an exploratory factor analysis. Clin Diabetes Endocrinol 2015; 1:15 71. Institute for Safe Medication Practices. ISMP guidelines for optimizing safe subcutaneous insulin use in adults, 2017. Accessed 4 August 2025. Available from https://www.ismp.org/ sites/default/files/attachments/2018-09/ ISMP138D-Insulin%20Guideline-090718.pdf . 72. Najmi U, Haque WZ, Ansari U, et al. Inpatient insulin pen implementation, waste, and potential cost savings: a community hospital experience. J Diabetes Sci Technol 2021;15:741  747 73. MacMaster HW, Gonzalez S, Maruoka A, et al. Development and Implementation of a subcutaneous insulin pen label bar code scanning protocol to prevent wrong-patient insulin pen errors. Jt Comm J Qual Patient Saf 2019;45: 380  386 74. Umpierrez GE, Smiley D, Jacobs S, et al. Randomized study of basal-bolus insulin therapy in the inpatient managemen","tf":{"15":2,"21":1,"45":1,"69":1,"70":1,"71":1,"72":1,"73":1,"74":1,"380":1,"386":1,"741":1,"747":1,"807":1,"813":1,"2015":2,"2017":1,"2018":1,"2019":1,"2020":1,"2021":1,"2025":1,"ical":1,"patients":2,"with":3,"type":2,"diabetes":5,"randomized":3,"controlled":1,"trial":1,"in":4,"latin":1,"america":1,"endocr":1,"pract":1,"zhang":2,"xiang":1,"et":5,"al":5,"comparison":1,"of":4,"weight":1,"based":2,"insulin":9,"titration":2,"wit":1,"and":3,"glucose":1,"using":2,"basal":2,"bolus":2,"algorithm":1,"hospitalized":1,"multicenter":1,"clinical":1,"study":2,"bmj":1,"open":1,"res":1,"care":1,"e001261":1,"veronesi":1,"poerio":1,"cs":1,"braus":1,"determinants":1,"nurse":1,"satisfaction":1,"pen":4,"devices":1,"safety":1,"needles":1,"an":1,"exploratory":1,"factor":1,"analysis":1,"clin":1,"endocrinol":1,"institute":1,"for":2,"safe":2,"medication":1,"practices":1,"ismp":2,"guidelines":1,"optimizing":1,"subcutaneous":2,"use":1,"adults":1,"accessed":1,"august":1,"available":1,"from":1,"https":1,"www":1,"org":1,"sites":1,"default":1,"files":1,"attachments":1,"09":1,"ismp138d":1,"20guideline":1,"090718":1,"pdf":1,"najmi":1,"haque":1,"wz":1,"ansari":1,"inpatient":2,"implementation":2,"waste":1,"potential":1,"cost":1,"savings":1,"community":1,"hospital":1,"experience":1,"sci":1,"technol":1,"macmaster":1,"hw":1,"gonzalez":1,"maruoka":1,"development":1,"label":1,"bar":1,"code":1,"scanning":1,"protocol":1,"to":1,"prevent":1,"wrong":1,"patient":2,"errors":1,"jt":1,"comm":1,"qual":1,"saf":1,"umpierrez":1,"ge":1,"smiley":1,"jacobs":1,"therapy":1,"the":1,"managemen":1},"len":199},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":14,"chunkId":"ada-2026-hosp-p14-c5","text":"in pen label bar code scanning protocol to prevent wrong-patient insulin pen errors. Jt Comm J Qual Patient Saf 2019;45: 380  386 74. Umpierrez GE, Smiley D, Jacobs S, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care 2011;34: 256  261 75. Migdal AL, Fortin-Leung C, Pasquel F, Wang H, Peng L, Umpierrez GE. Inpatient glycemic control with sliding scale insulin in noncritical patients with type 2 diabetes: who can slide? J Hosp Med 2021;16:462  468 76. Colunga-Lozano LE, Gonzalez Torres FJ, Delgado-Figueroa N, et al. Sliding scale insulin for non-critically ill hospitalised adults with diabetes mellitus. Cochrane Database Syst Rev 2018;11:CD011296 77. Bellido V, Suarez L, Rodriguez MG, et al. Comparison of basal-bolus and premixed insulin regimens in hospitalized patients with type 2 diabetes. Diabetes Care 2015;38:2211  2216 78. Galindo RJ, Pasquel FJ, Vellanki P, et al. Degludec hospital trial: a randomized controlled trial comparing insulin degludec U100 and glargine U100 for the inpatient management of patients with type 2 diabetes. Diabetes Obes Metab 2022;24:42  49 79. Pasquel FJ, Lansang MC, Khowaja A, et al. A randomized controlled trial comparing glargine U300 and glargine U100 for the inpatient management of medicine and surgery patients wi","tf":{"11":1,"16":1,"24":1,"34":1,"38":1,"42":1,"45":1,"49":1,"74":1,"75":1,"76":1,"77":1,"78":1,"79":1,"256":1,"261":1,"380":1,"386":1,"462":1,"468":1,"2011":1,"2015":1,"2018":1,"2019":1,"2021":1,"2022":1,"2211":1,"2216":1,"in":4,"pen":2,"label":1,"bar":1,"code":1,"scanning":1,"protocol":1,"to":1,"prevent":1,"wrong":1,"patient":2,"insulin":6,"errors":1,"jt":1,"comm":1,"qual":1,"saf":1,"umpierrez":2,"ge":2,"smiley":1,"jacobs":1,"et":5,"al":6,"randomized":3,"study":1,"of":5,"basal":2,"bolus":2,"therapy":1,"the":3,"inpatient":4,"management":3,"patients":5,"with":6,"type":4,"diabetes":8,"undergoing":1,"general":1,"surgery":3,"rabbit":1,"care":2,"migdal":1,"fortin":1,"leung":1,"pasquel":3,"wang":1,"peng":1,"glycemic":1,"control":1,"sliding":2,"scale":2,"noncritical":1,"who":1,"can":1,"slide":1,"hosp":1,"med":1,"colunga":1,"lozano":1,"le":1,"gonzalez":1,"torres":1,"fj":3,"delgado":1,"figueroa":1,"for":3,"non":1,"critically":1,"ill":1,"hospitalised":1,"adults":1,"mellitus":1,"cochrane":1,"database":1,"syst":1,"rev":1,"cd011296":1,"bellido":1,"suarez":1,"rodriguez":1,"mg":1,"comparison":1,"and":4,"premixed":1,"regimens":1,"hospitalized":1,"galindo":1,"rj":1,"vellanki":1,"degludec":2,"hospital":1,"trial":3,"controlled":2,"comparing":2,"u100":3,"glargine":3,"obes":1,"metab":1,"lansang":1,"mc":1,"khowaja":1,"u300":1,"medicine":1,"wi":1},"len":210},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":14,"chunkId":"ada-2026-hosp-p14-c6","text":" patients with type 2 diabetes. Diabetes Obes Metab 2022;24:42  49 79. Pasquel FJ, Lansang MC, Khowaja A, et al. A randomized controlled trial comparing glargine U300 and glargine U100 for the inpatient management of medicine and surgery patients with type 2 diabetes: glargine U300 hospital trial. Diabetes Care 2020;43:1242  1248 80. Perez A, Carrasco-Snchez FJ, Gonzlez C, et al. Efficacy and safety of insulin glargine 300 U/mL (Gla-300) during hospitalization and therapy intensification at discharge in patients with insufficiently controlled type 2 diabetes: results of the phase IV COBALTA trial. BMJ Open Diabetes Res Care 2020;8:e001518 81. Tripathy PR, Lansang MC. U-500 regular insulin use in hospitalized patients. Endocr Pract 2015;21:54  58 82. Palladino CE, Eberly ME, Emmons JT, Tannock LR. Management of U-500 insulin users during inpatient admissions within a Veterans Affairs Medical Center. Diabetes Res Clin Pract 2016;114:32  36 83. Mendez CE, Umpierrez GE. Management of type 1 diabetes in the hospital setting. Curr Diab Rep 2017;17:98 84. Kosiborod MN, Angermann CE, Collins SP, et al. Effects of empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure: results from the EMPULSE trial. Circulation 2022;146:279  288 85. Tamaki S, Yamada T, Watanabe T, et al. Effect of empagliflozin as an add-on therapy o","tf":{"17":1,"21":1,"24":1,"32":1,"36":1,"42":1,"43":1,"49":1,"54":1,"58":1,"79":1,"80":1,"81":1,"82":1,"83":1,"84":1,"85":1,"98":1,"114":1,"146":1,"279":1,"288":1,"300":2,"500":2,"1242":1,"1248":1,"2015":1,"2016":1,"2017":1,"2020":2,"2022":2,"patients":5,"with":3,"type":4,"diabetes":8,"obes":1,"metab":1,"pasquel":1,"fj":2,"lansang":2,"mc":2,"khowaja":1,"et":4,"al":4,"randomized":1,"controlled":2,"trial":4,"comparing":1,"glargine":4,"u300":2,"and":5,"u100":1,"for":2,"the":4,"inpatient":2,"management":3,"of":8,"medicine":1,"surgery":1,"hospital":2,"care":2,"perez":1,"carrasco":1,"nchez":1,"gonz":1,"lez":1,"efficacy":1,"safety":1,"insulin":3,"ml":1,"gla":1,"during":2,"hospitalization":1,"therapy":2,"intensification":1,"at":1,"discharge":1,"in":4,"insufficiently":1,"results":2,"phase":1,"iv":1,"cobalta":1,"bmj":1,"open":1,"res":2,"e001518":1,"tripathy":1,"pr":1,"regular":1,"use":1,"hospitalized":2,"endocr":1,"pract":2,"palladino":1,"ce":3,"eberly":1,"me":1,"emmons":1,"jt":1,"tannock":1,"lr":1,"users":1,"admissions":1,"within":1,"veterans":1,"affairs":1,"medical":1,"center":1,"clin":1,"mendez":1,"umpierrez":1,"ge":1,"setting":1,"curr":1,"diab":1,"rep":1,"kosiborod":1,"mn":1,"angermann":1,"collins":1,"sp":1,"effects":1,"empagliflozin":2,"on":2,"symptoms":1,"physical":1,"limitations":1,"quality":1,"life":1,"acute":1,"heart":1,"failure":1,"from":1,"empulse":1,"circulation":1,"tamaki":1,"yamada":1,"watanabe":1,"effect":1,"as":1,"an":1,"add":1},"len":215},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":14,"chunkId":"ada-2026-hosp-p14-c7","text":"toms, physical limitations, and quality of life in patients hospitalized for acute heart failure: results from the EMPULSE trial. Circulation 2022;146:279  288 85. Tamaki S, Yamada T, Watanabe T, et al. Effect of empagliflozin as an add-on therapy on decongestion and renal function in patients with diabetes hospitalized for acute decompensated heart failure: a prospective randomized controlled study. Circ Heart Fail 2021;14:e007048 86. Cunningham JW, Vaduganathan M, Claggett BL, et al. Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction. J Am Coll Cardiol 2022;80:1302  1310 87. Salah HM, AlAref SJ, Khan MS, et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol 2022;21:20 88. Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multi-national randomized trial. Nat Med 2022;28:568  574 89. Jhund PS, Ponikowski P, Docherty KF, et al. Dapagliflozin and recurrent heart failure hos- S352 Diabetes Care in the Hospital Diabetes Care Volume 49, Supplement 1, January 2026 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S339/848851/dc26s016.pdf by guest on 17 ","tf":{"14":1,"17":1,"20":1,"21":1,"28":1,"49":2,"80":1,"85":1,"86":1,"87":1,"88":1,"89":1,"146":1,"279":1,"288":1,"568":1,"574":1,"1302":1,"1310":1,"2021":1,"2022":4,"2026":1,"848851":1,"toms":1,"physical":1,"limitations":1,"and":7,"quality":1,"of":3,"life":1,"in":6,"patients":5,"hospitalized":4,"for":3,"acute":4,"heart":7,"failure":6,"results":1,"from":2,"the":3,"empulse":1,"trial":2,"circulation":1,"tamaki":1,"yamada":1,"watanabe":1,"et":5,"al":6,"effect":1,"empagliflozin":2,"as":1,"an":1,"add":1,"on":3,"therapy":1,"decongestion":1,"renal":1,"function":1,"with":4,"diabetes":4,"decompensated":1,"prospective":1,"randomized":2,"controlled":1,"study":1,"circ":1,"fail":1,"e007048":1,"cunningham":1,"jw":1,"vaduganathan":1,"claggett":1,"bl":1,"dapagliflozin":2,"recently":1,"mildly":1,"reduced":1,"or":1,"preserved":1,"ejection":1,"fraction":1,"am":1,"coll":1,"cardiol":1,"salah":1,"hm":1,"aref":1,"sj":1,"khan":1,"ms":1,"efficacy":1,"safety":1,"sodium":1,"glucose":1,"cotransporter":1,"inhibitors":1,"initiation":1,"without":1,"type":1,"systematic":1,"review":1,"meta":1,"analysis":1,"cardiovasc":1,"diabetol":1,"voors":1,"aa":1,"angermann":1,"ce":1,"teerlink":1,"jr":1,"sglt2":1,"inhibitor":1,"multi":1,"national":1,"nat":1,"med":1,"jhund":1,"ps":1,"ponikowski":1,"docherty":1,"kf":1,"recurrent":1,"hos":1,"s352":1,"care":3,"hospital":1,"volume":1,"supplement":2,"january":1,"downloaded":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"s339":1,"dc26s016":1,"by":1,"guest":1},"len":208},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":14,"chunkId":"ada-2026-hosp-p14-c8","text":"apagliflozin and recurrent heart failure hos- S352 Diabetes Care in the Hospital Diabetes Care Volume 49, Supplement 1, January 2026 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S339/848851/dc26s016.pdf by guest on 17 February 2026","tf":{"17":1,"49":2,"2026":2,"848851":1,"apagliflozin":1,"and":1,"recurrent":1,"heart":1,"failure":1,"hos":1,"s352":1,"diabetes":2,"care":3,"in":1,"the":1,"hospital":1,"volume":1,"supplement":2,"january":1,"downloaded":1,"from":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"s339":1,"dc26s016":1,"by":1,"guest":1,"on":1,"february":1},"len":39},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":15,"chunkId":"ada-2026-hosp-p15-c0","text":"pitalizations in heart failure with reduced ejection fraction: an analysis of DAPA-HF. Circulation 2021; 143:1962  1972 90. U.S. Food and Drug Administration. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Accessed 4 August 2025. Available from https://www.fda.gov/ drugs/drug-safety-and-availability/fda-revises-labels- sglt2-inhibitors-diabetes-include-warnings-about- too-much-acid-blood-and-serious 91. Vellanki P, Rasouli N, Baldwin D, et al.; Linagliptin Inpatient Research Group. Glycaemic efficacy and safety of linagliptin compared to a basal-bolus insulin regimen in patients with type 2 diabetes undergoing non-cardiac surgery: a multicentre randomized clinical trial. Diabetes Obes Metab 2019;21:837  843 92. Pasquel FJ, Gianchandani R, Rubin DJ, et al. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol 2017;5:125  133 93. Garg R, Schuman B, Hurwitz S, Metzger C, Bhandari S. Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients. BMJ Open Diabetes Res Care 2017;5: e000394 94. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA adds warning","tf":{"21":1,"90":1,"91":1,"92":1,"93":1,"94":1,"125":1,"133":1,"143":1,"837":1,"843":1,"1962":1,"1972":1,"2017":2,"2019":1,"2021":1,"2025":1,"pitalizations":1,"in":4,"heart":1,"failure":1,"with":3,"reduced":1,"ejection":1,"fraction":1,"an":1,"analysis":1,"of":6,"dapa":1,"hf":1,"circulation":1,"food":2,"and":8,"drug":4,"administration":2,"fda":5,"revises":2,"labels":2,"sglt2":2,"inhibitors":2,"for":3,"diabetes":7,"to":2,"include":2,"warnings":2,"about":2,"too":2,"much":2,"acid":2,"the":2,"blood":2,"serious":2,"urinary":1,"tract":1,"infections":1,"accessed":1,"august":1,"available":1,"from":1,"https":1,"www":1,"gov":1,"drugs":1,"safety":4,"availability":1,"vellanki":1,"rasouli":1,"baldwin":1,"et":2,"al":2,"linagliptin":2,"inpatient":1,"research":1,"group":1,"glycaemic":1,"efficacy":3,"compared":1,"basal":1,"bolus":1,"insulin":1,"regimen":1,"patients":3,"type":2,"undergoing":1,"non":3,"cardiac":1,"surgery":2,"multicentre":2,"randomized":1,"clinical":1,"trial":2,"obes":1,"metab":1,"pasquel":1,"fj":1,"gianchandani":1,"rubin":1,"dj":1,"sitagliptin":1,"hospital":2,"management":1,"general":1,"medicine":1,"sita":1,"prospective":1,"open":2,"label":1,"inferiority":1,"randomised":1,"lancet":1,"endocrinol":1,"garg":1,"schuman":1,"hurwitz":1,"metzger":1,"bhandari":1,"saxagliptin":1,"glycemic":1,"control":1,"critically":1,"ill":1,"hospitalized":1,"bmj":1,"res":1,"care":1,"e000394":1,"communication":1,"adds":1,"warning":1},"len":196},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":15,"chunkId":"ada-2026-hosp-p15-c1","text":"zger C, Bhandari S. Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients. BMJ Open Diabetes Res Care 2017;5: e000394 94. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin. Accessed 4 August 2025. Available from https://www.fda.gov/Drugs/DrugSafety/ ucm486096.htm 95. Fushimi N, Shibuya T, Yoshida Y, Ito S, Hachiya H, Mori A. Dulaglutide-combined basal plus correction insulin therapy contributes to ideal glycemic control in non-critical hospitalized patients. J Diabetes Investig 2020;11:125  131 96. Fayfman M, Galindo RJ, Rubin DJ, et al. A randomized controlled trial on the safety and efficacy of exenatide therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes. Diabetes Care 2019;42:450  456 97. Lake A, Arthur A, Byrne C, Davenport K, Yamamoto JM, Murphy HR. The effect of hypoglycaemia during hospital admission on health-related outcomes for people with diabetes: a systematic review and meta-analysis. Diabet Med 2019;36:1349  1359 98. Garg R, Hurwitz S, Turchin A, Trivedi A. Hypoglycemia, with or without insulin therapy, is associated with increased mortality among hos- pitalized patients. Diabetes Care 2013;36:1107  1110 99. Ilcewicz HN, Hennessey EK,","tf":{"11":1,"36":2,"42":1,"94":1,"95":1,"96":1,"97":1,"98":1,"99":1,"125":1,"131":1,"450":1,"456":1,"1107":1,"1110":1,"1349":1,"1359":1,"2013":1,"2017":1,"2019":2,"2020":1,"2025":1,"zger":1,"bhandari":1,"safety":3,"and":6,"efficacy":2,"of":5,"saxagliptin":2,"for":3,"glycemic":2,"control":2,"in":2,"non":2,"critically":1,"ill":1,"hospitalized":2,"patients":4,"bmj":1,"open":1,"diabetes":7,"res":1,"care":3,"e000394":1,"food":1,"drug":2,"administration":1,"fda":3,"communication":1,"adds":1,"warnings":1,"about":1,"heart":1,"failure":1,"risk":1,"to":2,"labels":1,"type":2,"medicines":1,"containing":1,"alogliptin":1,"accessed":1,"august":1,"available":1,"from":1,"https":1,"www":1,"gov":1,"drugs":1,"drugsafety":1,"ucm486096":1,"htm":1,"fushimi":1,"shibuya":1,"yoshida":1,"ito":1,"hachiya":1,"mori":1,"dulaglutide":1,"combined":1,"basal":1,"plus":1,"correction":1,"insulin":2,"therapy":3,"contributes":1,"ideal":1,"critical":1,"investig":1,"fayfman":1,"galindo":1,"rj":1,"rubin":1,"dj":1,"et":1,"al":1,"randomized":1,"controlled":1,"trial":1,"on":2,"the":3,"exenatide":1,"inpatient":1,"management":1,"general":1,"medicine":1,"surgery":1,"with":4,"lake":1,"arthur":1,"byrne":1,"davenport":1,"yamamoto":1,"jm":1,"murphy":1,"hr":1,"effect":1,"hypoglycaemia":1,"during":1,"hospital":1,"admission":1,"health":1,"related":1,"outcomes":1,"people":1,"systematic":1,"review":1,"meta":1,"analysis":1,"diabet":1,"med":1,"garg":1,"hurwitz":1,"turchin":1,"trivedi":1,"hypoglycemia":1,"or":1,"without":1,"is":1,"associated":1,"increased":1,"mortality":1,"among":1,"hos":1,"pitalized":1,"ilcewicz":1,"hn":1,"hennessey":1,"ek":1},"len":196},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":15,"chunkId":"ada-2026-hosp-p15-c2","text":"Med 2019;36:1349  1359 98. Garg R, Hurwitz S, Turchin A, Trivedi A. Hypoglycemia, with or without insulin therapy, is associated with increased mortality among hos- pitalized patients. Diabetes Care 2013;36:1107  1110 99. Ilcewicz HN, Hennessey EK, Smith CB. Evaluation of the impact of an inpatient hyperglycemia protocol on glycemic control. J Pharm Pharm Sci 2019;22:85  92 100. Sinha Gregory N, Seley JJ, Gerber LM, Tang C, Brillon D. Decreased rates of hypoglycemia following implementation of a comprehensive computerized insulin order set and titration algorithm in the inpatient setting. Hosp Pract (1995) 2016;44:260  265 101. McCall AL, Lieb DC, Gianchandani R, et al. Management of individuals with diabetes at high risk for hypoglycemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2023; 108:529  562 102. Akirov A, Grossman A, Shochat T, Shimon I. Mortality among hospitalized patients with hypoglycemia: insulin related and noninsulin related. J Clin Endocrinol Metab 2017;102: 416  424 103. Amori RE, Pittas AG, Siegel RD, et al. Inpatient medical errors involving glucose-lowering medications and their impact on patients: review of 2,598 incidents from a voluntary electronic error-reporting database. Endocr Pract 2008;14: 535  542 104. Alwan D, Chipps E, Yen P-Y, Dungan K. Evaluation of the timing and coordination of prandial insulin administ","tf":{"14":1,"22":1,"36":2,"44":1,"85":1,"92":1,"98":1,"99":1,"100":1,"101":1,"102":2,"103":1,"104":1,"108":1,"260":1,"265":1,"416":1,"424":1,"529":1,"535":1,"542":1,"562":1,"598":1,"1107":1,"1110":1,"1349":1,"1359":1,"1995":1,"2008":1,"2013":1,"2016":1,"2017":1,"2019":2,"2023":1,"med":1,"garg":1,"hurwitz":1,"turchin":1,"trivedi":1,"hypoglycemia":4,"with":4,"or":1,"without":1,"insulin":4,"therapy":1,"is":1,"associated":1,"increased":1,"mortality":2,"among":2,"hos":1,"pitalized":1,"patients":3,"diabetes":2,"care":1,"ilcewicz":1,"hn":1,"hennessey":1,"ek":1,"smith":1,"cb":1,"evaluation":2,"of":8,"the":3,"impact":2,"an":2,"inpatient":3,"hyperglycemia":1,"protocol":1,"on":2,"glycemic":1,"control":1,"pharm":2,"sci":1,"sinha":1,"gregory":1,"seley":1,"jj":1,"gerber":1,"lm":1,"tang":1,"brillon":1,"decreased":1,"rates":1,"following":1,"implementation":1,"comprehensive":1,"computerized":1,"order":1,"set":1,"and":4,"titration":1,"algorithm":1,"in":1,"setting":1,"hosp":1,"pract":2,"mccall":1,"al":3,"lieb":1,"dc":1,"gianchandani":1,"et":2,"management":1,"individuals":1,"at":1,"high":1,"risk":1,"for":1,"endocrine":1,"society":1,"clinical":1,"practice":1,"guideline":1,"clin":2,"endocrinol":2,"metab":2,"akirov":1,"grossman":1,"shochat":1,"shimon":1,"hospitalized":1,"related":2,"noninsulin":1,"amori":1,"re":1,"pittas":1,"ag":1,"siegel":1,"rd":1,"medical":1,"errors":1,"involving":1,"glucose":1,"lowering":1,"medications":1,"their":1,"review":1,"incidents":1,"from":1,"voluntary":1,"electronic":1,"error":1,"reporting":1,"database":1,"endocr":1,"alwan":1,"chipps":1,"yen":1,"dungan":1,"timing":1,"coordination":1,"prandial":1,"administ":1},"len":198},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":15,"chunkId":"ada-2026-hosp-p15-c3","text":"heir impact on patients: review of 2,598 incidents from a voluntary electronic error-reporting database. Endocr Pract 2008;14: 535  542 104. Alwan D, Chipps E, Yen P-Y, Dungan K. Evaluation of the timing and coordination of prandial insulin administration in the hospital. Diabetes Res Clin Pract 2017;131:18  32 105. Hung AM, Siew ED, Wilson OD, et al. Risk of hypoglycemia following hospital discharge in patients with diabetes and acute kidney injury. Diabetes Care 2018;41:503  512 106. Pratiwi C, Mokoagow MI, Made Kshanti IA, Soewondo P. The risk factors of inpatient hypoglycemia: a systematic review. Heliyon 2020; 6:e03913 107. Maynard G, Kulasa K, Ramos P, et al. Impact of a hypoglycemia reduction bundle and a systems approach to inpatient glycemic management. Endocr Pract 2015;21:355  367 108. Milligan PE, Bocox MC, Pratt E, Hoehner CM, Krettek JE, Dunagan WC. Multifaceted approach to reducing occurrence of severe hypoglycemia in a large healthcare system. Am J Health Syst Pharm 2015;72:1631  1641 109. Rickels MR. Hypoglycemia-associated autonomic failure, counterregulatory responses, and therapeutic options in type 1 diabetes. Ann N Y Acad Sci 2019;1454:68  79 110. Dendy JA, Chockalingam V, Tirumalasetty NN, et al. Identifying risk factors for severe hypoglycemia in hospitalized patients with diabetes. Endocr Pract 2014;20:1051  1056 111. Ulmer BJ, Kara A, Mariash CN","tf":{"14":1,"18":1,"20":1,"21":1,"32":1,"41":1,"68":1,"72":1,"79":1,"104":1,"105":1,"106":1,"107":1,"108":1,"109":1,"110":1,"111":1,"131":1,"355":1,"367":1,"503":1,"512":1,"535":1,"542":1,"598":1,"1051":1,"1056":1,"1454":1,"1631":1,"1641":1,"2008":1,"2014":1,"2015":2,"2017":1,"2018":1,"2019":1,"2020":1,"heir":1,"impact":2,"on":1,"patients":3,"review":2,"of":7,"incidents":1,"from":1,"voluntary":1,"electronic":1,"error":1,"reporting":1,"database":1,"endocr":3,"pract":4,"alwan":1,"chipps":1,"yen":1,"dungan":1,"evaluation":1,"the":3,"timing":1,"and":4,"coordination":1,"prandial":1,"insulin":1,"administration":1,"in":5,"hospital":2,"diabetes":5,"res":1,"clin":1,"hung":1,"am":2,"siew":1,"ed":1,"wilson":1,"od":1,"et":3,"al":3,"risk":3,"hypoglycemia":6,"following":1,"discharge":1,"with":2,"acute":1,"kidney":1,"injury":1,"care":1,"pratiwi":1,"mokoagow":1,"mi":1,"made":1,"kshanti":1,"ia":1,"soewondo":1,"factors":2,"inpatient":2,"systematic":1,"heliyon":1,"e03913":1,"maynard":1,"kulasa":1,"ramos":1,"reduction":1,"bundle":1,"systems":1,"approach":2,"to":2,"glycemic":1,"management":1,"milligan":1,"pe":1,"bocox":1,"mc":1,"pratt":1,"hoehner":1,"cm":1,"krettek":1,"je":1,"dunagan":1,"wc":1,"multifaceted":1,"reducing":1,"occurrence":1,"severe":2,"large":1,"healthcare":1,"system":1,"health":1,"syst":1,"pharm":1,"rickels":1,"mr":1,"associated":1,"autonomic":1,"failure":1,"counterregulatory":1,"responses":1,"therapeutic":1,"options":1,"type":1,"ann":1,"acad":1,"sci":1,"dendy":1,"ja":1,"chockalingam":1,"tirumalasetty":1,"nn":1,"identifying":1,"for":1,"hospitalized":1,"ulmer":1,"bj":1,"kara":1,"mariash":1,"cn":1},"len":203},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":15,"chunkId":"ada-2026-hosp-p15-c4","text":"es. Ann N Y Acad Sci 2019;1454:68  79 110. Dendy JA, Chockalingam V, Tirumalasetty NN, et al. Identifying risk factors for severe hypoglycemia in hospitalized patients with diabetes. Endocr Pract 2014;20:1051  1056 111. Ulmer BJ, Kara A, Mariash CN. Temporal occurrences and recurrence patterns of hypo- glycemia during hospitalization. Endocr Pract 2015;21:501  507 112. Shah BR, Walji S, Kiss A, James JE, Lowe JM. Derivation and validation of a risk-prediction tool for hypoglycemia in hospitalized adults with diabetes: the Hypoglycemia During Hospitalization (HyDHo) score. Can J Diabetes 2019;43:278  282.e1 113. Mathioudakis NN, Everett E, Routh S, et al. Development and validation of a prediction model for insulin-associated hypoglycemia in non-critically ill hospitalized adults. BMJ Open Diabetes Res Care 2018;6:e000499 114. Curll M, Dinardo M, Noschese M, Korytkowski MT. Menu selection, glycaemic control and satisfaction with standard and patient-controlled consistent carbohydrate meal plans in hospitalised patients with diabetes. Qual Saf Health Care 2010;19:355  359 115. Drincic AT, Knezevich JT, Akkireddy P. Nutrition and hyperglycemia management in the inpatient setting (meals on demand, parenteral, or enteral nutrition). Curr Diab Rep 2017;17:59 116. Korytkowski M, Draznin B, Drincic A. Food, fasting, insulin, and glycemic control in the hospital. In Managing Diabet","tf":{"17":1,"19":1,"20":1,"21":1,"43":1,"59":1,"68":1,"79":1,"110":1,"111":1,"112":1,"113":1,"114":1,"115":1,"116":1,"278":1,"282":1,"355":1,"359":1,"501":1,"507":1,"1051":1,"1056":1,"1454":1,"2010":1,"2014":1,"2015":1,"2017":1,"2018":1,"2019":2,"es":1,"ann":1,"acad":1,"sci":1,"dendy":1,"ja":1,"chockalingam":1,"tirumalasetty":1,"nn":2,"et":2,"al":2,"identifying":1,"risk":2,"factors":1,"for":3,"severe":1,"hypoglycemia":4,"in":7,"hospitalized":3,"patients":2,"with":4,"diabetes":5,"endocr":2,"pract":2,"ulmer":1,"bj":1,"kara":1,"mariash":1,"cn":1,"temporal":1,"occurrences":1,"and":7,"recurrence":1,"patterns":1,"of":3,"hypo":1,"glycemia":1,"during":2,"hospitalization":2,"shah":1,"br":1,"walji":1,"kiss":1,"james":1,"je":1,"lowe":1,"jm":1,"derivation":1,"validation":2,"prediction":2,"tool":1,"adults":2,"the":3,"hydho":1,"score":1,"can":1,"e1":1,"mathioudakis":1,"everett":1,"routh":1,"development":1,"model":1,"insulin":2,"associated":1,"non":1,"critically":1,"ill":1,"bmj":1,"open":1,"res":1,"care":2,"e000499":1,"curll":1,"dinardo":1,"noschese":1,"korytkowski":2,"mt":1,"menu":1,"selection":1,"glycaemic":1,"control":2,"satisfaction":1,"standard":1,"patient":1,"controlled":1,"consistent":1,"carbohydrate":1,"meal":1,"plans":1,"hospitalised":1,"qual":1,"saf":1,"health":1,"drincic":2,"at":1,"knezevich":1,"jt":1,"akkireddy":1,"nutrition":2,"hyperglycemia":1,"management":1,"inpatient":1,"setting":1,"meals":1,"on":1,"demand":1,"parenteral":1,"or":1,"enteral":1,"curr":1,"diab":1,"rep":1,"draznin":1,"food":1,"fasting":1,"glycemic":1,"hospital":1,"managing":1,"diabet":1},"len":198},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":15,"chunkId":"ada-2026-hosp-p15-c5","text":"hyperglycemia management in the inpatient setting (meals on demand, parenteral, or enteral nutrition). Curr Diab Rep 2017;17:59 116. Korytkowski M, Draznin B, Drincic A. Food, fasting, insulin, and glycemic control in the hospital. In Managing Diabetes and Hyperglycemia in the Hospital Setting . Alexandria, VA, American Diabetes Association, 2016. p. 70-83 117. Mabrey ME, Setji TL. Patient self-management of diabetes care in the inpatient setting: pro. J Diabetes Sci Technol 2015;9:1152  1154 118. Shah AD, Rushakoff RJ. Patient self- management of diabetes care in the inpatient setting: con. J Diabetes Sci Technol 2015;9: 1155  1157 119. Flanagan D, Dhatariya K, Kilvert A; Joint British Diabetes Societies (JBDS) for Inpatient Care group and Guidelines writing group. Self- management of diabetes in hospital: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabet Med 2018;35: 992  996 120. Umpierrez GE, Klonoff DC. Diabetes technology update: use of insulin pumps and continuous glucose monitoring in the hospital. Diabetes Care 2018;41:1579  1589 121. Kalangi ST, Bokka SM, Anand S, Garg R. Regular insulin versus NPH insulin for continuous enteral tube feeding in hospitalized patients. Clinical Diabetes 2025:cd240103 122. Mehta PB, Kohn MA, Rov-Ikpah E, et al. Novel automated self-adjusting subcutaneous insulin algorithm improves glycemic ","tf":{"17":1,"35":1,"41":1,"59":1,"70":1,"83":1,"116":1,"117":1,"118":1,"119":1,"120":1,"121":1,"122":1,"992":1,"996":1,"1152":1,"1154":1,"1155":1,"1157":1,"1579":1,"1589":1,"2015":2,"2016":1,"2017":1,"2018":2,"2025":1,"hyperglycemia":2,"management":4,"in":9,"the":7,"inpatient":5,"setting":4,"meals":1,"on":1,"demand":1,"parenteral":1,"or":1,"enteral":2,"nutrition":1,"curr":1,"diab":1,"rep":1,"korytkowski":1,"draznin":1,"drincic":1,"food":1,"fasting":1,"insulin":5,"and":4,"glycemic":2,"control":1,"hospital":4,"managing":1,"diabetes":12,"alexandria":1,"va":1,"american":1,"association":1,"mabrey":1,"me":1,"setji":1,"tl":1,"patient":2,"self":4,"of":4,"care":5,"pro":1,"sci":2,"technol":2,"shah":1,"ad":1,"rushakoff":1,"rj":1,"con":1,"flanagan":1,"dhatariya":1,"kilvert":1,"joint":2,"british":2,"societies":2,"jbds":2,"for":3,"group":3,"guidelines":1,"writing":1,"guideline":1,"from":1,"diabet":1,"med":1,"umpierrez":1,"ge":1,"klonoff":1,"dc":1,"technology":1,"update":1,"use":1,"pumps":1,"continuous":2,"glucose":1,"monitoring":1,"kalangi":1,"st":1,"bokka":1,"sm":1,"anand":1,"garg":1,"regular":1,"versus":1,"nph":1,"tube":1,"feeding":1,"hospitalized":1,"patients":1,"clinical":1,"cd240103":1,"mehta":1,"pb":1,"kohn":1,"ma":1,"rov":1,"ikpah":1,"et":1,"al":1,"novel":1,"automated":1,"adjusting":1,"subcutaneous":1,"algorithm":1,"improves":1},"len":201},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":15,"chunkId":"ada-2026-hosp-p15-c6","text":"ular insulin versus NPH insulin for continuous enteral tube feeding in hospitalized patients. Clinical Diabetes 2025:cd240103 122. Mehta PB, Kohn MA, Rov-Ikpah E, et al. Novel automated self-adjusting subcutaneous insulin algorithm improves glycemic control and physician efficiency in hospitalized patients. J Diabetes Sci Technol 2024;18:541  548 123. Olveira G, Abun J, Lpez R, et al. Regular insulin added to total parenteral nutrition vs subcutaneous glargine in non-critically ill diabetic inpatients, a multicenter randomized clinical trial: INSUPAR trial. Clin Nutr 2020;39:388  394 124. Aberer F, Hochfellner DA, Sourij H, Mader JK. A practical guide for the management of steroid induced hyperglycaemia in the hospital. J Clin Med 2021;10:2154 125. Bajaj MA, Zale AD, Morgenlander WR, Abusamaan MS, Mathioudakis N. Insulin dosing and glycemic outcomes among steroid-treated hospitalized patients. Endocr Pract 2022;28: 774  779 126. Kleinhans M, Albrecht LJ, Benson S, Fuhrer D, Dissemond J, Tan S. Continuous glucose monitoring of steroid-induced hyperglycemia in patients with dermatologic diseases. J Diabetes Sci Technol 2024;18:904  910 127. Burt MG, Roberts GW, Aguilar-Loza NR, Frith P, Stranks SN. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab 2011;96:1789  1796 128. Khowaja A, Alkhaddo JB, Rana Z,","tf":{"10":1,"18":2,"28":1,"39":1,"96":1,"122":1,"123":1,"124":1,"125":1,"126":1,"127":1,"128":1,"388":1,"394":1,"541":1,"548":1,"774":1,"779":1,"904":1,"910":1,"1789":1,"1796":1,"2011":1,"2020":1,"2021":1,"2022":1,"2024":2,"2025":1,"2154":1,"ular":1,"insulin":5,"versus":1,"nph":1,"for":3,"continuous":3,"enteral":1,"tube":1,"feeding":1,"in":6,"hospitalized":3,"patients":5,"clinical":2,"diabetes":3,"cd240103":1,"mehta":1,"pb":1,"kohn":1,"ma":2,"rov":1,"ikpah":1,"et":2,"al":2,"novel":1,"automated":1,"self":1,"adjusting":1,"subcutaneous":2,"algorithm":1,"improves":1,"glycemic":3,"control":1,"and":2,"physician":1,"efficiency":1,"sci":2,"technol":2,"olveira":1,"abu":1,"pez":1,"regular":1,"added":1,"to":1,"total":1,"parenteral":1,"nutrition":1,"vs":1,"glargine":1,"non":1,"critically":1,"ill":1,"diabetic":1,"inpatients":1,"multicenter":1,"randomized":1,"trial":2,"insupar":1,"clin":3,"nutr":1,"aberer":1,"hochfellner":1,"da":1,"sourij":1,"mader":1,"jk":1,"practical":1,"guide":1,"the":2,"management":1,"of":3,"steroid":3,"induced":2,"hyperglycaemia":1,"hospital":1,"med":1,"bajaj":1,"zale":1,"ad":1,"morgenlander":1,"wr":1,"abusamaan":1,"ms":1,"mathioudakis":1,"dosing":1,"outcomes":1,"among":1,"treated":1,"endocr":1,"pract":1,"kleinhans":1,"albrecht":1,"lj":1,"benson":1,"fuhrer":1,"dissemond":1,"tan":1,"glucose":1,"monitoring":2,"hyperglycemia":1,"with":1,"dermatologic":1,"diseases":1,"burt":1,"mg":1,"roberts":1,"gw":1,"aguilar":1,"loza":1,"nr":1,"frith":1,"stranks":1,"sn":1,"circadian":1,"patterns":1,"receiving":1,"prednisolone":1,"copd":1,"endocrinol":1,"metab":1,"khowaja":1,"alkhaddo":1,"jb":1,"rana":1},"len":195},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":15,"chunkId":"ada-2026-hosp-p15-c7","text":"4  910 127. Burt MG, Roberts GW, Aguilar-Loza NR, Frith P, Stranks SN. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab 2011;96:1789  1796 128. Khowaja A, Alkhaddo JB, Rana Z, Fish L. Glycemic control in hospitalized patients with diabetes receiving corticosteroids using a neutral protamine Hagedorn insulin protocol: a randomized clinical trial. Diabetes Ther 2018;9:1647  1655 129. Kwon S, Hermayer KL, Hermayer K. Glucocorticoid-induced hyperglycemia. Am J Med Sci 2013;345:274  277 130. Brady V, Thosani S, Zhou S, Bassett R, Busaidy NL, Lavis V. Safe and effective dosing of basal-bolus insulin in patients receiving high-dose steroids for hyper-cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy. Diabetes Technol Ther 2014;16:874  879 131. Cheng Y-C, Guerra Y, Morkos M, et al. Insulin management in hospitalized patients with diabetes mellitus on high-dose glucocorticoids: management of steroid-exacerbated hyperglycemia. PLoS One 2021;16:e0256682 diabetesjournals.org/care Diabetes Care in the Hospital S353 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S339/848851/dc26s016.pdf by guest on 17 February 2026","tf":{"16":2,"17":1,"49":1,"96":1,"127":1,"128":1,"129":1,"130":1,"131":1,"274":1,"277":1,"345":1,"874":1,"879":1,"910":1,"1647":1,"1655":1,"1789":1,"1796":1,"2011":1,"2013":1,"2014":1,"2018":1,"2021":1,"2026":1,"848851":1,"burt":1,"mg":1,"roberts":1,"gw":1,"aguilar":1,"loza":1,"nr":1,"frith":1,"stranks":1,"sn":1,"continuous":1,"monitoring":1,"of":3,"circadian":1,"glycemic":2,"patterns":1,"in":5,"patients":4,"receiving":3,"prednisolone":1,"for":2,"copd":1,"clin":1,"endocrinol":1,"metab":1,"khowaja":1,"alkhaddo":1,"jb":1,"rana":1,"fish":1,"control":1,"hospitalized":2,"with":2,"diabetes":5,"corticosteroids":1,"using":1,"neutral":1,"protamine":1,"hagedorn":1,"insulin":3,"protocol":1,"randomized":1,"clinical":1,"trial":1,"ther":2,"kwon":1,"hermayer":2,"kl":1,"glucocorticoid":1,"induced":1,"hyperglycemia":2,"am":1,"med":1,"sci":1,"brady":1,"thosani":1,"zhou":1,"bassett":1,"busaidy":1,"nl":1,"lavis":1,"safe":1,"and":2,"effective":1,"dosing":1,"basal":1,"bolus":1,"high":2,"dose":2,"steroids":1,"hyper":1,"cyclophosphamide":1,"doxorubicin":1,"vincristine":1,"dexamethasone":1,"chemotherapy":1,"technol":1,"cheng":1,"guerra":1,"morkos":1,"et":1,"al":1,"management":2,"mellitus":1,"on":2,"glucocorticoids":1,"steroid":1,"exacerbated":1,"plos":1,"one":1,"e0256682":1,"diabetesjournals":2,"org":2,"care":3,"the":1,"hospital":1,"s353":1,"downloaded":1,"from":1,"http":1,"article":1,"pdf":2,"supplement":1,"s339":1,"dc26s016":1,"by":1,"guest":1,"february":1},"len":169},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":16,"chunkId":"ada-2026-hosp-p16-c0","text":"132. Todd LA, Vigersky RA. Evaluating perioperative glycemic control of non-cardiac surgical patients with diabetes. Mil Med 2021;186:e867  e872 133. Ramos M, Khalpey Z, Lipsitz S, et al. Relationship of perioperative hyperglycemia and postoperative infections in patients who undergo general and vascular surgery. Ann Surg 2008; 248:585  591 134. van den Boom W, Schroeder RA, Manning MW, Setji TL, Fiestan G-O, Dunson DB. Effect of A1C and glucose on postoperative mortality in noncardiac and cardiac surgeries. Diabetes Care 2018;41:782  788 135. Martin ET, Kaye KS, Knott C, et al. Diabetes and risk of surgical site infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol 2016;37:88  99 136. King JT, Goulet JL, Perkal MF, Rosenthal RA. Glycemic control and infections in patients with diabetes undergoing noncardiac surgery. Ann Surg 2011;253:158  165 137. Ata A, Lee J, Bestle SL, Desemone J, Stain SC. Postoperative hyperglycemia and surgical site infection in general surgery patients. Arch Surg 2010;145:858  864 138. Kwon S, Thompson R, Dellinger P, Yanez D, Farrohki E, Flum D. Importance of perioperative glycemic control in general surgery: a report from the Surgical Care and Outcomes Assessment Program. Ann Surg 2013;257:8  14 139. Garg R, Schuman B, Bader A, et al. Effect of preoperative diabetes management on glycemic control and clinical outcomes ","tf":{"14":1,"37":1,"41":1,"88":1,"99":1,"132":1,"133":1,"134":1,"135":1,"136":1,"137":1,"138":1,"139":1,"145":1,"158":1,"165":1,"186":1,"248":1,"253":1,"257":1,"585":1,"591":1,"782":1,"788":1,"858":1,"864":1,"2008":1,"2010":1,"2011":1,"2013":1,"2016":1,"2018":1,"2021":1,"todd":1,"la":1,"vigersky":1,"ra":3,"evaluating":1,"perioperative":3,"glycemic":4,"control":5,"of":6,"non":1,"cardiac":2,"surgical":4,"patients":4,"with":2,"diabetes":5,"mil":1,"med":1,"e867":1,"e872":1,"ramos":1,"khalpey":1,"lipsitz":1,"et":4,"al":3,"relationship":1,"hyperglycemia":2,"and":10,"postoperative":3,"infections":2,"in":5,"who":1,"undergo":1,"general":3,"vascular":1,"surgery":4,"ann":3,"surg":4,"van":1,"den":1,"boom":1,"schroeder":1,"manning":1,"mw":1,"setji":1,"tl":1,"fiestan":1,"dunson":1,"db":1,"effect":2,"a1c":1,"glucose":1,"on":2,"mortality":1,"noncardiac":2,"surgeries":1,"care":2,"martin":1,"kaye":1,"ks":1,"knott":1,"risk":1,"site":2,"infection":2,"systematic":1,"review":1,"meta":1,"analysis":1,"infect":1,"hosp":1,"epidemiol":1,"king":1,"jt":1,"goulet":1,"jl":1,"perkal":1,"mf":1,"rosenthal":1,"undergoing":1,"ata":1,"lee":1,"bestle":1,"sl":1,"desemone":1,"stain":1,"sc":1,"arch":1,"kwon":1,"thompson":1,"dellinger":1,"yanez":1,"farrohki":1,"flum":1,"importance":1,"report":1,"from":1,"the":1,"outcomes":2,"assessment":1,"program":1,"garg":1,"schuman":1,"bader":1,"preoperative":1,"management":1,"clinical":1},"len":205},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":16,"chunkId":"ada-2026-hosp-p16-c1","text":"ycemic control in general surgery: a report from the Surgical Care and Outcomes Assessment Program. Ann Surg 2013;257:8  14 139. Garg R, Schuman B, Bader A, et al. Effect of preoperative diabetes management on glycemic control and clinical outcomes after elective surgery. Ann Surg 2018;267:858  862 140. Okabayashi T, Shima Y, Sumiyoshi T, et al. Intensive versus intermediate glucose control in surgical intensive care unit patients. Diabetes Care 2014;37:1516  1524 141. Underwood P, Askari R, Hurwitz S, Chamarthi B, Garg R. Preoperative A1C and clinical outcomes in patients with diabetes undergoing major noncardiac surgical procedures. Diabetes Care 2014;37:611  616 142. Chen P, Hallock KK, Mulvey CL, Berg AS, Cherian VT. The effect of elevated A1C on immediate postoperative complications: a prospective observational study. Clin Diabetes 2018;36:128  132 143. Yu A, Truong Q, Whitfield K, et al. Impact of preoperative haemoglobin A1c levels on postoperative outcomes in adults undergoing major noncardiac surgery: a systematic review. Diabet Med 2024;41:e15380 144. Tao X, Matur AV, Palmisciano P, et al. Preoperative HbA1c and postoperative outcomes in spine surgery: a systematic review and meta- analysis. Spine (Phila Pa 1976) 2023;48:1155  1165 145. Duggan EW, Carlson K, Umpierrez GE. Perioperative hyperglycemia management: an update. Anesthesiology 2017;126:547  560 146. B","tf":{"14":1,"36":1,"37":2,"41":1,"48":1,"126":1,"128":1,"132":1,"139":1,"140":1,"141":1,"142":1,"143":1,"144":1,"145":1,"146":1,"257":1,"267":1,"547":1,"560":1,"611":1,"616":1,"858":1,"862":1,"1155":1,"1165":1,"1516":1,"1524":1,"1976":1,"2013":1,"2014":2,"2017":1,"2018":2,"2023":1,"2024":1,"ycemic":1,"control":3,"in":5,"general":1,"surgery":4,"report":1,"from":1,"the":2,"surgical":3,"care":4,"and":5,"outcomes":5,"assessment":1,"program":1,"ann":2,"surg":2,"garg":2,"schuman":1,"bader":1,"et":4,"al":4,"effect":2,"of":3,"preoperative":4,"diabetes":5,"management":2,"on":3,"glycemic":1,"clinical":2,"after":1,"elective":1,"okabayashi":1,"shima":1,"sumiyoshi":1,"intensive":2,"versus":1,"intermediate":1,"glucose":1,"unit":1,"patients":2,"underwood":1,"askari":1,"hurwitz":1,"chamarthi":1,"a1c":3,"with":1,"undergoing":2,"major":2,"noncardiac":2,"procedures":1,"chen":1,"hallock":1,"kk":1,"mulvey":1,"cl":1,"berg":1,"as":1,"cherian":1,"vt":1,"elevated":1,"immediate":1,"postoperative":3,"complications":1,"prospective":1,"observational":1,"study":1,"clin":1,"yu":1,"truong":1,"whitfield":1,"impact":1,"haemoglobin":1,"levels":1,"adults":1,"systematic":2,"review":2,"diabet":1,"med":1,"e15380":1,"tao":1,"matur":1,"av":1,"palmisciano":1,"hba1c":1,"spine":2,"meta":1,"analysis":1,"phila":1,"pa":1,"duggan":1,"ew":1,"carlson":1,"umpierrez":1,"ge":1,"perioperative":1,"hyperglycemia":1,"an":1,"update":1,"anesthesiology":1},"len":195},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":16,"chunkId":"ada-2026-hosp-p16-c2","text":"perative outcomes in spine surgery: a systematic review and meta- analysis. Spine (Phila Pa 1976) 2023;48:1155  1165 145. Duggan EW, Carlson K, Umpierrez GE. Perioperative hyperglycemia management: an update. Anesthesiology 2017;126:547  560 146. Bellon F, Sol I, Gimenez-Perez G, et al. Perioperative glycaemic control for people with diabetes undergoing surgery. Cochrane Database Syst Rev 2023;8:CD007315 147. Perez-Guzman MC, Duggan E, Gibanica S, et al. continuous glucose monitoring in the operating room and cardiac intensive care unit. Diabetes Care 2021;44:e50  e52 148. Cruz P, McKee AM, Chiang H-H, et al. Perioperative care of patients using wearable diabetes devices. Anesth Analg 2025;140:2  12 149. Demma LJ, Carlson KT, Duggan EW, Morrow JG, Umpierrez G. Effect of basal insulin dosage on blood glucose concentration in ambulatory surgery patients with type 2 diabetes. J Clin Anesth 2017;36:184  188 150. Dixit AA, Bateman BT, Hawn MT, Odden MC, Sun EC. Preoperative SGLT2 inhibitor use and postoperative diabetic ketoacidosis. JAMA Surg 2025;160:423  430 151. Tallarico RT, Jing B, Lu K, et al. Postoperative outcomes among sodium-glucose cotransporter 2 inhibitor users. JAMA Surg 2025;160:681  689 152. Steinhorn B, Wiener-Kronish J. Dose- dependent relationship between SGLT2 inhibitor hold time and risk for postoperative anion gap acidosis: a single-centre retrospectiv","tf":{"12":1,"36":1,"44":1,"48":1,"126":1,"140":1,"145":1,"146":1,"147":1,"148":1,"149":1,"150":1,"151":1,"152":1,"160":2,"184":1,"188":1,"423":1,"430":1,"547":1,"560":1,"681":1,"689":1,"1155":1,"1165":1,"1976":1,"2017":2,"2021":1,"2023":2,"2025":3,"perative":1,"outcomes":2,"in":3,"spine":2,"surgery":3,"systematic":1,"review":1,"and":4,"meta":1,"analysis":1,"phila":1,"pa":1,"duggan":3,"ew":2,"carlson":2,"umpierrez":2,"ge":1,"perioperative":3,"hyperglycemia":1,"management":1,"an":1,"update":1,"anesthesiology":1,"bellon":1,"sol":1,"gimenez":1,"perez":2,"et":4,"al":4,"glycaemic":1,"control":1,"for":2,"people":1,"with":2,"diabetes":4,"undergoing":1,"cochrane":1,"database":1,"syst":1,"rev":1,"cd007315":1,"guzman":1,"mc":2,"gibanica":1,"continuous":1,"glucose":3,"monitoring":1,"the":1,"operating":1,"room":1,"cardiac":1,"intensive":1,"care":3,"unit":1,"e50":1,"e52":1,"cruz":1,"mckee":1,"am":1,"chiang":1,"of":2,"patients":2,"using":1,"wearable":1,"devices":1,"anesth":2,"analg":1,"demma":1,"lj":1,"kt":1,"morrow":1,"jg":1,"effect":1,"basal":1,"insulin":1,"dosage":1,"on":1,"blood":1,"concentration":1,"ambulatory":1,"type":1,"clin":1,"dixit":1,"aa":1,"bateman":1,"bt":1,"hawn":1,"mt":1,"odden":1,"sun":1,"ec":1,"preoperative":1,"sglt2":2,"inhibitor":3,"use":1,"postoperative":3,"diabetic":1,"ketoacidosis":1,"jama":2,"surg":2,"tallarico":1,"rt":1,"jing":1,"lu":1,"among":1,"sodium":1,"cotransporter":1,"users":1,"steinhorn":1,"wiener":1,"kronish":1,"dose":1,"dependent":1,"relationship":1,"between":1,"hold":1,"time":1,"risk":1,"anion":1,"gap":1,"acidosis":1,"single":1,"centre":1,"retrospectiv":1},"len":202},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":16,"chunkId":"ada-2026-hosp-p16-c3","text":"odium-glucose cotransporter 2 inhibitor users. JAMA Surg 2025;160:681  689 152. Steinhorn B, Wiener-Kronish J. Dose- dependent relationship between SGLT2 inhibitor hold time and risk for postoperative anion gap acidosis: a single-centre retrospective analysis. Br J Anaesth 2023;131:682  686 153. Wang R, Kave B, McIlroy E, Kyi M, Colman PG, Fourlanos S. Metabolic outcomes in patients with diabetes mellitus administered SGLT2 inhibitors immediately before emergency or elective surgery: single centre experience and recommendations. Br J Anaesth 2021;127:e5  e7 154. Klein SR, Hobai IA. Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report. Can J Anaesth 2023; 70:1394  1396 155. Sen S, Potnuru PP, Hernandez N, et al. Glucagon-like peptide-1 receptor agonist use and residual gastric content before anesthesia. JAMA Surg 2024;159:660  667 156. U.S. Food and Drug Administration. Drug safety-related labeling changes (SrLC). Ozempic (semaglutide). Accessed 4 August 2025. Available from https://www.accessdata.fda.gov/scripts/ cder/safetylabelingchanges/index.cfm?event= searchdetail.page&DrugNameID=2183 157. Santos LB, Mizubuti GB, da Silva LM, et al. Effect of various perioperative semaglutide interruption intervals on residual gastric content assessed by esophagogastroduodenoscopy: a retrospective single center observational study. J Clin Anest","tf":{"70":1,"127":1,"131":1,"152":1,"153":1,"154":1,"155":1,"156":1,"157":1,"159":1,"160":1,"660":1,"667":1,"681":1,"682":1,"686":1,"689":1,"1394":1,"1396":1,"2021":1,"2023":2,"2024":1,"2025":2,"2183":1,"odium":1,"glucose":1,"cotransporter":1,"inhibitor":2,"users":1,"jama":2,"surg":2,"steinhorn":1,"wiener":1,"kronish":1,"dose":1,"dependent":1,"relationship":1,"between":1,"sglt2":2,"hold":1,"time":1,"and":5,"risk":1,"for":1,"postoperative":1,"anion":1,"gap":1,"acidosis":1,"single":3,"centre":2,"retrospective":2,"analysis":1,"br":2,"anaesth":3,"wang":1,"kave":1,"mcilroy":1,"kyi":1,"colman":1,"pg":1,"fourlanos":1,"metabolic":1,"outcomes":1,"in":1,"patients":1,"with":1,"diabetes":1,"mellitus":1,"administered":1,"inhibitors":1,"immediately":1,"before":2,"emergency":1,"or":1,"elective":1,"surgery":1,"experience":1,"recommendations":1,"e5":1,"e7":1,"klein":1,"sr":1,"hobai":1,"ia":1,"semaglutide":3,"delayed":1,"gastric":3,"emptying":1,"intraoperative":1,"pulmonary":1,"aspiration":1,"case":1,"report":1,"can":1,"sen":1,"potnuru":1,"pp":1,"hernandez":1,"et":2,"al":2,"glucagon":1,"like":1,"peptide":1,"receptor":1,"agonist":1,"use":1,"residual":2,"content":2,"anesthesia":1,"food":1,"drug":2,"administration":1,"safety":1,"related":1,"labeling":1,"changes":1,"srlc":1,"ozempic":1,"accessed":1,"august":1,"available":1,"from":1,"https":1,"www":1,"accessdata":1,"fda":1,"gov":1,"scripts":1,"cder":1,"safetylabelingchanges":1,"index":1,"cfm":1,"event":1,"searchdetail":1,"page":1,"drugnameid":1,"santos":1,"lb":1,"mizubuti":1,"gb":1,"da":1,"silva":1,"lm":1,"effect":1,"of":1,"various":1,"perioperative":1,"interruption":1,"intervals":1,"on":1,"assessed":1,"by":1,"esophagogastroduodenoscopy":1,"center":1,"observational":1,"study":1,"clin":1,"anest":1},"len":185},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":16,"chunkId":"ada-2026-hosp-p16-c4","text":"83 157. Santos LB, Mizubuti GB, da Silva LM, et al. Effect of various perioperative semaglutide interruption intervals on residual gastric content assessed by esophagogastroduodenoscopy: a retrospective single center observational study. J Clin Anesth 2024;99:111668 158. Silveira SQ, da Silva LM, de Campos Vieira Abib A, et al. Relationship between perioperative semaglutide use and residual gastric content: a retrospective analysis of patients undergoing elective upper endoscopy. J Clin Anesth 2023; 87:111091 159. Chen Y-H, Zink T, Chen Y-W, et al. Postoperative aspiration pneumonia among adults using GLP-1 receptor agonists. JAMA Netw Open 2025;8:e250081 160. Facciorusso A, Ramai D, Dhar J, et al. Effects of glucagon-like peptide-1 receptor agonists on upper gastrointestinal endoscopy: a meta-analysis. Clin Gastroenterol Hepatol 2025; 23:715  725.e3 e713 161. American Society of Anesthesiologists. American Society of Anesthesiologists consensus- based guidance on preoperative management of patients (adults and children) on glucagon-like peptide-1 (GLP-1) receptor agonists. Accessed 21 August 2025. Available from https://www.asahq. org/about-asa/newsroom/news-releases/2023/ 06/american-society-of-anesthesiologists-consensus- based-guidance-on-preoperative 162. Kindel TL, Wang AY, Wadhwa A, et al.; Society of American Gastrointestinal and Endoscopic Surgeons. Multisociety clini","tf":{"21":1,"23":1,"83":1,"87":1,"99":1,"157":1,"158":1,"159":1,"160":1,"161":1,"162":1,"715":1,"725":1,"2023":2,"2024":1,"2025":3,"111091":1,"111668":1,"santos":1,"lb":1,"mizubuti":1,"gb":1,"da":2,"silva":2,"lm":2,"et":5,"al":5,"effect":1,"of":8,"various":1,"perioperative":2,"semaglutide":2,"interruption":1,"intervals":1,"on":5,"residual":2,"gastric":2,"content":2,"assessed":1,"by":1,"esophagogastroduodenoscopy":1,"retrospective":2,"single":1,"center":1,"observational":1,"study":1,"clin":3,"anesth":2,"silveira":1,"sq":1,"de":1,"campos":1,"vieira":1,"abib":1,"relationship":1,"between":1,"use":1,"and":3,"analysis":2,"patients":2,"undergoing":1,"elective":1,"upper":2,"endoscopy":2,"chen":2,"zink":1,"postoperative":1,"aspiration":1,"pneumonia":1,"among":1,"adults":2,"using":1,"glp":2,"receptor":3,"agonists":3,"jama":1,"netw":1,"open":1,"e250081":1,"facciorusso":1,"ramai":1,"dhar":1,"effects":1,"glucagon":2,"like":2,"peptide":2,"gastrointestinal":2,"meta":1,"gastroenterol":1,"hepatol":1,"e3":1,"e713":1,"american":4,"society":4,"anesthesiologists":3,"consensus":2,"based":2,"guidance":2,"preoperative":2,"management":1,"children":1,"accessed":1,"august":1,"available":1,"from":1,"https":1,"www":1,"asahq":1,"org":1,"about":1,"asa":1,"newsroom":1,"news":1,"releases":1,"06":1,"kindel":1,"tl":1,"wang":1,"ay":1,"wadhwa":1,"endoscopic":1,"surgeons":1,"multisociety":1,"clini":1},"len":187},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":16,"chunkId":"ada-2026-hosp-p16-c5","text":" org/about-asa/newsroom/news-releases/2023/ 06/american-society-of-anesthesiologists-consensus- based-guidance-on-preoperative 162. Kindel TL, Wang AY, Wadhwa A, et al.; Society of American Gastrointestinal and Endoscopic Surgeons. Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surg Obes Relat Dis 2024;20:1183  1186 163. Oprea AD, Ostapenko LJ, Sweitzer B, et al. Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Im- provement (SPAQI) multidisciplinary consensus statement. Br J Anaesth 2025;135:48  78 164. El-Boghdadly K, Dhesi J, Fabb P, et al. Elective peri-operative management of adults taking glucagon-like peptide-1 receptor agonists, glucose- dependent insulinotropic peptide agonists and sodium-glucose cotransporter-2 inhibitors: a multi- disciplinary consensus statement: a consensus statement from the Association of Anaesthetists, Association of British Clinical Diabetologists, British Obesity and Metabolic Surgery Society, Centre for Perioperative Care, Joint British Diabetes Societies for Inpatient Care, Royal College of Anaesthetists, Society for Obesity and Bariatric Anaesthesia and UK Clinical Pharmacy Association. Anaesthesia 2025;80:412  424 165. Umpierrez GE, Davis GM, ElSayed NA, et al. Hypergl","tf":{"20":1,"48":1,"78":1,"80":1,"135":1,"162":1,"163":1,"164":1,"165":1,"412":1,"424":1,"1183":1,"1186":1,"2023":1,"2024":1,"2025":2,"org":1,"about":1,"asa":1,"newsroom":1,"news":1,"releases":1,"06":1,"american":2,"society":5,"of":8,"anesthesiologists":1,"consensus":4,"based":1,"guidance":2,"on":1,"preoperative":1,"kindel":1,"tl":1,"wang":1,"ay":1,"wadhwa":1,"et":4,"al":4,"gastrointestinal":1,"and":6,"endoscopic":1,"surgeons":1,"multisociety":1,"clinical":3,"practice":1,"for":5,"the":3,"safe":1,"use":1,"glucagon":3,"like":3,"peptide":4,"receptor":3,"agonists":4,"in":1,"perioperative":4,"period":1,"surg":1,"obes":1,"relat":1,"dis":1,"oprea":1,"ad":1,"ostapenko":1,"lj":1,"sweitzer":1,"management":2,"patients":1,"taking":2,"assessment":1,"quality":1,"im":1,"provement":1,"spaqi":1,"multidisciplinary":1,"statement":3,"br":1,"anaesth":1,"el":1,"boghdadly":1,"dhesi":1,"fabb":1,"elective":1,"peri":1,"operative":1,"adults":1,"glucose":2,"dependent":1,"insulinotropic":1,"sodium":1,"cotransporter":1,"inhibitors":1,"multi":1,"disciplinary":1,"from":1,"association":3,"anaesthetists":2,"british":3,"diabetologists":1,"obesity":2,"metabolic":1,"surgery":1,"centre":1,"care":2,"joint":1,"diabetes":1,"societies":1,"inpatient":1,"royal":1,"college":1,"bariatric":1,"anaesthesia":2,"uk":1,"pharmacy":1,"umpierrez":1,"ge":1,"davis":1,"gm":1,"elsayed":1,"na":1,"hypergl":1},"len":186},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":16,"chunkId":"ada-2026-hosp-p16-c6","text":"t British Diabetes Societies for Inpatient Care, Royal College of Anaesthetists, Society for Obesity and Bariatric Anaesthesia and UK Clinical Pharmacy Association. Anaesthesia 2025;80:412  424 165. Umpierrez GE, Davis GM, ElSayed NA, et al. Hyperglycemic crises in adults with diabetes: a consensus report. Diabetes Care 2024;47: 1257  1275 166. Desai D, Mehta D, Mathias P, Menon G, Schubart UK. health care utilization and burden of diabetic ketoacidosis in the U.S. over the past decade: a nationwide analysis. Diabetes Care 2018;41:1631  1638 167. Long B, Lentz S, Koyfman A, Gottlieb M. Euglycemic diabetic ketoacidosis: etiologies, evaluation, and management. Am J Emerg Med 2021;44:157  160 168. Pasquel FJ, Tsegka K, Wang H, et al. Clinical outcomes in patients with isolated or combined diabetic ketoacidosis and hyperosmolar hyper- glycemic state: a retrospective, hospital-based cohort study. Diabetes Care 2020;43:349  357 169. McCoy RG, Herrin J, Galindo RJ, et al. Rates of hypoglycemic and hyperglycemic emergencies among U.S. adults with diabetes, 2011  2020. Diabetes Care 2023;46:e69  e71 170. Zhong VW, Juhaeri J, Mayer-Davis EJ. Trends in hospital admission for diabetic ketoacidosis in adults with type 1 and type 2 diabetes in England, 1998-2013: a retrospective cohort study. Diabetes Care 2018;41:1870  1877 171. Everett EM, Copeland TP, Moin T, Wisk LE. National tre","tf":{"41":2,"43":1,"44":1,"46":1,"47":1,"80":1,"157":1,"160":1,"165":1,"166":1,"167":1,"168":1,"169":1,"170":1,"171":1,"349":1,"357":1,"412":1,"424":1,"1257":1,"1275":1,"1631":1,"1638":1,"1870":1,"1877":1,"1998":1,"2011":1,"2013":1,"2018":2,"2020":2,"2021":1,"2023":1,"2024":1,"2025":1,"british":1,"diabetes":9,"societies":1,"for":3,"inpatient":1,"care":7,"royal":1,"college":1,"of":3,"anaesthetists":1,"society":1,"obesity":1,"and":7,"bariatric":1,"anaesthesia":2,"uk":2,"clinical":2,"pharmacy":1,"association":1,"umpierrez":1,"ge":1,"davis":2,"gm":1,"elsayed":1,"na":1,"et":3,"al":3,"hyperglycemic":2,"crises":1,"in":6,"adults":3,"with":4,"consensus":1,"report":1,"desai":1,"mehta":1,"mathias":1,"menon":1,"schubart":1,"health":1,"utilization":1,"burden":1,"diabetic":4,"ketoacidosis":4,"the":2,"over":1,"past":1,"decade":1,"nationwide":1,"analysis":1,"long":1,"lentz":1,"koyfman":1,"gottlieb":1,"euglycemic":1,"etiologies":1,"evaluation":1,"management":1,"am":1,"emerg":1,"med":1,"pasquel":1,"fj":1,"tsegka":1,"wang":1,"outcomes":1,"patients":1,"isolated":1,"or":1,"combined":1,"hyperosmolar":1,"hyper":1,"glycemic":1,"state":1,"retrospective":2,"hospital":2,"based":1,"cohort":2,"study":2,"mccoy":1,"rg":1,"herrin":1,"galindo":1,"rj":1,"rates":1,"hypoglycemic":1,"emergencies":1,"among":1,"e69":1,"e71":1,"zhong":1,"vw":1,"juhaeri":1,"mayer":1,"ej":1,"trends":1,"admission":1,"type":2,"england":1,"everett":1,"em":1,"copeland":1,"tp":1,"moin":1,"wisk":1,"le":1,"national":1,"tre":1},"len":200},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":16,"chunkId":"ada-2026-hosp-p16-c7","text":"is EJ. Trends in hospital admission for diabetic ketoacidosis in adults with type 1 and type 2 diabetes in England, 1998-2013: a retrospective cohort study. Diabetes Care 2018;41:1870  1877 171. Everett EM, Copeland TP, Moin T, Wisk LE. National trends in pediatric admissions for diabetic ketoacidosis, 2006  2016. J Clin Endo- crinol Metab 2021;106:2343  2354 172. OReilly JE, Jeyam A, Caparrotta TM, et al.; Scottish Diabetes Research Network Epidemiology Group. Rising rates and widening socioeconomic disparities in diabetic ketoacidosis in type 1 diabetes in scotland: a nationwide retrospective cohort observational study. Diabetes Care 2021; 44:2010  2017 173. McCoy RG, Herrin J, Galindo RJ, et al. All- cause mortality after hypoglycemic and hyper- glycemic emergencies among U.S. adults with diabetes, 2011  2020. Diabetes Res Clin Pract 2023;197:110263 174. El-Mohandes N, Yee G, Bhutta BS, Huecker MR. In Pediatric diabetic ketoacidosis. StatPearls. Treasure Island, FL, 2025. Accessed 4 August 2025. Available from https://www.ncbi.nlm.nih .gov/pubmed/29262031 175. Shaka H, Wani F, El-Amir Z, et al. Comparing patient characteristics and outcomes S354 Diabetes Care in the Hospital Diabetes Care Volume 49, Supplement 1, January 2026 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S339/848851/dc26s016.pdf by guest on 17 February 2026","tf":{"17":1,"41":1,"44":1,"49":2,"106":1,"171":1,"172":1,"173":1,"174":1,"175":1,"197":1,"1870":1,"1877":1,"1998":1,"2006":1,"2010":1,"2011":1,"2013":1,"2016":1,"2017":1,"2018":1,"2020":1,"2021":2,"2023":1,"2025":2,"2026":2,"2343":1,"2354":1,"110263":1,"848851":1,"29262031":1,"is":1,"ej":1,"trends":2,"in":9,"hospital":2,"admission":1,"for":2,"diabetic":4,"ketoacidosis":4,"adults":2,"with":2,"type":3,"and":4,"diabetes":9,"england":1,"retrospective":2,"cohort":2,"study":2,"care":5,"everett":1,"em":1,"copeland":1,"tp":1,"moin":1,"wisk":1,"le":1,"national":1,"pediatric":2,"admissions":1,"clin":2,"endo":1,"crinol":1,"metab":1,"reilly":1,"je":1,"jeyam":1,"caparrotta":1,"tm":1,"et":3,"al":3,"scottish":1,"research":1,"network":1,"epidemiology":1,"group":1,"rising":1,"rates":1,"widening":1,"socioeconomic":1,"disparities":1,"scotland":1,"nationwide":1,"observational":1,"mccoy":1,"rg":1,"herrin":1,"galindo":1,"rj":1,"all":1,"cause":1,"mortality":1,"after":1,"hypoglycemic":1,"hyper":1,"glycemic":1,"emergencies":1,"among":1,"res":1,"pract":1,"el":2,"mohandes":1,"yee":1,"bhutta":1,"bs":1,"huecker":1,"mr":1,"statpearls":1,"treasure":1,"island":1,"fl":1,"accessed":1,"august":1,"available":1,"from":2,"https":1,"www":1,"ncbi":1,"nlm":1,"nih":1,"gov":1,"pubmed":1,"shaka":1,"wani":1,"amir":1,"comparing":1,"patient":1,"characteristics":1,"outcomes":1,"s354":1,"the":1,"volume":1,"supplement":2,"january":1,"downloaded":1,"http":1,"diabetesjournals":1,"org":1,"article":1,"pdf":2,"s339":1,"dc26s016":1,"by":1,"guest":1,"on":1,"february":1},"len":199},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":17,"chunkId":"ada-2026-hosp-p17-c0","text":"in type 1 versus type 2 diabetes with diabetic ketoacidosis: a review and a propensity-matched nationwide analysis. J Investig Med 2021;69: 1196  1200 176. Shaka H, El-Amir Z, Wani F, et al. Hospitalizations and inpatient mortality for hyperosmolar hyperglycemic state over a decade. Diabetes Res Clin Pract 2022;185:109230 177. Shand JAD, Morrow P, Braatvedt G. Mortality after discharge from hospital following an episode of diabetic ketoacidosis. Acta Diabetol 2022;59:1485  1492 178. Anis TR, Boudreau M, Thornton T. Comparing the efficacy of a nurse-driven and a physician- driven diabetic ketoacidosis (DKA) treatment protocol. Clin Pharmacol 2021;13:197  202 179. Harrison VS, Rustico S, Palladino AA, Ferrara C, Hawkes CP. Glargine co-administration with intravenous insulin in pediatric diabetic keto- acidosis is safe and facilitates transition to a subcutaneous regimen. Pediatr Diabetes 2017;18: 742  748 180. Rao P, Jiang S-F, Kipnis P, et al. Evaluation of outcomes following hospital-wide implementation of a subcutaneous insulin protocol for diabetic ketoacidosis. JAMA Netw Open 2022;5:e226417 181. Kitabchi AE, Umpierrez GE, Fisher JN, Murphy MB, Stentz FB. Thirty years of personal experience in hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state. J Clin Endocrinol Metab 2008;93:1541  1552 182. Alnuaimi A, Mach T, Reynier P, Filion KB, Lipes J,","tf":{"13":1,"18":1,"59":1,"69":1,"93":1,"176":1,"177":1,"178":1,"179":1,"180":1,"181":1,"182":1,"185":1,"197":1,"202":1,"742":1,"748":1,"1196":1,"1200":1,"1485":1,"1492":1,"1541":1,"1552":1,"2008":1,"2017":1,"2021":2,"2022":3,"109230":1,"in":3,"type":2,"versus":1,"diabetes":3,"with":2,"diabetic":6,"ketoacidosis":5,"review":1,"and":5,"propensity":1,"matched":1,"nationwide":1,"analysis":1,"investig":1,"med":1,"shaka":1,"el":1,"amir":1,"wani":1,"et":2,"al":2,"hospitalizations":1,"inpatient":1,"mortality":2,"for":2,"hyperosmolar":2,"hyperglycemic":3,"state":2,"over":1,"decade":1,"res":1,"clin":3,"pract":1,"shand":1,"jad":1,"morrow":1,"braatvedt":1,"after":1,"discharge":1,"from":1,"hospital":2,"following":2,"an":1,"episode":1,"of":5,"acta":1,"diabetol":1,"anis":1,"tr":1,"boudreau":1,"thornton":1,"comparing":1,"the":1,"efficacy":1,"nurse":1,"driven":2,"physician":1,"dka":1,"treatment":1,"protocol":2,"pharmacol":1,"harrison":1,"vs":1,"rustico":1,"palladino":1,"aa":1,"ferrara":1,"hawkes":1,"cp":1,"glargine":1,"co":1,"administration":1,"intravenous":1,"insulin":2,"pediatric":1,"keto":1,"acidosis":1,"is":1,"safe":1,"facilitates":1,"transition":1,"to":1,"subcutaneous":2,"regimen":1,"pediatr":1,"rao":1,"jiang":1,"kipnis":1,"evaluation":1,"outcomes":1,"wide":1,"implementation":1,"jama":1,"netw":1,"open":1,"e226417":1,"kitabchi":1,"ae":1,"umpierrez":1,"ge":1,"fisher":1,"jn":1,"murphy":1,"mb":1,"stentz":1,"fb":1,"thirty":1,"years":1,"personal":1,"experience":1,"crises":1,"endocrinol":1,"metab":1,"alnuaimi":1,"mach":1,"reynier":1,"filion":1,"kb":1,"lipes":1},"len":189},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":17,"chunkId":"ada-2026-hosp-p17-c1","text":"her JN, Murphy MB, Stentz FB. Thirty years of personal experience in hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state. J Clin Endocrinol Metab 2008;93:1541  1552 182. Alnuaimi A, Mach T, Reynier P, Filion KB, Lipes J, Yu OHY. A systematic review and meta- analysis comparing outcomes between using subcutaneous insulin and continuous insulin infusion in managing adult patients with diabetic ketoacidosis. BMC Endocr Disord 2024;24:133 183. Gonalves-Bradley DC, Lannin NA, Clemson L, Cameron ID, Shepperd S. Discharge planning from hospital. Cochrane Database Syst Rev 2022; 2:CD000313 184. Gregory NS, Seley JJ, Dargar SK, Galla N, Gerber LM, Lee JI. Strategies to prevent readmission in high-risk patients with diabetes: the importance of an interdisciplinary approach. Curr Diab Rep 2018;18:54 185. Rubin DJ, Shah AA. Predicting and preventing acute care re-utilization by patients with diabetes. Curr Diab Rep 2021;21:34 186. Rinaldi A, Snider M, James A, et al. The impact of a diabetes transitions of care clinic on hospital utilization and patient care. Ann Pharmacother 2023;57:127  132 187. Patel N, Swami J, Pinkhasova D, et al. Sex differences in glycemic measures, complications, discharge disposition, and postdischarge emergency room visits and readmission among non-critically ill, hospitalized patients with diabetes. BMJ Open Diabetes Res Care 2022","tf":{"18":1,"21":1,"24":1,"34":1,"54":1,"57":1,"93":1,"127":1,"132":1,"133":1,"182":1,"183":1,"184":1,"185":1,"186":1,"187":1,"1541":1,"1552":1,"2008":1,"2018":1,"2021":1,"2022":2,"2023":1,"2024":1,"her":1,"jn":1,"murphy":1,"mb":1,"stentz":1,"fb":1,"thirty":1,"years":1,"of":4,"personal":1,"experience":1,"in":4,"hyperglycemic":2,"crises":1,"diabetic":2,"ketoacidosis":2,"and":7,"hyperosmolar":1,"state":1,"clin":1,"endocrinol":1,"metab":1,"alnuaimi":1,"mach":1,"reynier":1,"filion":1,"kb":1,"lipes":1,"yu":1,"ohy":1,"systematic":1,"review":1,"meta":1,"analysis":1,"comparing":1,"outcomes":1,"between":1,"using":1,"subcutaneous":1,"insulin":2,"continuous":1,"infusion":1,"managing":1,"adult":1,"patients":4,"with":4,"bmc":1,"endocr":1,"disord":1,"gon":1,"alves":1,"bradley":1,"dc":1,"lannin":1,"na":1,"clemson":1,"cameron":1,"id":1,"shepperd":1,"discharge":2,"planning":1,"from":1,"hospital":2,"cochrane":1,"database":1,"syst":1,"rev":1,"cd000313":1,"gregory":1,"ns":1,"seley":1,"jj":1,"dargar":1,"sk":1,"galla":1,"gerber":1,"lm":1,"lee":1,"ji":1,"strategies":1,"to":1,"prevent":1,"readmission":2,"high":1,"risk":1,"diabetes":5,"the":2,"importance":1,"an":1,"interdisciplinary":1,"approach":1,"curr":2,"diab":2,"rep":2,"rubin":1,"dj":1,"shah":1,"aa":1,"predicting":1,"preventing":1,"acute":1,"care":4,"re":1,"utilization":2,"by":1,"rinaldi":1,"snider":1,"james":1,"et":2,"al":2,"impact":1,"transitions":1,"clinic":1,"on":1,"patient":1,"ann":1,"pharmacother":1,"patel":1,"swami":1,"pinkhasova":1,"sex":1,"differences":1,"glycemic":1,"measures":1,"complications":1,"disposition":1,"postdischarge":1,"emergency":1,"room":1,"visits":1,"among":1,"non":1,"critically":1,"ill":1,"hospitalized":1,"bmj":1,"open":1,"res":1},"len":202},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":17,"chunkId":"ada-2026-hosp-p17-c2","text":"J, Pinkhasova D, et al. Sex differences in glycemic measures, complications, discharge disposition, and postdischarge emergency room visits and readmission among non-critically ill, hospitalized patients with diabetes. BMJ Open Diabetes Res Care 2022;10:e002722 188. Pandya N, Hames E, Sandhu S. Challenges and strategies for managing diabetes in the elderly in long-term care settings. Diabetes Spectr 2020;33:236  245 189. Agency for Healthcare Research and Quality. Patient Safety Network  Readmissions and adverse events after discharge. Accessed 22 August 2024. Available from https://psnet.ahrq .gov/primer.aspx?primerID=11 190. Rubin DJ. Hospital readmission of patients with diabetes. Curr Diab Rep 2015;15:17 191. Jiang HJ, Stryer D, Friedman B, Andrews R. Multiple hospitalizations for patients with diabetes. Diabetes Care 2003;26:1421  1426 192. Wu EQ, Zhou S, Yu A, et al. Outcomes associated with post-discharge insulin continuity in US patients with type 2 diabetes mellitus initiating insulin in the hospital. Hosp Pract (1995) 2012;40: 40  48 193. Maldonado MR, DAmico S, Rodriguez L, Iyer D, Balasubramanyam A. Improved outcomes in indigent patients with ketosis-prone diabetes: effect of a dedicated diabetes treatment unit. Endocr Pract 2003;9:26  32 194. Shaka H, Aguilera M, Aucar M, et al. Rate and predictors of 30-day readmission following diabetic ketoacidosis in type","tf":{"10":1,"11":1,"15":1,"17":1,"22":1,"26":2,"30":1,"32":1,"33":1,"40":2,"48":1,"188":1,"189":1,"190":1,"191":1,"192":1,"193":1,"194":1,"236":1,"245":1,"1421":1,"1426":1,"1995":1,"2003":2,"2012":1,"2015":1,"2020":1,"2022":1,"2024":1,"pinkhasova":1,"et":3,"al":3,"sex":1,"differences":1,"in":7,"glycemic":1,"measures":1,"complications":1,"discharge":3,"disposition":1,"and":6,"postdischarge":1,"emergency":1,"room":1,"visits":1,"readmission":3,"among":1,"non":1,"critically":1,"ill":1,"hospitalized":1,"patients":5,"with":6,"diabetes":10,"bmj":1,"open":1,"res":1,"care":3,"e002722":1,"pandya":1,"hames":1,"sandhu":1,"challenges":1,"strategies":1,"for":3,"managing":1,"the":2,"elderly":1,"long":1,"term":1,"settings":1,"spectr":1,"agency":1,"healthcare":1,"research":1,"quality":1,"patient":1,"safety":1,"network":1,"readmissions":1,"adverse":1,"events":1,"after":1,"accessed":1,"august":1,"available":1,"from":1,"https":1,"psnet":1,"ahrq":1,"gov":1,"primer":1,"aspx":1,"primerid":1,"rubin":1,"dj":1,"hospital":2,"of":3,"curr":1,"diab":1,"rep":1,"jiang":1,"hj":1,"stryer":1,"friedman":1,"andrews":1,"multiple":1,"hospitalizations":1,"wu":1,"eq":1,"zhou":1,"yu":1,"outcomes":2,"associated":1,"post":1,"insulin":2,"continuity":1,"us":1,"type":2,"mellitus":1,"initiating":1,"hosp":1,"pract":2,"maldonado":1,"mr":1,"amico":1,"rodriguez":1,"iyer":1,"balasubramanyam":1,"improved":1,"indigent":1,"ketosis":1,"prone":1,"effect":1,"dedicated":1,"treatment":1,"unit":1,"endocr":1,"shaka":1,"aguilera":1,"aucar":1,"rate":1,"predictors":1,"day":1,"following":1,"diabetic":1,"ketoacidosis":1},"len":199},{"docId":"ada-2026-hosp","docTitle":"ADA Standards 2026  Hospital Care","file":"ada-2026-hospital.pdf","page":17,"chunkId":"ada-2026-hosp-p17-c3","text":"s in indigent patients with ketosis-prone diabetes: effect of a dedicated diabetes treatment unit. Endocr Pract 2003;9:26  32 194. Shaka H, Aguilera M, Aucar M, et al. Rate and predictors of 30-day readmission following diabetic ketoacidosis in type 1 diabetes mellitus: a US analysis. J Clin Endocrinol Metab 2021;106: 2592  2599 195. Hirschman KB, Bixby MB. Transitions in care from the hospital to home for patients with diabetes. Diabetes Spectr 2014;27: 192  195 196. Herges JR, Galindo RJ, Neumiller JJ, Heien HC, Umpierrez GE, McCoy RG. Glucagon prescribing and costs among U.S. adults with diabetes, 2011  2021. Diabetes Care 2023;46: 620  627 197. de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: improving Global Outcomes (KDIGO). Diabetes Care 2022;45: 3075  3090 198. Roussel R, Riveline J-P, Vicaut E, et al. important drop in rate of acute diabetes complications in people with type 1 or type 2 diabetes after initiation of flash glucose monitoring in France: the RELIEF study. Diabetes Care 2021;44: 1368  1376 diabetesjournals.org/care Diabetes Care in the Hospital S355 Downloaded from http://diabetesjournals.org/care/article-pdf/49/Supplement_1/S339/848851/dc26s016.pdf by guest on 17 February 2026","tf":{"17":1,"26":1,"27":1,"30":1,"32":1,"44":1,"45":1,"46":1,"49":1,"106":1,"192":1,"194":1,"195":2,"196":1,"197":1,"198":1,"620":1,"627":1,"1368":1,"1376":1,"2003":1,"2011":1,"2014":1,"2021":3,"2022":1,"2023":1,"2026":1,"2592":1,"2599":1,"3075":1,"3090":1,"848851":1,"in":8,"indigent":1,"patients":2,"with":4,"ketosis":1,"prone":1,"diabetes":14,"effect":1,"of":4,"dedicated":1,"treatment":1,"unit":1,"endocr":1,"pract":1,"shaka":1,"aguilera":1,"aucar":1,"et":3,"al":3,"rate":2,"and":3,"predictors":1,"day":1,"readmission":1,"following":1,"diabetic":1,"ketoacidosis":1,"type":3,"mellitus":1,"us":1,"analysis":1,"clin":1,"endocrinol":1,"metab":1,"hirschman":1,"kb":1,"bixby":1,"mb":1,"transitions":1,"care":7,"from":2,"the":4,"hospital":2,"to":1,"home":1,"for":1,"spectr":1,"herges":1,"jr":1,"galindo":1,"rj":1,"neumiller":1,"jj":1,"heien":1,"hc":1,"umpierrez":1,"ge":1,"mccoy":1,"rg":1,"glucagon":1,"prescribing":1,"costs":1,"among":1,"adults":1,"de":1,"boer":1,"ih":1,"khunti":1,"sadusky":1,"management":1,"chronic":1,"kidney":2,"disease":2,"consensus":1,"report":1,"by":2,"american":1,"association":1,"ada":1,"improving":1,"global":1,"outcomes":1,"kdigo":1,"roussel":1,"riveline":1,"vicaut":1,"important":1,"drop":1,"acute":1,"complications":1,"people":1,"or":1,"after":1,"initiation":1,"flash":1,"glucose":1,"monitoring":1,"france":1,"relief":1,"study":1,"diabetesjournals":2,"org":2,"s355":1,"downloaded":1,"http":1,"article":1,"pdf":2,"supplement":1,"s339":1,"dc26s016":1,"guest":1,"on":1,"february":1},"len":201},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":1,"chunkId":"dc-2024-p1-c0","text":"Special Article Pharmacologic Glycemic Management of Type 2 Diabetes in Adults  2024 Update Diabetes Canada Clinical Practice Guidelines Expert Working Group: Baiju R. Shah MD, FRCPC, PhD; Harpreet S. Bajaj MD, MPH, FACE; Sonia Butalia MD, FRCPC, MSc; Kaberi Dasgupta MD, CM, MSc; Dean T. Eurich BSP, PhD; Rahul Jain MD, CCFP, MScCH; Karen Leung MD, MSc, CCFP(COE); Kerry Mansell BSP, PharmD, MBA; Scot Simpson BSP, PharmD, MSc Key Messages \u000f Metformin should be the initial agent of choice in most people with type 2 diabetes who require pharmacotherapy to reach glycemic targets. \u000f Insulin should be initiated immediately, with or without met- formin, in individuals with metabolic decompensation and/or severe symptomatic hyperglycemia. \u000f When glycated hemoglobin (A1C) is more than 1.5% above target, other antihyperglycemic agents in combination with metformin may be needed. \u000f Certain glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors should be used for cardiorenal protection in people with high cardio- vascular (CV) risk, heart failure (HF), or chronic kidney disease (CKD). These medications should be initiated if these comorbid- ities or complications are already present at diagnosis or if they develop over the person  s lifetime, even if the A1C is in target. \u000f Choice of additional antihyperglycemic agents, when treat- ment ","tf":{"2024":1,"special":1,"article":1,"pharmacologic":1,"glycemic":2,"management":1,"of":3,"type":2,"diabetes":3,"in":6,"adults":1,"update":1,"canada":1,"clinical":1,"practice":1,"guidelines":1,"expert":1,"working":1,"group":1,"baiju":1,"shah":1,"md":6,"frcpc":2,"phd":2,"harpreet":1,"bajaj":1,"mph":1,"face":1,"sonia":1,"butalia":1,"msc":4,"kaberi":1,"dasgupta":1,"cm":1,"dean":1,"eurich":1,"bsp":3,"rahul":1,"jain":1,"ccfp":2,"mscch":1,"karen":1,"leung":1,"coe":1,"kerry":1,"mansell":1,"pharmd":2,"mba":1,"scot":1,"simpson":1,"key":1,"messages":1,"metformin":2,"should":4,"be":5,"the":3,"initial":1,"agent":1,"choice":2,"most":1,"people":2,"with":5,"who":1,"require":1,"pharmacotherapy":1,"to":1,"reach":1,"targets":1,"insulin":1,"initiated":2,"immediately":1,"or":5,"without":1,"met":1,"formin":1,"individuals":1,"metabolic":1,"decompensation":1,"and":2,"severe":1,"symptomatic":1,"hyperglycemia":1,"when":2,"glycated":1,"hemoglobin":1,"a1c":2,"is":2,"more":1,"than":1,"above":1,"target":2,"other":1,"antihyperglycemic":2,"agents":2,"combination":1,"may":1,"needed":1,"certain":1,"glucagon":1,"like":1,"peptide":1,"receptor":1,"agonists":1,"glp1":1,"ras":1,"sodium":1,"glucose":1,"cotransporter":1,"sglt2":1,"inhibitors":1,"used":1,"for":1,"cardiorenal":1,"protection":1,"high":1,"cardio":1,"vascular":1,"cv":1,"risk":1,"heart":1,"failure":1,"hf":1,"chronic":1,"kidney":1,"disease":1,"ckd":1,"these":2,"medications":1,"if":3,"comorbid":1,"ities":1,"complications":1,"are":1,"already":1,"present":1,"at":1,"diagnosis":1,"they":1,"develop":1,"over":1,"person":1,"lifetime":1,"even":1,"additional":1,"treat":1,"ment":1},"len":202},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":1,"chunkId":"dc-2024-p1-c1","text":"dications should be initiated if these comorbid- ities or complications are already present at diagnosis or if they develop over the person  s lifetime, even if the A1C is in target. \u000f Choice of additional antihyperglycemic agents, when treat- ment intensi fi cation is required to improve glycemia, should consider individual priorities, preferences, and comorbidities. Clinical priorities may include weight loss, avoidance of hypoglycemia, desired magnitude of glucose lowering, cost, side-effect pro fi le, possibility of pregnancy, and comorbidities. \u000f Insulin regimens in type 2 diabetes should be tailored to the individual to reach individualized glycemic levels and mini- mize the risk of hypoglycemia. Insulin should be introduced in a stepwise approach, and other antihyperglycemic agents should be continued and/or initiated to further improve gly- cemia and reduce insulin dose requirements. Key Messages for People Living With Diabetes \u000f Most people who have type 2 diabetes will need glucose- lowering medications to reach their personal glucose targets. \u000f Metformin is generally the fi rst choice because of its effectiveness, mild side effects, safety track record, and low cost. \u000f Multiple medications that work in different ways may be needed if glucose levels are very high, or if they remain high with just 1 medication. The decision about which other medications to use depends","tf":{"dications":1,"should":5,"be":5,"initiated":2,"if":5,"these":1,"comorbid":1,"ities":1,"or":4,"complications":1,"are":2,"already":1,"present":1,"at":1,"diagnosis":1,"they":2,"develop":1,"over":1,"the":6,"person":1,"lifetime":1,"even":1,"a1c":1,"is":3,"in":4,"target":1,"choice":2,"of":6,"additional":1,"antihyperglycemic":2,"agents":2,"when":1,"treat":1,"ment":1,"intensi":1,"fi":3,"cation":1,"required":1,"to":6,"improve":2,"glycemia":1,"consider":1,"individual":2,"priorities":2,"preferences":1,"and":7,"comorbidities":2,"clinical":1,"may":2,"include":1,"weight":1,"loss":1,"avoidance":1,"hypoglycemia":2,"desired":1,"magnitude":1,"glucose":4,"lowering":2,"cost":2,"side":2,"effect":1,"pro":1,"le":1,"possibility":1,"pregnancy":1,"insulin":3,"regimens":1,"type":2,"diabetes":3,"tailored":1,"reach":2,"individualized":1,"glycemic":1,"levels":2,"mini":1,"mize":1,"risk":1,"introduced":1,"stepwise":1,"approach":1,"other":2,"continued":1,"further":1,"gly":1,"cemia":1,"reduce":1,"dose":1,"requirements":1,"key":1,"messages":1,"for":1,"people":2,"living":1,"with":2,"most":1,"who":1,"have":1,"will":1,"need":1,"medications":3,"their":1,"personal":1,"targets":1,"metformin":1,"generally":1,"rst":1,"because":1,"its":1,"effectiveness":1,"mild":1,"effects":1,"safety":1,"track":1,"record":1,"low":1,"multiple":1,"that":1,"work":1,"different":1,"ways":1,"needed":1,"very":1,"high":2,"remain":1,"just":1,"medication":1,"decision":1,"about":1,"which":1,"use":1,"depends":1},"len":205},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":1,"chunkId":"dc-2024-p1-c2","text":"ide effects, safety track record, and low cost. \u000f Multiple medications that work in different ways may be needed if glucose levels are very high, or if they remain high with just 1 medication. The decision about which other medications to use depends on many factors, including glucose levels, other health problems, and medication costs. \u000f Certain medications have speci fi c bene fi ts on the heart and the kidneys for people who have these problems already. There- fore, these medications should be used by anybody with these problems, even if their glucose levels are already good. \u000f Sometimes, people with type 2 diabetes also need insulin. Different types of insulin may be needed at different times of day. Other glucose-lowering medications are usually continued because they can reduce the amount of insulin needed. \u000f People with type 2 diabetes should discuss the pros and cons of different treatment plans with their health-care providers to decide together on what approach is best. Introduction The United Kingdom Prospective Diabetes Study (UKPDS) established the importance of glycemic management to reduce the risk of long-term complications in people with type 2 diabetes [1]. More recently, clinical trials have demonstrated that certain glucose-lowering medications can reduce cardiac and renal com- plications of diabetes in certain populations, beyond the effects of glucose lowe","tf":{"ide":1,"effects":2,"safety":1,"track":1,"record":1,"and":5,"low":1,"cost":1,"multiple":1,"medications":6,"that":2,"work":1,"in":3,"different":4,"ways":1,"may":2,"be":3,"needed":3,"if":3,"glucose":6,"levels":3,"are":3,"very":1,"high":2,"or":1,"they":2,"remain":1,"with":6,"just":1,"medication":2,"the":9,"decision":1,"about":1,"which":1,"other":3,"to":3,"use":1,"depends":1,"on":3,"many":1,"factors":1,"including":1,"health":2,"problems":3,"costs":1,"certain":3,"have":3,"speci":1,"fi":2,"bene":1,"ts":1,"heart":1,"kidneys":1,"for":1,"people":4,"who":1,"these":3,"already":2,"there":1,"fore":1,"should":2,"used":1,"by":1,"anybody":1,"even":1,"their":2,"good":1,"sometimes":1,"type":3,"diabetes":5,"also":1,"need":1,"insulin":3,"types":1,"of":8,"at":1,"times":1,"day":1,"lowering":2,"usually":1,"continued":1,"because":1,"can":2,"reduce":3,"amount":1,"discuss":1,"pros":1,"cons":1,"treatment":1,"plans":1,"care":1,"providers":1,"decide":1,"together":1,"what":1,"approach":1,"is":1,"best":1,"introduction":1,"united":1,"kingdom":1,"prospective":1,"study":1,"ukpds":1,"established":1,"importance":1,"glycemic":1,"management":1,"risk":1,"long":1,"term":1,"complications":1,"more":1,"recently":1,"clinical":1,"trials":1,"demonstrated":1,"cardiac":1,"renal":1,"com":1,"plications":1,"populations":1,"beyond":1,"lowe":1},"len":213},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":1,"chunkId":"dc-2024-p1-c3","text":"cations in people with type 2 diabetes [1]. More recently, clinical trials have demonstrated that certain glucose-lowering medications can reduce cardiac and renal com- plications of diabetes in certain populations, beyond the effects of glucose lowering alone. We conducted a thorough review of the existing evidence to support people living with type 2 diabetes and their health-care providers in the selection of glucose-lowering agents. This review spanned the period from June 2020 to February 2023, and updates the last guideline published in 2020. This chapter focusses exclusively on pharmacologic glycemic management for type 2 diabetes in adults. Physical activity [2], nutri- tion therapy [3], self-management education and support [4], and weight management [5] are other important components of glycemic management for type 2 diabetes, and are discussed in their own chapters. Similarly, related topics, such as targets for glycemic man- agement [6], glucose monitoring [7], management of hypoglycemia [8], and remission of type 2 diabetes [9], are addressed in other chapters. Initiating Pharmacotherapy After counselling and support for health behaviour modi fi cation is provided, pharmacotherapy may be required to reach glycemic Contents lists available at ScienceDirect Canadian Journal of Diabetes j o u r n a l h o m e p a g e : w w w . c a n a d i a n j o u r n a l o f d i a b ","tf":{"2020":2,"2023":1,"cations":1,"in":7,"people":2,"with":2,"type":5,"diabetes":7,"more":1,"recently":1,"clinical":1,"trials":1,"have":1,"demonstrated":1,"that":1,"certain":2,"glucose":4,"lowering":3,"medications":1,"can":1,"reduce":1,"cardiac":1,"and":8,"renal":1,"com":1,"plications":1,"of":8,"populations":1,"beyond":1,"the":5,"effects":1,"alone":1,"we":1,"conducted":1,"thorough":1,"review":2,"existing":1,"evidence":1,"to":3,"support":3,"living":1,"their":2,"health":2,"care":1,"providers":1,"selection":1,"agents":1,"this":2,"spanned":1,"period":1,"from":1,"june":1,"february":1,"updates":1,"last":1,"guideline":1,"published":1,"chapter":1,"focusses":1,"exclusively":1,"on":1,"pharmacologic":1,"glycemic":4,"management":5,"for":4,"adults":1,"physical":1,"activity":1,"nutri":1,"tion":1,"therapy":1,"self":1,"education":1,"weight":1,"are":3,"other":2,"important":1,"components":1,"discussed":1,"own":1,"chapters":2,"similarly":1,"related":1,"topics":1,"such":1,"as":1,"targets":1,"man":1,"agement":1,"monitoring":1,"hypoglycemia":1,"remission":1,"addressed":1,"initiating":1,"pharmacotherapy":2,"after":1,"counselling":1,"behaviour":1,"modi":1,"fi":1,"cation":1,"is":1,"provided":1,"may":1,"be":1,"required":1,"reach":1,"contents":1,"lists":1,"available":1,"at":1,"sciencedirect":1,"canadian":1,"journal":1},"len":180},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":1,"chunkId":"dc-2024-p1-c4","text":"r health behaviour modi fi cation is provided, pharmacotherapy may be required to reach glycemic Contents lists available at ScienceDirect Canadian Journal of Diabetes j o u r n a l h o m e p a g e : w w w . c a n a d i a n j o u r n a l o f d i a b e t e s . c o m 1499-2671/  2024 Canadian Diabetes Association. The Canadian Diabetes Association is the registered owner of the name Diabetes Canada. https://doi.org/10.1016/j.jcjd.2024.08.002 Can J Diabetes 48 (2024) 415 e 424","tf":{"10":1,"48":1,"415":1,"424":1,"1016":1,"1499":1,"2024":3,"2671":1,"health":1,"behaviour":1,"modi":1,"fi":1,"cation":1,"is":2,"provided":1,"pharmacotherapy":1,"may":1,"be":1,"required":1,"to":1,"reach":1,"glycemic":1,"contents":1,"lists":1,"available":1,"at":1,"sciencedirect":1,"canadian":3,"journal":1,"of":2,"diabetes":5,"association":2,"the":3,"registered":1,"owner":1,"name":1,"canada":1,"https":1,"doi":1,"org":1,"jcjd":1,"08":1,"002":1,"can":1},"len":57},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":2,"chunkId":"dc-2024-p2-c0","text":"targets and to optimize cardiorenal risk (Figure 1). Metformin is the recommended fi rst-line antihyperglycemic medication for most people. The preference for metformin as the initial agent is based on its durable ef fi cacy in lowering A1C, absence of risk for hypo- glycemia or weight gain, relatively mild side-effect pro fi le, long- term safety track record, and affordability. Further, metformin monotherapy in newly-diagnosed participants who had over- weight in the UKPDS demonstrated CV and all-cause mortality bene fi ts [10]. Metformin monotherapy has comparable A1C- lowering effects to sulfonylureas, but better glycemic durability [11], negligible risk of hypoglycemia [12], no weight gain [12,13], and lower CV risk [13]. Metformin has better A1C lowering and weight loss than dipeptidyl peptidase-4 (DPP4) inhibitors [12,14]. To date, no studies have demonstrated superiority of SGLT2 inhibitors, GLP1-RAs, or glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists (GIP/GLP1- RAs) over metformin as fi rst-line therapy in people newly diag- nosed with type 2 diabetes. Metformin should be started at a low dose (i.e. 250 mg or 500 mg twice daily with meals) and gradually increased over several weeks to a target dose of 2,000 mg daily. This slow increase minimizes the risk of gastrointestinal side effects. Minimal improvements in glucose occur at do","tf":{"10":1,"11":1,"12":3,"13":2,"14":1,"250":1,"500":1,"targets":1,"and":6,"to":4,"optimize":1,"cardiorenal":1,"risk":5,"figure":1,"metformin":7,"is":2,"the":5,"recommended":1,"fi":5,"rst":2,"line":2,"antihyperglycemic":1,"medication":1,"for":3,"most":1,"people":2,"preference":1,"as":2,"initial":1,"agent":1,"based":1,"on":1,"its":1,"durable":1,"ef":1,"cacy":1,"in":5,"lowering":3,"a1c":3,"absence":1,"of":5,"hypo":1,"glycemia":1,"or":3,"weight":4,"gain":2,"relatively":1,"mild":1,"side":2,"effect":1,"pro":1,"le":1,"long":1,"term":1,"safety":1,"track":1,"record":1,"affordability":1,"further":1,"monotherapy":2,"newly":2,"diagnosed":1,"participants":1,"who":1,"had":1,"over":3,"ukpds":1,"demonstrated":2,"cv":2,"all":1,"cause":1,"mortality":1,"bene":1,"ts":1,"has":2,"comparable":1,"effects":2,"sulfonylureas":1,"but":1,"better":2,"glycemic":1,"durability":1,"negligible":1,"hypoglycemia":1,"no":2,"lower":1,"loss":1,"than":1,"dipeptidyl":1,"peptidase":1,"dpp4":1,"inhibitors":2,"date":1,"studies":1,"have":1,"superiority":1,"sglt2":1,"glp1":2,"ras":2,"glucose":2,"dependent":1,"insulinotropic":1,"polypeptide":1,"glucagon":1,"like":1,"peptide":1,"receptor":1,"agonists":1,"gip":1,"therapy":1,"diag":1,"nosed":1,"with":2,"type":1,"diabetes":1,"should":1,"be":1,"started":1,"at":2,"low":1,"dose":2,"mg":3,"twice":1,"daily":2,"meals":1,"gradually":1,"increased":1,"several":1,"weeks":1,"target":1,"000":1,"this":1,"slow":1,"increase":1,"minimizes":1,"gastrointestinal":1,"minimal":1,"improvements":1,"occur":1,"do":1},"len":215},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":2,"chunkId":"dc-2024-p2-c1","text":"low dose (i.e. 250 mg or 500 mg twice daily with meals) and gradually increased over several weeks to a target dose of 2,000 mg daily. This slow increase minimizes the risk of gastrointestinal side effects. Minimal improvements in glucose occur at doses above this level. However, metformin cannot be used in everyone, such as those with a history of lactic acidosis, an estimated glomerular fi ltration rate (eGFR) < 15 mL/min/1.73 m 2 , or severe hepatic dysfunction. People who have evidence of metabolic decompensation (e.g. marked hyperglycemia, ketosis, hyperosmolar state or uninten- tional weight loss related to hyperglycemia) and/or severe symptomatic hyperglycemia (e.g. polyuria, polydipsia, or visual blurring) should be started immediately on insulin, with or without metformin, regardless of A1C level. Once stable, it may be possible to taper or discontinue insulin and replace it with other agents as required. Even in the absence of metabolic decompen- sation, people with marked hyperglycemia (e.g. A1C more than 1.5% above target) may require the initiation of other anti- hyperglycemic agents in combination with metformin at diag- nosis for faster and greater improvements in glucose [15 e 20]. These additional agents may be able to be reduced or withdrawn over time if glycemia improves. Combining metformin with another agent at the outset lowers average A1C values by 0.4% t","tf":{"15":2,"20":1,"73":1,"250":1,"500":1,"low":1,"dose":2,"mg":3,"or":8,"twice":1,"daily":2,"with":7,"meals":1,"and":4,"gradually":1,"increased":1,"over":2,"several":1,"weeks":1,"to":4,"target":2,"of":7,"000":1,"this":2,"slow":1,"increase":1,"minimizes":1,"the":4,"risk":1,"gastrointestinal":1,"side":1,"effects":1,"minimal":1,"improvements":2,"in":5,"glucose":2,"occur":1,"at":3,"doses":1,"above":2,"level":2,"however":1,"metformin":4,"cannot":1,"be":5,"used":1,"everyone":1,"such":1,"as":2,"those":1,"history":1,"lactic":1,"acidosis":1,"an":1,"estimated":1,"glomerular":1,"fi":1,"ltration":1,"rate":1,"egfr":1,"ml":1,"min":1,"severe":2,"hepatic":1,"dysfunction":1,"people":2,"who":1,"have":1,"evidence":1,"metabolic":2,"decompensation":1,"marked":2,"hyperglycemia":4,"ketosis":1,"hyperosmolar":1,"state":1,"uninten":1,"tional":1,"weight":1,"loss":1,"related":1,"symptomatic":1,"polyuria":1,"polydipsia":1,"visual":1,"blurring":1,"should":1,"started":1,"immediately":1,"on":1,"insulin":2,"without":1,"regardless":1,"a1c":3,"once":1,"stable":1,"it":2,"may":3,"possible":1,"taper":1,"discontinue":1,"replace":1,"other":2,"agents":3,"required":1,"even":1,"absence":1,"decompen":1,"sation":1,"more":1,"than":1,"require":1,"initiation":1,"anti":1,"hyperglycemic":1,"combination":1,"diag":1,"nosis":1,"for":1,"faster":1,"greater":1,"these":1,"additional":1,"able":1,"reduced":1,"withdrawn":1,"time":1,"if":1,"glycemia":1,"improves":1,"combining":1,"another":1,"agent":1,"outset":1,"lowers":1,"average":1,"values":1,"by":1},"len":208},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":2,"chunkId":"dc-2024-p2-c2","text":"g- nosis for faster and greater improvements in glucose [15 e 20]. These additional agents may be able to be reduced or withdrawn over time if glycemia improves. Combining metformin with another agent at the outset lowers average A1C values by 0.4% to Figure 1. Pharmacotherapy for type 2 diabetes, to reach glycemic targets and optimize cardiorenal risk. A1C , glycated hemoglobin. B.R. Shah et al. / Can J Diabetes 48 (2024) 415 e 424 416","tf":{"15":1,"20":1,"48":1,"415":1,"416":1,"424":1,"2024":1,"nosis":1,"for":2,"faster":1,"and":2,"greater":1,"improvements":1,"in":1,"glucose":1,"these":1,"additional":1,"agents":1,"may":1,"be":2,"able":1,"to":3,"reduced":1,"or":1,"withdrawn":1,"over":1,"time":1,"if":1,"glycemia":1,"improves":1,"combining":1,"metformin":1,"with":1,"another":1,"agent":1,"at":1,"the":1,"outset":1,"lowers":1,"average":1,"a1c":2,"values":1,"by":1,"figure":1,"pharmacotherapy":1,"type":1,"diabetes":2,"reach":1,"glycemic":1,"targets":1,"optimize":1,"cardiorenal":1,"risk":1,"glycated":1,"hemoglobin":1,"shah":1,"et":1,"al":1,"can":1},"len":66},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":3,"chunkId":"dc-2024-p3-c0","text":"1% more than metformin alone and increases the chances of having an A1C < 7% at 6 months by 40% [14 e 16,20]. The initial use of multiple agents at submaximal doses has also been shown to result in fewer side effects than monotherapy at maximal doses [21 e 25]. Certain GLP1-RAs and SGLT2 inhibitors are demonstrated in clinical trials to have speci fi c bene fi ts in people with high CV risk, HF, or CKD, as discussed below. These agents should be used as initial pharmacotherapy for individuals who already have these comorbidities or complications at the time of type 2 diabetes diagnosis. In general, initiating combination therapy of these agents with metformin is recommended because the majority of participants in these trials were on concomitant metformin therapy. A1C will typically decrease by about 0.5% to 1.5% with mono- therapy, varying with the baseline A1C level and the speci fi c agent used. In general, the higher the baseline A1C, the greater the A1C reduction observed for any given agent. However, the A1C- lowering ef fi cacy of SGLT2 inhibitors declines with decreasing eGFR. The maximum effect of non-insulin antihyperglycemic agent monotherapy generally occurs within 3 to 6 months [26,27]. Treatment Intensi fi cation or Modi fi cation Over time, the function and number of beta cells can decline in those with type 2 diabetes, which results in higher glucose levels [28]","tf":{"14":1,"16":1,"20":1,"21":1,"25":1,"26":1,"27":1,"28":1,"40":1,"more":1,"than":2,"metformin":3,"alone":1,"and":4,"increases":1,"the":13,"chances":1,"of":8,"having":1,"an":1,"a1c":6,"at":4,"months":2,"by":2,"initial":2,"use":1,"multiple":1,"agents":3,"submaximal":1,"doses":2,"has":1,"also":1,"been":1,"shown":1,"to":4,"result":1,"in":8,"fewer":1,"side":1,"effects":1,"monotherapy":2,"maximal":1,"certain":1,"glp1":1,"ras":1,"sglt2":2,"inhibitors":2,"are":1,"demonstrated":1,"clinical":1,"trials":2,"have":2,"speci":2,"fi":6,"bene":1,"ts":1,"people":1,"with":6,"high":1,"cv":1,"risk":1,"hf":1,"or":3,"ckd":1,"as":2,"discussed":1,"below":1,"these":4,"should":1,"be":1,"used":2,"pharmacotherapy":1,"for":2,"individuals":1,"who":1,"already":1,"comorbidities":1,"complications":1,"time":2,"type":2,"diabetes":2,"diagnosis":1,"general":2,"initiating":1,"combination":1,"therapy":3,"is":1,"recommended":1,"because":1,"majority":1,"participants":1,"were":1,"on":1,"concomitant":1,"will":1,"typically":1,"decrease":1,"about":1,"mono":1,"varying":1,"baseline":2,"level":1,"agent":3,"higher":2,"greater":1,"reduction":1,"observed":1,"any":1,"given":1,"however":1,"lowering":1,"ef":1,"cacy":1,"declines":1,"decreasing":1,"egfr":1,"maximum":1,"effect":1,"non":1,"insulin":1,"antihyperglycemic":1,"generally":1,"occurs":1,"within":1,"treatment":1,"intensi":1,"cation":2,"modi":1,"over":1,"function":1,"number":1,"beta":1,"cells":1,"can":1,"decline":1,"those":1,"which":1,"results":1,"glucose":1,"levels":1},"len":224},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":3,"chunkId":"dc-2024-p3-c1","text":"mic agent monotherapy generally occurs within 3 to 6 months [26,27]. Treatment Intensi fi cation or Modi fi cation Over time, the function and number of beta cells can decline in those with type 2 diabetes, which results in higher glucose levels [28]. Thus, people with diabetes and their health-care providers need to continually monitor glycemia and consider stepwise intensi fi cation of pharmacotherapy when glycemic values rise above targets. When considering pharmacotherapy intensi fi cation, health- care providers should fi rst assess for and address potential pre- cipitants of increasing A1C (e.g. infection, ischemia, concomitant medications, changes in eating or physical activity). They should also explore medication adherence and barriers to adherence, such as adverse drug effects, costs, beliefs, and preferences. After these assessments, dose adjustments and/or additional anti- hyperglycemic medications may be considered, with a goal of meeting the glycemic target within 3 to 6 months [29]. Health behaviour interventions, including nutritional therapy and physical activity, should continue to be optimized while pharmacotherapy is being intensi fi ed. When new agents are added to improve glycemic levels, existing glucose-lowering medications should generally be continued unless contraindicated. When selecting additional antihyperglycemic agents, agent- speci fi c advantag","tf":{"26":1,"27":1,"28":1,"29":1,"mic":1,"agent":2,"monotherapy":1,"generally":2,"occurs":1,"within":2,"to":6,"months":2,"treatment":1,"intensi":4,"fi":7,"cation":4,"or":3,"modi":1,"over":1,"time":1,"the":2,"function":1,"and":8,"number":1,"of":4,"beta":1,"cells":1,"can":1,"decline":1,"in":3,"those":1,"with":3,"type":1,"diabetes":2,"which":1,"results":1,"higher":1,"glucose":2,"levels":2,"thus":1,"people":1,"their":1,"health":3,"care":2,"providers":2,"need":1,"continually":1,"monitor":1,"glycemia":1,"consider":1,"stepwise":1,"pharmacotherapy":3,"when":4,"glycemic":3,"values":1,"rise":1,"above":1,"targets":1,"considering":1,"should":4,"rst":1,"assess":1,"for":1,"address":1,"potential":1,"pre":1,"cipitants":1,"increasing":1,"a1c":1,"infection":1,"ischemia":1,"concomitant":1,"medications":3,"changes":1,"eating":1,"physical":2,"activity":2,"they":1,"also":1,"explore":1,"medication":1,"adherence":2,"barriers":1,"such":1,"as":1,"adverse":1,"drug":1,"effects":1,"costs":1,"beliefs":1,"preferences":1,"after":1,"these":1,"assessments":1,"dose":1,"adjustments":1,"additional":2,"anti":1,"hyperglycemic":1,"may":1,"be":3,"considered":1,"goal":1,"meeting":1,"target":1,"behaviour":1,"interventions":1,"including":1,"nutritional":1,"therapy":1,"continue":1,"optimized":1,"while":1,"is":1,"being":1,"ed":1,"new":1,"agents":2,"are":1,"added":1,"improve":1,"existing":1,"lowering":1,"continued":1,"unless":1,"contraindicated":1,"selecting":1,"antihyperglycemic":1,"speci":1,"advantag":1},"len":194},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":3,"chunkId":"dc-2024-p3-c2","text":"y is being intensi fi ed. When new agents are added to improve glycemic levels, existing glucose-lowering medications should generally be continued unless contraindicated. When selecting additional antihyperglycemic agents, agent- speci fi c advantages and disadvantages should be considered from an individualized person-centred perspective. Factors to consider include need and desire for weight loss, risks and importance of preventing hypoglycemia, the magnitude of glucose lowering required, costs and insurance coverage, adverse effect pro fi les, and comorbidities (Table 1). Maximum doses are often determined by renal function (eGFR), as indicated in Table 2. Simultaneous use of agents within the same class or with similar mechanisms of action (e.g. sulfonylureas and meglitinides; or DPP4 inhibitors, GIP/GLP1- RAs and GLP1-RAs) is not recommended. Several meta-analyses have summarized head-to-head com- parisons of metformin-based combinations [12,14,30 e 32]. These studies showed that combinations of metformin with sulfonyl- ureas, thiazolidinediones, SGLT2 inhibitors, DPP4 inhibitors, or GLP1-RAs have broadly comparable A1C-lowering bene fi ts [12,30 e 36]. In contrast, insulin does not have a dose limit and would therefore be expected to have the greatest potential for A1C lowering, although dose increases may be limited by hypoglycemia. Table 1 Antihyperglycemic agents for ","tf":{"12":2,"14":1,"30":2,"32":1,"36":1,"is":2,"being":1,"intensi":1,"fi":4,"ed":1,"when":2,"new":1,"agents":4,"are":2,"added":1,"to":4,"improve":1,"glycemic":1,"levels":1,"existing":1,"glucose":2,"lowering":4,"medications":1,"should":2,"generally":1,"be":4,"continued":1,"unless":1,"contraindicated":1,"selecting":1,"additional":1,"antihyperglycemic":2,"agent":1,"speci":1,"advantages":1,"and":8,"disadvantages":1,"considered":1,"from":1,"an":1,"individualized":1,"person":1,"centred":1,"perspective":1,"factors":1,"consider":1,"include":1,"need":1,"desire":1,"for":3,"weight":1,"loss":1,"risks":1,"importance":1,"of":6,"preventing":1,"hypoglycemia":2,"the":3,"magnitude":1,"required":1,"costs":1,"insurance":1,"coverage":1,"adverse":1,"effect":1,"pro":1,"les":1,"comorbidities":1,"table":3,"maximum":1,"doses":1,"often":1,"determined":1,"by":2,"renal":1,"function":1,"egfr":1,"as":1,"indicated":1,"in":2,"simultaneous":1,"use":1,"within":1,"same":1,"class":1,"or":3,"with":2,"similar":1,"mechanisms":1,"action":1,"sulfonylureas":1,"meglitinides":1,"dpp4":2,"inhibitors":3,"gip":1,"glp1":3,"ras":3,"not":2,"recommended":1,"several":1,"meta":1,"analyses":1,"have":4,"summarized":1,"head":2,"com":1,"parisons":1,"metformin":2,"based":1,"combinations":2,"these":1,"studies":1,"showed":1,"that":1,"sulfonyl":1,"ureas":1,"thiazolidinediones":1,"sglt2":1,"broadly":1,"comparable":1,"a1c":2,"bene":1,"ts":1,"contrast":1,"insulin":1,"does":1,"dose":2,"limit":1,"would":1,"therefore":1,"expected":1,"greatest":1,"potential":1,"although":1,"increases":1,"may":1,"limited":1},"len":200},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":3,"chunkId":"dc-2024-p3-c3","text":"ng bene fi ts [12,30 e 36]. In contrast, insulin does not have a dose limit and would therefore be expected to have the greatest potential for A1C lowering, although dose increases may be limited by hypoglycemia. Table 1 Antihyperglycemic agents for use in type 2 diabetes B.R. Shah et al. / Can J Diabetes 48 (2024) 415 e 424 417","tf":{"12":1,"30":1,"36":1,"48":1,"415":1,"417":1,"424":1,"2024":1,"ng":1,"bene":1,"fi":1,"ts":1,"in":2,"contrast":1,"insulin":1,"does":1,"not":1,"have":2,"dose":2,"limit":1,"and":1,"would":1,"therefore":1,"be":2,"expected":1,"to":1,"the":1,"greatest":1,"potential":1,"for":2,"a1c":1,"lowering":1,"although":1,"increases":1,"may":1,"limited":1,"by":1,"hypoglycemia":1,"table":1,"antihyperglycemic":1,"agents":1,"use":1,"type":1,"diabetes":2,"shah":1,"et":1,"al":1,"can":1},"len":54},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":4,"chunkId":"dc-2024-p4-c0","text":"While glucose lowering is broadly similar across agents in combination with metformin, impacts on hypoglycemia and weight change differ. The risk of hypoglycemia is lower with incretins, SGLT2 inhibitors, and thiazolidinediones compared to sulfonylureas and insulin [12,14,30 e 32,37,38]. Insulin, sulfonylureas, and thia- zolidinediones are associated with the most weight gain (1.5 to 5.0 kg), DPP4 inhibitors have a neutral effect on weight, while GIP/ GLP1-RAs, GLP1-RAs, and SGLT2 inhibitors lead to weight loss [12,14,30 e 32,39 e 42]. For the majority of people living with type 2 diabetes, for whom weight loss is a priority, treatment intensi fi - cation with a GIP/GLP1-RA or GLP1-RA may be preferred as they can induce weight loss and have negligible risk for hypoglycemia. SGLT2 inhibitors may also be preferred as they can also lead to some weight loss and have negligible risk for hypoglycemia. Where fi nancial barriers exist, sulfonylureas are the least expensive alter- native. The safety of incretin agents or SGLT2 inhibitors in preg- nancy is unknown; therefore, these agents should be avoided or discontinued in women who are pregnant, planning a pregnancy, or not using a reliable contraceptive method [43]. In some subgroups of people with type 2 diabetes, individual SGLT2 inhibitors and GLP1-RAs offer speci fi c cardiorenal bene fi ts. These medications should be prioritize","tf":{"12":2,"14":2,"30":2,"32":2,"37":1,"38":1,"39":1,"42":1,"43":1,"while":2,"glucose":1,"lowering":1,"is":4,"broadly":1,"similar":1,"across":1,"agents":3,"in":4,"combination":1,"with":6,"metformin":1,"impacts":1,"on":2,"hypoglycemia":4,"and":8,"weight":7,"change":1,"differ":1,"the":5,"risk":3,"of":4,"lower":1,"incretins":1,"sglt2":5,"inhibitors":6,"thiazolidinediones":1,"compared":1,"to":4,"sulfonylureas":3,"insulin":2,"thia":1,"zolidinediones":1,"are":3,"associated":1,"most":1,"gain":1,"kg":1,"dpp4":1,"have":3,"neutral":1,"effect":1,"gip":2,"glp1":5,"ras":3,"lead":2,"loss":4,"for":4,"majority":1,"people":2,"living":1,"type":2,"diabetes":2,"whom":1,"priority":1,"treatment":1,"intensi":1,"fi":4,"cation":1,"ra":2,"or":4,"may":2,"be":4,"preferred":2,"as":2,"they":2,"can":2,"induce":1,"negligible":2,"also":2,"some":2,"where":1,"nancial":1,"barriers":1,"exist":1,"least":1,"expensive":1,"alter":1,"native":1,"safety":1,"incretin":1,"preg":1,"nancy":1,"unknown":1,"therefore":1,"these":2,"should":2,"avoided":1,"discontinued":1,"women":1,"who":1,"pregnant":1,"planning":1,"pregnancy":1,"not":1,"using":1,"reliable":1,"contraceptive":1,"method":1,"subgroups":1,"individual":1,"offer":1,"speci":1,"cardiorenal":1,"bene":1,"ts":1,"medications":1,"prioritize":1},"len":217},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":4,"chunkId":"dc-2024-p4-c1","text":"gnant, planning a pregnancy, or not using a reliable contraceptive method [43]. In some subgroups of people with type 2 diabetes, individual SGLT2 inhibitors and GLP1-RAs offer speci fi c cardiorenal bene fi ts. These medications should be prioritized for individuals from these subgroups, and are indicated even if the A1C is in target. Evidence and recommendations for these subgroups are summarized below and in Figure 1. Individuals at high CV risk Randomized trials [44 e 50] and meta-analyses of these trials [51 e 57] have demonstrated the bene fi ts of certain GLP1-RAs and SGLT2 inhibitors in people with type 2 diabetes at high CV risk. The GLP1-RAs dulaglutide [44], liraglutide [45], and subcutaneous semaglutide [46] reduce major adverse CV events (MACE) in people at high CV risk. Alongside CV disease bene fi ts, there is evidence for reductions in microvascular disease, including renal and retinal events, with these agents. Other GLP1-RAs, such as lixisenatide [58], long-acting exenatide [59], and oral semaglutide [60], have not been shown to impact cardiorenal outcomes. Similarly, 4 landmark trials have been completed with SGLT2 inhibitors in people at high CV risk: CANVAS and CANVAS-R [47], EMPA-REG OUTCOME [48], DECLARE-TIMI 58 [49], and VERTIS-CV [50]. Both canagli fl ozin and empagli fl ozin reduce MACE outcomes in this population; dapagli fl ozin and ertugli fl ozin d","tf":{"43":1,"44":2,"45":1,"46":1,"47":1,"48":1,"49":1,"50":2,"51":1,"57":1,"58":2,"59":1,"60":1,"gnant":1,"planning":1,"pregnancy":1,"or":1,"not":2,"using":1,"reliable":1,"contraceptive":1,"method":1,"in":8,"some":1,"subgroups":3,"of":3,"people":4,"with":4,"type":2,"diabetes":2,"individual":1,"sglt2":3,"inhibitors":3,"and":13,"glp1":4,"ras":4,"offer":1,"speci":1,"fi":4,"cardiorenal":2,"bene":3,"ts":3,"these":5,"medications":1,"should":1,"be":1,"prioritized":1,"for":3,"individuals":2,"from":1,"are":2,"indicated":1,"even":1,"if":1,"the":3,"a1c":1,"is":2,"target":1,"evidence":2,"recommendations":1,"summarized":1,"below":1,"figure":1,"at":4,"high":4,"cv":7,"risk":4,"randomized":1,"trials":3,"meta":1,"analyses":1,"have":3,"demonstrated":1,"certain":1,"dulaglutide":1,"liraglutide":1,"subcutaneous":1,"semaglutide":2,"reduce":2,"major":1,"adverse":1,"events":2,"mace":2,"alongside":1,"disease":2,"there":1,"reductions":1,"microvascular":1,"including":1,"renal":1,"retinal":1,"agents":1,"other":1,"such":1,"as":1,"lixisenatide":1,"long":1,"acting":1,"exenatide":1,"oral":1,"been":2,"shown":1,"to":1,"impact":1,"outcomes":2,"similarly":1,"landmark":1,"completed":1,"canvas":2,"empa":1,"reg":1,"outcome":1,"declare":1,"timi":1,"vertis":1,"both":1,"canagli":1,"fl":4,"ozin":4,"empagli":1,"this":1,"population":1,"dapagli":1,"ertugli":1},"len":222},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":4,"chunkId":"dc-2024-p4-c2","text":"2 inhibitors in people at high CV risk: CANVAS and CANVAS-R [47], EMPA-REG OUTCOME [48], DECLARE-TIMI 58 [49], and VERTIS-CV [50]. Both canagli fl ozin and empagli fl ozin reduce MACE outcomes in this population; dapagli fl ozin and ertugli fl ozin do not. Individual components of the MACE composite endpoint have shown incon- sistent effects between trials owing to low event rates, heteroge- neity of study populations, and methodological decisions. Beyond MACE, SGLT2 inhibitors have also shown reductions in HF and renal outcomes for individuals at high CV risk. Importantly, however, the de fi nition of  high CV risk  was quite variable between these trials. Some recruited only people with established CV disease, while most enrolled both those with Table 2 Maximum daily dose of glucose-lowering medications (regular release formulations unless speci fi ed with footnotes) B.R. Shah et al. / Can J Diabetes 48 (2024) 415 e 424 418","tf":{"47":1,"48":2,"49":1,"50":1,"58":1,"415":1,"418":1,"424":1,"2024":1,"inhibitors":2,"in":3,"people":2,"at":2,"high":3,"cv":5,"risk":3,"canvas":2,"and":6,"empa":1,"reg":1,"outcome":1,"declare":1,"timi":1,"vertis":1,"both":2,"canagli":1,"fl":4,"ozin":4,"empagli":1,"reduce":1,"mace":3,"outcomes":2,"this":1,"population":1,"dapagli":1,"ertugli":1,"do":1,"not":1,"individual":1,"components":1,"of":4,"the":2,"composite":1,"endpoint":1,"have":2,"shown":2,"incon":1,"sistent":1,"effects":1,"between":2,"trials":2,"owing":1,"to":1,"low":1,"event":1,"rates":1,"heteroge":1,"neity":1,"study":1,"populations":1,"methodological":1,"decisions":1,"beyond":1,"sglt2":1,"also":1,"reductions":1,"hf":1,"renal":1,"for":1,"individuals":1,"importantly":1,"however":1,"de":1,"fi":2,"nition":1,"was":1,"quite":1,"variable":1,"these":1,"some":1,"recruited":1,"only":1,"with":3,"established":1,"disease":1,"while":1,"most":1,"enrolled":1,"those":1,"table":1,"maximum":1,"daily":1,"dose":1,"glucose":1,"lowering":1,"medications":1,"regular":1,"release":1,"formulations":1,"unless":1,"speci":1,"ed":1,"footnotes":1,"shah":1,"et":1,"al":1,"can":1,"diabetes":1},"len":149},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":5,"chunkId":"dc-2024-p5-c0","text":"established CV disease and those at older ages with multiple CV risk factors. There was signi fi cant heterogeneity across trials in the de fi nitions of this latter group: the minimum age threshold ranged from 50 to 60; the list of eligible risk factors was variable (including risk factors like hypertension, dyslipidemia, tobacco use, micro- albuminuria, left ventricular systolic or diastolic dysfunction, and longer duration of diabetes); and some trials required 2 risk factors to be present in addition to age while others only required 1. Meta-analyses of both the GLP1-RA trials [51 e 55] and the SGLT2 inhibitor trials [55 e 57] found that the bene fi t of these agents among those with established CV disease was clear; however, the bene fi t for those with multiple CV risk factors only was less certain. In the absence of multiple CV risk factors, there is no robust evidence for the use of any speci fi c second-line antihyperglycemic agent for the prevention of MACE. Individuals with HF Randomized controlled trials of dapagli fl ozin and empagli fl ozin have demonstrated cardiorenal bene fi ts for people who have HF with either reduced ejection fraction \u0014 40% [61,62] or preserved ejection fraction > 40% [63,64]. Approximately one-half of individ- uals in these trials did not have diabetes. The bene fi ts of dapagli- fl ozin and empagli fl ozin were observed in the composite ou","tf":{"40":2,"50":1,"51":1,"55":2,"57":1,"60":1,"61":1,"62":1,"63":1,"64":1,"established":2,"cv":5,"disease":2,"and":6,"those":3,"at":1,"older":1,"ages":1,"with":5,"multiple":3,"risk":6,"factors":6,"there":2,"was":4,"signi":1,"fi":7,"cant":1,"heterogeneity":1,"across":1,"trials":6,"in":5,"the":12,"de":1,"nitions":1,"of":11,"this":1,"latter":1,"group":1,"minimum":1,"age":2,"threshold":1,"ranged":1,"from":1,"to":3,"list":1,"eligible":1,"variable":1,"including":1,"like":1,"hypertension":1,"dyslipidemia":1,"tobacco":1,"use":2,"micro":1,"albuminuria":1,"left":1,"ventricular":1,"systolic":1,"or":2,"diastolic":1,"dysfunction":1,"longer":1,"duration":1,"diabetes":2,"some":1,"required":2,"be":1,"present":1,"addition":1,"while":1,"others":1,"only":2,"meta":1,"analyses":1,"both":1,"glp1":1,"ra":1,"sglt2":1,"inhibitor":1,"found":1,"that":1,"bene":4,"these":2,"agents":1,"among":1,"clear":1,"however":1,"for":4,"less":1,"certain":1,"absence":1,"is":1,"no":1,"robust":1,"evidence":1,"any":1,"speci":1,"second":1,"line":1,"antihyperglycemic":1,"agent":1,"prevention":1,"mace":1,"individuals":1,"hf":2,"randomized":1,"controlled":1,"dapagli":2,"fl":4,"ozin":4,"empagli":2,"have":3,"demonstrated":1,"cardiorenal":1,"ts":2,"people":1,"who":1,"either":1,"reduced":1,"ejection":2,"fraction":2,"preserved":1,"approximately":1,"one":1,"half":1,"individ":1,"uals":1,"did":1,"not":1,"were":1,"observed":1,"composite":1,"ou":1},"len":233},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":5,"chunkId":"dc-2024-p5-c1","text":"uced ejection fraction \u0014 40% [61,62] or preserved ejection fraction > 40% [63,64]. Approximately one-half of individ- uals in these trials did not have diabetes. The bene fi ts of dapagli- fl ozin and empagli fl ozin were observed in the composite outcomes of CV death or hospitalization for HF across major subgroups, including those with and without diabetes, HF with reduced or preserved ejection fraction, New York Heart Association functional class, and the presence or absence of CKD [65,66]. Furthermore, SGLT2 inhibitors may reduce MACE and renal outcomes in those with a history of HF [67]. Individuals with CKD Several large-scale randomized controlled trials have demon- strated bene fi ts of speci fi c SGLT2 inhibitors on cardiorenal out- comes among people with CKD. The CREDENCE, DAPA-CKD, and EMPA-KIDNEY trials showed that canagli fl ozin, dapagli fl ozin, and empagli fl ozin, respectively, are associated with a reduction in the composite outcome of death from renal or CV causes, end-stage renal disease, or worsening of serum creatinine or eGFR [68 e 70]. Importantly, one-third of individuals in DAPA-CKD and more than one-half of individuals in EMPA-KIDNEY did not have type 2 dia- betes, and subgroup analysis showed similar results between the participants with and without diabetes. These trials also showed bene fi ts of these agents on CV and HF endpoints among people wit","tf":{"40":2,"61":1,"62":1,"63":1,"64":1,"65":1,"66":1,"67":1,"68":1,"70":1,"uced":1,"ejection":3,"fraction":3,"or":7,"preserved":2,"approximately":1,"one":3,"half":2,"of":11,"individ":1,"uals":1,"in":6,"these":3,"trials":4,"did":2,"not":2,"have":3,"diabetes":3,"the":6,"bene":3,"fi":4,"ts":3,"dapagli":2,"fl":5,"ozin":5,"and":10,"empagli":2,"were":1,"observed":1,"composite":2,"outcomes":2,"cv":3,"death":2,"hospitalization":1,"for":1,"hf":4,"across":1,"major":1,"subgroups":1,"including":1,"those":2,"with":7,"without":2,"reduced":1,"new":1,"york":1,"heart":1,"association":1,"functional":1,"class":1,"presence":1,"absence":1,"ckd":5,"furthermore":1,"sglt2":2,"inhibitors":2,"may":1,"reduce":1,"mace":1,"renal":3,"history":1,"individuals":3,"several":1,"large":1,"scale":1,"randomized":1,"controlled":1,"demon":1,"strated":1,"speci":1,"on":2,"cardiorenal":1,"out":1,"comes":1,"among":2,"people":2,"credence":1,"dapa":2,"empa":2,"kidney":2,"showed":3,"that":1,"canagli":1,"respectively":1,"are":1,"associated":1,"reduction":1,"outcome":1,"from":1,"causes":1,"end":1,"stage":1,"disease":1,"worsening":1,"serum":1,"creatinine":1,"egfr":1,"importantly":1,"third":1,"more":1,"than":1,"type":1,"dia":1,"betes":1,"subgroup":1,"analysis":1,"similar":1,"results":1,"between":1,"participants":1,"also":1,"agents":1,"endpoints":1,"wit":1},"len":230},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":5,"chunkId":"dc-2024-p5-c2","text":"of individuals in EMPA-KIDNEY did not have type 2 dia- betes, and subgroup analysis showed similar results between the participants with and without diabetes. These trials also showed bene fi ts of these agents on CV and HF endpoints among people with CKD [71]. Meta-analyses of the CKD subgroups in the atherosclerotic CV disease and HF trials of SGLT2 inhibitors simi- larly demonstrated bene fi ts on CV, HF, and renal outcomes. Although a similar meta-analysis of the CKD subgroups from GLP1- RA trials did not demonstrate consistent bene fi ts [72], the recently published FLOW trial speci fi cally examined renal outcomes for subcutaneous semaglutide in individuals with type 2 diabetes and CKD [73]. However, this trial was not included in the literature review for this update and so is not discussed here. Insulin Treatment With Type 2 Diabetes A combination of non-insulin antihyperglycemic agents and insulin is often effective to manage glucose levels. The insulin regimen in type 2 diabetes should be tailored to the individual to reach their individualized glycemic levels and to minimize risk of hypoglycemia. The mode of insulin administration (injections vs continuous subcutaneous infusion), the number of insulin injec- tions (1 to 4 per day), and the timing of injections will depend on each individual  s situation. Adding insulin to non-insulin anti- hyperglycemic agents may r","tf":{"71":1,"72":1,"73":1,"of":10,"individuals":2,"in":5,"empa":1,"kidney":1,"did":2,"not":4,"have":1,"type":4,"dia":1,"betes":1,"and":10,"subgroup":1,"analysis":2,"showed":2,"similar":2,"results":1,"between":1,"the":11,"participants":1,"with":4,"without":1,"diabetes":4,"these":2,"trials":3,"also":1,"bene":3,"fi":4,"ts":3,"agents":3,"on":3,"cv":3,"hf":3,"endpoints":1,"among":1,"people":1,"ckd":4,"meta":2,"analyses":1,"subgroups":2,"atherosclerotic":1,"disease":1,"sglt2":1,"inhibitors":1,"simi":1,"larly":1,"demonstrated":1,"renal":2,"outcomes":2,"although":1,"from":1,"glp1":1,"ra":1,"demonstrate":1,"consistent":1,"recently":1,"published":1,"flow":1,"trial":2,"speci":1,"cally":1,"examined":1,"for":2,"subcutaneous":2,"semaglutide":1,"however":1,"this":2,"was":1,"included":1,"literature":1,"review":1,"update":1,"so":1,"is":2,"discussed":1,"here":1,"insulin":8,"treatment":1,"combination":1,"non":2,"antihyperglycemic":1,"often":1,"effective":1,"to":6,"manage":1,"glucose":1,"levels":2,"regimen":1,"should":1,"be":1,"tailored":1,"individual":2,"reach":1,"their":1,"individualized":1,"glycemic":1,"minimize":1,"risk":1,"hypoglycemia":1,"mode":1,"administration":1,"injections":2,"vs":1,"continuous":1,"infusion":1,"number":1,"injec":1,"tions":1,"per":1,"day":1,"timing":1,"will":1,"depend":1,"each":1,"situation":1,"adding":1,"anti":1,"hyperglycemic":1,"may":1},"len":217},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":5,"chunkId":"dc-2024-p5-c3","text":"istration (injections vs continuous subcutaneous infusion), the number of insulin injec- tions (1 to 4 per day), and the timing of injections will depend on each individual  s situation. Adding insulin to non-insulin anti- hyperglycemic agents may result in better glycemic levels with a lower dose of insulin [74], and may induce less weight gain and less hypoglycemia than that seen when non-insulin antihyperglycemic agents are stopped and insulin is used alone [75,76]. Figure 2 summarizes a stepwise approach to insulin regimens for people with type 2 diabetes. As a fi rst step, a single daily injection of an intermediate-acting (NPH) [77] or long-acting insulin analogue (insulin glargine U-100, insulin glargine U-300, insulin detemir, or insulin degludec) [78 e 80] may be added, particularly for people with fasting hyperglycemia. Insulin icodec was recently approved in Canada with once-weekly dosing; how- ever, it was not included in the literature review for this update and so is not discussed here. Incretins and SGLT2 inhibitors have been shown to be ef fi cacious at further lowering glucose levels when combined with insulin therapy [81 e 94]. These agents should therefore be continued and/or initiated for people starting basal insulin. The basal insulin dose should be titrated to the fasting glucose levels; insulin requirements will likely increase as diabetes progresses, a","tf":{"74":1,"75":1,"76":1,"77":1,"78":1,"80":1,"81":1,"94":1,"100":1,"300":1,"istration":1,"injections":2,"vs":1,"continuous":1,"subcutaneous":1,"infusion":1,"the":5,"number":1,"of":4,"insulin":17,"injec":1,"tions":1,"to":5,"per":1,"day":1,"and":7,"timing":1,"will":2,"depend":1,"on":1,"each":1,"individual":1,"situation":1,"adding":1,"non":2,"anti":1,"hyperglycemic":1,"agents":3,"may":3,"result":1,"in":3,"better":1,"glycemic":1,"levels":3,"with":5,"lower":1,"dose":2,"induce":1,"less":2,"weight":1,"gain":1,"hypoglycemia":1,"than":1,"that":1,"seen":1,"when":2,"antihyperglycemic":1,"are":1,"stopped":1,"is":2,"used":1,"alone":1,"figure":1,"summarizes":1,"stepwise":1,"approach":1,"regimens":1,"for":4,"people":3,"type":1,"diabetes":2,"as":2,"fi":2,"rst":1,"step":1,"single":1,"daily":1,"injection":1,"an":1,"intermediate":1,"acting":2,"nph":1,"or":3,"long":1,"analogue":1,"glargine":2,"detemir":1,"degludec":1,"be":4,"added":1,"particularly":1,"fasting":2,"hyperglycemia":1,"icodec":1,"was":2,"recently":1,"approved":1,"canada":1,"once":1,"weekly":1,"dosing":1,"how":1,"ever":1,"it":1,"not":2,"included":1,"literature":1,"review":1,"this":1,"update":1,"so":1,"discussed":1,"here":1,"incretins":1,"sglt2":1,"inhibitors":1,"have":1,"been":1,"shown":1,"ef":1,"cacious":1,"at":1,"further":1,"lowering":1,"glucose":2,"combined":1,"therapy":1,"these":1,"should":2,"therefore":1,"continued":1,"initiated":1,"starting":1,"basal":2,"titrated":1,"requirements":1,"likely":1,"increase":1,"progresses":1},"len":212},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":5,"chunkId":"dc-2024-p5-c4","text":"apy [81 e 94]. These agents should therefore be continued and/or initiated for people starting basal insulin. The basal insulin dose should be titrated to the fasting glucose levels; insulin requirements will likely increase as diabetes progresses, and higher doses may be needed over time. If glycemia is suboptimal on treatment regimens that include basal insulin with other agents, bolus insulin at mealtimes (short- or rapid-acting analogues) may be added. Generally, once bolus insulin is introduced into a treatment regimen, either as a separate mealtime bolus or as part of a premixed regimen, insulin secreta- gogues, such as sulfonylureas and meglitinides, should be dis- continued due to an increased risk for hypoglycemia. Concomitant therapy with metformin, incretins, and SGLT2 inhibitors should be continued with regimens containing bolus insulin to support gly- cemic management with less risk of weight gain and hypoglycemia [75,76,81 e 102]. Bolus insulin should be initiated using a stepwise approach, starting with 1 injection at the largest meal and then introducing additional mealtime injections later, if needed. This approach was shown to be as ef fi cacious at A1C lowering as a full basal-bolus regimen, but is associated with less hypoglycemia and greater satisfaction after 1 year [103]. Bolus insulin doses are titrated to the postprandial glucose levels. Lower rates of ","tf":{"75":1,"76":1,"81":2,"94":1,"102":1,"103":1,"apy":1,"these":1,"agents":2,"should":5,"therefore":1,"be":8,"continued":3,"and":7,"or":3,"initiated":2,"for":2,"people":1,"starting":2,"basal":4,"insulin":10,"the":4,"dose":1,"titrated":2,"to":5,"fasting":1,"glucose":2,"levels":2,"requirements":1,"will":1,"likely":1,"increase":1,"as":6,"diabetes":1,"progresses":1,"higher":1,"doses":2,"may":2,"needed":2,"over":1,"time":1,"if":2,"glycemia":1,"is":3,"suboptimal":1,"on":1,"treatment":2,"regimens":2,"that":1,"include":1,"with":6,"other":1,"bolus":7,"at":3,"mealtimes":1,"short":1,"rapid":1,"acting":1,"analogues":1,"added":1,"generally":1,"once":1,"introduced":1,"into":1,"regimen":3,"either":1,"separate":1,"mealtime":2,"part":1,"of":3,"premixed":1,"secreta":1,"gogues":1,"such":1,"sulfonylureas":1,"meglitinides":1,"dis":1,"due":1,"an":1,"increased":1,"risk":2,"hypoglycemia":3,"concomitant":1,"therapy":1,"metformin":1,"incretins":1,"sglt2":1,"inhibitors":1,"containing":1,"support":1,"gly":1,"cemic":1,"management":1,"less":2,"weight":1,"gain":1,"using":1,"stepwise":1,"approach":2,"injection":1,"largest":1,"meal":1,"then":1,"introducing":1,"additional":1,"injections":1,"later":1,"this":1,"was":1,"shown":1,"ef":1,"fi":1,"cacious":1,"a1c":1,"lowering":1,"full":1,"but":1,"associated":1,"greater":1,"satisfaction":1,"after":1,"year":1,"are":1,"postprandial":1,"lower":1,"rates":1},"len":210},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":5,"chunkId":"dc-2024-p5-c5","text":"was shown to be as ef fi cacious at A1C lowering as a full basal-bolus regimen, but is associated with less hypoglycemia and greater satisfaction after 1 year [103]. Bolus insulin doses are titrated to the postprandial glucose levels. Lower rates of hypoglycemia have been observed in some studies of individuals with type 2 diabetes treated with rapid- acting insulin analogues compared to those treated with short- acting (regular) insulin [104 e 107]. Use of long-acting basal insu- lin analogues reduces the relative risk of symptomatic and nocturnal hypoglycemia compared to treatment with NPH insulin [104,108-110]. Insulin degludec is associated with lower rates of overall, symptomatic, nocturnal, and severe hypoglycemia compared to glargine U-100 [78,80,111 e 113]. There is also some evidence of lower hypoglycemia rates with glargine U-300 compared to glargine U-100 [114]. Ef fi cacy and rates of hypogly- cemia are similar between glargine U-100 and detemir [115]. Recommendations Initial pharmacologic glycemic management 1. Physical activity, nutrition therapy, self-management educa- tion and support, and weight management are important components of glycemic management for type 2 diabetes, both at onset and throughout the course of the disease, and should be incorporated into every person  s individualized care plan [Grade D, Consensus]. 2. Once the decision to initiate pharm","tf":{"78":1,"80":1,"100":3,"103":1,"104":2,"107":1,"108":1,"110":1,"111":1,"113":1,"114":1,"115":1,"300":1,"was":1,"shown":1,"to":7,"be":2,"as":2,"ef":2,"fi":2,"cacious":1,"at":2,"a1c":1,"lowering":1,"full":1,"basal":2,"bolus":2,"regimen":1,"but":1,"is":3,"associated":2,"with":7,"less":1,"hypoglycemia":5,"and":9,"greater":1,"satisfaction":1,"after":1,"year":1,"insulin":5,"doses":1,"are":3,"titrated":1,"the":5,"postprandial":1,"glucose":1,"levels":1,"lower":3,"rates":4,"of":9,"have":1,"been":1,"observed":1,"in":1,"some":2,"studies":1,"individuals":1,"type":2,"diabetes":2,"treated":2,"rapid":1,"acting":3,"analogues":2,"compared":4,"those":1,"short":1,"regular":1,"use":1,"long":1,"insu":1,"lin":1,"reduces":1,"relative":1,"risk":1,"symptomatic":2,"nocturnal":2,"treatment":1,"nph":1,"degludec":1,"overall":1,"severe":1,"glargine":4,"there":1,"also":1,"evidence":1,"cacy":1,"hypogly":1,"cemia":1,"similar":1,"between":1,"detemir":1,"recommendations":1,"initial":1,"pharmacologic":1,"glycemic":2,"management":4,"physical":1,"activity":1,"nutrition":1,"therapy":1,"self":1,"educa":1,"tion":1,"support":1,"weight":1,"important":1,"components":1,"for":1,"both":1,"onset":1,"throughout":1,"course":1,"disease":1,"should":1,"incorporated":1,"into":1,"every":1,"person":1,"individualized":1,"care":1,"plan":1,"grade":1,"consensus":1,"once":1,"decision":1,"initiate":1,"pharm":1},"len":206},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":5,"chunkId":"dc-2024-p5-c6","text":"tant components of glycemic management for type 2 diabetes, both at onset and throughout the course of the disease, and should be incorporated into every person  s individualized care plan [Grade D, Consensus]. 2. Once the decision to initiate pharmacotherapy is made, met- formin is recommended as the initial antihyperglycemic medication because of its durable ef fi cacy in lowering A1C, negligible risk for hypoglycemia or weight gain [12] [Grade A, Level 1A], relatively mild side-effect pro fi le, long-term track record, and affordability. Initial dose should be low (250 mg or 500 mg twice daily with meals) to minimize risk of B.R. Shah et al. / Can J Diabetes 48 (2024) 415 e 424 419","tf":{"12":1,"48":1,"250":1,"415":1,"419":1,"424":1,"500":1,"2024":1,"tant":1,"components":1,"of":4,"glycemic":1,"management":1,"for":2,"type":1,"diabetes":2,"both":1,"at":1,"onset":1,"and":3,"throughout":1,"the":4,"course":1,"disease":1,"should":2,"be":2,"incorporated":1,"into":1,"every":1,"person":1,"individualized":1,"care":1,"plan":1,"grade":2,"consensus":1,"once":1,"decision":1,"to":2,"initiate":1,"pharmacotherapy":1,"is":2,"made":1,"met":1,"formin":1,"recommended":1,"as":1,"initial":2,"antihyperglycemic":1,"medication":1,"because":1,"its":1,"durable":1,"ef":1,"fi":2,"cacy":1,"in":1,"lowering":1,"a1c":1,"negligible":1,"risk":2,"hypoglycemia":1,"or":2,"weight":1,"gain":1,"level":1,"1a":1,"relatively":1,"mild":1,"side":1,"effect":1,"pro":1,"le":1,"long":1,"term":1,"track":1,"record":1,"affordability":1,"dose":1,"low":1,"mg":2,"twice":1,"daily":1,"with":1,"meals":1,"minimize":1,"shah":1,"et":1,"al":1,"can":1},"len":109},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":6,"chunkId":"dc-2024-p6-c0","text":"gastrointestinal side effects, with gradual increase to maximum dose [Grade D, Consensus]. 3. Insulin, with or without metformin, is recommended as initial pharmacologic therapy for individuals with metabolic decom- pensation (e.g. marked hyperglycemia, ketosis, hyperosmolar state, or unintentional weight loss related to hyperglycemia) and/or severe symptomatic hyperglycemia (polyuria, poly- dipsia, visual blurring). Once metabolically stable, it may be possible to taper or discontinue insulin and replace it with other agents, as required [Grade D, Consensus]. 4. Even in the absence of metabolic decompensation, combina- tion therapy is recommended as initial pharmacologic therapy for people with marked hyperglycemia (e.g. A1C more than 1.5% above target) [15,17,18] [Grade B, Level 2]. a. Choice of the second agent to start alongside metformin should be based on the individual  s priorities, preferences, and comorbidities [Grade D, Consensus]. 5. For individuals with cardiovascular or renal comorbidities at the time of diabetes diagnosis, speci fi c GLP1-RAs and/or SGLT2 inhibitors should also be used as initial pharmacotherapy for cardiorenal protection (see recommendation #10). Ongoing assessment 6. Dose adjustments, substitutions, and/or addition of other antihyperglycemic medications should be made in order to reach the target A1C within 3 to 6 months [Grade D, Consensus]. ","tf":{"10":1,"15":1,"17":1,"18":1,"gastrointestinal":1,"side":1,"effects":1,"with":6,"gradual":1,"increase":1,"to":6,"maximum":1,"dose":2,"grade":5,"consensus":4,"insulin":2,"or":7,"without":1,"metformin":2,"is":2,"recommended":2,"as":4,"initial":3,"pharmacologic":2,"therapy":3,"for":4,"individuals":2,"metabolic":2,"decom":1,"pensation":1,"marked":2,"hyperglycemia":4,"ketosis":1,"hyperosmolar":1,"state":1,"unintentional":1,"weight":1,"loss":1,"related":1,"and":5,"severe":1,"symptomatic":1,"polyuria":1,"poly":1,"dipsia":1,"visual":1,"blurring":1,"once":1,"metabolically":1,"stable":1,"it":2,"may":1,"be":4,"possible":1,"taper":1,"discontinue":1,"replace":1,"other":2,"agents":1,"required":1,"even":1,"in":2,"the":5,"absence":1,"of":4,"decompensation":1,"combina":1,"tion":1,"people":1,"a1c":2,"more":1,"than":1,"above":1,"target":2,"level":1,"choice":1,"second":1,"agent":1,"start":1,"alongside":1,"should":3,"based":1,"on":1,"individual":1,"priorities":1,"preferences":1,"comorbidities":2,"cardiovascular":1,"renal":1,"at":1,"time":1,"diabetes":1,"diagnosis":1,"speci":1,"fi":1,"glp1":1,"ras":1,"sglt2":1,"inhibitors":1,"also":1,"used":1,"pharmacotherapy":1,"cardiorenal":1,"protection":1,"see":1,"recommendation":1,"ongoing":1,"assessment":1,"adjustments":1,"substitutions":1,"addition":1,"antihyperglycemic":1,"medications":1,"made":1,"order":1,"reach":1,"within":1,"months":1},"len":185},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":6,"chunkId":"dc-2024-p6-c1","text":"cardiorenal protection (see recommendation #10). Ongoing assessment 6. Dose adjustments, substitutions, and/or addition of other antihyperglycemic medications should be made in order to reach the target A1C within 3 to 6 months [Grade D, Consensus]. 7. Cardiovascular and renal status should be reviewed at least annually to determine if treatment intensi fi cation or modi fi - cation is required [Grade D, Consensus]. 8. Before intensifying pharmacologic therapy, assess for potential precipitants of increasing A1C, such as infection, ischemia, concomitant medications, or changes in eating or physical activity. Explore medication adherence and barriers to adher- ence, such as adverse drug effects, costs, beliefs, and prefer- ences [Grade D, Consensus]. Treatment intensi fi cation or modi fi cation 9. For individuals who do not have CV or renal comorbidities, choice of an antihyperglycemic medication when treatment DECISION TO INITIATE INSULIN (from Figure 1) Glycemic targets not met, or symptomatic hyperglycemia / metabolic decompensation IF GLYCEMIC TARGETS NOT MET IF GLYCEMIC TARGETS NOT MET Educate on prevention and management of hypoglycemia. If cardiorenal comorbidities change, reassess other antihyperglycemic agents.  Start basal insulin  Titrate dose to meet fasting glucose target  Continue to optimize other antihyperglycemic agents  Add one injection per day of bolus i","tf":{"10":1,"cardiorenal":2,"protection":1,"see":1,"recommendation":1,"ongoing":1,"assessment":1,"dose":2,"adjustments":1,"substitutions":1,"and":5,"or":7,"addition":1,"of":5,"other":3,"antihyperglycemic":4,"medications":2,"should":2,"be":2,"made":1,"in":2,"order":1,"to":7,"reach":1,"the":1,"target":2,"a1c":2,"within":1,"months":1,"grade":3,"consensus":3,"cardiovascular":1,"renal":2,"status":1,"reviewed":1,"at":1,"least":1,"annually":1,"determine":1,"if":4,"treatment":3,"intensi":2,"fi":4,"cation":4,"modi":2,"is":1,"required":1,"before":1,"intensifying":1,"pharmacologic":1,"therapy":1,"assess":1,"for":2,"potential":1,"precipitants":1,"increasing":1,"such":2,"as":2,"infection":1,"ischemia":1,"concomitant":1,"changes":1,"eating":1,"physical":1,"activity":1,"explore":1,"medication":2,"adherence":1,"barriers":1,"adher":1,"ence":1,"adverse":1,"drug":1,"effects":1,"costs":1,"beliefs":1,"prefer":1,"ences":1,"individuals":1,"who":1,"do":1,"not":4,"have":1,"cv":1,"comorbidities":2,"choice":1,"an":1,"when":1,"decision":1,"initiate":1,"insulin":2,"from":1,"figure":1,"glycemic":3,"targets":3,"met":3,"symptomatic":1,"hyperglycemia":1,"metabolic":1,"decompensation":1,"educate":1,"on":1,"prevention":1,"management":1,"hypoglycemia":1,"change":1,"reassess":1,"agents":2,"start":1,"basal":1,"titrate":1,"meet":1,"fasting":1,"glucose":1,"continue":1,"optimize":1,"add":1,"one":1,"injection":1,"per":1,"day":1,"bolus":1},"len":189},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":6,"chunkId":"dc-2024-p6-c2","text":"poglycemia. If cardiorenal comorbidities change, reassess other antihyperglycemic agents.  Start basal insulin  Titrate dose to meet fasting glucose target  Continue to optimize other antihyperglycemic agents  Add one injection per day of bolus insulin , with the largest meal  Titrate dose to meet postprandial glucose target  Consider stopping secretagogues to prevent hypoglycemia  Advance to multiple injections of bolus insulin at all meals  Titrate doses to meet postprandial glucose target  Avoid secretagogues Basal-Plus B L D bed Basal-Bolus or Multiple Daily Injections B L D bed Basal B L D bed Figure 2. Stepwise approach to insulin regimens for people with type 2 diabetes. B , breakfast; D , dinner; L , lunch. B.R. Shah et al. / Can J Diabetes 48 (2024) 415 e 424 420","tf":{"48":1,"415":1,"420":1,"424":1,"2024":1,"poglycemia":1,"if":1,"cardiorenal":1,"comorbidities":1,"change":1,"reassess":1,"other":2,"antihyperglycemic":2,"agents":2,"start":1,"basal":4,"insulin":4,"titrate":3,"dose":2,"to":7,"meet":3,"fasting":1,"glucose":3,"target":3,"continue":1,"optimize":1,"add":1,"one":1,"injection":1,"per":1,"day":1,"of":2,"bolus":3,"with":2,"the":1,"largest":1,"meal":1,"postprandial":2,"consider":1,"stopping":1,"secretagogues":2,"prevent":1,"hypoglycemia":1,"advance":1,"multiple":2,"injections":2,"at":1,"all":1,"meals":1,"doses":1,"avoid":1,"plus":1,"bed":3,"or":1,"daily":1,"figure":1,"stepwise":1,"approach":1,"regimens":1,"for":1,"people":1,"type":1,"diabetes":2,"breakfast":1,"dinner":1,"lunch":1,"shah":1,"et":1,"al":1,"can":1},"len":105},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":7,"chunkId":"dc-2024-p7-c0","text":"intensi fi cation is required should be based on the individual  s priorities, preferences, and comorbidities (see Figure 1 and Table 1) [12]. Clinical priorities may include weight loss, avoidance of hypoglycemia, desired magnitude of glucose lowering, cost, side-effect pro fi le, possibility of pregnancy, and comorbidities [Grade D, Consensus]. 10. Priority should be given to medications with speci fi c car- diorenal bene fi ts for certain subgroups of individuals, regard- less of the A1C level. a. A GLP1-RA and/or SGLT2 inhibitor with demonstrated evi- dence of bene fi t is recommended for individuals at high CV risk [44 e 48,51 e 57] [Grade A, Level 1A for dulaglutide, lir- aglutide, or subcutaneous semaglutide; Grade A, Level 1A for empagli fl ozin; Grade B, Level 2 for canagli fl ozin]. b. An SGLT2 inhibitor with demonstrated evidence of bene fi t is recommended for individuals with HF with reduced ejec- tion fraction [61,62] or HF with preserved ejection fraction [63,64] [Grade A, Level 1A for dapagli fl ozin or empagli fl ozin]. c. An SGLT2 inhibitor with demonstrated evidence of bene fi t is recommended for individuals with CKD [68 e 70] [Grade A, Level 1A for canagli fl ozin, dapagli fl ozin, or empagli fl ozin]. Adding insulin to current antihyperglycemic therapy 11. All individuals starting insulin should receive education on the prevention and management of hypogl","tf":{"10":1,"11":1,"12":1,"44":1,"48":1,"51":1,"57":1,"61":1,"62":1,"63":1,"64":1,"68":1,"70":1,"intensi":1,"fi":7,"cation":1,"is":4,"required":1,"should":3,"be":2,"based":1,"on":2,"the":3,"individual":1,"priorities":2,"preferences":1,"and":5,"comorbidities":2,"see":1,"figure":1,"table":1,"clinical":1,"may":1,"include":1,"weight":1,"loss":1,"avoidance":1,"of":9,"hypoglycemia":1,"desired":1,"magnitude":1,"glucose":1,"lowering":1,"cost":1,"side":1,"effect":1,"pro":1,"le":1,"possibility":1,"pregnancy":1,"grade":6,"consensus":1,"priority":1,"given":1,"to":2,"medications":1,"with":8,"speci":1,"car":1,"diorenal":1,"bene":4,"ts":1,"for":9,"certain":1,"subgroups":1,"individuals":5,"regard":1,"less":1,"a1c":1,"level":6,"glp1":1,"ra":1,"or":5,"sglt2":3,"inhibitor":3,"demonstrated":3,"evi":1,"dence":1,"recommended":3,"at":1,"high":1,"cv":1,"risk":1,"1a":4,"dulaglutide":1,"lir":1,"aglutide":1,"subcutaneous":1,"semaglutide":1,"empagli":3,"fl":7,"ozin":7,"canagli":2,"an":2,"evidence":2,"hf":2,"reduced":1,"ejec":1,"tion":1,"fraction":2,"preserved":1,"ejection":1,"dapagli":2,"ckd":1,"adding":1,"insulin":2,"current":1,"antihyperglycemic":1,"therapy":1,"all":1,"starting":1,"receive":1,"education":1,"prevention":1,"management":1,"hypogl":1},"len":214},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":7,"chunkId":"dc-2024-p7-c1","text":"h CKD [68 e 70] [Grade A, Level 1A for canagli fl ozin, dapagli fl ozin, or empagli fl ozin]. Adding insulin to current antihyperglycemic therapy 11. All individuals starting insulin should receive education on the prevention and management of hypoglycemia [Grade D, Consensus]. 12. A single daily injection of a basal insulin is recommended as the initial insulin regimen when adding to current anti- hyperglycemic therapy (see Figure 2), with dosing titrated to reach the fasting glucose target [Grade D, Consensus]. a. Long-acting insulin analogues should be considered over NPH insulin to reduce the risk of hypoglycemia [104,108 e 110] [Grade A, Level 1A]. b. Insulin degludec or insulin glargine U-300 may be consid- ered over other long-acting insulin analogues to reduce the risk of nocturnal hypoglycemia [78,80,111 e 114] [Grade B, Level 2 for individuals with risk factors for hypoglycemia; Grade C, Level 3 for other individuals]. 13. An incretin and/or SGLT2 inhibitor should be continued or initiated when introducing basal insulin [81 e 102] [Grade A, Level 1A]. 14. If bolus insulin is required, it should be initiated using a step- wise approach [103], starting with 1 injection at the largest meal and then introducing additional mealtime injections later if needed (see Figure 2). Dosing should be titrated to reach postprandial glucose targets [Grade B, Level 2]. a. Rapid-acting ","tf":{"11":1,"12":1,"13":1,"14":1,"68":1,"70":1,"78":1,"80":1,"81":1,"102":1,"103":1,"104":1,"108":1,"110":1,"111":1,"114":1,"300":1,"ckd":1,"grade":8,"level":6,"1a":3,"for":4,"canagli":1,"fl":3,"ozin":3,"dapagli":1,"or":4,"empagli":1,"adding":2,"insulin":11,"to":6,"current":2,"antihyperglycemic":1,"therapy":2,"all":1,"individuals":3,"starting":2,"should":5,"receive":1,"education":1,"on":1,"the":6,"prevention":1,"and":3,"management":1,"of":4,"hypoglycemia":4,"consensus":2,"single":1,"daily":1,"injection":2,"basal":2,"is":2,"recommended":1,"as":1,"initial":1,"regimen":1,"when":2,"anti":1,"hyperglycemic":1,"see":2,"figure":2,"with":3,"dosing":2,"titrated":2,"reach":2,"fasting":1,"glucose":2,"target":1,"long":2,"acting":3,"analogues":2,"be":5,"considered":1,"over":2,"nph":1,"reduce":2,"risk":3,"degludec":1,"glargine":1,"may":1,"consid":1,"ered":1,"other":2,"nocturnal":1,"factors":1,"an":1,"incretin":1,"sglt2":1,"inhibitor":1,"continued":1,"initiated":2,"introducing":2,"if":2,"bolus":1,"required":1,"it":1,"using":1,"step":1,"wise":1,"approach":1,"at":1,"largest":1,"meal":1,"then":1,"additional":1,"mealtime":1,"injections":1,"later":1,"needed":1,"postprandial":1,"targets":1,"rapid":1},"len":204},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":7,"chunkId":"dc-2024-p7-c2","text":"ise approach [103], starting with 1 injection at the largest meal and then introducing additional mealtime injections later if needed (see Figure 2). Dosing should be titrated to reach postprandial glucose targets [Grade B, Level 2]. a. Rapid-acting insulin analogues may be considered over short-acting (regular) insulin to reduce the risk of hypo- glycemia [104 e 107] [Grade B, Level 2]. b. Insulin secretagogues (sulfonylureas and meglitinides) should be discontinued to reduce the risk of hypoglycemia [Grade D, Consensus]. External Reviewers The authors are thankful to our external reviewers for their insightful feedback and the lending of their time and expertise: J.M. Gamble PhD; Ronald M. Goldenberg MD, FRCPC, FACE; Lorraine L. Lipscombe MD, MSc, FRCPC; and Ron J. Sigal MD, MPH, FRCPC. Author Disclosures B.R.S. is funded by the University of Toronto as the Novo Nordisk Research Chair in Equitable Care of Diabetes and Related Condi- tions; H.S.B. reports trial fees paid to his institution by Amgen, AstraZeneca, Anji, Biomea, Boehringer Ingelheim, Eli Lilly, Glaxo SmithKline, Ionis, Kowa, Novartis, Novo Nordisk, and P fi zer; S.S. reports research funding from Merck through their investigator- initiated grant program; S.B., K.D., D.T.E., K.L., K.M., and R.J. have no con fl icts to disclose. References [1] UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose con","tf":{"103":1,"104":1,"107":1,"ise":1,"approach":1,"starting":1,"with":1,"injection":1,"at":1,"the":7,"largest":1,"meal":1,"and":8,"then":1,"introducing":1,"additional":1,"mealtime":1,"injections":1,"later":1,"if":1,"needed":1,"see":1,"figure":1,"dosing":1,"should":2,"be":3,"titrated":1,"to":6,"reach":1,"postprandial":1,"glucose":2,"targets":1,"grade":3,"level":2,"rapid":1,"acting":2,"insulin":3,"analogues":1,"may":1,"considered":1,"over":1,"short":1,"regular":1,"reduce":2,"risk":2,"of":5,"hypo":1,"glycemia":1,"secretagogues":1,"sulfonylureas":1,"meglitinides":1,"discontinued":1,"hypoglycemia":1,"consensus":1,"external":2,"reviewers":2,"authors":1,"are":1,"thankful":1,"our":1,"for":1,"their":3,"insightful":1,"feedback":1,"lending":1,"time":1,"expertise":1,"gamble":1,"phd":1,"ronald":1,"goldenberg":1,"md":3,"frcpc":3,"face":1,"lorraine":1,"lipscombe":1,"msc":1,"ron":1,"sigal":1,"mph":1,"author":1,"disclosures":1,"is":1,"funded":1,"by":2,"university":1,"toronto":1,"as":1,"novo":2,"nordisk":2,"research":2,"chair":1,"in":1,"equitable":1,"care":1,"diabetes":2,"related":1,"condi":1,"tions":1,"reports":2,"trial":1,"fees":1,"paid":1,"his":1,"institution":1,"amgen":1,"astrazeneca":1,"anji":1,"biomea":1,"boehringer":1,"ingelheim":1,"eli":1,"lilly":1,"glaxo":1,"smithkline":1,"ionis":1,"kowa":1,"novartis":1,"fi":1,"zer":1,"funding":1,"from":1,"merck":1,"through":1,"investigator":1,"initiated":1,"grant":1,"program":1,"have":1,"no":1,"con":2,"fl":1,"icts":1,"disclose":1,"references":1,"uk":1,"prospective":1,"study":1,"ukpds":1,"group":1,"intensive":1,"blood":1},"len":191},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":7,"chunkId":"dc-2024-p7-c3","text":"reports research funding from Merck through their investigator- initiated grant program; S.B., K.D., D.T.E., K.L., K.M., and R.J. have no con fl icts to disclose. References [1] UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treat- ment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131):837 e 53. [2] Sigal RJ, Armstrong MJ, Bacon SL, Boule NG, Dasgupta K, Kenny GP, et al. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Physical activity and diabetes. Can J Diabetes 2018;42(Suppl. 1):S54 e 63. [3] Sievenpiper JL, Chan CB, Dworatzek PD, Freeze C, Williams SL. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Manage- ment of Diabetes in Canada: Nutrition therapy. Can J Diabetes 2018;42- (Suppl. 1):S64 e 79. [4] Sherifali D, Berard LD, Gucciardi E, MacDonald B, MacNeill G. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Manage- ment of Diabetes in Canada: Self-management education and support. Can J Diabetes 2018;42(Suppl. 1):S36 e 41. [5] Wharton S, Pedersen SD, Lau DJR, Sharma AM. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Weight management in diabetes. Can J Diabetes 2018;42(Suppl. 1","tf":{"33":1,"41":1,"42":4,"53":1,"63":1,"79":1,"352":1,"837":1,"1998":1,"2018":8,"9131":1,"reports":1,"research":1,"funding":1,"from":1,"merck":1,"through":1,"their":1,"investigator":1,"initiated":1,"grant":1,"program":1,"and":8,"have":1,"no":1,"con":1,"fl":1,"icts":1,"to":1,"disclose":1,"references":1,"uk":1,"prospective":1,"diabetes":16,"study":1,"ukpds":2,"group":1,"intensive":1,"blood":1,"glucose":1,"control":1,"with":3,"sulphonylureas":1,"or":1,"insulin":1,"compared":1,"conventional":1,"treat":1,"ment":3,"risk":1,"of":5,"complications":1,"in":6,"patients":1,"type":1,"lancet":1,"sigal":1,"rj":1,"armstrong":1,"mj":1,"bacon":1,"sl":2,"boule":1,"ng":1,"dasgupta":1,"kenny":1,"gp":1,"et":1,"al":1,"canada":8,"clinical":4,"practice":4,"guidelines":4,"for":4,"the":4,"prevention":4,"management":4,"physical":1,"activity":1,"can":4,"suppl":4,"s54":1,"sievenpiper":1,"jl":1,"chan":1,"cb":1,"dworatzek":1,"pd":1,"freeze":1,"williams":1,"manage":2,"nutrition":1,"therapy":1,"s64":1,"sherifali":1,"berard":1,"ld":1,"gucciardi":1,"macdonald":1,"macneill":1,"self":1,"education":1,"support":1,"s36":1,"wharton":1,"pedersen":1,"sd":1,"lau":1,"djr":1,"sharma":1,"am":1,"weight":1},"len":194},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":7,"chunkId":"dc-2024-p7-c4","text":"etes 2018;42(Suppl. 1):S36 e 41. [5] Wharton S, Pedersen SD, Lau DJR, Sharma AM. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Weight management in diabetes. Can J Diabetes 2018;42(Suppl. 1): S124 e 9. [6] Imran SA, Agarwal G, Bajaj HS, Ross S. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Tar- gets for glycemic control. Can J Diabetes 2018;42(Suppl. 1):S42 e 5. [7] Berard LD, Siemens R, Woo V. Diabetes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Monitoring glycemic control. Can J Diabetes 2018;42(Suppl. 1):S47 e 53. [8] Lega IC, Yale JF, Chadha A, Paty B, Roscoe R, Snider M, Steier J. Hypoglycemia in adults. Can J Diabetes 2023;47(7):548 e 59. [9] MacKay D, Chan C, Dasgupta K, Dominy C, Gagner M, Jin S, Kim J, et al. Remission of type 2 diabetes. Can J Diabetes 2023;46(8):753 e 61. [10] UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood- glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:P854 e 65. [11] Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O  Neill MC, Zinman B, Viberti G; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N ","tf":{"10":1,"11":1,"34":1,"41":1,"42":4,"46":1,"47":1,"53":1,"59":1,"61":1,"65":1,"352":1,"548":1,"753":1,"1998":1,"2018":7,"2023":2,"etes":1,"suppl":4,"s36":1,"wharton":1,"pedersen":1,"sd":1,"lau":1,"djr":1,"sharma":1,"am":1,"diabetes":15,"canada":6,"clinical":3,"practice":3,"guidelines":3,"for":4,"the":3,"prevention":3,"and":3,"management":4,"of":6,"in":6,"weight":1,"can":5,"s124":1,"imran":1,"sa":1,"agarwal":1,"bajaj":1,"hs":1,"ross":1,"tar":1,"gets":1,"glycemic":3,"control":3,"s42":1,"berard":1,"ld":1,"siemens":1,"woo":1,"monitoring":1,"s47":1,"lega":1,"ic":1,"yale":1,"jf":1,"chadha":1,"paty":1,"roscoe":1,"snider":1,"steier":1,"hypoglycemia":1,"adults":1,"mackay":1,"chan":1,"dasgupta":1,"dominy":1,"gagner":1,"jin":1,"kim":1,"et":1,"al":1,"remission":1,"type":2,"uk":1,"prospective":1,"study":2,"ukpds":2,"group":2,"effect":1,"intensive":1,"blood":1,"glucose":1,"with":2,"metformin":2,"on":1,"complications":1,"overweight":1,"patients":1,"lancet":1,"p854":1,"kahn":1,"se":1,"haffner":1,"sm":1,"heise":1,"ma":1,"herman":1,"wh":1,"holman":1,"rr":1,"jones":1,"np":1,"kravitz":1,"bg":1,"lachin":1,"jm":1,"neill":1,"mc":1,"zinman":1,"viberti":1,"adopt":1,"durability":1,"rosiglitazone":1,"or":1,"glyburide":1,"monotherapy":1},"len":198},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":7,"chunkId":"dc-2024-p7-c5","text":" Lancet 1998;352:P854 e 65. [11] Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O  Neill MC, Zinman B, Viberti G; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427 e 43. [12] Maruthur NM, Tseng E, Hut fl ess S, Wilson LM, Suarez-Cuervo C, Berger Z, Chu Y, Iyoha E, Segal JB, Bolen S. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis. Ann Intern Med 2016;164:740 e 51. [13] Hong J, Zhang Y, Lai S, Lv A, Su Q, Dong Y, Zhou Z, Tang W, Zhao J, Cui L, Zou D, Wang D, Li H, Liu C, Wu G, Shen J, Zhu D, Wang W, Shen W, Ning G; SPREAD-DIMCAD Investigators. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 2013;36:1304 e 11. [14] Palmer SC, Mavridis D, Nicolucci A, Johnson DW, Tonelli M, Craig JC, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: A meta-analysis. JAMA 2016;316:313 e 24. [15] Phung OJ, Sobieraj DM, Engel SS, Rajpathak SN. Early combination therapy for the treatment of type 2 diabetes mellitus: Systematic review and meta- analysis. Diabetes Obes Metab 2014;16:410 e 7. [16] Rosenstock J, Chuck L, Gonzalez-Ortiz M, Me","tf":{"11":2,"12":1,"13":1,"14":1,"15":1,"16":2,"24":1,"36":1,"43":1,"51":1,"65":1,"164":1,"313":1,"316":1,"352":1,"355":1,"410":1,"740":1,"1304":1,"1998":1,"2006":1,"2013":1,"2014":1,"2016":2,"2427":1,"lancet":1,"p854":1,"kahn":1,"se":1,"haffner":1,"sm":1,"heise":1,"ma":1,"herman":1,"wh":1,"holman":1,"rr":1,"jones":1,"np":1,"kravitz":1,"bg":1,"lachin":1,"jm":1,"neill":1,"mc":1,"zinman":1,"viberti":1,"adopt":1,"study":1,"group":1,"glycemic":1,"durability":1,"of":4,"rosiglitazone":1,"metformin":3,"or":2,"glyburide":1,"monotherapy":2,"engl":1,"med":2,"maruthur":1,"nm":1,"tseng":1,"hut":1,"fl":1,"ess":1,"wilson":1,"lm":1,"suarez":1,"cuervo":1,"berger":1,"chu":1,"iyoha":1,"segal":1,"jb":1,"bolen":1,"diabetes":7,"medications":1,"as":1,"based":1,"combination":2,"therapy":2,"for":2,"type":4,"systematic":2,"review":2,"and":4,"meta":3,"analysis":3,"ann":1,"intern":1,"hong":1,"zhang":1,"lai":1,"lv":1,"su":1,"dong":1,"zhou":1,"tang":1,"zhao":1,"cui":1,"zou":1,"wang":2,"li":1,"liu":1,"wu":1,"shen":2,"zhu":1,"ning":1,"spread":1,"dimcad":1,"investigators":1,"effects":1,"versus":1,"glipizide":1,"on":1,"cardiovascular":1,"outcomes":2,"in":2,"patients":2,"with":3,"coronary":1,"artery":1,"disease":1,"care":1,"palmer":1,"sc":1,"mavridis":1,"nicolucci":1,"johnson":1,"dw":1,"tonelli":1,"craig":1,"jc":1,"et":1,"al":1,"comparison":1,"clinical":1,"adverse":1,"events":1,"associated":1,"glucose":1,"lowering":1,"drugs":1,"jama":1,"phung":1,"oj":1,"sobieraj":1,"dm":1,"engel":1,"ss":1,"rajpathak":1,"sn":1,"early":1,"the":1,"treatment":1,"mellitus":1,"obes":1,"metab":1,"rosenstock":1,"chuck":1,"gonzalez":1,"ortiz":1,"me":1},"len":203},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":7,"chunkId":"dc-2024-p7-c6","text":". [15] Phung OJ, Sobieraj DM, Engel SS, Rajpathak SN. Early combination therapy for the treatment of type 2 diabetes mellitus: Systematic review and meta- analysis. Diabetes Obes Metab 2014;16:410 e 7. [16] Rosenstock J, Chuck L, Gonzalez-Ortiz M, Merton K, Craig J, Capuano G, Qiu R. Initial combination therapy with canagli fl ozin plus metformin versus each component as monotherapy for drug naive type 2 diabetes. Diabetes Care 2016;39:353 e 62. [17] Gao W, Dong J, Liu J, Li Y, Liu F, Yang L, et al. Ef fi cacy and safety of initial combination of DPP-IV inhibitors and metformin versus metformin mono- therapy in type 2 diabetes: A systematic review of randomized controlled trials. Diabetes Obes Metab 2014;16:179 e 85. [18] Milder TY, Stocker SL, Abdel Shaheed C, McGrath-Cadell L, Samocha-Bonet D, Green fi eld JR, et al. Combination therapy with an SGLT2 inhibitor as initial treatment for type 2 diabetes: A systematic review and meta-analysis. J Clin Med 2019;8(1):45. [19] Matthews DR, Paldnius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S; VERIFY study group. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy B.R. Shah et al. / Can J Diabetes 48 (2024) 415 e 424 421","tf":{"15":1,"16":3,"17":1,"18":1,"19":1,"39":1,"45":1,"48":1,"62":1,"85":1,"179":1,"353":1,"410":1,"415":1,"421":1,"424":1,"2014":2,"2016":1,"2019":1,"2024":1,"phung":1,"oj":1,"sobieraj":1,"dm":1,"engel":1,"ss":1,"rajpathak":1,"sn":1,"early":2,"combination":5,"therapy":5,"for":3,"the":1,"treatment":2,"of":5,"type":4,"diabetes":8,"mellitus":1,"systematic":3,"review":3,"and":5,"meta":2,"analysis":2,"obes":2,"metab":2,"rosenstock":1,"chuck":1,"gonzalez":1,"ortiz":1,"merton":1,"craig":1,"capuano":1,"qiu":1,"initial":3,"with":3,"canagli":1,"fl":1,"ozin":1,"plus":1,"metformin":5,"versus":3,"each":1,"component":1,"as":2,"monotherapy":2,"drug":1,"naive":1,"care":1,"gao":1,"dong":1,"liu":2,"li":1,"yang":1,"et":3,"al":3,"ef":1,"fi":2,"cacy":1,"safety":1,"dpp":1,"iv":1,"inhibitors":1,"mono":1,"in":1,"randomized":1,"controlled":1,"trials":1,"milder":1,"ty":1,"stocker":1,"sl":1,"abdel":1,"shaheed":1,"mcgrath":1,"cadell":1,"samocha":1,"bonet":1,"green":1,"eld":1,"jr":1,"an":2,"sglt2":1,"inhibitor":1,"clin":1,"med":1,"matthews":1,"dr":1,"pald":1,"nius":1,"pm":1,"proot":1,"chiang":1,"stumvoll":1,"del":1,"prato":1,"verify":1,"study":1,"group":1,"glycaemic":1,"durability":1,"vildagliptin":1,"sequential":1,"shah":1,"can":1},"len":184},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":8,"chunkId":"dc-2024-p8-c0","text":"in newly diagnosed type 2 diabetes (VERIFY): A 5-year, multicentre, rand- omised, double-blind trial. Lancet 2019;394(10208):1519 e 29. [20] Frias JP, Zimmer Z, Lam RLH, Amorin G, Ntabadde C, Iredale C, et al. Double- blind, randomized clinical trial assessing the ef fi cacy and safety of early initi- ation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study. Diabetes Obes Metab 2019; 21(5):1128 e 35. [21] Hadjadj S, Rosenstock J, Meinicke T, Woerle HJ, Broedl UC. Initial combina- tion of empagli fl ozin and metformin in patients with type 2 diabetes. Dia- betes Care 2016;39:1718 e 28. [22] Garber AJ, Larsen J, Schneider SH, Piper BA, Henry D; Glyburide/Metformin Initial Therapy Study Group. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab 2002;4:201 e 8. [23] Rosenstock J, Goldstein BJ, Vinik AI, O  Neill MC, Porter LE, Heise MA, Kravitz B, Dirani RG, Freed MI; RESULT Study Group. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients ( > 60 years): The Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study. Diabetes Obes Metab 2006;8:49 e 57. [24] Rosenstock J, Rood J, Cobitz A, Huang C, Garber A. Improvement in glycaemic control with rosiglitazone/me","tf":{"20":1,"21":2,"22":1,"23":1,"24":1,"28":1,"29":1,"35":1,"39":1,"49":1,"57":1,"60":1,"201":1,"394":1,"1128":1,"1519":1,"1718":1,"2002":1,"2006":1,"2016":1,"2019":2,"10208":1,"in":5,"newly":1,"diagnosed":1,"type":5,"diabetes":8,"verify":1,"year":1,"multicentre":1,"rand":1,"omised":1,"double":2,"blind":2,"trial":2,"lancet":1,"frias":1,"jp":1,"zimmer":1,"lam":1,"rlh":1,"amorin":1,"ntabadde":1,"iredale":1,"et":1,"al":1,"randomized":1,"clinical":1,"assessing":1,"the":4,"ef":1,"fi":1,"cacy":1,"and":2,"safety":1,"of":6,"early":3,"initi":1,"ation":1,"sitagliptin":1,"during":1,"metformin":4,"uptitration":1,"treatment":2,"patients":3,"with":3,"composit":1,"study":4,"obes":3,"metab":3,"hadjadj":1,"rosenstock":3,"meinicke":1,"woerle":1,"hj":1,"broedl":1,"uc":1,"initial":3,"combina":1,"tion":1,"empagli":1,"fl":1,"ozin":1,"dia":1,"betes":1,"care":1,"garber":2,"aj":1,"larsen":1,"schneider":1,"sh":1,"piper":1,"ba":1,"henry":1,"glyburide":2,"therapy":3,"group":2,"simultaneous":1,"is":1,"superior":1,"to":2,"component":1,"monotherapy":1,"as":1,"an":1,"pharmacological":1,"for":1,"goldstein":1,"bj":1,"vinik":1,"ai":1,"neill":1,"mc":1,"porter":1,"le":1,"heise":1,"ma":1,"kravitz":1,"dirani":1,"rg":1,"freed":1,"mi":1,"result":2,"effect":1,"addition":1,"rosiglitazone":3,"sulphonylurea":2,"older":1,"years":1,"vs":1,"titration":1,"rood":1,"cobitz":1,"huang":1,"improvement":1,"glycaemic":1,"control":1,"me":1},"len":198},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":8,"chunkId":"dc-2024-p8-c1","text":" 2 diabetes patients ( > 60 years): The Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study. Diabetes Obes Metab 2006;8:49 e 57. [24] Rosenstock J, Rood J, Cobitz A, Huang C, Garber A. Improvement in glycaemic control with rosiglitazone/metformin fi xed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control. Diabetes Obes Metab 2006;8:643 e 9. [25] Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A. Initial treatment with rosiglitazone/metformin fi xed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab 2006;8:650 e 60. [26] Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering ef fi cacy: A meta-regression analysis. Diabetes Care 2006;29:2137 e 9. [27] Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. The effect of oral antidiabetic agents on A1C levels: A systematic review and meta- analysis. Diabetes Care 2010;33:1859 e 64. [28] Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfo- nylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005 e 12. [29] Paul SK, Klein K, Th","tf":{"12":1,"24":1,"25":1,"26":1,"27":1,"28":1,"29":2,"33":1,"49":2,"57":1,"60":2,"64":1,"281":1,"643":1,"650":1,"1859":1,"1999":1,"2005":1,"2006":4,"2010":1,"2137":1,"diabetes":10,"patients":4,"years":1,"the":2,"rosiglitazone":4,"early":1,"vs":1,"sulphonylurea":1,"titration":1,"result":1,"study":2,"obes":3,"metab":3,"rosenstock":2,"rood":2,"cobitz":2,"huang":1,"garber":2,"improvement":1,"in":4,"glycaemic":2,"control":3,"with":9,"metformin":4,"fi":3,"xed":2,"dose":2,"combination":2,"therapy":2,"type":3,"very":1,"poor":1,"biswas":1,"chou":1,"initial":1,"treatment":1,"compared":1,"monotherapy":1,"either":1,"or":2,"uncontrolled":1,"bloomgarden":1,"zt":1,"dodis":1,"viscoli":1,"cm":1,"holmboe":1,"es":1,"inzucchi":1,"se":1,"lower":1,"baseline":1,"glycemia":1,"reduces":1,"apparent":1,"oral":2,"agent":1,"glucose":1,"lowering":1,"ef":1,"cacy":1,"meta":2,"regression":1,"analysis":2,"care":2,"sherifali":1,"nerenberg":1,"pullenayegum":1,"cheng":1,"je":1,"gerstein":1,"hc":1,"effect":1,"of":1,"antidiabetic":1,"agents":1,"on":1,"a1c":1,"levels":1,"systematic":1,"review":1,"and":1,"turner":1,"rc":1,"cull":1,"ca":1,"frighi":1,"holman":1,"rr":1,"glycemic":1,"diet":1,"sulfo":1,"nylurea":1,"insulin":1,"mellitus":1,"progressive":1,"requirement":1,"for":1,"multiple":1,"therapies":1,"ukpds":2,"uk":1,"prospective":1,"group":1,"jama":1,"paul":1,"sk":1,"klein":1,"th":1},"len":192},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":8,"chunkId":"dc-2024-p8-c2","text":"rol with diet, sulfo- nylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005 e 12. [29] Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensi fi cation increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol 2015;14:100. [30] Mearns ES, Sobieraj DM, White CM, Saulsberry WJ, Kohn CG, Doleh Y, Zaccaro E, Coleman CI. Comparative ef fi cacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: A network meta-analysis. PLoS One 2015;10:e0125879. [31] Mishriky BM, Cummings DM, Tanenberg RJ. The ef fi cacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis. Dia- betes Res Clin Pract 2015;109:378 e 88. [32] Foroutan N, Muratov S, Levine M. Safety and ef fi cacy of dipeptidyl peptidase- 4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis. Clin Invest Med 2016;39:E48 e 62. [33] Chubb B, Gupta P, Gupta J, Nuhoho S, Kallenbach K, Orme M. Once-daily oral semaglutide versus injectable GLP-1 RAs in people with type 2 diabetes inadequately controlled","tf":{"10":1,"12":1,"14":1,"29":1,"30":1,"31":1,"32":1,"33":1,"39":1,"49":1,"62":1,"88":1,"100":1,"109":1,"281":1,"378":1,"1999":1,"2005":1,"2015":3,"2016":1,"rol":1,"with":6,"diet":1,"sulfo":1,"nylurea":1,"metformin":4,"or":1,"insulin":1,"in":7,"patients":4,"type":6,"diabetes":7,"mellitus":2,"progressive":1,"requirement":1,"for":2,"multiple":1,"therapies":1,"ukpds":2,"uk":1,"prospective":1,"study":1,"group":1,"jama":1,"paul":1,"sk":1,"klein":1,"thorsted":1,"bl":1,"wolden":1,"ml":1,"khunti":1,"delay":1,"treatment":1,"intensi":1,"fi":4,"cation":1,"increases":1,"the":2,"risks":1,"of":4,"cardiovascular":1,"events":1,"cardiovasc":1,"diabetol":1,"mearns":1,"es":1,"sobieraj":1,"dm":2,"white":1,"cm":1,"saulsberry":1,"wj":1,"kohn":1,"cg":1,"doleh":1,"zaccaro":1,"coleman":1,"ci":1,"comparative":1,"ef":3,"cacy":3,"and":5,"safety":3,"antidiabetic":1,"drug":1,"regimens":1,"added":1,"to":3,"monotherapy":1,"network":1,"meta":3,"analysis":3,"plos":1,"one":1,"e0125879":1,"mishriky":1,"bm":1,"cummings":1,"tanenberg":1,"rj":1,"dpp4":1,"inhibitors":2,"compared":1,"sulfonylureas":1,"as":1,"add":1,"on":1,"therapy":2,"systematic":2,"review":2,"dia":1,"betes":1,"res":1,"clin":2,"pract":1,"foroutan":1,"muratov":1,"levine":1,"dipeptidyl":1,"peptidase":1,"vs":1,"sulfonylurea":1,"based":1,"combination":1,"invest":1,"med":1,"e48":1,"chubb":1,"gupta":2,"nuhoho":1,"kallenbach":1,"orme":1,"once":1,"daily":1,"oral":1,"semaglutide":1,"versus":1,"injectable":1,"glp":1,"ras":1,"people":1,"inadequately":1,"controlled":1},"len":207},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":8,"chunkId":"dc-2024-p8-c3","text":"tus: Systematic review and meta-analysis. Clin Invest Med 2016;39:E48 e 62. [33] Chubb B, Gupta P, Gupta J, Nuhoho S, Kallenbach K, Orme M. Once-daily oral semaglutide versus injectable GLP-1 RAs in people with type 2 diabetes inadequately controlled on basal insulin: Systematic review and network meta-analysis diabetes therapy. Res Treat Educ Diabetes Relat Disord 2021; 12(5):1325 e 39. [34] Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012;2: e001007. [35] Hartley P, Shentu Y, Betz-Schiff P, Golm GT, Sisk CM, Engel SS, Shankar RR. Ef fi cacy and tolerability of sitagliptin compared with glimepiride in elderly patients with type 2 diabetes mellitus and inadequate glycemic control: A randomized, double-blind, non-inferiority trial. Drugs Aging 2015;32: 469 e 76. [36] Zhong X, Lai D, Ye Y, Yang X, Yu B, Huang Y. Ef fi cacy and safety of empa- gli fl ozin as add-on to metformin for type 2 diabetes: A systematic review and meta-analysis. Eur J Clin Pharmacol 2016;72:655 e 63. [37] Zhou JB, Bai L, Wang Y, Yang JK. The bene fi ts and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: Accumulated evidence from randomised controlled trial. Int J Clin Pract 2016;70:132 e 41. [38] Min SH, Yoon JH, Hahn S, Cho YM. Comparison between SGLT2 inhibitors and DPP4 inhibitors a","tf":{"12":1,"32":1,"33":1,"34":1,"35":1,"36":1,"37":1,"38":1,"39":2,"41":1,"62":1,"63":1,"70":1,"72":1,"76":1,"132":1,"469":1,"655":1,"1325":1,"2012":1,"2015":1,"2016":3,"2021":1,"tus":1,"systematic":4,"review":4,"and":8,"meta":3,"analysis":3,"clin":3,"invest":1,"med":1,"e48":1,"chubb":1,"gupta":2,"nuhoho":1,"kallenbach":1,"orme":1,"once":1,"daily":1,"oral":1,"semaglutide":1,"versus":1,"injectable":1,"glp":1,"ras":1,"in":4,"people":1,"with":4,"type":5,"diabetes":7,"inadequately":1,"controlled":2,"on":2,"basal":1,"insulin":1,"network":1,"therapy":2,"res":1,"treat":1,"educ":1,"relat":1,"disord":1,"clar":1,"gill":1,"ja":1,"court":1,"waugh":1,"of":4,"sglt2":2,"receptor":1,"inhibitors":4,"dual":1,"or":1,"triple":1,"bmj":1,"open":1,"e001007":1,"hartley":1,"shentu":1,"betz":1,"schiff":1,"golm":1,"gt":1,"sisk":1,"cm":1,"engel":1,"ss":1,"shankar":1,"rr":1,"ef":2,"fi":3,"cacy":2,"tolerability":1,"sitagliptin":1,"compared":1,"glimepiride":1,"elderly":1,"patients":2,"mellitus":1,"inadequate":1,"glycemic":1,"control":1,"randomized":1,"double":1,"blind":1,"non":1,"inferiority":1,"trial":2,"drugs":1,"aging":1,"zhong":1,"lai":1,"ye":1,"yang":2,"yu":1,"huang":1,"safety":1,"empa":1,"gli":1,"fl":1,"ozin":1,"as":1,"add":1,"to":1,"metformin":1,"for":2,"eur":1,"pharmacol":1,"zhou":1,"jb":1,"bai":1,"wang":1,"jk":1,"the":1,"bene":1,"ts":1,"risks":1,"dpp4":2,"vs":1,"sulfonylureas":1,"accumulated":1,"evidence":1,"from":1,"randomised":1,"int":1,"pract":1,"min":1,"sh":1,"yoon":1,"jh":1,"hahn":1,"cho":1,"ym":1,"comparison":1,"between":1},"len":214},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":8,"chunkId":"dc-2024-p8-c4","text":"-inhibitors vs. sulfonylureas for patients with type 2 diabetes: Accumulated evidence from randomised controlled trial. Int J Clin Pract 2016;70:132 e 41. [38] Min SH, Yoon JH, Hahn S, Cho YM. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: A systematic review with indirect comparison meta-analysis. Diabetes Metab Res Rev 2016;33. [39] Liu SC, Tu YK, Chien MN, Chien KL. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: A network meta-analysis. Diabetes Obes Metab 2012;14:810 e 20. [40] Mearns ES, Saulsberry WJ, White CM, Kohn CG, Lemieux S, Sihabout A, et al. Ef fi cacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in type 2 diabetes: A network meta-analysis. Diabet Med 2015;32:1530 e 40. [41] Lee CMY, Woodward M, Colagiuri S. Triple therapy combinations for the treatment of type 2 diabetes  a network meta-analysis. Diabetes Res Clin Pract 2016;116:149 e 58. [42] Lozano-Ortega G, Goring S, Bennett HA, Bergenheim K, Sternhufvud C, Mukherjee J. Network meta-analysis of treatments for type 2 diabetes mel- litus following failure with metformin plus sulfonylurea. Curr Med Res Opin 2016;32:807 e 16. [43] Feig D, Berger H, Donovan L, Godbout A, Kader T, Keely E, Sanghera R. Dia- betes Canada 2018 Cli","tf":{"14":1,"16":1,"20":1,"32":2,"33":1,"38":1,"39":1,"40":2,"41":2,"42":1,"43":1,"58":1,"70":1,"116":1,"132":1,"149":1,"807":1,"810":1,"1530":1,"2012":1,"2015":1,"2016":4,"2018":1,"inhibitors":3,"vs":1,"sulfonylureas":1,"for":3,"patients":2,"with":4,"type":6,"diabetes":9,"accumulated":1,"evidence":1,"from":1,"randomised":1,"controlled":1,"trial":1,"int":1,"clin":2,"pract":2,"min":1,"sh":1,"yoon":1,"jh":1,"hahn":1,"cho":1,"ym":1,"comparison":2,"between":1,"sglt2":1,"and":4,"dpp4":1,"added":3,"to":3,"insulin":1,"therapy":3,"in":3,"systematic":1,"review":1,"indirect":1,"meta":5,"analysis":5,"metab":2,"res":3,"rev":1,"liu":1,"sc":1,"tu":1,"yk":1,"chien":2,"mn":1,"kl":1,"effect":1,"of":4,"antidiabetic":1,"agents":1,"metformin":3,"on":1,"glycaemic":1,"control":1,"hypoglycaemia":1,"weight":1,"change":1,"network":4,"obes":1,"mearns":1,"es":1,"saulsberry":1,"wj":1,"white":1,"cm":1,"kohn":1,"cg":1,"lemieux":1,"sihabout":1,"et":1,"al":1,"ef":1,"fi":1,"cacy":1,"safety":1,"antihyperglycaemic":1,"drug":1,"regimens":1,"sulphonylurea":1,"diabet":1,"med":2,"lee":1,"cmy":1,"woodward":1,"colagiuri":1,"triple":1,"combinations":1,"the":1,"treatment":1,"lozano":1,"ortega":1,"goring":1,"bennett":1,"ha":1,"bergenheim":1,"sternhufvud":1,"mukherjee":1,"treatments":1,"mel":1,"litus":1,"following":1,"failure":1,"plus":1,"sulfonylurea":1,"curr":1,"opin":1,"feig":1,"berger":1,"donovan":1,"godbout":1,"kader":1,"keely":1,"sanghera":1,"dia":1,"betes":1,"canada":1,"cli":1},"len":205},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":8,"chunkId":"dc-2024-p8-c5","text":"k meta-analysis of treatments for type 2 diabetes mel- litus following failure with metformin plus sulfonylurea. Curr Med Res Opin 2016;32:807 e 16. [43] Feig D, Berger H, Donovan L, Godbout A, Kader T, Keely E, Sanghera R. Dia- betes Canada 2018 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada: Diabetes and pregnancy. Can J Diabetes 2018;42(Suppl. 1):S255 e 82. [44] Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probst fi eld J, Riesmeyer JS, Riddle MC, Rydn L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double- blind, randomised placebo-controlled trial. Lancet 2019;394:121 e 30. [45] Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 dia- betes. N Engl J Med 2016;375:311 e 22. [46] Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jdar E, Leit","tf":{"16":1,"22":1,"30":1,"32":1,"42":1,"43":1,"44":1,"45":1,"46":1,"82":1,"121":1,"311":1,"375":1,"394":1,"807":1,"2016":2,"2018":2,"2019":1,"meta":1,"analysis":1,"of":2,"treatments":1,"for":2,"type":3,"diabetes":5,"mel":1,"litus":1,"following":1,"failure":1,"with":1,"metformin":1,"plus":1,"sulfonylurea":1,"curr":1,"med":2,"res":1,"opin":1,"feig":1,"berger":1,"donovan":1,"godbout":1,"kader":1,"keely":1,"sanghera":1,"dia":2,"betes":2,"canada":2,"clinical":1,"practice":1,"guidelines":1,"the":1,"prevention":1,"and":4,"management":1,"in":3,"pregnancy":1,"can":1,"suppl":1,"s255":1,"gerstein":1,"hc":1,"colhoun":1,"hm":1,"dagenais":1,"gr":1,"diaz":1,"lakshmanan":1,"pais":1,"probst":1,"fi":1,"eld":1,"riesmeyer":1,"js":1,"riddle":1,"mc":1,"ryd":1,"xavier":1,"atisso":1,"cm":1,"dyal":1,"hall":1,"rao":1,"melacini":1,"wong":1,"avezum":1,"basile":1,"chung":1,"conget":1,"cushman":1,"wc":1,"franek":1,"hancu":1,"hanefeld":1,"holt":1,"jansky":1,"keltai":1,"lanas":1,"leiter":1,"la":1,"lopez":1,"jaramillo":1,"cardona":1,"munoz":1,"eg":1,"pirags":1,"pogosova":1,"raubenheimer":1,"pj":1,"shaw":1,"je":1,"sheu":1,"wh":1,"temelkova":1,"kurktschiev":1,"rewind":2,"investigators":2,"dulaglutide":1,"cardiovascular":2,"outcomes":2,"double":1,"blind":1,"randomised":1,"placebo":1,"controlled":1,"trial":2,"lancet":1,"marso":2,"sp":2,"daniels":1,"gh":1,"brown":1,"frandsen":1,"kristensen":1,"mann":1,"jf":1,"nauck":1,"ma":1,"nissen":1,"se":1,"pocock":1,"poulter":1,"nr":1,"ravn":1,"ls":1,"steinberg":1,"wm":1,"stockner":1,"zinman":1,"bergenstal":1,"rm":1,"buse":1,"jb":1,"leader":2,"steering":1,"committee":1,"liraglutide":1,"engl":1,"bain":1,"sc":1,"consoli":1,"eliaschewitz":1,"fg":1,"dar":1,"leit":1},"len":191},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":8,"chunkId":"dc-2024-p8-c6","text":", Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 dia- betes. N Engl J Med 2016;375:311 e 22. [46] Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jdar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbll T; SUSTAIN-6 Investigators. Semaglutide and cardiovascular out- comes in patients with type 2 diabetes. N Engl J Med 2016;375:1834 e 44. [47] Neal B, Perkovic V, Neal B, Perkovic V, Matthews DR. Canagli fl ozin and car- diovascular and renal events in type 2 diabetes. N Engl J Med 2017;377: 644 e 57. [48] Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagli fl ozin, cardiovascular outcomes, and mor- tality in type 2 diabetes. N Engl J Med 2015;373:2117 e 28. [49] Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE e TIMI 58 Investigators. Dapagli fl ozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380: 347 e 57. [50] Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B","tf":{"22":1,"28":1,"44":1,"46":1,"47":1,"48":1,"49":1,"50":1,"57":2,"58":1,"311":1,"347":1,"373":1,"375":2,"377":1,"380":1,"644":1,"1834":1,"2015":1,"2016":2,"2017":1,"2019":1,"2117":1,"zinman":2,"bergenstal":1,"rm":1,"buse":1,"jb":1,"leader":2,"steering":1,"committee":1,"trial":1,"investigators":4,"liraglutide":1,"and":6,"cardiovascular":4,"outcomes":3,"in":5,"type":5,"dia":1,"betes":1,"engl":5,"med":5,"marso":1,"sp":1,"bain":1,"sc":1,"consoli":1,"eliaschewitz":1,"fg":1,"dar":1,"leiter":2,"la":2,"lingvay":1,"rosenstock":1,"seufert":1,"warren":1,"ml":1,"woo":1,"hansen":1,"holst":1,"ag":1,"pettersson":1,"vilsb":1,"ll":1,"sustain":1,"semaglutide":1,"out":1,"comes":1,"patients":1,"with":1,"diabetes":4,"neal":2,"perkovic":2,"matthews":1,"dr":1,"canagli":1,"fl":3,"ozin":3,"car":1,"diovascular":1,"renal":1,"events":1,"wanner":1,"lachin":1,"jm":1,"fitchett":1,"bluhmki":1,"hantel":1,"mattheus":1,"devins":1,"johansen":1,"oe":1,"woerle":1,"hj":1,"broedl":1,"uc":1,"inzucchi":1,"se":1,"empa":1,"reg":1,"outcome":1,"empagli":1,"mor":1,"tality":1,"wiviott":1,"sd":1,"raz":1,"bonaca":1,"mp":1,"mosenzon":1,"kato":1,"et":1,"cahn":1,"silverman":1,"mg":1,"zelniker":1,"ta":1,"kuder":1,"jf":1,"murphy":1,"sa":1,"bhatt":1,"dl":1,"mcguire":1,"dk":1,"wilding":1,"jph":1,"ruff":1,"ct":1,"gause":1,"nilsson":1,"iam":1,"fredriksson":1,"johansson":1,"pa":1,"langkilde":1,"am":1,"sabatine":1,"ms":1,"declare":1,"timi":1,"dapagli":1,"cannon":1,"cp":1,"pratley":1,"dagogo":1,"jack":1,"mancuso":1,"huyck":1,"masiukiewicz":1,"charbonnel":1},"len":197},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":8,"chunkId":"dc-2024-p8-c7","text":"A, Langkilde AM, Sabatine MS; DECLARE e TIMI 58 Investigators. Dapagli fl ozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380: 347 e 57. [50] Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZI, McGuire DK; VERTIS CV Investigators. Cardiovascular outcomes with ertugli fl ozin in type 2 diabetes. N Engl J Med 2020;383(15):1425 e 35. [51] Sattar N, Lee MM, Kristensen SL, Branch KR, Del Prato S, Khurmi NS, Gerstein HC. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials. The lancet Diabetes Endocrinol 2021;9(10):653 e 62. [52] Kristensen SL, Rrth R, Jhund PS, Docherty KF, Sattar N, Preiss D, McMurray JJ. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endo- crinol 2019;7(10):776 e 85. [53] Giugliano D, Scappaticcio L, Longo M, Caruso P, Maiorino MI, Bellastella G, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: An updated meta-analysis of eight CVOTs. Cardiovasc Diabetol 2021;20:1 e 11. [54] Mannucci E, Dicembrini I, Nreu B, Monami M. Glucagon-like peptide-1 r","tf":{"10":2,"11":1,"15":1,"20":1,"35":1,"50":1,"51":1,"52":1,"53":1,"54":1,"57":1,"58":1,"62":1,"85":1,"347":1,"380":1,"383":1,"653":1,"776":1,"1425":1,"2019":2,"2020":1,"2021":2,"langkilde":1,"am":1,"sabatine":1,"ms":1,"declare":1,"timi":1,"investigators":2,"dapagli":1,"fl":2,"ozin":2,"and":6,"cardiovascular":5,"outcomes":5,"in":5,"type":5,"diabetes":7,"engl":2,"med":2,"cannon":1,"cp":1,"pratley":1,"dagogo":1,"jack":1,"mancuso":1,"huyck":1,"masiukiewicz":1,"charbonnel":1,"frederich":1,"gallo":1,"cosentino":1,"shih":1,"wj":1,"gantz":1,"terra":1,"sg":1,"cherney":1,"dzi":1,"mcguire":1,"dk":1,"vertis":1,"cv":1,"with":5,"ertugli":1,"sattar":2,"lee":1,"mm":1,"kristensen":2,"sl":2,"branch":1,"kr":1,"del":1,"prato":1,"khurmi":1,"ns":1,"gerstein":1,"hc":1,"mortality":2,"kidney":2,"glp":3,"receptor":3,"agonists":3,"patients":2,"systematic":2,"review":2,"meta":3,"analysis":3,"of":3,"randomised":1,"trials":2,"the":1,"lancet":2,"endocrinol":1,"rth":1,"jhund":1,"ps":1,"docherty":1,"kf":1,"preiss":1,"mcmurray":1,"jj":1,"outcome":1,"endo":1,"crinol":1,"giugliano":1,"scappaticcio":1,"longo":1,"caruso":1,"maiorino":1,"mi":1,"bellastella":1,"et":1,"al":1,"cardiorenal":1,"an":1,"updated":1,"eight":1,"cvots":1,"cardiovasc":1,"diabetol":1,"mannucci":1,"dicembrini":1,"nreu":1,"monami":1,"glucagon":1,"like":1,"peptide":1},"len":190},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":8,"chunkId":"dc-2024-p8-c8","text":"ino MI, Bellastella G, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: An updated meta-analysis of eight CVOTs. Cardiovasc Diabetol 2021;20:1 e 11. [54] Mannucci E, Dicembrini I, Nreu B, Monami M. Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and sub- group analysis of randomized controlled trials. Diabetes Obes Metab 2020; 22(2):203 e 11. [55] D  Andrea E, Kesselheim AS, Franklin JM, Jung EH, Hey SP, Patorno E. Het- erogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: A systematic review and meta- analysis. Cardiovasc Diabetol 2020;19(1):154. [56] McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZ, Dagogo-Jack S, et al. Association of SGLT2 inhibitors with cardiovascular and kidney out- comes in patients with type 2 diabetes: A meta-analysis. JAMA Cardiol 2021; 6(2):148 e 58. [57] Rahman H, Khan SU, Lone AN, Ghosh P, Kunduru M, Sharma S, et al. Sodium- glucose cotransporter-2 inhibitors and primary prevention of atherosclerotic cardiovascular disease: A meta-analysis of randomized trials and systematic review. J Am Heart Assoc 2023;12(16):e030578. [58] Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurra","tf":{"11":2,"12":1,"16":1,"19":1,"20":1,"22":1,"54":1,"55":1,"56":1,"57":1,"58":2,"148":1,"154":1,"203":1,"2020":2,"2021":2,"2023":1,"ino":1,"mi":1,"bellastella":1,"et":3,"al":3,"glp":1,"receptor":2,"agonists":2,"and":8,"cardiorenal":1,"outcomes":2,"in":4,"type":3,"diabetes":4,"an":3,"updated":2,"meta":5,"analysis":6,"of":7,"eight":1,"cvots":1,"cardiovasc":2,"diabetol":2,"mannucci":1,"dicembrini":1,"nreu":1,"monami":1,"glucagon":1,"like":1,"peptide":1,"cardiovascular":5,"patients":2,"with":3,"without":1,"prior":1,"events":2,"sub":1,"group":1,"randomized":2,"controlled":1,"trials":2,"obes":1,"metab":1,"andrea":1,"kesselheim":1,"as":1,"franklin":1,"jm":1,"jung":1,"eh":1,"hey":1,"sp":1,"patorno":1,"het":1,"erogeneity":1,"antidiabetic":1,"treatment":1,"effect":1,"on":1,"the":1,"risk":1,"major":1,"adverse":1,"systematic":2,"review":2,"mcguire":1,"dk":1,"shih":1,"wj":1,"cosentino":1,"charbonnel":1,"cherney":1,"dz":1,"dagogo":1,"jack":1,"association":1,"sglt2":1,"inhibitors":2,"kidney":1,"out":1,"comes":1,"jama":1,"cardiol":1,"rahman":1,"khan":1,"su":1,"lone":1,"ghosh":1,"kunduru":1,"sharma":1,"sodium":1,"glucose":1,"cotransporter":1,"primary":1,"prevention":1,"atherosclerotic":1,"disease":1,"am":1,"heart":1,"assoc":1,"e030578":1,"pfeffer":1,"ma":1,"claggett":1,"diaz":1,"dickstein":1,"gerstein":1,"hc":1,"ber":1,"lv":1,"lawson":1,"fc":1,"ping":1,"wei":1,"lewis":1,"ef":1,"maggioni":1,"ap":1,"mcmurra":1},"len":195},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":8,"chunkId":"dc-2024-p8-c9","text":"ardiovascular disease: A meta-analysis of randomized trials and systematic review. J Am Heart Assoc 2023;12(16):e030578. [58] Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probst fi eld JL, Riddle MC, Solomon SD, Tardif JC; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247 e 57. [59] Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, hman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377:1228 e 39. [60] Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsbll T, Warren ML, Bain SC; PIONEER 6 Investigators. Oral B.R. Shah et al. / Can J Diabetes 48 (2024) 415 e 424 422","tf":{"12":1,"16":1,"39":1,"48":1,"57":1,"58":1,"59":1,"60":1,"373":1,"377":1,"415":1,"422":1,"424":1,"1228":1,"2015":1,"2017":1,"2023":1,"2024":1,"2247":1,"ardiovascular":1,"disease":1,"meta":1,"analysis":1,"of":2,"randomized":1,"trials":1,"and":2,"systematic":1,"review":1,"am":1,"heart":1,"assoc":1,"e030578":1,"pfeffer":1,"ma":2,"claggett":1,"diaz":1,"dickstein":1,"gerstein":1,"hc":1,"ber":1,"lv":1,"lawson":1,"fc":1,"ping":1,"wei":1,"lewis":1,"ef":1,"maggioni":2,"ap":2,"mcmurray":1,"jj":1,"probst":1,"fi":1,"eld":1,"jl":1,"riddle":1,"mc":1,"solomon":1,"sd":2,"tardif":1,"jc":2,"elixa":1,"investigators":2,"lixisenatide":1,"in":2,"patients":1,"with":1,"type":2,"diabetes":3,"acute":1,"coronary":1,"syndrome":1,"engl":2,"med":2,"holman":1,"rr":1,"bethel":1,"mentz":1,"rj":1,"thompson":1,"vp":1,"lokhnygina":1,"buse":1,"jb":1,"chan":1,"choi":1,"gustavson":1,"sm":1,"iqbal":1,"marso":1,"sp":1,"hman":1,"pagidipati":1,"nj":1,"poulter":1,"ramachandran":1,"zinman":1,"hernandez":1,"af":1,"exscel":1,"study":1,"group":1,"effects":1,"once":1,"weekly":1,"exenatide":1,"on":1,"cardiovascular":1,"outcomes":1,"husain":1,"birkenfeld":1,"al":2,"donsmark":1,"dungan":1,"eliaschewitz":1,"fg":1,"franco":1,"dr":1,"jeppesen":1,"ok":1,"lingvay":1,"mosenzon":1,"pedersen":1,"tack":1,"cj":1,"thomsen":1,"vilsb":1,"ll":1,"warren":1,"ml":1,"bain":1,"sc":1,"pioneer":1,"oral":1,"shah":1,"et":1,"can":1},"len":153},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":9,"chunkId":"dc-2024-p9-c0","text":"semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019;381:841 e 51. [61] McMurray JJ, Solomon SD, Inzucchi SE, Kber L, Kosiborod MN, Martinez FA, et al. Dapagli fl ozin in patients with heart failure and reduced ejection frac- tion. N Engl J Med 2021;381(21):1995 e 2008. [62] Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Zannad F. Cardiovascular and renal outcomes with empagli fl ozin in heart failure. N Engl J Med 2020;383(15):1413 e 24. [63] Solomon SD, McMurray JJ, Claggett B, de Boer RA, DeMets D, Hernandez AF, Langkilde AM. Dapagli fl ozin in heart failure with mildly reduced or pre- served ejection fraction. N Engl J Med 2022;387(12):1089 e 98. [64] Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bhm M, Packer M. Empagli fl ozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385(16):1451 e 61. [65] Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, Solomon SD. SGLT2 inhibitors in patients with heart failure: A comprehensive meta-analysis of fi ve randomised controlled trials. Lancet 2022;400(10354):757 e 67. [66] Cardoso R, Graffunder FP, Ternes CM, Fernandes A, Rocha AV, Fernandes G, Bhatt DL. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis. eClinicalM","tf":{"12":1,"15":1,"16":1,"21":1,"24":1,"51":1,"61":2,"62":1,"63":1,"64":1,"65":1,"66":1,"67":1,"98":1,"381":2,"383":1,"385":1,"387":1,"400":1,"757":1,"841":1,"1089":1,"1413":1,"1451":1,"1995":1,"2008":1,"2019":1,"2020":1,"2021":2,"2022":2,"10354":1,"semaglutide":1,"and":5,"cardiovascular":3,"outcomes":2,"in":7,"patients":4,"with":7,"type":1,"diabetes":1,"engl":5,"med":5,"mcmurray":2,"jj":2,"solomon":3,"sd":5,"inzucchi":1,"se":1,"ber":1,"kosiborod":1,"mn":1,"martinez":1,"fa":1,"et":1,"al":1,"dapagli":2,"fl":4,"ozin":4,"heart":7,"failure":7,"reduced":2,"ejection":3,"frac":1,"tion":1,"packer":2,"anker":2,"butler":2,"filippatos":2,"pocock":1,"sj":1,"carson":1,"zannad":1,"renal":1,"empagli":2,"claggett":2,"de":2,"boer":2,"ra":2,"demets":1,"hernandez":2,"af":2,"langkilde":1,"am":1,"mildly":1,"or":1,"pre":1,"served":1,"fraction":2,"ferreira":1,"jp":1,"bocchi":1,"hm":1,"preserved":1,"vaduganathan":1,"docherty":1,"kf":1,"bl":1,"jhund":1,"ps":1,"sglt2":2,"inhibitors":2,"comprehensive":1,"meta":2,"analysis":2,"of":1,"fi":1,"ve":1,"randomised":1,"controlled":1,"trials":1,"lancet":1,"cardoso":1,"graffunder":1,"fp":1,"ternes":1,"cm":1,"fernandes":2,"rocha":1,"av":1,"bhatt":1,"dl":1,"decrease":1,"death":1,"hospitalizations":1,"systematic":1,"review":1,"eclinicalm":1},"len":208},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":9,"chunkId":"dc-2024-p9-c1","text":"66] Cardoso R, Graffunder FP, Ternes CM, Fernandes A, Rocha AV, Fernandes G, Bhatt DL. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis. eClinicalMedicine 2021;36. [67] Giugliano D, Longo M, Scappaticcio L, Bellastella G, Maiorino MI, Esposito K. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: A meta-analysis of 11 CVOTs. Cardiovasc Diabetol 2021;20: 1 e 11. [68] Perkovic V, Jardine MJ, Neal B, et al; Credence Trial Investigators. Canagli- fl ozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380(24):2295 e 306. [69] Hiddo J, Heerspink L, Stefnsson Bergur V, Correa-Rotter Ricardo, Chertow Glenn M, et al; the DAPA-CKD Trial Committees and Investigators. Dapagli fl ozin in patients with chronic kidney disease. N Engl J Med 2020; 383:1436 e 46. [70] The EMPA-KIDNEY Collaborative Group. Empagli fl ozin in patients with chronic kidney disease. N Engl J Med 2023;388:117 e 27. [71] Staplin N, Roddick AJ, Emberson J, Reith C, Riding A, Wonnacott A, et al. Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: A meta-analysis of large placebo-controlled randomized trials. eClinicalMedicine 2021;41:101163. [72] Yamada T, Wakabayashi M, Bhalla A, Chopra N, Miyashita H, Mikami T, et al. Car","tf":{"11":2,"20":1,"24":1,"27":1,"36":1,"41":1,"46":1,"66":1,"67":1,"68":1,"69":1,"70":1,"71":1,"72":1,"117":1,"306":1,"380":1,"383":1,"388":1,"1436":1,"2019":1,"2020":1,"2021":3,"2023":1,"2295":1,"101163":1,"cardoso":1,"graffunder":1,"fp":1,"ternes":1,"cm":1,"fernandes":2,"rocha":1,"av":1,"bhatt":1,"dl":1,"sglt2":1,"inhibitors":2,"decrease":1,"cardiovascular":1,"death":1,"and":6,"heart":2,"failure":2,"hospitalizations":1,"in":6,"patients":4,"with":4,"systematic":1,"review":1,"meta":3,"analysis":3,"eclinicalmedicine":2,"giugliano":1,"longo":1,"scappaticcio":1,"bellastella":1,"maiorino":1,"mi":1,"esposito":1,"sglt":1,"cardiorenal":1,"outcomes":2,"or":1,"without":1,"type":2,"diabetes":2,"of":3,"cvots":1,"cardiovasc":1,"diabetol":1,"perkovic":1,"jardine":1,"mj":1,"neal":1,"et":4,"al":4,"credence":1,"trial":2,"investigators":2,"canagli":1,"fl":3,"ozin":3,"renal":1,"nephropathy":1,"engl":3,"med":3,"hiddo":1,"heerspink":1,"stef":1,"nsson":1,"bergur":1,"correa":1,"rotter":1,"ricardo":1,"chertow":1,"glenn":1,"the":2,"dapa":1,"ckd":1,"committees":1,"dapagli":1,"chronic":2,"kidney":3,"disease":2,"empa":1,"collaborative":1,"group":1,"empagli":1,"staplin":1,"roddick":1,"aj":1,"emberson":1,"reith":1,"riding":1,"wonnacott":1,"net":1,"effects":1,"sodium":1,"glucose":1,"co":1,"transporter":1,"inhibition":1,"different":1,"patient":1,"groups":1,"large":1,"placebo":1,"controlled":1,"randomized":1,"trials":1,"yamada":1,"wakabayashi":1,"bhalla":1,"chopra":1,"miyashita":1,"mikami":1,"car":1},"len":192},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":9,"chunkId":"dc-2024-p9-c2","text":"dium-glucose co-transporter-2 inhibition in different patient groups: A meta-analysis of large placebo-controlled randomized trials. eClinicalMedicine 2021;41:101163. [72] Yamada T, Wakabayashi M, Bhalla A, Chopra N, Miyashita H, Mikami T, et al. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and network meta-analysis. Cardiovasc Diabetol 2021;20(1):14. [73] Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024;391:109 e 21. [74] Johnson JL, Wolf SL, Kabadi UM. Ef fi cacy of insulin and sulfonylurea com- bination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. Arch Intern Med 1996;156:259 e 64. [75] United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998;128:165 e 75. [76] Hemmingsen B, Christensen LL, Wetterslev J, Vaag A, Gluud C, Lund SS, Almdal T.","tf":{"14":1,"20":1,"21":1,"24":1,"41":1,"64":1,"72":1,"73":1,"74":1,"75":2,"76":1,"109":1,"128":1,"156":1,"165":1,"259":1,"391":1,"1996":1,"1998":1,"2021":2,"2024":1,"101163":1,"dium":1,"glucose":1,"co":1,"transporter":1,"inhibition":1,"in":5,"different":1,"patient":1,"groups":1,"meta":3,"analysis":3,"of":4,"large":1,"placebo":2,"controlled":4,"randomized":3,"trials":2,"eclinicalmedicine":1,"yamada":1,"wakabayashi":1,"bhalla":1,"chopra":1,"miyashita":1,"mikami":1,"et":1,"al":1,"cardiovascular":1,"and":6,"renal":1,"outcomes":1,"with":5,"sglt":1,"inhibitors":1,"versus":1,"glp":1,"receptor":1,"agonists":1,"patients":3,"type":4,"diabetes":6,"mellitus":1,"chronic":2,"kidney":2,"disease":2,"systematic":1,"review":1,"network":1,"cardiovasc":1,"diabetol":1,"perkovic":1,"tuttle":1,"kr":1,"rossing":1,"mahaffey":1,"kw":1,"mann":1,"jfe":1,"bakris":1,"baeres":1,"fmm":1,"idorn":1,"bosch":1,"traberg":1,"lausvig":1,"nl":1,"pratley":1,"flow":1,"trial":2,"committees":1,"investigators":1,"effects":1,"semaglutide":1,"on":1,"engl":1,"med":3,"johnson":1,"jl":1,"wolf":1,"sl":1,"kabadi":1,"um":1,"ef":1,"fi":1,"cacy":1,"insulin":2,"sulfonylurea":2,"com":1,"bination":1,"therapy":3,"ii":1,"the":1,"arch":1,"intern":2,"united":2,"kingdom":2,"prospective":2,"study":2,"group":1,"year":1,"comparing":1,"metformin":1,"newly":1,"diagnosed":1,"that":1,"could":1,"not":1,"be":1,"diet":1,"ann":1,"hemmingsen":1,"christensen":1,"ll":1,"wetterslev":1,"vaag":1,"gluud":1,"lund":1,"ss":1,"almdal":1},"len":194},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":9,"chunkId":"dc-2024-p9-c3","text":"ea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998;128:165 e 75. [76] Hemmingsen B, Christensen LL, Wetterslev J, Vaag A, Gluud C, Lund SS, Almdal T. Comparison of metformin and insulin versus insulin alone for type 2 diabetes: Systematic review of randomised clinical trials with meta- analyses and trial sequential analyses. BMJ 2012;344:e1771. [77] Yki-Jrvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992;327:1426 e 33. [78] Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T, Endahl L, Mathieu C; NN1250-3579 (BEGIN Once Long) Trial Investigators. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012;35:2464 e 71. [79] Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631 e 6. [80] Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group. Ef fi cacy","tf":{"24":1,"28":1,"33":1,"35":1,"71":1,"75":1,"76":1,"77":1,"78":1,"79":1,"80":1,"128":1,"165":1,"327":1,"344":1,"631":1,"901":1,"1426":1,"1992":1,"1998":1,"2001":1,"2012":2,"2464":1,"3579":1,"ea":1,"insulin":11,"and":4,"metformin":2,"therapy":3,"in":4,"patients":3,"with":5,"newly":1,"diagnosed":1,"type":4,"diabetes":7,"that":1,"could":1,"not":1,"be":1,"controlled":1,"diet":1,"ann":1,"intern":1,"med":2,"hemmingsen":1,"christensen":1,"ll":1,"wetterslev":1,"vaag":1,"gluud":1,"lund":1,"ss":2,"almdal":1,"comparison":3,"of":4,"versus":2,"alone":1,"for":1,"systematic":1,"review":1,"randomised":1,"clinical":1,"trials":1,"meta":1,"analyses":2,"trial":3,"sequential":1,"bmj":1,"e1771":1,"yki":1,"rvinen":1,"kauppila":1,"kujansuu":1,"lahti":1,"marjanen":1,"niskanen":1,"et":1,"al":1,"regimens":1,"non":1,"dependent":1,"mellitus":1,"engl":1,"zinman":2,"philis":1,"tsimikas":1,"cariou":1,"handelsman":1,"rodbard":1,"hw":1,"johansen":1,"endahl":1,"mathieu":1,"nn1250":1,"begin":2,"once":2,"long":2,"investigators":1,"degludec":1,"glargine":2,"naive":1,"year":1,"randomized":1,"treat":1,"to":1,"target":1,"care":2,"rosenstock":1,"schwartz":1,"sl":1,"clark":1,"cm":1,"jr":1,"park":1,"gd":1,"donley":1,"dw":1,"edwards":1,"mb":1,"basal":1,"week":1,"hoe":1,"nph":1,"marso":1,"sp":1,"mcguire":1,"dk":1,"poulter":1,"nr":1,"emerson":1,"pieber":1,"tr":1,"pratley":1,"re":1,"haahr":1,"pm":1,"lange":1,"brown":1,"frandsen":1,"moses":1,"skibsted":1,"kvist":1,"buse":1,"jb":1,"devote":1,"study":1,"group":1,"ef":1,"fi":1,"cacy":1},"len":203},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":9,"chunkId":"dc-2024-p9-c4","text":"e (HOE 901) and NPH insulin. Diabetes Care 2001;24:631 e 6. [80] Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group. Ef fi cacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 2017;377:723 e 32. [81] Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, Hoogwerf BJ, Rosenstock J. Use of twice-daily exenatide in basal insulin- treated patients with type 2 diabetes: A randomized, controlled trial. Ann Intern Med 2011;154:103 e 12. [82] Arnolds S, Dellweg S, Clair J, Dain MP, Nauck MA, Rave K, Kapitza C. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: A proof-of-concept study. Diabetes Care 2010;33:1509 e 15. [83] Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R. Effect of sax- agliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin 2012;28:513 e 23. [84] Vilsboll T, Rosenstock J, Yki-Jarvinen H, Cefalu WT, Chen Y, Luo E, Musser B, et al. Ef fi cacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:167 e 77. [85] Zinman B, Ahrn B, Neubacher D, Patel S, Woe","tf":{"12":2,"15":1,"23":1,"24":1,"28":1,"32":1,"33":1,"77":1,"80":1,"81":1,"82":1,"83":1,"84":1,"85":1,"103":1,"154":1,"167":1,"377":1,"513":1,"631":1,"723":1,"901":1,"1509":1,"2001":1,"2010":2,"2011":1,"2012":1,"2017":1,"hoe":1,"and":4,"nph":1,"insulin":6,"diabetes":7,"care":2,"marso":1,"sp":1,"mcguire":1,"dk":1,"zinman":2,"poulter":1,"nr":1,"emerson":1,"ss":1,"pieber":1,"tr":1,"pratley":1,"re":1,"haahr":1,"pm":1,"lange":1,"brown":1,"frandsen":1,"moses":1,"skibsted":1,"kvist":1,"buse":2,"jb":2,"devote":1,"study":2,"group":1,"ef":2,"fi":2,"cacy":2,"safety":2,"of":6,"degludec":1,"versus":1,"glargine":2,"in":5,"type":4,"engl":1,"med":3,"bergenstal":1,"rm":1,"glass":1,"lc":1,"heilmann":1,"cr":1,"lewis":1,"ms":1,"kwan":1,"ay":1,"hoogwerf":1,"bj":1,"rosenstock":2,"use":1,"twice":1,"daily":1,"exenatide":2,"basal":1,"treated":1,"patients":3,"with":6,"randomized":1,"controlled":2,"trial":1,"ann":1,"intern":1,"arnolds":1,"dellweg":1,"clair":1,"dain":1,"mp":1,"nauck":1,"ma":1,"rave":1,"kapitza":1,"further":1,"improvement":1,"postprandial":1,"glucose":1,"control":1,"addition":1,"or":2,"sitagliptin":2,"to":2,"combination":1,"therapy":3,"metformin":2,"proof":1,"concept":1,"barnett":1,"ah":1,"charbonnel":1,"donovan":1,"fleming":1,"chen":2,"effect":1,"sax":1,"agliptin":1,"as":1,"add":1,"on":2,"poorly":1,"alone":1,"combined":1,"curr":1,"res":1,"opin":1,"vilsboll":1,"yki":1,"jarvinen":1,"cefalu":1,"wt":1,"luo":1,"musser":1,"et":1,"al":1,"when":1,"added":1,"obes":1,"metab":1,"ahr":1,"neubacher":1,"patel":1,"woe":1},"len":214},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":9,"chunkId":"dc-2024-p9-c5","text":"J, Yki-Jarvinen H, Cefalu WT, Chen Y, Luo E, Musser B, et al. Ef fi cacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:167 e 77. [85] Zinman B, Ahrn B, Neubacher D, Patel S, Woerle HJ, Johansen OE. Ef fi cacy and cardiovascular safety of linagliptin as an add-on to insulin in type 2 diabetes: A pooled comprehensive post hoc analysis. Can J Diabetes 2016;40:50 e 7. [86] Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Ways K, Desai M, Shaw W, Capuano G, Alba M, Jiang J, Vercruysse F, Meininger G, Matthews D; CANVAS Trial Collaborative Group. Ef fi cacy and safety of canagli fl ozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care 2015;38: 403 e 11. [87] Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ, Broedl UC; EMPA-REG MDI Trial Investigators. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagli fl ozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 2014;37:1815 e 23. [88] Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S; Dapagli fl ozin 006 Study Group. Dapagli fl ozin in patients with type 2 diabetes receiving high doses of insulin: Ef fi cacy and safety over 2 yea","tf":{"11":1,"12":1,"23":1,"37":1,"38":1,"40":1,"50":1,"77":1,"85":1,"86":1,"87":1,"88":1,"167":1,"403":1,"1815":1,"2010":1,"2014":1,"2015":1,"2016":1,"yki":1,"jarvinen":1,"cefalu":1,"wt":1,"chen":1,"luo":1,"musser":1,"et":1,"al":1,"ef":4,"fi":4,"cacy":4,"and":5,"safety":4,"of":6,"sitagliptin":1,"when":2,"added":2,"to":3,"insulin":6,"therapy":2,"in":6,"patients":3,"with":6,"type":5,"diabetes":9,"obes":1,"metab":1,"zinman":1,"ahr":1,"neubacher":1,"patel":1,"woerle":2,"hj":2,"johansen":1,"oe":1,"cardiovascular":1,"linagliptin":1,"as":1,"an":2,"add":1,"on":1,"pooled":1,"comprehensive":1,"post":1,"hoc":1,"analysis":1,"can":1,"neal":1,"perkovic":1,"de":1,"zeeuw":1,"mahaffey":1,"kw":1,"fulcher":1,"ways":1,"desai":1,"shaw":1,"capuano":1,"alba":1,"jiang":1,"vercruysse":1,"meininger":1,"matthews":1,"canvas":1,"trial":2,"collaborative":1,"group":2,"canagli":1,"fl":4,"ozin":4,"inhibitor":1,"sodium":1,"glucose":2,"cotransporter":1,"used":1,"conjunction":1,"care":2,"rosenstock":1,"jelaska":1,"frappin":1,"salsali":1,"kim":1,"broedl":1,"uc":1,"empa":1,"reg":1,"mdi":1,"investigators":1,"improved":1,"control":1,"weight":1,"loss":1,"lower":1,"doses":2,"no":1,"increased":1,"hypoglycemia":1,"empagli":1,"titrated":1,"multiple":1,"daily":1,"injections":1,"obese":1,"inadequately":1,"controlled":1,"wilding":1,"jp":1,"woo":1,"rohwedder":1,"sugg":1,"parikh":1,"dapagli":2,"006":1,"study":1,"receiving":1,"high":1,"over":1,"yea":1},"len":208},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":9,"chunkId":"dc-2024-p9-c6","text":"pe 2 diabetes. Diabetes Care 2014;37:1815 e 23. [88] Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S; Dapagli fl ozin 006 Study Group. Dapagli fl ozin in patients with type 2 diabetes receiving high doses of insulin: Ef fi cacy and safety over 2 years. Diabetes Obes Metab 2014;16: 124 e 36. [89] Liakos A, Karagiannis T, Athanasiadou E, Sarigianni M, Mainou M, Papatheodorou K, Bekiari E, Tsapas A. Ef fi cacy and safety of empagli fl ozin for type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab 2014;16:984 e 93. [90] Kim YG, Min SH, Hahn S, Oh TJ, Park KS, Cho YM. Ef fi cacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 2016;116:86 e 95. [91] Ahmann A, Rodbard HW, Rosenstock J, Lahtela JT, de Loredo L, Torne K, Boopalan A, Nauck MA; NN2211-3917 Study Group. Ef fi cacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: A randomized, placebo- controlled trial. Diabetes Obes Metab 2015;17:1056 e 64. [92] Rosenstock J, Guerci B, Hanefeld M, Gentile S, Aronson R, Tinahones FJ, Roy- Duval C, Souhami E, Wardecki M, Ye J, Perfetti R, Heller S; GetGoal Duo-2 Trial Investigators. Prandial options to advance basal insulin glargine ther- apy: Testing ","tf":{"16":2,"17":1,"23":1,"36":1,"37":1,"64":1,"86":1,"88":1,"89":1,"90":1,"91":1,"92":1,"93":1,"95":1,"116":1,"124":1,"984":1,"1056":1,"1815":1,"2014":3,"2015":1,"2016":1,"3917":1,"pe":1,"diabetes":10,"care":1,"wilding":1,"jp":1,"woo":1,"rohwedder":1,"sugg":1,"parikh":1,"dapagli":2,"fl":3,"ozin":3,"006":1,"study":2,"group":2,"in":3,"patients":3,"with":4,"type":4,"receiving":1,"high":1,"doses":1,"of":5,"insulin":4,"ef":4,"fi":4,"cacy":4,"and":6,"safety":4,"over":1,"years":1,"obes":3,"metab":3,"liakos":1,"karagiannis":1,"athanasiadou":1,"sarigianni":1,"mainou":1,"papatheodorou":1,"bekiari":1,"tsapas":1,"empagli":1,"for":1,"systematic":2,"review":2,"meta":2,"analysis":2,"kim":1,"yg":1,"min":1,"sh":1,"hahn":1,"oh":1,"tj":1,"park":1,"ks":1,"cho":1,"ym":1,"the":1,"addition":1,"dipeptidyl":1,"peptidase":1,"inhibitor":1,"to":3,"therapy":1,"res":1,"clin":1,"pract":1,"ahmann":1,"rodbard":1,"hw":1,"rosenstock":2,"lahtela":1,"jt":1,"de":1,"loredo":1,"torn":1,"boopalan":1,"nauck":1,"ma":1,"nn2211":1,"liraglutide":1,"versus":1,"placebo":2,"added":1,"basal":2,"analogues":1,"or":1,"without":1,"metformin":1,"randomized":1,"controlled":1,"trial":2,"guerci":1,"hanefeld":1,"gentile":1,"aronson":1,"tinahones":1,"fj":1,"roy":1,"duval":1,"souhami":1,"wardecki":1,"ye":1,"perfetti":1,"heller":1,"getgoal":1,"duo":1,"investigators":1,"prandial":1,"options":1,"advance":1,"glargine":1,"ther":1,"apy":1,"testing":1},"len":206},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":9,"chunkId":"dc-2024-p9-c7","text":"4. [92] Rosenstock J, Guerci B, Hanefeld M, Gentile S, Aronson R, Tinahones FJ, Roy- Duval C, Souhami E, Wardecki M, Ye J, Perfetti R, Heller S; GetGoal Duo-2 Trial Investigators. Prandial options to advance basal insulin glargine ther- apy: Testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes: The GetGoal Duo-2 trial. Dia- betes Care 2016;39:1318 e 28. [93] Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodrguez . Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: The SURPASS-5 random- ized clinical trial. JAMA 2022;327(6):534 e 45. [94] Rosenstock J, Fras JP, Rodbard HW, Tof S, Sears E, Huh R, Fernndez Land L, Patel H. Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: The SURPASS-6 randomized clinical trial. JAMA 2023;330(17): 1631 e 40. [95] Mathieu C, Rodbard HW, Cariou B, Handelsman Y, Philis-Tsimikas A, Ocampo Francisco AM, et al. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab 2014;16(7):636 e 44. [96] Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes:","tf":{"16":1,"17":1,"28":1,"39":1,"40":1,"44":1,"45":1,"92":1,"93":1,"94":1,"95":1,"96":1,"327":1,"330":1,"534":1,"636":1,"1318":1,"1631":1,"2014":1,"2016":1,"2022":1,"2023":1,"rosenstock":2,"guerci":1,"hanefeld":1,"gentile":1,"aronson":1,"tinahones":1,"fj":1,"roy":1,"duval":1,"souhami":1,"wardecki":1,"ye":1,"perfetti":1,"heller":1,"getgoal":2,"duo":2,"trial":4,"investigators":1,"prandial":1,"options":1,"to":4,"advance":1,"basal":6,"insulin":9,"glargine":2,"ther":1,"apy":1,"testing":1,"lixisenatide":1,"plus":2,"versus":2,"glulisine":1,"either":1,"as":2,"or":1,"bolus":1,"in":4,"type":5,"diabetes":6,"the":4,"dia":1,"betes":1,"care":1,"dahl":1,"onishi":1,"norwood":1,"huh":2,"bray":1,"patel":2,"rodr":1,"guez":1,"effect":1,"of":4,"subcutaneous":1,"tirzepatide":2,"vs":2,"placebo":1,"added":2,"titrated":1,"on":2,"glycemic":1,"control":1,"patients":1,"with":2,"surpass":2,"random":1,"ized":1,"clinical":2,"jama":2,"fr":1,"jp":1,"rodbard":2,"hw":2,"tof":1,"sears":1,"fern":1,"ndez":1,"land":1,"lispro":1,"randomized":1,"mathieu":1,"cariou":1,"handelsman":1,"philis":1,"tsimikas":1,"ocampo":1,"francisco":1,"am":1,"et":1,"al":1,"comparison":1,"adding":1,"liraglutide":1,"single":1,"daily":1,"dose":1,"aspart":1,"degludec":1,"subjects":1,"begin":1,"victoza":1,"add":1,"obes":1,"metab":1,"eng":1,"kramer":1,"ck":1,"zinman":1,"retnakaran":1,"glucagon":1,"like":1,"peptide":1,"receptor":1,"agonist":1,"and":1,"combination":1,"treatment":1,"for":1,"management":1},"len":197},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":9,"chunkId":"dc-2024-p9-c8","text":"h type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab 2014;16(7):636 e 44. [96] Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: A systematic review and meta-analysis. Lancet 2014;384(9961): 2228 e 34. [97] Maiorino MI, Chiodini P, Bellastella G, Capuano A, Esposito K, Giugliano D. Insulin and glucagon-like peptide 1 receptor agonist combination therapy in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Care 2017;40(4):614 e 24. [98] Wysham CH, Lin J, Kuritzky L. Safety and ef fi cacy of a glucagon-like peptide- 1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: Results of a meta-analysis. Postgrad Med 2017;129(4):436 e 45. [99] Pozzilli P, Norwood P, Jdar E, Davies MJ, Ivanyi T, Jiang H, et al. Placebo- controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9). Diabetes Obes Metab 2017;19(7): 1024 e 31. [100] Rodbard HW, Lingvay I, Reed J, de la Rosa R, Rose L, Sugimoto D, et al. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A ran- domized, controlled trial. J Clin ","tf":{"16":1,"19":1,"24":1,"31":1,"34":1,"40":1,"44":1,"45":1,"96":1,"97":1,"98":1,"99":1,"100":1,"129":1,"384":1,"436":1,"614":1,"636":1,"1024":1,"2014":2,"2017":3,"2228":1,"9961":1,"type":6,"diabetes":9,"begin":1,"victoza":1,"add":1,"on":1,"obes":2,"metab":2,"eng":1,"kramer":1,"ck":1,"zinman":1,"retnakaran":1,"glucagon":4,"like":4,"peptide":4,"receptor":4,"agonist":4,"and":5,"basal":4,"insulin":7,"combination":2,"treatment":1,"for":1,"the":2,"management":1,"of":6,"systematic":2,"review":2,"meta":3,"analysis":3,"lancet":1,"maiorino":1,"mi":1,"chiodini":1,"bellastella":1,"capuano":1,"esposito":1,"giugliano":1,"therapy":2,"in":4,"randomized":2,"controlled":3,"trials":1,"care":1,"wysham":1,"ch":1,"lin":1,"kuritzky":1,"safety":1,"ef":1,"fi":1,"cacy":1,"added":2,"to":3,"versus":1,"with":3,"or":1,"without":1,"rapid":1,"acting":1,"patients":2,"results":1,"postgrad":1,"med":1,"pozzilli":1,"norwood":1,"dar":1,"davies":1,"mj":1,"ivanyi":1,"jiang":1,"et":2,"al":2,"placebo":1,"trial":2,"addition":1,"once":1,"weekly":1,"dulaglutide":1,"titrated":1,"daily":1,"glargine":1,"award":1,"rodbard":1,"hw":1,"lingvay":1,"reed":1,"de":1,"la":1,"rosa":1,"rose":1,"sugimoto":1,"semaglutide":1,"sustain":1,"ran":1,"domized":1,"clin":1},"len":196},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":9,"chunkId":"dc-2024-p9-c9","text":" diabetes (AWARD-9). Diabetes Obes Metab 2017;19(7): 1024 e 31. [100] Rodbard HW, Lingvay I, Reed J, de la Rosa R, Rose L, Sugimoto D, et al. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A ran- domized, controlled trial. J Clin Endocrinol Metab 2018;103(6):2291 e 301. [101] Kesavadev J, Pillai PBS, Shankar A, Krishnan G, Jothydev S. Sitagliptin 100 mg vs glimepiride 1-3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM). Endocr Connect 2017;6(8):748 e 57. [102] Ledesma G, Umpierrez GE, Morley JE, Lewis-D  Agostino D, Keller A, Meinicke T, et al. Ef fi cacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial. Diabetes Obes Metab 2019;21(11):2465 e 73. [103] Rodbard HW, Visco VE, Andersen H, Hiort LC, Shu DH. Treatment intensi fi - cation with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): A randomised, treat-to-target clinical trial. Lancet Diabetes Endocrinol 2014;2:30 e 7. B.R. Shah et al. / Can J Diabetes 48 (2024) 415 e 424 423","tf":{"11":1,"19":1,"21":1,"30":1,"31":1,"48":1,"57":1,"73":1,"100":2,"101":1,"102":1,"103":2,"301":1,"415":1,"423":1,"424":1,"748":1,"1024":1,"2014":1,"2017":2,"2018":1,"2019":1,"2024":1,"2291":1,"2465":1,"diabetes":8,"award":1,"obes":2,"metab":3,"rodbard":2,"hw":2,"lingvay":1,"reed":1,"de":1,"la":1,"rosa":1,"rose":1,"sugimoto":1,"et":3,"al":3,"semaglutide":1,"added":1,"to":4,"basal":2,"insulin":4,"in":3,"type":3,"sustain":1,"ran":1,"domized":1,"controlled":1,"trial":3,"clin":1,"endocrinol":2,"kesavadev":1,"pillai":1,"pbs":1,"shankar":1,"krishnan":1,"jothydev":1,"sitagliptin":1,"mg":2,"vs":1,"glimepiride":1,"as":1,"an":1,"add":1,"on":2,"and":2,"metformin":1,"swim":1,"endocr":1,"connect":1,"ledesma":1,"umpierrez":1,"ge":1,"morley":1,"je":1,"lewis":1,"agostino":1,"keller":1,"meinicke":1,"ef":1,"fi":2,"cacy":1,"safety":1,"of":2,"linagliptin":1,"improve":1,"glucose":1,"control":1,"older":1,"people":1,"with":3,"stable":1,"therapy":2,"randomized":1,"visco":1,"ve":1,"andersen":1,"hiort":1,"lc":1,"shu":1,"dh":1,"treatment":1,"intensi":1,"cation":1,"stepwise":1,"addition":1,"prandial":1,"aspart":1,"boluses":1,"compared":1,"full":1,"bolus":1,"fullstep":1,"study":1,"randomised":1,"treat":1,"target":1,"clinical":1,"lancet":1,"shah":1,"can":1},"len":165},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":10,"chunkId":"dc-2024-p10-c0","text":"[104] Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H. Ef fi cacy and safety of insulin analogues for the management of diabetes mellitus: A meta-analysis. CMAJ 2009;180:385 e 97. [105] Anderson JH Jr, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin- dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Arch Intern Med 1997;157:1249 e 55. [106] Anderson JH Jr, Brunelle RL, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group. Clin Ther 1997;19: 62 e 72. [107] Mannucci E, Monami M, Marchionni N. Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: A meta-analysis. Diabetes Obes Metab 2009;11(1):53 e 9. [108] Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, Kaiser T, Pieber TR, Siebenhofer A. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;(2):CD005613. [109] Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: A meta-analysis. Diabetes Res Clin Pract 2008;81:184 e 9. [110] Rys P, Wojciechowski P, Rogoz-Sitek A, Niesyczy \u0013 ns","tf":{"11":1,"19":1,"53":1,"55":1,"62":1,"72":1,"81":1,"97":1,"104":1,"105":1,"106":1,"107":1,"108":1,"109":1,"110":1,"157":1,"180":1,"184":1,"385":1,"1249":1,"1997":2,"2007":1,"2008":1,"2009":2,"singh":1,"sr":1,"ahmad":1,"lal":1,"yu":1,"bai":1,"bennett":1,"ef":1,"fi":1,"cacy":1,"and":2,"safety":1,"of":3,"insulin":13,"analogues":4,"for":2,"the":1,"management":1,"diabetes":8,"mellitus":4,"meta":3,"analysis":3,"cmaj":1,"anderson":2,"jh":2,"jr":2,"brunelle":2,"rl":2,"keohane":1,"koivisto":2,"va":2,"trautmann":2,"me":2,"vignati":2,"dimarchi":2,"mealtime":2,"treatment":2,"with":2,"analog":1,"improves":1,"postprandial":1,"hyperglycemia":1,"hypoglycemia":1,"in":3,"patients":1,"non":1,"dependent":1,"multicenter":2,"lispro":2,"study":2,"group":2,"arch":1,"intern":1,"med":1,"improved":1,"using":1,"an":1,"analogue":1,"clin":2,"ther":1,"mannucci":2,"monami":2,"marchionni":2,"short":1,"acting":3,"vs":1,"regular":1,"human":3,"type":3,"obes":1,"metab":1,"horvath":1,"jeitler":1,"berghold":1,"ebrahim":1,"sh":1,"gratzer":1,"tw":1,"plank":1,"kaiser":1,"pieber":1,"tr":1,"siebenhofer":1,"long":2,"versus":2,"nph":2,"isophane":1,"cochrane":1,"database":1,"syst":1,"rev":1,"cd005613":1,"res":1,"pract":1,"rys":1,"wojciechowski":1,"rogoz":1,"sitek":1,"niesyczy":1,"ns":1},"len":192},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":10,"chunkId":"dc-2024-p10-c1","text":"07;(2):CD005613. [109] Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: A meta-analysis. Diabetes Res Clin Pract 2008;81:184 e 9. [110] Rys P, Wojciechowski P, Rogoz-Sitek A, Niesyczy \u0013 nski G, Lis J, Syta A, Malecki MT. Systematic review and metaanalysis of randomized clinical trials comparing ef fi cacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetol 2015;52:649 e 62. [111] Ratner RE, Gough SC, Mathieu C, Del Prato S, Bode B, Mersebach H, Endahl L, Zinman B. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: A pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2013;15:175 e 84. [112] Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN, Kvist K, Norwood P. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes. The SWITCH 2 Randomized Clinical Trial. JAMA 2017;318(1):45 e 56. [113] Heller SR, DeVries JH, Wysham C, Hansen CT, Hansen MV, Frier BM. Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2. Diabetes Obes Metab 2019;21(7):1634 e 41. [114] Clements JN, Bello L. Insulin glargine 300 u","tf":{"15":1,"21":1,"41":1,"45":1,"52":1,"56":1,"62":1,"81":1,"84":1,"109":1,"110":1,"111":1,"112":1,"113":1,"114":1,"175":1,"184":1,"300":1,"318":1,"649":1,"1634":1,"2008":1,"2013":1,"2015":1,"2017":1,"2019":1,"07":1,"cd005613":1,"monami":1,"marchionni":1,"mannucci":1,"long":1,"acting":1,"insulin":13,"analogues":1,"versus":2,"nph":2,"human":1,"in":5,"type":6,"diabetes":8,"meta":2,"analysis":2,"res":1,"clin":1,"pract":1,"rys":1,"wojciechowski":1,"rogoz":1,"sitek":1,"niesyczy":1,"nski":1,"lis":1,"syta":1,"malecki":1,"mt":1,"systematic":1,"review":1,"and":3,"metaanalysis":1,"of":5,"randomized":2,"clinical":2,"trials":2,"comparing":1,"ef":1,"fi":1,"cacy":1,"safety":1,"outcomes":1,"glargine":5,"with":6,"premixed":1,"preparations":1,"or":1,"detemir":1,"mellitus":1,"acta":1,"diabetol":1,"ratner":1,"re":1,"gough":1,"sc":1,"mathieu":1,"del":1,"prato":1,"bode":1,"mersebach":1,"endahl":1,"zinman":1,"hypoglycaemia":2,"risk":1,"degludec":3,"compared":1,"pre":1,"planned":1,"phase":1,"obes":2,"metab":2,"wysham":2,"bhargava":1,"chaykin":1,"de":1,"la":1,"rosa":1,"handelsman":1,"troelsen":1,"ln":1,"kvist":1,"norwood":1,"effect":1,"vs":1,"u100":2,"on":1,"hypoglycemia":1,"patients":1,"the":1,"switch":2,"trial":1,"jama":1,"heller":1,"sr":1,"devries":1,"jh":1,"hansen":2,"ct":1,"mv":1,"frier":1,"bm":1,"lower":1,"rates":1,"older":1,"individuals":1,"using":1,"results":1,"from":1,"clements":1,"jn":1,"bello":1},"len":198},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":10,"chunkId":"dc-2024-p10-c2","text":" Frier BM. Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2. Diabetes Obes Metab 2019;21(7):1634 e 41. [114] Clements JN, Bello L. Insulin glargine 300 units/mL: A new basal insulin product for diabetes mellitus. Am J Health Syst Pharm 2016;73:359 e 66. [115] Zhuang YG, Peng H, Huang F. A meta-analysis of clinical therapeutic effect of insulin glargine and insulin detemir for patients with type 2 diabetes mel- litus. Eur Rev Med Pharmacol Sci 2013;17:2566 e 70. [116] de Jager J, Kooy A, Lehert P, Wulffel MG, van der Kolk J, Bets D, Verburg J, Donker AJ, Stehouwer CD. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 de fi ciency: Randomised pla- cebo controlled trial. BMJ 2010;340:c2181. [117] Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, Bray GA, Schade DS, Temprosa MG, White NH, Crandall JP; Diabetes Prevention Program Research Group. Long-term metformin use and vitamin B12 de fi ciency in the diabetes prevention program outcomes study. J Clin Endocrinol Metab 2016;101:1754 e 61. [118] Niafar M, Hai F, Porhomayon J, Nader ND. The role of metformin on vitamin B12 de fi ciency: A meta-analysis review. Intern Emerg Med 2015;10:93 e 102. [119] Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestina","tf":{"10":1,"12":1,"17":1,"21":1,"41":1,"61":1,"66":1,"70":1,"73":1,"93":1,"101":1,"102":1,"114":1,"115":1,"116":1,"117":1,"118":1,"119":1,"300":1,"340":1,"359":1,"1634":1,"1754":1,"2010":1,"2013":1,"2015":1,"2016":2,"2019":1,"2566":1,"frier":1,"bm":1,"lower":1,"rates":1,"of":5,"hypoglycaemia":1,"in":3,"older":1,"individuals":1,"with":4,"type":3,"diabetes":7,"using":1,"insulin":6,"degludec":1,"versus":1,"glargine":3,"u100":1,"results":1,"from":1,"switch":1,"obes":1,"metab":2,"clements":1,"jn":1,"bello":1,"units":1,"ml":1,"new":1,"basal":1,"product":1,"for":2,"mellitus":1,"am":1,"health":1,"syst":1,"pharm":1,"zhuang":1,"yg":1,"peng":1,"huang":1,"meta":2,"analysis":2,"clinical":1,"therapeutic":1,"effect":1,"and":3,"detemir":1,"patients":2,"mel":1,"litus":1,"eur":1,"rev":1,"med":2,"pharmacol":1,"sci":1,"de":4,"jager":1,"kooy":1,"lehert":1,"wulffel":1,"mg":2,"van":1,"der":1,"kolk":1,"bets":1,"verburg":1,"donker":1,"aj":1,"stehouwer":1,"cd":1,"long":2,"term":2,"treatment":1,"metformin":3,"risk":1,"vitamin":3,"fi":3,"ciency":3,"randomised":1,"pla":1,"cebo":1,"controlled":1,"trial":1,"bmj":1,"c2181":1,"aroda":1,"vr":1,"edelstein":1,"sl":1,"goldberg":1,"rb":1,"knowler":1,"wc":1,"marcovina":1,"sm":1,"orchard":1,"tj":1,"bray":1,"ga":1,"schade":1,"ds":1,"temprosa":1,"white":1,"nh":1,"crandall":1,"jp":1,"prevention":2,"program":2,"research":1,"group":1,"use":1,"b12":2,"the":2,"outcomes":1,"study":1,"clin":1,"endocrinol":1,"niafar":1,"hai":1,"porhomayon":1,"nader":1,"nd":1,"role":1,"on":1,"review":1,"intern":1,"emerg":1,"blonde":1,"dailey":1,"ge":1,"jabbour":1,"sa":1,"reasner":1,"ca":1,"mills":1,"dj":1,"gastrointestina":1},"len":218},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":10,"chunkId":"dc-2024-p10-c3","text":"6;101:1754 e 61. [118] Niafar M, Hai F, Porhomayon J, Nader ND. The role of metformin on vitamin B12 de fi ciency: A meta-analysis review. Intern Emerg Med 2015;10:93 e 102. [119] Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate- release metformin tablets: Results of a retrospective cohort study. Curr Med Res Opin 2004;20:565 e 72. [120] Ali S, Fonseca V. Overview of metformin: Special focus on metformin extended release. Expert Opin Pharmacother 2012;13:1797 e 805. [121] Jabbour S, Ziring B. Advantages of extended-release metformin in patients with type 2 diabetes mellitus. Postgrad Med 2011;123:15 e 23. [122] Levy J, Cobas RA, Gomes MB. Assessment of ef fi cacy and tolerability of once daily extended release metformin in patients with type 2 diabetes mellitus. Diabetol Metab Syndr 2010;2:16. [123] Li L, Shen J, Bala MM, Busse JW, Ebrahim S, Vandvik PO, Rios LP, Malaga G, Wong E, Sohani Z, Guyatt GH, Sun X. Incretin treatment and risk of pancre- atitis in patients with type 2 diabetes mellitus: Systematic review and meta- analysis of randomised and non-randomised studies. BMJ 2014;348:g2366. [124] Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: A m","tf":{"10":1,"13":1,"15":1,"16":1,"20":1,"23":1,"61":1,"72":1,"93":1,"101":1,"102":1,"118":1,"119":1,"120":1,"121":1,"122":1,"123":2,"124":1,"348":1,"565":1,"805":1,"1754":1,"1797":1,"2004":1,"2010":1,"2011":1,"2012":1,"2014":1,"2015":1,"niafar":1,"hai":1,"porhomayon":1,"nader":1,"nd":1,"the":1,"role":1,"of":9,"metformin":7,"on":2,"vitamin":1,"b12":1,"de":1,"fi":2,"ciency":1,"meta":2,"analysis":2,"review":2,"intern":1,"emerg":1,"med":3,"blonde":1,"dailey":1,"ge":1,"jabbour":2,"sa":1,"reasner":1,"ca":1,"mills":1,"dj":1,"gastrointestinal":1,"tolerability":2,"extended":4,"release":5,"tablets":2,"compared":1,"to":1,"immediate":1,"results":1,"retrospective":1,"cohort":1,"study":1,"curr":1,"res":1,"opin":2,"ali":1,"fonseca":1,"overview":1,"special":1,"focus":1,"expert":1,"pharmacother":1,"ziring":1,"advantages":1,"in":4,"patients":4,"with":4,"type":4,"diabetes":4,"mellitus":3,"postgrad":1,"levy":1,"cobas":1,"ra":1,"gomes":1,"mb":1,"assessment":1,"ef":1,"cacy":1,"and":5,"once":1,"daily":1,"diabetol":1,"metab":1,"syndr":1,"li":1,"shen":1,"bala":1,"mm":1,"busse":1,"jw":1,"ebrahim":1,"vandvik":1,"po":1,"rios":1,"lp":1,"malaga":1,"wong":1,"sohani":1,"guyatt":1,"gh":1,"sun":1,"incretin":1,"treatment":1,"risk":2,"pancre":1,"atitis":1,"systematic":1,"randomised":2,"non":1,"studies":1,"bmj":1,"g2366":1,"udell":1,"ja":1,"cavender":1,"ma":1,"bhatt":1,"dl":1,"chatterjee":1,"farkouh":1,"me":1,"scirica":1,"bm":1,"glucose":1,"lowering":1,"drugs":1,"or":2,"strategies":1,"cardiovascular":1,"outcomes":1,"at":1,"for":1},"len":209},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":10,"chunkId":"dc-2024-p10-c4","text":"domised and non-randomised studies. BMJ 2014;348:g2366. [124] Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: A meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 2015;3:356 e 66. [125] Li L, Li S, Deng K, Liu J, Vandvik PO, Zhao P, Zhang L, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ 2016;352:i610. [126] Caparrotta TM, Templeton JB, Clay TA, Wild SH, Reynolds RM, Webb DJ, Colhoun HM. Glucagon-like peptide 1 receptor agonist (GLP1RA) exposure and outcomes in type 2 diabetes: A systematic review of population-based observational studies. Diabetes Ther 2021;12(4):969 e 89. [127] Colacci M, Fralick J, Odutayo A, Fralick M. Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type 2 diabetes: A systematic review and meta-analysis. Can J Diabetes 2022;46(1): 10 e 5. [128] Alba M, Xie J, Fung A, Desai M. The effects of canagli fl ozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus. Curr Med Res Opin 2016;32:1375 e 85. [129] Bilezikian JP, Watts NB, Usiskin K, Polidori D, Fung A, Sullivan D, Ros","tf":{"10":1,"12":1,"32":1,"46":1,"66":1,"85":1,"89":1,"124":1,"125":1,"126":1,"127":1,"128":1,"129":1,"348":1,"352":1,"356":1,"969":1,"1375":1,"2014":1,"2015":1,"2016":2,"2021":1,"2022":1,"domised":1,"and":9,"non":1,"randomised":3,"studies":3,"bmj":2,"g2366":1,"udell":1,"ja":1,"cavender":1,"ma":1,"bhatt":1,"dl":1,"chatterjee":1,"farkouh":1,"me":1,"scirica":1,"bm":1,"glucose":3,"lowering":1,"drugs":1,"or":2,"strategies":1,"cardiovascular":1,"outcomes":2,"in":4,"patients":2,"with":3,"at":1,"risk":3,"for":1,"type":5,"diabetes":8,"meta":3,"analysis":3,"of":6,"controlled":1,"trials":1,"lancet":1,"endocrinol":1,"li":2,"deng":1,"liu":1,"vandvik":1,"po":1,"zhao":1,"zhang":1,"et":1,"al":1,"dipeptidyl":1,"peptidase":1,"inhibitors":2,"heart":1,"failure":1,"systematic":3,"review":3,"observational":2,"i610":1,"caparrotta":1,"tm":1,"templeton":1,"jb":1,"clay":1,"ta":1,"wild":1,"sh":1,"reynolds":1,"rm":1,"webb":1,"dj":1,"colhoun":1,"hm":1,"glucagon":1,"like":1,"peptide":1,"receptor":1,"agonist":1,"glp1ra":1,"exposure":1,"population":1,"based":1,"ther":1,"colacci":1,"fralick":2,"odutayo":1,"sodium":2,"cotransporter":1,"diabetic":1,"ketoacidosis":1,"among":1,"adults":1,"can":1,"alba":1,"xie":1,"fung":2,"desai":1,"the":1,"effects":1,"canagli":1,"fl":1,"ozin":1,"co":1,"transporter":1,"inhibitor":1,"on":1,"mineral":1,"metabolism":1,"bone":1,"mellitus":1,"curr":1,"med":1,"res":1,"opin":1,"bilezikian":1,"jp":1,"watts":1,"nb":1,"usiskin":1,"polidori":1,"sullivan":1,"ros":1},"len":200},{"docId":"dc-2024","docTitle":"Diabetes Canada 2024 Update","file":"diabetes-canada-2024.pdf","page":10,"chunkId":"dc-2024-p10-c5","text":"canagli fl ozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus. Curr Med Res Opin 2016;32:1375 e 85. [129] Bilezikian JP, Watts NB, Usiskin K, Polidori D, Fung A, Sullivan D, Rosenthal N. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagli fl ozin. J Clin Endocrinol Metab 2016;101: 44 e 51. [130] Puckrin R, Saltiel MP, Reynier P, Azoulay L, Yu OHY, Filion KB. SGLT-2 inhibitors and the risk of infections: A systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 2018;55:503 e 14. [131] Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: A population-based cohort study. Ann Intern Med 2019;171:248 e 56. [132] Shi Q, Nong K, Vandvik PO, Guyatt GH, Schnell O, Rydn L, Marx N, et al. Bene fi ts and harms of drug treatment for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials. BMJ 2023;381:e074068. B.R. Shah et al. / Can J Diabetes 48 (2024) 415 e 424 424","tf":{"14":1,"32":1,"44":1,"48":1,"51":1,"55":1,"56":1,"85":1,"101":1,"129":1,"130":1,"131":1,"132":1,"171":1,"248":1,"381":1,"415":1,"424":2,"503":1,"1375":1,"2016":2,"2018":1,"2019":1,"2023":1,"2024":1,"canagli":2,"fl":2,"ozin":2,"sodium":2,"glucose":2,"co":1,"transporter":1,"inhibitor":1,"on":1,"mineral":2,"metabolism":1,"and":7,"bone":3,"in":2,"patients":2,"with":3,"type":3,"diabetes":4,"mellitus":1,"curr":1,"med":2,"res":1,"opin":1,"bilezikian":1,"jp":1,"watts":1,"nb":1,"usiskin":1,"polidori":1,"fung":1,"sullivan":1,"rosenthal":1,"evaluation":1,"of":5,"density":1,"biomarkers":1,"treated":1,"clin":1,"endocrinol":1,"metab":1,"puckrin":1,"saltiel":1,"mp":1,"reynier":1,"azoulay":1,"yu":1,"ohy":1,"filion":1,"kb":1,"sglt":1,"inhibitors":2,"the":2,"risk":2,"infections":2,"systematic":2,"review":2,"meta":2,"analysis":2,"randomized":1,"controlled":2,"trials":2,"acta":1,"diabetol":1,"dave":1,"cv":1,"schneeweiss":1,"kim":1,"fralick":1,"tong":1,"patorno":1,"cotransporter":1,"for":2,"severe":1,"urinary":1,"tract":1,"population":1,"based":1,"cohort":1,"study":1,"ann":1,"intern":1,"shi":1,"nong":1,"vandvik":1,"po":1,"guyatt":1,"gh":1,"schnell":1,"ryd":1,"marx":1,"et":2,"al":2,"bene":1,"fi":1,"ts":1,"harms":1,"drug":1,"treatment":1,"network":1,"randomised":1,"bmj":1,"e074068":1,"shah":1,"can":1},"len":172},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":1,"chunkId":"ccs-2022-p1-c0","text":"Society Guidelines 2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults Primary Panel: G.B. John Mancini, MD (Co-chair), a Eileen O  Meara, MD (Co-chair), b Shelley Zieroth, MD, c Mathieu Bernier, MD, d Alice Y.Y. Cheng, MD, e David Z.I. Cherney, MD, PhD, f Kim A. Connelly, MD, g Justin Ezekowitz, MBBCh, MSc, h Ronald M. Goldenberg, MD, i Lawrence A. Leiter, MD, j Gihad Nesrallah, MD, MSc, j,k Breay W. Paty, MD, l Marie-Eve Pich \u0013 e, MD, PhD, d Peter Senior, MBBS, PhD, m Abhinav Sharma, MD, n Subodh Verma, MD, PhD, o Vincent Woo, MD, c Secondary Panel: Pol Darras, MD, l Jonathan Y. Gabor, MD, p Jean Gr \u0013 egoire, MD, b Eva Lonn, MD, q James A. Stone, MD, PhD, r Jean-Franois Yale, MD, s Colin Yeung, MD, MPH, t and Deborah Zimmerman, MD, MSc u a Division of Cardiology, Centre for Cardiovascular Innovation, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; b Division of Cardiology, Montreal Heart Institute, Universit \u0013 e de Montr \u0013 eal, Montreal, Quebec, Canada; c Max Rady College of Medicine, Section of Cardiology, University of Manitoba, Winnipeg, Manitoba, Canada; d Institut Universitaire de Cardiologie et de Pneumologie de Qu \u0013 ebec, Universit \u0013 e Laval, Qu \u0013 ebec, Quebec, Canada; e Division of Endocrinology, Unity Health Toronto and Trillium H","tf":{"2022":1,"society":2,"guidelines":1,"canadian":1,"cardiovascular":2,"guideline":1,"for":3,"use":1,"of":9,"glp":1,"receptor":1,"agonists":1,"and":3,"sglt2":1,"inhibitors":1,"cardiorenal":1,"risk":1,"reduction":1,"in":1,"adults":1,"primary":1,"panel":2,"john":1,"mancini":1,"md":23,"co":2,"chair":2,"eileen":1,"meara":1,"shelley":1,"zieroth":1,"mathieu":1,"bernier":1,"alice":1,"cheng":1,"david":1,"cherney":1,"phd":5,"kim":1,"connelly":1,"justin":1,"ezekowitz":1,"mbbch":1,"msc":3,"ronald":1,"goldenberg":1,"lawrence":1,"leiter":1,"gihad":1,"nesrallah":1,"breay":1,"paty":1,"marie":1,"eve":1,"pich":1,"peter":1,"senior":1,"mbbs":1,"abhinav":1,"sharma":1,"subodh":1,"verma":1,"vincent":1,"woo":1,"secondary":1,"pol":1,"darras":1,"jonathan":1,"gabor":1,"jean":2,"gr":1,"egoire":1,"eva":1,"lonn":1,"james":1,"stone":1,"fran":1,"ois":1,"yale":1,"colin":1,"yeung":1,"mph":1,"deborah":1,"zimmerman":1,"division":3,"cardiology":3,"centre":1,"innovation":1,"department":1,"medicine":2,"university":2,"british":2,"columbia":2,"vancouver":1,"canada":4,"montreal":2,"heart":1,"institute":1,"universit":2,"de":4,"montr":1,"eal":1,"quebec":2,"max":1,"rady":1,"college":1,"section":1,"manitoba":2,"winnipeg":1,"institut":1,"universitaire":1,"cardiologie":1,"et":1,"pneumologie":1,"qu":2,"ebec":2,"laval":1,"endocrinology":1,"unity":1,"health":1,"toronto":1,"trillium":1},"len":188},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":1,"chunkId":"ccs-2022-p1-c1","text":"f Cardiology, University of Manitoba, Winnipeg, Manitoba, Canada; d Institut Universitaire de Cardiologie et de Pneumologie de Qu \u0013 ebec, Universit \u0013 e Laval, Qu \u0013 ebec, Quebec, Canada; e Division of Endocrinology, Unity Health Toronto and Trillium Health Partners, University of Toronto, Toronto, Ontario, Canada; f Division of Nephrology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada; g Keenan Research Center for Biomedical Science, St Michael  s Hospital, Toronto, Ontario, Canada, and Division of Cardiology, University of Toronto, Toronto, Ontario, Canada; h Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada; i LMC Diabetes and Endocrinology, Vaughan, Ontario, Canada; j Li Ka Shing Knowledge Institute, St Michael  s Hospital, University of Toronto, Toronto, Ontario, Canada; k Division of Nephrology, Department of Medicine, Humber River Hospital, North York, Ontario, Canada; l Division of Endocrinology, University of British Columbia, Vancouver, British Columbia, Canada; m Alberta Diabetes Institute, Edmonton, Alberta, Canada; n Division of Cardiology, McGill University Health Centre, Montreal, Quebec, Canada; o Division of Cardiac Surgery, St Michael  s Hospital, University of Toronto, Toronto, Ontario, Canada; p Department of Cardiology, Selkirk Regional Health Centre, Selkirk, Manitoba, Canada; q D","tf":{"cardiology":5,"university":10,"of":19,"manitoba":3,"winnipeg":1,"canada":15,"institut":1,"universitaire":1,"de":3,"cardiologie":1,"et":1,"pneumologie":1,"qu":2,"ebec":2,"universit":1,"laval":1,"quebec":2,"division":8,"endocrinology":3,"unity":1,"health":5,"toronto":12,"and":3,"trillium":1,"partners":1,"ontario":8,"nephrology":2,"department":3,"medicine":2,"network":1,"keenan":1,"research":1,"center":1,"for":1,"biomedical":1,"science":1,"st":3,"michael":3,"hospital":4,"alberta":4,"edmonton":2,"lmc":1,"diabetes":2,"vaughan":1,"li":1,"ka":1,"shing":1,"knowledge":1,"institute":2,"humber":1,"river":1,"north":1,"york":1,"british":2,"columbia":2,"vancouver":1,"mcgill":1,"centre":2,"montreal":1,"cardiac":1,"surgery":1,"selkirk":2,"regional":1},"len":169},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":1,"chunkId":"ccs-2022-p1-c2","text":"ll University Health Centre, Montreal, Quebec, Canada; o Division of Cardiac Surgery, St Michael  s Hospital, University of Toronto, Toronto, Ontario, Canada; p Department of Cardiology, Selkirk Regional Health Centre, Selkirk, Manitoba, Canada; q Department of Medicine and Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada; r Libin Cardiovascular Institute of Alberta, Calgary, Alberta, Canada; s Division of Endocrinology and Metabolism, McGill University, Montreal, Quebec, Canada; t Division of Cardiology (Regina), Department of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada; u Division of Nephrology, Department of Medicine, Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada ABSTRACT This guideline synthesizes clinical trial data supporting the role of glucagon-like peptide-1 receptor agonists and sodium-glucose co- transporter 2 inhibitors (SGLT2i) for treatment of heart failure (HF), chronic kidney disease, and for optimizing prevention of cardiorenal morbidity and mortality in patients with type 2 diabetes. It is on the R \u0013 ESUM \u0013 E La pr \u0013 esente ligne directrice synth \u0013 etise les donn \u0013 ees d  essais cliniques con fi rmant le rle des agonistes des r \u0013 ecepteurs du peptide-1 apparent \u0013 e au glucagon (arGLP-1) et des inhibiteurs du cotransporteur sodium- glucose de type 2 (iSGLT2) dans le traitement de ","tf":{"ll":1,"university":6,"health":3,"centre":2,"montreal":2,"quebec":2,"canada":8,"division":4,"of":15,"cardiac":1,"surgery":1,"st":1,"michael":1,"hospital":2,"toronto":2,"ontario":3,"department":4,"cardiology":2,"selkirk":2,"regional":1,"manitoba":1,"medicine":3,"and":5,"population":1,"research":1,"institute":2,"mcmaster":1,"hamilton":1,"libin":1,"cardiovascular":1,"alberta":2,"calgary":1,"endocrinology":1,"metabolism":1,"mcgill":1,"regina":1,"saskatchewan":2,"saskatoon":1,"nephrology":1,"ottawa":3,"abstract":1,"this":1,"guideline":1,"synthesizes":1,"clinical":1,"trial":1,"data":1,"supporting":1,"the":2,"role":1,"glucagon":2,"like":1,"peptide":2,"receptor":1,"agonists":1,"sodium":2,"glucose":2,"co":1,"transporter":1,"inhibitors":1,"sglt2i":1,"for":2,"treatment":1,"heart":1,"failure":1,"hf":1,"chronic":1,"kidney":1,"disease":1,"optimizing":1,"prevention":1,"cardiorenal":1,"morbidity":1,"mortality":1,"in":1,"patients":1,"with":1,"type":2,"diabetes":1,"it":1,"is":1,"on":1,"esum":1,"la":1,"pr":1,"esente":1,"ligne":1,"directrice":1,"synth":1,"etise":1,"les":1,"donn":1,"ees":1,"essais":1,"cliniques":1,"con":1,"fi":1,"rmant":1,"le":3,"des":3,"agonistes":1,"ecepteurs":1,"du":2,"apparent":1,"au":1,"arglp":1,"et":1,"inhibiteurs":1,"cotransporteur":1,"de":2,"isglt2":1,"dans":1,"traitement":1},"len":180},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":1,"chunkId":"ccs-2022-p1-c3","text":"rice synth \u0013 etise les donn \u0013 ees d  essais cliniques con fi rmant le rle des agonistes des r \u0013 ecepteurs du peptide-1 apparent \u0013 e au glucagon (arGLP-1) et des inhibiteurs du cotransporteur sodium- glucose de type 2 (iSGLT2) dans le traitement de l  insuf fi sance cardia- que (IC) et de l  insuf fi sance r \u0013 enale chronique ainsi que dans la Canadian Journal of Cardiology 38 (2022) 1153 e 1167 Received for publication March 16, 2022. Accepted April 21, 2022. Corresponding author: Dr G.B. John Mancini, Rm 9111, 2775 Laurel Street, Vancouver, British Columbia V5Z 1M9, Canada. Tel.:  1-604-875- 5477; fax:  1-604-875-5471. E-mail: mancini@mail.ubc.ca The disclosure information of the authors and reviewers is available from the CCS on their guidelines library at www.ccs.ca. This statement was developed following a thorough consideration of medical literature and the best available evidence and clinical experience. It represents the consensus of a Canadian panel comprised of multidisciplinary experts on this topic with a mandate to formulate disease-speci fi c recom- mendations. These recommendations are aimed to provide a reasonable and practical approach to care for specialists and allied health professionals obliged with the duty of bestowing optimal care to patients and families, and can be subject to change as scienti fi c knowledge and technology advance and as practice ","tf":{"16":1,"21":1,"38":1,"604":2,"875":2,"1153":1,"1167":1,"2022":3,"2775":1,"5471":1,"5477":1,"9111":1,"rice":1,"synth":1,"etise":1,"les":1,"donn":1,"ees":1,"essais":1,"cliniques":1,"con":1,"fi":5,"rmant":1,"le":3,"des":3,"agonistes":1,"ecepteurs":1,"du":2,"peptide":1,"apparent":1,"au":1,"glucagon":1,"arglp":1,"et":2,"inhibiteurs":1,"cotransporteur":1,"sodium":1,"glucose":1,"de":3,"type":1,"isglt2":1,"dans":2,"traitement":1,"insuf":2,"sance":2,"cardia":1,"que":2,"ic":1,"enale":1,"chronique":1,"ainsi":1,"la":1,"canadian":2,"journal":1,"of":6,"cardiology":1,"received":1,"for":2,"publication":1,"march":1,"accepted":1,"april":1,"corresponding":1,"author":1,"dr":1,"john":1,"mancini":2,"rm":1,"laurel":1,"street":1,"vancouver":1,"british":1,"columbia":1,"v5z":1,"1m9":1,"canada":1,"tel":1,"fax":1,"mail":2,"ubc":1,"ca":2,"the":6,"disclosure":1,"information":1,"authors":1,"and":9,"reviewers":1,"is":1,"available":2,"from":1,"ccs":2,"on":2,"their":1,"guidelines":1,"library":1,"at":1,"www":1,"this":2,"statement":1,"was":1,"developed":1,"following":1,"thorough":1,"consideration":1,"medical":1,"literature":1,"best":1,"evidence":1,"clinical":1,"experience":1,"it":1,"represents":1,"consensus":1,"panel":1,"comprised":1,"multidisciplinary":1,"experts":1,"topic":1,"with":2,"mandate":1,"to":5,"formulate":1,"disease":1,"speci":1,"recom":1,"mendations":1,"these":1,"recommendations":1,"are":1,"aimed":1,"provide":1,"reasonable":1,"practical":1,"approach":1,"care":2,"specialists":1,"allied":1,"health":1,"professionals":1,"obliged":1,"duty":1,"bestowing":1,"optimal":1,"patients":1,"families":1,"can":1,"be":1,"subject":1,"change":1,"as":2,"scienti":1,"knowledge":1,"technology":1,"advance":1,"practice":1},"len":209},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":1,"chunkId":"ccs-2022-p1-c4","text":"le and practical approach to care for specialists and allied health professionals obliged with the duty of bestowing optimal care to patients and families, and can be subject to change as scienti fi c knowledge and technology advance and as practice patterns evolve. The statement is not intended to be a substitute for physicians using their individual judgement in managing clinical care in consultation with the patient, with appropriate regard to all the individual circumstances of the patient, diagnostic and treatment options available and available resources. Adherence to these recommendations will not necessarily produce successful outcomes in every case. https://doi.org/10.1016/j.cjca.2022.04.029 0828-282X/  2022 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved. i An update to this article is included at the end","tf":{"10":1,"1016":1,"2022":2,"le":1,"and":8,"practical":1,"approach":1,"to":7,"care":3,"for":2,"specialists":1,"allied":1,"health":1,"professionals":1,"obliged":1,"with":3,"the":6,"duty":1,"of":2,"bestowing":1,"optimal":1,"patients":1,"families":1,"can":1,"be":2,"subject":1,"change":1,"as":2,"scienti":1,"fi":1,"knowledge":1,"technology":1,"advance":1,"practice":1,"patterns":1,"evolve":1,"statement":1,"is":2,"not":2,"intended":1,"substitute":1,"physicians":1,"using":1,"their":1,"individual":2,"judgement":1,"in":3,"managing":1,"clinical":1,"consultation":1,"patient":2,"appropriate":1,"regard":1,"all":2,"circumstances":1,"diagnostic":1,"treatment":1,"options":1,"available":2,"resources":1,"adherence":1,"these":1,"recommendations":1,"will":1,"necessarily":1,"produce":1,"successful":1,"outcomes":1,"every":1,"case":1,"https":1,"doi":1,"org":1,"cjca":1,"04":1,"029":1,"0828":1,"282x":1,"canadian":1,"cardiovascular":1,"society":1,"published":1,"by":1,"elsevier":1,"inc":1,"rights":1,"reserved":1,"an":1,"update":1,"this":1,"article":1,"included":1,"at":1,"end":1},"len":129},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":2,"chunkId":"ccs-2022-p2-c0","text":"The Canadian cardiovascular community has encouraged cardiorenal risk reduction with glucagon-like peptide-1 re- ceptor agonists (GLP-1RA) and sodium-glucose co-trans- porter 2 inhibitors (SGLT2i) for patients with type 2 diabetes (T2D) who have or are at risk of cardiovascular (CV) disease. 1,2 However, to date, no formal guideline has been published by the Canadian Cardiovascular Society (CCS) regarding the use of these agents. Moreover, the application of SGLT2i has expanded beyond management of T2D to include the treatment of heart failure (HF) and chronic kidney disease (CKD) in individuals with and without diabetes. The purpose of this guideline is to assist CV practitioners in the safe and effective use of these 2 drug classes while building upon and remaining concordant with the most recent, high-quality guidelines published by Dia- betes Canada, 3,4 the CCS/Canadian Heart Failure Society (CHFS), 5 and the Kidney Disease Improving Global Out- comes (KDIGO). 6 Although complex patients are best managed by a shared care model, this guideline is also intended to help any CV specialist identify situations when a more proactive or even lead role might be warranted when simple and safe implementation is quite feasible. The reader is advised to consider the specialty guidelines for comprehensive diagnosis and management of patients with T2D, HF, or CKD, including management of","tf":{"the":12,"canadian":3,"cardiovascular":3,"community":1,"has":3,"encouraged":1,"cardiorenal":1,"risk":2,"reduction":1,"with":5,"glucagon":1,"like":1,"peptide":1,"re":1,"ceptor":1,"agonists":1,"glp":1,"1ra":1,"and":8,"sodium":1,"glucose":1,"co":1,"trans":1,"porter":1,"inhibitors":1,"sglt2i":2,"for":2,"patients":3,"type":1,"diabetes":2,"t2d":3,"who":1,"have":1,"or":3,"are":2,"at":1,"of":9,"cv":3,"disease":3,"however":1,"to":5,"date":1,"no":1,"formal":1,"guideline":3,"been":1,"published":2,"by":3,"society":2,"ccs":2,"regarding":1,"use":2,"these":2,"agents":1,"moreover":1,"application":1,"expanded":1,"beyond":1,"management":3,"include":1,"treatment":1,"heart":2,"failure":2,"hf":2,"chronic":1,"kidney":2,"ckd":2,"in":2,"individuals":1,"without":1,"purpose":1,"this":2,"is":4,"assist":1,"practitioners":1,"safe":2,"effective":1,"drug":1,"classes":1,"while":1,"building":1,"upon":1,"remaining":1,"concordant":1,"most":1,"recent":1,"high":1,"quality":1,"guidelines":2,"dia":1,"betes":1,"canada":1,"chfs":1,"improving":1,"global":1,"out":1,"comes":1,"kdigo":1,"although":1,"complex":1,"best":1,"managed":1,"shared":1,"care":1,"model":1,"also":1,"intended":1,"help":1,"any":1,"specialist":1,"identify":1,"situations":1,"when":2,"more":1,"proactive":1,"even":1,"lead":1,"role":1,"might":1,"be":1,"warranted":1,"simple":1,"implementation":1,"quite":1,"feasible":1,"reader":1,"advised":1,"consider":1,"specialty":1,"comprehensive":1,"diagnosis":1,"including":1},"len":211},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":2,"chunkId":"ccs-2022-p2-c1","text":"r even lead role might be warranted when simple and safe implementation is quite feasible. The reader is advised to consider the specialty guidelines for comprehensive diagnosis and management of patients with T2D, HF, or CKD, including management of glycosylated hemoglobin (A1c). The recommendations in this guideline are speci fi cally intended for cardiorenal risk reduction. Treatment recommendations for symp- tomatic hyperglycemia, metabolically decompensated patients with T2D, patients with type 1 diabetes, patients receiving dialysis or with severely compromised renal function (estimated glomerular fi ltration rate [eGFR] < 20 mL/min/1.73 m 2 ), or patients with acutely decom- pensated HF or CKD are beyond the scope of this guideline. We assembled a panel of content and methods experts with representation from key Canadian partner organizations including Diabetes Canada, the CHFS, and the Canadian Society of Nephrology, drawing from community and aca- demic practice settings, with broad geographic representation and considering equity and diversity. We conducted a de novo systematic review and meta-analysis on the basis of a series of focused Population, Intervention, Comparison, Outcome (PICO) questions in which the interventions were SGLT2i and GLP-1RA, and in which the comparator was standard care. The meta-analysis was speci fi cally commissioned by the CCS to support ","tf":{"20":1,"73":1,"even":1,"lead":1,"role":1,"might":1,"be":1,"warranted":1,"when":1,"simple":1,"and":10,"safe":1,"implementation":1,"is":2,"quite":1,"feasible":1,"the":11,"reader":1,"advised":1,"to":2,"consider":1,"specialty":1,"guidelines":1,"for":3,"comprehensive":1,"diagnosis":1,"management":2,"of":7,"patients":5,"with":7,"t2d":2,"hf":2,"or":4,"ckd":2,"including":2,"glycosylated":1,"hemoglobin":1,"a1c":1,"recommendations":2,"in":3,"this":2,"guideline":2,"are":2,"speci":2,"fi":3,"cally":2,"intended":1,"cardiorenal":1,"risk":1,"reduction":1,"treatment":1,"symp":1,"tomatic":1,"hyperglycemia":1,"metabolically":1,"decompensated":1,"type":1,"diabetes":2,"receiving":1,"dialysis":1,"severely":1,"compromised":1,"renal":1,"function":1,"estimated":1,"glomerular":1,"ltration":1,"rate":1,"egfr":1,"ml":1,"min":1,"acutely":1,"decom":1,"pensated":1,"beyond":1,"scope":1,"we":2,"assembled":1,"panel":1,"content":1,"methods":1,"experts":1,"representation":2,"from":2,"key":1,"canadian":2,"partner":1,"organizations":1,"canada":1,"chfs":1,"society":1,"nephrology":1,"drawing":1,"community":1,"aca":1,"demic":1,"practice":1,"settings":1,"broad":1,"geographic":1,"considering":1,"equity":1,"diversity":1,"conducted":1,"de":1,"novo":1,"systematic":1,"review":1,"meta":2,"analysis":2,"on":1,"basis":1,"series":1,"focused":1,"population":1,"intervention":1,"comparison":1,"outcome":1,"pico":1,"questions":1,"which":2,"interventions":1,"were":1,"sglt2i":1,"glp":1,"1ra":1,"comparator":1,"was":2,"standard":1,"care":1,"commissioned":1,"by":1,"ccs":1,"support":1},"len":200},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":2,"chunkId":"ccs-2022-p2-c2","text":"ries of focused Population, Intervention, Comparison, Outcome (PICO) questions in which the interventions were SGLT2i and GLP-1RA, and in which the comparator was standard care. The meta-analysis was speci fi cally commissioned by the CCS to support this guideline. 7 This guideline focused on the critical outcomes of total mortality, CV mortality, nonfatal myocardial infarction (MI), nonfatal stroke, major adverse cardiac events (MACE: CV death, nonfatal MI, or nonfatal stroke), basis of a companion systematic review and meta-analysis guided by a focused set of population, intervention, control, and outcomes (PICO) questions that address priority cardiorenal end points. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system and a modi fi ed Delphi process were used. We encourage comprehensive assessment of cardiovascular (CV) patients with routine measurement of estimated glomerular fi ltration rate, urinary albumin-creatinine ratio, glycosylated hemoglobin (A1c), and documentation of left ventricular ejection fraction (LVEF) when evalu- ating symptoms of HF. For patients with HF, we recommend integra- tion of SGLT2i with other guideline-directed pharmacotherapy for the reduction of hospitalization for HF when LVEF is > 40% and for the reduction of all-cause and CV mortality, hospitalization for HF, and renal protection when LVEF is \u0014 40%. In pat","tf":{"40":2,"ries":1,"of":12,"focused":3,"population":2,"intervention":2,"comparison":1,"outcome":1,"pico":2,"questions":2,"in":3,"which":2,"the":8,"interventions":1,"were":2,"sglt2i":2,"and":10,"glp":1,"1ra":1,"comparator":1,"was":2,"standard":1,"care":1,"meta":2,"analysis":2,"speci":1,"fi":3,"cally":1,"commissioned":1,"by":2,"ccs":1,"to":1,"support":1,"this":2,"guideline":3,"on":1,"critical":1,"outcomes":2,"total":1,"mortality":3,"cv":4,"nonfatal":4,"myocardial":1,"infarction":1,"mi":2,"stroke":2,"major":1,"adverse":1,"cardiac":1,"events":1,"mace":1,"death":1,"or":1,"basis":1,"companion":1,"systematic":1,"review":1,"guided":1,"set":1,"control":1,"that":1,"address":1,"priority":1,"cardiorenal":1,"end":1,"points":1,"grading":1,"recommendations":1,"assessment":2,"development":1,"evaluation":1,"grade":1,"system":1,"modi":1,"ed":1,"delphi":1,"process":1,"used":1,"we":2,"encourage":1,"comprehensive":1,"cardiovascular":1,"patients":2,"with":3,"routine":1,"measurement":1,"estimated":1,"glomerular":1,"ltration":1,"rate":1,"urinary":1,"albumin":1,"creatinine":1,"ratio":1,"glycosylated":1,"hemoglobin":1,"a1c":1,"documentation":1,"left":1,"ventricular":1,"ejection":1,"fraction":1,"lvef":3,"when":3,"evalu":1,"ating":1,"symptoms":1,"hf":4,"for":5,"recommend":1,"integra":1,"tion":1,"other":1,"directed":1,"pharmacotherapy":1,"reduction":2,"hospitalization":2,"is":2,"all":1,"cause":1,"renal":1,"protection":1,"pat":1},"len":201},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":2,"chunkId":"ccs-2022-p2-c3","text":"- tion of SGLT2i with other guideline-directed pharmacotherapy for the reduction of hospitalization for HF when LVEF is > 40% and for the reduction of all-cause and CV mortality, hospitalization for HF, and renal protection when LVEF is \u0014 40%. In patients with albuminuric chronic kidney disease, we recommend integration of SGLT2i with other guideline-directed pharmacotherapy to reduce all-cause and CV mortality, nonfatal myocardial infarction, and hospitalization for HF. We provide recommendations and algorithms for the selection of glucagon-like peptide-1 receptor agonists and SGLT2i for patients with type 2 diabetes and either established atherosclerotic CV disease or risk factors for atherosclerotic CV disease to reduce all-cause and CV mortality, nonfatal stroke, and for the prevention of hospitalization for HF and decline in renal function. We offer practical advice for safe use of these diabetes-associated agents with profound cardiorenal bene fi ts. pr \u0013 evention optimis \u0013 ee de la morbidit \u0013 e et de la mortalit \u0013 e cardior \u0013 enales chez les patients atteints de diabte de type 2. Elle repose sur une revue syst \u0013 ematique et une m \u0013 eta-analyse compl \u0013 ementaires utilisant un ensemble pr \u0013 ecis de questions PICO (population, intervention, com- paraison, et objectifs) sur des paramtres cardior \u0013 enaux prioritaires. Le systme GRADE ( Grading of Recommendations Assessment","tf":{"40":2,"tion":1,"of":8,"sglt2i":3,"with":5,"other":2,"guideline":2,"directed":2,"pharmacotherapy":2,"for":11,"the":4,"reduction":2,"hospitalization":4,"hf":4,"when":2,"lvef":2,"is":2,"and":11,"all":3,"cause":3,"cv":5,"mortality":3,"renal":2,"protection":1,"in":2,"patients":3,"albuminuric":1,"chronic":1,"kidney":1,"disease":3,"we":3,"recommend":1,"integration":1,"to":2,"reduce":2,"nonfatal":2,"myocardial":1,"infarction":1,"provide":1,"recommendations":2,"algorithms":1,"selection":1,"glucagon":1,"like":1,"peptide":1,"receptor":1,"agonists":1,"type":2,"diabetes":2,"either":1,"established":1,"atherosclerotic":2,"or":1,"risk":1,"factors":1,"stroke":1,"prevention":1,"decline":1,"function":1,"offer":1,"practical":1,"advice":1,"safe":1,"use":1,"these":1,"associated":1,"agents":1,"profound":1,"cardiorenal":1,"bene":1,"fi":1,"ts":1,"pr":2,"evention":1,"optimis":1,"ee":1,"de":5,"la":2,"morbidit":1,"et":3,"mortalit":1,"cardior":2,"enales":1,"chez":1,"les":1,"atteints":1,"diab":1,"te":1,"elle":1,"repose":1,"sur":2,"une":2,"revue":1,"syst":2,"ematique":1,"eta":1,"analyse":1,"compl":1,"ementaires":1,"utilisant":1,"un":1,"ensemble":1,"ecis":1,"questions":1,"pico":1,"population":1,"intervention":1,"com":1,"paraison":1,"objectifs":1,"des":1,"param":1,"tres":1,"enaux":1,"prioritaires":1,"le":1,"me":1,"grade":1,"grading":1,"assessment":1},"len":208},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":2,"chunkId":"ccs-2022-p2-c4","text":"une m \u0013 eta-analyse compl \u0013 ementaires utilisant un ensemble pr \u0013 ecis de questions PICO (population, intervention, com- paraison, et objectifs) sur des paramtres cardior \u0013 enaux prioritaires. Le systme GRADE ( Grading of Recommendations Assessment, Devel- opment and Evaluation ) et une m \u0013 ethode Delphi modi fi \u0013 ee ont \u0013 et \u0013 e uti- lis \u0013 es. Nous pr \u0013 econisons une \u0013 evaluation complte des patients atteints de maladies cardiovasculaires (CV) par des mesures syst \u0013 ematiques du d \u0013 ebit de fi ltration glom \u0013 erulaire estim \u0013 e, du rapport albumine-cr \u0013 eatinine urinaire et du taux d  h \u0013 emoglobine glyqu \u0013 ee (HbA 1c ). La fraction d  \u0013 ejection ventriculaire gauche (FEVG) devrait aussi tre document \u0013 ee lors de l  \u0013 evaluation des symptmes d  IC. En pr \u0013 esence d  IC, nous recommandons d  int \u0013 egrer les iSGLT2  d  autres pharmacoth \u0013 erapies fond \u0013 ees sur les lignes directrices pour r \u0013 eduire la fr \u0013 equence des hos- pitalisations pour IC lorsque la FEVG > 40 %, r \u0013 eduire la mortalit \u0013 e toutes causes confondues et la mortalit \u0013 e cardiovasculaire, r \u0013 eduire les hospitalisations pour IC ainsi que pour pr \u0013 eserver la fonction r \u0013 enale chez les patients dont la FEVG \u0014 40 %. En pr \u0013 esence de n \u0013 ephropathie chronique avec albuminurie, nous recommandons d  int \u0013 egrer les iSGLT2  d  autres pharmacoth \u0013 erapies fond \u0013 ees sur les lignes directrices pour r ","tf":{"40":2,"une":3,"eta":1,"analyse":1,"compl":2,"ementaires":1,"utilisant":1,"un":1,"ensemble":1,"pr":5,"ecis":1,"de":5,"questions":1,"pico":1,"population":1,"intervention":1,"com":1,"paraison":1,"et":5,"objectifs":1,"sur":3,"des":5,"param":1,"tres":1,"cardior":1,"enaux":1,"prioritaires":1,"le":1,"syst":2,"me":1,"grade":1,"grading":1,"of":1,"recommendations":1,"assessment":1,"devel":1,"opment":1,"and":1,"evaluation":3,"ethode":1,"delphi":1,"modi":1,"fi":2,"ee":3,"ont":1,"uti":1,"lis":1,"es":1,"nous":3,"econisons":1,"te":1,"patients":2,"atteints":1,"maladies":1,"cardiovasculaires":1,"cv":1,"par":1,"mesures":1,"ematiques":1,"du":3,"ebit":1,"ltration":1,"glom":1,"erulaire":1,"estim":1,"rapport":1,"albumine":1,"cr":1,"eatinine":1,"urinaire":1,"taux":1,"emoglobine":1,"glyqu":1,"hba":1,"1c":1,"la":7,"fraction":1,"ejection":1,"ventriculaire":1,"gauche":1,"fevg":3,"devrait":1,"aussi":1,"tre":1,"document":1,"lors":1,"sympt":1,"mes":1,"ic":4,"en":2,"esence":2,"recommandons":2,"int":2,"egrer":2,"les":6,"isglt2":2,"autres":2,"pharmacoth":2,"erapies":2,"fond":2,"ees":2,"lignes":2,"directrices":2,"pour":5,"eduire":3,"fr":1,"equence":1,"hos":1,"pitalisations":1,"lorsque":1,"mortalit":2,"toutes":1,"causes":1,"confondues":1,"cardiovasculaire":1,"hospitalisations":1,"ainsi":1,"que":1,"eserver":1,"fonction":1,"enale":1,"chez":1,"dont":1,"ephropathie":1,"chronique":1,"avec":1,"albuminurie":1},"len":196},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":2,"chunkId":"ccs-2022-p2-c5","text":"er la fonction r \u0013 enale chez les patients dont la FEVG \u0014 40 %. En pr \u0013 esence de n \u0013 ephropathie chronique avec albuminurie, nous recommandons d  int \u0013 egrer les iSGLT2  d  autres pharmacoth \u0013 erapies fond \u0013 ees sur les lignes directrices pour r \u0013 eduire la mortalit \u0013 e toutes causes confondues et la mortalit \u0013 e d  origine CV, r \u0013 eduire le risque d  infarctus du myocarde non mortel et les hospitalisations pour IC. Nous pr \u0013 esentons des recommandations et des algorithmes pour la s \u0013 election d  arGLP-1 et d  iSGLT2 pour les pa- tients atteints de diabte de type 2 et d  une maladie CV ath \u0013 eroscl \u0013 ereuse \u0013 etablie ou pr \u0013 esentant des facteurs de risque de maladie CV ath \u0013 eroscl \u0013 ereuse a fi n de r \u0013 eduire la mortalit \u0013 e toutes causes confondues, la mortalit \u0013 e CV ainsi que les AVC non mortels et pour la pr \u0013 evention des hospitalisations pour IC et le d \u0013 eclin de la fonction r \u0013 enale. Nous offrons aussi des conseils pratiques sur l  utilisation s \u0013 ecuritaire de ces agents associ \u0013 es au diabte qui ont de profonds avantages cardior \u0013 enaux. 1154 Canadian Journal of Cardiology Volume 38 2022","tf":{"38":1,"40":1,"1154":1,"2022":1,"er":1,"la":9,"fonction":2,"enale":2,"chez":1,"les":6,"patients":1,"dont":1,"fevg":1,"en":1,"pr":4,"esence":1,"de":9,"ephropathie":1,"chronique":1,"avec":1,"albuminurie":1,"nous":3,"recommandons":1,"int":1,"egrer":1,"isglt2":2,"autres":1,"pharmacoth":1,"erapies":1,"fond":1,"ees":1,"sur":2,"lignes":1,"directrices":1,"pour":6,"eduire":3,"mortalit":4,"toutes":2,"causes":2,"confondues":2,"et":7,"origine":1,"cv":4,"le":2,"risque":2,"infarctus":1,"du":1,"myocarde":1,"non":2,"mortel":1,"hospitalisations":2,"ic":2,"esentons":1,"des":5,"recommandations":1,"algorithmes":1,"election":1,"arglp":1,"pa":1,"tients":1,"atteints":1,"diab":2,"te":2,"type":1,"une":1,"maladie":2,"ath":2,"eroscl":2,"ereuse":2,"etablie":1,"ou":1,"esentant":1,"facteurs":1,"fi":1,"ainsi":1,"que":1,"avc":1,"mortels":1,"evention":1,"eclin":1,"offrons":1,"aussi":1,"conseils":1,"pratiques":1,"utilisation":1,"ecuritaire":1,"ces":1,"agents":1,"associ":1,"es":1,"au":1,"qui":1,"ont":1,"profonds":1,"avantages":1,"cardior":1,"enaux":1,"canadian":1,"journal":1,"of":1,"cardiology":1,"volume":1},"len":169},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":3,"chunkId":"ccs-2022-p3-c0","text":"hospitalization for HF, and composite kidney outcomes with emphasis on signi fi cant decline in eGFR, progression to end- stage kidney disease, or death from kidney disease. Using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach, we derived pooled estimates for each PICO question and appraised evidence certainty on an outcome-by-outcome basis. With GRADE, evidence certainty is appraised across 5 domains: risk of bias, indirectness, imprecision, inconsistency, and publication bias. This extensive and detailed analysis is provided in the companion article. 7 We used a modi fi ed Delphi process in which panelists voted on and suggested re fi nements to draft statements to derive the fi nal statements. All con fl icts of interest were declared. For recom- mendations to go forward a two-thirds voting majority was required. It should be emphasized that the voting was primarily an evaluation of the commissioned meta-analysis which, by design, included all available data and not just trial-speci fi c data. Practical points were identi fi ed through surveying the panel members, and through examining other published guidelines. 3-6 The primary writing group also submitted a draft for peer-review by a secondary panel, after which peer-review was undertaken by the CCS Guideline Committee. Simulta- neously but separately, the de novo systematic review","tf":{"hospitalization":1,"for":4,"hf":1,"and":8,"composite":1,"kidney":3,"outcomes":1,"with":2,"emphasis":1,"on":3,"signi":1,"fi":6,"cant":1,"decline":1,"in":3,"egfr":1,"progression":1,"to":4,"end":1,"stage":1,"disease":2,"or":1,"death":1,"from":1,"using":1,"the":9,"grading":1,"of":4,"recommendations":1,"assessment":1,"development":1,"evaluation":2,"grade":2,"approach":1,"we":2,"derived":1,"pooled":1,"estimates":1,"each":1,"pico":1,"question":1,"appraised":2,"evidence":2,"certainty":2,"an":2,"outcome":2,"by":4,"basis":1,"is":2,"across":1,"domains":1,"risk":1,"bias":2,"indirectness":1,"imprecision":1,"inconsistency":1,"publication":1,"this":1,"extensive":1,"detailed":1,"analysis":2,"provided":1,"companion":1,"article":1,"used":1,"modi":1,"ed":2,"delphi":1,"process":1,"which":3,"panelists":1,"voted":1,"suggested":1,"re":1,"nements":1,"draft":2,"statements":2,"derive":1,"nal":1,"all":2,"con":1,"fl":1,"icts":1,"interest":1,"were":2,"declared":1,"recom":1,"mendations":1,"go":1,"forward":1,"two":1,"thirds":1,"voting":2,"majority":1,"was":3,"required":1,"it":1,"should":1,"be":1,"emphasized":1,"that":1,"primarily":1,"commissioned":1,"meta":1,"design":1,"included":1,"available":1,"data":2,"not":1,"just":1,"trial":1,"speci":1,"practical":1,"points":1,"identi":1,"through":2,"surveying":1,"panel":2,"members":1,"examining":1,"other":1,"published":1,"guidelines":1,"primary":1,"writing":1,"group":1,"also":1,"submitted":1,"peer":2,"review":3,"secondary":1,"after":1,"undertaken":1,"ccs":1,"guideline":1,"committee":1,"simulta":1,"neously":1,"but":1,"separately":1,"de":1,"novo":1,"systematic":1},"len":210},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":3,"chunkId":"ccs-2022-p3-c1","text":"her published guidelines. 3-6 The primary writing group also submitted a draft for peer-review by a secondary panel, after which peer-review was undertaken by the CCS Guideline Committee. Simulta- neously but separately, the de novo systematic review and meta- analysis supporting this guideline was peer-reviewed. 7 The overall goal of the process was to produce guidelines on the basis of the best, most comprehensive, and most up to date evidence that would allow clinicians and patients to make collaborative treatment decisions. These guidelines were un- dertaken under the auspices of the Guideline Committee of the CCS without representation or funding from the pharmaceu- tical or device industry. Evidence Synthesis and Recommendations at a Glance As indicated previously, the recommendations are on the basis of a companion, systematic review and meta-analysis to which the reader is referred for details of data synthesis and GRADE tables summarizing evidence quality. 7 Table 1 herein is a summary of the relative bene fi ts (hazard ratios [HRs]) and event reductions per 1000 treated patients. The resulting recommendations are provided in Table 2. A summary of the speci fi c trials, the medications used, and the cardiorenal out- comes that were signi fi cantly improved are provided in Table 3. A general approach to the integration of GLP-1RA and SGLT2i as cardiorenal agents into ca","tf":{"1000":1,"her":1,"published":1,"guidelines":3,"the":20,"primary":1,"writing":1,"group":1,"also":1,"submitted":1,"draft":1,"for":2,"peer":3,"review":4,"by":2,"secondary":1,"panel":1,"after":1,"which":2,"was":3,"undertaken":1,"ccs":2,"guideline":3,"committee":2,"simulta":1,"neously":1,"but":1,"separately":1,"de":1,"novo":1,"systematic":2,"and":9,"meta":2,"analysis":2,"supporting":1,"this":1,"reviewed":1,"overall":1,"goal":1,"of":9,"process":1,"to":5,"produce":1,"on":2,"basis":2,"best":1,"most":2,"comprehensive":1,"up":1,"date":1,"evidence":3,"that":2,"would":1,"allow":1,"clinicians":1,"patients":2,"make":1,"collaborative":1,"treatment":1,"decisions":1,"these":1,"were":2,"un":1,"dertaken":1,"under":1,"auspices":1,"without":1,"representation":1,"or":2,"funding":1,"from":1,"pharmaceu":1,"tical":1,"device":1,"industry":1,"synthesis":2,"recommendations":3,"at":1,"glance":1,"as":2,"indicated":1,"previously":1,"are":3,"companion":1,"reader":1,"is":2,"referred":1,"details":1,"data":1,"grade":1,"tables":1,"summarizing":1,"quality":1,"table":3,"herein":1,"summary":2,"relative":1,"bene":1,"fi":3,"ts":1,"hazard":1,"ratios":1,"hrs":1,"event":1,"reductions":1,"per":1,"treated":1,"resulting":1,"provided":2,"in":2,"speci":1,"trials":1,"medications":1,"used":1,"cardiorenal":2,"out":1,"comes":1,"signi":1,"cantly":1,"improved":1,"general":1,"approach":1,"integration":1,"glp":1,"1ra":1,"sglt2i":1,"agents":1,"into":1,"ca":1},"len":211},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":3,"chunkId":"ccs-2022-p3-c2","text":"in Table 2. A summary of the speci fi c trials, the medications used, and the cardiorenal out- comes that were signi fi cantly improved are provided in Table 3. A general approach to the integration of GLP-1RA and SGLT2i as cardiorenal agents into cardiovascular prac- tice is provided in Figure 1. Screening The opportunity to help reduce cardiorenal morbidity and mortality through the use of diabetes-related drugs requires vigilance in identi fi cation of appropriate patients for therapy. Assessment of HF symptoms is commonplace and fosters appropriate use of imaging and biomarker tests to identify HF and its phenotype. Serum creatinine and eGFR are often measured to ensure appropriate CV drug dosing or in antic- ipation of diagnostic tests using contrast media. But measures of A1c and urine albumin-creatinine ratio (UACR) are often not included to identify patients who might well bene fi t from use of cardiorenal risk-reduction drugs. Consequently, we have included a general recommendation to undertake these tests as part of a comprehensive CV risk assessment. Moreover, digital health technologies might further facilitate Table 1. Summary of relative (hazard ratios) and absolute event reductions per 1000 treated patients for cardiorenal outcomes in study populations with heart failure, chronic kidney disease, or type 2 diabetes Study pa\u0002ent popula\u0002on T2D Class MACE All-cause m","tf":{"1000":1,"in":6,"table":3,"summary":2,"of":11,"the":6,"speci":1,"fi":4,"trials":1,"medications":1,"used":1,"and":9,"cardiorenal":5,"out":1,"comes":1,"that":1,"were":1,"signi":1,"cantly":1,"improved":1,"are":3,"provided":2,"general":2,"approach":1,"to":6,"integration":1,"glp":1,"1ra":1,"sglt2i":1,"as":2,"agents":1,"into":1,"cardiovascular":1,"prac":1,"tice":1,"is":2,"figure":1,"screening":1,"opportunity":1,"help":1,"reduce":1,"morbidity":1,"mortality":1,"through":1,"use":3,"diabetes":2,"related":1,"drugs":2,"requires":1,"vigilance":1,"identi":1,"cation":1,"appropriate":3,"patients":3,"for":2,"therapy":1,"assessment":2,"hf":2,"symptoms":1,"commonplace":1,"fosters":1,"imaging":1,"biomarker":1,"tests":3,"identify":2,"its":1,"phenotype":1,"serum":1,"creatinine":2,"egfr":1,"often":2,"measured":1,"ensure":1,"cv":2,"drug":1,"dosing":1,"or":2,"antic":1,"ipation":1,"diagnostic":1,"using":1,"contrast":1,"media":1,"but":1,"measures":1,"a1c":1,"urine":1,"albumin":1,"ratio":1,"uacr":1,"not":1,"included":2,"who":1,"might":2,"well":1,"bene":1,"from":1,"risk":2,"reduction":1,"consequently":1,"we":1,"have":1,"recommendation":1,"undertake":1,"these":1,"part":1,"comprehensive":1,"moreover":1,"digital":1,"health":1,"technologies":1,"further":1,"facilitate":1,"relative":1,"hazard":1,"ratios":1,"absolute":1,"event":1,"reductions":1,"per":1,"treated":1,"outcomes":1,"study":2,"populations":1,"with":1,"heart":1,"failure":1,"chronic":1,"kidney":1,"disease":1,"type":1,"pa":1,"ent":1,"popula":1,"on":1,"t2d":1,"class":1,"mace":1,"all":1,"cause":1},"len":211},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":3,"chunkId":"ccs-2022-p3-c3","text":"Summary of relative (hazard ratios) and absolute event reductions per 1000 treated patients for cardiorenal outcomes in study populations with heart failure, chronic kidney disease, or type 2 diabetes Study pa\u0002ent popula\u0002on T2D Class MACE All-cause mortality CV death Nonfatal MI Nonfatal stroke Hospitaliza\u0002on for HF CV death or hospitaliza\u0002on for HF Composite kidney outcome * HF LVEF  40% +/ SGLT2i NA 0.84  (0.72-0.97) 0.84 (0.71-0.98) NA NA 0.69 (0.64-0.75) 0.75 (0.69-0.81) 0.59  (0.42-0.83) Events per 1000 pts 22 (38 to 4) 17 (32 to 2) 46 (54 to 37) 52 (65 to 39) 9 (13 to 4) LVEF > 40% +/ SGLT2i NA 1.00 (0.89-1.13) 1.06 (0.80-1.40) NA NA 0.71 (0.62-0.82) 0.77 (0.68-0.87) 0.95 (0.73-1.24) Events per 1000 pts 31 (40 to 19) 35 (49 to 20) CKD Any LVEF +/ SGLT2i 0.83 (0.75-0.91) 0.82 (0.74-0.90) 0.85 (0.77-0.94) 0.77 (0.62-0.95) 0.78 (0.49-1.25) 0.63 (0.58-0.70) 0.73 (0.68-0.78) 0.64 (0.57-0.73) Events per 1000 pts 17 (25 to 9) 17 (24 to 9) 9 (13 to 3) 12 (19 to 3) 32 (37 to 26) 35 (41 to 28) 19 (23 to 14) T2D with either ASCVD or mul\u0002ple risk factors Any LVEF or eGFR + SGLT2i 0.88 (0.82-0.93) 0.85 (0.79-0.92) 0.85 (0.78-0.92) 0.90 (0.83-0.98) 0.99 (0.88-1.11) 0.68  (0.63-0.74) 0.76  (0.72-0.80) 0.65  (0.57-0.74) Events per 1000 pts 13 (19 to 7) 11 (15 to 6) 7 (11 to 4) 8 (8 to 1) 20 (23 to 16) 25 (29 to 21) 17 ","tf":{"11":3,"12":1,"13":4,"14":1,"15":1,"16":1,"17":4,"19":4,"20":2,"21":1,"22":1,"23":2,"24":2,"25":3,"26":1,"28":1,"29":1,"31":1,"32":2,"35":2,"37":2,"38":1,"39":1,"40":4,"41":1,"42":1,"46":1,"49":2,"52":1,"54":1,"57":2,"58":1,"59":1,"62":2,"63":2,"64":2,"65":2,"68":3,"69":2,"70":1,"71":2,"72":2,"73":3,"74":3,"75":3,"76":1,"77":3,"78":3,"79":1,"80":2,"81":1,"82":3,"83":3,"84":2,"85":3,"87":1,"88":2,"89":1,"90":2,"91":1,"92":2,"93":1,"94":1,"95":2,"97":1,"98":2,"99":1,"1000":5,"summary":1,"of":1,"relative":1,"hazard":1,"ratios":1,"and":1,"absolute":1,"event":1,"reductions":1,"per":5,"treated":1,"patients":1,"for":3,"cardiorenal":1,"outcomes":1,"in":1,"study":2,"populations":1,"with":2,"heart":1,"failure":1,"chronic":1,"kidney":2,"disease":1,"or":4,"type":1,"diabetes":1,"pa":1,"ent":1,"popula":1,"on":3,"t2d":2,"class":1,"mace":1,"all":1,"cause":1,"mortality":1,"cv":2,"death":2,"nonfatal":2,"mi":1,"stroke":1,"hospitaliza":2,"hf":3,"composite":1,"outcome":1,"lvef":4,"sglt2i":4,"na":6,"events":4,"pts":4,"to":20,"00":1,"06":1,"ckd":1,"any":2,"either":1,"ascvd":1,"mul":1,"ple":1,"risk":1,"factors":1,"egfr":1},"len":249},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":3,"chunkId":"ccs-2022-p3-c4","text":"0.93) 0.85 (0.79-0.92) 0.85 (0.78-0.92) 0.90 (0.83-0.98) 0.99 (0.88-1.11) 0.68  (0.63-0.74) 0.76  (0.72-0.80) 0.65  (0.57-0.74) Events per 1000 pts 13 (19 to 7) 11 (15 to 6) 7 (11 to 4) 8 (8 to 1) 20 (23 to 16) 25 (29 to 21) 17 (20 to 12) + GLP-1 RA 0.86 (0.80-0.93) 0.88 (0.82-0.94) 0.87 (0.80-0.94) 0.94 (0.88-1.02) 0.84  (0.76-0.94) 0.91 (0.83-1.002) 0.89 (0.81-0.98) 0.78 (0.70-0.87) Events per 1000 pts 16 (22 to 8) 9 (13 to 4) 6 (9 to 3) 4 (7 to 2) 6 (11 to 1) 21 (29 to 13) Numbers in parentheses represent 95% con fi dence intervals. 7 Cells shaded in green represent statistically signi fi cant hazard ratios for which data pertaining to absolute events per 1000 patients are provided. ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; CV, cardiovascular; eGFR, estimated glomerular fi ltration rate; GLP-1RA, glucagon-like peptide-1 receptor agonists; HF, heart failure; LVEF, left ventricular ejection fraction; MACE, major adverse cardiac events; MI, myocardial infarction; NA, not applicable; pts, patients; SGLT2i, sodium-glucose co-transporter 2 inhibitors; T2D, type 2 diabetes;  / \u0003 , with/without. * Hazard ratios are on the basis of the composite kidney outcomes de fi ned in the primary trials (see Supplemental Table S1). y Darker green shading indicates differences between heart failure with left ventricula","tf":{"11":4,"12":1,"13":3,"15":1,"16":2,"17":1,"19":1,"20":2,"21":2,"22":1,"23":1,"25":1,"29":2,"57":1,"63":1,"65":1,"68":1,"70":1,"72":1,"74":2,"76":2,"78":2,"79":1,"80":3,"81":1,"82":1,"83":2,"84":1,"85":2,"86":1,"87":2,"88":3,"89":1,"90":1,"91":1,"92":2,"93":2,"94":4,"95":1,"98":2,"99":1,"1000":3,"events":4,"per":3,"pts":3,"to":14,"glp":2,"ra":1,"02":1,"002":1,"numbers":1,"in":3,"parentheses":1,"represent":2,"con":1,"fi":4,"dence":1,"intervals":1,"cells":1,"shaded":1,"green":2,"statistically":1,"signi":1,"cant":1,"hazard":2,"ratios":2,"for":1,"which":1,"data":1,"pertaining":1,"absolute":1,"patients":2,"are":2,"provided":1,"ascvd":1,"atherosclerotic":1,"cardiovascular":2,"disease":2,"ckd":1,"chronic":1,"kidney":2,"cv":1,"egfr":1,"estimated":1,"glomerular":1,"ltration":1,"rate":1,"1ra":1,"glucagon":1,"like":1,"peptide":1,"receptor":1,"agonists":1,"hf":1,"heart":2,"failure":2,"lvef":1,"left":2,"ventricular":1,"ejection":1,"fraction":1,"mace":1,"major":1,"adverse":1,"cardiac":1,"mi":1,"myocardial":1,"infarction":1,"na":1,"not":1,"applicable":1,"sglt2i":1,"sodium":1,"glucose":1,"co":1,"transporter":1,"inhibitors":1,"t2d":1,"type":1,"diabetes":1,"with":2,"without":1,"on":1,"the":3,"basis":1,"of":1,"composite":1,"outcomes":1,"de":1,"ned":1,"primary":1,"trials":1,"see":1,"supplemental":1,"table":1,"s1":1,"darker":1,"shading":1,"indicates":1,"differences":1,"between":1,"ventricula":1},"len":210},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":3,"chunkId":"ccs-2022-p3-c5","text":"e 2 diabetes;  / \u0003 , with/without. * Hazard ratios are on the basis of the composite kidney outcomes de fi ned in the primary trials (see Supplemental Table S1). y Darker green shading indicates differences between heart failure with left ventricular ejection fraction \u0014 40% vs > 40%. z Darker green shading indicates differences between classes of medications. Mancini et al. 1155 CCS Guideline for Cardiorenal Risk Reduction","tf":{"40":2,"1155":1,"diabetes":1,"with":2,"without":1,"hazard":1,"ratios":1,"are":1,"on":1,"the":3,"basis":1,"of":2,"composite":1,"kidney":1,"outcomes":1,"de":1,"fi":1,"ned":1,"in":1,"primary":1,"trials":1,"see":1,"supplemental":1,"table":1,"s1":1,"darker":2,"green":2,"shading":2,"indicates":2,"differences":2,"between":2,"heart":1,"failure":1,"left":1,"ventricular":1,"ejection":1,"fraction":1,"vs":1,"classes":1,"medications":1,"mancini":1,"et":1,"al":1,"ccs":1,"guideline":1,"for":1,"cardiorenal":1,"risk":1,"reduction":1},"len":60},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":4,"chunkId":"ccs-2022-p4-c0","text":"identi fi cation of appropriate patients. 27 The reader is referred to the major society guidelines for more detailed recommen- dations regarding screening and symptom evaluation processes. 3-6 SGLT2i for the Treatment of HF PICO 1: In patients with HF and reduced ejection fraction (HFrEF; \u0014 40%) what is the role of SGLT2i and GLP-1RA compared with placebo for reduction of CV disease or hospitali- zation for HF? Our systematic review did not identify any large randomized clinical trials of GLP-1RA for the management of HF. Accordingly, our discussion and recommendations are on the basis of evidence from clinical trials of SGLT2i. The results of the D apagli fl ozin a nd P revention of A dverse Outcomes in H eart F ailure (DAPA-HF) trial 18 were described in the previous CCS/ CHFS guideline update. 5 During a median 18-month follow-up of 4744 patients with HFrEF, treatment with dapagli fl ozin 10 mg daily signi fi cantly reduced the composite primary end point of time to fi rst worsening of HF or death from CV causes (HR, 0.74; 95% con fi dence interval [CI], 0.65-0.85]; P < 0.001), as well as hospitalization for HF (HR, 0.70; 95% CI, 0.59-0.83) and CV death (HR, 0.82; 95% CI, 0.69-0.98). Importantly, 55% of patients did not have T2D, and the effect of dapagli- fl ozin was similar at any A1c level. 18 Ancillary studies have shown that bene fi ts were seen as early as 30 days aft","tf":{"10":1,"18":3,"27":1,"30":1,"40":1,"55":1,"59":1,"65":1,"69":1,"70":1,"74":1,"82":1,"83":1,"85":1,"95":3,"98":1,"4744":1,"identi":1,"fi":5,"cation":1,"of":15,"appropriate":1,"patients":4,"the":11,"reader":1,"is":2,"referred":1,"to":2,"major":1,"society":1,"guidelines":1,"for":6,"more":1,"detailed":1,"recommen":1,"dations":1,"regarding":1,"screening":1,"and":6,"symptom":1,"evaluation":1,"processes":1,"sglt2i":3,"treatment":2,"hf":7,"pico":1,"in":3,"with":4,"reduced":2,"ejection":1,"fraction":1,"hfref":2,"what":1,"role":1,"glp":2,"1ra":2,"compared":1,"placebo":1,"reduction":1,"cv":3,"disease":1,"or":2,"hospitali":1,"zation":1,"our":2,"systematic":1,"review":1,"did":2,"not":2,"identify":1,"any":2,"large":1,"randomized":1,"clinical":2,"trials":2,"management":1,"accordingly":1,"discussion":1,"recommendations":1,"are":1,"on":1,"basis":1,"evidence":1,"from":2,"results":1,"apagli":1,"fl":3,"ozin":3,"nd":1,"revention":1,"dverse":1,"outcomes":1,"eart":1,"ailure":1,"dapa":1,"trial":1,"were":2,"described":1,"previous":1,"ccs":1,"chfs":1,"guideline":1,"update":1,"during":1,"median":1,"month":1,"follow":1,"up":1,"dapagli":2,"mg":1,"daily":1,"signi":1,"cantly":1,"composite":1,"primary":1,"end":1,"point":1,"time":1,"rst":1,"worsening":1,"death":2,"causes":1,"hr":3,"con":1,"dence":1,"interval":1,"ci":3,"001":1,"as":4,"well":1,"hospitalization":1,"importantly":1,"have":2,"t2d":1,"effect":1,"was":1,"similar":1,"at":1,"a1c":1,"level":1,"ancillary":1,"studies":1,"shown":1,"that":1,"bene":1,"ts":1,"seen":1,"early":1,"days":1,"aft":1},"len":240},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":4,"chunkId":"ccs-2022-p4-c1","text":", 0.59-0.83) and CV death (HR, 0.82; 95% CI, 0.69-0.98). Importantly, 55% of patients did not have T2D, and the effect of dapagli- fl ozin was similar at any A1c level. 18 Ancillary studies have shown that bene fi ts were seen as early as 30 days after treatment initiation. 28 Additionally, diuretic dose was not modi fi ed during the trial for most patients, 29 quality of life was improved, 30 and blood pressure (BP) was reduced by an average of approximately 2 mm Hg. 31 Outcomes were not modi fi ed by baseline kidney Table 2. Practice recommendations for use of GLP-1RA or SGLT2i for cardiorenal risk reduction in adults Process Pracce Statement Strength of Recommendaon Quality of Evidence Screening 1 CV specialists are encouraged to assess kidney and glycemic status through measurement of eGFR, UACR, and A1c and to document LVEF when evaluang symptoms of HF.   Recommendaons Treatment of HF In adults with HF and LVEF  40%, we recommend use of SGLT2i to reduce all- cause and CV mortality, hospitalizaon for HF, and the composite end point of significant decline in eGFR, progression to end-stage kidney disease or death due to kidney disease. Strong Moderate In adults with HF and LVEF > 40%, we recommend use of SGLT2i to reduce hospitalizaon for HF. Strong Moderate Treatment of CKD In adults with CKD (UACR > 20 mg/mmol, eGFR  25 mL/min/1.73m 2 ), we recommend use of SGLT2i","tf":{"18":1,"20":1,"25":1,"28":1,"29":1,"30":2,"31":1,"40":2,"55":1,"59":1,"69":1,"82":1,"83":1,"95":1,"98":1,"and":10,"cv":3,"death":2,"hr":1,"ci":1,"importantly":1,"of":15,"patients":2,"did":1,"not":3,"have":2,"t2d":1,"the":3,"effect":1,"dapagli":1,"fl":1,"ozin":1,"was":4,"similar":1,"at":1,"any":1,"a1c":2,"level":1,"ancillary":1,"studies":1,"shown":1,"that":1,"bene":1,"fi":3,"ts":1,"were":2,"seen":1,"as":2,"early":1,"days":1,"after":1,"treatment":3,"initiation":1,"additionally":1,"diuretic":1,"dose":1,"modi":2,"ed":2,"during":1,"trial":1,"for":5,"most":1,"quality":2,"life":1,"improved":1,"blood":1,"pressure":1,"bp":1,"reduced":1,"by":2,"an":1,"average":1,"approximately":1,"mm":1,"hg":1,"outcomes":1,"baseline":1,"kidney":4,"table":1,"practice":1,"recommendations":1,"use":4,"glp":1,"1ra":1,"or":2,"sglt2i":4,"cardiorenal":1,"risk":1,"reduction":1,"in":5,"adults":4,"process":1,"prac":1,"ce":1,"statement":1,"strength":1,"recommenda":2,"on":3,"evidence":1,"screening":1,"specialists":1,"are":1,"encouraged":1,"to":6,"assess":1,"glycemic":1,"status":1,"through":1,"measurement":1,"egfr":3,"uacr":2,"document":1,"lvef":3,"when":1,"evalua":1,"ng":1,"symptoms":1,"hf":6,"ons":1,"with":3,"we":3,"recommend":3,"reduce":2,"all":1,"cause":1,"mortality":1,"hospitaliza":2,"composite":1,"end":2,"point":1,"significant":1,"decline":1,"progression":1,"stage":1,"disease":2,"due":1,"strong":2,"moderate":2,"ckd":2,"mg":1,"mmol":1,"ml":1,"min":1,"73m":1},"len":244},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":4,"chunkId":"ccs-2022-p4-c2","text":"dney disease. Strong Moderate In adults with HF and LVEF > 40%, we recommend use of SGLT2i to reduce hospitalizaon for HF. Strong Moderate Treatment of CKD In adults with CKD (UACR > 20 mg/mmol, eGFR  25 mL/min/1.73m 2 ), we recommend use of SGLT2i to reduce the composite of significant decline in eGFR, progression to end-stage kidney disease or death due to kidney disease, all-cause and CV mortality, nonfatal MI, and hospitalizaon for HF. Strong Moderate Prevenon of cardiorenal events in adults with either T2D and ASCVD or mulple risk factors for ASCVD In adults with T2D and either ASCVD or mulple risk factors for ASCVD, we recommend use of: A. GLP-1RA or SGLT2i to reduce the risk of all-cause, or CV mortality or MACE; Strong Moderate B. SGLT2i to reduce the risk of hospitalizaon for HF or the composite of significant decline in eGFR, progression to end-stage kidney disease or death due to kidney disease; Strong Moderate C. GLP-1RA to reduce the risk of nonfatal stroke. Strong Moderate According to current Canadian product monographs, initiation of dapagli fl ozin is not recommended for eGFR < 25 mL/min/1.73 m 2 , empagli fl ozin and canagli fl ozin are not recommended for eGFR < 30 mL/min/1.73 m 2 . Conversion of UACR 200 mg/g  22.6 mg/mmol, which was rounded to 20 mg/mmol for clinical translation in Canada. 1 The screening recommendation is a  good practice statemen","tf":{"20":2,"22":1,"25":2,"30":1,"40":1,"73":2,"200":1,"dney":1,"disease":5,"strong":6,"moderate":6,"in":7,"adults":4,"with":4,"hf":4,"and":6,"lvef":1,"we":3,"recommend":3,"use":3,"of":12,"sglt2i":4,"to":11,"reduce":5,"hospitaliza":3,"on":4,"for":8,"treatment":1,"ckd":2,"uacr":2,"mg":4,"mmol":3,"egfr":5,"ml":3,"min":3,"73m":1,"the":6,"composite":2,"significant":2,"decline":2,"progression":2,"end":2,"stage":2,"kidney":4,"or":8,"death":2,"due":2,"all":2,"cause":2,"cv":2,"mortality":2,"nonfatal":2,"mi":1,"preven":1,"cardiorenal":1,"events":1,"either":2,"t2d":2,"ascvd":4,"mul":2,"ple":2,"risk":5,"factors":2,"glp":2,"1ra":2,"mace":1,"stroke":1,"according":1,"current":1,"canadian":1,"product":1,"monographs":1,"initiation":1,"dapagli":1,"fl":3,"ozin":3,"is":2,"not":2,"recommended":2,"empagli":1,"canagli":1,"are":1,"conversion":1,"which":1,"was":1,"rounded":1,"clinical":1,"translation":1,"canada":1,"screening":1,"recommendation":1,"good":1,"practice":1,"statemen":1},"len":241},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":4,"chunkId":"ccs-2022-p4-c3","text":" ozin and canagli fl ozin are not recommended for eGFR < 30 mL/min/1.73 m 2 . Conversion of UACR 200 mg/g  22.6 mg/mmol, which was rounded to 20 mg/mmol for clinical translation in Canada. 1 The screening recommendation is a  good practice statement  which was not derived from a PICO question or extensive literature review but which, nevertheless, was considered by the panel through the same modi fi ed Delphi process used to evaluate the other recommendations. A1c, glycosylated hemoglobin; ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; CV, cardiovascular; eGFR, estimated glomerular fi ltration rate; GLP-1RA, glucagon-like peptide-1 receptor agonists; HF, heart failure; LVEF, left ventricular ejection fraction; MACE, major adverse cardiac events; MI, myocardial infarction; SGLT2i, sodium-glucose co-transporter 2 inhibitors; T2D, type 2 diabetes; UACR, urine albumin-creatinine ratio. GOOD PRACTICE STATEMENT Cardiovascular specialists are encouraged to assess kidney and glycemic status through measurement of eGFR, UACR, and A1c and to document left ventricular ejection fraction (LVEF) when evaluating symptoms of HF. 1156 Canadian Journal of Cardiology Volume 38 2022","tf":{"20":1,"22":1,"30":1,"38":1,"73":1,"200":1,"1156":1,"2022":1,"ozin":2,"and":4,"canagli":1,"fl":1,"are":2,"not":2,"recommended":1,"for":2,"egfr":3,"ml":1,"min":1,"conversion":1,"of":4,"uacr":3,"mg":3,"mmol":2,"which":3,"was":3,"rounded":1,"to":4,"clinical":1,"translation":1,"in":1,"canada":1,"the":4,"screening":1,"recommendation":1,"is":1,"good":2,"practice":2,"statement":2,"derived":1,"from":1,"pico":1,"question":1,"or":1,"extensive":1,"literature":1,"review":1,"but":1,"nevertheless":1,"considered":1,"by":1,"panel":1,"through":2,"same":1,"modi":1,"fi":2,"ed":1,"delphi":1,"process":1,"used":1,"evaluate":1,"other":1,"recommendations":1,"a1c":2,"glycosylated":1,"hemoglobin":1,"ascvd":1,"atherosclerotic":1,"cardiovascular":3,"disease":2,"ckd":1,"chronic":1,"kidney":2,"cv":1,"estimated":1,"glomerular":1,"ltration":1,"rate":1,"glp":1,"1ra":1,"glucagon":1,"like":1,"peptide":1,"receptor":1,"agonists":1,"hf":2,"heart":1,"failure":1,"lvef":2,"left":2,"ventricular":2,"ejection":2,"fraction":2,"mace":1,"major":1,"adverse":1,"cardiac":1,"events":1,"mi":1,"myocardial":1,"infarction":1,"sglt2i":1,"sodium":1,"glucose":1,"co":1,"transporter":1,"inhibitors":1,"t2d":1,"type":1,"diabetes":1,"urine":1,"albumin":1,"creatinine":1,"ratio":1,"specialists":1,"encouraged":1,"assess":1,"glycemic":1,"status":1,"measurement":1,"document":1,"when":1,"evaluating":1,"symptoms":1,"canadian":1,"journal":1,"cardiology":1,"volume":1},"len":171},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":5,"chunkId":"ccs-2022-p5-c0","text":"Table 3. Summary of medications associated with statistically signi fi cant cardiorenal outcome reductions in major randomized clinical trials* (class and medication listed in alphabetical order) Class Medication Major adverse cardiac events All-cause mortality Cardiovascular mortality Nonfatal stroke Hospitalization for HF Cardiovascular death or hospitalization for HF Kidney composite outcome y GLP-1 receptor agonist Albiglutide z Harmony Outcomes 8 Dulaglutide REWIND 9 REWIND 9 REWIND 9 Efpeglenatide z AMPLITUDE-O 10 AMPLITUDE-O 10 AMPLITUDE-O 10 Exenatide ER EXSCEL 11 Liraglutide LEADER 12 LEADER 12 LEADER 12 LEADER 12 Semaglutide SUSTAIN 6 13 PIONEER 6 14 PIONEER 6 14 SUSTAIN-6 13 SUSTAIN 6 13 SGLT2 inhibitor Canagli fl ozin CANVAS Program, 15 CREDENCE 16 CANVAS Program, 15 CREDENCE 16 CANVAS Program, 15 CREDENCE 16 CANVAS Program, 15 CREDENCE 16 Dapagli fl ozin DAPA-CKD, 17 DAPA-HF 18 DAPA-HF 18 DECLARE-TIMI 58, 19 DAPA- CKD, 17 DAPA-HF 18 DECLARE-TIMI 58, 19 DAPA-CKD, 17 DAPA- HF 18 DECLARE-TIMI 58, 19 DAPA-CKD 17 Empagli fl ozin EMPA-REG OUTCOME 20 EMPA-REG OUTCOME 20 EMPA-REG OUTCOME 20 EMPA-REG OUTCOME, 20 EMPEROR-Reduced, 21 EMPEROR-Preserved 22 EMPA-REG OUTCOME, 20 EMPEROR-Reduced, 21 EMPEROR-Preserved 22 EMPA-REG OUTCOME, 20 EMPEROR- Reduced 21 Ertugli fl ozin z VERTIS-CV 23 Sotagli fl ozin z SCORED, 24 SOLOIST-WHF 25 SCORED, 24 SOLOIST-WHF 25 SCORED, 24 SOLOIST- W","tf":{"10":3,"11":1,"12":4,"13":3,"14":2,"15":4,"16":4,"17":4,"18":4,"19":3,"20":6,"21":3,"22":2,"23":1,"24":3,"25":2,"58":3,"table":1,"summary":1,"of":1,"medications":1,"associated":1,"with":1,"statistically":1,"signi":1,"fi":1,"cant":1,"cardiorenal":1,"outcome":8,"reductions":1,"in":2,"major":2,"randomized":1,"clinical":1,"trials":1,"class":2,"and":1,"medication":2,"listed":1,"alphabetical":1,"order":1,"adverse":1,"cardiac":1,"events":1,"all":1,"cause":1,"mortality":2,"cardiovascular":2,"nonfatal":1,"stroke":1,"hospitalization":2,"for":2,"hf":6,"death":1,"or":1,"kidney":1,"composite":1,"glp":1,"receptor":1,"agonist":1,"albiglutide":1,"harmony":1,"outcomes":1,"dulaglutide":1,"rewind":3,"efpeglenatide":1,"amplitude":3,"exenatide":1,"er":1,"exscel":1,"liraglutide":1,"leader":4,"semaglutide":1,"sustain":3,"pioneer":2,"sglt2":1,"inhibitor":1,"canagli":1,"fl":5,"ozin":5,"canvas":4,"program":4,"credence":4,"dapagli":1,"dapa":8,"ckd":4,"declare":3,"timi":3,"empagli":1,"empa":6,"reg":6,"emperor":5,"reduced":3,"preserved":2,"ertugli":1,"vertis":1,"cv":1,"sotagli":1,"scored":3,"soloist":3,"whf":2},"len":219},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":5,"chunkId":"ccs-2022-p5-c1","text":" 21 EMPEROR-Preserved 22 EMPA-REG OUTCOME, 20 EMPEROR-Reduced, 21 EMPEROR-Preserved 22 EMPA-REG OUTCOME, 20 EMPEROR- Reduced 21 Ertugli fl ozin z VERTIS-CV 23 Sotagli fl ozin z SCORED, 24 SOLOIST-WHF 25 SCORED, 24 SOLOIST-WHF 25 SCORED, 24 SOLOIST- WHF 25 AMPLITUDE-O, Effect of Efpeglenatide on Cardiovascular Outcomes; CANVAS, Can agli fl ozin Cardio v ascular A ssessment S tudy; CREDENCE, C anagli fl ozin and R enal E vents in D iabetes With E stablished N ephropathy C linical E valuation; DAPA-CKD, D apagli fl ozin a nd P revention of A dverse Outcomes in C hronic K idney D isease; DAPA-HF, D apagli fl ozin a nd P revention of A dverse Outcomes in H eart F ailure; DECLARE-TIMI 58, D apagli fl ozin E ffect on C ardiovascu lar E vents- T hrombolysis i n M yocardial I nfarction; EMPA-REG OUTCOME, Empa gli fl ozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients e R emoving E xcess G lucose; EMPEROR-Preserved, Emp agli fl ozin Outcom e T r ial in Patients With Chr o nic Hea r t Failure With Preserved Ejection Fraction; EMPEROR-Reduced, Emp agli fl ozin Outcom e T r ial in Patients With Chr o nic Hea r t Failure With Reduced Ejection Fraction; ER, extended release; EXSCEL, Ex enatide Study of C ardiovascular E vent L owering; GLP-1, glucagon-like peptide-1; Harmony Outcomes, Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on M","tf":{"20":2,"21":3,"22":2,"23":1,"24":3,"25":3,"58":1,"emperor":6,"preserved":4,"empa":4,"reg":3,"outcome":4,"reduced":4,"ertugli":1,"fl":10,"ozin":10,"vertis":1,"cv":1,"sotagli":1,"scored":3,"soloist":3,"whf":3,"amplitude":1,"effect":2,"of":5,"efpeglenatide":1,"on":3,"cardiovascular":2,"outcomes":4,"canvas":1,"can":1,"agli":3,"cardio":1,"ascular":1,"ssessment":1,"tudy":1,"credence":1,"anagli":1,"and":1,"enal":1,"vents":2,"in":6,"iabetes":1,"with":5,"stablished":1,"ephropathy":1,"linical":1,"valuation":1,"dapa":2,"ckd":1,"apagli":3,"nd":2,"revention":2,"dverse":2,"hronic":1,"idney":1,"isease":1,"hf":1,"eart":1,"ailure":1,"declare":1,"timi":1,"ffect":1,"ardiovascu":1,"lar":1,"hrombolysis":1,"yocardial":1,"nfarction":1,"gli":1,"event":1,"trial":1,"type":1,"diabetes":1,"mellitus":1,"patients":3,"emoving":1,"xcess":1,"lucose":1,"emp":2,"outcom":2,"ial":2,"chr":2,"nic":2,"hea":2,"failure":2,"ejection":2,"fraction":2,"er":1,"extended":1,"release":1,"exscel":1,"ex":1,"enatide":1,"study":1,"ardiovascular":1,"vent":1,"owering":1,"glp":1,"glucagon":1,"like":1,"peptide":1,"harmony":1,"albiglutide":1,"when":1,"added":1,"to":1,"standard":1,"blood":1,"glucose":1,"lowering":1,"therapies":1},"len":202},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":5,"chunkId":"ccs-2022-p5-c2","text":"With Reduced Ejection Fraction; ER, extended release; EXSCEL, Ex enatide Study of C ardiovascular E vent L owering; GLP-1, glucagon-like peptide-1; Harmony Outcomes, Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus; HF, heart failure; LEADER, L iraglutide E ffect and A ction in D iabetes: E valuation of Cardiovascular Outcome R esults; PIONEER 6, P eptide I nn o vatio n for E arly Diab e tes T r eatment 6; REWIND, R esearching Cardiovascular E vents With a W eekly In cretin in D iabetes; SCORED, Effect of S otagli fl ozin on C ardi o vascular and R enal E vents in Patients With Type 2 D iabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk; SGLT2, sodium-glucose co-transporter 2; SOLOIST-WHF, Effect of So taglif lo zin on Card i ova s cular Events in Patients With T ype 2 Diabetes Post W orsening H eart F ailure; SUSTAIN 6, S emaglutide U nabated S us tain ability in Treatment of Type 2 Diabetes 6; VERTIS-CV, E v aluation or Ert ugli fl ozin Eff i cacy and S afety C ardio v ascular Outcomes Trial. * This table re fl ects data considered suitable for the systematic review and meta-analysis, which used hazard ratios-time to event data, adjusted for other covariates. 7 On the basis of those criteria, a study using lixisenatide 26 showed neutral results for all cri","tf":{"26":1,"with":5,"reduced":1,"ejection":1,"fraction":1,"er":1,"extended":1,"release":1,"exscel":1,"ex":1,"enatide":1,"study":2,"of":7,"ardiovascular":1,"vent":1,"owering":1,"glp":1,"glucagon":1,"like":1,"peptide":1,"harmony":1,"outcomes":2,"effect":3,"albiglutide":1,"when":1,"added":1,"to":2,"standard":1,"blood":1,"glucose":2,"lowering":1,"therapies":1,"on":4,"major":1,"cardiovascular":4,"events":2,"in":7,"subjects":1,"type":3,"diabetes":3,"mellitus":1,"hf":1,"heart":1,"failure":1,"leader":1,"iraglutide":1,"ffect":1,"and":5,"ction":1,"iabetes":3,"valuation":1,"outcome":1,"esults":1,"pioneer":1,"eptide":1,"nn":1,"vatio":1,"for":4,"arly":1,"diab":1,"tes":1,"eatment":1,"rewind":1,"esearching":1,"vents":2,"eekly":1,"cretin":1,"scored":1,"otagli":1,"fl":3,"ozin":2,"ardi":1,"vascular":1,"enal":1,"patients":2,"moderate":1,"renal":1,"impairment":1,"who":1,"are":1,"at":1,"risk":1,"sglt2":1,"sodium":1,"co":1,"transporter":1,"soloist":1,"whf":1,"so":1,"taglif":1,"lo":1,"zin":1,"card":1,"ova":1,"cular":1,"ype":1,"post":1,"orsening":1,"eart":1,"ailure":1,"sustain":1,"emaglutide":1,"nabated":1,"us":1,"tain":1,"ability":1,"treatment":1,"vertis":1,"cv":1,"aluation":1,"or":1,"ert":1,"ugli":1,"eff":1,"cacy":1,"afety":1,"ardio":1,"ascular":1,"trial":1,"this":1,"table":1,"re":1,"ects":1,"data":2,"considered":1,"suitable":1,"the":2,"systematic":1,"review":1,"meta":1,"analysis":1,"which":1,"used":1,"hazard":1,"ratios":1,"time":1,"event":1,"adjusted":1,"other":1,"covariates":1,"basis":1,"those":1,"criteria":1,"using":1,"lixisenatide":1,"showed":1,"neutral":1,"results":1,"all":1,"cri":1},"len":199},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":5,"chunkId":"ccs-2022-p5-c3","text":" ects data considered suitable for the systematic review and meta-analysis, which used hazard ratios-time to event data, adjusted for other covariates. 7 On the basis of those criteria, a study using lixisenatide 26 showed neutral results for all critical end points of interest for this guideline and is not shown. Similarly, no individual trial showed signi fi cant reduction in nonfatal myocardial infarction. y Kidney composite outcome de fi nitions are provided in Supplemental Table S1. z Not available or approved in Canada. Mancini et al. 1157 CCS Guideline for Cardiorenal Risk Reduction","tf":{"26":1,"1157":1,"ects":1,"data":2,"considered":1,"suitable":1,"for":5,"the":2,"systematic":1,"review":1,"and":2,"meta":1,"analysis":1,"which":1,"used":1,"hazard":1,"ratios":1,"time":1,"to":1,"event":1,"adjusted":1,"other":1,"covariates":1,"on":1,"basis":1,"of":2,"those":1,"criteria":1,"study":1,"using":1,"lixisenatide":1,"showed":2,"neutral":1,"results":1,"all":1,"critical":1,"end":1,"points":1,"interest":1,"this":1,"guideline":2,"is":1,"not":2,"shown":1,"similarly":1,"no":1,"individual":1,"trial":1,"signi":1,"fi":2,"cant":1,"reduction":2,"in":3,"nonfatal":1,"myocardial":1,"infarction":1,"kidney":1,"composite":1,"outcome":1,"de":1,"nitions":1,"are":1,"provided":1,"supplemental":1,"table":1,"s1":1,"available":1,"or":1,"approved":1,"canada":1,"mancini":1,"et":1,"al":1,"ccs":1,"cardiorenal":1,"risk":1},"len":91},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":6,"chunkId":"ccs-2022-p6-c0","text":"function and dapagli fl ozin was associated with a slower eGFR decline compared with placebo in diabetes and nondiabetes cohorts. 32 The Emp agli fl ozin Outcom e T r ial in Patients With Chr o nic Hea r t Failure With Reduced Ejection Fraction (EM- PEROR-Reduced) trial, 21 which compared empagli fl ozin 10 mg daily with placebo in patients with symptomatic HFrEF, showed results concordant with the DAPA-HF study. Partici- pants had an LVEF \u0014 40% and elevated N-terminal pro hor- mone brain natriuretic peptide levels that varied according to LVEF and atrial fi brillation status. Enrollment could occur with an eGFR as low as 20 mL/min/1.73 m 2 . During a median follow-up of 16 months, CV death or hospitalization for HF occurred in 19.4% of participants in the empagli fl ozin group and in 24.7% of the placebo group (HR, 0.75; 95% CI, 0.65- 0.86; P < 0.001) and the bene fi t was comparable in those with or without diabetes. The total number of hospitalizations for HF was lower in the empagli fl ozin group (HR, 0.70; 95% CI, 0.58- 0.85; P < 0.001), as was the annual rate of decline in eGFR ( \u0003 0.55 vs \u0003 2.28 mL/min/1.73 m 2 per year; P < 0.001). Use of background therapy for HFrEF was excellent in both trials. Notably, sacubitril-valsartan served as a renin-angiotensin in- hibitor in approximately 11% of patients in DAPA-HF and approximately 19% in EMPEROR-Reduced at baseline (concor","tf":{"10":1,"11":1,"16":1,"19":2,"20":1,"21":1,"24":1,"28":1,"32":1,"40":1,"55":1,"58":1,"65":1,"70":1,"73":2,"75":1,"85":1,"86":1,"95":2,"function":1,"and":7,"dapagli":1,"fl":5,"ozin":5,"was":5,"associated":1,"with":9,"slower":1,"egfr":3,"decline":2,"compared":2,"placebo":3,"in":14,"diabetes":2,"nondiabetes":1,"cohorts":1,"the":8,"emp":1,"agli":1,"outcom":1,"ial":1,"patients":3,"chr":1,"nic":1,"hea":1,"failure":1,"reduced":3,"ejection":1,"fraction":1,"em":1,"peror":1,"trial":1,"which":1,"empagli":3,"mg":1,"daily":1,"symptomatic":1,"hfref":2,"showed":1,"results":1,"concordant":1,"dapa":2,"hf":4,"study":1,"partici":1,"pants":1,"had":1,"an":2,"lvef":2,"elevated":1,"terminal":1,"pro":1,"hor":1,"mone":1,"brain":1,"natriuretic":1,"peptide":1,"levels":1,"that":1,"varied":1,"according":1,"to":1,"atrial":1,"fi":2,"brillation":1,"status":1,"enrollment":1,"could":1,"occur":1,"as":4,"low":1,"ml":2,"min":2,"during":1,"median":1,"follow":1,"up":1,"of":7,"months":1,"cv":1,"death":1,"or":2,"hospitalization":1,"for":3,"occurred":1,"participants":1,"group":3,"hr":2,"ci":2,"001":3,"bene":1,"comparable":1,"those":1,"without":1,"total":1,"number":1,"hospitalizations":1,"lower":1,"annual":1,"rate":1,"vs":1,"per":1,"year":1,"use":1,"background":1,"therapy":1,"excellent":1,"both":1,"trials":1,"notably":1,"sacubitril":1,"valsartan":1,"served":1,"renin":1,"angiotensin":1,"hibitor":1,"approximately":2,"emperor":1,"at":1,"baseline":1,"concor":1},"len":232},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":6,"chunkId":"ccs-2022-p6-c1","text":"0.001). Use of background therapy for HFrEF was excellent in both trials. Notably, sacubitril-valsartan served as a renin-angiotensin in- hibitor in approximately 11% of patients in DAPA-HF and approximately 19% in EMPEROR-Reduced at baseline (concordant with clinical practice at the time of recruitment for these trials). Cardiac resynchronization therapy was used in 7.5% of patients in DAPA-HF and in 12% in EMPEROR- Reduced. Implantable cardioverter de fi brillators, with or without cardiac resynchronization therapy, were used in 26% and 31%, respectively. No treatment interactions were noted among SGLT2i and these baseline therapies. 21 Treatment with SGLT2i showed no excess in hypovolemia, hypoglycemia, or renal side effects compared with placebo. A meta-analysis of the 2 trials shows that SGLT2i reduce morbidity and mortality in patients with symptomatic HFrEF, whether T2D is present or not. 33 The CCS/CHFS guideline was one of the fi rst worldwide to endorse SGLT2i as foundational therapy for patients with HFrEF in concert with angiotensin receptor neprilysin inhibitor (ARNI), or angiotensin-converting enzyme inhibitor (ACEi)/ angiotensin receptor blocker (ARB), b -blocker, and mineralo- corticoid receptor antagonist (MRA). 5 Figure 1. Integration of glucagon-like peptide-1 receptor antagonists (GLP-1RA) and sodium-glucose co-transporter 2 inhibitors (SGLT2i) into cardio- ","tf":{"11":1,"12":1,"19":1,"21":1,"26":1,"31":1,"33":1,"001":1,"use":1,"of":7,"background":1,"therapy":4,"for":3,"hfref":3,"was":3,"excellent":1,"in":13,"both":1,"trials":3,"notably":1,"sacubitril":1,"valsartan":1,"served":1,"as":2,"renin":1,"angiotensin":4,"hibitor":1,"approximately":2,"patients":4,"dapa":2,"hf":2,"and":7,"emperor":2,"reduced":2,"at":2,"baseline":2,"concordant":1,"with":7,"clinical":1,"practice":1,"the":4,"time":1,"recruitment":1,"these":2,"cardiac":2,"resynchronization":2,"used":2,"implantable":1,"cardioverter":1,"de":1,"fi":2,"brillators":1,"or":4,"without":1,"were":2,"respectively":1,"no":2,"treatment":2,"interactions":1,"noted":1,"among":1,"sglt2i":5,"therapies":1,"showed":1,"excess":1,"hypovolemia":1,"hypoglycemia":1,"renal":1,"side":1,"effects":1,"compared":1,"placebo":1,"meta":1,"analysis":1,"shows":1,"that":1,"reduce":1,"morbidity":1,"mortality":1,"symptomatic":1,"whether":1,"t2d":1,"is":1,"present":1,"not":1,"ccs":1,"chfs":1,"guideline":1,"one":1,"rst":1,"worldwide":1,"to":1,"endorse":1,"foundational":1,"concert":1,"receptor":4,"neprilysin":1,"inhibitor":2,"arni":1,"converting":1,"enzyme":1,"acei":1,"blocker":2,"arb":1,"mineralo":1,"corticoid":1,"antagonist":1,"mra":1,"figure":1,"integration":1,"glucagon":1,"like":1,"peptide":1,"antagonists":1,"glp":1,"1ra":1,"sodium":1,"glucose":1,"co":1,"transporter":1,"inhibitors":1,"into":1,"cardio":1},"len":201},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":6,"chunkId":"ccs-2022-p6-c2","text":"angiotensin receptor blocker (ARB), b -blocker, and mineralo- corticoid receptor antagonist (MRA). 5 Figure 1. Integration of glucagon-like peptide-1 receptor antagonists (GLP-1RA) and sodium-glucose co-transporter 2 inhibitors (SGLT2i) into cardio- vascular practice. ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; HF, heart failure; MRF, multiple risk factors; T2D, type 2 diabetes. * In patients with high stroke risk, or history of transient ischemic attack/stroke, consider initial integration of GLP-1RA into management plan followed by integration of SGLT2i on the basis of changes in heart failure or kidney status or for further glycosylated hemoglobin (A1c)-lowering. 1158 Canadian Journal of Cardiology Volume 38 2022","tf":{"38":1,"1158":1,"2022":1,"angiotensin":1,"receptor":3,"blocker":2,"arb":1,"and":2,"mineralo":1,"corticoid":1,"antagonist":1,"mra":1,"figure":1,"integration":3,"of":6,"glucagon":1,"like":1,"peptide":1,"antagonists":1,"glp":2,"1ra":2,"sodium":1,"glucose":1,"co":1,"transporter":1,"inhibitors":1,"sglt2i":2,"into":2,"cardio":1,"vascular":1,"practice":1,"ascvd":1,"atherosclerotic":1,"cardiovascular":1,"disease":2,"ckd":1,"chronic":1,"kidney":2,"hf":1,"heart":2,"failure":2,"mrf":1,"multiple":1,"risk":2,"factors":1,"t2d":1,"type":1,"diabetes":1,"in":2,"patients":1,"with":1,"high":1,"stroke":2,"or":3,"history":1,"transient":1,"ischemic":1,"attack":1,"consider":1,"initial":1,"management":1,"plan":1,"followed":1,"by":1,"on":1,"the":1,"basis":1,"changes":1,"status":1,"for":1,"further":1,"glycosylated":1,"hemoglobin":1,"a1c":1,"lowering":1,"canadian":1,"journal":1,"cardiology":1,"volume":1},"len":103},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":7,"chunkId":"ccs-2022-p7-c0","text":"Our systematic review and meta-analysis (Table 1) in- dicates that use of SGLT2i in patients with LVEF \u0014 40% is associated with a 16% reduction in all-cause mortality or CV mortality, a 31% reduction in hospitalization for HF, and a 41% reduction in the composite kidney outcome of signi fi - cant decline in eGFR, progression to end-stage kidney disease, or death due to kidney disease. 7 Practical tip. SGLT2i can be considered in stabilized HF patients. They are not indicated for the treatment of type 1 diabetes, or for patients receiving dialysis or with severely compromised renal function (eGFR < 20 mL/min/1.73 m 2 ). Clinicians should refer to the appropriate guidelines for condi- tions such as symptomatic hyperglycemia, metabolically decompensated patients with T2D, as well as for acute renal failure. Consider temporary discontinuation of SGLT2i therapy in the context of acute events (see Figs. 2 and 3), and permanent discontinuation if eGFR remains < 20 mL/min/1.73 m 2 . PICO 2: In patients with HF and preserved ejection fraction (HFpEF; > 40%) what is the role of novel antihyperglycemic agents compared with placebo for reduction of CV death or hospitalization for HF? The Emp agli fl ozin Outcom e T r ial in Patients With Chr o nic Hea r t Failure With Preserved Ejection Fraction (EMPEROR-Preserved) 22 trial was the fi rst phase III ran- domized double-blind placebo-control","tf":{"16":1,"20":2,"22":1,"31":1,"40":2,"41":1,"73":2,"our":1,"systematic":1,"review":1,"and":5,"meta":1,"analysis":1,"table":1,"in":10,"dicates":1,"that":1,"use":1,"of":7,"sglt2i":3,"patients":6,"with":8,"lvef":1,"is":2,"associated":1,"reduction":4,"all":1,"cause":1,"mortality":2,"or":5,"cv":2,"hospitalization":2,"for":7,"hf":4,"the":7,"composite":1,"kidney":3,"outcome":1,"signi":1,"fi":2,"cant":1,"decline":1,"egfr":3,"progression":1,"to":3,"end":1,"stage":1,"disease":2,"death":2,"due":1,"practical":1,"tip":1,"can":1,"be":1,"considered":1,"stabilized":1,"they":1,"are":1,"not":1,"indicated":1,"treatment":1,"type":1,"diabetes":1,"receiving":1,"dialysis":1,"severely":1,"compromised":1,"renal":2,"function":1,"ml":2,"min":2,"clinicians":1,"should":1,"refer":1,"appropriate":1,"guidelines":1,"condi":1,"tions":1,"such":1,"as":3,"symptomatic":1,"hyperglycemia":1,"metabolically":1,"decompensated":1,"t2d":1,"well":1,"acute":2,"failure":2,"consider":1,"temporary":1,"discontinuation":2,"therapy":1,"context":1,"events":1,"see":1,"figs":1,"permanent":1,"if":1,"remains":1,"pico":1,"preserved":3,"ejection":2,"fraction":2,"hfpef":1,"what":1,"role":1,"novel":1,"antihyperglycemic":1,"agents":1,"compared":1,"placebo":2,"emp":1,"agli":1,"fl":1,"ozin":1,"outcom":1,"ial":1,"chr":1,"nic":1,"hea":1,"emperor":1,"trial":1,"was":1,"rst":1,"phase":1,"iii":1,"ran":1,"domized":1,"double":1,"blind":1,"control":1},"len":215},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":7,"chunkId":"ccs-2022-p7-c1","text":"n of CV death or hospitalization for HF? The Emp agli fl ozin Outcom e T r ial in Patients With Chr o nic Hea r t Failure With Preserved Ejection Fraction (EMPEROR-Preserved) 22 trial was the fi rst phase III ran- domized double-blind placebo-controlled trial to achieve its primary end point in patients with symptomatic HFpEF ( > 40%). In this landmark trial the composite of CV death or HF hospitalization was signi fi cantly reduced in patients who were randomized to empagli fl ozin 10 mg vs placebo and standard of care therapy (HR, 0.79; 95% CI, 0.69-0.90; P < 0.0003). A total of 5988 patients were randomized with a median follow-up of 26 months. Standard of care therapy included 80% of patients receiving renin angiotensin in- hibitor or ARNI, 38% receiving MRA, 86% receiving b - blocker, and 70% receiving statins in the placebo arm, which was not signi fi cantly different from the empagli fl ozin ran- domized group. The reduction in the primary composite end point was driven predominantly by a reduction in fi rst hospitalization for HF (HR, 0.71; 95% CI, 0.60-0.83). The fi rst hierarchical secondary end point of total ( fi rst and recurrent) HF hospitalization was signi fi cantly reduced (HR, 0.73; 95% CI, 0.61-0.88; P < 0.001) as was the second secondary end point, which was the slope of decline in glomerular fi ltration rate ( \u0003 3.3 mL/min/1.73 m 2 for those receiving empag","tf":{"10":1,"22":1,"26":1,"38":1,"40":1,"60":1,"61":1,"69":1,"70":1,"71":1,"73":2,"79":1,"80":1,"83":1,"86":1,"88":1,"90":1,"95":3,"5988":1,"of":9,"cv":2,"death":2,"or":3,"hospitalization":4,"for":3,"hf":4,"the":10,"emp":1,"agli":1,"fl":3,"ozin":3,"outcom":1,"ial":1,"in":9,"patients":5,"with":4,"chr":1,"nic":1,"hea":1,"failure":1,"preserved":2,"ejection":1,"fraction":1,"emperor":1,"trial":3,"was":7,"fi":8,"rst":4,"phase":1,"iii":1,"ran":2,"domized":2,"double":1,"blind":1,"placebo":3,"controlled":1,"to":2,"achieve":1,"its":1,"primary":2,"end":4,"point":4,"symptomatic":1,"hfpef":1,"this":1,"landmark":1,"composite":2,"signi":3,"cantly":3,"reduced":2,"who":1,"were":2,"randomized":2,"empagli":2,"mg":1,"vs":1,"and":3,"standard":2,"care":2,"therapy":2,"hr":3,"ci":3,"0003":1,"total":2,"median":1,"follow":1,"up":1,"months":1,"included":1,"receiving":5,"renin":1,"angiotensin":1,"hibitor":1,"arni":1,"mra":1,"blocker":1,"statins":1,"arm":1,"which":2,"not":1,"different":1,"from":1,"group":1,"reduction":2,"driven":1,"predominantly":1,"by":1,"hierarchical":1,"secondary":2,"recurrent":1,"001":1,"as":1,"second":1,"slope":1,"decline":1,"glomerular":1,"ltration":1,"rate":1,"ml":1,"min":1,"those":1,"empag":1},"len":230},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":7,"chunkId":"ccs-2022-p7-c2","text":" recurrent) HF hospitalization was signi fi cantly reduced (HR, 0.73; 95% CI, 0.61-0.88; P < 0.001) as was the second secondary end point, which was the slope of decline in glomerular fi ltration rate ( \u0003 3.3 mL/min/1.73 m 2 for those receiving empagli fl ozin vs \u0003 5.7 mL/min/1.73 m 2 for those receiving placebo; P < 0.0001). This aligned with fi ndings in the EMPEROR-Reduced trial. In contrast to P rospective Comparison of AR NI With A RB G lobal O utcomes in HF With Preserved Ejectio n Fraction (PARAGON-HF) 34 there was no heterogeneity for treatment effect for the primary end point relevant to sex or baseline LVEF on the basis of pre- de fi ned tertiles of LVEF. There was also no heterogeneity for treatment bene fi t on the basis of the presence or absence of diabetes. 35 The safety pro fi le was similar to that previously recognized in HFrEF patient cohorts. Additional data pre- sented with an alpha protected pooled analysis of EMPEROR-Reduced and EMPEROR-Preserved suggest that empagli fl ozin is an agent that will be bene fi cial across a continuum of ejection fraction although bene fi t was not seen with ejection fraction > 65%. 36,37 The role of GLP-1RA and related agents in HFpEF might be clari fi ed by ongoing studies. 30,38,39 On the basis of our meta-analysis (Table 1), use of SGLT2i is associated with a 29% reduction in hospitalization for HF. In contrast to the res","tf":{"29":1,"30":1,"34":1,"35":1,"36":1,"37":1,"38":1,"39":1,"61":1,"65":1,"73":3,"88":1,"95":1,"recurrent":1,"hf":4,"hospitalization":2,"was":7,"signi":1,"fi":9,"cantly":1,"reduced":3,"hr":1,"ci":1,"001":1,"as":1,"the":11,"second":1,"secondary":1,"end":2,"point":2,"which":1,"slope":1,"of":11,"decline":1,"in":8,"glomerular":1,"ltration":1,"rate":1,"ml":2,"min":2,"for":6,"those":2,"receiving":2,"empagli":2,"fl":2,"ozin":2,"vs":1,"placebo":1,"0001":1,"this":1,"aligned":1,"with":6,"ndings":1,"emperor":3,"trial":1,"contrast":2,"to":4,"rospective":1,"comparison":1,"ar":1,"ni":1,"rb":1,"lobal":1,"utcomes":1,"preserved":2,"ejectio":1,"fraction":3,"paragon":1,"there":2,"no":2,"heterogeneity":2,"treatment":2,"effect":1,"primary":1,"relevant":1,"sex":1,"or":2,"baseline":1,"lvef":2,"on":3,"basis":3,"pre":2,"de":1,"ned":1,"tertiles":1,"also":1,"bene":3,"presence":1,"absence":1,"diabetes":1,"safety":1,"pro":1,"le":1,"similar":1,"that":3,"previously":1,"recognized":1,"hfref":1,"patient":1,"cohorts":1,"additional":1,"data":1,"sented":1,"an":2,"alpha":1,"protected":1,"pooled":1,"analysis":2,"and":2,"suggest":1,"is":2,"agent":1,"will":1,"be":2,"cial":1,"across":1,"continuum":1,"ejection":2,"although":1,"not":1,"seen":1,"role":1,"glp":1,"1ra":1,"related":1,"agents":1,"hfpef":1,"might":1,"clari":1,"ed":1,"by":1,"ongoing":1,"studies":1,"our":1,"meta":1,"table":1,"use":1,"sglt2i":1,"associated":1,"reduction":1,"res":1},"len":239},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":7,"chunkId":"ccs-2022-p7-c3","text":"%. 36,37 The role of GLP-1RA and related agents in HFpEF might be clari fi ed by ongoing studies. 30,38,39 On the basis of our meta-analysis (Table 1), use of SGLT2i is associated with a 29% reduction in hospitalization for HF. In contrast to the results in patients with HFrEF, the results in patients with HFpEF do not support a signi fi cant reduction in either all- cause or CV mortality or in reducing the composite kidney outcome. 7 Practical tip. This recommendation is on the basis of the results of the EMPEROR-Preserved trial (empagli fl ozin 10 mg daily vs placebo in addition to recommended HF therapy) but trials using other SGLT2i are pending. The recommen- dation is intended for stabilized patients. SGLT2i are not indicated for the treatment of type 1 diabetes, or for patients receiving dialysis or with severely compromised renal function (eGFR < 20 mL/min/1.73 m 2 ). General discussion High value is placed on use of therapies that reduce CV mortality and hospitalization for HF in well conducted ran- domized controlled trials. Medications such as ARNI and SGLT2i have clinical bene fi ts in patients treated with ACEi or ARB, b -blockers, and MRA as background therapy. The mechanisms of action are complementary in patients with HFrEF and underscore a multidrug approach. Preference is given to the use of pharmacotherapy in pa- tients with symptomatic HFrEF regardless of New","tf":{"10":1,"20":1,"29":1,"30":1,"36":1,"37":1,"38":1,"39":1,"73":1,"the":12,"role":1,"of":10,"glp":1,"1ra":1,"and":5,"related":1,"agents":1,"in":12,"hfpef":2,"might":1,"be":1,"clari":1,"fi":3,"ed":1,"by":1,"ongoing":1,"studies":1,"on":3,"basis":2,"our":1,"meta":1,"analysis":1,"table":1,"use":3,"sglt2i":4,"is":5,"associated":1,"with":7,"reduction":2,"hospitalization":2,"for":5,"hf":3,"contrast":1,"to":3,"results":3,"patients":6,"hfref":3,"do":1,"not":2,"support":1,"signi":1,"cant":1,"either":1,"all":1,"cause":1,"or":5,"cv":2,"mortality":2,"reducing":1,"composite":1,"kidney":1,"outcome":1,"practical":1,"tip":1,"this":1,"recommendation":1,"emperor":1,"preserved":1,"trial":1,"empagli":1,"fl":1,"ozin":1,"mg":1,"daily":1,"vs":1,"placebo":1,"addition":1,"recommended":1,"therapy":2,"but":1,"trials":2,"using":1,"other":1,"are":3,"pending":1,"recommen":1,"dation":1,"intended":1,"stabilized":1,"indicated":1,"treatment":1,"type":1,"diabetes":1,"receiving":1,"dialysis":1,"severely":1,"compromised":1,"renal":1,"function":1,"egfr":1,"ml":1,"min":1,"general":1,"discussion":1,"high":1,"value":1,"placed":1,"therapies":1,"that":1,"reduce":1,"well":1,"conducted":1,"ran":1,"domized":1,"controlled":1,"medications":1,"such":1,"as":2,"arni":1,"have":1,"clinical":1,"bene":1,"ts":1,"treated":1,"acei":1,"arb":1,"blockers":1,"mra":1,"background":1,"mechanisms":1,"action":1,"complementary":1,"underscore":1,"multidrug":1,"approach":1,"preference":1,"given":1,"pharmacotherapy":1,"pa":1,"tients":1,"symptomatic":1,"regardless":1,"new":1},"len":230},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":7,"chunkId":"ccs-2022-p7-c4","text":" -blockers, and MRA as background therapy. The mechanisms of action are complementary in patients with HFrEF and underscore a multidrug approach. Preference is given to the use of pharmacotherapy in pa- tients with symptomatic HFrEF regardless of New York Heart Association functional class. The writing group acknowledges lack of data that have directly compared dapagli fl ozin and empagli fl ozin in the management of HFrEF. Local accessi- bility to these agents and eGFR might provide guidance as to which agent is selected as a component of the 4 standard therapies for HFrEF. The writing group also acknowledges lack of evidence that has compared different strategies for the RECOMMENDATION 1. In adults with HF and LVEF \u0014 40%, we recommend use of SGLT2i to reduce all-cause and CV mortality, hospitalization for HF, and the composite end point of signi fi cant decline in eGFR, progression to end-stage kidney disease, or death due to kidney disease (Strong Recommendation; Moderate-Quality Evidence). RECOMMENDATION 2. In adults with HF and LVEF > 40%, we recommend use of SGLT2i to reduce hospitalization for HF (Strong Recommendation; Moderate-Quality Evidence). Mancini et al. 1159 CCS Guideline for Cardiorenal Risk Reduction","tf":{"40":2,"1159":1,"blockers":1,"and":8,"mra":1,"as":3,"background":1,"therapy":1,"the":8,"mechanisms":1,"of":10,"action":1,"are":1,"complementary":1,"in":6,"patients":1,"with":4,"hfref":4,"underscore":1,"multidrug":1,"approach":1,"preference":1,"is":2,"given":1,"to":7,"use":3,"pharmacotherapy":1,"pa":1,"tients":1,"symptomatic":1,"regardless":1,"new":1,"york":1,"heart":1,"association":1,"functional":1,"class":1,"writing":2,"group":2,"acknowledges":2,"lack":2,"data":1,"that":2,"have":1,"directly":1,"compared":2,"dapagli":1,"fl":2,"ozin":2,"empagli":1,"management":1,"local":1,"accessi":1,"bility":1,"these":1,"agents":1,"egfr":2,"might":1,"provide":1,"guidance":1,"which":1,"agent":1,"selected":1,"component":1,"standard":1,"therapies":1,"for":5,"also":1,"evidence":3,"has":1,"different":1,"strategies":1,"recommendation":4,"adults":2,"hf":4,"lvef":2,"we":2,"recommend":2,"sglt2i":2,"reduce":2,"all":1,"cause":1,"cv":1,"mortality":1,"hospitalization":2,"composite":1,"end":2,"point":1,"signi":1,"fi":1,"cant":1,"decline":1,"progression":1,"stage":1,"kidney":2,"disease":2,"or":1,"death":1,"due":1,"strong":2,"moderate":2,"quality":2,"mancini":1,"et":1,"al":1,"ccs":1,"guideline":1,"cardiorenal":1,"risk":1,"reduction":1},"len":190},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":8,"chunkId":"ccs-2022-p8-c0","text":"sequence in which guideline-directed medical therapies are prescribed. Evidence from the recent Effect of So taglif lo zin on Card i ova s cular Events in Patients With T ype 2 Diabetes Post W orsening H eart F ailure (SOLOIST-WHF) trial 25 suggests that sotagli fl ozin (a sodium-glucose co-transporter 1/2 inhibitor, not yet available in Canada) could be used safely before discharge or shortly thereafter in patients with T2D who were hemodynamically stabilized after hospitali- zation for HF. Sotagli fl ozin signi fi cantly reduced the risk of achieving the primary end point of CV death, hospitalization for HF, or urgent visit for HF (51.0 vs 76.3 events per 100 patient-years; HR, 0.67; 95% CI, 0.52-0.85). The value of early initiation is a primary focus of 1 ongoing and 1 completed trial. 40,41 The Emp agli fl ozin 10 mg Compared to Placebo, Initiated in Patients Hospitalised for Ac u te Heart Fai l ure (de Novo or Decompensated Chronic HF) Who Have Been S tabilis e d (EMPULSE) trial had not been pub- lished at the time of the fi nal draft of this report and is not included in our meta-analysis. 41 It included fewer than 600 patients, but using the win ratio approach (a new approach to the analysis of composite end points in clinical trials on the basis of the clinical priority attached to each component), it suggests that the use of SGLT2i in patients hospitalized for acute HF","tf":{"10":1,"25":1,"40":1,"41":2,"51":1,"52":1,"67":1,"76":1,"85":1,"95":1,"100":1,"600":1,"sequence":1,"in":8,"which":1,"guideline":1,"directed":1,"medical":1,"therapies":1,"are":1,"prescribed":1,"evidence":1,"from":1,"the":12,"recent":1,"effect":1,"of":10,"so":1,"taglif":1,"lo":1,"zin":1,"on":2,"card":1,"ova":1,"cular":1,"events":2,"patients":5,"with":2,"ype":1,"diabetes":1,"post":1,"orsening":1,"eart":1,"ailure":1,"soloist":1,"whf":1,"trial":3,"suggests":2,"that":2,"sotagli":2,"fl":3,"ozin":3,"sodium":1,"glucose":1,"co":1,"transporter":1,"inhibitor":1,"not":3,"yet":1,"available":1,"canada":1,"could":1,"be":1,"used":1,"safely":1,"before":1,"discharge":1,"or":3,"shortly":1,"thereafter":1,"t2d":1,"who":2,"were":1,"hemodynamically":1,"stabilized":1,"after":1,"hospitali":1,"zation":1,"for":5,"hf":5,"signi":1,"fi":2,"cantly":1,"reduced":1,"risk":1,"achieving":1,"primary":2,"end":2,"point":1,"cv":1,"death":1,"hospitalization":1,"urgent":1,"visit":1,"vs":1,"per":1,"patient":1,"years":1,"hr":1,"ci":1,"value":1,"early":1,"initiation":1,"is":2,"focus":1,"ongoing":1,"and":2,"completed":1,"emp":1,"agli":1,"mg":1,"compared":1,"to":3,"placebo":1,"initiated":1,"hospitalised":1,"ac":1,"te":1,"heart":1,"fai":1,"ure":1,"de":1,"novo":1,"decompensated":1,"chronic":1,"have":1,"been":2,"tabilis":1,"empulse":1,"had":1,"pub":1,"lished":1,"at":1,"time":1,"nal":1,"draft":1,"this":1,"report":1,"included":2,"our":1,"meta":1,"analysis":2,"it":2,"fewer":1,"than":1,"but":1,"using":1,"win":1,"ratio":1,"approach":2,"new":1,"composite":1,"points":1,"clinical":2,"trials":1,"basis":1,"priority":1,"attached":1,"each":1,"component":1,"use":1,"sglt2i":1,"hospitalized":1,"acute":1},"len":234},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":8,"chunkId":"ccs-2022-p8-c1","text":"s, but using the win ratio approach (a new approach to the analysis of composite end points in clinical trials on the basis of the clinical priority attached to each component), it suggests that the use of SGLT2i in patients hospitalized for acute HF (HFrEF or HFpEF) can provide signi fi cant net clinical bene fi t, including reduced rates of rehospitalization and death within 90 days compared with placebo and regardless of the type of HF or diabetes status. In addition, improvements in quality of life metrics were seen and therapy was well tolerated compared with placebo with no cases of diabetic ketoacidosis (DKA) in either group. Although it would not have met our criteria for meta-analysis, another novel trial showed that patient-centred quality of life outcomes were improved with canagli fl ozin with similar results for patients with HFrEF and HFpEF, and for patients with and without T2D. 42 Integration of SGLT2i in the Management of Patients With CKD PICO 3: In patients with CKD what is the role of novel anti- hyperglycemic agents compared with placebo for reduction of the composite of kidney death, progression to dialysis, or reduction of eGFR? An ongoing study is evaluating the role of GLP-1RA in patients with established CKD 43 but completed trials pertain solely to SGLT2i. The fi rst trial in the setting of CKD was the C anagli fl ozin and R enal E vents in D iabetes ","tf":{"42":1,"43":1,"90":1,"but":2,"using":1,"the":13,"win":1,"ratio":1,"approach":2,"new":1,"to":4,"analysis":2,"of":17,"composite":2,"end":1,"points":1,"in":10,"clinical":3,"trials":2,"on":1,"basis":1,"priority":1,"attached":1,"each":1,"component":1,"it":2,"suggests":1,"that":2,"use":1,"sglt2i":3,"patients":6,"hospitalized":1,"for":5,"acute":1,"hf":2,"hfref":2,"or":3,"hfpef":2,"can":1,"provide":1,"signi":1,"fi":3,"cant":1,"net":1,"bene":1,"including":1,"reduced":1,"rates":1,"rehospitalization":1,"and":7,"death":2,"within":1,"days":1,"compared":3,"with":11,"placebo":3,"regardless":1,"type":1,"diabetes":1,"status":1,"addition":1,"improvements":1,"quality":2,"life":2,"metrics":1,"were":2,"seen":1,"therapy":1,"was":2,"well":1,"tolerated":1,"no":1,"cases":1,"diabetic":1,"ketoacidosis":1,"dka":1,"either":1,"group":1,"although":1,"would":1,"not":1,"have":1,"met":1,"our":1,"criteria":1,"meta":1,"another":1,"novel":2,"trial":2,"showed":1,"patient":1,"centred":1,"outcomes":1,"improved":1,"canagli":1,"fl":2,"ozin":2,"similar":1,"results":1,"without":1,"t2d":1,"integration":1,"management":1,"ckd":4,"pico":1,"what":1,"is":2,"role":2,"anti":1,"hyperglycemic":1,"agents":1,"reduction":2,"kidney":1,"progression":1,"dialysis":1,"egfr":1,"an":1,"ongoing":1,"study":1,"evaluating":1,"glp":1,"1ra":1,"established":1,"completed":1,"pertain":1,"solely":1,"rst":1,"setting":1,"anagli":1,"enal":1,"vents":1,"iabetes":1},"len":234},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":8,"chunkId":"ccs-2022-p8-c2","text":" reduction of eGFR? An ongoing study is evaluating the role of GLP-1RA in patients with established CKD 43 but completed trials pertain solely to SGLT2i. The fi rst trial in the setting of CKD was the C anagli fl ozin and R enal E vents in D iabetes With E stablished N ephropathy C linical E valuation (CREDENCE) trial undertaken in patients with T2D, eGFR 30 to < 90 mL/min/1.73 m 2 and UACR 33.9-565 mg/mmol. 16 All patients were receiving baseline ACEi or ARB, and were assigned to treatment with canagli fl ozin at a dose of 100 mg daily or placebo. The trial was stopped early (with 4401 patients randomized and a median follow-up of 2.6 years) because of overwhelming bene fi t: the composite of end-stage kidney disease, doubling of serum creatinine, and kidney or CV death was reduced in subjects who received canagli fl ozin compared with placebo (43.2 vs 61.2 events per 1000 patient-years; P < 0.00001). Bene fi cial effects were noted irrespective of baseline A1c, including among patients with A1c between 6.5% and 7%. The D apagli fl ozin a nd P revention of A dverse Outcomes in C hronic K idney D isease (DAPA-CKD) trial 17 showed that dapagli fl ozin, used in addition to standard therapy, also reduced kidney and CV outcomes in patients with established CKD. In 4304 participants, with or without T2D, with an eGFR between 25 and 75 mL/min/1.73 m 2 and albuminuria (a UACR of 22.6-","tf":{"16":1,"17":1,"22":1,"25":1,"30":1,"33":1,"43":2,"61":1,"73":2,"75":1,"90":1,"100":1,"565":1,"1000":1,"4304":1,"4401":1,"reduction":1,"of":11,"egfr":3,"an":2,"ongoing":1,"study":1,"is":1,"evaluating":1,"the":7,"role":1,"glp":1,"1ra":1,"in":9,"patients":6,"with":10,"established":2,"ckd":4,"but":1,"completed":1,"trials":1,"pertain":1,"solely":1,"to":4,"sglt2i":1,"fi":3,"rst":1,"trial":4,"setting":1,"was":3,"anagli":1,"fl":5,"ozin":5,"and":9,"enal":1,"vents":1,"iabetes":1,"stablished":1,"ephropathy":1,"linical":1,"valuation":1,"credence":1,"undertaken":1,"t2d":2,"ml":2,"min":2,"uacr":2,"mg":2,"mmol":1,"all":1,"were":3,"receiving":1,"baseline":2,"acei":1,"or":4,"arb":1,"assigned":1,"treatment":1,"canagli":2,"at":1,"dose":1,"daily":1,"placebo":2,"stopped":1,"early":1,"randomized":1,"median":1,"follow":1,"up":1,"years":2,"because":1,"overwhelming":1,"bene":2,"composite":1,"end":1,"stage":1,"kidney":3,"disease":1,"doubling":1,"serum":1,"creatinine":1,"cv":2,"death":1,"reduced":2,"subjects":1,"who":1,"received":1,"compared":1,"vs":1,"events":1,"per":1,"patient":1,"00001":1,"cial":1,"effects":1,"noted":1,"irrespective":1,"a1c":2,"including":1,"among":1,"between":2,"apagli":1,"nd":1,"revention":1,"dverse":1,"outcomes":2,"hronic":1,"idney":1,"isease":1,"dapa":1,"showed":1,"that":1,"dapagli":1,"used":1,"addition":1,"standard":1,"therapy":1,"also":1,"participants":1,"without":1,"albuminuria":1},"len":231},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":8,"chunkId":"ccs-2022-p8-c3","text":"at dapagli fl ozin, used in addition to standard therapy, also reduced kidney and CV outcomes in patients with established CKD. In 4304 participants, with or without T2D, with an eGFR between 25 and 75 mL/min/1.73 m 2 and albuminuria (a UACR of 22.6-565.6 mg/mmol) who were randomized to dapagli fl ozin 10 mg daily or placebo, the primary composite of a sustained decline in eGFR of at least 50%, end-stage kidney disease, or death from kidney or CV causes was Figure 2. Management of antihyperglycemic medications when adding SGLT2i (eGFR \u0015 45 mL/min/1.73 m 2 ) or glucagon-like peptide-1 receptor antagonists (GLP-1RA). A1c, glycosylated hemoglobin; eGFR, estimated glomerular fi ltration rate; SGLT2i, sodium-glucose co-transporter 2 in- hibitors.* SGLT2i have markedly reduced glycemic-lowering ef fi cacy when eGFR < 45 mL/min/1.72 m 2 , so there is less concern about hypogly- cemia with insulin or insulin secretagogues (meglitinides or sulfonylureas). 1160 Canadian Journal of Cardiology Volume 38 2022","tf":{"10":1,"22":1,"25":1,"38":1,"45":2,"50":1,"72":1,"73":2,"75":1,"565":1,"1160":1,"2022":1,"4304":1,"at":2,"dapagli":2,"fl":2,"ozin":2,"used":1,"in":5,"addition":1,"to":2,"standard":1,"therapy":1,"also":1,"reduced":2,"kidney":3,"and":3,"cv":2,"outcomes":1,"patients":1,"with":4,"established":1,"ckd":1,"participants":1,"or":7,"without":1,"t2d":1,"an":1,"egfr":5,"between":1,"ml":3,"min":3,"albuminuria":1,"uacr":1,"of":5,"mg":2,"mmol":1,"who":1,"were":1,"randomized":1,"daily":1,"placebo":1,"the":1,"primary":1,"composite":1,"sustained":1,"decline":1,"least":1,"end":1,"stage":1,"disease":1,"death":1,"from":1,"causes":1,"was":1,"figure":1,"management":1,"antihyperglycemic":1,"medications":1,"when":2,"adding":1,"sglt2i":3,"glucagon":1,"like":1,"peptide":1,"receptor":1,"antagonists":1,"glp":1,"1ra":1,"a1c":1,"glycosylated":1,"hemoglobin":1,"estimated":1,"glomerular":1,"fi":2,"ltration":1,"rate":1,"sodium":1,"glucose":1,"co":1,"transporter":1,"hibitors":1,"have":1,"markedly":1,"glycemic":1,"lowering":1,"ef":1,"cacy":1,"so":1,"there":1,"is":1,"less":1,"concern":1,"about":1,"hypogly":1,"cemia":1,"insulin":2,"secretagogues":1,"meglitinides":1,"sulfonylureas":1,"canadian":1,"journal":1,"cardiology":1,"volume":1},"len":158},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":9,"chunkId":"ccs-2022-p9-c0","text":"reduced by 44% (HR, 0.56; 95% CI, 0.45-0.68; P < 0.001). The HR for composite of death from CV causes or hospitalization for HF was 0.71 (95% CI, 0.55-0.92; P < 0.009). All-cause mortality was also signi fi cantly reduced (HR, 0.69; 95% CI, 0.53-0.88; P < .004) and the excellent safety pro fi le of dapagli fl ozin was con fi rmed in this group. Not available at the time of data synthesis and publication of this guideline, the Empa gli fl ozin Once Daily to Assess Cardio-renal Outcomes in Patients With Chronic Kidney Disease (EMPA-KIDNEY) study, undertaken in patients with established CKD, which compared empagli fl ozin 10 mg with placebo, was stopped early after achieving positive ef fi cacy on the basis of the primary end point (a composite of kidney disease progression or cardiovascular death) thereby further supporting the role of SGLT2i for car- diorenal protection. 44 On the basis of our meta-analysis of the available data, Table 1 shows substantial bene fi t in all critical end points of interest except for reduction of nonfatal stroke. 7 The 36% reduction in the composite kidney outcome was also associ- ated with all-cause (18%) and CV mortality (15%) re- ductions, a 23% reduction in nonfatal MI, and a 37% reduction in hospitalization for HF. 7 Practical tip. Referral to a specialist with expertise in CKD should be considered in the following situations: progressive loss","tf":{"10":1,"15":1,"18":1,"23":1,"36":1,"37":1,"44":2,"45":1,"53":1,"55":1,"56":1,"68":1,"69":1,"71":1,"88":1,"92":1,"95":3,"reduced":2,"by":1,"hr":3,"ci":3,"001":1,"the":12,"for":5,"composite":3,"of":11,"death":2,"from":1,"cv":2,"causes":1,"or":2,"hospitalization":2,"hf":2,"was":5,"009":1,"all":3,"cause":2,"mortality":2,"also":2,"signi":1,"fi":5,"cantly":1,"004":1,"and":4,"excellent":1,"safety":1,"pro":1,"le":1,"dapagli":1,"fl":3,"ozin":3,"con":1,"rmed":1,"in":9,"this":2,"group":1,"not":1,"available":2,"at":1,"time":1,"data":2,"synthesis":1,"publication":1,"guideline":1,"empa":2,"gli":1,"once":1,"daily":1,"to":2,"assess":1,"cardio":1,"renal":1,"outcomes":1,"patients":2,"with":5,"chronic":1,"kidney":4,"disease":2,"study":1,"undertaken":1,"established":1,"ckd":2,"which":1,"compared":1,"empagli":1,"mg":1,"placebo":1,"stopped":1,"early":1,"after":1,"achieving":1,"positive":1,"ef":1,"cacy":1,"on":2,"basis":2,"primary":1,"end":2,"point":1,"progression":1,"cardiovascular":1,"thereby":1,"further":1,"supporting":1,"role":1,"sglt2i":1,"car":1,"diorenal":1,"protection":1,"our":1,"meta":1,"analysis":1,"table":1,"shows":1,"substantial":1,"bene":1,"critical":1,"points":1,"interest":1,"except":1,"reduction":4,"nonfatal":2,"stroke":1,"outcome":1,"associ":1,"ated":1,"re":1,"ductions":1,"mi":1,"practical":1,"tip":1,"referral":1,"specialist":1,"expertise":1,"should":1,"be":1,"considered":1,"following":1,"situations":1,"progressive":1,"loss":1},"len":231},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":9,"chunkId":"ccs-2022-p9-c1","text":"8%) and CV mortality (15%) re- ductions, a 23% reduction in nonfatal MI, and a 37% reduction in hospitalization for HF. 7 Practical tip. Referral to a specialist with expertise in CKD should be considered in the following situations: progressive loss of kidney function, urine UACR persistently > 60 mg/ mmol, or progressive rise in UACR despite appropriate therapy, eGFR < 30 mL/min/1.73 m 2 , inability to continue kidney-protective therapies because of adverse effects, such as hyperkalemia or a > 30% increase in serum creatinine within 3 months of starting SGLT2i, ACEi, or ARB, inability to achieve target BP, or signs/symptoms of another underlying kidney disease, such as glomerulonephritis. Figure 3. Practical approach to the use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) for treatment of cardiovascular disease. A1c, gly- cosylated hemoglobin; ASCVD, atherosclerotic cardiovascular disease; CLI, critical limb ischemia; DKA, diabetic ketoacidosis; DM, diabetes mellitus; eGFR, estimated glomerular fi ltration rate; GMI, genital mycotic infection; od qam, once daily every morning; SADMANS, sulfonylureas, angiotensin-converting enzyme inhibitors, diuretics and direct renin inhibitors, metformin, angiotensin receptor blockers, nonsteroidal anti- in fl ammatory drugs, sodium-glucose co-transporter 2 inhibitors; T2D, type 2 diabetes. RECOMMENDATION 3. In adults with CKD (UA","tf":{"15":1,"23":1,"30":2,"37":1,"60":1,"73":1,"and":3,"cv":1,"mortality":1,"re":1,"ductions":1,"reduction":2,"in":8,"nonfatal":1,"mi":1,"hospitalization":1,"for":2,"hf":1,"practical":2,"tip":1,"referral":1,"to":4,"specialist":1,"with":2,"expertise":1,"ckd":2,"should":1,"be":1,"considered":1,"the":2,"following":1,"situations":1,"progressive":2,"loss":1,"of":6,"kidney":3,"function":1,"urine":1,"uacr":2,"persistently":1,"mg":1,"mmol":1,"or":4,"rise":1,"despite":1,"appropriate":1,"therapy":1,"egfr":2,"ml":1,"min":1,"inability":2,"continue":1,"protective":1,"therapies":1,"because":1,"adverse":1,"effects":1,"such":2,"as":2,"hyperkalemia":1,"increase":1,"serum":1,"creatinine":1,"within":1,"months":1,"starting":1,"sglt2i":2,"acei":1,"arb":1,"achieve":1,"target":1,"bp":1,"signs":1,"symptoms":1,"another":1,"underlying":1,"disease":3,"glomerulonephritis":1,"figure":1,"approach":1,"use":1,"sodium":2,"glucose":2,"co":2,"transporter":2,"inhibitors":4,"treatment":1,"cardiovascular":2,"a1c":1,"gly":1,"cosylated":1,"hemoglobin":1,"ascvd":1,"atherosclerotic":1,"cli":1,"critical":1,"limb":1,"ischemia":1,"dka":1,"diabetic":1,"ketoacidosis":1,"dm":1,"diabetes":2,"mellitus":1,"estimated":1,"glomerular":1,"fi":1,"ltration":1,"rate":1,"gmi":1,"genital":1,"mycotic":1,"infection":1,"od":1,"qam":1,"once":1,"daily":1,"every":1,"morning":1,"sadmans":1,"sulfonylureas":1,"angiotensin":2,"converting":1,"enzyme":1,"diuretics":1,"direct":1,"renin":1,"metformin":1,"receptor":1,"blockers":1,"nonsteroidal":1,"anti":1,"fl":1,"ammatory":1,"drugs":1,"t2d":1,"type":1,"recommendation":1,"adults":1,"ua":1},"len":188},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":9,"chunkId":"ccs-2022-p9-c2","text":"ng enzyme inhibitors, diuretics and direct renin inhibitors, metformin, angiotensin receptor blockers, nonsteroidal anti- in fl ammatory drugs, sodium-glucose co-transporter 2 inhibitors; T2D, type 2 diabetes. RECOMMENDATION 3. In adults with CKD (UACR > 20 mg/mmol and eGFR \u0015 25 mL/min/1.73 m 2 ), we recommend use of SGLT2i to reduce the composite of signi fi cant decline in eGFR, progression to end stage kidney disease, or kidney death, all-cause and CV mortality, nonfatal MI, and hospitalization for HF (Strong recommendation, Moderate-Quality Evidence). Mancini et al. 1161 CCS Guideline for Cardiorenal Risk Reduction","tf":{"20":1,"25":1,"73":1,"1161":1,"ng":1,"enzyme":1,"inhibitors":3,"diuretics":1,"and":4,"direct":1,"renin":1,"metformin":1,"angiotensin":1,"receptor":1,"blockers":1,"nonsteroidal":1,"anti":1,"in":3,"fl":1,"ammatory":1,"drugs":1,"sodium":1,"glucose":1,"co":1,"transporter":1,"t2d":1,"type":1,"diabetes":1,"recommendation":2,"adults":1,"with":1,"ckd":1,"uacr":1,"mg":1,"mmol":1,"egfr":2,"ml":1,"min":1,"we":1,"recommend":1,"use":1,"of":2,"sglt2i":1,"to":2,"reduce":1,"the":1,"composite":1,"signi":1,"fi":1,"cant":1,"decline":1,"progression":1,"end":1,"stage":1,"kidney":2,"disease":1,"or":1,"death":1,"all":1,"cause":1,"cv":1,"mortality":1,"nonfatal":1,"mi":1,"hospitalization":1,"for":2,"hf":1,"strong":1,"moderate":1,"quality":1,"evidence":1,"mancini":1,"et":1,"al":1,"ccs":1,"guideline":1,"cardiorenal":1,"risk":1,"reduction":1},"len":92},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":10,"chunkId":"ccs-2022-p10-c0","text":"General discussion Because of the close inter-relationship of CKD and CV disease, recognizing these clinical entities and their prognostic effect is of great importance. A diagnosis of CKD is made in people with an eGFR < 60 mL/min/1.73 m 2 and/or random UACR \u0015 2.0 mg/mmol on at least 2 of 3 samples over a 3-month period. 6 Measuring eGFR and UACR on an annual basis (at a minimum) is recommended for patients with CV disease or multiple risk factors. The reviewed trials indicate cardiorenal bene fi ts of SGLT2i in patients regardless of dia- betes status. Among those living with CKD and T2D, it should be emphasized that reduction in the onset and pro- gression of CKD can also be enhanced by attaining optimal A1c and BP goals. For the latter, incorporation of an ACEi or an ARB is warranted. Moreover, even when patients with T2D and CKD have achieved A1c goals, one of the SGLT2i should be included to reduce risks of CKD progression, HF, and MACE. In patients with T2D and CKD who have not achieved individualized glycemic targets despite use of met- formin and SGLT2i, or who are unable to use those medi- cations, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 6 recommend long-acting GLP-1RA. This is further supported by secondary analyses of some of the GLP-1RA trials in patients with T2D. 45 Although this guideline supports this recommendation, we have not made an","tf":{"45":1,"60":1,"73":1,"general":1,"discussion":1,"because":1,"of":14,"the":7,"close":1,"inter":1,"relationship":1,"ckd":7,"and":11,"cv":2,"disease":3,"recognizing":1,"these":1,"clinical":1,"entities":1,"their":1,"prognostic":1,"effect":1,"is":5,"great":1,"importance":1,"diagnosis":1,"made":2,"in":5,"people":1,"with":6,"an":5,"egfr":2,"ml":1,"min":1,"or":4,"random":1,"uacr":2,"mg":1,"mmol":1,"on":2,"at":2,"least":1,"samples":1,"over":1,"month":1,"period":1,"measuring":1,"annual":1,"basis":1,"minimum":1,"recommended":1,"for":2,"patients":5,"multiple":1,"risk":1,"factors":1,"reviewed":1,"trials":2,"indicate":1,"cardiorenal":1,"bene":1,"fi":1,"ts":1,"sglt2i":3,"regardless":1,"dia":1,"betes":1,"status":1,"among":1,"those":2,"living":1,"t2d":4,"it":1,"should":2,"be":3,"emphasized":1,"that":1,"reduction":1,"onset":1,"pro":1,"gression":1,"can":1,"also":1,"enhanced":1,"by":2,"attaining":1,"optimal":1,"a1c":2,"bp":1,"goals":2,"latter":1,"incorporation":1,"acei":1,"arb":1,"warranted":1,"moreover":1,"even":1,"when":1,"have":3,"achieved":2,"one":1,"included":1,"to":2,"reduce":1,"risks":1,"progression":1,"hf":1,"mace":1,"who":2,"not":2,"individualized":1,"glycemic":1,"targets":1,"despite":1,"use":2,"met":1,"formin":1,"are":1,"unable":1,"medi":1,"cations":1,"kidney":1,"improving":1,"global":1,"outcomes":1,"kdigo":1,"guidelines":1,"recommend":1,"long":1,"acting":1,"glp":2,"1ra":2,"this":3,"further":1,"supported":1,"secondary":1,"analyses":1,"some":1,"although":1,"guideline":1,"supports":1,"recommendation":1,"we":1},"len":235},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":10,"chunkId":"ccs-2022-p10-c1","text":"oving Global Outcomes (KDIGO) guidelines 6 recommend long-acting GLP-1RA. This is further supported by secondary analyses of some of the GLP-1RA trials in patients with T2D. 45 Although this guideline supports this recommendation, we have not made an explicit recommendation in this regard because no dedi- cated CKD trials using this class are currently complete. The available evidence from other trials is summarized in the accompanying de novo meta-analysis 7 but the kidney out- comes de fi nitions have varied among trials (Supplemental Table S1). Moreover, because of our focus on cardiorenal bene fi ts, and considering that SGLT2i have been studied in clinical trials dedicated to patients with CKD, we believe that SGLT2i should be part of fi rst-line treatment in patients with CKD and T2D and that the inclusion of drugs with proven cardiorenal bene fi ts should be independent of whether the patient is taking metformin or not. It should be emphasized, however, that the A1c-lowering effect of SGLT2i is dimin- ished in the presence of CKD, and is minor at eGFR 30-45 mL/min/1.73 m 2 and absent at an eGFR of < 30 mL/min/ 1.73 m 2 . Integration of GLP-1RA or SGLT2i in Patients With T2D With or at Risk of atherosclerotic CVD PICO 4: In patients with T2D and either atherosclerotic CVD (ASCVD) or high CV risk, what is the role of novel anti- hyperglycemic agents compared with placebo f","tf":{"30":2,"45":2,"73":2,"oving":1,"global":1,"outcomes":1,"kdigo":1,"guidelines":1,"recommend":1,"long":1,"acting":1,"glp":3,"1ra":3,"this":5,"is":6,"further":1,"supported":1,"by":1,"secondary":1,"analyses":1,"of":12,"some":1,"the":9,"trials":5,"in":8,"patients":5,"with":8,"t2d":4,"although":1,"guideline":1,"supports":1,"recommendation":2,"we":2,"have":3,"not":2,"made":1,"an":2,"explicit":1,"regard":1,"because":2,"no":1,"dedi":1,"cated":1,"ckd":4,"using":1,"class":1,"are":1,"currently":1,"complete":1,"available":1,"evidence":1,"from":1,"other":1,"summarized":1,"accompanying":1,"de":2,"novo":1,"meta":1,"analysis":1,"but":1,"kidney":1,"out":1,"comes":1,"fi":4,"nitions":1,"varied":1,"among":1,"supplemental":1,"table":1,"s1":1,"moreover":1,"our":1,"focus":1,"on":1,"cardiorenal":2,"bene":2,"ts":2,"and":6,"considering":1,"that":4,"sglt2i":4,"been":1,"studied":1,"clinical":1,"dedicated":1,"to":1,"believe":1,"should":3,"be":3,"part":1,"rst":1,"line":1,"treatment":1,"inclusion":1,"drugs":1,"proven":1,"independent":1,"whether":1,"patient":1,"taking":1,"metformin":1,"or":4,"it":1,"emphasized":1,"however":1,"a1c":1,"lowering":1,"effect":1,"dimin":1,"ished":1,"presence":1,"minor":1,"at":3,"egfr":2,"ml":2,"min":2,"absent":1,"integration":1,"risk":2,"atherosclerotic":2,"cvd":2,"pico":1,"either":1,"ascvd":1,"high":1,"cv":1,"what":1,"role":1,"novel":1,"anti":1,"hyperglycemic":1,"agents":1,"compared":1,"placebo":1},"len":237},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":10,"chunkId":"ccs-2022-p10-c2","text":"gration of GLP-1RA or SGLT2i in Patients With T2D With or at Risk of atherosclerotic CVD PICO 4: In patients with T2D and either atherosclerotic CVD (ASCVD) or high CV risk, what is the role of novel anti- hyperglycemic agents compared with placebo for reduction of a composite of CV death, nonfatal MI, or nonfatal stroke? The initial trial that used empagli fl ozin published in 2015, through to the most recent trial that used efpeglena- tide published in 2021 were evaluated in detail in the accompanying systematic review and meta-analysis. 7 Table 1 shows that MACE was reduced similarly by both classes with a relative risk reduction of 12%-14%. These classes were also associated with similar relative risk reductions in all-cause (12%-15%) and CV mortality (13%-15%). Reduction in nonfatal MI was noted only with SGLT2i but the effect was modest (10% relative risk reduction). Because this effect was not statistically different from the neutral effects on nonfatal MI associated with the GLP-1RA class, we make no recommendation on the basis of this end point. The SGLT2i class showed signi fi cant relative risk reduction for the pre- vention of the composite kidney outcomes (35%) and for hospitalization for HF (32%) compared with placebo and superior to GLP-1RA. As noted previously, currently we do not have any large clinical trials for the treatment of HF or CKD in patients with or ","tf":{"10":1,"12":2,"13":1,"14":1,"15":2,"32":1,"35":1,"2015":1,"2021":1,"gration":1,"of":9,"glp":3,"1ra":3,"or":6,"sglt2i":3,"in":9,"patients":3,"with":10,"t2d":2,"at":1,"risk":6,"atherosclerotic":2,"cvd":2,"pico":1,"and":5,"either":1,"ascvd":1,"high":1,"cv":3,"what":1,"is":1,"the":12,"role":1,"novel":1,"anti":1,"hyperglycemic":1,"agents":1,"compared":2,"placebo":2,"for":5,"reduction":5,"composite":2,"death":1,"nonfatal":4,"mi":3,"stroke":1,"initial":1,"trial":2,"that":3,"used":2,"empagli":1,"fl":1,"ozin":1,"published":2,"through":1,"to":2,"most":1,"recent":1,"efpeglena":1,"tide":1,"were":2,"evaluated":1,"detail":1,"accompanying":1,"systematic":1,"review":1,"meta":1,"analysis":1,"table":1,"shows":1,"mace":1,"was":4,"reduced":1,"similarly":1,"by":1,"both":1,"classes":2,"relative":4,"these":1,"also":1,"associated":2,"similar":1,"reductions":1,"all":1,"cause":1,"mortality":1,"noted":2,"only":1,"but":1,"effect":2,"modest":1,"because":1,"this":2,"not":2,"statistically":1,"different":1,"from":1,"neutral":1,"effects":1,"on":2,"class":2,"we":2,"make":1,"no":1,"recommendation":1,"basis":1,"end":1,"point":1,"showed":1,"signi":1,"fi":1,"cant":1,"pre":1,"vention":1,"kidney":1,"outcomes":1,"hospitalization":1,"hf":2,"superior":1,"as":1,"previously":1,"currently":1,"do":1,"have":1,"any":1,"large":1,"clinical":1,"trials":1,"treatment":1,"ckd":1},"len":234},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":10,"chunkId":"ccs-2022-p10-c3","text":"ion of the composite kidney outcomes (35%) and for hospitalization for HF (32%) compared with placebo and superior to GLP-1RA. As noted previously, currently we do not have any large clinical trials for the treatment of HF or CKD in patients with or without T2D using GLP-1RA. Finally, the important but less common outcome of nonfatal stroke was reduced with GLP-1RA, particularly in the S emaglutide U nabated S us tain ability in Treatment of Type 2 Diabetes (SUSTAIN) 6 trial (semaglutide once weekly injection) and R esearching Cardiovascular E vents With a W eekly In cretin in D iabetes (REWIND; dulaglu- tide) trials. 9,46,47 The systematic review and meta-analysis (Table 1) indicates a relative risk reduction of nonfatal stroke of 16% associated with use of GLP-1RA. Practical tip. A combination of SGLT2i and GLP-1RA might theoretically improve cardiorenal bene fi ts in patients with T2D and either ASCVD or multiple risk factors for ASCVD whose A1c remains suboptimal despite initial treat- ment with only one of these agents or if clinical status changes (eg, new onset HF or CKD; Fig. 1). General discussion The principles of pharmacotherapy for patients with T2D have been thoroughly reviewed by Diabetes Canada. 3,4 Achievement of target glucose levels, especially in the early years after T2D diagnosis, reduces the incidence and progres- sion of microvascular complications and, i","tf":{"16":1,"32":1,"35":1,"46":1,"47":1,"ion":1,"of":12,"the":8,"composite":1,"kidney":1,"outcomes":1,"and":8,"for":5,"hospitalization":1,"hf":3,"compared":1,"with":8,"placebo":1,"superior":1,"to":1,"glp":5,"1ra":5,"as":1,"noted":1,"previously":1,"currently":1,"we":1,"do":1,"not":1,"have":2,"any":1,"large":1,"clinical":2,"trials":2,"treatment":2,"or":5,"ckd":2,"in":7,"patients":3,"without":1,"t2d":4,"using":1,"finally":1,"important":1,"but":1,"less":1,"common":1,"outcome":1,"nonfatal":2,"stroke":2,"was":1,"reduced":1,"particularly":1,"emaglutide":1,"nabated":1,"us":1,"tain":1,"ability":1,"type":1,"diabetes":2,"sustain":1,"trial":1,"semaglutide":1,"once":1,"weekly":1,"injection":1,"esearching":1,"cardiovascular":1,"vents":1,"eekly":1,"cretin":1,"iabetes":1,"rewind":1,"dulaglu":1,"tide":1,"systematic":1,"review":1,"meta":1,"analysis":1,"table":1,"indicates":1,"relative":1,"risk":2,"reduction":1,"associated":1,"use":1,"practical":1,"tip":1,"combination":1,"sglt2i":1,"might":1,"theoretically":1,"improve":1,"cardiorenal":1,"bene":1,"fi":1,"ts":1,"either":1,"ascvd":2,"multiple":1,"factors":1,"whose":1,"a1c":1,"remains":1,"suboptimal":1,"despite":1,"initial":1,"treat":1,"ment":1,"only":1,"one":1,"these":1,"agents":1,"if":1,"status":1,"changes":1,"eg":1,"new":1,"onset":1,"fig":1,"general":1,"discussion":1,"principles":1,"pharmacotherapy":1,"been":1,"thoroughly":1,"reviewed":1,"by":1,"canada":1,"achievement":1,"target":1,"glucose":1,"levels":1,"especially":1,"early":1,"years":1,"after":1,"diagnosis":1,"reduces":1,"incidence":1,"progres":1,"sion":1,"microvascular":1,"complications":1},"len":215},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":10,"chunkId":"ccs-2022-p10-c4","text":"therapy for patients with T2D have been thoroughly reviewed by Diabetes Canada. 3,4 Achievement of target glucose levels, especially in the early years after T2D diagnosis, reduces the incidence and progres- sion of microvascular complications and, in the long term (more than 10 years), is associated with reduced CV outcomes. 48-51 In parallel with achieving the A1c goal, it is also recommended that GLP-1RA or SGLT2i be included for patients with T2D with or at high risk of ASCVD to reduce cardiorenal risk, irrespective of A1c. Thus, substitution of (replacing rather than adding) an RECOMMENDATION 4. In adults with T2D and either established ASCVD or multiple risk factors for ASCVD, we recommend use of: a. GLP-1RA or SGLT2i to reduce the risk of all-cause or CV mortality or MACE (Strong Recommenda- tion; Moderate-Quality Evidence), b. SGLT2i to reduce the risk of hospitalization for HF or the composite of signi fi cant decline in eGFR, progression to end stage kidney disease or kidney death (Strong Recommendation; Moderate-Quality Evidence), c. GLP-1RA to reduce the risk of nonfatal stroke (Strong Recommendation; Moderate-Quality Evidence). 1162 Canadian Journal of Cardiology Volume 38 2022","tf":{"10":1,"38":1,"48":1,"51":1,"1162":1,"2022":1,"therapy":1,"for":4,"patients":2,"with":6,"t2d":4,"have":1,"been":1,"thoroughly":1,"reviewed":1,"by":1,"diabetes":1,"canada":1,"achievement":1,"of":11,"target":1,"glucose":1,"levels":1,"especially":1,"in":5,"the":8,"early":1,"years":2,"after":1,"diagnosis":1,"reduces":1,"incidence":1,"and":3,"progres":1,"sion":1,"microvascular":1,"complications":1,"long":1,"term":1,"more":1,"than":2,"is":2,"associated":1,"reduced":1,"cv":2,"outcomes":1,"parallel":1,"achieving":1,"a1c":2,"goal":1,"it":1,"also":1,"recommended":1,"that":1,"glp":3,"1ra":3,"or":8,"sglt2i":3,"be":1,"included":1,"at":1,"high":1,"risk":6,"ascvd":3,"to":5,"reduce":4,"cardiorenal":1,"irrespective":1,"thus":1,"substitution":1,"replacing":1,"rather":1,"adding":1,"an":1,"recommendation":3,"adults":1,"either":1,"established":1,"multiple":1,"factors":1,"we":1,"recommend":1,"use":1,"all":1,"cause":1,"mortality":1,"mace":1,"strong":3,"recommenda":1,"tion":1,"moderate":3,"quality":3,"evidence":3,"hospitalization":1,"hf":1,"composite":1,"signi":1,"fi":1,"cant":1,"decline":1,"egfr":1,"progression":1,"end":1,"stage":1,"kidney":2,"disease":1,"death":1,"nonfatal":1,"stroke":1,"canadian":1,"journal":1,"cardiology":1,"volume":1},"len":191},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":11,"chunkId":"ccs-2022-p11-c0","text":"agent with cardiorenal bene fi t might be appropriate if people are at or near A1c target. The choice of initial pharmacotherapy has emerged as an area of uncertainty in patients with newly diagnosed T2D who have or are at risk of ASCVD. Although most guidelines continue to recommend metformin as fi rst-line anti- hyperglycemic therapy, the European Society of Cardiology diabetes guideline 52 recommends that GLP-1RA or SGLT2i should be fi rst-line therapy in individuals with ASCVD or at high or very high CV risk. Although there have been no speci fi c trials to show cardiorenal bene fi t for GLP-1RA or SGLT2i when used as fi rst-line therapy or as monotherapy or in newly diagnosed T2D, the bene fi t seen in the CV outcome trials has not been found to vary with the duration of diabetes, suggesting that similar bene fi ts might be seen early in the course of disease. 4 The bene fi ts are also not dependent on the presence of metformin. 8,53-55 Therefore, the inclusion of GLP-1RA or SGLT2i at the time of diagnosis of T2D in patients with ASCVD or multiple risk factors is a reasonable option and aligns with the views of Diabetes Canada. 3,4 In addition, the traditional role of metformin in the early man- agement of T2D is not always appropriate if not tolerated or contraindicated (eg, eGFR < 30 mL/min/1.73 m 2 ). In HF, including HFrEF and HFpEF, SGLT2i used in addition to other ev","tf":{"30":1,"52":1,"53":1,"55":1,"73":1,"agent":1,"with":6,"cardiorenal":2,"bene":5,"fi":9,"might":2,"be":3,"appropriate":2,"if":2,"people":1,"are":3,"at":4,"or":11,"near":1,"a1c":1,"target":1,"the":13,"choice":1,"of":13,"initial":1,"pharmacotherapy":1,"has":2,"emerged":1,"as":4,"an":1,"area":1,"uncertainty":1,"in":10,"patients":2,"newly":2,"diagnosed":2,"t2d":4,"who":1,"have":2,"risk":3,"ascvd":3,"although":2,"most":1,"guidelines":1,"continue":1,"to":4,"recommend":1,"metformin":3,"rst":3,"line":3,"anti":1,"hyperglycemic":1,"therapy":3,"european":1,"society":1,"cardiology":1,"diabetes":3,"guideline":1,"recommends":1,"that":2,"glp":3,"1ra":3,"sglt2i":4,"should":1,"individuals":1,"high":2,"very":1,"cv":2,"there":1,"been":2,"no":1,"speci":1,"trials":2,"show":1,"for":1,"when":1,"used":2,"monotherapy":1,"seen":2,"outcome":1,"not":4,"found":1,"vary":1,"duration":1,"suggesting":1,"similar":1,"ts":2,"early":2,"course":1,"disease":1,"also":1,"dependent":1,"on":1,"presence":1,"therefore":1,"inclusion":1,"time":1,"diagnosis":1,"multiple":1,"factors":1,"is":2,"reasonable":1,"option":1,"and":2,"aligns":1,"views":1,"canada":1,"addition":2,"traditional":1,"role":1,"man":1,"agement":1,"always":1,"tolerated":1,"contraindicated":1,"eg":1,"egfr":1,"ml":1,"min":1,"hf":1,"including":1,"hfref":1,"hfpef":1,"other":1,"ev":1},"len":247},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":11,"chunkId":"ccs-2022-p11-c1","text":" 3,4 In addition, the traditional role of metformin in the early man- agement of T2D is not always appropriate if not tolerated or contraindicated (eg, eGFR < 30 mL/min/1.73 m 2 ). In HF, including HFrEF and HFpEF, SGLT2i used in addition to other evidence-based HF therapies but without treatment with metformin were shown to improve major HF-related outcomes and quality of life within a short period of time after initiation of therapy. Moreover, bene fi t was seen in pa- tients with and those without T2D. 8,53-55 SGLT2i reduce hospitalization for HF 15,20 and reduce progression of nephropathy 15,19 in persons with T2D and CV risk factors only; bene fi ts to reduce MACE or mortality, at least within the short-term duration of the trials to date, are less certain. 56,57 Conversely, in such patients, GLP-1RA seem to reduce MACE, 9,12,13 a factor that might help selection between SGLT2i or GLP-1RA for A1c reduction. Our ana- lyses (Table 1) indicate that the reduction of nonfatal stroke is strongest for GLP-1RA, which might also factor into the initial choice of classes. Opinions vary about whether bene fi cial effects are general to a class or speci fi c to individual agents. Although network meta-analyses have attempted to provide comparisons of speci fi c SGLT2i or GLP-1RA, no head-to-head trials are currently available that help differentiate between medications within either o","tf":{"12":1,"13":1,"15":2,"19":1,"20":1,"30":1,"53":1,"55":1,"56":1,"57":1,"73":1,"in":7,"addition":2,"the":6,"traditional":1,"role":1,"of":10,"metformin":2,"early":1,"man":1,"agement":1,"t2d":3,"is":2,"not":2,"always":1,"appropriate":1,"if":1,"tolerated":1,"or":5,"contraindicated":1,"eg":1,"egfr":1,"ml":1,"min":1,"hf":4,"including":1,"hfref":1,"and":5,"hfpef":1,"sglt2i":4,"used":1,"to":9,"other":1,"evidence":1,"based":1,"therapies":1,"but":1,"without":2,"treatment":1,"with":3,"were":1,"shown":1,"improve":1,"major":1,"related":1,"outcomes":1,"quality":1,"life":1,"within":3,"short":2,"period":1,"time":1,"after":1,"initiation":1,"therapy":1,"moreover":1,"bene":3,"fi":5,"was":1,"seen":1,"pa":1,"tients":1,"those":1,"reduce":4,"hospitalization":1,"for":3,"progression":1,"nephropathy":1,"persons":1,"cv":1,"risk":1,"factors":1,"only":1,"ts":1,"mace":2,"mortality":1,"at":1,"least":1,"term":1,"duration":1,"trials":2,"date":1,"are":3,"less":1,"certain":1,"conversely":1,"such":1,"patients":1,"glp":4,"1ra":4,"seem":1,"factor":2,"that":3,"might":2,"help":2,"selection":1,"between":2,"a1c":1,"reduction":2,"our":1,"ana":1,"lyses":1,"table":1,"indicate":1,"nonfatal":1,"stroke":1,"strongest":1,"which":1,"also":1,"into":1,"initial":1,"choice":1,"classes":1,"opinions":1,"vary":1,"about":1,"whether":1,"cial":1,"effects":1,"general":1,"class":1,"speci":2,"individual":1,"agents":1,"although":1,"network":1,"meta":1,"analyses":1,"have":1,"attempted":1,"provide":1,"comparisons":1,"no":1,"head":2,"currently":1,"available":1,"differentiate":1,"medications":1,"either":1},"len":234},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":11,"chunkId":"ccs-2022-p11-c2","text":"class or speci fi c to individual agents. Although network meta-analyses have attempted to provide comparisons of speci fi c SGLT2i or GLP-1RA, no head-to-head trials are currently available that help differentiate between medications within either of these 2 classes. 56,58 Consequently, the writing group consensus emphasizes class effects but recognizes that some outcomes have been associated with speci fi c agents (Table 3). Using both classes together to achieve glycemic targets when needed appears to be a reasonable option. However, it is not known whether additional cardiorenal bene fi t can be expected by combining both classes, although the potential mechanisms might be complementary. The most recent GLP-1RA CV outcome trial showed similar bene fi t whether the patient was using SGLT2i or not. 10,59 Finally, an individualized approach to therapy should also weigh the in- dividual  s preferences, costs and coverage, side effect pro fi le, consideration of kidney function and glucose-lowering ef fi - cacy, desire for weight loss, and comorbidities such as frailty. Although diminished kidney function attenuates the glucose- lowering effects of SGLT2i, cardiorenal protection is main- tained with an eGFR > 20-25 mL/min/1.73 m 2 . 21,22,36 Practical Considerations for Integrating GLP- 1RA and SGLT2i Into Practice When using these classes for cardiorenal bene fi t, one must co","tf":{"10":1,"20":1,"21":1,"22":1,"25":1,"36":1,"56":1,"58":1,"59":1,"73":1,"class":2,"or":3,"speci":3,"fi":8,"to":6,"individual":1,"agents":2,"although":3,"network":1,"meta":1,"analyses":1,"have":2,"attempted":1,"provide":1,"comparisons":1,"of":4,"sglt2i":4,"glp":3,"1ra":3,"no":1,"head":2,"trials":1,"are":1,"currently":1,"available":1,"that":2,"help":1,"differentiate":1,"between":1,"medications":1,"within":1,"either":1,"these":2,"classes":4,"consequently":1,"the":6,"writing":1,"group":1,"consensus":1,"emphasizes":1,"effects":2,"but":1,"recognizes":1,"some":1,"outcomes":1,"been":1,"associated":1,"with":2,"table":1,"using":3,"both":2,"together":1,"achieve":1,"glycemic":1,"targets":1,"when":2,"needed":1,"appears":1,"be":3,"reasonable":1,"option":1,"however":1,"it":1,"is":2,"not":2,"known":1,"whether":2,"additional":1,"cardiorenal":3,"bene":3,"can":1,"expected":1,"by":1,"combining":1,"potential":1,"mechanisms":1,"might":1,"complementary":1,"most":1,"recent":1,"cv":1,"outcome":1,"trial":1,"showed":1,"similar":1,"patient":1,"was":1,"finally":1,"an":2,"individualized":1,"approach":1,"therapy":1,"should":1,"also":1,"weigh":1,"in":1,"dividual":1,"preferences":1,"costs":1,"and":4,"coverage":1,"side":1,"effect":1,"pro":1,"le":1,"consideration":1,"kidney":2,"function":2,"glucose":2,"lowering":2,"ef":1,"cacy":1,"desire":1,"for":3,"weight":1,"loss":1,"comorbidities":1,"such":1,"as":1,"frailty":1,"diminished":1,"attenuates":1,"protection":1,"main":1,"tained":1,"egfr":1,"ml":1,"min":1,"practical":1,"considerations":1,"integrating":1,"into":1,"practice":1,"one":1,"must":1,"co":1},"len":213},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":11,"chunkId":"ccs-2022-p11-c3","text":"ering effects of SGLT2i, cardiorenal protection is main- tained with an eGFR > 20-25 mL/min/1.73 m 2 . 21,22,36 Practical Considerations for Integrating GLP- 1RA and SGLT2i Into Practice When using these classes for cardiorenal bene fi t, one must consider potential side effects and advise on strategies to minimize them (Table 4 and Fig. 2). 3-5,60-65 The most common side effects of GLP-1RA are gastroin- testinal (nausea, vomiting, diarrhea). These side effects are most prominent at initiation of treatment and usually improve over time. Mitigation strategies are shown in Table 4. Note that a dipeptidyl peptidase 4 (DPP-4) inhibitor can be dis- continued when adding GLP-1RA because they are both incretin-based therapies and the DPP-4 inhibitor is redundant Table 4. Side effects and mitigation strategies Mitigation strategies Side effects of SGLT2 inhibitor use Genital mycotic infections \u000f Explain mechanism of action \u000f Maintain genital hygiene (rinse, wipe; advise that episodes rarely recur after treatment) \u000f Consider prescription of anti- mycotic agent at time of initiation to be used if infection occurs Volume depletion \u000f Adequate hydration \u000f Hold in acute illness or preoperative Hypoglycemia \u000f Potential exists if used in combina- tion with insulin secretagogues or insulin and eGFR \u0015 45 mL/min/ 1.73 m 2 . See Figure 2 for mitigation strategies Diabetic ketoacidosis \u000f Do not use","tf":{"20":1,"21":1,"22":1,"25":1,"36":1,"45":1,"60":1,"65":1,"73":2,"ering":1,"effects":6,"of":7,"sglt2i":2,"cardiorenal":2,"protection":1,"is":2,"main":1,"tained":1,"with":2,"an":1,"egfr":2,"ml":2,"min":2,"practical":1,"considerations":1,"for":3,"integrating":1,"glp":3,"1ra":3,"and":7,"into":1,"practice":1,"when":2,"using":1,"these":2,"classes":1,"bene":1,"fi":1,"one":1,"must":1,"consider":2,"potential":2,"side":5,"advise":2,"on":1,"strategies":5,"to":2,"minimize":1,"them":1,"table":3,"fig":1,"the":2,"most":2,"common":1,"are":4,"gastroin":1,"testinal":1,"nausea":1,"vomiting":1,"diarrhea":1,"prominent":1,"at":2,"initiation":2,"treatment":2,"usually":1,"improve":1,"over":1,"time":2,"mitigation":4,"shown":1,"in":3,"note":1,"that":2,"dipeptidyl":1,"peptidase":1,"dpp":2,"inhibitor":3,"can":1,"be":2,"dis":1,"continued":1,"adding":1,"because":1,"they":1,"both":1,"incretin":1,"based":1,"therapies":1,"redundant":1,"sglt2":1,"use":2,"genital":2,"mycotic":2,"infections":1,"explain":1,"mechanism":1,"action":1,"maintain":1,"hygiene":1,"rinse":1,"wipe":1,"episodes":1,"rarely":1,"recur":1,"after":1,"prescription":1,"anti":1,"agent":1,"used":2,"if":2,"infection":1,"occurs":1,"volume":1,"depletion":1,"adequate":1,"hydration":1,"hold":1,"acute":1,"illness":1,"or":2,"preoperative":1,"hypoglycemia":1,"exists":1,"combina":1,"tion":1,"insulin":2,"secretagogues":1,"see":1,"figure":1,"diabetic":1,"ketoacidosis":1,"do":1,"not":1},"len":206},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":11,"chunkId":"ccs-2022-p11-c4","text":"ydration \u000f Hold in acute illness or preoperative Hypoglycemia \u000f Potential exists if used in combina- tion with insulin secretagogues or insulin and eGFR \u0015 45 mL/min/ 1.73 m 2 . See Figure 2 for mitigation strategies Diabetic ketoacidosis \u000f Do not use in type 1 diabetes \u000f Do not discontinue insulin without the advice of a diabetes specialist; cautiously reduce insulin by 10%- 20% at a time \u000f Hold SGLT2i in acute illness \u000f Hold SGLT2i for 2-3 days before scheduled surgery or procedures \u000f Patients without diabetes not at risk Amputation \u000f Uncertain risk with canagli fl ozin but increased risk not seen with other SGLT2i \u000f Emphasis on preventative foot care (monitor for new pain, tenderness, sores, ulcers, and infections in the legs and feet) \u000f Risk factors that predispose to the need for amputation should be considered when choosing medication \u000f Hold during active foot ulcer Side effects of GLP-1 receptor agonists Gastrointestinal (nausea, vomiting, diarrhea) \u000f Usually transient \u000f Slow titration of dose \u000f Smaller meals; stop eating when no longer hungry \u000f Avoid spicy foods \u000f Maintain adequate hydration \u000f May use antiemetics if required Hypoglycemia \u000f Potential exists if used in combina- tion with insulin secretagogues or insulin. See Figure 2 for mitigation strategies eGFR, estimated glomerular fi ltration rate; GLP-1, glucagon-like peptide- 1; SGLT2, sodium-glucose co-transporter ","tf":{"10":1,"20":1,"45":1,"73":1,"ydration":1,"hold":4,"in":6,"acute":2,"illness":2,"or":4,"preoperative":1,"hypoglycemia":2,"potential":2,"exists":2,"if":3,"used":2,"combina":2,"tion":2,"with":4,"insulin":6,"secretagogues":2,"and":3,"egfr":2,"ml":1,"min":1,"see":2,"figure":2,"for":5,"mitigation":2,"strategies":2,"diabetic":1,"ketoacidosis":1,"do":2,"not":4,"use":2,"type":1,"diabetes":3,"discontinue":1,"without":2,"the":3,"advice":1,"of":3,"specialist":1,"cautiously":1,"reduce":1,"by":1,"at":2,"time":1,"sglt2i":3,"days":1,"before":1,"scheduled":1,"surgery":1,"procedures":1,"patients":1,"risk":4,"amputation":2,"uncertain":1,"canagli":1,"fl":1,"ozin":1,"but":1,"increased":1,"seen":1,"other":1,"emphasis":1,"on":1,"preventative":1,"foot":2,"care":1,"monitor":1,"new":1,"pain":1,"tenderness":1,"sores":1,"ulcers":1,"infections":1,"legs":1,"feet":1,"factors":1,"that":1,"predispose":1,"to":1,"need":1,"should":1,"be":1,"considered":1,"when":2,"choosing":1,"medication":1,"during":1,"active":1,"ulcer":1,"side":1,"effects":1,"glp":2,"receptor":1,"agonists":1,"gastrointestinal":1,"nausea":1,"vomiting":1,"diarrhea":1,"usually":1,"transient":1,"slow":1,"titration":1,"dose":1,"smaller":1,"meals":1,"stop":1,"eating":1,"no":1,"longer":1,"hungry":1,"avoid":1,"spicy":1,"foods":1,"maintain":1,"adequate":1,"hydration":1,"may":1,"antiemetics":1,"required":1,"estimated":1,"glomerular":1,"fi":1,"ltration":1,"rate":1,"glucagon":1,"like":1,"peptide":1,"sglt2":1,"sodium":1,"glucose":1,"co":1,"transporter":1},"len":199},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":11,"chunkId":"ccs-2022-p11-c5","text":"Hypoglycemia \u000f Potential exists if used in combina- tion with insulin secretagogues or insulin. See Figure 2 for mitigation strategies eGFR, estimated glomerular fi ltration rate; GLP-1, glucagon-like peptide- 1; SGLT2, sodium-glucose co-transporter 2; SGLT2i, sodium-glucose co- transporter 2 inhibitors. Mancini et al. 1163 CCS Guideline for Cardiorenal Risk Reduction","tf":{"1163":1,"hypoglycemia":1,"potential":1,"exists":1,"if":1,"used":1,"in":1,"combina":1,"tion":1,"with":1,"insulin":2,"secretagogues":1,"or":1,"see":1,"figure":1,"for":2,"mitigation":1,"strategies":1,"egfr":1,"estimated":1,"glomerular":1,"fi":1,"ltration":1,"rate":1,"glp":1,"glucagon":1,"like":1,"peptide":1,"sglt2":1,"sodium":2,"glucose":2,"co":2,"transporter":2,"sglt2i":1,"inhibitors":1,"mancini":1,"et":1,"al":1,"ccs":1,"guideline":1,"cardiorenal":1,"risk":1,"reduction":1},"len":49},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":12,"chunkId":"ccs-2022-p12-c0","text":"in that situation. In the SUSTAIN 6 trial of subcutaneous once weekly semaglutide, more retinopathy events occurred in the semaglutide group. However, this increase appears to be due to the rapid and robust glucose-lowering in people with marked hyperglycemia and preexisting retinopathy d a phe- nomenon previously observed in studies of insulin. In those patients, glucose-lowering is still desired but simultaneous regular examinations by an eye care professional is critical so that any changes can be addressed in a timely fashion. The long-term bene fi ts of glucose control on the eyes far outweigh any acute risk. The most common adverse effect of SGLT2i is genital mycotic infections (GMIs). Women (10%-15% risk), those with previous GMI, and uncircumcised men are at highest risk. GMI risk can be reduced with appropriate genital hy- giene strategies and when they occur, can typically be managed with antifungal drugs and do not require discon- tinuation of therapy. The risk of hypoglycemia is an important consideration if patients are using insulin secretagogues (meglitinides and sulfonylureas) and/or insulin (Fig. 2). The risk of hypogly- cemia is greater if the eGFR is > 45 mL/min/m 2 or the A1c is close to target in which case a reduced dose of insulin secre- tagogues and/or insulin should be considered and additional self-blood glucose monitoring and counselling around hypogl","tf":{"10":1,"15":1,"45":1,"in":8,"that":2,"situation":1,"the":10,"sustain":1,"trial":1,"of":8,"subcutaneous":1,"once":1,"weekly":1,"semaglutide":2,"more":1,"retinopathy":2,"events":1,"occurred":1,"group":1,"however":1,"this":1,"increase":1,"appears":1,"to":3,"be":5,"due":1,"rapid":1,"and":10,"robust":1,"glucose":4,"lowering":2,"people":1,"with":4,"marked":1,"hyperglycemia":1,"preexisting":1,"phe":1,"nomenon":1,"previously":1,"observed":1,"studies":1,"insulin":5,"those":2,"patients":2,"is":7,"still":1,"desired":1,"but":1,"simultaneous":1,"regular":1,"examinations":1,"by":1,"an":2,"eye":1,"care":1,"professional":1,"critical":1,"so":1,"any":2,"changes":1,"can":3,"addressed":1,"timely":1,"fashion":1,"long":1,"term":1,"bene":1,"fi":1,"ts":1,"control":1,"on":1,"eyes":1,"far":1,"outweigh":1,"acute":1,"risk":6,"most":1,"common":1,"adverse":1,"effect":1,"sglt2i":1,"genital":2,"mycotic":1,"infections":1,"gmis":1,"women":1,"previous":1,"gmi":2,"uncircumcised":1,"men":1,"are":2,"at":1,"highest":1,"reduced":2,"appropriate":1,"hy":1,"giene":1,"strategies":1,"when":1,"they":1,"occur":1,"typically":1,"managed":1,"antifungal":1,"drugs":1,"do":1,"not":1,"require":1,"discon":1,"tinuation":1,"therapy":1,"hypoglycemia":1,"important":1,"consideration":1,"if":2,"using":1,"secretagogues":1,"meglitinides":1,"sulfonylureas":1,"or":3,"fig":1,"hypogly":1,"cemia":1,"greater":1,"egfr":1,"ml":1,"min":1,"a1c":1,"close":1,"target":1,"which":1,"case":1,"dose":1,"secre":1,"tagogues":1,"should":1,"considered":1,"additional":1,"self":1,"blood":1,"monitoring":1,"counselling":1,"around":1,"hypogl":1},"len":220},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":12,"chunkId":"ccs-2022-p12-c1","text":"ogly- cemia is greater if the eGFR is > 45 mL/min/m 2 or the A1c is close to target in which case a reduced dose of insulin secre- tagogues and/or insulin should be considered and additional self-blood glucose monitoring and counselling around hypoglycemia symptoms and treatment are recommended. The risk of hypoglycemia is lower if A1c is > 8%. If SGLT2i are used in those with eGFR < 45 mL/min/1.73 m 2 the risk is lower because the glycemic-lowering effect of SGLT2i is minimal. In contrast, for GLP-1RA, the potential for glucose- lowering is present across the eGFR spectrum. To decide if adjustment of existing insulin secretagogues and/or insulin is needed, consider the current A1c. If A1c is > 8%, then the addition of these agents is less likely to cause hypoglycemia but the patient should be counselled about the potential for hypoglycemia. However, if the A1c is \u0014 8%, then a reduction in the dose or discontinuation of the insulin secretagogue is warranted to avoid hypoglycemia. In the case of insulin, dose reduction by 10%-20% or more might be required to avoid hypoglycemia. Communication with the patient  s diabetes team is critical when any such changes to therapy are being considered, especially for SGLT2i, as aggressive reduction of insulin is a risk factor for DKA. SGLT2i have been associated with DKA (incidence 0.1%) among patients with diabetes. Patients with SGLT2i- ","tf":{"10":1,"20":1,"45":2,"73":1,"ogly":1,"cemia":1,"is":15,"greater":1,"if":6,"the":16,"egfr":3,"ml":2,"min":2,"or":5,"a1c":5,"close":1,"to":6,"target":1,"in":5,"which":1,"case":2,"reduced":1,"dose":3,"of":8,"insulin":7,"secre":1,"tagogues":1,"and":5,"should":2,"be":3,"considered":2,"additional":1,"self":1,"blood":1,"glucose":2,"monitoring":1,"counselling":1,"around":1,"hypoglycemia":6,"symptoms":1,"treatment":1,"are":3,"recommended":1,"risk":3,"lower":2,"sglt2i":5,"used":1,"those":1,"with":5,"because":1,"glycemic":1,"lowering":2,"effect":1,"minimal":1,"contrast":1,"for":5,"glp":1,"1ra":1,"potential":2,"present":1,"across":1,"spectrum":1,"decide":1,"adjustment":1,"existing":1,"secretagogues":1,"needed":1,"consider":1,"current":1,"then":2,"addition":1,"these":1,"agents":1,"less":1,"likely":1,"cause":1,"but":1,"patient":2,"counselled":1,"about":1,"however":1,"reduction":3,"discontinuation":1,"secretagogue":1,"warranted":1,"avoid":2,"by":1,"more":1,"might":1,"required":1,"communication":1,"diabetes":2,"team":1,"critical":1,"when":1,"any":1,"such":1,"changes":1,"therapy":1,"being":1,"especially":1,"as":1,"aggressive":1,"factor":1,"dka":2,"have":1,"been":1,"associated":1,"incidence":1,"among":1,"patients":2},"len":224},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":12,"chunkId":"ccs-2022-p12-c2","text":"ical when any such changes to therapy are being considered, especially for SGLT2i, as aggressive reduction of insulin is a risk factor for DKA. SGLT2i have been associated with DKA (incidence 0.1%) among patients with diabetes. Patients with SGLT2i- associated DKA might present with normal or only modestly elevated blood glucose level ( < 14 mmol/L). Inadequate insulin remains the cause of DKA and therefore, mitigation strategies shown in Table 4 can reduce the risk. Nonspeci fi c symptoms associated with DKA include: Figure 4. Practical approach to the use of glucagon-like peptide-1 receptor antagonists (GLP-1RA) for cardiorenal risk reduction. A1c, glycosylated hemoglobin; ASCVD, atherosclerotic cardiovascular disease; ESKD, end-stage kidney disease; GI, gastrointestinal; T1D, type 1 diabetes; T2D, type 2 diabetes; SC, subcutaneously. 1164 Canadian Journal of Cardiology Volume 38 2022","tf":{"14":1,"38":1,"1164":1,"2022":1,"ical":1,"when":1,"any":1,"such":1,"changes":1,"to":2,"therapy":1,"are":1,"being":1,"considered":1,"especially":1,"for":3,"sglt2i":3,"as":1,"aggressive":1,"reduction":2,"of":4,"insulin":2,"is":1,"risk":3,"factor":1,"dka":5,"have":1,"been":1,"associated":3,"with":5,"incidence":1,"among":1,"patients":2,"diabetes":3,"might":1,"present":1,"normal":1,"or":1,"only":1,"modestly":1,"elevated":1,"blood":1,"glucose":1,"level":1,"mmol":1,"inadequate":1,"remains":1,"the":3,"cause":1,"and":1,"therefore":1,"mitigation":1,"strategies":1,"shown":1,"in":1,"table":1,"can":1,"reduce":1,"nonspeci":1,"fi":1,"symptoms":1,"include":1,"figure":1,"practical":1,"approach":1,"use":1,"glucagon":1,"like":1,"peptide":1,"receptor":1,"antagonists":1,"glp":1,"1ra":1,"cardiorenal":1,"a1c":1,"glycosylated":1,"hemoglobin":1,"ascvd":1,"atherosclerotic":1,"cardiovascular":1,"disease":2,"eskd":1,"end":1,"stage":1,"kidney":1,"gi":1,"gastrointestinal":1,"t1d":1,"type":2,"t2d":1,"sc":1,"subcutaneously":1,"canadian":1,"journal":1,"cardiology":1,"volume":1},"len":125},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":13,"chunkId":"ccs-2022-p13-c0","text":"shortness of breath, nausea, vomiting, abdominal pain, confusion, anorexia, excessive thirst, and lethargy. Patients without diabetes are not at risk of DKA when these agents are used. 64 SGLT2i use might result in a temporary decrease in eGFR of up to 15%-25%, which generally resolves in 1-3 months and is not usually a sign of acute kidney injury. The decrease in eGFR is expected and results from a decrease in intra- glomerular pressure induced by these agents, conceptually similar to what is seen with ACEi and ARB. In fact, trial evidence suggests that there is no increase or even a reduction in acute kidney injury. 61 Accordingly, this eGFR reduction should not result in premature discontinuation of SGLT2i, which favourably modi fi es kidney outcomes. Despite this reassurance, attention to volume status is always required, especially when SGLT2i, ARNIs, and loop diuretics are used in combination because of their additive effects to promote diuresis. SGLT2i should be stopped temporarily in the setting of concomitant dehydrating illness as part of  sick day  management. 62 Caution is warranted in patients with very low and variable BP or when kidney function is already extremely compromised. Currently, canagli fl ozin and dapagli fl ozin are contraindicated in patients undergoing dialysis and empagli- fl ozin is contraindicated in patients with an eGFR < 20 mL/ min/1.73 m 2 ","tf":{"15":1,"20":1,"25":1,"61":1,"62":1,"64":1,"73":1,"shortness":1,"of":8,"breath":1,"nausea":1,"vomiting":1,"abdominal":1,"pain":1,"confusion":1,"anorexia":1,"excessive":1,"thirst":1,"and":8,"lethargy":1,"patients":4,"without":1,"diabetes":1,"are":4,"not":3,"at":1,"risk":1,"dka":1,"when":3,"these":2,"agents":2,"used":2,"sglt2i":4,"use":1,"might":1,"result":2,"in":13,"temporary":1,"decrease":3,"egfr":4,"up":1,"to":4,"which":2,"generally":1,"resolves":1,"months":1,"is":8,"usually":1,"sign":1,"acute":2,"kidney":4,"injury":2,"the":2,"expected":1,"results":1,"from":1,"intra":1,"glomerular":1,"pressure":1,"induced":1,"by":1,"conceptually":1,"similar":1,"what":1,"seen":1,"with":3,"acei":1,"arb":1,"fact":1,"trial":1,"evidence":1,"suggests":1,"that":1,"there":1,"no":1,"increase":1,"or":2,"even":1,"reduction":2,"accordingly":1,"this":2,"should":2,"premature":1,"discontinuation":1,"favourably":1,"modi":1,"fi":1,"es":1,"outcomes":1,"despite":1,"reassurance":1,"attention":1,"volume":1,"status":1,"always":1,"required":1,"especially":1,"arnis":1,"loop":1,"diuretics":1,"combination":1,"because":1,"their":1,"additive":1,"effects":1,"promote":1,"diuresis":1,"be":1,"stopped":1,"temporarily":1,"setting":1,"concomitant":1,"dehydrating":1,"illness":1,"as":1,"part":1,"sick":1,"day":1,"management":1,"caution":1,"warranted":1,"very":1,"low":1,"variable":1,"bp":1,"function":1,"already":1,"extremely":1,"compromised":1,"currently":1,"canagli":1,"fl":3,"ozin":3,"dapagli":1,"contraindicated":2,"undergoing":1,"dialysis":1,"empagli":1,"an":1,"ml":1,"min":1},"len":217},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":13,"chunkId":"ccs-2022-p13-c1","text":"le BP or when kidney function is already extremely compromised. Currently, canagli fl ozin and dapagli fl ozin are contraindicated in patients undergoing dialysis and empagli- fl ozin is contraindicated in patients with an eGFR < 20 mL/ min/1.73 m 2 . As indicated previously, referral to a specialist with expertise in CKD should be considered in the following situations: progressive loss of kidney function, urine UACR persistently > 60 mg/mmol, or progressive increase in UACR despite appropriate therapy, eGFR < 30 mL/min/1.73 m 2 , inability to continue kidney-protective therapies because of adverse effects, such as hyperkalemia or a > 30% increase in serum creatinine within 3 months of starting SGLT2i, ACEi, or ARB, inability to achieve target BP, or signs/symptoms of another underlying kidney disease, such as glomerulonephritis. The increased risk of amputation seen in the large, long- term Can agli fl ozin Cardio v ascular A ssessment S tudy (CANVAS) trial for canagli fl ozin, and select observational studies, merits further research but overall, there is currently no consistent evidence of SGLT2i exposure and increased risk of amputation. 65 Summary and Conclusions A remarkable paradigm shift has occurred with the avail- ability of diabetes-related drugs with proven cardiorenal bene fi ts in patients with and without T2D. We summarize our overview for appropriate, safe, and","tf":{"20":1,"30":2,"60":1,"65":1,"73":2,"le":1,"bp":2,"or":5,"when":1,"kidney":4,"function":2,"is":3,"already":1,"extremely":1,"compromised":1,"currently":2,"canagli":2,"fl":5,"ozin":5,"and":7,"dapagli":1,"are":1,"contraindicated":2,"in":8,"patients":3,"undergoing":1,"dialysis":1,"empagli":1,"with":5,"an":1,"egfr":2,"ml":2,"min":2,"as":3,"indicated":1,"previously":1,"referral":1,"to":3,"specialist":1,"expertise":1,"ckd":1,"should":1,"be":1,"considered":1,"the":4,"following":1,"situations":1,"progressive":2,"loss":1,"of":8,"urine":1,"uacr":2,"persistently":1,"mg":1,"mmol":1,"increase":2,"despite":1,"appropriate":2,"therapy":1,"inability":2,"continue":1,"protective":1,"therapies":1,"because":1,"adverse":1,"effects":1,"such":2,"hyperkalemia":1,"serum":1,"creatinine":1,"within":1,"months":1,"starting":1,"sglt2i":2,"acei":1,"arb":1,"achieve":1,"target":1,"signs":1,"symptoms":1,"another":1,"underlying":1,"disease":1,"glomerulonephritis":1,"increased":2,"risk":2,"amputation":2,"seen":1,"large":1,"long":1,"term":1,"can":1,"agli":1,"cardio":1,"ascular":1,"ssessment":1,"tudy":1,"canvas":1,"trial":1,"for":2,"select":1,"observational":1,"studies":1,"merits":1,"further":1,"research":1,"but":1,"overall":1,"there":1,"no":1,"consistent":1,"evidence":1,"exposure":1,"summary":1,"conclusions":1,"remarkable":1,"paradigm":1,"shift":1,"has":1,"occurred":1,"avail":1,"ability":1,"diabetes":1,"related":1,"drugs":1,"proven":1,"cardiorenal":1,"bene":1,"fi":1,"ts":1,"without":1,"t2d":1,"we":1,"summarize":1,"our":1,"overview":1,"safe":1},"len":208},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":13,"chunkId":"ccs-2022-p13-c2","text":"mputation. 65 Summary and Conclusions A remarkable paradigm shift has occurred with the avail- ability of diabetes-related drugs with proven cardiorenal bene fi ts in patients with and without T2D. We summarize our overview for appropriate, safe, and effective use of SGLT2i in Figure 3 and for GLP-1RA in Figure 4. CV medicine continues to progress with numerous new in- terventions shown to be clearly superior to historical standards of care and requiring practitioners to balance the proven bene fi ts with administrative, economic, and access issues. These factors can complicate physician-patient decisions in the early stages of implementation but ultimately, evidence shows that more general incorporation of these treatments in appropriate patients will alter the natural course of disease. Achieving A1c targets continues to be an important goal for T2D. Also critical is the expeditious reduction of cardiorenal risk, thereby mandating a paradigm shift in prioritization of therapies. The profound bene fi ts noted in the treatment of established HF or CKD or in the prevention of cardiorenal morbidity or mortality are not strongly tied to A1c-lowering. Accordingly, their initiation should not be predicated on the need for additional A1c-lowering. While upholding the principle of judicious stewardship of health care resources, it is imperative to advocate for lowering all hurdles to ","tf":{"65":1,"mputation":1,"summary":1,"and":6,"conclusions":1,"remarkable":1,"paradigm":2,"shift":2,"has":1,"occurred":1,"with":5,"the":10,"avail":1,"ability":1,"of":12,"diabetes":1,"related":1,"drugs":1,"proven":2,"cardiorenal":3,"bene":3,"fi":3,"ts":3,"in":9,"patients":2,"without":1,"t2d":2,"we":1,"summarize":1,"our":1,"overview":1,"for":5,"appropriate":2,"safe":1,"effective":1,"use":1,"sglt2i":1,"figure":2,"glp":1,"1ra":1,"cv":1,"medicine":1,"continues":2,"to":8,"progress":1,"numerous":1,"new":1,"terventions":1,"shown":1,"be":3,"clearly":1,"superior":1,"historical":1,"standards":1,"care":2,"requiring":1,"practitioners":1,"balance":1,"administrative":1,"economic":1,"access":1,"issues":1,"these":2,"factors":1,"can":1,"complicate":1,"physician":1,"patient":1,"decisions":1,"early":1,"stages":1,"implementation":1,"but":1,"ultimately":1,"evidence":1,"shows":1,"that":1,"more":1,"general":1,"incorporation":1,"treatments":1,"will":1,"alter":1,"natural":1,"course":1,"disease":1,"achieving":1,"a1c":3,"targets":1,"an":1,"important":1,"goal":1,"also":1,"critical":1,"is":2,"expeditious":1,"reduction":1,"risk":1,"thereby":1,"mandating":1,"prioritization":1,"therapies":1,"profound":1,"noted":1,"treatment":1,"established":1,"hf":1,"or":3,"ckd":1,"prevention":1,"morbidity":1,"mortality":1,"are":1,"not":2,"strongly":1,"tied":1,"lowering":3,"accordingly":1,"their":1,"initiation":1,"should":1,"predicated":1,"on":1,"need":1,"additional":1,"while":1,"upholding":1,"principle":1,"judicious":1,"stewardship":1,"health":1,"resources":1,"it":1,"imperative":1,"advocate":1,"all":1,"hurdles":1},"len":213},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":13,"chunkId":"ccs-2022-p13-c3","text":"o A1c-lowering. Accordingly, their initiation should not be predicated on the need for additional A1c-lowering. While upholding the principle of judicious stewardship of health care resources, it is imperative to advocate for lowering all hurdles to access of these classes of agents. Accordingly, the recommendations put forward can be considered ideal and aspirational, requiring tailoring to the speci fi c and changing clinical environment faced by individuals with T2D, CKD, or HF and their health care professionals. This will require shared decision-making with the patient that re fl ects interdisciplinary collaboration from cardiologists, nephrologists, endocrinologists, primary care physicians, and pharmacists who should make every effort to integrate these diabetes-related agents with cardiorenal bene fi ts into an overall and individualized treatment plan. References 1. Mancini GBJ, Cheng AY, Connelly K, et al. Diabetes for cardiologists: practical issues in diagnosis and management. Can J Cardiol 2017;33: 366-77. 2. Mancini GBJ, Cheng AY, Connelly K, et al. CardioDiabetes: core competencies for cardiovascular clinicians in a rapidly evolving era of type 2 diabetes management. Can J Cardiol 2018;34:1350-61. 3. Lipscombe L, Butalia S, Dasgupta K, et al. Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update. Can J Diabetes 2020;44:575-91. 4. Senior PA, ","tf":{"33":1,"34":1,"44":1,"61":1,"77":1,"91":1,"366":1,"575":1,"1350":1,"2017":1,"2018":1,"2020":2,"a1c":2,"lowering":3,"accordingly":2,"their":2,"initiation":1,"should":2,"not":1,"be":2,"predicated":1,"on":1,"the":5,"need":1,"for":4,"additional":1,"while":1,"upholding":1,"principle":1,"of":6,"judicious":1,"stewardship":1,"health":2,"care":3,"resources":1,"it":1,"is":1,"imperative":1,"to":4,"advocate":1,"all":1,"hurdles":1,"access":1,"these":2,"classes":1,"agents":2,"recommendations":1,"put":1,"forward":1,"can":4,"considered":1,"ideal":1,"and":6,"aspirational":1,"requiring":1,"tailoring":1,"speci":1,"fi":2,"changing":1,"clinical":1,"environment":1,"faced":1,"by":1,"individuals":1,"with":3,"t2d":1,"ckd":1,"or":1,"hf":1,"professionals":1,"this":1,"will":1,"require":1,"shared":1,"decision":1,"making":1,"patient":1,"that":1,"re":1,"fl":1,"ects":1,"interdisciplinary":1,"collaboration":1,"from":1,"cardiologists":2,"nephrologists":1,"endocrinologists":1,"primary":1,"physicians":1,"pharmacists":1,"who":1,"make":1,"every":1,"effort":1,"integrate":1,"diabetes":5,"related":1,"cardiorenal":1,"bene":1,"ts":1,"into":1,"an":1,"overall":1,"individualized":1,"treatment":1,"plan":1,"references":1,"mancini":2,"gbj":2,"cheng":2,"ay":2,"connelly":2,"et":3,"al":3,"practical":1,"issues":1,"in":3,"diagnosis":1,"management":3,"cardiol":2,"cardiodiabetes":1,"core":1,"competencies":1,"cardiovascular":1,"clinicians":1,"rapidly":1,"evolving":1,"era":1,"type":2,"lipscombe":1,"butalia":1,"dasgupta":1,"pharmacologic":1,"glycemic":1,"adults":1,"update":1,"senior":1,"pa":1},"len":197},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":13,"chunkId":"ccs-2022-p13-c4","text":"apidly evolving era of type 2 diabetes management. Can J Cardiol 2018;34:1350-61. 3. Lipscombe L, Butalia S, Dasgupta K, et al. Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update. Can J Diabetes 2020;44:575-91. 4. Senior PA, Houlden RL, Kim J, et al. Pharmacologic glycemic man- agement of type 2 diabetes in adults: 2020 update - the user  s guide. Can J Diabetes 2020;44:592-6. 5. O  Meara E, McDonald M, Chan M, et al. CCS/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis. Can J Cardiol 2020;36:159-69. 6. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes manage- ment in chronic kidney disease. Kidney Int 2020;98:S1-115. 7. Ali MU, Mancini GBJ, Fitzpatrick-Lewis D, et al. The effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists on cardiorenal outcomes: systematic review and meta- analysis. Can J Cardiol 2022;38:1201-10. 8. Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and car- diovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo- controlled trial. Lancet 2018;392:1519-29. 9. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and car-","tf":{"10":1,"29":1,"34":1,"36":1,"38":1,"44":2,"61":1,"69":1,"91":1,"98":1,"115":1,"159":1,"392":1,"575":1,"592":1,"1201":1,"1350":1,"1519":1,"2018":2,"2020":7,"2022":1,"apidly":1,"evolving":1,"era":1,"of":4,"type":4,"diabetes":8,"management":2,"can":5,"cardiol":3,"lipscombe":1,"butalia":1,"dasgupta":1,"et":6,"al":6,"pharmacologic":2,"glycemic":2,"in":6,"adults":2,"update":3,"senior":1,"pa":1,"houlden":1,"rl":1,"kim":1,"man":1,"agement":1,"the":2,"user":1,"guide":1,"meara":1,"mcdonald":1,"chan":1,"ccs":1,"chfs":1,"heart":1,"failure":1,"guidelines":1,"clinical":2,"trial":2,"on":2,"functional":1,"mitral":1,"regurgitation":1,"sglt2":1,"inhibitors":2,"arni":1,"hfpef":1,"and":6,"tafamidis":1,"amyloidosis":1,"kidney":3,"disease":3,"improving":1,"global":1,"outcomes":4,"kdigo":2,"work":1,"group":1,"practice":1,"guideline":1,"for":1,"manage":1,"ment":1,"chronic":1,"int":1,"s1":1,"ali":1,"mu":1,"mancini":1,"gbj":1,"fitzpatrick":1,"lewis":1,"effectiveness":1,"sodium":1,"glucose":1,"cotransporter":1,"glucagon":1,"like":1,"peptide":1,"receptor":1,"agonists":1,"cardiorenal":1,"systematic":1,"review":1,"meta":1,"analysis":1,"hernandez":1,"af":1,"green":1,"jb":1,"janmohamed":1,"albiglutide":1,"car":2,"diovascular":1,"patients":1,"with":1,"cardiovascular":1,"harmony":1,"double":1,"blind":1,"randomised":1,"placebo":1,"controlled":1,"lancet":1,"gerstein":1,"hc":1,"colhoun":1,"hm":1,"dagenais":1,"gr":1,"dulaglutide":1},"len":199},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":13,"chunkId":"ccs-2022-p13-c5","text":"- diovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo- controlled trial. Lancet 2018;392:1519-29. 9. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and car- diovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394:121-30. 10. Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med 2021;385: 896-907. 11. Holman RR, Bethel MA, Hernandez AF. Once-weekly exenatide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377: 2502. 12. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and car- diovascular outcomes in type 2 diabetes. N Engl J Med 2016;375: 311-22. Mancini et al. 1165 CCS Guideline for Cardiorenal Risk Reduction","tf":{"10":1,"11":1,"12":1,"22":1,"29":1,"30":1,"121":1,"311":1,"375":1,"377":1,"385":1,"392":1,"394":1,"896":1,"907":1,"1165":1,"1519":1,"2016":1,"2017":1,"2018":1,"2019":1,"2021":1,"2502":1,"diovascular":3,"outcomes":6,"in":5,"patients":1,"with":2,"type":5,"diabetes":5,"and":5,"cardiovascular":3,"disease":1,"harmony":1,"double":2,"blind":2,"randomised":2,"placebo":2,"controlled":2,"trial":2,"lancet":2,"gerstein":2,"hc":2,"colhoun":1,"hm":1,"dagenais":1,"gr":1,"et":4,"al":4,"dulaglutide":1,"car":2,"rewind":1,"sattar":1,"rosenstock":1,"renal":1,"efpeglenatide":1,"engl":3,"med":3,"holman":1,"rr":1,"bethel":1,"ma":1,"hernandez":1,"af":1,"once":1,"weekly":1,"exenatide":1,"marso":1,"sp":1,"daniels":1,"gh":1,"brown":1,"frandsen":1,"liraglutide":1,"mancini":1,"ccs":1,"guideline":1,"for":1,"cardiorenal":1,"risk":1,"reduction":1},"len":127},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":14,"chunkId":"ccs-2022-p14-c0","text":"13. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375: 1834-44. 14. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019;381:841-51. 15. Neal B, Perkovic V, Mahaffey KW, et al. Canagli fl ozin and cardiovas- cular and renal events in type 2 diabetes. N Engl J Med 2017;377: 644-57. 16. Perkovic V, Jardine MJ, Neal B, et al. Canagli fl ozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295-306. 17. Heerspink HJL, Stefnsson BV, Correa-Rotter R, et al. Dapagli fl ozin in patients with chronic kidney disease. N Engl J Med 2020;383:1436-46. 18. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagli fl ozin in pa- tients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995-2008. 19. Wiviott SD, Raz I, Bonaca MP, et al. Dapagli fl ozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347-57. 20. Zinman B, Wanner C, Lachin JM, et al. Empagli fl ozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373: 2117-28. 21. Packer M, Anker SD, Butler J, et al. Empagli fl ozin in patients with heart failure, reduced ejection fraction, and volume overload: EMPEROR- Reduced Trial. J Am Coll Cardiol 2021;77:1381-92. 22. Anker S","tf":{"13":1,"14":1,"15":1,"16":1,"17":1,"18":1,"19":1,"20":1,"21":1,"22":1,"28":1,"44":1,"46":1,"51":1,"57":2,"77":1,"92":1,"306":1,"347":1,"373":1,"375":1,"377":1,"380":2,"381":2,"383":1,"644":1,"841":1,"1381":1,"1436":1,"1834":1,"1995":1,"2008":1,"2015":1,"2016":1,"2017":1,"2019":4,"2020":1,"2021":1,"2117":1,"2295":1,"marso":1,"sp":1,"bain":1,"sc":1,"consoli":1,"et":9,"al":10,"semaglutide":2,"and":10,"cardiovascular":4,"outcomes":5,"in":9,"patients":4,"with":5,"type":6,"diabetes":6,"engl":8,"med":8,"husain":1,"birkenfeld":1,"donsmark":1,"oral":1,"neal":2,"perkovic":2,"mahaffey":1,"kw":1,"canagli":2,"fl":7,"ozin":7,"cardiovas":1,"cular":1,"renal":2,"events":1,"jardine":1,"mj":1,"nephropathy":1,"heerspink":1,"hjl":1,"stef":1,"nsson":1,"bv":1,"correa":1,"rotter":1,"dapagli":3,"chronic":1,"kidney":1,"disease":1,"mcmurray":1,"jjv":1,"solomon":1,"sd":3,"inzucchi":1,"se":1,"pa":1,"tients":1,"heart":2,"failure":2,"reduced":3,"ejection":2,"fraction":2,"wiviott":1,"raz":1,"bonaca":1,"mp":1,"zinman":1,"wanner":1,"lachin":1,"jm":1,"empagli":2,"mortality":1,"packer":1,"anker":2,"butler":1,"volume":1,"overload":1,"emperor":1,"trial":1,"am":1,"coll":1,"cardiol":1},"len":227},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":14,"chunkId":"ccs-2022-p14-c1","text":" diabetes. N Engl J Med 2015;373: 2117-28. 21. Packer M, Anker SD, Butler J, et al. Empagli fl ozin in patients with heart failure, reduced ejection fraction, and volume overload: EMPEROR- Reduced Trial. J Am Coll Cardiol 2021;77:1381-92. 22. Anker SD, Butler J, Filippatos G, et al. Empagli fl ozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451-61. 23. Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugli fl ozin in type 2 diabetes. N Engl J Med 2020;383:1425-35. 24. Bhatt DL, Szarek M, Pitt B, et al. Sotagli fl ozin in patients with diabetes and chronic kidney disease. N Engl J Med 2021;384:129-39. 25. Bhatt DL, Szarek M, Steg PG, et al. Sotagli fl ozin in patients with dia- betes and recent worsening heart failure. N Engl J Med 2021;384: 117-28. 26. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373: 2247-57. 27. Whitelaw S, Pellegrini DM, Mamas MA, Cowie M, Van Spall HGC. Barriers and facilitators of the uptake of digital health technology in cardiovascular care: a systematic scoping review. Eur Heart J Digit Health 2021;2:62-74. 28. Martinez FA, Serenelli M, Nicolau JC, et al. Ef fi cacy and safety of dapagli fl ozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. Circulation 2020;141:100-11","tf":{"11":1,"21":1,"22":1,"23":1,"24":1,"25":1,"26":1,"27":1,"28":3,"35":1,"39":1,"57":1,"61":1,"62":1,"74":1,"77":1,"92":1,"100":1,"117":1,"129":1,"141":1,"373":2,"383":1,"384":2,"385":1,"1381":1,"1425":1,"1451":1,"2015":2,"2020":2,"2021":5,"2117":1,"2247":1,"diabetes":4,"engl":6,"med":6,"packer":1,"anker":2,"sd":2,"butler":2,"et":7,"al":7,"empagli":2,"fl":6,"ozin":6,"in":8,"patients":4,"with":7,"heart":5,"failure":4,"reduced":3,"ejection":3,"fraction":3,"and":6,"volume":1,"overload":1,"emperor":1,"trial":1,"am":1,"coll":1,"cardiol":1,"filippatos":1,"preserved":1,"cannon":1,"cp":1,"pratley":1,"dagogo":1,"jack":1,"cardiovascular":2,"outcomes":1,"ertugli":1,"type":2,"bhatt":2,"dl":2,"szarek":2,"pitt":1,"sotagli":2,"chronic":1,"kidney":1,"disease":1,"steg":1,"pg":1,"dia":1,"betes":1,"recent":1,"worsening":1,"pfeffer":1,"ma":2,"claggett":1,"diaz":1,"lixisenatide":1,"acute":1,"coronary":1,"syndrome":1,"whitelaw":1,"pellegrini":1,"dm":1,"mamas":1,"cowie":1,"van":1,"spall":1,"hgc":1,"barriers":1,"facilitators":1,"of":3,"the":1,"uptake":1,"digital":1,"health":2,"technology":1,"care":1,"systematic":1,"scoping":1,"review":1,"eur":1,"digit":1,"martinez":1,"fa":1,"serenelli":1,"nicolau":1,"jc":1,"ef":1,"fi":1,"cacy":1,"safety":1,"dapagli":1,"according":1,"to":1,"age":1,"insights":1,"from":1,"dapa":1,"hf":1,"circulation":1},"len":227},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":14,"chunkId":"ccs-2022-p14-c2","text":"iew. Eur Heart J Digit Health 2021;2:62-74. 28. Martinez FA, Serenelli M, Nicolau JC, et al. Ef fi cacy and safety of dapagli fl ozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF. Circulation 2020;141:100-11. 29. Jackson AM, Dewan P, Anand IS, et al. Dapagli fl ozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation 2020;142:1040-54. 30. Kosiborod MN, Jhund PS, Docherty KF, et al. Effects of dapagli fl ozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation 2020;141:90-9. 31. Serenelli M, Bhm M, Inzucchi SE, et al. Effect of dapagli fl ozin ac- cording to baseline systolic blood pressure in the Dapagli fl ozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). Eur Heart J 2020;41:3402-18. 32. Jhund PS, Solomon SD, Docherty KF, et al. Ef fi cacy of dapagli fl ozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation 2021;143:298-309. 33. Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 2020;396:819-29. 34. Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-nepr","tf":{"11":1,"18":1,"28":1,"29":2,"30":1,"31":1,"32":1,"33":1,"34":1,"41":1,"54":1,"62":1,"74":1,"90":1,"100":1,"141":2,"142":1,"143":1,"298":1,"309":1,"396":1,"819":1,"1040":1,"2020":5,"2021":2,"3402":1,"iew":1,"eur":2,"heart":8,"digit":1,"health":1,"martinez":1,"fa":1,"serenelli":2,"nicolau":1,"jc":1,"et":7,"al":7,"ef":2,"fi":2,"cacy":2,"and":8,"safety":1,"of":8,"dapagli":6,"fl":6,"ozin":6,"in":8,"failure":6,"with":7,"reduced":6,"ejection":5,"fraction":5,"according":1,"to":2,"age":1,"insights":1,"from":2,"dapa":6,"hf":6,"circulation":4,"jackson":1,"am":1,"dewan":1,"anand":2,"is":2,"diuretic":1,"use":1,"patients":4,"kosiborod":1,"mn":1,"jhund":2,"ps":2,"docherty":2,"kf":2,"effects":1,"on":2,"symptoms":1,"function":2,"quality":1,"life":1,"results":2,"the":3,"trial":2,"hm":1,"inzucchi":1,"se":1,"effect":1,"ac":1,"cording":1,"baseline":1,"systolic":1,"blood":1,"pressure":1,"prevention":1,"adverse":1,"outcomes":2,"solomon":2,"sd":2,"renal":1,"zannad":1,"ferreira":1,"jp":1,"pocock":1,"sj":1,"sglt2":1,"inhibitors":1,"meta":1,"analysis":1,"emperor":1,"trials":1,"lancet":1,"mcmurray":1,"jjv":1,"angiotensin":1,"nepr":1},"len":240},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":14,"chunkId":"ccs-2022-p14-c3","text":"a JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 2020;396:819-29. 34. Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381:1609-20. 35. Anker SD, Butler J, Filippatos G, et al. Effect of empagli fl ozin on car- diovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-Reduced trial. Circulation 2021;143:337-49. 36. Packer M, Butler J, Zannad F, et al. Empagli fl ozin and major renal outcomes in heart failure. N Engl J Med 2021;385:1531-3. 37. Butler J, Packer M, Filippatos G, et al. Effect of empagli fl ozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J 2022;43:416-26. 38. ClinicalTrials.gov. A study of tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity (SUM- MIT). Available at: https://clinicaltrials.gov/ct2/show/NCT04847557. Accessed November 29, 2021. 39. ClinicalTrials.gov. Research study to investigate how well semaglutide works in people living with heart failure and obesity (STEP-HFpEF). Available at: https://clinicaltrials.gov/ct2/show/NCT04788511. Accessed November 15, 2021. 40. ClinicalTria","tf":{"15":1,"20":1,"26":1,"29":2,"34":1,"35":1,"36":1,"37":1,"38":1,"39":1,"40":1,"43":1,"49":1,"143":1,"337":1,"381":1,"385":1,"396":1,"416":1,"819":1,"1531":1,"1609":1,"2019":1,"2020":1,"2021":4,"2022":1,"jp":1,"pocock":1,"sj":1,"et":5,"al":5,"sglt2":1,"inhibitors":1,"in":7,"patients":3,"with":8,"heart":8,"failure":7,"reduced":3,"ejection":4,"fraction":4,"meta":1,"analysis":1,"of":5,"the":3,"emperor":2,"and":5,"dapa":1,"hf":1,"trials":1,"lancet":1,"solomon":1,"sd":2,"mcmurray":1,"jjv":1,"anand":1,"is":1,"angiotensin":1,"neprilysin":1,"inhibition":1,"preserved":2,"engl":2,"med":2,"anker":1,"butler":3,"filippatos":2,"effect":2,"empagli":3,"fl":3,"ozin":3,"on":1,"car":1,"diovascular":1,"renal":2,"outcomes":2,"by":1,"baseline":1,"diabetes":1,"status":1,"results":1,"from":1,"trial":1,"circulation":1,"packer":2,"zannad":1,"major":1,"across":1,"spectrum":1,"left":1,"ventricular":1,"eur":1,"clinicaltrials":4,"gov":4,"study":2,"tirzepatide":1,"ly3298176":1,"participants":1,"obesity":2,"sum":1,"mit":1,"available":2,"at":2,"https":2,"ct2":2,"show":2,"nct04847557":1,"accessed":2,"november":2,"research":1,"to":1,"investigate":1,"how":1,"well":1,"semaglutide":1,"works":1,"people":1,"living":1,"step":1,"hfpef":1,"nct04788511":1,"clinicaltria":1},"len":212},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":14,"chunkId":"ccs-2022-p14-c4","text":"39. ClinicalTrials.gov. Research study to investigate how well semaglutide works in people living with heart failure and obesity (STEP-HFpEF). Available at: https://clinicaltrials.gov/ct2/show/NCT04788511. Accessed November 15, 2021. 40. ClinicalTrials.gov. Dapagli fl ozin and effect on cardiovascular events in acute heart failure - thrombolysis in myocardial infarction 68 (DAPA ACT HF-TIMI 68). Available at: https://clinicaltrials.gov/ct2/show/ NCT04363697. Accessed November 8, 2021. 41. Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagli fl ozin in patients hospitalized for acute heart failure: a multina- tional randomized trial. Nat Med 2022;28:568-74. 42. Spertus JA, Birmingham MC, Nassif M, et al. The SGLT2 inhibitor canagli fl ozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nat Med 2022;28:809-13. 43. ClinicalTrials.gov. A research study to see how semaglutide works compared to placebo in people with type 2 diabetes and chronic kidney disease (FLOW). Available at: https://clinicaltrials.gov/ct2/show/ NCT03819153. Accessed November 29, 2021. 44. EMPA-Kidney Collaborative Group. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrol Dial Transplant 2022;37:1317-29. 45. Shaman AM, Bain SC, Bakris GL, et al. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kid","tf":{"13":1,"15":1,"28":2,"29":2,"37":1,"39":1,"40":1,"41":1,"42":1,"43":1,"44":1,"45":1,"68":2,"74":1,"568":1,"809":1,"1317":1,"2021":3,"2022":3,"clinicaltrials":6,"gov":6,"research":2,"study":2,"to":3,"investigate":1,"how":2,"well":1,"semaglutide":3,"works":2,"in":6,"people":2,"living":1,"with":2,"heart":4,"failure":4,"and":5,"obesity":1,"step":1,"hfpef":1,"available":3,"at":3,"https":3,"ct2":3,"show":3,"nct04788511":1,"accessed":3,"november":3,"dapagli":1,"fl":3,"ozin":3,"effect":2,"on":2,"cardiovascular":1,"events":1,"acute":2,"thrombolysis":1,"myocardial":1,"infarction":1,"dapa":1,"act":1,"hf":2,"timi":1,"nct04363697":1,"voors":1,"aa":1,"angermann":1,"ce":1,"teerlink":1,"jr":1,"et":3,"al":3,"the":5,"sglt2":2,"inhibitor":2,"empagli":1,"patients":1,"hospitalized":1,"for":1,"multina":1,"tional":1,"randomized":2,"trial":3,"nat":2,"med":2,"spertus":1,"ja":1,"birmingham":1,"mc":1,"nassif":1,"canagli":1,"chief":1,"remote":1,"patient":1,"centered":1,"see":1,"compared":1,"placebo":1,"type":1,"diabetes":1,"chronic":1,"kidney":3,"disease":1,"flow":1,"nct03819153":1,"empa":2,"collaborative":1,"group":1,"design":1,"recruitment":1,"baseline":1,"characteristics":1,"of":2,"nephrol":1,"dial":1,"transplant":1,"shaman":1,"am":1,"bain":1,"sc":1,"bakris":1,"gl":1,"glucagon":1,"like":1,"peptide":1,"receptor":1,"agonists":1,"liraglutide":1,"kid":1},"len":211},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":14,"chunkId":"ccs-2022-p14-c5","text":" Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrol Dial Transplant 2022;37:1317-29. 45. Shaman AM, Bain SC, Bakris GL, et al. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney out- comes in patients with type 2 diabetes: a pooled analysis of SUSTAIN 6 and LEADER trials. Circulation 2022;145:575-85. 46. Leiter LA, Bain SC, Hramiak I, et al. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk pro fi le in the SUSTAIN 6 trial. Cardiovasc Diabetol 2019;18:73. 47. Goldenberg RM, Cheng AYY, Fitzpatrick T, Gilbert JD, Verma S, Hopyan JJ. Bene fi ts of GLP-1 (glucagon-like peptide 1) receptor agonists for stroke reduction in type 2 diabetes: a call to action for neurologists. Stroke 2022;53:1813-22. 48. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood- glucose control with sulphonylureas or insulin compared with 1166 Canadian Journal of Cardiology Volume 38 2022","tf":{"18":1,"22":1,"29":1,"37":1,"38":1,"45":1,"46":1,"47":1,"48":1,"53":1,"73":1,"85":1,"145":1,"575":1,"1166":1,"1317":1,"1813":1,"2019":1,"2022":4,"design":1,"recruitment":1,"and":4,"baseline":2,"characteristics":1,"of":6,"the":3,"empa":1,"kidney":2,"trial":2,"nephrol":1,"dial":1,"transplant":1,"shaman":1,"am":1,"bain":2,"sc":2,"bakris":1,"gl":1,"et":2,"al":2,"effect":1,"glucagon":2,"like":2,"peptide":2,"receptor":2,"agonists":2,"semaglutide":2,"liraglutide":1,"on":1,"out":1,"comes":1,"in":4,"patients":1,"with":5,"type":3,"diabetes":4,"pooled":1,"analysis":2,"sustain":2,"leader":1,"trials":1,"circulation":1,"leiter":1,"la":1,"hramiak":1,"cardiovascular":1,"risk":2,"reduction":2,"once":1,"weekly":1,"subjects":1,"post":1,"hoc":1,"gender":1,"age":1,"cv":1,"pro":1,"fi":2,"le":1,"cardiovasc":1,"diabetol":1,"goldenberg":1,"rm":1,"cheng":1,"ayy":1,"fitzpatrick":1,"gilbert":1,"jd":1,"verma":1,"hopyan":1,"jj":1,"bene":1,"ts":1,"glp":1,"for":2,"stroke":2,"call":1,"to":1,"action":1,"neurologists":1,"uk":1,"prospective":1,"study":1,"ukpds":1,"group":1,"intensive":1,"blood":1,"glucose":1,"control":1,"sulphonylureas":1,"or":1,"insulin":1,"compared":1,"canadian":1,"journal":1,"cardiology":1,"volume":1},"len":162},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":15,"chunkId":"ccs-2022-p15-c0","text":"conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53. 49. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89. 50. ACCORD Study Group. Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes. Diabetes Care 2016;39: 701-8. 51. Mancini GBJ, Maron DJ, Hartigan PM, et al. Lifestyle, glycosylated hemoglobin A1c, and survival among patients with stable ischemic heart disease and diabetes. J Am Coll Cardiol 2019;73:2049-58. 52. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on dia- betes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020;41:255-323. 53. Inzucchi SE, Fitchett D, Juri \u0014 si \u0013 c-Er \u0014 zen D, et al. Are the cardiovascular and kidney bene fi ts of empagli fl ozin in fl uenced by baseline glucose-lowering therapy? Diabetes Obes Metab 2020;22:631-9. 54. Ferrannini G, Gerstein H, Colhoun HM, et al. Similar cardiovascular outcomes in patients with diabetes and established or high risk for cor- onary vascular disease treated with dulaglutide with and without baseline metformin. Eur Heart J 2021;42:2565-73. 55. Crowley MJ, McGuire DK, Alexopoulos AS, et al. Effects of liraglutide on cardiovascular outcomes in type 2 diabetes ","tf":{"10":1,"22":1,"33":1,"39":1,"41":1,"42":1,"49":1,"50":1,"51":1,"52":1,"53":2,"54":1,"55":1,"58":1,"73":2,"89":1,"255":1,"323":1,"352":1,"359":1,"631":1,"701":1,"837":1,"1577":1,"1998":1,"2008":1,"2016":1,"2019":2,"2020":2,"2021":1,"2049":1,"2565":1,"conventional":1,"treatment":1,"and":7,"risk":2,"of":6,"complications":1,"in":6,"patients":3,"with":6,"type":3,"diabetes":8,"ukpds":1,"lancet":1,"holman":1,"rr":1,"paul":1,"sk":1,"bethel":1,"ma":1,"matthews":1,"dr":1,"neil":1,"haw":1,"year":2,"follow":1,"up":1,"intensive":2,"glucose":2,"control":2,"engl":1,"med":1,"accord":1,"study":1,"group":1,"nine":1,"effects":2,"years":1,"glycemic":1,"on":3,"cardiovascular":5,"outcomes":3,"care":1,"mancini":1,"gbj":1,"maron":1,"dj":1,"hartigan":1,"pm":1,"et":5,"al":5,"lifestyle":1,"glycosylated":1,"hemoglobin":1,"a1c":1,"survival":1,"among":1,"stable":1,"ischemic":1,"heart":3,"disease":2,"am":1,"coll":1,"cardiol":1,"cosentino":1,"grant":1,"pj":1,"aboyans":1,"esc":1,"guidelines":1,"dia":1,"betes":1,"pre":1,"diseases":1,"developed":1,"collaboration":1,"the":2,"easd":1,"eur":2,"inzucchi":1,"se":1,"fitchett":1,"juri":1,"si":1,"er":1,"zen":1,"are":1,"kidney":1,"bene":1,"fi":1,"ts":1,"empagli":1,"fl":2,"ozin":1,"uenced":1,"by":1,"baseline":2,"lowering":1,"therapy":1,"obes":1,"metab":1,"ferrannini":1,"gerstein":1,"colhoun":1,"hm":1,"similar":1,"established":1,"or":1,"high":1,"for":1,"cor":1,"onary":1,"vascular":1,"treated":1,"dulaglutide":1,"without":1,"metformin":1,"crowley":1,"mj":1,"mcguire":1,"dk":1,"alexopoulos":1,"as":1,"liraglutide":1},"len":220},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":15,"chunkId":"ccs-2022-p15-c1","text":"h risk for cor- onary vascular disease treated with dulaglutide with and without baseline metformin. Eur Heart J 2021;42:2565-73. 55. Crowley MJ, McGuire DK, Alexopoulos AS, et al. Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use: post hoc analyses of the LEADER trial. Diabetes Care 2020;43:e108-10. 56. Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) re- ceptor agonists for type 2 diabetes: systematic review and network meta- analysis of randomised controlled trials. BMJ 2021;372:m4573. 57. Wright AK, Carr MJ, Kontopantelis E, et al. Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes. Diabetes Care 2022;45:909-18. 58. Duan XY, Liu SY, Yin DG. Comparative ef fi cacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: a network meta-analysis based on cardiovascular or renal outcome trials. Medicine (Baltimore) 2021;100:e26431. 59. Lam CSP, Ramasundarahettige C, Branch KRH, et al. Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose co- transporter-2 inhibition use in type 2 diabetes: exploratory","tf":{"10":1,"18":1,"42":1,"43":1,"45":1,"55":1,"56":1,"57":1,"58":1,"59":1,"73":1,"100":1,"372":1,"909":1,"2020":1,"2021":3,"2022":1,"2565":1,"risk":1,"for":2,"cor":1,"onary":1,"vascular":1,"disease":1,"treated":1,"with":5,"dulaglutide":1,"and":9,"without":3,"baseline":2,"metformin":2,"eur":1,"heart":2,"crowley":1,"mj":2,"mcguire":1,"dk":1,"alexopoulos":1,"as":1,"et":4,"al":4,"effects":1,"of":5,"liraglutide":1,"on":3,"cardiovascular":3,"outcomes":3,"in":4,"type":5,"diabetes":7,"patients":2,"use":2,"post":1,"hoc":1,"analyses":1,"the":1,"leader":1,"trial":1,"care":2,"e108":1,"palmer":1,"sc":1,"tendal":1,"mustafa":1,"ra":1,"sodium":3,"glucose":3,"cotransporter":2,"protein":1,"sglt":1,"inhibitors":2,"glucagon":2,"like":2,"peptide":2,"glp":2,"re":1,"ceptor":1,"agonists":3,"systematic":1,"review":1,"network":2,"meta":2,"analysis":2,"randomised":1,"controlled":1,"trials":2,"bmj":1,"m4573":1,"wright":1,"ak":1,"carr":1,"kontopantelis":1,"primary":1,"prevention":1,"failure":1,"events":1,"sglt2":1,"receptor":2,"their":1,"combination":1,"duan":1,"xy":1,"liu":1,"sy":1,"yin":1,"dg":1,"comparative":1,"ef":1,"fi":1,"cacy":1,"inhibitor":1,"interventions":1,"cardiorenal":1,"based":1,"or":1,"renal":1,"outcome":1,"medicine":1,"baltimore":1,"e26431":1,"lam":1,"csp":1,"ramasundarahettige":1,"branch":1,"krh":1,"efpeglenatide":1,"clinical":1,"concomitant":1,"co":1,"transporter":1,"inhibition":1,"exploratory":1},"len":202},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":15,"chunkId":"ccs-2022-p15-c2","text":"tcome trials. Medicine (Baltimore) 2021;100:e26431. 59. Lam CSP, Ramasundarahettige C, Branch KRH, et al. Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose co- transporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial. Circulation 2022;145:565-74. 60. Lingvay I, Leiter LA. Use of GLP-1 RAs in cardiovascular disease pre- vention: a practical guide. Circulation 2018;137:2200-2. 61. Lin DS, Lee JK, Chen WJ. Clinical adverse events associated with sodium-glucose cotransporter 2 inhibitors: a meta-analysis involving 10 randomized clinical trials and 71 553 individuals. J Clin Endocrinol Metab 2021;106:2133-45. 62. Diabetes Canada Clinical Practice Guidelines Expert Committee. Dia- betes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in canada: sick-day medication list. Can J Diabetes 2018;42:S316. 63. Canadian Heart Failure Society. Practical approach to SGLT2 inhibitors for treatment of cardiovascular disease. Available at: https://heartfailure.ca/ sites/default/ fi les/chfs_practical_approach_algorithm_sglt2i.pdf. Accessed November 8, 2021. 64. Goldenberg RM. Sodium-glucose cotransporter-2 inhibitors increase the risk of diabetic ketoacidosis in adults with type 2 diabetes: should we be concerned in people without diabetes? Can J Diabetes 2022;46:109. 65. Fralick M, Kim SC, S","tf":{"10":1,"42":1,"45":1,"46":1,"59":1,"60":1,"61":1,"62":1,"63":1,"64":1,"65":1,"71":1,"74":1,"100":1,"106":1,"109":1,"137":1,"145":1,"553":1,"565":1,"2018":3,"2021":3,"2022":2,"2133":1,"2200":1,"tcome":1,"trials":2,"medicine":1,"baltimore":1,"e26431":1,"lam":1,"csp":1,"ramasundarahettige":1,"branch":1,"krh":1,"et":1,"al":1,"efpeglenatide":1,"and":4,"clinical":5,"outcomes":1,"with":3,"without":2,"concomitant":1,"sodium":3,"glucose":3,"co":1,"transporter":1,"inhibition":1,"use":2,"in":5,"type":2,"diabetes":7,"exploratory":1,"analysis":2,"of":5,"the":3,"amplitude":1,"trial":1,"circulation":2,"lingvay":1,"leiter":1,"la":1,"glp":1,"ras":1,"cardiovascular":2,"disease":2,"pre":1,"vention":1,"practical":3,"guide":1,"lin":1,"ds":1,"lee":1,"jk":1,"chen":1,"wj":1,"adverse":1,"events":1,"associated":1,"cotransporter":2,"inhibitors":3,"meta":1,"involving":1,"randomized":1,"individuals":1,"clin":1,"endocrinol":1,"metab":1,"canada":3,"practice":2,"guidelines":2,"expert":1,"committee":1,"dia":1,"betes":1,"for":2,"prevention":1,"management":1,"sick":1,"day":1,"medication":1,"list":1,"can":2,"s316":1,"canadian":1,"heart":1,"failure":1,"society":1,"approach":2,"to":1,"sglt2":1,"treatment":1,"available":1,"at":1,"https":1,"heartfailure":1,"ca":1,"sites":1,"default":1,"fi":1,"les":1,"chfs":1,"algorithm":1,"sglt2i":1,"pdf":1,"accessed":1,"november":1,"goldenberg":1,"rm":1,"increase":1,"risk":1,"diabetic":1,"ketoacidosis":1,"adults":1,"should":1,"we":1,"be":1,"concerned":1,"people":1,"fralick":1,"kim":1,"sc":1},"len":197},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":15,"chunkId":"ccs-2022-p15-c3","text":"r 8, 2021. 64. Goldenberg RM. Sodium-glucose cotransporter-2 inhibitors increase the risk of diabetic ketoacidosis in adults with type 2 diabetes: should we be concerned in people without diabetes? Can J Diabetes 2022;46:109. 65. Fralick M, Kim SC, Schneeweiss S, Everett BM, Glynn RJ, Patorno E. Risk of amputation with canagli fl ozin across categories of age and car- diovascular risk in three US nationwide databases: cohort study. BMJ 2020;370:m2812. Supplementary Material To access the supplementary material accompanying this article, visit the online version of the Canadian Journal of Cardiology at www.onlinecjc.ca and at https://doi.org/10. 1016/j.cjca.2022.04.029. Mancini et al. 1167 CCS Guideline for Cardiorenal Risk Reduction","tf":{"10":1,"46":1,"64":1,"65":1,"109":1,"370":1,"1016":1,"1167":1,"2020":1,"2021":1,"2022":2,"goldenberg":1,"rm":1,"sodium":1,"glucose":1,"cotransporter":1,"inhibitors":1,"increase":1,"the":4,"risk":4,"of":5,"diabetic":1,"ketoacidosis":1,"in":3,"adults":1,"with":2,"type":1,"diabetes":3,"should":1,"we":1,"be":1,"concerned":1,"people":1,"without":1,"can":1,"fralick":1,"kim":1,"sc":1,"schneeweiss":1,"everett":1,"bm":1,"glynn":1,"rj":1,"patorno":1,"amputation":1,"canagli":1,"fl":1,"ozin":1,"across":1,"categories":1,"age":1,"and":2,"car":1,"diovascular":1,"three":1,"us":1,"nationwide":1,"databases":1,"cohort":1,"study":1,"bmj":1,"m2812":1,"supplementary":2,"material":2,"to":1,"access":1,"accompanying":1,"this":1,"article":1,"visit":1,"online":1,"version":1,"canadian":1,"journal":1,"cardiology":1,"at":2,"www":1,"onlinecjc":1,"ca":1,"https":1,"doi":1,"org":1,"cjca":1,"04":1,"029":1,"mancini":1,"et":1,"al":1,"ccs":1,"guideline":1,"for":1,"cardiorenal":1,"reduction":1},"len":113},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":16,"chunkId":"ccs-2022-p16-c0","text":"Update Canadian Journal of Cardiology Volume 38, Issue 12, December 2022, Page 1979 https://doi.org/10.1016/j.cjca.2022.10.008 DOI:","tf":{"10":2,"12":1,"38":1,"1016":1,"1979":1,"2022":2,"update":1,"canadian":1,"journal":1,"of":1,"cardiology":1,"volume":1,"issue":1,"december":1,"page":1,"https":1,"doi":2,"org":1,"cjca":1,"008":1},"len":23},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":17,"chunkId":"ccs-2022-p17-c0","text":"Errata Erratum to  Syncope in Patients With Severe Aortic Stenosis: More Than Just an Obstruction Issue  [Can J Cardiol (2021):284-291]. In the article,  Syncope in Patients With Severe Aortic Ste- nosis: More Than Just an Obstruction Issue  by Francisco- Pascual et al., published in the February 2021 issue (Can J Cardiol 202;37:284-291), an incomplete af fi liation was assigned to 2 of the authors, Jaume Francisco-Pascual and Ignacio Ferreira Gonzlez. These authors were incorrectly assigned the af fi liation  Universitat Autnoma de Barcelona, Bellaterra, Spain,  but the correct af fi liation for these authors should have been listed as  Department of Medicine, Uni- versitat Autnoma de Barcelona, Bellaterra, Spain.  Canadian Journal of Cardiology 38 (2022) 1979 e 1980 Erratum to  2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults  [Can J Cardiol (2022):1153-1167]. In the article,  2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults  by Mancini et al., pub- lished in the August 2022 issue (Can J Cardiol 2022;38:1153-67), an author was accidentally omitted from the author list. Jonathan Y. Gabor, MD, should have been listed as the second author in the Secondary Panel section. Dr Gabo","tf":{"37":1,"38":2,"67":1,"202":1,"284":2,"291":2,"1153":2,"1167":1,"1979":1,"1980":1,"2021":2,"2022":6,"errata":1,"erratum":2,"to":3,"syncope":2,"in":9,"patients":2,"with":2,"severe":2,"aortic":2,"stenosis":1,"more":2,"than":2,"just":2,"an":4,"obstruction":2,"issue":4,"can":4,"cardiol":4,"the":10,"article":2,"ste":1,"nosis":1,"by":2,"francisco":2,"pascual":2,"et":2,"al":2,"published":1,"february":1,"incomplete":1,"af":3,"fi":3,"liation":3,"was":2,"assigned":2,"of":5,"authors":3,"jaume":1,"and":3,"ignacio":1,"ferreira":1,"gonz":1,"lez":1,"these":2,"were":1,"incorrectly":1,"universitat":1,"aut":2,"noma":2,"de":2,"barcelona":2,"bellaterra":2,"spain":2,"but":1,"correct":1,"for":5,"should":2,"have":2,"been":2,"listed":2,"as":2,"department":1,"medicine":1,"uni":1,"versitat":1,"canadian":3,"journal":1,"cardiology":1,"cardiovascular":2,"society":2,"guideline":2,"use":2,"glp":2,"receptor":2,"agonists":2,"sglt2":2,"inhibitors":2,"cardiorenal":2,"risk":2,"reduction":2,"adults":2,"mancini":1,"pub":1,"lished":1,"august":1,"author":3,"accidentally":1,"omitted":1,"from":1,"list":1,"jonathan":1,"gabor":1,"md":1,"second":1,"secondary":1,"panel":1,"section":1,"dr":1,"gabo":1},"len":217},{"docId":"ccs-2022","docTitle":"CCS 2022 GLP-1RA/SGLT2i","file":"ccs-2022-glp1-sglt2.pdf","page":17,"chunkId":"ccs-2022-p17-c1","text":"Mancini et al., pub- lished in the August 2022 issue (Can J Cardiol 2022;38:1153-67), an author was accidentally omitted from the author list. Jonathan Y. Gabor, MD, should have been listed as the second author in the Secondary Panel section. Dr Gabor is af fi liated with the Department of Cardiology, Selkirk Regional Health Centre, Selkirk, Manitoba, Canada. This information has been corrected in the online version of the article. Erratum to  Evaluation of Saline-Enhanced Radiofrequency Needle-Tip Ablation for Ventricular Tachycardia (SERF VT CANADA Trial)  [Can J Cardiol (2022):1277-1285]. In the article,  Evaluation of Saline-Enhanced Radio- frequency Needle-Tip Ablation for Ventricular Tachycardia (SERF VT CANADA Trial)  by Sanchez-Somonte et al., published in the August 2022 issue (Can J Cardiol 2022;38:1277-1285), the second author  s surname was misspelled as Dryda. The correct spelling is Dyrda . This information has been corrected in the online version of the article. https://doi.org/10.1016/j.cjca.2022.10.007 0828-282X/  2022 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","tf":{"10":2,"38":2,"67":1,"1016":1,"1153":1,"1277":2,"1285":2,"2022":7,"mancini":1,"et":2,"al":2,"pub":1,"lished":1,"in":6,"the":13,"august":2,"issue":2,"can":3,"cardiol":3,"an":1,"author":4,"was":2,"accidentally":1,"omitted":1,"from":1,"list":1,"jonathan":1,"gabor":2,"md":1,"should":1,"have":1,"been":3,"listed":1,"as":2,"second":2,"secondary":1,"panel":1,"section":1,"dr":1,"is":2,"af":1,"fi":1,"liated":1,"with":1,"department":1,"of":5,"cardiology":1,"selkirk":2,"regional":1,"health":1,"centre":1,"manitoba":1,"canada":3,"this":2,"information":2,"has":2,"corrected":2,"online":2,"version":2,"article":3,"erratum":1,"to":1,"evaluation":2,"saline":2,"enhanced":2,"radiofrequency":1,"needle":2,"tip":2,"ablation":2,"for":2,"ventricular":2,"tachycardia":2,"serf":2,"vt":2,"trial":2,"radio":1,"frequency":1,"by":2,"sanchez":1,"somonte":1,"published":2,"surname":1,"misspelled":1,"dryda":1,"correct":1,"spelling":1,"dyrda":1,"https":1,"doi":1,"org":1,"cjca":1,"007":1,"0828":1,"282x":1,"canadian":1,"cardiovascular":1,"society":1,"elsevier":1,"inc":1,"all":1,"rights":1,"reserved":1},"len":176},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":1,"chunkId":"aace-2023-p1-c0","text":"AACE Consensus Statement American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm e 2023 Update Susan L. Samson, MD, PhD, FRCPC, FACE a , Priyathama Vellanki, MD b , Lawrence Blonde, MD, FACP, MACE c , Elena A. Christo fi des, MD, FACE d , Rodolfo J. Galindo, MD, FACE e , Irl B. Hirsch, MD f , Scott D. Isaacs, MD, FACP, FACE g , Kenneth E. Izuora, MD, MBA, FACE h , Cecilia C. Low Wang, MD, FACP i , Christine L. Twining, MD, FACE j , Guillermo E. Umpierrez, MD, CDCES, MACP, FACE k , Willy Marcos Valencia, MD, MSc l a Chair of Task Force; Chair of the Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Mayo Clinic, Jacksonville, Florida b Vice Chair of Task Force; Associate Professor of Medicine, Department of Medicine, Division of Endocrinology, Metabolism and Lipids, Emory University School of Medicine, Emory University; Section Chief, Endocrinology, Grady Memorial Hospital, Atlanta, Georgia c Director, Ochsner Diabetes Clinical Research Unit, Frank Riddick Diabetes Institute, Department of Endocrinology, Ochsner Health, New Orleans, Louisiana d Endocrinology Associates, Inc., Columbus, Ohio e Associate Professor of Medicine, University of Miami Miller School of Medicine; Director, Comprehensive Diabetes Center, Lennar Medical Center, UMiami Health System; Director, Diabetes Management, Jackso","tf":{"2023":1,"aace":1,"consensus":2,"statement":2,"american":1,"association":1,"of":14,"clinical":2,"endocrinology":6,"comprehensive":2,"type":1,"diabetes":6,"management":2,"algorithm":1,"update":1,"susan":1,"samson":1,"md":12,"phd":1,"frcpc":1,"face":7,"priyathama":1,"vellanki":1,"lawrence":1,"blonde":1,"facp":3,"mace":1,"elena":1,"christo":1,"fi":1,"des":1,"rodolfo":1,"galindo":1,"irl":1,"hirsch":1,"scott":1,"isaacs":1,"kenneth":1,"izuora":1,"mba":1,"cecilia":1,"low":1,"wang":1,"christine":1,"twining":1,"guillermo":1,"umpierrez":1,"cdces":1,"macp":1,"willy":1,"marcos":1,"valencia":1,"msc":1,"chair":3,"task":2,"force":2,"the":1,"division":2,"and":2,"metabolism":2,"department":3,"medicine":6,"mayo":1,"clinic":1,"jacksonville":1,"florida":1,"vice":1,"associate":2,"professor":2,"lipids":1,"emory":2,"university":3,"school":2,"section":1,"chief":1,"grady":1,"memorial":1,"hospital":1,"atlanta":1,"georgia":1,"director":3,"ochsner":2,"research":1,"unit":1,"frank":1,"riddick":1,"institute":1,"health":2,"new":1,"orleans":1,"louisiana":1,"associates":1,"inc":1,"columbus":1,"ohio":1,"miami":1,"miller":1,"center":2,"lennar":1,"medical":1,"umiami":1,"system":1,"jackso":1},"len":175},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":1,"chunkId":"aace-2023-p1-c1","text":"docrinology Associates, Inc., Columbus, Ohio e Associate Professor of Medicine, University of Miami Miller School of Medicine; Director, Comprehensive Diabetes Center, Lennar Medical Center, UMiami Health System; Director, Diabetes Management, Jackson Memorial Health System, Miami, Florida f Professor of Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, Washington g Department of Medicine, Emory University School of Medicine, Atlanta, Georgia h Professor, Department of Internal Medicine, Endocrinology, Kirk Kerkorian School of Medicine, University of Nevada Las Vegas, Las Vegas, Nevada i Professor of Medicine, Department of Medicine, Division of Endocrinology, Metabolism, and Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado j Endocrinology, Diabetes and Metabolism, Maine Medical Center, Maine Health, Scarborough, Maine k Professor of Medicine, Emory University School of Medicine, Division of Endocrinology, Metabolism; Chief of Diabetes and Endocrinology, Grady Health Systems, Atlanta, Georgia l Endocrinology and Metabolism Institute, Center for Geriatric Medicine, Cleveland Clinic, Cleveland, Ohio a r t i c l e i n f o Article history: Received 19 December 2022 Received in revised form 31 January 2023 Accepted 6 February 2023 Available online 5 May 2023 Key words: diabetes algorithm diabetes management diabetes mel","tf":{"19":1,"31":1,"2022":1,"2023":3,"docrinology":1,"associates":1,"inc":1,"columbus":1,"ohio":2,"associate":1,"professor":5,"of":20,"medicine":14,"university":6,"miami":2,"miller":1,"school":5,"director":2,"comprehensive":1,"diabetes":8,"center":4,"lennar":1,"medical":3,"umiami":1,"health":4,"system":2,"management":2,"jackson":1,"memorial":1,"florida":1,"department":4,"washington":2,"seattle":1,"emory":2,"atlanta":2,"georgia":2,"internal":1,"endocrinology":6,"kirk":1,"kerkorian":1,"nevada":2,"las":2,"vegas":2,"division":2,"metabolism":4,"and":4,"colorado":2,"anschutz":1,"campus":1,"aurora":1,"maine":3,"scarborough":1,"chief":1,"grady":1,"systems":1,"institute":1,"for":1,"geriatric":1,"cleveland":2,"clinic":1,"article":1,"history":1,"received":2,"december":1,"in":1,"revised":1,"form":1,"january":1,"accepted":1,"february":1,"available":1,"online":1,"may":1,"key":1,"words":1,"algorithm":1,"mel":1},"len":171},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":1,"chunkId":"aace-2023-p1-c2","text":"land Clinic, Cleveland, Ohio a r t i c l e i n f o Article history: Received 19 December 2022 Received in revised form 31 January 2023 Accepted 6 February 2023 Available online 5 May 2023 Key words: diabetes algorithm diabetes management diabetes mellitus a b s t r a c t Objective: This consensus statement provides (1) visual guidance in concise graphic algorithms to assist with clinical decision-making of health care professionals in the management of persons with type 2 diabetes mellitus to improve patient care and (2) a summary of details to support the visual guidance found in each algorithm. Methods: The American Association of Clinical Endocrinology (AACE) selected a task force of medical experts who updated the 2020 AACE Comprehensive Type 2 Diabetes Management Algorithm based on the 2022 AACE Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan and consensus of task force authors. Results: This algorithm for management of persons with type 2 diabetes includes 11 distinct sections: (1) Principles for the Management of Type 2 Diabetes; (2) Complications-Centric Model for the Care of Persons with Overweight/Obesity; (3) Prediabetes Algorithm; (4) Atherosclerotic Cardiovascular Disease Risk Reduction Algorithm: Dyslipidemia; (5) Atherosclerotic Cardiovascular Disease Risk * Address correspondence to the American Association of Clinical Endocri","tf":{"11":1,"19":1,"31":1,"2020":1,"2022":2,"2023":3,"land":1,"clinic":1,"cleveland":1,"ohio":1,"article":1,"history":1,"received":2,"december":1,"in":4,"revised":1,"form":1,"january":1,"accepted":1,"february":1,"available":1,"online":1,"may":1,"key":1,"words":1,"diabetes":8,"algorithm":6,"management":5,"mellitus":3,"objective":1,"this":2,"consensus":2,"statement":1,"provides":1,"visual":2,"guidance":2,"concise":1,"graphic":1,"algorithms":1,"to":4,"assist":1,"with":4,"clinical":4,"decision":1,"making":1,"of":10,"health":1,"care":4,"professionals":1,"the":8,"persons":3,"type":4,"improve":1,"patient":1,"and":2,"summary":1,"details":1,"support":1,"found":1,"each":1,"methods":1,"american":2,"association":2,"endocrinology":1,"aace":3,"selected":1,"task":2,"force":2,"medical":1,"experts":1,"who":1,"updated":1,"comprehensive":2,"based":1,"on":1,"practice":1,"guideline":1,"developing":1,"plan":1,"authors":1,"results":1,"for":3,"includes":1,"distinct":1,"sections":1,"principles":1,"complications":1,"centric":1,"model":1,"overweight":1,"obesity":1,"prediabetes":1,"atherosclerotic":2,"cardiovascular":2,"disease":2,"risk":2,"reduction":1,"dyslipidemia":1,"address":1,"correspondence":1,"endocri":1},"len":177},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":1,"chunkId":"aace-2023-p1-c3","text":"Overweight/Obesity; (3) Prediabetes Algorithm; (4) Atherosclerotic Cardiovascular Disease Risk Reduction Algorithm: Dyslipidemia; (5) Atherosclerotic Cardiovascular Disease Risk * Address correspondence to the American Association of Clinical Endocrinology, 7643 Gate Parkwy, Suite 104-328, Jacksonville, FL 32256. Email address : publications@aace.com. Disclaimer: This document represents the of fi cial position of the American Association of Clinical Endocrinology on the subject matter at the time of publication. Subject matter experts who participated on the task force used their judgment and experience supported by relevant scienti fi c evidence as available. Every effort was made to achieve consensus among the task force members. Consensus statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician. We encourage health care professionals to use this information in conjunction with their best clinical judgement. The presented guidance may not be appropriate in all situations. Any decision(s) by health care professionals to apply this guidance provided in this consensus statement must be made in consideration of local resources and individual patient circumstances. Endocrine Practice TM www.endocrinepractice.org https://doi.org/10.1016/j.eprac.2023.02.001 1530-891X/  2023 AA","tf":{"10":1,"104":1,"328":1,"1016":1,"1530":1,"2023":2,"7643":1,"32256":1,"overweight":1,"obesity":1,"prediabetes":1,"algorithm":2,"atherosclerotic":2,"cardiovascular":2,"disease":2,"risk":2,"reduction":1,"dyslipidemia":1,"address":2,"correspondence":1,"to":6,"the":9,"american":2,"association":2,"of":7,"clinical":3,"endocrinology":2,"gate":1,"parkwy":1,"suite":1,"jacksonville":1,"fl":1,"email":1,"publications":1,"aace":1,"com":1,"disclaimer":1,"this":4,"document":1,"represents":1,"fi":2,"cial":1,"position":1,"on":2,"subject":2,"matter":2,"at":1,"time":1,"publication":1,"experts":1,"who":1,"participated":1,"task":2,"force":2,"used":1,"their":2,"judgment":2,"and":3,"experience":1,"supported":1,"by":2,"relevant":1,"scienti":1,"evidence":1,"as":1,"available":1,"every":1,"effort":1,"was":1,"made":2,"achieve":1,"consensus":3,"among":1,"members":1,"statements":1,"are":2,"meant":1,"provide":1,"guidance":3,"but":1,"they":1,"not":2,"be":3,"considered":1,"prescriptive":1,"for":1,"any":2,"individual":2,"patient":2,"cannot":1,"replace":1,"clinician":1,"we":1,"encourage":1,"health":2,"care":2,"professionals":2,"use":1,"information":1,"in":4,"conjunction":1,"with":1,"best":1,"judgement":1,"presented":1,"may":1,"appropriate":1,"all":1,"situations":1,"decision":1,"apply":1,"provided":1,"statement":1,"must":1,"consideration":1,"local":1,"resources":1,"circumstances":1,"endocrine":1,"practice":1,"tm":1,"www":1,"endocrinepractice":1,"org":2,"https":1,"doi":1,"eprac":1,"02":1,"001":1,"891x":1,"aa":1},"len":195},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":1,"chunkId":"aace-2023-p1-c4","text":"this guidance provided in this consensus statement must be made in consideration of local resources and individual patient circumstances. Endocrine Practice TM www.endocrinepractice.org https://doi.org/10.1016/j.eprac.2023.02.001 1530-891X/  2023 AACE. Published by Elsevier Inc. All rights reserved. Endocrine Practice 29 (2023) 305 e 340 i An update to this article is included at the end","tf":{"10":1,"29":1,"305":1,"340":1,"1016":1,"1530":1,"2023":3,"this":3,"guidance":1,"provided":1,"in":2,"consensus":1,"statement":1,"must":1,"be":1,"made":1,"consideration":1,"of":1,"local":1,"resources":1,"and":1,"individual":1,"patient":1,"circumstances":1,"endocrine":2,"practice":2,"tm":1,"www":1,"endocrinepractice":1,"org":2,"https":1,"doi":1,"eprac":1,"02":1,"001":1,"891x":1,"aace":1,"published":1,"by":1,"elsevier":1,"inc":1,"all":1,"rights":1,"reserved":1,"an":1,"update":1,"to":1,"article":1,"is":1,"included":1,"at":1,"the":1,"end":1},"len":61},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":2,"chunkId":"aace-2023-p2-c0","text":"diabetes treatment type 2 diabetes Reduction Algorithm: Hypertension; (6) Complications-Centric Algorithm for Glycemic Control; (7) Glucose-Centric Algorithm for Glycemic Control; (8) Algorithm for Adding/Intensifying Insulin; (9) Pro fi les of Antihyperglycemic Medications; (10) Pro fi les of Weight-Loss Medications (new); and (11) Vaccine Recommendations for Persons with Diabetes Mellitus (new), which summarizes recom- mendations from the Advisory Committee on Immunization Practices of the U.S. Centers for Disease Control and Prevention. Conclusions: Aligning with the 2022 AACE diabetes guideline update, this 2023 diabetes algorithm update emphasizes lifestyle modi fi cation and treatment of overweight/obesity as key pillars in the management of prediabetes and diabetes mellitus and highlights the importance of appropriate management of atherosclerotic risk factors of dyslipidemia and hypertension. One notable new theme is an emphasis on a complication-centric approach, beyond glucose levels, to frame decisions regarding fi rst-line pharmacologic choices for the treatment of persons with diabetes. The algorithm also includes access/cost of medications as factors related to health equity to consider in clinical decision-making.  2023 AACE. Published by Elsevier Inc. All rights reserved. Introduction The fi rst iteration of the American Association of Clinical Endocrinology (A","tf":{"10":1,"11":1,"2022":1,"2023":2,"diabetes":7,"treatment":3,"type":1,"reduction":1,"algorithm":6,"hypertension":2,"complications":1,"centric":3,"for":6,"glycemic":2,"control":3,"glucose":2,"adding":1,"intensifying":1,"insulin":1,"pro":2,"fi":5,"les":2,"of":12,"antihyperglycemic":1,"medications":3,"weight":1,"loss":1,"new":3,"and":6,"vaccine":1,"recommendations":1,"persons":2,"with":3,"mellitus":2,"which":1,"summarizes":1,"recom":1,"mendations":1,"from":1,"the":9,"advisory":1,"committee":1,"on":2,"immunization":1,"practices":1,"centers":1,"disease":1,"prevention":1,"conclusions":1,"aligning":1,"aace":2,"guideline":1,"update":2,"this":1,"emphasizes":1,"lifestyle":1,"modi":1,"cation":1,"overweight":1,"obesity":1,"as":2,"key":1,"pillars":1,"in":2,"management":2,"prediabetes":1,"highlights":1,"importance":1,"appropriate":1,"atherosclerotic":1,"risk":1,"factors":2,"dyslipidemia":1,"one":1,"notable":1,"theme":1,"is":1,"an":1,"emphasis":1,"complication":1,"approach":1,"beyond":1,"levels":1,"to":3,"frame":1,"decisions":1,"regarding":1,"rst":2,"line":1,"pharmacologic":1,"choices":1,"also":1,"includes":1,"access":1,"cost":1,"related":1,"health":1,"equity":1,"consider":1,"clinical":2,"decision":1,"making":1,"published":1,"by":1,"elsevier":1,"inc":1,"all":1,"rights":1,"reserved":1,"introduction":1,"iteration":1,"american":1,"association":1,"endocrinology":1},"len":189},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":2,"chunkId":"aace-2023-p2-c1","text":"s/cost of medications as factors related to health equity to consider in clinical decision-making.  2023 AACE. Published by Elsevier Inc. All rights reserved. Introduction The fi rst iteration of the American Association of Clinical Endocrinology (AACE) algorithm for glycemic control was pub- lished in 2009 and expanded on the visual guidance provided by the American College of Endocrinology (ACE)/AACE Diabetes Road Maps to help clinicians navigate the expanded classes of approved antihyperglycemic agents. 1,2 At that time, thiazolidinediones (TZDs), alpha-glucosidase inhibitors, metformin, and sulfonylureas (SUs)/glinides were in use, with the addition of exenatide as well as dipeptidyl peptidase-4 inhibitors (DPP-4is). The next update was in 2013 with publication of the Comprehensive Type 2 Diabetes (T2D) Management Algorithm, which incorporated new sections on the management of overweight/obesity, dyslipidemia, and hyperten- sion (HTN). 3 Revisions to this fi rst iteration have been incorporated on a yearly basis through 2020, 4-8 and the task force is grateful for the contributions and framework provided by previous authors of the algorithm (see Acknowledgments). In 2022, the AACE published the Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan e 2022 Update, 9 which provided 170 revised or new graded recommendations accompanied by detailed","tf":{"170":1,"2009":1,"2013":1,"2020":1,"2022":2,"2023":1,"cost":1,"of":9,"medications":1,"as":3,"factors":1,"related":1,"to":4,"health":1,"equity":1,"consider":1,"in":5,"clinical":3,"decision":1,"making":1,"aace":4,"published":2,"by":4,"elsevier":1,"inc":1,"all":1,"rights":1,"reserved":1,"introduction":1,"the":14,"fi":2,"rst":2,"iteration":2,"american":2,"association":1,"endocrinology":2,"algorithm":3,"for":2,"glycemic":1,"control":1,"was":2,"pub":1,"lished":1,"and":5,"expanded":2,"on":3,"visual":1,"guidance":1,"provided":3,"college":1,"ace":1,"diabetes":3,"road":1,"maps":1,"help":1,"clinicians":1,"navigate":1,"classes":1,"approved":1,"antihyperglycemic":1,"agents":1,"at":1,"that":1,"time":1,"thiazolidinediones":1,"tzds":1,"alpha":1,"glucosidase":1,"inhibitors":2,"metformin":1,"sulfonylureas":1,"sus":1,"glinides":1,"were":1,"use":1,"with":2,"addition":1,"exenatide":1,"well":1,"dipeptidyl":1,"peptidase":1,"dpp":1,"4is":1,"next":1,"update":2,"publication":1,"comprehensive":2,"type":1,"t2d":1,"management":2,"which":2,"incorporated":2,"new":2,"sections":1,"overweight":1,"obesity":1,"dyslipidemia":1,"hyperten":1,"sion":1,"htn":1,"revisions":1,"this":1,"have":1,"been":1,"yearly":1,"basis":1,"through":1,"task":1,"force":1,"is":1,"grateful":1,"contributions":1,"framework":1,"previous":1,"authors":1,"see":1,"acknowledgments":1,"practice":1,"guideline":1,"developing":1,"mellitus":1,"care":1,"plan":1,"revised":1,"or":1,"graded":1,"recommendations":1,"accompanied":1,"detailed":1},"len":197},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":2,"chunkId":"aace-2023-p2-c2","text":"the algorithm (see Acknowledgments). In 2022, the AACE published the Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan e 2022 Update, 9 which provided 170 revised or new graded recommendations accompanied by detailed, evidence-based rationales. This 2023 algorithm update builds on previous versions of the algorithm but with the incorporation of new management approaches that align with the 2022 AACE clin- ical practice guideline (CPG) on diabetes mellitus (DM). The algo- rithm is intended as a more concise document than the guideline, providing easily accessible, visual guidance for decision-making in the clinic setting. This summary is not intended to iterate all of the evidence base behind the algorithmic pathways, as this is detailed in the 2022 AACE DM CPG update. 9 Instead, the objective of this summary is to provide a written guide or  roadmap  through the graphic depictions of the algorithm contents. The process for updating the algorithm involved multiple meetings of task force members/authors between January 2022 and November 2022. Smaller groups focused on speci fi c algo- rithm subsections, which were then brought to the complete task force for discussion and peer review. It was intentional that a proportion of algorithm task force members overlapped with the diabetes CPG task force to ensure continuity and alignment with the 2022 ","tf":{"170":1,"2022":7,"2023":1,"the":20,"algorithm":6,"see":1,"acknowledgments":1,"in":3,"aace":3,"published":1,"clinical":1,"practice":2,"guideline":3,"developing":1,"diabetes":3,"mellitus":2,"comprehensive":1,"care":1,"plan":1,"update":3,"which":2,"provided":1,"revised":1,"or":2,"new":2,"graded":1,"recommendations":1,"accompanied":1,"by":1,"detailed":2,"evidence":2,"based":1,"rationales":1,"this":4,"builds":1,"on":3,"previous":1,"versions":1,"of":7,"but":1,"with":4,"incorporation":1,"management":1,"approaches":1,"that":2,"align":1,"clin":1,"ical":1,"cpg":3,"dm":2,"algo":2,"rithm":2,"is":4,"intended":2,"as":2,"more":1,"concise":1,"document":1,"than":1,"providing":1,"easily":1,"accessible":1,"visual":1,"guidance":1,"for":3,"decision":1,"making":1,"clinic":1,"setting":1,"summary":2,"not":1,"to":4,"iterate":1,"all":1,"base":1,"behind":1,"algorithmic":1,"pathways":1,"instead":1,"objective":1,"provide":1,"written":1,"guide":1,"roadmap":1,"through":1,"graphic":1,"depictions":1,"contents":1,"process":1,"updating":1,"involved":1,"multiple":1,"meetings":1,"task":4,"force":4,"members":2,"authors":1,"between":1,"january":1,"and":3,"november":1,"smaller":1,"groups":1,"focused":1,"speci":1,"fi":1,"subsections":1,"were":1,"then":1,"brought":1,"complete":1,"discussion":1,"peer":1,"review":1,"it":1,"was":1,"intentional":1,"proportion":1,"overlapped":1,"ensure":1,"continuity":1,"alignment":1},"len":209},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":2,"chunkId":"aace-2023-p2-c3","text":"ons, which were then brought to the complete task force for discussion and peer review. It was intentional that a proportion of algorithm task force members overlapped with the diabetes CPG task force to ensure continuity and alignment with the 2022 published guideline recommendations. In this 2023 algorithm, there continues to be an emphasis on lifestyle modi fi cation and treatment of overweight/obesity as key pillars of the management of prediabetes and DM. In addition, the importance of appropriate management of the atherosclerotic risk factors of dyslipidemia and HTN is highlighted. One notable new theme is an obvious emphasis on a complication-centric approach, beyond glucose levels, to frame decisions regarding fi rst-line pharmacologic choices for the treatment of persons with DM, as recommended in the 2022 AACE DM CPG update 9 and by other organizations. 10,11 However, the task force mem- bers/authors acknowledge that health care disparities and lack of access to newer medications remain a signi fi cant barrier for some persons with DM. The algorithm is divided into discrete graphic sections that outline the principles for management of T2D (Algorithm Fig. 1) and guide management of adiposity-based chronic disease (ABCD) (Algorithm Fig. 2), prediabetes (Algorithm Fig. 3), and Abbreviations AACE, American Association of Endocrinology; ABCD, adiposity-based chronic disea","tf":{"10":1,"11":1,"2022":2,"2023":1,"ons":1,"which":1,"were":1,"then":1,"brought":1,"to":5,"the":11,"complete":1,"task":4,"force":4,"for":4,"discussion":1,"and":9,"peer":1,"review":1,"it":1,"was":1,"intentional":1,"that":3,"proportion":1,"of":12,"algorithm":6,"members":1,"overlapped":1,"with":4,"diabetes":1,"cpg":2,"ensure":1,"continuity":1,"alignment":1,"published":1,"guideline":1,"recommendations":1,"in":3,"this":1,"there":1,"continues":1,"be":1,"an":2,"emphasis":2,"on":2,"lifestyle":1,"modi":1,"fi":3,"cation":1,"treatment":2,"overweight":1,"obesity":1,"as":2,"key":1,"pillars":1,"management":4,"prediabetes":2,"dm":4,"addition":1,"importance":1,"appropriate":1,"atherosclerotic":1,"risk":1,"factors":1,"dyslipidemia":1,"htn":1,"is":3,"highlighted":1,"one":1,"notable":1,"new":1,"theme":1,"obvious":1,"complication":1,"centric":1,"approach":1,"beyond":1,"glucose":1,"levels":1,"frame":1,"decisions":1,"regarding":1,"rst":1,"line":1,"pharmacologic":1,"choices":1,"persons":2,"recommended":1,"aace":2,"update":1,"by":1,"other":1,"organizations":1,"however":1,"mem":1,"bers":1,"authors":1,"acknowledge":1,"health":1,"care":1,"disparities":1,"lack":1,"access":1,"newer":1,"medications":1,"remain":1,"signi":1,"cant":1,"barrier":1,"some":1,"divided":1,"into":1,"discrete":1,"graphic":1,"sections":1,"outline":1,"principles":1,"t2d":1,"fig":3,"guide":1,"adiposity":2,"based":2,"chronic":2,"disease":1,"abcd":2,"abbreviations":1,"american":1,"association":1,"endocrinology":1,"disea":1},"len":210},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":2,"chunkId":"aace-2023-p2-c4","text":"management of T2D (Algorithm Fig. 1) and guide management of adiposity-based chronic disease (ABCD) (Algorithm Fig. 2), prediabetes (Algorithm Fig. 3), and Abbreviations AACE, American Association of Endocrinology; ABCD, adiposity-based chronic disease; ABI, ankle-brachial index; ACE, American College of Endocrinology; ACEi, angiotensin-converting enzyme inhibitor; AGI, alpha-glucosidase inhibitor; AKI, acute kidney injury; apo B, apolipoprotein B; ARB, angiotensin II receptor blocker; ASCVD, atherosclerotic cardiovascular disease; ATP, Adult Treatment Panel; A1C, hemoglobin A1C; BeAM, bedtime minus morning prebreakfast glucose; BG, blood glucose; BMI, body mass index; BP, blood pressure; BRC-QR, bromocriptine quick release; CAD, coronary artery disease; CCB, calcium channel blocker; CDC, U.S. Centers for Disease Control and Prevention; CGM, continuous glucose monitoring; CHF, congestive heart failure; CK, creatine kinase; CKD, chronic kidney disease; COLSVL, colesevelam; CoQ10, coenzyme q10; CPG, clinical practice guideline; CrCl, creatinine clearance; CV, cardiovascular; CVD, cardiovascular disease; CVOT, cardiovascular outcomes trial; DA, dopamine agonist; DASH, Dietary Approaches to Stop Hypertension; DKA, diabetic ketoacidosis; DKD, diabetic kidney disease; DM, diabetes mellitus; DPP-4i, dipeptidyl peptidase-4 inhibitor; eGFR, estimated glomerular fi ltration rate; ER, ext","tf":{"management":2,"of":4,"t2d":1,"algorithm":3,"fig":3,"and":3,"guide":1,"adiposity":2,"based":2,"chronic":3,"disease":8,"abcd":2,"prediabetes":1,"abbreviations":1,"aace":1,"american":2,"association":1,"endocrinology":2,"abi":1,"ankle":1,"brachial":1,"index":2,"ace":1,"college":1,"acei":1,"angiotensin":2,"converting":1,"enzyme":1,"inhibitor":3,"agi":1,"alpha":1,"glucosidase":1,"aki":1,"acute":1,"kidney":3,"injury":1,"apo":1,"apolipoprotein":1,"arb":1,"ii":1,"receptor":1,"blocker":2,"ascvd":1,"atherosclerotic":1,"cardiovascular":4,"atp":1,"adult":1,"treatment":1,"panel":1,"a1c":2,"hemoglobin":1,"beam":1,"bedtime":1,"minus":1,"morning":1,"prebreakfast":1,"glucose":3,"bg":1,"blood":2,"bmi":1,"body":1,"mass":1,"bp":1,"pressure":1,"brc":1,"qr":1,"bromocriptine":1,"quick":1,"release":1,"cad":1,"coronary":1,"artery":1,"ccb":1,"calcium":1,"channel":1,"cdc":1,"centers":1,"for":1,"control":1,"prevention":1,"cgm":1,"continuous":1,"monitoring":1,"chf":1,"congestive":1,"heart":1,"failure":1,"ck":1,"creatine":1,"kinase":1,"ckd":1,"colsvl":1,"colesevelam":1,"coq10":1,"coenzyme":1,"q10":1,"cpg":1,"clinical":1,"practice":1,"guideline":1,"crcl":1,"creatinine":1,"clearance":1,"cv":1,"cvd":1,"cvot":1,"outcomes":1,"trial":1,"da":1,"dopamine":1,"agonist":1,"dash":1,"dietary":1,"approaches":1,"to":1,"stop":1,"hypertension":1,"dka":1,"diabetic":2,"ketoacidosis":1,"dkd":1,"dm":1,"diabetes":1,"mellitus":1,"dpp":1,"4i":1,"dipeptidyl":1,"peptidase":1,"egfr":1,"estimated":1,"glomerular":1,"fi":1,"ltration":1,"rate":1,"er":1,"ext":1},"len":175},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":2,"chunkId":"aace-2023-p2-c5","text":"rial; DA, dopamine agonist; DASH, Dietary Approaches to Stop Hypertension; DKA, diabetic ketoacidosis; DKD, diabetic kidney disease; DM, diabetes mellitus; DPP-4i, dipeptidyl peptidase-4 inhibitor; eGFR, estimated glomerular fi ltration rate; ER, extended release; FBG, fasting blood glucose; FDA, U.S. Food and Drug Administration; FPG, fasting plasma glucose; GERD, gastroesophageal re fl ux disease; GI, gastrointestinal; GIP/GLP-1 RA, glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist; GLN, glinide; GLP-1 RA, glucagon-like peptide-1 receptor agonist; GMI, glucose management indicator; GU, genitourinary; HCP, health care professional; HDL-C, high-density lipoprotein cholesterol; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HR, hazard ratio; HTN, hypertension; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; IPE, icosapent ethyl; IV, intravenous; LADA, latent autoimmune diabetes in adults; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); LV, left ventricle; MACE, major adverse cardiovascular event; MEN2, multiple endocrine neoplasia type 2; MET, metformin; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; MTC, medullary thyroid carcinoma; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NCEP, National Cholesterol Education Program; ","tf":{"rial":1,"da":1,"dopamine":1,"agonist":3,"dash":1,"dietary":1,"approaches":1,"to":1,"stop":1,"hypertension":2,"dka":1,"diabetic":2,"ketoacidosis":1,"dkd":1,"kidney":1,"disease":3,"dm":1,"diabetes":2,"mellitus":1,"dpp":1,"4i":1,"dipeptidyl":1,"peptidase":1,"inhibitor":1,"egfr":1,"estimated":1,"glomerular":1,"fi":1,"ltration":1,"rate":1,"er":1,"extended":1,"release":1,"fbg":1,"fasting":3,"blood":1,"glucose":6,"fda":1,"food":1,"and":2,"drug":1,"administration":1,"fpg":1,"plasma":1,"gerd":1,"gastroesophageal":1,"re":1,"fl":1,"ux":1,"gi":1,"gastrointestinal":1,"gip":1,"glp":2,"ra":2,"dependent":1,"insulinotropic":1,"polypeptide":1,"glucagon":2,"like":2,"peptide":2,"receptor":3,"gln":1,"glinide":1,"gmi":1,"management":1,"indicator":1,"gu":1,"genitourinary":1,"hcp":1,"health":1,"care":1,"professional":1,"hdl":1,"high":1,"density":2,"lipoprotein":3,"cholesterol":3,"hf":1,"heart":2,"failure":2,"hfpef":1,"with":1,"preserved":1,"ejection":1,"fraction":1,"hr":1,"hazard":1,"ratio":1,"htn":1,"ifg":1,"impaired":2,"igt":1,"tolerance":1,"ipe":1,"icosapent":1,"ethyl":1,"iv":1,"intravenous":1,"lada":1,"latent":1,"autoimmune":1,"in":1,"adults":1,"ldl":1,"low":1,"lp":1,"lv":1,"left":1,"ventricle":1,"mace":1,"major":1,"adverse":1,"cardiovascular":1,"event":1,"men2":1,"multiple":1,"endocrine":1,"neoplasia":1,"type":1,"met":1,"metformin":1,"mi":1,"myocardial":1,"infarction":1,"mra":1,"mineralocorticoid":1,"antagonist":1,"mtc":1,"medullary":1,"thyroid":1,"carcinoma":1,"nafld":1,"nonalcoholic":2,"fatty":1,"liver":1,"nash":1,"steatohepatitis":1,"ncep":1,"national":1,"education":1,"program":1},"len":172},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":2,"chunkId":"aace-2023-p2-c6","text":"pe 2; MET, metformin; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; MTC, medullary thyroid carcinoma; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NCEP, National Cholesterol Education Program; NPH, neutral protamine Hagedorn; OA, osteoarthritis; OGTT, oral glucose tolerance test; OSA, obstructive sleep apnea; PCOS, polycystic ovary syndrome; PCSK9, proprotein convertase subtilisin/kexin type 9; PG, plasma glucose; PPG, postprandial glucose; PRAML, pramlintide; PVD, peripheral vascular disease; Rx, medical prescription; SAMS, statin-associated muscle symptoms; sCR, serum creatinine; SGLT2i, sodium glucose cotransporter 2 inhibitor; SU, sulfonylurea; TDD, total daily dose; TG, triglyceride; TIA, transient ischemic attack; TIR, time in range; TZD, thiazolidinedione; T1D, type 1 diabetes; T2D, type 2 diabetes; UACR, urine albumin-to-creatinine ratio; VLDL, very low-density lipoprotein S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 306","tf":{"29":1,"305":1,"306":1,"340":1,"2023":1,"pe":1,"met":1,"metformin":1,"mi":1,"myocardial":1,"infarction":1,"mra":1,"mineralocorticoid":1,"receptor":1,"antagonist":1,"mtc":1,"medullary":1,"thyroid":1,"carcinoma":1,"nafld":1,"nonalcoholic":2,"fatty":1,"liver":1,"disease":2,"nash":1,"steatohepatitis":1,"ncep":1,"national":1,"cholesterol":1,"education":1,"program":1,"nph":1,"neutral":1,"protamine":1,"hagedorn":1,"oa":1,"osteoarthritis":1,"ogtt":1,"oral":1,"glucose":4,"tolerance":1,"test":1,"osa":1,"obstructive":1,"sleep":1,"apnea":1,"pcos":1,"polycystic":1,"ovary":1,"syndrome":1,"pcsk9":1,"proprotein":1,"convertase":1,"subtilisin":1,"kexin":1,"type":3,"pg":1,"plasma":1,"ppg":1,"postprandial":1,"praml":1,"pramlintide":1,"pvd":1,"peripheral":1,"vascular":1,"rx":1,"medical":1,"prescription":1,"sams":1,"statin":1,"associated":1,"muscle":1,"symptoms":1,"scr":1,"serum":1,"creatinine":2,"sglt2i":1,"sodium":1,"cotransporter":1,"inhibitor":1,"su":1,"sulfonylurea":1,"tdd":1,"total":1,"daily":1,"dose":1,"tg":1,"triglyceride":1,"tia":1,"transient":1,"ischemic":1,"attack":1,"tir":1,"time":1,"in":1,"range":1,"tzd":1,"thiazolidinedione":1,"t1d":1,"diabetes":2,"t2d":1,"uacr":1,"urine":1,"albumin":1,"to":1,"ratio":1,"vldl":1,"very":1,"low":1,"density":1,"lipoprotein":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":127},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":3,"chunkId":"aace-2023-p3-c0","text":"atherosclerotic risk factors of dyslipidemia (Algorithm Fig. 4) and HTN (Algorithm Fig. 5). In addition, the algorithms for anti- hyperglycemic agents include both complication-centric (Algo- rithm Fig. 6) and glucose-centric (Algorithm Fig. 7) approaches, and there is direction for insulin initiation and titration (Algorithm Fig. 8). Convenient tables summarizing the bene fi ts and risks of anti- hyperglycemic medications (updated) (Algorithm Fig. 9) and weight-loss pharmacotherapy (new) (Algorithm Fig. 10) are pro- vided. A new table of immunization guidance is provided that summarizes recommendations from the Advisory Committee on Immunization Practices of the U.S. Centers for Disease Control and Prevention (CDC) (Algorithm Fig. 11). Principles of the AACE Comprehensive T2D Management Algorithm Following are the principles of this algorithm for the manage- ment of T2D (Algorithm Fig. 1). Lifestyle modi fi cation underlies all therapy. Lifestyle modi fi cation includes exercise, healthy dietary changes, smoking cessation, and reduced alcohol intake. Additional aspects of lifestyle modi fi cation include assessment and management of sleep disorders and depression. The Complications-Centric Model for the Care of Per- sons with Overweight/Obesity (Algorithm Fig. 2) emphasizes the underlying components of a comprehensive assessment for staging overweight/obesity in the context of","tf":{"10":1,"11":1,"atherosclerotic":1,"risk":1,"factors":1,"of":12,"dyslipidemia":1,"algorithm":11,"fig":10,"and":10,"htn":1,"in":2,"addition":1,"the":11,"algorithms":1,"for":6,"anti":2,"hyperglycemic":2,"agents":1,"include":2,"both":1,"complication":1,"centric":3,"algo":1,"rithm":1,"glucose":1,"approaches":1,"there":1,"is":2,"direction":1,"insulin":1,"initiation":1,"titration":1,"convenient":1,"tables":1,"summarizing":1,"bene":1,"fi":4,"ts":1,"risks":1,"medications":1,"updated":1,"weight":1,"loss":1,"pharmacotherapy":1,"new":2,"are":2,"pro":1,"vided":1,"table":1,"immunization":2,"guidance":1,"provided":1,"that":1,"summarizes":1,"recommendations":1,"from":1,"advisory":1,"committee":1,"on":1,"practices":1,"centers":1,"disease":1,"control":1,"prevention":1,"cdc":1,"principles":2,"aace":1,"comprehensive":2,"t2d":2,"management":2,"following":1,"this":1,"manage":1,"ment":1,"lifestyle":3,"modi":3,"cation":3,"underlies":1,"all":1,"therapy":1,"includes":1,"exercise":1,"healthy":1,"dietary":1,"changes":1,"smoking":1,"cessation":1,"reduced":1,"alcohol":1,"intake":1,"additional":1,"aspects":1,"assessment":2,"sleep":1,"disorders":1,"depression":1,"complications":1,"model":1,"care":1,"per":1,"sons":1,"with":1,"overweight":2,"obesity":2,"emphasizes":1,"underlying":1,"components":1,"staging":1,"context":1},"len":190},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":3,"chunkId":"aace-2023-p3-c1","text":"f sleep disorders and depression. The Complications-Centric Model for the Care of Per- sons with Overweight/Obesity (Algorithm Fig. 2) emphasizes the underlying components of a comprehensive assessment for staging overweight/obesity in the context of ABCD and provides guidance on proposed interventions to improve the overall health of persons with overweight/obesity. Maintain or achieve optimal weight. Excess weight results in insulin resistance and increases the risk for prediabetes and T2D, but also leads to multiple complications beyond dysglycemia that comprise ABCD and lead to excess morbidity and mortality. Lifestyle inter- vention to achieve weight loss is a key pillar of the comprehensive treatment of persons with prediabetes to decrease progression to T2D. Weight loss also improves many of the cardiometabolic and biomechanical components of ABCD, including increased glycemia, dyslipidemia, elevated blood pressure (BP), cardiovascular disease (CVD), nonalcoholic fatty liver disease (NAFLD), sleep apnea, and osteoarthritis, albeit with varied thresholds ranging from > 5% to > 15% of body weight. Choice of antihyperglycemic therapy re fl ects glycemic targets, atherosclerotic cardiovascular disease (ASCVD), congestive heart failure (CHF), chronic kidney disease (CKD), overweight/obesity, and NAFLD. Although glycemic control has an essential role in the prevention and decr","tf":{"15":1,"sleep":2,"disorders":1,"and":10,"depression":1,"the":9,"complications":2,"centric":1,"model":1,"for":3,"care":1,"of":10,"per":1,"sons":1,"with":4,"overweight":4,"obesity":4,"algorithm":1,"fig":1,"emphasizes":1,"underlying":1,"components":2,"comprehensive":2,"assessment":1,"staging":1,"in":3,"context":1,"abcd":3,"provides":1,"guidance":1,"on":1,"proposed":1,"interventions":1,"to":7,"improve":1,"overall":1,"health":1,"persons":2,"maintain":1,"or":1,"achieve":2,"optimal":1,"weight":5,"excess":2,"results":1,"insulin":1,"resistance":1,"increases":1,"risk":1,"prediabetes":2,"t2d":2,"but":1,"also":2,"leads":1,"multiple":1,"beyond":1,"dysglycemia":1,"that":1,"comprise":1,"lead":1,"morbidity":1,"mortality":1,"lifestyle":1,"inter":1,"vention":1,"loss":2,"is":1,"key":1,"pillar":1,"treatment":1,"decrease":1,"progression":1,"improves":1,"many":1,"cardiometabolic":1,"biomechanical":1,"including":1,"increased":1,"glycemia":1,"dyslipidemia":1,"elevated":1,"blood":1,"pressure":1,"bp":1,"cardiovascular":2,"disease":4,"cvd":1,"nonalcoholic":1,"fatty":1,"liver":1,"nafld":2,"apnea":1,"osteoarthritis":1,"albeit":1,"varied":1,"thresholds":1,"ranging":1,"from":1,"body":1,"choice":1,"antihyperglycemic":1,"therapy":1,"re":1,"fl":1,"ects":1,"glycemic":2,"targets":1,"atherosclerotic":1,"ascvd":1,"congestive":1,"heart":1,"failure":1,"chf":1,"chronic":1,"kidney":1,"ckd":1,"although":1,"control":1,"has":1,"an":1,"essential":1,"role":1,"prevention":1,"decr":1},"len":192},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":3,"chunkId":"aace-2023-p3-c2","text":"erapy re fl ects glycemic targets, atherosclerotic cardiovascular disease (ASCVD), congestive heart failure (CHF), chronic kidney disease (CKD), overweight/obesity, and NAFLD. Although glycemic control has an essential role in the prevention and decreased progression of T2D complications, there is evidence for the positive impact of individual pharmacotherapies on outcomes of comorbidities beyond glycemic control. Clinicians should use the coexistence of these frequently associated condi- tions to select the antihyperglycemic therapy or therapies with the most potential for improved overall outcomes. The 2022 AACE CPG update on a DM comprehensive care plan 9 recommends that  if there is established or high risk for ASCVD, heart failure [HF], and/ or CKD, clinicians should prescribe a glucagon-like peptide-1 re- ceptor agonist (GLP-1 RA) or a sodium glucose cotransporter 2 in- hibitor (SGLT2i) with proven ef fi cacy for the speci fi c condition(s)  independent of glycemic control. 9 Additional considerations could include the choice of a medication with potential bene fi t for stroke Algorithm Fig. 1. Principles of the AACE Comprehensive Type 2 Diabetes Management Algorithm. AACE  American Association of Endocrinology. S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 307","tf":{"29":1,"305":1,"307":1,"340":1,"2022":1,"2023":1,"erapy":1,"re":2,"fl":1,"ects":1,"glycemic":4,"targets":1,"atherosclerotic":1,"cardiovascular":1,"disease":2,"ascvd":2,"congestive":1,"heart":2,"failure":2,"chf":1,"chronic":1,"kidney":1,"ckd":2,"overweight":1,"obesity":1,"and":3,"nafld":1,"although":1,"control":3,"has":1,"an":1,"essential":1,"role":1,"in":2,"the":9,"prevention":1,"decreased":1,"progression":1,"of":8,"t2d":1,"complications":1,"there":2,"is":2,"evidence":1,"for":5,"positive":1,"impact":1,"individual":1,"pharmacotherapies":1,"on":2,"outcomes":2,"comorbidities":1,"beyond":1,"clinicians":2,"should":2,"use":1,"coexistence":1,"these":1,"frequently":1,"associated":1,"condi":1,"tions":1,"to":1,"select":1,"antihyperglycemic":1,"therapy":1,"or":4,"therapies":1,"with":3,"most":1,"potential":2,"improved":1,"overall":1,"aace":3,"cpg":1,"update":1,"dm":1,"comprehensive":2,"care":1,"plan":1,"recommends":1,"that":1,"if":1,"established":1,"high":1,"risk":1,"hf":1,"prescribe":1,"glucagon":1,"like":1,"peptide":1,"ceptor":1,"agonist":1,"glp":1,"ra":1,"sodium":1,"glucose":1,"cotransporter":1,"hibitor":1,"sglt2i":1,"proven":1,"ef":1,"fi":3,"cacy":1,"speci":1,"condition":1,"independent":1,"additional":1,"considerations":1,"could":1,"include":1,"choice":1,"medication":1,"bene":1,"stroke":1,"algorithm":2,"fig":1,"principles":1,"type":1,"diabetes":1,"management":1,"american":1,"association":1,"endocrinology":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":182},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":4,"chunkId":"aace-2023-p4-c0","text":"or NAFLD (eg, pioglitazone). This important paradigm shift was the impetus for the updated Complications-Centric Algorithm for Glycemic Control (Algorithm Fig. 6). The Pro fi les of Anti- hyperglycemic Medications table (Algorithm Fig. 9) also summa- rizes key aspects of the bene fi ts and risks of available pharmacotherapies from this perspective. Choice of therapy includes ease of use and access. The armamen- tarium of antihyperglycemic agents has expanded over the past 2 decades beyond the insulin secretagogues (SUs/glinides), TZDs, and metformin. Large prospective clinical trials have con fi rmed the ef fi - cacy of new medical therapies for glycemic control but also revealed a positive impact on progression of ASCVD, CHF, and diabetic kidney disease (DKD) or CKD in those with DM. The evolution of basal and rapid-acting analog insulins has also led to improvements in pre- dictability of glucose response with decreased hypoglycemia. Ideally, decision-making regarding prescription of antihyperglycemic agents and insulin analogs should be based on what is most likely to bene fi t the patient, balanced with the risks and potential side effects. However, barriers to access including availability, cost, insurance coverage, and formularies need to be considered, and this is acknowledged in the Glucose-Centric Algorithm for Glycemic Con- trol (Algorithm Fig. 7) and the table outlin","tf":{"or":2,"nafld":1,"eg":1,"pioglitazone":1,"this":3,"important":1,"paradigm":1,"shift":1,"was":1,"the":13,"impetus":1,"for":4,"updated":1,"complications":1,"centric":2,"algorithm":5,"glycemic":3,"control":2,"fig":3,"pro":1,"fi":5,"les":1,"of":11,"anti":1,"hyperglycemic":1,"medications":1,"table":2,"also":3,"summa":1,"rizes":1,"key":1,"aspects":1,"bene":2,"ts":1,"and":10,"risks":2,"available":1,"pharmacotherapies":1,"from":1,"perspective":1,"choice":1,"therapy":1,"includes":1,"ease":1,"use":1,"access":2,"armamen":1,"tarium":1,"antihyperglycemic":2,"agents":2,"has":2,"expanded":1,"over":1,"past":1,"decades":1,"beyond":1,"insulin":2,"secretagogues":1,"sus":1,"glinides":1,"tzds":1,"metformin":1,"large":1,"prospective":1,"clinical":1,"trials":1,"have":1,"con":2,"rmed":1,"ef":1,"cacy":1,"new":1,"medical":1,"therapies":1,"but":1,"revealed":1,"positive":1,"impact":1,"on":2,"progression":1,"ascvd":1,"chf":1,"diabetic":1,"kidney":1,"disease":1,"dkd":1,"ckd":1,"in":3,"those":1,"with":3,"dm":1,"evolution":1,"basal":1,"rapid":1,"acting":1,"analog":1,"insulins":1,"led":1,"to":4,"improvements":1,"pre":1,"dictability":1,"glucose":2,"response":1,"decreased":1,"hypoglycemia":1,"ideally":1,"decision":1,"making":1,"regarding":1,"prescription":1,"analogs":1,"should":1,"be":2,"based":1,"what":1,"is":2,"most":1,"likely":1,"patient":1,"balanced":1,"potential":1,"side":1,"effects":1,"however":1,"barriers":1,"including":1,"availability":1,"cost":1,"insurance":1,"coverage":1,"formularies":1,"need":1,"considered":1,"acknowledged":1,"trol":1,"outlin":1},"len":210},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":4,"chunkId":"aace-2023-p4-c1","text":"ide effects. However, barriers to access including availability, cost, insurance coverage, and formularies need to be considered, and this is acknowledged in the Glucose-Centric Algorithm for Glycemic Con- trol (Algorithm Fig. 7) and the table outlining the Pro fi les of Weight- Loss Medications (Algorithm Fig. 10). Optimal hemoglobin A1c (A1C) is \u0014 6.5% or as close to normal as is safe and achievable for most patients. For most patients, an A1C of \u0014 6.5% should be targeted. 9 Achieving this A1C goal may require targeting fasting plasma glucose (FPG) to < 110 mg/dL and 2-hour postprandial glucose (PPG) to < 140 mg/dL. 9 The impact of tight glycemic control for the prevention and/or decreased progression of microvascular and microangiopathic complications of T2D is well established. 12-14 Although there are epidemiologic data supporting an association of A1C and CVD/all-cause mortality on a contin- uum, 15 early clinical trial evidence did not directly support that there was mitigation of negative macrovascular disease outcomes with intensive glucose lowering and there was an association with negative CVD outcomes with hypoglycemic events. 16 Pharmaco- logic therapies that have a lower risk of hypoglycemia and have proven ef fi cacy in cardiovascular outcomes trials (CVOTs), partic- ularly GLP-1 RA and SGLT2i, may allow for stricter glycemic control. However, the key word is  s","tf":{"10":1,"12":1,"14":1,"15":1,"16":1,"110":1,"140":1,"ide":1,"effects":1,"however":2,"barriers":1,"to":5,"access":1,"including":1,"availability":1,"cost":1,"insurance":1,"coverage":1,"and":11,"formularies":1,"need":1,"be":2,"considered":1,"this":2,"is":5,"acknowledged":1,"in":2,"the":6,"glucose":4,"centric":1,"algorithm":3,"for":5,"glycemic":3,"con":1,"trol":1,"fig":2,"table":1,"outlining":1,"pro":1,"fi":2,"les":1,"of":8,"weight":1,"loss":1,"medications":1,"optimal":1,"hemoglobin":1,"a1c":5,"or":2,"as":2,"close":1,"normal":1,"safe":1,"achievable":1,"most":2,"patients":2,"an":3,"should":1,"targeted":1,"achieving":1,"goal":1,"may":2,"require":1,"targeting":1,"fasting":1,"plasma":1,"fpg":1,"mg":2,"dl":2,"hour":1,"postprandial":1,"ppg":1,"impact":1,"tight":1,"control":2,"prevention":1,"decreased":1,"progression":1,"microvascular":1,"microangiopathic":1,"complications":1,"t2d":1,"well":1,"established":1,"although":1,"there":3,"are":1,"epidemiologic":1,"data":1,"supporting":1,"association":2,"cvd":2,"all":1,"cause":1,"mortality":1,"on":1,"contin":1,"uum":1,"early":1,"clinical":1,"trial":1,"evidence":1,"did":1,"not":1,"directly":1,"support":1,"that":2,"was":2,"mitigation":1,"negative":2,"macrovascular":1,"disease":1,"outcomes":3,"with":3,"intensive":1,"lowering":1,"hypoglycemic":1,"events":1,"pharmaco":1,"logic":1,"therapies":1,"have":2,"lower":1,"risk":1,"hypoglycemia":1,"proven":1,"ef":1,"cacy":1,"cardiovascular":1,"trials":1,"cvots":1,"partic":1,"ularly":1,"glp":1,"ra":1,"sglt2i":1,"allow":1,"stricter":1,"key":1,"word":1},"len":213},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":4,"chunkId":"aace-2023-p4-c2","text":"vents. 16 Pharmaco- logic therapies that have a lower risk of hypoglycemia and have proven ef fi cacy in cardiovascular outcomes trials (CVOTs), partic- ularly GLP-1 RA and SGLT2i, may allow for stricter glycemic control. However, the key word is  safe  with consideration of patient- speci fi c characteristics that would recommend a less stringent A1C target (eg, 7%-8%), including the following 9,13,14,17 : \u000f Limited life expectancy \u000f History of severe hypoglycemia \u000f Hypoglycemia unawareness \u000f Advanced renal disease \u000f Other severe comorbid conditions with a high risk for CVD events \u000f Long T2D disease duration with dif fi culty to attain an A1C goal \u000f Prohibitive cognitive and/or psychological status Individualize all glycemic targets (A1C, glucose management indica- tor [GMI], time in range [TIR], fasting blood glucose [FBG], and PPG). A1C is a convenient measurement in the clinical setting that is widely used to assess glycemic control and should be measured every 3 months when not at goal and a minimum of twice per year in persons at goal. A1C also has limitations and can be imprecise in some populations, including people with altered red blood cell lifespan, hemoglobinopathies, CKD, and some racial backgrounds. In addition, other glucose parameters have been shown to correlate with outcomes, such as TIR, as generated by continuous glucose monitoring (CGM). It is recommende","tf":{"13":1,"14":1,"16":1,"17":1,"vents":1,"pharmaco":1,"logic":1,"therapies":1,"that":3,"have":3,"lower":1,"risk":2,"of":4,"hypoglycemia":3,"and":8,"proven":1,"ef":1,"fi":3,"cacy":1,"in":6,"cardiovascular":1,"outcomes":2,"trials":1,"cvots":1,"partic":1,"ularly":1,"glp":1,"ra":1,"sglt2i":1,"may":1,"allow":1,"for":2,"stricter":1,"glycemic":3,"control":2,"however":1,"the":3,"key":1,"word":1,"is":4,"safe":1,"with":5,"consideration":1,"patient":1,"speci":1,"characteristics":1,"would":1,"recommend":1,"less":1,"stringent":1,"a1c":5,"target":1,"eg":1,"including":2,"following":1,"limited":1,"life":1,"expectancy":1,"history":1,"severe":2,"unawareness":1,"advanced":1,"renal":1,"disease":2,"other":2,"comorbid":1,"conditions":1,"high":1,"cvd":1,"events":1,"long":1,"t2d":1,"duration":1,"dif":1,"culty":1,"to":3,"attain":1,"an":1,"goal":3,"prohibitive":1,"cognitive":1,"or":1,"psychological":1,"status":1,"individualize":1,"all":1,"targets":1,"glucose":4,"management":1,"indica":1,"tor":1,"gmi":1,"time":1,"range":1,"tir":2,"fasting":1,"blood":2,"fbg":1,"ppg":1,"convenient":1,"measurement":1,"clinical":1,"setting":1,"widely":1,"used":1,"assess":1,"should":1,"be":2,"measured":1,"every":1,"months":1,"when":1,"not":1,"at":2,"minimum":1,"twice":1,"per":1,"year":1,"persons":1,"also":1,"has":1,"limitations":1,"can":1,"imprecise":1,"some":2,"populations":1,"people":1,"altered":1,"red":1,"cell":1,"lifespan":1,"hemoglobinopathies":1,"ckd":1,"racial":1,"backgrounds":1,"addition":1,"parameters":1,"been":1,"shown":1,"correlate":1,"such":1,"as":2,"generated":1,"by":1,"continuous":1,"monitoring":1,"cgm":1,"it":1,"recommende":1},"len":208},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":4,"chunkId":"aace-2023-p4-c3","text":"ltered red blood cell lifespan, hemoglobinopathies, CKD, and some racial backgrounds. In addition, other glucose parameters have been shown to correlate with outcomes, such as TIR, as generated by continuous glucose monitoring (CGM). It is recommended that TIR (glucose range 70- 180 mg/dL) be > 70%, combined with minimal time below range (4% for < 70 mg/dL and < 1% for < 54 mg/dL). 18-20 CGM also can generate the GMI, which is of utility as a surrogate for an A1C. 21 When available, these alternative glucose parameters should be incor- porated for monitoring and adjustment of therapy. Get to goal as soon as possible (adjust \u0014 3 months). Therapeutic inertia d failure of clinicians to escalate therapy or initiate new therapies d is a major threat to achieving improved health outcomes in persons with overweight/obesity, prediabetes, and T2D. 22,23 Clini- cians should continuously evaluate treatment goals at each visit, ideally \u0014 3 months, and consider making therapeutic changes to more rapidly achieve targets for glucose, lipids, and BP. Avoid hypoglycemia. Hypoglycemia, de fi ned as blood glucose (BG) < 70 mg/dL, is associated with an increased risk for adverse out- comes including mortality. 14,16 Therefore, the optimal treatment for T2D should take into account the risk of hypoglycemia. Anti- hyperglycemic agents and A1C goals should be chosen to avoid hypoglycemia. 9 Agents su","tf":{"14":1,"16":1,"18":1,"20":1,"21":1,"22":1,"23":1,"54":1,"70":4,"180":1,"ltered":1,"red":1,"blood":2,"cell":1,"lifespan":1,"hemoglobinopathies":1,"ckd":1,"and":7,"some":1,"racial":1,"backgrounds":1,"in":2,"addition":1,"other":1,"glucose":6,"parameters":2,"have":1,"been":1,"shown":1,"to":6,"correlate":1,"with":4,"outcomes":2,"such":1,"as":6,"tir":2,"generated":1,"by":1,"continuous":1,"monitoring":2,"cgm":2,"it":1,"is":4,"recommended":1,"that":1,"range":2,"mg":4,"dl":4,"be":3,"combined":1,"minimal":1,"time":1,"below":1,"for":7,"also":1,"can":1,"generate":1,"the":3,"gmi":1,"which":1,"of":4,"utility":1,"surrogate":1,"an":2,"a1c":2,"when":1,"available":1,"these":1,"alternative":1,"should":4,"incor":1,"porated":1,"adjustment":1,"therapy":2,"get":1,"goal":1,"soon":1,"possible":1,"adjust":1,"months":2,"therapeutic":2,"inertia":1,"failure":1,"clinicians":1,"escalate":1,"or":1,"initiate":1,"new":1,"therapies":1,"major":1,"threat":1,"achieving":1,"improved":1,"health":1,"persons":1,"overweight":1,"obesity":1,"prediabetes":1,"t2d":2,"clini":1,"cians":1,"continuously":1,"evaluate":1,"treatment":2,"goals":2,"at":1,"each":1,"visit":1,"ideally":1,"consider":1,"making":1,"changes":1,"more":1,"rapidly":1,"achieve":1,"targets":1,"lipids":1,"bp":1,"avoid":2,"hypoglycemia":4,"de":1,"fi":1,"ned":1,"bg":1,"associated":1,"increased":1,"risk":2,"adverse":1,"out":1,"comes":1,"including":1,"mortality":1,"therefore":1,"optimal":1,"take":1,"into":1,"account":1,"anti":1,"hyperglycemic":1,"agents":2,"chosen":1,"su":1},"len":216},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":4,"chunkId":"aace-2023-p4-c4","text":" increased risk for adverse out- comes including mortality. 14,16 Therefore, the optimal treatment for T2D should take into account the risk of hypoglycemia. Anti- hyperglycemic agents and A1C goals should be chosen to avoid hypoglycemia. 9 Agents such as DPP-4i, GLP-1 RA, and SGLT2i have a lower risk of hypoglycemia compared with that of insulin and SUs and are preferred to achieve optimal glycemic goals. CGM is highly recommended to assist persons with diabetes in reaching goals safely. CGM has provided a major advance in the treatment of persons with all forms of DM. For those persons with T2D, and on basal insulin, clinical trials have shown that CGM is associated with increased TIR, improved A1C, and decreased hy- poglycemia, including severe hypoglycemic events. 24-26 The 2021 AACE CPG: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus 20 discusses the different ave- nues for application of CGM including for all persons with DM on multiple-dose insulin ( \u0015 3 injections/day) or an insulin pump as well as those who have frequent or severe hypoglycemia, nocturnal hypoglycemia, or hypoglycemia unawareness. 20 Real-time CGM or intermittently scanned CGM including alarms or alerts is recom- mended, particularly for persons with hypoglycemia who would bene fi t from these warnings. 20 However, as an alternative, inter- mittently scanned CGM may a","tf":{"14":1,"16":1,"20":3,"24":1,"26":1,"2021":1,"increased":2,"risk":3,"for":6,"adverse":1,"out":1,"comes":1,"including":4,"mortality":1,"therefore":1,"the":7,"optimal":2,"treatment":2,"t2d":2,"should":2,"take":1,"into":1,"account":1,"of":8,"hypoglycemia":7,"anti":1,"hyperglycemic":1,"agents":2,"and":6,"a1c":2,"goals":3,"be":1,"chosen":1,"to":3,"avoid":1,"such":1,"as":4,"dpp":1,"4i":1,"glp":1,"ra":1,"sglt2i":1,"have":3,"lower":1,"compared":1,"with":8,"that":2,"insulin":4,"sus":1,"are":1,"preferred":1,"achieve":1,"glycemic":1,"cgm":7,"is":3,"highly":1,"recommended":1,"assist":1,"persons":6,"diabetes":2,"in":3,"reaching":1,"safely":1,"has":1,"provided":1,"major":1,"advance":1,"all":2,"forms":1,"dm":2,"those":2,"on":2,"basal":1,"clinical":1,"trials":1,"shown":1,"associated":1,"tir":1,"improved":1,"decreased":1,"hy":1,"poglycemia":1,"severe":2,"hypoglycemic":1,"events":1,"aace":1,"cpg":1,"use":1,"advanced":1,"technology":1,"management":1,"mellitus":1,"discusses":1,"different":1,"ave":1,"nues":1,"application":1,"multiple":1,"dose":1,"injections":1,"day":1,"or":5,"an":2,"pump":1,"well":1,"who":2,"frequent":1,"nocturnal":1,"unawareness":1,"real":1,"time":1,"intermittently":1,"scanned":2,"alarms":1,"alerts":1,"recom":1,"mended":1,"particularly":1,"would":1,"bene":1,"fi":1,"from":1,"these":1,"warnings":1,"however":1,"alternative":1,"inter":1,"mittently":1,"may":1},"len":220},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":4,"chunkId":"aace-2023-p4-c5","text":"areness. 20 Real-time CGM or intermittently scanned CGM including alarms or alerts is recom- mended, particularly for persons with hypoglycemia who would bene fi t from these warnings. 20 However, as an alternative, inter- mittently scanned CGM may also provide valuable information in persons who are newly diagnosed with T2D and/or at low risk for hypoglycemia. Diagnostic (professional use) CGM can be used for new T2D diagnosis and for those with hypoglycemia but without access to personal CGM and can be educational for the person with T2D (eg, effects on behaviors including diet and exercise) and also aid the clinician in investigating avenues to improve glycemic control with medical therapies. Comorbidities must be managed for comprehensive care. Hypertension and dyslipidemia are comorbidities often associated with T2D that further increase the risk for complications including CVD, chronic kidney failure, and retinopathy. Improvements in glycemic control must be accompanied by treatment of concomi- tant dyslipidemia and HTN for optimized outcomes. Complications-Centric Model for the Care of Persons with Overweight/Obesity (ABCD) Lifestyle intervention is the essential foundation for the man- agement of persons with prediabetes and T2D. Although the phrase lifestyle intervention is often thought of in relation to nutrition, weight loss, and exercise, a comprehensive plan also ","tf":{"20":2,"areness":1,"real":1,"time":1,"cgm":5,"or":3,"intermittently":1,"scanned":2,"including":3,"alarms":1,"alerts":1,"is":3,"recom":1,"mended":1,"particularly":1,"for":10,"persons":4,"with":8,"hypoglycemia":3,"who":2,"would":1,"bene":1,"fi":1,"from":1,"these":1,"warnings":1,"however":1,"as":1,"an":1,"alternative":1,"inter":1,"mittently":1,"may":1,"also":3,"provide":1,"valuable":1,"information":1,"in":4,"are":2,"newly":1,"diagnosed":1,"t2d":5,"and":10,"at":1,"low":1,"risk":2,"diagnostic":1,"professional":1,"use":1,"can":2,"be":4,"used":1,"new":1,"diagnosis":1,"those":1,"but":1,"without":1,"access":1,"to":3,"personal":1,"educational":1,"the":7,"person":1,"eg":1,"effects":1,"on":1,"behaviors":1,"diet":1,"exercise":2,"aid":1,"clinician":1,"investigating":1,"avenues":1,"improve":1,"glycemic":2,"control":2,"medical":1,"therapies":1,"comorbidities":2,"must":2,"managed":1,"comprehensive":2,"care":2,"hypertension":1,"dyslipidemia":2,"often":2,"associated":1,"that":1,"further":1,"increase":1,"complications":2,"cvd":1,"chronic":1,"kidney":1,"failure":1,"retinopathy":1,"improvements":1,"accompanied":1,"by":1,"treatment":1,"of":4,"concomi":1,"tant":1,"htn":1,"optimized":1,"outcomes":1,"centric":1,"model":1,"overweight":1,"obesity":1,"abcd":1,"lifestyle":2,"intervention":2,"essential":1,"foundation":1,"man":1,"agement":1,"prediabetes":1,"although":1,"phrase":1,"thought":1,"relation":1,"nutrition":1,"weight":1,"loss":1,"plan":1},"len":207},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":4,"chunkId":"aace-2023-p4-c6","text":"ifestyle intervention is the essential foundation for the man- agement of persons with prediabetes and T2D. Although the phrase lifestyle intervention is often thought of in relation to nutrition, weight loss, and exercise, a comprehensive plan also should include assessment, counseling, and intervention of sleep hygiene and sleep disorders, promotion of healthy habits beyond diet, including moderation of alcohol intake and cessation of smoking, and S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 308","tf":{"29":1,"305":1,"308":1,"340":1,"2023":1,"ifestyle":1,"intervention":3,"is":2,"the":3,"essential":1,"foundation":1,"for":1,"man":1,"agement":1,"of":6,"persons":1,"with":1,"prediabetes":1,"and":6,"t2d":1,"although":1,"phrase":1,"lifestyle":1,"often":1,"thought":1,"in":1,"relation":1,"to":1,"nutrition":1,"weight":1,"loss":1,"exercise":1,"comprehensive":1,"plan":1,"also":1,"should":1,"include":1,"assessment":1,"counseling":1,"sleep":2,"hygiene":1,"disorders":1,"promotion":1,"healthy":1,"habits":1,"beyond":1,"diet":1,"including":1,"moderation":1,"alcohol":1,"intake":1,"cessation":1,"smoking":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":76},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":5,"chunkId":"aace-2023-p5-c0","text":"monitoring for mood disturbances that can impact success in incorporating durable change (Algorithm Fig. 2). In addition, with advances in weight management, clinicians must consider and incorporate pharmacologic and surgical interventions, including bariatric procedures, as indicated based on a patient-centered assessment. In 2017, AACE published a position statement on the diagnostic term ABCD. 27 The objective of the document was to embrace the importance of viewing overweight/obesity as a chronic disease and to emphasize the importance of assessing persons with overweight/ obesity for the existence of or risk for associated complications, beyond body mass index (BMI), including the following: \u000f Prediabetes \u000f Dyslipidemia \u000f HTN \u000f NAFLD \u000f ASCVD \u000f CHF with reduced ejection fraction \u000f Heart failure with preserved ejection fraction \u000f CKD \u000f Obstructive sleep apnea (OSA) \u000f Osteoarthritis \u000f Gastroesophageal re fl ux disease \u000f Urinary incontinence \u000f Hypogonadism \u000f Polycystic ovary syndrome \u000f Reduced fertility Determination of the presence of ABCD complications allows for staging of persons with overweight/obesity, which can impact the approach to interventions. \u000f Step 1 is to calculate BMI with the understanding of the pub- lished thresholds of what is overweight ( \u0015 25 kg/m 2 ) or obese ( \u0015 30 kg/m 2 ), noting that lower thresholds for overweight/ obesity may apply for South, East,","tf":{"25":1,"27":1,"30":1,"2017":1,"monitoring":1,"for":6,"mood":1,"disturbances":1,"that":2,"can":2,"impact":2,"success":1,"in":4,"incorporating":1,"durable":1,"change":1,"algorithm":1,"fig":1,"addition":1,"with":6,"advances":1,"weight":1,"management":1,"clinicians":1,"must":1,"consider":1,"and":3,"incorporate":1,"pharmacologic":1,"surgical":1,"interventions":2,"including":2,"bariatric":1,"procedures":1,"as":2,"indicated":1,"based":1,"on":2,"patient":1,"centered":1,"assessment":1,"aace":1,"published":1,"position":1,"statement":1,"the":11,"diagnostic":1,"term":1,"abcd":2,"objective":1,"of":9,"document":1,"was":1,"to":4,"embrace":1,"importance":2,"viewing":1,"overweight":5,"obesity":4,"chronic":1,"disease":2,"emphasize":1,"assessing":1,"persons":2,"existence":1,"or":2,"risk":1,"associated":1,"complications":2,"beyond":1,"body":1,"mass":1,"index":1,"bmi":2,"following":1,"prediabetes":1,"dyslipidemia":1,"htn":1,"nafld":1,"ascvd":1,"chf":1,"reduced":2,"ejection":2,"fraction":2,"heart":1,"failure":1,"preserved":1,"ckd":1,"obstructive":1,"sleep":1,"apnea":1,"osa":1,"osteoarthritis":1,"gastroesophageal":1,"re":1,"fl":1,"ux":1,"urinary":1,"incontinence":1,"hypogonadism":1,"polycystic":1,"ovary":1,"syndrome":1,"fertility":1,"determination":1,"presence":1,"allows":1,"staging":1,"which":1,"approach":1,"step":1,"is":2,"calculate":1,"understanding":1,"pub":1,"lished":1,"thresholds":2,"what":1,"kg":2,"obese":1,"noting":1,"lower":1,"may":1,"apply":1,"south":1,"east":1},"len":189},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":5,"chunkId":"aace-2023-p5-c1","text":"proach to interventions. \u000f Step 1 is to calculate BMI with the understanding of the pub- lished thresholds of what is overweight ( \u0015 25 kg/m 2 ) or obese ( \u0015 30 kg/m 2 ), noting that lower thresholds for overweight/ obesity may apply for South, East, and Southeast Asian persons ( \u0015 23.5 kg/m 2 for overweight and \u0015 25 kg/m 2 for obese). \u000f Step 2 provides further classi fi cation of the stage of overweight/ obesity by assessing for the presence of ABCD complications, as listed above. Previous AACE guidance documents have utilized stages 0, 1, and 2 for ABCD severity, but a recent AACE consensus statement centered on obesity stigma and weight bias 28 recom- mends a shift to stages 1, 2, and 3 to avoid inviting treatment inertia at stage 0, where primary prevention must still be in place. The revised staging also incorporates weight bias/stigma and mental health as key components of ABCD that should be addressed in addition to the cardiometabolic and biomechanical complications which can be improved by treatment of obesity. Patients may have an elevated BMI but lack physical complica- tions (Stage 1). Alternatively, patients without a substantially elevated BMI may already have manifested components of ABCD, and action is required. Stage 2 obesity includes patients who have \u0015 1 mild-to-moderate obesity complications. The highest stage 3 includes patients with multiple and/or more s","tf":{"23":1,"25":2,"28":1,"30":1,"proach":1,"to":6,"interventions":1,"step":2,"is":3,"calculate":1,"bmi":3,"with":2,"the":7,"understanding":1,"of":8,"pub":1,"lished":1,"thresholds":2,"what":1,"overweight":4,"kg":4,"or":2,"obese":2,"noting":1,"that":2,"lower":1,"for":6,"obesity":6,"may":3,"apply":1,"south":1,"east":1,"and":9,"southeast":1,"asian":1,"persons":1,"provides":1,"further":1,"classi":1,"fi":1,"cation":1,"stage":5,"by":2,"assessing":1,"presence":1,"abcd":4,"complications":3,"as":2,"listed":1,"above":1,"previous":1,"aace":2,"guidance":1,"documents":1,"have":4,"utilized":1,"stages":2,"severity":1,"but":2,"recent":1,"consensus":1,"statement":1,"centered":1,"on":1,"stigma":2,"weight":2,"bias":2,"recom":1,"mends":1,"shift":1,"avoid":1,"inviting":1,"treatment":2,"inertia":1,"at":1,"where":1,"primary":1,"prevention":1,"must":1,"still":1,"be":3,"in":2,"place":1,"revised":1,"staging":1,"also":1,"incorporates":1,"mental":1,"health":1,"key":1,"components":2,"should":1,"addressed":1,"addition":1,"cardiometabolic":1,"biomechanical":1,"which":1,"can":1,"improved":1,"patients":4,"an":1,"elevated":2,"lack":1,"physical":1,"complica":1,"tions":1,"alternatively":1,"without":1,"substantially":1,"already":1,"manifested":1,"action":1,"required":1,"includes":2,"who":1,"mild":1,"moderate":1,"highest":1,"multiple":1,"more":1},"len":205},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":5,"chunkId":"aace-2023-p5-c2","text":"ubstantially elevated BMI may already have manifested components of ABCD, and action is required. Stage 2 obesity includes patients who have \u0015 1 mild-to-moderate obesity complications. The highest stage 3 includes patients with multiple and/or more severe complica- tions and applies to patients already diagnosed with T2D as a severe ABCD complication. The combination of BMI with stage is helpful to inform the clinician of needed interventions. Algorithm Fig. 2. Complications-Centric Model for the Care of Persons with Overweight/Obesity (Adiposity-Based Chronic Disease). S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 309","tf":{"29":1,"305":1,"309":1,"340":1,"2023":1,"ubstantially":1,"elevated":1,"bmi":2,"may":1,"already":2,"have":2,"manifested":1,"components":1,"of":4,"abcd":2,"and":3,"action":1,"is":2,"required":1,"stage":3,"obesity":3,"includes":2,"patients":3,"who":1,"mild":1,"to":3,"moderate":1,"complications":2,"the":4,"highest":1,"with":4,"multiple":1,"or":1,"more":1,"severe":2,"complica":1,"tions":1,"applies":1,"diagnosed":1,"t2d":1,"as":1,"complication":1,"combination":1,"helpful":1,"inform":1,"clinician":1,"needed":1,"interventions":1,"algorithm":1,"fig":1,"centric":1,"model":1,"for":1,"care":1,"persons":1,"overweight":1,"adiposity":1,"based":1,"chronic":1,"disease":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":94},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":6,"chunkId":"aace-2023-p6-c0","text":"\u000f Step 3 requires implementation of a comprehensive lifestyle modi fi cation plan for the patient that encompasses all aspects of the health of the patient and includes nutrition, physical activ- ity, sleep, counseling, medications, and interventions. Nutrition For persons above optimal weight, caloric deprivation of 500 to 1000 kcal daily energy de fi cit in the context of a healthy diet should be initiated to promote weight loss. In the context of ABCD, a minimum threshold of > 5% to \u0015 10% is needed to have a positive impact on glycemia, BP, and lipids. Weight loss of \u0015 15% may help to mitigate other ABCD complications such as OSA and nonalcoholic steatohepatitis. The selection of a diet should be personalized, but choices include Mediterranean, low-fat, low-carbohydrate, very low e carbohydrate, vegetarian, vegan, and Dietary Approaches to Stop Hypertension (DASH) diets. Structured diets with prepared meals or liquid meal replacements may increase adherence to the calorie limitations. Adherence also may be improved with weight- loss programs or apps that encourage external accountability. Physical Activity A plan for physical activity should take into account any physical limitations and disabilities, some of which may derive from over- weight/obesity itself. Ideally, the amount of physical activity should progress to include moderate, aerobic exercise \u0015 150 minutes per week","tf":{"10":1,"15":1,"150":1,"500":1,"1000":1,"step":1,"requires":1,"implementation":1,"of":11,"comprehensive":1,"lifestyle":1,"modi":1,"fi":2,"cation":1,"plan":2,"for":3,"the":8,"patient":2,"that":2,"encompasses":1,"all":1,"aspects":1,"health":1,"and":6,"includes":1,"nutrition":2,"physical":5,"activ":1,"ity":1,"sleep":1,"counseling":1,"medications":1,"interventions":1,"persons":1,"above":1,"optimal":1,"weight":5,"caloric":1,"deprivation":1,"to":8,"kcal":1,"daily":1,"energy":1,"de":1,"cit":1,"in":2,"context":2,"healthy":1,"diet":2,"should":4,"be":3,"initiated":1,"promote":1,"loss":3,"abcd":2,"minimum":1,"threshold":1,"is":1,"needed":1,"have":1,"positive":1,"impact":1,"on":1,"glycemia":1,"bp":1,"lipids":1,"may":4,"help":1,"mitigate":1,"other":1,"complications":1,"such":1,"as":1,"osa":1,"nonalcoholic":1,"steatohepatitis":1,"selection":1,"personalized":1,"but":1,"choices":1,"include":2,"mediterranean":1,"low":3,"fat":1,"carbohydrate":2,"very":1,"vegetarian":1,"vegan":1,"dietary":1,"approaches":1,"stop":1,"hypertension":1,"dash":1,"diets":2,"structured":1,"with":2,"prepared":1,"meals":1,"or":2,"liquid":1,"meal":1,"replacements":1,"increase":1,"adherence":2,"calorie":1,"limitations":2,"also":1,"improved":1,"programs":1,"apps":1,"encourage":1,"external":1,"accountability":1,"activity":3,"take":1,"into":1,"account":1,"any":1,"disabilities":1,"some":1,"which":1,"derive":1,"from":1,"over":1,"obesity":1,"itself":1,"ideally":1,"amount":1,"progress":1,"moderate":1,"aerobic":1,"exercise":1,"minutes":1,"per":1,"week":1},"len":204},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":6,"chunkId":"aace-2023-p6-c1","text":"ivity should take into account any physical limitations and disabilities, some of which may derive from over- weight/obesity itself. Ideally, the amount of physical activity should progress to include moderate, aerobic exercise \u0015 150 minutes per week divided into 3 to 5 sessions, combined with 2 to 3 sessions of resistance training per week. Sleep Reduced sleep duration is associated with adverse outcomes, including obesity, T2D, HTN, CVD, and mortality. In adults > 18 years of age, 6 to 8 hours of sleep per night is recommended. OSA is highly prevalent in persons with T2D and/or obesity. Clinicians should incorporate routine screening for sleep disorders either clinically, with questions about symptoms of OSA (eg, snoring, choking, daytime sleepiness, fatigue, and nonrestorative sleep), or using a formal screening tool, such as the STOP-Bang question- naire. 29 Testing with home oximetry or a formal sleep study may be indicated. Persons who meet criteria for OSA should be referred for appropriate diagnostic studies and intervention, such as with pre- scription of a continuous positive airway pressure device. Counseling Depression and diabetes distress are prevalent in persons with T2D and can result in nonadherence to diet, exercise, and medi- cation regimens. Potential formal screening tools include the WHO Wellbeing Index, 30 the Patient Health Questionaire-9, 31 or the Beck","tf":{"18":1,"29":1,"30":1,"31":1,"150":1,"ivity":1,"should":4,"take":1,"into":2,"account":1,"any":1,"physical":2,"limitations":1,"and":8,"disabilities":1,"some":1,"of":7,"which":1,"may":2,"derive":1,"from":1,"over":1,"weight":1,"obesity":3,"itself":1,"ideally":1,"the":5,"amount":1,"activity":1,"progress":1,"to":5,"include":2,"moderate":1,"aerobic":1,"exercise":2,"minutes":1,"per":3,"week":2,"divided":1,"sessions":2,"combined":1,"with":7,"resistance":1,"training":1,"sleep":6,"reduced":1,"duration":1,"is":3,"associated":1,"adverse":1,"outcomes":1,"including":1,"t2d":3,"htn":1,"cvd":1,"mortality":1,"in":4,"adults":1,"years":1,"age":1,"hours":1,"night":1,"recommended":1,"osa":3,"highly":1,"prevalent":2,"persons":3,"or":4,"clinicians":1,"incorporate":1,"routine":1,"screening":3,"for":3,"disorders":1,"either":1,"clinically":1,"questions":1,"about":1,"symptoms":1,"eg":1,"snoring":1,"choking":1,"daytime":1,"sleepiness":1,"fatigue":1,"nonrestorative":1,"using":1,"formal":3,"tool":1,"such":2,"as":2,"stop":1,"bang":1,"question":1,"naire":1,"testing":1,"home":1,"oximetry":1,"study":1,"be":2,"indicated":1,"who":2,"meet":1,"criteria":1,"referred":1,"appropriate":1,"diagnostic":1,"studies":1,"intervention":1,"pre":1,"scription":1,"continuous":1,"positive":1,"airway":1,"pressure":1,"device":1,"counseling":1,"depression":1,"diabetes":1,"distress":1,"are":1,"can":1,"result":1,"nonadherence":1,"diet":1,"medi":1,"cation":1,"regimens":1,"potential":1,"tools":1,"wellbeing":1,"index":1,"patient":1,"health":1,"questionaire":1,"beck":1},"len":207},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":6,"chunkId":"aace-2023-p6-c2","text":"nd diabetes distress are prevalent in persons with T2D and can result in nonadherence to diet, exercise, and medi- cation regimens. Potential formal screening tools include the WHO Wellbeing Index, 30 the Patient Health Questionaire-9, 31 or the Beck Depression Inventory III. 32 Appropriate referral for cognitive behavioral therapy or medical intervention should be considered when depression is present. Medications Weight-loss medications should be considered, in combination with a reduced-calorie diet, to achieve and sustain weight-loss goals in patients with BMI 27 kg/m 2 to 29.9 kg/m 2 with T2D or \u0015 1 ABCD complication and all persons with a BMI > 30 kg/m 2 . See also Pro fi les of Weight-Loss Medications (Algorithm Fig. 10). Caution is required for persons > 65 years of age with T2D and ABCD; assessment of bone health and sarcopenia is important. Interventions Metabolic (bariatric) procedures are an effective option for persons with T2D and ABCD and should be considered in persons with a BMI of 30 kg/m 2 to 34.9 kg/m 2 with uncontrolled DM in spite of lifestyle and medical therapy and BMI > 35 kg/m 2 and \u0015 1 ABCD complications, including prediabetes, that can be remedied with weight loss. Prediabetes Algorithm Prediabetes is a cardiometabolic state resulting from failure of the pancreas to compensate for insulin resistance most often caused by overweight/obesity. Prediabete","tf":{"10":1,"27":1,"29":1,"30":3,"31":1,"32":1,"34":1,"35":1,"65":1,"nd":1,"diabetes":1,"distress":1,"are":2,"prevalent":1,"in":6,"persons":5,"with":10,"t2d":4,"and":11,"can":2,"result":1,"nonadherence":1,"to":5,"diet":2,"exercise":1,"medi":1,"cation":1,"regimens":1,"potential":1,"formal":1,"screening":1,"tools":1,"include":1,"the":4,"who":1,"wellbeing":1,"index":1,"patient":1,"health":2,"questionaire":1,"or":3,"beck":1,"depression":2,"inventory":1,"iii":1,"appropriate":1,"referral":1,"for":4,"cognitive":1,"behavioral":1,"therapy":2,"medical":2,"intervention":1,"should":3,"be":4,"considered":3,"when":1,"is":4,"present":1,"medications":3,"weight":4,"loss":4,"combination":1,"reduced":1,"calorie":1,"achieve":1,"sustain":1,"goals":1,"patients":1,"bmi":4,"kg":6,"abcd":4,"complication":1,"all":1,"see":1,"also":1,"pro":1,"fi":1,"les":1,"of":6,"algorithm":2,"fig":1,"caution":1,"required":1,"years":1,"age":1,"assessment":1,"bone":1,"sarcopenia":1,"important":1,"interventions":1,"metabolic":1,"bariatric":1,"procedures":1,"an":1,"effective":1,"option":1,"uncontrolled":1,"dm":1,"spite":1,"lifestyle":1,"complications":1,"including":1,"prediabetes":3,"that":1,"remedied":1,"cardiometabolic":1,"state":1,"resulting":1,"from":1,"failure":1,"pancreas":1,"compensate":1,"insulin":1,"resistance":1,"most":1,"often":1,"caused":1,"by":1,"overweight":1,"obesity":1,"prediabete":1},"len":211},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":6,"chunkId":"aace-2023-p6-c3","text":"including prediabetes, that can be remedied with weight loss. Prediabetes Algorithm Prediabetes is a cardiometabolic state resulting from failure of the pancreas to compensate for insulin resistance most often caused by overweight/obesity. Prediabetes continues to be de fi ned by the presence of impaired fasting glucose (IFG) (100-125 mg/dL) and/or impaired glucose tolerance (IGT) (140-199 mg/dL) at 2 hours of an oral glucose tolerance test (OGTT) with ingestion of 75 g of glucose. 9 A1C values of 5.7% to 6.4% may indicate chronic hyper- glycemia and the existence of prediabetes, but an OGTT should be used to con fi rm diagnosis (Algorithm Fig. 3). 9 Metabolic syndrome using National Cholesterol Education Program Adult Treatment Panel III criteria is considered a prediabetes equivalent, so that persons diagnosed with metabolic syndrome are at high risk for developing DM. 33,34 The prediabetes algorithm includes medical nutrition therapy (with reduction and modi fi cation of caloric intake to achieve weight loss in those who are overweight or obese), appropriately prescribed physical activity, avoidance of tobacco products, and adequate sleep quantity and quality. Additional topics commonly taught in DM self-management education and support programs outline principles of glycemia treatment options; BG monitoring; insulin dosage adjustments; acute complications of DM; and pre- ve","tf":{"33":1,"34":1,"75":1,"100":1,"125":1,"140":1,"199":1,"including":1,"prediabetes":7,"that":2,"can":1,"be":3,"remedied":1,"with":4,"weight":2,"loss":2,"algorithm":3,"is":2,"cardiometabolic":1,"state":1,"resulting":1,"from":1,"failure":1,"of":11,"the":4,"pancreas":1,"to":5,"compensate":1,"for":2,"insulin":2,"resistance":1,"most":1,"often":1,"caused":1,"by":2,"overweight":2,"obesity":1,"continues":1,"de":1,"fi":3,"ned":1,"presence":1,"impaired":2,"fasting":1,"glucose":4,"ifg":1,"mg":2,"dl":2,"and":7,"or":2,"tolerance":2,"igt":1,"at":2,"hours":1,"an":2,"oral":1,"test":1,"ogtt":2,"ingestion":1,"a1c":1,"values":1,"may":1,"indicate":1,"chronic":1,"hyper":1,"glycemia":2,"existence":1,"but":1,"should":1,"used":1,"con":1,"rm":1,"diagnosis":1,"fig":1,"metabolic":2,"syndrome":2,"using":1,"national":1,"cholesterol":1,"education":2,"program":1,"adult":1,"treatment":2,"panel":1,"iii":1,"criteria":1,"considered":1,"equivalent":1,"so":1,"persons":1,"diagnosed":1,"are":2,"high":1,"risk":1,"developing":1,"dm":3,"includes":1,"medical":1,"nutrition":1,"therapy":1,"reduction":1,"modi":1,"cation":1,"caloric":1,"intake":1,"achieve":1,"in":2,"those":1,"who":1,"obese":1,"appropriately":1,"prescribed":1,"physical":1,"activity":1,"avoidance":1,"tobacco":1,"products":1,"adequate":1,"sleep":1,"quantity":1,"quality":1,"additional":1,"topics":1,"commonly":1,"taught":1,"self":1,"management":1,"support":1,"programs":1,"outline":1,"principles":1,"options":1,"bg":1,"monitoring":1,"dosage":1,"adjustments":1,"acute":1,"complications":1,"pre":1,"ve":1},"len":206},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":6,"chunkId":"aace-2023-p6-c4","text":"ate sleep quantity and quality. Additional topics commonly taught in DM self-management education and support programs outline principles of glycemia treatment options; BG monitoring; insulin dosage adjustments; acute complications of DM; and pre- vention, recognition, and treatment of hypoglycemia. There are ample data that prediabetes confers an increased risk for progression to T2D and ASCVD. 35-37 Therefore, in addition to prevention of progression to overt T2D, other key goals in the treatment of prediabetes and metabolic syndrome should include weight loss and/or prevention of weight gain, mitigation of the CVD risk factors HTN and dyslipidemia, and prevention of progression of NAFLD. Although ABCD is a risk factor for prediabetes and subsequent DM, these are distinct entities that can occur independently, so the presence of prediabetes should alert the clinician to assess for additional complications of ABCD to guide clinical decision-making and therapeutic choices (see section on Complications-Centric Model for the Care of Persons with Overweight/Obesity [Algorithm Fig. 2]). If overweight/obesity and/or ABCD is absent, the possibility of other etiologies of elevated glucose beyond insulin resistance should be considered, including the potential for latent autoim- mune diabetes in adults, which would merit screening for type 1 diabetes antibodies. Weight loss is highly e","tf":{"35":1,"37":1,"ate":1,"sleep":1,"quantity":1,"and":12,"quality":1,"additional":2,"topics":1,"commonly":1,"taught":1,"in":4,"dm":3,"self":1,"management":1,"education":1,"support":1,"programs":1,"outline":1,"principles":1,"of":14,"glycemia":1,"treatment":3,"options":1,"bg":1,"monitoring":1,"insulin":2,"dosage":1,"adjustments":1,"acute":1,"complications":3,"pre":1,"vention":1,"recognition":1,"hypoglycemia":1,"there":1,"are":2,"ample":1,"data":1,"that":2,"prediabetes":4,"confers":1,"an":1,"increased":1,"risk":3,"for":6,"progression":3,"to":5,"t2d":2,"ascvd":1,"therefore":1,"addition":1,"prevention":3,"overt":1,"other":2,"key":1,"goals":1,"the":7,"metabolic":1,"syndrome":1,"should":3,"include":1,"weight":3,"loss":2,"or":2,"gain":1,"mitigation":1,"cvd":1,"factors":1,"htn":1,"dyslipidemia":1,"nafld":1,"although":1,"abcd":3,"is":3,"factor":1,"subsequent":1,"these":1,"distinct":1,"entities":1,"can":1,"occur":1,"independently":1,"so":1,"presence":1,"alert":1,"clinician":1,"assess":1,"guide":1,"clinical":1,"decision":1,"making":1,"therapeutic":1,"choices":1,"see":1,"section":1,"on":1,"centric":1,"model":1,"care":1,"persons":1,"with":1,"overweight":2,"obesity":2,"algorithm":1,"fig":1,"if":1,"absent":1,"possibility":1,"etiologies":1,"elevated":1,"glucose":1,"beyond":1,"resistance":1,"be":1,"considered":1,"including":1,"potential":1,"latent":1,"autoim":1,"mune":1,"diabetes":2,"adults":1,"which":1,"would":1,"merit":1,"screening":1,"type":1,"antibodies":1,"highly":1},"len":206},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":6,"chunkId":"aace-2023-p6-c5","text":"ossibility of other etiologies of elevated glucose beyond insulin resistance should be considered, including the potential for latent autoim- mune diabetes in adults, which would merit screening for type 1 diabetes antibodies. Weight loss is highly effective in preventing the progression of prediabetes to T2D. Lifestyle intervention to promote weight loss is essential, but the addition of weight-loss pharmacotherapies or bariatric procedures may need to be considered depending on pa- tient-speci fi c characteristics, including stage of obesity (see section on Complications-Centric Model for the Care of Persons with Overweight/Obesity [Algorithm Fig. 2]). Data have shown that weight reduction of 7% to 10% in persons with overweight/obesity is an important threshold, as this degree of weight loss has been demonstrated to be highly effective in preventing progression to T2D. 38,39 Lifestyle interventions that have been shown to reduce pro- gression to T2D 38,40,41 and decrease the risk of CVD should be a part of the strategy for all individuals with prediabetes independent of S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 310","tf":{"10":1,"29":1,"38":2,"39":1,"40":1,"41":1,"305":1,"310":1,"340":1,"2023":1,"ossibility":1,"of":11,"other":1,"etiologies":1,"elevated":1,"glucose":1,"beyond":1,"insulin":1,"resistance":1,"should":2,"be":4,"considered":2,"including":2,"the":6,"potential":1,"for":4,"latent":1,"autoim":1,"mune":1,"diabetes":2,"in":4,"adults":1,"which":1,"would":1,"merit":1,"screening":1,"type":1,"antibodies":1,"weight":5,"loss":4,"is":3,"highly":2,"effective":2,"preventing":2,"progression":2,"prediabetes":2,"to":8,"t2d":3,"lifestyle":2,"intervention":1,"promote":1,"essential":1,"but":1,"addition":1,"pharmacotherapies":1,"or":1,"bariatric":1,"procedures":1,"may":1,"need":1,"depending":1,"on":2,"pa":1,"tient":1,"speci":1,"fi":1,"characteristics":1,"stage":1,"obesity":3,"see":1,"section":1,"complications":1,"centric":1,"model":1,"care":1,"persons":2,"with":3,"overweight":2,"algorithm":1,"fig":1,"data":1,"have":2,"shown":2,"that":2,"reduction":1,"an":1,"important":1,"threshold":1,"as":1,"this":1,"degree":1,"has":1,"been":2,"demonstrated":1,"interventions":1,"reduce":1,"pro":1,"gression":1,"and":1,"decrease":1,"risk":1,"cvd":1,"part":1,"strategy":1,"all":1,"individuals":1,"independent":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":178},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":7,"chunkId":"aace-2023-p7-c0","text":"weight status. This should involve a healthy meal plan, such as the Mediterranean 42,43 or DASH diet. 44,45 Other diets including low-fat, low-carbohydrate, vegetarian, and vegan diets can also be consid- ered. Regular physical activity through a combination of aerobic and resistance exercises to achieve \u0015 150 minutes per week of moderately intense aerobic exercise over 3 to 5 sessions and resistance exercise consisting of single-set repetitions targeting the major muscle groups 2 to 3 times per week should be added. 46-50 Nonexercise active leisure activities should be encouraged to reduce sedentary behavior. Behavioral health should be incorpo- rated for optimal outcomes. Pharmacotherapy for weight loss should be considered when lifestyle measures alone are inadequate to achieve goal weight loss in those with ABCD. The U.S. Food and Drug Administration (FDA) \u0005 approved agents shown to have ef fi cacy to achieve weight-loss goals that impact prediabetes include semaglutide 2.4 mg, lir- aglutide 3 mg, and phentermine/topiramate-extended release (ER). 39,51-54 Tirzepatide is a weekly dual glucose-dependent insu- linotropic polypeptide (GIP) and GLP-1 RA that has been shown to cause substantial weight loss in persons with overweight/obesity but has not received regulatory approval for this indication at this time. 55 Other weight-loss medications approved by the FDA (naltrexone-E","tf":{"39":1,"42":1,"43":1,"44":1,"45":1,"46":1,"50":1,"51":1,"54":1,"55":1,"150":1,"weight":6,"status":1,"this":3,"should":5,"involve":1,"healthy":1,"meal":1,"plan":1,"such":1,"as":1,"the":4,"mediterranean":1,"or":1,"dash":1,"diet":1,"other":2,"diets":2,"including":1,"low":2,"fat":1,"carbohydrate":1,"vegetarian":1,"and":6,"vegan":1,"can":1,"also":1,"be":5,"consid":1,"ered":1,"regular":1,"physical":1,"activity":1,"through":1,"combination":1,"of":3,"aerobic":2,"resistance":2,"exercises":1,"to":8,"achieve":3,"minutes":1,"per":2,"week":2,"moderately":1,"intense":1,"exercise":2,"over":1,"sessions":1,"consisting":1,"single":1,"set":1,"repetitions":1,"targeting":1,"major":1,"muscle":1,"groups":1,"times":1,"added":1,"nonexercise":1,"active":1,"leisure":1,"activities":1,"encouraged":1,"reduce":1,"sedentary":1,"behavior":1,"behavioral":1,"health":1,"incorpo":1,"rated":1,"for":3,"optimal":1,"outcomes":1,"pharmacotherapy":1,"loss":5,"considered":1,"when":1,"lifestyle":1,"measures":1,"alone":1,"are":1,"inadequate":1,"goal":1,"in":2,"those":1,"with":2,"abcd":1,"food":1,"drug":1,"administration":1,"fda":2,"approved":2,"agents":1,"shown":2,"have":1,"ef":1,"fi":1,"cacy":1,"goals":1,"that":2,"impact":1,"prediabetes":1,"include":1,"semaglutide":1,"mg":2,"lir":1,"aglutide":1,"phentermine":1,"topiramate":1,"extended":1,"release":1,"er":1,"tirzepatide":1,"is":1,"weekly":1,"dual":1,"glucose":1,"dependent":1,"insu":1,"linotropic":1,"polypeptide":1,"gip":1,"glp":1,"ra":1,"has":2,"been":1,"cause":1,"substantial":1,"persons":1,"overweight":1,"obesity":1,"but":1,"not":1,"received":1,"regulatory":1,"approval":1,"indication":1,"at":1,"time":1,"medications":1,"by":1,"naltrexone":1},"len":209},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":7,"chunkId":"aace-2023-p7-c1","text":"e (GIP) and GLP-1 RA that has been shown to cause substantial weight loss in persons with overweight/obesity but has not received regulatory approval for this indication at this time. 55 Other weight-loss medications approved by the FDA (naltrexone-ER/bupropion-ER, short-term phentermine, or orlistat) could be considered if the above medications are not tolerated or are not accessible to the patient (see Algorithm Fig. 10, Pro fi les of Weight-Loss Medications). A nonpharmacologic option for persons with a BMI > 25 mg/kg 2 is hydrogel capsules, containing cellulose and citric acid, taken before meals, which achieved \u0015 5% weight loss in a majority of participants in placebo-controlled trials, including persons with prediabetes and T2D. 56 Additional devices that have regulatory approval by the FDA for the treatment of obesity, but not T2D, include intragastric balloons, transpyloric shuttle, and gastric aspiration. 57-59 Bariatric procedures are more effective than life- style interventions and medications in weight reduction and should be considered in those with prediabetes with a BMI > 35 kg/ m 2 . 60 For patients with prediabetes who do not meet the BMI criteria of overweight/obesity but who still require intervention for pre- diabetes after implementation of lifestyle modi fi cations, pharma- cologic agents with evidence of ef fi cacy in preventing progression to T2D should","tf":{"10":1,"25":1,"35":1,"55":1,"56":1,"57":1,"59":1,"60":1,"gip":1,"and":6,"glp":1,"ra":1,"that":2,"has":2,"been":1,"shown":1,"to":3,"cause":1,"substantial":1,"weight":5,"loss":4,"in":6,"persons":3,"with":7,"overweight":2,"obesity":3,"but":3,"not":5,"received":1,"regulatory":2,"approval":2,"for":5,"this":2,"indication":1,"at":1,"time":1,"other":1,"medications":4,"approved":1,"by":2,"the":6,"fda":2,"naltrexone":1,"er":2,"bupropion":1,"short":1,"term":1,"phentermine":1,"or":2,"orlistat":1,"could":1,"be":2,"considered":2,"if":1,"above":1,"are":3,"tolerated":1,"accessible":1,"patient":1,"see":1,"algorithm":1,"fig":1,"pro":1,"fi":3,"les":1,"of":6,"nonpharmacologic":1,"option":1,"bmi":3,"mg":1,"kg":2,"is":1,"hydrogel":1,"capsules":1,"containing":1,"cellulose":1,"citric":1,"acid":1,"taken":1,"before":1,"meals":1,"which":1,"achieved":1,"majority":1,"participants":1,"placebo":1,"controlled":1,"trials":1,"including":1,"prediabetes":3,"t2d":3,"additional":1,"devices":1,"have":1,"treatment":1,"include":1,"intragastric":1,"balloons":1,"transpyloric":1,"shuttle":1,"gastric":1,"aspiration":1,"bariatric":1,"procedures":1,"more":1,"effective":1,"than":1,"life":1,"style":1,"interventions":1,"reduction":1,"should":2,"those":1,"patients":1,"who":2,"do":1,"meet":1,"criteria":1,"still":1,"require":1,"intervention":1,"pre":1,"diabetes":1,"after":1,"implementation":1,"lifestyle":1,"modi":1,"cations":1,"pharma":1,"cologic":1,"agents":1,"evidence":1,"ef":1,"cacy":1,"preventing":1,"progression":1},"len":213},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":7,"chunkId":"aace-2023-p7-c2","text":" who do not meet the BMI criteria of overweight/obesity but who still require intervention for pre- diabetes after implementation of lifestyle modi fi cations, pharma- cologic agents with evidence of ef fi cacy in preventing progression to T2D should be considered. Although there are currently no drugs approved by the FDA with an indication to prevent the progression of prediabetes to T2D, metformin, pioglitazone, and acarbose have evidence of ef fi cacy in clinical trials. 38,61,62 Despite the interventions discussed above, persons with pre- diabetes are at high risk to progress to T2D. Clinicians are directed to sections on the Complications-Centric Algorithm for Glycemic Control (Algorithm Fig. 6) and the Glucose-Centric Algorithm for Glycemic Control (Algorithm Fig. 7) for further guidance on anti- hyperglycemic pharmacotherapy. ASCVD Risk Reduction Algorithm: Dyslipidemia Treatment of dyslipidemia (Algorithm Fig. 4) is an essential component of DM and prediabetes management. The combined effects of insulin de fi ciency, insulin resistance, and hyperglycemia cause multiple disruptions in lipoprotein metabolism. 63-68 This leads to an especially atherogenic state characterized by increased levels of apolipoprotein B (apo B) e containing particles, including Algorithm Fig. 3. Prediabetes Algorithm. S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e ","tf":{"29":1,"38":1,"61":1,"62":1,"63":1,"68":1,"305":1,"2023":1,"who":2,"do":1,"not":1,"meet":1,"the":7,"bmi":1,"criteria":1,"of":9,"overweight":1,"obesity":1,"but":1,"still":1,"require":1,"intervention":1,"for":4,"pre":2,"diabetes":2,"after":1,"implementation":1,"lifestyle":1,"modi":1,"fi":4,"cations":1,"pharma":1,"cologic":1,"agents":1,"with":3,"evidence":2,"ef":2,"cacy":2,"in":3,"preventing":1,"progression":2,"to":7,"t2d":3,"should":1,"be":1,"considered":1,"although":1,"there":1,"are":3,"currently":1,"no":1,"drugs":1,"approved":1,"by":2,"fda":1,"an":3,"indication":1,"prevent":1,"prediabetes":3,"metformin":1,"pioglitazone":1,"and":4,"acarbose":1,"have":1,"clinical":1,"trials":1,"despite":1,"interventions":1,"discussed":1,"above":1,"persons":1,"at":1,"high":1,"risk":2,"progress":1,"clinicians":1,"directed":1,"sections":1,"on":2,"complications":1,"centric":2,"algorithm":8,"glycemic":2,"control":2,"fig":4,"glucose":1,"further":1,"guidance":1,"anti":1,"hyperglycemic":1,"pharmacotherapy":1,"ascvd":1,"reduction":1,"dyslipidemia":2,"treatment":1,"is":1,"essential":1,"component":1,"dm":1,"management":1,"combined":1,"effects":1,"insulin":2,"de":1,"ciency":1,"resistance":1,"hyperglycemia":1,"cause":1,"multiple":1,"disruptions":1,"lipoprotein":1,"metabolism":1,"this":1,"leads":1,"especially":1,"atherogenic":1,"state":1,"characterized":1,"increased":1,"levels":1,"apolipoprotein":1,"apo":1,"containing":1,"particles":1,"including":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":198},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":7,"chunkId":"aace-2023-p7-c3","text":"to an especially atherogenic state characterized by increased levels of apolipoprotein B (apo B) e containing particles, including Algorithm Fig. 3. Prediabetes Algorithm. S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 311","tf":{"29":1,"305":1,"311":1,"340":1,"2023":1,"to":1,"an":1,"especially":1,"atherogenic":1,"state":1,"characterized":1,"by":1,"increased":1,"levels":1,"of":1,"apolipoprotein":1,"apo":1,"containing":1,"particles":1,"including":1,"algorithm":2,"fig":1,"prediabetes":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":31},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":8,"chunkId":"aace-2023-p8-c0","text":"triglyceride (TG)-rich very low-density lipoprotein (VLDL), inter- mediate-density lipoprotein, and remnant particles resulting in low levels of high-density lipoprotein-cholesterol (HDL-C) and increased levels of small, dense, low-density lipoprotein cholesterol (LDL-C). 69-71 Additional detailed guidance for management of dyslipidemia is available in the 2017 AACE Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease 72 and the 2020 Algorithm on the Management of Dyslipidemia and Prevention of Cardiovascular Disease. 73 Step 1. Assess Lipid Panel at First Visit or at Diagnosis All adult persons with prediabetes or T2D should be screened with a lipid panel at diagnosis and annually to assess ASCVD risk. The standard lipid panel includes total cholesterol, TG levels, HDL- C, and LDL-C. Fasting lipid panels are not necessary for therapeutic decisions, and nonfasting lipid panels may aid patient compliance with timely blood draws. 74 Secondary causes of dyslipidemia should be excluded. There may be a contributing underlying medical condition or medication, and intervention d if medically appropriate d may improve or resolve the abnormalities. Evaluation should begin with a medical, family, and nutrition history. Review all medications, over-the- counter medications, and supplements. Laboratory testing for thyroid, renal, and liver function may expose ","tf":{"69":1,"71":1,"72":1,"73":1,"74":1,"2017":1,"2020":1,"triglyceride":1,"tg":2,"rich":1,"very":1,"low":3,"density":4,"lipoprotein":4,"vldl":1,"inter":1,"mediate":1,"and":12,"remnant":1,"particles":1,"resulting":1,"in":2,"levels":3,"of":8,"high":1,"cholesterol":3,"hdl":2,"increased":1,"small":1,"dense":1,"ldl":2,"additional":1,"detailed":1,"guidance":1,"for":4,"management":3,"dyslipidemia":4,"is":1,"available":1,"the":6,"aace":1,"guidelines":1,"prevention":2,"cardiovascular":2,"disease":2,"algorithm":1,"on":1,"step":1,"assess":2,"lipid":5,"panel":3,"at":3,"first":1,"visit":1,"or":4,"diagnosis":2,"all":2,"adult":1,"persons":1,"with":4,"prediabetes":1,"t2d":1,"should":3,"be":3,"screened":1,"annually":1,"to":1,"ascvd":1,"risk":1,"standard":1,"includes":1,"total":1,"fasting":1,"panels":2,"are":1,"not":1,"necessary":1,"therapeutic":1,"decisions":1,"nonfasting":1,"may":4,"aid":1,"patient":1,"compliance":1,"timely":1,"blood":1,"draws":1,"secondary":1,"causes":1,"excluded":1,"there":1,"contributing":1,"underlying":1,"medical":2,"condition":1,"medication":1,"intervention":1,"if":1,"medically":1,"appropriate":1,"improve":1,"resolve":1,"abnormalities":1,"evaluation":1,"begin":1,"family":1,"nutrition":1,"history":1,"review":1,"medications":2,"over":1,"counter":1,"supplements":1,"laboratory":1,"testing":1,"thyroid":1,"renal":1,"liver":1,"function":1,"expose":1},"len":197},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":8,"chunkId":"aace-2023-p8-c1","text":"improve or resolve the abnormalities. Evaluation should begin with a medical, family, and nutrition history. Review all medications, over-the- counter medications, and supplements. Laboratory testing for thyroid, renal, and liver function may expose secondary causes. Persons with baseline LDL-C > 190 mg/dL should be investigated for familial hypercholesterolemia. With extremely high TG levels, a diagnosis of familial chylomicronemia syndrome is a possibility. With both disorders, referral to a lipid specialist for assessment and management is recommended. Additional secondary causes of dyslipidemia include medical conditions such as overweight or obesity, hyperglycemia, hypo- thyroidism, pregnancy, stage \u0015 3 CKD (particularly with albumin- uria), nephrotic syndrome, cholestatic disease, lipodystrophy, paraproteinemia (eg, dysgammaglobulinemia, multiple myeloma), and chronic in fl ammatory conditions (eg, rheumatoid arthritis, systemic lupus erythematosus). Medications that can cause or exacerbate dyslipidemia include oral estrogens and progestins, anabolic steroids, selective estrogen receptor modulators, highly active antiretroviral therapy such as protease inhibitors for the treatment of HIV, immunosuppressive medications (eg, cyclosporine, mammalian target of rapamycin kinase inhibitor), glucocorticoids, retinoids, interferon, taxol de- rivatives, L-asparaginase, cyclophosph","tf":{"190":1,"improve":1,"or":3,"resolve":1,"the":3,"abnormalities":1,"evaluation":1,"should":2,"begin":1,"with":5,"medical":2,"family":1,"and":6,"nutrition":1,"history":1,"review":1,"all":1,"medications":4,"over":1,"counter":1,"supplements":1,"laboratory":1,"testing":1,"for":4,"thyroid":1,"renal":1,"liver":1,"function":1,"may":1,"expose":1,"secondary":2,"causes":2,"persons":1,"baseline":1,"ldl":1,"mg":1,"dl":1,"be":1,"investigated":1,"familial":2,"hypercholesterolemia":1,"extremely":1,"high":1,"tg":1,"levels":1,"diagnosis":1,"of":4,"chylomicronemia":1,"syndrome":2,"is":2,"possibility":1,"both":1,"disorders":1,"referral":1,"to":1,"lipid":1,"specialist":1,"assessment":1,"management":1,"recommended":1,"additional":1,"dyslipidemia":2,"include":2,"conditions":2,"such":2,"as":2,"overweight":1,"obesity":1,"hyperglycemia":1,"hypo":1,"thyroidism":1,"pregnancy":1,"stage":1,"ckd":1,"particularly":1,"albumin":1,"uria":1,"nephrotic":1,"cholestatic":1,"disease":1,"lipodystrophy":1,"paraproteinemia":1,"eg":3,"dysgammaglobulinemia":1,"multiple":1,"myeloma":1,"chronic":1,"in":1,"fl":1,"ammatory":1,"rheumatoid":1,"arthritis":1,"systemic":1,"lupus":1,"erythematosus":1,"that":1,"can":1,"cause":1,"exacerbate":1,"oral":1,"estrogens":1,"progestins":1,"anabolic":1,"steroids":1,"selective":1,"estrogen":1,"receptor":1,"modulators":1,"highly":1,"active":1,"antiretroviral":1,"therapy":1,"protease":1,"inhibitors":1,"treatment":1,"hiv":1,"immunosuppressive":1,"cyclosporine":1,"mammalian":1,"target":1,"rapamycin":1,"kinase":1,"inhibitor":1,"glucocorticoids":1,"retinoids":1,"interferon":1,"taxol":1,"de":1,"rivatives":1,"asparaginase":1,"cyclophosph":1},"len":167},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":8,"chunkId":"aace-2023-p8-c2","text":"l therapy such as protease inhibitors for the treatment of HIV, immunosuppressive medications (eg, cyclosporine, mammalian target of rapamycin kinase inhibitor), glucocorticoids, retinoids, interferon, taxol de- rivatives, L-asparaginase, cyclophosphamide, atypical antipsychotic agents, beta-blockers, and thiazide diuretics. Although bile acid sequestrants can reduce cholesterol, these agents may also increase TG levels and should be used cautiously in patients with elevated TG levels. In addition, TG levels and LDL-C levels may change as glycemic control improves, so the impact of initiation of anti- hyperglycemic therapy must be taken into account when consid- ering adding or titrating antilipid therapies. Ancillary apo B measurement is recommended to assess for residual ASCVD risk from remnant and small dense lipoproteins not revealed with a standard lipid panel. 75-78 Apo B is superior for predication of ASCVD risk over LDL-C and is more accurate than non-HDL-C. 79,80 There are additional biomarkers, including high sensitivity C-reactive protein, 81 lipoprotein(a) (Lp[a]), 82 coronary artery calcium score, 83-86 and ankle-brachial index (ABI) 87 that are independently associated with increased risk of ASCVD events, and these may be helpful when the lipid management goal is unclear. 88 Algorithm Fig. 4. Atherosclerotic Cardiovascular Disease Risk Reduction Algorithm: Dyslipi","tf":{"75":1,"78":1,"79":1,"80":1,"81":1,"82":1,"83":1,"86":1,"87":1,"88":1,"therapy":2,"such":1,"as":2,"protease":1,"inhibitors":1,"for":3,"the":3,"treatment":1,"of":6,"hiv":1,"immunosuppressive":1,"medications":1,"eg":1,"cyclosporine":1,"mammalian":1,"target":1,"rapamycin":1,"kinase":1,"inhibitor":1,"glucocorticoids":1,"retinoids":1,"interferon":1,"taxol":1,"de":1,"rivatives":1,"asparaginase":1,"cyclophosphamide":1,"atypical":1,"antipsychotic":1,"agents":2,"beta":1,"blockers":1,"and":7,"thiazide":1,"diuretics":1,"although":1,"bile":1,"acid":1,"sequestrants":1,"can":1,"reduce":1,"cholesterol":1,"these":2,"may":3,"also":1,"increase":1,"tg":3,"levels":4,"should":1,"be":3,"used":1,"cautiously":1,"in":2,"patients":1,"with":3,"elevated":1,"addition":1,"ldl":2,"change":1,"glycemic":1,"control":1,"improves":1,"so":1,"impact":1,"initiation":1,"anti":1,"hyperglycemic":1,"must":1,"taken":1,"into":1,"account":1,"when":2,"consid":1,"ering":1,"adding":1,"or":1,"titrating":1,"antilipid":1,"therapies":1,"ancillary":1,"apo":2,"measurement":1,"is":4,"recommended":1,"to":1,"assess":1,"residual":1,"ascvd":3,"risk":4,"from":1,"remnant":1,"small":1,"dense":1,"lipoproteins":1,"not":1,"revealed":1,"standard":1,"lipid":2,"panel":1,"superior":1,"predication":1,"over":1,"more":1,"accurate":1,"than":1,"non":1,"hdl":1,"there":1,"are":2,"additional":1,"biomarkers":1,"including":1,"high":1,"sensitivity":1,"reactive":1,"protein":1,"lipoprotein":1,"lp":1,"coronary":1,"artery":1,"calcium":1,"score":1,"ankle":1,"brachial":1,"index":1,"abi":1,"that":1,"independently":1,"associated":1,"increased":1,"events":1,"helpful":1,"management":1,"goal":1,"unclear":1,"algorithm":2,"fig":1,"atherosclerotic":1,"cardiovascular":1,"disease":1,"reduction":1,"dyslipi":1},"len":197},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":8,"chunkId":"aace-2023-p8-c3","text":"al index (ABI) 87 that are independently associated with increased risk of ASCVD events, and these may be helpful when the lipid management goal is unclear. 88 Algorithm Fig. 4. Atherosclerotic Cardiovascular Disease Risk Reduction Algorithm: Dyslipidemia. S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 312","tf":{"29":1,"87":1,"88":1,"305":1,"312":1,"340":1,"2023":1,"al":2,"index":1,"abi":1,"that":1,"are":1,"independently":1,"associated":1,"with":1,"increased":1,"risk":2,"of":1,"ascvd":1,"events":1,"and":1,"these":1,"may":1,"be":1,"helpful":1,"when":1,"the":1,"lipid":1,"management":1,"goal":1,"is":1,"unclear":1,"algorithm":2,"fig":1,"atherosclerotic":1,"cardiovascular":1,"disease":1,"reduction":1,"dyslipidemia":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"endocrine":1,"practice":1},"len":48},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":9,"chunkId":"aace-2023-p9-c0","text":"When the decision to initiate or intensify treatment is uncertain, such as for a person with prediabetes and without previous CV events, a risk calculator can also be helpful to estimate 10-year risk for ASCVD (Table 1). Step 2. Initiate Lifestyle Intervention The most common secondary cause of dyslipidemia is a diet high in carbohydrates and/or simple sugars combined with a sedentary lifestyle. Excessive alcohol consumption also contributes to dyslipidemia, particularly hypertriglyceridemia; minimization of alcohol consumption should be encouraged. Persons with dyslipi- demia should be provided with tools to promote weight loss with caloric deprivation if overweight/obese. Loss of body weight \u0015 5% improves TG levels and continued further decline in TG levels is noted even at > 15% weight loss. 89 Counseling on lifestyle in- terventions is essential and should include advice on a healthful diet (whole-foods, plant-based, Mediterranean, and DASH diets); avoidance of processed foods, saturated fat, simple carbohydrates, white starches, and added sugars; and increased intake of dietary fi ber (30-40 g per day) and lean proteins (eg, fi sh, lean meat, and skinless poultry). 73 Exercise regimens should include a minimum of 150 minutes per week of moderate-intensity activity divided into 3 to 5 sessions per week, along with \u0015 2 resistance training sessions per week. 73 Step 3. Determ","tf":{"10":1,"15":1,"30":1,"40":1,"73":2,"89":1,"150":1,"when":1,"the":2,"decision":1,"to":5,"initiate":2,"or":2,"intensify":1,"treatment":1,"is":4,"uncertain":1,"such":1,"as":1,"for":2,"person":1,"with":6,"prediabetes":1,"and":9,"without":1,"previous":1,"cv":1,"events":1,"risk":2,"calculator":1,"can":1,"also":2,"be":3,"helpful":1,"estimate":1,"year":1,"ascvd":1,"table":1,"step":2,"lifestyle":3,"intervention":1,"most":1,"common":1,"secondary":1,"cause":1,"of":7,"dyslipidemia":2,"diet":2,"high":1,"in":3,"carbohydrates":2,"simple":2,"sugars":2,"combined":1,"sedentary":1,"excessive":1,"alcohol":2,"consumption":2,"contributes":1,"particularly":1,"hypertriglyceridemia":1,"minimization":1,"should":4,"encouraged":1,"persons":1,"dyslipi":1,"demia":1,"provided":1,"tools":1,"promote":1,"weight":3,"loss":3,"caloric":1,"deprivation":1,"if":1,"overweight":1,"obese":1,"body":1,"improves":1,"tg":2,"levels":2,"continued":1,"further":1,"decline":1,"noted":1,"even":1,"at":1,"counseling":1,"on":2,"terventions":1,"essential":1,"include":2,"advice":1,"healthful":1,"whole":1,"foods":2,"plant":1,"based":1,"mediterranean":1,"dash":1,"diets":1,"avoidance":1,"processed":1,"saturated":1,"fat":1,"white":1,"starches":1,"added":1,"increased":1,"intake":1,"dietary":1,"fi":2,"ber":1,"per":4,"day":1,"lean":2,"proteins":1,"eg":1,"sh":1,"meat":1,"skinless":1,"poultry":1,"exercise":1,"regimens":1,"minimum":1,"minutes":1,"week":3,"moderate":1,"intensity":1,"activity":1,"divided":1,"into":1,"sessions":2,"along":1,"resistance":1,"training":1,"determ":1},"len":204},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":9,"chunkId":"aace-2023-p9-c1","text":" sh, lean meat, and skinless poultry). 73 Exercise regimens should include a minimum of 150 minutes per week of moderate-intensity activity divided into 3 to 5 sessions per week, along with \u0015 2 resistance training sessions per week. 73 Step 3. Determine Patient-Speci fi c Lipid Targets Treatment targets are based on the duration of T2D and the presence of traditional ASCVD risk factors, including advancing age, HTN, CKD stage \u0015 3, smoking, family history of premature ASCVD in males < 55 years of age and females < 65 years of age, low HDL-C, or high non e HDL-C. Assessment of the patient  s risk category helps to determine lipid treatment targets and direct appropriate lipid- lowering therapy. Patients with prediabetes or T2D can be classi fi ed to set goals of therapy as follows: \u000f High risk ( < 10% 10-year risk): T2D duration < 10 years and < 2 additional traditional ASCVD risk factors with no target organ damage o Goal: LDL-C < 100 mg/dL, apo B < 90 mg/dL, and non e HDL-C < 130 mg/dL \u000f Very high risk (10%-20% 10-year risk): T2D > 10 years with \u0015 2 traditional ASCVD risk factors and no target organ damage o Goal: LDL-C < 70 mg/dL, apo B < 80 mg/dL, and non e HDL-C < 100 mg/dL \u000f Extreme risk ( > 20% 10-year risk): T2D or prediabetes plus established ASCVD or target organ damage (left ventricular [LV] systolic or diastolic dysfunction, estimated glomerular fi ltration rate [eGF","tf":{"10":7,"20":2,"55":1,"65":1,"70":1,"73":2,"80":1,"90":1,"100":2,"130":1,"150":1,"sh":1,"lean":1,"meat":1,"and":8,"skinless":1,"poultry":1,"exercise":1,"regimens":1,"should":1,"include":1,"minimum":1,"of":9,"minutes":1,"per":3,"week":3,"moderate":1,"intensity":1,"activity":1,"divided":1,"into":1,"to":3,"sessions":2,"along":1,"with":4,"resistance":1,"training":1,"step":1,"determine":2,"patient":2,"speci":1,"fi":3,"lipid":3,"targets":3,"treatment":2,"are":1,"based":1,"on":1,"the":3,"duration":2,"t2d":5,"presence":1,"traditional":3,"ascvd":5,"risk":10,"factors":3,"including":1,"advancing":1,"age":3,"htn":1,"ckd":1,"stage":1,"smoking":1,"family":1,"history":1,"premature":1,"in":1,"males":1,"years":4,"females":1,"low":1,"hdl":4,"or":5,"high":3,"non":3,"assessment":1,"category":1,"helps":1,"direct":1,"appropriate":1,"lowering":1,"therapy":2,"patients":1,"prediabetes":2,"can":1,"be":1,"classi":1,"ed":1,"set":1,"goals":1,"as":1,"follows":1,"year":3,"additional":1,"no":2,"target":3,"organ":3,"damage":3,"goal":2,"ldl":2,"mg":6,"dl":6,"apo":2,"very":1,"extreme":1,"plus":1,"established":1,"left":1,"ventricular":1,"lv":1,"systolic":1,"diastolic":1,"dysfunction":1,"estimated":1,"glomerular":1,"ltration":1,"rate":1,"egf":1},"len":225},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":9,"chunkId":"aace-2023-p9-c2","text":" apo B < 80 mg/dL, and non e HDL-C < 100 mg/dL \u000f Extreme risk ( > 20% 10-year risk): T2D or prediabetes plus established ASCVD or target organ damage (left ventricular [LV] systolic or diastolic dysfunction, estimated glomerular fi ltration rate [eGFR] < 45 mL/min/1.73 m 2 , or ABI < 0.9) o Goal: LDL-C < 55 mg/dL, apo B < 70 mg/dL, and non e HDL-C < 90 mg/dL Step 4. Initiate a Statin as First-Line Therapy Unless contraindicated, a statin should be used as the fi rst-line therapy for dyslipidemia in persons with T2D. High-risk patients (T2D with < 10% 10-year risk) should be started on moderate- intensity statin therapy, which results in an LDL-C reduction in the range of 30% to 40% (Table 2). For patients with prediabetes, the bene fi ts of statin therapy should be weighed in the context of their ASCVD risk score and the minor risk of progression to T2D with statin use. 90,91 For persons at very high risk (10%-20% 10- year risk) and extreme risk ( > 20% 10-year risk), high-intensity statin therapy, which lowers LDL-C by 50% to 60%, should be started regardless of baseline LDL-C level (Table 2). 9,92,93 Residual risk can persist even with maximally tolerated statin therapy in persons with multiple risk factors and persons with stable clinical ASCVD. Lipids should initially be monitored at 6- to 12-week intervals to determine if intensi fi cation of therapy is needed and then at ","tf":{"10":6,"12":1,"20":3,"30":1,"40":1,"45":1,"50":1,"55":1,"60":1,"70":1,"73":1,"80":1,"90":2,"91":1,"92":1,"93":1,"100":1,"apo":2,"mg":5,"dl":5,"and":6,"non":2,"hdl":2,"extreme":2,"risk":12,"year":4,"t2d":4,"or":4,"prediabetes":2,"plus":1,"established":1,"ascvd":3,"target":1,"organ":1,"damage":1,"left":1,"ventricular":1,"lv":1,"systolic":1,"diastolic":1,"dysfunction":1,"estimated":1,"glomerular":1,"fi":4,"ltration":1,"rate":1,"egfr":1,"ml":1,"min":1,"abi":1,"goal":1,"ldl":4,"step":1,"initiate":1,"statin":7,"as":2,"first":1,"line":2,"therapy":7,"unless":1,"contraindicated":1,"should":5,"be":5,"used":1,"the":5,"rst":1,"for":3,"dyslipidemia":1,"in":5,"persons":4,"with":7,"high":3,"patients":2,"started":2,"on":1,"moderate":1,"intensity":2,"which":2,"results":1,"an":1,"reduction":1,"range":1,"of":6,"to":5,"table":2,"bene":1,"ts":1,"weighed":1,"context":1,"their":1,"score":1,"minor":1,"progression":1,"use":1,"at":3,"very":1,"lowers":1,"by":1,"regardless":1,"baseline":1,"level":1,"residual":1,"can":1,"persist":1,"even":1,"maximally":1,"tolerated":1,"multiple":1,"factors":1,"stable":1,"clinical":1,"lipids":1,"initially":1,"monitored":1,"week":1,"intervals":1,"determine":1,"if":1,"intensi":1,"cation":1,"is":1,"needed":1,"then":1},"len":236},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":9,"chunkId":"aace-2023-p9-c3","text":" with maximally tolerated statin therapy in persons with multiple risk factors and persons with stable clinical ASCVD. Lipids should initially be monitored at 6- to 12-week intervals to determine if intensi fi cation of therapy is needed and then at less frequent intervals (eg, 6 months) once goals are attained. Some patients may manifest statin intolerance. Statin-associ- ated muscle symptoms (SAMS) are characterized by bilateral muscle symptoms d pain, weakness, cramping, and stiff- ness d associated with onset of statin use, but the causality is not always clear. 94,95 The incidence of statin intolerance is in the range of 5% to 20%, with lower rates in placebo-controlled trials; clinical trials with direct queries about muscle symptoms did not show a signi fi cant difference in the rates of muscle symptoms among statin and placebo groups. 94 SAMS may resolve with discontinuation and recur when rechallenged with the same or alternative statin. Management includes acknowledging the patient  s symptoms and considering the addition of creatine kinase (CK). The FDA e accepted de fi nition of statin-induced myopathy is pain or weakness accompanied by a CK level > 10-fold higher than the upper limit of normal laboratory range, but this is rare ( < 0.1% over placebo). The risk of severe rhabdomyolysis with CK > 40-fold, the upper limit of normal is approximately 1 to 4 in 10,000 p","tf":{"10":2,"12":1,"20":1,"40":1,"94":2,"95":1,"with":9,"maximally":1,"tolerated":1,"statin":8,"therapy":2,"in":5,"persons":2,"multiple":1,"risk":2,"factors":1,"and":6,"stable":1,"clinical":2,"ascvd":1,"lipids":1,"should":1,"initially":1,"be":1,"monitored":1,"at":2,"to":4,"week":1,"intervals":2,"determine":1,"if":1,"intensi":1,"fi":3,"cation":1,"of":10,"is":6,"needed":1,"then":1,"less":1,"frequent":1,"eg":1,"months":1,"once":1,"goals":1,"are":2,"attained":1,"some":1,"patients":1,"may":2,"manifest":1,"intolerance":2,"associ":1,"ated":1,"muscle":4,"symptoms":5,"sams":2,"characterized":1,"by":2,"bilateral":1,"pain":2,"weakness":2,"cramping":1,"stiff":1,"ness":1,"associated":1,"onset":1,"use":1,"but":2,"the":11,"causality":1,"not":2,"always":1,"clear":1,"incidence":1,"range":2,"lower":1,"rates":2,"placebo":3,"controlled":1,"trials":2,"direct":1,"queries":1,"about":1,"did":1,"show":1,"signi":1,"cant":1,"difference":1,"among":1,"groups":1,"resolve":1,"discontinuation":1,"recur":1,"when":1,"rechallenged":1,"same":1,"or":2,"alternative":1,"management":1,"includes":1,"acknowledging":1,"patient":1,"considering":1,"addition":1,"creatine":1,"kinase":1,"ck":3,"fda":1,"accepted":1,"de":1,"nition":1,"induced":1,"myopathy":1,"accompanied":1,"level":1,"fold":2,"higher":1,"than":1,"upper":2,"limit":2,"normal":2,"laboratory":1,"this":1,"rare":1,"over":1,"severe":1,"rhabdomyolysis":1,"approximately":1,"000":1},"len":218},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":9,"chunkId":"aace-2023-p9-c4","text":"ss accompanied by a CK level > 10-fold higher than the upper limit of normal laboratory range, but this is rare ( < 0.1% over placebo). The risk of severe rhabdomyolysis with CK > 40-fold, the upper limit of normal is approximately 1 to 4 in 10,000 per year. 94 Risk factors for myopathy include age > 65 years, female sex, low BMI, East Asian heritage, history of muscle symptoms, impaired renal and/or hepatic function, DM, HIV infection, concomitant medications (eg, fi brates, erythromycin, fl uconazole), vitamin D de fi ciency, hypothyroidism, and acute infection. 73 Drug in- teractions should be considered, particularly for concomitant medications and statins that have high fi rst-pass metabolism and are metabolized through CYP3A4 (eg, simvastatin, lovastatin). When symptoms resolve, and if myopathy was not severe, a rechallenge with a lower dose or less frequent dosing (1-3 times per Table 1 ASCVD 10-year Risk Calculators Reynolds CVD Risk Score http://www.reynoldsriskscore.org/ Framingham CVD Risk Score https://www.framinghamheartstudy. org/fhs-risk-functions/hard-coronary- heart-disease-10-year-risk/ American College of Cardiology/ American Heart Association Pooled Cohort CVD Risk Calculator http://www.cvriskcalculator.com/ Multi-Ethnic Study of Atherosclerosis (MESA) Risk Score https://www.mesa-nhlbi.org/ MESACHDRisk/MesaRiskScore/ RiskScore.aspx Table 2 Intensity of Stati","tf":{"10":4,"40":1,"65":1,"73":1,"94":1,"ss":1,"accompanied":1,"by":1,"ck":2,"level":1,"fold":2,"higher":1,"than":1,"the":3,"upper":2,"limit":2,"of":7,"normal":2,"laboratory":1,"range":1,"but":1,"this":1,"is":2,"rare":1,"over":1,"placebo":1,"risk":9,"severe":2,"rhabdomyolysis":1,"with":2,"approximately":1,"to":1,"in":2,"000":1,"per":2,"year":3,"factors":1,"for":2,"myopathy":2,"include":1,"age":1,"years":1,"female":1,"sex":1,"low":1,"bmi":1,"east":1,"asian":1,"heritage":1,"history":1,"muscle":1,"symptoms":2,"impaired":1,"renal":1,"and":5,"or":2,"hepatic":1,"function":1,"dm":1,"hiv":1,"infection":2,"concomitant":2,"medications":2,"eg":2,"fi":3,"brates":1,"erythromycin":1,"fl":1,"uconazole":1,"vitamin":1,"de":1,"ciency":1,"hypothyroidism":1,"acute":1,"drug":1,"teractions":1,"should":1,"be":1,"considered":1,"particularly":1,"statins":1,"that":1,"have":1,"high":1,"rst":1,"pass":1,"metabolism":1,"are":1,"metabolized":1,"through":1,"cyp3a4":1,"simvastatin":1,"lovastatin":1,"when":1,"resolve":1,"if":1,"was":1,"not":1,"rechallenge":1,"lower":1,"dose":1,"less":1,"frequent":1,"dosing":1,"times":1,"table":2,"ascvd":1,"calculators":1,"reynolds":1,"cvd":3,"score":3,"http":2,"www":4,"reynoldsriskscore":1,"org":3,"framingham":1,"https":2,"framinghamheartstudy":1,"fhs":1,"functions":1,"hard":1,"coronary":1,"heart":2,"disease":1,"american":2,"college":1,"cardiology":1,"association":1,"pooled":1,"cohort":1,"calculator":1,"cvriskcalculator":1,"com":1,"multi":1,"ethnic":1,"study":1,"atherosclerosis":1,"mesa":2,"nhlbi":1,"mesachdrisk":1,"mesariskscore":1,"riskscore":1,"aspx":1,"intensity":1,"stati":1},"len":205},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":9,"chunkId":"aace-2023-p9-c5","text":"gy/ American Heart Association Pooled Cohort CVD Risk Calculator http://www.cvriskcalculator.com/ Multi-Ethnic Study of Atherosclerosis (MESA) Risk Score https://www.mesa-nhlbi.org/ MESACHDRisk/MesaRiskScore/ RiskScore.aspx Table 2 Intensity of Statin Therapy Low Intensity Moderate Intensity High Intensity Simvastatin 10 mg 10 mg 20-40 mg  Pravastatin 10-20 mg 10-20 mg 40-80 mg  Lovastatin 20 mg 20 mg 40 mg  Fluvastatin 20-40 mg 20-40 mg 40 mg BID/80 mg XL  Pitavastatin 1 mg 1 mg 2-4 mg  Atorvastatin  10-20 mg 40-80 mg Rosuvastatin  5-10 mg 20-40 mg Modi fi ed from 9,92,93 . S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 313","tf":{"10":6,"20":9,"29":1,"40":8,"80":3,"92":1,"93":1,"305":1,"313":1,"340":1,"2023":1,"gy":1,"american":1,"heart":1,"association":1,"pooled":1,"cohort":1,"cvd":1,"risk":2,"calculator":1,"http":1,"www":2,"cvriskcalculator":1,"com":1,"multi":1,"ethnic":1,"study":1,"of":2,"atherosclerosis":1,"mesa":2,"score":1,"https":1,"nhlbi":1,"org":1,"mesachdrisk":1,"mesariskscore":1,"riskscore":1,"aspx":1,"table":1,"intensity":4,"statin":1,"therapy":1,"low":1,"moderate":1,"high":1,"simvastatin":1,"mg":20,"pravastatin":1,"lovastatin":1,"fluvastatin":1,"bid":1,"xl":1,"pitavastatin":1,"atorvastatin":1,"rosuvastatin":1,"modi":1,"fi":1,"ed":1,"from":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":114},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":10,"chunkId":"aace-2023-p10-c0","text":"week), or use of a hydrophilic statin with less association with myopathy (eg, pitavastatin, fl uvastatin) may allow continuation of statin therapy. Even though observational studies showed that normalization of 25-hydroxy-vitamin D 3 levels 96 may help with statin-induced myopathy, a secondary analysis of the VITamin D and OmegA-3 Trial (VITAL) showed that the frequency of statin- induced myopathy did not differ with vitamin D supplementation compared with placebo. 97 However, adding coenzyme Q10 sup- plementation can be considered. 96 Step 5A. Intensify Therapy to Achieve Lipid Target In persons with T2D, additional laboratory testing of lipid levels should be undertaken at frequent intervals (every 6-12 weeks) to direct titration of the statin or addition of an adjunct therapy in order to achieve lipid targets; less frequent testing intervals can be considered once lipid goals are consistently achieved. If lipid targets cannot be achieved with maximally tolerated statin therapy, then the addition of the cholesterol absorption inhibitor ezetimibe (10 mg/day) should be considered. If treatment goals are not met on a maximally tolerated statin combined with ezetimibe, additional therapy with a bile acid sequestrant (colesevelam, colestipol, cholestyramine) or bempedoic acid (adenosine triphosphate-cit- rate lyase inhibitor) is an option. In extreme risk patients with lipid valu","tf":{"10":1,"12":1,"25":1,"96":2,"97":1,"week":1,"or":3,"use":1,"of":9,"hydrophilic":1,"statin":7,"with":10,"less":2,"association":1,"myopathy":3,"eg":1,"pitavastatin":1,"fl":1,"uvastatin":1,"may":2,"allow":1,"continuation":1,"therapy":5,"even":1,"though":1,"observational":1,"studies":1,"showed":2,"that":2,"normalization":1,"hydroxy":1,"vitamin":3,"levels":2,"help":1,"induced":2,"secondary":1,"analysis":1,"the":5,"and":1,"omega":1,"trial":1,"vital":1,"frequency":1,"did":1,"not":2,"differ":1,"supplementation":1,"compared":1,"placebo":1,"however":1,"adding":1,"coenzyme":1,"q10":1,"sup":1,"plementation":1,"can":2,"be":5,"considered":3,"step":1,"5a":1,"intensify":1,"to":3,"achieve":2,"lipid":6,"target":1,"in":3,"persons":1,"t2d":1,"additional":2,"laboratory":1,"testing":2,"should":2,"undertaken":1,"at":1,"frequent":2,"intervals":2,"every":1,"weeks":1,"direct":1,"titration":1,"addition":2,"an":2,"adjunct":1,"order":1,"targets":2,"once":1,"goals":2,"are":2,"consistently":1,"achieved":2,"if":2,"cannot":1,"maximally":2,"tolerated":2,"then":1,"cholesterol":1,"absorption":1,"inhibitor":2,"ezetimibe":2,"mg":1,"day":1,"treatment":1,"met":1,"on":1,"combined":1,"bile":1,"acid":2,"sequestrant":1,"colesevelam":1,"colestipol":1,"cholestyramine":1,"bempedoic":1,"adenosine":1,"triphosphate":1,"cit":1,"rate":1,"lyase":1,"is":1,"option":1,"extreme":1,"risk":1,"patients":1,"valu":1},"len":202},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":10,"chunkId":"aace-2023-p10-c1","text":"ated statin combined with ezetimibe, additional therapy with a bile acid sequestrant (colesevelam, colestipol, cholestyramine) or bempedoic acid (adenosine triphosphate-cit- rate lyase inhibitor) is an option. In extreme risk patients with lipid values above targets on maximal high-intensity statin in combi- nation with the above-mentioned add-on therapies, there may be a need for more aggressive therapy with a proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) or inclisiran (PCSK9 siRNA), with consideration of approved indications and access. Step 5B. Hypertriglyceridemia Management Management of hypertriglyceridemia also is important for optimal lipid levels with a goal of < 150 mg/dL in persons with T2D. If needed, pioglitazone and/or insulin may improve both glycemic control and TG levels. In persons with fasting TG level of > 200 mg/dL despite a maximally tolerated statin, optimal glucose control, tight adherence to a healthy diet (eg, avoidance of simple carbohydrates, fruit juices, and alcohol), feno fi brate, and/or high-dose prescription grade omega-3 fatty acid may help to achieve goals for TG levels and non e HDL-C. Over-the-counter fi sh oil supplements are not approved by the FDA for hypertriglyceridemia. In persons with a fasting TG level of > 200 mg/dL despite a maximally tolerated statin, optimal glucose control, tight adherence to a healthy diet, ","tf":{"150":1,"200":2,"ated":1,"statin":4,"combined":1,"with":10,"ezetimibe":1,"additional":1,"therapy":2,"bile":1,"acid":3,"sequestrant":1,"colesevelam":1,"colestipol":1,"cholestyramine":1,"or":4,"bempedoic":1,"adenosine":1,"triphosphate":1,"cit":1,"rate":1,"lyase":1,"inhibitor":2,"is":2,"an":1,"option":1,"in":5,"extreme":1,"risk":1,"patients":1,"lipid":2,"values":1,"above":2,"targets":1,"on":2,"maximal":1,"high":2,"intensity":1,"combi":1,"nation":1,"the":3,"mentioned":1,"add":1,"therapies":1,"there":1,"may":3,"be":1,"need":1,"for":4,"more":1,"aggressive":1,"proprotein":1,"convertase":1,"subtilisin":1,"kexin":1,"type":1,"pcsk9i":1,"inclisiran":1,"pcsk9":1,"sirna":1,"consideration":1,"of":6,"approved":2,"indications":1,"and":6,"access":1,"step":1,"5b":1,"hypertriglyceridemia":3,"management":2,"also":1,"important":1,"optimal":3,"levels":3,"goal":1,"mg":3,"dl":3,"persons":3,"t2d":1,"if":1,"needed":1,"pioglitazone":1,"insulin":1,"improve":1,"both":1,"glycemic":1,"control":3,"tg":4,"fasting":2,"level":2,"despite":2,"maximally":2,"tolerated":2,"glucose":2,"tight":2,"adherence":2,"to":3,"healthy":2,"diet":2,"eg":1,"avoidance":1,"simple":1,"carbohydrates":1,"fruit":1,"juices":1,"alcohol":1,"feno":1,"fi":2,"brate":1,"dose":1,"prescription":1,"grade":1,"omega":1,"fatty":1,"help":1,"achieve":1,"goals":1,"non":1,"hdl":1,"over":1,"counter":1,"sh":1,"oil":1,"supplements":1,"are":1,"not":1,"by":1,"fda":1},"len":206},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":10,"chunkId":"aace-2023-p10-c2","text":"e HDL-C. Over-the-counter fi sh oil supplements are not approved by the FDA for hypertriglyceridemia. In persons with a fasting TG level of > 200 mg/dL despite a maximally tolerated statin, optimal glucose control, tight adherence to a healthy diet, feno fi - brate, and/or high-dose prescription grade omega-3 fatty acid may help to achieve goals for TG levels and non e HDL-C. However, the CV risk reduction with addition of fi brates, on the background of an optimally dosed statin, for TG levels > 200 to 500 mg/dL has not been de fi nitively established. The incidence of CV events in T2D with TG levels > 200 was not reduced by pema fi brate in the Pema fi brate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Pa- tients with Diabetes (PROMINENT) trial, despite lowering of TG, VLDL, remnant cholesterol, and Apo C-III levels. 98 However, sub- group analysis and meta-analyses of trials with fi brates have shown improved ASCVD outcomes in persons with elevated TG levels ( > 200 mg/dL) and/or HDL-C ( < 40 mg/dL). 9,72,99-101 The Reduction of Cardiovascular Events with Icosapent Ethyl - Intervention Trial (REDUCE-IT) demonstrated that the addition of icosapent ethyl (IPE) to statin therapy positively reduced CVD events by 25% in T2D participants with TG levels > 135 mg/dL and ASCVD or age > 50 years and a second CV risk factor, although this effect was independent of TG ","tf":{"25":1,"40":1,"50":1,"72":1,"98":1,"99":1,"101":1,"135":1,"200":4,"500":1,"hdl":3,"over":1,"the":8,"counter":1,"fi":7,"sh":1,"oil":1,"supplements":1,"are":1,"not":3,"approved":1,"by":4,"fda":1,"for":3,"hypertriglyceridemia":1,"in":6,"persons":2,"with":8,"fasting":1,"tg":8,"level":1,"of":9,"mg":5,"dl":5,"despite":2,"maximally":1,"tolerated":1,"statin":3,"optimal":1,"glucose":1,"control":1,"tight":1,"adherence":1,"to":5,"healthy":1,"diet":1,"feno":1,"brate":3,"and":7,"or":3,"high":1,"dose":1,"prescription":1,"grade":1,"omega":1,"fatty":1,"acid":1,"may":1,"help":1,"achieve":1,"goals":1,"levels":6,"non":1,"however":2,"cv":3,"risk":2,"reduction":2,"addition":2,"brates":2,"on":1,"background":1,"an":1,"optimally":1,"dosed":1,"has":1,"been":1,"de":1,"nitively":1,"established":1,"incidence":1,"events":3,"t2d":2,"was":2,"reduced":2,"pema":2,"reduce":2,"cardiovascular":2,"outcomes":2,"reducing":1,"triglycerides":1,"pa":1,"tients":1,"diabetes":1,"prominent":1,"trial":2,"lowering":1,"vldl":1,"remnant":1,"cholesterol":1,"apo":1,"iii":1,"sub":1,"group":1,"analysis":1,"meta":1,"analyses":1,"trials":1,"have":1,"shown":1,"improved":1,"ascvd":2,"elevated":1,"icosapent":2,"ethyl":2,"intervention":1,"it":1,"demonstrated":1,"that":1,"ipe":1,"therapy":1,"positively":1,"cvd":1,"participants":1,"age":1,"years":1,"second":1,"factor":1,"although":1,"this":1,"effect":1,"independent":1},"len":234},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":10,"chunkId":"aace-2023-p10-c3","text":"ated that the addition of icosapent ethyl (IPE) to statin therapy positively reduced CVD events by 25% in T2D participants with TG levels > 135 mg/dL and ASCVD or age > 50 years and a second CV risk factor, although this effect was independent of TG level lowering. 102 Potential concerns about the magnitude of the bene fi cial effect of IPE with use of the mineral oil placebo in REDUCE-IT have been voiced, but overall, IPE should be considered if TG levels are > 135 mg/dL in persons with T2D and with established ASCVD or \u0015 2 additional traditional CVD risk factors. For severe hypertriglyceridemia (TG levels \u0015 1000 mg/dL), a very low-fat diet may be required in addition to a fi brate and/or pre- scription omega-3 fatty acid. For refractory cases, if the fasting TG level remains > 1000 mg/dL, niacin may be needed to lower TG levels and reduce the risk of pancreatitis. Notably, niacin may lower TG levels and Lp(a) but does not reduce ASCVD and can worsen glycemia. ASCVD Risk Reduction Algorithm: Hypertension HTN is prevalent among persons with T2D and increases the risk of macrovascular and microvascular complications of DM. 103 The coexistence of prediabetes and HTN also increases the risk of CV events. 104 Data from the UK Prospective Diabetes Study (UKPDS) demonstrated that increased BP control in persons with T2D decreased the risk of death related to DM and micro- and macro- ","tf":{"25":1,"50":1,"102":1,"103":1,"104":1,"135":2,"1000":2,"ated":1,"that":2,"the":11,"addition":2,"of":11,"icosapent":1,"ethyl":1,"ipe":3,"to":4,"statin":1,"therapy":1,"positively":1,"reduced":1,"cvd":2,"events":2,"by":1,"in":5,"t2d":4,"participants":1,"with":6,"tg":7,"levels":5,"mg":4,"dl":4,"and":12,"ascvd":4,"or":3,"age":1,"years":1,"second":1,"cv":2,"risk":7,"factor":1,"although":1,"this":1,"effect":2,"was":1,"independent":1,"level":2,"lowering":1,"potential":1,"concerns":1,"about":1,"magnitude":1,"bene":1,"fi":2,"cial":1,"use":1,"mineral":1,"oil":1,"placebo":1,"reduce":3,"it":1,"have":1,"been":1,"voiced":1,"but":2,"overall":1,"should":1,"be":3,"considered":1,"if":2,"are":1,"persons":3,"established":1,"additional":1,"traditional":1,"factors":1,"for":2,"severe":1,"hypertriglyceridemia":1,"very":1,"low":1,"fat":1,"diet":1,"may":3,"required":1,"brate":1,"pre":1,"scription":1,"omega":1,"fatty":1,"acid":1,"refractory":1,"cases":1,"fasting":1,"remains":1,"niacin":2,"needed":1,"lower":2,"pancreatitis":1,"notably":1,"lp":1,"does":1,"not":1,"can":1,"worsen":1,"glycemia":1,"reduction":1,"algorithm":1,"hypertension":1,"htn":2,"is":1,"prevalent":1,"among":1,"increases":2,"macrovascular":1,"microvascular":1,"complications":1,"dm":2,"coexistence":1,"prediabetes":1,"also":1,"data":1,"from":1,"uk":1,"prospective":1,"diabetes":1,"study":1,"ukpds":1,"demonstrated":1,"increased":1,"bp":1,"control":1,"decreased":1,"death":1,"related":1,"micro":1,"macro":1},"len":237},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":10,"chunkId":"aace-2023-p10-c4","text":"existence of prediabetes and HTN also increases the risk of CV events. 104 Data from the UK Prospective Diabetes Study (UKPDS) demonstrated that increased BP control in persons with T2D decreased the risk of death related to DM and micro- and macro- vascular complications, which has been con fi rmed in subsequent clinical trials. 105,106 AACE has set a systolic BP goal for the majority of patients with T2D as < 130 mm Hg with a diastolic BP goal of < 80 mm Hg (Algo- rithm Fig. 5). 9 A lower target can be considered for persons with micro- or macroalbuminuria, moderate/high risk for or with estab- lished ASCVD, peripheral vascular disease, or retinopathy. It is recognized that some persons with T2D may not tolerate a goal of < 130/80 mm Hg, including those with autonomic neuropathy with orthostatic hypotension, acute coronary syndrome (acute myocardial infarction [MI] or unstable angina), frailty, or medication intolerance. The accuracy of BP measurement in the clinical setting should be ensured using appropriately maintained and calibrated equipment, trained and pro fi cient medical staff, and with the patient in the appropriate position (ie, sitting in a chair with feet on fl oor, arm supported at heart level) with a correctly sized cuff. Ideally, serial measurements should be taken and averaged. Step 1. Initiate Lifestyle Interventions Weight loss of \u0015 5% lowers BP with the l","tf":{"80":2,"104":1,"105":1,"106":1,"130":2,"existence":1,"of":8,"prediabetes":1,"and":7,"htn":1,"also":1,"increases":1,"the":9,"risk":3,"cv":1,"events":1,"data":1,"from":1,"uk":1,"prospective":1,"diabetes":1,"study":1,"ukpds":1,"demonstrated":1,"that":2,"increased":1,"bp":5,"control":1,"in":5,"persons":3,"with":12,"t2d":3,"decreased":1,"death":1,"related":1,"to":1,"dm":1,"micro":2,"macro":1,"vascular":2,"complications":1,"which":1,"has":2,"been":1,"con":1,"fi":2,"rmed":1,"subsequent":1,"clinical":2,"trials":1,"aace":1,"set":1,"systolic":1,"goal":3,"for":3,"majority":1,"patients":1,"as":1,"mm":3,"hg":3,"diastolic":1,"algo":1,"rithm":1,"fig":1,"lower":1,"target":1,"can":1,"be":3,"considered":1,"or":5,"macroalbuminuria":1,"moderate":1,"high":1,"estab":1,"lished":1,"ascvd":1,"peripheral":1,"disease":1,"retinopathy":1,"it":1,"is":1,"recognized":1,"some":1,"may":1,"not":1,"tolerate":1,"including":1,"those":1,"autonomic":1,"neuropathy":1,"orthostatic":1,"hypotension":1,"acute":2,"coronary":1,"syndrome":1,"myocardial":1,"infarction":1,"mi":1,"unstable":1,"angina":1,"frailty":1,"medication":1,"intolerance":1,"accuracy":1,"measurement":1,"setting":1,"should":2,"ensured":1,"using":1,"appropriately":1,"maintained":1,"calibrated":1,"equipment":1,"trained":1,"pro":1,"cient":1,"medical":1,"staff":1,"patient":1,"appropriate":1,"position":1,"ie":1,"sitting":1,"chair":1,"feet":1,"on":1,"fl":1,"oor":1,"arm":1,"supported":1,"at":1,"heart":1,"level":1,"correctly":1,"sized":1,"cuff":1,"ideally":1,"serial":1,"measurements":1,"taken":1,"averaged":1,"step":1,"initiate":1,"lifestyle":1,"interventions":1,"weight":1,"loss":1,"lowers":1},"len":218},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":10,"chunkId":"aace-2023-p10-c5","text":"ition (ie, sitting in a chair with feet on fl oor, arm supported at heart level) with a correctly sized cuff. Ideally, serial measurements should be taken and averaged. Step 1. Initiate Lifestyle Interventions Weight loss of \u0015 5% lowers BP with the largest impact in persons who lose 10% to > 15%. 89,107 Exercise several times per week is also an important component in the treatment of HTN, because there are reductions in both systolic and diastolic BP with endurance (aerobic) and dynamic resistance training. 108 Patients also should be counseled on limiting dietary sodium such as with the DASH diet. 109 Mediterranean diets also have been demonstrated to lower BP. 110 Step 2. Start an Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker Angiotensin-converting enzyme inhibitors (ACEis) or angio- tensin II receptor blockers (ARBs) are considered fi rst-line therapies for HTN in persons with T2D, particularly in those with DKD. Both agents are ef fi cacious, but there is no additional bene fi t for coad- ministration of an ACEi and an ARB together, and combination may cause harm. 111-114 The dose should be titrated up on a regular basis (minimum every 2-3 months) to reach the BP goal. For those per- sons who manifest intolerance to an ACEi (eg, cough), an ARB can be substituted. If the initial BP is > 150/100 mm Hg, dual therapy may need to be used at the outs","tf":{"10":1,"15":1,"89":1,"100":1,"107":1,"108":1,"109":1,"110":1,"111":1,"114":1,"150":1,"ition":1,"ie":1,"sitting":1,"in":6,"chair":1,"with":7,"feet":1,"on":3,"fl":1,"oor":1,"arm":1,"supported":1,"at":2,"heart":1,"level":1,"correctly":1,"sized":1,"cuff":1,"ideally":1,"serial":1,"measurements":1,"should":3,"be":5,"taken":1,"and":5,"averaged":1,"step":2,"initiate":1,"lifestyle":1,"interventions":1,"weight":1,"loss":1,"of":3,"lowers":1,"bp":5,"the":7,"largest":1,"impact":1,"persons":2,"who":2,"lose":1,"to":5,"exercise":1,"several":1,"times":1,"per":2,"week":1,"is":3,"also":3,"an":6,"important":1,"component":1,"treatment":1,"htn":2,"because":1,"there":2,"are":3,"reductions":1,"both":2,"systolic":1,"diastolic":1,"endurance":1,"aerobic":1,"dynamic":1,"resistance":1,"training":1,"patients":1,"counseled":1,"limiting":1,"dietary":1,"sodium":1,"such":1,"as":1,"dash":1,"diet":1,"mediterranean":1,"diets":1,"have":1,"been":1,"demonstrated":1,"lower":1,"start":1,"angiotensin":3,"converting":2,"enzyme":2,"inhibitor":1,"or":2,"ii":2,"receptor":2,"blocker":1,"inhibitors":1,"aceis":1,"angio":1,"tensin":1,"blockers":1,"arbs":1,"considered":1,"fi":3,"rst":1,"line":1,"therapies":1,"for":3,"t2d":1,"particularly":1,"those":2,"dkd":1,"agents":1,"ef":1,"cacious":1,"but":1,"no":1,"additional":1,"bene":1,"coad":1,"ministration":1,"acei":2,"arb":2,"together":1,"combination":1,"may":2,"cause":1,"harm":1,"dose":1,"titrated":1,"up":1,"regular":1,"basis":1,"minimum":1,"every":1,"months":1,"reach":1,"goal":1,"sons":1,"manifest":1,"intolerance":1,"eg":1,"cough":1,"can":1,"substituted":1,"if":1,"initial":1,"mm":1,"hg":1,"dual":1,"therapy":1,"need":1,"used":1,"outs":1},"len":232},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":10,"chunkId":"aace-2023-p10-c6","text":" up on a regular basis (minimum every 2-3 months) to reach the BP goal. For those per- sons who manifest intolerance to an ACEi (eg, cough), an ARB can be substituted. If the initial BP is > 150/100 mm Hg, dual therapy may need to be used at the outset (see Step 3. Add-on Therapy). Step 3. Add-on Therapy If the BP goal is not achieved with optimally titrated ACEi or ARB therapy alone, additional add-on therapy is needed. Other antihy- pertensive agents also have shown ef fi cacy in slowing GFR decline S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 314","tf":{"29":1,"100":1,"150":1,"305":1,"314":1,"340":1,"2023":1,"up":1,"on":4,"regular":1,"basis":1,"minimum":1,"every":1,"months":1,"to":3,"reach":1,"the":4,"bp":3,"goal":2,"for":1,"those":1,"per":1,"sons":1,"who":1,"manifest":1,"intolerance":1,"an":2,"acei":2,"eg":1,"cough":1,"arb":2,"can":1,"be":2,"substituted":1,"if":2,"initial":1,"is":3,"mm":1,"hg":1,"dual":1,"therapy":5,"may":1,"need":1,"used":1,"at":1,"outset":1,"see":1,"step":2,"add":3,"not":1,"achieved":1,"with":1,"optimally":1,"titrated":1,"or":1,"alone":1,"additional":1,"needed":1,"other":1,"antihy":1,"pertensive":1,"agents":1,"also":1,"have":1,"shown":1,"ef":1,"fi":1,"cacy":1,"in":1,"slowing":1,"gfr":1,"decline":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":104},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":11,"chunkId":"aace-2023-p11-c0","text":"in persons with T2D and HTN, including diuretics and calcium channel blockers. 115 A thiazide diuretic (eg, hydrochlorothiazide, chlorthalidone, indapamide) is an effective second-line antihyper- tensive, and there are numerous combination pills with ACEi or ARBs with the potential to increase adherence. The dihydropyridine calcium channel blockers amlodipine or nifedipine also can be considered as add-on therapies. Understanding that many persons with HTN can require mul- tiple antihypertensive medications to achieve their goal BP, addi- tional therapies can include b -blockade. Notably, b -blockers can be associated with weight gain, thought to be secondary to decreased energy expenditure. 116,117 This may be more pronounced with older agents such as atenolol or metoprolol, so the use of newer a - b blockade (carvedilol, labetalol, dilevalol) or b 1-selective agents (nebivolol or betaxolol) may be more weight sparing. The central a 2 agonist (clonidine) or a peripheral a 1 RA (eg, doxazosin, prazosin, terazosin) may be needed for persons who are still hypertensive despite multiple therapies. Hydralazine also may be an effective adjunct therapy but requires multiple doses throughout the day. Primary hyperaldosteronism is an underdiagnosed cause of endocrine HTN, and there should be a low threshold for screening. 118,119 For the purposes of this algorithm, patients should be sc","tf":{"115":1,"116":1,"117":1,"118":1,"119":1,"in":1,"persons":3,"with":6,"t2d":1,"and":4,"htn":3,"including":1,"diuretics":1,"calcium":2,"channel":2,"blockers":3,"thiazide":1,"diuretic":1,"eg":2,"hydrochlorothiazide":1,"chlorthalidone":1,"indapamide":1,"is":2,"an":3,"effective":2,"second":1,"line":1,"antihyper":1,"tensive":1,"there":2,"are":2,"numerous":1,"combination":1,"pills":1,"acei":1,"or":6,"arbs":1,"the":6,"potential":1,"to":4,"increase":1,"adherence":1,"dihydropyridine":1,"amlodipine":1,"nifedipine":1,"also":2,"can":4,"be":9,"considered":1,"as":2,"add":1,"on":1,"therapies":3,"understanding":1,"that":1,"many":1,"require":1,"mul":1,"tiple":1,"antihypertensive":1,"medications":1,"achieve":1,"their":1,"goal":1,"bp":1,"addi":1,"tional":1,"include":1,"blockade":2,"notably":1,"associated":1,"weight":2,"gain":1,"thought":1,"secondary":1,"decreased":1,"energy":1,"expenditure":1,"this":2,"may":4,"more":2,"pronounced":1,"older":1,"agents":2,"such":1,"atenolol":1,"metoprolol":1,"so":1,"use":1,"of":3,"newer":1,"carvedilol":1,"labetalol":1,"dilevalol":1,"selective":1,"nebivolol":1,"betaxolol":1,"sparing":1,"central":1,"agonist":1,"clonidine":1,"peripheral":1,"ra":1,"doxazosin":1,"prazosin":1,"terazosin":1,"needed":1,"for":3,"who":1,"still":1,"hypertensive":1,"despite":1,"multiple":2,"hydralazine":1,"adjunct":1,"therapy":1,"but":1,"requires":1,"doses":1,"throughout":1,"day":1,"primary":1,"hyperaldosteronism":1,"underdiagnosed":1,"cause":1,"endocrine":1,"should":2,"low":1,"threshold":1,"screening":1,"purposes":1,"algorithm":1,"patients":1,"sc":1},"len":199},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":11,"chunkId":"aace-2023-p11-c1","text":"junct therapy but requires multiple doses throughout the day. Primary hyperaldosteronism is an underdiagnosed cause of endocrine HTN, and there should be a low threshold for screening. 118,119 For the purposes of this algorithm, patients should be screened if they have resistant HTN ( > 140/90 mm Hg) on \u0015 3 medications, including a maximum-dose diuretic. A mineralocor- ticoid receptor antagonist (MRA) (eg, eplerenone, spironolactone) is the rational choice for the medical management of primary hyperaldosteronism but also can be considered for resistant HTN in persons with T2D. More frequent laboratory monitoring of potas- sium levels and kidney function should be performed in persons on a combination of an ACEi or ARB with an MRA. There also are data supporting the bene fi ts of the nonsteroidal MRA fi nerenone for progression of CKD and risk of HF, ASCVD events, and related mortality in persons with T2D and microalbuminuria (urine albu- min-to-creatinine ratio \u0015 30 mg/g), macroalbuminuria, or more advanced CKD but with an eGFR > 25 mL/min/1.73 m 2 . 120-123 Although fi nerenone can modestly reduce systolic BP, its effects are independent of pretreatment BP levels, and regulatory approval is for risk reduction for eGFR decline, end-stage kidney disease, CV death, nonfatal MI, and hospitalization for HF in persons with CKD and T2D. 124 For those persons initiated on GLP-1 RA or ","tf":{"25":1,"30":1,"73":1,"90":1,"118":1,"119":1,"120":1,"123":1,"124":1,"140":1,"junct":1,"therapy":1,"but":3,"requires":1,"multiple":1,"doses":1,"throughout":1,"the":6,"day":1,"primary":2,"hyperaldosteronism":2,"is":3,"an":4,"underdiagnosed":1,"cause":1,"of":9,"endocrine":1,"htn":3,"and":8,"there":2,"should":3,"be":4,"low":1,"threshold":1,"for":9,"screening":1,"purposes":1,"this":1,"algorithm":1,"patients":1,"screened":1,"if":1,"they":1,"have":1,"resistant":2,"mm":1,"hg":1,"on":3,"medications":1,"including":1,"maximum":1,"dose":1,"diuretic":1,"mineralocor":1,"ticoid":1,"receptor":1,"antagonist":1,"mra":3,"eg":1,"eplerenone":1,"spironolactone":1,"rational":1,"choice":1,"medical":1,"management":1,"also":2,"can":2,"considered":1,"in":4,"persons":5,"with":5,"t2d":3,"more":2,"frequent":1,"laboratory":1,"monitoring":1,"potas":1,"sium":1,"levels":2,"kidney":2,"function":1,"performed":1,"combination":1,"acei":1,"or":3,"arb":1,"are":2,"data":1,"supporting":1,"bene":1,"fi":3,"ts":1,"nonsteroidal":1,"nerenone":2,"progression":1,"ckd":3,"risk":2,"hf":2,"ascvd":1,"events":1,"related":1,"mortality":1,"microalbuminuria":1,"urine":1,"albu":1,"min":2,"to":1,"creatinine":1,"ratio":1,"mg":1,"macroalbuminuria":1,"advanced":1,"egfr":2,"ml":1,"although":1,"modestly":1,"reduce":1,"systolic":1,"bp":2,"its":1,"effects":1,"independent":1,"pretreatment":1,"regulatory":1,"approval":1,"reduction":1,"decline":1,"end":1,"stage":1,"disease":1,"cv":1,"death":1,"nonfatal":1,"mi":1,"hospitalization":1,"those":1,"initiated":1,"glp":1,"ra":1},"len":220},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":11,"chunkId":"aace-2023-p11-c2","text":"endent of pretreatment BP levels, and regulatory approval is for risk reduction for eGFR decline, end-stage kidney disease, CV death, nonfatal MI, and hospitalization for HF in persons with CKD and T2D. 124 For those persons initiated on GLP-1 RA or SGLT2i, there may be a mild reduction in BP when these agents are started. 125-128 Complications-Centric Algorithm for Glycemic Control Persons with T2D experience signi fi cant morbidity caused by ASCVD, which is the leading cause of mortality in T2D despite contemporary therapy with lipid-modifying, antiplatelet, and antihypertensive agents. 129 Therapeutic lifestyle changes remain a fundamental component of glycemic control and should include a healthy meal plan, regular physical activity, healthful behavior practices, and weight management. Importantly, some agents belonging to 2 of the newer classes of antihyperglycemic agents, GLP-1 RA and SGLT2i, have been demonstrated in large, interna- tional, multicenter randomized, controlled trials to reduce ASCVD risk in persons with T2D and established ASCVD as well as in those at high risk for ASCVD. The CVOTs demonstrate that each anti- hyperglycemic agent has distinct effects on various components of CV risk, with some showing reduction in CV death, improvement in CKD, reduction in hospitalization for HF, and/or reduced risk of Algorithm Fig. 5. Atherosclerotic Cardiovascular Diseas","tf":{"124":1,"125":1,"128":1,"129":1,"endent":1,"of":7,"pretreatment":1,"bp":2,"levels":1,"and":9,"regulatory":1,"approval":1,"is":2,"for":7,"risk":5,"reduction":4,"egfr":1,"decline":1,"end":1,"stage":1,"kidney":1,"disease":1,"cv":3,"death":2,"nonfatal":1,"mi":1,"hospitalization":2,"hf":2,"in":9,"persons":4,"with":5,"ckd":2,"t2d":4,"those":2,"initiated":1,"on":2,"glp":2,"ra":2,"or":2,"sglt2i":2,"there":1,"may":1,"be":1,"mild":1,"when":1,"these":1,"agents":4,"are":1,"started":1,"complications":1,"centric":1,"algorithm":2,"glycemic":2,"control":2,"experience":1,"signi":1,"fi":1,"cant":1,"morbidity":1,"caused":1,"by":1,"ascvd":4,"which":1,"the":3,"leading":1,"cause":1,"mortality":1,"despite":1,"contemporary":1,"therapy":1,"lipid":1,"modifying":1,"antiplatelet":1,"antihypertensive":1,"therapeutic":1,"lifestyle":1,"changes":1,"remain":1,"fundamental":1,"component":1,"should":1,"include":1,"healthy":1,"meal":1,"plan":1,"regular":1,"physical":1,"activity":1,"healthful":1,"behavior":1,"practices":1,"weight":1,"management":1,"importantly":1,"some":2,"belonging":1,"to":2,"newer":1,"classes":1,"antihyperglycemic":1,"have":1,"been":1,"demonstrated":1,"large":1,"interna":1,"tional":1,"multicenter":1,"randomized":1,"controlled":1,"trials":1,"reduce":1,"established":1,"as":2,"well":1,"at":1,"high":1,"cvots":1,"demonstrate":1,"that":1,"each":1,"anti":1,"hyperglycemic":1,"agent":1,"has":1,"distinct":1,"effects":1,"various":1,"components":1,"showing":1,"improvement":1,"reduced":1,"fig":1,"atherosclerotic":1,"cardiovascular":1,"diseas":1},"len":208},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":11,"chunkId":"aace-2023-p11-c3","text":"yperglycemic agent has distinct effects on various components of CV risk, with some showing reduction in CV death, improvement in CKD, reduction in hospitalization for HF, and/or reduced risk of Algorithm Fig. 5. Atherosclerotic Cardiovascular Disease Risk Reduction Algorithm: Hypertension. S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 315","tf":{"29":1,"305":1,"315":1,"340":1,"2023":1,"yperglycemic":1,"agent":1,"has":1,"distinct":1,"effects":1,"on":1,"various":1,"components":1,"of":2,"cv":2,"risk":3,"with":1,"some":1,"showing":1,"reduction":3,"in":3,"death":1,"improvement":1,"ckd":1,"hospitalization":1,"for":1,"hf":1,"and":1,"or":1,"reduced":1,"algorithm":2,"fig":1,"atherosclerotic":1,"cardiovascular":1,"disease":1,"hypertension":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":52},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":12,"chunkId":"aace-2023-p12-c0","text":"stroke. There is a need for a paradigm shift from an exclusively glucose-centric approach to add a complications-centric approach in the algorithm for glycemic control of persons with T2D (Algo- rithm Fig. 6). Three of the GLP-1 RAs have been demonstrated to signi fi cantly lower the risk of major adverse cardiovascular events (MACEs) (the composite endpoint  3-point MACE  includes nonfatal MI, nonfatal stroke, and CV death), whereas SGLT2is lower the risk of hospital- ization for HF, improve renal outcomes, and some reduce the risk of CV death and/or MACE. The de fi nition of high risk was not consistent across all CVOTs, but generally included albuminuria or proteinuria, HTN and LV hypertrophy, LV systolic or diastolic dysfunction, and/or ABI < 0.9. A 2021 meta-analysis of GLP-1 RA CVOTs found a 14% (hazard ratio [HR] 0.86, 95% con fi dence interval [CI] 0.80-0.93, P < .001) reduction in risk of MACEs in persons with or without established ASCVD, A1C, or background anti- hyperglycemic therapy. 130 Therefore, when persons with T2D have established ASCVD or are at high risk, a GLP-1 RA with proven CV bene fi t (eg, liraglutide, semaglutide, or dulaglutide) should be initiated as a fi rst-line therapy independent of A1C goal or other antihyperglycemic treatments, including metformin. 9 As an alter- native to GLP-1 RA, with consideration of comorbidities, potential side effects","tf":{"14":1,"80":1,"86":1,"93":1,"95":1,"130":1,"2021":1,"stroke":2,"there":1,"is":1,"need":1,"for":3,"paradigm":1,"shift":1,"from":1,"an":2,"exclusively":1,"glucose":1,"centric":2,"approach":2,"to":3,"add":1,"complications":1,"in":3,"the":7,"algorithm":1,"glycemic":1,"control":1,"of":10,"persons":3,"with":5,"t2d":2,"algo":1,"rithm":1,"fig":1,"three":1,"glp":4,"ras":1,"have":2,"been":1,"demonstrated":1,"signi":1,"fi":5,"cantly":1,"lower":2,"risk":6,"major":1,"adverse":1,"cardiovascular":1,"events":1,"maces":2,"composite":1,"endpoint":1,"point":1,"mace":2,"includes":1,"nonfatal":2,"mi":1,"and":5,"cv":3,"death":2,"whereas":1,"sglt2is":1,"hospital":1,"ization":1,"hf":1,"improve":1,"renal":1,"outcomes":1,"some":1,"reduce":1,"or":9,"de":1,"nition":1,"high":2,"was":1,"not":1,"consistent":1,"across":1,"all":1,"cvots":2,"but":1,"generally":1,"included":1,"albuminuria":1,"proteinuria":1,"htn":1,"lv":2,"hypertrophy":1,"systolic":1,"diastolic":1,"dysfunction":1,"abi":1,"meta":1,"analysis":1,"ra":3,"found":1,"hazard":1,"ratio":1,"hr":1,"con":1,"dence":1,"interval":1,"ci":1,"001":1,"reduction":1,"without":1,"established":2,"ascvd":2,"a1c":2,"background":1,"anti":1,"hyperglycemic":1,"therapy":2,"therefore":1,"when":1,"are":1,"at":1,"proven":1,"bene":1,"eg":1,"liraglutide":1,"semaglutide":1,"dulaglutide":1,"should":1,"be":1,"initiated":1,"as":2,"rst":1,"line":1,"independent":1,"goal":1,"other":1,"antihyperglycemic":1,"treatments":1,"including":1,"metformin":1,"alter":1,"native":1,"consideration":1,"comorbidities":1,"potential":1,"side":1,"effects":1},"len":218},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":12,"chunkId":"aace-2023-p12-c1","text":"maglutide, or dulaglutide) should be initiated as a fi rst-line therapy independent of A1C goal or other antihyperglycemic treatments, including metformin. 9 As an alter- native to GLP-1 RA, with consideration of comorbidities, potential side effects, and/or patient preference, clinicians may recommend initiating an SGLT2i with proven CV bene fi t to reduce the risk of MACE or CV death in persons with T2D and established ASCVD. 131,132 For persons with T2D and established ASCVD or at high risk for ASCVD, the use of an SGLT2i reduces the risk of hos- pitalization for HF regardless of background antihyperglycemic therapy, CV therapy, or A1C, 9 and in persons with HF and/or CKD, SGLT2i should be initiated as fi rst-line therapy. SGLT2is clearly have been shown to signi fi cantly and robustly reduce the risk of hospitalization for HF or CV death in persons with T2D with or without ASCVD and to improve HF-related symptoms in persons with established HF regardless of LV ejection fraction, background glucose-lowering therapies, or HF therapies. 9 A recent meta-analysis showed that use of an SGLT2i resulted in a 32% reduction in risk of hospitalization for HF (HR 0.68 [95% CI 0.61- 0.76]) and a 15% reduction in CV death (HR 0.85 [95% CI 0.78-0.93]) compared with placebo. 133 SGLT2is should be recommended in persons with T2D and HF regardless of A1C goal or other anti- hyperglycemic tre","tf":{"15":1,"32":1,"61":1,"68":1,"76":1,"78":1,"85":1,"93":1,"95":2,"131":1,"132":1,"133":1,"maglutide":1,"or":11,"dulaglutide":1,"should":3,"be":3,"initiated":2,"as":3,"fi":4,"rst":2,"line":2,"therapy":4,"independent":1,"of":11,"a1c":3,"goal":2,"other":2,"antihyperglycemic":2,"treatments":1,"including":1,"metformin":1,"an":4,"alter":1,"native":1,"to":4,"glp":1,"ra":1,"with":10,"consideration":1,"comorbidities":1,"potential":1,"side":1,"effects":1,"and":9,"patient":1,"preference":1,"clinicians":1,"may":1,"recommend":1,"initiating":1,"sglt2i":4,"proven":1,"cv":5,"bene":1,"reduce":2,"the":4,"risk":5,"mace":1,"death":3,"in":8,"persons":6,"t2d":4,"established":3,"ascvd":4,"for":5,"at":1,"high":1,"use":2,"reduces":1,"hos":1,"pitalization":1,"hf":8,"regardless":3,"background":2,"ckd":1,"sglt2is":2,"clearly":1,"have":1,"been":1,"shown":1,"signi":1,"cantly":1,"robustly":1,"hospitalization":2,"without":1,"improve":1,"related":1,"symptoms":1,"lv":1,"ejection":1,"fraction":1,"glucose":1,"lowering":1,"therapies":2,"recent":1,"meta":1,"analysis":1,"showed":1,"that":1,"resulted":1,"reduction":2,"hr":2,"ci":2,"compared":1,"placebo":1,"recommended":1,"anti":1,"hyperglycemic":1,"tre":1},"len":232},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":12,"chunkId":"aace-2023-p12-c2","text":"pitalization for HF (HR 0.68 [95% CI 0.61- 0.76]) and a 15% reduction in CV death (HR 0.85 [95% CI 0.78-0.93]) compared with placebo. 133 SGLT2is should be recommended in persons with T2D and HF regardless of A1C goal or other anti- hyperglycemic treatments, including metformin. Studies with DPP-4i have shown neutrality compared with placebo regarding MACEs but saxagliptin has been shown to in- crease the rate of HF hospitalizations. 134 There also was a trend for HF hospitalizations with alogliptin in post hoc analysis of the EXAMINE trial, so caution is advised with use of this agent for persons with New York Heart Association Class III or IV CHF. 135 TZDs can worsen fl uid retention and should not be used in persons who have symptomatic HF, and initiation of pioglitazone is contra- indicated in individuals with New York Heart Association Class III or Class IV CHF. 136 However, in patients with insulin resistance but without DM who experienced a stroke or transient ischemic attack, pioglitazone has been shown to reduce the risk of acute coronary syndromes. 137 Studies of acarbose on CVD have been limited to patients with impaired glucose tolerance, with 1 study reporting a nearly 50% reduction in MACEs 138 associated with decreased postprandial glucose, while another showed no effect, 139 albeit in patients with already established CVD. The risk of stroke is markedly increase","tf":{"15":1,"50":1,"61":1,"68":1,"76":1,"78":1,"85":1,"93":1,"95":2,"133":1,"134":1,"135":1,"136":1,"137":1,"138":1,"139":1,"pitalization":1,"for":3,"hf":5,"hr":2,"ci":2,"and":4,"reduction":2,"in":9,"cv":1,"death":1,"compared":2,"with":13,"placebo":2,"sglt2is":1,"should":2,"be":2,"recommended":1,"persons":3,"t2d":1,"regardless":1,"of":8,"a1c":1,"goal":1,"or":4,"other":1,"anti":1,"hyperglycemic":1,"treatments":1,"including":1,"metformin":1,"studies":2,"dpp":1,"4i":1,"have":3,"shown":3,"neutrality":1,"regarding":1,"maces":2,"but":2,"saxagliptin":1,"has":2,"been":3,"to":3,"crease":1,"the":4,"rate":1,"hospitalizations":2,"there":1,"also":1,"was":1,"trend":1,"alogliptin":1,"post":1,"hoc":1,"analysis":1,"examine":1,"trial":1,"so":1,"caution":1,"is":3,"advised":1,"use":1,"this":1,"agent":1,"new":2,"york":2,"heart":2,"association":2,"class":3,"iii":2,"iv":2,"chf":2,"tzds":1,"can":1,"worsen":1,"fl":1,"uid":1,"retention":1,"not":1,"used":1,"who":2,"symptomatic":1,"initiation":1,"pioglitazone":2,"contra":1,"indicated":1,"individuals":1,"however":1,"patients":3,"insulin":1,"resistance":1,"without":1,"dm":1,"experienced":1,"stroke":2,"transient":1,"ischemic":1,"attack":1,"reduce":1,"risk":2,"acute":1,"coronary":1,"syndromes":1,"acarbose":1,"on":1,"cvd":2,"limited":1,"impaired":1,"glucose":2,"tolerance":1,"study":1,"reporting":1,"nearly":1,"associated":1,"decreased":1,"postprandial":1,"while":1,"another":1,"showed":1,"no":1,"effect":1,"albeit":1,"already":1,"established":1,"markedly":1,"increase":1},"len":226},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":12,"chunkId":"aace-2023-p12-c3","text":"glucose tolerance, with 1 study reporting a nearly 50% reduction in MACEs 138 associated with decreased postprandial glucose, while another showed no effect, 139 albeit in patients with already established CVD. The risk of stroke is markedly increased in DM, with a National Health and Nutrition Examination Survey study demonstrating an Algorithm Fig. 6. Complications-Centric Algorithm for Glycemic Control. S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 316","tf":{"29":1,"50":1,"138":1,"139":1,"305":1,"316":1,"340":1,"2023":1,"glucose":2,"tolerance":1,"with":4,"study":2,"reporting":1,"nearly":1,"reduction":1,"in":3,"maces":1,"associated":1,"decreased":1,"postprandial":1,"while":1,"another":1,"showed":1,"no":1,"effect":1,"albeit":1,"patients":1,"already":1,"established":1,"cvd":1,"the":1,"risk":1,"of":1,"stroke":1,"is":1,"markedly":1,"increased":1,"dm":1,"national":1,"health":1,"and":1,"nutrition":1,"examination":1,"survey":1,"demonstrating":1,"an":1,"algorithm":2,"fig":1,"complications":1,"centric":1,"for":1,"glycemic":1,"control":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":68},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":13,"chunkId":"aace-2023-p13-c0","text":"odds ratio of 28 (95% CI 19-41). 140 Across meta-analyses, GLP-1 RA appear to reduce risk of stroke by 15% to 17% in persons with T2D and prior ASCVD or at high risk for ASCVD. 9,130,141,142 The 3 GLP-1 RA agents approved by the FDA to reduce the risk of MACEs (including stroke) are dulaglutide (with or without established ASCVD), liraglutide, and subcutaneous semaglutide (in persons with established CVD). 143 In persons with T2D and ASCVD or those at high risk for ASCVD, use of GLP-1 RA with proven bene fi t is recommended to reduce stroke risk. 9 Pioglitazone, a TZD, appears to reduce the risk of recurrent stroke and should also be considered to reduce the risk of recurrent stroke in persons with insulin resistance, prediabetes, or T2D and a prior transient ischemic attack (TIA) or stroke. 9,144,145 With regard to stroke and SGLT2i, 2 meta- analyses have shown that there was a reduced HR of 0.5 for hem- orrhagic stroke when pooling data from completed SGLT2i trials, while there was no signi fi cant impact on ischemic stroke. 146,147 Nearly 50% of U.S. adults with kidney failure have DM. 148 The evidence for bene fi t of SGLT2is to reduce adverse renal outcomes is robust, with an approximately 38% reduction in composite out- comes, which varied across trials but included worsening of eGFR or creatinine, end-stage kidney disease with or without need for kidney replacement thera","tf":{"15":1,"17":1,"19":1,"28":1,"38":1,"41":1,"50":1,"95":1,"130":1,"140":1,"141":1,"142":1,"143":1,"144":1,"145":1,"146":1,"147":1,"148":1,"odds":1,"ratio":1,"of":10,"ci":1,"across":2,"meta":2,"analyses":2,"glp":3,"ra":3,"appear":1,"to":8,"reduce":6,"risk":7,"stroke":9,"by":2,"in":5,"persons":4,"with":10,"t2d":3,"and":6,"prior":2,"ascvd":5,"or":7,"at":2,"high":2,"for":5,"the":6,"agents":1,"approved":1,"fda":1,"maces":1,"including":1,"are":1,"dulaglutide":1,"without":2,"established":2,"liraglutide":1,"subcutaneous":1,"semaglutide":1,"cvd":1,"those":1,"use":1,"proven":1,"bene":2,"fi":3,"is":2,"recommended":1,"pioglitazone":1,"tzd":1,"appears":1,"recurrent":2,"should":1,"also":1,"be":1,"considered":1,"insulin":1,"resistance":1,"prediabetes":1,"transient":1,"ischemic":2,"attack":1,"tia":1,"regard":1,"sglt2i":2,"have":2,"shown":1,"that":1,"there":2,"was":2,"reduced":1,"hr":1,"hem":1,"orrhagic":1,"when":1,"pooling":1,"data":1,"from":1,"completed":1,"trials":2,"while":1,"no":1,"signi":1,"cant":1,"impact":1,"on":1,"nearly":1,"adults":1,"kidney":3,"failure":1,"dm":1,"evidence":1,"sglt2is":1,"adverse":1,"renal":1,"outcomes":1,"robust":1,"an":1,"approximately":1,"reduction":1,"composite":1,"out":1,"comes":1,"which":1,"varied":1,"but":1,"included":1,"worsening":1,"egfr":1,"creatinine":1,"end":1,"stage":1,"disease":1,"need":1,"replacement":1,"thera":1},"len":236},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":13,"chunkId":"aace-2023-p13-c1","text":" reduce adverse renal outcomes is robust, with an approximately 38% reduction in composite out- comes, which varied across trials but included worsening of eGFR or creatinine, end-stage kidney disease with or without need for kidney replacement therapy or transplant, kidney death, or CV death. 133 Use of an SGLT2i with proven bene fi t is recommended as foundational therapy to reduce progression of DKD and CVD risk for persons with T2D and DKD with eGFR 25 mL/min/1.73 m 2 or 20 mL/ min/1.73 m 2 if HF is also present. 9,149,150 Two prospective placebo- controlled trials have examined the impact of dapagli fl ozin (included participants with eGFR 25 to 70 mL/min/1.73 2 and 200- 5000 mg urine albumin/g creatinine) and empagli fl ozin (included participants with eGFR 20 to < 45 mL/min/1.73 m 2 or > 45 mL/min/ 1.73 m 2 with > 200 mg urine albumin/g creatinine) decline in eGFR and progression of CKD, with a majority of participants enrolled with known T2D. 151,152 Dapagli fl ozin slowed the rate of decline more in patients with T2D than in patients without T2D, while the impact on eGFR decline was similar for both groups with empa- gli fl ozin. GLP-1 RAs also are an option to reduce progression of albuminuria, eGFR decline, and ASCVD risk in persons with T2D and DKD with eGFR 15 mL/min/1.73 m 2 . 9,153,154 The A1C target should be individualized in persons with T2D and ASCVD or at hi","tf":{"15":1,"20":2,"25":2,"38":1,"45":2,"70":1,"73":6,"133":1,"149":1,"150":1,"151":1,"152":1,"153":1,"154":1,"200":2,"5000":1,"reduce":3,"adverse":1,"renal":1,"outcomes":1,"is":3,"robust":1,"with":15,"an":3,"approximately":1,"reduction":1,"in":6,"composite":1,"out":1,"comes":1,"which":1,"varied":1,"across":1,"trials":2,"but":1,"included":3,"worsening":1,"of":8,"egfr":8,"or":7,"creatinine":3,"end":1,"stage":1,"kidney":3,"disease":1,"without":2,"need":1,"for":3,"replacement":1,"therapy":2,"transplant":1,"death":2,"cv":1,"use":1,"sglt2i":1,"proven":1,"bene":1,"fi":1,"recommended":1,"as":1,"foundational":1,"to":4,"progression":3,"dkd":3,"and":8,"cvd":1,"risk":2,"persons":3,"t2d":6,"ml":6,"min":6,"if":1,"hf":1,"also":2,"present":1,"two":1,"prospective":1,"placebo":1,"controlled":1,"have":1,"examined":1,"the":4,"impact":2,"dapagli":2,"fl":4,"ozin":4,"participants":3,"mg":2,"urine":2,"albumin":2,"empagli":1,"decline":4,"ckd":1,"majority":1,"enrolled":1,"known":1,"slowed":1,"rate":1,"more":1,"patients":2,"than":1,"while":1,"on":1,"was":1,"similar":1,"both":1,"groups":1,"empa":1,"gli":1,"glp":1,"ras":1,"are":1,"option":1,"albuminuria":1,"ascvd":2,"a1c":1,"target":1,"should":1,"be":1,"individualized":1,"at":1,"hi":1},"len":242},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":13,"chunkId":"aace-2023-p13-c2","text":" ozin. GLP-1 RAs also are an option to reduce progression of albuminuria, eGFR decline, and ASCVD risk in persons with T2D and DKD with eGFR 15 mL/min/1.73 m 2 . 9,153,154 The A1C target should be individualized in persons with T2D and ASCVD or at high risk for ASCVD, with a target A1C of \u0014 6.5% in most nonpregnant adults if it can be achieved safely. Consideration of life expectancy, disease duration, presence or absence of micro- and macrovascular complications, CV disease risk factors, comorbid conditions, and risk of hypoglycemia as well as cognitive and psy- chological status must be considered. 9,16 Newer antihyperglycemic agents such as GLP-1 RA and SGLT2i are associated with a lower risk of hypoglycemia unless used with SUs, glinides, and/or insulin. Less stringent A1C goals (7%-8%) should be adopted in persons with a history of severe hypoglycemia, hypoglycemia unawareness, limited life expectancy, advanced renal disease, extensive comorbid conditions, or longstanding DM in whom the A1C goal has been dif fi cult to attain despite intensive efforts as long as the person remains free of hyperglycemia-associated symptoms. 9,13,14,17 If further lowering of the A1C is needed to achieve the indi- vidualized glycemic target(s) and renal function is GFR > 30 mL/ min/1.73 m 2 , metformin should be considered if the patient is not already taking this agent. Each medication shoul","tf":{"13":1,"14":1,"15":1,"16":1,"17":1,"30":1,"73":2,"153":1,"154":1,"ozin":1,"glp":2,"ras":1,"also":1,"are":2,"an":1,"option":1,"to":3,"reduce":1,"progression":1,"of":9,"albuminuria":1,"egfr":2,"decline":1,"and":9,"ascvd":3,"risk":5,"in":5,"persons":3,"with":7,"t2d":2,"dkd":1,"ml":2,"min":2,"the":6,"a1c":5,"target":3,"should":3,"be":5,"individualized":1,"or":4,"at":1,"high":1,"for":1,"most":1,"nonpregnant":1,"adults":1,"if":3,"it":1,"can":1,"achieved":1,"safely":1,"consideration":1,"life":2,"expectancy":2,"disease":3,"duration":1,"presence":1,"absence":1,"micro":1,"macrovascular":1,"complications":1,"cv":1,"factors":1,"comorbid":2,"conditions":2,"hypoglycemia":4,"as":5,"well":1,"cognitive":1,"psy":1,"chological":1,"status":1,"must":1,"considered":2,"newer":1,"antihyperglycemic":1,"agents":1,"such":1,"ra":1,"sglt2i":1,"associated":2,"lower":1,"unless":1,"used":1,"sus":1,"glinides":1,"insulin":1,"less":1,"stringent":1,"goals":1,"adopted":1,"history":1,"severe":1,"unawareness":1,"limited":1,"advanced":1,"renal":2,"extensive":1,"longstanding":1,"dm":1,"whom":1,"goal":1,"has":1,"been":1,"dif":1,"fi":1,"cult":1,"attain":1,"despite":1,"intensive":1,"efforts":1,"long":1,"person":1,"remains":1,"free":1,"hyperglycemia":1,"symptoms":1,"further":1,"lowering":1,"is":3,"needed":1,"achieve":1,"indi":1,"vidualized":1,"glycemic":1,"function":1,"gfr":1,"metformin":1,"patient":1,"not":1,"already":1,"taking":1,"this":1,"agent":1,"each":1,"medication":1,"shoul":1},"len":220},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":13,"chunkId":"aace-2023-p13-c3","text":",14,17 If further lowering of the A1C is needed to achieve the indi- vidualized glycemic target(s) and renal function is GFR > 30 mL/ min/1.73 m 2 , metformin should be considered if the patient is not already taking this agent. Each medication should be up-titrated to the maximally tolerated approved dose and additional anti- hyperglycemic agents should be added on to achieve glycemic targets. If the initial A1C is > 7.5%, early combination therapy with 2 agents may be needed, and for those with an initial A1C of > 9% or 1.5% above goal, then 2 or 3 antihyperglycemic agents should be initiated concomitantly. If there is symptomatic hyperglycemia, an A1C > 10% and/or BG > 300 mg/dL, suggestive of marked insulin de fi ciency, basal insulin should be initiated to reduce glucose as safely and promptly as possible. In this scenario, use of a combi- nation basal insulin with a GLP-1 RA can also be considered, but with the understanding that GLP-1 RA will require a titration phase that could potentially delay glycemic control. Clinicians should refer to the Algorithm for Adding/Intensifying Insulin section (Al- gorithm Fig. 8) and the Pro fi les of Antihyperglycemic Medications table (Algorithm Fig. 9) for additional guidance. If a person with T2D does not have established or high risk for ASCVD, HF, stroke/TIA, or CKD, then the clinician should refer to the Glucose-Centric Algorithm","tf":{"10":1,"14":1,"17":1,"30":1,"73":1,"300":1,"if":5,"further":1,"lowering":1,"of":5,"the":10,"a1c":4,"is":5,"needed":2,"to":6,"achieve":2,"indi":1,"vidualized":1,"glycemic":3,"target":1,"and":6,"renal":1,"function":1,"gfr":1,"ml":1,"min":1,"metformin":1,"should":7,"be":7,"considered":2,"patient":1,"not":2,"already":1,"taking":1,"this":2,"agent":1,"each":1,"medication":1,"up":1,"titrated":1,"maximally":1,"tolerated":1,"approved":1,"dose":1,"additional":2,"anti":1,"hyperglycemic":1,"agents":3,"added":1,"on":1,"targets":1,"initial":2,"early":1,"combination":1,"therapy":1,"with":5,"may":1,"for":4,"those":1,"an":2,"or":5,"above":1,"goal":1,"then":2,"antihyperglycemic":2,"initiated":2,"concomitantly":1,"there":1,"symptomatic":1,"hyperglycemia":1,"bg":1,"mg":1,"dl":1,"suggestive":1,"marked":1,"insulin":4,"de":1,"fi":2,"ciency":1,"basal":2,"reduce":1,"glucose":2,"as":2,"safely":1,"promptly":1,"possible":1,"in":1,"scenario":1,"use":1,"combi":1,"nation":1,"glp":2,"ra":2,"can":1,"also":1,"but":1,"understanding":1,"that":2,"will":1,"require":1,"titration":1,"phase":1,"could":1,"potentially":1,"delay":1,"control":1,"clinicians":1,"refer":2,"algorithm":3,"adding":1,"intensifying":1,"section":1,"al":1,"gorithm":1,"fig":2,"pro":1,"les":1,"medications":1,"table":1,"guidance":1,"person":1,"t2d":1,"does":1,"have":1,"established":1,"high":1,"risk":1,"ascvd":1,"hf":1,"stroke":1,"tia":1,"ckd":1,"clinician":1,"centric":1},"len":220},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":13,"chunkId":"aace-2023-p13-c4","text":" fi les of Antihyperglycemic Medications table (Algorithm Fig. 9) for additional guidance. If a person with T2D does not have established or high risk for ASCVD, HF, stroke/TIA, or CKD, then the clinician should refer to the Glucose-Centric Algorithm for Glycemic Control section (Algorithm Fig. 7) and the Pro fi les of Antihyperglycemic Medications table (Algorithm Fig. 9). Glucose-Centric Algorithm for Glycemic Control The Glucose-Centric Algorithm for Glycemic Control (Algorithm Fig. 7) is for determining initial and add-on therapies for persons with DM but without established or high risk for ASCVD, HF, stroke/ TIA, or CKD. Metformin should be initiated if there is no contrain- dication (eg, GFR < 30 mL/min/1.73 m 2 ). In order to maximize tolerability, metformin should be started at a low dose and titrated over the course of a few weeks to the maximally tolerated dose. 16 The newer antihyperglycemic agents such as GLP-1 RA and SGLT2i are associated with low risk of hypoglycemia unless combined with SUs, glinides, and/or insulin. Given that T2D is a progressive disease, many individuals will require > 1 antihyperglycemic medication to achieve their indi- vidualized A1C target over the course of the disease. Clinicians should consider multiple factors when selecting the second agent, including presence of overweight or obesity, hypoglycemia risk, access/cost, and presence of ","tf":{"16":1,"30":1,"73":1,"fi":2,"les":2,"of":7,"antihyperglycemic":4,"medications":2,"table":2,"algorithm":7,"fig":4,"for":8,"additional":1,"guidance":1,"if":2,"person":1,"with":4,"t2d":2,"does":1,"not":1,"have":1,"established":2,"or":6,"high":2,"risk":4,"ascvd":2,"hf":2,"stroke":2,"tia":2,"ckd":2,"then":1,"the":10,"clinician":1,"should":4,"refer":1,"to":4,"glucose":3,"centric":3,"glycemic":3,"control":3,"section":1,"and":6,"pro":1,"is":3,"determining":1,"initial":1,"add":1,"on":1,"therapies":1,"persons":1,"dm":1,"but":1,"without":1,"metformin":2,"be":2,"initiated":1,"there":1,"no":1,"contrain":1,"dication":1,"eg":1,"gfr":1,"ml":1,"min":1,"in":1,"order":1,"maximize":1,"tolerability":1,"started":1,"at":1,"low":2,"dose":2,"titrated":1,"over":2,"course":2,"few":1,"weeks":1,"maximally":1,"tolerated":1,"newer":1,"agents":1,"such":1,"as":1,"glp":1,"ra":1,"sglt2i":1,"are":1,"associated":1,"hypoglycemia":2,"unless":1,"combined":1,"sus":1,"glinides":1,"insulin":1,"given":1,"that":1,"progressive":1,"disease":2,"many":1,"individuals":1,"will":1,"require":1,"medication":1,"achieve":1,"their":1,"indi":1,"vidualized":1,"a1c":1,"target":1,"clinicians":1,"consider":1,"multiple":1,"factors":1,"when":1,"selecting":1,"second":1,"agent":1,"including":1,"presence":2,"overweight":1,"obesity":1,"access":1,"cost":1},"len":211},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":13,"chunkId":"aace-2023-p13-c5","text":"on to achieve their indi- vidualized A1C target over the course of the disease. Clinicians should consider multiple factors when selecting the second agent, including presence of overweight or obesity, hypoglycemia risk, access/cost, and presence of severe hyperglycemia. Patients often present with > 1 of these factors, so using a patient-centered, shared decision-making approach is important. The order that medications are listed in the algorithm denotes the suggested preference hierarchy for selection. In those patients with over- weight or obesity and the additional goal of weight loss, dual GIP/ GLP-1 RA, GLP-1 RA, or SGLT2i class are preferred options. Persons with a history of hypoglycemia, at high risk of hypoglycemia. and/or at risk for severe complications from hypoglycemia should prefer- entially be initiated with an agent associated with low risk for hypoglycemia, including GLP-1 RA, SGLT2i, dual GIP/GLP-1 RA, TZD, or DPP-4i. For many persons with T2D, access and cost are barriers to receiving newer antihyperglycemic agents. In this situation, a TZD, SU, or glinide would be the more economical choices. While TZDs are associated with low risk for hypoglycemia and have shown bene fi t for NAFLD, they also can increase weight, so patients must be counseled accordingly. Lastly, patients with symptomatic hy- perglycemia and/or an A1C > 10% suggestive of marked insulin de ","tf":{"10":1,"on":1,"to":2,"achieve":1,"their":1,"indi":1,"vidualized":1,"a1c":2,"target":1,"over":2,"the":8,"course":1,"of":8,"disease":1,"clinicians":1,"should":2,"consider":1,"multiple":1,"factors":2,"when":1,"selecting":1,"second":1,"agent":2,"including":2,"presence":2,"overweight":1,"or":7,"obesity":2,"hypoglycemia":6,"risk":5,"access":2,"cost":2,"and":6,"severe":2,"hyperglycemia":1,"patients":4,"often":1,"present":1,"with":8,"these":1,"so":2,"using":1,"patient":1,"centered":1,"shared":1,"decision":1,"making":1,"approach":1,"is":1,"important":1,"order":1,"that":1,"medications":1,"are":4,"listed":1,"in":3,"algorithm":1,"denotes":1,"suggested":1,"preference":1,"hierarchy":1,"for":6,"selection":1,"those":1,"weight":3,"additional":1,"goal":1,"loss":1,"dual":2,"gip":2,"glp":4,"ra":4,"sglt2i":2,"class":1,"preferred":1,"options":1,"persons":2,"history":1,"at":2,"high":1,"complications":1,"from":1,"prefer":1,"entially":1,"be":3,"initiated":1,"an":2,"associated":2,"low":2,"tzd":2,"dpp":1,"4i":1,"many":1,"t2d":1,"barriers":1,"receiving":1,"newer":1,"antihyperglycemic":1,"agents":1,"this":1,"situation":1,"su":1,"glinide":1,"would":1,"more":1,"economical":1,"choices":1,"while":1,"tzds":1,"have":1,"shown":1,"bene":1,"fi":1,"nafld":1,"they":1,"also":1,"can":1,"increase":1,"must":1,"counseled":1,"accordingly":1,"lastly":1,"symptomatic":1,"hy":1,"perglycemia":1,"suggestive":1,"marked":1,"insulin":1,"de":1},"len":215},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":13,"chunkId":"aace-2023-p13-c6","text":"ciated with low risk for hypoglycemia and have shown bene fi t for NAFLD, they also can increase weight, so patients must be counseled accordingly. Lastly, patients with symptomatic hy- perglycemia and/or an A1C > 10% suggestive of marked insulin de fi ciency should start basal insulin to improve glycemia as quickly as possible. Basal insulin can be initiated with or without initiation and titration of a GLP-1 RA if the patient is not already on this class of agents. Some patients with severe hyperglycemia may need simultaneous initiation of bolus insulin. Clinicians should refer to the Algorithm for Adding/Intensifying Insulin section (Algorithm Fig. 8) for more guidance about initiating or advancing insulin therapy. In persons with newly diagnosed T2D who are drug naive, prospective studies support the initiation of combination therapy to achieve glycemic targets more quickly as compared with a stepwise approach. 155,156 For recently diagnosed individuals with S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 317","tf":{"10":1,"29":1,"155":1,"156":1,"305":1,"317":1,"340":1,"2023":1,"ciated":1,"with":7,"low":1,"risk":1,"for":5,"hypoglycemia":1,"and":3,"have":1,"shown":1,"bene":1,"fi":2,"nafld":1,"they":1,"also":1,"can":2,"increase":1,"weight":1,"so":1,"patients":3,"must":1,"be":2,"counseled":1,"accordingly":1,"lastly":1,"symptomatic":1,"hy":1,"perglycemia":1,"or":3,"an":1,"a1c":1,"suggestive":1,"of":5,"marked":1,"insulin":6,"de":1,"ciency":1,"should":2,"start":1,"basal":2,"to":3,"improve":1,"glycemia":1,"as":3,"quickly":2,"possible":1,"initiated":1,"without":1,"initiation":3,"titration":1,"glp":1,"ra":1,"if":1,"the":3,"patient":1,"is":1,"not":1,"already":1,"on":1,"this":1,"class":1,"agents":1,"some":1,"severe":1,"hyperglycemia":1,"may":1,"need":1,"simultaneous":1,"bolus":1,"clinicians":1,"refer":1,"algorithm":2,"adding":1,"intensifying":1,"section":1,"fig":1,"more":2,"guidance":1,"about":1,"initiating":1,"advancing":1,"therapy":2,"in":1,"persons":1,"newly":1,"diagnosed":2,"t2d":1,"who":1,"are":1,"drug":1,"naive":1,"prospective":1,"studies":1,"support":1,"combination":1,"achieve":1,"glycemic":1,"targets":1,"compared":1,"stepwise":1,"approach":1,"recently":1,"individuals":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":160},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":14,"chunkId":"aace-2023-p14-c0","text":"T2D and an A1C \u0015 7.5%, early combination therapy may also be considered, usually with metformin combined with another agent that does not cause hypoglycemia, particularly a GLP-1 RA, SGLT2i, or DPP-4i. 9 Clinicians should be cognizant that combination of incretin-based therapies is not recommended (ie, DPP-4i with GLP- 1 RA or dual GIP/GLP-1 RA). Antihyperglycemic medications should be titrated to the maximally tolerated dose to achieve the indi- vidualized A1C goal, and additional antihyperglycemic agents should be considered in a timely fashion to avoid therapeutic inertia. If the A1C is > 9% or > 1.5% above goal, \u0015 2 antihyperglycemic agents may need to be initiated at once. 9 Alternative agents and those associated with concerns regarding adverse effects or inef- fectiveness are listed in the algorithm and the clinician is referred to the Pro fi les of Antihyperglycemic Medications table (Algorithm Fig. 9) for more details regarding the risks and bene fi ts of each antihyperglycemic class. Algorithm for Adding/Intensifying Insulin The overall goal of insulin therapy is to achieve glycemic control after failure of noninsulin antihyperglycemic agents. Glycemic targets should be individualized, although an A1C of 6.5% to 7% for persons on insulin is recommended for most patients (Algorithm Fig. 8). Although A1C is a key measure, insulin titration requires use of multiple glyce","tf":{"t2d":1,"and":5,"an":2,"a1c":5,"early":1,"combination":2,"therapy":2,"may":2,"also":1,"be":6,"considered":2,"usually":1,"with":4,"metformin":1,"combined":1,"another":1,"agent":1,"that":2,"does":1,"not":2,"cause":1,"hypoglycemia":1,"particularly":1,"glp":3,"ra":3,"sglt2i":1,"or":4,"dpp":2,"4i":2,"clinicians":1,"should":4,"cognizant":1,"of":7,"incretin":1,"based":1,"therapies":1,"is":6,"recommended":2,"ie":1,"dual":1,"gip":1,"antihyperglycemic":6,"medications":2,"titrated":1,"to":7,"the":8,"maximally":1,"tolerated":1,"dose":1,"achieve":2,"indi":1,"vidualized":1,"goal":3,"additional":1,"agents":4,"in":2,"timely":1,"fashion":1,"avoid":1,"therapeutic":1,"inertia":1,"if":1,"above":1,"need":1,"initiated":1,"at":1,"once":1,"alternative":1,"those":1,"associated":1,"concerns":1,"regarding":2,"adverse":1,"effects":1,"inef":1,"fectiveness":1,"are":1,"listed":1,"algorithm":4,"clinician":1,"referred":1,"pro":1,"fi":2,"les":1,"table":1,"fig":2,"for":4,"more":1,"details":1,"risks":1,"bene":1,"ts":1,"each":1,"class":1,"adding":1,"intensifying":1,"insulin":4,"overall":1,"glycemic":2,"control":1,"after":1,"failure":1,"noninsulin":1,"targets":1,"individualized":1,"although":2,"persons":1,"on":1,"most":1,"patients":1,"key":1,"measure":1,"titration":1,"requires":1,"use":1,"multiple":1,"glyce":1},"len":204},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":14,"chunkId":"aace-2023-p14-c1","text":"hyperglycemic agents. Glycemic targets should be individualized, although an A1C of 6.5% to 7% for persons on insulin is recommended for most patients (Algorithm Fig. 8). Although A1C is a key measure, insulin titration requires use of multiple glycemic parameters including FBG, premeal or 2-hour postprandial BG, and data from CGM, when available, including TIR, time below range, and GMI. 21 In general, targets for fasting and premeal glucose are < 110 mg/dL without hypoglycemia and can be individualized based on a person  s comorbidities and clinical status. The use of CGM is recommended for persons treated with insulin to optimize glycemic control while minimizing hypoglycemia. 20 Symptomatic Hyperglycemia Basal with or without prandial insulin treatment may be needed as initial therapy if the A1C is > 10% and/or glucose values are > 300 mg/dL, combined with catabolic symptoms, such as weight loss. If symptomatic hyperglycemia is present, a GLP-1 RA alone is not recommended as it requires titration and may delay glucose con- trol. The goal of initial intensive insulin therapy for symptomatic hyperglycemia is to reduce glucose levels safely and promptly. After improved glycemic control is achieved with short-term insulin therapy, especially with a new diagnosis of DM, 157 a role for non- insulin antihyperglycemic agents could be considered. Failure of Noninsulin Antihyperglyc","tf":{"10":1,"20":1,"21":1,"110":1,"157":1,"300":1,"hyperglycemic":1,"agents":2,"glycemic":4,"targets":2,"should":1,"be":4,"individualized":2,"although":2,"an":1,"a1c":3,"of":6,"to":3,"for":6,"persons":2,"on":2,"insulin":7,"is":8,"recommended":3,"most":1,"patients":1,"algorithm":1,"fig":1,"key":1,"measure":1,"titration":2,"requires":2,"use":2,"multiple":1,"parameters":1,"including":2,"fbg":1,"premeal":2,"or":3,"hour":1,"postprandial":1,"bg":1,"and":8,"data":1,"from":1,"cgm":2,"when":1,"available":1,"tir":1,"time":1,"below":1,"range":1,"gmi":1,"in":1,"general":1,"fasting":1,"glucose":4,"are":2,"mg":2,"dl":2,"without":2,"hypoglycemia":2,"can":1,"based":1,"person":1,"comorbidities":1,"clinical":1,"status":1,"the":3,"treated":1,"with":5,"optimize":1,"control":2,"while":1,"minimizing":1,"symptomatic":3,"hyperglycemia":3,"basal":1,"prandial":1,"treatment":1,"may":2,"needed":1,"as":3,"initial":2,"therapy":3,"if":2,"values":1,"combined":1,"catabolic":1,"symptoms":1,"such":1,"weight":1,"loss":1,"present":1,"glp":1,"ra":1,"alone":1,"not":1,"it":1,"delay":1,"con":1,"trol":1,"goal":1,"intensive":1,"reduce":1,"levels":1,"safely":1,"promptly":1,"after":1,"improved":1,"achieved":1,"short":1,"term":1,"especially":1,"new":1,"diagnosis":1,"dm":1,"role":1,"non":1,"antihyperglycemic":1,"could":1,"considered":1,"failure":1,"noninsulin":1,"antihyperglyc":1},"len":207},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":14,"chunkId":"aace-2023-p14-c2","text":"els safely and promptly. After improved glycemic control is achieved with short-term insulin therapy, especially with a new diagnosis of DM, 157 a role for non- insulin antihyperglycemic agents could be considered. Failure of Noninsulin Antihyperglycemic Treatments For most persons who need intensi fi cation of glycemic control and who are already undergoing 3 to 4 oral therapies, a GLP-1 RA or GIP/GLP-1 RA should be the initial choice, if not already in use. 9 If glycemic targets are not achieved with these therapies, basal Algorithm Fig. 7. Glucose-Centric Algorithm for Glycemic Control. S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 318","tf":{"29":1,"157":1,"305":1,"318":1,"340":1,"2023":1,"els":1,"safely":1,"and":2,"promptly":1,"after":1,"improved":1,"glycemic":4,"control":3,"is":1,"achieved":2,"with":3,"short":1,"term":1,"insulin":2,"therapy":1,"especially":1,"new":1,"diagnosis":1,"of":3,"dm":1,"role":1,"for":3,"non":1,"antihyperglycemic":2,"agents":1,"could":1,"be":2,"considered":1,"failure":1,"noninsulin":1,"treatments":1,"most":1,"persons":1,"who":2,"need":1,"intensi":1,"fi":1,"cation":1,"are":2,"already":2,"undergoing":1,"to":1,"oral":1,"therapies":2,"glp":2,"ra":2,"or":1,"gip":1,"should":1,"the":1,"initial":1,"choice":1,"if":2,"not":2,"in":1,"use":1,"targets":1,"these":1,"basal":1,"algorithm":2,"fig":1,"glucose":1,"centric":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":101},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":15,"chunkId":"aace-2023-p15-c0","text":"insulin should be added alone or as a basal insulin/GLP-1 RA combination injection. Stepwise addition of prandial insulin at 1 to 3 meals is recommended if additional glycemic control is required. Basal Insulin Initiation The dose of basal insulin can be based on A1C levels at the time of initiation. For an A1C < 8%, basal insulin can be started at 0.1 to 0.2 U/kg/day and for an A1C > 8%, 0.2 to 0.3 U/kg/day can be considered. Analog insulins, including detemir, glargine, or deglu- dec are preferred over human insulins such as neutral protamine Hagedorn (NPH) to reduce hypoglycemia. 9,158 After basal insulin is initiated, discontinuation of SUs is recommended. Fixed-dose GLP- 1 RA and basal insulin combinations also can provide improved glycemic control when basal insulin alone has not achieved targets. 159 Basal Insulin Titration Basal insulin should be titrated every 2 to 3 days to reach gly- cemic targets with a goal FBG of < 110 mg/dL without hypoglycemia. Because of the longer half-life of insulin degludec, slower titration every 3 to 5 days is recommended. Persons taking insulin can be counseled on how to titrate insulin doses independently based on self-monitoring of blood glucose. 160,161 One approach to titration of basal insulin is to use the FBG and increase by 20% if > 180 mg/dL, 10% if 140 to 180 mg/dL, and 1 unit if 110 to 139 mg/dL. Insulin doses should be reduce","tf":{"10":1,"20":1,"110":2,"139":1,"140":1,"158":1,"159":1,"160":1,"161":1,"180":2,"insulin":16,"should":3,"be":7,"added":1,"alone":2,"or":2,"as":2,"basal":10,"glp":2,"ra":2,"combination":1,"injection":1,"stepwise":1,"addition":1,"of":9,"prandial":1,"at":3,"to":12,"meals":1,"is":6,"recommended":3,"if":4,"additional":1,"glycemic":2,"control":2,"required":1,"initiation":2,"the":4,"dose":2,"can":5,"based":2,"on":3,"a1c":3,"levels":1,"time":1,"for":2,"an":2,"started":1,"kg":2,"day":2,"and":4,"considered":1,"analog":1,"insulins":2,"including":1,"detemir":1,"glargine":1,"deglu":1,"dec":1,"are":1,"preferred":1,"over":1,"human":1,"such":1,"neutral":1,"protamine":1,"hagedorn":1,"nph":1,"reduce":2,"hypoglycemia":2,"after":1,"initiated":1,"discontinuation":1,"sus":1,"fixed":1,"combinations":1,"also":1,"provide":1,"improved":1,"when":1,"has":1,"not":1,"achieved":1,"targets":2,"titration":3,"titrated":1,"every":2,"days":2,"reach":1,"gly":1,"cemic":1,"with":1,"goal":1,"fbg":2,"mg":4,"dl":4,"without":1,"because":1,"longer":1,"half":1,"life":1,"degludec":1,"slower":1,"persons":1,"taking":1,"counseled":1,"how":1,"titrate":1,"doses":2,"independently":1,"self":1,"monitoring":1,"blood":1,"glucose":1,"one":1,"approach":1,"use":1,"increase":1,"by":1,"unit":1},"len":229},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":15,"chunkId":"aace-2023-p15-c1","text":" independently based on self-monitoring of blood glucose. 160,161 One approach to titration of basal insulin is to use the FBG and increase by 20% if > 180 mg/dL, 10% if 140 to 180 mg/dL, and 1 unit if 110 to 139 mg/dL. Insulin doses should be reduced as follows for fasting hypoglycemia: FBG < 70 mg/dL, decreased by 10% to 20%; FBG < 40 mg/dL, decreased by 20% to 40%. If the basal insulin dose is > 0.5 units/kg/day or the bedtime minus morning prebreakfast glucose score is > 50 mg/dL, 162 pran- dial insulin should be considered. Initiation of Prandial Insulin Rapid-acting insulin analogs are preferred over human insulin preparations (eg, regular insulin) because of their comparatively earlier onset of action. Prandial insulin can be initiated at the largest meal at 10% of the basal insulin dose or 5 units, with stepwise addition to other meals as additional glycemic control is needed. 163,164 Alternatively, prandial insulin can be started at all meals simultaneously at 50% of the total daily dose divided by the number of meals. 163,164 Although less preferred, fi xed-dose premixed insulins that combine a long-acting and short-acting insulin can also be considered for persons who may have concerns about multiple insulins and injections. Although premixed insulin requires fewer injections, it also has less fl exibility for dosing adjustments and may increase hypoglycemia. 9,165 N","tf":{"10":3,"20":3,"40":2,"50":2,"70":1,"110":1,"139":1,"140":1,"160":1,"161":1,"162":1,"163":2,"164":2,"165":1,"180":2,"independently":1,"based":1,"on":1,"self":1,"monitoring":1,"of":8,"blood":1,"glucose":2,"one":1,"approach":1,"to":7,"titration":1,"basal":3,"insulin":13,"is":4,"use":1,"the":7,"fbg":3,"and":5,"increase":2,"by":4,"if":4,"mg":6,"dl":6,"unit":1,"doses":1,"should":2,"be":5,"reduced":1,"as":2,"follows":1,"for":3,"fasting":1,"hypoglycemia":2,"decreased":2,"dose":4,"units":2,"kg":1,"day":1,"or":2,"bedtime":1,"minus":1,"morning":1,"prebreakfast":1,"score":1,"pran":1,"dial":1,"considered":2,"initiation":1,"prandial":3,"rapid":1,"acting":3,"analogs":1,"are":1,"preferred":2,"over":1,"human":1,"preparations":1,"eg":1,"regular":1,"because":1,"their":1,"comparatively":1,"earlier":1,"onset":1,"action":1,"can":3,"initiated":1,"at":4,"largest":1,"meal":1,"with":1,"stepwise":1,"addition":1,"other":1,"meals":3,"additional":1,"glycemic":1,"control":1,"needed":1,"alternatively":1,"started":1,"all":1,"simultaneously":1,"total":1,"daily":1,"divided":1,"number":1,"although":2,"less":2,"fi":1,"xed":1,"premixed":2,"insulins":2,"that":1,"combine":1,"long":1,"short":1,"also":2,"persons":1,"who":1,"may":2,"have":1,"concerns":1,"about":1,"multiple":1,"injections":2,"requires":1,"fewer":1,"it":1,"has":1,"fl":1,"exibility":1,"dosing":1,"adjustments":1},"len":234},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":15,"chunkId":"aace-2023-p15-c2","text":" insulin can also be considered for persons who may have concerns about multiple insulins and injections. Although premixed insulin requires fewer injections, it also has less fl exibility for dosing adjustments and may increase hypoglycemia. 9,165 Nonetheless, premixed insulin may offer an alternative to achieve adequate glycemic control due to simplicity of the insulin regimen and increased adherence. Prandial Insulin Titration Goal premeal glucose targets are 110 to 140 mg/dL. 9 Prandial insulin should be titrated every 2 to 3 days, based on the premeal glucose of the meal until glycemic targets are met. One approach is to titrate prandial insulin as follows: Algorithm Fig. 8. Algorithm for Adding/Intensifying Insulin. S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 319","tf":{"29":1,"110":1,"140":1,"165":1,"305":1,"319":1,"340":1,"2023":1,"insulin":8,"can":1,"also":2,"be":2,"considered":1,"for":3,"persons":1,"who":1,"may":3,"have":1,"concerns":1,"about":1,"multiple":1,"insulins":1,"and":3,"injections":2,"although":1,"premixed":2,"requires":1,"fewer":1,"it":1,"has":1,"less":1,"fl":1,"exibility":1,"dosing":1,"adjustments":1,"increase":1,"hypoglycemia":1,"nonetheless":1,"offer":1,"an":1,"alternative":1,"to":5,"achieve":1,"adequate":1,"glycemic":2,"control":1,"due":1,"simplicity":1,"of":2,"the":3,"regimen":1,"increased":1,"adherence":1,"prandial":3,"titration":1,"goal":1,"premeal":2,"glucose":2,"targets":2,"are":2,"mg":1,"dl":1,"should":1,"titrated":1,"every":1,"days":1,"based":1,"on":1,"meal":1,"until":1,"met":1,"one":1,"approach":1,"is":1,"titrate":1,"as":1,"follows":1,"algorithm":2,"fig":1,"adding":1,"intensifying":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":120},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":16,"chunkId":"aace-2023-p16-c0","text":"\u000f For pre-midday meal glucose > 110 mg/dL, increase the morning meal dose by 10% to 20% \u000f For pre-evening glucose > 140 mg/dL, increase the midday meal dose by 10% to 20% \u000f For bedtime glucose > 140 mg/dL, increase the pre-evening meal dose by 10% \u000f Fixed-dose insulin can be titrated by 2 units every 2 to 3 days relying on the morning FBG because of the presence of basal insulin Hypoglycemia For premeal hypoglycemia (glucose < 70 mg/dL), prandial insu- lin should be adjusted with the following approach: \u000f For pre-midday meal glucose < 70 mg/dL, decrease AM meal dose by 10% to 20% \u000f For pre-evening meal glucose < 70mg/dL, decrease pre-midday meal dose by 10% to 20% \u000f For bedtime glucose < 70 mg/dL, decrease pre-evening meal dose by 10% to 20% Persons with DM on insulin and their families/companions should be educated on the symptoms and treatment of hypogly- cemia ( < 70 mg/dL) and severe hypoglycemia ( < 54 mg/dL). If a person can safely swallow, an oral source of glucose (eg, tablets, fruit juice) should be given. 166 For a person who is unresponsive or unable to take oral glucose, glucagon should be administered. There are multiple formulations of glucagon available. While older glucagon formulations require reconstitution before subcutaneous or intramuscular injection, soluble glucagon and a glucagon analog, dasiglucagon, are available that do not require reconstitution and ","tf":{"10":6,"20":5,"54":1,"70":4,"110":1,"140":2,"166":1,"for":8,"pre":7,"midday":4,"meal":9,"glucose":9,"mg":8,"dl":9,"increase":3,"the":7,"morning":2,"dose":7,"by":7,"to":7,"evening":4,"bedtime":2,"fixed":1,"insulin":3,"can":2,"be":5,"titrated":1,"units":1,"every":1,"days":1,"relying":1,"on":3,"fbg":1,"because":1,"of":5,"presence":1,"basal":1,"hypoglycemia":3,"premeal":1,"prandial":1,"insu":1,"lin":1,"should":4,"adjusted":1,"with":2,"following":1,"approach":1,"decrease":3,"am":1,"70mg":1,"persons":1,"dm":1,"and":5,"their":1,"families":1,"companions":1,"educated":1,"symptoms":1,"treatment":1,"hypogly":1,"cemia":1,"severe":1,"if":1,"person":2,"safely":1,"swallow":1,"an":1,"oral":2,"source":1,"eg":1,"tablets":1,"fruit":1,"juice":1,"given":1,"who":1,"is":1,"unresponsive":1,"or":2,"unable":1,"take":1,"glucagon":5,"administered":1,"there":1,"are":2,"multiple":1,"formulations":2,"available":2,"while":1,"older":1,"require":2,"reconstitution":2,"before":1,"subcutaneous":1,"intramuscular":1,"injection":1,"soluble":1,"analog":1,"dasiglucagon":1,"that":1,"do":1,"not":1},"len":229},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":16,"chunkId":"aace-2023-p16-c1","text":"e formulations of glucagon available. While older glucagon formulations require reconstitution before subcutaneous or intramuscular injection, soluble glucagon and a glucagon analog, dasiglucagon, are available that do not require reconstitution and are ready for immediate injection. 167,168 Intranasal glucagon also has been shown to be ef fi cacious. 169-173 Pro fi les of Antihyperglycemic Medications The table of Pro fi les of Antihyperglycemic Medications (Algo- rithm Fig. 9) provides a summary of clinically relevant information for approved medical therapies for the treatment of persons with T2D. Details regarding the mechanisms of action and evidence of bene fi ts or harms are outside the scope of this algorithm; clinicians are encouraged to consult the 2022 AACE Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan 9 for more details. The organization of the pharmacologic agents (left to right) and the information selected for each medication (top to bottom) pro- vide a framework for clinicians to select from the multiple available antihyperglycemic medications and to incorporate the highlighted bene fi ts or cautions in discussions with patients. Medications on the left side of the table potentially have more positive indications to be considered fi rst-line compared with agents on the right side of the table. Pro fi les of Weight-Loss Medic","tf":{"167":1,"168":1,"169":1,"173":1,"2022":1,"formulations":2,"of":13,"glucagon":5,"available":3,"while":1,"older":1,"require":2,"reconstitution":2,"before":1,"subcutaneous":1,"or":3,"intramuscular":1,"injection":2,"soluble":1,"and":5,"analog":1,"dasiglucagon":1,"are":4,"that":1,"do":1,"not":1,"ready":1,"for":6,"immediate":1,"intranasal":1,"also":1,"has":1,"been":1,"shown":1,"to":7,"be":2,"ef":1,"fi":7,"cacious":1,"pro":4,"les":3,"antihyperglycemic":3,"medications":4,"the":14,"table":3,"algo":1,"rithm":1,"fig":1,"provides":1,"summary":1,"clinically":1,"relevant":1,"information":2,"approved":1,"medical":1,"therapies":1,"treatment":1,"persons":1,"with":3,"t2d":1,"details":2,"regarding":1,"mechanisms":1,"action":1,"evidence":1,"bene":2,"ts":2,"harms":1,"outside":1,"scope":1,"this":1,"algorithm":1,"clinicians":2,"encouraged":1,"consult":1,"aace":1,"clinical":1,"practice":1,"guideline":1,"developing":1,"diabetes":1,"mellitus":1,"comprehensive":1,"care":1,"plan":1,"more":2,"organization":1,"pharmacologic":1,"agents":2,"left":2,"right":2,"selected":1,"each":1,"medication":1,"top":1,"bottom":1,"vide":1,"framework":1,"select":1,"from":1,"multiple":1,"incorporate":1,"highlighted":1,"cautions":1,"in":1,"discussions":1,"patients":1,"on":2,"side":2,"potentially":1,"have":1,"positive":1,"indications":1,"considered":1,"rst":1,"line":1,"compared":1,"weight":1,"loss":1,"medic":1},"len":207},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":16,"chunkId":"aace-2023-p16-c2","text":"ene fi ts or cautions in discussions with patients. Medications on the left side of the table potentially have more positive indications to be considered fi rst-line compared with agents on the right side of the table. Pro fi les of Weight-Loss Medications The table of Pro fi les of Weight-Loss Medications (Algorithm Fig. 10) summarizes weight-loss therapies currently approved by the FDA regarding approximate ef fi cacy for weight loss, dosing and Algorithm Fig. 9. Pro fi les of Antihyperglycemic Medications. S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 320","tf":{"10":1,"29":1,"305":1,"320":1,"340":1,"2023":1,"ene":1,"fi":6,"ts":1,"or":1,"cautions":1,"in":1,"discussions":1,"with":2,"patients":1,"medications":4,"on":2,"the":6,"left":1,"side":2,"of":6,"table":3,"potentially":1,"have":1,"more":1,"positive":1,"indications":1,"to":1,"be":1,"considered":1,"rst":1,"line":1,"compared":1,"agents":1,"right":1,"pro":3,"les":3,"weight":4,"loss":4,"algorithm":2,"fig":2,"summarizes":1,"therapies":1,"currently":1,"approved":1,"by":1,"fda":1,"regarding":1,"approximate":1,"ef":1,"cacy":1,"for":1,"dosing":1,"and":1,"antihyperglycemic":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":97},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":17,"chunkId":"aace-2023-p17-c0","text":"delivery, and potential side effects and contraindications. For a discussion of the evidence for use of these medications for persons with obesity, prediabetes, or T2D, the clinician should consult the 2022 AACE Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan. 9 Vaccine Recommendations for Persons with Diabetes Vaccine-preventable illnesses caused by bacteria and viruses result in signi fi cant morbidity and mortality, with worse outcomes among high-risk populations like persons with DM. 174-176 Vacci- nations are effective in reducing the severity and associated morbidity and mortality related to these vaccine-preventable ill- nesses. 174,177 However, the rates of vaccination are suboptimal among patients with DM. 178 The CDC Advisory Committee on Immunization Practices (ACIP) maintains a comprehensive and updated reference for age-appro- priate vaccine recommendations (https://www.cdc.gov/vaccines/ schedules/). 179 The AACE supports these recommendations from the CDC/ACIP (Algorithm Fig. 11). The key vaccines recommended for patients with DM also are detailed in the 2022 AACE DM CPG. 9 Despite the evidence supporting effectiveness of vaccinations among patients with DM, most health care professionals (HCPs) do not routinely evaluate the vaccination status of their patients who rely on the HCP  s recommendations to get vaccinated. 180 This ","tf":{"11":1,"174":2,"176":1,"177":1,"178":1,"179":1,"180":1,"2022":2,"delivery":1,"and":7,"potential":1,"side":1,"effects":1,"contraindications":1,"for":6,"discussion":1,"of":5,"the":13,"evidence":2,"use":1,"these":3,"medications":1,"persons":3,"with":7,"obesity":1,"prediabetes":1,"or":1,"t2d":1,"clinician":1,"should":1,"consult":1,"aace":3,"clinical":1,"practice":1,"guideline":1,"developing":1,"diabetes":2,"mellitus":1,"comprehensive":2,"care":2,"plan":1,"vaccine":4,"recommendations":4,"preventable":2,"illnesses":1,"caused":1,"by":1,"bacteria":1,"viruses":1,"result":1,"in":3,"signi":1,"fi":1,"cant":1,"morbidity":2,"mortality":2,"worse":1,"outcomes":1,"among":3,"high":1,"risk":1,"populations":1,"like":1,"dm":5,"vacci":1,"nations":1,"are":3,"effective":1,"reducing":1,"severity":1,"associated":1,"related":1,"to":2,"ill":1,"nesses":1,"however":1,"rates":1,"vaccination":2,"suboptimal":1,"patients":4,"cdc":3,"advisory":1,"committee":1,"on":2,"immunization":1,"practices":1,"acip":2,"maintains":1,"updated":1,"reference":1,"age":1,"appro":1,"priate":1,"https":1,"www":1,"gov":1,"vaccines":2,"schedules":1,"supports":1,"from":1,"algorithm":1,"fig":1,"key":1,"recommended":1,"also":1,"detailed":1,"cpg":1,"despite":1,"supporting":1,"effectiveness":1,"vaccinations":1,"most":1,"health":1,"professionals":1,"hcps":1,"do":1,"not":1,"routinely":1,"evaluate":1,"status":1,"their":1,"who":1,"rely":1,"hcp":1,"get":1,"vaccinated":1,"this":1},"len":201},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":17,"chunkId":"aace-2023-p17-c1","text":"he evidence supporting effectiveness of vaccinations among patients with DM, most health care professionals (HCPs) do not routinely evaluate the vaccination status of their patients who rely on the HCP  s recommendations to get vaccinated. 180 This re- sults in missed opportunities to increase uptake of preventive vaccines. To address this gap in care, the CDC developed a set of steps that form a framework for implementing vaccinations in clinics called the Standards for Adult Immunization Practice (https://www.cdc.gov/vaccines/hcp/adults/for-practice/standards/ index.html). 181 These steps, summarized below, recognize that many HCPs may not be vaccine providers but that they can still play a signi fi cant role in getting their patients vaccinated. \u000f Assess immunization status of all persons with DM at every encounter. This involves staying up to date with the latest vac- cine recommendations, implementing protocols that facilitate review of patient immunization status by the care team, and sending reminders for vaccinations. 182 \u000f Strongly recommend vaccines to patients who are not fully vaccinated. Recommendation from the HCP is a strong predictor of vaccine acceptance by patients. 183 Address patient questions and concerns, explain bene fi ts of vaccination, and highlight positive experiences with vaccinations. \u000f Administer the vaccines you stock and for those you do not st","tf":{"180":1,"181":1,"182":1,"183":1,"he":1,"evidence":1,"supporting":1,"effectiveness":1,"of":8,"vaccinations":4,"among":1,"patients":5,"with":4,"dm":2,"most":1,"health":1,"care":3,"professionals":1,"hcps":2,"do":2,"not":4,"routinely":1,"evaluate":1,"the":8,"vaccination":2,"status":3,"their":2,"who":2,"rely":1,"on":1,"hcp":3,"recommendations":2,"to":5,"get":1,"vaccinated":3,"this":3,"re":1,"sults":1,"in":4,"missed":1,"opportunities":1,"increase":1,"uptake":1,"preventive":1,"vaccines":4,"address":2,"gap":1,"cdc":2,"developed":1,"set":1,"steps":2,"that":4,"form":1,"framework":1,"for":5,"implementing":2,"clinics":1,"called":1,"standards":2,"adult":1,"immunization":3,"practice":2,"https":1,"www":1,"gov":1,"adults":1,"index":1,"html":1,"these":1,"summarized":1,"below":1,"recognize":1,"many":1,"may":1,"be":1,"vaccine":2,"providers":1,"but":1,"they":1,"can":1,"still":1,"play":1,"signi":1,"fi":2,"cant":1,"role":1,"getting":1,"assess":1,"all":1,"persons":1,"at":1,"every":1,"encounter":1,"involves":1,"staying":1,"up":1,"date":1,"latest":1,"vac":1,"cine":1,"protocols":1,"facilitate":1,"review":1,"patient":2,"by":2,"team":1,"and":4,"sending":1,"reminders":1,"strongly":1,"recommend":1,"are":1,"fully":1,"recommendation":1,"from":1,"is":1,"strong":1,"predictor":1,"acceptance":1,"questions":1,"concerns":1,"explain":1,"bene":1,"ts":1,"highlight":1,"positive":1,"experiences":1,"administer":1,"you":2,"stock":1,"those":1,"st":1},"len":209},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":17,"chunkId":"aace-2023-p17-c2","text":"a strong predictor of vaccine acceptance by patients. 183 Address patient questions and concerns, explain bene fi ts of vaccination, and highlight positive experiences with vaccinations. \u000f Administer the vaccines you stock and for those you do not stock, refer your patient to facilities that can provide these vaccines. Know the local resources where you can refer your patients for vaccination. \u000f Document vaccines administered in your of fi ce or by other vaccine providers in the electronic health record (EHR). Make sure the EHR communicates with your state  s immunization information sys- tem in a bidirectional manner to consolidate vaccination records. Documentations will ensure patients get the vaccinations they need and will prevent unnecessary vaccinations. Algorithm Fig. 10. Pro fi les of Weight-Loss Medications. S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 321","tf":{"10":1,"29":1,"183":1,"305":1,"321":1,"340":1,"2023":1,"strong":1,"predictor":1,"of":4,"vaccine":2,"acceptance":1,"by":2,"patients":3,"address":1,"patient":2,"questions":1,"and":4,"concerns":1,"explain":1,"bene":1,"fi":3,"ts":1,"vaccination":3,"highlight":1,"positive":1,"experiences":1,"with":2,"vaccinations":3,"administer":1,"the":5,"vaccines":3,"you":3,"stock":2,"for":2,"those":1,"do":1,"not":1,"refer":2,"your":4,"to":2,"facilities":1,"that":1,"can":2,"provide":1,"these":1,"know":1,"local":1,"resources":1,"where":1,"document":1,"administered":1,"in":3,"ce":1,"or":1,"other":1,"providers":1,"electronic":1,"health":1,"record":1,"ehr":2,"make":1,"sure":1,"communicates":1,"state":1,"immunization":1,"information":1,"sys":1,"tem":1,"bidirectional":1,"manner":1,"consolidate":1,"records":1,"documentations":1,"will":2,"ensure":1,"get":1,"they":1,"need":1,"prevent":1,"unnecessary":1,"algorithm":1,"fig":1,"pro":1,"les":1,"weight":1,"loss":1,"medications":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":133},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":18,"chunkId":"aace-2023-p18-c0","text":"When incorporated into routine clinic visits, these steps will be effective in increasing vaccinations and providing protection for patients with DM. Having a properly trained staff and a culture of vaccine con fi dence in the entire clinical practice are important in ensuring that all health care team members are engaged in efforts to improve patient vaccinations. Other measures recommended to improve vaccination rates include making vaccinations more convenient, coadministration of compatible vaccines, and making use of vaccination champions in the clinical setting. 184 Review Process Drafts of this consensus statement were reviewed and approved by all task force members, the AACE CPG Oversight Committee, the AACE Board of Directors, and peer reviewers for Endocrine Practice . Disclosures The Task Force was empaneled in accordance with the AACE Con fl ict of Interest (COI) Policy and approved by the AACE COI Subcommittee, Clinical Practice Guidelines Oversight Committee, and AACE executive leadership. All members of the expert Task Force completed disclosures related to commercial and direct fi nancial relationships within the preceding 12 months with com- panies that develop products connected with endocrine disorders. Categories for disclosure included employment, stock or other ownership, direct fi nancial relationships (eg, speaker or consul- tant), research funding, auth","tf":{"12":1,"184":1,"when":1,"incorporated":1,"into":1,"routine":1,"clinic":1,"visits":1,"these":1,"steps":1,"will":1,"be":1,"effective":1,"in":6,"increasing":1,"vaccinations":3,"and":8,"providing":1,"protection":1,"for":3,"patients":1,"with":4,"dm":1,"having":1,"properly":1,"trained":1,"staff":1,"culture":1,"of":7,"vaccine":1,"con":2,"fi":3,"dence":1,"the":9,"entire":1,"clinical":3,"practice":3,"are":2,"important":1,"ensuring":1,"that":2,"all":3,"health":1,"care":1,"team":1,"members":3,"engaged":1,"efforts":1,"to":3,"improve":2,"patient":1,"other":2,"measures":1,"recommended":1,"vaccination":2,"rates":1,"include":1,"making":2,"more":1,"convenient":1,"coadministration":1,"compatible":1,"vaccines":1,"use":1,"champions":1,"setting":1,"review":1,"process":1,"drafts":1,"this":1,"consensus":1,"statement":1,"were":1,"reviewed":1,"approved":2,"by":2,"task":3,"force":3,"aace":5,"cpg":1,"oversight":2,"committee":2,"board":1,"directors":1,"peer":1,"reviewers":1,"endocrine":2,"disclosures":2,"was":1,"empaneled":1,"accordance":1,"fl":1,"ict":1,"interest":1,"coi":2,"policy":1,"subcommittee":1,"guidelines":1,"executive":1,"leadership":1,"expert":1,"completed":1,"related":1,"commercial":1,"direct":2,"nancial":2,"relationships":2,"within":1,"preceding":1,"months":1,"com":1,"panies":1,"develop":1,"products":1,"connected":1,"disorders":1,"categories":1,"disclosure":1,"included":1,"employment":1,"stock":1,"or":2,"ownership":1,"eg":1,"speaker":1,"consul":1,"tant":1,"research":1,"funding":1,"auth":1},"len":201},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":18,"chunkId":"aace-2023-p18-c1","text":"ceding 12 months with com- panies that develop products connected with endocrine disorders. Categories for disclosure included employment, stock or other ownership, direct fi nancial relationships (eg, speaker or consul- tant), research funding, authorship or panel involvement on a guideline or white paper related to an overlapping topic, or other situations related to a perceived COI. The AACE COI Subcommittee reviewed disclosures of potential authors against an AACE- approved list of affected companies related to the topic of this consensus statement and made recommendations regarding who could serve on the Task Force in the noncon fl icted majority, those who could serve in the con fl icted minority with management strategy, and those who were disquali fi ed from serving on the Task Force. Members of this Task Force were reminded throughout development to update potential disclosures if any new relation- ships/potential COI arose during their appointments and to verify currency of disclosures. AACE made every effort to minimize the potential for COI that could in fl uence guidance provided in this consensus statement. S.L.S. is a member of the AACE Board of Directors and Executive Committee and has received research support to Mayo Clinic from Corcept, served on a steering committee, and been a national or overall principal investigator from Chiasma and Novartis, and is ABIM","tf":{"12":1,"ceding":1,"months":1,"with":3,"com":1,"panies":1,"that":2,"develop":1,"products":1,"connected":1,"endocrine":1,"disorders":1,"categories":1,"for":2,"disclosure":1,"included":1,"employment":1,"stock":1,"or":6,"other":2,"ownership":1,"direct":1,"fi":2,"nancial":1,"relationships":1,"eg":1,"speaker":1,"consul":1,"tant":1,"research":2,"funding":1,"authorship":1,"panel":1,"involvement":1,"on":4,"guideline":1,"white":1,"paper":1,"related":3,"to":7,"an":2,"overlapping":1,"topic":2,"situations":1,"perceived":1,"coi":4,"the":8,"aace":4,"subcommittee":1,"reviewed":1,"disclosures":3,"of":7,"potential":4,"authors":1,"against":1,"approved":1,"list":1,"affected":1,"companies":1,"this":3,"consensus":2,"statement":2,"and":8,"made":2,"recommendations":1,"regarding":1,"who":3,"could":3,"serve":2,"task":3,"force":3,"in":4,"noncon":1,"fl":3,"icted":2,"majority":1,"those":2,"con":1,"minority":1,"management":1,"strategy":1,"were":2,"disquali":1,"ed":1,"from":3,"serving":1,"members":1,"reminded":1,"throughout":1,"development":1,"update":1,"if":1,"any":1,"new":1,"relation":1,"ships":1,"arose":1,"during":1,"their":1,"appointments":1,"verify":1,"currency":1,"every":1,"effort":1,"minimize":1,"uence":1,"guidance":1,"provided":1,"is":2,"member":1,"board":1,"directors":1,"executive":1,"committee":2,"has":1,"received":1,"support":1,"mayo":1,"clinic":1,"corcept":1,"served":1,"steering":1,"been":1,"national":1,"overall":1,"principal":1,"investigator":1,"chiasma":1,"novartis":1,"abim":1},"len":212},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":18,"chunkId":"aace-2023-p18-c2","text":" member of the AACE Board of Directors and Executive Committee and has received research support to Mayo Clinic from Corcept, served on a steering committee, and been a national or overall principal investigator from Chiasma and Novartis, and is ABIM Chair, Longitudinal Knowledge Assessment Approval Com- mittee for Endocrinology, Diabetes, and Metabolism. P.V. is a consultant for Takeda Pharmaceutical Company and has been a national or overall principal investigator for National Institutes of Health grant K23 DK 11324-01A1. L.B. is a consultant, with payment to Ochsner Health, for Corcept Therapeutics, Merck, Novo Nordisk, Salix Pharmaceuticals, and Sano fi . E.A.C. received research support to company from Abbott and AbbVie; is a consultant for Ascendis, Boehringer Ingelheim, and Novo Nordisk; is a speaker for Amryt, AstraZeneca, Bayer, Corcept, Eli Lilly, Boehringer Ingelheim, and Novo Nordisk; designed study protocol and is a national principal investigator for the GLITTER1 diabetes mellitus trial funded by Gan & Lee pharmaceuticals; is owner of Endocrinology Associates, Inc; and is part-owner of MediZen. R.J.G. is or has been a consultant for Algorithm Fig. 11. Vaccine Recommendations for Persons with Diabetes Mellitus. S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 322","tf":{"11":1,"29":1,"305":1,"322":1,"340":1,"2023":1,"11324":1,"member":1,"of":5,"the":2,"aace":1,"board":1,"directors":1,"and":13,"executive":1,"committee":2,"has":3,"received":2,"research":2,"support":2,"to":3,"mayo":1,"clinic":1,"from":3,"corcept":3,"served":1,"on":1,"steering":1,"been":3,"national":4,"or":3,"overall":2,"principal":3,"investigator":3,"chiasma":1,"novartis":1,"is":9,"abim":1,"chair":1,"longitudinal":1,"knowledge":1,"assessment":1,"approval":1,"com":1,"mittee":1,"for":9,"endocrinology":2,"diabetes":3,"metabolism":1,"consultant":4,"takeda":1,"pharmaceutical":1,"company":2,"institutes":1,"health":2,"grant":1,"k23":1,"dk":1,"01a1":1,"with":2,"payment":1,"ochsner":1,"therapeutics":1,"merck":1,"novo":3,"nordisk":3,"salix":1,"pharmaceuticals":2,"sano":1,"fi":1,"abbott":1,"abbvie":1,"ascendis":1,"boehringer":2,"ingelheim":2,"speaker":1,"amryt":1,"astrazeneca":1,"bayer":1,"eli":1,"lilly":1,"designed":1,"study":1,"protocol":1,"glitter1":1,"mellitus":2,"trial":1,"funded":1,"by":1,"gan":1,"lee":1,"owner":2,"associates":1,"inc":1,"part":1,"medizen":1,"algorithm":1,"fig":1,"vaccine":1,"recommendations":1,"persons":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":183},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":19,"chunkId":"aace-2023-p19-c0","text":"2023 AACE Type 2 Diabetes Algorithm Title Page. AACE  American Association of Endocrinology. S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 323","tf":{"29":1,"305":1,"323":1,"340":1,"2023":2,"aace":2,"type":1,"diabetes":1,"algorithm":1,"title":1,"page":1,"american":1,"association":1,"of":1,"endocrinology":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":24},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":20,"chunkId":"aace-2023-p20-c0","text":"2023 AACE Type 2 Diabetes Algorithm Table of Contents. AACE  American Association of Endocrinology. S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 324","tf":{"29":1,"305":1,"324":1,"340":1,"2023":2,"aace":2,"type":1,"diabetes":1,"algorithm":1,"table":1,"of":2,"contents":1,"american":1,"association":1,"endocrinology":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":25},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":21,"chunkId":"aace-2023-p21-c0","text":"S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 325","tf":{"29":1,"305":1,"325":1,"340":1,"2023":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":12},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":22,"chunkId":"aace-2023-p22-c0","text":"S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 326","tf":{"29":1,"305":1,"326":1,"340":1,"2023":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":12},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":23,"chunkId":"aace-2023-p23-c0","text":"S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 327","tf":{"29":1,"305":1,"327":1,"340":1,"2023":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":12},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":24,"chunkId":"aace-2023-p24-c0","text":"S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 328","tf":{"29":1,"305":1,"328":1,"340":1,"2023":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":12},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":25,"chunkId":"aace-2023-p25-c0","text":"S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 329","tf":{"29":1,"305":1,"329":1,"340":1,"2023":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":12},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":26,"chunkId":"aace-2023-p26-c0","text":"S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 330","tf":{"29":1,"305":1,"330":1,"340":1,"2023":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":12},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":27,"chunkId":"aace-2023-p27-c0","text":"S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 331","tf":{"29":1,"305":1,"331":1,"340":1,"2023":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":12},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":28,"chunkId":"aace-2023-p28-c0","text":"S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 332","tf":{"29":1,"305":1,"332":1,"340":1,"2023":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":12},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":29,"chunkId":"aace-2023-p29-c0","text":"S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 333","tf":{"29":1,"305":1,"333":1,"340":1,"2023":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":12},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":30,"chunkId":"aace-2023-p30-c0","text":"S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 334","tf":{"29":1,"305":1,"334":1,"340":1,"2023":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":12},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":31,"chunkId":"aace-2023-p31-c0","text":"S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 335","tf":{"29":1,"305":1,"335":1,"340":1,"2023":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":12},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":32,"chunkId":"aace-2023-p32-c0","text":"Bayer, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, P fi zer, Sano fi , and Weight Watchers; has received research support to Emory University for investigator-initiated studies and been a national or overall principal investigator for Dexcom, Eli Lilly and Company, and Novo Nordisk; and has been partially supported by the National Institute of Diabetes and Digestive and Kidney Dis- eases (NIDDK) of the National Institutes of Health under Award Numbers P30DK111024-04S, 1K23DK123384. I.B.H. is on the advi- sory boards of Abbott, Bigfoot, GWave, and Roche; received research support from Beta Bionics, Insulet, and Medtronic Dia- betes Care; participated in development of a consensus report on the Management of Type 1 Diabetes in Adults for the American Diabetes Association and European Association for the Study of Diabetes and an Endocrine Society guideline on inpatient diabetes management. S.D.I. is a member of the AACE Board of Directors and Executive Committee and is a consultant (without pay) for Myovant Sciences, Madrigal Pharmaceuticals, Siemens, and Novo Nordisk. K.E.I. is a member of the AACE Board of Directors and has received research support from Novo Nordisk and is on the board of the Nevada Clinical Endocrinologists Association. C.C.L. receives research support to Jaeb Coordinating Center and the University of Colorado for investigator-initiated studies ","tf":{"bayer":1,"boehringer":1,"ingelheim":1,"eli":2,"lilly":2,"and":18,"company":2,"novo":4,"nordisk":4,"fi":2,"zer":1,"sano":1,"weight":1,"watchers":1,"has":3,"received":3,"research":4,"support":4,"to":2,"emory":1,"university":2,"for":6,"investigator":3,"initiated":2,"studies":2,"been":2,"national":3,"or":1,"overall":1,"principal":1,"dexcom":1,"partially":1,"supported":1,"by":1,"the":11,"institute":1,"of":13,"diabetes":5,"digestive":1,"kidney":1,"dis":1,"eases":1,"niddk":1,"institutes":1,"health":1,"under":1,"award":1,"numbers":1,"p30dk111024":1,"04s":1,"1k23dk123384":1,"is":5,"on":4,"advi":1,"sory":1,"boards":1,"abbott":1,"bigfoot":1,"gwave":1,"roche":1,"from":2,"beta":1,"bionics":1,"insulet":1,"medtronic":1,"dia":1,"betes":1,"care":1,"participated":1,"in":2,"development":1,"consensus":1,"report":1,"management":2,"type":1,"adults":1,"american":1,"association":3,"european":1,"study":1,"an":1,"endocrine":1,"society":1,"guideline":1,"inpatient":1,"member":2,"aace":2,"board":3,"directors":2,"executive":1,"committee":1,"consultant":1,"without":1,"pay":1,"myovant":1,"sciences":1,"madrigal":1,"pharmaceuticals":1,"siemens":1,"nevada":1,"clinical":1,"endocrinologists":1,"receives":1,"jaeb":1,"coordinating":1,"center":1,"colorado":1},"len":201},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":32,"chunkId":"aace-2023-p32-c1","text":"d has received research support from Novo Nordisk and is on the board of the Nevada Clinical Endocrinologists Association. C.C.L. receives research support to Jaeb Coordinating Center and the University of Colorado for investigator-initiated studies from Dexcom, Inc, is treasurer of the American College of Diabetology, secretary of the Clinical Diabetes and Endocrine Institute, and chair of the Advisory Committee for the FDA on Endocrinologic and Metabolic Drugs, whose views are not represented herein. G.E.U. has received research support and been a national or overall principal investi- gator for AstraZeneca, Dexcom, and Novo Nordisk; serves as pres- ident, Medicine & Science, for the American Diabetes Association; and participated in development of the Endocrine Society guideline on hospital diabetes and Society of Critical Care guideline on ICU diabetes. W.M.V. and C.L.T. have no con fl icts of interest to disclose. Acknowledgment The task force is grateful for the invaluable contributions of authors of preceding versions of the AACE Comprehensive Type 2 Diabetes Management Algorithm and the ACE/AACE Diabetes Roadmaps who laid the foundation for this 2023 update: Martin J. Abrahamson, Joshua I. Barzilay, Lawrence Blonde, Zachary T. Bloomgarden, Michael A. Bush, Samuel Dagogo-Jack, Jaime A. Davidson, Michael B. Davidson, Michael H. Davidson, Ralph A. DeFronzo, Daniel Einhorn,","tf":{"2023":1,"has":2,"received":2,"research":3,"support":3,"from":2,"novo":2,"nordisk":2,"and":11,"is":3,"on":4,"the":14,"board":1,"of":12,"nevada":1,"clinical":2,"endocrinologists":1,"association":2,"receives":1,"to":2,"jaeb":1,"coordinating":1,"center":1,"university":1,"colorado":1,"for":6,"investigator":1,"initiated":1,"studies":1,"dexcom":2,"inc":1,"treasurer":1,"american":2,"college":1,"diabetology":1,"secretary":1,"diabetes":6,"endocrine":2,"institute":1,"chair":1,"advisory":1,"committee":1,"fda":1,"endocrinologic":1,"metabolic":1,"drugs":1,"whose":1,"views":1,"are":1,"not":1,"represented":1,"herein":1,"been":1,"national":1,"or":1,"overall":1,"principal":1,"investi":1,"gator":1,"astrazeneca":1,"serves":1,"as":1,"pres":1,"ident":1,"medicine":1,"science":1,"participated":1,"in":1,"development":1,"society":2,"guideline":2,"hospital":1,"critical":1,"care":1,"icu":1,"have":1,"no":1,"con":1,"fl":1,"icts":1,"interest":1,"disclose":1,"acknowledgment":1,"task":1,"force":1,"grateful":1,"invaluable":1,"contributions":1,"authors":1,"preceding":1,"versions":1,"aace":2,"comprehensive":1,"type":1,"management":1,"algorithm":1,"ace":1,"roadmaps":1,"who":1,"laid":1,"foundation":1,"this":1,"update":1,"martin":1,"abrahamson":1,"joshua":1,"barzilay":1,"lawrence":1,"blonde":1,"zachary":1,"bloomgarden":1,"michael":3,"bush":1,"samuel":1,"dagogo":1,"jack":1,"jaime":1,"davidson":3,"ralph":1,"defronzo":1,"daniel":1,"einhorn":1},"len":193},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":32,"chunkId":"aace-2023-p32-c2","text":"e foundation for this 2023 update: Martin J. Abrahamson, Joshua I. Barzilay, Lawrence Blonde, Zachary T. Bloomgarden, Michael A. Bush, Samuel Dagogo-Jack, Jaime A. Davidson, Michael B. Davidson, Michael H. Davidson, Ralph A. DeFronzo, Daniel Einhorn, Vivian A. Fonseca, Alan J. Garber, Jeffrey R. Garber, James Garvin III, W. Timothy Garvey, George Grunberger, Yehuda Handelsman, Richard Hellman, Robert R. Henry, Irl B. Hirsch, Edward S. Horton, Paul S. Jellinger, Harold Lebovitz, Philip Levy, Janet B. McGill, Jeffrey I. Mechanick, Etie S. Moghissi, Leigh Perreault, Victor L. Roberts, Helena W. Rodbard, Paul D. Rosenblit, Susan L. Samson, Stanley S. Schwartz, and Guillermo E. Umpierrez. Funding This comprehensive management algorithm for type 2 diabetes was developed with fi nancial support from the American Associa- tion of Clinical Endocrinology (AACE). AACE received no outside funding for the development of this consensus statement. All members who served on this AACE task force completed work on the manuscript electronically and met via video conferences. Volunteer authors on this task force received no remuneration for their participation in development of this consensus statement. Panel Composition The Task Force was empaneled in accordance with the AACE Con fl ict of Interest and Diversity, Equity, and Inclusion policies. This consensus statement was developed by a group of","tf":{"2023":1,"foundation":1,"for":4,"this":7,"update":1,"martin":1,"abrahamson":1,"joshua":1,"barzilay":1,"lawrence":1,"blonde":1,"zachary":1,"bloomgarden":1,"michael":3,"bush":1,"samuel":1,"dagogo":1,"jack":1,"jaime":1,"davidson":3,"ralph":1,"defronzo":1,"daniel":1,"einhorn":1,"vivian":1,"fonseca":1,"alan":1,"garber":2,"jeffrey":2,"james":1,"garvin":1,"iii":1,"timothy":1,"garvey":1,"george":1,"grunberger":1,"yehuda":1,"handelsman":1,"richard":1,"hellman":1,"robert":1,"henry":1,"irl":1,"hirsch":1,"edward":1,"horton":1,"paul":2,"jellinger":1,"harold":1,"lebovitz":1,"philip":1,"levy":1,"janet":1,"mcgill":1,"mechanick":1,"etie":1,"moghissi":1,"leigh":1,"perreault":1,"victor":1,"roberts":1,"helena":1,"rodbard":1,"rosenblit":1,"susan":1,"samson":1,"stanley":1,"schwartz":1,"and":4,"guillermo":1,"umpierrez":1,"funding":2,"comprehensive":1,"management":1,"algorithm":1,"type":1,"diabetes":1,"was":3,"developed":2,"with":2,"fi":1,"nancial":1,"support":1,"from":1,"the":5,"american":1,"associa":1,"tion":1,"of":5,"clinical":1,"endocrinology":1,"aace":4,"received":2,"no":2,"outside":1,"development":2,"consensus":3,"statement":3,"all":1,"members":1,"who":1,"served":1,"on":3,"task":3,"force":3,"completed":1,"work":1,"manuscript":1,"electronically":1,"met":1,"via":1,"video":1,"conferences":1,"volunteer":1,"authors":1,"remuneration":1,"their":1,"participation":1,"in":2,"panel":1,"composition":1,"empaneled":1,"accordance":1,"con":1,"fl":1,"ict":1,"interest":1,"diversity":1,"equity":1,"inclusion":1,"policies":1,"by":1,"group":1},"len":182},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":32,"chunkId":"aace-2023-p32-c3","text":"cipation in development of this consensus statement. Panel Composition The Task Force was empaneled in accordance with the AACE Con fl ict of Interest and Diversity, Equity, and Inclusion policies. This consensus statement was developed by a group of credentialed medical professionals in the fi eld of endocrinology. Participants on this task force included current AACE members in good standing. Updating Policy AACE reviews and updates or retires its guidance documents every 3 to 5 years or after signi fi cant scienti fi c developments or change in public policy as determined by AACE executive leader- ship, the AACE Clinical Practice Guidelines Oversight Committee, and relevant AACE disease state network(s). Document Expiration Date : June 2026 References 1. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American As- sociation of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract . 2009;15(6):540 e 559. https://doi.org/10.4158/ ep.15.6.540 2. Jellinger PS, Davidson JA, Blonde L, et al. Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. Endocr Pract . 2007;13(3):260 e 268. https://doi.org/10.4158/ep.13.3.260 3. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. ","tf":{"10":2,"13":2,"15":2,"260":2,"268":1,"540":2,"559":1,"2007":1,"2009":1,"2013":1,"2026":1,"4158":2,"cipation":1,"in":6,"development":1,"of":6,"this":3,"consensus":3,"statement":3,"panel":2,"composition":1,"the":4,"task":3,"force":3,"was":2,"empaneled":1,"accordance":1,"with":1,"aace":8,"con":1,"fl":1,"ict":1,"interest":1,"and":4,"diversity":1,"equity":1,"inclusion":1,"policies":1,"developed":1,"by":3,"group":1,"credentialed":1,"medical":1,"professionals":1,"fi":3,"eld":1,"endocrinology":2,"participants":1,"on":2,"included":1,"current":1,"members":1,"good":1,"standing":1,"updating":1,"policy":2,"reviews":1,"updates":1,"or":3,"retires":1,"its":1,"guidance":1,"documents":1,"every":1,"to":2,"years":1,"after":1,"signi":1,"cant":1,"scienti":1,"developments":1,"change":1,"public":1,"as":2,"determined":1,"executive":1,"leader":1,"ship":1,"clinical":2,"practice":1,"guidelines":1,"oversight":1,"committee":1,"relevant":1,"disease":1,"state":1,"network":1,"document":1,"expiration":1,"date":1,"june":1,"references":1,"rodbard":1,"hw":1,"jellinger":2,"ps":2,"davidson":2,"ja":2,"et":3,"al":3,"an":2,"american":2,"sociation":1,"endocrinologists":1,"college":1,"type":2,"diabetes":4,"mellitus":2,"algorithm":2,"for":1,"glycemic":2,"control":2,"endocr":2,"pract":2,"https":2,"doi":2,"org":2,"ep":2,"blonde":1,"road":2,"maps":1,"achieve":1,"ace":1,"map":1,"garber":1,"aj":1,"abrahamson":1,"mj":1,"barzilay":1,"ji":1,"comprehensive":1,"management":1},"len":210},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":32,"chunkId":"aace-2023-p32-c4","text":"trol in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. Endocr Pract . 2007;13(3):260 e 268. https://doi.org/10.4158/ep.13.3.260 3. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract . 2013;19(2):327 e 336. https:// doi.org/10.4158/endp.19.2.a38267720403k242 4. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algo- rithm  2015 executive summary. Endocr Pract . 2015;21(12):1403 e 1414. https://doi.org/10.4158/ep151063.Cs 5. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algo- rithm  2016 executive summary. Endocr Pract . 2016;22(1):84 e 113. https:// doi.org/10.4158/ep151126.Cs 6. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2018 executive summary. Endocr Pract . 2018;24(1):91 e 120. https://doi.org/ 10.4158/cs-2017-0153 7. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Assoc","tf":{"10":5,"12":1,"13":2,"19":2,"21":1,"22":1,"24":1,"84":1,"91":1,"113":1,"120":1,"260":2,"268":1,"327":1,"336":1,"1403":1,"1414":1,"2007":1,"2013":2,"2015":2,"2016":2,"2017":1,"2018":2,"4158":5,"trol":1,"in":1,"type":4,"diabetes":6,"mellitus":1,"ace":1,"aace":2,"road":1,"map":1,"task":1,"force":1,"endocr":5,"pract":5,"https":5,"doi":5,"org":5,"ep":1,"garber":5,"aj":5,"abrahamson":5,"mj":5,"barzilay":5,"ji":5,"et":5,"al":5,"comprehensive":4,"management":4,"algorithm":2,"endp":1,"a38267720403k242":1,"consensus":4,"statement":4,"by":4,"the":7,"american":7,"association":3,"of":6,"clinical":3,"endocrinologists":3,"and":3,"college":3,"endocrinology":3,"on":3,"algo":2,"rithm":2,"executive":3,"summary":3,"ep151063":1,"cs":3,"ep151126":1,"0153":1,"assoc":1},"len":207},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":32,"chunkId":"aace-2023-p32-c5","text":"y on the comprehensive type 2 diabetes management algorithm - 2018 executive summary. Endocr Pract . 2018;24(1):91 e 120. https://doi.org/ 10.4158/cs-2017-0153 7. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2019 executive summary. Endocr Pract . 2019;25(1):69 e 100. https://doi.org/ 10.4158/cs-2018-0535 8. Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract . 2020;26(1):107 e 139. https:// doi.org/10.4158/cs-2019-0472 9. Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update. Endocr Pract . 2022;28(10):923 e 1049. https://doi.org/10.1016/j.eprac.2022.08.002 10. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Dia- betes Care . 2022;45(11):2753 e 2786. https://doi.org/10.2337/dci22-0034 11. Handelsman Y, Ander","tf":{"10":7,"11":2,"24":1,"25":1,"26":1,"28":1,"45":1,"69":1,"91":1,"100":1,"107":1,"120":1,"139":1,"923":1,"1016":1,"1049":1,"2017":1,"2018":3,"2019":3,"2020":2,"2022":5,"2337":1,"2753":1,"2786":1,"4158":3,"on":3,"the":8,"comprehensive":4,"type":4,"diabetes":7,"management":4,"algorithm":3,"executive":3,"summary":3,"endocr":4,"pract":4,"https":5,"doi":5,"org":5,"cs":3,"0153":1,"garber":2,"aj":2,"abrahamson":1,"mj":2,"barzilay":1,"ji":1,"et":4,"al":4,"consensus":3,"statement":2,"by":3,"american":6,"association":5,"of":7,"clinical":4,"endocrinologists":2,"and":3,"college":2,"endocrinology":3,"0535":1,"handelsman":2,"grunberger":1,"0472":1,"blonde":1,"umpierrez":1,"ge":1,"reddy":1,"ss":1,"practice":1,"guideline":1,"developing":1,"mellitus":1,"care":2,"plan":1,"update":1,"eprac":1,"08":1,"002":1,"davies":1,"aroda":1,"vr":1,"collins":1,"bs":1,"hyperglycemia":1,"in":1,"report":1,"ada":1,"european":1,"for":1,"study":1,"easd":1,"dia":1,"betes":1,"dci22":1,"0034":1,"ander":1},"len":205},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":32,"chunkId":"aace-2023-p32-c6","text":" type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Dia- betes Care . 2022;45(11):2753 e 2786. https://doi.org/10.2337/dci22-0034 11. Handelsman Y, Anderson JE, Bakris GL, et al. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and meta- bolic diseases. J Diabetes Complications . 2022;36(2), 108101. https://doi.org/ 10.1016/j.jdiacomp.2021.108101 12. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet . 2010;376(9739):419 e 430. https:// doi.org/10.1016/s0140-6736(10)60576-4 13. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med . 2008;358(24):2560 e 2572. https://doi.org/10.1056/NEJMoa0802987 14. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med . 2008;358(24):2545 e 2559. https://doi.org/10.1056/NEJMoa0802743 15. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in N","tf":{"10":6,"11":2,"12":1,"13":1,"14":1,"15":1,"24":2,"36":1,"45":1,"358":2,"376":1,"419":1,"430":1,"1016":2,"1056":2,"2008":2,"2010":1,"2021":1,"2022":3,"2337":1,"2545":1,"2559":1,"2560":1,"2572":1,"2753":1,"2786":1,"6736":1,"9739":1,"60576":1,"108101":2,"type":4,"diabetes":9,"consensus":1,"report":1,"by":1,"the":6,"american":1,"association":3,"ada":1,"and":4,"european":2,"for":2,"study":2,"of":7,"easd":1,"dia":1,"betes":1,"care":1,"https":5,"doi":5,"org":5,"dci22":1,"0034":1,"handelsman":1,"anderson":1,"je":1,"bakris":1,"gl":1,"et":4,"al":4,"dcrm":1,"multispecialty":1,"practice":1,"recommendations":1,"management":1,"cardiorenal":1,"meta":1,"bolic":1,"diseases":1,"complications":1,"jdiacomp":1,"ismail":1,"beigi":1,"craven":1,"banerji":1,"ma":1,"effect":1,"intensive":3,"treatment":1,"hyperglycaemia":1,"on":1,"microvascular":1,"outcomes":2,"in":6,"an":1,"analysis":1,"accord":1,"randomised":1,"trial":1,"lancet":1,"s0140":1,"patel":1,"macmahon":1,"chalmers":1,"blood":1,"glucose":2,"control":2,"vascular":1,"patients":1,"with":2,"engl":2,"med":2,"nejmoa0802987":1,"action":1,"to":1,"cardiovascular":2,"risk":1,"group":1,"gerstein":1,"hc":1,"miller":1,"me":1,"effects":1,"lowering":1,"nejmoa0802743":1,"khaw":1,"kt":1,"wareham":1,"bingham":1,"luben":1,"welch":1,"day":1,"hemoglobin":1,"a1c":1,"disease":1,"mortality":1,"adults":1,"prospective":1,"investigation":1,"into":1,"cancer":1},"len":207},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":32,"chunkId":"aace-2023-p32-c7","text":":2545 e 2559. https://doi.org/10.1056/NEJMoa0802743 15. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med . 2004;141(6):413 e 420. https://doi.org/10.7326/0003-4819-141-6- 200409210-00006 S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 336","tf":{"10":2,"15":1,"29":1,"141":2,"305":1,"336":1,"340":1,"413":1,"420":1,"1056":1,"2004":1,"2023":1,"2545":1,"2559":1,"4819":1,"7326":1,"200409210":1,"https":2,"doi":2,"org":2,"nejmoa0802743":1,"khaw":1,"kt":1,"wareham":1,"bingham":1,"luben":1,"welch":1,"day":1,"association":1,"of":1,"hemoglobin":1,"a1c":1,"with":1,"cardiovascular":1,"disease":1,"and":1,"mortality":1,"in":2,"adults":1,"the":1,"european":1,"prospective":1,"investigation":1,"into":1,"cancer":1,"norfolk":1,"ann":1,"intern":1,"med":1,"0003":1,"00006":1,"samson":1,"vellanki":1,"blonde":1,"et":1,"al":1,"endocrine":1,"practice":1},"len":64},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":33,"chunkId":"aace-2023-p33-c0","text":"16. Rodriguez-Gutierrez R, Gonzalez-Gonzalez JG, Zu ~ niga-Hernandez JA, McCoy RG. Bene fi ts and harms of intensive glycemic control in patients with type 2 diabetes. BMJ . 2019;367:I5887. https://doi.org/10.1136/bmj.I5887 17. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular com- plications in veterans with type 2 diabetes. N Engl J Med . 2009;360(2): 129 e 139. https://doi.org/10.1056/NEJMoa0808431 18. Vigersky RA, McMahon C. The relationship of hemoglobin a1c to time-in- range in patients with diabetes. Diabetes Technol Ther . 2019;21(2):81 e 85. https://doi.org/10.1089/dia.2018.0310 19. Beck RW, Bergenstal RM, Cheng P, et al. The relationships between time in range, hyperglycemia metrics, and HbA1c. J Diabetes Sci Technol . 2019;13(4): 614 e 626. https://doi.org/10.1177/1932296818822496 20. Grunberger G, Sherr J, Allende M, et al. American Association of Clinical Endocrinology clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus. Endocr Pract . 2021;27(6): 505 e 537. https://doi.org/10.1016/j.eprac.2021.04.008 21. Bergenstal RM, Beck RW, Close KL, et al. Glucose management indicator (GMI): A new term for estimating A1C from continuous glucose monitoring. Diabetes Care . 2018;41(11):2275 e 2280. https://doi.org/10.2337/ dc18-1581 22. Powell RE, Zaccardi F, Beebe C, et al. Strategies for overcomin","tf":{"10":6,"11":1,"13":1,"16":1,"17":1,"18":1,"19":1,"20":1,"21":2,"22":1,"27":1,"41":1,"81":1,"85":1,"129":1,"139":1,"360":1,"367":1,"505":1,"537":1,"614":1,"626":1,"1016":1,"1056":1,"1089":1,"1136":1,"1177":1,"1581":1,"2009":1,"2018":2,"2019":3,"2021":2,"2275":1,"2280":1,"2337":1,"rodriguez":1,"gutierrez":1,"gonzalez":2,"jg":1,"zu":1,"niga":1,"hernandez":1,"ja":1,"mccoy":1,"rg":1,"bene":1,"fi":1,"ts":1,"and":3,"harms":1,"of":5,"intensive":1,"glycemic":1,"control":2,"in":6,"patients":2,"with":4,"type":2,"diabetes":7,"bmj":2,"i5887":2,"https":6,"doi":6,"org":6,"duckworth":1,"abraira":1,"moritz":1,"et":5,"al":5,"glucose":3,"vascular":1,"com":1,"plications":1,"veterans":1,"engl":1,"med":1,"nejmoa0808431":1,"vigersky":1,"ra":1,"mcmahon":1,"the":4,"relationship":1,"hemoglobin":1,"a1c":2,"to":1,"time":2,"range":2,"technol":2,"ther":1,"dia":1,"0310":1,"beck":2,"rw":2,"bergenstal":2,"rm":2,"cheng":1,"relationships":1,"between":1,"hyperglycemia":1,"metrics":1,"hba1c":1,"sci":1,"1932296818822496":1,"grunberger":1,"sherr":1,"allende":1,"american":1,"association":1,"clinical":2,"endocrinology":1,"practice":1,"guideline":1,"use":1,"advanced":1,"technology":1,"management":2,"persons":1,"mellitus":1,"endocr":1,"pract":1,"eprac":1,"04":1,"008":1,"close":1,"kl":1,"indicator":1,"gmi":1,"new":1,"term":1,"for":2,"estimating":1,"from":1,"continuous":1,"monitoring":1,"care":1,"dc18":1,"powell":1,"re":1,"zaccardi":1,"beebe":1,"strategies":1,"overcomin":1},"len":217},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":33,"chunkId":"aace-2023-p33-c1","text":" al. Glucose management indicator (GMI): A new term for estimating A1C from continuous glucose monitoring. Diabetes Care . 2018;41(11):2275 e 2280. https://doi.org/10.2337/ dc18-1581 22. Powell RE, Zaccardi F, Beebe C, et al. Strategies for overcoming therapeutic inertia in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab . 2021;23(9):2137 e 2154. https://doi.org/10.1111/dom.14455 23. Khunti K, Gomes MB, Pocock S, et al. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. Dia- betes Obes Metab . 2018;20(2):427 e 437. https://doi.org/10.1111/dom.13088 24. Martens T, Beck RW, Bailey R, et al. Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal in- sulin: a randomized clinical trial. JAMA . 2021;325(22):2262 e 2272. https:// doi.org/10.1001/jama.2021.7444 25. Karter AJ, Parker MM, Moffet HH, Gilliam LK, Dlott R. Association of real-time continuous glucose monitoring with glycemic control and acute metabolic events among patients with insulin-treated diabetes. JAMA . 2021;325(22): 2273 e 2284. https://doi.org/10.1001/jama.2021.6530 26. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose- sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multice","tf":{"10":5,"11":1,"20":1,"22":3,"23":2,"24":1,"25":1,"26":1,"41":1,"325":2,"427":1,"437":1,"1001":2,"1111":2,"1581":1,"2018":2,"2021":5,"2137":1,"2154":1,"2262":1,"2272":1,"2273":1,"2275":1,"2280":1,"2284":1,"2337":1,"6530":1,"7444":1,"13088":1,"14455":1,"al":4,"glucose":6,"management":2,"indicator":1,"gmi":1,"new":1,"term":1,"for":4,"estimating":1,"a1c":1,"from":1,"continuous":3,"monitoring":4,"diabetes":7,"care":1,"https":5,"doi":5,"org":5,"dc18":1,"powell":1,"re":1,"zaccardi":1,"beebe":1,"et":3,"strategies":1,"overcoming":1,"therapeutic":2,"inertia":2,"in":5,"type":4,"systematic":2,"review":2,"and":2,"meta":1,"analysis":1,"obes":2,"metab":2,"dom":2,"khunti":1,"gomes":1,"mb":1,"pocock":1,"the":2,"treatment":1,"of":4,"hyperglycaemia":1,"patients":3,"with":5,"dia":1,"betes":1,"martens":1,"beck":1,"rw":1,"bailey":1,"effect":1,"on":1,"glycemic":2,"control":2,"treated":3,"basal":1,"sulin":1,"randomized":1,"clinical":1,"trial":1,"jama":4,"karter":1,"aj":1,"parker":1,"mm":1,"moffet":1,"hh":1,"gilliam":1,"lk":1,"dlott":1,"association":1,"real":1,"time":1,"acute":1,"metabolic":1,"events":1,"among":1,"insulin":2,"haak":1,"hanaire":1,"ajjan":1,"hermanns":1,"riveline":1,"jp":1,"rayman":1,"flash":1,"sensing":1,"technology":1,"as":1,"replacement":1,"blood":1,"multice":1},"len":211},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":33,"chunkId":"aace-2023-p33-c2","text":"https://doi.org/10.1001/jama.2021.6530 26. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose- sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther . 2017;8(1):55 e 73. https://doi.org/ 10.1007/s13300-016-0223-6 27. Mechanick JI, Hurley DL, Garvey WT. Adiposity-based chronic disease as a new diagnostic term: the American Association of Clinical Endocrinologists and American College of Endocrinology position statement. Endocr Pract . 2017;23(3):372 e 378. https://doi.org/10.4158/ep161688.Ps 28. Nadolsky K, Addison B, Agarwal M, et al. American Association of Clinical Endocrinology consensus statement: addressing stigma and bias in the diagnosis and management of patients with obesity/adiposity-based chronic disease and assessing bias and stigmatization as determinants of disease severity. Endocr Pract . 2023;29:IN PRESS. https://doi.org/10.1016/j.eprac. 2023.03.272 29. Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. Anesthesiology . 2008;108(5):812 e 821. https://doi.org/10.1097/ALN.0b013e31816d83e4 30. Topp CW, stergaard SD, Sndergaard S, Bech P. The WHO-5 Well-Being In- dex: a systematic review of the literature. Psychother Psychosom . 2015;84(3): 167","tf":{"10":5,"23":1,"26":1,"27":1,"28":1,"29":2,"30":1,"55":1,"73":1,"84":1,"108":1,"167":1,"272":1,"372":1,"378":1,"812":1,"821":1,"1001":1,"1007":1,"1016":1,"1097":1,"2008":1,"2015":1,"2017":2,"2021":1,"2023":2,"4158":1,"6530":1,"https":5,"doi":5,"org":5,"jama":1,"haak":1,"hanaire":1,"ajjan":1,"hermanns":1,"riveline":1,"jp":1,"rayman":1,"flash":1,"glucose":2,"sensing":1,"technology":1,"as":3,"replacement":1,"for":3,"blood":1,"monitoring":1,"the":5,"management":2,"of":7,"insulin":1,"treated":1,"type":1,"diabetes":2,"multicenter":1,"open":1,"label":1,"randomized":1,"controlled":1,"trial":1,"ther":1,"s13300":1,"016":1,"0223":1,"mechanick":1,"ji":1,"hurley":1,"dl":1,"garvey":1,"wt":1,"adiposity":2,"based":2,"chronic":2,"disease":3,"new":1,"diagnostic":1,"term":1,"american":3,"association":2,"clinical":2,"endocrinologists":1,"and":5,"college":1,"endocrinology":2,"position":1,"statement":2,"endocr":2,"pract":2,"ep161688":1,"ps":1,"nadolsky":1,"addison":1,"agarwal":1,"et":2,"al":2,"consensus":1,"addressing":1,"stigma":1,"bias":2,"in":3,"diagnosis":1,"patients":2,"with":1,"obesity":1,"assessing":1,"stigmatization":1,"determinants":1,"severity":1,"press":1,"eprac":1,"03":1,"chung":1,"yegneswaran":1,"liao":1,"stop":1,"questionnaire":1,"tool":1,"to":1,"screen":1,"obstructive":1,"sleep":1,"apnea":1,"anesthesiology":1,"aln":1,"0b013e31816d83e4":1,"topp":1,"cw":1,"stergaard":1,"sd":1,"ndergaard":1,"bech":1,"who":1,"well":1,"being":1,"dex":1,"systematic":1,"review":1,"literature":1,"psychother":1,"psychosom":1},"len":200},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":33,"chunkId":"aace-2023-p33-c3","text":"apnea. Anesthesiology . 2008;108(5):812 e 821. https://doi.org/10.1097/ALN.0b013e31816d83e4 30. Topp CW, stergaard SD, Sndergaard S, Bech P. The WHO-5 Well-Being In- dex: a systematic review of the literature. Psychother Psychosom . 2015;84(3): 167 e 176. https://doi.org/10.1159/000376585 31. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med . 2001;16(9):606 e 613. https://doi.org/ 10.1046/j.1525-1497.2001.016009606.x 32. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry . 1961;4:561 e 571. https://doi.org/ 10.1001/archpsyc.1961.01710120031004 33. Bethel MA, Hyland KA, Chacra AR, et al. Updated risk factors should be used to predict development of diabetes. J Diabetes Complications . 2017;31(5): 859 e 863. https://doi.org/10.1016/j.jdiacomp.2017.02.012 34. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) fi nal report. Circulation . 2002;106(25): 3143 e 3421. 35. de Vegt F, Dekker JM, Jager A, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA . 2001;285(16):2109 e 2113. https://doi.org/10.1001/ jama.285.16.2109 36. Lakka HM, Laaksonen DE, Lakka","tf":{"10":6,"16":3,"25":1,"30":1,"31":2,"32":1,"33":1,"34":1,"35":1,"36":1,"84":1,"106":1,"108":1,"167":1,"176":1,"285":2,"561":1,"571":1,"606":1,"613":1,"812":1,"821":1,"859":1,"863":1,"1001":2,"1016":1,"1046":1,"1097":1,"1159":1,"1497":1,"1525":1,"1961":2,"2001":3,"2002":1,"2008":1,"2015":1,"2017":2,"2109":2,"2113":1,"3143":1,"3421":1,"apnea":1,"anesthesiology":1,"https":6,"doi":6,"org":6,"aln":1,"0b013e31816d83e4":1,"topp":1,"cw":1,"stergaard":1,"sd":1,"ndergaard":1,"bech":1,"the":5,"who":1,"well":1,"being":1,"in":3,"dex":1,"systematic":1,"review":1,"of":6,"literature":1,"psychother":1,"psychosom":1,"000376585":1,"kroenke":1,"spitzer":1,"rl":1,"williams":1,"jb":1,"phq":1,"validity":1,"brief":1,"depression":2,"severity":1,"measure":1,"gen":2,"intern":1,"med":1,"016009606":1,"beck":1,"at":1,"ward":1,"ch":1,"mendelson":1,"mock":1,"erbaugh":1,"an":1,"inventory":1,"for":1,"measuring":1,"arch":1,"psychiatry":1,"archpsyc":1,"01710120031004":1,"bethel":1,"ma":1,"hyland":1,"ka":1,"chacra":1,"ar":1,"et":2,"al":2,"updated":1,"risk":1,"factors":1,"should":1,"be":1,"used":1,"to":1,"predict":1,"development":1,"diabetes":3,"complications":1,"jdiacomp":1,"02":1,"012":1,"third":1,"report":2,"national":1,"cholesterol":2,"education":1,"program":1,"ncep":1,"expert":1,"panel":2,"on":1,"detection":1,"evaluation":1,"and":2,"treatment":2,"high":1,"blood":1,"adults":1,"adult":1,"iii":1,"fi":1,"nal":1,"circulation":1,"de":2,"vegt":1,"dekker":1,"jm":1,"jager":1,"relation":1,"impaired":1,"fasting":1,"postload":1,"glucose":1,"with":1,"incident":1,"type":1,"dutch":1,"population":1,"hoorn":1,"study":1,"jama":2,"lakka":2,"hm":1,"laaksonen":1},"len":217},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":33,"chunkId":"aace-2023-p33-c4","text":"r JM, Jager A, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA . 2001;285(16):2109 e 2113. https://doi.org/10.1001/ jama.285.16.2109 36. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA . 2002;288(21):2709 e 2716. https://doi.org/10.1001/jama.288.21.2709 37. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested de fi nitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol . 2002;156(11):1070 e 1077. https:// doi.org/10.1093/aje/kwf145 38. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med . 2002;346(6):393 e 403. https://doi.org/10.1056/NEJMoa012512 39. Garvey WT, Ryan DH, Henry R, et al. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care . 2014;37(4):912 e 921. https:// doi.org/10.2337/dc13-1518 40. Laaksonen DE, Lindstr  om J, Lakka TA, et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes . 2005;54(1):158 e 16","tf":{"10":5,"11":1,"16":3,"21":2,"36":1,"37":2,"38":1,"39":1,"40":1,"54":1,"156":1,"158":1,"285":2,"288":2,"346":1,"393":1,"403":1,"912":1,"921":1,"1001":2,"1056":1,"1070":1,"1077":1,"1093":1,"1518":1,"2001":1,"2002":3,"2005":1,"2014":1,"2109":2,"2113":1,"2337":1,"2709":2,"2716":1,"jm":1,"jager":1,"et":5,"al":5,"relation":1,"of":7,"impaired":1,"fasting":1,"and":7,"postload":1,"glucose":1,"with":4,"incident":1,"type":4,"diabetes":8,"in":6,"dutch":1,"population":1,"the":6,"hoorn":1,"study":3,"jama":4,"https":5,"doi":5,"org":5,"lakka":5,"hm":2,"laaksonen":3,"de":4,"ta":3,"metabolic":4,"syndrome":4,"total":1,"cardiovascular":1,"disease":1,"mortality":1,"middle":1,"aged":1,"men":1,"niskanen":1,"lk":1,"kaplan":1,"ga":1,"salonen":1,"jt":1,"development":1,"mellitus":1,"application":1,"validation":1,"recently":1,"suggested":1,"fi":1,"nitions":1,"prospective":1,"cohort":1,"am":1,"epidemiol":1,"aje":1,"kwf145":1,"knowler":1,"wc":1,"barrett":1,"connor":1,"fowler":1,"se":1,"reduction":1,"incidence":1,"lifestyle":1,"intervention":1,"or":1,"metformin":1,"engl":1,"med":1,"nejmoa012512":1,"garvey":1,"wt":1,"ryan":1,"dh":1,"henry":1,"prevention":3,"subjects":1,"prediabetes":1,"treated":1,"phentermine":1,"topiramate":1,"extended":1,"release":1,"care":1,"dc13":1,"lindstr":1,"om":1,"physical":1,"activity":1,"finnish":1},"len":223},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":33,"chunkId":"aace-2023-p33-c5","text":" Diabetes Care . 2014;37(4):912 e 921. https:// doi.org/10.2337/dc13-1518 40. Laaksonen DE, Lindstr  om J, Lakka TA, et al. Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes . 2005;54(1):158 e 165. https://doi.org/10.2337/diabetes.54.1.158 41. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care . 1997;20(4):537 e 544. https://doi.org/10.2337/diacare.20.4.537 42. Salas-Salvad \u0013 o J, Bull \u0013 o M, Estruch R, et al. Prevention of diabetes with Medi- terranean diets: a subgroup analysis of a randomized trial. Ann Intern Med . 2014;160(1):1 e 10. https://doi.org/10.7326/m13-1725 43. Salas-Salvad \u0013 o J, Bull \u0013 o M, Babio N, et al. Erratum. Reduction in the inci- dence of type 2 diabetes with the Mediterranean diet: Results of the PREDIMED-Reus nutrition intervention randomized trial. Diabetes Care 2011;34:14-19. Diabetes Care . 2018;41(10):2259-2260. https://doi.org/10. 2337/dc18-er10 44. Svetkey LP, Simons-Morton D, Vollmer WM, et al. Effects of dietary patterns on blood pressure: subgroup analysis of the Dietary Approaches to Stop Hy- pertension (DASH) randomized clinical trial. Arch Intern Med . 1999;159(3): 285 e 293. https://doi.org/10.1001/archinte.159.3.285 45. Sacks FM, Svetkey LP, Vollmer WM, et al. Effect","tf":{"10":8,"14":1,"19":1,"20":2,"34":1,"37":1,"40":1,"41":2,"42":1,"43":1,"44":1,"45":1,"54":2,"158":2,"159":2,"160":1,"165":1,"285":2,"293":1,"537":2,"544":1,"912":1,"921":1,"1001":1,"1518":1,"1725":1,"1997":1,"1999":1,"2005":1,"2011":1,"2014":2,"2018":1,"2259":1,"2260":1,"2337":4,"7326":1,"diabetes":11,"care":4,"https":6,"doi":6,"org":6,"dc13":1,"laaksonen":1,"de":1,"lindstr":1,"om":1,"lakka":1,"ta":1,"et":6,"al":6,"physical":1,"activity":1,"in":4,"the":7,"prevention":3,"of":8,"type":2,"finnish":1,"study":2,"pan":1,"xr":1,"li":1,"gw":1,"hu":1,"yh":1,"effects":2,"diet":2,"and":2,"exercise":1,"preventing":1,"niddm":1,"people":1,"with":3,"impaired":1,"glucose":1,"tolerance":1,"da":1,"qing":1,"igt":1,"diacare":1,"salas":2,"salvad":2,"bull":2,"estruch":1,"medi":1,"terranean":1,"diets":1,"subgroup":2,"analysis":2,"randomized":3,"trial":3,"ann":1,"intern":2,"med":2,"m13":1,"babio":1,"erratum":1,"reduction":1,"inci":1,"dence":1,"mediterranean":1,"results":1,"predimed":1,"reus":1,"nutrition":1,"intervention":1,"dc18":1,"er10":1,"svetkey":2,"lp":2,"simons":1,"morton":1,"vollmer":2,"wm":2,"dietary":2,"patterns":1,"on":1,"blood":1,"pressure":1,"approaches":1,"to":1,"stop":1,"hy":1,"pertension":1,"dash":1,"clinical":1,"arch":1,"archinte":1,"sacks":1,"fm":1,"effect":1},"len":228},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":33,"chunkId":"aace-2023-p33-c6","text":"od pressure: subgroup analysis of the Dietary Approaches to Stop Hy- pertension (DASH) randomized clinical trial. Arch Intern Med . 1999;159(3): 285 e 293. https://doi.org/10.1001/archinte.159.3.285 45. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med . 2001;344(1):3 e 10. https://doi.org/10.1056/nejm200101043440101 46. Colberg SR, Sigal RJ, Fernhall B, et al. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement executive summary. Diabetes Care . 2010;33(12): 2692 e 2696. https://doi.org/10.2337/dc10-1548 47. Colberg SR, Sigal RJ, Fernhall B, et al. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement. Diabetes Care . 2010;33(12):e147 e e167. https:// doi.org/10.2337/dc10-9990 48. Dai X, Zhai L, Chen Q, et al. Two-year-supervised resistance training prevented diabetes incidence in people with prediabetes: a randomised control trial. Diabetes Metab Res Rev . 2019;35(5), e3143. https://doi.org/10.1002/dmrr.3143 49. Aguiar EJ, Morgan PJ, Collins CE, Plotnikoff RC, Callister R. Ef fi cacy of in- terventions that include diet, aerobic and resistance training componen","tf":{"10":6,"12":2,"33":2,"35":1,"45":1,"46":1,"47":1,"48":1,"49":1,"159":2,"285":2,"293":1,"344":1,"1001":1,"1002":1,"1056":1,"1548":1,"1999":1,"2001":1,"2010":2,"2019":1,"2337":2,"2692":1,"2696":1,"3143":1,"9990":1,"od":1,"pressure":2,"subgroup":1,"analysis":1,"of":5,"the":6,"dietary":3,"approaches":2,"to":2,"stop":2,"hy":1,"pertension":1,"dash":3,"randomized":1,"clinical":1,"trial":2,"arch":1,"intern":1,"med":2,"https":5,"doi":5,"org":5,"archinte":1,"sacks":1,"fm":1,"svetkey":1,"lp":1,"vollmer":1,"wm":1,"et":4,"al":4,"effects":1,"on":1,"blood":1,"reduced":1,"sodium":2,"and":6,"hypertension":1,"diet":2,"collaborative":1,"research":1,"group":1,"engl":1,"nejm200101043440101":1,"colberg":2,"sr":2,"sigal":2,"rj":2,"fernhall":2,"exercise":2,"type":2,"diabetes":8,"american":4,"college":2,"sports":2,"medicine":2,"association":2,"joint":2,"position":2,"statement":2,"executive":1,"summary":1,"care":2,"dc10":2,"e147":1,"e167":1,"dai":1,"zhai":1,"chen":1,"two":1,"year":1,"supervised":1,"resistance":2,"training":2,"prevented":1,"incidence":1,"in":2,"people":1,"with":1,"prediabetes":1,"randomised":1,"control":1,"metab":1,"res":1,"rev":1,"e3143":1,"dmrr":1,"aguiar":1,"ej":1,"morgan":1,"pj":1,"collins":1,"ce":1,"plotnikoff":1,"rc":1,"callister":1,"ef":1,"fi":1,"cacy":1,"terventions":1,"that":1,"include":1,"aerobic":1,"componen":1},"len":214},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":33,"chunkId":"aace-2023-p33-c7","text":"d control trial. Diabetes Metab Res Rev . 2019;35(5), e3143. https://doi.org/10.1002/dmrr.3143 49. Aguiar EJ, Morgan PJ, Collins CE, Plotnikoff RC, Callister R. Ef fi cacy of in- terventions that include diet, aerobic and resistance training components for type 2 diabetes prevention: a systematic review with meta-analysis. Int J Behav Nutr Phys Act . 2014;11:2. https://doi.org/10.1186/1479-5868-11-2 50. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol . 2014;63(25 Pt B):2960 e 2984. https://doi.org/10.1016/ j.jacc.2013.11.003 51. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med . 2021;384(11):989 e 1002. https://doi.org/10.1056/NEJMoa2032183 52. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA . 2021;325(14):1403 e 1413. https://doi.org/10.1001/jama.2021.1831 53. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly sub- cutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP ","tf":{"10":5,"11":4,"14":1,"25":1,"35":1,"49":1,"50":1,"51":1,"52":1,"53":1,"63":1,"325":1,"384":1,"989":1,"1001":1,"1002":2,"1016":1,"1056":1,"1186":1,"1403":1,"1413":1,"1479":1,"1831":1,"2013":2,"2014":2,"2019":1,"2021":3,"2960":1,"2984":1,"3143":1,"5868":1,"control":1,"trial":2,"diabetes":2,"metab":1,"res":1,"rev":1,"e3143":1,"https":5,"doi":5,"org":5,"dmrr":1,"aguiar":1,"ej":1,"morgan":1,"pj":1,"collins":1,"ce":1,"plotnikoff":1,"rc":1,"callister":1,"ef":1,"fi":1,"cacy":1,"of":5,"in":4,"terventions":1,"that":1,"include":1,"diet":1,"aerobic":1,"and":1,"resistance":1,"training":1,"components":1,"for":1,"type":1,"prevention":1,"systematic":1,"review":1,"with":4,"meta":1,"analysis":1,"int":1,"behav":1,"nutr":1,"phys":1,"act":1,"eckel":1,"rh":1,"jakicic":1,"jm":1,"ard":1,"jd":1,"et":4,"al":4,"aha":1,"acc":1,"guideline":1,"on":4,"lifestyle":1,"management":1,"to":2,"reduce":1,"cardiovascular":1,"risk":1,"report":1,"the":3,"american":2,"college":1,"cardiology":1,"heart":1,"association":1,"task":1,"force":1,"practice":1,"guidelines":1,"am":1,"coll":1,"cardiol":1,"pt":1,"jacc":1,"003":1,"wilding":1,"jph":1,"batterham":1,"rl":1,"calanna":1,"once":1,"weekly":2,"semaglutide":3,"adults":3,"overweight":3,"or":3,"obesity":3,"engl":1,"med":1,"nejmoa2032183":1,"wadden":1,"ta":1,"bailey":1,"ts":1,"billings":1,"lk":1,"effect":2,"subcutaneous":1,"vs":2,"placebo":2,"as":1,"an":1,"adjunct":1,"intensive":1,"behavioral":1,"therapy":1,"body":1,"weight":2,"step":2,"randomized":1,"clinical":1,"jama":2,"rubino":1,"abrahamsson":1,"davies":1,"continued":1,"sub":1,"cutaneous":1,"loss":1,"maintenance":1},"len":224},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":33,"chunkId":"aace-2023-p33-c8","text":"2021;325(14):1403 e 1413. https://doi.org/10.1001/jama.2021.1831 53. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly sub- cutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA . 2021;325(14):1414 e 1425. https://doi.org/10.1001/jama.2021.3224 54. le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet . 2017;389(10077): 1399 e 1409. https://doi.org/10.1016/s0140-6736(17)30069-7 55. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med . 2022;387(3):205 e 216. https://doi.org/ 10.1056/NEJMoa2206038 56. Greenway FL, Aronne LJ, Raben A, et al. A randomized, double-blind, placebo- controlled study of Gelesis100: a novel nonsystemic oral hydrogel for weight loss. Obesity (Silver Spring) . 2019;27(2):205 e 216. https://doi.org/10.1002/ oby.22347 57. Genco A, Bruni T, Doldi SB, et al. BioEnterics intragastric balloon: The Italian experience with 2,515 patients. Obes Surg . 2005;15(8):1161 e 1164. https:// doi.org/10.1381/0960892055002202 58. Ponce J, Woodman G, Swain J, et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastri","tf":{"10":6,"14":2,"15":1,"17":1,"27":1,"53":1,"54":1,"55":1,"56":1,"57":1,"58":1,"205":2,"216":2,"325":2,"387":1,"389":1,"515":1,"1001":2,"1002":1,"1016":1,"1056":1,"1161":1,"1164":1,"1381":1,"1399":1,"1403":1,"1409":1,"1413":1,"1414":1,"1425":1,"1831":1,"2005":1,"2017":1,"2019":1,"2021":4,"2022":1,"3224":1,"6736":1,"10077":1,"22347":1,"30069":1,"https":6,"doi":6,"org":6,"jama":3,"rubino":1,"abrahamsson":1,"davies":1,"et":6,"al":6,"effect":1,"of":5,"continued":1,"weekly":2,"sub":1,"cutaneous":1,"semaglutide":1,"vs":1,"placebo":3,"on":1,"weight":3,"loss":2,"maintenance":1,"in":2,"adults":1,"with":3,"overweight":1,"or":1,"obesity":3,"the":4,"step":1,"randomized":3,"clinical":1,"trial":4,"le":1,"roux":1,"cw":1,"astrup":1,"fujioka":1,"years":1,"liraglutide":1,"versus":1,"for":3,"type":1,"diabetes":1,"risk":1,"reduction":1,"and":1,"management":1,"individuals":1,"prediabetes":1,"randomised":1,"double":2,"blind":2,"lancet":1,"s0140":1,"jastreboff":1,"am":1,"aronne":2,"lj":2,"ahmad":1,"nn":1,"tirzepatide":1,"once":1,"treatment":1,"engl":1,"med":1,"nejmoa2206038":1,"greenway":1,"fl":1,"raben":1,"controlled":2,"study":1,"gelesis100":1,"novel":1,"nonsystemic":1,"oral":1,"hydrogel":1,"silver":1,"spring":1,"oby":1,"genco":1,"bruni":1,"doldi":1,"sb":1,"bioenterics":1,"intragastric":1,"balloon":1,"italian":1,"experience":1,"patients":1,"obes":1,"surg":1,"0960892055002202":1,"ponce":1,"woodman":1,"swain":1,"reduce":1,"pivotal":2,"prospective":1,"dual":1,"intragastri":1},"len":213},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":33,"chunkId":"aace-2023-p33-c9","text":"n experience with 2,515 patients. Obes Surg . 2005;15(8):1161 e 1164. https:// doi.org/10.1381/0960892055002202 58. Ponce J, Woodman G, Swain J, et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis . 2015;11(4):874 e 881. https:// doi.org/10.1016/j.soard.2014.12.006 59. Marinos G, Eliades C, Raman Muthusamy V, Greenway F. Weight loss and improved quality of life with a nonsurgical endoscopic treatment for obesity: clinical results from a 3- and 6-month study. Surg Obes Relat Dis . 2014;10(5): 929 e 934. https://doi.org/10.1016/j.soard.2014.03.005 60. Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients un- dergoing bariatric procedures - 2019 update: Cosponsored by American As- sociation of Clinical Endocrinologists/ American College of Endocrinology, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists - Executive summary. Endocr Pract . 2019;25(12):1346 e 1359. https://doi.org/10.4158/gl- 2019-0406 S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 337","tf":{"10":5,"11":1,"12":2,"15":1,"25":1,"29":1,"58":1,"59":1,"60":1,"305":1,"337":1,"340":1,"515":1,"874":1,"881":1,"929":1,"934":1,"1016":2,"1161":1,"1164":1,"1346":1,"1359":1,"1381":1,"2005":1,"2014":3,"2015":1,"2019":3,"2023":1,"4158":1,"experience":1,"with":2,"patients":2,"obes":3,"surg":3,"https":4,"doi":4,"org":4,"0960892055002202":1,"ponce":1,"woodman":1,"swain":1,"et":3,"al":3,"the":4,"reduce":1,"pivotal":2,"trial":2,"prospective":1,"randomized":1,"controlled":1,"of":7,"dual":1,"intragastric":1,"balloon":1,"for":4,"treatment":2,"obesity":4,"relat":2,"dis":2,"soard":2,"006":1,"marinos":1,"eliades":1,"raman":1,"muthusamy":1,"greenway":1,"weight":1,"loss":1,"and":4,"improved":1,"quality":1,"life":1,"nonsurgical":2,"endoscopic":1,"clinical":3,"results":1,"from":1,"month":1,"study":1,"03":1,"005":1,"mechanick":1,"ji":1,"apovian":1,"brethauer":1,"practice":2,"guidelines":1,"perioperative":1,"nutrition":1,"metabolic":2,"support":1,"un":1,"dergoing":1,"bariatric":2,"procedures":1,"update":1,"cosponsored":1,"by":1,"american":4,"as":1,"sociation":1,"endocrinologists":1,"college":1,"endocrinology":1,"society":3,"surgery":1,"medicine":1,"association":1,"anesthesiologists":1,"executive":1,"summary":1,"endocr":1,"pract":1,"gl":1,"0406":1,"samson":1,"vellanki":1,"blonde":1,"endocrine":1},"len":183},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":34,"chunkId":"aace-2023-p34-c0","text":"61. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet . 2002;359(9323):2072 e 2077. https://doi.org/10.1016/s0140-6736(02) 08905-5 62. DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes pre- vention in impaired glucose tolerance. N Engl J Med . 2011;364(12): 1104 e 1115. https://doi.org/10.1056/NEJMoa1010949 63. Flores-Le Roux JA, Comin J, Pedro-Botet J, et al. Seven-year mortality in heart failure patients with undiagnosed diabetes: an observational study. Car- diovasc Diabetol . 2011;10:39. https://doi.org/10.1186/1475-2840-10-39 64. Giraldez RR, Clare RM, Lopes RD, et al. Prevalence and clinical out- comes of undiagnosed diabetes mellitus and prediabetes among pa- tients with high-risk non-ST-segment elevation acute coronary syndrome. Am Heart J . 2013;165(6):918 e 925.e2. https://doi.org/ 10.1016/j.ahj.2013.01.005 65. Norhammar A, Tenerz A, Nilsson G, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet . 2002;359(9324):2140 e 2144. https://doi.org/ 10.1016/s0140-6736(02)09089-x 66. Wang N, Fulcher J, Abeysuriya N, et al. Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic re","tf":{"10":7,"12":1,"39":2,"61":1,"62":1,"63":1,"64":1,"65":1,"66":1,"165":1,"359":2,"364":1,"918":1,"925":1,"1016":3,"1056":1,"1104":1,"1115":1,"1186":1,"1475":1,"2002":2,"2011":2,"2013":2,"2072":1,"2077":1,"2140":1,"2144":1,"2840":1,"6736":2,"9323":1,"9324":1,"chiasson":1,"jl":1,"josse":1,"rg":1,"gomis":1,"hanefeld":1,"karasik":1,"laakso":1,"acarbose":1,"for":3,"prevention":2,"of":4,"type":1,"diabetes":5,"mellitus":3,"the":2,"stop":1,"niddm":1,"randomised":1,"trial":1,"lancet":2,"https":5,"doi":5,"org":5,"s0140":2,"02":2,"08905":1,"defronzo":1,"ra":1,"tripathy":1,"schwenke":1,"dc":1,"et":5,"al":5,"pioglitazone":1,"pre":1,"vention":1,"in":3,"impaired":1,"glucose":2,"tolerance":1,"engl":1,"med":1,"nejmoa1010949":1,"flores":1,"le":1,"roux":1,"ja":1,"comin":1,"pedro":1,"botet":1,"seven":1,"year":1,"mortality":1,"heart":2,"failure":1,"patients":2,"with":3,"undiagnosed":2,"an":1,"observational":1,"study":2,"car":1,"diovasc":1,"diabetol":1,"giraldez":1,"rr":1,"clare":1,"rm":1,"lopes":1,"rd":1,"prevalence":1,"and":3,"clinical":1,"out":1,"comes":1,"prediabetes":1,"among":1,"pa":1,"tients":1,"high":1,"risk":1,"non":1,"st":1,"segment":1,"elevation":1,"acute":2,"coronary":1,"syndrome":1,"am":1,"e2":1,"ahj":1,"01":1,"005":1,"norhammar":1,"tenerz":1,"nilsson":1,"metabolism":1,"myocardial":1,"infarction":1,"no":1,"previous":1,"diagnosis":1,"prospective":1,"09089":1,"wang":1,"fulcher":1,"abeysuriya":1,"intensive":1,"ldl":1,"cholesterol":1,"lowering":1,"treatment":1,"beyond":1,"current":1,"recommendations":1,"major":1,"vascular":1,"events":1,"systematic":1,"re":1},"len":214},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":34,"chunkId":"aace-2023-p34-c1","text":"359(9324):2140 e 2144. https://doi.org/ 10.1016/s0140-6736(02)09089-x 66. Wang N, Fulcher J, Abeysuriya N, et al. Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants. Lancet Diabetes Endocrinol . 2020;8(1):36 e 49. https://doi.org/10.1016/s2213-8587(19)30388-2 67. de Ritter R, Sep SJS, van der Kallen CJH, et al. Adverse differences in car- diometabolic risk factor levels between individuals with pre-diabetes and normal glucose metabolism are more pronounced in women than in men: the Maastricht Study. BMJ Open Diabetes Res Care . 2019;7(1), e000787. https:// doi.org/10.1136/bmjdrc-2019-000787 68. Hashemi Madani N, Ismail-Beigi F, Poustchi H, et al. Impaired fasting glucose and major adverse cardiovascular events by hypertension and dyslipidemia status: the Golestan cohort study. BMC Cardiovasc Disord . 2020;20(1):113. https://doi.org/10.1186/s12872-020-01390-8 69. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia . 2003;46(6):733 e 749. https://doi.org/10.1007/s00125-003-1111-y 70. Halcox JP, Banegas JR, Roy C, et al. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. BMC","tf":{"10":5,"19":1,"20":1,"36":1,"46":1,"49":1,"66":1,"67":1,"68":1,"69":1,"70":1,"113":1,"327":1,"359":1,"733":1,"749":1,"1007":1,"1016":2,"1111":1,"1136":1,"1186":1,"2003":1,"2019":2,"2020":2,"2140":1,"2144":1,"6736":1,"8587":1,"9324":1,"30388":1,"https":5,"doi":5,"org":5,"s0140":1,"02":1,"09089":1,"wang":1,"fulcher":1,"abeysuriya":1,"et":4,"al":4,"intensive":1,"ldl":1,"cholesterol":1,"lowering":1,"treatment":2,"beyond":1,"current":1,"recommendations":1,"for":1,"the":4,"prevention":2,"of":4,"major":2,"vascular":1,"events":2,"systematic":1,"review":1,"and":5,"meta":1,"analysis":1,"randomised":1,"trials":1,"including":1,"037":1,"participants":1,"lancet":1,"diabetes":3,"endocrinol":1,"s2213":1,"de":1,"ritter":1,"sep":1,"sjs":1,"van":1,"der":1,"kallen":1,"cjh":1,"adverse":2,"differences":1,"in":5,"car":1,"diometabolic":1,"risk":1,"factor":1,"levels":1,"between":1,"individuals":1,"with":1,"pre":1,"normal":1,"glucose":2,"metabolism":1,"are":1,"more":1,"pronounced":1,"women":1,"than":1,"men":1,"maastricht":1,"study":3,"bmj":1,"open":1,"res":1,"care":1,"e000787":1,"bmjdrc":1,"000787":1,"hashemi":1,"madani":1,"ismail":1,"beigi":1,"poustchi":1,"impaired":1,"fasting":1,"cardiovascular":2,"by":1,"hypertension":1,"dyslipidemia":2,"status":1,"golestan":1,"cohort":1,"bmc":2,"cardiovasc":1,"disord":1,"s12872":1,"020":1,"01390":1,"taskinen":1,"mr":1,"diabetic":1,"dyslipidaemia":1,"from":1,"basic":1,"research":1,"to":1,"clinical":1,"practice":1,"diabetologia":1,"s00125":1,"003":1,"halcox":1,"jp":1,"banegas":1,"jr":1,"roy":1,"prevalence":1,"atherogenic":1,"primary":1,"disease":1,"europe":1,"eurika":1,"cross":1,"sectional":1,"observational":1},"len":207},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":34,"chunkId":"aace-2023-p34-c2","text":" https://doi.org/10.1007/s00125-003-1111-y 70. Halcox JP, Banegas JR, Roy C, et al. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study. BMC Cardiovasc Disord . 2017;17(1):160. https://doi.org/10.1186/s12872-017-0591-5 71. Jin JL, Zhang HW, Cao YX, et al. Association of small dense low-density lipo- protein with cardiovascular outcome in patients with coronary artery disease and diabetes: a prospective, observational cohort study. Cardiovasc Diabetol . 2020;19(1):45. https://doi.org/10.1186/s12933-020-01015-6 72. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract . 2017;23(Suppl 2):1 e 87. https://doi.org/10.4158/ ep171764.Appgl 73. Handelsman Y, Jellinger PS, Guerin CK, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive sum- mary. Endocr Pract . 2020;26(10):1196 e 1224. https://doi.org/10.4158/cs- 2020-0490 74. Mora S, Chang CL, Moorthy MV, Sever PS. Association of nonfasting vs fasting lipid levels with risk of major c","tf":{"10":6,"17":1,"19":1,"23":1,"26":1,"45":1,"70":1,"71":1,"72":1,"73":1,"74":1,"87":1,"160":1,"1007":1,"1111":1,"1186":2,"1196":1,"1224":1,"2017":2,"2020":4,"4158":2,"https":5,"doi":5,"org":5,"s00125":1,"003":1,"halcox":1,"jp":1,"banegas":1,"jr":1,"roy":1,"et":4,"al":4,"prevalence":1,"and":6,"treatment":1,"of":13,"atherogenic":1,"dyslipidemia":3,"in":3,"the":3,"primary":1,"prevention":3,"cardiovascular":4,"disease":4,"europe":1,"eurika":1,"cross":1,"sectional":1,"observational":2,"study":2,"bmc":1,"cardiovasc":2,"disord":1,"s12872":1,"017":1,"0591":1,"jin":1,"jl":1,"zhang":1,"hw":1,"cao":1,"yx":1,"association":4,"small":1,"dense":1,"low":1,"density":1,"lipo":1,"protein":1,"with":3,"outcome":1,"patients":1,"coronary":1,"artery":1,"diabetes":1,"prospective":1,"cohort":1,"diabetol":1,"s12933":1,"020":1,"01015":1,"jellinger":2,"ps":3,"handelsman":2,"rosenblit":1,"pd":1,"american":4,"clinical":2,"endocrinologists":2,"college":2,"endocrinology":2,"guidelines":1,"for":1,"management":2,"endocr":2,"pract":2,"suppl":1,"ep171764":1,"appgl":1,"guerin":1,"ck":1,"consensus":1,"statement":1,"by":1,"on":1,"algorithm":1,"executive":1,"sum":1,"mary":1,"cs":1,"0490":1,"mora":1,"chang":1,"cl":1,"moorthy":1,"mv":1,"sever":1,"nonfasting":1,"vs":1,"fasting":1,"lipid":1,"levels":1,"risk":1,"major":1},"len":207},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":34,"chunkId":"aace-2023-p34-c3","text":"diovascular disease algorithm - 2020 executive sum- mary. Endocr Pract . 2020;26(10):1196 e 1224. https://doi.org/10.4158/cs- 2020-0490 74. Mora S, Chang CL, Moorthy MV, Sever PS. Association of nonfasting vs fasting lipid levels with risk of major coronary events in the anglo-scandinavian cardiac outcomes trial-lipid lowering arm. JAMA Intern Med . 2019;179(7): 898 e 905. https://doi.org/10.1001/jamainternmed.2019.0392 75. Sathiyakumar V, Park J, Quispe R, et al. Impact of novel low-density lipo- protein-cholesterol assessment on the utility of secondary non-high-density lipoprotein-c and apolipoprotein b targets in selected worldwide dyslipide- mia guidelines. Circulation . 2018;138(3):244 e 254. https://doi.org/10.1161/ circulationaha.117.032463 76. Sniderman AD, St-Pierre AC, Cantin B, Dagenais GR, Despr \u0013 es JP, Lamarche B. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol . 2003;91(10): 1173 e 1177. https://doi.org/10.1016/s0002-9149(03)00262-5 77. Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipopro- tein B and non-HDL cholesterol better re fl ect residual risk than LDL choles- terol in statin-treated patients. J Am Coll Cardiol . 2021;77(11):1439 e 1450. https://doi.org/10.1016/j.jacc.2021.01.027 78. Khan SU, Khan MU, Valavoor S, et al. Association of lowering apolipoprotein ","tf":{"10":7,"11":1,"26":1,"74":1,"75":1,"76":1,"77":2,"78":1,"91":1,"117":1,"138":1,"179":1,"244":1,"254":1,"898":1,"905":1,"1001":1,"1016":2,"1161":1,"1173":1,"1177":1,"1196":1,"1224":1,"1439":1,"1450":1,"2003":1,"2018":1,"2019":2,"2020":3,"2021":2,"4158":1,"9149":1,"diovascular":1,"disease":1,"algorithm":1,"executive":1,"sum":1,"mary":1,"endocr":1,"pract":1,"https":5,"doi":5,"org":5,"cs":1,"0490":1,"mora":1,"chang":1,"cl":1,"moorthy":1,"mv":1,"sever":1,"ps":1,"association":2,"of":6,"nonfasting":1,"vs":1,"fasting":1,"lipid":2,"levels":2,"with":1,"risk":3,"major":1,"coronary":1,"events":1,"in":3,"the":3,"anglo":1,"scandinavian":1,"cardiac":1,"outcomes":1,"trial":1,"lowering":2,"arm":1,"jama":1,"intern":1,"med":1,"jamainternmed":1,"0392":1,"sathiyakumar":1,"park":1,"quispe":1,"et":2,"al":2,"impact":1,"novel":1,"low":1,"density":2,"lipo":1,"protein":1,"cholesterol":3,"assessment":1,"on":1,"utility":1,"secondary":1,"non":2,"high":1,"lipoprotein":1,"and":3,"apolipoprotein":3,"targets":1,"selected":1,"worldwide":1,"dyslipide":1,"mia":1,"guidelines":1,"circulation":1,"circulationaha":1,"032463":1,"sniderman":1,"ad":1,"st":1,"pierre":1,"ac":1,"cantin":1,"dagenais":1,"gr":1,"despr":1,"es":1,"jp":1,"lamarche":1,"concordance":1,"discordance":1,"between":1,"plasma":1,"indexes":1,"atherosclerotic":1,"am":2,"cardiol":2,"s0002":1,"03":1,"00262":1,"johannesen":1,"cdl":1,"mortensen":1,"mb":1,"langsted":1,"nordestgaard":1,"bg":1,"apolipopro":1,"tein":1,"hdl":1,"better":1,"re":1,"fl":1,"ect":1,"residual":1,"than":1,"ldl":1,"choles":1,"terol":1,"statin":1,"treated":1,"patients":1,"coll":1,"jacc":1,"01":1,"027":1,"khan":2,"su":1,"mu":1,"valavoor":1},"len":213},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":34,"chunkId":"aace-2023-p34-c4","text":"better re fl ect residual risk than LDL choles- terol in statin-treated patients. J Am Coll Cardiol . 2021;77(11):1439 e 1450. https://doi.org/10.1016/j.jacc.2021.01.027 78. Khan SU, Khan MU, Valavoor S, et al. Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: sys- tematic review and meta-analysis of trials. Eur J Prev Cardiol . 2020;27(12): 1255 e 1268. https://doi.org/10.1177/2047487319871733 79. Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol . 2019;4(12): 1287 e 1295. https://doi.org/10.1001/jamacardio.2019.3780 80. Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Out- comes . May 2011;4(3):337 e 345. https://doi.org/10.1161/circoutcomes. 110.959247 81. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation . 2008;118(22):2243 e 2251, 4p following 2251. https://doi.org/10.1161/circulationaha.108.814251 82. Viney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised l","tf":{"10":5,"11":1,"12":2,"22":1,"27":1,"77":1,"78":1,"79":1,"80":1,"81":1,"82":1,"108":1,"110":1,"118":1,"337":1,"345":1,"1001":1,"1016":1,"1161":2,"1177":1,"1255":1,"1268":1,"1287":1,"1295":1,"1439":1,"1450":1,"2008":1,"2011":1,"2019":2,"2020":1,"2021":2,"2243":1,"2251":2,"3780":1,"814251":1,"959247":1,"better":1,"re":1,"fl":1,"ect":1,"residual":1,"risk":4,"than":1,"ldl":1,"choles":1,"terol":1,"in":2,"statin":1,"treated":1,"patients":1,"am":1,"coll":1,"cardiol":3,"https":5,"doi":5,"org":5,"jacc":1,"01":1,"027":1,"khan":2,"su":1,"mu":1,"valavoor":1,"et":4,"al":4,"association":1,"of":4,"lowering":2,"apolipoprotein":4,"with":2,"cardiovascular":4,"outcomes":1,"across":1,"various":1,"lipid":1,"therapies":1,"sys":1,"tematic":1,"review":2,"and":4,"meta":2,"analysis":2,"trials":1,"eur":1,"prev":1,"2047487319871733":1,"sniderman":2,"ad":2,"thanassoulis":1,"glavinovic":1,"particles":1,"disease":1,"narrative":1,"jama":1,"jamacardio":1,"williams":1,"contois":1,"jh":1,"low":1,"density":2,"lipoprotein":2,"cholesterol":2,"non":1,"high":1,"as":1,"markers":1,"circ":1,"cardiovasc":1,"qual":1,"out":1,"comes":1,"may":1,"circoutcomes":1,"ridker":1,"pm":1,"paynter":1,"np":1,"rifai":1,"gaziano":1,"jm":1,"cook":1,"nr":1,"reactive":1,"protein":1,"parental":1,"history":1,"improve":1,"global":1,"prediction":1,"the":1,"reynolds":1,"score":1,"for":1,"men":1,"circulation":1,"4p":1,"following":1,"circulationaha":1,"viney":1,"nj":1,"van":1,"capelleveen":1,"jc":1,"geary":1,"rs":1,"antisense":1,"oligonucleotides":1,"targeting":1,"people":1,"raised":1},"len":206},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":34,"chunkId":"aace-2023-p34-c5","text":"re for men. Circulation . 2008;118(22):2243 e 2251, 4p following 2251. https://doi.org/10.1161/circulationaha.108.814251 82. Viney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double- blind, placebo-controlled, dose-ranging trials. Lancet . 2016;388(10057): 2239 e 2253. https://doi.org/10.1016/s0140-6736(16)31009-1 83. Lee JH, Han D, Hartaigh B \u0013 O, et al. Warranty period of zero coronary artery calcium score for predicting all-cause mortality according to cardiac risk burden in asymptomatic Korean adults. Circ J . 2016;80(11):2356 e 2361. https://doi.org/10.1253/circj.CJ-16-0731 84. Pereira AC, Gomez LM, Bittencourt MS, et al. Age, gender, and race-based coronary artery calcium score percentiles in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Clin Cardiol . 2016;39(6):352 e 359. https:// doi.org/10.1002/clc.22539 85. Al Rifai M, McEvoy JW, Nasir K, et al. Traditional cardiovascular disease risk factors associated with one-year all-cause mortality among those with cor- onary artery calcium scores \u0015 400. Atherosclerosis . 2015;241(2):495 e 497. https://doi.org/10.1016/j.atherosclerosis.2015.06.002 86. Lai R, Ju J, Lin Q, Xu H. Coronary artery calci fi cation under statin therapy and ts effect on cardiovascular outcomes: a systematic review and meta-analysis","tf":{"10":5,"11":1,"16":2,"22":1,"39":1,"80":1,"82":1,"83":1,"84":1,"85":1,"86":1,"108":1,"118":1,"241":1,"352":1,"359":1,"388":1,"400":1,"495":1,"497":1,"1002":1,"1016":2,"1161":1,"1253":1,"2008":1,"2015":2,"2016":3,"2239":1,"2243":1,"2251":2,"2253":1,"2356":1,"2361":1,"6736":1,"10057":1,"22539":1,"31009":1,"814251":1,"re":1,"for":2,"men":1,"circulation":1,"4p":1,"following":1,"https":5,"doi":5,"org":5,"circulationaha":1,"viney":1,"nj":1,"van":1,"capelleveen":1,"jc":1,"geary":1,"rs":1,"et":4,"al":5,"antisense":1,"oligonucleotides":1,"targeting":1,"apolipoprotein":1,"in":3,"people":1,"with":3,"raised":1,"lipoprotein":1,"two":1,"randomised":1,"double":1,"blind":1,"placebo":1,"controlled":1,"dose":1,"ranging":1,"trials":1,"lancet":1,"s0140":1,"lee":1,"jh":1,"han":1,"hartaigh":1,"warranty":1,"period":1,"of":2,"zero":1,"coronary":3,"artery":4,"calcium":3,"score":2,"predicting":1,"all":2,"cause":2,"mortality":2,"according":1,"to":1,"cardiac":1,"risk":2,"burden":1,"asymptomatic":1,"korean":1,"adults":1,"circ":1,"circj":1,"cj":1,"0731":1,"pereira":1,"ac":1,"gomez":1,"lm":1,"bittencourt":1,"ms":1,"age":1,"gender":1,"and":3,"race":1,"based":1,"percentiles":1,"the":1,"brazilian":1,"longitudinal":1,"study":1,"adult":1,"health":1,"elsa":1,"brasil":1,"clin":1,"cardiol":1,"clc":1,"rifai":1,"mcevoy":1,"jw":1,"nasir":1,"traditional":1,"cardiovascular":2,"disease":1,"factors":1,"associated":1,"one":1,"year":1,"among":1,"those":1,"cor":1,"onary":1,"scores":1,"atherosclerosis":2,"06":1,"002":1,"lai":1,"ju":1,"lin":1,"xu":1,"calci":1,"fi":1,"cation":1,"under":1,"statin":1,"therapy":1,"ts":1,"effect":1,"on":1,"outcomes":1,"systematic":1,"review":1,"meta":1,"analysis":1},"len":216},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":34,"chunkId":"aace-2023-p34-c6","text":"clerosis . 2015;241(2):495 e 497. https://doi.org/10.1016/j.atherosclerosis.2015.06.002 86. Lai R, Ju J, Lin Q, Xu H. Coronary artery calci fi cation under statin therapy and ts effect on cardiovascular outcomes: a systematic review and meta-analysis. Front Cardiovasc Med . 2020;7, 600497. https://doi.org/10.3389/ fcvm.2020.600497 87. Nie F, He J, Cao H, Hu X. Predictive value of abnormal ankle-brachial index in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract . 2021;174, 108723. https://doi.org/10.1016/j.diabres.2021.108723 88. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in pa- tients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol . 2008;51(15):1512 e 1524. https://doi.org/ 10.1016/j.jacc.2008.02.034 89. Wing RR, Lang W, Wadden TA, et al. Bene fi ts of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care . 2011;34(7):1481 e 1486. https://doi.org/ 10.2337/dc10-2415 90. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive- dose compared with moderate-dose statin therapy: a meta-analysis. JAMA . 2011;305(24):2556 e 2564. https://doi.org/10.1001/jama.2011.860 91. Sattar N, Preiss D, Murray HM, et al. Statins and risk of inci","tf":{"10":6,"15":1,"24":1,"34":1,"51":1,"86":1,"87":1,"88":1,"89":1,"90":1,"91":1,"174":1,"241":1,"305":1,"495":1,"497":1,"860":1,"1001":1,"1016":3,"1481":1,"1486":1,"1512":1,"1524":1,"2008":2,"2011":3,"2015":2,"2020":2,"2021":2,"2337":1,"2415":1,"2556":1,"2564":1,"3389":1,"108723":2,"600497":2,"clerosis":1,"https":6,"doi":6,"org":6,"atherosclerosis":1,"06":1,"002":1,"lai":1,"ju":1,"lin":1,"xu":1,"coronary":1,"artery":1,"calci":1,"fi":2,"cation":1,"under":1,"statin":2,"therapy":2,"and":5,"ts":2,"effect":1,"on":1,"cardiovascular":2,"outcomes":1,"systematic":1,"review":1,"meta":3,"analysis":3,"front":1,"cardiovasc":1,"med":1,"fcvm":1,"nie":1,"he":1,"cao":1,"hu":1,"predictive":1,"value":1,"of":5,"abnormal":1,"ankle":1,"brachial":1,"index":1,"in":4,"patients":1,"with":5,"diabetes":6,"res":1,"clin":1,"pract":1,"diabres":1,"brunzell":1,"jd":1,"davidson":1,"furberg":1,"cd":1,"et":4,"al":4,"lipoprotein":1,"management":1,"pa":1,"tients":1,"cardiometabolic":1,"risk":4,"consensus":1,"conference":1,"report":1,"from":1,"the":2,"american":2,"association":1,"college":1,"cardiology":1,"foundation":1,"am":1,"coll":1,"cardiol":1,"jacc":1,"02":1,"034":1,"wing":1,"rr":1,"lang":1,"wadden":1,"ta":1,"bene":1,"modest":1,"weight":1,"loss":1,"improving":1,"factors":1,"overweight":1,"obese":1,"individuals":1,"type":1,"care":1,"dc10":1,"preiss":2,"seshasai":1,"sr":1,"welsh":1,"incident":1,"intensive":1,"dose":2,"compared":1,"moderate":1,"jama":2,"sattar":1,"murray":1,"hm":1,"statins":1,"inci":1},"len":221},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":34,"chunkId":"aace-2023-p34-c7","text":" al. Risk of incident diabetes with intensive- dose compared with moderate-dose statin therapy: a meta-analysis. JAMA . 2011;305(24):2556 e 2564. https://doi.org/10.1001/jama.2011.860 91. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet . 2010;375(9716):735 e 742. https://doi.org/10.1016/s0140-6736(09)61965-6 92. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart As- sociation Task Force on Practice Guidelines. J Am Coll Cardiol . 2014;63(25 Pt B):2889 e 2934. https://doi.org/10.1016/j.jacc.2013.11.002 93. Correction. J Am Coll Cardiol . 2015;66(24):2812. https://doi.org/10.1016/ j.jacc.2015.11.019 94. Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scienti fi c statement from the American Heart Association. Arte- rioscler Thromb Vasc Biol . 2019;39(2):e38 e e81. https://doi.org/10.1161/ atv.0000000000000073 95. Correction to: Statin safety and associated adverse events: a scienti fi c state- ment From the American Heart Association. Arterioscler Thromb Vasc Biol . 2019;39(5):e158. https://doi.org/10.1161/atv.0000000000000081 96. Qu H, Guo M, Chai H, Wang WT, Gao ZY, Shi DZ. ","tf":{"10":6,"11":2,"24":2,"25":1,"39":2,"63":1,"66":1,"91":1,"92":1,"93":1,"94":1,"95":1,"96":1,"305":1,"375":1,"735":1,"742":1,"860":1,"1001":1,"1016":3,"1161":2,"2010":1,"2011":2,"2013":2,"2014":1,"2015":2,"2019":2,"2556":1,"2564":1,"2812":1,"2889":1,"2934":1,"6736":1,"9716":1,"61965":1,"al":4,"risk":3,"of":6,"incident":2,"diabetes":2,"with":2,"intensive":1,"dose":2,"compared":1,"moderate":1,"statin":4,"therapy":1,"meta":2,"analysis":2,"jama":2,"https":6,"doi":6,"org":6,"sattar":1,"preiss":2,"murray":1,"hm":1,"et":3,"statins":1,"and":3,"collaborative":1,"randomised":1,"trials":1,"lancet":1,"s0140":1,"09":1,"stone":1,"nj":1,"robinson":1,"jg":1,"lichtenstein":1,"ah":1,"acc":1,"aha":1,"guideline":1,"on":2,"the":4,"treatment":1,"blood":1,"cholesterol":1,"to":2,"reduce":1,"atherosclerotic":1,"cardiovascular":1,"in":1,"adults":1,"report":1,"american":4,"college":1,"cardiology":1,"heart":3,"as":1,"sociation":1,"task":1,"force":1,"practice":1,"guidelines":1,"am":2,"coll":2,"cardiol":2,"pt":1,"jacc":2,"002":1,"correction":2,"019":1,"newman":1,"cb":1,"tobert":1,"ja":1,"safety":2,"associated":2,"adverse":2,"events":2,"scienti":2,"fi":2,"statement":1,"from":2,"association":2,"arte":1,"rioscler":1,"thromb":2,"vasc":2,"biol":2,"e38":1,"e81":1,"atv":2,"0000000000000073":1,"state":1,"ment":1,"arterioscler":1,"e158":1,"0000000000000081":1,"qu":1,"guo":1,"chai":1,"wang":1,"wt":1,"gao":1,"zy":1,"shi":1,"dz":1},"len":223},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":34,"chunkId":"aace-2023-p34-c8","text":"tin safety and associated adverse events: a scienti fi c state- ment From the American Heart Association. Arterioscler Thromb Vasc Biol . 2019;39(5):e158. https://doi.org/10.1161/atv.0000000000000081 96. Qu H, Guo M, Chai H, Wang WT, Gao ZY, Shi DZ. Effects of coenzyme q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials. J Am Heart Assoc . 2018;7(19), e009835. https://doi.org/ 10.1161/jaha.118.009835 97. Hlatky MA, Gonzalez PE, Manson JE, et al. Statin-associated muscle symptoms among new statin users randomly assigned to vitamin D or placebo. JAMA Cardiol . 2023;8(1):74 e 80. https://doi.org/10.1001/jamacardio.2022.4250 98. Das Pradhan A, Glynn RJ, Fruchart JC, et al. Triglyceride lowering with pema fi brate to reduce cardiovascular risk. N Engl J Med . 2022;387(21): 1923 e 1934. https://doi.org/10.1056/NEJMoa2210645 99. Scott R, O'Brien R, Fulcher G, et al. Effects of feno fi brate treatment on car- diovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Feno fi brate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care . 2009;32(3): 493 e 498. https://doi.org/10.2337/dc08-1543 100. Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipi","tf":{"10":5,"19":1,"21":1,"32":1,"39":1,"74":1,"80":1,"96":1,"97":1,"98":1,"99":1,"100":1,"118":1,"387":1,"493":1,"498":1,"795":1,"1001":1,"1056":1,"1161":2,"1543":1,"1923":1,"1934":1,"2009":1,"2018":1,"2019":1,"2022":2,"2023":1,"2337":1,"4250":1,"tin":1,"safety":1,"and":3,"associated":2,"adverse":1,"events":1,"scienti":1,"fi":4,"state":1,"ment":1,"from":1,"the":3,"american":1,"heart":2,"association":1,"arterioscler":1,"thromb":1,"vasc":1,"biol":1,"e158":1,"https":5,"doi":5,"org":5,"atv":1,"0000000000000081":1,"qu":1,"guo":1,"chai":1,"wang":1,"wt":1,"gao":1,"zy":1,"shi":1,"dz":1,"effects":2,"of":4,"coenzyme":1,"q10":1,"on":3,"statin":3,"induced":1,"myopathy":1,"an":1,"updated":1,"meta":1,"analysis":1,"randomized":1,"controlled":1,"trials":1,"am":1,"assoc":1,"e009835":1,"jaha":1,"009835":1,"hlatky":1,"ma":1,"gonzalez":1,"pe":1,"manson":1,"je":1,"et":3,"al":3,"muscle":1,"symptoms":1,"among":1,"new":1,"users":1,"randomly":1,"assigned":1,"to":2,"vitamin":1,"or":2,"placebo":1,"jama":1,"cardiol":1,"jamacardio":1,"das":1,"pradhan":1,"glynn":1,"rj":1,"fruchart":1,"jc":1,"triglyceride":2,"lowering":2,"with":3,"pema":1,"brate":3,"reduce":1,"cardiovascular":2,"risk":3,"engl":1,"med":1,"nejmoa2210645":1,"scott":1,"brien":1,"fulcher":1,"feno":2,"treatment":1,"car":1,"diovascular":1,"disease":1,"in":3,"individuals":1,"type":1,"diabetes":3,"various":1,"components":1,"metabolic":1,"syndrome":1,"intervention":1,"event":1,"field":1,"study":1,"care":1,"dc08":1,"bruckert":1,"labreuche":1,"deplanque":1,"touboul":1,"pj":1,"amarenco":1,"fibrates":1,"effect":1,"is":1,"greater":1,"patients":1,"high":1,"levels":1,"atherogenic":1,"dyslipi":1},"len":215},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":34,"chunkId":"aace-2023-p34-c9","text":"etes Care . 2009;32(3): 493 e 498. https://doi.org/10.2337/dc08-1543 100. Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia pro fi le: a systematic review and meta-analysis. J Cardiovasc Pharmacol . 2011;57(2):267 e 272. https://doi.org/10.1097/ FJC.0b013e318202709f 101. Lee M, Saver JL, Tow fi ghi A, Chow J, Ovbiagele B. Ef fi cacy of fi brates for car- diovascular risk reduction in persons with atherogenic dyslipidemia: a meta- analysis. Atherosclerosis . 2011;217(2):492 e 498. https://doi.org/10.1016/ j.atherosclerosis.2011.04.020 102. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med . 2019;380(1):11 e 22. https:// doi.org/10.1056/NEJMoa1812792 103. Suh DC, Kim CM, Choi IS, Plauschinat CA, Barone JA. Trends in blood pressure control and treatment among type 2 diabetes with comorbid hypertension in the United States: 1988-2004. J Hypertens . 2009;27(9):1908 e 1916. https:// doi.org/10.1097/HJH.0b013e32832d4aee S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 338","tf":{"10":5,"11":1,"22":1,"27":1,"29":1,"32":1,"57":1,"100":1,"101":1,"102":1,"103":1,"217":1,"267":1,"272":1,"305":1,"338":1,"340":1,"380":1,"492":1,"493":1,"498":2,"1016":1,"1056":1,"1097":2,"1543":1,"1908":1,"1916":1,"1988":1,"2004":1,"2009":2,"2011":3,"2019":1,"2023":1,"2337":1,"etes":1,"care":1,"https":5,"doi":5,"org":5,"dc08":1,"bruckert":1,"labreuche":1,"deplanque":1,"touboul":1,"pj":1,"amarenco":1,"fibrates":1,"effect":1,"on":1,"cardiovascular":2,"risk":3,"is":2,"greater":1,"in":4,"patients":1,"with":4,"high":1,"triglyceride":1,"levels":1,"or":1,"atherogenic":2,"dyslipidemia":2,"pro":1,"fi":4,"le":1,"systematic":1,"review":1,"and":2,"meta":2,"analysis":2,"cardiovasc":1,"pharmacol":1,"fjc":1,"0b013e318202709f":1,"lee":1,"saver":1,"jl":1,"tow":1,"ghi":1,"chow":1,"ovbiagele":1,"ef":1,"cacy":1,"of":1,"brates":1,"for":2,"car":1,"diovascular":1,"reduction":2,"persons":1,"atherosclerosis":2,"04":1,"020":1,"bhatt":1,"dl":1,"steg":1,"pg":1,"miller":1,"et":2,"al":2,"icosapent":1,"ethyl":1,"hypertriglyceridemia":1,"engl":1,"med":1,"nejmoa1812792":1,"suh":1,"dc":1,"kim":1,"cm":1,"choi":1,"plauschinat":1,"ca":1,"barone":1,"ja":1,"trends":1,"blood":1,"pressure":1,"control":1,"treatment":1,"among":1,"type":1,"diabetes":1,"comorbid":1,"hypertension":1,"the":1,"united":1,"states":1,"hypertens":1,"hjh":1,"0b013e32832d4aee":1,"samson":1,"vellanki":1,"blonde":1,"endocrine":1,"practice":1},"len":180},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":35,"chunkId":"aace-2023-p35-c0","text":"104. Liu HH, Cao YX, Li S, et al. Impacts of prediabetes mellitus alone or plus hyper- tension on the coronary severity and cardiovascular outcomes. Hypertension . 2018;71(6):1039 e 1046. https://doi.org/10.1161/hypertensionaha.118.11063 105. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ . 1998;317(7160):703 e 713. 106. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ . 2000;321(7258):412 e 419. https:// doi.org/10.1136/bmj.321.7258.412 107. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. In fl uence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension . 2003;42(5):878 e 884. https://doi.org/10.1161/01.Hyp.0000094221.86888.Ae 108. Cornelissen VA, Smart NA. Exercise training for blood pressure: a systematic review and meta-analysis. J Am Heart Assoc . 2013;2(1), e004473. https:// doi.org/10.1161/jaha.112.004473 109. Conlin PR. The dietary approaches to stop hypertension (DASH) clinical trial: implications for lifestyle modi fi cations in the treatment of hypertensive pa- tients. Cardiol Rev . 1999;7(5):284 e 288. https://doi.org/10.1097/00045415- 199909000-00013 110. Davi","tf":{"10":5,"36":1,"38":1,"42":1,"71":1,"104":1,"105":1,"106":1,"107":1,"108":1,"109":1,"110":1,"112":1,"118":1,"284":1,"288":1,"317":1,"321":2,"412":2,"419":1,"703":1,"713":1,"878":1,"884":1,"1039":1,"1046":1,"1097":1,"1136":1,"1161":3,"1998":1,"1999":1,"2000":1,"2003":1,"2013":1,"2018":1,"7160":1,"7258":2,"11063":1,"86888":1,"199909000":1,"liu":1,"hh":1,"cao":1,"yx":1,"li":1,"et":2,"al":2,"impacts":1,"of":7,"prediabetes":1,"mellitus":1,"alone":1,"or":1,"plus":1,"hyper":1,"tension":1,"on":2,"the":3,"coronary":1,"severity":1,"and":5,"cardiovascular":1,"outcomes":1,"hypertension":3,"https":5,"doi":5,"org":5,"hypertensionaha":1,"tight":1,"blood":4,"pressure":4,"control":1,"risk":1,"macrovascular":2,"microvascular":2,"complications":2,"in":3,"type":2,"diabetes":3,"ukpds":2,"uk":1,"prospective":2,"study":2,"group":1,"bmj":3,"adler":1,"ai":1,"stratton":1,"im":1,"neil":1,"ha":1,"association":1,"systolic":1,"with":1,"observational":1,"neter":1,"je":1,"stam":1,"be":1,"kok":1,"fj":1,"grobbee":1,"de":1,"geleijnse":1,"jm":1,"fl":1,"uence":1,"weight":1,"reduction":1,"meta":2,"analysis":2,"randomized":1,"controlled":1,"trials":1,"01":1,"hyp":1,"0000094221":1,"ae":1,"cornelissen":1,"va":1,"smart":1,"na":1,"exercise":1,"training":1,"for":2,"systematic":1,"review":1,"am":1,"heart":1,"assoc":1,"e004473":1,"jaha":1,"004473":1,"conlin":1,"pr":1,"dietary":1,"approaches":1,"to":1,"stop":1,"dash":1,"clinical":1,"trial":1,"implications":1,"lifestyle":1,"modi":1,"fi":1,"cations":1,"treatment":1,"hypertensive":1,"pa":1,"tients":1,"cardiol":1,"rev":1,"00045415":1,"00013":1,"davi":1},"len":216},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":35,"chunkId":"aace-2023-p35-c1","text":" The dietary approaches to stop hypertension (DASH) clinical trial: implications for lifestyle modi fi cations in the treatment of hypertensive pa- tients. Cardiol Rev . 1999;7(5):284 e 288. https://doi.org/10.1097/00045415- 199909000-00013 110. Davis CR, Hodgson JM, Woodman R, Bryan J, Wilson C, Murphy KJ. A Mediterranean diet lowers blood pressure and improves endothelial func- tion: results from the MedLey randomized intervention trial. Am J Clin Nutr . 2017;105(6):1305 e 1313. https://doi.org/10.3945/ajcn.116.146803 111. Saglimbene V, Palmer SC, Ruospo M, et al. The Long-term Impact of Renin- Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): a randomized, controlled trial. J Am Soc Nephrol . 2018;29(12):2890 e 2899. https://doi.org/10.1681/asn.2018040443 112. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med . 2013;369(20):1892 e 1903. https://doi.org/10.1056/NEJMoa1303154 113. Palmer SC, Mavridis D, Navarese E, et al. Comparative ef fi cacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet . 2015;385(9982):2047 e 2056. https://doi.org/ 10.1016/s0140-6736(14)62459-4 114. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med . 2008;358(15):15","tf":{"10":5,"12":1,"14":1,"15":2,"20":1,"29":1,"105":1,"110":1,"111":1,"112":1,"113":1,"114":1,"116":1,"284":1,"288":1,"358":1,"369":1,"385":1,"1016":1,"1056":1,"1097":1,"1305":1,"1313":1,"1681":1,"1892":1,"1903":1,"1999":1,"2008":1,"2013":1,"2015":1,"2017":1,"2018":1,"2047":1,"2056":1,"2890":1,"2899":1,"3945":1,"6736":1,"9982":1,"62459":1,"146803":1,"199909000":1,"2018040443":1,"the":5,"dietary":1,"approaches":1,"to":1,"stop":1,"hypertension":1,"dash":1,"clinical":1,"trial":3,"implications":1,"for":3,"lifestyle":1,"modi":1,"fi":2,"cations":1,"in":3,"treatment":2,"of":4,"hypertensive":1,"pa":1,"tients":1,"cardiol":1,"rev":1,"https":5,"doi":5,"org":5,"00045415":1,"00013":1,"davis":1,"cr":1,"hodgson":1,"jm":1,"woodman":1,"bryan":1,"wilson":1,"murphy":1,"kj":1,"mediterranean":1,"diet":1,"lowers":1,"blood":2,"pressure":2,"and":3,"improves":1,"endothelial":1,"func":1,"tion":1,"results":1,"from":1,"medley":1,"randomized":2,"intervention":1,"am":2,"clin":1,"nutr":1,"ajcn":1,"saglimbene":1,"palmer":2,"sc":2,"ruospo":1,"et":4,"al":4,"long":1,"term":1,"impact":1,"renin":1,"angiotensin":2,"system":1,"ras":1,"inhibition":2,"on":1,"cardiorenal":1,"outcomes":1,"lirico":1,"controlled":1,"soc":1,"nephrol":1,"asn":1,"fried":1,"lf":1,"emanuele":1,"zhang":1,"jh":1,"combined":1,"diabetic":1,"nephropathy":1,"engl":2,"med":2,"nejmoa1303154":1,"mavridis":1,"navarese":1,"comparative":1,"ef":1,"cacy":1,"safety":1,"lowering":1,"agents":1,"adults":1,"with":1,"diabetes":1,"kidney":1,"disease":1,"network":1,"meta":1,"analysis":1,"lancet":1,"s0140":1,"yusuf":1,"teo":1,"kk":1,"pogue":1,"telmisartan":1,"ramipril":1,"or":1,"both":1,"patients":1,"at":1,"high":1,"risk":1,"vascular":1,"events":1},"len":214},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":35,"chunkId":"aace-2023-p35-c2","text":"twork meta-analysis. Lancet . 2015;385(9982):2047 e 2056. https://doi.org/ 10.1016/s0140-6736(14)62459-4 114. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med . 2008;358(15):1547 e 1559. https:// doi.org/10.1056/NEJMoa0801317 115. Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hyperten- sive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med . 2005;165(8):936 e 946. https://doi.org/10.1001/archinte.165.8.936 116. Pischon T, Sharma AM. Use of beta-blockers in obesity hypertension: poten- tial role of weight gain. Obes Rev . 2001;2(4):275 e 280. https://doi.org/ 10.1046/j.1467-789x.2001.00044.x 117. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension . 2001;37(2):250 e 254. https://doi.org/10.1161/01.hyp.37.2.250 118. Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scienti fi c statement from the American Heart Association. Hypertension . 2018;72(5):e53 e e90. https://doi.org/10.1161/ hyp.0000000000000084 119. Williams TA, Reincke M. Management of endocrine disease","tf":{"10":6,"14":1,"15":1,"37":2,"72":1,"114":1,"115":1,"116":1,"117":1,"118":1,"119":1,"165":2,"250":2,"254":1,"275":1,"280":1,"358":1,"385":1,"936":2,"946":1,"1001":1,"1016":1,"1046":1,"1056":1,"1161":2,"1467":1,"1547":1,"1559":1,"2001":3,"2005":1,"2008":1,"2015":1,"2018":1,"2047":1,"2056":1,"6736":1,"9982":1,"62459":1,"twork":1,"meta":1,"analysis":2,"lancet":1,"https":6,"doi":6,"org":6,"s0140":1,"yusuf":1,"teo":1,"kk":1,"pogue":1,"et":3,"al":3,"telmisartan":1,"ramipril":1,"or":2,"both":1,"in":3,"patients":2,"at":1,"high":2,"risk":2,"for":1,"vascular":1,"events":1,"engl":1,"med":2,"nejmoa0801317":1,"rahman":1,"pressel":1,"davis":1,"br":1,"renal":1,"outcomes":1,"hyperten":1,"sive":1,"treated":1,"with":1,"an":1,"angiotensin":1,"converting":1,"enzyme":1,"inhibitor":1,"calcium":1,"channel":1,"blocker":1,"vs":1,"diuretic":1,"report":1,"from":2,"the":2,"antihypertensive":1,"and":3,"lipid":1,"lowering":1,"treatment":1,"to":1,"prevent":1,"heart":2,"attack":1,"trial":1,"allhat":1,"arch":1,"intern":1,"archinte":1,"pischon":2,"sharma":2,"am":2,"use":1,"of":3,"beta":2,"blockers":2,"obesity":1,"hypertension":4,"poten":1,"tial":1,"role":1,"weight":2,"gain":2,"obes":1,"rev":1,"789x":1,"00044":1,"hardt":1,"kunz":1,"luft":1,"fc":1,"hypothesis":1,"adrenergic":1,"receptor":1,"systematic":1,"01":1,"hyp":2,"carey":1,"rm":1,"calhoun":1,"da":1,"bakris":1,"gl":1,"resistant":1,"detection":1,"evaluation":1,"management":2,"scienti":1,"fi":1,"statement":1,"american":1,"association":1,"e53":1,"e90":1,"0000000000000084":1,"williams":1,"ta":1,"reincke":1,"endocrine":1,"disease":1},"len":213},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":35,"chunkId":"aace-2023-p35-c3","text":"sion: detection, evaluation, and management: a scienti fi c statement from the American Heart Association. Hypertension . 2018;72(5):e53 e e90. https://doi.org/10.1161/ hyp.0000000000000084 119. Williams TA, Reincke M. Management of endocrine disease: diagnosis and management of primary aldosteronism: the Endocrine Society guideline 2016 revisited. Eur J Endocrinol . 2018;179(1):R19 e R29. https://doi.org/10.1530/eje- 17-0990 120. Bakris GL, Agarwal R, Anker SD, et al. Effect of fi nerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med . 2020;383(23):2219 e 2229. https://doi.org/10.1056/NEJMoa2025845 121. Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with fi nerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J . 2022;43(6):474 e 484. https://doi.org/ 10.1093/eurheartj/ehab777 122. Corrigendum to: Cardiovascular and kidney outcomes with fi nerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J . 2022;43(20):1989. https://doi.org/10.1093/eurheartj/ ehab886 123. Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with fi nerenone in kidney disease and type 2 diabetes. N Engl J Med . 2021;385(24):2252 e 2263. https://doi.org/10.1056/NEJMoa2110956 124. U.S. Food & Drug Administration (FDA). Kerendia ( fi nere","tf":{"10":6,"17":1,"20":1,"23":1,"24":1,"43":2,"72":1,"119":1,"120":1,"121":1,"122":1,"123":1,"124":1,"179":1,"383":1,"385":1,"474":1,"484":1,"1056":2,"1093":2,"1161":1,"1530":1,"1989":1,"2016":1,"2018":2,"2020":1,"2021":1,"2022":2,"2219":1,"2229":1,"2252":1,"2263":1,"sion":1,"detection":1,"evaluation":1,"and":7,"management":3,"scienti":1,"fi":6,"statement":1,"from":1,"the":4,"american":1,"heart":3,"association":1,"hypertension":1,"e53":1,"e90":1,"https":6,"doi":6,"org":6,"hyp":1,"0000000000000084":1,"williams":1,"ta":1,"reincke":1,"of":3,"endocrine":2,"disease":5,"diagnosis":1,"primary":1,"aldosteronism":1,"society":1,"guideline":1,"revisited":1,"eur":3,"endocrinol":1,"r19":1,"r29":1,"eje":1,"0990":1,"bakris":1,"gl":1,"agarwal":3,"anker":1,"sd":1,"et":3,"al":3,"effect":1,"nerenone":4,"on":1,"chronic":3,"kidney":6,"outcomes":3,"in":4,"type":4,"diabetes":4,"engl":2,"med":2,"nejmoa2025845":1,"filippatos":2,"pitt":2,"cardiovascular":3,"with":5,"patients":2,"fidelity":2,"pooled":2,"analysis":2,"eurheartj":2,"ehab777":1,"corrigendum":1,"to":1,"ehab886":1,"events":1,"nejmoa2110956":1,"food":1,"drug":1,"administration":1,"fda":1,"kerendia":1,"nere":1},"len":205},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":35,"chunkId":"aace-2023-p35-c4","text":"ilippatos G, Agarwal R, et al. Cardiovascular events with fi nerenone in kidney disease and type 2 diabetes. N Engl J Med . 2021;385(24):2252 e 2263. https://doi.org/10.1056/NEJMoa2110956 124. U.S. Food & Drug Administration (FDA). Kerendia ( fi nerenone) prescribing information. Accessed December 1, 2022. https://www.accessdata.fda.gov/ drugsatfda_docs/label/2021/215341s000lbl.pdf 125. Mazidi M, Rezaie P, Gao HK, Kengne AP. Effect of sodium-glucose cotransport- 2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc . 2017;6(6), e004007. https://doi.org/10.1161/ jaha.116.004007 126. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens . 2014;8(4): 262 e 275.e9. https://doi.org/10.1016/j.jash.2014.01.007 127. Sun F, Wu S, Guo S, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract . 2015;110(1):26 e 37. https://doi.org/10.1016/j.diabres.2015.07.015 128. Berra C, Manfrini R, Regazzoli D, et al. Blood pressure control in type 2 dia- betes mellitus with arterial hypertension.","tf":{"10":4,"22":1,"24":1,"26":1,"37":1,"43":1,"110":1,"116":1,"124":1,"125":1,"126":1,"127":1,"128":1,"262":1,"275":1,"385":1,"528":1,"1016":2,"1056":1,"1161":1,"2014":2,"2015":2,"2017":1,"2021":2,"2022":1,"2252":1,"2263":1,"ilippatos":1,"agarwal":1,"et":3,"al":3,"cardiovascular":1,"events":1,"with":5,"fi":2,"nerenone":2,"in":3,"kidney":1,"disease":1,"and":5,"type":4,"diabetes":4,"engl":1,"med":1,"https":5,"doi":4,"org":4,"nejmoa2110956":1,"food":1,"drug":1,"administration":1,"fda":2,"kerendia":1,"prescribing":1,"information":1,"accessed":1,"december":1,"www":1,"accessdata":1,"gov":1,"drugsatfda":1,"docs":1,"label":1,"215341s000lbl":1,"pdf":1,"mazidi":1,"rezaie":1,"gao":1,"hk":1,"kengne":1,"ap":1,"effect":1,"of":4,"sodium":2,"glucose":2,"cotransport":1,"inhibitors":2,"on":3,"blood":4,"pressure":4,"people":1,"mellitus":2,"systematic":3,"review":3,"meta":3,"analysis":3,"randomized":1,"control":2,"trials":1,"patients":2,"am":2,"heart":2,"assoc":1,"e004007":1,"jaha":1,"004007":1,"baker":1,"wl":1,"smyth":1,"lr":1,"riche":1,"dm":1,"bourret":1,"em":1,"chamberlin":1,"kw":1,"white":1,"wb":1,"effects":1,"co":1,"transporter":1,"soc":1,"hypertens":1,"e9":1,"jash":1,"01":1,"007":1,"sun":1,"wu":1,"guo":1,"impact":1,"glp":1,"receptor":1,"agonists":1,"rate":1,"hypertension":2,"among":1,"network":1,"res":1,"clin":1,"pract":1,"diabres":1,"07":1,"015":1,"berra":1,"manfrini":1,"regazzoli":1,"dia":1,"betes":1,"arterial":1},"len":208},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":35,"chunkId":"aace-2023-p35-c5","text":"iew and network meta-analysis. Diabetes Res Clin Pract . 2015;110(1):26 e 37. https://doi.org/10.1016/j.diabres.2015.07.015 128. Berra C, Manfrini R, Regazzoli D, et al. Blood pressure control in type 2 dia- betes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists. Pharmacol Res . 2020;160, 105052. https://doi.org/10.1016/j.phrs.2020.105052 129. Raghavan S, Vassy JL, Ho YL, et al. Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults. J Am Heart Assoc . 2019;8(4), e011295. https://doi.org/10.1161/jaha.118.011295 130. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol . 2021;9(10):653 e 662. https://doi.org/10.1016/s2213-8587(21) 00203-5 131. Neal B, Perkovic V, Mahaffey KW, et al. Canagli fl ozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med . 2017;377(7):644 e 657. https:// doi.org/10.1056/NEJMoa1611925 132. Zinman B, Wanner C, Lachin JM, et al. Empagli fl ozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med . 2015;373(22):2117 e 2128. https://doi.org/10.1056/NEJMoa1504720 133. McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhib","tf":{"10":7,"21":1,"22":1,"26":1,"37":1,"110":1,"118":1,"128":1,"129":1,"130":1,"131":1,"132":1,"133":1,"160":1,"373":1,"377":1,"644":1,"653":1,"657":1,"662":1,"1016":3,"1056":2,"1161":1,"2015":3,"2017":1,"2019":1,"2020":2,"2021":1,"2117":1,"2128":1,"8587":1,"105052":2,"iew":1,"and":8,"network":1,"meta":2,"analysis":2,"diabetes":6,"res":2,"clin":1,"pract":1,"https":6,"doi":6,"org":6,"diabres":1,"07":1,"015":1,"berra":1,"manfrini":1,"regazzoli":1,"et":6,"al":6,"blood":1,"pressure":1,"control":1,"in":5,"type":4,"dia":1,"betes":1,"mellitus":2,"with":3,"arterial":1,"hypertension":1,"the":1,"important":1,"ancillary":1,"role":1,"of":4,"sglt2":2,"inhibitors":1,"glp1":1,"receptor":2,"agonists":2,"pharmacol":1,"phrs":1,"raghavan":1,"vassy":1,"jl":1,"ho":1,"yl":1,"related":1,"all":1,"cause":1,"cardiovascular":4,"mortality":3,"national":1,"cohort":1,"adults":1,"am":1,"heart":1,"assoc":1,"e011295":1,"jaha":1,"011295":1,"sattar":1,"lee":1,"mmy":1,"kristensen":1,"sl":1,"kidney":1,"outcomes":2,"glp":1,"patients":1,"systematic":1,"review":1,"randomised":1,"trials":1,"lancet":1,"endocrinol":1,"s2213":1,"00203":1,"neal":1,"perkovic":1,"mahaffey":1,"kw":1,"canagli":1,"fl":2,"ozin":2,"renal":1,"events":1,"engl":2,"med":2,"nejmoa1611925":1,"zinman":1,"wanner":1,"lachin":1,"jm":1,"empagli":1,"nejmoa1504720":1,"mcguire":1,"dk":1,"shih":1,"wj":1,"cosentino":1,"association":1,"inhib":1},"len":215},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":35,"chunkId":"aace-2023-p35-c6","text":"r C, Lachin JM, et al. Empagli fl ozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med . 2015;373(22):2117 e 2128. https://doi.org/10.1056/NEJMoa1504720 133. McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta- analysis. JAMA Cardiol . 2021;6(2):148 e 158. https://doi.org/10.1001/ jamacardio.2020.4511 134. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular out- comes in patients with type 2 diabetes mellitus. N Engl J Med . 2013;369(14): 1317 e 1326. https://doi.org/10.1056/NEJMoa1307684 135. Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet . 2015;385(9982):2067 e 2076. https://doi.org/10.1016/s0140-6736(14)62225-x 136. U.S. Food & Drug Administration (FDA). Actos (pioglitazone hydrochloride) prescribing information. Accessed January 31, 2023. https://www.accessdata. fda.gov/drugsatfda_docs/label/2011/021073s043s044lbl.pdf 137. Young LH, Viscoli CM, Curtis JP, et al. Cardiac outcomes after ischemic stroke or transient ischemic attack: effects of pioglitazone in patients with insulin resistance without diabetes mellitus. Circulation . 2017;135(20):1882 e 1893. https://doi.org","tf":{"10":4,"14":2,"20":1,"22":1,"31":1,"133":1,"134":1,"135":2,"136":1,"137":1,"148":1,"158":1,"369":1,"373":1,"385":1,"1001":1,"1016":1,"1056":2,"1317":1,"1326":1,"1882":1,"1893":1,"2011":1,"2013":1,"2015":2,"2017":1,"2020":1,"2021":1,"2023":1,"2067":1,"2076":1,"2117":1,"2128":1,"4511":1,"6736":1,"9982":1,"62225":1,"lachin":1,"jm":1,"et":5,"al":5,"empagli":1,"fl":1,"ozin":1,"cardiovascular":3,"outcomes":4,"and":4,"mortality":2,"in":6,"type":4,"diabetes":5,"engl":2,"med":2,"https":6,"doi":5,"org":5,"nejmoa1504720":1,"mcguire":1,"dk":1,"shih":1,"wj":1,"cosentino":1,"association":1,"of":2,"sglt2":1,"inhibitors":1,"with":5,"kidney":1,"patients":4,"meta":1,"analysis":1,"jama":1,"cardiol":1,"jamacardio":1,"scirica":1,"bm":1,"bhatt":1,"dl":1,"braunwald":1,"saxagliptin":1,"out":1,"comes":1,"mellitus":2,"nejmoa1307684":1,"zannad":1,"cannon":1,"cp":1,"cushman":1,"wc":1,"heart":1,"failure":1,"taking":1,"alogliptin":1,"versus":1,"placebo":1,"examine":1,"multicentre":1,"randomised":1,"double":1,"blind":1,"trial":1,"lancet":1,"s0140":1,"food":1,"drug":1,"administration":1,"fda":2,"actos":1,"pioglitazone":2,"hydrochloride":1,"prescribing":1,"information":1,"accessed":1,"january":1,"www":1,"accessdata":1,"gov":1,"drugsatfda":1,"docs":1,"label":1,"021073s043s044lbl":1,"pdf":1,"young":1,"lh":1,"viscoli":1,"cm":1,"curtis":1,"jp":1,"cardiac":1,"after":1,"ischemic":2,"stroke":1,"or":1,"transient":1,"attack":1,"effects":1,"insulin":1,"resistance":1,"without":1,"circulation":1},"len":203},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":35,"chunkId":"aace-2023-p35-c7","text":"oung LH, Viscoli CM, Curtis JP, et al. Cardiac outcomes after ischemic stroke or transient ischemic attack: effects of pioglitazone in patients with insulin resistance without diabetes mellitus. Circulation . 2017;135(20):1882 e 1893. https://doi.org/10.1161/circulationaha.116.024863 138. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA . 2003;290(4): 486 e 494. https://doi.org/10.1001/jama.290.4.486 139. Holman RR, Coleman RL, Chan JCN, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol . 2017;5(11):877 e 886. https://doi.org/10.1016/ s2213-8587(17)30309-1 140. Ren Z, Fu X. Stroke risk factors in United States: an analysis of the 2013-2018 National Health and Nutrition Examination Survey. Int J Gen Med . 2021;14: 6135 e 6147. https://doi.org/10.2147/ijgm.S327075 141. Grewal S, Zaman N, Borgatta L, Nudy M, Foy AJ, Peterson B. Usefulness of glucagon-like peptide-1 receptor agonists to reduce adverse cardiovascular disease events in patients with type 2 diabetes mellitus. Am J Cardiol . 2021;154:48 e 53. https://doi.org/10.1016/j.amjcard.2021.05.04","tf":{"10":5,"11":1,"14":1,"17":1,"20":1,"48":1,"53":1,"116":1,"135":1,"138":1,"139":1,"140":1,"141":1,"154":1,"290":2,"486":2,"494":1,"877":1,"886":1,"1001":1,"1016":2,"1161":1,"1882":1,"1893":1,"2003":1,"2013":1,"2017":2,"2018":1,"2021":3,"2147":1,"6135":1,"6147":1,"8587":1,"30309":1,"oung":1,"lh":1,"viscoli":1,"cm":1,"curtis":1,"jp":1,"et":2,"al":2,"cardiac":1,"outcomes":2,"after":1,"ischemic":2,"stroke":2,"or":1,"transient":1,"attack":1,"effects":2,"of":5,"pioglitazone":1,"in":5,"patients":4,"with":4,"insulin":1,"resistance":1,"without":1,"diabetes":4,"mellitus":2,"circulation":1,"https":5,"doi":5,"org":5,"circulationaha":1,"024863":1,"chiasson":1,"jl":1,"josse":1,"rg":1,"gomis":1,"hanefeld":1,"karasik":1,"laakso":1,"acarbose":2,"treatment":1,"and":5,"the":3,"risk":2,"cardiovascular":3,"disease":3,"hypertension":1,"impaired":2,"glucose":2,"tolerance":2,"stop":1,"niddm":1,"trial":2,"jama":2,"holman":1,"rr":1,"coleman":1,"rl":1,"chan":1,"jcn":1,"on":1,"coronary":1,"heart":1,"ace":1,"randomised":1,"double":1,"blind":1,"placebo":1,"controlled":1,"lancet":1,"endocrinol":1,"s2213":1,"ren":1,"fu":1,"factors":1,"united":1,"states":1,"an":1,"analysis":1,"national":1,"health":1,"nutrition":1,"examination":1,"survey":1,"int":1,"gen":1,"med":1,"ijgm":1,"s327075":1,"grewal":1,"zaman":1,"borgatta":1,"nudy":1,"foy":1,"aj":1,"peterson":1,"usefulness":1,"glucagon":1,"like":1,"peptide":1,"receptor":1,"agonists":1,"to":1,"reduce":1,"adverse":1,"events":1,"type":1,"am":1,"cardiol":1,"amjcard":1,"05":1,"04":1},"len":211},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":35,"chunkId":"aace-2023-p35-c8","text":"dy M, Foy AJ, Peterson B. Usefulness of glucagon-like peptide-1 receptor agonists to reduce adverse cardiovascular disease events in patients with type 2 diabetes mellitus. Am J Cardiol . 2021;154:48 e 53. https://doi.org/10.1016/j.amjcard.2021.05.043 142. Malhotra K, Katsanos AH, Lambadiari V, et al. GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis. J Neurol . 2020;267(7):2117 e 2122. https://doi.org/10.1007/s00415-020- 09813-4 143. Das SR, Everett BM, Birtcher KK, et al. 2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol . 2020;76(9):1117 e 1145. https:// doi.org/10.1016/j.jacc.2020.05.037 144. Lee M, Saver JL, Liao HW, Lin CH, Ovbiagele B. Pioglitazone for secondary stroke prevention: a systematic review and meta-analysis. Stroke . 2017;48(2): 388 e 393. https://doi.org/10.1161/strokeaha.116.013977 145. Spence JD, Viscoli CM, Inzucchi SE, et al. Pioglitazone therapy in patients with stroke and prediabetes: a post hoc analysis of the IRIS randomized clinical trial. JAMA Neurol . 2019;76(5):526 e 535. https://doi.org/10.1001/ jamaneurol.2019.0079 146. Zhou Z, Jardine MJ, Li Q, et al. Effect of SGLT2 inhibitors on stroke and atrial fi brillation in diabetic ki","tf":{"10":5,"48":2,"53":1,"76":2,"116":1,"142":1,"143":1,"144":1,"145":1,"146":1,"154":1,"267":1,"388":1,"393":1,"526":1,"535":1,"1001":1,"1007":1,"1016":2,"1117":1,"1145":1,"1161":1,"2017":1,"2019":2,"2020":4,"2021":2,"2117":1,"2122":1,"dy":1,"foy":1,"aj":1,"peterson":1,"usefulness":1,"of":5,"glucagon":1,"like":1,"peptide":1,"receptor":2,"agonists":2,"to":1,"reduce":1,"adverse":1,"cardiovascular":2,"disease":1,"events":1,"in":5,"patients":3,"with":3,"type":2,"diabetes":3,"mellitus":1,"am":2,"cardiol":2,"https":5,"doi":5,"org":5,"amjcard":1,"05":2,"043":1,"malhotra":1,"katsanos":1,"ah":1,"lambadiari":1,"et":4,"al":4,"glp":1,"for":3,"stroke":5,"prevention":2,"systematic":2,"review":2,"and":4,"meta":2,"analysis":3,"neurol":2,"s00415":1,"020":1,"09813":1,"das":1,"sr":1,"everett":1,"bm":1,"birtcher":1,"kk":1,"expert":1,"consensus":1,"decision":1,"pathway":1,"on":2,"novel":1,"therapies":1,"risk":1,"reduction":1,"report":1,"the":2,"american":1,"college":1,"cardiology":1,"solution":1,"set":1,"oversight":1,"committee":1,"coll":1,"jacc":1,"037":1,"lee":1,"saver":1,"jl":1,"liao":1,"hw":1,"lin":1,"ch":1,"ovbiagele":1,"pioglitazone":2,"secondary":1,"strokeaha":1,"013977":1,"spence":1,"jd":1,"viscoli":1,"cm":1,"inzucchi":1,"se":1,"therapy":1,"prediabetes":1,"post":1,"hoc":1,"iris":1,"randomized":1,"clinical":1,"trial":1,"jama":1,"jamaneurol":1,"0079":1,"zhou":1,"jardine":1,"mj":1,"li":1,"effect":1,"sglt2":1,"inhibitors":1,"atrial":1,"fi":1,"brillation":1,"diabetic":1,"ki":1},"len":216},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":35,"chunkId":"aace-2023-p35-c9","text":"t hoc analysis of the IRIS randomized clinical trial. JAMA Neurol . 2019;76(5):526 e 535. https://doi.org/10.1001/ jamaneurol.2019.0079 146. Zhou Z, Jardine MJ, Li Q, et al. Effect of SGLT2 inhibitors on stroke and atrial fi brillation in diabetic kidney disease: results from the CREDENCE trial and meta-analysis. Stroke . 2021;52(5):1545 e 1556. https://doi.org/10.1161/ strokeaha.120.031623 147. Tsai WH, Chuang SM, Liu SC, et al. Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta- analysis. Sci Rep . 2021;11(1), 15364. https://doi.org/10.1038/s41598-021- 94945-4 148. Schroeder EB, Powers JD, O'Connor PJ, et al. Prevalence of chronic kidney disease among individuals with diabetes in the SUPREME-DM Project, 2005- 2011. J Diabetes Complications . 2015;29(5):637 e 643. https://doi.org/10.1016/ j.jdiacomp.2015.04.007 149. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagli fl ozin in heart failure. N Engl J Med . 2020;383(15):1413 e 1424. https://doi.org/10.1056/NEJMoa2022190 S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 339","tf":{"10":5,"11":1,"15":1,"29":2,"52":1,"76":1,"120":1,"146":1,"147":1,"148":1,"149":1,"305":1,"339":1,"340":1,"383":1,"526":1,"535":1,"637":1,"643":1,"1001":1,"1016":1,"1038":1,"1056":1,"1161":1,"1413":1,"1424":1,"1545":1,"1556":1,"2005":1,"2011":1,"2015":2,"2019":2,"2020":1,"2021":2,"2023":1,"15364":1,"94945":1,"hoc":1,"analysis":3,"of":4,"the":3,"iris":1,"randomized":1,"clinical":1,"trial":2,"jama":1,"neurol":1,"https":5,"doi":5,"org":5,"jamaneurol":1,"0079":1,"zhou":1,"jardine":1,"mj":1,"li":1,"et":5,"al":5,"effect":1,"sglt2":2,"inhibitors":2,"on":2,"stroke":3,"and":5,"atrial":1,"fi":1,"brillation":1,"in":4,"diabetic":1,"kidney":2,"disease":2,"results":1,"from":1,"credence":1,"meta":2,"strokeaha":1,"031623":1,"tsai":1,"wh":1,"chuang":1,"sm":1,"liu":1,"sc":1,"effects":1,"its":1,"subtypes":1,"patients":1,"with":3,"type":1,"diabetes":3,"systematic":1,"review":1,"sci":1,"rep":1,"s41598":1,"021":1,"schroeder":1,"eb":1,"powers":1,"jd":1,"connor":1,"pj":1,"prevalence":1,"chronic":1,"among":1,"individuals":1,"supreme":1,"dm":1,"project":1,"complications":1,"jdiacomp":1,"04":1,"007":1,"packer":1,"anker":1,"sd":1,"butler":1,"cardiovascular":1,"renal":1,"outcomes":1,"empagli":1,"fl":1,"ozin":1,"heart":1,"failure":1,"engl":1,"med":1,"nejmoa2022190":1,"samson":1,"vellanki":1,"blonde":1,"endocrine":1,"practice":1},"len":188},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":36,"chunkId":"aace-2023-p36-c0","text":"150. Zannad F, Ferreira JP, Pocock SJ, et al. Cardiac and kidney bene fi ts of empa- gli fl ozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced. Circulation . 2021;143(4):310 e 321. https://doi.org/ 10.1161/circulationaha.120.051685 151. Heerspink HJL, Jongs N, Chertow GM, et al. Effect of dapagli fl ozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespeci fi ed analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol . 2021;9(11):743 e 754. https://doi.org/10.1016/ s2213-8587(21)00242-4 152. Herrington WG, Staplin N, Wanner C, et al. Empagli fl ozin in patients with chronic kidney disease. N Engl J Med . 2023;388(2):117 e 127. https://doi.org/ 10.1056/NEJMoa2204233 153. Mann JFE, Fonseca V, Mosenzon O, et al. Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease. Circulation . 2018;138(25):2908 e 2918. https://doi.org/ 10.1161/circulationaha.118.036418 154. Mann JFE, Fonseca VA, Poulter NR, et al. Safety of liraglutide in type 2 diabetes and chronic kidney disease. Clin J Am Soc Nephrol . 2020;15(4):465 e 473. https://doi.org/10.2215/cjn.11881019 155. Abdul-Ghani M, Puckett C, Adams J, et al. Durability of triple combination therapy versus stepwise addition therapy in patients with n","tf":{"10":5,"11":1,"15":1,"21":1,"25":1,"117":1,"118":1,"120":1,"127":1,"138":1,"143":1,"150":1,"151":1,"152":1,"153":1,"154":1,"155":1,"310":1,"321":1,"388":1,"465":1,"473":1,"743":1,"754":1,"1016":1,"1056":1,"1161":2,"2018":1,"2020":1,"2021":2,"2023":1,"2215":1,"2908":1,"2918":1,"8587":1,"11881019":1,"zannad":1,"ferreira":1,"jp":1,"pocock":1,"sj":1,"et":6,"al":6,"cardiac":1,"and":4,"kidney":7,"bene":1,"fi":2,"ts":1,"of":7,"empa":1,"gli":1,"fl":3,"ozin":3,"in":7,"heart":1,"failure":1,"across":1,"the":3,"spectrum":1,"function":2,"insights":1,"from":2,"emperor":1,"reduced":1,"circulation":2,"https":5,"doi":5,"org":5,"circulationaha":2,"051685":1,"heerspink":1,"hjl":1,"jongs":1,"chertow":1,"gm":1,"effect":1,"dapagli":1,"on":2,"rate":1,"decline":1,"patients":4,"with":5,"chronic":4,"disease":4,"without":1,"type":3,"diabetes":4,"prespeci":1,"ed":1,"analysis":1,"dapa":1,"ckd":1,"trial":1,"lancet":1,"endocrinol":1,"s2213":1,"00242":1,"herrington":1,"wg":1,"staplin":1,"wanner":1,"empagli":1,"engl":1,"med":1,"nejmoa2204233":1,"mann":2,"jfe":2,"fonseca":2,"mosenzon":1,"effects":1,"liraglutide":2,"versus":2,"placebo":1,"cardiovascular":1,"events":1,"mellitus":1,"036418":1,"va":1,"poulter":1,"nr":1,"safety":1,"clin":1,"am":1,"soc":1,"nephrol":1,"cjn":1,"abdul":1,"ghani":1,"puckett":1,"adams":1,"durability":1,"triple":1,"combination":1,"therapy":2,"stepwise":1,"addition":1},"len":222},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":36,"chunkId":"aace-2023-p36-c1","text":"and chronic kidney disease. Clin J Am Soc Nephrol . 2020;15(4):465 e 473. https://doi.org/10.2215/cjn.11881019 155. Abdul-Ghani M, Puckett C, Adams J, et al. Durability of triple combination therapy versus stepwise addition therapy in patients with new-onset T2DM: 3-year follow-up of EDICT. Diabetes Care . 2021;44(2):433 e 439. https:// doi.org/10.2337/dc20-0978 156. Matthews DR, Pald \u0013 anius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet . 2019;394(10208):1519 e 1529. https://doi.org/10.1016/s0140- 6736(19)32131-2 157. Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. Lancet Dia- betes Endocrinol . 2013;1(1):28 e 34. https://doi.org/10.1016/s2213-8587(13) 70006-8 158. Mannucci E, Caiulo C, Naletto L, Madama G, Monami M. Ef fi cacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes: a network meta-analysis of randomized controlled trials. Endocrine . 2021;74(3):508 e 517. https://doi.org/10.1007/s12020-021-02889-6 159. Men P, Qu S, Luo W, Li C, Zhai S. Comparison of lixisenatide in combination with basal insulin vs","tf":{"10":5,"13":1,"15":1,"19":1,"28":1,"34":1,"44":1,"74":1,"155":1,"156":1,"157":1,"158":1,"159":1,"394":1,"433":1,"439":1,"465":1,"473":1,"508":1,"517":1,"1007":1,"1016":2,"1519":1,"1529":1,"2013":1,"2019":1,"2020":1,"2021":2,"2215":1,"2337":1,"6736":1,"8587":1,"10208":1,"32131":1,"70006":1,"11881019":1,"and":5,"chronic":1,"kidney":1,"disease":1,"clin":1,"am":1,"soc":1,"nephrol":1,"https":5,"doi":5,"org":5,"cjn":1,"abdul":1,"ghani":1,"puckett":1,"adams":1,"et":1,"al":1,"durability":2,"of":7,"triple":1,"combination":3,"therapy":4,"versus":2,"stepwise":1,"addition":1,"in":4,"patients":1,"with":3,"new":1,"onset":1,"t2dm":1,"year":2,"follow":1,"up":1,"edict":1,"diabetes":4,"care":1,"dc20":1,"0978":1,"matthews":1,"dr":1,"pald":1,"anius":1,"pm":1,"proot":1,"chiang":1,"stumvoll":1,"del":1,"prato":1,"glycaemic":1,"an":1,"early":1,"vildagliptin":1,"metformin":2,"sequential":1,"monotherapy":1,"newly":1,"diagnosed":1,"type":3,"verify":1,"multicentre":1,"randomised":1,"double":1,"blind":1,"trial":1,"lancet":2,"s0140":1,"kramer":1,"ck":1,"zinman":1,"retnakaran":1,"short":1,"term":1,"intensive":1,"insulin":3,"mellitus":1,"systematic":1,"review":1,"meta":2,"analysis":2,"dia":1,"betes":1,"endocrinol":1,"s2213":1,"mannucci":1,"caiulo":1,"naletto":1,"madama":1,"monami":1,"ef":1,"fi":1,"cacy":1,"safety":1,"different":1,"basal":2,"prandial":1,"analogues":1,"for":1,"the":1,"treatment":1,"network":1,"randomized":1,"controlled":1,"trials":1,"endocrine":1,"s12020":1,"021":1,"02889":1,"men":1,"qu":1,"luo":1,"li":1,"zhai":1,"comparison":1,"lixisenatide":1,"vs":1},"len":206},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":36,"chunkId":"aace-2023-p36-c2","text":"e 2 diabetes: a network meta-analysis of randomized controlled trials. Endocrine . 2021;74(3):508 e 517. https://doi.org/10.1007/s12020-021-02889-6 159. Men P, Qu S, Luo W, Li C, Zhai S. Comparison of lixisenatide in combination with basal insulin vs other insulin regimens for the treatment of patients with type 2 diabetes inadequately controlled by basal insulin: systematic review, network meta-analysis and cost-effectiveness analysis. Diabetes Obes Metab . 2020;22(1):107 e 115. https://doi.org/10.1111/dom.13871 160. Yki-J  arvinen H, Juurinen L, Alvarsson M, et al. Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care . 2007;30(6):1364 e 1369. https://doi.org/10.2337/dc06- 1357 161. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care . 2003;26(11):3080 e 3086. https://doi.org/10.2337/ diacare.26.11.3080 162. Zisman A, Morales F, Stewart J, Stuhr A, Vlajnic A, Zhou R. BeAM value: an indicator of the need to initiate and intensify prandial therapy in patients with type 2 diabetes mellitus receiving basal insulin. BMJ Open Diabetes Res Care . 2016;4(1), e000171. https://doi.org/10.1136/bmjdrc-2015- 000171 ","tf":{"10":5,"11":2,"22":1,"26":2,"30":1,"74":1,"107":1,"115":1,"159":1,"160":1,"161":1,"162":1,"508":1,"517":1,"1007":1,"1111":1,"1136":1,"1357":1,"1364":1,"1369":1,"2003":1,"2007":1,"2015":1,"2016":1,"2020":1,"2021":1,"2337":2,"3080":2,"3086":1,"13871":1,"diabetes":7,"network":2,"meta":2,"analysis":3,"of":7,"randomized":3,"controlled":2,"trials":1,"endocrine":1,"https":5,"doi":5,"org":5,"s12020":1,"021":1,"02889":1,"men":1,"qu":1,"luo":1,"li":1,"zhai":1,"comparison":1,"lixisenatide":1,"in":4,"combination":2,"with":3,"basal":3,"insulin":7,"vs":1,"other":1,"regimens":1,"for":1,"the":3,"treatment":1,"patients":4,"type":4,"inadequately":1,"by":2,"systematic":1,"review":1,"and":4,"cost":1,"effectiveness":1,"obes":1,"metab":1,"dom":1,"yki":1,"arvinen":1,"juurinen":1,"alvarsson":1,"et":1,"al":1,"initiate":3,"aggressive":1,"titration":1,"education":1,"study":1,"to":4,"compare":1,"initiation":1,"therapy":3,"diabetic":2,"individually":1,"groups":1,"care":3,"dc06":1,"riddle":1,"mc":1,"rosenstock":1,"gerich":1,"treat":1,"target":1,"trial":1,"addition":1,"glargine":1,"or":1,"human":1,"nph":1,"oral":1,"diacare":1,"zisman":1,"morales":1,"stewart":1,"stuhr":1,"vlajnic":1,"zhou":1,"beam":1,"value":1,"an":1,"indicator":1,"need":1,"intensify":1,"prandial":1,"mellitus":1,"receiving":1,"bmj":1,"open":1,"res":1,"e000171":1,"bmjdrc":1,"000171":1},"len":205},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":36,"chunkId":"aace-2023-p36-c3","text":", Zhou R. BeAM value: an indicator of the need to initiate and intensify prandial therapy in patients with type 2 diabetes mellitus receiving basal insulin. BMJ Open Diabetes Res Care . 2016;4(1), e000171. https://doi.org/10.1136/bmjdrc-2015- 000171 163. Owens DR, Luzio SD, Sert-Langeron C, Riddle MC. Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study. Diabetes Obes Metab . 2011;13(11):1020 e 1027. https://doi.org/10.1111/ j.1463-1326.2011.01459.x 164. Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA. Introducing a simpli fi ed approach to insulin therapy in type 2 diabetes: a comparison of two single- dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab . 2008;10(12):1178 e 1185. https://doi.org/10.1111/ j.1463-1326.2008.00967.x 165. Vora J, Cohen N, Evans M, Hockey A, Speight J, Whately-Smith C. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (Lan- Scape). Diabetes Obes Metab . 2015;17(12):1133 e 1141. https://doi.org/ 10.1111/dom.12528 166. Carlson JN, Schunder-Tatzber S, Neilson CJ, Hood N. Dietary sugars versus glucose tablets f","tf":{"10":5,"11":1,"12":2,"13":1,"17":1,"24":1,"163":1,"164":1,"165":1,"166":1,"1020":1,"1027":1,"1111":3,"1133":1,"1136":1,"1141":1,"1178":1,"1185":1,"1326":2,"1463":2,"2008":2,"2011":2,"2015":2,"2016":1,"12528":1,"zhou":1,"beam":1,"value":1,"an":1,"indicator":1,"of":7,"the":1,"need":1,"to":2,"initiate":1,"and":3,"intensify":1,"prandial":2,"therapy":2,"in":4,"patients":1,"with":3,"type":4,"diabetes":8,"mellitus":1,"receiving":1,"basal":2,"insulin":11,"bmj":1,"open":2,"res":1,"care":1,"e000171":1,"https":4,"doi":4,"org":4,"bmjdrc":1,"000171":1,"owens":1,"dr":1,"luzio":1,"sd":1,"sert":1,"langeron":1,"riddle":1,"mc":1,"effects":1,"initiation":1,"titration":1,"single":2,"pre":1,"dose":2,"glulisine":3,"while":1,"continuing":1,"titrated":1,"glargine":3,"month":1,"proof":1,"concept":1,"study":1,"obes":3,"metab":3,"01459":1,"lankisch":1,"mr":1,"ferlinz":1,"kc":1,"leahy":1,"jl":1,"scherbaum":1,"wa":1,"introducing":1,"simpli":1,"fi":1,"ed":1,"approach":1,"comparison":1,"two":1,"regimens":1,"plus":2,"oral":1,"antidiabetic":1,"drugs":1,"00967":1,"vora":1,"cohen":1,"evans":1,"hockey":1,"speight":1,"whately":1,"smith":1,"intensifying":1,"regimen":1,"after":1,"optimization":1,"adults":1,"week":1,"randomized":1,"label":1,"trial":1,"comparing":1,"biphasic":1,"aspart":1,"lan":1,"scape":1,"dom":1,"carlson":1,"jn":1,"schunder":1,"tatzber":1,"neilson":1,"cj":1,"hood":1,"dietary":1,"sugars":1,"versus":1,"glucose":1,"tablets":1},"len":209},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":36,"chunkId":"aace-2023-p36-c4","text":"rgine plus insulin glulisine with biphasic insulin aspart (Lan- Scape). Diabetes Obes Metab . 2015;17(12):1133 e 1141. https://doi.org/ 10.1111/dom.12528 166. Carlson JN, Schunder-Tatzber S, Neilson CJ, Hood N. Dietary sugars versus glucose tablets for fi rst-aid treatment of symptomatic hypoglycaemia in awake patients with diabetes: a systematic review and meta-analysis. Emerg Med J . 2017;34(2):100 e 106. https://doi.org/10.1136/emermed-2015- 205637 167. Newswanger B, Ammons S, Phadnis N, et al. Development of a highly stable, nonaqueous glucagon formulation for delivery via infusion pump systems. J Diabetes Sci Technol . 2015;9(1):24 e 33. https://doi.org/10.1177/ 1932296814565131 168. H  ovelmann U, Bysted BV, Mouritzen U, et al. Pharmacokinetic and pharma- codynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog. Diabetes Care . 2018;41(3):531 e 537. https://doi.org/10.2337/ dc17-1402 169. Christiansen MP, Cummins M, Prestrelski S, Close NC, Nguyen A, Junaidi K. Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: two randomized crossover non-inferiority studies. BMJ Open Diabetes Res Care . 2021;9(1), e002137. https://doi.org/10.1136/bmjdrc-2021- 002137 170. Pontiroli AE. Intranasal glucagon: a promising approach for treatment of se- ve","tf":{"10":5,"12":1,"17":1,"24":1,"33":1,"34":1,"41":1,"100":1,"106":1,"166":1,"167":1,"168":1,"169":1,"170":1,"531":1,"537":1,"1111":1,"1133":1,"1136":2,"1141":1,"1177":1,"1402":1,"2015":3,"2017":1,"2018":1,"2021":2,"2337":1,"12528":1,"205637":1,"rgine":1,"plus":1,"insulin":2,"glulisine":1,"with":2,"biphasic":1,"aspart":1,"lan":1,"scape":1,"diabetes":5,"obes":1,"metab":1,"https":5,"doi":5,"org":5,"dom":1,"carlson":1,"jn":1,"schunder":1,"tatzber":1,"neilson":1,"cj":1,"hood":1,"dietary":1,"sugars":1,"versus":1,"glucose":1,"tablets":1,"for":4,"fi":1,"rst":1,"aid":1,"treatment":2,"of":6,"symptomatic":2,"hypoglycaemia":1,"in":1,"awake":1,"patients":1,"systematic":1,"review":1,"and":3,"meta":1,"analysis":1,"emerg":1,"med":1,"emermed":1,"newswanger":1,"ammons":1,"phadnis":1,"et":2,"al":2,"development":1,"highly":1,"stable":2,"nonaqueous":1,"glucagon":5,"formulation":1,"delivery":1,"via":1,"infusion":1,"pump":1,"systems":1,"sci":1,"technol":1,"1932296814565131":1,"ovelmann":1,"bysted":1,"bv":1,"mouritzen":1,"pharmacokinetic":1,"pharma":1,"codynamic":1,"characteristics":1,"dasiglucagon":1,"novel":1,"soluble":1,"analog":1,"care":2,"dc17":1,"christiansen":1,"mp":1,"cummins":1,"prestrelski":1,"close":1,"nc":1,"nguyen":1,"junaidi":1,"comparison":1,"ready":1,"to":2,"use":1,"liquid":1,"injection":1,"administered":1,"by":1,"autoinjector":1,"emergency":1,"kit":1,"the":1,"relief":1,"severe":1,"hypoglycemia":1,"two":1,"randomized":1,"crossover":1,"non":1,"inferiority":1,"studies":1,"bmj":1,"open":1,"res":1,"e002137":1,"bmjdrc":1,"002137":1,"pontiroli":1,"ae":1,"intranasal":1,"promising":1,"approach":1,"se":1,"ve":1},"len":198},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":36,"chunkId":"aace-2023-p36-c5","text":"f severe hypoglycemia: two randomized crossover non-inferiority studies. BMJ Open Diabetes Res Care . 2021;9(1), e002137. https://doi.org/10.1136/bmjdrc-2021- 002137 170. Pontiroli AE. Intranasal glucagon: a promising approach for treatment of se- vere hypoglycemia. J Diabetes Sci Technol . 2015;9(1):38 e 43. https://doi.org/ 10.1177/1932296814557518 171. Rickels MR, Ruedy KJ, Foster NC, et al. Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: a randomized crossover noninferiority study. Diabetes Care . 2016;39(2):264 e 270. https:// doi.org/10.2337/dc15-1498 172. Sherr JL, Ruedy KJ, Foster NC, et al. Glucagon nasal powder: a promising alternative to intramuscular glucagon in youth with type 1 diabetes. Diabetes Care . 2016;39(4):555 e 562. https://doi.org/10.2337/dc15-1606 173. U.S. Food & Drug Administration (FDA). Baqsimi (glucagon) nasal powder prescribing information. Accessed November 28, 2022. https://www. accessdata.fda.gov/drugsatfda_docs/label/2019/210134s000lbl.pdf 174. Casanova L, Gobin N, Villani P, Verger P. Bias in the measure of the effec- tiveness of seasonal in fl uenza vaccination among diabetics. Prim Care Dia- betes . 2016;10(6):398 e 406. https://doi.org/10.1016/j.pcd.2016.05.005 175. Smith SA, Poland GA. Use of in fl uenza and pneumococcal vaccines in people with diabetes. Diabetes Care . 2000;23(1):95 e 108","tf":{"10":6,"23":1,"28":1,"38":1,"39":2,"43":1,"95":1,"108":1,"170":1,"171":1,"172":1,"173":1,"174":1,"175":1,"264":1,"270":1,"398":1,"406":1,"555":1,"562":1,"1016":1,"1136":1,"1177":1,"1498":1,"1606":1,"2000":1,"2015":1,"2016":4,"2019":1,"2021":2,"2022":1,"2337":2,"severe":1,"hypoglycemia":3,"two":1,"randomized":2,"crossover":2,"non":1,"inferiority":1,"studies":1,"bmj":1,"open":1,"diabetes":8,"res":1,"care":5,"e002137":1,"https":6,"doi":5,"org":5,"bmjdrc":1,"002137":1,"pontiroli":1,"ae":1,"intranasal":2,"glucagon":5,"promising":2,"approach":1,"for":2,"treatment":2,"of":5,"se":1,"vere":1,"sci":1,"technol":1,"1932296814557518":1,"rickels":1,"mr":1,"ruedy":2,"kj":2,"foster":2,"nc":2,"et":2,"al":2,"insulin":1,"induced":1,"in":6,"adults":1,"with":3,"type":2,"noninferiority":1,"study":1,"dc15":2,"sherr":1,"jl":1,"nasal":2,"powder":2,"alternative":1,"to":1,"intramuscular":1,"youth":1,"food":1,"drug":1,"administration":1,"fda":2,"baqsimi":1,"prescribing":1,"information":1,"accessed":1,"november":1,"www":1,"accessdata":1,"gov":1,"drugsatfda":1,"docs":1,"label":1,"210134s000lbl":1,"pdf":1,"casanova":1,"gobin":1,"villani":1,"verger":1,"bias":1,"the":2,"measure":1,"effec":1,"tiveness":1,"seasonal":1,"fl":2,"uenza":2,"vaccination":1,"among":1,"diabetics":1,"prim":1,"dia":1,"betes":1,"pcd":1,"05":1,"005":1,"smith":1,"sa":1,"poland":1,"ga":1,"use":1,"and":1,"pneumococcal":1,"vaccines":1,"people":1},"len":209},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":36,"chunkId":"aace-2023-p36-c6","text":"za vaccination among diabetics. Prim Care Dia- betes . 2016;10(6):398 e 406. https://doi.org/10.1016/j.pcd.2016.05.005 175. Smith SA, Poland GA. Use of in fl uenza and pneumococcal vaccines in people with diabetes. Diabetes Care . 2000;23(1):95 e 108. https://doi.org/10.2337/ diacare.23.1.95 176. Gregory JM, Slaughter JC, Duffus SH, et al. COVID-19 severity is tripled in the diabetes community: A prospective analysis of the pandemic's impact in type 1 and type 2 diabetes. Diabetes Care . 2021;44(2):526 e 532. https://doi.org/ 10.2337/dc20-2260 177. Dos Santos G, Tahrat H, Bekkat-Berkani R. Immunogenicity, safety, and effectiveness of seasonal in fl uenza vaccination in patients with diabetes mellitus: a systematic review. Hum Vaccin Immunother . 2018;14(8): 1853 e 1866. https://doi.org/10.1080/21645515.2018.1446719 178. Lu PJ, Hung MC, Srivastav A, et al. Surveillance of vaccination coverage among adult populations -United States, 2018. MMWR Surveill Summ . 2021;70(3): 1 e 26. https://doi.org/10.15585/mmwr.ss7003a1 179. Centers for Disease Control and Prevention. Immunization schedules. Accessed November 10, 2022. https://www.cdc.gov/vaccines/schedules/ 180. Hurley LP, Bridges CB, Harpaz R, et al. U.S. physicians' perspective of adult vaccine delivery. Ann Intern Med . 2014;160(3):161. https://doi.org/10.7326/ m13-2332 181. Centers for Disease Control and Prevention. Standards ","tf":{"10":8,"14":1,"19":1,"23":2,"26":1,"44":1,"70":1,"95":2,"108":1,"160":1,"161":1,"175":1,"176":1,"177":1,"178":1,"179":1,"180":1,"181":1,"398":1,"406":1,"526":1,"532":1,"1016":1,"1080":1,"1853":1,"1866":1,"2000":1,"2014":1,"2016":2,"2018":3,"2021":2,"2022":1,"2260":1,"2332":1,"2337":2,"7326":1,"15585":1,"1446719":1,"21645515":1,"za":1,"vaccination":3,"among":2,"diabetics":1,"prim":1,"care":3,"dia":1,"betes":1,"https":7,"doi":6,"org":6,"pcd":1,"05":1,"005":1,"smith":1,"sa":1,"poland":1,"ga":1,"use":1,"of":5,"in":6,"fl":2,"uenza":2,"and":5,"pneumococcal":1,"vaccines":2,"people":1,"with":2,"diabetes":6,"diacare":1,"gregory":1,"jm":1,"slaughter":1,"jc":1,"duffus":1,"sh":1,"et":3,"al":3,"covid":1,"severity":1,"is":1,"tripled":1,"the":2,"community":1,"prospective":1,"analysis":1,"pandemic":1,"impact":1,"type":2,"dc20":1,"dos":1,"santos":1,"tahrat":1,"bekkat":1,"berkani":1,"immunogenicity":1,"safety":1,"effectiveness":1,"seasonal":1,"patients":1,"mellitus":1,"systematic":1,"review":1,"hum":1,"vaccin":1,"immunother":1,"lu":1,"pj":1,"hung":1,"mc":1,"srivastav":1,"surveillance":1,"coverage":1,"adult":2,"populations":1,"united":1,"states":1,"mmwr":2,"surveill":1,"summ":1,"ss7003a1":1,"centers":2,"for":2,"disease":2,"control":2,"prevention":2,"immunization":1,"schedules":2,"accessed":1,"november":1,"www":1,"cdc":1,"gov":1,"hurley":1,"lp":1,"bridges":1,"cb":1,"harpaz":1,"physicians":1,"perspective":1,"vaccine":1,"delivery":1,"ann":1,"intern":1,"med":1,"m13":1,"standards":1},"len":217},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":36,"chunkId":"aace-2023-p36-c7","text":"v/vaccines/schedules/ 180. Hurley LP, Bridges CB, Harpaz R, et al. U.S. physicians' perspective of adult vaccine delivery. Ann Intern Med . 2014;160(3):161. https://doi.org/10.7326/ m13-2332 181. Centers for Disease Control and Prevention. Standards for adult immunization practice. Accessed November 10, 2022. https://www.cdc.gov/vaccines/hcp/ adults/for-practice/standards/index.html 182. Jacobson Vann JC, Jacobson RM, Coyne-Beasley T, Asafu-Adjei JK, Szilagyi PG. Patient reminder and recall interventions to improve immunization rates. Cochrane Database Syst Rev . 2018;1:CD003941. https://doi.org/10.1002/ 14651858.CD003941.pub3 183. Johnson DR, Nichol KL, Lipczynski K. Barriers to adult immunization. Am J Med . 2008;121(7 Suppl 2):S28 e S35. https://doi.org/10.1016/j.amjmed.2008.05.005 184. Nowalk MP, Moehling KK, Zhang S, Raviotta JM, Zimmerman RK, Lin CJ. Using the 4 Pillars to increase vaccination among high-risk adults: who bene fi ts? Am J Manag Care . 2017;23(11):651 e 655. S.L. Samson, P. Vellanki, L. Blonde et al. Endocrine Practice 29 (2023) 305 e 340 340","tf":{"10":4,"11":1,"23":1,"29":1,"121":1,"160":1,"161":1,"180":1,"181":1,"182":1,"183":1,"184":1,"305":1,"340":2,"651":1,"655":1,"1002":1,"1016":1,"2008":2,"2014":1,"2017":1,"2018":1,"2022":1,"2023":1,"2332":1,"7326":1,"14651858":1,"vaccines":2,"schedules":1,"hurley":1,"lp":1,"bridges":1,"cb":1,"harpaz":1,"et":2,"al":2,"physicians":1,"perspective":1,"of":1,"adult":3,"vaccine":1,"delivery":1,"ann":1,"intern":1,"med":2,"https":4,"doi":3,"org":3,"m13":1,"centers":1,"for":3,"disease":1,"control":1,"and":2,"prevention":1,"standards":2,"immunization":3,"practice":3,"accessed":1,"november":1,"www":1,"cdc":1,"gov":1,"hcp":1,"adults":2,"index":1,"html":1,"jacobson":2,"vann":1,"jc":1,"rm":1,"coyne":1,"beasley":1,"asafu":1,"adjei":1,"jk":1,"szilagyi":1,"pg":1,"patient":1,"reminder":1,"recall":1,"interventions":1,"to":3,"improve":1,"rates":1,"cochrane":1,"database":1,"syst":1,"rev":1,"cd003941":2,"pub3":1,"johnson":1,"dr":1,"nichol":1,"kl":1,"lipczynski":1,"barriers":1,"am":2,"suppl":1,"s28":1,"s35":1,"amjmed":1,"05":1,"005":1,"nowalk":1,"mp":1,"moehling":1,"kk":1,"zhang":1,"raviotta":1,"jm":1,"zimmerman":1,"rk":1,"lin":1,"cj":1,"using":1,"the":1,"pillars":1,"increase":1,"vaccination":1,"among":1,"high":1,"risk":1,"who":1,"bene":1,"fi":1,"ts":1,"manag":1,"care":1,"samson":1,"vellanki":1,"blonde":1,"endocrine":1},"len":165},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":37,"chunkId":"aace-2023-p37-c0","text":"Update 1 of 2 Endocrine Practice Volume 29, Issue 9, September 2023, Page 746 https://doi.org/10.1016/j.eprac.2023.06.009 DOI:","tf":{"10":1,"29":1,"746":1,"1016":1,"2023":2,"update":1,"of":1,"endocrine":1,"practice":1,"volume":1,"issue":1,"september":1,"page":1,"https":1,"doi":2,"org":1,"eprac":1,"06":1,"009":1},"len":21},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":38,"chunkId":"aace-2023-p38-c0","text":"Erratum In the May 2023 issue of Endocrine Practice , the paper by Samson et al (Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm d 2023 Update. Endocr Pract. 2023;29(5):305 e 340) contained inaccurate af fi liation information for Dr Kenneth Izuora. Dr Izuora  s correct title is Professor and not Associate Professor as originally published. The corrected af fi liation info is as follows: Professor, Department of Internal Medicine, Endocrinology, Kirk Kerkorian School of Medicine, University of Nevada Las Vegas, Las Vegas, Nevada DOI of original article: https://doi.org/10.1016/j.eprac.2023.02.001. Endocrine Practice TM www.endocrinepractice.org https://doi.org/10.1016/j.eprac.2023.06.009 1530-891X/  2023 AACE. Published by Elsevier Inc. All rights reserved. Endocrine Practice 29 (2023) 746","tf":{"10":2,"29":2,"305":1,"340":1,"746":1,"1016":2,"1530":1,"2023":7,"erratum":1,"in":1,"the":3,"may":1,"issue":1,"of":6,"endocrine":3,"practice":3,"paper":1,"by":2,"samson":2,"et":2,"al":2,"sl":1,"vellanki":1,"blonde":1,"american":1,"association":1,"clinical":1,"endocrinology":2,"consensus":1,"statement":1,"comprehensive":1,"type":1,"diabetes":1,"management":1,"algorithm":1,"update":1,"endocr":1,"pract":1,"contained":1,"inaccurate":1,"af":2,"fi":2,"liation":2,"information":1,"for":1,"dr":2,"kenneth":1,"izuora":2,"correct":1,"title":1,"is":2,"professor":3,"and":1,"not":1,"associate":1,"as":2,"originally":1,"published":2,"corrected":1,"info":1,"follows":1,"department":1,"internal":1,"medicine":2,"kirk":1,"kerkorian":1,"school":1,"university":1,"nevada":2,"las":2,"vegas":2,"doi":3,"original":1,"article":1,"https":2,"org":3,"eprac":2,"02":1,"001":1,"tm":1,"www":1,"endocrinepractice":1,"06":1,"009":1,"891x":1,"aace":1,"elsevier":1,"inc":1,"all":1,"rights":1,"reserved":1},"len":136},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":39,"chunkId":"aace-2023-p39-c0","text":"Update 2 of 2 Endocrine Practice Volume 29, Issue 12, December 2023, Page 1025 https://doi.org/10.1016/j.eprac.2023.09.008 DOI:","tf":{"10":1,"12":1,"29":1,"1016":1,"1025":1,"2023":2,"update":1,"of":1,"endocrine":1,"practice":1,"volume":1,"issue":1,"december":1,"page":1,"https":1,"doi":2,"org":1,"eprac":1,"09":1,"008":1},"len":22},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":40,"chunkId":"aace-2023-p40-c0","text":"Corrigendum Corrigendum on  American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm - 2023 Update  Authors of the American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm - 2023 Update. Endocr Pract. 2023 May;29(5):305-340. https://doi.org/10.1016/j.eprac.2023.02.001. PMID: 37150579 have identi fi ed an error and offer the following corrections: 1. On page 315 in the sentence:  The non-dihdropyridine calcium channel blockers   The correct statement is:  The dihydropyridine calcium channel blockers   2. On page 317 in the sentence:  The 3 GLP-1 RA agents approved by the FDA to reduce the risk of MACEs (including stroke) are dulaglutide (with or without established ASCVD), liraglutide, and subcutaneous semaglutide (in persons with established CVD).  139,143 Reference 139 should be deleted, as it was added inadvertently: 139. Holman RR, Coleman RL, Chan JCN, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5(11):877e886. https://doi.org/10.1016/s2213-8587(17)30309-1. Only reference 143 should appear after this sentence as:  The 3 GLP-1 RA agents approved by the FDA to","tf":{"10":2,"11":1,"17":1,"29":1,"139":3,"143":2,"305":1,"315":1,"317":1,"340":1,"1016":2,"2017":1,"2023":4,"8587":1,"30309":1,"37150579":1,"corrigendum":2,"on":4,"american":2,"association":2,"of":5,"clinical":2,"endocrinology":2,"consensus":2,"statement":3,"comprehensive":2,"type":2,"diabetes":4,"management":2,"algorithm":2,"update":2,"authors":1,"the":12,"endocr":1,"pract":1,"may":1,"https":2,"doi":2,"org":2,"eprac":1,"02":1,"001":1,"pmid":1,"have":1,"identi":1,"fi":1,"ed":1,"an":1,"error":1,"and":4,"offer":1,"following":1,"corrections":1,"page":2,"in":4,"sentence":3,"non":1,"dihdropyridine":1,"calcium":2,"channel":2,"blockers":2,"correct":1,"is":1,"dihydropyridine":1,"glp":2,"ra":2,"agents":2,"approved":2,"by":2,"fda":2,"to":2,"reduce":1,"risk":1,"maces":1,"including":1,"stroke":1,"are":1,"dulaglutide":1,"with":3,"or":1,"without":1,"established":2,"ascvd":1,"liraglutide":1,"subcutaneous":1,"semaglutide":1,"persons":1,"cvd":1,"reference":2,"should":2,"be":1,"deleted":1,"as":2,"it":1,"was":1,"added":1,"inadvertently":1,"holman":1,"rr":1,"coleman":1,"rl":1,"chan":1,"jcn":1,"et":1,"al":1,"effects":1,"acarbose":1,"cardiovascular":1,"outcomes":1,"patients":1,"coronary":1,"heart":1,"disease":1,"impaired":1,"glucose":1,"tolerance":1,"ace":1,"randomised":1,"double":1,"blind":1,"placebo":1,"controlled":1,"trial":1,"lancet":1,"endocrinol":1,"877e886":1,"s2213":1,"only":1,"appear":1,"after":1,"this":1},"len":201},{"docId":"aace-2023","docTitle":"AACE 2023 Algorithm","file":"aace-2023-algorithm.pdf","page":40,"chunkId":"aace-2023-p40-c1","text":"randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5(11):877e886. https://doi.org/10.1016/s2213-8587(17)30309-1. Only reference 143 should appear after this sentence as:  The 3 GLP-1 RA agents approved by the FDA to reduce the risk of MACEs (including stroke) are dulaglutide (with or without established ASCVD), liraglutide, and subcutaneous semaglutide (in persons with established CVD).  143 3. On page 329, Algorithm Fig. 5 (ASCVD Risk Reduction Algorithm: Hypertension) footnote 4, states:  Non-dihydropyridine amlodipine or nifedipine unless indication for dihydropyridine.  Footnote 4 incorrectly labels amlodipine and nifedipine as non-dihydropyridine medications. The intent was for the more vasodilatory dihydropyridines to be the fi rst choice among calcium channel blockers. Footnote 4 should state:  Dihydropyridine amlodipine or nifedipine unless indication for non-dihydropyridine.  DOI of original article: https://doi.org/10.1016/j.eprac.2023.02.001. Endocrine Practice TM www.endocrinepractice.org https://doi.org/10.1016/j.eprac.2023.09.008 1530-891X/  2023 AACE. Published by Elsevier Inc. All rights reserved. Endocrine Practice 29 (2023) 1025","tf":{"10":3,"11":1,"17":1,"29":1,"143":2,"329":1,"1016":3,"1025":1,"1530":1,"2017":1,"2023":4,"8587":1,"30309":1,"randomised":1,"double":1,"blind":1,"placebo":1,"controlled":1,"trial":1,"lancet":1,"diabetes":1,"endocrinol":1,"877e886":1,"https":3,"doi":4,"org":4,"s2213":1,"only":1,"reference":1,"should":2,"appear":1,"after":1,"this":1,"sentence":1,"as":2,"the":6,"glp":1,"ra":1,"agents":1,"approved":1,"by":2,"fda":1,"to":2,"reduce":1,"risk":2,"of":2,"maces":1,"including":1,"stroke":1,"are":1,"dulaglutide":1,"with":2,"or":3,"without":1,"established":2,"ascvd":2,"liraglutide":1,"and":2,"subcutaneous":1,"semaglutide":1,"in":1,"persons":1,"cvd":1,"on":1,"page":1,"algorithm":2,"fig":1,"reduction":1,"hypertension":1,"footnote":3,"states":1,"non":3,"dihydropyridine":5,"amlodipine":3,"nifedipine":3,"unless":2,"indication":2,"for":3,"incorrectly":1,"labels":1,"medications":1,"intent":1,"was":1,"more":1,"vasodilatory":1,"dihydropyridines":1,"be":1,"fi":1,"rst":1,"choice":1,"among":1,"calcium":1,"channel":1,"blockers":1,"state":1,"original":1,"article":1,"eprac":2,"02":1,"001":1,"endocrine":2,"practice":2,"tm":1,"www":1,"endocrinepractice":1,"09":1,"008":1,"891x":1,"aace":1,"published":1,"elsevier":1,"inc":1,"all":1,"rights":1,"reserved":1},"len":168}]}